European Position Paper on Rhinosinusitis and Nasal Polyps 2020 by Fokkens, W.J et al.


I 
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Wytske J. Fokkens1, Valerie J. Lund2, Claire Hopkins3, Peter W. Hellings1,4,11, 
Robert Kern5, Sietze Reitsma1, Sanna Toppila-Salmi6, Manuel Bernal-Sprekelsen7, 
Joaquim Mullol8, Isam Alobid9, Wilma Terezinha Anselmo-Lima10, Claus 
Bachert11,12, Fuad Baroody13, Christian von Buchwald14, Anders Cervin15, Noam 
Cohen16, Jannis Constantinidis17, Ludovic De Gabory18, Martin Desrosiers19, 
Zuzana Diamant20,21,22, Richard G. Douglas23, Philippe H. Gevaert24, Anita 
Hafner25, Richard J. Harvey26, Guy F. Joos27, Livije Kalogjera28, Andrew Knill29, 
Janwillem H. Kocks30, Basile N. Landis31, Jacqueline Limpens32, Sarah Lebeer33, 
Olga Lourenco34, Paolo M. Matricardi35, Cem Meco36,37, Liam O’Mahony38, Carl 
M. Philpott39,40, Dermot Ryan41,42, Rodney Schlosser43, Brent Senior44, Timothy L. 
Smith45, Thijs Teeling46, Peter Valentin Tomazic47, De Yun Wang48, Dehui Wang49, 
Luo Zhang50, Adrian M. Agius51, Cecilia Ahlström-Emanuelsson52, Rashid 
Alabri53, Silviu Albu54, Saied Alhabash55, Aleksandra Aleksic56, Mohammad 
Aloulah57, Mohannad Al-Qudah58, Saad Alsaleh59, Muaid Aziz Baban60, Tomislav 
Baudoin61, Tijmen Balvers62, Paolo Battaglia63, Juan David Bedoya64, Achim 
Beule65, Khaled M. Bofares66, Itzhak Braverman67, Eliza Brozek-Madry68, Richard 
Byaruhanga 69, Claudio Callejas70, Sean Carrie71, Lisa Caulley72, Desderius 
Chussi73, Eugenio de Corso74, Andre Coste75, Usama El Hadi76, Ahmed Elfarouk77, 
Philippe H. Eloy78, Shokrollah Farrokhi79, Giovanni Felisati80 , Michel D. Ferrari62, 
Roman Fishchuk81, Jessica W Grayson82, Paulo M. Goncalves83, Boris Grdinic84, 
Velimir Grgic28, Aneeza W. Hamizan85, Julio V. Heinichen86, Salina Husain87, Tang 
Ing Ping88, Justinas Ivaska89, Frodita Jakimovska90, Ljiljana Jovancevic91, Emily 
Kakande92, Reda Kamel93, Sergei Karpischenko94, Harsha H. Kariyawasam95, 
Hideyuki Kawauchi96,Anette Kjeldsen97, Ludger Klimek98, Antoni Krzeski99, 
Gabriela Kopacheva Barsova100, Sung Wam Kim101, Devyani Lal102 , José J. 
Letort103, Andrey Lopatin104, Abdelhak Mahdjoubi105, Alireza Mesbahi106, Jane 
Netkovski107, Dieudonné Nyenbue Tshipukane108, Andrés Obando-Valverde109, 
Mitsuhiro Okano110, Metin Onerci111, Yew Kwang Ong112, Richard Orlandi113, 
Nobuyoshi Otori114, Kheir Ouennoughy115, Muge Ozkan116, Aleksandar 
Peric117, Jan Plzak118, Emmanuel Prokopakis119, Nerayanan Prepageran120, 
Alkis Psaltis121, Benoit Pugin122, Marco Raftopulos1,123, Philippe Rombaux124, 
Herbert Riechelmann125, Semia Sahtout126, Caius-Codrut Sarafoleanu127, Kafui 
Searyoh128, Chae-Seo Rhee129, Jianbo Shi130, Mahdi Shkoukani131, Arthur K. 
Shukuryan132, Marian Sicak133, David Smyth134, Kornkiat Snidvongs135, Tanja 
Soklic Kosak136, Pär Stjärne137, Budi Sutikno138, Sverre Steinsvåg139, Pongsakorn 
Tantilipikorn140, Sanguansak Thanaviratananich141, Thuy Tran142, Jure Urbancic143, 
Arunas Valiulis144, Carolina Vasquez de Aparicio145, Dilyana Vicheva146, Paula 
M. Virkkula147, Gil Vicente148, Richard Voegels149, Martin Wagenmann150, Retno 
S. Wardani151, Antje Welge-Lussen152, Ian Witterick153, Erin Wright154, Dmytro 
Zabolotniy155, Bella Zsolt156, Casper P. Zwetsloot157
Rhinology Supplement 29: 
1 - 464, 2020
1. Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands
2. Royal National Throat, Nose and Ear Hospital, UCLH, London, United Kingdom
3. Ear, Nose and Throat Department, Guys and St. Thomas’ Hospital, London, United Kingdom
EPOS 2020
II
4. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, KU Leuven, Belgium
5. Department of Otorhinolaryngology - Head and Neck Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
6. Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
7. Department Hospital Quironsalud, University of Valencia, Valencia, Spain
8. Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain
9. Rhinology and Skull Base Unit, ENT Department, Hospital Clínic de Barcelona, Universidad de Barcelona, August Pi i Sunyer Biomedical Research Institute, Barce-
lona, Spain
10. Division of Otorhinolaryngology, Department of Ophthalmology, Otorhinolaryngology, Head and Neck Surgery, Ribeirao Preto Medical School-University of Sao 
Paulo, Sao Paulo, Brazil
11. Upper Airways Research Laboratory and ENT Department, University Hospital Ghent, Ghent, Belgium
12. Division of ENT Diseases, CLINTEC, Karolinska Institute, University of Stockholm, Stockholm, Sweden
13. Department of Otorhinolaryngology-Head and Neck Surgery, The University of Chicago Medicine and the Comer Children’s Hospital, Chicago, IL, USA
14. Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University, Hospital, Copenhagen, Denmark
15. Department of Otorhinolaryngology, Head and Neck Surgery, Royal Brisbane and Women’s Hospital; Faculty of Medicine, University of Queensland, Brisbane, 
Australia
16. 16. Department of Otorhinolaryngology - Head and Neck Surgery, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA
17. 1st Department of ORL, Head and Neck Surgery, Aristotle University, AHEPA Hospital, Thessaloniki, Greece
18. Rhinology and Plastic Surgery Unit, Otorhinolaryngology, Head and Neck Surgery and Pediatric ENT Department, CHU de Bordeaux, Hôpital Pellegrin, Centre F-X 
Michelet, Bordeaux, France
19. Department of ORL-HNS, Université de Montréal, Montreal, Canada
20. Dept of Respiratory Medicine and Allergology, Skane University in Lund, Sweden
21. Research Director Respiratory & Allergy, at QPS-Netherlands, Groningen, Netherlands
22. Affiliate to Charles University, Dept of Respiratory Diseases, in Prague, Czech Republic
23. Department of Surgery, The University of Auckland, Auckland, New Zealand
24. Department of Otorhinolaryngology, Ghent University, Ghent, Belgium
25. University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia
26. Rhinology and Skull Base Department, Applied Medical Research Centre, UNSW (Conjoint) and Macquarie University (Clinical), Sydney, Australia
27. Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
28. ENT Department, Zagreb School of Medicine; University Hospital Center “Sestre milosrdnice”, Zagreb, Croatia
29. Patient representative, Opuscomms, London, United Kingdom
30. Department of Inhalation Medicine, Observational Pragmatic Research Institute, Singapore
31. Rhinology-Olfactology Unit, Otorhinolaryngology Department, University Hospital of Geneva, Geneva, Switzerland
32. Medical Information Specialist, Medical Library, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands
33. Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium
34. FCS – UBI Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
35. Department of Pediatric Pneumology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
36. Department of Otorhinolaryngology, Head and Neck Surgery, Ankara University, Ankara, Turkey
37. Department of Otorhinolaryngology, Head and Neck Surgery, Salzburg Paracelsus Medical University, Salzburg, Austria
38. Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland
39. Department of Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom
40. ENT Department, James Paget University Hospital, Great Yarmouth, United Kingdom
41. Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom
42. Optimum Patient Care, Cambridgeshire, United Kingdom
43. Department of Otorhinolaryngology – Head and Neck Surgery, Medical University of South Carolina, Charleston, USA
44. UNC Otorhinolaryngology / Head and Neck Surgery, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery and Department of Neurosurgery, University 
of North Carolina School of Medicine, Chapel Hill, NC, USA
45. Division of Rhinology and Sinus/Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, 
Oregon, USA
46. Patient representative, Task Force Healthcare, WTC Den Haag, The Netherlands
EPOS 2020
III
47. Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Graz, Graz, Austria
48. Department of Otorhinolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
49. Rhinology Division, ENT Department; Eye and ENT Hospital, Fudan University, Shanghai, China
50. Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Beijing, China
51. Department of Medicine and Surgery in the University of Malta
52. ENT-Department, Lund University, Sweden
53. ENT Division, Surgery Department, College of Medicine and Health and Sciences, Sultan Qaboos University, Muscat, Oman
54. Department of Otorhinolaryngology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
55. Department of ENT, Medcare UAE, Dubai
56. ENT  Department, University Clinical Centre, University of Banja Luka, Bosnia and Herzegovina
57. ENT Department, King Saud University, Riyadh, Kingdom of Saudi Arabia
58. Department of Otorhinolaryngology, Jordan University of Science & Technology, Irbid, Jordan
59. Department of Otorhinolaryngology - Head and Neck Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia
60. Department of Otorhinolaryngology - Head and Neck Surgery, University of Sulaimani, Sulaimayniha, Iraq
61. Dept. of ORL-HNS Sisters of Mercy University Medical Center, School of Medicine University of Zagreb, Croatia
62. Department of Neurology, Leiden University Medical Center (LUMC), LEiden, the Netherlands
63. Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
64. Department of Otorhinolaryngology, Universidad de Antioquia, Medellín, Colombia
65. Department of Otorhinolaryngology, University Clinic of Munster, Germany
66. Department of Otorhinolaryngology, Omar Al-Moukhtar University, Albyeda, Libya
67. Department of Otorhinolaryngology - Head and Neck Surgery, Hillel Yaffe Medical Center, Israel
68. Department of Otorhinolaryngology, Medical University of Warsaw, Poland
69. Department of ENT, Makerere University, Kampala, Uganda
70. Department of Otorhinolaryngology, Pontificia Catholic University, Santiago, Chile
71. Department of Otorhinolaryngology, Head and Neck Surgery, Newcastle University, United Kingdom
72. Department of Otorhinolaryngology, Head and Neck Surgery, University of Ottawa,Toronto, Canada
73. Department of Otorhinolaryngology, Kilimanjaro Christian Medical University College, Moshi, Tanzania
74. Department of Otorhinolaryngology , La Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
75. ORL et Chirurgie Cervico-Faciale, Université Paris-Est Créteil (UPEC), France
76. Department of Otorhinolaryngology, American University of Beirut, Lebanon
77. Department of Otorhinolaryngology, Cairo University, Egypt
78. Department of ENT, CHU UCL Namur, Yvoir, Belgium
79. Department of Immunology and Allergy, The Persian Gulf Tropical Medicine Research Center; The Persian Gulf Biomedical Research Institute, Bushehr University of 
Medical Sciences, Bushehr, Iran
80. Department of Head and Neck, University of Milan, Italy
81. Department of ENT- Organs Microsurgery, Central city clinical hospital of lvano-Frankivsk city council, Ivano-Frankivsk, Ukraine
82. Department of Otorhinolaryngology, Head and Neck Surgery, University of Alabama Birmingham, USA
83. ENT Department, Centro Hospitalar de Entre Douro e Vouga, Santa Maria da Feira, Portugal
84. ENT Department, General Hospital, Pula, Pula, Croatia
85. Department of Otorhinolaryngology, University Kebangsaan, Kuala Lumpur, Malasyia
86. Department of ENT of Hospital de Clínicas, Facultad de Ciencias Médicas, Universidad Nacional de Asunción, Paraguay
87. Department of Otorhinolaryngology, Head and Neck Surgery, National University of Malaysia, Kuala Lumpur, Malaysia
88. Department ORLHNS, University Malaysia Sarawak, Kuching, Malaysia
89. Clinic of Ear, Nose, Throat and Eye diseases, Vilnius University, Lithuania
90. ENT Department of Medical Faculty, St Cyril and Methodius University of Skopje, North Macedonia
91. Department of Otorhinolaryngology, Head and Neck Surgery, Clinical Centre of Vojvodina, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
92. Department of ENT Surgery, Mulago National Referral Hospital Kampala, Uganda
93. Department of Otorhinolaryngology, Head and Neck Surgery, Cairo University, Egypt
94. ENT Department, Director of Saint Petersburg Research Institute of Ear, Throat , Nose and Speech; Professor and Chairman of First Pavlov State Medical University, 
EPOS 2020
IV
Saint Petersburg, Russia
95.  Department of Allergy and Clinical Immunology, Royal National ENT Hospital, London, United Kingdom
96. Department of Otorhinolaryngology, Shimane University, Matsue, Shimane, Japan
97. Department of Otorhinolaryngology, Head and Neck Surgery, University of Southern Denmark, Odense, Denmark
98. Center of Rhinology and Allergology, Wiesbaden, Hesse, Germany
99. Department of Otorhinolaryngology, Warsaw Medical University, Warsaw, Poland
100. Department of Otorhinolaryngology, University If Medicine, st. Ciril and Methodius, Skopje, North Macedonia 
101. Department of Otorhinolaryngology, Head and Neck Surgery, Kyung Hee University, Seoul, South Korea
102. Department of Otorhinolaryngology, Head and Neck Surgery, Mayo Clinic in Arizona, Phoenix, Arizona, USA
103. Department of Otorhinolaryngology, Pontifica Catholic University of Ecuador, Quito, Ecuador
104.  Department of Otorhinolaryngology, Policlinic No.1- Senior ENT Consultant and Surgeon; President of Russian Rhinologic Society, Moscow, Russia
105. Clinique Mahabi, Setif, Algeria
106. Department of Facial Surgery, Khodadoust Hospital, Ordibehesht Hospital, Shiraz, Iran
107.  Department of Otorhinolaryngology-Head and Neck Surgery, St. Cyril and Methodius, Skopje, Republic of North Macedonia
108. Department of Otorhinolaryngology, University of Kinshasa, Kinshasa, Democratic Republic of Congo
109. Department of Otorhinolaryngology and Surgery, Hospital Mexico, University of Costa Rica, San Jose, Costa Rica
110. Department of Otorhinolaryngology, International University of Health and Welfare, Narita , Japan
111. Department of Otorhinolaryngology, Hacettepe, Ankara, Turkey
112. Department of Otorhinolaryngology, Head and Neck Surgery, University of Singapore, National University Hospital, Singapore
113. Department of Otorhinolaryngology, University of Utah, Salt Lake City, Utah, USA
114. Department of Otorhinolaryngology at The Jikei University School of Medicine,Tokyo, Japan
115. Department of Otorhinolaryngology-Head and Neck Surgery, Saad Dahleb Blida 1, Blida, Algeria
116. Department of Otorhinolaryngology, University of Health Sciences, Ankara City Hospital, Turkey
117. Department of Otorhinolaryngology, Military Medical Academy, Faculty of Medicine, University of Defense, Belgrade, Serbia
118. Department of Otorhinolaryngology, Head and Neck Surgery, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
119. Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Crete, Greece
120. Department of ENT, University Malaya, Kuala Lumpur, Malaysia
121. Department of Otorhinolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia
122. Department of Health Sciences and Technology, ETH Zürich, Switzerland
123.  Royal Australian College of Surgeons, Trainee Representative (Australia)
124.  Department of Otorhinolaryngology, University of Louvain, Brussels, Belgium
125. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Ulm, Baden-Wurttemberg, Germany
126.  Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia
127.  ENT&H NS Department, Santa Maria Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
128.  Surgery Ear, Nose and Throat Unit, School of Medicine and Dentistry, University of Ghana,  Korle-Bu Teaching Hospital, Accra, Ghana
129.  Department of Otorhinolaryngology, Head and Neck Surgery, Seoul, Seoul National University, Seoul, Korea
130.  Department of Rhinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
131. Department of Otorhinolaryngology, Head and Neck Surgery, Cleveland Clinic Abu Dhabi, United Arab Emirates
132. Department of Otorhinolaryngology, Yerevan State Medical University, Yerevan, Armenia
133.  Department of Otorhinolaryngology, Head and Neck Surgery, Central Military Hospital, Slovakia, Slovak Health University Bratislava and Catholic University, Ruzom-
berok, Slovakia
134. Department of Otorhinolaryngology, Head and Neck Surgery, Royal College of Surgeons in Ireland and University College Cork, Waterford, Ireland
135.  Department of Otorhinolaryngology, Chulalongkorn University, Bangkok, Thailand
136. University Medical Centre Ljubljana, Department of Otorhinolaryngology and Cervicofacial Surgery,   University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
137.  Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden
138. Department of Otorhinolaryngology, Head and Neck Surgery, University of Airlangga, Surabaya, Indonesia
139. Department of ORL, University of Bergen, Norway
140. Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
141. Department of Otorhinolaryngology, University of Khonkaen , Khonkaen, Thailand
EPOS 2020
V
142.  Department of ENT Hospital of Ho Chi Minh city, Faculty of medicine of Ho Chi Minh city Vietnam National University, Vietnam
143.  Department of Otorhinolaryngology and cervicofacial surgery, UMC Ljubljana, University of Ljubljana, Medical Faculty, Ljubljana, Slovenia
144.  Department of Children’s diseases, Vilnius University Medical Faculty, Institute of Clinical Medicine, Vilnius, Lithuania
145.  Department of Paediatric Surgery, National Hospital Benjamin Bloom, National University of El Salvador, San Salvador, El Salvador
146. Department of Otorhinolaryngology, Medical University Plovdiv, Bulgaria
147. Department of Otorhinolaryngology, Head and Neck Surgery, Helsinki, University Hospital, Helsinki, Finland 
148. Department of Otolaryngology, St. Luke’s Medical Centre, Quezon City, The Philippines
149. Department of Otorhinolaryngology, University of Sao Paulo, Sau Paulo, Brazil
150. Department of Otorhinolaryngology, Dusseldorf University Hospital, Dusseldorf, Germany
151. Department of Otorhinolaryngology Head and Neck Surgery, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia
152. Department of Otorhinolaryngology, University Hospital Basel, University Basel, Switzerland
153. Department of Otorhinolaryngology, Head and Neck Surgery, University of Ottawa,Toronto, Canada
154.  Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
155. State Institution of O.S. Kolomiychenko Institute of Othorhnilarungology of National Academy of Medical Sciences of Ukraine, Kiev, Ukraine
156. Department of Otorhinolaryngology, Head and Neck Surgery, University of Szeged, Hungary
157. Department of Neurology, Dijklander Ziekenhuis, Purmerend, The Netherlands
EPOS 2020
VI
Summary
The European Position Paper on Rhinosinusitis and Nasal Polyps 2020  is the update of similar evidence based position papers 
published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and 
clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on 
the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and 
addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery. EPOS2020 also involves new 
stakeholders, including pharmacists and patients, and addresses new target users who have become more involved in the 
management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, 
specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using 
over the counter treatments. The document provides suggestions for future research in this area and offers updated guidance 
for definitions and outcome measurements in research in different settings.
EPOS2020 contains chapters on definitions and classification where we have defined a large number of terms and indicated 
preferred terms. A new classification of CRS into primary and secondary CRS and further division into localized and diffuse 
disease, based on anatomic distribution is proposed. There are extensive chapters on epidemiology and predisposing factors, 
inflammatory mechanisms, (differential) diagnosis of facial pain, allergic rhinitis, genetics, cystic fibrosis, aspirin exacerbated 
respiratory disease, immunodeficiencies, allergic fungal rhinosinusitis and the relationship between upper and lower airways. 
The chapters on paediatric acute and chronic rhinosinusitis are totally rewritten. All available evidence for the management 
of acute rhinosinusitis and chronic rhinosinusitis with or without nasal polyps in adults and children is systematically 
reviewed and integrated care pathways based on the evidence are proposed. Despite considerable increases in the amount 
of quality publications in recent years, a large number of practical clinical questions remain. It was agreed that the best way 
to address these was to conduct a Delphi exercise . The results have been integrated into the respective sections. Last but not 
least, advice for patients and pharmacists and a new list of research needs are included. 
The full document can be downloaded for free on the website of this journal: http://www.rhinologyjournal.com.
To cite this article: Fokkens W.J., Lund V.J. , Hopkins C., Hellings P.W., Kern R., Reitsma S., et al. European Position Paper on Rhino-
sinusitis and Nasal Polyps 2020 Rhinology. 2020 Suppl. 29: 1-464.
MeSH keywords: Paranasal Sinus Diseases, Nasal Polyps, Therapeutics, Diagnosis, Asthma, Prevention and Control
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1.1. Summary
The European Position Paper on Rhinosinusitis and Nasal Polyps 
2020  is the update of similar evidence based position papers 
published in 2005 and 2007 and 2012(1-3). The core objective of 
the EPOS2020 guideline is to provide revised, up-to-date and 
clear evidence-based recommendations and integrated care 
pathways in ARS and CRS. EPOS2020 provides an update on 
the literature published and studies undertaken in the eight 
years since the EPOS2012 position paper was published and 
addresses areas not extensively covered in EPOS2012 such 
as paediatric CRS and sinus surgery. EPOS2020 also involves 
new stakeholders, including pharmacists and patients, and 
addresses new target users who have become more involved 
in the management and treatment of rhinosinusitis since the 
publication of the last EPOS document, including pharmacists, 
nurses, specialised care givers and indeed patients themselves, 
who employ increasing self-management of their condition 
using over the counter treatments. The document provides 
suggestions for future research in this area and offers updated 
guidance for definitions and outcome measurements in 
research in different settings.
EPOS2020 contains chapters on definitions and classification 
where we have defined a large number of terms and indicated 
preferred terms. A new classification of CRS into primary and 
secondary CRS and further division into localized and diffuse 
disease, based on anatomic distribution is proposed. There 
are extensive chapters on epidemiology and predisposing 
factors, inflammatory mechanisms, (differential) diagnosis 
of facial pain, allergic rhinitis, genetics, cystic fibrosis, aspirin 
exacerbated respiratory disease, immunodeficiencies, allergic 
fungal rhinosinusitis and the relationship between upper and 
lower airways. The chapters on paediatric acute and chronic 
rhinosinusitis are totally rewritten. All available evidence 
for the management of acute rhinosinusitis and chronic 
rhinosinusitis with or without nasal polyps in adults and children 
is systematically reviewed and integrated care pathways based 
on the evidence are proposed. Despite considerable increases 
in the amount of quality publications in recent years, a large 
number of practical clinical questions remain. It was agreed that 
the best way to address these was to conduct a Delphi exercise 
which is a structured communication technique, originally 
developed as a systematic, interactive forecasting method 
which relies on a panel of experts. The EPOS2020 group firstly 
prioritised the areas for consideration as a result of which we 
have concentrated on diagnostic issues in the first instance. The 
results have been integrated into the respective sections. Last 
but not least, advice for patients and pharmacists and a new list 
of research needs are included.
1.2. Classification, definitions and terminology     
1.2.1. Introduction
Rhinosinusitis is a common condition in most of the world, 
leading to a significant burden on society in terms of healthcare 
consumption and productivity loss(4-7). Acute rhinosinusitis 
(ARS) has a one-year prevalence of 6-15% and is usually the 
consequence of a viral common cold. ARS is usually a self-
limiting disease but serious complications leading to life 
threatening situations and even death have been described(8). 
It is one of the most common reasons for prescription of 
antibiotics and proper management is extremely pertinent in 
the context of the global crisis of resistance to antibiotics(9). 
Chronic rhinosinusitis (CRS) is a significant health problem and 
affects 5-12% of the general population. The major definitions 
are summarized here. For more definitions please refer to 
chapter 2.
1.2.2. Clinical definition of rhinosinusitis
1.2.2.1. Clinical definition of rhinosinusitis in adults
Rhinosinusitis  in adults is defined as:
 • inflammation of the nose and the paranasal sinuses 
characterised by two or more symptoms, one of which 
should be either nasal blockage / obstruction / congestion 
or nasal discharge (anterior / posterior nasal drip):
± facial pain/pressure 
± reduction or loss of smell 
and either
 • endoscopic signs of:
- nasal polyps, and/or
- mucopurulent discharge primarily from middle meatus and/
or
- oedema / mucosal obstruction primarily in middle meatus 
and/or
 • CT changes:
- mucosal changes within the ostiomeatal complex and/or 
sinuses 
1.2.2.2. Clinical definition of rhinosinusitis in children
Paediatric rhinosinusitis is defined as:
 • presence of two or more symptoms one of which should 
be either nasal blockage / obstruction / congestion or nasal 
discharge (anterior / posterior nasal drip):
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± facial pain/pressure
± cough 
and either
 • endoscopic signs of:
- nasal polyps, and/or
- mucopurulent discharge primarily from middle meatus and/
or
-oedema / mucosal obstruction primarily in middle meatus
and/or
• CT changes:
-mucosal changes within the ostiomeatal complex and/or 
sinuses 
1.2.2.3. Definition of CRS epidemiology studies and General 
Practice
For epidemiological studies and general practice, the definition 
of CRS is based on symptomatology usually without ENT 
examination or radiology. We are aware that this will give an 
over estimation of the prevalence due to overlap with allergic 
and non-allergic rhinitis(56-58).
1.2.2.4. Acute rhinosinusitis (ARS) in adults
Acute rhinosinusitis in adults is defined as: 
sudden onset of two or more symptoms, one of which should be 
either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip):
• ± facial pain/pressure 
• ± reduction or loss of smell
for <12 weeks; 
with symptom free intervals if the problem is recurrent, with 
validation by telephone or interview.
1.2.2.5. Acute rhinosinusitis in children
Acute rhinosinusitis in children is defined as: 
sudden onset of two or more of the symptoms:  
 • nasal blockage/obstruction/congestion 
 • or discoloured nasal discharge
 • or cough (daytime and night-time) 
for < 12 weeks; 
with symptom free intervals if the problem is recurrent; 
with validation by telephone or interview.
Questions on allergic symptoms (i.e. sneezing, watery 
rhinorrhoea, nasal itching, and itchy watery eyes) should be 
included.
1.2.2.5. Recurrent acute rhinosinusitis (RARS)
ARS can occur once or more than once in a defined time period. 
This is usually expressed as episodes/year but with complete 
resolution of symptoms between episodes.
Recurrent ARS (RARS) is defined as ≥ 4 episodes per year with 
symptom free intervals(42,78).
1.2.2.6. Definition of chronic rhinosinusitis in adults 
Chronic rhinosinusitis (with or without nasal polyps) in adults is 
defined as: 
presence of two or more symptoms, one of which should 
be either nasal blockage / obstruction / congestion or nasal 
discharge (anterior / posterior nasal drip): 
 • ± facial pain/pressure; 
 • ± reduction or loss of smell; 
for ≥12 weeks; 
with validation by telephone or interview.
Figure 1.2.1. Classification of primary CRS (Adapted from Grayson et al(154))
AFRS, allergic fungal rhinosinusitis; CCAD, central compartment allergic disease; CRSwNP, chronic rhinosinusitis with nasal polyps;
eCRS, eosinophilic CRS. 
Primary CRS
Anatomic distribution Endotype dominance Examples of phenotypes
Localized
(unilateral)
Diffuse
(bilateral)
Type 2
Non-type 2
Type 2
Non-type 2
Isolated sinusitis
eCRS
CRSwNP 
AFRS
CCAD
Non-eCRS
AFRS
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Questions on allergic symptoms (i.e. sneezing, watery 
rhinorrhoea, nasal itching, and itchy watery eyes) should be 
included.
1.2.2.7. Definition of chronic rhinosinusitis in children 
Chronic rhinosinusitis (with or without nasal polyps) in children 
is defined as: 
presence of two or more symptoms one of which should 
be either nasal blockage / obstruction / congestion or nasal 
discharge (anterior/posterior nasal drip): 
 • ± facial pain/pressure;  
 • ± cough; 
for ≥12 weeks; 
with validation by telephone or interview.
1.2.2.8. Definition of difficult-to-treat rhinosinusitis
This is defined as patients who have persistent symptoms of 
rhinosinusitis despite appropriate treatment (recommended 
medication and surgery). Although the majority of CRS patients 
can obtain control, some patients will not do so even with 
maximal medical therapy and surgery. 
Patients who do not reach an acceptable level of control despite 
adequate surgery, intranasal corticosteroid treatment and up 
to two short courses of antibiotics or systemic corticosteroids 
in the last year can be considered to have difficult-to-treat 
rhinosinusitis. 
No changes have been made compared to EPOS2012 in the 
definition of severity or in acute versus chronic(3). For acute 
rhinosinusitis the term ARS comprises viral ARS (common cold) 
and post-viral ARS. In EPOS2007, the term ‘non-viral ARS’ was 
chosen to indicate that most cases of ARS are not bacterial. 
However, this term apparently led to confusion and for that 
reason we decided in EPOS2012 to choose the term ‘post-viral 
ARS’ to express the same phenomenon. A small percentage 
of the patients with post-viral ARS will have acute bacterial 
rhinosinusitis (ABRS).Chronic rhinosinusitis has traditionally 
been classified into chronic rhinosinusitis with nasal polyps 
(CRSwNP) and without nasal polyps (CRSsNP). CRSwNP: chronic 
rhinosinusitis as defined above and bilateral, endoscopically 
visualised polyps in middle meatus; and CRSsNP: chronic 
rhinosinusitis as defined above and no visible polyps in middle 
meatus, if necessary following decongestant. 
This definition accepts that there is a spectrum of disease 
in CRS which includes polypoid change in the sinuses and/
or middle meatus but excludes those with polypoid disease 
presenting in the nasal cavity to avoid overlap. Moreover, 
it has become progressively clear that CRS is a complex 
disease consisting of several disease variants with different 
underlying pathophysiologies(10,11). The phenotypes do not 
provide full insight into all underlying cellular and molecular 
pathophysiologic mechanisms of CRS which becomes 
increasingly relevant because of the variable association with 
comorbidities such as asthma and responsiveness to different 
treatments including corticosteroids, surgery and biological 
agents(12-15). Better identification of endotypes might permit 
individualization of therapy that can be targeted against the 
pathophysiologic processes of a patient’s endotype, with 
potential for more effective treatment and better patient 
outcomes.
1.2.3. Classification of CRS
The EPOS2020 steering group has chosen to look at CRS in terms 
Figure 1.2.2. Classification of secondary CRS (Adapted from Grayson et al(154)).
CF, cystic fibrosis; EGPA, eosinophilic granulomatosis with polyangiitis (Churg-Strauss disease); GPA, granulomatosis with polyangiitis (Wegener’s 
disease); PCD, primary ciliary dyskinesia.
Secondary CRS
Anatomic distribution Endotype dominance Examples of phenotypes
Localized
(unilateral)
Diuse
(bilateral)
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Mechanical
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ammatory
Immunity
PCD
CF
GPA
EGPA
Selective 
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of primary and secondary (Figures 1.2.1. and 1.2.2.) and to divide 
each into localized and diffuse disease based on anatomic 
distribution. In primary CRS, the disease is considered by 
endotype dominance, either type 2 or non-type 2 (see 1.5.2.2.).
Clinically localized primary CRS is then subdivided into two 
phenotypes – allergic fungal rhinosinusitis (AFRS) or an 
isolated sinusitis. For diffuse CRS, the clinical phenotypes 
are predominantly eCRS and non-eCRS, determined by the 
histologic quantification of the numbers of eosinophilic, i.e. 
number/high powered field which the EPOS panel agreed to be 
10/hpf (400x) or higher.
For secondary CRS, again, the division is into localized or diffuse 
and then considered by four categories dependant on local 
pathology, mechanical, inflammatory and immunological 
factors. Thence a range of clinical phenotypes are included as 
shown.
There has been some discussion about a possible umbrella 
term of ‘eosinophilic fungal rhinosinusitis’ but it was agreed that 
‘allergic’ fungal rhinosinusitis should be retained as the principle 
term due to common usage, recognising that not all cases have 
evidence of an allergic reaction to fungi e.g. a positive skin prick 
and/or specific IgE (see also chapter 8.6).
1.2.4. Other consensus terms related to treatment 
From the many terms used regarding the sufficiency of medical 
treatment prior to surgery, ‘appropriate medical therapy’ 
is the preferred option of EPOS2020. Other decisions were 
the preferential use of the terms ‘irrigation’ or ‘rinsing’ when 
using saline therapy and with respect to duration of antibiotic 
courses, the EPOS panel also agreed that four weeks or less 
would be ‘short-term’, accepting that in general practice the 
duration is usually <10 days, and >4 weeks would be regarded 
as ‘long-term’. It was also acknowledged that the aim of 
short-term treatment was different from long-term in that 
short-term courses are generally given for significant acute 
bacterial infection whereas long term courses are given for 
their immunomodulatory properties. Immunomodulation 
encompasses all therapeutic interventions aimed at modifying 
the immune response and is the preferred over-riding term by 
EPOS2020. In the treatment of rhinosinusitis, it encompasses the 
use of biological agents and macrolides as above.
With respect to surgery, functional implies restitution of 
physiology and is usually, though not exclusively, applied to 
endoscopic sinus surgery. It should fulfil the following criteria:
• Creates a sinus cavity that incorporates the natural ostium;
• Allows adequate sinus ventilation;
• Facilitates mucociliary clearance;
• Facilitates instillation of topical therapies.
In contrast, a ‘Full FESS’ is defined as complete sinus opening 
including anterior and posterior ethmoidectomy, middle 
meatal antrostomies (likely large), sphenoidotomy and frontal 
opening (e.g. Draf IIa ).Extended endoscopic surgery is used 
in the same context as ‘full’ (e.g. Draf III) but could also include 
Figure 1.2.3. Assessment of current clinical control of CRS.
Controlled
(all of the following)
Partly controlled
(at least 1 present)
Uncontrolled
(3 or more present)
Nasal blockage1
Rhinorrhoea / Postnasal drip1
Facial pain / Pressure1
Smell1
Sleep disturbance or fatigue1
Nasal endoscopy 
(if available)
Rescue treatment 
(in last 6 months)
EPOS 2020: Assessment of current clinical control of CRS (in the last month)
1 Symptoms of CRS;   2 For research VAS ≤ 5;   3 For research VAS > 5;   4 Showing nasal polyps, mucopurulent secretions or inamed mucosa  
Not present or not bothersome2
Not present 
or not bothersome2
Little and mucous2
Normal 
or only slightly impaired2
Not present2
Healthy 
or almost healthy mucosa
Not needed
Present 
on most days of the week3
Present 
on most days of the week3
Mucopurulent 
on most days of the week3
Impaired3
Present3
Impaired3
Present3
Present 
on most days of the week3
Present 
on most days of the week3
Mucopurulent 
on most days of the week3
Diseased mucosa4 Diseased mucosa4
Need of 1 course of 
rescue treatment
Symptoms (as above) persist 
despite rescue treatment(s)
CRS, chronic rhinosinusitis; VAS, visual analogue scale.
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extension beyond the confines of sinuses i.e. skull base, orbit, 
pterygopalatine and infratemporal fossa. Finally, radical also 
includes significant removal of inflamed / dysfunctional mucosa.
1.2.5. Control of disease
In EPOS2012 we introduced the concept of control(3). The 
primary goal of any treatment, especially in chronic diseases, is 
to achieve and maintain clinical control, which can be defined 
as a disease state in which the patient does not have symptoms, 
or the symptoms are not impacting quality of life. In the last 
decade some studies have been performed that attempted to 
validate the EPOS2012 proposed measurement of control(15-17). 
Based on these validation studies, the EPOS2020 steering 
group thinks that the current EPOS2012 control criteria might 
overestimate the percentage of patients being uncontrolled. For 
research purposes we, therefore, recommend using a VAS scale 
for all symptoms: “not bothersome” can be substituted by ‘VAS ≤ 
5’, and ‘present / impaired’ by ‘VAS > 5’. Furthermore, we want to 
make sure that the symptoms are related to CRS and included 
that in the table. For example, a typical migraine headache 
should not be taken into account when evaluating control 
in CRS. The results of the validation studies also still require 
further psychometric validation (including internal consistency, 
responsiveness and known group differences) (Figure 1.2.3.).
Given the importance of the concept of disease control, from a 
clinical as well as from a research perspective, there still remains 
a need for a gold standard to assess disease control in CRS. 
1.2.6. Acute exacerbation of chronic rhinosinusitis (AECRS)
Acute exacerbation of chronic rhinosinusitis (AECRS) is defined 
as worsening of symptom intensity with return to baseline CRS 
symptom intensity, often after intervention with corticosteroids 
and/or antibiotics. The prevalence varies with the patient cohort 
being studied, season, and how the exacerbation was defined.
The precise aetiology of acute exacerbation of CRS is still unclear 
and is likely to be multifactorial. The role of bacterial infection 
may have been over-emphasised in the past. Certainly, there is 
a lack of bacterial airway pathogens identified in the majority 
of patients with exacerbation. It is possible that since many of 
these patients have had sinus surgery in the past, postoperative 
changes in the microbiome create a new microbial environment 
and other pathogens are in play. Microbial dysbiosis in the form 
of an altered balance of the bacterial flora rather than a single 
pathogen may elicit a host inflammatory response. 
Virus infections are perhaps more likely to be a key cause of 
exacerbation of CRS, especially with increasing evidence that 
rhinovirus infection can drive eosinophilic inflammation and 
a focus on prevention and management of virus infections 
may be more effective than treating secondary infections with 
antibiotics and eosinophilic flare ups with corticosteroids. 
However, this remains to be further investigated. 
Firm scientific evidence is still lacking on therapy of AECRS and 
only treatment recommendations based on clinical experience 
and expert opinion are available. However, due to the cyclic 
and self-limiting nature of AECRS one should be mindful of the 
‘regression to the mean phenomena’. A patient is more likely to 
seek treatment when they are at their worst, the likelihood of 
improvement is high regardless of treatment, which may distort 
the doctor’s clinical experience as well as rendering clinical 
trials lacking a placebo arm rather meaningless. In spite of this 
confounder, it is likely that steroids and antibiotics will remain 
the mainstay of treatment for the foreseeable future even 
though the role of antibiotics in the treatment of AECRS is not 
supported by the literature (see chapter 1.6 and 6.1).
Figure 1.3.1. Prevalence of cardinal symptoms of CRS (25, 26).
CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps.
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1.3. Burden of acute and chronic rhinosinusitis      
Chapter 3 covers the burden of rhinosinusitis, its impact on 
quality of life and the costs, both direct and indirect. 
1.3.1. Quality of life (QOL)
Both ARS and CRS are associated with significant adverse effects 
on quality of life using a variety of validated questionnaires 
including the general health Eq-5D(18, 19) and SF36(20, 21) and 
more rhinologic-specific SNOT16(22) and SNOT 22(23). Chronic 
rhinosinusitis produces greater quality of life impairment than 
acute(24). Gliklich and Metson first demonstrated the impact 
of CRS on global quality of life, finding that CRS had a greater 
impact on social functioning than angina or chronic heart 
failure(20). More recently, they have shown that health utility 
values, measured using the EQ-5D, were lower than the general 
population, and comparable to other chronic diseases such as 
asthma(19).
In CRS, the ‘cardinal’ symptoms are nasal obstruction or 
congestion, nasal discharge (which can be anterior or posterior), 
alteration in sense of smell and facial pain and pressure. These 
may vary in prevalence between unselected patients in primary 
care, CRS patients in the general population, in an outpatient 
setting and those undergoing surgery and in severity between 
those seen in outpatients and those undergoing surgery (Figure 
1.3.1).
Nasal obstruction and alteration in sense of smell and taste are 
both the most severe and prevalent symptoms in CRSwNP, while 
in CRSsNP, nasal obstruction is again the most severe, with facial 
pain and nasal discharge reported as equally severe as altered 
smell and taste(25, 26) (Figure 1.3.2.). In patients presenting to 
ENT clinics, the presence of cardinal symptoms has a positive 
predictive value of 39.9, with high sensitivity  but low specificity 
for a diagnosis of CRS(27). 
The overall severity rating of symptoms is obviously highly 
dependent upon the population being studied. Patients in 
secondary care awaiting surgery report mean symptom severity 
scores in the moderate to severe range, with a mean SNOT-22 
score of 42.0 compared with a control group where a mean 
score of 9.3 was reported(23). CRSsNP patients had higher pre-
operative baseline scores (44.2) compared with CRSwNP (41.0).
1.3.2.  Costs of rhinosinusitis
Health care spending is significantly greater in rhinosinusitis 
than in other diseases such as peptic ulcer disease, acute 
asthma, and hay fever(28).  In the USA, the direct costs for the 
management of CRS are now between $10 and $13 billion 
per year, or $2609 per patient per year. In Europe, Wahid et 
al. reported 2974 GBP on costs for primary and secondary 
care extrapolated for a year period compared to 555 GBP 
in the control group and 304 versus 51 GBP out-of-pocket 
expenditure(29). Lourijsen et al. found yearly direct costs of 1501 
euro per year in a group of patients with CRSwNP(30). Overall 
CRS leads to an incremental direct healthcare expenditure of 
2500 euro per patient per year. The highest direct costs were 
associated with patients who had recurrent polyposis after 
surgery(31). However, whilst surgery is expensive, varying from up 
to $11,000 in USA to $1100 in India(32-34), it results in a decrease in 
direct costs in the subsequent two post-operative years(35). 
The indirect costs of rhinosinusitis are much greater than the 
direct costs. Since 85% of patients with rhinosinusitis are of 
working age (range: 18-65 years old), indirect costs such as 
missed workdays (absenteeism) and decreased productivity at 
work (presenteeism) significantly add to the economic burden 
Figure 1.3.2. Severity of cardinal symptoms of CRS. (25, 26)
CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps.
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Therapy
Level of 
evidence
GRADE recommendation
Antibiotics 1a (-) There is no evidence of benefit from antibiotics for the common cold or for persisting acute purulent 
rhinitis in children or adults. There is evidence that antibiotics cause significant adverse effects in adults 
when given for the common cold and in all ages when given for acute purulent rhinitis. Routine use of 
antibiotics for these conditions is not recommended.
Nasal corticosteroid 1a (-) The current evidence does not support the use of nasal corticosteroids for symptomatic relief from the 
common cold
Antihistamines 1a Antihistamines have a limited short-term (days 1 and 2 of treatment) beneficial effect on severity of over-
all symptoms in adults but not in the mid to long term. There is no clinically significant effect on nasal 
obstruction, rhinorrhoea or sneezing
Decongestant  (oral / nasal) Ia The current evidence suggests that multiple doses of decongestants may have a small positive effect on 
subjective measures of nasal congestion in adults with the common cold. Decongestants do not seem to 
increase the risk of adverse events in adults in the short term.
Paracetamol 
(Acetaminophen)
Ia Paracetamol may help relieve nasal obstruction and rhinorrhoea but does not appear to improve other cold 
symptoms (including sore throat, malaise, sneezing and cough)
 NSAIDs Ia NSAIDs do not significantly reduce the total symptom score, or duration of colds. However, for outcomes 
related to the analgesic effects of NSAIDs (headache, ear pain and muscle and joint pain) NSAIDs produce 
significant benefits, and malaise shows a borderline benefit, although throat irritation is not improved. Chills 
show mixed results. For respiratory symptoms, cough and nasal discharge scores are not improved, but the 
sneezing score is significantly improved. There is no evidence of increased frequency of adverse effects in 
the NSAID treatment groups. 
Antihistamine-decongestant-
analgesic combinations
Ia Antihistamine-analgesic-decongestant combinations have some general benefit in adults and older 
children with common cold. These benefits must be weighed against the risk of adverse effects. There is no 
evidence of effectiveness in young children.
Ipratropium bromide Ia The existing evidence suggests that ipratropium bromide is likely to be effective in ameliorating 
rhinorrhoea. Ipratropium bromide has no effect on nasal congestion and its use is associated with more 
side effects compared to placebo or no treatment although these appeared to be well tolerated and self-
limiting.
Nasal irrigation with saline Ib Nasal saline irrigation possibly has benefits for relieving the symptoms of acute URTIs mainly in children and 
is considered an option by the EPOS steering group.
Steam / heated humidified air 1a (-) The current evidence does not show any benefits or harms from the use of heated, humidified air delivered 
for the treatment of the common cold.
Probiotics Ia Probiotics may be more beneficial than placebo for preventing acute URTIs. However, the quality of the 
evidence was (very) low.
Vitamin C Ia Given the consistent effect of vitamin C on the duration and severity of colds in regular supplementation 
studies, and the low cost and safety, it may be worthwhile for common cold patients to test on an 
individual basis whether therapeutic vitamin C is beneficial for them.
Vaccines 1b (-) There are no conclusive results to support the use of vaccines for preventing the common cold in healthy 
people. This is in contrast to influenza vaccines.
Exercise Ia Regular, moderate-intensity exercise may have an effect on the prevention of the common cold.
Echinacea 1a (-) Echinacea products have not been shown to provide benefits for treating colds, although, there could be 
a weak benefit from some Echinacea products: the results of individual prophylaxis trials consistently show 
positive (if non-significant) trends, although potential effects are of questionable clinical relevance.
Zinc Ia Zinc administered as zinc acetate or zinc gluconate lozenges at a dose of >=75 mg/day and taken 
within 24 hours of onset of symptoms significantly reduces the duration of common cold. For those 
considering using zinc it is advised to use it at this dose throughout the cold. Regarding prophylactic zinc 
supplementation, currently no firm recommendation can be made because of insufficient data.
Herbal medicine (excluding 
Echinacae)
Ib Some herbal medicines like BNO1016, Cineole and Andrographis paniculata SHA-10 extract have significant 
impact on symptoms of common cold without important adverse events. A formal systematic review is 
missing.
Fusafungine Ia Fusafungine is an effective treatment of common cold especially when administered early. However, 
serious allergic reactions involving bronchospasm although rare have occurred after the use of fusafungine. 
For that reason, the medication is no longer on the market.
Table 1.4.1. Treatment evidence and recommendations for adults and children with acute viral rhinosinusitis (common cold)*.
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Table 1.4.2. Treatment evidence and recommendations for adults with acute post-viral rhinosinusitis.
Therapy
Level of 
evidence
GRADE recommendation
Antibiotics 1a (-) There is no benefit from prescribing antibiotics for post viral ARS in adults. There is no effect on 
cure or duration of disease and there are more adverse events. Based on the moderate level of 
evidence and the fact that acute post-viral rhinosinusitis is a self-limiting disease, the EPOS2020 
steering group advises against the use of antibiotics for adults in this situation.
Nasal corticosteroids 1a Nasal corticosteroids are effective in reducing total symptom score in adults suffering from 
acute post-viral rhinosinusitis. However, the effect is small. Nasal corticosteroids have not been 
shown to have an effect on QOL. Acute post-viral rhinosinusitis is a self-limiting disease. Based 
on the moderate quality of the evidence and the small effect size the EPOS2020 steering group 
advises only to prescribe a nasal corticosteroid when reduction of the symptoms of the acute 
post-viral rhinosinusitis is considered necessary.
Systemic corticosteroids 1a Systemic corticosteroids, with or without antibiotics do not have a positive effect on recovery 
at 7-14 days. There is a small but significant effect of systemic corticosteroids versus placebo 
on facial pain at days 4-7 after start of the treatment. There are no studies comparing systemic 
corticosteroids to nasal corticosteroids. The quality of the evidence is low. Based on the 
evidence, the numbers needed to treat and the potential harm of systemic corticosteroids, 
the EPOS2020 steering group advises against the use of systemic corticosteroids in patients 
suffering from acute post-viral rhinosinusitis.
Decongestant  (oral / nasal) Ib Nasal decongestants may be effective in improving mucociliary clearance throughout the 
acute phase of the disease. No studies have been performed evaluating the effect on resolution 
or reduction of symptoms of postviral ARS. Based on the absence of clinically relevant data, 
the EPOS2020 steering group cannot advise on the use of decongestants in acute post-viral 
rhinosinusitis.
Nasal irrigation with saline Ib One small study did not find a difference between saline nasal spray versus no treatment. 
One very small study found a larger effect of high volume versus low volume saline rinsing 
on purulent rhinorrhoea and post-nasal drip. Based on the very low quality of the evidence 
no strong advice can be given about the use of nasal saline irrigation although on theoretical 
grounds saline can be expected to be beneficial rather than harmful.
Homeopathy Ib We found one study evaluating the effect of homeopathy (sinfrontal) showing a significant 
reduction of symptoms and radiographic improvement versus placebo. Based on the limited 
evidence the EPOS2020 steering group cannot give clear advice on the use of homeopathy in 
acute post-viral rhinosinusitis.
Herbal medicine Ib Some herbal medicines like BNO1016 tablets and Pelargonium sidoides drops  and Myrtol 
(and other essential oil) capsules have significant impact on symptoms of acute postviral 
rhinosinusitis without significant adverse events. 
ARS, acute rhinosinusitis; QOL, quality of life.
Table 1.4.3. Treatment evidence and recommendations for children with acute post-viral rhinosinusitis.
Therapy
Level of 
evidence
GRADE recommendation
Antibiotics 1a (-) The use of antibiotics in children with acute post-viral rhinosinusitis is not associated with greater 
cure/significant improvement.  Based on the moderate level of evidence and the fact that acute 
post-viral rhinosinusitis is a self-limiting disease, the EPOS2020 steering group advises against the 
use of antibiotics for children in this situation.
Nasal corticosteroids 1a Nasal corticosteroids seem to be effective in reducing total symptom score in children 
suffering from acute post-viral rhinosinusitis on top of (ineffective) antibiotics. Acute post-
viral rhinosinusitis is a self-limiting disease. Based on the very low quality of the evidence the 
EPOS2020 steering group cannot advise on the use of nasal corticosteroids in children with acute 
post-viral rhinosinusitis.
Antihistamines 1b (-) There is one study evaluating antihistamines versus placebo in addition to (ineffective) antibiotics 
in children with post-viral ARS showing no additive effect of antihistamines over the treatment 
given. Based on the very low quality of the evidence, the EPOS2020 steering group cannot advise 
on the use of antihistamines in post-viral ARS.
Bacterial lysates Ib One study has shown benefit in the use of OM-85-BV for shortening the duration of illness. 
ARS, acute rhinosinusitis.
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of the disease(35). As a consequence, rhinosinusitis is one of the 
top 10 most costly health conditions to US employers(36). Overall, 
the total indirect costs of CRS were estimated to be in excess of 
$20 billion per year in the USA(37) mainly due to presenteeism.
1.4. Acute rhinosinusitis including common cold 
and recurrent ARS in adults and children
Chapter 4 describes the epidemiology, pathophysiology, 
diagnosis and differential diagnosis, and management of ARS in 
adults and children. Also, a new integrated care pathway based 
on all the evidence is proposed.
1.4.1. Epidemiology
In EPOS2012 the division of ARS into viral ARS (common cold), 
post-viral ARS and ABRS (acute bacterial rhinosinusitis) was 
proposed. In the last decade studies have been performed using 
this classification. In a recent Dutch paper using the GA2LEN 
questionnaire a prevalence of 18%  (17-21%) was found  for 
symptoms pointing to post-viral ARS in three different cities 
in the Netherlands(38).  ABRS is a rare disease with an incidence 
of 0.5-2%  of  viral ARS (common cold)(2, 39). RARS is defined as 
≥ 4 episodes per year with symptom free intervals(40-43). Each 
episode must meet the criteria for acute post-viral (or bacterial) 
rhinosinusitis. The EPOS2020 steering group advises to have at 
least one proven diagnosis of post-viral ARS with endoscopy 
and/or CT scan before a diagnosis of RARS is considered.
1.4.2. Predisposing factors for ARS and RARS
Predisposing factors for ARS are seldom evaluated. There is 
some indication that anatomical abnormalities may predispose 
to recurrent acute rhinosinusitis (RARS)(44-47). Active and passive 
smoking predisposes to ARS and there is some evidence that 
concomitant chronic disease may increase the chance of getting 
ARS following an influenza infection(48-50). 
Other potential factors like allergy and GORD do not seem to 
Figure 1.4.1. Integrated care pathway of acute rhinosinusitis.
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predispose to ARS(51, 52).  
1.4.3. Pathophysiology of ARS
The pathophysiology of ARS is systematically evaluated, 
again trying to organize the literature based on the different 
categories of ARS. Since EPOS2012, there have been increasing 
experimental data supporting the fact that nasal epithelium is 
the primary portal of entry for respiratory viruses as well as an 
active component of initial host responses against viral infection. 
The cascade of inflammation initiated by nasal epithelial cells 
will lead to damage by the infiltrating cells, causing oedema, 
engorgement, fluid extravasation, mucus production and 
sinus obstruction in the process, eventually leading to ARS or 
exacerbating ARS (see chapter 4.2.).
1.4.3. Diagnosis and differential diagnosis of ARS in adults 
and children
Post-viral ARS is a common condition in the community, usually 
following viral URTI. Most acute viral URTI infections are self-
limiting, thus post-viral ARS should not be diagnosed before       
10 days’ duration of symptoms unless there is a clear worsening 
of symptoms after five days.
Subjective assessment should take into account the severity 
and the duration of symptoms (see above). The recommended 
method of assessing severity of symptoms is with a visual 
analogue scale (VAS) recorded by the patient on a 10cm line 
giving a score on a measurable continuum of 1 to 10. 
Bacterial infection may occur in ARS, but in most cases anti-
biotics have little effect on the course of the illness (see 1.4.5.).
A number of studies have attempted to provide clinicians with 
combinations of symptoms and signs predicting more severe 
disease, particularly of a bacterial infection and the likelihood 
of a response to antibiotics(53). The EPOS2020 steering group 
decided to maintain suggestions made in the earlier EPOS 
versions: at least three of five symptoms of discoloured 
discharge, severe local pain, fever, elevated ESR/CRP and 
double sickening.   
1.4.5. Treatment of ARS in adults and children
For EPOS2020 a systematic review was performed evaluating 
treatment of the different categories of ARS (viral, post-viral or 
ABRS) separately. For acute viral rhinosinusitis we found many 
excellent systematic reviews and report on them. For post-viral 
rhinosinusitis and ABRS a systematic review of the literature 
has been performed for children and adults. The different 
treatments, levels of evidence and GRADE recommendations are 
reported in Tables 1.4.1-1.4.5. For medication not mentioned in 
these tables, we could not find RCTs. 
Table 1.4.4. Treatment evidence and recommendations for adults with acute bacterial rhinosinusitis (ABRS).
Therapy
Level of 
evidence
GRADE recommendation
Antibiotics 1a Antibiotics are effective in a select group of patients with symptoms and signs suggestive of ABRS. From the limited 
data available (two studies versus one) it seems that amoxicillin/penicillin (beta-lactams) especially are effective 
and moxifloxacin (fluoroquinone) is not. The efficacy of beta-lactams is evident at day three where patients 
already experience better symptom improvement and continues with a higher number of cures at completion of 
treatment. However, careful patient selection for those with ABRS is needed to avoid unnecessary use of antibiotics 
and side effects.
Antihistamines 1b (-) There is one study evaluating antihistamines versus placebo in adults with allergic rhinitis and ABRS showing no 
effect. Based on the very low quality of the evidence, the EPOS2020 steering group cannot advise on the use of 
antihistamines in post-viral ARS and ABRS.
Nasal irrigation with 
saline
1b (-) One study comparing hypertonic saline nasal spray, isotonic saline nasal spray and no treatment in addition to 
antibiotics did not find a difference between the groups. Based on the very low quality of the evidence no advice 
can be given about the use of nasal saline irrigation.
Sodium Hyaluronate Ib One study evaluating sodium hyaluronate compared to placebo in a nebulizer ampoule for nasal douching in 
addition to levofloxacin and prednisone showed significantly fewer symptoms and better smell threshold in the  
sodium hyaluronate group. Based on the very low quality of the evidence no advice can be given about the use of 
sodium hyaluronate.
ABRS, acute bacterial rhinosinusitis; ARS, acute rhinosinusitis.
Table 1.4.5. Treatment evidence and recommendations for children with acute bacterial rhinosinusitis (ABRS).
Therapy
Level of 
evidence
GRADE recommendation
Antibiotics 1a (-) Data on the effect of antibiotics on the cure/improvement of symptoms in ABRS in children are very limited. There 
are only two studies with limited numbers that do not show a significant difference over placebo but do show a 
significant higher percentage of adverse events. Larger trials are needed to explain the difference between adults 
where antibiotics in ABRS has been shown to be effective and this outcome.
  Mucolytics 1b (-) Erdosteine as an adjunct to antibiotic was not more effective than placebo
ABRS, acute bacterial rhinosinusitis.
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Based on the systematic review, a new integrated care pathway 
is proposed (Figure 1.4.1.). In this figure it is emphasized 
that the treatment of almost all patients with ARS should be 
symptomatic, if needed, combined with local corticosteroids. 
The place for antibiotics is very limited and they should only be 
given in situations pointing to severe disease with symptoms 
and signs such as high fever, double sickening, severe pain and 
elevated ESR(3).
Finally, in chapter 4 the complications of ABRS are discussed.
Complications of bacterial rhinosinusitis are rare but potentially 
serious. However, a number of studies have shown that they 
are not prevented by routine prescribing of antibiotics. A low 
threshold of suspicion must always be maintained for their early 
diagnosis.
1.5. Epidemiology, predisposing factors, 
pathophysiology , and diagnosis of CRS 
1.5.1. Epidemiology and predisposing factors
The overall prevalence of symptom-based CRS in the population 
has been found to be between 5.5% and 28%(4, 5, 54, 55), CRS 
is more common in smokers than in non-smokers(4). The 
prevalence of self-reported physician-diagnosed CRS is highly 
correlated with the prevalence of EPOS-diagnosed CRS(4). When 
symptoms are combined with endoscopy or CT scan prevalence 
is reduced to 3-6%(56-58). 
CRS is associated with asthma, with a prevalence of asthma 
around 25% in patients with CRS compared to 5% in the 
general population. CRS is also associated with COPD, 
N-ERD, hypogammaglobulinemia, and GORD (see chapter 
5.1). Smoking, air-pollution and occupational exposure are 
negatively correlated with CRS (symptoms). 
The prevalence of allergy in CRS may vary by phenotype, with 
CCAD and AFRS having a stronger association than CRSwNP and 
CRSsNP(59, 60).  An important percentage of subjects diagnosed 
with chronic upper airway disease report alcohol-induced 
worsening of their symptoms(61).
1.5.2. Genetics
The current knowledge base on the genomics of CRS disease 
offers the promise of identifying new mechanisms of disease 
development and markers predicting optimal response 
to available therapies. However, for the moment, genetics 
do not allow prediction of disease or outcome and its uses 
are currently restricted to extreme cases to understand the 
molecular underpinning of pathologies. It is probable that over 
the coming years we will identify individual or complex genetic 
traits conferring susceptibility to CRS, evolution of disease, and 
response to medical or surgical treatment(62, 63). 
1.5.3. The emerging clinical relevance of CRS 
pathophysiology
Research into the aetiology and pathogenesis of chronic 
rhinosinusitis has been largely irrelevant to the clinician, with 
minimal impact on management. Historically, CRS has been 
divided into two groups based on the presence or absence of 
polyps and, in rough overview, corticosteroids were commonly 
used for CRSwNP and antibiotics for CRSsNP. The rationale for 
these regimens was based on decades-old presumptions that 
CRSsNP was the result of an incompletely treated acute bacterial 
infection that then became ‘chronic’ and CRSwNP had some 
relationship to local or systemic ‘allergy’. Surgery was the only 
option for failures. It has been clear for at least 20 years that this 
assessment was simplistic at best. The emerging view was that 
CRS was a syndrome with a multifactorial aetiology resulting 
from a dysfunctional interaction between various environmental 
factors and the host immune system. It was, however, very 
unclear which environmental and host factors were important 
CRS, chronic rhinosinusitis.
Figure 1.5.1. Aetiology and pathogenesis of CRS.
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even in the population at large, let alone in an individual CRS 
patient. Nevertheless, research was undertaken with the initial 
goal of examining causation of CRS as a route to therapy. Later, 
the results of these efforts shifted emphasis toward the tissue 
effects generated by those causative factors and away from the 
factors themselves. The following brief synopsis describes how 
that 20-year journey is finally beginning to impact how we treat 
patients with CRS. 
Research into the aetiology and pathogenesis of CRS was first 
energized by the work on fungus, which was proposed as 
the key aetiologic agent, at least in patients with recalcitrant 
CRS. This was followed shortly after with Staphylococcus 
aureus being proposed as a rival pathogen, perhaps in biofilm 
format to enable greater resistance. Later, the more general 
hypothesis of microbial dysbiosis was proposed, wherein the 
collective microbial community was abnormal and pathogenic, 
propagating sinonasal inflammation occurred at anatomically 
vulnerable sites. Unfortunately, therapies directed at fungi, 
staphyloccus aureus and even the microbiome as a whole have 
been, at best, underwhelming. This suggested the opposite 
therapeutic tactic: shift attention away from antimicrobials and 
towards the goal of correcting any immune dysfunction in the 
individual CRS patient. By then it was understood that both 
the nose and sinuses were not sterile: a process which begins 
at birth with the rapid colonization by viruses, bacteria and 
fungi. In healthy individuals, the mucosa serves as a relative 
barrier modulating interaction with the host immune system, 
promoting tolerance and symbiosis as well as preventing 
or limiting inflammation. In patients with CRS, the barrier is 
penetrated with resultant chronic inflammation leading to, in 
many cases, tissue remodeling and clinical symptoms. In theory, 
identification of specific genetic or epigenetic variations in the 
host immune system that permit CRS to develop should be 
possible, providing targets for future therapies. Unfortunately, 
outside of cystic fibrosis and CFTR, the genetics of CRS 
appear to be quite complex for the typical patient, involving 
multiple genes, each with a small effect size. Moreover, genetic 
studies on the large populations necessary to identify these 
genes would be very expensive and have generally not been 
undertaken. Effectively, this approach was rendered impractical 
and therapeutic approaches to manage CRS based on putative 
aetiologies – either host or environment based – have made 
relatively little clinical impact. Nevertheless, this entire body of 
work revealed a great deal about the nature of the inflammation 
present in the tissue of CRS patients.
The failure of aetiology-based treatments for CRS is, in 
retrospect, not surprising since CRS is typically an adult onset 
disorder with diagnosis most commonly in the fifth decade of 
life. This extended premorbid time course suggests a complex 
host-environmental interaction, with great variability in nature, 
sequence and intensity of exogenous stressors including 
superimposed stochastic events. Dissecting out the process in 
an individual patient would be a daunting, if not impossible 
task that might still not lead to any therapeutic path forward. By 
analogy, identifying smoking as carcinogenic may help prevent 
future cancers through avoidance, but it will not significantly 
affect treatment recommendations for a patient who has already 
acquired the problem. The accompanying line drawing (Figure 
1.5.1.) illustrates a contemporary model of CRS pathogenesis. 
Rather than analysis of the complex and usually unknown 
factors that cause CRS in an individual patient, interest now is 
centred on the resulting inflammation that develops in the sinus 
tissue. The focus is toward the identification of the molecular 
pathway(s) or endotypes that have been activated. This effort 
has been aided by recent advances in our understanding of 
the physiologic immune response against pathogens across 
mucosal barriers. When the barrier is breached, a self-limited 
immunodefensive response is generated, characterized by 
a cellular and cytokine repertoire targeting one of the three 
classes of pathogens: type 1 immune responses target viruses; 
type 2 responses target parasites and type 3 target extracellular 
bacteria and fungi, all of which resolve with elimination of the 
pathogens and restoration of barrier integrity. In cases of CRS, 
barrier penetration results in a chronic inflammatory response 
that fails to resolve, but still typically utilizes the type 1, 2 or 
3 pathways alone, or in combinations. Type 2 inflammation 
is characterized by cytokines IL-4, IL-5 and IL-13 as well as 
activation and recruitment of eosinophils and mast cells. 
CRS research has revealed that patients with a pure or mixed 
type 2 endotype tend to be much more resistant to current 
therapies, exhibiting a high recurrence rate when compared 
with pure type 1 or 3 endotypes. Furthermore, while type 2 CRS 
clearly varies between patients by intensity of inflammation, 
subtypes may exist wherein discrete aspects of the pathway 
are relatively enhanced (e.g. mast cell activation, eosinophil 
activation, and plasma cells activity). Most importantly, biologic 
agents have now become available that target specific aspects 
of type 2 inflammation. In the very near future, it may be 
possible to offer personalized medicine for CRS patients where 
treatment is based on molecular biomarkers for the endotype or 
subendotype activated in an individual patient. 
Remodelling of sinonasal tissues in CRS consists most 
prominently of polyp formation, goblet cell hyperplasia and 
epithelial barrier abnormalities, which in aggregate, may 
account for many or most of the CRS symptoms. In the case 
of the barrier remodelling, the result is greater permeability, 
likely facilitating persistence or recurrence of CRS.  All of these 
changes are most apparent in type 2 CRS, possibly accounting 
for the observed greater symptomatology and higher rate 
of treatment failure. The precise relationship between the 
endotype and the remodelling pattern is not completely clear 
but recent evidence suggests that it may be cause and effect as 
depicted in Figure 1.5.1. Specifically, the use of biologic agents 
that suppress the type 2 endotype, also shrink polyps. Reversal 
of goblet cell hyperplasia has not yet been documented, but 
in vitro studies suggest that barrier-related remodelling is 
driven directly, in large measure, by canonical type 2 cytokines. 
Biologic agents that suppress type 2 inflammation may, 
therefore, suppress the inflammation, reverse the remodelling 
and limit recurrence, thereby altering the clinical course of 
the most severe CRS phenotypes. Further research into type 
2 inflammation will be extremely helpful in the use of these 
powerful drugs, which have the potential to revolutionize CRS 
treatment(64).
EPOS 2020
12
EPOS 2020: Care pathways for CRS
One of which should be nasal obstruction 
and/or discoloured discharge
± facial pain/pressure
± reduction or loss of smell
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• Self-education / e-Health
• Saline spray / rinses
• INCS (if OTC)
• Avoid antibiotics
• Avoid exacerbating factors
Self-Care
6-12 weeks: 
improvement?
+
-
Refer to Primary Care
• Saline rinses
• INCS (if not OTC)
• Educate compliance/technique
• Avoid antibiotics
• Check treatable traits and comorbidities
Primary care follow-up
PRESENCE OF ALARM SYMPTOMS
• Periorbital oedema/erythema
• Displaced globe
• Double vision
• Ophthalmoplegia
• Reduced visual acuity
• Severe headache
• Frontal swelling
• Signs of sepsis
• Signs of meningitis
• Neurological signs
• Unilateral symptoms
• Bleeding
• Crusting
• Cacosmia
IMMEDIATE REFERRAL
Refer to Secondary / Tertiary Care
Check treatable traits / comorbidities
History and full ENT exam
Nasal endoscopy
Diuse / bilateral CRS
Localized / unilateral CRS
Follow EPOS 2020 management scheme 
on diuse / bilateral CRS
CT scan 
(urgent if suspicion of tumour)
Diagnosis rejected
Reconsider dierential diagnosis
Diagnosis conrmed
Surgery likely
Refer if necessary / suspected malignancy
Consider CT scan 
Reconsider dierential diagnosisNo (apparent) CRS
+
+
-
6-12 weeks: 
improvement?
Figure 1.6.1. Treatment evidence and recommendations for adults with chronic rhinosinusitis.
CRS: chronic rhinosinusitis; CT, computed tomography; INCS, intranasal corticosteroids spray; OTC, over-the-counter. 
1.5.4. Differential diagnosis and diagnostic tools
1.5.4.1. Differential diagnosis 
It was decided to include more information in EPOS2020 to 
better allow differential diagnosis of rhinosinusitis from certain 
other conditions and common symptoms, notably allergic 
and non-allergic rhinitis, olfactory loss and facial pain. We also 
include an updated and expanded range of diagnostic tools, 
though many have not substantially changed since 2012.
Upper airway diseases present with a variable pattern of 
common symptoms such as nasal obstruction and discharge, 
making the epidemiological diagnosis of CRS difficult to 
differentiate from allergic and nonallergic rhinitis based on 
symptomatic grounds.  Combining data from different studies 
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Figure 1.6.2. EPOS2020 management scheme on diffuse CRS.
Primary
diuse CRS
AMT (± OCS)
or
FESS
Consider:
Diuse / bilateral CRS Presence of:
• Bleeding / crusting
• Severe pain
• Tissue loss
• Involvement of other organs
Secondary diuse CRS
(e.g. vasculitis / immune disorder)
• Serologic investigations
• Consider biopsy
• CT scan
• Involve appropriate specialists 
  to treat underlying disease
Appropriate medical therapy (AMT)
• Nasal steroid (drops / spray / rinses)
• Saline rinses
• Educate technique / compliance
• Consider OCS
Additional work-up: 
CT-scan, SPT, lab; reconsider treatable traits, compliance
Type 2
• Main complaint often smell loss 
  or blockage/congestion
• N-ERD and/or asthma
• Atopy
NE: polyps, eosinophilic mucin
Lab: elevated IgE, eosinophilia
AMT (± longterm antibiotics)
or
FESS
AFRS
• Young
• Atopy
• Warm humid climate
• Asthma
• SPT: positive for fungi
Consider:
• MRI of sinuses with contrast
• Ophthalmology and 
  neurosurgery consultation
• Preoperative OCS
FESS
• Tailored (extended) surgery 
  to remove all debris
• Histopathology
  eosinophils, hyphae, CL crystals
• Culture fungus
Saline rinses 
INCS
OCS
Consider immunotherapy
Repeat imaging with 
concern for recurrence
Additional therapy
Consider:
• Biologicals
• ATAD in case of N-ERD
• OCS taper
• Revision surgery
Additional therapy
Consider:
• Xylitol rinses
• Longterm antibiotics
• Revision surgery
Additional investigations
Consider:
• Secondary diuse CRS 
  (e.g. vasculitis / immune disorder)
- -
+
-
6-12 weeks: improvement?
-
+
+
ALARM SYMPTOMS
• Periorbital oedema/erythema
• Displaced globe
• Double vision
• Ophthalmoplegia
• Reduced visual acuity
• Severe headache
• Frontal swelling
• Signs of sepsis
• Signs of meningitis
• Neurological signs
• Unilateral symptoms
• Bleeding
• Crusting
• Cacosmia
6-12 weeks: 
improvement?
6-12 weeks: 
improvement?
Non-type 2 
• Main complaint often 
  discharge/facial pain
• Less asthma
• Less atopy
NE: purulence
Lab: normal IgE, no eosinophilia
For explanation of (primary and secondary) diffuse CRS see 1.2.3.
AMT, appropriate medical therapy; ATAD, Aspirin treatment after desensitisation; CL, Charcot Leyden; CRS, chronic rhinosinusitis; CT, computed 
tomography; FESS, functional endoscopic sinus surgery; INCS, intranasal corticosteroid spray; MRI, magnetic resonance imaging; NE, nasal endoscopy; 
N-ERD, NSAID-exacerbated respiratory disease; OCS, Oral corticosteroids; SPT, Skin prick test.
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leads to a picture of significant overlap in prevalence and 
severity of symptomatology. However, as there are generally 
less inflammatory changes seen on CT sinuses in AR and NAR 
than CRS(65) a combination of symptoms, CT scan and nasal 
endoscopy can point in the right direction. 
Olfactory loss is one of the cardinal symptoms of CRS but has 
a wide differential diagnosis(66). The prevalence of olfactory 
disorders in the general population is estimated to be 3-5 % for 
total smell loss (anosmia) and 15-25 % for partial impairment 
(hyposmia)(67, 68). In CRS the mechanism leading to olfactory 
impairment is twofold: inflammatory and purely mechanical 
due to obstruction of the olfactory cleft(69, 70), which explains why 
not all patients have an olfactory benefit from surgical removal 
of polyps alone but also require subsequent anti-inflammatory 
treatment. However, CRS-related olfactory loss has a good 
success rate of improvement if the CRS is treated even if not 
always sustained in the long-term.
Facial pain is another cardinal symptom of CRS which can 
occur in many other conditions(71). However, facial pain when 
it occurs alone is rarely caused by CRS and, therefore, when 
it occurs without other nasal complaints or abnormalities on 
examination, it should not (primarily) be addressed surgically.
1.5.4.2. Diagnostic tools
The different imaging modalities in diagnosing rhinosinusitis 
[conventional X-ray, computerized tomography (CT), cone 
beam CT and magnetic resonance imaging (MRI)] have been 
evaluated(72). Overall CT scan remains the gold standard in the 
radiologic evaluation of rhinologic disease, notably CRS(73-75). 
However, in acute rhinosinusitis, the diagnosis is made on 
clinical grounds and CT is not recommended(3) unless the 
condition persists despite treatment, or a complication is 
suspected(76). Conventional sinus X-rays are no longer indicated 
in either ARS or CRS.
The most commonly used and validated scoring system of 
sinonasal inflammatory change remains the Lund-Mackay 
score (LMS) which gives a maximum score of 24 or 12/side(77). 
An LMS of 2 or less has an excellent negative predictive value, 
and an LMS of 5 or more has an excellent positive predictive 
value, strongly indicating true disease. In CRS, CT was not 
normally recommended until after an appropriate course of 
medical therapy had failed(3, 78) and without an intervening 
acute episode but more recent studies suggest that early CT 
scanning may be more cost-effective as compared to extended 
courses of antibiotics given empirically and is preferred by 
patients(79-81).Multi-detector CT (MDCT) scanners and cone-
beam CT are reducing the radiation dose whilst preserving 
image quality by shortening the scan time and using post-
processing techniques(82, 83) without compromising anatomical 
accuracy(84),making them increasingly attractive(85, 86). 
In the measurement of health-related quality-of-life (HRQL), a 
wide range of validated patient reporting outcome measures 
(PROMS) are available but currently none of the established 
PROMS capture all the desired aspects of CRS; the SNOT-22 
fails to capture disease duration or medication usage. Current 
recommendations include the use of SNOT-22 scores repeated 
over time, Lund Kennedy endoscopic scores, and additional 
questions to evaluate the need for systemic medications or 
progression to surgery, compliance with and side effects of 
treatment, additional information on symptom frequency, and 
impact on ability to perform normal activities(87). 
Nasal endoscopy remains an essential part of the rhinological 
examination. A recent systematic review analysed the accuracy 
of nasal endoscopy in diagnosing chronic rhinosinusitis (CRS) 
compared with paranasal sinus computed tomography (CT). 
Sixteen observational or retrospective studies were included 
resulting in a high correlation (r=0.85; 95% confidence interval 
[CI][0.78–0.94], p<0.0001, I2 77%) between endoscopy and CT in 
terms of the diagnostic accuracy for CRS(88). 
A clinical history supported with a skin prick test or serum IgE 
measuremernt will probably remain the gold standard of the 
upper airway allergy diagnosis but advances are expected from 
the molecular in vitro diagnosis which may change this trend, 
due to improved technology which enables faster diagnosis on 
a broader panel of allergens(89, 90). 
As CRS patients are commonly not fully aware of their olfactory 
impairment, or are unable to estimate the severity of the loss, 
the use of smell tests is recommended in order to objectively 
evaluate this disorder(91, 92). The most widely used remain the 
North American UPSIT(93), its short version (SIT, B-SIT) and the 
European Sniffin’Sticks(94). Although there are many others, 
all have cultural bias and there have been recent advances to 
overcome this with culturally unbiased, universally usable smell 
tests(95).
Nasal obstruction is the most significant of the cardinal 
symptoms of rhinosinusitis and nasal patency may be 
objectively evaluated with peak nasal inspiratory flow 
(PNIF), (active anterior) rhinomanometry (AAR), and acoustic 
rhinometry (AR) Newer methods such as computational fluid 
dynamics(96) are presently mainly used for research purposes(97, 98) 
but may be of value in the future.
In addition to confirming diagnosis, histopathology is becoming 
more important to assist in endotyping of inflammatory 
disease, thereby directing potential therapies, e.g. biologics. 
Eosinophilic CRS (eCRS) requires quantification of the numbers 
of eosinophils, i.e. number/high powered field (HPF (400x) and 
EPOS2020 supports 10 or >/HPF.  Further stratification may be 
made between those with10-100 eosinophils per HPF in two 
or more areas and those with >100 eosinophils per HPF in two 
or more areas(99). The amount of eosinophilic infiltration and 
the overall intensity of the inflammatory response are closely 
related to the prognosis and severity of disease(100). Until recently 
most blood tests in patients with CRS were performed to 
diagnose immunodeficiencies and vasculitis. However, recently 
the options to treat with biologicals has put more emphasis 
on markers of type 2 disease, although as it stands we are not 
aware of biomarkers that can predict response to biologicals in 
CRS(101).
For microbiology, in addition to the standard culture-dependant 
tests, newer culture-independent techniques including next 
generation sequencing may provide significant insight into 
CRS pathophysiology. This could include sequencing of all DNA 
(metagenomics) or all transcribed RNA (metatranscriptomics) 
or identification of proteins (metaproteomics) or metabolites 
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(metabolomics), showing not only the true diversity and 
structure, but also the full genetic potential and in situ activity of 
the mucosa-associated microbiota(102).
EPOS2020 also includes an update on mucociliary testing and 
other tests for primary ciliary dyskinesia (PCD), sweat testing 
and other tests for cystic fibrosis and advances in genetic 
testing as well as new diagnostic tools for N-ERD. Finally, the 
lower respiratory tract is not forgotten and the full range of 
available investigations are covered from peak expiratory flow to 
provocation tests and expired nitric oxide measurement.
1.6. Management of chronic rhinosinusitis in adults
1.6.1. Introduction
An important difference compared to EPOS2012 is that we 
have decided to move away from differentiating between the 
management of CRSsNP and CRSwNP per se. The understanding 
of the last decade of endotyping of CRS and the consequences 
of endotypes for the management of disease has led to the 
decision to describe management of CRS based on endotyping 
and phenotyping. 
We propose a new clinical classification based on the disease 
being localized (often unilateral) or diffuse (always bilateral). 
Both these groups can be further divided into type 2 or non-
type 2 disease (Figure 1.2.1.). The major challenge is to find 
reliable biomarkers that define type 2 inflammation and predict 
reaction to medication. Unfortunately, recent large studies 
with monoclonal antibodies directed at type 2 endotypes 
have not found reliable biomarkers to predict response to 
treatment(103, 104). For the moment the combination of phenotype 
(e.g. CRSwNP, N-ERD), response to treatment (systemic 
corticosteroids) and possibly also markers like eosinophils, 
periostin and IgE either in blood or tissue lead us to the best 
estimation of the endotype and reaction to treatment. This 
is a rapidly evolving field at the moment and we expect that 
frequent updates will be necessary.
1.6.2. Management of CRS: an integrated care pathway
For the management of CRS, a full systematic review of the 
literature has been performed (see chapter 6 and Table 1.6.1.). 
Many forms of localised CRS (Figure 1.2.1.) in general, either type 
2 or non-type 2, are not responsive to medical treatment and 
need surgery. For that reason, we advise patients with unilateral 
disease to be referred to secondary care for further diagnosis. 
Many studies do not make a clear differentiation between 
CRSsNP and CRSwNP. Very few studies further define CRS 
phenotypes or endotypes in the disease. CRS research has 
revealed that patients with a pure or mixed type 2 endotype 
tend to be more resistant to current therapies, exhibiting a 
high recurrence rate when compared with pure type 1 or 3 
endotypes. 
For diffuse, bilateral CRS, local corticosteroids and saline remain 
the mainstay of the treatment (Figure 1.6.1.).
Furthermore, the integrated care pathway (ICP) advises to check 
treatable traits, to avoid exacerbating factors and advises against 
the use of antibiotics. In secondary care, nasal endoscopy can 
confirm disease, point to secondary CRS (e.g. vasculitis) and 
further differentiate between localized and diffuse disease 
(Figure 1.6.2.). 
In addition,  emphasis is put on optimum techniques of 
medication delivery and compliance. If treatment with nasal 
steroid and saline is insufficient, an additional work-up with CT 
scan and endotyping is relevant. Depending on the endotype 
indication, treatment can be tailored to a more type 2 or non-
type 2 profile. International guidelines differ regarding whether 
long-term antibiotics and oral steroids should be included as 
part of adequate medical therapy (AMT), reflecting conflicting 
evidence in the current literature(3, 78, 105), and concerns with 
regard to side-effects. There is a lot of debate on the appropriate 
moment for surgery for CRS(105).  In a recent study for adult 
patients with uncomplicated CRS, it was agreed that ESS could 
be appropriately offered when the CT Lund-Mackay score was 
≥1 and there had been a minimum trial of at least eight weeks’ 
duration of a topical intranasal corticosteroid plus a short-course 
of systemic corticosteroid (CRSwNP) or either a short-course of a 
broad spectrum / culture-directed systemic antibiotic or the use 
of a prolonged course of systemic low-dose anti-inflammatory 
antibiotic (CRSsNP) with a post-treatment total SNOT-22 score 
≥20. These criteria were considered the minimal threshold, 
and clearly not all patients who meet the criteria should have 
surgery, but their application should reduce unnecessary 
surgery and practice variation. A subsequent study applied 
these criteria retrospectively to patients recruited to a multi-
centre cohort study and found that patients where surgery was 
deemed ‘inappropriate’ reported significantly less improvement 
in their quality of life postoperatively(106).
It is important to emphasize that CRS is a chronic disease and 
ESS a step in the management that is primarily aimed at creating 
better conditions for local treatment. After surgery continuous 
appropriate medical treatment is mandatory.
If surgery in combination with appropriate medical treatment 
fails, additional therapy can be considered. Options are the 
use of aspirin treatment after aspirin desensitisation (ATAD)(107), 
longer (tapering) treatment with OCS, long term antibiotics( 108) 
and/or biologicals when indicated.
1.6.3. New treatment options with biologicals (monoclonal 
antibodies)
The acceptance of dupilumab (anti IL-4Rα) for the treatment 
of CRSwNP by the US Food and Drug Administration(FDA) and 
European Medicines Agency (EMA) in 2019 has significantly 
changed the treatment options in type 2 type CRS and it 
is expected that other monoclonal antibodies will follow. 
Until 2019 monoclonal antibodies could only be prescribed 
in patients with concomitant (severe) asthma. Within the 
EUFOREA setting, the positioning of biologics in the ICP of 
CRS with criteria for use and stopping of biologics have been 
published(101). The EPOS2020 steering group made some 
modifications and tightening of these criteria. They concluded 
that biologicals are indicated in a patient with bilateral polyps,  
who had had sinus surgery or was not fit for surgery and who 
had three of the following characteristics: evidence of type 2 
disease (tissue eosinopils  ≥10/HPF or blood eosinophils ≥250 
OR total IgE ≥100), need for at least two courses of systemic 
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Figure 1.6.3. Indications for biological treatment in CRS.
Presence of bilateral polyps in a patient who had ESS*
THREE criteria are required
Indications for biological treatment in CRSwNP 
• Evidence of type 2 inflammation
• Need for systemic corticosteroids or 
  contraindication to systemic steroids 
• Significantly impaired quality of life 
• Significant loss of smell 
• Diagnosis of comorbid asthma
 Tissue eos ≥10/hpf, OR blood eos ≥250u/l, OR total IgE ≥100IU/ml
 ≥ 2 courses per yr, OR long term (>3 months) 
 low dose steroids 
 SNOT-22 ≥ 40
 Anosmic on smell test (score depending on test)
 Asthma needing regular inhaled corticosteroids
Criteria Cut-off points
*exceptional circumstances excluded (e.g., not fit for surgery)
CRS, chronic rhinosinusitis; CRSwNP: chronic rhinosinusitis with nasal polyps; ESS, endoscopic sinus surgery; hpf: high power field (x400); SNOT-22, 
sino-nasal outcome test-22.
Figure 1.6.4. Response criteria for biologicals in the treatment of CRS.
Evaluation of 5 criteria
Dening response to biological treatment in CRSwNP
• Reduced nasal polyp size
• Reduced need for systemic corticosteroids
• Improved quality of life
• Improved sense of smell
• Reduced impact of co-morbidities No response
0 criteria
Poor response
1-2 criteria
Moderate response
3-4 criteria
Excellent response
5 criteria
Evaluate treatment response after 16 weeks
Evaluate treatment response after 1 year
Discontinue 
treatment
if no response 
in any 
of the criteria
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Therapy
Level of 
evidence
GRADE recommendation
Short term antibiotics for CRS 1b (-) There are only two small placebo-controlled studies, one in CRS and one in acute exacerbation of CRS. Both show no 
effect on symptomatology apart from significantly reduced postnasal drip symptom scores at week 2 in the CRS study. 
Seven studies evaluated two different antibiotics regimes, of which only one was placebo-controlled. One out of seven 
studies in patients with CRS showed a significant effect on SNOT at 2 and 4 weeks and also one study a significant  
improvment in symptoms of infection at day 3 to 5 in one antibiotic versus another in a mixed group of patients with 
CRS and with acute exacerbation. The other 5 studies showed no difference in symptomatology. Only two of these seven 
studies, both of which were negative, evaluated the effect after one month.
The EPOS2020 steering group, is uncertain, due to the very low quality of the evidence, whether or not the use of a short 
course of antibiotics has an impact on patient outcomes in adults with CRS compared with placebo. Also, due to the very 
low quality of the evidence, it is uncertain whether or not the use of a short course of antibiotics has an impact on patient 
outcomes in adults with acute exacerbations of CRS compared with placebo. Gastrointestinal-related adverse events 
(diarrhoea and anorexia) are frequently reported. 
Short term antibiotics for acute 
exacerbation of CRS
1b (-) The EPOS2020 steering group, is uncertain, due to the very low quality of the evidence, whether or not the use of a 
short course of antibiotics has an impact on patient outcomes in adults with acute exacerbations of CRS compared with 
placebo. Gastrointestinal-related adverse events (diarrhoea and anorexia) are frequently reported.
Longterm antibiotics for CRS 1a (-) The EPOS2020 steering group, due to the low quality of the evidence, is uncertain whether or not the use of long-term 
antibiotics has an impact on patient outcomes in adults with CRS, particularly in the light of potentially increased risks of 
cardiovascular events for some macrolides. Further studies with larger population sizes are needed and are underway .
Topical antibiotics 1b (-) Topical antibacterial therapy does not seem to be more effective than placebo in improving symptoms in patients 
with CRS. However, it may give a clinically non-relevant improvement in symptoms, SNOT-22 and LK endoscopic score 
compared to oral antibiotics. The EPOS2020 steering group, due to the very low quality of the evidence, is uncertain 
whether or not the use of topical antibiotic therapy has an impact on patient outcomes in adults with CRS compared with 
placebo.
Nasal corticosteroids 1a There is high-quality evidence that long term use of nasal corticosteroids is effective and safe for treating patients with 
CRS. They have impact on nasal symptoms and quality of life improvement, although the effect on SNOT-22 is smaller 
than the minimal clinically important difference. The effect size on symptomatology is larger in CRSwNP (SMD -0.93, 
95% CI -1.43 to -0.44) than in CRSsNP (SMD -0.30, 95% CI -0.46). The meta-analysis did not show differences between 
different kinds of nasal corticosteroids. Although in meta-analysis higher dosages and some different delivery methods 
seem to have a larger effect size on symptomatology, direct comparisons are mostly missing. For CRSwNP, nasal 
corticosteroids reduce nasal polyp size. When administered after endoscopic sinus surgery, nasal corticosteroids prevent 
polyp recurrence. Nasal corticosteroids are well tolerated. Most adverse events reported are mild to moderate in severity. 
Nasal corticosteroids do not affect intraocular pressure or lens opacity. The EPOS2020 steering group advises to use nasal 
corticosteroids in patients with CRS. Based on the low to very low quality of the evidence for higher dosages or different 
delivery methods and the paucity of direct comparisons the steering committee cannot advise in favour of higher 
dosages or certain delivery methods.
Corticosteroid-eluting implants 1a The placement of corticosteroid-eluting sinus implants in the ethmoid of patients with recurrent polyposis after sinus 
surgery has a significant but small (0.3 on a 0-3 scale) impact on nasal obstruction but significantly reduces the need 
for surgery and reduces nasal polyp score. Based on the moderate to high quality of the evidence the steering group 
considered the use of corticosteroid-eluting sinus implants in the ethmoid an option. 
Systemic corticosteroids 1a ¸ A short course of systemic corticosteroid, with or without local corticosteroid treatment results in a significant reduction 
in total symptom score and nasal polyp score. Although the effect on the nasal polyp score remains significant up to 
three months after the start of treatment by that time there is no longer an effect on the symptom score. The EPOS2020 
steering group felt that 1-2 courses of systemic corticosteroids per year can be a useful addition to nasal corticosteroid 
treatment in patients with partially or uncontrolled disease. A short course of systemic corticosteroid postoperatively does 
not seem to have an effect on quality of life. Systemic corticosteroids can have significant side effects.
Antihistamines Ib There is one study reporting on the effect of antihistamines in partly allergic patients with CRSwNP. Although there was no 
difference in total symptom score, the days with a symptom score ≤1 was higher in the treated group. The quality of the 
evidence comparing antihistamines with placebo was very low. There is insufficient evidence to decide on the effect of 
the regular use of antihistamines in the treatment of patients with CRS.
Anti-leukotrienes 1b (-) Based on the very low quality of the available evidence, the EPOS2020 steering group is unsure about the potential 
use of montelukast in CRS and does not recommend its use unless in situations where patients do not tolerate nasal 
corticosteroids. Also, the quality of the evidence comparing montelukast with nasal corticosteroid is low. Based on the 
evidence, the steering group does not advise adding montelukast to nasal corticosteroid but studies evaluating the effect 
of montelukast in patients that failed nasal corticosteroids are missing.
Decongestant  Ib There is one small study in CRSwNP patients showing a significantly better effect of oxymetazoline combined with MFNS 
than MFNS alone without inducing rebound swelling. There was no effect of xylometazoline compared to saline in the 
early postoperative period. This review found a low level of certainty that adding a nasal decongestant to intranasal 
corticosteroids improves symptomatology in CRS. Although the risk of rebound swelling was not shown in this study, the 
EPOS2020 steering group suggests in general not to use nasal decongestants in CRS. In situations where the nose is very 
blocked, the temporary addition of a nasal decongestant to nasal corticosteroid treatment can be considered.
Table 1.6.1. Treatment evidence and recommendations for adults with chronic rhinosinusitis.
EPOS 2020
18
Therapy Level of 
evidence
GRADE recommendation
Nasal irrigation with saline Ia There are a large number of trials evaluating the efficacy of nasal irrigation. However, the quality of the studies is not 
always very good which makes it difficult to give a strong recommendation. However, the data show:  
Nasal irrigation with isotonic saline or Ringer’s lactate has efficacy in CRS patients. 
There is insufficient data to show that a large volume is more effective than a nasal spray.  
The addition of xylitol, sodium hyaluronate, and xyloglucan to nasal saline irrigation may have a positive effect.  
The addition of baby shampoo, honey, or dexpanthenol as well as higher temperature and higher salt concentration do 
not confer additional benefit. 
The steering group advises the use of nasal saline irrigation with isotonic saline or Ringer’s lactate with or without the 
addition of xylitol, sodium hyaluronate, and/or xyloglucan and advises against the use of baby shampoo and hypertonic 
saline solutions due to side effects.
Aspirin treatment after 
desensitization (ATAD) with oral 
aspirin in N-ERD
Ia Oral ATAD has been shown to be significantly more effective and clinically relevant than placebo in improving QOL 
(measured with SNOT) and total nasal symptom score in patients with N-ERD. However, the change in SNOT from treating 
with oral ATAD compared to placebo did not reach the clinically important mean difference. ATAD reduced symptoms 
after six months compared to placebo. However, ATAD is associated with significant adverse effects, and the risks of not 
taking the medication strictly on a daily basis puts a burden on patient and caregiver. 
Based on these data, the EPOS2020 steering group suggests that ATAD can be a treatment for N-ERD patients with 
CRSwNP whenever there is confidence in the patient’s compliance. 
Aspirin treatment after 
desensitization (ATAD) with nasal 
lysine aspirin in N-ERD
1b (-) ATAD with lysine aspirin and platelet inhibitors (like Pradugrel) have not been shown to be an effective treatment in 
CRSwNP patients with N-ERD and are not advised. 
Low salicylate diet Ib Diets, like low salicylate diet have been shown to improve endoscopic scores and may improve symptoms compared to 
a normal diet in patients with N-ERD. However, the quality of the evidence at this moment is not enough to draw further 
conclusions.
Local and systemic antifungal 
treatments
1a (-) Local and systemic antifungal treatments do not have a positive effect of QOL, symptoms and signs of disease in patients 
with CRS. The EPOS2020 steering group advises against the use of anti-mycotics in CRS.
Anti-IgE Ib Anti-IgE (amalizumab) therapy has been proposed as a promising biologic therapy for CRS. Two RCTs that evaluated anti-
IgE monoclonal antibody (omalizumab) did not show impact on disease specific QOL but one study did show an effect 
on the physical domain of SF-36 and AQLQ. One study demonstrated lower symptom scores (change from baseline in anti 
IgE group) for nasal congestion, anterior rhinorrhoea, loss of sense of smell, wheeze and dyspnoea, a significant reduction 
of NPS on endoscopic examination, and Lund-MacKay scores on radiologic imaging. Due to the small study population 
in the existing studies, further studies with larger population sizes are needed and are underway. The available data are 
insufficient to advise on the use of anti-IgE in CRSwNP at this moment.  
Anti-Il-5 Ib There is only one large sufficiently powered study with mepolizumab that showed a significant reduction in patients’ need 
for surgery and an improvement in symptoms. Unlike in CRS, there is a significant experience with anti-Il5 in other type 
2 driven diseases like asthma that do show a favourable safety profile so far. The EPOS2020 steering group advises use of 
mepolizumab in patients with CRSwNP fulfilling the criteria for treatment with monoclonal antibodies (when approved).
Anti IL-4/IL-13 (IL-4 receptor α) Ia At the moment the only anti-Il-4 treatment studied in CRS is dupilumab. Dupilumab is the only monoclonal antibody 
that is approved for the treatment of CRSwNP so far.  When evaluating all trials with dupilumab, the drug seems to induce 
conjunctivitis in trials in patients with atopic dermatitis but not in trials with asthma and CRSwNP.  No other adverse 
events have been reported in the literature until now.  The EPOS steering group advises to use dupilumab in patients with 
CRSwNP fulfilling the criteria for treatment with monoclonal antibodies.
Probiotics 1b (-) Although probiotic therapies show theoretical promise, the two studies performed so far did not show any differences 
compared to placebo. For this reason, the EPOS2020 steering group advises against the use of probiotics for the treatment 
of patients with CRS.
Muco-active agents 1b Data on the effect of muco-active agents in CRS are very limited. The only DBPCT evaluating the addition of 
S-carboxymethylcysteine to clarithromycin showed a significantly higher percentage of patients with effective response 
and improved characteristics of nasal discharge at 12 weeks. The EPOS2020 steering group considered the quality of the 
data insufficient to advise on the use of muco-active agents in the treatment of patients with CRS.
Herbal treatment 1b Of five RCTs evaluating herbal treatment, a large DBPCT, using tablets, showed overall no effect, although a post-hoc 
sensitivity analysis, showed a significant benefit in major symptom score at 12 weeks of treatment over placebo in patients 
with a diagnosis of CRS for >1 year and a baseline MSS >9 (out of max 15). Of the four studies evaluating different local 
herbal treatment, three showed a favourable effect. However, not all studies were blinded and the quality of the studies 
was variable.  
The treatment does not show significantly more adverse events than placebo. The quality of the evidence for the local 
treatment is low.  Based on the available data, the EPOS2020 group cannot advise on the use of herbal medicine in CRS.
Acupuncture and traditional 
Chinese medicine 
1b (-) There is no evidence that traditional Chinese medicine or acupuncture is more effective than placebo in the treatment of 
CRS. The safety of Chinese medicine is unclear because most of the papers are not (easily) accessible. Minor and serious 
adverse events can occur during the use of acupuncture and related modalities, contrary to the common impression 
that acupuncture is harmless. For this reason, the EPOS2020 steering group advises against the use of traditional Chinese 
medicine or acupuncture.
Table 1.6.1. Cont.
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Therapy Level of 
evidence
GRADE recommendation
Oral verapamil 1b A very small pilot study showed significant improvement in QOL (SNOT-22), polyp score (VAS), and CT scan (LM-score) of 
oral verapamil over placebo. (Potential) side effects limited the dosage.  
The quality of the evidence for oral verapamil is very low. Based on the potential side effects the EPOS2020 steering group 
advises against the use of oral verapamil. 
Nasal furosemide 1b A recent DBPCT study showed significantly reduced QOL (SNOT-22) scores and polyp score (VAS), and significantly 
more patients with an NPS of 0 in the furosemide nasal spray treated group versus placebo. There was no indication of a 
difference in adverse events between topical furosemide and placebo. However, the quality of the evidence is very low. 
The EPOS2020 steering group cannot advise on the use of nasal furosemide.
Capsaicin 1b Capsaicin showed a significant decrease in nasal obstruction and nasal polyp score in two small studies, however data on 
other symptoms like rhinorrhea and smell are either non-significant or unreported. The quality of the evidence is low and 
the EPOS steering group concludes that capsaicin may be an option in treatment of CRS in patients with CRSwNP but that 
larger studies are needed.
Proton-pump inhibitors 1b (-) Proton-pump inhibitors have been shown in one study to be not effective. Moreover, long term use of proton pump 
inhibitors has been associated with increased risk of cardiovascular disease. The EPOS2020 steering group therefore does 
advise against the use of proton pump inhibitors in the treatment of CRS.
Bacterial lysate 1b There is one DBPCT from 1989 comparing the bacterial lysate Broncho-Vaxom to placebo in a large group of CRS patients 
resulting in a significant decrease in purulent nasal discharge and headache over the full six month period compared to 
placebo and reduced opacification of the sinus X-ray. Based on this limited evidence, the EPOS2020 steering group cannot 
advise on the use of Broncho-Vaxom in the treatment of CRS. 
Phototherapy 1b (-) We identified two trials with opposing findings. The quality of the evidence for the use of phototherapy in patients with 
CRS is very low. Based on the evidence, the EPOS2020 steering group cannot make a recommendation on the use of 
phototherapy in patients with CRS.
Filgastrim (r-met-HuG-CSF) 1b (-) There is one study evaluating Filgastrim compared to placebo in CRS. There was no significant difference in effect on QOL 
between the two groups. Based on the evidence, the EPOS2020 steering group cannot make a recommendation on the 
use of Filgastrim in patients with CRS.
Collodial silver nasal spray 1b (-) One very small study did not find differences between nasal colloidal silver spray and placebo. Based on the evidence, the 
EPOS2020 steering group cannot make a recommendation on the use of collodial silver nasal spray in patients with CRS.
ATAD, Aspirin treatment after desensitisation ; CI, confidence interval; CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; 
CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, double blind placebo controlled trial; LK, Lund Kennedy; LM, Lund-Mackay score; MFNS, 
mometasone fuorate nasal spray; MSS, major symptom score; N-ERD, NSAID-exacerbated respiratory disease; NPS, nasal polyp score; QOL, quality of 
life; RCT, randomised controlled trial; SNOT-22, sino-nasal outcome test-22; SMD, standard mean difference.
Table 1.6.1. Cont.
corticosteroids or continuous use of systemic corticosteroids 
(≥2 courses per year OR long term (>3 months) low dose 
steroids OR contraindication to systemic steroids), significantly 
impaired quality of life ( SNOT-22 ≥40), anosmic on smell test 
and/or a diagnosis of comorbid asthma needing regular inhaled 
corticosteroids (Figure 1.6.3.).  
The response criteria for biologicals have been taken from the 
EUFOREA paper (Figure 1.6.4.), although the EPOS2020 group 
also discussed whether there was an indication to repeat 
surgery in patients on biologicals to give them a better starting 
point. It was decided that we had insufficient data to advise on 
surgery whilst on biologicals before deciding that they are not 
effective and that this is a research need. 
1.6.4. Conclusion
EPOS2020 provides a full evidence based systematic review of 
the management of CRS that has been incorporated into an 
integrated care pathway (Figures 1.6.1. and 1.6.2.).  A significant 
shift in the management of CRS has occurred since EPOS2012. 
The options of biologicals in the treatment of type 2 CRS will be 
a paradigm shift in the management of the disease. The exact 
positioning of this presently very expensive treatment needs 
to be determined. (Figures 1.6.3. and 1.6.4.).EPOS2020 further 
emphasizes the criteria for (revision) surgery in the disease.
1.7.Paediatric chronic rhinosinusitis
1.7.1. Epidemiology and predisposing factors
This section has been considerably expanded, reflecting new 
literature. The prevalence of CRS in paediatric patients is now 
estimated to be up to 4%(109).Both passive and active cigarette 
smoking are associated with chronic rhinitis and rhinosinusitis 
in children(110) though a clear and definitive causal relationship 
between allergic rhinitis and CRS  has not been established(111). 
Evidence suggests that the adenoids may act as a reservoir for 
pathogenic bacteria, rather than a source of obstruction(112, 
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Table 1.7.1. Evidence supporting therapy of CRS in children.
CRS, chronic rhinosinusitis; FESS, functional endoscopic sinus surgery.
Therapy
Level of 
evidence
GRADE recommendation
Antibiotics 1b (-) There is no high level evidence to support the efficacy of either short or long term antibiotics for 
CRS in children.  
Nasal corticosteroids 5 There is no evidence regarding the efficacy of intranasal steroids in the treatment of CRS in 
children.  Nevertheless the EPOS steering group is supportive of their use in light of their anti-
inflammatory effects and excellent safety record in children.
Systemic Steroids 1b (+) Adding a taper course of systemic steroids to an antibiotic (not effective on its own) is more 
effective than placebo in the treatment of paediatric CRS.  Judicious use of this regimen is 
advised considering systemic side effects. 
Saline Irrigation Ib (+) There are a few clinical trials demonstrating the efficacy of saline irrigations in paediatric patients 
with CRS. The EPOS steering group is supportive of the use  of saline in light of the excellent 
safety record in children.
Adenoidectomy 4 Adenoidectomy is effective in younger children with symptoms of CRS.  The EPOS steering group 
supports adenoidectomy in young children refractory to appropriate medical therapy.
FESS 4 FESS is safe and effective for the treatment of older children with CRS refractory to medical 
therapy or previous adenoidectomy.
113) whilst the relationship between GORD and CRS in children 
remains controversial(114). A large database study suggests a 
significant familial risk associated with paediatric CRS(115) but 
studies on monozygotic twins have not shown that both siblings 
always develop polyps, indicating that environmental factors 
are as likely as genetic ones to influence the occurrence of nasal 
polyps.
1.7.2. Inflammatory mechanisms
Multiple studies suggest upregulation of different inflammatory 
substances important in adaptive and innate immunity as well 
as tissue remodelling in sinus tissues, adenoids, nasal lavage, 
mucus and serum in children with CRS. Although the evidence 
is still scarce, these studies suggest a role for inflammatory 
mechanisms in paediatric CRS.  Although many of the markers 
parallel those seen in adults, the data is very heterogeneous 
and does not yet lend itself to endotyping.  Inflammatory 
cytokines are present in sinus tissues of children with CRS and 
are more abundant when concomitant asthma is present(116). 
Although more evidence is emerging to support upregulation 
of inflammatory markers in paranasal sinus tissues and nasal 
lavages of children with CRS, the data is also relatively limited 
and heterogeneous and again does not yet lend itself to 
endotyping.  
1.7.3. Management of paediatric CRS including integrated 
care pathway
Medical therapy remains the mainstay of management of 
paediatric chronic rhinosinusitis (Table 1.7.1.). Saline nasal 
irrigation is recommended for the treatment of CRS in 
children. Addition of nasal antibiotics to saline irrigations is 
not recommended.  There is currently no evidence to support 
treatment of children with CRS with either oral or intravenous 
antibiotics. There is also no evidence to support the utilization of 
prolonged macrolide therapy in children with CRS. 
Intranasal steroids are recommended for use in children with 
CRS despite the absence of good level evidence.  This is based 
on safety in children and favourable efficacy data in adults with 
CRS (see chapter 6) and children with rhinitis(117). 
There is hardly any scientific support for other ancillary therapies 
such as antihistamines (intranasal or oral), leukotriene modifiers, 
decongestants (intranasal or oral), or mucus thinners and these 
treatments are not recommended. Exceptions are using ancillary 
therapies when indicated for concomitant disease such as 
allergic rhinitis or GORD.
Surgical intervention is considered for patients with CRS who 
have failed appropriate medical therapy (and, less commonly, in 
complicated acute rhinosinusitis). It seems that adenoidectomy 
with / without antral irrigation is certainly the simplest and 
safest first procedure to consider in younger children with 
symptoms of CRS. Evidence suggests that antral irrigation 
should be considered in addition to an adenoidectomy in 
children with asthma who have more severe disease on 
preoperative CT scans. FESS is a safe and possibly effective 
surgical modality in children with CRS and can be used as 
primary modality or after failure of adenoidectomy in older 
children.  Decisions on use depend on severity of disease, age 
and existing co-morbidities. The rate of major complications 
following paediatric FESS was 0.6%, and the rate of minor 
complications 2%.  
The systematic review of the literature resulted in an integrated 
care pathway for paediatric CRS (Figure 1.7.1.). The differential 
diagnosis in primary care is broad with the most essential 
diagnosis in young children being adenoid hypertrophy / 
adenoiditis. In secondary and tertiary care, the ICP also advises 
saline irrigation and INCS as first line treatment followed by 
adenoidectomy with or without sinus irrigation if insufficient. 
FESS is reserved for older children who fail adenoidectomy (with 
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Figure 1.7.1. Integrated care pathway in paediatric CRS. 
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sinus irrigation). CRS in children may be an indication of severe 
diseases such as immunodeficiencies, cystic fibrosis or primary 
ciliary dyskinesia. Practitioners should be aware of these and 
also of serious complications needing immediate referral. 
1.8. Concomitant diseases in chronic rhinosinusitis
Chapter 8 discusses the role of concomitant diseases in CRS. 
The role of allergy, including central compartment atopic 
disease, immunodeficiencies and their role in CRS,  a  work-up 
for ENTs before referring to immunologists, lower airway disease 
including asthma, cystic fibrosis  and PCD, fungal rhinosinusitis, 
vasculitis and granulomatous diseases and their role in CRS are 
all discussed.
1.8.1. Role of allergy and chronic rhinosinusitis
It has become clear in recent years that the role of allergy in CRS 
depends on different phenotypes / endotypes of CRS. In some 
phenotypes / endotypes such as AFRS or central compartment 
atopic disease, allergy seems to play an important role whilst 
in others the prevalence does not seem to be higher than in 
the general population, although even in these patient groups, 
allergy can be an aggravating factor. Allergic rhinitis (AR) is a 
highly prevalent disease and there is a significant overlap in 
symptomatology between CRS and AR. It is not always easy to 
evaluate the role of sensitization to allergens in patients with 
CRS especially in perennial sensitisations.  Optimal treatment of 
the allergic rhinitis seems advisable.
1.8.2. Immunodeficiencies and their role in CRS
Conditions that are associated with immunodeficiency are 
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of clinical importance to rhinologists because some patients 
who present with CRS are predisposed to their condition by 
an underlying immunodeficient state. Immunodeficiency 
conditions may cause CRS patients to respond less favourably 
to standard therapies, and some patients require specific 
treatment for their immunodeficiencies in order for their CRS to 
be optimally treated.
Testing of immune function in all patients who present with 
CRS is almost certainly unwarranted as it is likely to produce 
more false positive results than true positives. However, it is 
recommended that recalcitrance to standard treatments (and 
particularly rapid recurrence of symptoms after stopping 
antibiotics) and association of CRS with lower respiratory 
tract infections (pneumonia, particularly if recurrent, or 
bronchiectasis) are used to identify those patients who warrant 
some form of immune testing.
For CRS patients suspected of having humoral 
immunodeficiency because of the characteristics of their 
presentation or their response to treatment, measurement 
of serum immunoglobulin levels is the key investigation. 
If the levels are normal, but the suspicion of humoral 
immunodeficiency is high, referral to a clinical immunologist is 
recommended. 
The best approach for confirming a diagnosis of an antibody-
deficiency disorder is the measurement of serum-specific 
antibody titres (usually IgG) in response to vaccine antigens. 
This approach involves immunizing a patient with protein 
antigens (e.g. tetanus toxoid) and polysaccharide antigens (e.g. 
pneumococcus) and assessing pre- and post-immunization 
antibody levels.
Treatment of patients with primary immune deficiency 
may consist of long-term antibiotics, often at half dose, 
pneumococcal vaccinations and immunoglobulin replacement 
therapy.
The prevalence of secondary immune deficiency is 
rising due to the increased use of immunosuppressive 
agents such as rituximab, corticosteroids and other drugs 
and otorhinolaryngologists need to directly ask about 
immunosuppressive agents in their history taking. 
1.8.3. Lower airway disease including asthma in relation to 
CRS
Given the epidemiologic and pathophysiologic connection 
between CRS and lower respiratory airway disease(11, 118) the 
concept of global airway disease has gained more interest,  
leading to better diagnosis and therapeutic approaches in 
patients with global airway disease. Lower airway inflammation 
often co-exists in CRS, with up to two thirds of patients with 
CRS affected by comorbid asthma, COPD or bronchiectasis. 
Endoscopic sinus surgery in asthma has been reported to 
improve multiple clinical asthma parameters with improved 
overall asthma control, reduced frequency of asthma attacks 
and number of hospitalizations, as well as decreased use of oral 
and inhaled corticosteroids.
1.8.4. Cystic fibrosis
Cystic fibrosis (CF) is a life-shortening genetic condition caused 
by a mutation in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene leading to defective chloride channels, 
which results in secretions with more than double the viscosity 
of secretions of a non-CF individuals. In the Western world 
national screening programs on specific genetic disorders 
including CF have been implemented for newborns. Bilateral 
nasal polyposis in children may be a clinical indicator of CF. 
A major goal in the treatment of patients with CF is thus 
to prevent or delay chronic lung infections. There is a high 
concordance of bacteria cultured from the paranasal sinuses 
(based on irrigations, swabs, or mucosal biopsies) and from the 
lungs. 
The treatment of CF is currently symptomatic whilst the 
treatment of the underlying genetic defect, thus curing the 
disease, has not yet been possible. However, new treatment 
options such as (the combination of ) Ivacaftor, a CFTR 
potentiator, and Tezacaftor, a selective CFTR corrector, have 
shown promising results in improving rhinologic QOL in 
patients with CF. 
Figure 1.8.1. An overview of the interaction of fungi and the human immune response.
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Several studies have evaluated the effect of sinus surgery on 
pulmonary function with divergent conclusions. Sinus surgery 
is recommended in CF patients without chronic lung infection 
or with a transplanted lung in an attempt to eradicate gram-
negative bacteria in the paranasal sinuses, thereby avoiding 
or preventing re-colonisation of the lungs. Detecting gram-
negative sinus bacteria at an early stage is an important step 
towards eradicating the bacteria and avoiding a chronic 
bacterial sinus infection. The use of topical antibiotics correlates 
with improvement in symptom and endoscopic scoring and is 
safe.
1.8.5. Primary ciliary dyskinesia
Primary ciliary dyskinesia (PCD) is a collection of rare inherited 
disorders that affects motile cilia and is primarily inherited in 
an autosomal recessive manner. Situs inversus (i.e. Kartagener 
syndrome) exists in approximately half of all PCD cases. Both 
men and women diagnosed with PCD commonly present 
with fertility disorders as the reproductive process is largely 
dependent on ciliary function. PCD has a strong association 
with history of CRS, being associated with CRSwNP in 15-30% 
of patients, and is commonly seen in children with CRS.  PCD 
also predisposes to bacterial infections commonly including 
H. influenza, S. pneumoniae and P. aeruginosa. In the absence 
of hard clinical and paraclinical criteria for diagnosing PCD, 
confirming the diagnosis with clinical exam alone is a challenge. 
An electron microscopic analysis of cilia can yield valuable 
information about ciliary ultrastructure and function. However, 
it should be noted that cilia may appear normal in patients 
that present with symptoms strongly suggestive of PCD due to 
mutations that can result in normal structure. 
A number of studies have shown that exhaled nitric oxide (NO), 
particularly nasal NO production levels, are low in PCD patients. 
An nNO cut-off value of <77nl/min can allow detection of PCD 
with a sensitivity and specificity of 98% and >99%, respectively, 
after excluding CF and acute viral respiratory infections. 
Prolonged macrolide therapy has been shown to produce 
marked improvement in symptomatology of PCD due to the 
anti-inflammatory and immune-mediating properties of the 
antibiotic. Surgical intervention (ESS) may be required when 
medical therapy has failed. 
1.8.6. Fungal rhinosinusitis
Fungi are ubiquitous in our environment and with dedicated 
assessments they can be found in nasal mucus from almost all 
healthy and diseased sinuses. However, there are several forms 
of sinus disease that are associated with fungi as pathogens. In 
these situations, rather than the fungi determining the disease 
process, it is usually the host immune state that determines the 
clinical presentation (Figure 1.8.1).  
There was much prior debate regarding the role of fungi in 
CRSwNP. Some authors had proposed that a response to fungi 
might be the basis for most type 2 dominated polypoid forms 
of CRS. However, subsequent research has not supported this(119, 
120). Thus, this chapter will discuss these three phenotypes of 
‘fungal’ related CRS but an intentional focus is made on AFRS 
as a unique phenotype, and its treatment, within the broader 
definition of CRS. 
A fungal ball is a non-invasive collection of fungal debris. 
Recent studies indicate that anatomic variants are not major 
contributors to their formation, which in the maxillary sinus 
is more often related to dental interventions(121-123). Neo-
osteogenesis of the maxillary sinus wall is common with fungal 
balls compared to normal patients and is independent of 
bacterial coinfection(124). Isolated maxillary or sphenoid sinus 
opacification is a marker of neoplasia in 18% and malignancy 
in 7-10% of patients presenting with these radiologic findings 
so clinicians should be wary of conservative management and 
have a low threshold for early surgical intervention(125). Little 
has changed in the management of fungal balls since 2012 
which remains surgical, consisting of removal via an adequate 
antrostomy. However, persistent dysfunction of the sinus 
cavity with mucostasis was reported to be as high as 18%  and, 
therefore, some authors have proposed a medial maxillectomy 
for some maxillary cases(126). Invasive fungal rhinosinusitis 
(IFRS) is almost always associated with immunocompromise, 
of which diabetes (50%) and haematologic malignancy (40%) 
account for 90% of the immunosuppression reported(127). IFRS 
is defined as any state in which fungal hyphae can be seen 
‘within’ the mucosal tissue, demonstrating classic angio-invasion 
or other infiltrative patterns(128) which result in thrombosis, 
tissue infarction and necrosis. Although originally several 
forms of invasive disease were described: granulomatous, 
chronic and fulminant, they all potentially represent an 
immunocompromised host reaction to the fungus(129). The 
most common causative pathogens remain the Zygomycetes 
(Rhizopus, Mucor, Rhizomucor) and the Aspergillus species. 
Unilateral disease on radiology is typical(130, 131) but loss of 
contrast enhancement on MRI is more sensitive (86%) than CT 
(69%) in detecting invasive fungal disease(132). Serum analysis via 
PCR (serum or whole blood) and/or galactomannan for invasive 
aspergillosis can be useful(133).
There are three principles for treatment:
1. Systemic antifungals therapy should be started;
2. Patients should undergo, at least, endoscopic surgical 
debridement of necrotic sinonasal tissue, which may 
need to be repeated;
3. The patient’s immune suppression should be reduced 
when feasible. 
Allergic fungal rhinosinusitis (AFRS) is a subset of polypoid 
chronic rhinosinusitis that is characterized by the presence of 
eosinophilic mucin with non-invasive fungal hyphae within the 
sinuses and a type I hypersensitivity to fungi. The EPOS2020 
steering group discussed whether the term ‘eosinophilic fungal 
rhinosinusitis’ would be a better umbrella term but it was 
agreed that ‘allergic fungal rhinosinusitis’ should be retained as 
the principle term due to common usage, recognising that not 
all cases have evidence of an allergic reaction to fungi. AFRS 
accounts for about 5-10% of CRS cases(134).
Ideally all five of the major criteria in the original Bent-Kuhn 
diagnostic criteria should be met to make the diagnosis as three 
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of the five are common in most cases of CRSwNP. These major 
criteria consist of the following(135):
1. Nasal polyposis;
2. Fungi on staining;
3. Eosinophilic mucin without fungal invasion into sinus 
tissue;
4. Type I hypersensitivity to fungi and;
5. Characteristic radiological findings with soft tissue 
differential densities on CT scanning and unilaterality or 
anatomically discrete sinus involvement.
The minor criteria include bone erosion, Charcot Leyden 
Crystals, unilateral disease, peripheral eosinophilia, positive 
fungal culture and the absence of immunodeficiency or 
diabetes(136). CT shows densely packed hyperdensities in the 
sinuses with expansion and erosion of the bony walls whereas 
on MRI signal voids occur on both T1 and T2 sequences(137).
The mainstay of treatment remains surgery as medical 
treatment alone is usually ineffective. However, oral steroids 
both pre- and postoperatively are of benefit(138). Nebulised 
topical corticosteroids reduce recurrence(139) and allergen 
immunotherapy was also helpful in atopic individuals but 
studies are retrospective and underpowered. There is some 
evidence that oral antifungals may reduce recurrence but do not 
improve symptoms.
Fungal rhinosinusitis remains an important phenotype of CRS in 
its invasive and non-invasive forms. Clinicians should have a low 
threshold for seeking its diagnosis, especially in the presence of 
the immunocompromised. The mainstay of treatment remains 
surgical though may be combined with medical therapies in 
invasive and allergic forms. See Figure 1.6.2. which includes an 
integrated care pathway for AFRS although the steering group 
realized that diagnosis in primary and secondary care can be 
difficult. 
1.8.7. Vasculitis
ANCA-associated vasculitis includes GPA, EGPA and microscopic 
polyangiitis (MPA) and frequently affect the upper respiratory 
tract and specifically the sinonasal region where they may be 
mistaken for more common forms of chronic rhinosinusitis.
Classically GPA affects the nose, lungs and kidneys but can 
present in any system and limited forms of the disease are 
recognised. Two thirds of patients initially present with an 
ENT-related symptom, of which the majority are rhinological. 
During the course of the disease, the majority of GPA patients 
experience nasal symptoms with patients experiencing crusting 
(75%), discharge (70%), nasal stuffiness (65%), bleeding (59%), 
reduced sense of smell (52%) and facial pain (33%)(140, 141). ANCA 
tests have become the mainstay of diagnosis in vasculitis. 
A positive c-ANCA test and proteinase-3 (PR3) will confirm 
the clinical diagnosis of GPA in up to 95% of patients with 
active systemic disease. An ANCA test should be considered 
in any patient with suspicious clinical manifestations, in 
particular nasal crusting and bleeding, especially if they feel 
disproportionally unwell(142).  
Cocaine abuse in the form of nasal ‘snorting’ can resemble the 
sinonasal symptoms of GPA and can give c-ANCA and PR-3 
positivity, making differentiation between the conditions 
difficult(143). Without treatment the mean survival of systemic 
GPA is five months. Modern immunosuppressive treatment 
following a strategy of combined remission, induction and 
maintenance has markedly improved this to a mean survival 
of 21.7 years from diagnosis assisted by higher awareness 
and earlier diagnosis.  Nasal irrigation, topical intranasal 
corticosteroid sprays or creams e.g. triamcinolone and/or a 
nasal lubricant such as 25% glucose and glycerine drops, honey 
ointment or an aqueous gel are usually recommended together 
with regular debridement of the crusts. The possible aetiological 
role of Staphylococcus aureus has led to the use of long-term 
oral co-trimoxazole (trimethoprim-sulfamethoxazole) and 
topical anti-staphylococcal creams in the nose. Reconstructive 
surgery has a very limited role and is associated with poor 
outcomes, increased scarring and adhesions so should be a last 
resort.  Eosinophilic granulomatosis with polyangiitis (EGPA) 
(previously Churg Strauss Syndrome) is a rare form of vasculitis 
characterised by adult onset asthma, severe rhinitis, nasal polyps 
and other systemic manifestations as a result of widespread 
eosinophilic granulomatous infiltration of tissues(144). EGPA 
should be considered in any patient with severe nasal polyposis 
who is not responding to conventional therapy. Active EGPA is 
characterised by marked peripheral eosinophilia (usually >1500 
cells/ul or >10%) and ANCA-positivity is found in a proportion 
of the patients. In most patients, disease control is achieved 
with immunosuppressant therapy, usually oral prednisolone +/- 
cytotoxic drugs such as pulsed cyclophosphamide, azathioprine, 
mycophenolate mofetil and methotrexate dependent on 
the severity of the disease at presentation.  Sarcoidosis is 
a chronic multi-system inflammatory disease of unknown 
aetiology characterised by non-caseating granuloma. There is 
no definitive test for sarcoidosis other than a positive biopsy. 
Blood tests may include raised serum and urinary calcium levels, 
raised alkaline phosphatase and raised serum angiotensin-
converting enzyme (SACE) but none are diagnostic (sensitivity 
60%; specificity 70%). Systemic steroids remain the mainstay of 
treatment in sarcoidosis, though hydroxychloroquine, steroid-
sparing cytotoxic agents such as methotrexate and TNF-alpha 
antagonists such as infliximab are being used.
1.9. Patient participation, prediction, precision 
medicine and implementation
1.9.1. Patient participation in CRS 
Patient participation in rhinosinusitis can relate on an individual 
basis to participation of the patient in the design and/or 
discussion of the treatment plan, or to participation in the 
follow-up after medical or surgical treatment(145). There is limited 
research on the impact of patient participation on outcomes of 
treatment in CRS. 
Patient involvement, moreover,  is recognized as a key 
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component of clinical practice guideline development with 
important implications for guideline implementability(146). 
Aspects of patient participation are covered for the first time 
in EPOS2020 because patient involvement is essential in 
the development of their future care. Patients were actively 
involved in the development of EPOS2020. Recent mobile health 
initiatives to educate patients on CRS, on correct medication use 
and  treatment options have been implemented in certain areas 
in Europe with success(147). Whilst they allow a more proactive 
follow-up of patients with remote monitoring of symptoms by 
physicians(147, 148) the impact of e-health on CRS outcomes still 
needs to be defined and proven.
For individual patients, shared decision-making is one of the 
four cardinal principles of Precision Medicine(149). In order 
to improve compliance, it is important to explain the aim 
of ongoing usage or any maintenance treatments to both 
control symptoms and reduce need for recurrent interventions. 
Information on the safety of treatment and instructions for use 
must be provided in all necessary languages. While physicians 
are likely to understand the chronic nature of sinus disease 
in many patients and the need for ongoing treatment, it is 
essential to share this with the patient from the outset. The aim 
of treatment is to achieve adequate control of symptoms with as 
little need for intervention as possible; for many this will involve 
ongoing usage of intranasal treatments and in some, repeated 
need for systemic treatments or surgical interventions. Some 
patients will remain inadequately controlled despite receiving 
optimum current evidence-based care. Cure, with an absence 
of symptoms in the setting of no ongoing medication usage, 
is unusual in CRS with the exception of localized sinus disease 
where there has been a curable cause, such as an odontogenic 
source. 
1.9.2. Primary, secondary and tertiary disease prevention in 
CRS
Prevention may be considered as primary, secondary and 
tertiary(150). Primary prevention aims to reduce incidence of 
disease by reducing exposure to risk factors or triggers. CRS 
is a heterogeneous disease, where inflammation, mucociliary 
dysfunction and changes in the microbial community interact 
with differing influences to cause disease;  the aetiology is likely 
multifactorial, and opportunities to prevent targeting specific 
causes will likely vary between subgroups. Occupational and 
environmental factors, especially exposure to tobacco smoke, 
are of increasing importance in primary prevention and the 
effects of global warming should be carefully monitored. 
Co-morbidities such as allergy, asthma and GORD should be 
considered. Genetic and microbiological factors will likely 
become of greater importance. Early diagnosis and selection 
of the optimal treatment is central to secondary prevention. 
Optimising medical treatment and consideration of the timing 
and extent of surgery can improve outcomes.  In tertiary 
prevention, a careful review of ongoing treatment, technique 
and compliance with medication should be undertaken. 
Growth in digital healthcare and patient apps may encourage 
self-management and increase compliance. There are a small 
number of studies using big data sets that suggest that 
endoscopic sinus surgery for CRS reduces the yearly incidence 
of new asthma diagnoses. Those patients who have later 
surgery may develop higher rates of asthma than those who 
undergo surgery at an earlier timepoint. Finally, the prevention 
of recurrent disease is important. Continued use of intranasal 
corticosteroids after surgery has been shown to improve 
postoperative endoscopic scores in all CRS patients and, in 
those with CRSwNP, reduce risk of recurrence. Adherence 
with prescribed postoperative medications dropped to only 
42% at 12 months after surgery in one study, despite regular 
telephone contact; strategies to improve this such as utilizing 
digital technology will likely be important in future. One can 
also imagine that other forms of ensuring the application of 
postoperative medication, e.g. by drug eluting stents, may solve 
the problem of compliance. A small number of studies have 
found that ongoing occupational exposure to irritants may 
increase risk of recurrence. Any factors thought to be involved 
in the underlying aetiology of CRS in each individual patient 
should be addressed where possible to reduce risk of recurrence.
In contrast to the large number of studies evaluating changes 
in HRQOL after treatment, few studies have evaluated patient 
satisfaction with outcomes of treatment, and only following 
surgical interventions. Although data is limited, it appears that 
pre-treatment counselling to ensure that a patient has realistic 
expectations of treatment outcomes is important to avoid a 
dissatisfied patient. This is in respect to improvement overall 
and in those symptoms deemed to be most important to the 
patient, as well as optimizing outcomes with respect to their 
nasal symptoms.
1.9.3. Prediction
There are no studies evaluating the natural history of untreated 
CRS although there is some evidence for the adverse effects 
of delayed surgical treatment(151). Notwithstanding ethical 
considerations, there is clearly an urgent need for more 
research in this area. Similarly, there are very few studies 
predicting outcomes of medical treatment.  When predicting 
outcomes following sinus surgery, a number of studies have 
shown that the preoperative symptom score such as SNOT-22 
is the best predictor of outcome(152, 153). Primary surgery has 
better outcomes than revision. When loss of smell is a major 
symptom, response in olfactory function to oral corticosteroids 
(OCS) predicts the outcome of surgery. Prediction of recurrent 
disease involves many factors including age, gender, ethnicity, 
co-morbidities, and duration of disease. Both blood and tissue 
eosinophil levels can be measured with little additional expense 
and may be used to help predict risk of recurrence and need for 
targeted postoperative care.
1.9.4. Precision medicine
In 2015 President Obama launched the precision medicine 
initiative: “delivering the right treatment at the right time, every 
time, to the right person”. The  principles of precision medicine 
can be implemented within existing adult treatment algorithms 
for CRS(149). At the time of diagnosis, prediction of success of the 
initiated treatment as well as patient participation in decisions 
regarding the treatment plan can be undertaken. Precision 
EPOS 2020
26
 References
1. Fokkens W, Lund V, Mullol J. European position 
paper on rhinosinusitis and nasal polyps 2007. 
Rhinol Suppl. 2007:1-136.
2. Fokkens W, Lund V, Bachert C, et al. European 
position paper on rhinosinusitis and nasal 
polyps. Rhinol Suppl. 2005:1-87.
3. Fokkens WJ, Lund VJ, Mullol J, et al. European 
Position Paper on Rhinosinusitis and Nasal Polyps 
2012. Rhinol Suppl. 2012;23:3 p preceding table 
of contents, 1-298.
4. Hastan D, Fokkens WJ, Bachert C, et al. Chronic 
rhinosinusitis in Europe--an underestimated 
disease. A GA(2)LEN study. Allergy 2011;66:1216-
23.
5. Hirsch AG, Stewart WF, Sundaresan AS, et 
al. Nasal and sinus symptoms and chronic 
rhinosinusitis in a population-based sample. 
Allergy 2017;72:274-81.
6. Obaseki D, Potts J, Joos G, et al. The relation 
of airway obstruction to asthma, chronic 
rhinosinusitis and age: results from a population 
survey of adults. Allergy 2014;69:1205-14.
7. Sundaresan AS, Hirsch AG, Storm M, et al. 
Occupational and environmental risk factors 
for chronic rhinosinusitis: a systematic review. 
International Forum of Allergy & Rhinol. 
2015;5:996-1003.
8. Piatt  Jr. JH. Intracranial suppuration complicating 
sinusitis among children: an epidemiological and 
clinical study. J Neurosurg Pediatr 2011;7:567-74.
9. Jaume F, Quintó L, Alobid I, Mullol J. Overuse 
of diagnostic tools and medications in acute 
rhinosinusitis in Spain: a population-based study 
(the PROSINUS study). BMJ open 2018;8:e018788.
10. Wei B, Liu F, Zhang J, et al. Multivariate analysis 
of inflammatory endotypes in recurrent nasal 
polyposis in a Chinese population. Rhinology 
2018;56:216-26.
11.    Tomassen P, Vandeplas G, Van Zele T, et al. 
Inflammatory endotypes of chronic rhinosinusitis 
based on cluster analysis of biomarkers. J Allergy 
Clin Immunol. 2016;137:1449-56.e4. 
12. Jarvis D, Newson R, Lotvall J, et al. Asthma 
in adults and its association with chronic 
rhinosinusitis: the GA2LEN survey in Europe. 
Allergy. 2012;67:91-8.
13. Hakansson K, Thomsen SF, Konge L, Mortensen 
J, Backer V, von Buchwald C. A comparative 
and descriptive study of asthma in chronic 
rhinosinusitis with nasal polyps. Am J Rhinol 
Allergy. 2014;28:383-7.
14. Samitas K, Carter A, Kariyawasam HH, Xanthou 
G. Upper and lower airway remodelling 
mechanisms in asthma, allergic rhinitis and 
chronic rhinosinusitis: The one airway concept 
revisited. Allergy 2018;73:993-1002.
15. van der Veen J, Seys SF, Timmermans M, 
et al. Real-life study showing uncontrolled 
rhinosinusitis after sinus surgery in a tertiary 
referral centre. Allergy 2017;72:282-90.
16. Snidvongs K, Heller GZ, Sacks R, Harvey 
RJ. Validity of European position paper on 
rhinosinusitis disease control assessment 
and modifications in chronic rhinosinusitis. 
Otolaryngol Head Neck Surg. 2014;150:479-86.
17. Calus L, Van Bruaene N, Bosteels C, et al. Twelve-
year follow-up study after endoscopic sinus 
surgery in patients with chronic rhinosinusitis 
with nasal polyposis. Clin and Transl Allergy. 
2019;9:30.
18. Stjärne P, Odebäck P, Ställberg B, Lundberg J, 
Olsson P. High costs and burden of illness in 
acute rhinosinusitis: real-life treatment patterns 
and outcomes in Swedish primary care. Primary 
Care Resp Journal. 2012;21:174-9.
19. Remenschneider AK, Scangas G, Meier JC, et al. 
EQ-5D-derived health utility values in patients 
undergoing surgery for chronic rhinosinusitis. 
Laryngoscope 2015;125:1056-61.
20. Gliklich RE, Metson R. The health impact 
of chronic sinusitis in patients seeking 
otolaryngologic care.  Otolaryngol Head Neck 
Surg. 1995;113:104-9.
21. Teul I, Zbislawski W, Baran S, Czerwinski F, 
Lorkowski J. Quality of life of patients with 
diseases of sinuses. J Physiol Pharmacol. 2007;58 
Suppl 5:691-7.
22. Garbutt J, Spitznagel E, Piccirillo J. Use of the 
modified SNOT-16 in primary care patients with 
clinically diagnosed acute rhinosinusitis. Arch of 
Otolaryng--Head & Neck Surg 2011;137:792-7.
23. Hopkins C, Browne JP, Slack R, et al. The national 
comparative audit of surgery for nasal polyposis 
and chronic rhinosinusitis. Clinical Otolaryngol. 
2006;31:390-8.
24. Teul I, Baran S, Zbislawski W. Upper respiratory 
tract diseases in self-evaluation of health 
status of Polish students based on the SF-36 
questionnaire. J Physiol Pharmacol. 2008;59 
Suppl 6:697-707.
25. Dietz de Loos DA, Hopkins C, Fokkens WJ. 
Symptoms in chronic rhinosinusitis with 
and without nasal polyps. Laryngoscope 
2013;123:57-63.
26. Abdalla S, Alreefy H, Hopkins C. Prevalence of 
sinonasal outcome test (SNOT-22) symptoms 
in patients undergoing surgery for chronic 
medicine allows real-time clinical decision support at the point 
of care with implementation of harmonized care based on 
quality criteria and allows patients to be treated and monitored 
more precisely and effectively to better meet their individual 
needs. It brings together clinicians from many inter-related 
specialities, scientists and above all patients in a collaborative 
effort to provide the most efficient and effective management.
1.9.5. Implementation
The implementation of high-quality guidelines  and position 
papers is essential to improve clinical practice and public health. 
We tried to make EPOS2020 implementable by writing a clear 
and concise executive summary with extensive chapters with 
all the evidence behind it. We hope that the executive summary 
will be translated in all necessary languages. Furthermore, we 
reached out to many key opinion leaders all over the world 
to review and comment on the document and included their 
suggestions in the final text. We do realize that not all advice 
in EPOS2020 can be followed in all health care systems and 
social circumstances. A full implementation plan will be written 
separately to the EPOS2020 document in the near future.
1.10. Pharmacist perspective on rhinosinusitis
Chapter 10 gives the pharmacist’s perspective on rhinosinusitis 
and offers specific advice to pharmacists on how to differentiate 
and treat the various forms of ARS (common cold, post-viral 
rhinosinusitis and acute bacterial rhinosinusitis) and CRS in 
contradistinction to allergic rhinitis. Special emphasis has 
been placed on the avoidance of antibiotics in the treatment 
of rhinosinusitis and the role that the pharmacist can have in 
advising patients on the correct use of nasal sprays.
1.11. Research priorities in rhinosinusitis
Chapter 11 gives an overview of research priorities. In many 
areas of rhinosinusitis, evidence is still of low quality and most 
subchapters in EPOS2020 originally ended with: ‘more research 
is needed to provide high quality evidence’. We decided, 
therefore, to remove the majority of these exortations and to 
collate the most urgent questions in this final chapter.
1.12 Methods used in EPOS2020
In chapter 12 the methods used in EPOS2020 are discussed. 
We describe the development strategy used in EPOS2020, 
which has been published before we started the work(155). We 
did a full systematic review of the literature and used GRADE 
methodology for recommendations. On a large number of 
practical clinical questions with no or or very low level of 
evidence we conducted a Delphi exercise.
EPOS 2020
27
rhinosinusitis in the England and Wales National 
prospective audit. Clin Otolaryngol 2012;37:276-
82.
27. Bhattacharyya N, Lee LN. Evaluating the 
diagnosis of chronic rhinosinusitis based on 
clinical guidelines and endoscopy. Otolaryngol 
Head Neck Surg. 2010;143:147-51.
28. Bhattacharyya N. Contemporary assessment of 
the disease burden of sinusitisThe economic 
burden and symptom manifestations of chronic 
rhinosinusitis. Am J Rhinol Allergy. 2009;23:392-5.
29. Wahid NW, Smith R, Clark A, Salam M, Philpott 
C. The Socioeconomic Cost of Chronic 
Rhinosinusitis Study. Rhinology 2020;58,2:112-
125.
30. Lourijsen ES, Fokkens WJ, Reitsma S. Direct 
and indirect costs of Dutch adult patients 
with Chronic Rhinosinusitis with nasal polyps. 
Rhinology 2020;3:213-217.
31. Bhattacharyya N. Assessing the additional 
disease burden of polyps in chronic 
rhinosinusitis. The Annals of otology, rhinology, 
and laryngology 2009;118:185-9.
32. Gross  Mark;Burgess LP, Rick; Sheridan. 
Endoscopic Sinus Surgery Complications in 
Residency. Laryngoscope 1997;107:1080-5.
33. Gliklich RE, Metson R. Economic implications of 
chronic sinusitis. Otolaryngol Head Neck Surg. 
1998;118:344-9.
34. Bhattacharyya N, Orlandi RR, Grebner 
J, Martinson M. Cost burden of chronic 
rhinosinusitis: a claims-based study. Otolaryngol 
Head Neck Surg. 2011;144:440-5.
35. Blackwell DL, Collins JG, Coles R. Summary 
health statistics for U.S. adults: National Health 
Interview Survey, 1997. Vital Health Stat. 10 
2002:1-109.
36. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. 
The health and productivity cost burden of the 
“top 10” physical and mental health conditions 
affecting six large U.S. employers in 1999. J 
Occup Environ Med. 2003;45:5-14.
37. Rudmik L. Economics of Chronic Rhinosinusitis. 
Current Allergy and Asthma Reports 2017;17:20.
38. Hoffmans R, Wagemakers A, van Drunen C, 
Hellings P, Fokkens W. Acute and chronic 
rhinosinusitis and allergic rhinitis in relation to 
comorbidity, ethnicity and environment. PloS 
one 2018;13:e0192330.
39. Revai K, Dobbs LA, Nair S, Patel JA, Grady JJ, 
Chonmaitree T. Incidence of acute otitis media 
and sinusitis complicating upper respiratory 
tract infection: the effect of age. Pediatrics 
2007;119:e1408-12.
40. Benninger MS, Ferguson BJ, Hadley JA, et 
al. Adult chronic rhinosinusitis: Definitions, 
diagnosis, epidemiology, and pathophysiology. 
Otolaryngol - Head & Neck Surg. 2003;129:S1-32.
41. Shapiro DJ, Gonzales R, Cabana MD, Hersh AL. 
National trends in visit rates and antibiotic 
prescribing for children with acute sinusitis. 
Pediatrics. 2011;127:28-34.
42. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, 
et al. Clinical practice guideline (update): Adult 
sinusitis. Otolaryngology - Head and Neck 
Surgery (United States) 2015;152:S1-S39.
43. Leung R, Almassian S, Kern R, Conley D, Tan 
B, Chandra R. Patient level decision making 
in recurrent acute rhinosinusitis: a cost-
benefit threshold for surgery. Laryngoscope. 
2013;123:11-6.
44. Alkire BC, Bhattacharyya N. An assessment 
of sinonasal anatomic variants potentially 
associated with recurrent acute rhinosinusitis. 
Laryngoscope. 2010;120:631-4.
45. Jain R, Stow N, Douglas R. Comparison of 
anatomical abnormalities in patients with limited 
and diffuse chronic rhinosinusitis. Int Forum 
Allergy Rhinol. 2013;3:493-6.
46. Loftus PA, Lin J, Tabaee A. Anatomic variants of 
the paranasal sinuses in patients with recurrent 
acute rhinosinusitis. Int Forum of Allergy & 
Rhinol. 2016;6:328-33.
47. Costa ML, Psaltis AJ, Nayak JV, Hwang PH. 
Medical therapy vs surgery for recurrent 
acute rhinosinusitis. Int Forum Allergy Rhinol. 
2015;5:667-73.
48. De Sario M, Katsouyanni K, Michelozzi P. Climate 
change, extreme weather events, air pollution 
and respiratory health in Europe. Eur Resp 
Journal. 2013, 826-43.
49. Kuiper JR, Hirsch AG, Bandeen-Roche K, et al. 
Prevalence, severity, and risk factors for acute 
exacerbations of nasal and sinus symptoms 
by chronic rhinosinusitis status. Allergy. 
2018;73:1244-53.
50. Eyigor H, Basak S. [Evaluation of predisposing 
factors and bacteriologic agents in pediatric 
rhinosinusitis]. Kulak Burun Bogaz Ihtis Derg 
2005;15:49-55.
51. Pant H, Ferguson BJ, Macardle PJ. The role of 
allergy in rhinosinusitis. Curr Opin Otolaryngol 
Head Neck Surg. 2009;17:232-8.
52. Flook EP, Kumar BN. Is there evidence to link 
acid reflux with chronic sinusitis or any nasal 
symptoms? A review of the evidence. Rhinology. 
2011;49:11-6.
53. Seresirikachorn K, Snidvongs K, Chitsuthipakorn 
W, et al. EPOS2012 has better specificity com-
pared to IDSA2012 for diagnosing acute bacterial 
rhinosinusitis. Rhinology. 2018;56:241-4.
54. Pilan RR, Pinna FR, Bezerra TF, et al. Prevalence 
of chronic rhinosinusitis in Sao Paulo. Rhinology. 
2012;50:129-38.
55. Shi JB, Fu QL, Zhang H, et al. Epidemiology 
of chronic rhinosinusitis: results from a cross-
sectional survey in seven Chinese cities. Allergy. 
2015;70:533-9.
56. Dietz de Loos D, Lourijsen ES, Wildeman MAM, 
et al. Prevalence of chronic rhinosinusitis in the 
general population based on sinus radiology 
and symptomatology. J Allergy Clin Immunol. 
2019;143:1207-14.
57. Tomassen P, Newson RB, Hoffmans R, et al. 
Reliability of EP3OS symptom criteria and 
nasal endoscopy in the assessment of chronic 
rhinosinusitis--a GA(2) LEN study. Allergy. 
2011;66:556-61.
58. Hirsch AG, Nordberg C, Bandeen-Roche K, et al. 
Radiologic sinus inflammation and symptoms 
of chronic rhinosinusitis in a population-based 
sample. Allergy. 2019, 10.1111/all.14106.
59. Hamizan AW, Loftus PA, Alvarado R, et al. Allergic 
phenotype of chronic rhinosinusitis based on 
radiologic pattern of disease. Laryngoscope. 
2018;128:2015-21.
60. Philpott CM, Erskine S, Hopkins C, et al. 
Prevalence of asthma, aspirin sensitivity and 
allergy in chronic rhinosinusitis: data from the 
UK National Chronic Rhinosinusitis Epidemiology 
Study. Respiratory research 2018;19:129.
61. De Schryver E, Derycke L, Campo P, et al. Alcohol 
hyper-responsiveness in chronic rhinosinusitis 
with nasal polyps. Clin Exp Allergy 2016, 10.1111/
cea.12836.
62. Endam LM, Filali-Mouhim A, Boisvert P, Boulet 
L-P, Bosse Y, Desrosiers M. Genetic variations 
in taste receptors are associated with chronic 
rhinosinusitis: a replication study. Int forum All & 
Rhinology. 2014;4:200-6.
63. Purnell PR, Addicks BL, Zalzal HG, et al. Single 
Nucleotide Polymorphisms in Chemosensory 
Pathway Genes GNB3, TAS2R19, and TAS2R38 Are 
Associated with Chronic Rhinosinusitis. Int Arch 
Allergy Immunol. 2019;180:72-8.
64. Stevens WW, Peters AT, Tan BK, et al. Associations 
Between Inflammatory Endotypes and Clinical 
Presentations in Chronic Rhinosinusitis. The 
Jof Allergy and Clin Immunol In Practice. 2019, 
10.1016/j.jaip.2019.05.009.
65. Brook CD, Kuperstock JE, Rubin SJ, Ryan MW, 
Platt MP. The association of allergic sensitization 
with radiographic sinus opacification. Am J 
Rhinol Allergy 2017;31:12-5.
66. Hummel T, Whitcroft KL, Andrews P, et al. Position 
paper on olfactory dysfunction. Rhinology 
Supplement 2017;54:1-30.
67. Stogbauer J, Wirkner K, Engel C, et al. Prevalence 
and risk factors of smell dysfunction - a 
comparison between five German population-
based studies. Rhinology. 2019, 10.4193/
Rhin19.181.
68. Landis BN, Hummel T. New evidence for high 
occurrence of olfactory dysfunctions within the 
population. Am J Med. 2006;119:91-2.
69. Lane AP, Turner J, May L, Reed R. A genetic model 
of chronic rhinosinusitis-associated olfactory 
inflammation reveals reversible functional 
impairment and dramatic neuroepithelial 
reorganization. J Neurosci. 2010;30:2324-9.
70. Pfaar O, Landis BN, Frasnelli J, Huttenbrink 
KB, Hummel T. Mechanical obstruction of the 
olfactory cleft reveals differences between 
orthonasal and retronasal olfactory functions. 
Chem Senses. 2006;31:27-31.
71. Jones NS. Sinogenic facial pain: Diagnosis and 
management. Otolaryngol Clin North Am. 
2005;38:1311-25.
72. Kirsch CFE, Bykowski J, Aulino JM, et al. ACR 
Appropriateness Criteria((R)) Sinonasal Disease. J 
Am Coll Radiol 2017;14:S550-9.
73. Younis RT, Anand VK, Davidson B. The role 
of computed tomography and magnetic 
resonance imaging in patients with sinusitis with 
complications. Laryngoscope 2002;112:224-9.
74. Bhattacharyya N. A comparison of symptom 
scores and radiographic staging systems in 
chronic rhinosinusitis. American J of Rhinology 
EPOS 2020
28
2005;19:175-9.
75. Lund VJ, Kennedy DW. Staging for rhinosinusitis. 
Otolaryng - Head & Neck Surg. 1997;117:S35-40.
76. Bayonne E, Kania R, Tran P, Huy B, Herman P. 
Intracranial complications of rhinosinusitis. A 
review, typical imaging data and algorithm of 
management*. Rhinology. 2009;47:59-65.
77. Lund VJ, Mackay IS. Staging in rhinosinusitus. 
Rhinology. 1993;31:183-4.
78. Orlandi RR, Kingdom TT, Hwang PH, et al. 
International Consensus Statement on Allergy 
and Rhinology: Rhinosinusitis. Int Forum Allergy 
Rhinol. 2016;6 Suppl 1:S22-S209.
79. Amine M, Lininger L, Fargo KN, Welch KC. 
Outcomes of endoscopy and computed 
tomography in patients with chronic 
rhinosinusitis. Int Forum Allergy Rhinol.  
2013;3:73-9.
80. Daramola OO, Lidder AK, Ramli R, et al. Patient 
knowledge and perception of computed 
tomography scan in the management of 
chronic rhinosinusitis symptoms. Laryngoscope. 
2015;125:791-5.
81. Leung RM, Chandra RK, Kern RC, Conley DB, 
Tan BK. Primary care and upfront computed 
tomography scanning in the diagnosis of chronic 
rhinosinusitis: A cost-based decision analysis. 
Laryngoscope. 2014;124:12-8.
82. Bulla S, Blanke P, Hassepass F, et al. Reducing 
the radiation dose for low-dose CT of the 
paranasal sinuses using iterative reconstruction: 
Feasibility and image quality. Eur J of Radiology. 
2012;81:2246-50.
83. Sodickson A. CT radiation risks coming into 
clearer focus. BMJ. 2013;346:f3102-f.
84. Fraczek M, Guzinski M, Morawska-Kochman M, 
Krecicki T. Investigation of sinonasal anatomy 
via low-dose multidetector CT examination in 
chronic rhinosinusitis patients with higher risk 
for perioperative complications. Eur Arch of Oto-
Rhino-Laryngol. 2017;274:787-93.
85. Gevaert P, Van Bruaene N, Cattaert T, et al. 
Mepolizumab, a humanized anti-IL-5 mAb, as a 
treatment option for severe nasal polyposis. J of 
Allergy and Clin. Imm. 2011;128:988-9.
86. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody 
FM, Naclerio RM. A randomized, double-blind, 
placebo-controlled trial of anti-IgE for chronic 
rhinosinusitis. Rhinology. 2010;48:318-24.
87. Hopkins C, Hettige R, Soni-Jaiswal A, et al. 
CHronic Rhinosinusitis Outcome MEasures 
(CHROME), developing a core outcome set for 
trials of interventions in chronic rhinosinusitis. 
Rhinology. 2018;56:22-32.
88. Kim DH, Seo Y, Kim KM, Lee S, Hwang SH. 
Usefulness of Nasal Endoscopy for Diagnosing 
Patients With Chronic Rhinosinusitis: A Meta-
Analysis. Am J Rhinol Allergy. 2019, 10.1177/1945
892419892157:1945892419892157.
89. Flores Kim J, McCleary N, Nwaru BI, Stoddart A, 
Sheikh A. Diagnostic accuracy, risk assessment, 
and cost-effectiveness of component-resolved 
diagnostics for food allergy: A systematic review. 
Allergy. 2018;73:1609-21.
90. Eiringhaus K, Renz H, Matricardi P, Skevaki C. 
Component-Resolved Diagnosis in Allergic 
Rhinitis and Asthma. J Appl Lab Med 2019;3:883-
98.
91. Lotsch J, Hummel T. A data science-based 
analysis of seasonal patterns in outpatient 
presentations due to olfactory dysfunction. 
Rhinology. 2019, 10.4193/Rhin19.099.
92. Rimmer J, Hellings P, Lund VJ, et al. European 
position paper on diagnostic tools in rhinology. 
Rhinology. 2019;57:1-41.
93. Kern RC. Chronic sinusitis and anosmia: 
pathologic changes in the olfactory mucosa. 
Laryngoscope. 2000;110:1071-7.
94. Apter AJ, Gent JF, Frank ME. Fluctuating olfactory 
sensitivity and distorted odor perception in 
allergic rhinitis. Arch Otolaryngol Head Neck 
Surg. 1999;125:1005-10.
95. Hsieh JW, Keller A, Wong M, Jiang R-S, Vosshall 
LB. SMELL-S and SMELL-R: Olfactory tests not 
influenced by odor-specific insensitivity or prior 
olfactory experience. Proc of the Nat Academy of 
Sciences. 2017;114:11275-84.
96. Leite SHP, Jain R, Douglas RG. The clinical 
implications of computerised fluid dynamic 
modelling in rhinology. Rhinology. 2019;57:2-9.
97. Wong E, Inthavong K, Singh N. Comment on the 
European position paper on diagnostic tools 
in rhinology - computational fluid dynamics. 
Rhinology. 2019, 10.4193/Rhin19.269.
98. Rimmer J. Reply to the letter by Wong et al. 
Rhinology. 2019, 10.4193/Rhin19.296.1.
99. Snidvongs K, Lam M, Sacks R, et al. Structured 
histopathology profiling of chronic rhinosinusitis 
in routine practice. Int Forum All & Rhinology. 
2012;2:376-85.
100. Jiang N, Kern RC, Altman KW. Histopathological 
evaluation of chronic rhinosinusitis: a critical 
review. Am J of Rhinol & Allergy. 2013;27:396-
402.
101. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA 
consensus on biologics for CRSwNP with or 
without asthma. Allergy. 2019;74:2312-9.
102. Hoggard M, Zoing M, Biswas K, Taylor MW, 
Douglas RG. The sinonasal mycobiota in chronic 
rhinosinusitis and control patients. Rhinology. 
2019;57:190-9.
103. Bachert C, Han JK, Desrosiers M, et al. Efficacy 
and safety of dupilumab in patients with severe 
chronic rhinosinusitis with nasal polyps (LIBERTY 
NP SINUS-24 and LIBERTY NP SINUS-52): results 
from two multicentre, randomised, double-blind, 
placebo-controlled, parallel-group phase 3 trials. 
Lancet. 2019;394:1638-50.
104. Bachert C, Sousa AR, Lund VJ, et al. Reduced 
need for surgery in severe nasal polyposis with 
mepolizumab: Randomized trial. J Allergy Clin 
Immunol. 2017;140:1024-31.e14.
105. Rudmik L, Soler ZM, Hopkins C, et al. Defining 
appropriateness criteria for endoscopic sinus 
surgery during management of uncomplicated 
adult chronic rhinosinusitis: a RAND/UCLA 
appropriateness study. Int Forum Allergy Rhinol. 
2016;6:557-67.
106. Beswick DM, Mace JC, Rudmik L, Soler ZM, 
DeConde AS, Smith TL. Productivity changes 
following medical and surgical treatment of 
chronic rhinosinusitis by symptom domain. Int 
Forum Allergy Rhinol. 2018;8:1395-405.
107. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis 
and management of NSAID-Exacerbated 
Respiratory Disease (N-ERD)-a EAACI position 
paper. Allergy. 2018, 10.1111/all.13599.
108. Oakley GM, Christensen JM, Sacks R, Earls 
P, Harvey RJ. Characteristics of macrolide 
responders in persistent post-surgical 
rhinosinusitis. Rhinology. 2018;56:111-7.
109. Sidell D, Shapiro NL, Bhattacharyya N. Obesity 
and the risk of chronic rhinosinusitis, allergic 
rhinitis, and acute otitis media in school-age 
children. Laryngoscope. 2013;123:2360-3.
110. Reh DD, Higgins TS, Smith TL. Impact of tobacco 
smoke on chronic rhinosinusitis: A review of the 
literature. Int. Forum of Allergy and Rhinol. 2012, 
362-9.
111. Georgalas C, Vlastos I, Picavet V, van Drunen C, 
Garas G, Prokopakis E. Is chronic rhinosinusitis 
related to allergic rhinitis in adults and children? 
Applying epidemiological guidelines for 
causation. Allergy. 2014;69:828-33.
112. Neff L, Adil EA. What is the role of the adenoid in 
pediatric chronic rhinosinusitis? Laryngoscope. 
2015;125:1282-3.
113. Belcher R, Virgin F. The Role of the Adenoids in 
Pediatric Chronic Rhinosinusitis. Med Sci. (Basel) 
2019;7.
114. Brietzke SE, Shin JJ, Choi S, et al. Clinical 
consensus statement: pediatric chronic 
rhinosinusitis. Otolaryngol - Head & Neck 
Surgery. 2014;151:542-53.
115. Orb Q, Curtin K, Oakley GM, et al. Familial risk of 
pediatric chronic rhinosinusitis. Laryngoscope. 
2016;126:739-45.
116. Skoner DP, Anfuso A, Ramadan H, et al. Sinus and 
adenoid inflammation in children with chronic 
rhinosinusitis and asthma. Am J of Resp and Crit 
Care Med. 2015;191.
117. Schenkel EJ, Skoner DP, Bronsky EA, et al. 
Absence of growth retardation in children 
with perennial allergic rhinitis after one year of 
treatment with mometasone furoate aqueous 
nasal spray. Pediatrics. 2000;105:E22.
118. Yoo KH, Ahn HR, Park JK, et al. Burden of 
Respiratory Disease in Korea: An Observational 
Study on Allergic Rhinitis, Asthma, COPD, and 
Rhinosinusitis. Allergy Asthma Immunol Res. 
2016;8:527-34.
119. Orlandi RR, Marple BF. The role of fungus in 
chronic rhinosinusitis. Otolaryngol Clin North Am 
2010;43:531-7, viii.
120. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: 
European position paper on rhinosinusitis 
and nasal polyps 2012. A summary for 
otorhinolaryngologists. Rhinology. 2012;50:1-12.
121. Oshima H, Nomura K, Sugawara M, Arakawa K, 
Oshima T, Katori Y. Septal deviation is associated 
with maxillary sinus fungus ball in male patients. 
The Tohoku J of exp medicine. 2014;232:201-6.
122. Yoon YH, Xu J, Park SK, Heo JH, Kim YM, Rha KS. 
A retrospective analysis of 538 sinonasal fungus 
ball cases treated at a single tertiary medical 
EPOS 2020
29
center in Korea (1996-2015). Int Forum Allergy 
Rhinol. 2017;7:1070-5.
123. Park GY, Kim HY, Min JY, Dhong HJ, Chung SK. 
Endodontic treatment: a significant risk factor 
for the development of maxillary fungal ball. Clin 
Exp Otorhinolaryngol. 2010;3:136-40.
124. Jun YJ, Shin JM, Lee JY, Baek BJ. Bony Changes 
in a Unilateral Maxillary Sinus Fungal Ball. J 
Craniofac Surg. 2018;29:e44-e7.
125. Knisely A, Holmes T, Barham H, Sacks R, Harvey 
R. Isolated sphenoid sinus opacification: 
A systematic review. Am J Otolaryngol. 
2017;38:237-43.
126. Nomura K, Asaka D, Nakayama T, et al. Sinus 
fungus ball in the Japanese population: clinical 
and imaging characteristics of 104 cases. Int J 
Otolaryngol. 2013;2013:731640.
127. Turner JH, Soudry E, Nayak JV, Hwang PH. 
Survival outcomes in acute invasive fungal 
sinusitis: a systematic review and quantitative 
synthesis of published evidence. Laryngoscope. 
2013;123:1112-8.
128. Trief D, Gray ST, Jakobiec FA, et al. Invasive fungal 
disease of the sinus and orbit: a comparison 
between mucormycosis and Aspergillus. Br J 
Ophthalmol 2016;100:184-8.
129. deShazo RD, O’Brien M, Chapin K, Soto-Aguilar 
M, Gardner L, Swain R. A new classification and 
diagnostic criteria for invasive fungal sinusitis. 
Arch. of Otolaryngol. -- Head & Neck Surgery. 
1997;123:1181-8.
130. Wandell GM, Miller C, Rathor A, et al. A multi-
institutional review of outcomes in biopsy-
proven acute invasive fungal sinusitis. Int Forum 
Allergy Rhinol. 2018;8:1459-68.
131. Payne SJ, Mitzner R, Kunchala S, Roland L, 
McGinn JD. Acute Invasive Fungal Rhinosinusitis: 
A 15-Year Experience with 41 Patients. 
Otolaryngol Head Neck Surg. 2016;154:759-64.
132. Groppo ER, El-Sayed IH, Aiken AH, Glastonbury 
CM. Computed tomography and magnetic 
resonance imaging characteristics of acute 
invasive fungal sinusitis. Arch Otolaryngol Head 
Neck Surg. 2011;137:1005-10.
133. Arvanitis M, Anagnostou T, Mylonakis E. 
Galactomannan and Polymerase Chain Reaction-
Based Screening for Invasive Aspergillosis 
Among High-Risk Hematology Patients: A 
Diagnostic Meta-analysis. Clin Infect Dis. 
2015;61:1263-72.
134. Bakhshaee M, Fereidouni M, Nourollahian M, 
Movahed R. The presence of fungal-specific IgE in 
serum and sinonasal tissue among patients with 
sinonasal polyposis. Eur. Archives of Oto-rhino-
laryng. 2014;271:2871-5.
135. Bent 3rd JP, Kuhn FA, Bent JP, Kuhn FA. Diagnosis 
of allergic fungal sinusitis. Otolaryngol Head 
Neck Surg. 1994;111:580-8.
136. deShazo RD, Swain RE. Diagnostic criteria for 
allergic fungal sinusitis. J of Allergy & Clin.
Immunology. 1995;96:24-35.
137. Aribandi M, McCoy VA, Bazan C, 3rd. Imaging 
features of invasive and noninvasive fungal 
sinusitis: a review. Radiographics. 2007;27:1283-
96.
138. Landsberg R, Segev Y, DeRowe A, Landau T, Khafif 
A, Fliss DM. Systemic corticosteroids for allergic 
fungal rhinosinusitis and chronic rhinosinusitis 
with nasal polyposis: a comparative study. 
Otolaryngol Head Neck Surg. 2007;136:252-7.
139. Dai Q, Duan C, Liu Q, Yu H. Effect of nebulized 
budesonide on decreasing the recurrence of 
allergic fungal rhinosinusitis. Am J of otolaryngol. 
2017;38:321-4.
140. Gottschlich S, Ambrosch P, Kramkowski D, et 
al. Head and neck manifestations of Wegener’s 
granulomatosis. Rhinology. 2006;44:227-33.
141. Srouji IA, Andrews P, Edwards C, Lund VJ. Patterns 
of presentation and diagnosis of patients with 
Wegener’s granulomatosis: ENT aspects. The J of 
Laryngol and otology. 2007;121:653-8.
142. Bossuyt X, Cohen Tervaert J-W, Arimura 
Y, et al. Position paper: Revised 2017 
international consensus on testing of ANCAs 
in granulomatosis with polyangiitis and 
microscopic polyangiitis. Nature reviews 
Rheumatol. 2017;13:683-92.
143. Trimarchi M, Bertazzoni G, Bussi M. Cocaine 
induced midline destructive lesions. Rhinology. 
2014;52:104-11.
144. Greco A, Marinelli C, Fusconi M, et al. Clinic 
manifestations in granulomatosis with 
polyangiitis. Int. J of immunopath pharmacol. 
2016;29:151-9.
145. Hellings PW. Joint action with European CRSwNP 
Patients for better outcomes. Rhinology. 
2019;57:321.
146. Pugin B, Deneyer L, Bachert C, et al. Patient 
Advisory Board for Chronic Rhinosinusitis - A 
EUFOREA initiative. Rhinology. 2019;57:331-5.
147. Seys SF, Bousquet J, Bachert C, et al. 
mySinusitisCoach: patient empowerment in 
chronic rhinosinusitis using mobile technology. 
Rhinology. 2018;56:209-15.
148. Khanwalkar AR, Shen J, Kern RC, et al. Utilization 
of a novel interactive mobile health platform to 
evaluate functional outcomes and pain following 
septoplasty and functional endoscopic sinus 
surgery. Int Forum Allergy Rhinol. 2019;9:345-51.
149. Hellings PW, Fokkens WJ, Bachert C, et al. 
Positioning the principles of precision medicine 
in care pathways for allergic rhinitis and chronic 
rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS 
ICP statement. Allergy. 2017;72:1297-305.
150. Hopkins C, Surda P, Bast F, Hettige R, Walker A, 
Hellings PW. Prevention of chronic rhinosinusitis. 
Rhinology. 2018;56:307-15.
151. Hopkins C, Rimmer J, Lund VJ. Does time to 
endoscopic sinus surgery impact outcomes in 
Chronic Rhinosinusitis? Prospective findings 
from the National Comparative Audit of Surgery 
for Nasal Polyposis and Chronic Rhinosinusitis. 
Rhinology. 2015;53:10-7.
152. Hopkins C, Rudmik L, Lund VJ. The predictive 
value of the preoperative Sinonasal Outcome 
Test-22 score in patients undergoing endoscopic 
sinus surgery for chronic rhinosinusitis. 
Laryngoscope. 2015;125:1779-84.
153. Rudmik L, Soler ZM, Hopkins C. Using 
postoperative SNOT-22 to help predict the 
probability of revision sinus surgery. Rhinology. 
2016;54:111-6.
154. Grayson JW, Hopkins C, Mori E, Senior B, Harvey 
RJ. Contemporary Classification of Chronic 
Rhinosinusitis Beyond Polyps vs No Polyps: A 
Review. JAMA Otolaryngol Head Neck Surg. 
2020; doi: 10.1001/jamaoto.2020.1453.
155. Fokkens W, Desrosiers M, Harvey R, et al. 
EPOS2020: development strategy and goals 
for the latest European Position Paper on 
Rhinosinusitis. Rhinology 2019;57:162-8.
EPOS 2020
30
31
  EPOS 2020 POSITION PAPER
2.1. Defintions
2.1.1. Sinusitis vs. rhinosinusitis 
Rhinosinusitis recognises that rhinitis and sinusitis co-exist and 
that physiologically and pathophysiologically it is difficult to 
make a distinction between the nose and sinuses although one 
area may be more evidently affected than another. This term 
was first used in the early 1990s and has been widely adopted 
internationally(1-9). 
In primary care, GPs may distinguish between rhinosinusitis 
and rhinitis, in secondary care ENT surgeons may distinguish 
between phenotypes of rhinosinusitis and in tertiary care, rhino-
logists may distinguish between rhinosinusitis endotypes.
In primary care, patients with symptoms of nasal obstruction, 
discharge, pressure, pain, lack of barotrauma and often retained 
sense of smell are likely to have rhinitis only(10). Additionally, 
those who are younger (<35 years) with seasonality, distinct 
allergen exacerbations and involvement of other sites (conjunc-
tiva, lung, skin) are likely to have rhinitis(11-13).
2.1.2. Clinical definition
2.1.2.1. Adults 
Rhinosinusitis = inflammation of the nose and paranasal sinuses 
characterised by two or more symptoms*, one of which should 
be either nasal blockage/obstruction/congestion or nasal 
discharge (anterior/posterior nasal drip):
• ± facial pain/pressure
• ± reduction or loss of sense of smell
and either
• endoscopic signs of: 
- nasal polyps and/or
- mucopurulent discharge primarily from middle meatus 
and/or 
- oedema/mucosal obstruction primarily in middle meatus 
and/or
• CT changes:
- mucosal changes within the ostiomeatal complex and/or 
sinuses
[Minimal thickening, involving only 1 or 2 walls and not the 
ostial area is unlikely to represent rhinosinusitis(14, 15)]
[*It is recognised that symptoms have high sensitivity, but low 
specificity hence the need for objective findings.]
2.1.2.2. Children 
Rhinosinusitis = inflammation of the nose and paranasal sinuses 
characterised by two or more symptoms, one of which should 
be either nasal blockage/obstruction/congestion or nasal 
discharge (anterior/posterior nasal drip):
• ± facial pain
• ± cough(16)
and either
• endoscopic signs of:
- nasal polyps and/or
- mucopurulent discharge primarily from middle meatus 
and/or 
- oedema/mucosal obstruction primarily in middle meatus
and/or
• CT changes: 
- mucosal changes within the ostiomeatal complex and/or 
sinuses
2.1.3. Definition for epidemiology studies and General 
Practice 
For epidemiological studies and general practice, the definition 
is based on symptomatology usually without ENT examination 
or radiology.
2.1.3.1. Acute rhinosinusitis (ARS) in adults 
Acute rhinosinusitis in adults is defined as: 
sudden onset of two or more symptoms, one of which should be 
either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip): 
• ± facial pain/pressure, 
• ± reduction or loss of smell 
for <12 weeks; 
with symptom free intervals if the problem is recurrent, with 
validation by telephone or interview.
2.1.3.2. Acute rhinosinusitis in children 
Acute rhinosinusitis in children is defined as: 
2. Classification, definitions and terminology
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sudden onset of two or more of the symptoms: 
• nasal blockage/obstruction/congestion 
• or discoloured nasal discharge
• or cough (daytime and night-time) 
for < 12 weeks; 
with symptom free intervals if the problem is recurrent; 
with validation by telephone or interview.
Questions on allergic symptoms (i.e. sneezing, watery rhinor-
rhoea, nasal itching, and itchy watery eyes) should be included. 
2.1.3.3. Recurrent acute rhinosinusitis (RARS)
ARS can occur once or more than once in a defined time period. 
This is usually expressed as episodes/year but with complete 
resolution of symptoms between episodes.
Recurrent ARS (RARS) is defined as ≥ 4 episodes per year with 
symptom free intervals(3, 17). 
2.1.3.3. Definition of chronic rhinosinusitis in adults 
Chronic rhinosinusitis (with or without nasal polyps) in adults is 
defined as: 
presence of two or more symptoms, one of which should be 
either nasal blockage / obstruction / congestion or nasal dischar-
ge (anterior / posterior nasal drip): 
• ± facial pain/pressure; 
• ± reduction or loss of smell; 
for ≥12 weeks; 
with validation by telephone or interview.
Questions on allergic symptoms (i.e. sneezing, watery rhinor-
rhoea, nasal itching, and itchy watery eyes) should be included.
2.1.3.4. Definition of chronic rhinosinusitis in children 
Chronic rhinosinusitis (with or without nasal polyps) in children 
is defined as: 
presence of two or more symptoms one of which should be 
either nasal blockage / obstruction / congestion or nasal dischar-
ge (anterior/posterior nasal drip): 
• ± facial pain/pressure; 
• ± cough; 
for ≥12 weeks; 
with validation by telephone or interview.
2.1.4. Definition for research 
For research purposes acute rhinosinusitis is defined as per the 
clinical definition. Bacteriology (antral tap, middle meatal cul-
ture) and/or radiology (CT) are advised, but not obligatory. 
For research purposes chronic rhinosinusitis is defined as per 
the clinical definition and should be based on phenotypes and 
endotypes, with and without previous surgery. It may include 
sub-analysis for other co-morbidities. 
2.1.4.1. Definition of chronic rhinosinusitis when no earlier 
sinus surgery has been performed 
Chronic rhinosinusitis with nasal polyps: bilateral, endoscopi-
cally visualised in middle meatus. 
Chronic rhinosinusitis without nasal polyps: no visible polyps in 
middle meatus, if necessary following decongestant.
This definition accepts that there is a spectrum of disease in CRS 
which includes polypoid change in the sinuses and/or middle 
meatus but excludes those with polypoid disease presenting in 
the nasal cavity to avoid overlap.
2.1.4.2. Definition of chronic rhinosinusitis when sinus sur-
gery has been performed 
Once surgery has altered the anatomy of the lateral wall, the 
presence of polyps is defined as bilateral pedunculated lesions 
as opposed to cobblestoned mucosa >6 months after surgery 
on endoscopic examination. Any mucosal disease without overt 
polyps should be regarded as chronic rhinosinusitis without 
nasal polyps.
2.1.4.3. Co-morbidities for sub-analysis in research 
The following conditions should be considered for sub-analysis: 
1. NSAID-exacerbated respiratory disease (N-ERD). Aspirin 
sensitivity based on positive oral, bronchial, or nasal provo-
cation or an obvious history; 
2. Asthma / bronchial hyper-reactivity / chronic obstructive 
pulmonary disease (COPD) / bronchiectasies based on 
symptoms, respiratory function tests; 
3. Allergy based on specific serum specific immunoglobulin E 
(IgE) or Skin Prick Test (SPT);
4. Total IgE in serum (treatment effects may be influenced by 
IgE level);
5. Eosinophil levels in blood and tissue. 
2.1.4.4. Exclusion from general studies 
Patients with the following diseases should be excluded from 
general studies, but may be the subject of a specific study de-
pending on phenotype: 
1. Cystic fibrosis based on positive sweat test or DNA alleles; 
2. Gross immunodeficiency (congenital or acquired); 
3. Congenital mucociliary problems (e.g. primary ciliary dyski-
nesia (PCD)); 
4. Non-invasive fungal balls and invasive fungal disease; 
5. Systemic vasculitis and granulomatous diseases; 
6. Cocaine abuse; 
7. Neoplasia.
2.2. Classification of CRS
The EPOS2020 steering group have chosen to look at CRS in 
terms of primary and secondary (Figures 2.2.1. and 2.2.2.) and to 
EPOS 2020
33
minantly eCRS and non-eCRS, determined by the histologic 
quantification of the numbers of eosinophilic, i.e. number/high 
powered field which the EPOS panel agreed to be 10/hpf or 
higher.
For secondary CRS, again, the division is into localized or diffuse 
and then considered by four categories dependant on local pa-
divide each into localized and diffuse disease based on anato-
mic distribution. In primary CRS, the disease is considered by 
endotype dominance, either type 2 or non-type 2 (see 1.5.2.2.).
Clinically localized primary CRS is then subdivided into two 
phenotypes – allergic fungal rhinosinusitis (AFRS) or an isolated 
sinusitis. For diffuse CRS, the clinical phenotypes are predo-
AFRS, allergic fungal rhinosinusitis; CCAD, central compartment allergic disease; CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosi-
nusitis with nasal polyps; eCRS, eosinophilic CRS; OMC, ostiomeatal complex. 
Figure 2.2.2. Classification of secondary CRS (Adapted from Grayson et al(154)).
Figure 2.2.1. Classification of primary CRS (Adapted from Grayson et al(154))
CRS, chronic rhinosinusitis; PCD, primary ciliary dyskinesia.; CF, cystic fibrosis; GPA, granulomatosis with polyangiitis (Wegener’s 
disease); EGPA, eosinophilic granulomatosis with polyangiitis (Churg-Strauss disease).
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separate term to describe patients with prolonged acute rhino-
sinusitis was not necessary because the number of patients who 
have such a prolonged course is small and there are very little 
data on which to offer evidence based recommendations on 
how to manage these patients. 
2.4. Severity of disease
2.4.1. Severity
•        Mild = VAS 0-3
•        Moderate=VAS >3-7
•        Severe = VAS >7-10
Based on VAS 0-10 (not troublesome to worst thinkable trou-
blesome)(19)
VAS >5 affects patient QOL (validated in adult CRS only)
VAS degree of severity correlates with SNOT 22(20, 21) 
2.4.2. SCUAD: Severe Chronic Upper Airway Disease(22) 
Patients whose symptoms are inadequately controlled despite 
adequate (i.e. effective, safe, acceptable) pharmacologic treat-
ment based on guidelines. Includes severe uncontrolled allergic 
rhinitis, nonallergic rhinitis, chronic rhinosinusitis, N-ERD or 
occupational airway diseases. Defined by impaired quality of life 
(QoL), social functioning, sleep, school/work performance.
2.4.3. Acute complications
Sudden onset of disease beyond local site.
2.5. Exacerbation vs. recurrence 
Exacerbation: aggravation [Oxford English Dictionary (OED)] – 
implies increase of a problem against background of disease(23) 
as in acute exacerbation of chronic rhinosinusitis (AECRS) (See 
also 5.1.3.) Recurrence: come back, return, repeat, occurring 
again (OED), – implies a disease episode after a period without 
the problem.
Also, in the literature the term ‘acute on chronic’ can be found. 
The EPOS steering group felt that the term 
‘exacerbation of CRS’ was more appropriate and 
also consistent with the term used in other 
respiratory diseases, such as asthma.
2.6. Control and failure
2.6.1. Control: dominate, command, hold in check, regulate 
(OED) (see section 2.22.)
A disease state in which the patients do not have symptoms, or 
the symptoms do not adversely affect quality of life, if possible 
combined with a healthy or almost healthy mucosa and only 
need for local medication. 
thology, mechanical, inflammatory and immunological factors. 
Thence a range of clinical phenotypes are included as shown.
2.3. Duration (adults and children)
2.3.1. Acute <12 weeks with sudden onset and complete re-
solution of symptoms (<4 weeks in ICOR)(4, 7-9) (Figure 2.3.1.)
EPOS recognises acute viral, acute post-viral and 
acute bacterial rhinosinusitis.
2.3.1.1. Common cold
Acute viral rhinosinusitis: duration of symptoms <10 days
2.3.1.2. Acute post-viral
Increase in symptoms >5 days or persistent symptoms >10 days 
with <12 weeks duration 
2.3.1.3. Acute bacterial
Defined by at least three symptoms / signs:
• discoloured mucus; 
• severe local pain; 
• fever >38°C; 
• raised CRP/ESR; 
• ‘double’ sickening.
It was noted that in many cases of acute bacterial rhinosinusitis, 
the disease is unilateral(18).
(See chapter 4 for extensive discussion.)
2.3.2. Prolonged acute rhinosinusitis
We recognise that in general, acute rhinosinusitis will usually 
last a maximum of a few weeks. In the literature a number of dif-
ferent classifications have been proposed. In the past the term 
‘subacute’ was sometimes used to fill the gap between acute 
and chronic rhinosinusitis. However, the EPOS group felt that a 
Figure 2.3.1. Definition of acute rhinosinusitis.
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In asthma, the Global Initiative for Asthma (GINA) guidelines 
have defined the term ‘control’ as effective management of 
the clinical characteristics of the disease, including symptoms, 
nocturnal awakening, reliever use, limitation of activity, and 
lung function, as well as future risk of adverse outcomes. Three 
levels of asthma control have been established (well controlled, 
partially controlled, and uncontrolled)(24). 
2.6.2. Failure: uncontrolled 
Using a VAS of 0-10, partially or uncontrolled patients will have 
symptoms of nasal blockage, discharge, facial pain/pressure, re-
duced sense of smell and sleep disturbance of >5 in addition to 
nasal endoscopy findings and the need for rescue medication.
2.6.3 Difficult-to-treat rhinosinusitis
Patients who have persistent symptoms of rhinosinusitis despite 
appropriate treatment (recommended medication and surgery). 
Although the majority of CRS patients can obtain control, some 
patients will not do so even with the maximal medical therapy 
and surgery. 
Patients who do not reach an acceptable level of control despite 
adequate surgery, intranasal corticosteroid treatment and up 
to two short courses of antibiotics or systemic corticosteroids in 
the last year can be considered to have difficult-to-treat rhinosi-
nusitis. 
2.7. Phenotype
An organism distinguishable from others by clinical features e.g. 
N-ERD using symptoms, endoscopy ± NPs, ± CT.
2.8. Endotype 
Features within an individual e.g. raised IgE, IL-5, eosinophilia, 
periostin and based on a pathophysiological mechanism.
2.9. Comorbidities
2.9.1.  Comorbidity
Comorbidity is the presence of one or more additional diseases 
or disorders co-occurring with a primary disease or disorder 
or any distinct additional entity that has existed or may occur 
during the clinical course of a patient who has the index disease 
under study. In chronic rhinosinusitis these are divided into 
respiratory and other systemic conditions.
2.9.2. United airway disease
A pathological continuum due to the interaction between upper 
and lower airways in allergy, asthma, infection and inflamma-
tion(25). 
2.10. Medical therapy 
2.10.1. Maximal
The most possible, greatest.
2.10.2. Appropriate
The most suitable in the circumstances.
2.10.3. Adequate
Satisfactory or suitable in amount, just enough to produce the 
desired effect.
2.10.4. Sufficient
The same as adequate.
2.10.5. Tailored
Specific or adapted for a particular condition or person (as in 
precision / personalised medicine).
2.10.6. Best
Finest, greatest, top, foremost, leading, pre-eminent, premier, 
prime, first, chief, principal, supreme, of the highest quality, su-
perlative, unrivalled, second to none, without equal, nonpareil, 
unsurpassed, unsurpassable, peerless, matchless, unparalleled, 
unbeaten, unbeatable, unexcelled, optimum, optimal, ultimate, 
surpassing, incomparable, ideal, perfect (OED).
2.10.7. Optimal 
As for ‘best’!
Of these terms, ‘appropriate medical therapy’ is 
the preferred option of the EPO2020 
steering group.
2.11. Surgical therapy
2.11.1. Polypectomy
Removal of polyps  from the nose or post-surgical cavity without 
altering the bone anatomy. 
2.11.2. Minimal
Least tissue removal compatible with clinical improvement, 
conservation of mucosa.
2.11.3. Full as in ‘Full FESS’
Complete sinus opening including anterior and posterior 
ethmoidectomy, middle meatal antrostomies (likely large), 
sphenoidotomy and frontal opening (e.g. Draf IIa ).
2.11.4. Extended
Used in same context as ‘full’ (e.g. Draf III) but could also include 
extension beyond confines of sinuses i.e. skull base, orbit, pte-
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2.14.3. Adult
A legal adult is a person who has attained the age of majority 
and is therefore regarded as independent, self-sufficient, and 
responsible, e.g. >18 years in UK.
2.15. Integrated care pathways
An integrated care pathway (ICP) is a multidisciplinary outline of 
anticipated care, placed in an appropriate timeframe, to help a 
patient with a specific condition or set of symptoms move pro-
gressively through a clinical experience to positive outcomes.
2.16. Recalcitrant vs. refractory to treatment
2.16.1 Recalcitrant 
Difficult to manage or operate; not responsive to treatment.
2.16.2. Refractory
Resistant to cure.
According to the OED, recalcitrant and refractory are synony-
mous. 
The EPOS steering group prefers ‘recalcitrant’.
2.17. Nasal douche / lavage / irrigation / rinsing 
2.17.1. Douche
A stream of water applied for cleansing purposes.
 
2.17.2. Lavage
The therapeutic washing out of an organ.
 
2.17.3. Irrigation
Washing out or flushing a wound or body opening with a stream 
of water.
2.17.4. Rinsing
To cleanse by washing with fluid. 
The EPO2020 steering group prefers ‘irrigation’ 
or ‘rinsing’.
2.18. Immunomodulation and immunotherapy 
2.18.1. Immunomodulation 
Immunomodulation encompasses all therapeutic interventions 
aimed at modifying the immune response and is the preferred 
over-riding term by the EPO2020 steering group. In the treatment 
of rhinosinusitis, it encompasses the use of biological agents 
and macrolides.
rygopalatine and infratemporal fossa.
2.11.5. Radical
Also used in same context as ‘full’ but could include significant 
removal of inflamed /dysfunctional mucosa’.
2.11.6. Functional
Implies restitution of physiology and is usually, though not 
exclusively, applied to endoscopic sinus surgery. It should fulfil 
the following criteria:
• Creates a sinus cavity that incorporates the natural ostium;
• Allows adequate sinus ventilation;
• Facilitates mucociliary clearance;
• Facilitates instillation of topical therapies.
2.12. Precision medicine vs. personalised medi-
cine
2.12.1. Precision medicine
Medical care designed to optimize efficiency or therapeutic be-
nefit for particular groups of patients, especially by using gene-
tic or molecular profiling by tailoring therapy to the individual.
2.12.2. Personalised medicine
A type of medical care in which treatment is customized for an 
individual patient.
2.13. Burden of rhinosinusitis 
2.13.1. Quality of life
The standard of health, comfort, and happiness experienced by 
an individual or group.
2.13.2. Outcomes 
Results – subjective / objective; patient / provider; generic / 
disease-specific.
2.13.3. Cost
Direct and Indirect (costs that are directly or not directly accoun-
table to the treatment itself (can be fixed or variable)).
2.14. Age 
2.14.1. Child
A young human being below the age of puberty or below the 
legal age of majority i.e. a minor.
2.14.2. Paediatric
Medical care of infants, children and adolescents. Maximum age 
varies e.g. up to 21 years in USA.
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2.20.2. Long-term
>2 weeks i.e. 4, 6, 8, 10, 12, etc. up to years. 
The EPO2020 steering group agreed that four 
weeks or less would be ‘short-term’, accepting that 
in general practice the duration is usually <10 
days, and >4 weeks would be regarded as 
‘long-term’.
They also acknowledged that the aim of short-
term treatment was different from long-term. 
Short-term courses are generally given for acute 
bacterial infection whereas long term courses are 
given for their immunomodulatory properties.
2.21. Other definitions
2.21.1. Eosinophilic fungal rhinosinusitis vs. ‘allergic’ fungal 
rhinosinusitis
The EPO2020 steering group discussed this umbrella term for 
fungal rhinosinusitis but it was agreed that ‘allergic’ fungal 
rhinosinusitis should be retained as the principle term due to 
common usage, recognising that not all cases have evidence 
of an allergic reaction to fungi e.g. a positive skin prick and/or 
specific IgE.
It was agreed that ‘allergic’ fungal rhinosinusitis 
should be retained as the principle term due to 
common usage.
2.21.2. Eosinophilic rhinosinusitis (eCRS) 
Requires quantification of the numbers of eosinophils, i.e. num-
ber / high powered field which varies in the literature [8-12/hpf 
(400x)](32, 33). 
The EPO2020 steering group prefers 10/hpf.
2.21.3. Central compartment disease
A variant of CRS with polypoid changes of the entire central 
sinonasal compartment (i.e. the middle and superior turbinates, 
and the posterosuperior nasal septum), while the lateral sinus 
mucosa remains relatively normal, likely due to allergy(34).
2.22. Concept of Control of CRS
2.22.1. Introduction
The primary goal of any treatment, especially in chronic disea-
ses, is to achieve and maintain clinical control, which can be 
defined as a disease state in which the patient does not have 
symptoms, or the symptoms are not impacting quality of life 
(QoL)(35).
2.18.2 Immunotherapy
Treatment to stimulate or restore the ability of the immune sys-
tem to fight infection and disease OR treatment or prevention of 
disease (such as an autoimmune disorder, allergy, or cancer) that 
involves the stimulation, enhancement, suppression, or desen-
sitization of the immune system. Generally, this term is used in 
relation to the treatment of allergy.
2.18.3. Biological therapy
A type of treatment that uses substances made from living orga-
nisms to treat disease. 
2.19. Allergy
2.19.1. Allergy
A damaging immune response by the body to a substance, 
especially a particular food, pollen, fur, or dust, to which it has 
become hypersensitive. 
2.19.2. Allergic rhinitis
A symptomatic IgE-driven inflammation of the nasal mucosa(26). 
An IgE-mediated inflammatory nasal condition resulting from 
allergen introduction in a sensitized individual(27). 
2.19.3. Entopy or local allergic rhinitis (LAR)
A phenotype of allergic rhinitis characterised by a localised nasal 
allergic response in patients with negative skin prick testing to 
inhalant allergens and non-detectable serum specific IgE antibo-
dies. Diagnosis is based on a positive response to nasal allergen 
provocation(28-30).
2.19.4. Atopy
Atopy refers to the genetic tendency to develop allergic 
diseases such as allergic rhinitis, asthma and atopic dermatitis 
(eczema). Atopy is typically associated with heightened immune 
responses to common allergens, especially inhaled allergens 
and food allergens(26). 
A genetic disposition to develop an allergic reaction (as allergic 
rhinitis, asthma, or atopic dermatitis) and produce elevated 
levels of IgE upon exposure to an environmental antigen and 
especially one inhaled or ingested.
An inherited predisposition to produce IgE antibody(27). 
2.19.5. Atopic march
The progression from atopic dermatitis in infants and children to 
allergic rhinitis and/or asthma(31).
2.20. Duration of antibiotic courses
2.20.1. Short-term
Applied to anything from 2-3-5-7-10-14 days in the literature. 
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The EPOS expert committee proposed to combine the severity 
of patients’ symptoms, aspect of nasal mucosa and medical 
intake as parameters of control. The proposed CRS control test 
takes into account the presence and severity of the four major 
sinonasal symptoms, sleep disturbance and/or fatigue, nasal 
endoscopic evaluation and need for oral medication. Based on 
the presence of none, one or more items from this list, patients 
are divided into those with controlled, partly controlled and 
uncontrolled rhinosinusitis. 
2.22.2. Validation of the EPOS 2012 criteria for disease 
control
Since the criteria for CRS control proposed by the EPOS expert 
panel in 2012 are largely based on opinion rather than data-
driven, further validation was required.
A systematic literature search on control in CRS produced three 
papers summarized in Table 2.22.1. 
In a study of van der Veen et al. 19.5% of patients (n=389) met 
the criteria of well controlled CRS when being evaluated 3-5 
years after ESS, whereas 36.8% had partly controlled and 43.7% 
had uncontrolled CRS(37). Very stable results were recorded in 
the smaller (n=47), prospective 12 year follow-up study by Calus 
et al., where 40% of patients was uncontrolled 6 years after 
ESS, 44% was partially controlled and only 16% was control-
led(38). Although the percentage of uncontrolled patients after 
surgery was similar in both studies, it was surprisingly high as 
the perception of success of FESS is currently estimated higher 
with reported success rates of up to 80%(39). It is important to 
A number of tools are currently being used in daily clinical 
practice and research context, to evaluate different aspects of 
disease control in chronic rhinosinusitis (CRS). These include QoL 
and symptom severity questionnaires, but also more objective 
measurements such as endoscopic scoring systems.
However, the concept of control of disease is relatively new in 
the field of chronic rhinosinusitis (CRS). The European Position 
Paper on Rhinosinusitis (EPOS) 2012 incorporated criteria for 
the assessment of CRS control, to address the lack of unifor-
mity in the application and interpretation of existing tools in 
the context of disease control (Figure 2.22.1). Such staging 
systems can be useful in clinical practice to evaluate burden of 
disease, to guide management and to assess quality of care, 
especially since there is still a significant group of patients with 
CRS who remain uncontrolled despite receiving a combination 
of adequate medical treatment and endoscopic sinus surgery 
(ESS) following evidence-based guidelines(35, 36). A variety of 
factors can be associated with inadequate disease control and 
it is important to first define this group of patients in order to 
identify and address these contributing factors and to optimize 
CRS management(36). 
Furthermore, the concept of control can be used in a research 
context to better characterize patient populations or as an out-
come measurement for preventive or therapeutic interventions.
The primary goal of any treatment, especially in chronic disea-
ses, is to achieve and maintain clinical control, which can be 
defined as a disease state in which the patient does not have 
symptoms, or the symptoms are not impacting quality of life.
Figure 2.22.1. Assessment of current clinical control of CRS.
Controlled
(all of the following)
Partly controlled
(at least 1 present)
Uncontrolled
(3 or more present)
Nasal blockage1
Rhinorrhoea / Postnasal drip1
Facial pain / Pressure1
Smell1
Sleep disturbance or fatigue1
Nasal endoscopy 
(if available)
Rescue treatment 
(in last 6 months)
EPOS 2020: Assessment of current clinical control of CRS (in the last month)
1 Symptoms of CRS;   2 For research VAS ≤ 5;   3 For research VAS > 5;   4 Showing nasal polyps, mucopurulent secretions or inamed mucosa  
Not present or not bothersome2
Not present 
or not bothersome2
Little and mucous2
Normal 
or only slightly impaired2
Not present2
Healthy 
or almost healthy mucosa
Not needed
Present 
on most days of the week3
Present 
on most days of the week3
Mucopurulent 
on most days of the week3
Impaired3
Present3
Impaired3
Present3
Present 
on most days of the week3
Present 
on most days of the week3
Mucopurulent 
on most days of the week3
Diseased mucosa4 Diseased mucosa4
Need of 1 course of 
rescue treatment
Symptoms (as above) persist 
despite rescue treatment(s)
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difficult-to-treat group of patients. Aspirin intolerance was also 
associated with lower percentages of CRS control after FESS(37). 
A first comparison was performed between EPOS assessment of 
CRS control with both VAS global symptom scores and SNOT-
22 scores(37). The average VAS total nasal symptom scores of 
controlled, partly and uncontrolled groups were 0.8, 2.7 and 
5.7 respectively. The average SNOT-22 scores were 9.7, 22.2 and 
44.8, respectively(37). 
Van der Veen et al. also evaluated the added value of nasal 
endoscopy for defining disease control in CRS patients. In 95.1% 
of the cases, performing a nasal endoscopy did not cause a shift 
in the control category that was defined by just the presence of 
symptoms and use of systemic medication(37). Although nasal 
endoscopy is described as optional (‘if available’) in the EPOS 
control criteria, this might have been a barrier to apply them in 
some study protocols, as this was also explicitly mentioned by 
the authors of one of the studies reviewed(40). This is especially 
the case in large-scale studies and/or studies involving non-ENT 
practitioners.
Snidvongs et al. conducted a prospective trial in which 106 
patients undergoing ESS were evaluated at 6 and 12 months 
after surgery to investigate if the EPOS 2012 CRS control staging 
system, or any modification of this system, correlates with both 
patient and physician reports of disease(41). They selected a mo-
dified staging system using Nasal Obstruction, Systemic medica-
tion and Endoscopic inflammation (‘NOSE’) based on predictive 
note that patients included in the studies by van der Veen et 
al. and Calus et al. had been treated in a tertiary referral centre 
for rhinologic diseases, causing a bias towards the more severe 
spectrum of disease. Also, the success rate in other studies was 
defined as symptomatic improvement after FESS and belon-
ging to the uncontrolled group does of course not exclude a 
beneficial effect of surgery. This is also shown in the study of 
van der Veen et al., where 10 out of 21 patients (47.6%) who 
were telephoned and asked how they perceived CRS control 
after FESS, regarded themselves as having controlled CRS. When 
EPOS criteria were applied on these patients, only four of them 
(19.1%) met the criteria of being controlled(37). Calus et al. also 
focused on how patients appraised their condition. Twelve years 
after FESS, 97.4% of patients reported general therapeutic relief 
(21.1% reported a complete, 36.8% a marked, 26.3% a moderate 
and 13.2% a slight relief over time)(38). Regarding the distribution 
of patients over the 3 EPOS categories of control, a significant 
change towards more control was found 6 (p = 0.001) and 12 
years (p < 0.001) after surgery, when compared to the distribu-
tion prior to FESS(38). Due to its cross-sectional design, improve-
ment of disease control could not be evaluated by van der Veen 
et al., since there were no data available from before surgery. 
They did see a significant higher proportion of women compa-
red to men in the uncontrolled group. Patients that had revision 
FESS were less frequently controlled compared to the ones 
that had primary FESS, suggesting that they might form a more 
Table 2.22.1.  Overview of clinical studies that used the EPOS control criteria (March 2012 – June 2019).
Study Objectives Methods
Snidvongs, 
2014(41)
To develop a chronic rhinosinusitis (CRS) 
disease control staging system that predicts 
patient and physician opinion. This involved 
exploring the predictive capacity of the 
proposed EPOS-2012 staging system and 
other potential scoring systems based on 
patient symptoms and objective criteria.
Design: Prospective study 
Population: Adult CRS patients undergoing ESS were recruited from a tertiary referral 
clinic.
Method: Patients (n = 106) returned at 6 months and 12 months after ESS. 
Symptoms, endoscopy score, and systemic medication used were collected at each 
visit along with physician’s and patient’s report of their condition as either "controlled, 
"partly controlled," or "uncontrolled". Ordinal regression was used for modelling a sta-
ging system. The EPOS criteria and various combinations were assessed. Kappa agree-
ments between the staging systems and patient/physician reports were analysed.
van der 
Veen, 
2017(37)
To study the degree of CRS control using 
novel EPOS control criteria at 3–5 years 
after a functional endoscopic sinus 
surgery (FESS) and correlate these data to 
symptoms scores (VAS & SNOT-22).
To study the influence of performing nasal 
endoscopy on defining patients’ level of 
control based on EPOS criteria.
Design: Cross-sectional study
Population: Adult CRS patients who had undergone bilateral FESS for chronic inflam-
matory sinonasal disease 3–5 years prior to the study were included. 
Method: Patients received a postal questionnaire asking for control items according 
to EPOS control criteria, visual analogue scale (VAS) scores for total and individual 
sinonasal symptoms, sinonasal outcome test (SNOT)-22 and Short Form (SF)-36 
questionnaires. 
389 of the 560 patients included in the study returned a filled questionnaire (69,0% 
response rate). Among patients who responded, 81 (20.8%) accepted the invitation 
for a voluntary outpatient visit where nasal endoscopy was performed.
Calus, 
2019(38)
To monitor recurrence and revision surgery 
over 12 years after endoscopic sinus sur-
gery in CRSwNP patients.
To validate EPOS 2012 control criteria
Design: Prospective study, however EPOS control criteria were evaluated retrospecti-
vely.
Population: Adult patients (n = 47) with CRSwNP, undergoing primary or revision 
extended endoscopic sinus surgery, were followed. 
Method: Clinical symptoms, total nasal endoscopic polyp score and inflammatory 
markers in tissue, nasal secretions and serum were evaluated before, 6 years and 12 
years after surgery.
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2.22.3. Alternative tools for (indirect) assessment of CRS 
control
All clinicians involved in the treatment of CRS aim to achieve cli-
nical control in their patients. Nevertheless, the methods used to 
assess CRS control in daily practice are still very heterogeneous 
and the idea of controlled disease can differ between physicians. 
Uniformity in the routine application and interpretation of 
the existing tools for assessment of CRS control is lacking as a 
consensus on assessment criteria has not yet been reached. This 
is in contrast to asthma control assessment criteria in the GINA 
(Global Initiative for Asthma) guidelines, which are widely accep-
ted and are recommended as good clinical practice(43).
Apart from the CRS control criteria proposed by the EPOS 
2012, numerous other tools for assessing (elements of ) control, 
disease severity and/or Quality of Life are already being used in 
clinical practice and research. In 2017, a Core Outcome Set for 
four key domains of CRS was selected by the CHROME-study. 
For the domain ‘control of disease’ they proposed three measu-
rement tools: need for systemic medication (steroid or antibio-
tic), progression to surgery and the Lund-Kennedy endoscopic 
score(44).
The SNOT-22 and VAS for total as well as individual sinonasal 
symptoms are both validated tools that are widely known 
among clinicians and researchers in the field of CRS and used for 
assessing Quality of Life and symptom severity respectively(45, 
46). More recently, in this age of big data and precision medicine, 
mobile health technology has been emerging and mobile ap-
plications are being developed for numerous diseases, including 
CRS(42). Sedaghat et al. investigated chronic rhinosinusitis control 
from the patient and physician perspectives in 209 patients. 
Participants were asked to rate their global level of CRS control 
as “not at all,” “a little,” “somewhat,” “very,” and “completely”(47). This 
5 scale control scores by patients and physicians were compa-
red to the SNOT-22(48) and also reported the number of sinus 
infections, CRS-related antibiotic courses taken, CRS-related oral 
corticosteroid courses taken, and missed days of work or school 
due to CRS, all in the last 3 months. While both patients and 
physicians rely on the burden of CRS symptomatology, patients 
consider primarily nasal symptoms while physicians include 
nasal and extra-nasal symptoms of CRS in determining CRS 
control. Physicians also independently consider CRS-related an-
tibiotic use, as a reflection of acute bacterial CRS exacerbations, 
and CRS-related oral corticosteroid use in the determination of 
global CRS control.
2.22.3.1. SNOT-22
The SNOT-22 questionnaire is a 22-item, disease-specific, health-
related questionnaire assessing quality of life in CRS patients, 
that has been validated in multiple languages (see 5.3.4.2). 
Van der Veen et al. showed significant differences in SNOT-22 
scores between the three stages of control based on the EPOS 
strength. More specifically, they evaluated which symptoms 
were, as a single factor, associated with patient’s report (nasal 
obstruction p = 0.02) and which nasal endoscopy features were, 
as a single factor, associated with physician’s report of disease 
progression (endoscopic mucosal inflammation p < 0.001 and 
thick and/or purulent discharge p = 0.01). Unfortunately, data 
concerning the use of EPOS control criteria is rather limited and 
no comparison can be made with results from the other studies, 
e.g. on patients’ distribution in the different EPOS control cate-
gories before and (six and 12 months) after surgery.
After analysis of kappa agreements between the staging 
systems and the patient’s and physician’s reports, they arrived 
to the conclusion that both the EPOS and the NOSE criteria 
for control had significant agreement with these reports. They 
propose the NOSE system, as a modified version of the EPOS 
criteria, since it has fewer criteria (i.e. fewer symptoms) to assess 
and they found better agreement with physician and patient 
rated control in their study. It is not entirely clear from the article 
how the criteria used in these patients’ and physicians’ reports of 
disease control were established. This is an important considera-
tion to make, since they largely determine the primary outcome 
of this study, namely the kappa agreement between these 
reports and the different investigated disease control staging 
systems.
Two other studies mentioned the EPOS control criteria but did 
not use them in real-life studies with CRS patients and are for 
that reason not listed in Table 2.22.1. 
The first was an article published by Hellings et al. in 2013(36). 
They reviewed the state of the art on control of both allergic 
rhinitis and CRS, emphasizing the importance of this concept to 
define those patients with poorly controlled disease. They pro-
pose a treatment algorithm for CRS in relation to the categories 
of control provided in EPOS 2012, with proposed treatments 
based on the EPOS 2012 treatment algorithms. Secondly, they 
describe the wide variety of factors that can contribute to a lack 
of control and divide them into four categories: disease-related 
factors, diagnosis-related factors, treatment-related factors and 
patient-related factors.
Another article published by Doulaptsi et al. in 2018 correlates 
VAS and SNOT-22 scores in 180 CRS patients(40). They mention 
the EPOS 2012 criteria for CRS control, but decided that applying 
them was not feasible in their postal questionnaire survey. In-
stead they used VAS total nasal symptom score to assess disease 
control, using the following cut-off points: well controlled (VAS 
≤ 2), partly controlled (VAS >2 and ≤5), uncontrolled (VAS > 5). 
These cut-off values were based on the study of van der Veen et 
al. and have also recently been used in a mobile app for patients 
with CRS, developed by the European Forum for Research and 
Education in Allergy and Airway diseases (EUFOREA)(37, 42).
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control criteria(37). More prospective studies comparing these dif-
ferent scoring systems are needed to validate these results.
Considering its ability to predict CRS control status, it is impor-
tant to note that some variables of SNOT-22, e.g. ear symptoms 
and emotional disorders, are not disease-specific.
2.22.3.2. VAS
The VAS is widely used by rhinologists both in research and in 
daily practice. Patients quantify the severity of their symptoms 
on a 10-cm scale, with 0 meaning total absence of symptom(s) 
and 10 being the worst thinkable severity (46) (see 5.3.4.2). 
VAS for total nasal symptoms is already being used in clinical 
practice, based on the EPOS guidelines, to classify CRS into mild, 
moderate and severe disease(49) and has also been incorporated 
and validated in several mHealth apps(42, 50).
Van der Veen et al. compared VAS scores to the EPOS control cri-
teria and the three categories of CRS control showed significant 
differences in mean total and individual VAS scores, as was also 
the case with the SNOT-22 scores(37). Another interesting finding 
in this study, was that only uncontrolled patients had VAS scores 
higher than 5. The mean VAS score for total nasal symptoms in 
this uncontrolled group was 5.5, which is relatively low when 
comparing to the cut-off values used to classify CRS severity(35). 
Based on these findings, Doulaptsi et al. created new cut-off 
points for VAS TNSS to define the level of disease control: well 
controlled (VAS ≤ 2), partly controlled (VAS > 2 and ≤ 5), uncon-
trolled (VAS > 5) (7). Using these cut-off points, 10% of patients 
were classified as well controlled, 28.3% as partly controlled, and 
61.7% as uncontrolled(40). 
Recently, these same cut-off points have also been used in the 
mySinusitisCoach app to assess CRS control(42). Taking into ac-
count its ease of use and its applicability in mHealth tools, the 
role of VAS in assessment of disease severity, monitoring disease 
and maybe also assessment of disease control might become 
even more prominent in coming years.
However, regarding its use in assessment of CRS control, it 
is important to consider that these VAS scores are patient-
reported outcomes, lacking any form of objective support such 
as medication use or nasal endoscopic evaluation. Also, VAS 
scores for individual symptoms might not all be equally useful 
in predicting disease control, as e.g. rhinorrhea, facial pain or 
hyposmia may also be caused by numerous other conditions.
2.22.3.3. Other questionnaires 
Over the course of years, many other questionnaires have been 
used to evaluate CRS symptoms and/or their impact on QoL 
and general health status (see 5.3.4.2) These include the Sinus 
Control Test (SCT) the 31-Item Rhinosinusitis Outcome Measure 
(RSOM-31), the 20-Item Sino-Nasal Outcome Test (SNOT-20), 
the Sinonasal questionnaire (SNAQ-11) and the Rhinosinusitis 
Disability Index (RSDI)15.
In addition, the 36-item Short Form (SF-36), the 12-item Short 
Form (SF-12) and the EuroQol-5Dimension-5Level (EQ-5D-5L) 
are health questionnaires that are designed to assess general, 
health-related QoL and to be applied to all health conditions. 
The SF-36 was also included in the study of van der Veen et al. 
and, as was the case for VAS and SNOT-22 scores, SF-36 scores 
were significantly different when comparing the 3 categories of 
CRS control based on EPOS criteria(37).
2.22.4. Recommendations and future needs
Based on the results of van der Veen et al., showing a mean 
VAS of 5.5 for total nasal symptoms, the EPOS2020 steering 
group think that the current EPOS2012 control criteria might 
overestimate the number of patients being uncontrolled. For 
research purposes we therefore recommend using a VAS scale 
for all symptoms: “not bothersome” can be substituted by ‘VAS 
< 5’, and ‘present/impaired’ by ‘VAS ≥ 5. This is in keeping with 
the VAS score of 5 or more that has already been proposed to 
evaluate symptom control in allergic rhinitis(51).
The fact that only one feature has to be present for a patient to 
be classified as partly controlled, is something else that we think 
should be reconsidered. This is especially important since sleep 
disturbance and/or fatigue and also, but to lesser extent, rhinor-
rhoea, facial pain, loss of smell and even nasal obstruction can 
all possibly be attributed to other medical conditions. Based on 
the results of van der Veen et al., we have changed the criteria so 
that these symptoms must be related to CRS (37). For example, a 
typical migraine headache should not be taken into account.
Generally, there is a need for additional, large-scale studies, pre-
ferably with long follow up to confirm the high percentage of 
uncontrolled patients after surgery as shown by Calus et al. and 
van der Veen et al. and to further evaluate the responsiveness of 
the EPOS criteria to treatment(37, 38).
These studies will help to explore differences in disease control 
(based on EPOS criteria) between men and women, patients 
undergoing primary or revision FESS, and between different 
phenotypes e.g. with or without nasal polyps, AR, asthma, AERD, 
and endotypes based on inflammatory patterns. Such data 
will likely prove to be valuable in predicting patients at risk of 
having uncontrolled disease.
2.22.5. Conclusion
Since the third EPOS update was published in 2012, only a few 
studies have applied the proposed criteria for assessment of cur-
rent disease control and the results of these studies still require 
further psychometric validation (including internal consistency, 
responsiveness and known group differences).
Given the importance of the concept of disease control, from a 
clinical as well as from a research perspective, there still remains 
a need for a gold standard to assess disease control in CRS. 
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3.1. Quality of life (QOL)
3.1.1. The burden of ARS
Few studies have measured the impact of ARS on quality of life, 
in contrast to the myriad of studies reporting on both direct and 
indirect costs. This may reflect the short-lived duration of illness, 
with patients usually returning to their pre-morbid health status. 
Of studies that do report on symptoms, many fail to differentiate 
between ARS and ABRS.
In a prospective study of 150 adult patients with ARS, 88% 
patients reported pain and discomfort, and 43% had difficulties 
performing normal daily activities at the onset of an episode 
of ARS, measured using the Eq-5D(1). By day 15 only 31.5% 
reported pain or discomfort and all but 1.4% had fully returned 
to normal daily activities. A  study of 1585 adults diagnosed 
with acute rhinosinusitis, found the most common presenting 
symptoms were moderate-to-severe nasal obstruction (80.4%), 
facial pain (74.5%), rhinorrhoea (70.4%), and headache (63.6%)
(2). Symptoms were indicated as having a moderate to very 
significant effect on activities of daily living (71.6% of patients), 
leisure (63.1%), and professional/school activities (59.2%). In 
contrast, in children, cough is the most prevalent symptom in 
both presumed URTIs and ARS(3).
A prospective study of 2610 patients diagnosed with ARS accor-
ding to the EPOS 2012(4) criteria separated patients into viral ARS 
(36%) and post-viral ARS (63%). Assessment of the severity of 
symptoms using a VAS found that 2% reported mild symptoms 
at baseline, 51% moderate symptoms and 44% reported 
symptoms to be severe. There was no significant difference in 
the frequency of nasal obstruction (98 vs. 97%), rhinorrhoea (95 
vs 94%) facial pain and pressure (76 vs. 77%) or loss of smell (59 
vs. 63%) comparing viral and post-viral groups. Disease severity 
measured using a VAS did not differ at baseline between groups 
(6.98 for viral vs. 7.13 for post viral ARS). Disease specific QOL 
measured with the SNOT-16 found statistically higher baseline 
scores in the post-viral group (38.7 vs. 36.0 in the viral ARS 
group), however, this difference is not clinically significant, 
A comparative study performed using the SF-36 found that pa-
tients with acute rhinosinusitis (which was not clearly defined) 
reported impaired quality of life compared with a control popu-
lation, but were not as severely affected as patients with chronic 
rhinosinusitis(5).
There are two validated disease-specific quality of life instru-
ments for use in ARS. The Measurement of Acute Rhinosinusitis 
Instrument (MARS) demonstrates significantly higher scores 
in patients with ARS than healthy controls. The SNOT-16, a 
derivative of the RSOM-31 instrument originally developed and 
validated in a chronic rhinosinusitis cohort, has also been valida-
ted for use in ARS(6). 
3.1.2. The burden of CRS
CRS is associated with a wide range of symptoms, across sino-
nasal, aural, sleep and general domains. The ‘cardinal’ symptoms 
are considered to be nasal obstruction or congestion, nasal 
discharge (which can be anterior or posterior), alteration in 
sense of smell and facial pain and pressure.
Population studies show that symptoms of nasal obstruction 
and discharge are common. In a survey of unselected patients 
in primary care (Figure 3.1.1.)(7), 11.9% of adults sampled fulfilled 
the EPOS criteria for rhinosinusitis.  With repeated review at six 
months, symptoms were persistent in 4.7% of the cohort(8), sug-
gesting the presence of CRS.
Using EPOS criteria to identify CRS in responses from a ran-
dom sample of the general population, thereby preferentially 
selecting those with nasal obstruction and /or discharge shows 
a high prevalence of cardinal symptoms  but  provides only 
limited insight into the severity of patients with CRS successfully 
managed in a primary care setting(9), as selection bias will likely 
identify more severe patients in secondary care. 
The majority of studies evaluating the prevalence and severity 
of symptoms analyse responses in patients referred to secon-
dary care, or those undergoing sinus surgery, therefore selecting 
those with symptoms more resistant to treatment in primary 
care. Surveys of patients seen in ENT outpatient clinics(10) and 
those electing sinus surgery(11) show that the cardinal symptoms 
are reported as the most severe and prevalent. Nasal obstruc-
tion and alteration in sense of smell and taste are both the most 
severe and prevalent symptoms in CRSwNP, while in CRSsNP, 
facial pain and nasal discharge are reported as equally severe as 
altered smell and taste, with nasal obstruction again being the 
most severe (Figures 3.1.1. and 3.1.2.). Fatigue and waking up 
3. Burden of acute and chronic rhinosinusitis
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tired are also highly prevalent and bothersome. When a group 
of CRS patients (not differentiated by polyp status) were asked 
what symptoms they felt were the most important to experience 
improvement in after surgery, nasal obstruction was rated as 
"extremely" or "very" important by 93% of patients, followed by 
smell/taste, thick nasal discharge, need to blow nose, postnasal 
discharge, and sleep symptoms (range 61-72%)(12).
In patients presenting to ENT clinics, the presence of cardinal 
symptoms has a positive predictive value of 39.9, with high 
sensitivity  but low specificity(13) for a diagnosis of CRS. Similarly, 
when patients undergoing CT imaging for non-sinogenic condi-
tions were surveyed, 50% of those who reported CRS symptoms 
were found to have normal CT scans (Lund-Mackay =0)(14).  
Asymptomatic changes are commonplace on CT imaging(14). 
Individual symptoms cannot be used to reliably differentiate  
between CRS and other conditions, although the presence of 
hyposmia is predictive of CRS(15), while facial pain is negatively 
predictive(16).
The overall severity rating of symptoms is obviously highly 
dependent upon the population being studied. When asked 
how bothersome their symptoms were overall, the CRS patients 
identified in the general population study reported mean scores 
of 8.2 and 7.8 for CRSwNP and CRSsNP respectively, on a VAS 
scale of range 0-10. Patients in secondary care awaiting surgery 
report mean symptom severity scores in the moderate to severe 
range, with a mean SNOT-22 score of 42.0(17), compared with 
a control group where a mean score of 9.3 was reported. The 
median score of 7.0 was proposed as a threshold  for normal 
scores(18); CRSsNP patients had higher pre-operative baseline 
scores (44.2) compared with CRSwNP (41.0). 
CRS has been shown to impact on patients’ health related qua-
lity of life. Significant differences are found in all domains of the 
SF-36 compared with healthy controls(19). In a landmark paper, 
Gliklich and Metson first demonstrated the impact of CRS on 
global quality of life, finding that CRS had a greater impact on 
social functioning than angina or chronic heart failure(20). More 
recently, they have shown that health utility values, measured 
using the EQ-5D, were lower than the general population, and 
Figure 3.1.1. Prevalence of cardinal symptoms of CRS in unselected patients in primary care, and CRS patients in the general population, in an outpa-
tient setting and those undergoing surgery.
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tion with long-term ramifications with regard to both medical 
and surgical treatments, associated total cost, as well as the 
impact of disease on patient productivity and quality-adjusted 
life years(24). Total costs are often divided between direct and 
indirect costs where direct costs primarily refer to traditional 
healthcare costs such as physician visits, prescription medical 
therapy and surgery while indirect costs refer primarily to lost 
productivity in those suffering rhinosinusitis(25). Conservative 
estimates suggest that for CRS, total costs are in excess of $30 
billion per year in the USA with $20 billion accounted for in 
indirect costs(26).
3.2.1. Direct costs
3.2.1.1. Direct costs of chronic rhinosinusitis
In 2009, Bhattacharyya published an assessment of the eco-
nomic disease burden of rhinosinusitis(27). Data were extracted 
from the National Health Interview Survey over a 10-year period 
of 1997-2006 in the USA. One-year disease prevalence showed 
comparable to other chronic diseases such as asthma(21). This is 
further discussed in the section on PROMS (see section 5.3.1.4.).
Symptom severity has been shown to be influenced by gender, 
with females reporting greater symptom severity and impact on 
their quality of life, when measured with disease specific instru-
ments or with global measures, such as the SF-36 or Eq-5D(19, 21). 
Co-morbid depressive illness is associated with worse CRS-speci-
fic quality of life(22). Symptom severity may be in part determined 
by severity of disease but is further modified by intrinsic patient 
features (gender, ethnicity, religious and cultural beliefs), co-
existing illnesses and extrinsic features such as socio-economic 
factors, and support systems. This likely explains the mismatch 
commonly found between objective and patient rated disease 
severity scales, such as has been found with radiological staging 
and symptom scores(23).
3.2. Costs of rhinosinusitis
Research concerning the socioeconomic impact of rhinosinusitis 
is a nascent field.  In particular, CRSw/sNP is a common condi-
Figure 3.1.2. Severity of cardinal symptoms of CRS in patient cohorts seeking outpatient care and undergoing surgery.
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an assessment of the additional disease burden of nasal polyps 
in CRS(35). Patients were included according to the Rhinosinusitis 
Symptom Inventory (Task Force on Rhinosinusitis criteria) and 
by findings with nasal endoscopy and on CT (Lund MacKay 
score). Three groups were composed: one with CRS without 
nasal polyps (CRSsNP), a second group with CRS with nasal po-
lyps (CRSwNP) and a third with CRS with recurrent nasal polyps 
after surgery. While the groups with and without nasal polyps 
showed a clear difference in phenotype, this did not trans-
late into a difference in expenditures for physician visits and 
medication costs between the first two groups. However, there 
was a difference in total medication costs for the last group with 
recurrent polyps after surgery with a higher cost for this group 
of $866 compared to the $570 for Group 1 and $565 for Group 
2. Further study of the differences in cost in patients with polyps 
were studied by Bhattacharyya et al. in 2019 using the Truven 
Health MarketScan US claims database(36). Annual incremental 
costs were $11,507 higher for patients with CRSwNP versus 
those without CRS. Costs were higher in subgroups of patients 
with CRSwNP undergoing functional endoscopy sinus surgery 
(FESS), with a comorbid diagnosis of asthma, receiving oral corti-
costeroids, or macrolides versus the overall CRSwNP group. This 
study did not include, generally speaking, patients treated with 
biologics. The authors concluded that patients with CRSwNP 
with high clinical burden had higher overall costs than CRSwNP 
patients without. 
The highest direct costs were associated with 
patients who had recurrent polyposis after 
surgery.
Evaluating incremental direct costs is important to determine 
the cost directly attributable to the management of CRS. In 
2011, an evaluation calculated the incremental health care 
utilization and expenditure for CRS in the USA(31). Patient data 
were extracted from the Medical Expenditure Panel Survey. For 
utilization of health care, data show that CRS patients incurred 
3.5 additional office visits and 5.5 additional prescriptions com-
pared to patients without CRS. This extra utilization of health-
care evokes higher expenditures; a patient with CRS would have 
a substantial incremental increase in health care expenditures 
of approximately $800 per year consisting of $346 (±$130) for 
office-based expenditures, $397(±$88) for prescription expendi-
tures and $90 (±$24) for self-expenditures.
CRS leads to an incremental direct healthcare 
expenditure of 2500 euro per patient per year. 
Direct costs associated with severe CRS that eventually requires 
surgery have received additional attention. Bhattacharyya et al. 
reported the costs of managing CRS in the year prior to and fol-
that one quarter (23%) of patients with CRS visited an emergen-
cy department, one third (34%) saw a medical specialist, more 
than half (56%) spent $500 or more per year on health care. 
Health care spending was significantly greater in rhinosinusitis 
than that of other diseases such as peptic ulcer disease, acute 
asthma, and hay fever. In Europe two studies reported on direct 
costs of CRS, Wahid et al. reported £2974 on costs for primary 
and secondary care extrapolated for a year period compared to 
£555 in the control group and £304 versus £51 out-of-pocket ex-
penditure (28). Lourijsen et al. found yearly direct costs of €1501 
per year in a group of patients with CRSwNP(29). 
Health care spending was significantly greater in 
rhinosinusitis than in other diseases such as peptic 
ulcer disease, acute asthma, and hay fever.
Direct costs of CRS, over and above inflation, appear to be incre-
asing in the USA where most estimates originate. In 1999, Ray et 
al. estimated the total direct cost in the USA at nearly $6 billion 
per year(30). In 2011, Bhattacharyya estimated direct costs to be 
$8.6 billion(31). In 2017, Rudmik established that the overall direct 
costs of CRS had increased to between $10 and $13 billion(26).
In the USA, the direct costs for the management 
of CRS have risen in recent years and are now 
between $10 and $13 billion per year, or $2609 per 
patient per year.
While total direct costs are important, in 2002, Murphy et al. exa-
mined the direct costs of an individual patient with CRS in the 
USA per year(32). These patients accounted for 43% more outpa-
tient and 25% more urgent care visits than patients without CRS. 
Patients with CRS filed 43% more prescriptions but had fewer 
inpatient hospital stays. The direct cost of treating an individual 
patient with CRS was $2,609 per year, 6% more than the average 
adult. In Europe, a study executed by van Agthoven established 
that the direct costs of a patient treated in a university hospital 
for severe chronic rhinosinusitis were €1861/year(33). 
The impact of nasal polyps on direct costs has also been a 
subject of interest. In Sweden, Berggren evaluated the costs 
of a scenario treating CRSwNP with budesonide following by 
sinus surgery when indicated versus direct surgery followed by 
budesonide(34). For the surgical intervention a comparison was 
made between in-patient FESS, in the office polypectomy under 
sedation or in the office polypectomy under local anaesthesia. 
The scenario of treating CRSwNP with budesonide following by 
sinus surgery was due to the high success of the nasal cortico-
steroid treatment alone (yearly costs €409-602) , significantly 
less expensive than the scenarios that started with surgery: 
from €67 for the polypectomy in local treatment to €976 for the 
in-patient FESS. In the US, Bhattacharyya’s 2009 study provided 
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lowing endoscopic sinus surgery (ESS)(37). Data from the Market 
Scan Commercial Claims and Encounters Database from 2003 to 
2008 were evaluated. Patients with nasal polyps were excluded 
from this study. All sinus-related healthcare utilization costs 
were rolled into the study (medication, office visits, diagnostic 
assessment with radiology and endoscopy). Results show that 
in the year prior to ESS, costs increase to approximately $2,500 
with a clear increase in the six months directly preceding ESS; 
the first three months account for $361 and final three months 
account for $1,965. This is due to an increase in office visits, 
diagnostic investigations and medication use. The increase in 
prescription medication is primarily due to a higher antibiotic 
use; from $75 in the first three months to $225 in the second 
three months. The ESS-procedure and the 45-day post proce-
dure period account for $7,726 ($7,554 – $7,898). In the first year 
following ESS, costs drop by $885 to an average of $1,564 per 
year. In the second year post procedure they drop an additional 
$446 to $1,118 per year. This decrease was mostly due to fewer 
physician visits; there was only a minor change in the costs of 
anti-inflammatory medication. 
Endoscopic sinus surgery is expensive but results 
in a decrease in direct costs in the subsequent two 
post-operative years.
Surgery for CRS represents a substantial direct cost and depends 
on geography(37-39). Based on the literature, the direct costs of 
ESS in the USA range between $8,500 and $11,000. However, 
direct costs are lower in Canada ($3,700), Taiwan ($1,900), and 
India ($1,100), all of these direct costs measured in 2016 USD.
 
Patients with recurrent acute rhinosinusitis have 
average direct health care costs of $1,091/year 
(USA 2012).
3.2.1.2. Direct costs of acute rhinosinusitis
While most ENT specialists spend much of their clinical time 
treating CRS, acute rhinosinusitis also presents in both non-re-
current (acute bacterial rhinosinusitis, ABRS) and recurrent forms 
(recurrent acute rhinosinusitis, RARS)(40). Much less is known 
about the costs related to RARS. In 2004, Anand estimated that 
there were approximately 20 million cases of ABRS yearly in 
the USA(41). However, RARS is more commonly treated by the 
rhinologist and it is estimated that 1 in 3,000 adults suffer from 
RARS(42). In 2012, Bhattacharyya found that RARS required an 
average of 5.6 health care visits/year and 9.4 prescriptions filled 
(40% antibiotic). Only 20% of patients had either nasal endo-
scopy or CT scan annually, indicating that it is likely that only a 
small proportion of these patients are referred for ENT-specialist 
evaluation. The individual patient annual direct healthcare costs 
of recurrent acute rhinosinusitis (RARS) averaged $1,091/year: 
$210 for antibiotics, $452 for other sinus-related prescriptions, 
$47 for imaging and $382 for other visit costs.
3.2.2. Indirect costs for ARS and CRS
The studies of direct medical costs of rhinosinusitis demonstrate 
a tremendous socioeconomic burden. Interestingly, the indirect 
costs of rhinosinusitis are much greater than the direct costs. 
Since 85% of patients with rhinosinusitis are of working age 
(range: 18-65 years old), indirect costs such as missed workdays 
(absenteeism) and decreased productivity at work (presentee-
ism) significantly add to the economic burden of the disease(43).
Rhinosinusitis is one of the top 10 most costly 
health conditions to US employers.
Goetzel et al. attempted to quantify the indirect costs of rhi-
nosinusitis(44). Their 2003 study resulted in rhinosinusitis being 
named one of the top 10 most costly health conditions to US 
employers. A large multi-employer database was used to track 
insurance claims through employee health insurance, absentee 
days, and short-term disability claims. Episodes of illness were 
linked to missed workdays and disability claims, accurately cor-
relating absenteeism to a given disease. In a large sample size 
(~375,000 employees), total healthcare payments per employee 
per year for rhinosinusitis (both acute and chronic) were found 
to be $60.17, 46% of which came from the cost of absenteeism 
and disability. These figures approximate the cost to employers, 
disregarding the cost incurred by other parties, and therefore 
tremendously underestimate the entire economic burden of the 
disease.
Indirect costs account for a majority of the total 
costs of rhinosinusitis.
Ray et al. estimated by the 1994 National Health Interview 
Survey that the number of missed workdays due to rhinosi-
nusitis was 12.5 million and restricted activity days was 58.7 
million days(45). In his 2003 study, Bhattacharyya used patient-
completed surveys from 322 patients to estimate the direct and 
indirect costs of chronic rhinosinusitis(46). Patients completed 
a survey assessing symptoms of disease, detailing medication 
use, and quantifying missed workdays attributable to CRS. 
The report concluded that the cost of treating CRS per patient 
totalled $1,539 per year with 40% of these costs due to indirect 
costs of missed work; the mean number of missed workdays in 
this sample of 322 patients was 4.8 days/year (95% CI: 3.4 - 6.1). 
The study was followed up in 2009 and 2012 using data from 
the National Health Interview Survey between 1997 and 2006 
encompassing nearly 315,000 individuals and reported that 
patients with rhinosinusitis missed on average 5.7 days of work 
per year(27). These cohorts report on all patients with CRS and 
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therefore include less severe forms of the disease that are likely 
never referred for ENT-specialist management. Stankiewicz et 
al. reported on the rates of absenteeism and presenteeism in 
a population of 56 patients undergoing surgical intervention 
for chronic rhinosinusitis. Prior to surgery, they reported a 6.5% 
rate of absenteeism (i.e. 6.5% of work time missed) and 36% 
rate of presenteeism (reduction of on-the-job effectiveness). 
When combined, the rate of absenteeism and presenteeism 
yielded a 38% work productivity loss in the study population, 
but no dollar value was placed on this figure(47. Supporting this, 
Stull et al. reported that nasal congestion alone resulted in poor 
sleep, increased fatigue, and daytime sleepiness contributing to 
decreased work productivity(48). In 2014, Rudmik et al. specifi-
cally evaluated recalcitrant CRS in 55 patients and found that 
patients with this more severe form of CRS had mean annual 
presenteeism and absenteeism rates of 25 - 39 days per patient 
per year equating to an average indirect cost of over $10,000 per 
patient per year(49). Overall, the total indirect costs of CRS were 
estimated to be in excess of $20 billion per year in the USA(26). 
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4.1. Epidemiology of acute rhinosinusitis (ARS)
4.1.1. Common cold, post-viral rhinosinusitis and acute 
bacterial rhinosinusitis
Many patients consult their primary care clinician or pharmacist 
with problems associated with upper respiratory infections. The 
majority are self-limiting and can be classified as common colds. 
Common colds are defined as acute viral rhinosinusitis with 
a duration of symptoms of <10 days (but less than 12 weeks) 
(Figure 4.1.1). 
When symptoms increase after five days, or when symptoms are 
persistent for more than 10 days, with less than 12 weeks dura-
tion, then EPOS classifies this as acute post-viral rhinosinusitis. 
Only a minority of acute rhinosinusitis is from bacterial origin. 
Acute bacterial rhinosinusitis if defined by EPOS by at least three 
symptoms/signs of the five below:
• Discoloured mucus
• Severe local pain (often unilateral) 
• Fever > 38°C
• Raised CRP/ESR 
• ‘double’ sickening
This chapter describes the epidemiology and predisposing 
factors for different forms of acute rhinosinusitis (ARS).
4.1.2. Incidence of ARS in the population
ARS is a common problem, the precise incidence of which is 
difficult to estimate. The incidence of acute viral rhinosinusitis 
(common cold) is very high, as previously described(1) and as 
summarised in Table 4.1.1. It has been estimated that adults 
suffer two to five episodes of viral ARS (or colds) per year and 
school children may suffer seven to 10 colds per year(1, 2). In a re-
cent Dutch paper using the GA2LEN questionnaire a prevalence 
of 18% (17-21%) was found for symptoms pointing to post-viral/
ABRS ARS in three different cities in the Netherlands(3). 
Approximately 0.5-2% of viral upper respiratory tract infections 
are complicated by bacterial infection(1, 4)(Figure 4.1.2.). 
4.1.2.1. Incidence of acute bacterial rhinosinusitis (ABRS)
The precise incidence of ABRS is not known. This has been 
placed at 0.5-2.% of all viral infections(5). To develop acute bacte-
rial rhinosinusitis it is reasonable to assume that this is a compli-
cation of (post)viral ARS, a recent review described a collection 
of factors which make this outcome more likely (Table 4.1.2.)(6). 
It is also important to understand the natural history of a bout of 
ARS and the spectrum of symptoms which accompany it (Figure 
4.1.3). It can be seen that the majority of the symptom complex 
has resolved by day 7 but that nasal discharge and cough may 
last for a further three or four days (Figure 4.1.3.). It is clear that 
most symptoms, however, resolve by day 5 and that in general it 
Figure 4.1.1. Definition of acute rhinosinusitis.
4. Acute rhinosinusitis including common cold - and 
recurrent ARS in adults and children
Fig 4.1.2. The incidence of different forms of ARS: Common cold, postvi-
ral rhinosinusitis and acute bacterial rhinosinusitis (ABRS). Antibiotics are 
only indicated in a small part of the patients with ABRS.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
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is impossible to differentiate between bacterial and non-bacteri-
al before this time, although the possibility of bacterial infection 
increases if there is deterioration in symptoms after day 5(6). 
However, some guidelines state that symptoms should go on 
for longer before bacteria are implicated(7). A recent review and 
meta-analysis suggests that the percentage of bacterial infection 
is somewhat higher than has previously been thought, but 
recognises the complexity of the diagnosis in both radiograp-
hical diagnosis, with abnormal findings being associated with 
the presence of non-pathogenic bacteria and bacterial sampling 
techniques which may suggest differing levels of infection or 
contamination. They found that even when the strictest clinical 
and radiologic criteria are applied, only 53% of cultures are posi-
tive for pathogenic bacteria. They recommend further research 
is needed(8).
What is very clear is that bacterial rhinosinusitis is greatly 
over-diagnosed with concomitant overuse of both diagnostic 
tools and of antibiotics, with up to 60% receiving a course of 
antibiotics on day 1 of an event(9-11). Furthermore, early adminis-
tration of antibiotics appears to have little or no bearing on the 
development of complications of ARS(12-14).
4.1.3. Health seeking in ARS
Patients with common cold and post-viral rhinosinusitis will 
often seek help from their GP. 
In a three-year case-control study of the Dutch population, van 
Gageldonk-Lafeber estimated that annually, 900,000 individual 
patients (545/10,000 patient years) consulted their primary care 
physician for acute respiratory tract infection and that the most 
common aetiology was viral infection(15).
In the USA, between 2000-2009, acute rhinosinusitis was 
diagnosed in 0.5% (95% confidence interval (CI), 0.4%-0.5%) of 
Table 4.1.1. Acute rhinosinusitis (ARS) incidence and prevalence in primary care studies.
Study Author, year Evidence  Type of study
Hoffmans 
2018(3)
Prevalence of (post-viral and ABRS) ARS based on the EPOS criteria 18% (17-
21%)
Prospective population study
Hoffmans 
2015(17)
Incidence of (acute) rhinosinusitis in primary care in the Netherlands 
18.8/1000 patient years
Retrospective primary care morbidity 
registration
Uijen 
2011(374)
Incidence of acute rhinosinusitis during 2002 to 2008: 
0-4 years: 2/1000 per year in all years.    
5-14 years: 7/1000 in 2002 reducing to 4/1000 in 2008 (p<0.001)
12-17 years: 18/1000 per year in all years.
Retrospective, population study
Oskarsson 
2011(375)
Incidence of ARS is 3.4 cases per 100 inhabitants per year, or 1 in 29.4 patients 
visit their GP due to acute rhinosinusitis.
Retrospective population study
Wang 
2011(176)
6-10% of patients present at GP, otolaryngologist or paediatric out-patient 
practices with ARS
Multi-national questionnaire survey
Bhattacharyya
2011(31)
Point prevalence of 0.035% for recurrent acute rhinosinusitis during 2003-
2008.
Retrospective cohort study
Meltzer, Kaliner, Kaliner 
2011, 1997, 1997(168, 376)
1 in 7 adults affected by rhinosinusitis in USA Guidelines
Neumark 
2009(45)
7.5% of consultations for respiratory tract infections (or 1 in every 13.3) were 
attributable to sinusitis. Expanding to all primary care consultations, 19.3 
consultations/1000 patients were attributable to sinusitis.
Prospective population study
Bhattacharyya 
2009(50, 377)
For 1997-2006, 1-year prevalence of sinusitis (all forms) was 15.2% Retrospective cohort study
Fokkens 
2007(378)
For 1999, 8.4% of the Dutch population reported at least one episode of acute 
rhinosinusitis.
Guideline
van Gageldonk-Lafeber 
2005(15)
Incidence of acute respiratory tract infection (including ARS) during 2000-
2003 was 54.5 cases /1000 patient-years, or 1 in every 18.3 consultations
Prospective case-control study
Cherry 
2005(379)
In the USA, upper respiratory tract infection is third most common cause of a 
primary care consultation, of which a third is attributable to ARS.
National Survey
Louie 
2005(380)
In US study conducted during January to March 2002, 9% of previously heal-
thy patients presented with acute sinusitis.
Prospective study
Varonen, Rautakorpi 
2004, 2001(381, 382)
During 1998-1999, 12% of patients were diagnosed with ARS. 12% of consulta-
tions for infection (all cause) over this time period were attributable to ARS.
Cross-sectional multi-centre 
epidemiological survey
Bachert 
2003(2)
Between July 2000 and June 2001 6.3 million separate diagnoses of acute 
sinusitis were identified in Germany, resulting in 8.3 million prescription
Review
ABRS, acute bacterial rhinosinusitis; ARS, acute rhinosinusitis; GP, general practitioner.
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diagnostic criteria differ from place to place and environment. 
Primary care, by its very nature sees the vast majority of patients 
with acute respiratory infections, however, diagnostic labelling 
and subsequent coding is not always accurate with failure to dif-
ferentiate between acute and chronic rhinosinusitis(17). Similarly 
patients presenting to academic centres of excellence appear 
to have lower diagnostic rates, probably due to a more rigorous 
diagnostic approach(20). Thus any estimation of incidence and 
prevalence has to be largely inferred from examining data col-
lected retrospectively while providing routine clinical care, or 
collected prospectively.
A recent study suggests that both prevalence of viruses and 
climatic factors influence the expression of influenza type 
illness, suggesting that fluctuations in variability of numbers 
of presentations are to be expected(21). Studies of prescribing 
habits may also shed light as to what the real prevalence of 
patients with ARS seeking medical attention might be in the 
general population. A retrospective study of 3.7 million patients 
revealed that 74,359 patients had had a consultation for ARS 
over a two-year time span suggesting a consultation rate of 1% 
of the population per annum(22). A longitudinal study of 856 pri-
mary care trainees in Australia (108.759 individual consultations 
with 169,303 problems/diagnoses) resulted in a prevalence of 
0.9% of acute rhinosinusitis of all problems or 1.39% of indivi-
dual consultations(23). 
A cross-sectional study including GPs from two Nordic coun-
tries, two Baltic countries and two Hispano-American countries 
registered patients with respiratory tract infections (RTIs) during 
three weeks in January 2008. In total, 618 participating GPs 
registered 33.273 patients with RTIs, of whom 1150 (3.46%) were 
considered to have acute post-viral or acute bacterial rhinosinu-
sitis as defined by EPOS. Over 50% of the patients with acute rhi-
nosinusitis had symptoms for <5 days and most had no fever(24).
The wide variability in diagnostic rates may also indicate geo-
graphical factors, the cost or ease of accessing healthcare, diag-
nostic norms in differing countries, patient expectations, patient 
worries, concerns or beliefs, and clinical expertise(24).
This problem is further compounded and confounded with 
misdiagnosis especially regarding migraine headaches(25-27).
4.1.4. Conclusion
In summary, it is difficult to give a precise estimate of the pre-
valence of ARS. Viral ARS (common cold) is very common and 
it has been estimated that adults suffer two to five and school 
children may suffer seven to 10 episodes per year. The only 
available prospective population study evaluating EPOS defined 
post-viral ARS (and ABRS) points to a prevalence of 18%(3) and 
(post-viral and ABRS) ARS is likely to be responsible for 1-2% of 
consultations in primary care. Carefully constructed prospective 
epidemiological studies with valid diagnoses of ARS may give a 
clearer picture of the real burden of ARS.
all outpatient visits among adults, averaging 19.4 visits (95% CI, 
16.5-22.3) per 1000 adults and this did not change during the 
study period(16). A recent Dutch paper found a comparable figure 
using two different Dutch GP registries; an incidence of con-
sultations for acute rhinosinusitis of 18.8- 28.7 per 1000 patient 
years. Because these registries do not make a clear differentia-
tion between ARS and CRS a proportion of these consultation 
might have been for CRS. Medication was prescribed in over 
90% of cases(17). 
A global analysis reveals that unspecified Upper Respiratory 
Tract Infection (URTI) is the most common cause for consulta-
tion in the developing world and the second most common 
reason for consultation. In contrast, acute rhinosinusitis was 
not specified by clinicians although patients rated it as the 
thirteenth most common cause for seeking medical help(18). A 
very detailed study of activity in Australian primary care demon-
strated that acute /chronic rhinosinusitis accounted for 0.8% of 
total problems but was encountered in 1.3% of consultations 
(in primary care patients frequently consult with more than one 
clinical problem)(19).
It is, however, difficult to be precise concerning prevalence: 
Table 4.1.2. Predisposing factors for acute bacterial rhinosinusitis.
Dental: infections and procedures 
Iatrogenic causes: sinus surgery, nasogastric tubes, nasal packing, 
mechanical ventilation
Immunodeficiency: human immunodeficiency virus infection, im-
munoglobulin deficiencies Impaired ciliary motility: smoking, cystic 
fibrosis, Kartagener syndrome, immotile cilia syndrome
Mechanical obstruction: deviated nasal septum, nasal polyps, hyper-
trophic middle turbinates, tumour, trauma, foreign body, 
granulomatosis with polyangiitis  
Mucosal oedema: preceding viral upper respiratory infection, allergic 
rhinitis, vasomotor rhinitis
FIgure 4.1.3. Common cold symptoms.
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4.2. Recurrent ARS (RARS)
RARS is defined as ≥4 episodes per year with symptom free in-
tervals(7, 28-30). Each episode must meet the criteria for acute post-
viral (or bacterial) rhinosinusitis. Recurrent ARS may be conside-
red distinct from ARS and CRS. Using data from a medical claims 
database for 13.1 million patients from 2003 to 2008, the point 
prevalence of recurrent ARS has been reported to be 0.035%, 
considerably lower than that of ARS(31). However, in the study by 
Hoffmans et al. only four out of 5574 ARS patients visiting their 
GP met this categorisation(17). Whether RARS should be conside-
red a form of acute or CRS requires further discussion. 
Lee et al. (32) underlined the diagnostic challenge when it comes 
to RARS, and this is due to the relative lack of awareness and 
also the sporadic diagnosis by different healthcare providers. 
Most of the time, endoscopy is clear and CT sinuses do not show 
Figure 4.2.1. Delphi: In the diagnosis of recurrent acute rhinosinusitis do you 
rely on: History alone?
Figure 4.2.2. Delphi: In the diagnosis of recurrent acute rhinosinusitis do you 
rely on: History + positive objective findings, i.e. endoscopy and/or CT?
Figure 4.2.3. Delphi: In the diagnosis of recurrent acute rhinosinusitis: Is it 
essential to examine the patient with a CT-sinuses during (or shortly after) 
an acute episode if endoscopy has not been performed?
Figure 4.2.4. Delphi: In the diagnosis of recurrent acute rhinosinusitis: Is it 
essential to examine the patient with a CT sinuses during (or shortly after) 
an acute episode if endoscopy has been performed and is normal?
Figure 4.2.5. Delphi: In the diagnosis of recurrent acute rhinosinusitis: Is it 
essential to examine the patient with a CT of sinuses during (or shortly after) an 
acute episode if endoscopy has been performed and is abnormal?
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acquiring an acute respiratory illness was 2.9 (95% CI: 2.8- 3.0) in 
January to March, 1.8 (95% CI: 1.7-1.9) in October to December 
and 1.4 (95% CI: 1.3-1.5) in April to June. In an audit of compli-
cations of ARS, Babar-Craig et al. reported that 69% of patients 
were admitted during the winter months of November to 
April(12). Similar patterns have been reported in acute exacerba-
tions of CRS(46) and upper respiratory tract infections(47). Climate 
variations have been reported to induce facial pain similar to 
ARS. Chinook or Föhn winds are weather events in which a 
rapidly moving warm, high-pressurised wind enters a specific 
location. The pressure changes that occur during the Chinook 
may induce facial pain similar to that experienced in rhinosinu-
sitis pain. Rudmik et al. report that compared to controls, the 
presence of concha bullosa and spheno ethmoidal cell (Onodi 
cell; p=0.004), and larger maxillary sinus size (right, p=0.015; left, 
p=0.002) are all associated with complaints of Chinook heada-
che(47, 48). However, as the Lund-Mackay (LM) score was higher in 
the control group, the authors conclude that CRS is unlikely to 
be associated with the Chinook induced facial pain. Exposure to 
air pollution(49-51), irritants used in the preparation of pharmaceu-
tical products(52), during photocopying(53) and forest fire smoke(54) 
have all been associated with an increase in the prevalence of 
symptoms of ARS. Of importance in seasonality of ARS is the 
presence of CRS which seems to predispose to ARS especially 
in the winter months, whereas ARS was more common in those 
without CRS in the spring months(55). This study also quantified 
the effect of no previous past history of CRS compared to those 
who had a previous and current history of CRS, demonstrating 
an increasing incidence gradient also shown for never, former 
(1.01) and current smokers (1.53), the presence of asthma 
symptoms, a diagnosis of hay fever (1.36), migraine (1.55), anxi-
ety (0.96-1.29), sinus surgery (1,46-1.74), being Caucasian (1.5) 
and female gender (1.35). Broadly similar results were found 
in a study from the Netherlands(3). A review of the literature by 
De Sario et al. described how the role of our changing climate, 
outdoor pollution, temperature, wild-fires, and desert storms 
may act synergistically to present a challenge to those suffering 
from respiratory disease(44).
4.3.2. Anatomical factors 
Abnormalities on radiology are often seen in the healthy popu-
lation. Two recent studies, one in Japan and one in the Nether-
lands reported on radiology in healthy populations and found 
significant percentages that could be misinterpreted as abnor-
malities pointing to ARS or CRS. The Dutch study showed some 
abnormality (LM>0) in 43% of the population and 14% had a LM 
score ≥ 4 pointing to ARS or CRS(56). The Japanese study was in 
an elderly population and found 17% LM>0 and 7.4% LM score 
≥ 4 respectively(57). 
It has been suggested that anatomical variation is more likely 
to be of causal significance in patients with RARS(33, 58-60) with 
any significant mucosal thickening(33). The EPOS2020 steering 
group advises to have at least one proven diagnosis of post-viral 
ARS with endoscopy and/or CT scan before a diagnosis of RARS 
is considered (Figures 4.2.1.-4.2.5.) .
4.3. Factors associated with ARS and RARS
There appear to be many factors which impact upon ARS, and 
it is likely that many people suffering from a bout of ARS have 
more than one contributing factor. In a recent questionnaire-
based study from the Netherlands, the factors which predis-
posed to increased likelihood of ARS were: a doctor-diagnosis of 
CRS, allergic rhinitis, female gender, eczema, itchy rash and smo-
king. Increasing age was a protective factor(3). In the Netherlands 
non-Caucasian ethnicity was also a protective factor, but this 
clearly depends on other factors as, for example, in a study from 
the USA, being Caucasian was protective(34), suggesting that 
risk factors have different impacts in different locations. There 
is limited evidence on predisposing factors in RARS(35) though it 
appears that the majority of episodes follow viral ARS and some 
patients are immunodeficient(36, 37), mainly IgA deficient and 
common variable immunodeficient(38-40).
4.3.1. Environmental exposures
Using a matched case-control study design conducted in a 
Dutch population over the period 2000 to 2003, van Gageldonk-
Lafeber et al.(41) reported that exposure to an individual(s) with 
respiratory complaints, inside or outside of the immediate 
household was an independent risk factor for attending their 
GP with an acute respiratory tract infection (adjusted odds ratio 
(OR)=1.9 and adjusted OR=3.7, respectively). In contrast, pa-
tients with children in secondary education, who had dampness 
or mould at home, or had exposure to passive smoking were 
less likely to visit their GP compared to those without children, 
mould or dampness or passive smoking exposure respectively. 
Increased levels of dampness, but not mould, in the home 
has been associated with rhinosinusitis(42). Seasonal trends in 
occurrences of ARS have been reported. This is of course to be 
expected and is common knowledge that does not need to be 
over-elaborated as acute viral infections are the most common 
cause of upper respiratory tract infections including acute rhino-
sinusitis(43). What has become clear is that weather patterns are 
increasingly variable which will impact on many of the currently 
identified risk factors(21, 44).
In a study of respiratory tract infections, Neumark et al. reported 
seasonal variation in the incidence rate of rhinosinusitis from 
1999 through to 2005, with increased incidence in the first 
quarter of each year(45). For acute respiratory illnesses in 2000 
to 2003, van Gageldonk-Lafeber et al. reported similar seasonal 
trends to those of Neumark(15). Compared to July to September, 
van Gageldonk-Lafeber et al. reported that the relative risk of 
EPOS 2020
58
episodes of ARS, or bacteriological and radiological findings 
suggesting that the presence of allergy may be incidental. 
In a comparative case-control study of Israeli air force pilots, Ula-
novski reported that 33% of pilots with a history of AR and 21% 
of the control group had one or more episodes of ARS (p=0.09)
(72). In 2009, Pant et al. undertook a review of allergy in rhinosi-
nusitis. In agreement with the above literature, they concluded 
that insufficient evidence exists to confirm seasonal or peren-
nial AR as a significant predisposing factor for ARS(73). Lin et al. 
reported that children with atopy were more likely to develop 
ARS(74). They reported that atopic children with ARS reported sig-
nificantly higher symptoms (including dizziness, sneeze, snore, 
itchy or burning eyes, eye congestion and tearing) as well as 
significantly higher levels of anxiety, dyspnoea, chest tightness, 
and lower nasal peak inspiratory flow than non-atopic children 
with ARS. A more recent study in children demonstrated that 
although ARS was common in the studied population, there was 
no difference in incidence between those sensitised to grass 
pollen and those not sensitised but that the most common risk 
factor was an acute viral infection(75). We are not aware of studies 
evaluating the role of allergy in RARS.
In summary, there appears to be little to support the presence of 
allergic rhinitis as a risk factor for developing ARS. 
There appears to be little to support the presence 
of allergic rhinitis as a risk factor for developing 
ARS.
4.3.5. Ciliary impairment 
Ciliary impairment has been demonstrated to be a feature of 
both viral and bacterial rhinosinusitis(1). This includes both the 
loss of cilia and ciliated cells as well as a disruption of normal 
mucociliary flow. Smoking and allergy have been implicated in 
the disruption of cilia function. Indeed, impaired mucociliary 
clearance in AR patients predisposes patients to ARS(76). 
Ciliary impairment has also been associated with cigarette smo-
king. In vitro studies have demonstrated that cigarette smoke 
condensate and cigarette smoke extract impair ciliogenesis in a 
dose-dependent manner(77). Clinical studies have also reported 
that exposure to passive smoking increases the levels of matrix 
metalloproteinase 9 (MMP-9), a gelatinase associated with tissue 
modelling which is significantly increased in nasal secretions of 
children(78) exposed to passive smoking. As increased production 
of MMP-9 has been found in the acute allergic response in the 
nose and lungs, the implications for the involvement of MMP-9, 
ciliary function, allergic response, and smoking in ARS needs 
further exploration. 
4.3.6. Smoking 
Limited research exists on the impact of smoking on ARS. Using 
data from the 1970 US National Health Interview Survey, and 
infraorbital cells and concha bullosa most often cited. In a small 
retrospective study on CT in 36 patients with RARS versus 42 
controls, the LM score was 2.25 in the RARS group compared 
with 1.27 in the controls, notably related to the presence of 
infraorbital cells(58). However, the presence of an anatomic vari-
ant did not correlate with the pattern of inflammation in a small 
retrospective study(60). Endoscopy and CT were shown to be 
undertaken less frequently than in CRS, 9.2% in the first three 
years and 40% in the first four years, respectively(31). 
In conclusion, there are limited data correlating anatomical 
factors to (recurrent) ARS. Abnormalities seen on radiology are 
also common in a healthy population. 
It has been suggested that anatomical variation is 
more likely to be of causal significance in patients 
with RARS patients.
4.3.3. Odontogenic infections
Odontogenic infections, or infections arising from dental 
sources, causing acute maxillary sinusitis have been reported 
in the literature. Bomeli et al. reported that oroantral fistula and 
periodontal disease plus either a projecting tooth root or peri-
apical abscess were significantly identified as sources of acute 
maxillary sinusitis(61). Furthermore, they demonstrated that the 
greater the extent of fluid opacification and mucosal thickening, 
the greater the likelihood of an identifiable dental infective 
source. In a computed tomography (CT) radiological study of 
the maxillary sinus in elderly dentate and edentulous patients, 
Mathew et al. reported an increased prevalence of mucosal 
thickenings (74.3 versus 25.6; p<0.05 ) and mucous cysts (2.1% 
versus 0) in dentate patients compared to edentate controls, 
but most of these abnormalities can be considered chronic(62). A 
recent retrospective analysis from Finland suggests that some 
15% of ARS may be odontogenic in nature(63).
In patients with (recurrent) ARS, odontogenic 
sources of infections should be considered. 
4.3.4. Allergy 
The role of allergy in ARS is the subject of much debate with 
literature both supporting and disputing a role for allergy in 
predisposing for ARS(64). Schatz et al. reported that the odds of 
developing an episode of ARS was 4.4 times higher in patients 
with rhinitis than in healthy controls(65). The major difficulty is 
the high prevalence of around 30% depending on the location 
of allergy in the population worldwide(66-70). In 1989, Savolainen 
reported that 25% of 224 patients with acute maxillary sinusitis 
had allergy, as verified by allergy questionnaire, skin testing and 
nasal smears, with a further 6.5% of patients having probable 
allergy(71). However, upon comparison of those with and without 
allergy, no differences were found in the number of previous 
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4.3.8. Anxiety and depression 
Poor mental health or anxiety and depression have been signifi-
cantly associated with ARS. In a study of 47,202 college students 
aged 18 to 24 years, Adams et al. reported that the prevalence of 
acute infectious illness, which included bronchitis, ear infection, 
rhinosinusitis, and strep throat, ranged from 8% to 29%, while 
the prevalence of anxiety and depression ranged from 12% to 
20%, respectively(88). It is important to recognise the confoun-
ding impact of smoking as smoking contributes to ARS but also 
to anxiety/depression. Those who stop smoking demonstrate an 
improvement in mood and quality of life with reduced levels of 
anxiety and depression(89).
4.3.9. Concomitant chronic disease
 Concomitant chronic disease (bronchitis, asthma, cardiovascu-
lar disease, diabetes mellitus, or malignant cancer) in children 
has been associated with an increased risk of developing ARS 
secondary to influenza. Loughlin et al. reported that the overall 
incidence rate of developing ARS following influenza ranged 
from 0.9 to 1.3 in children aged 0 to 14 years. While the inci-
dence of ARS subsequent to influenza in healthy children aged 
5-14 years was 1.2 (95% CI: 0.9 – 1.5), this increased to 3.1 (95% 
CI: 1.5 – 5.8) in children with chronic disease (rate ratio: 2.7 (95% 
CI: 1.5 – 5.4). Increased monitoring of children with chronic 
disease who develop influenza may be necessary(90).
4.3.10. Conclusion
Predisposing factors for ARS are seldom evaluated. There is 
some indication that anatomical abnormalities may predispose 
for RARS. Active and passive smoking predisposes to ARS and 
there is some indication that concomitant chronic disease may 
increase the chance of getting ARS following an influenza infec-
tion. Other potential factors like allergy and GORD do not seem 
to predispose to ARS. 
4.4 Pathophysiology of ARS
ARS can be divided into acute viral rhinosinusitis, post-viral rhi-
nosinusitis and acute bacterial rhinosinusitis. ABRS is frequently 
preceded by acute viral rhinosinusitis or common cold(91). In 
addition to the strain and virulence of individual viruses, the se-
verity and pathogenesis of ARS is highly dependent on the host 
factors or predisposing conditions, such as age, host defence 
parameters or immune deficiency, previous infection or immuni-
zation, pre-existing mucosal inflammation caused by exposure 
to allergens, pathogens or other environmental risk factors, and 
anatomic deformity of the nose and sinuses. 
The pathogenesis and pathophysiology of ARS is incompletely 
understood. This is mainly due to the lack of prospective clinical 
and laboratory studies in patients being performed during the 
natural course of ARS. In the literature, most reported studies 
after excluding families with children with chronic respiratory 
illness, Bonham and Wilson reported that children from house-
holds with one or more adult cigarette smokers had significantly 
more restricted activity and bed-disability days than children 
from families with non-smoking adults(79). This difference was 
found to be due to children from families with active smokers 
having more episodes of acute respiratory illness (including 
ARS). Comparable significant results were found when families 
in which 45 cigarettes or more were consumed per day were 
compared to families with non-smoking adults. The authors 
concluded that higher cigarette consumption was associated 
with increased predisposition for acute respiratory illness. In 
a paediatric characterisation study of 76 patients with acute 
rhinosinusitis aged 4-18 years, Eyigör and Başak reported that 
51.3% (39 patients) were exposed to second-hand smoke and 
2.6% (two patients) were active smokers(80). Based on their 
population, the authors concluded that exposure to primary 
or second hand smoke were predisposing factors for ARS. In a 
study characterising the respiratory symptoms of adult postal 
workers in Zagreb, Croatia, the prevalence of rhinosinusitis in 
active smokers was 53.1% compared to 26.4% in non-smokers, 
although no information was available on whether the rhinosi-
nusitis was recurrent acute or chronic in nature(81). 
Active and passive smoking has been shown to alter the normal 
bacterial flora present in the nasopharyngeal spaces, resul-
ting in the colonisation of more potential pathogens than in 
non-smokers(82). Following smoking cessation, the microbial 
population has been shown to revert back to that found in 
non-smokers(83). The impact of smoking cessation programmes 
on the incidence and prevalence of ARS is unknown. In vitro and 
in vivo studies have recently shown increased MMP-9 produc-
tion in children exposed to passive smokers(78) and increased 
complement activation in human respiratory epithelial cells and 
mice exposed to cigarette smoke extract(84). Whether increased 
MMP-9 production or complement activation due to exposure 
to cigarette smoke predisposes to ARS is unknown and requires 
further investigation. More recent studies confirm the negative 
impact of smoking(55). 
Active and passive smoking predisposes to (R)ARS.
4.3.7. Laryngopharyngeal reflux 
Little is known about the association of ARS and laryngopha-
ryngeal reflux. As reviewed by Pacheco-Galván et al., epidemio-
logical studies conducted between 1997 and 2006 have shown 
significant associations between gastro-oesophageal reflux 
disease (GORD) and rhinosinusitis(85). However, in a recent syste-
matic review, Flook and Kumar showed only a poor association 
between acid reflux, nasal symptoms, and ARS(86). The role of 
reflux in ARS remains unclear(87).
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The nasal epithelium is the primary portal of entry 
for respiratory viruses and immediate target for 
viral replication in the airway. It serves as a 
mechanical barrier to protect from 
environmental factors, microorganisms, and 
toxins, but also participates in both innate and 
adaptive immune responses.
RV infection can upregulate the expression of ICAM-1 via IL-1β 
and nuclear factor (NF)-κB-dependent mechanisms, directly 
enhancing infectivity and promoting inflammatory cell infiltra-
tion(100, 106, 107). In nasal polyp epithelium, higher expression of 
α-2,3-SA and α-2,6-SA will lead to the entry of more avian and 
seasonal influenza virus infection than normal nasal mucosa(108). 
In in vitro culture of differentiated nasal, tracheal and bronchial 
cells, the α-2,3-SA and α-2,6-SA receptors were located in cilia-
ted and non-ciliated cells, respectively(109). Therefore, influenza 
virus likely targets non-ciliated cells in the nose, as the α-2,6-SA 
receptor is expressed in both the nose and trachea(110). 
Immune responses
The nasal epithelium not only serves as a mechanical barrier to 
protect from environmental factors, microorganisms, and toxins, 
but also participates in both innate  (non-specific) and adap-
tive immune responses. The pseudostratified airway surface 
epithelium can be damaged in different degrees depending 
on the type of viruses and can also regenerate to restore its 
were carried out using human volunteers, in vitro study of 
human tissue or cell lines, and experimental animals. These 
results have yet to be validated in human patients with naturally 
acquired viral infection and ARS.
ARS can theoretically be divided into viral (common cold) and 
post-viral rhinosinusitis. A small subgroup of ARS is caused by 
bacteria (ABRS). The pathogenesis and inflammatory mecha-
nisms of viral and post-viral infection, and ABRS (if it occurs) can 
considerably overlap as can their clinical presentation. 
ARS can theoretically be divided into viral 
(common cold), post-viral rhinosinusitis and a 
small subgroup of acute bacterial rhinosinusitis. 
4.4.1. Viral rhinosinusitis
Viral rhinosinusitis (or the common cold) is, by definition, an 
acute rhinitis induced by respiratory viruses, such as rhinovi-
rus (RV), respiratory syncytial virus (RSV), influenza virus (IFV), 
coronavirus (CorV), parainfluenza virus (PIV), adenovirus (AdeV) 
and enterovirus (EV)(35, 91, 92). RV and CorV are the most common 
viruses isolated from adult ARS, accounting for approximately 
50% of viral ARS diagnosis(93). In children, there is a wider variety 
of responsible viruses, i.e. besides rhinoviruses and coronaviru-
ses, one can also expect to find RSV, parainfluenza viruses and 
adenoviruses. Geographically, there are also other viruses isola-
ted from patients with ARS, e.g. human bocavirus is frequently 
isolated from ARS cases(94). With the new development of more 
sensitive and high-throughput viral detecting and screening 
techniques, multiple viruses can be detected. It is, however, 
relatively difficult to identify key viruses that cause or exacerbate 
ARS in clinical practice.
Post-viral ARS and ABRS are frequently preceded 
by acute viral rhinosinusitis or common cold.
4.4.1.1 Nasal epithelium
Receptors 
The nasal epithelium is the primary portal of entry for respi-
ratory viruses and immediate target for viral replication in the 
airway(95-98). It is also an active component of initial host respon-
ses against viral infection. Nasal epithelial cells express various 
receptors recognizing specific viruses, such as intercellular ad-
hesion molecule-1 (ICAM-1)(99, 100), toll-like receptor 3 (TLR3)(101), 
α-2,3-linked sialic acid (α-2,3-SA)/α-2,6-SA containing receptor 
(102), retinoic acid inducible gene 1 (RIG-1, also known as DDX58)
(101, 103), and MDA4 (also known as IFIHI)(103). Upon infection the 
virus enters by receptor-mediated endocytosis, followed by ex-
pression and replication of the viral genome within hours after 
infection(99, 104, 105) (Figure 4.4.1.). 
Figure 4.4.1.  Nasal epithelium is the primary portal of entry for respi-
ratory viruses as well as an active component of initial host responses 
against viral infection. The cascade of inflammation initiated by nasal 
epithelial cells will lead to damage by the infiltrating cells, causing 
oedema, engorgement, fluid extravasation, mucus production and sinus 
obstruction in the process, eventually leading to postviralARS or even 
ABRS.
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viral infections. For example, rhinoviruses tend to express much 
weaker signatures compared to influenza infection(97); and infec-
tions such as RSV tend to elicit a sustained response following 
infection compared to other viruses(124). Therefore, studies to 
differentiate the pathogenic mechanism of different respiratory 
viruses are pivotal to understand their differential symptoms 
and severity in ARS, further highlighting the need for viral detec-
tion for symptom management of ARS. 
Motile cilia
In an early study, a significant and long-lasting (up to 32 days) 
impairment of nasal mucociliary clearance functions such as a 
fall in the number of ciliated cells and a moderate and short-
lasting change in beating frequency and intracellular synchrony 
were observed in patients with common cold(125). More recent 
studies have further confirmed that impaired ciliogenesis was 
prominent following viral infections(126), consistently leading to 
loss of cilia and ciliated cell ultrastructural abnormalities (i.e., 
cytoplasmic blebbing, swollen mitochondria)(97, 111, 127, 128). 
In vitro studies from human nasal epithelial cell models de-
monstrated that downregulation of ciliogenesis marker Foxj1 
and upregulation of goblet cell marker Mucin5AC indicated the 
altered muco-ciliary function due to RV infection (clone RV16)
(97). In another study, RSV was found to infect preferentially the 
ciliated cells in human primary nasal epithelium. A portion of 
the RSV proteins (F and G) were trafficked into the cilia between 
24 and 48 hour-post-infection followed by extensive cilia loss 
at five days-post-infection(129). For influenza, the infection was 
followed by apoptotic and necrotic cell death causing the loss of 
epithelium including ciliated cells, impacting ciliary function(111). 
Goblet cells
The mucosal lining of the nasal cavity is coated by a mucus 
layer 10 to 15 µm thick. Mucus is supplied by goblet cells in the 
epithelium and submucous seromucous glands. Sinus secreti-
ons are a mixture of glycoproteins, other glandular products, 
and plasma proteins. Secretions are rich in lysozyme, lactoferrin, 
albumin, secretory leukoprotease inhibitors, and mucopro-
teins(130). In an ideal scenario, immediately after viral infection, 
a timely immune response is elicited, culminating in early viral 
elimination with minimal damage to the host. However, the 
cascade of inflammation initiated by the epithelial cells normally 
leads to damage by the infiltrating cells, causing oedema, 
engorgement, fluid extravasation, mucus production and sinus 
obstruction, eventually leading to ARS or exacerbating ARS(131).
It has been reported that common cold symptoms may result 
from release of inflammatory mediators, such as bradykinin 
and TAME-esterase activity (but not histamine), into the nasal 
mucosa and secretions(132). There is a luminal entry of plasma, 
including large binding proteins such as fibrinogen and α2 –ma-
croglobulin, which may bind and transport a variety of cytokines 
defence functions. Therefore, the interactions between the nasal 
epithelium and invading pathogens play key roles in the disease 
progression and subsequent immune responses against the 
virus, thus contributing to both disease burden and combating 
infection of the nasal epithelium.
Many studies indicate that the nasal epithelium actively trig-
gers innate immune responses and also modulates adaptive 
immunity against these viruses(95, 96, 111). Nasal epithelial-specific 
transcriptomic signatures may significantly influence the down-
stream immune responses and homeostasis that define the 
pathology of respiratory infection and complications(97, 112-114). In 
addition, respiratory viruses are also implicated to disrupt cilia 
and tight junction integrity in airway epithelial cells through 
the modulation of ZO-1, claudin-1 and occludin in the airway 
epithelial barrier(115-117).
Nasal epithelial cells elicit their own repertoire of immune 
responses and actively prevent pathogens from damaging the 
airway(111, 118). Upon infection, they not only release anti-micro-
bial surfactants and mucus to delay pathogen transmission in 
the airway(114, 119), but also express and secrete various cytokines 
and chemokines to drive immune responses against invading 
pathogens in the airways(120, 121). In an in vitro study, H3N2 (Ai-
chi/7) infection of human primary nasal epithelial cells, showed: 
1) highly efficient viral replication dynamics starting as early 
as four hours post-infection (hpi); 2) upregulation of four main 
pathogen recognition receptors (PRRs) RIG-I, NLRP3, TLR3 and 
TLR7; 3) exponentially elevated IFN-α2, IFN-β, IL-28A and IL-29 (8 
to 72 hpi) at both intracellular mRNA and secreted protein levels; 
4) a rapid production and release of chemokines IP-10, CXCL11, 
and RANTES and inflammasome markers including IL-1α, IL-
1β, IL-6, IL-8, TNFα and TGFβ after 24-72 hpi; 5) indices of cell 
damage and death showed a steady decline in viability, integrity 
and survival rate from 16 to 72 hpi. These findings demonstrated 
quantitatively virus-host relationship, transmission capacity and 
virulence of the respiratory viruses in the upper airway(111).
Transcriptomic signatures
The transcriptomic changes of infected nasal epithelial cells 
revealed differential regulation of 11 targets (CD38, HERC5, 
HERC6, IFI6, IFIH1, LGALS3BP, LY6E, MX1, PARP12, RTP4, ZBP1) 
creating influenza-specific signatures(122). Hence, these key 
transcriptomic signatures during influenza are nasal-initiated, 
underscoring the potential application of nasal epithelial 
responses in rapid and sensitive molecular-based diagnostics to 
improve influenza detection(98). In addition, recent studies have 
highlighted the strong expression of interferon lambda (IFN-λ, 
including IL-28A and IL29) as an important factor for limiting 
influenza viral spread, and potentially other viruses(97, 98, 111, 123). 
On the other hand, while other viruses express highly similar 
transcriptomic signatures exerting antiviral effects, the magni-
tude and response-time of the signatures may differ between 
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Post-viral rhinosinusitis is not an indicator of 
development of bacterial infection as only a small 
percentage of the patients with ARS 
will have ABRS.
4.4.3. Acute bacterial rhinosinusitis
Acute bacterial rhinosinusitis (ABRS) is an uncommon compli-
cation of viral upper respiratory tract infections that may cause 
mucosal damage and bacterial super-infection. Damage or 
disruption of mucociliary function due to viral infection is pro-
bably a major cause of super- or secondary bacterial infection. 
Bacterial and fungal infections are normally accompanied by 
viral infections, as observed in the common cold (RV-infection), 
and recurrent or chronic rhinosinusitis(144-146). Streptococcus pneu-
moniae, Hemophilus influenzae and Moraxella catarrhalis are the 
most frequent bacteria in rhinosinusitis(146). RV-1b infection 
can promote the internalization of Staphylococcus aureus into 
non-fully permissive cultured pneumocytes with a mechanism 
that involves the virus-induced release of IL-6 and IL-8, and the 
overexpression of ICAM-1(145). RV infection also promotes expres-
sion of cell adhesion molecules and bacterial adherence to 
primary human respiratory epithelial cells(147-149). Furthermore, in 
RV-infected nasal epithelial cells (NECs) from the nasopharynx, 
TNF-α expression was increased by Aspergillus infection(150). 
Viral infection of the nasal mucosa may trigger an inflammatory 
cascade thought to be responsible for the cold symptoms, but 
also forming the basis for immunological defence. The process 
of clearing the virus generates dead epithelial and infiltrating 
cells that contribute to the pathology of ARS. Such nasal epithe-
lial-specific transcriptomic alterations may significantly influence 
the downstream immune responses and homeostasis that de-
fine the pathology of respiratory infection and complications(97, 
98, 112, 114). It also creates an environment suitable for secondary 
bacterial infections (such as Staphylococcus aureus and Strepto-
coccus pneumoniae), representing another factor exacerbating 
ARS symptoms initiated by a viral infection(95, 139, 151, 152).
Viral infection of the nasal mucosa may trigger an 
inflammatory cascade thought to be responsible 
for the cold symptoms, but also forming the basis 
for immunological defence.
It has been suggested that respiratory virus infection induces 
the production of type I interferons (IFNs), inhibiting both the 
recruitment of circulating neutrophils and macrophages to the 
lung following bacterial challenge and the differentiation of 
antibacterial T helper 17 (TH17) cells from naive T cells or other 
T helper (TH) cell types (such as TH1 and TH2 cells). This then 
potentiates host susceptibility to secondary bacterial infection(95, 
153). Interleukin-10 (IL-10) production by influenza virus-specific 
effector T cells may inhibit the ability of innate immune cells, 
in both the common cold and allergic rhinitis(133). In addition, 
it has been shown that rhinovirus infection induces mucus 
hypersecretion, which may contribute to a progress from watery 
rhinorrhoea to mucoid discharge during the common cold(134). 
Viral interaction with goblet cells may also contribute to 
symptoms and aggravation of ARS. For example, MUC5AC 
production from goblet cells increased following RV and RSV 
infection(97, 135), while MUC5B was found to increase following in-
fection with human metapneumovirus (hMPV) in epithelial cell 
lines(136). With influenza virus, goblet cells produce sialic acid rich 
glycoprotein decoys in the mucus layer to prevent influenza bin-
ding to the epithelial cells(137, 138). However, the virus circumvents 
the sialic acid rich mucus layer via neuraminidase mediated 
cleavage of the sialic acids(138). This interaction also contributes 
to secondary bacterial aggravation of ARS with cleaved sialic 
acid serving as additional nutrient sources for bacteria such as S. 
pneumoniae(139). Hence, the role of goblet cells in the pathoge-
nesis of ARS is complex and multifaceted requiring controlled 
studies with appropriate models to establish their roles with 
different viruses. 
Other factors
Other factors such as soluble chemical factors, kinins, nitric 
oxide, nerve stimulation and neuromediators, may play im-
portant roles in the pathophysiology or pathogenesis of viral 
rhinosinusitis have been previously reviewed in EPOS 2012(91). 
Additionally, membrane tethered mucins (including MUC1, 
MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16, 
MUC17, MUC20, and MUC21) that are expressed by the mucosal 
epithelium unlike secreted mucins expressed by goblet cells, 
may also play a role in viral ARS(140, 141). For example, MUC1 has 
been implicated in influenza infection and its subsequent 
inflammatory responses(142, 143); while MUC4 and MUC16 may 
also play a role in forming a protective barrier against invading 
pathogens(141). 
4.4.2. Post-viral rhinosinusitis
In EPOS 2012 the term ‘post-viral ARS’ has been recommended 
in order to express the phenomenon of increase of symptoms 
after 5 days or persistent symptoms after 10 days with less than 
12 weeks duration(91). It is not an indicator of development of 
bacterial infection as only a small percentage of the patients 
with ARS will have ABRS. 
The pathophysiology and pathogenic mechanisms of post-viral 
rhinosinusitis remain unclear. Viral infection of the nose and 
sinuses induces multiple changes, which include infiltration and 
activation of various inflammatory cells in the sinonasal mucosa 
and defects in the host and adaptive immune defence functions, 
as well as increase the risk of bacterial superinfection. Therefore, 
in most patients, this is a time frame for recovery from a single 
episode of ARS to complete resolution.
EPOS 2020
63
response against invading viruses, especially in the context of 
influenza(111). Furthermore, the nasal cells could initiate cross-talk 
between innate and adaptive immunity via strong production 
of adaptive immune-activating cytokines and chemokines. A 
recent study showed that H3N2 infection of the nasal epithe-
lium was associated with significant increase in interferons 
(IFN-α, IFN-γ, IL-29), pro-inflammatory cytokines (TNF-α, BDNF, 
IL-3) and viral-associated chemokines (IP-10, MCP-3, I-TAC, MIG), 
detectable as early as 24h post infection(158). This translates into 
rapid monocyte, NK-cell and innate T-cell (MAIT and γδ T-cells) 
activation, evident with CD38+ and/or CD69+ upregulation(158). 
Therefore, an understanding of the predominant type and 
underlying mechanisms of mucosal inflammation triggered by 
common viral infections will allow us to identify targets for bet-
ter management of chronic airway inflammatory diseases.
There are also critical down-regulated functions in nasal epithe-
lium related to multiple metabolic and DNA damage responses 
against influenza that are not observed in blood or serum 
samples(98, 159-163). Such reductions in metabolic function and 
related metabolites at the primary influenza infection site may 
be an interesting area for future investigation to understand 
their relationships with viral replication and immune functions. 
In addition, these changes in the metabolic and homeostatic 
pathways are unique to the nasal epithelium.
Key points | What’s new since EPOS 2012
Since EPOS 2012, there has been increasing experimental data 
supporting the fact that nasal epithelium is the primary portal 
of entry for respiratory viruses as well as an active component of 
initial host responses against viral infection. The cascade of in-
flammation initiated by nasal epithelial cells will lead to damage 
by the infiltrating cells, causing oedema, engorgement, fluid 
extravasation, mucus production and sinus obstruction in the 
process, eventually leading to postviral ARS or even ABRS.
4.5. Diagnosis and differential diagnosis of ARS in 
adults and children
4.5.1. Update from EPOS 2012
Although the diagnosis and differential diagnosis of ARS has not 
changed substantially, there is more evidence on the prevalence 
of symptoms and the predictive value of individual and com-
bined symptoms on the diagnosis of (bacterial) acute rhinosinu-
sitis. This update reflects that new information.
in particular macrophages, to kill bacteria. Finally, the direct 
interaction and/or infection of innate immune cells — such as 
macrophages, neutrophils and natural killer (NK) cells — with 
influenza virus suppresses the ability of these cells to take up 
and kill bacteria(95).
S. pneumoniae infection is commonly associated with the aggra-
vation of viral infections(154). Studies have shown that influenza 
infection alters the gene expression of S. pneumoniae promoting 
dispersal from biofilms on the nasal mucosa(154, 155). As respiratory 
viruses induce a similar antiviral repertoire in the nasal epithe-
lium, these viruses can cause similar dispersal of S. pneumoniae 
into the airway mucosa.
4.4.4. Host defence mechanism
The anti-viral immune response involves innate and specific 
components and requires the coordinated actions of many diffe-
rent cell types including neutrophils, macrophages, eosinophils, 
dendritic cells, epithelial cells, mast cells, natural killer cells and 
B- and T-lymphocytes. Coordination of this response involves 
numerous cytokines and chemokines.
It is often speculated that the T-helper 1 (Th1) response is 
initiated from the epithelial innate immune response via toll-
like receptors 3, 7 and 9 (TLR 3, TLR7 and TLR9) due to the virus 
infection(111, 156). Depending on the type of virus, the pathogen-
sensing molecules in turn activate the production and secre-
tion of nuclear factor-κB (NF-κB), interferon-β (IFN-β), tumour 
necrosis factor-α (TNFα) and interleukins-1β, 6 and 8 (IL-1 β, IL-6 
and IL-8), which are potent inducers or recruiters of neutrophils 
and macrophages(92, 95). The initial action of neutrophils against 
virus-infected cells usually contributes to the early symptoms of 
an acute respiratory virus infection. Following this, the further 
secretion of TNFα and interferon-γ (IFN-γ) increases the recruit-
ment of Th1 cells and cytotoxic T-cells leading to the clearance 
of the viral pathogens and viral-infected cells.
IFNγ production by influenza virus-specific effector T cells 
decreases the expression of macrophage receptor with collage-
nous structure (MARCO) by alveolar macrophages and inhibits 
the ingestion of bacteria by these cells. It is known that through 
secretion of type I IFNs (IFN-α/β), the first line innate immunity 
defence in the infected cells, the neighbouring uninfected cells 
would be alerted to trigger its antiviral mechanisms. IFN-β is 
involved in the upregulation of antiviral proteins, induction of 
apoptosis to inhibit the viral replication, and removal of infected 
cells in the normal airways upon RV infection(157).
In addition, type III IFNs (IL-28A and IL-29) are shown to be 
strongly responsive to H3N2 infection, particularly their respon-
ses were found as early as 4 hpi and peaked at 24-48 hpi(111). It is, 
therefore, important to look at the antiviral responses shown by 
IFNs where we will be able to assess viral pathogenesis differen-
ces in the nasal epithelium.
Naïve epithelial cells evoke an appropriate type-1 inflammatory 
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ARS is sub-divided into ‘acute viral rhinosinusitis’ (synonymous 
with the ‘common cold’), in which the duration of symptoms is 
less than 10 days, usually a self-limiting condition that frequent-
ly does not present to clinicians, ‘acute post-viral rhinosinusitis’, 
defined by an increase in symptoms after five days or persisten-
ce beyond 10 days(176) and ‘acute bacterial rhinosinusitis’ defined 
by at least three symptoms/signs – discoloured mucus, severe 
local pain, fever>38’, raised CRP/ESR, ‘double’ sickening.
4.5.3.1. Assessment of ARS symptoms
Most acute viral URTI infections are self-limiting, 
thus post-viral ARS should not be diagnosed 
before 10 days duration of symptoms unless there 
is a clear worsening of symptoms after five days.
The subjective assessment of ARS in adults is based on the pres-
ence and severity of symptoms.
• Nasal blockage, congestion or stuffiness
• Nasal discharge or postnasal drip, often mucopurulent
• Facial pain or pressure, headache, and
• Reduction/loss of smell
Besides these local symptoms, distant and systemic symptoms 
may occur. Associated symptoms are pharyngeal, laryngeal, and 
tracheal irritation causing sore throat, dysphonia, and cough, 
and general symptoms including drowsiness, malaise, and 
fever. There is little reliable evidence of the relative frequency of 
different symptoms in ARS in community practice. Individual va-
riations of these general symptom patterns are many(177-181). Only 
a small proportion of patients with purulent rhinosinusitis, wit-
hout coexisting chest disease, complain of cough(178). In patients 
with a suspicion of infection, facial or dental pain (especially 
if unilateral) have been found to be predictors of acute maxil-
lary sinusitis, when validated by maxillary antral aspiration(178) 
or paranasal sinus radiographs(179). The symptoms of ARS occur 
abruptly without a history of recent nasal or sinus symptoms. A 
history of sudden worsening of pre-existing symptoms suggests 
an acute exacerbation of chronic rhinosinusitis, which should be 
diagnosed by similar criteria and treated in a similar way to ARS.
In children acute rhinosinusitis is defined as a sudden onset of 
two or more of the following symptoms: nasal blockage/ob-
struction/congestion or discoloured nasal discharge or cough 
(daytime and night-time) for <12 weeks.
Subjective assessment should take into account the severity and 
the duration of symptoms (see above). The recommended me-
thod of assessing severity of symptoms is with the use of a visual 
analogue scale (VAS) recorded by the patient on a 10cm line 
giving a score on a measurable continuum of 1 to 10. Disease-
specific questionnaires measuring quality of life impairment 
are available(182, 183) but not commonly used in clinical practice; a 
Post-viral ARS is a common condition in the 
community, usually following viral URTI.
4.5.2. Introduction
ARS is a common condition and is usually self-limiting. Many 
patients will self-manage or use over the counter remedies, so 
will not seek medical care or have a formal diagnosis made.
When medical care is sought, most patients will consult with a 
primary care physician, although in some health systems may 
directly access specialist services. Although educational efforts 
have been made to familiarize General Practitioners (GPs) with 
the concepts of rhinosinusitis and the diagnostic criteria for the 
diagnosis of ARS(164), ‘sinusitis’ is commonly used as a diagnos-
tic label, and as this is frequently considered by GPs an acute 
bacterial rather than inflammatory condition(165), antibiotics are 
extensively prescribed(166, 167). The dissemination of the EP3OS(1) 
and other recent guidelines(168, 169) emphasizing the inflammatory 
nature of ARS and providing standardization of diagnostic crite-
ria and use of investigations has led to more rational diagnosis 
and management in some(167, 170) but not all(171, 172) settings. In 
addition to misunderstandings concerning the inflammatory 
nature of ARS(171), concern over the risk of septic complications 
from untreated bacterial disease may be a factor in the ongoing 
high use of antibiotics in ARS. Observational evidence indicates, 
however, that complications are rare(13, 173) usually manifest early 
in the course of the illness with severe symptoms(174, 175), and that 
antibiotic treatment of ARS in general practice does not prevent 
complications(12, 13). 
Observational evidence indicates that antibiotic 
treatment of ARS in general practice does not 
prevent complications.
Guidelines agree that in uncomplicated cases, ARS is diagnosed 
on clinical criteria and supplementary investigations are not re-
quired(168). In particular patient groups and in those with severe 
or atypical symptoms, additional diagnostic procedures may be 
needed, as discussed below. ARS is frequently an isolated clinical 
event and a self-limiting condition, although may be recurrent 
in some cases. 
4.5.3. Clinical diagnosis in primary care
ARS is diagnosed by the acute onset of typical 
symptoms that include nasal blockage, discharge, 
facial pain or pressure and reduction in smell.
In the primary care setting (and for epidemiological research), 
ARS is defined by symptomatology without detailed ENT exa-
mination or imaging. ARS is defined by the presence of relevant 
symptoms for up to 12 weeks (see Chapter 2).
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4.5.3.3. Clinical examination
Anterior rhinoscopy
Although anterior rhinoscopy alone is a very limited investiga-
tion, it should be performed in the primary care setting as part 
of the clinical assessment of suspected ARS as it may reveal 
supportive findings such as nasal inflammation, mucosal oe-
dema and purulent nasal discharge, and can sometimes reveal 
previously unsuspected findings such as polyps or anatomical 
abnormalities.
Temperature
The presence of a fever of >38°C indicates the presence of a 
more severe illness and the possible need for more active treat-
ment, particularly in conjunction with more severe symptoms. A 
fever of >38°C is significantly associated with the presence of a 
positive bacteriologic culture, predominantly S. pneumoniae and 
H. influenzae, obtained by sinus aspiration or lavage(185).
Inspection and palpation of sinuses
Acute rhinosinusitis does not lead to swelling or redness of 
maxillofacial area unless there is a dental origin when the diag-
nostic odds ratio is 0.97. Data on local tenderness are inconclu-
sive(184). 
Nasal endoscopy
Nasal endoscopy is not generally available in routine primary 
care settings and is not required in the clinical diagnosis of ARS 
in these circumstances. 
C-reactive protein (CRP)
CRP is a haematological biomarker (available as rapid assay 
near-patient testing kits) and is raised in bacterial infection. Its 
use has been advocated in respiratory tract infection(186) as an 
aid to targeting bacterial infection and thus limiting unnecessa-
ry antibiotic use. A low or normal CRP may identify patients with 
a low likelihood of bacterial infection and who are unlikely to 
need or benefit from antibiotics. CRP guided treatment has been 
associated with a reduction in antibiotic use without any impair-
ment of outcomes(187) and CRP levels are significantly correlated 
with changes in CT scans(188) and a raised CRP is predictive of a 
positive bacterial culture on sinus puncture or lavage(185, 189).
Procalcitonin
Procalcitonin has also been advocated as a potential haema-
tological biomarker indicating more severe bacterial infection 
and investigated as a tool for guiding antibiotic prescribing in 
respiratory tract infections in the community. A recent review re-
vealed two randomised controlled trials (RCTs) aiming to reduce 
antibiotic prescription with procalcitonin as guiding marker(190). 
These studies did show reduced antibiotic prescriptions without 
detrimental effects on outcomes.
good clinician will, however, informally assess the impact of ARS 
on their patient as part of a full clinical assessment. The VAS can 
be used to assess overall and individual symptom severity (see 
below) or patients can be asked to simply rate their symptoms 
as absent, mild, moderate or severe. 
Patient reported purulence of nasal discharge has been recom-
mended as a diagnostic criterion for acute bacterial rhinosinusi-
tis(169), and is prioritized by GPs as a feature indicating the need 
for antibiotics(167). However, the positive likelihood ratio for (pu-
rulent) nasal discharge as a symptom (LR+ 1.3) and on physical 
examination (LR+ 0.88) do not support using purulent discharge 
to identify bacterial origin(184).
Facial or dental pain, especially when unilateral, has been found 
to be a predictor of acute maxillary sinusitis. Retained sinus 
secretions in patients with suspected bacterial infection can be 
confirmed by maxillary antral aspiration(178) or paranasal sinus 
radiographs(179). Pain on bending forwards and toothache in the 
upper jaw, particularly when unilateral, are often interpreted 
by GPs as indicative of more severe disease and the need for 
antibiotics(167), although with limited supporting evidence. The 
presence of toothache in the upper jaw has a positive likelihood 
ratio for the presence of acute bacterial rhinosinusitis of 2.0, 
which ranks this symptom as one of the highest predictors(184).
Bacterial infection may occur in ARS, but in most 
cases antibiotics have little effect on the 
course of the illness.
4.5.3.2. Clinical rules for the prediction of bacterial disease 
A number of studies have attempted to provide clinicians with 
combinations of symptoms and signs predicting more severe 
disease, particularly of a bacterial infection and the likelihood of 
a response to antibiotics. A recent meta-analysis tried to com-
bine all these studies(184). However, in such a meta-analysis it is 
very important for the prediction to choose the right population 
(primary care patients with at least 10 days of symptoms or in-
crease of symptoms after five days in which the GP felt antibio-
tics were needed) and the right  gold standard. The EPOS group 
in 2007 decided to base their advice on the study of Lindbaek(186) 
who chose an air fluid level or total opacification at CT scan as 
the gold standard in a population of primary care patients in 
which the doctor suspected ARS requiring antibiotics. We do not 
believe abnormalities on CT scan in general or abnormalities at 
sinus X-ray or ultrasound are good gold standards, neither do 
we consider patients sent in for an antral puncture to the ENT 
the ideal population.  For that reason, we decided to stick to 
suggestions as made in the earlier EPOS versions: at least three 
of five symptoms of discoloured discharge, severe local pain, 
fever, elevated ESR/CRP.  We appreciate that a study is required 
to determine the best clinical predictors in a carefully selected 
population.
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The differentiation of AR from ARS is made mainly on the basis 
of a prior history of allergy and atopy, and exposure to an aller-
gen (usually an aeroallergen) to which the patient is sensitized. 
Ocular symptoms are common in AR, in particular in patients 
allergic to outdoor allergens, but not in ARS. Mucopurulent 
rhinorrhoea, pain, nasal obstruction without other symptoms 
and anosmia are uncommon in AR. Diagnostic tests for AR are 
based on the demonstration of allergen-specific IgE in the skin 
(skin tests) or the blood (specific IgE), and may be considered to 
clarify the diagnosis, particularly in those with severe or persis-
tent symptoms.
Orodontal disease
Patients with orodontal disease may present to primary care 
physicians with ill-defined facial pain, with or without fever and 
toothache. The absence of other ARS-associated symptoms such 
as rhinorrhoea, nasal discharge and smell disturbance will make 
ARS a less likely diagnosis, although in some cases doubt may 
persist. A dental assessment and dental radiography may be 
required to clarify the diagnosis. ARS may occur more frequently 
and have overlapping symptoms in patients with orodontal 
disease(61).
Rare diseases
Facial pain syndromes
A number of conditions can present acutely with facial pain and 
nasal symptoms, including migraine and cluster headaches. The 
differential diagnosis of facial pain is discussed in Chapter 5.3.3. 
Vasculitis
Autoimmune vasculitides such as granulomatosis with polyangi-
itis, eosinophilic granulomatosis with polyangiitis or sarcoidosis 
may involve the nose and sinuses and on rare occasions may 
present acutely. The presence of other suggestive symptoms 
and an atypical clinical course can alert the clinician to alterna-
tive diagnoses. (See Chapter 8.7.)
Acute invasive fungal rhinosinusitis
In immunosuppressed patients and in (uncontrolled) diabetics, 
acute invasive fungal rhinosinusitis may present in a similar way 
to ARS, but with severe and rapidly progressive symptoms(193, 194). 
When this diagnosis is suspected, a more aggressive diagnos-
tic approach is required as a delay in diagnosis worsens the 
prognosis. (See Chapter 8.6.)
CSF leak
Unilateral watery rhinorrhoea is uncommon and should raise 
suspicion of cerebrospinal fluid leakage(195).
4.5.3.5. Warning signs of complications of ABRS 
Septic complications of ABRS represent a potential medical 
Erythrocyte sedimentation rate (ESR) and plasma viscosity
Markers of inflammation such as ESR and plasma viscosity are 
raised in ABRS, may reflect disease severity and can indicate 
the need for more aggressive treatment in a similar way to CRP. 
ESR levels are correlated with CT changes in ARS(251) with an 
ESR of >10 predictive of sinus fluid levels or sinus opacity on CT 
scans(189). Raised ESR has a positive likelihood ratio for rhinosi-
nusitis of 2,61 and a negative likelihood ratio of 0,68(187), with 
higher ERS levels increasing the likelihood of the presence of 
rhinosinusitis. Additional investigations such as imaging, micro-
biology and nasal nitric oxide measures are not required in the 
diagnosis of ARS in routine practice. 
4.5.3.4. Differential diagnosis of ARS in clinical practice 
The symptoms of ARS are non-specific and may overlap with a 
number of other conditions, from which it should be differenti-
ated.
Viral upper respiratory tract infection (URTI) 
The symptoms of the common cold and of self-limiting viral   
URTIs overlap with those of post-viral ARS. Indeed, all episodes 
of postviral ARS will start as a viral URTI but manifest a prolon-
ged illness beyond 10 days or with worsening symptoms after 
five days. Most common colds are associated with rhinovirus 
infection with symptoms peaking by three days(191), and the 
majority of patients not seeking medical care. The diagnosis is 
clinical and supportive advice, symptomatic treatment and reas-
surance are generally the only interventions required.
Allergic rhinitis (AR)
AR is a common global condition affecting at least 10-20% of 
the adult population(192). AR is the most common form of non-in-
fectious rhinitis and is associated with an IgE-mediated immune 
response against allergens. Since the nasal mucosa is conti-
nuous with that of the paranasal sinuses, congestion of the ostia 
may result in rhinosinusitis, which does not exist without rhini-
tis, so AR may be part of an allergic rhinosinusitis with similar 
symptoms to those of ARS (and CRS). Symptoms of AR include 
rhinorrhoea (non-purulent), nasal obstruction, nasal itching, and 
sneezing, which are reversible spontaneously or with treatment. 
AR is subdivided into “intermittent” or “persistent” disease. Inter-
mittent rhinitis may occur suddenly in response to exposure to 
a specific allergen, and so cause diagnostic confusion between 
AR and ARS. Seasonal AR is related to a wide variety of outdoor 
allergens such as pollens or moulds, and sudden exposure to 
such aeroallergens or to others (e.g. cat and dog dander in sen-
sitized individuals) can cause acute onset of symptoms. In AR, 
there will usually be a history of similar symptoms in response 
to similar exposures, often with a seasonal pattern. Non-specific 
irritants such as air pollution and viral infection may aggravate 
symptoms in symptomatic AR patients. 
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diagnosis and treatment with open or endoscopic sinus surgery 
(see Chapter 8.6.). The diagnosis is usually histopathological, so 
early endoscopic evaluation is indicated, with open biopsy if 
doubt remains(193, 194).
4.5.6. Conclusion
Acute rhinosinusitis may be divided into a viral common cold, 
post-viral or acute bacterial rhinosinusitis depending on the 
duration and severity of the symptoms. There have been some 
recent studies supporting the symptom base, but more are 
required to reduce the inappropriate use of antibiotics.
4.6. Medical management of ARS
4.6.1. Introduction
As mentioned before, ARS is divided into acute viral rhinosinusi-
tis, acute post-viral rhinosinusitis and acute bacterial rhinosinu-
sitis. For the definitions see Chapters 2 and 3. 
In recent years a large number of systematic reviews and meta-
analyses have covered the significant parts of the management 
of acute viral rhinosinusitis (often called common cold and/or 
upper respiratory tract infection). For that reason, this chapter 
contains a short overview of these systematic reviews and meta-
analysis. For acute post-viral rhinosinusitis and acute bacterial 
rhinosinusitis new systematic reviews and meta-analysis are 
performed in this chapter.
4.6.2. Management of acute viral rhinosinusitis (common 
cold)
In recent years a large number of systematic reviews and meta-
analyses have covered the significant parts of the manage-
ment of acute viral rhinosinusitis. For that reason, this chapter 
contains a short overview of the systematic reviews and meta-
analysis published after 2012. For the search performed please 
see Chapter 11.
emergency and require prompt recognition by generalists and 
immediate referral to secondary care for assessment (Chapter 
4.7; Table 4.5.1.). Observational surveys suggest that these 
complications occur rarely but early in the course of the disease, 
and that outcomes are not influenced by the use or non-use of 
antibiotics in primary care(13, 175).
Complications of ARS are uncommon, but vital 
to identify early. They occur early in the course of 
the illness and primary care clinicians need to be 
vigilant for the danger signs and symptoms.
4.5.4. Diagnosis of ARS in specialist care 
Although uncomplicated ARS is more likely to present to 
primary care physicians, in some health systems patients may 
present acutely to specialists or may be referred early for a 
specialist assessment, usually to a rhinologist or ENT specialist. 
Generally, the diagnosis may be made clinically using the same 
criteria outlined above, but sometimes more detailed diagnostic 
investigations may be applied. Immediate referral and/or hospi-
talization are indicated for any of the symptoms listed in Table 
4.5.1. These investigations include nasal endoscopy and imaging 
(see Chapters 5.3.4.1., 5.3.4.3.).
4.5.5. Diagnosis of ARS in specific settings
4.5.5.1. Diagnosis for research
In research settings, a more formal diagnosis may be required. 
In such settings, a variable combination of symptoms, ima-
ging findings, examination findings, and bacteriology samples 
(obtained from middle meatus or from sinus puncture) may be 
required for confirmation of the diagnosis as specified in the 
study protocol. The diagnostic criteria used must be specified in 
research studies to allow comparison of results between studies.
4.5.5.2. Diagnosis of ARS in the intensive care unit
ABRS is common in ICU (with risk factors including naso-gastric 
tubes, mechanical ventilation, failure of defence mechanisms 
and pronged supine posture), and is associated with poor 
outcomes. Sepsis may involve multiple sinuses(196). As a conse-
quence, more aggressive diagnostic processes may be appro-
priate such as CT scanning to confirm the diagnosis(197), and 
sinus puncture which is safe in skilled hands and can provide 
important microbiological information to confirm the diagnosis 
and guide therapy(196).
4.5.5.3. Diagnosis of ARS in immunosuppressed patients 
Immunosuppressed patients are much more vulnerable to com-
plications of ABRS, and a more aggressive diagnostic approach 
is required. Acute invasive fungal rhinosinusitis(290) is a serious 
disease with high mortality and morbidity and requires prompt 
Table 4.5.1. Warning symptoms of complications in ARS requiring imme-
diate referral / hospitalization.
Periorbital oedema/erythema
Displaced globe
Double vision
Ophthalmoplegia
Reduced visual acuity
Severe unilateral or bilateral frontal headache
Frontal swelling
Signs of meningitis
Neurological signs
Reduced consciousness
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was no difference between antihistamines and placebo in the 
mid-term (three to four days) to long term (six to 10 days). When 
evaluating individual symptoms such as nasal congestion, rhi-
norrhoea and sneezing, there was some beneficial effect of the 
sedating antihistamines compared to placebo (e.g. rhinorrhoea 
on day 3: mean difference (MD) -0.23, 95% CI -0.39 to -0.06 on 
a four- or five-point severity scale; sneezing on day 3: MD -0.35, 
95% CI -0.49 to -0.20 on a four-point severity scale), but this ef-
fect is clinically non-significant. Adverse events such as sedation 
were more commonly reported with sedating antihistamines 
although the differences were not statistically significant. Only 
two trials included children and the results were conflicting. The 
authors concluded that antihistamines have a limited short-term 
(days 1 and 2 of treatment) beneficial effect on severity of over-
all symptoms in adults but not in the mid to long term. There is 
no clinically significant effect on nasal obstruction, rhinorrhoea 
or sneezing(200).
4.6.2.4. Decongestants
In 2016, Deckx et al. published a Cochrane review on the ef-
ficacy, and short- and long-term safety, of topical and/or oral 
decongestants used in monotherapy to alleviate symptoms of 
the common cold in adults and children(201).The authors inclu-
ded 15 trials with 1838 participants. In six studies the interven-
tion was a single dose and in nine studies multiple doses were 
used. Eleven studies used oral decongestants; four studies used 
topical decongestants. Nine studies used pseudoephedrine 
and three studies used oxymetazoline. Nine studies compared 
multiple doses of topical or oral decongestants with placebo. 
Subjective measures of congestion were significantly better for 
the treatment group compared with placebo approximately 
three hours after the last dose (SMD 0.49, 95% CI 0.07 to 0.92; 
p=0.02); seven studies reported adverse events (six oral and one 
topical decongestant); meta-analysis showed that there was 
no statistical difference between the number of adverse events 
in the treatment group compared to the placebo group. The aut-
hors concluded that the current evidence suggests that multiple 
doses of decongestants may have a small positive effect on sub-
jective measures of nasal congestion in adults with the common 
cold. Due to the small number of studies that used a topical 
nasal decongestant, they were unable to draw conclusions on 
the effectiveness of oral versus topical decongestants. Decon-
gestants do not seem to increase the risk of adverse events in 
adults in the short term. 
4.6.2.5. Paracetamol (acetaminophen)
To investigate the effectiveness of paracetamol RCTs comparing 
paracetamol to placebo or no treatment in adults with the com-
mon cold four RCTs involving 758 participants were evaluated 
in a Cochrane review(202). Participants treated with paracetamol 
had significant improvements in nasal obstruction in two of the 
4.6.2.1. Antibiotics
Eleven randomized controlled trials compared any antibiotic 
therapy against placebo in people with symptoms of common 
cold(198). Participants receiving antibiotics for the common cold 
did no better in terms of lack of cure or persistence of symptoms 
than those on placebo (risk ratio (RR) 0.95, 95% CI 0.59 to 1.51, 
(random-effects)), based on a pooled analysis of six trials with 
a total of 1047 participants. The RR of adverse effects in the 
antibiotic group was 1.8, 95% CI 1.01 to 3.21, (random effects). 
Adult participants had a significantly greater risk of adverse ef-
fects with antibiotics than with placebo (RR 2.62, 95% CI 1.32 to 
5.18) (random effects) while there was no greater risk in children 
(RR 0.91, 95% CI 0.51 to 1.63). The pooled RR for persisting acute 
purulent rhinorrhoea with antibiotics compared to placebo was 
0.73 (95% CI 0.47 to 1.13) (random effects), based on four studies 
with 723 participants. There was an increase in adverse effects in 
the studies of antibiotics for acute purulent rhinitis (RR 1.46, 95% 
CI 1.10 to 1.94). The authors concluded that there is no evidence 
of benefit from antibiotics for the common cold or for persisting 
acute purulent rhinitis in children or adults. There is evidence 
that antibiotics cause significant adverse effects in adults when 
given for the common cold and in all ages when given for acute 
purulent rhinitis. Routine use of antibiotics for these conditions 
is not recommended.
4.6.2.2. Nasal corticosteroids
The anti-inflammatory effects of nasal corticosteroids may be 
beneficial in the common cold. In 2013, a Cochrane review was 
published to compare nasal corticosteroids versus usual care 
for the common cold on measures of symptom resolution and 
improvement in children and adults. Three trials (353 partici-
pants) were included. Two trials compared nasal corticosteroids 
to placebo and one trial compared nasal corticosteroids to usual 
care. In the two placebo-controlled trials, no benefit of nasal 
corticosteroids was demonstrated for duration or severity of 
symptoms. The authors concluded that the current evidence 
does not support the use of nasal corticosteroids for symptoma-
tic relief from the common cold(199).
4.6.2.3. Antihistamines
To assess the effects of antihistamines on the common cold 
the authors of a Cochrane review included 18 RCTs, which 
were reported in 17 publications (one publication reports on 
two trials) with 4342 participants (of which 212 were children) 
suffering from the common cold, both naturally occurring 
and experimentally induced. The interventions consisted of 
an antihistamine as monotherapy compared with placebo. In 
adults there was a short-term beneficial effect of antihistamines 
on severity of overall symptoms: on day 1 or 2 of treatment 45% 
had a beneficial effect with antihistamines versus 38% with pla-
cebo (odds ratio (OR) 0.74, 95% CI 0.60 to 0.92). However, there 
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4.6.2.8. Ipratropium bromide
A Cochrane review was published in 2013 to determine the 
effect of ipratropium bromide versus placebo or no treatment 
on severity of rhinorrhoea and nasal congestion in children 
and adults with the common cold(205). Seven trials with a total 
of 2144 participants were included. Four studies (1959 partici-
pants) addressed subjective change in severity of rhinorrhoea. 
All studies were consistent in reporting statistically significant 
changes in favour of ipratropium bromide. Nasal congestion was 
reported in four studies and was found to have no significant 
difference between the groups. Two studies found a positive res-
ponse in the ipratropium bromide group for the global assess-
ment of overall improvement. Side effects were more frequent 
in the ipratropium bromide group, OR 2.09 (95% CI 1.40 to 3.11). 
Commonly encountered side effects included nasal dryness, 
blood tinged mucus and epistaxis. The authors concluded that 
for people with the common cold, the existing evidence sug-
gests that ipratropium bromide is likely to be effective in amelio-
rating rhinorrhoea. Ipratropium bromide had no effect on nasal 
congestion and its use was associated with more side effects 
compared to placebo or no treatment although these appeared 
to be well tolerated and self-limiting. 
4.6.2.9. Nasal irrigation with saline 
Nasal irrigation with saline is often employed as an (adjunct) 
treatment for URTI symptoms. The Cochrane review publis-
hed in 2015 identified five RCTs that randomised 544 children 
(three studies) and 205 adults (exclusively from two studies). All 
included studies compared saline irrigation to routine care or 
other nose sprays, rather than placebo. Most outcome measures 
differed greatly between included studies and, , could not be 
pooled. Most results showed no difference between nasal saline 
treatment and control. However, one larger trial, conducted 
with children, did show a significant reduction in nasal secre-
tion score (MD -0.31, 95% CI -0.48 to -0.14) and nasal breathing 
(obstruction) score (MD -0.33, 95% CI -0.47 to -0.19) in the saline 
group. The trial also showed a significant reduction in the use 
of decongestant medication by the saline group. Minor nasal 
discomfort and/or irritation was the only side effect reported 
by a minority of participants. The authors concluded that nasal 
saline irrigation possibly has benefits for relieving the symptoms 
of acute URTIs(206).
4.6.2.10. Steam / heated humidified air
Background: Heated, humidified air has long been used by com-
mon cold sufferers. The theoretical basis is that steam may help 
congested mucus drain better and heat may destroy cold virus 
as it does in vitro. The Cochrane review in 2017 included six trials 
from five publications involving a total of 387 participants(207). 
The authors reported that it is uncertain whether heated, hu-
midified air provides symptomatic relief for the common cold, 
four studies. One study showed that paracetamol was superior 
to placebo in decreasing rhinorrhoea severity but was not su-
perior for treating sneezing and coughing. Paracetamol did not 
improve sore throat or malaise in two of the four studies. Results 
were inconsistent for some symptoms. Two studies showed 
that headache and achiness improved more in the paracetamol 
group than in the placebo group, while one study showed no 
difference between the paracetamol and placebo group. None 
of the included studies reported the duration of common cold 
symptoms. Minor side effects in the paracetamol group were 
reported in two of the four studies. One of them used a combi-
nation of pseudoephedrine and paracetamol. The authors con-
cluded that paracetamol may help relieve nasal obstruction and 
rhinorrhoea but does not appear to improve some other cold 
symptoms (including sore throat, malaise, sneezing and cough). 
4.6.2.6. NSAIDs
Non-steroidal anti-inflammatory drugs (NSAIDs) have been 
widely used for the treatment of pain and fever associated 
with the common cold. A Cochrane review performed in 2009 
includes nine RCTs, describing 37 comparisons: six were NSAIDs 
versus placebo, and three were NSAIDs versus NSAIDs(203). A total 
of 1064 patients with the common cold were included. The aut-
hors reported that NSAIDs did not significantly reduce the total 
symptom score, or duration of colds. However, for outcomes 
related to the analgesic effects of NSAIDs (headache, ear pain 
and muscle and joint pain) NSAIDs produced significant bene-
fits, and malaise showed a borderline benefit, although throat 
irritation was not improved. Chills showed mixed results. For res-
piratory symptoms, cough and nasal discharge scores were not 
improved, but the sneezing score significantly improved. They 
found no evidence of increased frequency of adverse effects in 
the NSAID treatment groups. The authors recommended NSAIDs 
for relieving discomfort or pain caused by the common cold. 
4.6.2.7. Antihistamine-decongestant-analgesic combinations
To assess the effectiveness of antihistamine-decongestant-anal-
gesic combinations in reducing the duration and alleviating the 
symptoms of the common cold in adults and children 27 trials 
(5117 participants) of common cold treatments were evaluated 
in a Cochrane review(204). Fourteen trials studied antihistamine-
decongestant combinations; two antihistamine-analgesic; six 
analgesic-decongestant; and five antihistamine-analgesic-
decongestant combinations. In 21 trials the control intervention 
was placebo and in six trials an active substance. The evidence 
in this systematic review suggests that antihistamine-analgesic-
decongestant combinations have some general benefit in adults 
and older children. These benefits must be weighed against the 
risk of adverse effects. There is no evidence of effectiveness in 
young children. 
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4.6.2.12. Vitamin C
In 2013, a Cochrane review on the use of vitamin C for preven-
ting and treating the common cold appeared(209). In the review 
29 placebo-controlled trials evaluating 11,306 participants 
contributed to the meta-analysis on the RR of developing a 
cold whilst taking vitamin C regularly over the study period. In 
the general community trials involving 10,708 participants, the 
pooled RR was 0.97 (CI interval 0.94 to 1.00). Five trials involving 
a total of 598 marathon runners, skiers and soldiers on subarc-
tic exercises yielded a pooled RR of 0.48 (95% CI 0.35 to 0.64). 
Thirty-one comparisons examined the effect of regular vitamin 
C on common cold duration (9745 episodes). In adults the du-
ration of colds was reduced by 8% (3% to 12%) and in children 
by 14% (7% to 21%). In children, 1-2 g/day vitamin C shortened 
colds by 18%. The severity of colds was also reduced by regular 
vitamin C administration. Seven comparisons examined the 
effect of therapeutic vitamin C (3249 episodes). No consistent 
effect of vitamin C was seen on the duration or severity of 
colds in the therapeutic trials. The authors concluded that the 
failure of vitamin C supplementation to reduce the incidence of 
colds in the general population indicates that routine vitamin 
C supplementation is not justified, yet vitamin C may be useful 
for people exposed to brief periods of severe physical exercise. 
Regular supplementation trials have shown that vitamin C redu-
ces the duration of colds, but this was not replicated in the few 
therapeutic trials that have been carried out. Nevertheless, given 
the consistent effect of vitamin C on the duration and severity 
of colds in the regular supplementation studies, and the low 
cost and safety, it may be worthwhile for common cold patients 
to test on an individual basis whether therapeutic vitamin C is 
beneficial for them. Further therapeutic RCTs are warranted.
In 2018 and 2019, four systematic reviews investigated effects 
of vitamin C on common cold(210-213). However, none of these 
systematic reviews included newer studies than included in the 
Cochrane review(209). So these reviews were not considered.
4.6.2.13. Vaccines
In 2017, a Cochrane review was published to assess the clinical 
effectiveness and safety of vaccines for preventing the common 
cold in healthy people(214). The development of vaccines for the 
common cold has been difficult because of antigenic variability 
of the common cold virus and the indistinguishable multiple 
other viruses. There is uncertainty regarding the efficacy and 
safety of interventions for preventing the common cold in 
healthy people.
The review includes only one RCT dating from the 1960s with an 
overall high risk of bias. The authors found no conclusive results 
to support the use of vaccines for preventing the common cold 
in healthy people compared with placebo. 
as the fixed-effect analysis showed evidence of an effect (OR 
0.30, 95% CI 0.16 to 0.56; two studies, 149 participants), but the 
random-effects analysis showed no significant difference in the 
results (OR 0.22, 95% CI 0.03 to 1.95). No studies demonstrated 
an exacerbation of clinical symptom scores. One study conduc-
ted in the USA demonstrated worsened nasal resistance, but an 
earlier Israeli study showed improvement. One study examined 
viral shedding in nasal washings, finding no significant diffe-
rence between treatment and placebo groups (OR 0.47, 95% CI 
0.04 to 5.19). As judged by the subjective response to therapy 
the number of participants reporting resolution of symptoms 
was not significantly higher in the heated humidified group (OR 
0.58, 95% CI 0.28 to 1.18; two studies, 124 participants). There 
was significant heterogeneity in the effects of heated, humidi-
fied air on different outcomes, therefore, the authors graded 
the quality of the evidence as low. Some studies reported minor 
adverse events (including discomfort or irritation of the nose). 
The authors concluded that the current evidence does not show 
any benefits or harms from the use of heated, humidified air 
delivered for the treatment of the common cold. 
4.6.2.11. Probiotics 
In 2015, a Cochrane review assessing the effectiveness and 
safety of probiotics (any specified strain or dose), compared with 
placebo, in the prevention of acute URTIs in people of all ages, 
who are at risk of acute URTIs was published(208).
The authors included 13 RCTs, although they could only extract 
data to meta-analyse 12 trials, which involved 3720 participants 
including children, adults (aged around 40 years) and older peo-
ple. We found that probiotics were better than placebo when 
measuring the number of participants experiencing episodes 
of acute URTI (at least one episode: OR: 0.53; 95% CI=0.37-0.76, 
p<.001, low quality evidence; at least three episodes: OR: 0.53; 
95% CI=0.36-0.80, p=.002, low quality evidence); the mean du-
ration of an episode of acute URTI (MD: -1.89; 95% CI = -2.03 to 
-1.75, p<.001, low quality evidence); reduced antibiotic prescrip-
tion rates for acute URTIs (OR: 0.65; 95% CI = 0.45-0.94, moderate 
quality evidence) and cold-related school absence (OR: 0.10; 
95% CI=0.02-0.47, very low quality evidence). Probiotics and 
placebo were similar when measuring the rate ratio of episodes 
of acute URTI (rate ratio: 0.83; 95% CI=0.66-1.05, p=.12, very low 
quality evidence) and adverse events (OR: 0.88; 95% CI=0.65-
1.19, p=.40, low quality evidence). Side effects of probiotics were 
minor and gastrointestinal symptoms were the most common. 
The authors concluded that probiotics were better than placebo 
in reducing the number of participants experiencing episodes of 
acute URTI, the mean duration of an episode of acute URTI, an-
tibiotic use and cold-related school absence. This indicates that 
probiotics may be more beneficial than placebo for preventing 
acute URTIs. However, the quality of the evidence was low or 
very low(208).
EPOS 2020
71
88%), school absence (p=0.0003) and prescription of antibiotics 
(p<0.00001) was lower in the zinc group. Overall adverse events 
(OR 1.58, 95% CI 1.19 to 2.09) (p=0.002), bad taste (OR 2.31, 95% 
CI 1.71 to 3.11) (p<0.00001) and nausea (OR 2.15, 95% CI 1.44 to 
3.23) (p=0.002) were higher in the zinc group. The very high he-
terogeneity means that the averaged estimates must be viewed 
with caution. Authors' conclusions: Zinc administered within 24 
hours of onset of symptoms reduces the duration of common 
cold symptoms in healthy people, but some caution is needed 
due to the heterogeneity of the data. As the zinc lozenges 
formulation has been widely studied and there is a significant 
reduction in the duration of cold at a dose of >= 75 mg/day, for 
those considering using zinc it would be best to use it at this 
dose throughout the cold. Regarding prophylactic zinc sup-
plementation, currently no firm recommendation can be made 
because of insufficient data. When using zinc lozenges (not as 
syrup or tablets) the likely benefit has to be balanced against 
side effects, notably a bad taste and nausea(217). Based on the 
same studies additional meta-analysis were performed. Hemila 
et al. evaluated whether the allergy status and other characteris-
tics of common cold patients modify the effects of zinc acetate 
lozenges and concluded that since the effects of zinc acetate lo-
zenges were consistent between the compared subgroups, the 
overall estimates for effect seemed applicable over a wide range 
of common cold patients(218). Hemila furthermore compared the 
efficacy of zinc acetate lozenges with zinc gluconate and exa-
mined the dose-dependency of the effect and concluded that 
properly composed zinc gluconate lozenges may be as effective 
as zinc acetate lozenges. Moreover, he found no evidence that 
zinc doses over 100mg/day might lead to greater efficacy in the 
treatment of the common cold. Finally, the same group estima-
ted using individual patient data (IPD) meta-analysis the effect 
of zinc acetate lozenges on the rate of recovery from colds and 
found a three-fold increase in the rate of recovery from the com-
mon cold(219). From these meta-analyses it can be concluded that 
zinc administered as zinc acetate or zinc gluconate lozenges at 
a dose of >=75 mg/day and taken within 24 hours of onset of 
symptoms significantly reduces the duration of common cold. It 
is advised for those considering using zinc to use it at this dose 
throughout the cold. Regarding prophylactic zinc supplementa-
tion, currently no firm recommendation can be made because 
of insufficient data.
4.6.2.17. Herbal medicine (excluding Echinacae)
We are not aware of a systematic review analysing the effecti-
veness of herbal medicine in common cold. A recent review of 
Koch et al. included patients with symptoms and signs indi-
cative of viral rhinosinusitis (common cold), post-viral rhinosi-
nusitis and maybe a few patients with ABRS although in most 
studies high fever and/or severe illness were excluded(220) and, 
therefore,  could not be used. However, studies including large 
4.6.2.14. Exercise
In 2014, Lee et al. published a systematic review and meta-ana-
lysis to determine the effects of exercise on prevention of the 
common cold(215). Four randomized controlled trials with a total 
of 281 participants were included. The effect of exercise on the 
prevention of the common cold had a relative risk (RR) of 0.73 
(95% CI, 0.56 to 0.95; I(2) =7%). The mean difference of mean 
illness days between exercise group and control group was -3.50 
(95% CI, -6.06 to -0.94; I(2) =93%). The authors concluded that 
regular, moderate-intensity exercise may have an effect on the 
prevention of the common cold. 
4.6.2.15. Echinacea
To assess whether there is evidence that Echinacea preparations 
are effective and safe compared to placebo in the prevention 
and treatment of the common cold Karsch-Volk et al. included 
24 double-blind trials with 4631 participants including a total 
of 33 comparisons of Echinacea preparations and placebo in a 
Cochrane review(216). Ten trials with 13 comparisons investiga-
ted prevention and 15 trials with 20 comparisons investigated 
treatment of colds (one trial addressed both prevention and 
treatment). None of the 12 prevention comparisons reporting 
the number of patients with at least one cold episode found a 
statistically significant difference. However, a post hoc pooling 
of their results, suggests a relative risk reduction of 10% to 20%. 
Of the seven treatment trials reporting data on the duration of 
colds, only one showed a significant effect of Echinacea over 
placebo. The authors concluded that Echinacea products have 
not shown to provide benefits for treating colds, although, there 
could be a weak benefit from some Echinacea products: the 
results of individual prophylaxis trials consistently show positive 
(if non-significant) trends, although potential effects are of ques-
tionable clinical relevance. 
4.6.2.16. Zinc
To assess whether zinc (irrespective of the zinc salt or formu-
lation used) is efficacious in reducing the incidence, severity 
and duration of common cold symptoms placebo-controlled 
trials using zinc for at least five consecutive days to treat, or for 
at least five months to prevent the common cold. included 16 
therapeutic trials (1387 participants) and two preventive trials 
(394 participants). Intake of zinc was associated with a signifi-
cant reduction in the duration (days) (MD -1.03, 95% CI -1.72 
to -0.34) (p=0.003) (I<sup>2</sup> statistic =89%) but not the 
severity of common cold symptoms (MD -1.06, 95% CI -2.36 to 
0.23) (p=0.11) (I<sup>2</sup> statistic = 84%). The proportion 
of participants who were symptomatic after seven days of 
treatment was significantly smaller (OR 0.45, 95% CI 0.20 to 1.00) 
(p=0.05) than those in the control, (I<sup>2 </sup>statistic = 
75%). The incidence rate ratio (IRR) of developing a cold (IRR 
0.64, 95% CI 0.47 to 0.88) (p=0.006) (I<sup>2</sup> statistic = 
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with influenza with one study with patient with common cold. 
The study evaluating patients with common cold did not show a 
significant effect(229).
 In conclusion, some herbal medicines like BNO1016, cineole 
and andrographis paniculata SHA-10 extract have significant im-
pact on symptoms of common cold without important adverse 
events. A formal systematic review is missing.
4.6.2.18. Fusafungine
Fusafungine displays bacteriostatic activity and has anti-
inflammatory properties. Lund et al. described a pooled analysis 
of three randomised double-blind placebo-controlled parallel-
group studies in 532 patients with identical objectives design 
and dosage(230). The percentage of responders (patients with 
nasal symptom score improvement from day 0 to day 4) was 
61.5 ± 2.9% with fusafungine versus 46.8 ± 3.1% with placebo 
(p=0.009) with an odds ratio of 1.8 (p=0.01) in favour of fusaf-
ungine. The nasal symptom score distribution at day 4 showed 
an odds ratio of 1.56 (p=0.011) also in favour of fusafungine. 
For patients treated early the percentage of responders was 
65.9 ± 4.1% with fusafungine versus 38.3 ± 4.0% with placebo 
(p=0.022) with an OR of 3.08 (p=0.033) in favour of fusafun-
gine. The authors concluded that fusafungine is an effective 
treatment of common cold especially when administered early. 
However, serious allergic reactions involving bronchospasm alt-
hough rare have occurred after the use of fusafungine (https://
www.ema.europa.eu). For that reason, the medication is no 
longer on the market.
4.6.2.19 Homeopathy
 A systematic review by Hawke aimed at assessing the effec-
tiveness and safety of oral homoeopathic medicinal products 
compared with placebo or conventional therapy to prevent and 
treat acute respiratory infections in children (402). After the analy-
sis of eight RCTs including 1562 children, the authors reported 
no significant benefit of homoeopathic products compared to 
placebo on infection recurrence or cure rates in children. No 
similar study was found for the use of homoeopathic products 
in adults with respiratory tract infections.
4.6.2.20. Conclusion
In recent years a number of systematic reviews, many perfor-
med within the Cochrane collaboration have been performed 
evaluating the effectiveness of medication for the prevention 
and treatment of acute viral rhinosinusitis (common cold). The 
authors of these reviews concluded that to prevent common 
colds probiotics were better than placebo in reducing the 
number of participants experiencing episodes of acute URTI and 
that also moderate-intensity exercise may have an effect on the 
prevention of the common cold. 
It was concluded that the failure of vitamin C supplementation 
number of patients have been done evaluating the effectiveness 
of herbal medicine for common cold and, therefore, a short 
summary is given here. Four papers describe the effectiveness 
of BNO1016 (Sinupret) in patients with symptoms indicative of 
common cold(221-224). The two papers by Jund are both double 
blind placebo controlled trials (DBPCTs) and the study described 
in the 2012 papers has also been included in the 2015 paper. 
BNO1016 is an extract of five herbal drugs (gentian root, primula 
flower, sorrel herb, elder flower, and verbena herb) that has 
demonstrated antimicrobial and antiviral activity. The herbal 
drug combination was assessed for efficacy and tolerability in 
600 patients with acute viral rhinosinusitis in two DBPCT trials(221, 
222). A significant higher response to treatment, and significantly 
more improvement in SNOT-20, major symptoms score, rhinor-
rhoea, postnasal drip headache and facial pain were found at 
day 14 in favour of BNO1016. No serious adverse events were re-
ported in either trial. In a study of 64 patients with common cold 
Sinupret for eight days on top of antibiotic was evaluated(223). 
The Sinupret group had shorter duration of headache, impaired 
breathing, nasal discharge and olfactory impairment and faster 
resolution of clinical findings at rhinoscopy. Finally, a recent trial 
evaluated Sinupret syrup three times daily in a group of 184 
children (mean age 8.4 (6-11)) on top of saline and symptomatic 
medication(224). The children’s self-assessment of their condition 
during the first 10 days of the treatment for three symptoms 
(rhinorrhoea, facial pain, and headache) was significantly better 
in the Sinupret group than placebo on days 5-8. The physicians 
had a similar assessment. 
Two studies investigated cineole, an extract from eucalyptus 
oil with anti-inflammatory properties, in 302 patients with 
symptoms and signs indicative of viral rhinosinusitis, one versus 
placebo(225) and one versus an alternative herbal preparation(226). 
Both studies found a greater reduction in symptom scores, indi-
vidual symptom scores and rhinoscopy findings in the cineole 
group than in the control group after seven days of treatment. 
It can be concluded that the herbal medicine preparations 
BNO1016 and possibly also cineole have a significant impact on 
symptoms of common cold without important adverse events. 
Two studies evaluated the effectiveness of andrographis panicu-
lata SHA-10 extract (1200 mg/day) for five days in one study(227) 
and Kan Jang (85 mg standardized extract of andrographis pani-
culata SHA-10 and 10 mg of eleutherococcus senticosus extract) 
four tablets, three times daily, for five days(228) in reducing the 
prevalence and intensity of symptoms and signs in respectively 
158 and 200 patients with common cold as compared with a 
placebo. A significant decrease in the intensity of symptoms was 
observed for the Andrographis paniculate group compared to 
placebo in both studies. No adverse effects were observed or 
reported. Finally, Hawkins et al. published a systematic review 
about the potential use of black elderberry (sambucus nigra) for 
common cold. But they combined three studies with patients 
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to reduce the incidence of colds in the general population 
indicates that routine vitamin C supplementation is not justified, 
yet vitamin C may be useful for people exposed to brief periods 
of severe physical exercise. And finally, no conclusive results 
supported the use of vaccines for preventing the common cold 
in healthy people compared with placebo.
For the treatment of acute viral rhinosinusitis, the authors of 
these reviews concluded that there is no evidence of benefit 
from antibiotics for the common cold or for persisting acute 
purulent rhinitis in children or adults and that there is evidence 
that antibiotics cause significant adverse effects in adults when 
given for the common cold. Although the treatment has no 
significant adverse effect it was also concluded that the current 
evidence does not support the use of nasal corticosteroids for 
symptomatic relief from the common cold. There is however 
some low / very low-quality evidence that probiotics were bet-
ter than placebo in reducing the mean duration of an episode of 
acute URTI, antibiotic use and cold-related school absence. 
For symptomatic medication, it was concluded that antihistami-
nes have a limited short-term (days one and two of treatment) 
beneficial effect on severity of overall symptoms in adults but 
not in the mid to long term. There is no clinically significant ef-
fect on nasal obstruction, rhinorrhoea or sneezing, that multiple 
doses of decongestants may have a small positive effect on 
subjective measures of nasal congestion in adults with the com-
mon cold without increasing the risk of adverse events in adults 
in the short term. Moreover, it was concluded that paracetamol 
may help relieve nasal obstruction and rhinorrhoea but does not 
appear to improve some other cold symptoms (including sore 
throat, malaise, sneezing and cough), NSAIDs relieve discomfort 
or pain caused by the common cold and it was suggested that 
antihistamine-analgesic-decongestant combinations have some 
general benefit in adults and older children. These benefits must 
be weighed against the risk of adverse effects. The authors also 
concluded that ipratropium bromide is likely to be effective 
in ameliorating rhinorrhea in common cold but had no effect 
on nasal congestion and its use was associated with more side 
effects compared to placebo or no treatment although these 
appeared to be well tolerated and self-limiting. 
It was also concluded that because there is a consistent effect of 
vitamin C on the duration and severity of colds in supplementa-
tion studies, and the low cost and safety, it may be worthwhile 
for common cold patients to test on an individual basis whether 
therapeutic vitamin C is beneficial for them. The same holds for 
zinc administered as zinc acetate or zinc gluconate lozenges at 
a dose of >=75 mg/day and taken within 24 hours of onset of 
symptoms significantly reduces the duration of common cold. 
When using zinc lozenges the likely benefit has to be balanced 
against side effects, notably a bad taste and nausea. Also, nasal 
saline irrigation has possible benefits for relieving the symptoms 
of acute URTIs contrary to steam which does not show any be-
nefits or harms for the treatment of the common cold. 
Finally, it was concluded that Echinacea products have not 
been shown to provide benefits for treating colds, although, 
there could be a weak benefit from some Echinacea products. 
However, some herbal medicine like BN1016, Cineole and 
Andrographis paniculata SHA-10 extract seem to have a signifi-
cant impact on symptoms of common cold without important 
adverse events. 
4.6.3. Oral antibiotics – short courses
4.6.3.1. Short courses of oral antibiotics in adult patients with acute 
bacterial rhinosinusitis (ABRS) 
4.6.3.1.1. Summary of the evidence
ABRS involves a small portion of patients with ARS. ABRS is 
considered to be present when three or more of the following 
criteria are present: discoloured discharge, severe (unilateral 
dominance) facial pain, high fever (>38°C), double sickening or 
raised ESR / CRP(231). Antibiotics are thought to be useful in at 
least part of the patients with ABRS but poor patient selection 
increases the risk of unwanted antibiotics resistance. There is a 
need to assess the efficacy of antibiotics among patients who 
fulfil the criteria for ABRS. In this section, studies which com-
pared antibiotics with placebo for the treatment ABRS were 
assessed. 
Studies which involved adults and adolescents (12 years and 
above) with symptoms that fulfilled the criteria for ABRS were 
included. Studies without a placebo arm, involving children 
(under 12 years old), participants with other respiratory tract 
infection (such as otitis media, tonsillitis or pharyngitis) or inclu-
ding participants with symptoms lasting more than 12 weeks, 
were excluded. Only randomized controlled trials were conside-
red. The outcomes evaluated were the percentage of patients 
that achieved cure or improvement during or at the end of the 
treatment period.
Three studies were included(232-234), two double blinded placebo 
controlled randomized trials(232, 233) and one open labelled ran-
domized trial(234) (Table 4.6.1.). All studies involved participants 
who had symptoms and/or signs suggestive of ABRS. Lindbaek 
et al.(232) recruited patients with ABRS symptoms and abnorma-
lities at CT scan (total opacification or fluid level in any sinus). A 
score of one point was given for: symptoms lasting longer than 
seven days before the first visit, unilateral facial pain, pain in 
upper teeth, pain worsening on bending forward, two phases 
of disease, rhinorrhoea, nasal obstruction, sinus pain, malaise, 
fever above 38°C and hyposmia or anosmia and two extra points 
for purulent secretion resulting in a maximum severity score 
of 13 points. The participants in this study had a severity score 
between 7.8 to 8.8 which meant they would have at least six 
of the 11 symptoms assessed, and , therefore,  would fulfil the 
criteria for ABRS. Hadley et al.(233) included adults diagnosed by 
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Table 4.6.1. Antibiotics vs. placebo in acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Garbutt
2012(5) 
DBPCRT Adults with maxillary pain/
sinus tenderness, purulent 
secretions and rhinosinusitis 
symptoms which did not 
improve/worsened after 
7-28 days.
• Amoxicillin 1500mg 
3 times daily for 10 days 
(n=85)
• Placebo (n=81)
• Mean difference between 
groups (SNOT-16) day 3, 7, 
10 and 28
• Symptom improvement/
cure at day 3, 7, 10 and 28
• Days unable to perform 
usual activity
• Relapse or recurrence at 
day 28
• Adverse event
• SNOT-16 score was lower 
at day 7 in antibiotics group 
but no difference at day 3 
and 28
• More patients in antibiotic 
group had symptoms 
improvement at day 7 but 
not at day 3, 10 or 28
• No difference in other 
outcomes
Meltzer
2005(6) 
DBPCRT Adults (≥12y), clinical 
diagnosis acute sinusitis 
(7-28 days)
• Amoxicillin 500 mg three 
times daily   for 10 days 
(n=251)
• Placebo (n=252)
• MFNS 200 mg once daily 
with placebo spray in the 
evening (n=243)
• MFNS 200 mg twice daily 
(n=235)
• Mean symptoms score 
(diary)between day 2 to 15
• Global response at day 15
• Treatment failure during 
treatment
• Adverse event
• No difference in symptom 
score between antibiotics 
and placebo
• No difference in global 
response
• Treatment failure in 7.2% 
antibiotics and 10.7% 
placebo
• No difference in adverse 
event
Merenstein
2005(7) 
DBPCRT Adult (18y) with at least 
1symptom of sinusitis 
(purulent d/c, facial pain, 
pus in nasal cavity) for at 
least 7 days
• Amoxicillin 1 g twice daily 
for 10 days (n=67)
• Placebo twice daily for 10 
days (n=68)
• Patient reported improve-
ment at day 14
• Likert scale for feeling sick 
(0-10) at day 3, 7 and 14
• Days to improvement
• Adverse event
• No difference in improve-
ment at day 14
• No difference in likert 
score at day 3, 7 and 14
• Antibiotic group improved 
earlier (8.1 vs. 10.7 days)
Haye
1998(8) 
DBPCRT Adults (28-70y), GP practice, 
purulent nasal secretion 
(10-30 days) AND maxillary 
sinus pain/tenderness
• Azithromycin 500mg once 
daily for 3 days (n=87)
• Placebo (n=82)
• Cure or improvement, at 
day 3-5, day 10-12 days and 
day 23-27
• Relapse at day 27
• Adverse event
• No difference in overall 
cure or improvement at day 
23-27 but more patients 
with improvement in antibi-
otics group at day 10-12
• No difference in relapse
• No difference in adverse 
effect
Lindbaek
1998(9)
DBPCRT Adults with clinically 
diagnosed acute sinusitis 
AND mucosal thickening 
(≥5mm) on CT scan (exclude 
opacification). (Duration 
illness median 10-13 days 
from results.)
• Penicillin V 1,320 mg 3 
times daily for
10 days (n=20)
• Amoxicillin 500 mg 3 times 
daily for 10 days (n=22)
• Placebo (n=21)
• Number restored or much 
better at day 10
• Mean VAS score for sinus 
symptoms at day 10
• Duration of illness (feeling 
sick)
• No difference in number 
restored or much better 
between groups
• No difference in VAS 
between groups at day 10
• No difference in duration 
of illness
Stalman
1997(10)
DBPCRT Adults (15y) with symptoms 
of URTI at least 5 days. Pres-
ence of 2 out of 3 symptoms 
(common cold, purulent 
discharge, pain in maxillary 
sinus when bending)
• Doxycycline 100mg once 
daily for 10 days (n=98)
• Placebo (n=94)
• Days to cure (no pain)
• Cure or improvement day 
10 and day 42
• Side effect
• No difference in time to 
recover
• No difference in numbers 
cures or improvement at 
day 10 or day 42
• 17 in antibiotics and 2 in 
placebo group reported 
side effects
Van Bu-
chem
1997(11) 
DBPCRT Patients with maxillary 
sinusitis (acute onset of a 
common cold with sickness, 
headache, nose obstruction, 
discharge and tapping pain 
of the maxillary sinus) AND 
abnormal radiograph on 
Caldwell or water’s view 
(mucosal thickness >5mm, 
air fluid level, opacification). 
Mean symptom duration 2.2 
weeks.
• Amoxicillin 750mg 3 times 
daily for 7 days (n=108)
• Placebo (n=106)
• Cure or greatly decreased 
symptoms at 2 weeks
• Mean change symptom 
score after 2 weeks (scale 
1-5)
• Normal radiograph at 2 
weeks
• Relapse after 1 year
• Side effects
• No difference in cure
• No difference in symptoms 
score
• Normal radiographs at 2 
weeks were similar in both 
groups
• More side effects in antibi-
otics group
• No difference in relapse 
after 1 year
CT, computed tomography; DBPCRT, double blind placebo controlled randomised trial; dc, discharge; GP, general practitioner; MFNS, mometasone 
furoate nasal spray; SNOT-16, Sino-nasal Outcome Test-16; URTI, upper respiratory tract infection; VAS, visual analogue scale; y, years.
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clinical symptoms of rhinosinusitis [two major (purulent anterior 
or posterior nasal discharge and unilateral facial pain or malar 
tenderness) or one major and one minor symptom (frontal 
headache or fever >37.5oC axillary temp)] lasting between seven 
and 28 days and presence of air-fluid levels and/or opacification 
on Water’s view of a sinus X-ray and positive bacterial culture 
from a sinus puncture. Høsøien et al.(234) included patients with 
facial pain, purulent discharge, double sickening within 10 days 
initial improvement and neutrophilia. 
Three different types of antibiotics were used (moxifloxacin 
400mg daily)(233), penicillin V 1320mg three times daily(232) and 
amoxicillin 500mg three times daily(232, 234) for the duration of 
five to 10 days. Two studies used matched placebos while one 
study used ultrasound as comparison(234). Cure was defined as 
resolution of signs or symptoms after completion of treatment 
which did not need further intervention(233), or self-rated as 
either feeling restored or much better(232). Improvement was 
defined as improved clinical symptoms during the treatment 
phase. Hadley et al.(233) did not report any difference in improve-
ment or cure between antibiotics and placebo while Lindbaek 
et al.(232) reported significantly better improvement and cure rate 
for the antibiotics group. Høsøin et al.(234) compared antibiotics 
with ultrasound therapy and found little or no difference in the 
pain reduction between groups. Although this study reported 
a larger decrease in pain score at day 4 in the ultrasound group, 
the difference in pain reduction between the groups was small 
(1.5 out of 10). 
Two studies could be combined into a meta-analysis. In the 
study of Lindbaek two antibiotics were assessed and evaluated 
separately(232). At completion of treatment (day 6 to 10), the anti-
biotics group (two studies (three arms), 289 patients) showed a 
higher cure rate than placebo RR 1.36 (95% CI 1.16-1.59, I2=23%) 
(Figure 4.6.1.). The antibiotics group (two studies, 289 patients) 
also had more patients with improved symptoms at day three 
of treatment compared to placebo (RR 1.68 95% CI 1.04-2.71, 
I2=84%) (Figure 4.6.2.). Meta-analysis of adverse events did not 
quite reach significance in terms of more adverse events in the 
antibiotics group in these studies (RR 1.27 95% CI 0.87-1.86, I2 
64%) (Figure 4.6.3.).
4.6.3.1.2. Conclusion
Antibiotics are effective in a select group of patients with 
symptoms and signs suggestive of ABRS. From the limited data 
available (two studies versus one) it seems that especially am-
oxicillin / penicillin (beta-lactams) are effective and moxifloxacin 
(fluoroquinolone) is not. The efficacy of beta-lactams is evident 
at day three where patients already experience better symptom 
improvement and continues to have a higher number of cures 
at completion of treatment. However, careful patient selection 
for those with ABRS is needed to avoid unnecessary use of anti-
biotics and side effects. 
4.6.3.2. Short courses of oral antibiotics in children with ABRS
4.6.3.2.1. Summary of the evidence
Studies which involved children (<12 years of life) with 
symptoms that fulfilled the criteria for ABRS were included. Only 
randomized controlled trials were considered. The outcomes 
evaluated were the percentage of patients that achieved cure or 
improvement during or at the end of the treatment period.
Two small double blinded placebo controlled randomized trials 
were included(235, 236). Both studies involved at least partly child-
ren who had symptoms and/or signs suggestive of ABRS (Table 
4.6.2.). 
Wald et al.(235) included 56 children from one to 10 years of age 
(average five years) with ARS including one of three features 
(persistent symptoms >10 days, acutely worsening symptoms 
after day 5, or severe symptoms with fever ≥102F and purulent 
discharge for three consecutive days). In 24 (43%) children, the 
illness was classified as mild, whereas in the remaining 32 (57%) 
children it was severe. Children were randomly assigned to 
receive either amoxicillin (90 mg/kg) with potassium clavula-
nate (6.4 mg/kg) or placebo. Children’s conditions were rated as 
cured, improved, or failed according to scoring rules. Of the 28 
children who received the antibiotic, 14 (50%) were cured, four 
(14%) were improved, four (14%) experienced treatment failure, 
and six (21%) withdrew. Of the 28 children who received pla-
cebo, four (14%) were cured, five (18%) improved, and 19 (68%) 
experienced treatment failure. Children receiving the antibiotic 
were more likely to be cured (50% versus 14%) and less likely to 
have treatment failure (14% versus 68%) than children recei-
ving the placebo. There was no division between the mild and 
severe patients. Adverse events were reported in 44% children 
receiving antibiotics and in 4 14% children receiving the placebo 
(p=.014). The most common adverse event was diarrhoea, 
which, in general, was self-limited.
Ragab(236) included 53 children (<12 years, average five years) 
with URTI symptoms >10 days <28 days with at least three 
symptoms/signs pointing to ABRS (discharge (with unilateral 
predominance) and purulent secretion in the middle meatus, 
severe local pain (with unilateral predominance), fever (>38o8C), 
and double sickening) in a DBPCT comparing amoxicillin 100 
mg/kg/day to placebo. All patients were on saline irrigation. 
In the amoxicillin group clinical cure was observed in 83.9% in 
comparison to 71% patients in the placebo group (p=0.22). The-
re were also no differences between both groups in the repor-
ted nasal symptom scores, total symptoms scores improvements 
at day 7 (p=0.09 and 0.65) and day 14 (p=0.29 and 0.14), and 
the mean total PRQLQ values after the two weeks of treatment 
(p=0.06). Saline with placebo had less reported adverse effects 
than amoxicillin and nasal saline irrigations (p=0.005).
The studies could be combined into a meta-analysis considering 
cure at 14 days. Although both studies favoured antibiotics, 
there was no significant difference over placebo (RR 1.45 95% CI 
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Figure 4.6.3.  Forest plot of the effect of antibiotic versus placebo for adverse effects during treatment of adult patients with acute bacterial rhinosi-
nusitis
CI, confidence interval; M-H, Mantel Haenszel.
Figure 4.6.1. Forest plot of the effect of antibiotic versus placebo for cure at completion of intervention (day 6-10) in adult patients with acute bacte-
rial rhinosinusitis. 
CI, confidence interval; M-H, Mantel Haenszel.
Figure 4.6.2. Forest plot of the effect of antibiotic versus placebo to assess improvement at day 3 of treatment of adult patients with acute bacterial 
rhinosinusitis
CI, confidence interval; M-H, Mantel Haenszel.
Figure 4.6.4. Forest plot of the effect of antibiotic vs placebo for improvement at completion of intervention (day 14) in children with acute bacterial 
rhinosinusitis
CI, confidence interval; M-H, Mantel Haenszel.
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4.6.3.3. Short course of oral antibiotics in adult patients with acute 
post viral rhinosinusitis
4.6.3.3.1. Summary of the evidence 
Acute post viral rhinosinusitis is defined as having symptoms 
of acute rhinosinusitis (ARS) persisting for more than 10 days 
or worsening after five days(231). This section aims to assess the 
efficacy of antibiotics in the post viral ARS group. Studies were 
included which involved adults with ARS with symptoms of at 
least five days but less than 12 weeks (to exclude chronic rhi-
nosinusitis). Only double-blind placebo-controlled randomized 
trials were included.
Studies were excluded if the study population fulfilled the 
criteria for acute bacterial rhinosinusitis (ABRS) or if more than 
20% of the study population had symptoms for less than five 
days. The minimum duration of five days was used as a cut-
off to exclude patients with common cold. Studies without a 
placebo arm, involving children (under 12 years old) or involving 
participants with other respiratory tract infection (such as otitis 
media, tonsillitis or pharyngitis) were also excluded. The primary 
0.83-2.53, p=0.19, 2 RCT, n=118, I2=66%) (Figure 4.6.4.). 
The children on antibiotics had significantly more adverse 
events compared to the placebo (RR 2.50 95% CI 1.43-4.37, 
p=0.001, 2 RCT, n=118, I2=0%) (Figure 4.6.5.). 
4.6.3.2.2. Conclusion
Data on the effect of antibiotics on the cure/improvement of 
symptoms in ABRS in children are very limited. There are only 
two studies with limited numbers that do not show a significant 
difference over placebo but do show a significant higher percen-
tage of adverse events. Larger trials are needed to explain the 
difference between adults where antibiotics in ABRS has been 
shown to be effective (see paragraph 4.6.3.1.) and this outcome. 
Systematic reviews or meta-analysis of antibiotic use need to 
pay careful consideration to the different classes of antibiotics 
that target different bacterial molecular mechanisms, similarly 
to how different biologics will target different host molecular 
mechanisms (Figure 4.6.6.).
Figure 4.6.5. Forest plost of percentage of patients on antibiotics vs placebo for adverse effects during treatment for children with acute bacterial rhi-
nosinusitis.
CI, confidence interval; M-H, Mantel Haenszel.
Table 4.6.2. Double blind placebo controlled RCT on antibiotics in presumed ABRS in children.
Study Methods Participants Interventions Outcomes Results
Ragab 
2015(236)
DBPCRT Children (<12y average 5y) with URTI 
symptoms
>10 days <28 days. At least 3 
symptoms/signs (discharge (with 
unilateral 
predominance) and purulent secretion 
in the middle meatus, severe local pain 
(with unilateral predominance), fever
(>38,8oC), and double sickening).
• Amoxicillin 100 mg/
kg/day three times 
daily with normal sa-
line irrigation (n=41)
• Placebo with normal 
saline irrigation only 
(n=43)
• Clinical cure at day 
14 
• Mean total nasal 
symptoms score 
(TNSS) day 0-7 and 7
• PRQOL score
• Neutrophil counts on 
cytology
• Adverse event
• No difference in clinical 
cure
• No difference in TNSS
• No difference in PRQOL 
score at day 7 and 14
• No difference in neutrophil 
count at day 7 and day 14 
• More adverse event in 
antibiotic group
Wald 
2009(235) 
DBPCRT Children 1 to 10y (average 5y) (n=56, 
50 evaluated) with a clinical presen-
tation compatible with ABRS. One of 
three features (persistent symptoms 
>10 days, acutely worsening
symptoms after day 5, or severe
symptoms with fever ≥102F and puru-
lent discharge for 3 consecutive days).
• Amoxicillin (90 mg/
kg) with potassium 
clavulanate (6.4 mg/
kg) (n=22) (unclear 
how many days)
• Placebo (n=28)
• Cured (defined 
as clinical severity 
score <2) or improved 
(score decrease at 
least 50%) at day 14
• Adverse event
• Children receiving the anti-
biotic were more likely to be 
cured (50% vs. 14%, p=0.01)
• More adverse event in 
antibiotics group
ABRS, acute bacterial rhinosinusitis; DBPCRT, double blind placebo controlled randomised trial; PRQOL, patient rated quality of life; TNSS, total nasal 
symptoms score; y, years.
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rhinosinusitis which fulfilled the EPOS criteria for at least at least 
five days. There were three studies which required participants 
to have symptoms for at least seven days prior to randomiza-
tion(237-239) while one study required 10 days(240). Lindbaek et al.(241) 
did not specify duration of symptoms prior to recruitment but 
the median duration of illness for participants after randomizati-
on was 10 to 13.5 days after treatment indicating post viral ARS.
Garbutt et al.(237) reported higher improvement in the antibio-
tics group on day seven of treatment compared to the placebo 
group. However, this difference was not significant at comple-
tion of treatment at day 10. Haye et al.(240) assessed azithromycin 
for three days and reported more improvement in the antibio-
tics group at day 10-12. However, this difference was not seen 
at day 3 or 28. The other five studies(238, 239, 241-243) did not find any 
difference in improvement of symptoms or achievement of cure 
between groups at any time point. 
All but one of the studies could be combined into a meta-
analysis to determine the cure rate at day 10-14 (931 patients in 
seven studies)(237, 239-243). The use of antibiotics was not associated 
with greater cure at day 10-14 (RR 1.06 95% CI .98-1.14, I2=0%) 
(Figure 4.6.7).
There were three studies(239, 241, 243) which reported on the num-
ber of days needed to achieve cure after treatment. Only Meren-
stein et al.(239) reported an earlier cure for the antibiotics group 
(median: eight versus 12 days, p=0.04). The other two studies 
did not report significant differences in the number of days to 
cure between the antibiotics and the placebo group(241, 243).
Two studies(239, 242) including 233 patients could be pooled to 
assess the number of days to achieve cure. The use of antibiotics 
in post-viral ARS was not associated with earlier cure (SMD -0.43, 
95% CI -1.02—0.16, I2=73%) (Figure 4.6.8.).
Improvement of symptoms was assessed at day 3 of treatment 
in four studies. This was defined as complete/partial disappea-
rance of symptoms(240), patient reporting feeling a lot better/no 
symptoms(237), not feeling ill at day 3 of treatment(241) or without 
outcome is number of patients who obtained cure. Cure was 
defined as clinical resolution or significant improvement of 
symptoms which did not require any further intervention. The 
secondary outcomes assessed were number of days to cure and 
adverse effects.
Seven studies were included(237-243) (Table 4.6.1). Most studies 
evaluated amoxicillin(237-239, 241, 243) and three studies evaluated pe-
nicillin V(241), doxycycline(242) or azithromycin(240), respectively. The 
antibiotics were taken for seven to ten days except for azithro-
mycin (three days)(240). All participants had symptoms of acute 
Figure 4.6.6. Antibiotic classes and molecular targets.
Beta-lactams (e.g. Penicillin, Amoxicillin, Cefuroxime, Cefaclor) target 
peptidoglycan crosslinking in the cell wall. Beta-lactamase inhibitors 
(e.g. Clavulanate) target bacterial beta-lactamases that break down 
beta-lactam antibiotics. Fluoroquinolones (e.g. Ciprofloxacin) target 
DNA gyrase and Topoisomerase IV, thereby blocking DNA separation 
and cell division. Tetracylines (e.g. Doxycycline) target the 30s ribosomal 
submit thereby blocking protein synthesis. Similarly, macrolides (e.g. 
Clarithromycin, Roxithromycin, Azithromycin) target the 50s ribosomal 
submit thereby blocking protein synthesis.
Figure 4.6.7. Forest plot of the effect of antibiotic versus placebo for cure at completion of the intervention (days 10-14) in adult patients with acute 
post-viral acute rhinosinusitis. 
CI, confidence interval; M-H, Mantel Haenszel.
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treatment failure (worsening or no improvement of symptoms) 
at day 3 of treatment(238).
Four studies, including 907 patients could be pooled to assess 
improvement at day 3-4 of treatment(237, 238, 240, 241). There was a 
trend that the use of antibiotics was associated with greater im-
provement at day 3-4 of treatment compared to placebo but it 
just did not reach significance (RR 1.06, 95% CI 1.00-1.12, I2=0%) 
(Figure 4.6.9).
There were five studies(237-241) which used patient reported out-
come measures such as SNOT-16(237), questionnaire or symptoms 
score(238-241) to measure severity of nasal symptoms either scored 
daily in a diary, or upon baseline and follow up visits. Garbutt et 
al.(237) found that the SNOT-16 score was lower in the antibiotics 
group at day 7 of treatment, but this was not significant upon 
completion of treatment. Studies which assessed symptoms of 
rhinosinusitis(238, 239, 241, 243) assessed for common nasal symptoms 
such as rhinorrhea, nasal congestion, facial pain and feeling 
sick. These symptoms were either scored on a visual analogue 
scale or on an ordinal scale. There were no differences in the 
mean overall change in symptoms score(238, 241) from baseline 
between antibiotics and placebo. There was also no difference 
in the mean individual symptoms score between antibiotics 
and placebo(239, 243). It was not possible to combine data into a 
meta-analysis. This indicates that the use of antibiotics does not 
significantly reduce the symptoms burden of post viral rhinosi-
nusitis.
Figure 4.6.8. Forest plot of the effect of antibiotic versus placebo to assess the difference (mean difference) in the number of days to achieve cure after 
treatment in adult patients with acute post-viral acute rhinosinusitis
 CI, confidence interval; M-H, Mantel Haenszel.
Figure 4.6.9. Forest plot of the effect of antibiotic versus placebo to assess improvement at day 3 of treatment of adult patients with acute post-viral 
acute rhinosinusitis. 
CI, confidence interval; M-H, Mantel Haenszel.
CI, confidence interval; M-H, Mantel Haenszel.
Figure 4.6.10. Forest plot of the effect of antibiotics vs. placebo for adverse effects during treatment of adult patients with acute post-viral acute rhi-
nosinusitis.
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Table 4.6.3. Double blind placebo controlled RCT on antibiotics in post-viral ARS in children.
Study Methods Participants Interventions Outcomes Results
Khoshdel
2014(246)
RCT Children (4–15y, mean age 
7.6±2.86) with a clinical presen-
tation of mild - moderate post-
viral acute rhinosinusitis (recent 
upper respiratory infection, 
postnasal discharge and/or nasal 
congestion) for 10-30 days.
• Amoxicillin (80 mg/kg/day) in 
3 divided doses for 14 days with 
saline nasal irrigation (for 5 days) 
and 0.25% phenylephrine (for 2 
days) (n=50)
• Saline nasal irrigation (for 5 
days) and 0.25%
phenylephrine (for 2 days) (no 
placebo tablet) (n=50)
• Cure at day 3 and 14 
(Children visited at home 
and examined for com-
plete absence of sinusitis 
signs and symptoms).
• Cure better in amoxi-
cillin group at day 3 
(85 vs. 37.5%, p<0.01) 
but no difference at 
other time points.
Kristo
2005(245)
DBPCRT Children (4–10y) with acute
respiratory symptoms <3 weeks 
(average 8.4±5.6 days) sugges-
tive of post-viral rhinosinusitis 
(nasal discharge and obstruc-
tion, sneezing, cough) and an 
abnormal ultrasound finding 
of at least one maxillary sinus 
(mucosal thickening or fluid)
• Cefuroxime axetil in 125mg
capsules twice daily for 10 days 
(n=41)
• Placebo twice daily for 10 days 
(n=41)
• Cure, improve, unchan-
ged or deteriorate based 
on clinician assessment 
and parents’ opinion at 
day 14
• 14-day diary nasal 
symptoms score (total 
0-6) 
• Adverse effect
• No difference in 
% cure or improve 
between groups at 
day 14
• No difference in 
symptom score 
between groups at 
from day 1 to 14
• No difference in 
adverse effect
Garbutt
2001(244)
DBPCRT Children (1 to 18 years, average 
age 8y) with persistent sinus 
symptoms and a clinical diagno-
sis of acute post-viral rhinosinu-
sitis for 10 to 28 days
• Amoxicillin 40 mg/kg/d three 
times daily (n=58) for 14 days
• Amoxicillin-clavulanate 45 mg/
kg/d twice daily (n=48) for 14 
days
• Placebo twice daily for 14 days 
(n=55)
• Improvement (little or a 
lot better) at day 14 
• Change in sinus 
symptoms score using S5
score (0-3) at day 14
• Adverse effects of 
treatment 
• No difference in im-
provement at day 14 
• No difference in S5 
sinus symptoms score 
at day 14
• No difference in 
adverse event 
DBPCRT, double blind placebo controlled randomised trial; RCT, randomised controlled trial; y, years.
Figure 4.6.11. Forest plot of the effect of antibiotic versus placebo to assess improvement at day 10-14 of treatment of children with acute post-viral 
acute rhinosinusitis
CI, confidence interval; M-H, Mantel Haenszel.
Figure 4.6.12. Forest plot of the effect of antibiotics vs. placebo for adverse effects during treatment of children with acute post-viral acute rhinosi-
nusitis.
CI, confidence interval; M-H, Mantel Haenszel.
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4.6.3.4.2. Conclusion
The use of antibiotics in children with acute post-viral rhinosinu-
sitis is not associated with greater cure/significant improvement. 
Although the two studies that could be combined did not show 
significantly more side effects than placebo, studies in adults 
(see 4.6.3.3) did show significantly more side effects. Based on 
the moderate level of evidence and the fact that acute post-viral 
rhinosinusitis is a self-limiting disease, the EPOS2020 steering 
group advises against the use of antibiotics for children in this 
situation.
4.6.3.5. Methods that could change inappropriate prescription of 
antibiotics
Antibiotic resistance is a major public health problem. A major 
risk factor is irrational antibiotic use, e.g., in patients with com-
mon respiratory tract infections(247-250). Prescription of antibio-
tics in in Europe varies greatly; the highest rate in 2016 was in 
Greece (36.3 DDD per 1000 inhabitants daily(251)) and the lowest 
was in the Netherlands (10.4 DDD per 1000 inhabitants daily)(247, 
248). Higher rates of antibiotic resistance are shown in high antibi-
otic consuming countries (Figures 4.6.13 and 4.6.14). It has been 
shown that individuals prescribed an antibiotic in primary care 
for a respiratory or urinary infection develop bacterial resistance 
to that antibiotic. The effect is greatest in the month immedia-
tely after treatment but may persist for up to 12 months(252).
But even in countries in Northwest Europe substantially higher 
proportions of consultations result in an antibiotic prescription 
than was deemed appropriate according to what has been ad-
vised in guidelines, and presumed acute rhinosinusitis is one of 
the diseases where discrepancies are largest. In a study in the UK 
88% of the consultations for rhinosinusitis resulted in an antibi-
otic prescription where experts deemed 11% appropriate(22). The 
same was true in the Netherlands where 34% of the interviewed 
primary care physicians chose an antibiotic as treatment for a 
patient with moderate severe acute rhinosinusitis(171). Substan-
tial variation between practices is found(22, 253). 
A number of studies have evaluated measurements that could 
help to decrease the inappropriate prescription of antibiotics 
for acute rhinosinusitis(254-259). Most studies emphasize training 
of physician communication skills on the use of antibiotics(255, 
256), accountable justification and peer comparison(255, 256, 259) and 
training of physicians(256, 258). The use of a point-of-care C-reactive 
protein testing did not reduced antibiotic prescription in child-
ren with (non-severe) acute respiratory infections(254, 257).
4.6.4. Nasal corticosteroid in acute post-viral rhinosinusitis 
4.6.4.1. Nasal corticosteroid in acute post-viral rhinosinusitis in 
adults
4.6.4.1.1. Summary of the evidence
Finally, the antibiotics group had significantly more adverse 
events compared to the placebo group although there was a 
significant heterogeneity (1341patients, RR 1.28 95% CI 1.06-
1.54, I2=79%) (Figure 4.6.10).
4.6.3.3.2. Conclusion
In conclusion, there is no benefit of prescribing antibiotics for 
post viral ARS in adults. There is no effect on cure or duration of 
disease and there are more adverse events. Based on the mode-
rate level of evidence and the fact that acute post-viral rhinosi-
nusitis is a self-limiting disease, the EPOS2020 steering group 
advises against the use of antibiotics for adults in this situation.
4.6.3.4. Short course of oral antibiotics in children with acute post 
viral rhinosinusitis 
4.6.3.4.1. Summary of the evidence
This section aims to assess the efficacy of antibiotics in the 
post viral ARS group in children. Studies were included which 
involved children with ARS with symptoms of at least five days 
but less than 12 weeks (to exclude chronic rhinosinusitis). Only 
DBPCTs were included.
Studies were excluded if a significant proportion of the study 
population fulfilled the criteria for ABRS or if more than 20% 
of the study population had symptoms for less than five days. 
The minimum duration of five days was used as a cut-off to 
exclude patients with common cold. Studies without a placebo 
arm, and/or involving adults were also excluded. The primary 
outcome is number of patients who obtained cure/significant 
improvement at 10-14 days. The secondary outcomes assessed 
were number of days to cure and adverse effects.
Three studies were included: Garbutt, 2001; Kristo, 2005; and 
Khoshdel, 2014(244-246). The Garbutt study contained three arms. 
Two studies evaluated amoxicillin(244, 246), one amoxicillin with 
clavulanic acid(244) and one cefuroxime(245). The antibiotics were 
taken for 10-14 days. All participants had symptoms of acute 
post-viral rhinosinusitis which fulfilled the EPOS criteria for at 
least at least five days (Table 4.6.3.). 
Khoshdel et al.(246) found a higher cure rate in the amoxicillin 
group at day 3 (85 vs. 37.5% , p<0.01) but no difference at other 
time points. The other two studies did not find a significant dif-
ference between antibiotics and placebo(244, 245).
The studies could be combined into a meta-analysis to deter-
mine the cure rate at day 10-14 (366 patients in three studies) 
(244-246). The use of antibiotics was not associated with greater 
cure/significant improvement at day 10-14 (RR 1.02 95% CI .96-
1.08, I2=0%) (Figure 4.6.11.).
Two studies could be combined and could not show that the pa-
tients on antibiotics did have significantly more adverse events 
compared to the placebo group (RR 1.29 95% CI 0.69-4.38, 
p=0.44, 2 RCT (3 arms) , n=296, I2=0%) (Figure 4.6.12.).
EPOS 2020
82
Figure 4.6.13. Consumption of antibiotics for systemic use in the com-
munity by antibiotic group in 30 EU/EEA countries, 2013 (expressed in 
DDD per 1000 inhabitants and per day(251).
Figure 4.6.14. Proportion of macrolide Resistant (R) Streptococcus pneu-
monia isolates in participating countries in 2013(250).
reduced symptoms(261, 264, 265), the other two did not. The data 
were insufficiently reported to meta-analyse. Three studies(263, 264) 
evaluated the SNOT-20 score. The SNOT-20 is not validated for 
ARS but may give some impression of quality of life also in acute 
disease. The meta-analysis showed no significant difference 
between treatment with nasal corticosteroids and placebo alt-
hough the data showed significant heterogeneity (MD 0.13, 95% 
CI -0.04 to 0.31, p=0.14; 4 RCTs, n = 1120; Figure 4.6.15.). 
Four studies reported on total symptom score(238, 260, 265, 266). 
The studies could be combined into a meta-analysis. Both the 
analyses of the studies where nasal corticosteroid was the single 
treatment (SMD 0.32, 95% CI 0.15 to 0.50, p=0.0003; two (two 
arms) RCTs, n = 1860; Figure 4.6.16.) and where nasal corticoste-
roid was added to an antibiotic (that on its own has shown to be 
not effective (see paragraph 4.6.4.3.)) showed a significant effect 
over placebo (SMD 0.21, 95% CI 0.11 to 0.30, p<0.00001; two 
RCTs, n=1699; Figure 4.6.16.).
Some studies reported on separate symptoms where nasal 
congestion was often found to be significantly improved in the 
nasal corticosteroid group compared to placebo. No meta-ana-
lysis was performed. 
There was no difference in adverse events and/or in patients 
needing antibiotics in the studies that evaluated that parameter 
(Table 4.6.4.).
Finally, Svensson et al.(267) used a cost-effectiveness model to 
analyse the cost-effectiveness of mometasone furoate nasal 
spray (MFNS) compared with amoxicillin or placebo in the 
treatment of post-viral rhinosinusitis. Costs were reduced and 
quality-adjusted life years were increased with MFNS 200 µg 
twice daily compared with amoxicillin 500 mg three times daily. 
MFNS was cost-saving or cost-effective compared with amoxicil-
lin or non-active treatment in the sensitivity analyses regardless 
of the HRQOL measurement used. 
This section aims to assess the efficacy of nasal corticosteroids 
in adults with post-viral ARS. There are no studies evaluating the 
effect of nasal corticosteroids on ABRS. Studies were included 
if they involved adults with ARS with symptoms of at least five 
days but less than 12 weeks (to exclude chronic rhinosinusitis). 
Only double-blind placebo-controlled randomized trials publis-
hed after the year 1990, assessing the effects of nasal cortico-
steroids for patients who fulfilled the criteria of post-viral acute 
rhinosinusitis are included. Patients with common cold and 
acute bacterial rhinosinusitis (ABRS), are excluded. Nasal corti-
costeroids delivered into the nose and the paranasal sinuses by 
any delivery methods generally available in clinical practice are 
included. Outcomes included in this analysis are time to cure, 
quality of life, symptoms and adverse events.
Of the eight studies included in this section, five studies(238, 260-263) 
were placebo-controlled trials assessing the effects of nasal cor-
ticosteroids alone (Table 4.6.4.) and three were studies(264) evalu-
ating the effect of the addition of nasal corticosteroids to treat-
ment with antibiotics (Table 4.6.5.). The papers of Bachert(263) and 
Meltzer 2012(261) are post-hoc analyses of the data from Meltzer 
2005(238). All studies mainly evaluated patients meeting the EPOS 
criteria for acute post-viral rhinosinusitis although in the study 
of Dolor(264) duration of disease was not indicated. A number of 
studies evaluated more than one dosage of nasal corticoste-
roids. These are analysed separately in the meta-analysis. 
Five studies(260-262, 264, 265) reported on time to cure or reduction 
in symptoms. Three studies reported a reduced time to cure/
EPOS 2020
83
Table 4.6.4. Nasal corticosteroids compared to placebo in adult patients with acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Keith 
2012(260)
DBPCT 737 patients (age >12y) 
with acute post-viral 
rhinosinusitis
• FFNS 110μg once daily 
(n=240) for 2 weeks
• FFNS 110μg twice daily 
(n=252) for 2 weeks
• Placebo (n=245) for 2 
weeks 
During 1 month:
• SNOT-20
• Daily major symptom 
score (a composite 
score of three indivi-
dual symptoms (nasal 
congestion/stuffiness, 
sinus headache/pressure 
or facial pain/pressure, 
postnasal drip), each 
using a scale of 0–3. 
These assessments were 
conducted twice daily, 
before the morning and 
evening dose)
• Individual symptoms
• The first time to 
symptom improvement 
(defined as reduction 
of individual symptom 
scores of nasal con-
gestion/stuffiness, sinus 
headache/pressure or 
facial pain/pressure, and 
postnasal drip)
• Need of antibiotics
• Adverse events
Treatment with FFNS vs. 
placebo resulted in:
• No significant reduction 
in SNOT-20
• Significant reduction in 
major symptom score
• Significant reduction in 
congestion
• No significant difference 
in time to symptom 
improvement
• No difference in need 
for antibiotics
• No difference in adverse 
events
Meltzer 
2012(261)
DBPCT 728 patients (age >12y) 
with post-viral ARS
Post hoc analysis of 
Meltzer 2005(238)
• MFNS 200µg twice daily 
for 15 days (n=234)
• MFNS 200µg once daily 
for 15 days (n=243)
• Amoxicillin 500mg 3 
times daily for 15 days 
(n=248)
• Placebo for 15 days 
(n=246)
• MSS 
• The percentage of 
days with minimal MSS 
(defined as average am / 
pm MSS ≤4) for 1 month
• The percentage of days 
with minimal congestion 
(≤1) for 1 month
• Time to first day with 
minimal symptoms
Treatment with MFNS 
compared to placebo 
resulted in:
• Significantly reduced 
mean rhinosinusitis 
major symptom score
• Significantly reduced 
percentage of days with 
minimal MSS
• Significantly reduced 
percentage of days with 
minimal congestion
• Significantly reduced 
time to first day with 
minimal symptoms
Williamson 
2007(262)
DBPCT 240 adults post-viral ARS 
(207 analysed)
• 500mg of amoxicillin 3 
times per day for 7 days 
and 200µg budesonide in 
each nostril once per day 
for 10 days (n=46)
• 500mg of amoxicillin 3 
times per day for 7 days 
(n=54) 200µg budeso-
nide in each nostril 
once per day for 10 days 
(n=56)
• Placebo (n=51)
• Proportion of patients 
having symptoms lasting 
10 days or more
• Time to cure (graph)
• % cured at day 10
• Total symptom score 
No significant effect in 
any treatment group 
compared to placebo for 
all outcomes
Bachert 
2007(263)
Post hoc analysis of 
Meltzer 2005(238) 
although the dosa-
ge indicated here 
are twice as high 
as in the original 
paper (200µg twice 
and four times daily 
compared to once 
and twice daily in 
Meltzer 2005(238)
340 patients (331 ana-
lysed) with post-viral ARS 
• MFNS 200µg twice daily 
for 15 days (n=81)
• MFNS 200µg four times 
daily for 15 days (n=84)
• Amoxicillin 500mg 3 
times daily for 10 days 
(n=84)
• Placebo nasal spray and 
tablets (n=82)
• SNOT-20
• Global scores
Treatment with MFNS 
compared to placebo 
resulted in:
• Significant improve-
ment in SNOT-20
• Significant improve-
ment in global response 
to treatment 
EPOS 2020
84
Study Methods Participants Interventions Outcomes Results
Meltzer 
2005(238)
DBPCT Post-viral ARS (n=981) • MFNS 200µg once daily 
for 15 days (n=243)
• MFNS 200µg twice daily 
for 15 days (n=235)
• Amoxicillin 500mg 3 
times daily for 10 days 
(n=251)
• Placebo nasal spray and 
tablets (n=252)
• Mean am / pm MSS over 
days 2 to 15 of the treatment 
phase
• Mean major symptom score, 
total symptom score, and 
individual scores (average 
of am / pm scores) for each 
symptom averaged weekly 
and daily
• Safety assessments included 
disease recurrence during 
follow-up and adverse event 
monitoring
• MFNS 200mg twice daily 
produced significant symp-
tom improvements versus 
amoxicillin and placebo
• MFNS 200mg once daily pro-
duced significant symptom 
improvements versus placebo
• The incidence of treatment-
emergent adverse events was 
similar among the treatment 
groups
ARS, acute rhinosinusitis; DBPCT, double blind placebo controlled trial; FFNS, fluticasone furoate nasal spray; MFNS, mometasone furoate nasal spray; 
MSS, Mean Rhinosinusitis Major Symptom Score; SNOT-20, Sino-nasal Outcome Test-20; y, years.
Table 4.6.5. Nasal corticosteroid as addition to oral antibiotics in adult patients with acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Nayak 
2002(265)
DBPCT 967 post-viral rhinosinusitis 
patients
• MFNS 400µg nasal spray 
twice daily for 21 days 
(n=324)
• MFNS 200µg nasal spray 
twice daily for 21 days 
(n=318)
• Placebo nasal spray for 21 
days (n=325)  
All patients: amoxicillin/cla-
vulanate potassium 875mg, 
twice daily, for 21 days
• Mean improvement in 
daily symptom scores (0-3) 
for total symptoms, heada-
che, facial pain, congestion, 
purulent rhinorrhoea, 
postnasal drip, and cough 
over 15 days
• Overall therapeutic 
response to treatment (0-5) 
at day 21
• Onset of relief
• CT scan at day 21
• Adverse events
• Co-syntropin-stimulation 
plasma cortisol
Treatment with MFNS 400 
and 200 twice daily compa-
red to placebo resulted in a 
significantly:
• Larger mean reduction in 
total symptom scores and 
congestion than placebo
• Larger mean reduction in 
facial pain, rhinorrhoea and 
post-nasal drip than placebo
• Significantly better overall 
therapeutic response at day 
21 compared to placebo
• Significant faster onset of 
relief
• Comparable adverse events
No differences in CT scans, 
adverse events and plasma 
cortisol 
Dolor 
2001(264)
DBPCT 95 ARS patients with acute 
sinonasal symptoms and 
history of recurrent rhino-
sinusitis or chronic rhinitis 
(92 analyzed) (duration of 
disease unclear)
• FPNS 2 puffs twice daisy
• Placebo nasal spray in 
each nostril once daily for 
21 days (n=48)
All received 250mg of ce-
furoxime axetil twice daily 
for 10 days and 2 puffs of 
xylometazoline hydrochlo-
ride in each nostril twice 
daily for 3 days 
• Time to clinical success 
(patient reported cured or 
much improved) 
• Sinus symptoms score
• SNOT-20
• SF-12
• Mean work performance
Patients using FPNS had:
• Significantly shortened time 
to clinical success 
• Significantly shorter time to 
clinical success
• Improved work performance
• No significant differences in 
rhinosinusitis symptom 
Meltzer 
2000(266)
DBPCT 407 post-viral ARS patients • MFNS 400µg, twice daily 
(n=200)
• Placebo spray twice daily 
for 21 days (n=207)
All patients: 
Augmentin, 875 mg twice 
daily
• Daily symptom scores 
(0-3) for headache, facial 
pain, congestion, purulent 
rhinorrhoea, postnasal drip, 
and cough 
• Overall therapeutic 
response to treatment (0-5) 
at day 21
• CT scan at day 21
• Adverse events
• Significantly greater decre-
ase in total symptom score 
and headache, congestion, 
and facial pain compared 
with placebo. 
• No differences in other 
outcomes
• No difference in therapy-
related local adverse events 
CT, computed tomography; DBPCT, double blind placebo controlled trial; FPNS: fluticasone propionate nasal spray; MFNS, mometasone furoate nasal 
spray; SF-12, Short Form-12 (12-item short form QOL survey; SNOT-20, Sino-nasal Outcome Test-20.
Table 4.6.4.  Nasal corticosteroids compared to placebo in adult patients with acute post-viral rhinosinusitis. (continued)
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Figure 4.6.15. Forest plot of the effect of intranasal corticosteroids versus placebo on change from baseline SNOT-20 score in acute post-viral rhinosi-
nusitis. 
Figure 4.6.16. Forest plot of the effect of intranasal corticosteroids versus placebo on change from baseline of total symptom score in acute post-viral 
rhinosinusitis. 
CI, confidence interval; M-H, Mantel Haenszel.
CI, confidence interval; M-H, Mantel Haenszel.
4.6.4.1.2. Conclusion
Nasal corticosteroids are effective in reducing total symptom 
score in adults suffering from acute post-viral rhinosinusitis. 
However, the effect is small. Nasal corticosteroids have not been 
shown to have an effect on QOL. We downgraded the evidence 
because of high heterogeneity. Acute post-viral rhinosinusitis 
is a self-limiting disease. Based on the moderate quality of the 
evidence and the small effect size the EPOS2020 steering com-
mittee advises only to prescribe a nasal corticosteroid when 
reduction of the symptoms of the acute post-viral rhinosinusitis 
is considered necessary.
4.6.4.2. Nasal corticosteroid in acute post-viral rhinosinusitis 
in children
4.6.4.2.1. Summary of the evidence
This section aims to assess the efficacy of nasal corticosteroids in 
children with post-viral ARS. There are no studies evaluating the 
effect of nasal corticosteroids on ABRS. Studies were included if 
they involved children with ARS with symptoms of at least five 
days but less than 12 weeks (to exclude chronic rhinosinusitis). 
We identified two studies, one DBPCT and one single blind(268, 
269). Both evaluated the use of nasal corticosteroids on top of 
antibiotics. Both studies found a significantly larger decrease in 
symptoms and in one study more children were cured (21/50 
versus 2/50) (Table 4.6.8.).
4.6.4.2.2. Conclusion
Nasal corticosteroids seem to be effective in reducing total 
symptom score in children suffering from acute post-viral 
rhinosinusitis on top of (ineffective) antibiotics. Acute post-viral 
rhinosinusitis is a self-limiting disease. Based on the very low 
quality of the evidence the EPOS2020 steering committee can-
not advise on the use of nasal corticosteroids in children with 
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Table 4.6.6. Bacterial lysates in children with acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Barreto 
1998 (283)
DBPCT Children aged 18m-9y with 
ARS
• OM-85-BV (3.5mg) (n=26)
• Placebo (n=30) daily for 
10 days
Both groups received 
amoxicillin/clavulanic acid 
(40/10mg/kg) daily in 3 
doses for 21 days. 
• Improvement
• Convalescence
• OM-85-BV group improved 
sooner than the placebo group 
(5.56±4.98 vs. 10±8.49; p<0.05).
• OM-85-BV had significantly shor-
ter convalescence time compared 
to the placebo group (15.38±8.91 
vs. 20.28±7.17; p<0.05)
DBPCT, double blind placebo controlled trial; m, months; OM-85-BV, oral bacterial extract; y, years.
Table 4.6.7. Homeopathy for acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Zabolotnyi 
2007(285)
DBPCT Adults with radio-
graphic confirmed 
acute maxillary sinusitis 
(n=133).
Sinfrontal (n=57) vs. 
placebo (n=56); one tablet 
every hour until first im-
provement (max 12 tablets 
per day). After first sign of 
improvement or day 3, two 
tablets three times daily. 
Tablets had to be melted 
slowly in the mouth at least 
30 minutes before or after 
meals.
Assessed at day 0, 7, 14, 
and 21
• SSS
• Radiographic cure
• Clinical cure
• Improvement in health 
state (EQ-VAS)
• Ability to work or do 
usual activities
• Treatment outcome
• There was a significant reduction 
in the SSS compared to placebo 
(5.8±2.3[6.0] point vs. 2.3 ± 1.8[2.0] 
points; p<0.0001). 
• At 3 weeks, 68.4% of those on me-
dication had complete remission 
of symptoms compared to 8.9% of 
placebo patients. 
• Substantial radiographic impro-
vement was noted in significantly 
more patients in the Sinfrontal 
group compared to placebo (77.2% 
vs. 21.4%, p<0.0001).
• By day 7, 52.6% of patients in the 
Sinfrontal group were able to carry 
out daily activities compared to the 
17.9% in the placebo group. 
• The mean change for the EQ-VAS 
was significantly different for the 
Sinfrontal group compared to 
the placebo group (17.3±9.1 vs. 
6.2±8.1, p<0.01).
DBPCT, double blind placebo controlled trial; EQ-VAS: Euroqol visual analoque score; SSS, sinusitis severity score.
Table 4.6.8. Nasal corticosteroid as addition to oral antibiotics in children with acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Rahmati 
2013(268)
SBRT 100 children with mostly 
post-viral ARS (2 to 14 
years)
• Amoxicillin 80 to 100 mg/
kg/ day with FPNS 50 µg 
per nostril twice daily for 14 
days (n=50)
• Amoxicillin 80 to 100 mg/
kg/ day for 14 days (n=50)
At 10-14 days:
• Cure
• Total symptom score 
(0-50)
In the group receiving am-
oxicillin and FPNS compared 
to the groups with amoxicil-
lin alone:
• Significantly more patients 
were cured
• Symptom score was signifi-
cantly lower
Barlan 
1997(269)
DBPCT 151 (89 evaluated) children 
with mostly post-viral ARS 
(mean age 7y)
• Budesonide nasal spray 
bid, 50µg, to each nostril for 
3 weeks (n= 43)
• Placebo nasal spray bid, 
50µg, to each nostril for 3 
weeks (n=46)
All patients received amoxi-
cillin-clavulanate potassium, 
40mg/kg/d three times daily 
for 3 weeks
Evaluation in first 3 weeks:
• Daily record card (filled 
in by parents) symptom 
scores including purulent 
nasal discharge, cough 
and presence of fever and 
headache (0-3).
The budesonide group com-
pared to the placebo group 
showed:
• Significant larger impro-
vement in cough and nasal 
discharge scores at the end 
of second week but not 1st 
or 3rd week.
ARS, acute rhinosinusitis; DBPCT, double blind placebo controlled trial; FPNS, fluticasone propionate nasal spray; SBRT, single blind randomised trial; 
y, years.
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roids. The quality of the evidence is low. Based on the evidence, 
the numbers needed to treat and the potential harm of systemic 
corticosteroids, the EPOS2020 steering group advises against 
the use of systemic corticosteroids in patients suffering from 
acute post-viral rhinosinusitis. There is insufficient data in pa-
tients with ABRS to advise on treatment of ABRS.
4.6.6. Antihistamines (oral and local)
4.6.6.1. Summary of the evidence
While there has been some data showing efficacy of antihistami-
nes in common cold (see 4.6.2.), we found one study in children 
evaluating the addition of nasal oxymetazolone and oral syrup 
containing brompheniramine and phenylpropanolamine versus 
placebo to oral amoxicillin for 14 days. Responses to treatment 
were similar between the two groups. The authors concluded 
that decongestant antihistamine need not be given to the child 
with acute maxillary sinusitis(275). In addition, one such study in 
adults has been completed in acute bacterial rhinosinusitis.
Braun and colleagues(276) evaluated the use of antihistamines in 
acute bacterial rhinosinusitis (Table 4.6.10.). This study involved 
139 patients with a history of allergic rhinitis who were diag-
nosed with acute bacterial rhinosinusitis. This diagnosis was 
made upon visualization of purulent rhinorrhoea or purulence 
noted from the middle meatus on exam. These patients were 
randomized to receive either Loratadine (10mg) or placebo for 
28 days. Each group was also given the following: 14 days of 
antibiotics and 10 days of corticosteroids. Outcomes were eva-
luated at the end of treatment, and the addition of antihistami-
nes significantly decreased nasal obstruction (MD=−0.58; 95% 
CI =−0.85- −0.31, p<0.01), but did not reduce total symptom 
scores (MD=−1.25; 95% CI=−2.77-0.27, p=0.11), or rhinorrhoea 
symptoms (MD=−0.06; 95% CI=−0.37-0.25, p=0.71). Similar 
results were noted at day 14 with the addition of antihistamines, 
there was significantly decreased nasal obstruction (MD=−0.34; 
95% CI=−0.64- −0.04, p=0.02), but did not reduce total symptom 
scores (MD= −0.26; 95% CI=−3.11-0.59, p=0.18) or rhinorrhoea 
symptoms (MD=−0.12; 95% CI=−0.39-0.15, p=0.39).
4.6.6.2. Conclusion
In conclusion, there are two studies evaluating antihistamines 
versus placebo in addition to antibiotics; one in adults with 
ABRS the other in children with post-viral ARS. Both studies 
showed no additive effect of antihistamines over the treat-
ment given. Based on the very low quality of the evidence, the 
EPOS2020 steering group cannot advise on the use of antihista-
mines in post-viral ARS and ABRS. 
4.6.7. Antileukotrienes 
There is no evidence from RCTs for the use of anti-leukotrienes 
acute post-viral rhinosinusitis.
4.6.5. Oral corticosteroids
4.6.5.1. Summary of the evidence
Systemic corticosteroids could be effective by attenuating the 
inflammatory response. Systemic administration of cortico-
steroids may have advantages over nasal use, such as quicker 
onset of action, higher therapeutic levels and no risk of poor 
deliverance because of nasal congestion/sinus blockage. In 2014 
a Cochrane review of systemic corticosteroid therapy for acute 
rhinosinusitis suggested that oral corticosteroids in combination 
with antibiotics may be modestly beneficial for short-term relief 
of symptoms in acute rhinosinusitis(270). 
We analyzed four DBPC studies evaluating the effect of 3-7 days 
of systemic corticosteroids (varying dose) in patients with main-
ly post-viral rhinosinusitis (Table 4.6.9.)(271-274). In three studies the 
systemic corticosteroid was combined with antibiotics(272-274), in 
one it was given without antibiotics(271).
The inclusion criteria were not very clear in most studies but 
most resembled post-viral rhinosinusitis, although the study of 
Klossek included patients with less than five days of symptoms 
(common cold). 
Two studies looked at recovery at 7-14 days and found no dif-
ference(271, 274).
Three studies evaluated the proportion of patients with resolu-
tion of facial pain at day 4-7 after start of the treatment, these 
studies could be combined into a meta-analysis, showing a RR 
of 1.17 (95% CI 1.05-1.30), RD of 0.11 (0.03-0.18), 633 patients 
(Figure 4.6.17.) and showed a significant higher resolution of fa-
cial pain 4-7 days after start of systemic corticosteroid treatment 
than placebo. The differences were however, small and notably 
almost two-thirds of the patients had no symptoms after pla-
cebo treatment (197/316). The effect of systemic corticosteroids 
compared to placebo was not found at 10-14 days after start of 
the treatment.
Two studies could be combined to evaluate the proportion of 
patients with resolution of nasal discharge at day 4-7 after start 
of the treatment showing no significant differences in resolution 
of nasal discharge at day 4-7 ( RR of 1.24 (95% CI 0.88-1.74), 387 
patients (Figure 4.6.18.)). Also here, spontaneous recovery was 
high (72%). 
4.6.5.2. Conclusion
In conclusion, post-viral rhinosinusitis is a self-limiting disease. 
Systemic corticosteroids, with or without antibiotics do not have 
a positive effect on recovery at 7-14 days. There is a small but 
significant effect of systemic corticosteroids versus placebo on 
facial pain at days 4-7 after start of the treatment. There are no 
studies comparing systemic corticosteroids to nasal corticoste-
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Table 4.6.9. Studies comparing systemic corticosteroids versus placebo in patients with mainly acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Venekamp 
et al. 
2012(271)
DBPCT 185 patients with post-
viral rhinosinusitis (174 
evaluated)
• Prednisolone 30mg/d for 7 
days (n=88)
• Placebo for 7 days (n=86)
• The proportion of patients 
with resolution of symptoms 
(facial pain or pressure, nasal 
congestion or blockage, post-
nasal discharge, runny nose, 
poor sleep, cough and redu-
ced productivity) on day 7
• SNOT-20 on days 1, 7 and 14
• Median duration of symp-
tom
No clinically relevant bene-
ficial effects
Ratau 
2004(272)
DBPCT 42 patients with post-viral 
rhinosinusitis
• Betamethasone 1mg orally 
once a day for 5 days (n=21)
• Placebo tablets for 5 days 
(n=21)
All patients received 
amoxicillin-clavulanic acid 
625mg orally, three times 
daily for 5 days
• Change in treatment effects 
for the duration of therapy 
expressed as slope values 
based on a daily symptom 
score card (headache, facial 
pain, nasal congestion and 
dizziness) for 5 days 
• Percentage of patients with 
percussion tenderness and 
nasal secretions on day 6
• Use of paracetamol for 6 
days
Bethamethasone versus 
placebo resulted in: 
• Significantly larger reduc-
tion in headache (none/
mild versus moderate se-
vere) and facial pain, nasal 
congestion and dizziness 
(none versus symptoms)
• Significantly less patients 
with percussion tenderness 
and nasal secretions on 
day 6
• No significant difference 
in paracetamol taken
Klossek 
2004(273)
DBPCT 289 patients with common 
cold/acute rhinosinusitis 
with symptoms for <5 
days (prednisone n=142, 
placebo n=147)
• Prednisone (40-60kg 
bodyweight: 40mg, 60-80kg 
bodyweight: 60mg >80 kg 
bodyweight: 80mg), for 3 
days (n=142)
• Placebo (n=147)
Both groups treated with 
cefpodoxime 100 mg twice 
daily for 10 days
• Mean pain intensity dif-
ference, nasal obstruction 
(VAS) compared to baseline 
on day 1-3
• Paracetamol use in day 1-3
Prednisone versus placebo 
resulted in:
• Significant reduction in 
mean pain intensity dif-
ference, nasal obstruction 
and use of paracetamol at 
day 1-3
Gehanno 
2000(274)
DBPCT 417 adult patients with 
mainly post-viral rhinosi-
nusitis
• 8mg of methylprednisolone 
3 times daily (n=208) for 5 
days
• Placebo 3 times daily 
(n=209) for 5 days
All patients received 500mg 
of amoxicillin-clavulanate 
3 times daily for 5 days and 
half received 10 days
• Clinical and/or radiological 
recovery at day 14
• Craniofacial pain, nasal 
discharge at day 4
24mg methylprednisolone 
versus placebo resulted in:
• No difference in recovery
• Significant reduction in 
craniofacial pain but not in 
nasal discharge at day 4
DBPCT, double blind placebo controlled trial; VAS, visual analogue scale..
Figure 4.6.17. Proportion of patients with resolution of facial pain after 4-7 days of systemic corticosteroid treatment versus placebo. 
CI, confidence interval; M-H, Mantel Haenszel.
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MCC score of the oxymetazoline group, taken after three weeks, 
was not significantly different to any other intervention. In the 
oxymetazoline group, however, there was a significant impro-
vement in MCC scores throughout the duration of treatment. 
Interestingly, regardless of intervention, patients with post-viral 
ARS continued to have significantly poorer MCC scores com-
pared to healthy controls after three weeks of treatment. This 
study was limited in that the baseline MCC scores between 
groups were significantly different. The baseline MCC score in 
the oxymetazoline group was significantly higher than the other 
groups , therefore,  any improvements noted in this group could 
be attributed to a type 1 error. 
4.6.8.2. Conclusion
In adult acute post-viral rhinosinusitis nasal decongestants may 
be effective in improving mucociliary clearance throughout the 
acute phase of the disease but further RCTs are required. No 
studies are performed evaluating the effect of resolution or re-
duction of symptoms of ARS. Based on the absence of clinically 
relevant data, the EPOS2020 steering group cannot advise on 
in common colds,  post-viral ARS or ABRS. 
4.6.8. Nasal decongestants 
4.6.8.1. Summary of the evidence
Decongestants are commonly recommended by primary health 
care physicians, as well as otorhinolaryngologists, as part of 
the treatment for ARS. Although the current evidence suggests 
that multiple doses of decongestants may have a small positive 
effect on subjective measures of nasal congestion in adults with 
the common cold(201), their use in ARS has had limited investiga-
tion. We systematically reviewed nasal decongestants/vasocon-
strictors in ARS. Studies that included either ABRS or post-viral 
rhinosinusitis were included. The common cold was excluded.
We identified one randomised controlled (RCT) study that 
evaluated the impact of nasal decongestants on the clinical 
outcome of adult acute post-viral ARS. Inanli et al.(277) examined 
the effect of several different topical agents in 60 patients with 
post-viral ARS (as described in the paper although the authors 
speak about ABRS) on mucociliary clearance (MCC). The final 
Figure 4.6.18. Proportion of patients with resolution of nasal discharge after 4-7 days of systemic corticosteroid treatment versus placebo. 
Table 4.6.10. Antihistamines in ABRS and post-viral ARS.
Study Methods Participants Interventions Outcomes Results
Braun 
1997(276)
RCT, 
placebo-
control
130 adults with allergic 
rhinitis and ABRS
• Loratadine (10mg) four times 
daily) for 28 days (n=71)
• Placebo four times daily for 
28 days (n=68)
All patients received: Aug-
mentin (2g/day) x 14 days + 
prednisone 40mg four times 
daily x 4 days and 20mg for 
4 days
Assessed at 28 days:
• Total symptom score
• Nasal obstruction
• Rhinorrhoea
• Sneezing
• Nasal itching
• Cough
At 28 days:
• No significant reduction in 
total symptom scores 
• Significant decreased 
nasal obstruction 
• No significant decrease in 
other symptoms
McCormick 
1996(275)
DBPCT 68 children (age 6 (6-16y) 
with acute post-viral 
rhinosinusitis
• Nasal oxymetazolone and 
oral syrup containing bromp-
heniramine and phenylpro-
panolamine (age dependent 
dosage) (n=34)
• Placebo (n=34)
All children received amoxicil-
lin three times daily dosage 
depending on weight
Assessed at day 3 and 14:
• Mean symptom score 
No differences between the 
treatment groups.
ABRS, acute bacterial rhinosinusitis; RCT, randomised controlled trial; y, years
CI, confidence interval; M-H, Mantel Haenszel.
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4.6.10. Steam / heated air 
Steam inhalation has been proposed as an adjunct in the 
treatment of ARS. A systematic review identified two RCTs that 
examined the role of steam inhalation however both of these 
papers were excluded. Little et al.(281) examined the role of steam 
and analgesia in patients with respiratory tract infections. This 
paper was excluded as the patients were grouped into lower 
respiratory tract infections (LRTI) and non-LRTI cohorts. Patients 
with specific ARS symptoms were not specifically examined. 
Little et al.(282) compared the effectiveness of steam inhalation 
and nasal irrigation for CRS or recurrent ARS. This study was 
excluded because the first follow up assessment was three 
months after the intervention which is beyond the timeframe 
for assessment in patients with ARS. 
In conclusion, there are no eligible studies evaluating the effect 
of steam / heated air in post-viral ARS and ABRS.
4.6.11. Physical interventions
We identified one study evaluating the effect of ultrasound 
treatment in comparison to amoxicillin in the treatment of 48 
patients (42 analysed) with presumed ABRS(234). The experimen-
tal group received four consecutive days of ultrasound and the 
control group received a 10-day course of amoxicillin. There 
were no differences between the treatment groups, apart from 
a significantly larger decrease in pain around the nose at day 4. 
There were no other differences between the groups in terms of 
satisfaction with intervention, number of side-effects, or num-
ber of relapses. Due to the lack of a placebo group no relevant 
conclusions can be drawn from this study.
4.6.12. Bacterial lysates 
4.6.12.1 Summary of the evidence
Barreto et al.(283), evaluated the efficacy of OM-85-BV (3.5mg) 
versus placebo for 10 days, in addition to amoxicillin/clavula-
nic acid (40/10mg per kg for 21 days) in children with acute 
rhinosinusitis. They evaluated children from 18 months to nine 
years old with at least 30 days of the following symptoms: 
post-nasal discharge, nasal congestion, halitosis, facial pain and 
pressure, nasal mucosa irritation, fevers, retro-orbital headache 
and radiographic evidence of sinus opacification or oedema of 
bilateral paranasal sinuses. Patients were assessed on days 0, 3, 
15, 21, 30, 60, 90, and 180 for improvement of current infection 
and recurrent respiratory infections. Patients who received 
OM-85-BV had significantly shorter time to improvement when 
compared to the placebo group (5.56±4.98 vs. 10±8.49; p<0.05). 
The convalescence time was significantly shorter in the OM-85-
BV group when compared to the placebo group (15.38±8.91 vs. 
20.28±7.17; p<0.05). There was one adverse event, a rash, that 
disappeared three days after drug discontinuation (Table 4.6.6.). 
the use of decongestants in acute post-viral rhinosinusitis.
4.6.9. Saline 
4.6.9.1. Summary of the evidence
Saline irrigation and sprays are commonly recommended by pri-
mary health care physicians, as well as otorhinolaryngologists, 
as part of the treatment for ARS. 
We identified three RCTs evaluating the impact of nasal saline 
irrigations/sprays on clinical outcomes in adult patients with 
ARS. Studies that included either ABRS or post-viral rhinosinusi-
tis were included. The studies were different in design, duration 
and outcome measurements. Both studies reported no effect 
(Tables 4.6.11. and 4.6.12.). 
Adam et al.(278) examined 75 adults with ABRS in a partially 
blinded RCT. Hypertonic and normal saline nasal spray three 
times daily were compared. The study found no difference in 
symptoms between the groups on day 3 of their illness and 
no difference between the groups in the duration of recovery. 
Rabago et al.(279) examined in a non-blinded RCT the use of daily, 
high volume (150ml per side), hypertonic saline on patients with 
post-viral ARS and CRS. Eighty percent of the study population 
had a diagnosis of post-viral ARS, so this study was included. 
Outcomes were measured at six weeks, three months and six 
months. Results at six weeks are included as this is closest to 
the relevant ARS symptom time frame. The intervention group 
had no significant improvement in their Rhinosinusitis Disability 
Index (RSDI), single-Item Sinus Severity Assessment (SIA) and SF-
12 score. Gelardi et al.(280) evaluated the difference between the 
efficacy of two irrigation systems in 20 patients with acute (pre-
sumed post-viral) rhinosinusitis and who were further treated 
with levofloxacin 500 mg/day for 10 days and topical naphazo-
line (two puffs in each nostril) twice daily for seven days. Patients 
were randomly assigned to either a nasal syringe (10mL saline 
solution, three times daily for 14 days) or a high volume (250ml) 
warm saline irrigation system twice daily for 14 days. Nasal high 
volume warm saline irrigation compared to 10ml saline resulted 
in significantly less patients with purulent rhinorrhoea at seven 
days, and significantly less post-nasal drip at seven and 14 days. 
There were no differences in nasal obstruction of rhinomano-
metry.
4.6.9.2. Conclusion
Two relatively small studies, one in ABRS(278), one in post-viral 
ARS(279) did not find a difference between saline nasal spray 
versus no treatment. One very small study found a larger effect 
of high volume versus low volume saline rinsing on purulent 
rhinorrhoea and post-nasal drip. Based on the very low quality 
of the evidence no advice can be given about the use of nasal 
saline irrigation in ABRS or post-viral ARS.
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a placebo and patients were evaluated at four time points over 
the course of the study (day 0, 7, 14, and 21). There was a post-
observational phase of eight weeks where the patients were no 
longer on the study medication. Outcome measures included 
the sinusitis severity score (SSS) which consisted of the sum 
score of the following six symptoms: headache, maxillary pain, 
maxillary pain worsening on bending forward, percussion, or 
pressure; nasal obstruction, purulent nasal secretion, purulent 
nasal discharge visualized in the middle meatus of purulent 
post-nasal discharge. Each symptom was scored on a 0-4 scale 
(0 – not present, 4 – very severe). Each patient underwent sinus 
radiography which was scored on a modified version of the sys-
tem used by van Buchem(243) from not assessable (NA) to a score 
of 6 for an air-fluid level. A response was defined as a SSS of < 10 
point on day 7 and a reduction of the SSS ≥ 4 points from day 0 
to day 7 and a clinical cure was defined as complete remission 
of signs and symptoms (SSS=0) or substantial improvement de-
fined as reduction of signs and symptoms (each symptom SSS≤1 
4.6.12.2. Conclusion
One study has shown benefit in the use of OM-85-BV for shor-
tening the duration of illness in post-viral rhinosinusitis. Further 
studies should be conducted to determine efficacy in patients 
with post-viral and ABRS. 
4.6.13. Homeopathy 
4.6.13.1. Summary of the evidence
Two studies(284, 285) evaluated the use of homeopathy in acute 
post-viral rhinosinusitis. The study of Friese et al.(284) is excluded 
from this analysis because the patients had symptoms for three-
eight days at the beginning of the trial and thus did not fulfil the 
criteria for post-viral rhinosinusitis. 
There was one study(285) evaluating the use of Sinfrontal (Cin-
nabaris (Trit. D4), Ferrum phosphoricum (Trit. D3), Mercurius 
solubilis Hahnemanni (Trit. D6)). in acute maxillary sinusitis. This 
study consisted of 22 days of treatment with Sinfrontal versus 
Table 4.6.12. Saline use in adult post-viral ARS.
Study Methods Participants Interventions Outcomes Results
Gelardi 
2009 (280)
RCT, non-
blinded
20 adults with (post-viral?) ARS • High volume (250ml) 
warm saline irrigation sys-
tem twice daily for 14 days 
• Saline applied with a 10ml 
syringe 3 times daily for 
14 days 
All patients received 
levofloxacin 500 mg/day for 
10 days and topical napha-
zoline 2 puffs in each nostril 
twice daily for 7 days.
At 7,14 and 21 days:
• Symptoms
• Nasal endoscopy
• Rhinomanometry
The high volume warm 
saline irrigation compared 
to 10 ml saline resulted in:
• Significantly less patients 
with purulent rhinorrhoea 
at 7 days
• Significantly less post-
nasal drip at 7 and 14 days
• No difference in rhinoma-
nometry
Rabago 
2002 (279)
RCT, non-
blinded
76 adults with 2 episodes of 
ARS or 1 episode of CRS per 
year, for 2 consecutive years 
63 with diagnosis post-viral ARS
• 2.0% saline with baking 
soda 150ml per nostril daily 
(n=52)
• No treatment
Baseline, 6w, 3m, 6m:
• SF-12
• RSDI
• SIA
• Compliance diary
No significant difference in 
the reported outcomes.
ARS, acute rhinosinusitis; CRS, chronic rhinosinusitis; m, months; RCT, randomised controlled trial; RSDI, Rhinosinusitis Disability Index; SF-12, Short 
Form-12 (12-item short form QOL survey); SIA, Sinus Severity Assessment; w, weeks.
Table 4.6.11. Nasal saline spray in adult ABRS.
Study Methods Participants Interventions Outcomes Results
Adam 
1998(278)
RCT, partial 
blinding
Adults with ABRS (n=75) • HNS spray; 2 sprays per 
nostril, 3 times per day for 
10 days (n=26)
• NS spray; 2 sprays, each 
nostril, 3 times per day for 
10 days (n=23)
• No treatment (n=26)
All patients received antibi-
otics (unclear which one)
• Nasal symptom score on 
day 3
• Day of well-being (day of 
symptom resolution)
• No significant difference 
between the groups in:
• Day 3 nasal symptom 
scores
• Day of well-being 
between the groups
ABRS, acute bacterial rhinosinusitis; RCT, randomised controlled trial; HNS: hypertonic nasal saline; NS: nasal saline
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placebo as an adjunct to amoxicillin(290) and the study from Ba-
chert evaluating pelargonium sidoides versus placebo(291).
The frozen, dried, natural fluid extract of the Cyclamen euro-
paeum plant delivered intranasally is thought to have beneficial 
effects in relieving congestion by facilitating nasal drainage and 
has an anti-inflammatory effect. Cyclamen europaeum nasal 
spray as an adjunct to medical therapy (amoxicillin 500mg three 
times daily for days) was compared to placebo in 99 patients 
with post-viral rhinosinusitis(290). There was no difference 
between the groups for change in mean rhinosinusitis visual 
analogue scale scores of total symptom, nasal obstruction, 
facial pain or pressure, smell dysfunction, mucous secretions or 
sleep quality after 5-7 days. Similar trends were observed at day 
12-15. Of note, a reduction in facial pain significantly favoured 
Cyclamen europaeum (MD: -1.20, [-2.32, -0.08]; p=0.04) for the 
per protocol-population after five to seven days. Endoscopic 
evaluation demonstrated that mucous oedema or nasal obstruc-
tion was reduced to a significantly greater extent with Cyclamen 
europaeum than placebo after 5-7 days (MD: -0.76, [-1.44 to 
-0.08]; p<0.03). There were no significant between group diffe-
rences for mucopurulent secretion scores in the middle meatus 
at any time points evaluated. No patients needed additional 
treatment for rhinosinusitis during the study, and there were no 
medical complications associated with progression of ARS. Ad-
verse events were reported by 67% of the Cyclamen europaeum 
group and 29% of placebo recipients but no serious adverse 
events were reported. A DBPC study of Cyclamen europaeum 
versus placebo in a subgroup of 29 patients with presumed 
(post)viral rhinosinusitis showed a comparable improvement 
in total symptom scores but a significant difference between 
treatment groups in change in percent of sinus opacification 
in favour of Cyclamen. More treatment-related adverse events 
were reported in the placebo group (37.5%) than in the Cycla-
men group (15%). As the two studies were very different no 
meta-analysis could be performed. 
Pelargonium sidoides (P. sidoides), is an herbal remedy thought 
to be effective in the treatment of upper respiratory infecti-
ons(292). Only one RCT has evaluated its efficacy in 103 patients 
with presumed post-viral ARS(291). Patients were randomized to 
receive P. sidoides 60 drops orally three times daily or a matched 
placebo for a maximum of 22 days. The mean decrease in the 
sinusitis severity score at day 7 was 5.5 points in the P. sidoides 
group and 2.5 points in the placebo group (between group dif-
ference of 3.0 points; 95% CI [2.0 to 3.9]; p<0.0001). Significant 
treatment effects were also observed for SNOT-20 (0.6 vs. 0.2; 
p< 0.0001), EQ-VAS (18.1±14.1 vs. 5.1±11.0; p<0.0001) by day 7 
in the P. sidoides group versus placebo. Similarly, the duration 
of days patients were unable to work (8.7±6.4 vs. 15.9±11.8; 
p=0.002), the number of patients able to work or engage in 
usual activities (32 [63%] vs. 19 [37%]), and the number of 
patients improved from sleep disorders (40 [82%] vs. 27 [54%]; 
point). There was a significant reduction in the SSS compared 
to placebo (5.8±2.3[6.0] point vs. 2.3±1.8[2.0] points; p<0.0001). 
Patients in the Sinfrontal group met criteria as responders 
significantly more than the placebo group (66.7% vs. 5.4%, 
p<0.0001). Substantial radiographic improvement was noted in 
significantly more patients in the Sinfrontal group compared to 
placebo (77.2% vs. 21.4%, p<0.0001). By day 7, 52.6% of patients 
in the Sinfrontal group were able to carry out daily activities 
compared to the 17.9% in the placebo group. The mean change 
for the EQ-VAS was significantly different for the Sinfrontal 
group compared to the placebo group (17.3±9.1 vs. 6.2±8.1, 
p<0.01). Seven patients (6.3%) had adverse events during the 
study. Six patients (10.5%) in the active medication group and 
one (1.8%) in the placebo group had adverse events and these 
were most commonly gastrointestinal complaints. The events 
were most often connected to symptoms from lactose exposure 
as this was one of the main constituents of Sinfrontal and the 
placebo. This study was also evaluated from a health economic 
perspective. Sinfrontal led to incremental savings of 275 euros 
(95% CI 433, 103) per patient compared with placebo over 22 
days, essentially due to the markedly reduced absenteeism from 
work (7.83 vs. 12.9 workdays). Incremental utility amounted to 
0.0087 QALYs (95% CI 0.0052, 0.0123), or 3.2 quality-adjusted 
life-days (QALDs)(286) (Table 4.6.7.).
4.6.13.2. Conclusion
We found one study evaluating the effect of homeopathy (Sin-
frontal) and showing a significant reduction of symptoms and 
radiographic improvement versus placebo. Based on the limited 
evidence the EPOS2020 steering cannot give clear advice on the 
use of homeopathy in acute post-viral rhinosinusitis. 
4.6.14. Herbal compounds
4.6.14.1. Summary of the evidence
Herbal compounds have been extensively explored in the treat-
ment of upper respiratory tract diseases. Numerous randomized 
studies, of varying quality, have been performed to assess the 
efficacy and safety of herbal compounds in the treatment of vi-
ral, post-viral and acute bacterial ARS. However, in many studies 
it is unclear which groups of ARS patients have been studied. 
We found six DBPC randomized studies of the efficacy of herbal 
compounds in the treatment of presumed post-viral ARS (Table 
4.6.13.). Of these six trials, in four trials it is however unclear 
what the exact ARS phenotype of the patients was(228, 287-289). 
In these studies the duration of the symptoms after the acute 
onset was often not indicated and some patients were included 
that had signs that could point to ABRS such as high fever, or 
severe unilateral pain(228, 287). The only two studies that clearly in-
clude post-viral patients are the studies by Pfaar et al. evaluating 
the effectiveness of Cyclamen europaeum nasal spray versus 
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Table 4.6.13. Herbal compounds versus placebo in acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Pfaar 
2012(290)
DBPCT Adults with acute post-viral 
rhinosinusitis (n=99)
• Cyclamen europaeum 
nasal spray (1.3mg) once 
daily each nostril for 15 
days (n=48)
• Placebo for 15 days (n=51)
All patients received amoxi-
cillin 500 mg 3 times daily 
for the first 8 days
• TSS on day 5-7 (VAS)
• Individual symptom 
scores (nasal congestion, 
mucus secretion, facial 
pain, impairment of smell) 
on day 5-7 and 12-15 (VAS)
• Endoscopic findings on 
day 5-7 and 12-15
• Treatment failure/need for 
additional treatment
• Onset of medical compli-
cations of rhinosinusitis
• Sleep quality
• Overall patient- and 
investigator-assessed treat-
ment satisfaction
• Safety assessment
Compared to placebo, cyclamen 
europaeum resulted in:
• Improvement in mean patient 
(p=0.03) and investigator-satis-
faction scores (p=0.04) 
• No difference for change in 
mean TSS, nasal obstruction, 
facial pain or pressure, sleep 
quality (VAS), or endoscopic 
mucopurulent secretions 
• Improvement in endoscopic 
scores for nasal obstruction/
mucosal oedema at 5-7 days 
(p=0.03)
• No patients needed additional 
treatment for rhinosinusitis 
during the study, medical 
complications associated with 
progression of ARS
• Adverse events were reported 
by 67% of the cyclamen euro-
paeum group and 29% of pla-
cebo recipients but no serious 
adverse events were reported.
Ponikau 
2012(287)
DBPCT Adults with acute (post)
viral rhinosinusitis (n=29)
• Cyclamen europaeum 
nasal spray (2.6mg) once 
daily each nostril for 7 days 
(n=24)
• Placebo spray sterile 
water, once daily for 7 days 
(n=24)
• Percent sinus opacifica-
tion on CT scans at days 15, 
29 or endpoint 
• Reduction in TSS at 
endpoint
• Endoscopic inflammation 
at day 7
• Significant improvement in 
percent of sinus opacification in 
favour of cyclamen (p=0.045). 
• Comparable improvement in 
total symptom scores. 
• More treatment-related 
adverse events in the placebo 
group (37.5%) vs. cyclamen 
group (15%). 
Bachert 
2009(291)
DBPCT Adults with mostly 
symptoms of acute (post)
viral rhinosinusitis although 
some of the patients could 
have had ABRS (n=103)
• Pelargonium sidoides (P. 
sidoides) 60 drops orally 
three times daily for maxi-
mum 22 days (n=51)
• Matched placebo three 
times daily for maximum 22 
days (n=52)
• SSS at day 7
• Radiographic cure at day 
21
• SNOT-20 at day 7
• EQ-VAS on day 7
• Activity level on day 7
• Ability to work or engage 
in usual activities on day 7
• General well-being on 
day 7
• Patient and investigator-
reported treatment 
outcome on the IMOS
• Safety assessment
Compared to placebo, P. sidoi-
des demonstrated:
• Greater reduction in sinusitis 
severity score (p<0.0001) SNOT-
20 score (p<0.0001)
• Decrease in duration of inabi-
lity to work (p=0.002)
• Increase in subjects able to 
work or engage in usual activi-
ties (p=0.003), and subjects as-
sessed as a ‘major improvement’ 
on IMOS (p <0.0001) on day 7
• Radiographic improvement in 
the maxillary sinuses (p=0.002)
• No significant radiographic 
improvement in the frontal or 
ethmoid sinuses at day 21
Federspil 
1997(288)
Rando-
mized, 
double-
blind, 
double-
dummy, 
trial
Patients with acute (post)
viral rhinosinusitis (n=331)
• Myrtol standardized 4 
capsules of 300mg daily, for 
6±2 days (n=109)
• Essential oil (unregistered) 
4 capsules of 300 mg daily, 
for 6±2 days (n=110)
• Matched placebo, 4 
capsules daily for 6±2 days 
(n=111)
All patients received xylo-
methazoline 4dd2 puffs
• Difference in symptoms 
score before and after treat-
ment at 14 days
• Myrtol standardized and the 
other essential oil proved to be 
significantly superior to placebo
• Tolerance was slightly better 
for myrtol standardized in com-
parison to the essential oil
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patients with ARS were randomized to Sinupret or intranasal 
fluticasone furoate for 14 days. No differences between the two 
groups were found, most likely due to type II error. No adverse 
events were reported in the Sinupret group. Among the patients 
that received fluticasone furoate, three patients reported minor 
adverse events (epistaxis and nasal itching). 
4.6.15. Vaccination
There are no RCTs which demonstrate a direct effect of vacci-
nation on post-viral ARS. A systematic review which examined 
inactivated parental influenza virus vaccination reported 59% 
efficacy in preventing confirmed influenza (RR 0.41 95% CI 0.36-
0.47)(294). The pneumococcal vaccine also led to decrease in inva-
sive diseases (meningitis, bacteremia) and acute otitis media(295) 
but there was no data on decrease of ABRS or post-viral ARS(296).
There has been a shift in the organisms involved in ARS after 
the Heptavalent conjugate pneumococcal vaccine (PCNV7) was 
introduced with decreased isolated streptococcus pneumoniae 
but increased in isolated Haemophilus influenza culture among 
adults with acute maxillary sinusitis(297). How this will impact oc-
currences of ABRS is still under speculation(296, 298).
4.6.16. Sodium hyaluronate
One study evaluated 48 patients with ABRS following EPOS 
criteria that were treated with high molecular weight sodium 
hyaluronate (3%) plus saline solution (3mL sodium chloride-
NaCl-0.9 %) versus placebo using a nebulizer ampoule for nasal 
douching twice a day(299). All patients received levofloxacin 
(500mg for 10 days) and prednisone (50mg for eight days, 25mg 
for four days and 12, 5mg for four days). The hyaluronate group 
compared to placebo had significantly fewer symptoms and 
better smell threshold (Table 4.6.15.). 
In conclusion, sodium hyaluronate may have an additive effect 
to antibiotics in patients with ABRS.
p=0.003) on day 7 favoured P. sidoides. The investigator assessed 
the treatment outcome as a ‘major improvement’ in 15 (30%) in 
the P. sidoides group, compared to three (5.8%) patients in the 
placebo group (p< 0.0001) and treatment outcome assessment 
by the patients yielded to a similar pattern in favour of the P. 
sidoides group. Results also indicated a statistically significant 
superiority of P. sidoides for radiographic improvement in the 
maxillary sinuses (24 [69%] vs. 22[44%]; p=0.002). Six patients 
(11.8%) reported non-serious adverse events in the P. sidoides 
group compared to two patients (3.8%) in the placebo group. 
Federpil et al.(288) studied the efficacy of myrtol, an herbal extract 
from essential oils, as a therapeutic alternative for acute rhino-
sinusitis (n=331), in comparison to placebo and other essential 
oils. The results showed a statistically significant improvement of 
total rhinosinusitis symptoms score in the myrtol standardized 
group and the other essential oils group compared to placebo 
at 14 days (10.5 vs. 9.2 points) without difference between the 
myrtol and the other essential oils. 
BNO 1016 (Sinupret), an extract of five herbal drugs (gentian 
root, primula flower, sorrel herb, elder flower, and verbena herb) 
that has demonstrated antimicrobial and antiviral activity, has 
been investigated in common cold (see Chapter 4.6.17.). One 
study from Neubauer et al.(289) randomized 160 patients with 
symptoms and signs indicative of acute post-viral rhinosinusitis 
into Sinupret or placebo in addition to doxycycline and xylome-
tazoline. A greater percentage of patients in the Sinupret group 
reported complete resolution of symptoms (60.3% vs. 25.0%; 
p=0.0002) and were observed to have improvement in radio-
graphic findings after 14 days of treatment (84.0% vs. 68.4%; 
p=0.02) than in the placebo group. While Sinupret demonstra-
ted a small but significant effect on nasal obstruction (difference 
in response rates: 0.23, [0.09, 0.39]) and mucous swelling (0.32 
[0.17, 0.46]), there was no difference in response rates for nasal 
patency (0.10 [-0.05, 0.26]), nasal discharge (0 [-0.17, 0.20]) or 
headaches (0.15 [0.00, 0.3]). The efficacy of Sinupret was com-
pared in one study to fluticasone furoate (Table 4.6.14.)(293). Sixty 
Study Methods Participants Interventions Outcomes Results
Neubauer 
1994 (289)
DBPCT Patients with acute 
(post) viral rhinosinu-
sitis (n=160)
• Sinupret 2 tablets three 
times daily for 14 days 
(n=81)
• Placebo (sugar-coated 
tablets) 2 tablets three 
times daily for 14 days 
(n=79)
All patients received 
doxycycline and xylome-
talzoline
• Patient assessment of the 
therapy (three categories: 
asymptomatic/good ef-
fect/no effect) at 14 days
• Clinical symptoms of 
rhinosinusitis at 14 days
• Radiographic finding 
(completely opaque/sha-
dowed/nothing abnormal)
Compared to placebo, Sinupret demon-
strated
• Greater improvement in patient-repor-
ted complete resolution of symptoms 
(p=0.0002) 
• Improvement in radiographic findings 
after 14 days of treatment (p=0.02)
• Effect on nasal obstruction and muco-
sal swelling
• No difference in response rates for 
nasal patency, nasal discharge or 
headaches.
ABRS, acute bacterial rhinosinusitis; ARS, acute rhinosinusitis; DBPCT, double blind placebo controlled trial; EQ-VAS: Euroqol visual analoque score; 
IMOS, Integrated Medicine Outcomes Scale; SNOT-20, Sino-nasal Outcome Test-20; SSS, Sinusitis Severity Score; TSS, total symptom scores.
Table 4.6.13. Herbal compounds versus placebo in acute post-viral rhinosinusitis (continued)..
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Table 4.6.14. Herbal compounds versus corticosteroids in acute post-viral rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Passali 
2015(293)
Randomi-
zed, pros-
pective, 
open-label 
study
Adults with acute 
(post)viral rhinosinu-
sitis (n=60)
• Sinupret Forte 1 tablet 
3 times a day for 14 days 
(n=30)
• FFNS 55 µg in each nos-
tril, once a day for 14 days 
(n=30)
• MSS according to the investiga-
tor at day 3, day 7, 10, and 14
• SNOT- 20 score at day 3, day 7, 
10, and 14
• Concomitant medication for the 
treatment of acute rhinosinusitis
• Premature termination due 
to antibiotic therapy for acute 
rhinosinusitis
• Percentage of patients with MSS 
≤1 at day 14
• Percentage of patients with MSS 
>1 at day 14
• Safety assessment
• No statistical analyses 
performed.
• Comparable mean major 
symptom score, SNOT-20 
score, and percentage of 
patients at 14 days.
• No adverse events were 
reported in the Sinupret 
group. 
• Three patients in the FFNS 
treatment group reported 
minor adverse events (epis-
taxis and nasal itching).
FFNS, fluticasone fuorate nasal spray; MSS, major symptom scores; SNOT-20, Sino-nasal Outcome Test-20.
4.6.17. Mucolytics
To evaluate whether mucolytic agents have an adjuvant role 
with antibiotics in the treatment of children with ABRS, Unuvar 
et al. evaluated the effectiveness of erdosteine (5-8 mg/kg/day) 
versus placebo as an adjunct to antibiotic in 92 children (age 8.5 
± 3.2 years) with ABRS(300). They found no significant difference 
between the groups (Table 4.6.16.). 
4.7. Complications of acute bacterial rhinosinusitis 
(ABRS)
The complications of ABRS refer to periorbital, endocranial 
and osseous clinical conditions which are uncommon poten-
tially life-threatening events. The periorbital complications 
include preseptal cellulitis, orbital cellulitis, subperiosteal and 
intraorbital abscess; rapid diagnosis and treatment (including 
Table 4.6.15. Sodium hyaluronate versus placebo in ABRS.
Study Methods Participants Interventions Outcomes Results
Ciofalo 
2017(299)
DBPCT Adults with ABRS (EPOS 
criteria, details not 
given) (n=48)
• Sodium hyaluronate (3%) 
plus saline solution (3mL 
sodium chloride-NaCl-0.9 
%) twice daily (n=24)
• Placebo using a nebulizer 
ampoule for nasal douche 
twice a day (n=24)
All patients received 
levofloxacin (500 mg for 
10 days) and prednisone 
(50 mg for 8 days, 25 mg 
for 4 days and 12, 5 mg for 
4 days)
At 14–18 days and 30–35 
days:
• Symptoms (0-3)
• Smell (0-3)
• Smell test (threshold, dis-
crimination, identification)• 
Mucociliary clearance time
The hyaluronate group compared 
to placebo had:
• Significantly less nasal obstruc-
tion at 14 days 
• Significantly less nasal discharge 
at both time points
• Better smell (0-2) at 14 days but 
not at 30 days
• Significantly better median 
threshold smell score at both time-
points but no other differences in 
smell testing
• Significantly better mucociliary 
clearance time at both timepoints
ABRS, acute bacterial rhinosinusitis; DBPCT, double blind placebo controlled trial.
Table 4.6.16. Mucolytics versus placebo in ABRS.
Study Methods Participants Interventions Outcomes Results
Unuvar 
2010(300)
DBPCT Children (8.5 ± 3.2y) (81 
evaluated) with ABRS 
(n=92)
• Erdosteine (5-8mg/kg/
day) (n=49)
• Placebo (n=43)
All patients received antibi-
otics, dosage and duration 
unclear
• Cure at day 14
• Daily general impression 
for 14 days
• Daily symptoms for 14 
days
• No difference between 
the treatment groups
ABRS, acute bacterial rhinosinusitis; DBPCT, double blind placebo controlled trial.
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shown to be approximately three per million of the population 
per year (see Table 4.7.1.) despite very different utilization of 
antibiotics in the various countries and this number has not 
been reduced by the advent of widespread antibiotic prescri-
bing. In patients who are hospitalized with ABRS, the reported 
rate of complications varies from approximately 3% to 20%(12, 
320, 321), although there is selection bias and thus existing series 
likely overestimate the incidence of those complications. The 
highest number of admissions occurs from January to March(173, 
310). Seven studies (until 2019), attempting to collect nationwide 
or large-scale data were identified and the incidence results are 
briefly summarized below (Table 4.7.1.). In the majority of these 
studies, males are significantly more frequently affected than 
females and ABRS was more often the precipitating factor in 
children, whereas CRS with or without NP was more important 
in adults(173, 301, 322, 323). In all studies, the orbital complications are 
the most frequent while osseous appear to be relatively uncom-
mon (Table 4.7.1.). 
The incidence of ABRS complications has been 
shown to be approximately three per million of the 
population per year despite very different 
utilization of antibiotics in the various countries 
and this number has not been reduced by the 
advent of widespread antibiotic prescribing.
With regard to age predeliction, orbital complications seem to 
be more common in small children while intracranial complicati-
ons can occur at any age, with a preponderance of young adults 
around their 20th birthday(301, 324). The course of ABRS complica-
tions has been reported to become more prolonged in parallel 
with the age of the patients(311, 323). 
It is important to note that three studies in ABRS patients(301, 311, 
322) did not record any benefit for history of oral antimicrobial 
drug usage prior to the development of the complications. In 
this regard the study by Babar-Craig(12), which was based on 
returned questionnaires by members of the British Rhinology 
Society also showed that prescribing of antimicrobials for ABRS 
does not prevent the occurrence of complications. These facts, 
together with the risk of antibiotic resistance and possible 
masking of intracranial complications argue strongly against 
the routine use of antibiotics in ABRS(302). These studies also 
emphasise the need to be constantly vigilant for complications 
irrespective of whether antibiotics are being taken or not and 
complications may occur before the patient is seen in primary 
care.
Taking oral antibiotics did not provide any 
advantage in the prevention of complications.
intravenous antibiotics and / or surgical drainage) is imperative 
to avoid long-term morbidity and mortality. The endocranial 
complications include epidural empyema, subdural empyema, 
brain abscess, meningitis, encephalitis, superior sagittal and 
cavernous sinus thrombosis. These may present with non-
specific signs and symptoms and diagnosis requires high clinical 
suspicion from practitioners, especially in children. Osseous 
complications result from osteomyelitis and may present as a 
subperiosteal frontal bone abscess (Potts Puffy tumour) or a 
frontocutaneous fistula. The quantity and quality of high-quality 
studies is restricted, in part due to the frequency and emergen-
cy nature of many of the problems.
There are still cases in which acute bacterial sinus 
infection is associated with complications which 
can be due to sporadic, untreated or treated 
microbial infections.
4.7.1. Introduction
Despite the advent and broad use of antibiotic therapy during 
the last six decades, complications of rhinosinusitis still cause 
substantial morbidity and occasionally mortality. Due to con-
temporary diagnostic modalities [mainly CT and Magnetic Reso-
nance Imaging (MRI)] and improved surgical techniques (mainly 
endoscopic sinus surgery) incidence and related morbidity and 
mortality from complications of bacterial rhinosinusitis have 
dramatically decreased. However, there are still cases in which 
acute bacterial sinus infection is associated with complications 
which can be due to sporadic(12), untreated or treated microbial 
infections(301-303) or they could be overlooked due to lack of avai-
lability of contemporary diagnostic and therapeutic modalities 
in certain populations(304, 305). Other cases include those patients 
in whom prescription of oral antimicrobial agents is contraindi-
cated such as pregnant women(306-308). Complications of ABRS are 
typically classified as orbital (approximately 60-80%), intracra-
nial (approximately 15-20%) and rarely osseous (approximately 
5%)(302, 309-317) (Table 4.7.1.) though occasionally some unusual 
complications can develop (see below and Table 4.7.4.)(302, 303, 
318, 319). Recently a cohort study even associated acute bacterial 
rhinosinusitis with an increased risk for stroke(318). Although a 
cohort design is adequate to document causality, more studies 
are necessary to classify stroke as a complication of chronic or 
untreated rhinosinusitis(318).
4.7.2. Epidemiology of complications
Evidence with regard to the incidence and prevalence of the 
complications of rhinosinusitis is patchy and there is no consen-
sus on the exact prevalence of the different types of complicati-
ons. Furthermore, the causal link between the microbial sinus in-
fection and the reported complications is rarely if ever reported 
in the literature. The incidence of ABRS complications has been 
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Author, 
year, ref.
Country Age Disease Patients (Incidence per 
million population 
per year)
Orbital Intracra-
nial
Bone Soft 
tissue
Dennison 
2019(328)
Sweden Children ABRS 29 100%
El Mograbi 
2019(322)
Israel Adults  ABRS + 
CRS
70 100% 
(70)
2.8% 
concur-
rent (2)
Hamill 
2018(364)
USA Children ABRS 250 61.6% 
(154) 
11.6% 
(29)
Scholin Ask 
2017(323)
Sweden Children ABRS + 
CRS
213 3.6 (orbital only) 
Hospitalization boys 
5.3, girls 3.6 
80% 
(171)
Nicoli 
2016(383)
Finland Adults  / 
children
ABRS 3.2 (intracranial 
only)
  6
Chaiyasate 
2015(312)
China Adults / 
children
ABRS 1655 85 patients with 
complications
41 24 2 3
Capra 
2015(320)
USA Children ABRS 0.738 children in 
2000 and 0.605 in 
2009
Miah 
2015(314)
UK Adults / 
children
ABRS 31/248 21 9
Sedaghat 
2014(317)
USA Children ABRS 696 90.2% 9.8%
Hansen 
2012(301)
Netherlands (Natio-
nal Database 2004) 
Adults / 
children  
ABRS 48 (48/16.3 million=3 ) 67% 
(32)
33% 
(16) 
Piatt 
2011(384)
USA – National in- 
patient database 
(1997, 2000, 2001, 
2003, 2006)
Children ABRS 695 2.7 – 4.3  
Babar-Craig 
2010(12)
UK – national 
ques-tionnaire
Adults / 
children
ABRS 78 N/A 76% 9% 5%
Stoll 2006(14) France (2001-2003) Adults and 
adolescents
ABRS 43 (30/12 million= 2.5) 35% 
(15)
37% 
(16)
18% 
(8)
Oxford  
2005(316)
USA Children ABRS/CRS 104 N/A 91% 
(95)
16% 
(17)
3% 
(3)
Eufinger 
2001(313)
Germany Adults / 
children
ABRS 25 N/A 88% 
(22)
20%
(5)
2 pat. 
(had 
both)
Mortimore 
1997(315) 
South Africa Adults / 
children
ABRS/CRS 63 N/A 81% 
(51)
13% 
(8)
10% 
(6)
24% 
(15)  
Table 4.7.1. Epidemiological data of complications in ABRS.
ABRS, acute bacterial rhinosinusitis; CRS, chronic rhinosinusitis; N/A, not applicable.
4.7.3. Orbital complications of AΒRS 
4.7.3.1. Classification
Orbital complications, the most commonly related to ABRS, 
involve (in decreasing frequency) the ethmoid, maxillary, frontal 
and rarely the sphenoid sinuses (Table 4.7.2.). The infection 
spreads directly via the thin and often dehiscent lamina pa-
pyracea or a pre-existing anatomical abnormality in cases of 
recurrent periorbital cellulitis or through venous return(302, 303, 
309). Orbital complications commonly affect children(322, 323, 325-327) 
a population which is known to express fewer clinical signs and 
symptoms so it is mandatory to have a high level of clinical sus-
picion for the possibility of orbital complications in children with 
ABRS. Hospital admission due to acute rhinosinusitis in children 
decreased after the introduction of pneumococcal conjugate 
vaccine but there was no parallel decrease in the incidence of 
orbital complications(328, 329).
Despite the fact that the Chandler’s classification is widely 
used, it does present some problems. The orbital septum is the 
anterior limit of the orbit, therefore it has been suggested that 
pre-septal cellulitis should be classified as an eyelid, rather than 
an orbital infection(302). In this regard it has been argued that 
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complication of a URTI, dacryocystitis or skin infection while 
rhinosinusitis is an uncommon cause(302, 315, 326). Pre-septal cel-
lulitis presents with orbital pain, eyelid oedema, erythema and 
fever. On clinical examination there may be no evident propto-
sis and no limitation of eye movement. Of note these signs of 
proptosis and limited eye movement can be difficult to assess 
in paediatric patients(325, 326, 337). Most cases of pre-septal cellulitis 
respond to oral antibiotic therapy but if not timely and appropri-
ately treated, they can spread beyond the orbital septum(334, 335, 
338). In most cases, pre-septal cellulitis is a clinical diagnosis and 
due to the superficial nature of the inflammation, imaging is not 
necessary(302, 336).
4.7.3.3. Orbital cellulitis
Orbital cellulitis, orbital abscess and subperiosteal abscess are 
all complications that are more commonly associated with acute 
rhinosinusitis, in contrast with pre-septal cellulitis which more 
commonly occurs following upper respiratory tract infections 
(see above)(302). As the inflammation spreads through the orbit, 
proptosis (a protruding eyeball) develops together with some 
limitation of ocular movement (diplopia can present in extreme 
gaze) indicating orbital cellulitis. Other typical signs of orbital 
cellulitis are chemosis (conjunctival oedema), ocular pain and 
tenderness, as well as ophthalmoplegia (restricted and painful 
ocular movement) of the extraocular muscles(302). This com-
plication requires immediate and aggressive treatment with 
intravenous antibiotics and should be referred for detailed CT 
scan with contrast of the sinuses to distinguish between orbital 
cellulitis, intraorbital or subperiosteal abscess(336). However, there 
should be close monitoring for progression with a low threshold 
for surgical intervention as the few who do not respond to anti-
biotic therapy can progress rapidly over 24–48 h. In cases where 
a concomitant intracranial complication is also suspected, MRI 
scan better diagnoses orbital complications(313, 338-340). All three 
complications (orbital cellulitis, subperiosteal and intraorbital 
abscess) cause eyeball proptosis and limit ocular movement. 
Evidence of an abscess on the CT scan, progressive orbital 
findings or visual deterioration after initial intravenous (i.v) 
antibiotic therapy should be considered as indications for orbital 
exploration and drainage (see below). Repeated ophthalmologic 
examinations of visual acuity should take place and i.v. antibio-
tic therapy may be converted to oral when the patient has been 
afebrile for 48 hours and the ophthalmological symptoms and 
signs are resolving(302, 337, 341, 342).
Indications for surgical intervention in orbital complications of 
ABRS:
• Evidence of subperiosteal or intraorbital abscess on CT or 
MRI (with potential exception for small volume abscesses).
• Reduced visual acuity/reduced colour vision/affected af-
ferent pupillary reflex or inability to assess vision.
• Progression or no improvement in orbital signs (diplopia, 
pre-septal cellulitis is infrequently associated with rhinosinusitis 
and its clinical picture, its management and its prognosis dif-
ferentiate it from all other orbital infections(302). It has been sug-
gested that orbital involvement (more appropriately: post-septal 
cellulitis) presents with swelling, exophthalmos and impaired, 
painful extra-ocular eye movements with diplopia. With the ex-
ception of swelling, these features are not present in pre-septal 
cellulitis and differentiate it from true orbital infections(302). Ad-
ditionally, cavernous sinus thrombosis, as has been suggested 
by Mortimore in 1997(315) is an intracranial complication and not 
necessarily the end stage of orbital infection, while it is more 
often associated with sphenoid rather than ethmoid or frontal 
sinus infection(302). 
According to Chandler’s classification, orbital complications may 
be divided into five stages based on their clinical and radiologi-
cal findings(309):
• Stage 1: pre-septal cellulitis 
• Stage 2: orbital cellulitis 
• Stage 3: subperiosteal abscess 
• Stage 4: orbital abscess 
• Stage 5: cavernous sinus thrombosis 
Because Chandler’s classification remains the most commonly 
used and because we attempted to summarize the evidence 
from a number of papers, past and present, we still employ this 
classification in Table 4.7.2., although it was also debated in 
EPOS 2012(302).
Periorbital or orbital cellulitis may result from direct or vascu-
lar spread of the sinus infection(330-335). As the spread of sinus 
infection through the orbit follows a well-described pattern, the 
initial manifestations are oedema and erythema of the medial 
aspects of the eyelid. Spread of infection from the maxillary 
or the frontal sinus results in initial presentation with swelling 
of the lower or upper eyelid, respectively. Consultation with 
an ophthalmologist, in some cases twice daily, should always 
be sought for clinical and medicolegal reasons and objective 
assessment of proptosis (exophthalmometer), orbital pres-
sure (tonometer), visual acuity, colour vision (an important and 
early sign of deterioration) and eye movements should always 
be clearly documented(302, 315, 319). Snellen charts can be easily 
downloaded as free-of-charge android applications and are a 
quick and reproducible way of assessing visual acuity and colour 
vision by the non-expert.
4.7.3.2. Preseptal cellulitis
Preseptal cellulitis refers to the inflammation of the eyelid and 
conjunctiva and involves the tissues anterior to the orbital 
septum, if necessary. It can be identified on the CT scan as soft 
tissue swelling. The MRI T2 sequence is better in demonstra-
ting the inflammation in the soft tissues(336). It can occur as a 
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Table 4.7.2. Orbital complications of ABRS.
Author, 
year, ref.
N Age Disease Type of 
complications
Management
Tachibana 
2019(311)
21 Adults / children   ABRS/CRS Preseptal cellulitis (4)
Postseptal orbital cellulitis (8)
Subperioteal abscess (9) 
Surgical (23.8%)
Trivic 
2019(346)
61 Children                       ABRS Preseptal cellulitis (50.0%)
Orbital cellulitis (50%) 
Medical and Surgical
El Mograbi 
2019(322)
70 Adults                          ABRS/CRS Preseptal/orbital cellulitis (61.5%)
Orbital cellulitis (23%) 
Subperiosteal abscess (11%)
Orbital abscess (3%) 
Cavernous sinus thrombosis (1.5%)
Medical only
Medical only
Surgical, ESS (5), ESS & EXS (2)
Surgical, ESS (1), ESS & EXS (1)
Surgical, ESS (1)
Jabarin 
2019(344)
123 Children                       ABRS Preseptal cellulitis (57%)
Orbital cellulitis (1.5%)
Subperiosteal abscess (41.5%) 
Medical only 
Medical only
Medical (29), Surgical (24)
Gavriel 
2018(341)
37 Adults                           ABRS Preseptal cellulitis (49%)
Subperiosteal abscess (51%)
Medical only 
Medical (12), Surgical (7)
Scholin Ask 
2017(323)
203 Preschool children   ABRS Preseptal cellulitis (96.5% )
Orbital cellulitis/Subperiostal abscess (2.0%) 
Orbital abscess (1,5%) 
Medical only
Medical only
Medical (2), Surgical (1)
Chang 
2017(334)
71 Adults / children         ABRS/CRS Preseptal cellulitis (47%)
Orbital cellulitis (9.6%)
Subperiosteal abscess (19.3)
Orbital abscess (9.6%)
Surgical (13) 
Surgical (3)
Surgical (13) 
Surgical (6)
Li 
2017(385)
28 Children                     Preseptal cellulitis (1) 
Orbital cellulitis (9)
Subperiosteal orbital abscess (13) 
Orbital abscess (5)
Medical only  (8)
Medical and Surgical (20)
Wan 
2016(325)
31 Children                        ABRS Preseptal cellulitis (4 )
Orbital cellulitis (14) 
Subperiosteal abscess (13) 
Medical (16)
Surgical (15)
Miah 
2015(314)
31 Adults / children         ABRS Periorbital cellulitis (16)
Orbital abscess (6)
Intracranial abscess (9)
Radovani 
2013(335)
35 Adults / children         ABRS Preseptal cellulitis (15) 
Orbital cellulitis (10) 
Subperiosteal abscess (6) 
Orbital abscess (3) 
Cavernous sinus thrombosis (1)
Medical (12)
Medical and surgical (3)
Surgical
Surgical 
Surgical
Surgical
Al-Madani 
2013(333)
35 Adults / children          ABRS Preseptal cellulitis (26)
Orbital cellulitis (8)
Orbital abscess (2)
All medical
Surgical (1)
Huang 
2011(343)
64 Children                                                    ABRS Subperiosteal/intraorbital abscess 56% (36) 
Preseptal/orbital cellulitis 44% (28)
Medical only: 53% (34) 
Medical and surgical: 47% (30)
Georgakopoulos 
2010(326)
83 Children                      ABRS/CRS Preseptal cellulitis 83% (69)
Orbital cellulitis 12% (10)
Subperiosteal abscess 5% (4)
Medical only: 95% (79)
Surgical and medical: 5% (4)
Siedek 
2008(345)
127 Adults / children       ABRS/CRS Preseptal cellulitis 36% (46) 
Orbital cellulitis 44% (56)
Subperiosteal abscess 6% (8)
Intraorbital abscess 14% (17)
Medical only: 51% (65)
Surgical: 49% (62)
Eviatar 
2008(338)
52 Children                   ABRS Preseptal cellulitis 92% (48)
Subperiosteal abscess 8% (4)
Medical only: 98% (51)
Surgical: 2% (1)
Mekhitarian 
2007(327)
25 Children                   ABRS Preseptal cellulitis 96% (24)
Subperiosteal abscess 4% (1)
Medical only: 92% (23)
Surgical: 8% (2)
 Oxford 
2006(348)
43 Children                   ABRS Subperiosteal abscess 100% (43) Medical only: 42% (18)
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Author, 
year, ref.
N Age Disease Type of 
complications
Management
Mortimore 
1997(315)
51 Adults / children       ABRS Preseptal cellulitis 55% (28)
Orbital cellulitis 10% (5)
Subperiosteal abscess 33% (17)
Intraorbital abscess 2% (1)
Not stated
ABRS, acute bacterial rhinosinusitis; CRS, chronic rhinosinusitis; ESS, endoscopic sinus surgery; EXS external sinus surgery. 
Table 4.7.2. Orbital complications of ABRS continued
ophthalmoplegia, proptosis, swelling, chemosis) after 48 
hours intravenous antibiotics.
• Progression or no improvement in the general condition 
(fever, infection parameters) after 48 hours of intravenous 
antibiotics.
4.7.3.4. Subperiosteal and orbital abscess
A subperiosteal abscess forms between the periorbita and the 
sinuses and is located outside the ocular muscles (or extraconal). 
The clinical features of a subperiosteal abscess are oedema, 
erythema, chemosis and proptosis of the eyelid with limitation 
of ocular motility and as a consequence of extra-ocular muscle 
paralysis, the eyeball becomes fixed (ophthalmoplegia) and vi-
sual acuity diminishes. In most case series, high fever and raised 
leucocyte count as well as left shift (an increase in the number of 
immature leucocytes in the peripheral blood, particularly neu-
trophil band cells) have been reported as strongly associated 
with (subperiosteal or intraorbital) abscess formation(309, 311, 321, 322, 
325, 326, 333-335, 339, 341, 343-346). 
An orbital abscess is contained within the space defined by 
the ocular muscles and the eyeball ie intraconal and genera-
lly results from diagnostic delay, inappropriate antimicrobial 
treatment or immunosuppression of the patient(335, 341, 347) with 
a frequency of between 1.5% and 14% (Table 4.7.2.) in paedia-
tric studies of orbital complications. The clinical or radiological 
evidence of an abscess or the lack of clinical improvement after 
24-48 hours of i.v. antibiotics are indications for prompt surgical 
exploration and drainage, preferably via endoscopic approa-
ches.
As previously noted, a detailed CT scan of the sinuses with 
contrast and possibly with 3D reconstruction may help to 
distinguish between cellulitis and orbital or subperiosteal 
abscess. In the case of a subperiosteal abscess, the CT usually 
reveals oedema of the medial rectus muscle, lateralization of the 
periorbita and lateral downward displacement of the eyeball(336, 
337, 342). In cases where the CT scan shows obliteration of the 
detail of the extraocular musculature and of the optic nerve by 
a confluent mass, the orbital cellulitis has progressed to an intra-
orbital abscess, in which case there may sometimes be air in the 
orbit due to the presence of anaerobic bacteria. The diagnostic 
accuracy of clinical examination alone to determine an orbital 
abscess has been reported to be approximately 80% which rises 
to approximately 90% with the addition of CT imaging. MRI may 
be useful in cases of diagnostic uncertainty after a CT scan or 
when intracranial complications are suspected(348, 349). 
Subperiosteal abscess in children is not an absolute indication 
for immediate surgical intervention. Conservative measures 
can be safe and effective if appropriately used, depending 
on patient characteristics, exam findings, clinical course, and 
imaging(350). An ophthalmologist should check visual acuity from 
the early stages of the illness. Intravenous antimicrobial therapy 
should cover aerobic and anaerobic pathogens. Evidence of an 
abscess on the CT scan or absence of clinical improvement after 
24-48 hours of i.v. antibiotics are indications for orbital explora-
tion and drainage(349). Depending on the radiographic volume of 
the abscess, the decision to surgically explore may be prioritized 
if the volume appears to be large. In contrast, in small abscesses 
the most prudent decision would be to continue i.v. antibiotics 
and monitor the patient(351). A current guideline mandates that 
pre-septal and orbital cellulitis should be treated with antibi-
otics while subperiosteal and intraorbital abscesses require 
surgical exploration which should include not just the drainage 
of the abscess but also of the paranasal sinuses(302) as cellulitis 
can be expected to improve with proper antimicrobial therapy 
while drainage is the mainstay of treatment for any abscess. 
The guideline recommends an endoscopic approach to open 
the lamina papyracea and draining the abscess after complete 
ethmoidectomy. External approaches to lateral and medial 
orbital abscesses (lateral and medial orbitotomy) can also be 
used if necessary. However, there have been a number of recent 
studies showing good outcomes with i.v. antibiotics in children 
with subperiosteal abscesses(302, 345, 347, 349). In such cases, and 
provided there is(302): clear clinical improvement within 24-48 
hours; no decrease in visual acuity; small (<0.5-1 ml in volume); 
medially located subperiosteal abscess; no significant systemic 
involvement; the decision might be to withhold surgical drai-
nage and closely monitor the patient(341, 342). Importantly, it has 
recently been reported that the same conservative approach is 
also valid for adult patients with orbital abscesses. Gavriel et al. 
reported a similar prognosis between conservative medical and 
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structures by eroding the thin osseous walls of the sinuses(354-356, 
361). lnflammatory complications of the brain start as inflamma-
tion (ie encephalitis), which progresses to necrosis and lique-
faction of brain tissue, with a reactive connective tissue capsule 
forming around the brain abscess. 
A CT scan with contrast, as a minimum, is required for diagnosis 
as it allows for precise definition of osseous tissue involvement. 
MRI is considered to be the “gold-standard” as it is more sensitive 
than CT and should be the imaging modality of choice where 
available; further it has additional diagnostic value to exclude 
or confirm cavernous sinus thrombosis and also in cases with 
soft tissue involvement(336, 357). Studies show a high incidence 
of anaerobic organisms or mixed aerobic-anaerobic in patients 
with endocranial complications. In cases where meningitis is 
suspected and provided that any intracranial abscess has been 
definitely excluded by imaging, a lumbar puncture can be 
performed to properly determine the underlying pathogens 
and to customize antimicrobial therapy(357). Pathogens most 
commonly isolated following lumbar puncture are Streptococ-
cus and Staphylococcus species including methicillin-resistant  
(MRSA) and anaerobes(363-365). High dose long-term i.v. antimi-
crobial therapy followed by neurosurgical burr hole drainage, 
craniotomy for evacuation of the abscess or image guided 
aspiration, are usually required for successful treatment(312, 349, 354, 
359, 361). Current treatment involves joint neurosurgical drainage 
procedures and drainage of the paranasal sinuses (most often 
the frontal sinus) can be performed endoscopically(359, 362, 366). The 
rationale is to evacuate the intracranial collection and manage 
the source of infection using a rhinological approach which will 
provide microbiological samples. Lack of early sinus drainage 
has been associated with the need for repeated craniotomies(357, 
366). The prognosis of intracranial complications of acute bacterial 
rhinosinusitis depends on the severity of neurological signs and 
on the delay in diagnosis and management(354, 366). The mortality 
rate varies from 0% up to 19%(312, 361, 362, 367), (Table 4.7.3.), and 
is related to cortical veins thrombosis and to cerebral vascular 
infarction (357, 366).
4.7.5. Cavernous sinus thrombosis
Cavernous sinus thrombosis is a rare complication and has been 
estimated at a rate of less than 10% of all the intracranial com-
plications (Table 4.7.3.)(353, 356). The highly anastomotic venous 
system of the paranasal sinuses allows retrograde spread of 
infection to the cavernous sinus causing sepsis and multiple 
cranial nerve involvement(316, 330, 353, 356, 362, 368). Proptosis, ptosis, 
diplopia, chemosis, involvement of the eye motor nerves and 
impairment in the ophthalmic and maxillary branches of cranial 
nerve V(1) (ophthalmic nerve neuralgia) papilloedema and signs 
of meningeal irritation associated with spiking fevers and pros-
tration establish the diagnosis(301, 356, 361). Symptoms start in one 
eye and progress to the other. 
surgical approach in the treatment of orbital abscesses for adult 
patients(341). Therefore, based on this evidence, adult patients 
may also be candidates for watchful waiting instead of endo-
scopic drainage. Blindness may result from central retinal artery 
occlusion, optic neuritis, corneal ulceration, or panophthalmitis. 
It is not infrequent for sepsis to spread intracranially as well as 
anteriorly into the orbit(302, 303, 319). Patients with delayed admis-
sion and additional risk factors have a higher risk of irreversible 
blindness(352).
Subperiosteal abscess in children is not an 
absolute indication for immediate surgical 
intervention. Conservative measures can be safe 
and effective if appropriately used, depending 
on patient characteristics, exam findings, clinical 
course, and imaging.
4.7.4. Endocranial complications
Endocranial (or intracranial) complications of ABRS are epidural 
or subdural empyema, brain abscess, meningitis, cerebritis and 
superior sagittal and cavernous sinus thrombosis (Table 4.7.3.). 
These complications may present with non-specific symptoms 
and signs of a systematic inflammatory response (high fever, 
headache, lethargy, reduced consciousness) or with specific 
central nervous system signs due to focal neurologic damage or 
increased intracranial pressure. Of note, it is not uncommon for 
any of these complications to either present with non- specific 
symptoms including high fever accompanied by headache, or 
even to be silent(315). Although an intracranial abscess can be re-
latively asymptomatic, subtle affective and behavioural changes 
are not uncommon; these are signs of altered neurologic func-
tion, orientation and cognitive state. Gait instability and severe, 
progressive headache have also been reported to be common 
symptoms(302). The majority of the endocranial complications of 
ABRS however, present with more specific signs and symptoms 
that suggest the intracranial inflammatory involvement, such as 
nausea and vomiting, neck stiffness and altered mental state(301, 
312, 324, 347, 353-358). The clinical expression of subdural and epidural 
empyema is different. Subdural empyema often presents with 
neurologic symptoms as an emergency case. In contrast epidu-
ral empyema is more often diagnosed on imaging studies(359). 
Intracranial abscesses often become apparent through signs of 
increased intracranial pressure, meningeal irritation and focal 
neurologic deficit mainly of the third, sixth or seventh cranial 
nerves(301, 305, 316, 330, 347, 349, 360, 361). 
Endocranial complications are usually associated with frontoet-
hmoidal or sphenoid rhinosinusitis(312, 324, 354, 355, 357, 361, 362). Infecti-
ons can proceed from the paranasal cavities to the endocranial 
structures by two different routes: (a) haematologically – patho-
gens can pass through the diploic veins to reach the brain; (b) 
tissue continuity spread – pathogens can reach the intracranial 
EPOS 2020
102
Table 4.7.3. Endocranial complications in ABRS.
Author, 
year, ref.
N Complications Management (all had 
medical therapy)
Mortality / further defects
Mulvey 
2019(367)
43 Meningitis (10)
Epidural empyema (28)
Subdural empyema (19)
Intracerebral abscess (2)
ESS (43)
NS (23)
No mortality. 14 patients (16%) 
were readmitted for worsening 
symptoms or complications of 
treatments.
Schupper 
2018(361)
16 Epidural abscess (10)
Subdural abscess (9)
Intracerebral abscess (3)
Multiple abscesses in 6 cases
Cavernous sinus thrombosis (2)
Simultaneous ESS and NS as first 
procedure (16)
No mortality
Kou 
2018(362)
22 Subdural empyema (10)
Epidural abscess (10)
Meningitis (5)
Cerebral abscess (5)
Cavernous sinus thrombosis (2)
ESS (19)  
NS (8) 
Simultaneous ESS and NS (6) 
No mortality 
Neurologic deficits 4.5% (short 
follow up average: 7 months)
Patel 
2015(358)
27 Epidural empyema (14) 
Subdural empyema (9) 
Cerebral abscess (4) 
ESS (11) 
ESS and NS (18) 
Only NS (3)
No mortality 
Neurologic deficits cognitive/per-
sonality changes 33% (6 months 
follow up)
Garin 
2015(359)
17 Subdural empyema (9) 
Epidural empyema (8) 
ESS and NS (15) 
Only ESS (2)
No mortality 
Cognitive and schooling problems: 
subdural empyema 67%, epidural 
empyema 29%
Khamassi 
2015(366)
23 Subdural empyema (11) 
Epidural empyema (7) 
Intracerebral abscess (5) 
Cerebral thrombophlebitis (4)
Medical therapy only (3)
NS (19) 
ESS (1)
Mortality 8.7% 
Morbidity 34.7%
Chaiyasate 
2015(312)
24 Meningitis (13)
Brain abscess (5)
Cavernous thrombosis (8)
Transverse sinus and sigmoid sinus 
thrombosis (2)
Superior sagittal sinus (1)
Mortality 11.3% 
Morbidity 25.3%
Deutschmann 
2013(365)
50 Meningitis (23) 
Epidural abscess (10)
Subdural abscess (8)
Intracerebral abscess (3)
Cavernous sinus thrombosis (2)
Other (4)
Medical therapy only (23)
NS (14)
ESS (8)
Other (5)
No mortality 
Morbidity 6%
Hansen 
2012(301)
16 Subdural empyema (9)
Meningitis (3)
Epidural abscess (2)
Intracerebral abscess (2)
Encephalitis (1)
Superior sagittal sinus thrombosis (1)
Mortality 19%
Morbidity 19%
DelGaudio 
2010(355)
 23 Epidural empyema (8)
Subdural empyema (10)
Intracerebral abscesses (2)
Meningitis (3)
Only medical therapy (3)
ESS (1)
NS (18)
Mortality 4% 
Morbidity 12%
Bayonne 
2009(354)
25 Epidural empyema
Subdural empyema
Meningitis
Sequelae 16%
Mortality 0%
Germiller 
2006(357)
25 (mean 
age 13y) 
Epidural empyema (13)
Subdural empyema (9)
Meningitis (6)
Encephalitis (2)
Intracerebral abscess (2)
Cavernous sinus thrombosis (2)
ESS (21) 
EXS (7) 
NS (13)
Morbidity 8% 
Mortality 4%
Quraishi 
2006(305)
12 (mean 
age 14 y)
Frontal lobe abscess (2)
Subdural empyema (8)
Cavernous sinus thrombosis (2)
Mortality 8%
Morbidity 16 %
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Author, 
year, ref.
N Complications Management (all had 
medical therapy)
Mortality / further defects
Oxford 
2005(316)
18 (mean 
age 12 y)
Epidural empyema (7)
Subdural empyema (6)
Intracerebral abscess (2)
Meningitis (2)
Cavernous sinus thrombosis (1)
No mortality
Morbidity 11%
Younis 
2002(349)
39 Epidural empyema (7)
Subdural empyema (4)
Meningitis (21)
Intracerebral abscess (4)
Superior sagittal sinus thrombosis (1)
Medical therapy only (21)
NS (15) 
EXS (4)
ESS (2)
Sequelae 10% 
No mortality
Jones 
2002(347)
47 Subdural empyema 38%
Meningitis 2%
Epidural empyema 23%
Intracranial abscess 30%
NS (47) 
EXS (17)
ESS (6)
Mortality 2%
Morbidity 19%
Albu 
2001(353)
16 Meningitis (6)
Frontal lobe abscess (6)
Epidural empyema (5)
Subdural empyema ($)
Cavernous sinus thrombosis (2)
Mortality 6%
Morbidity 25%
Gallagher 
1998(356)
15 Meningitis 18%
Cerebral abscess 14%
Epidural empyema 23%
Mortality 7%
Morbidity 13%
Clayman 
1991(324)
24 Meningitis 29%
Cerebral abscess 46%
Epidural empyema 5%
Subdural empyema 8%
Cavernous sinus thrombosis 8%
Sagittal vein thrombosis 4%
Mortality 4%
Morbidity 33%
ABRS, acute bacterial rhinosinusitis; CRS, chronic rhinosinusitis; ESS, endoscopic sinus surgery; EXS, external sinus surgery; NS, neurosurgical proce-
dures.
Full blood count may show increased white blood cell count 
with left shift, C-reactive protein (CRP), erythrocyte sedimenta-
tion rate (ESR,) and D-dimer while lumbar puncture may show 
elevated opening pressure and pleocytosis even in culture ne-
gative samples whilst blood cultures are frequently positive(353, 
356). Screening for thrombophilia may give false results during 
anticoagulation therapy and should be delayed until after treat-
ment is completed.
The cornerstone of diagnosis is an MR venogram, demonstrating 
absence of venous flow in the affected cavernous sinus. High-
resolution CT scan with contrast can also show filling defects(336, 
337). Previous articles described an approximate mortality rate 
of 30% and a morbidity rate of 60% in the adult population but 
more recent articles report better results(369). Lize et al. reported 
seven patients who were treated for septic cavernous sinus 
thrombosis secondary to acute bacterial rhinosinusitis. All 
patients were treated with high dose i.v antibiotics, anticoagu-
lation therapy and endoscopic sinus drainage of the infected 
sinuses. They described a mortality rate of 0% but one patient 
developed permanent unilateral visual loss and four permanent 
neurologic deficits(370). Most experts recommend anticoagula-
tion, in the absence of strong contraindications (only if there is 
no evidence of severe bleeding risk or current hemorrhage by 
history, exam, and imaging) but the anticoagulation remains 
controversial. Retrospective reviews suggest a possible decrease 
in mortality and reduction in neurologic morbidity when anti-
coagulation is combined with antibiotics for septic cavernous 
sinus thrombosis but without support from prospective clinical 
trials(302) due to a lack of cases. Corticosteroids are often given 
with antibiotics but without proven efficacy. The potential be-
nefit would be decreased inflammation and vasogenic oedema 
surrounding cranial nerves and orbital structures. Immediate 
endoscopic drainage of the affected sinus (almost always the 
sphenoid) is mandatory.
4.7.6. Osseous complications
ABRS can also affect the bony sinus walls causing osteomyelitis 
and subperiosteal abscess, eventually involving the brain and 
the nervous system. Even though the most frequent intracranial 
route of spread is from the frontal sinus, any sinus infection can 
lead to osseous complications. The most common osseous com-
plications are osteomyelitis of the maxillary (typically in infancy) 
Table 4.7.3. Endocranial complications in ABRS (continued).
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4.7.7. Unusual complications of rhinosinusitis
A number of unusual complications have been reported in cases 
of patients with ABRS. These are presented in Table 4.7.4. It is 
important to note that the management of ABRS complications 
should always be multidisciplinary and close cooperation with 
other different specialties as ophthalmologists, neurologists/
neurosurgeons, paediatricians, radiologists and microbiologists 
is mandatory.
4.7.8. Follow-up of complications
ABRS complications may occasionally appear simultaneously 
(for example subperiosteal frontal abscess and intracranial ex-
tension, orbital and intracranial complications) and intracranial 
complications may have neurologic deficits. Therefore, a long 
term follow-up of 6-12 months is indicated for such patients in 
order to monitor for complete resolution of the disease as well 
as to exclude any disease recurrence or complication of treat-
ment. Meticulous care of the sinuses should be the first priority.
4.7.9. Conclusion
Complications of bacterial rhinosinusitis are rare but potentially 
serious. However, a number of studies have shown that they 
are not prevented by routine prescribing of antibiotics so a low 
threshold of suspicion must always be maintained for their early 
diagnosis. 
or the frontal bones(330, 336, 365, 371). 
The frontal sinus infection can cause osteitis and osteomyelitis 
of the frontal sinus walls and may develop into a subperiosteal 
abscess with soft tissue swelling and a doughy pitting oedema 
on the anterior wall (Pott's puffy tumour). A sino-cutaneaous 
fistula is a rarer presentation. Since the inflammatory process 
also extends posteriorly from the frontal sinus, directly or via 
thrombophlebitis of the valveless diploic veins, patients may 
have concomitant complications, such as meningitis, epidural 
and subdural empyema and brain abscess(316, 371, 372). 
Leong(316, 371, 372) reviewed 29 cases of Pott’s puffy tumour (PPT) 
and the most common aetiology was acute frontal sinusitis 
(62%). Bony complications develop in 3-10% of complicated 
ABRS cases(316, 371, 372).
Signs and symptoms of intracranial involvement are soft tissue 
oedema (especially of the superior eyelid), high fever, severe 
headache, meningeal irritation, nausea and vomiting, diplopia, 
photophobia, papillary oedema, coma and focal neurological 
signs. Ocular signs can appear contralaterally as well. Contrast- 
enhanced CT scan is needed to confirm the diagnosis. A lumbar 
puncture is not indicated if the intracranial pressure is elevated, 
but in certain cases it can also be of diagnostic value. Therapy 
originally included a combination of i.v. broad-spectrum antibio-
tics administration and surgical debridement of sequestered 
bone and drainage(302, 321, 373). There is a growing body of evidence 
that uncomplicated PPT can be managed successfully via an en-
doscopic approach/minimal external drainage, combined with 
long-term antibiotics(316, 371, 372).
There is a growing body of evidence that 
uncomplicated Pott’s puffy tumour can be ma-
naged successfully via an endoscopic approach/
minimal external drainage, combined with long-
term antibiotics.
Author, year (ref.) Type of complication Outcome
Abou-Al-Ahaar 2019(386) Clival osteomyelitis with VI, XII nerve palsy Complete recovery after medical and surgical therapy
Fabre 2018(387) Acute Stroke Complete recovery after medical therapy and ESS
Righini 2009(388) Acute ischemic stroke Minimal neurologic sequelae after medical therapy and ESS
Sanan 2017(340)
Intra-optic nerve abscess with vision loss
Stable ophthalmologic findings after medical therapy and 
ESS
Korkmaz 2017(389) Isolated unilateral upper lid ptosis Complete recovery after medical therapy 
Huth 2015(390) Thrombophlebitis temporal vein (without cavernous 
sinus thrombosis)
Complete recovery after medical therapy and ESS
Tien 2016(391) Nasal septal abscess (5 cases) No morbidity after medical and surgical therapy
Zielnik-Jurkiewicz 2005(392) Nasal septal and palatine process abscess No morbidity after medical and surgical therapy
Gradoni 2010(393) Nasal septal abscess No morbidity after medical and surgical therapy
Nomura 2014(394) Orbital hematoma Complete recovery after medical therapy and ESS
Table 4.7.4. Unusual complications of ABRS.
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Table 4.7.4. Unusual complications of ABRS, continued.
ESS, endoscopic sinus surgery.
Author, year (ref.) Type of complication Outcome
Nomura 2014(394)
Orbital hematoma
Complete recovery after medical therapy, ESS and superior 
orbitotomy
Yim 2013(395) Orbital abscess secondary to contralateral rhinosinu-
sitis
Complete recovery after medical therapy, ESS and superior 
orbitotomy
Chan 2009(396) Toxic Shock Syndrome Complete recovery after medical therapy and ESS
Chen MC 2019(330) Septic shock Complete recovery after medical therapy and ESS
Rimal 2006(332) Septicaemia Complete recovery after only medical therapy
Suzuki 2005(360) Internal carotid artery aneurysm with multiple cranial 
nerve palsy
Partial recovery of visual disturbance after endovascular coil 
placement of the aneurysm
Patel 2003(397) Lacrimal gland abscess Complete recovery after medical therapy and drainage
Mirza 2001(398) Lacrimal gland abscess Complete recovery after medical therapy and ESS
Sidwell 2001(399) Pyoderma gangrenosum of the eyelid Scarring of the eyelid after medical therapy
Sahjpaul 1999(400) Pituitary abscess and cavernous sinus thrombophle-
bitis
Blind right eye and pituitary insufficiency after medical 
therapy and ESS
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5.1. Epidemiology and predisposing factors of 
CRS
5.1.1.Epidemiology of CRS
The number of papers on epidemiology of chronic rhinosinusitis 
(CRS) is limited compared to papers on treatment. 
Surveys with questionnaires are the most common way to 
explore the field of CRS in order to screen the population and 
to determine the prevalence of CRS in the general population. 
It probably overestimates the prevalence of CRS due to overlap 
with other rhinologic diseases.
In recent years a number of population-based studies have been 
performed with questionnaires evaluating the prevalence of 
CRS based on the epidemiological definition from the EPOS2012 
document(1). 
Earlier studies in the USA in 2009 based on the National Health 
Interview Survey found 13% of adults to have “sinusitis”(2). 
The first of these studies was part of The Global Allergy and 
Asthma European Network (GA2LEN). It consisted of a postal 
questionnaire sent to a random sample of adults aged 15-75 
years in 19 centres in Europe. Participants reported symptoms 
of CRS, and doctor diagnosed CRS, allergic rhinitis, age, gender 
and smoking history. Information was obtained from 57,128 
responders living in 12 countries. The overall prevalence of CRS 
was 10.9% with a wide variation between countries ranging 
from 6.9 in Finland to 27.1 in Portugal. CRS was more com-
mon in smokers than in nonsmokers (odds ratio (OR) 1.7: 95% 
confidence interval (CI) 1.6-1.9). The prevalence of self-reported 
physician-diagnosed CRS within centres was highly correla-
ted with the prevalence of EPOS-diagnosed CRS. Subsequent 
studies following roughly the same method showed a preva-
lence of 5,5% in Brazil(3), 8% in China(4),11% in South Korea(5) and 
12% in the USA(6),16% in the Netherlands(7) and 28% in Iran(8). 
In a second phase of the GA²LEN Survey each centre invited 
120 randomly selected subjects with asthma, 120 with CRS, 40 
with asthma and CRS and 120 with neither asthma or CRS for a 
clinical study visit with further investigations among which was 
a questionnaire including the same questions as for the postal 
survey. Of the patients having an epidemiological diagnosis of 
CRS in the first phase, EPOS provides two definitions of CRS: a 
clinical diagnosis based on symptoms, supported by signs of 
mucosal inflammation found on imaging or with nasal endo-
scopy, and a symptom-based definition to be used in epide-
miologic research, without radiologic imaging or endoscopic 
examination(1). Due to the overlap of symptoms between CRS, 
acute rhinosinusitis and (non-)allergic rhinitis, it can be difficult 
or maybe impossible to discriminate between these diagnoses 
based on symptoms alone.
The addition of nasal endoscopy or computed tomography (CT) 
scan makes the diagnosis more reliable. Two studies evaluating 
the use of nasal endoscopy to make a clinical diagnosis of CRS in 
a population study showed reduction of the prevalence to 1.2% 
(88 of 7,343)(5) and 6.8%(9). Interestingly in the paper from Tomas-
sen et al., 38% of symptom-negative patients had a positive 
endoscopy. The reason for the discrepancies between these two 
papers is unclear. Both papers used the EPOS criteria of clinical 
CRS: the presence of polyps, presence of oedema in the middle 
meatus or presence of thick purulent discharge in the middle 
meatus to define endoscopy positive CRS. 
Also, two studies evaluated the use of CT scan to make a clinical 
diagnosis of CRS in a population study. In one study a group of 
subjects who underwent a computed tomographic or magne-
tic resonance imaging scan of the head for any non-rhinologic 
indication were asked to fill in the GA2LEN survey including the 
CRS questions(10). The scans were evaluated according to the 
Lund-Mackay (LM) scoring system. Eight hundred and thirty-four 
subjects were included, and 107 (12.8%) had epidemiologically 
based CRS according to EPOS. Of these subjects, 50% had an LM 
score of 0, 26% had an LM score of 1 to 3, and 23% had an LM 
score of 4 or greater. Twenty-five (3.0%) subjects had clinically 
based CRS (based on LM score >/=4), and 53 (6.4%) subjects had 
clinically based CRS (based on LM score >0). In subjects who 
did not report upper airway symptoms, 57% had an LM score 
of 0, 30% had an LM score of 1 to 3, and 12% had an LM score 
of 4 or greater. The authors found a prevalence of 3.0% to 6.4% 
of clinically based CRS (depending on an LM cut-off point; i.e., 
LM ≥ 4 or LM > 0, respectively) in a relatively randomly selected 
group of subjects. The other study(11) collected questionnaires 
and sinus CT scans from 646 participants selected from a source 
population of primary care patients. Symptom status was based 
on guideline criteria, and radiology was based on the LM score 
using cutoff points of ≥ 3, 4, or 6. The authors found a preva-
lence of 11.1%, 9.9%, and 5.7% among woman respectively, and 
16.1%, 14.6%, and 8.7% among men for the different LM cutoff 
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points. When combining with symptomatology, the proportion 
of clinically based CRS was 1.7%, 1.6%, and 0.45% among wo-
men and 8.8%, 7.5%, and 3.6% among men. The figures of these 
two studies are very comparable, pointing to a prevalence of 
CRS based on symptoms and CT scan of around 3%.
Finally, prevalence of CRS can be estimated from databases 
based on the diagnosis by physicians. Health care administrative 
databases allow for population-based cohort studies to generate 
large sample sizes with small financial and time expense. Howe-
ver, the risk of inaccurate cohort identification can lead to biased 
outcomes. Lui et al. showed that in 27 studies obtaining CRS-
specific data from a health records database, eight different CRS 
case definitions were identified and 13 administrative databases 
were evaluated. The most commonly used CRS case definition 
was the ICD-9 473.x code alone(12). The CRS case definition of 
>/=2 claims with a CRS ICD-9 code (471.x or 473.x) within two 
years of the reference case provides a balanced validity with a 
sensitivity of 77% and specificity of 79%(13). The data that can be 
used to evaluate prevalence and doctors’ visits are limited. 
In the year 2000, 2405 residents of Olmsted County were given 
an ICD-9 diagnosis code for CRS. Among these, 1627 (67.7%) 
were female and 778 (32.3%) were male. The overall age- and 
sex-adjusted prevalence per 100,000 was 1955 (1.96%)(14).
The mean age- and sex-standardized incidence of diagnosed 
CRS in Canada was reported to be 2.5 (range, 2.3-2.7) per 1000 
population. The estimated prevalence based on age-specific 
incidence varied between 18.8 (95% CI, 18.7-18.9) and 23.3 (95% 
CI, 23.1-23.5) per 1000 population during 2004-2005 to 2013-
2014, and no obvious growing trend was found. There was high 
geographic variation in the diagnosed incidence and prevalence 
of CRS(15). 
Studies from [general practitioner (GP)] databases often suffer 
from suboptimal differentiation between ARS and CRS. Hof-
fmans et al. showed that GPs often do not differentiate between 
the two diseases(16).
Xiao et al. (845) retrospectively reviewed a random sample of adult 
patients diagnosed with CRS in 2016, based on ICD-10 codes 
from primary care and otorhinolaryngology departments. The 
percentage of patients fullfilling the criteria of the American 
Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) 
was very low from GP patients (0.97) and low from otorhinola-
ryngologists’ patients (28.9%). Symptom duration <12 weeks 
was higher in primary care (81.6% vs. 53.6%, p<0.0001), as was 
lack of evidence of inflammation (97.4% vs. 50.0%, p<0.0001). 
Having <2 of the required symptoms was significantly higher 
in otorhinolaryngology (63.8% vs. 50.8%, p=0.013). The most 
commonly unevaluated symptom was decreased sense of smell 
(97.7% in primary care, 69.1% in otorhinolaryngology encoun-
ters). There is an obvious need for clear criteria to do research on 
CRS in healthcare.
5.1.1.1. CRS: difference between CRSwNP and CRSsNP
CRS can be classified into CRS with nasal polyps (CRSwNP) and 
CRS without nasal polyps (CRSsNP). Data on the prevalence of 
CRSwNP are limited. Two early Scandinavian studies(17, 18)
investigated the prevalence of nasal polyps in an adult popu-
lation. A random sample of 1,900 inhabitants over the age of 
20 years, stratified for age and gender, was drawn from the 
municipal population register in Skövde, Sweden, in December 
2000. The subjects were called to clinical visits that included 
questions about rhinitis, asthma, and aspirin intolerance and 
examination by nasal endoscopy. In total, 1,387 volunteers (73% 
of the sample) were investigated. The prevalence of nasal polyps 
was 2.7% (95% confidence interval, 1.9-3.5), and polyps were 
more frequent in men (2.2 to 1), the elderly (5% at > or =60 years 
of age), and asthmatics(18). Similar data were found in Denmark 
where over a 6-year period all polyp patients diagnosed for the 
first time (n=252; 174 males, 78 females) were prospectively 
registered at the study clinic and compared to an estimated 
background population. The mean estimated incidences for all 
age groups were 0.86 and 0.39 patients per thousand per year 
for males and females, respectively. With a disease duration of 
estimated 20 years, this would lead to a prevalence of 1.92 and 
0.78 for males and females. Using a validated questionnaire/
algorithm (90% specificity and sensitivity) in a population-
based random sample, Klossek et al. estimated a prevalence of 
2.11% (95% CI 1.83-2.39). CRSwNP patients (n=212, 45% males) 
were aged 49.4 ± 17.6 years. No gender preponderance was 
observed, but NP tended to increase with age. Mean duration of 
nasal symptoms was 22.4 ± 15.7 years. 
Tan et al. sought to determine incidence for CRSsNP and 
CRSwNP using electronic health records data from 446,480 
Geisinger Clinic primary care patients(19). The average incidence 
of CRS was 83 ± 13 CRSwNP cases per 100,000 person-years and 
1048 ± 78 CRSsNP cases per 100,000 person-years. Between 
2007 and 2009, 595 patients with incident CRSwNP and 7523 
patients with incident CRSsNP were identified and compared 
with 8118 control subjects. Compared with control subjects and 
patients with CRSsNP, patients with CRSwNP were older and 
more likely to be male. Finally Won et al. found a prevalence of 
CRSsNP and CRSwNP of 3.5 ± 0.2% and 2.5 ± 0.2% (mean ± SE), 
respectively. When classified by age group, the prevalence of 
CRSwNP increased with age in adults (≥18 years of age), which 
was particularly evident after 40 years of age and CRSsNP was 
more prevalent in subjects younger than 40 years. Those with 
CRSwNP were significantly more likely to be men, to have higher 
BMI, to smoke cigarettes, and to have asthma than the CRSsNP 
or no-CRS group. 
CRSwNP was significantly associated with adult-onset asthma 
(onset after 18 years of age) or late-onset asthma (onset after 40 
years of age), whereas CRS without nasal polyps was related to 
childhood-onset asthma (onset before 18 years) or early-onset 
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mendation is that allergy testing and treatment are an option in 
CRSwNP and CRSsNP. Since 2014, a few noteworthy studies have 
been published. A more recent non-systematic review points to 
the fact that different phenotypes/endoptypes of CRS may have 
a variable associations with allergy. The authors point to allergic 
fungal rhinosinusitis (AFRS) (see 8.6) and central compartment 
atopic disease (CCAD)(25)(see 8.1.2.1.) This point was also made 
in a recent study from the UK that analysed differences between 
different phenotypes of CRS and controls in secondary care(26). 
The analysis included 1470 study participants: 221 controls, 553 
CRSsNPs, 651 CRSwNPs and 45 AFRS. The prevalence of inhalant 
allergy was 13.1, 20.3, 31.0 and 33.3% respectively; house dust 
mite allergy was significantly higher in CRSwNPs (16%) compa-
red to CRSsNPs (9%) in this study. 
In conclusion, the prevalence of allergy in CRS may vary by phe-
notype, with CCAD and AFRS having a stronger association than 
CRSwNP and CRSsNP. Large studies evaluating relationships in 
different settings like the Philpott paper are needed.
5.1.2.2. Asthma and other lower airway diseases
Unlike for allergy and CRS, the relationship between CRS and 
asthma is indisputable.
The prevalence of asthma is around 25% in patients with CRS 
compared to 5% in the general population(27). GA2LEN(28) studied 
over 52,000 adults aged 18-75 years living in 19 centres in 12 
countries and concluded that there is a strong association 
between asthma and CRS. The association with asthma was 
stronger in those reporting both CRS and allergic rhinitis. In 
the earlier mentioned UK study(26), the prevalence of asthma 
was 9.95% in controls, 21.2% in patients with CRSsNP, 44.9% in 
CRSwNPs and 73.3% in patients AFRS. A subgroup of the earlier 
mentioned GA2LEN cohort, with and without asthma and CRS 
of 3337 participants were further analysed for decline in lung 
function. Participants with asthma had lower forced expiratory 
flow per second (FEV) and a steeper slope of FEV1 against age 
equivalent to smoking 1-2 packs of cigarettes per day. Those 
with atopy had a slope equivalent to controls, but neither CRS 
nor atopy alone were associated with such decline(29).
Chen et al.(30) identified patients newly diagnosed with asthma 
in Taiwan and analyzed the incidence of CRS in that population. 
After adjustment for gender, age and medical comorbidities, 
they showed that asthma is an independent predictor of CRS, 
with or without nasal polyps (OR: 2.58 for CRSsNP). The chrono-
logy of developing asthma or CRS first is variable. 
A Japanese study shows that there is no significant difference 
in onset times between the two diseases(31). Wheezing and 
respiratory discomfort are present in 31 to 42% of patients 
with CRSwNP, and asthma is reported by 26% of patients with 
CRSwNP, compared to 6% of controls(32). On the contrary, 7% of 
asthmatic patients have nasal polyps with a prevalence of 13% 
in non-atopic asthma and 5% in atopic asthma and they have 
asthma (onset before 40 years) in adults. The 2 CRS subgroups 
showed significant associations with current asthma but not 
with past asthma. However, the comorbid asthma rate was 
lower than 10% among subjects with CRS(20).
Soler et al.(21) in 2012 evaluated the role of gender and race in 
surgical outcomes for patients with CRSwNP and asthma. In his 
study, African Americans with CRSwNP had less improvement 
after endoscopic sinus surgery than Caucasians. This difference 
according to ethnicity must be proven because it could be 
confused by other socio-economic factors such as access to 
healthcare in this population. This study also shows that the 
prevalence of CRS was lower in the Asian (7%) and Hispanic 
population (8.6%) than in the black population (13.3%) or the 
Caucasian population (prevalence around 13% too). 
However, there is no significant difference regarding the gender. 
This is confirmed by the study of Hirsch et al.(6) in 2017 that 
found that women are more likely to have acute rhinosinusitis 
but that there is no sex ratio for CRS. Hoffmans et al.(7) had the 
same conclusions regarding ethnicity and gender in his study 
including 8,347 adults in the Netherlands in 2017.
Brescia et al.(22) in 2016 examined the difference in CRS preva-
lence between elderly and young people. After endoscopic 
sinus surgery, nasal polyps recurred less often in the elderly, 
maybe because in CRS in the elderly, there is less eosinophilic 
infiltration which is known to increase the risk of recurrence. 
Furthermore, the proportion of patients with allergy was signi-
ficantly higher in young people than in the elderly population, 
but there was no difference in the prevalence of asthma in both 
populations. Cho et al.(23) found the same result in his study, sug-
gesting that when CRS appears in the elderly the pathogenesis 
is different, less linked with allergy and eosinophilic infiltration, 
but more with nasal polyp formation. 
 
5.1.2. Predisposing factors of CRSwNP and CRSsNP
5.1.2.1. Allergy
The relationship between atopy and CRS has been well studied 
and resulted in many reviews. A systematic review was perfor-
med by Wilson in 2014(24). A total of 24 articles were found that 
met the inclusion criteria; 18 articles examined the relations-
hip between allergy and CRSwNP, with 10 articles showing an 
association, seven articles showing no association, and one 
article showing a possible association. Nine articles examined 
the relationship between allergy and CRSsNP, with four articles 
showing an association and five articles showing no association. 
Four studies directly compared the role of allergy in CRSwNP 
and CRSsNP, and, again, the results were mixed. No articles 
examined the outcomes of CRSsNP or CRSwNP following allergy 
treatment. The authors concluded that the role of allergy in 
CRSwNP and CRSsNP continues to be controversial, with the 
level of evidence poor. Based on the available data, the recom-
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respiratory reactions to NSAIDs was higher in participants with 
CRS symptoms and asthma symptoms in last 12 months but 
was not associated with allergic rhinitis(43). In the previously 
mentioned UK analysis(26) the prevalence of self- reported aspirin 
sensitivity was 2.3 in the control group, 3.3 in CRSsNP patients, 
9.6 in CRSwNP patients and 40% in the AFRS group. In this same 
study the AFRS and CRSwNPs group and to a lesser extent also 
the CRSsNP group were significantly more likely than controls 
to report symptom exacerbation due to ingestion of food 
groups with higher potential dietary salicylate content(44). The 
prevalence of N-ERD among patients with CRSwNP in a tertiary 
referral centre was 16%(45). Patients with aspirin-exacerbated 
respiratory disease (AERD) had undergone two-fold more sinus 
surgeries (p<.001) and were significantly younger at the time 
of their first surgery than were patients with CRSwNP without 
N-ERD. 
Upper airway disease in N-ERD patients is usually CRSwNP. On 
average, upper respiratory symptoms are worse, extent of opaci-
fication on CT scan and recurrence of nasal polyps after surgery 
are more frequent in N-ERD than in NSAIDs-tolerant CRSwNP 
patients(39, 45).
Diagnosis is mainly based on patient history and aspirin provo-
cation tests are only needed when the history is not clear (see 
also 5.3.4.14). 
5.1.2.4. Immune deficiencies
There is good evidence that immune deficiencies are more com-
mon in patients with CRS. A meta-analysis, which included 1418 
individuals with CRS from 13 studies, found that 23% of patients 
with difficult- to-treat CRS and 13% of individuals with recurrent 
CRS had immunoglobulin deficiencies(46). A recent study shows 
that the prevalence of immune deficiencies could be up to 50% 
in “difficult to treat” cases of CRS and that immunological tests 
should be undertaken in these cases(47). Other authors suggest 
integrating systematically immunological tests when exploring 
a diagnosis of CRS, particularly when it does not respond to 
standard treatment or have an impact on morbidity or quality 
of life(48). 
The most frequent immune deficiency found in these cases is 
Common Variable ImmunoDeficiency (CVID) (10 % cases) and 
Selective immunoglobulin A (IgA) deficiency (6% cases)(49). 
Selective IgA deficiency is the most common immunodeficiency 
with a prevalence of one in 600 individuals, but usually people 
are asymptomatic(47). However, many of the patients diagnosed 
in the series included in the meta-analysis had subclass or spe-
cific antibody deficiency. The laboratory criteria for diagnosing 
these conditions, and the clinical implications once the diagno-
ses are made, are not uniformly accepted. Many of the studies of 
the meta-analysis were performed in tertiary referral centres and 
this may have biased the population of patients studied toward 
having underlying immune defects. These reservations aside, it 
more nasal symptoms than patients that have CRS without 
asthma(33). In asthmatic CRS patients, a sizeable portion of CRS 
impact on QOL is indirectly mediated through the effect of 
CRS on poorer asthma control which may then drive decreased 
QOL(34).
Several authors reported on the higher incidence of CRS in 
chronic obstructive pulmonary disease (COPD) patients(35). The 
figures depend mostly on the definition of CRS applied in a 
study. Upper airway symptom frequency among COPD patients 
may be as high as 88%(33) but when more objective tests were 
applied for CRS diagnosis (such as CT scans), lower numbers 
were reported (53%). CRS symptoms significantly impair COPD 
patients’ quality of life. Smoking should be considered an impor-
tant risk factor of CRS(35). 
Within the GA2LEN network a multicentre cross-sectional case-
control study recruited 935 adults (869 eligible for analysis: 
237 CRSsNP; 445 CRSwNP; 187 controls). Comorbidities such 
as asthma, allergy, eczema, food allergy, urticaria, and chronic 
obstructive pulmonary disease were significantly more frequent 
in CRS patients(36). Another chronic pulmonary disease has been 
studied thanks to a National database analysis in Taiwan(37). They 
followed 68,058 patients and found 569 patients that developed 
CRS during the five years of follow-up. After adjustment COPD 
was an independent predictor of CRS without nasal polyps. 
Bronchiectasis is a chronic bronchial disease with permanent 
and irreversible destruction and dilatation of the bronchial wall, 
leading to retained secretions and recurrent infections. More 
than 50% of bronchiectasis are idiopathic but as it is a respira-
tory tract disease, some researchers studied the link between it 
and CRS. Guilemany et al.(38) found that 77% of bronchiectasis 
patients have CRS and 26% of them have nasal polyps; in both 
idiopathic and post-infective bronchiectasis. Some authors 
suggest that in bronchiectasis there is an impairment of ciliary 
function such as in Kartagener’s syndrome, explaining these 
results and the sinonasal symptomatology. 
5.1.2.3. Non-steroidal anti-inflammatory drug (NSAID)-exa-
cerbated respiratory disease (N-ERD)
Non-steroidal anti-inflammatory drug (NSAID)-exacerbated 
respiratory disease (N-ERD) is a chronic eosinophilic, inflam-
matory disorder of the respiratory tract occurring in patients 
with asthma and/or CRS with nasal polyps (CRSwNP), symptoms 
which are exacerbated by NSAIDs, including aspirin(39). 
The pathogenesis of N-ERD is related to dysregulation of eicosa-
noid synthesis(40) leading to an eosinophilic inflammation of the 
nasal and sinus membranes and an increased leukotriene pro-
duction that is further accentuated by cyclooxygenase (COX)-1 
inhibitor (aspirin or NSAIDs)(41). 
Respiratory symptoms following NSAID intake have been 
reported by 1.8% of the general European population and 
by 10% - 20% of patients with asthma(42). The prevalence of 
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is likely that the prevalence of hypogammaglobulinemia in CRS 
patients is significantly higher than in the general population.
5.1.2.5. Gastro-oesophageal reflux disease (GORD)
 Gastro-oesophageal reflux disease (GORD) is a common 
gastrointestinal disorder that affects approximately 10% of 
western populations and has been hypothesized to be one 
of the possible factors that induces CRS and contributes to its 
worsening. However, the relationship between GORD and CRS 
remains indeterminate due to its complexity, and it is not clear 
that an anti-reflux treatment would be indicated for patients 
with recurrent CRS. A recent meta-analysis(50) in 2016 gathered 
32 publications that assessed the prevalence or incidence of CRS 
in a GORD population or vice-versa. 
In a recent systematic review, Leason et al. included studies 
(n=32) that consisted of studies reporting pathogenic factors 
(n=20), epidemiological association (n=8), prognostic interac-
tions (n=3), and a combination of these outcomes (n=1). They 
concluded that the potential pathogenic roles for GORD in CRS 
were supported; CRS subjects had greater prevalence of intrana-
sal Helicobacter pylori and acid reflux than subjects without CRS. 
A more recent study also showed that CRS patients had signifi-
cantly higher incidences of gastro-oesophageal reflux measured 
with 24-h multichannel intraluminal impedance (MII)-pH mo-
nitoring compared with asymptomatic controls(51). CRS is more 
prevalent in GORD sufferers than those without GORD. Evidence 
is conflicting for GORD as a factor in CRS treatment failure. 
A second systematic review included 12 papers and found 
eight cross-sectional articles that suggested a relation between 
CRS and GORD, especially in CRS that is refractory to clinical or 
surgical treatment(52). However, the authors concluded that the 
groups are small and methodologies different. 
The association between GORD and CRS seems to be two-way 
and Leason et al. suggest that direct nasopharyngeal reflux 
leads to gastric acid and pepsin reflux directly in the nasal cavity, 
mostly in a lying position, inducing nasal inflammation that 
worsens CRS. Another hypothesis is the intranasal presence of 
H. pylori, a bacteria which has in fact been found in the nasal 
cavity(53); and as it is known for its aggression and its role in the 
pathogenicity of gastric ulcers, gastritis and gastric cancers, it 
is reasonable to suggest the same pathogenicity in the nasal 
cavity. Furthermore, as nasal pepsin, gastric acid and local 
eosinophilic infiltration are more prevalent in the nasal cavity 
in GORD patients(54) with CRS, the induced nasal inflammation 
is more important and explains the results of studies(55) finding 
that patients with GORD and CRS had more symptomatic CRS 
[higher Sino-Nasal Outcome Test (SNOT)-22 score, more CRS 
medication, more endoscopic sinus surgery] than patients with 
CRS without GORD. 
Another hypothesis is that corticosteroids and antibiotics given 
in CRS medication could induce or worsen GORD, mostly in 
recurrent and aggressive CRS. This suggests that there could be 
a benefit of giving an anti-reflux treatment to a patient with CRS 
even if he has no symptoms of GORD. However, it has not yet 
been shown that reducing gastroesophageal reflux symptoms 
correlates with a reduction of CRS symptoms (see also 6.1.23.1).
 
5.1.2.6. Nasal anatomic variations 
Anatomic variants have been studied because the obstruction 
of the ostiomeatal complex has been suggested as a risk factor 
for developing CRS(33). A systematic review analyzing the role of 
septal deviations in CRS demonstrated a significant association 
of septal deviation and rhinosinusitis. However, the clinical ef-
fect was modest and interestingly in all studies that examined 
the laterality of rhinosinusitis associated with septal deviation, 
inflammation was found bilaterally(56). A recent study(57) analyzed 
CT and nasal endoscopies in patients with CRS and found that 
88.2% of patients had a deviated nasal septum and 76.4% had 
concha bullosa. However, these numbers were close to those 
found in retrospective trials in the general population and are 
not significant.
Sedaghat et al.(58) studied CT scans of patients with CRS and 
found that sinonasal anatomic variants such as infra-orbital cells 
and frontal inter-sinus cells are related to faster progression of 
CRS, but this prevalence has not been compared to a population 
without CRS. Although patients with CRS do not necessarily 
have higher rates of specific anatomic variations, it appears that 
they can affect the progression of the disease. 
 
5.1.2.7. Microbiology
5.1.2.7.1. Bacteria and biofilms
The pathophysiology of CRS is multifactorial but mostly consi-
dered an inflammatory disease of the upper airways analogous 
to asthma in the lower airways. It is a multifactorial condition 
in which the microbiota may play a pathogenic role. Because 
the nose is not sterile, a culture of the sinus obtained via the 
nose will always grow microbes, and causality in CRS is not 
established by a positive culture. Trying to determine the role 
of infection based on a response to antibiotic treatment is also 
difficult. CRS in general also does not have a favorable reaction 
to treatment with either short term or long term antibiotics (see 
6.1.). Studies of the microbiology of CRS have demonstrated 
a variety of bacteria depending on geographic location, prior 
surgery, and recent antibiotic use. Staphylococcus aureus (SA) is 
a frequent colonizer in humans, and it is considered to be asso-
ciated with chronic airway diseases including CRS and asthma. 
In studies of general populations, nasal SA colonization had 
significant relationships with asthma prevalence. In studies of 
patients with CRS, positive associations were also found but had 
a considerable heterogeneity and the results were comparable 
between CRS with and without nasal polyps(59). Recent improve-
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supports the role of the transient viral infection as the initial 
inflammatory stimulus in the pathogenesis of acute exacerbati-
ons in CRS. 
5.1.2.7.3. Fungal infection 
Chronic fungal rhinosinusitis may represent a wide spectrum 
of disease ranging from the mild form of superficial coloniza-
tion (saprophytic fungal infestation and fungal ball), allergic 
manifestations (AFRS) to chronic granulomatous invasive fungal 
rhinosinusitis (see 8.6). 
5.1.2.8. Ciliary impairment
Motile ciliary disorders have been extensively investigated in 
primary ciliary dyskinesia (pcd), a rare and under-recognized 
genetic disease characterized by impaired mucociliary clea-
rance (see 9.5). Defective mucociliary clearance, evidenced by 
impaired ultrastructure and/or function of respiratory cilia, have 
also been implicated in CRS.
In healthy individuals, mucociliary clearance (MCC) is part of the 
innate defense mechanism and functions to protect the airways 
by trapping inhaled ambient pathogens within the mucus 
layer of epithelial surfaces and propelling it out of the airways 
through coordinated cilia movement. Normal functioning of 
MCC consists of two equally important components: mucus 
production and mucus transport. When MCC is compromised, 
airways become vulnerable to a vicious cycle of infection and 
obstruction. Extrinsic factors such as pollutants and microbes 
can directly and indirectly impact normal cilia function. This 
phenomenon is evident in patients with CRS who experience 
relentless cycles of infection and inflammation, resulting in 
ciliary loss and a hyperviscous mucus blanket generating dys-
functional mucociliary coupling. In addition to direct ciliary loss, 
cilia surviving the microbial and/or inflammatory insults appear 
not to function normally(68). Although the literature is conflicting 
regarding ciliary impairment and its changes in patients with 
CRS, recent work has suggested that a subset of patients with 
CRS have a blunted ciliary response to environmental stimuli 
that is reversible once the tissue is removed from the infected or 
inflamed sinonasal environment. This finding suggests that local 
exogenous factors can negatively modulate the ciliary dynamic 
response to stimuli.
Multiple environmental and exogenous factors alter the normal 
physiological state, and the resultant inflammatory cytokines 
secondarily exacerbate the impaired mucociliary clearance(69).
5.1.2.9. Smoking
Smoking should be considered an important risk factor of 
CRS(35). The GA2LEN survey showed that current smoking and 
ex-smoking are significantly associated with CRS(70). Tobacco is 
toxic to the nasal mucosa and cigarette smoking plays a signifi-
cant role in diseases of the upper airway because pollutants and 
ments in the microbiological techniques have greatly advanced 
our understanding of the complex nature of this interaction. 
The nature of the interaction between the microbiota and the 
local immune system is very complex and has not been fully 
elucidated. The role played by microbiomes in CRS is difficult to 
be clearly defined at the current time due to the difficulties in 
the laboratory techniques and small studies with limited sample 
size. It is likely that bacterial and fungal airway microbiomes are 
dynamic and experience natural shifts in diversity with time. 
The underlying reasons for these shifts appear to be a combi-
nation of changes in environmental climate and host factors. A 
small core community that persisted throughout the two year 
sampling period was identified: Corynebacterium, Propionibac-
terium and Staphylococcus, and one type of fungus, Malassezia 
restricta(60). 
The presence of biofilms in CRS patients was first demonstrated 
in 2004 via scanning electron microscopy of the nasal mucosa of 
CRS patients(61). A biofilm comprises any syntrophic consortium 
of microorganisms in which cells stick to each other and often 
also to a surface. These adherent cells become embedded with-
in a slimy extracellular matrix that is composed of extracellular 
polymeric substances. Because they have three-dimensional 
structure and represent a community lifestyle for microorga-
nisms, they have been metaphorically described as cities for 
microbes. Microbes form a biofilm in response to various dif-
ferent factors which may include cellular recognition of specific 
or non-specific attachment sites on a surface, nutritional cues, or 
in some cases, by exposure of planktonic cells to sub-inhibitory 
concentrations of antibiotics. A cell that switches to the biofilm 
mode of growth undergoes a phenotypic shift in behaviour 
in which large suites of genes are differentially regulated(62). 
Since the advent of biofilm detection in CRS, multiple bacterial 
organisms have been implicated including Staphylococus aureus, 
Pseudomonas aeruginosa, Haemophilus influenza and Moraxella 
catarrhalis. Of these, SA biofilms have the greatest association 
with severely recurrent and recalcitrant cases of CRS possibly be-
cause of their potential to produce antigens(63). Estimated rates 
of biofilm formation in patients with CRS range from 29 to 72%. 
CRS patients with biofilm have more severe disease preope-
ratively and persistence of postoperative symptoms, ongoing 
mucosal inflammation, and infections(64, 65).
5.1.2.7.2. Virus
The role of viral infections in inducing or exacerbating CRS has 
been studied and coronavirus was identified via molecular 
sequencing as the most common virus in patients with CRS(66). 
Parainfluenza virus has been identified as a major cause of post-
infectious olfactory dysfunction and could have a potential role 
in the pathogenesis of CRS(67). Acute exacerbations of CRS have 
been increasingly recognized as an important disease entity 
with a significant impact on the quality of life. Current evidence 
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toxins in cigarette smoke are pro-inflammatory and create oxi-
dative stress of the mucosa, leading to symptoms such as nasal 
obstruction, increased nasal secretion and mucosal dryness. 
Recent systematic reviews found a strong correlation between 
active and passive cigarette smoke with the prevalence of CRS. 
Paediatric patients exposed to secondhand smoke appear to 
have particularly poor outcomes(71, 72).
5.1.2.10. Pollution
The consequences of the World Trade Centre attack have clearly 
shown the relation between pollution and CRS. The enormous 
dust exposure of the firefighters resulted in a significant increase 
in prevalence of CRS that was correlated to the amount of inha-
lation and did not diminish by time since exposure(73). Recently 
air pollutants were shown to correlate with CRS symptom 
severity that may be influenced by exposure levels, with a more 
pronounced impact on CRSsNP patients(74). Geramas et al.(75) also 
concluded in their 2018 review that living in poor, crowded or 
old housing is associated with increased prevalence of CRS.
Until quite recently, the current state of the literature allowed 
us to make very few conclusions about the role of hazardous 
occupational risk in CRS(76). However, some recent studies show 
associations between occupational exposure to paper dust, 
cleaning agents, metal dust, animals, moisture/mould/mildew, 
poisonous gas and physically strenuous work(77-79). A recent 
Portuguese study(79) found an important correlation between 
occupational dust exposure and nasal polyps’ occurrence in 
textile workers and Mady et al.(74) suggest that exposure to air 
pollutants correlates with CRS symptom severity in CRSsNP. 
5.1.2.11. Obstructive sleep apnoea (OSA) 
Patients with undiagnosed obstructive sleep apnoea (OSA) 
often present to an otorhinolaryngologist with symptoms of 
CRS. In a retrospective analysis of adult patients at an academic 
practice with a rhinologic chief complaint, the authors showed 
that OSA and CRS have significant overlap in symptom profiles 
and that the SNOT-22 can help identify those with undiagnosed 
OSA. OSA should be suspected in patients who report a sleep-
related item as a most important symptom and display higher 
psychological and sleep domain scores(80). 
A retrospective study found that obstructive sleep apnoea(81) is 
an independent factor of risk for developing CRS [hazard ratio 
(HR) of 3.44 for males and 2.63 for females]. 
In a Taiwanese study evaluating patients who underwent FESS, 
38% complained of daytime sleepiness, and this sleep problem 
was correlated with the symptom of nasal obstruction. Obstruc-
tive sleep apnoea syndrome (OSAS) was diagnosed in 64.7% of 
the patients, but there was no correlation with the severity of 
rhinosinusitis. Nasal polyps did not worsen sleep problems in 
the CRS patients(82).
The exact relationship between these two overlapping diseases 
is not clear and further larger prospective studies are needed. 
5.1.2.12. Metabolic syndrome and obesity
Using the Korean National Health and Nutrition Examination 
Survey (KNHANES), Lee et al.(83) analyzed 12,015 individuals and 
found that the prevalence of CRS in patients with metabolic 
syndrome (high triglyceride level, reduced high-density lipopro-
tein level and elevated blood pressure) was significantly higher 
than in patients without metabolic syndrome (14.15 vs. 10.16%; 
p<0.05). This database was also used to show that obesity(84) is 
an independent factor in developing CRS (OR,1.46; 95%CI, 1.16-
1.84; p=0.001). The hypothesis is that there is a pro-inflamma-
tory condition secondary to excessive adipose tissue favouring 
the development of inflammatory diseases such as CRS. This 
association needs further study. 
 
5.1.2.13. Vitamin D (VD3)
There now is substantial literature to indicate that VD3 acts as 
an immunomodulator of adaptive and innate immunity locally 
within the respiratory epithelium. 
Stokes et al. included seven articles (four prospective and three 
retrospective studies), with a total of 539 patients in a systematic 
review. There were significantly lower VD3 levels in the polypoid 
phenotypes of CRS compared with controls. Low VD3 levels 
were often associated with an increased degree of inflammati-
on(85). The authors conclude that the available evidence indicate 
that there is a significant relationship between low VD3 levels 
and polypoid CRS phenotypes. The association between VD3 
levels and disease severity and VD3 potential for drug therapy 
remains unclear, which warrants further research in the area.
5.1.2.14. Alcohol
An important percentage of subjects diagnosed with chronic 
upper airway disease report alcohol-induced worsening of their 
symptoms. 
The highest prevalence of nasal and bronchial alcohol hyper-
responsiveness is observed in patients with N-ERD, followed by 
patients with CRSwNP, and less frequent in CRSsNP, and healthy 
controls. Alcohol hyper-responsiveness is significantly more 
prevalent in CRSwNP patients suffering from recurrent disease 
and in patients with severe symptomatology(86).
5.1.3. Acute exacerbations of CRS (AECRS)
5.1.3.1. Epidemiology and predisposing factors
5.1.3.1.1. Epidemiology
Acute exacerbation of chronic rhinosinusitis (AECRS) is defined 
as worsening of symptom intensity with return to baseline CRS 
symptom intensity, often after intervention with corticosteroids 
and or antibiotics. Exacerbation of nose and sinus symptoms, 
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nasal polyps, which was negatively associated with the risk of 
exacerbation(90).
5.1.3.2. Pathophysiology
5.1.3.2.1. Viruses
Over 160 serotypes of rhinoviruses have been identified and 
are considered important contributors or triggers of airway 
inflammation both in the upper and lower airway. It is believed 
that the rhinovirus initiates primary epithelial damage which 
is followed by secondary damage by the host anti-viral inflam-
matory response. This should ideally be timely and self-limiting, 
avoiding permanent inflammatory change in the sinonasal 
mucosa(91). The inflammatory response starts with activation of 
Toll like receptors (TLR 3,7 and 9) to initiate a cellular response, 
which induce the expression of interferons and cytokines, which 
in turn leads to recruitment of innate responders such as macro-
phages and neutrophils. More recently evidence has emerged 
that eosinophils are involved in anti-viral activities and are 
recruited to the site of rhinovirus infections explaining among 
other things asthma exacerbations seen during viral respiratory 
tract infections(92).
A recent comprehensive review found 147 publications studying 
the effect of rhinoviruses in CRS patients and concluded that; 1) 
rhinovirus infections have a higher prevalence in CRS patients 
than in the general population, 2) humans challenged in vivo 
with rhinoviruses will elicit a local inflammatory response evi-
dent by elevated cytokines (IL-6, IL-8) in nasal lavage and muco-
sal changes on MRI, and 3) in vitro challenge of nasal epithelial 
cells will produce a robust cytokine response mimicking the one 
found in vivo supporting the causality(93).
Rhinoviruses may also disturb the balance of the residential 
microbiome. A study where healthy participants were inocula-
ted with rhinoviruses revealed a shift in the resident microbiome 
where the abundance of Haemophilus parainfluenzae, Neisseria 
subflavia and Staphylococcus aureus increased. This change in 
the microbiota could help explain why virus infections predispo-
ses to secondary bacterial infections(94).
To sum up, virus infections are likely to be the main trigger for 
acute CRS exacerbations, where host response initiates or accen-
tuates an inflammatory reaction in the nose and sinus mucosa, 
including eosinophils, and has a potential to shift the residen-
tial microbiome towards an increased abundance of microbial 
airway pathogens.
5.1.3.2.2. Bacteria
The microbiology of exacerbations of CRS has been studied by 
Brook using traditional culture. He found that in the majority of 
cases the bacterial flora was similar to the one found in stable 
CRS patients, although Haemophilus influenzae was significantly 
more prevalent in the exacerbation group (9 positive cultures 
often considered as a bacterial infection, may in reality have a 
more complex background and depend on multiple factors. It 
could be due to a worsening of allergic rhinitis, an acute viral 
respiratory infection, exacerbation of asthma or other stress 
factors including depression. 
Nasal symptoms are common in the general population and 
without prior sinus CT it is difficult to precisely ascertain if an 
exacerbation of nasal symptoms was on a background of CRS. 
Large scale epidemiologic studies have, therefore, previously 
not been available. A recent epidemiologic study has tried to 
overcome this by studying acute exacerbation of nasal and 
sinus symptoms from a general population of 200 769 subjects, 
7847 were selected and mailed questions on nose and sinus 
symptoms according to EPOS2012 every four months over 16 
months. Subjects were classified into; current long-term CRS, 
current recent, past or never CRS. Prescription of oral antibiotics 
and or orals steroids were considered as a proper event of exa-
cerbation. Prevalence peaked in the winter months and peaked 
among long-term current CRS subjects, where 25.9% of patients 
had at least one exacerbation in the last 12 months compared to 
7.9% in the never CRS group(87).
Another study has followed 209 CRS patient from a tertiary 
care rhinology clinic monitoring the number of CRS infections, 
CRS-related antibiotic prescription and CRS-related oral corti-
costeroids taken. Ninety patients reported zero exacerbations, 
whereas 119 patients had three or more episodes during the 
prior 12 months(88).
In 108 asthmatic patients with CRS (69.9% with CRSwNP) the 
mean number of exacerbations of CRS was in the past 3 months 
0.8 episodes, it is unclear if this refer to a specific season, but 
if extrapolated it would suggest 2.4 episodes per year in this 
particular group of patients(89). The same study showed that 
frequency of acute exacerbation of CRS have a negative impact 
on asthma control.
A study on the effect of quality of life from acute exacerbations 
of CRS found that in 85 patients with a mean SNOT score of 36.8 
the patients had taken a mean of 1.5, SD=1.9 courses of antibio-
tics related to CRS in the past 12 months(90).
Thus, the prevalence varies with the patient cohort being stu-
died, season, and how the exacerbation was defined.
5.1.3.1.2. Predisposing factors
According to the previously mentioned epidemiologic study 
an increased prevalence of AECRS is more likely to be seen; in 
younger white, female, on medical assistance or having greater 
Charlson comorbidity index. Other risk factors identified in 
this study were CRS status, increased BMI, asthma, hay fever, 
migraine and history of sinus surgery(87).
The study by Phillips et al. identified an exacerbation prone phe-
notype associated with high sinonasal burden (SNOT score over 
24) and comorbid asthma and interestingly patients without 
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of 30 patients with exacerbation, compared to 2 of 32 in stable 
CRS)(95).
A more recent study using 16S ribosomal RNA for bacteria revie-
wed the sinus microbiotia during acute exacerbation of CRS in 
134 patients (65 CRSsNP, 55 CRSwNP and 14 AFRS). Of the bac-
teria identified, those with the highest relative abundance were 
Staphylococcus spp (21.3%), Pseudomonas (15.0%), Streptococcus 
(14.4%), and Staphylococcus aureus (12.4%). No consistent dif-
ferences among subgroups were noted and all various bacterial 
taxa and species were present in all clinical subgroups(96).
In 50 patients with a history of previous sinus surgery with acute 
exacerbation of CRS, most were found to have Staphylococcus 
aureus and S. epidermidis with six patients positive for Hae-
mophilus influenzae and 5 for Pseudomonas aeruginosa(97). This 
once again demonstrates that common airway pathogens only 
explain a small number of clinical exacerbations.
In summary, virus infections are likely to be the main trig-
ger for AECRS, where host response initiates or accentuates 
a symptomatic inflammatory reaction in the nose and sinus 
mucosa. Furthermore, rhinoviruses have the potential to shift 
the residential microbiome towards an increased abundance of 
microbial pathogens. Significant microbiological changes are, 
however, only identified in a small number of exacerbations sug-
gesting other mechanisms may be responsible.
Virus infections are likely to be the main trigger for AECRS and 
rhinoviruses have the potential to shift the residential microbio-
me towards an increased abundance of microbial pathogens.
5.2. Pathophysiology of chronic rhinosinusitis 
with and without nasal polyposis
5.2.1. Genetics and epigenetics of CRS
5.2.1.1. Genetics of CRS 
The study of DNA via the Human Genome Project in the late 
1990s was supposed to revolutionise medicine genes, allowing 
new understandings of implicated mechanisms and identifying 
new drug targets, with future treatments based on personalised 
genetic makeup(98). However, despite the considerable advances 
in technology and radical cost reductions of genotyping, early 
experience with use of association genetics was disappointing. 
Monogenic gene disorders, where transmission of variation(s) in 
the makeup of a single gene produce disease via well-described 
mechanisms (such as the Cystic Fibrosis Transmembrane Con-
ductance Regulator (CFTR) gene responsible for cystic fibrosis), 
were almost never found. Instead, for complex traits (such as 
height, intelligence, creativity), and traits for complex diseases 
(such as schizophrenia, diabetes and asthma) were found to be 
associated with a dizzying number of variations in wide variety 
of genes, all offering minor contributions to the observed phe-
notype(99). Indeed, for schizophrenia, a well described disease 
entity with distinctive symptoms, was found to be associated 
with variations in almost one hundred different genes(100). 
Compounding this difficulty was the genes identified are often 
at first glance difficult to integrate into mechanistic models – for 
example, one of the main associations in schizophrenia was with 
a gene coding for C4, an element of the complement casca-
de(101). Additionally, identified genetic factors may not so much 
modify the structure of an organ or a cellular organelle, but may 
instead increase susceptibility to an environmental influence, 
such as infection or colonisation with undesirable bacteria(102). It 
may then be the bacterial presence that contributes to persis-
tence or maintenance of disease. While this complicates the 
direct transposition of genetic results to the clinic, the field 
of genomics is again progressing, and mathematical approa-
ches being developed to make predictions based on multiple 
variations, rather than relying on a single one. A glimpse into the 
future is afforded by a recent commercial venture which analy-
ses combinations of SNPSs from the DNA of fertilised embryos 
to predict the fittest ones for implantation in vitro fertilisation 
(https://genomicprediction.com). This nevertheless may be of 
limited usefulness, as a simulation exercise using real GWAS data 
from large families showed that simulated embryos selected to 
be the smartest and tallest were only around 2.5 IQ points and 
2.5 centimetres above average. Screening human embryos for 
polygenic traits has limited utility(103).
CRS is nevertheless benefitting from the ‘genetics revolution’. For 
example, in studies from the group of Desrosiers identification 
of candidate genes associated with epithelial and basement 
membrane structure and function led to exploration of barrier 
function in epithelial cells from CRS patients. This culminated 
in the recent identification of a defect in tissue repair in CRS(104), 
opening up the possibility of new drug treatments, confirming 
that there is value in the genetics arena. Other insights still wai-
ting to bear fruit may become clearer as we better understand 
the role and functions of identified putative candidate genes. 
5.2.1.2. Genetics: an overview
The term ‘genetics’ encompasses transmissible gene variations 
causing or predisposing to development of disease or pheno-
type in question. Transmissible variations in gene function may 
also be induced by exposure to outside agents in a process ter-
med epigenetic regulation, or epigenetics. In a newer challenge, 
previously ignored short sequences of the genome called ‘mi-
croRNAs’ have been found to play important roles in regulation 
of gene function, and transmission of de-novo genetic material 
via bacterial viruses termed ‘bacteriophages’ may also modulate 
genetic makeup. 
The identification of a genetic basis to a disease may be dif-
ficult. Sinus physiology is a complex system, with multiple steps 
involved in even a single process such as pathogen recognition 
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comparisons between two or more groups, usually separated 
according to the element under study. Markers of genetic 
variation (‘microsatellites’ or single nucleotide polymorphisms 
(SNP)), single genes or multiple genes of a pathway are compa-
red to identify differences in frequency of identified traits. The 
modern era was ushered in by the introduction of ‘chips’ which 
allowed the simultaneous analysis of 100,000+ SNPs simulta-
neously, interrogating the entire genome in a hypothesis-free 
fashion (Genome wide association study (GWAS)). More recently, 
whole-genome sequencing has been used, however, bioin-
formatic analysis of results remains a rate-limiting step. For 
validation, find ings must be validated via replication in a second 
population and/or associated with genotype-specific variation 
in a biologic mechanism or in outcome. For a number of genetic 
findings, biological plausibility may not be evident as the role 
these genes play in normal function may not yet be described. 
One particular problem for CRS is difficulties with statistical 
methods required in genetic association studies; the size of re-
quired populations and the cost of studies. Analysing the typical 
one million different genetic variations simultaneously increases 
the risk of spurious association. Thus large, well-characterised 
populations (1,000-10,000 subjects) are required, with their at-
tendant costs. Caution must be thus be used when interpreting 
the results from CRS genetic studies in the literature. 
5.2.1.3. Implications of genetic association studies of CRS
Despite these challenges, genetic assessments of CRS are sug-
gesting links with exiting concepts of pathophysiology and 
extending the tantalizing promise of future results down the 
road. Published genetic association studies in CRS have incre-
ased in number over the past decade, increasing the number 
of potential gene candidates (Table 5.2.1.), and also repeatedly 
implicating certain genes, supporting their relevance to disease 
(Table 5.2.2.). Increased numbers allowed us to categorise gene 
candidates according to location or function. In both groups, 
candidate genes group loosely into regulation of immune func-
tion, barrier function, and a variety of SNPs in genes whose func-
tions are unknown or difficult to integrate into our current vision 
of CRS pathophysiology. Note that the high percentages of iden-
tified genes related to immune function may reflect a selection 
bias of candidate genes studied rather than their actual level of 
implication. As an example, barrier structure and function genes 
were not suspected in CRS, but were identified with ‘agnostic’ or 
‘hypothesis-free’ genome-wide approaches. Subsequently, dys-
function of the epithelial barrier has been confirmed in in vitro 
models as a novel pathway for CRS development and persisten-
ce. This improves our understanding of the disease process and 
opens potential new targets and approaches for therapy. 
5.2.1.4. Epigenetics in CRS
Epigenetics deals with changes in organisms brought about by 
and initiation of initial defensive responses. Variations in func-
tion of a number of different genes or regulatory elements may 
lead to dysfunction within this system, ultimately yielding the 
same common disease phenotype. In addition, different genetic 
variations within a same gene may produce variable degrees of 
dysfunction. 
The earliest identified genetic disorders were discovered 
because they showed a clear pattern of heritability, with well-
defined disease phenotype or by using markers such as the 
sweat chloride test used in cystic fibrosis (CF). These well-cha-
racterised genetic disorders implicated a single gene with a high 
penetrance and strong effects, which made the search for the 
genetic underpinnings of the disease much simpler. In contrast, 
most chronic disease such as asthma and CRS are considered 
‘complex diseases’ where multiple genes are believed to parti-
cipate in disease development, with each genetic factor having 
weak effects and thereby making only a partial contribution. In 
addition, the genetic basis may not be immediately obvious. For 
example, while it may seem obvious that an immune deficiency 
may predispose to chronic infection with bacteria, a defect 
in a gene involved of the epithelial barrier may lead to poor 
epithelial regeneration following viral insult, thereby facilitating 
bacterial sub-epithelially and thereby yielding the same result. 
Despite the considerable difficulties posed by the multiplicity 
of factors implicated in CRS pathogenesis, strong evidence 
nevertheless supports that there is nonetheless a hereditary 
component to CRS. A classic example is CF, where homozygous 
mutations in the CFTR gene lead to defects in chloride transport 
and yield the clinical manifestations of the disease. CRS, prefe-
rentially affecting the maxillary sinuses, is a consistent feature of 
CF. Other examples of well-characterised genetic diseases which 
include CRS in their phenotype include the forms of ciliary 
dyskinesia which can be coded for by at least 31 different genes 
implicated in coding a different portion of the structural arm of 
the cilia(105). 
More recent work by Oakley et al. assesses the heritability of 
CRSwNP and CRSsNP in a more general population. In a study 
of 1638 patients with CRSwNP and 24,200 CRSsNP patients, 
they identify that first-degree family members of affected 
subjects are 4.1 times more likely to develop CRSwNP and 2.4 
times more likely to develop CRSsNP(106). However, despite the 
demonstration of a heritable component, they still suggest an 
environmental factor as spouses of an affected patient are also 
2.0 times more likely to develop CRSsNP as well. This is comple-
mented by work from Sweden. Relatives of patients with nasal 
polyposis were screened for CRSwNP. 13.4% of the relatives had 
nasal polyps (compared to 2.7% in a control group randomly 
selected from the Swedish population). Thus the relative risk of 
the first-degree relatives having nasal polyps when compared to 
the control group was 4.9(107). 
Techniques used to identify the genetic basis of disease involve 
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modifications in gene expression not resulting directly from al-
teration of DNA sequences(108). This can lead to the modification 
of gene expression which can then be transmitted both intra-
generationally and inter-generationally. “Epigenetics” denote 
the way that genes interact with the environment in order to 
produce each individual phenotype. It is of significant interest 
that factors associated with increased risk of severity of disease 
such as cigarette smoking or Staphylococcus aureus are both 
implicated in epigenetic modification. 
Evidence of epigenetics in vivo is still limited, but nevertheless, 
the concepts suggested by these studies are intriguing and hold 
promise for the future(109-113). Most studies assessing blood or 
nasal epithelia obtained from brushing or raised nasal epithelial 
cultures derived from patients have identified that epigenetic 
changes are more pronounced in epithelium than in circulating 
blood, supporting the importance of contact with the external 
environment for their development. This suggests that patho-
gens might be playing a role in adapting the environment for 
evolutionary advantage, and underlines that genetics co-exist 
with environment, compounding the difficulties in finding a 
‘single-gene’ solution to the problem of CRS.
5.2.1.5. Clinical uses of genetics and genotyping in CRS
5.2.1.5.1. Characterisation of unexplained immune deficien-
cies
Immune deficiencies frequently present as a clinical portrait or 
phenotype, where an immune defect is suspected but which 
may not be specifically elucidated by common blood tests(114). 
However, sequencing suspect genes may identify the nature 
of the defect and allow for specific corrective therapy. A recent 
example of this has been the novel description of TLR3 receptor 
dysfunction first identified by sequencing patients with herpes 
simplex encephalitis(115). 
5.2.1.5.2. Assessment and selection of therapy for cystic 
fibrosis (CF)
CFTR genotyping is not recommended routinely in CRS patients 
but is instead performed only following demonstration of CFTR 
gene function impairment via sweat testing. In patients with 
positive test (high sweat chloride), this will be followed by gene 
testing for a panel of standard mutations then possibly gene 
sequencing. Type of mutation identified does not predict evo-
a. Immune system
Gene Reference
ALOX5AP Al-Shemari et al. 2008(804); Henmyr et al. 2014(805)
AOAH Bossé et al. 2009(806); Zhang et al. 2012(807)
IL1A Karjalainen et al. 2003(846); Erbek et al. 2007(808); Mfuna Endam et al. 2010(809)
IL1B Erbek et al. 2007(808); Bernstein et al. 2009(810)
IL10 Kim et al. 2009(811); Bernstein et al. 2009(810); Zhang 2012(812)
IL22RA1 Endam 2009(813); Henmyr 2014(805)
IL33 Buysschaert 2010(814); Kristjansson 2019(436)
IRAK-4 Tewfik et al. 2009(815); Zhang et al. 2011(816)
NOS1 Castano et al. 2009(817); Zhang et al. 2011(816); Henmyr et al. 2014(805)
NOS1AP Zhang et al. 2011(816); Henmyr et al. 2014(805)
TAS2R38 Adappa et al. 2014(116); Mfuna Endam et al. 2014(111); Purnell et al. 2019(117)
TGFB1 Henmyr et al. 2014(805)
TNFA Erbek et al. 2007(808); Bernstein et al. 2009(810); Batikhan et al. 2010(818)
b. Barrier and structural
Gene Reference
None None
c. Not easily categorised
Gene Reference
DCBLD2 Pasaje et al. 2012(819); Henmyr et al. 2014(805)
PARS2 Bossé et al. 2009(806); Henmyr et al. 2014(805)
RYBP Bossé et al. 2009(806); Zhang et al. 2011(816); Cormier et al. 2014(102) 
Table 5.2.1. List of genes associated with CRS in more than one study. Genes are grouped according to putative biological role: a. immune system 
related; b. epithelial barrier related; c. difficult to categorize.
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5.2.1.5.3. Predictive genetics in CRS
Given the multiplicity of implicated factors, it is unclear that 
genetic polymorphisms alone will allow planning of success 
vs. failure following therapy. However, a number of markers are 
already predicting type of bacteria likely to be recovered, which 
offers a beginning of a classification of CRS patients. 
lution, as the overall clinical picture is believed to be secondary 
to other ‘modifier’ genes. However, certain genotypes may 
predict response to Ivacaflor, a new drug enhancing CFTR gene 
function. 
Table 5.2.2. Genes reported in a single study. Genes are grouped according to putative biological role: a. immune system-related; b. epithelial barrier 
related; c. difficult to categorize.
a. Immune system
Gene Reference
ALOX15 Kristjansson et al. 2019(436)
ALOX5 Al-Shemari et al. 2008(804)
BDKRB2 Cormier et al. 2014(102) 
CD58 Pasaje et al. 2011(819)
CD8A Alromaih et al. 2013(820)
CIITA Bae et al. 2013(821)
CNTN5 Cormier et al. 2014(102) 
COX2 Sitarek et al. 2012(822)
CYSLTR1 (X)* Al-Shemari et al. 2008(804)
FOXP1 Kristjansson et al. 2019(436)
HLA-DQA1 Kristjansson et al. 2019(436)
HLA-DQB1 Schubert et al. 2004(823)
HLA-DRA Bohman et al. 2017(824)
IGFBP7 Cormier et al. 2014(102) 
IL1RL1 Castano et al. 2009(817) 
IL1RN Cheng et al. 2006(825) 
IL18R1 Kristjansson et al. 2019(436)
IL4 Zhang et al. 2012(807)
MET Sitarek et al. 2012(822)
MET1 Castano et al. 2010(826) 
OSF-2 (POSTN) Zielinska-Blizniewska et al. 2012(827)
PDGFD Cormier et al. 2014(102) 
PRKCH Cormier et al. 2014(102) 
RAC1 Cormier et al. 2014(102) 
SERPINA1 Kilty et al. 2010(828)
TAS2R19 Purnell et al. 2019(117)
TNFAIP3 Cormier et al. 2009(829) 
TP73 Tournas et al. 2010(830) 
TSLP Kristjansson et al. 2019(436)
VSIR Bohman et al. 2017(824)
b. Barrier and structural
Gene Reference
BICD2 Bohman et al. 2017(824)
CACNA1I Bossé et al. 2009(806)
CACNA2D1 Cormier et al. 2014(102) 
CACNG6 Lee et al. 2010(831)
CDH23 Cormier et al. 2014(102)
K6IRS2 Cormier et al. 2014(102)
KCNAM1 Purkey et al. 2014(786)
KCNQ5 Purkey et al. 2014(786)
K6IRS4 Cormier et al. 2014(102)
LAMA2 Bossé et al. 2009(806)
LAMB1 Bossé et al. 2009(806)
LF Zielinska-Blizniewska et al. 2012(827)
MMP9 Wang et al. 2010(832)
MSRA Bossé et al. 2009(806)
MUSK Bossé et al. 2009(806)
NARF Cormier et al. 2014(102)
NAV3 Bossé et al. 2009(806)
RPGR Bukowy-Bieryłło et al. 2013(833)
c. Not easily categorised
Gene Reference
C13orf7 Cormier et al. 2014(102)
CYP2S1 Kristjansson et al. 2019(436)
DPP10 Kim et al. 2015(834)
FAM79B Cormier et al. 2014(102)
GFRA1 Cormier et al. 2014(102)
GNB2 Purnell et al. 2019(117)
HLCS Bohman et al. 2017(824)
KIAA1456 Bossé et al. 2009(806)
MYRF Kristjansson et al. 2019(436)
PHF14 Cormier et al. 2014(102)
PIGT Cormier et al. 2014(102)
SLC13A3 Cormier et al. 2014(102)
SLC22A4 Kristjansson et al. 2019(436)
SLC5A1 Bohman et al. 2017(824)
TOMM34 Cormier et al. 2014(102)
TRHDE Cormier et al. 2014(102)
TRIP12 Bossé et al. 2009(806)
UBE3A Cormier et al. 2014(102)
UBE3C Pasaje et al. 2011(819)
10p14 Kristjansson et al. 2019(436)
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5.2.1.5.4. Taste receptors: predicting Gram-negative carri-
age
TAS2R38 polymorphisms have been associated with CRS(116). 
TAS2R38 codes for a type of bitter taste receptor, which is 
expressed in the airway and is implicated in innate immune 
defence. Activation of T2Rs by bitter stimuli are followed by se-
cretion of antimicrobial peptides, production of nitric oxide, and 
increased ciliary beat frequency. The protective genotype codes 
for ability to detect phenylthiocarbamide (PTC), which can be 
assessed by simple taste testing. Interestingly, in CRSsNP, the 
non-tasting (or non-protective) TAS2R38 genotype is associated 
with a higher rate of gram-negative bacterial carriage and a 
poor outcome. To this end, many physicians now profile taste as 
part of patient assessment, however, this does not yet identify 
optimal therapy. Additionally, there is a concern that the effect 
may not be similar in patients with CRSwNP. Also, taste receptors 
may also play role or have predictive value in CRS, notably the 
Table 5.2.3. Genetic polymorphisms associated with S. aureus carriage in 
CRSwNP patients(102).
a. Immune system
Gene
BDKRB2
CNTN5
IGFBP7
PDGFD
PRKCH
RAC1
b. Barrier and structural
Gene
CACNA2D1
CDH23
GFRA1
K6IRS2
K6IRS4
TOMM34
c. Not easily categorised
Gene
C13orf7
FAM79B 
NARF
PHF14
PIGT
RYBP
SLC13A3
TRHDE 
UBE3A
taste receptor TAS2R19 (rs10772420)(111, 117). This remains to be 
validated and replicated in other populations. 
5.2.1.6. Staphyloccus aureus carriage in CRSwNP
Genes associated with culture-positivity for S. aureus in CRSwNP 
patients has been assessed in an agnostic ‘hypothesis-free’ 
fashion using a pooling-based Genome-wide Association study 
(102). Presence of S. aureus in CRSwNP patients is associated with 
a number of genes loosely organised along reduced engulfment 
of bacteria, modulation of inflammatory response, and genes of 
barrier elements (Table 5.2.3.). This supports that CRS patients 
colonised with S. aureus may be subject to immune impairment 
and dysfunction of the epithelial barrier and may thus be exqui-
sitely sensitive to low level chronic bacterial infection with S. au-
reus. Attempts to predict S. aureus carriage in individual patients 
implicates several genes acting together to provide additive 
effects (Figure 5.2.1.). This supports the concept of multiple ge-
nes in a pathway interacting to yield a common final phenotype 
(S. aureus carriage) and aligns well with our current concepts of 
disease pathogenesis. Given the ubiquity of S. aureus in CRS and 
its association with a difficult evolution, having the capacity to 
identify patients at risk of S. aureus carriage prospectively might 
allow selection of patients for specific anti-S. aureus therapy. 
5.2.1.7. Summary and future perspectives
The current knowledge base in genomics of CRS disease of-
fers the tantalizing promise of identifying new mechanisms 
of disease development and of markers predicting optimal 
response to available therapies. However, for the moment, 
genetics do not allow prediction of disease or outcome and its 
uses are currently restricted to extreme cases to understand the 
molecular underpinnings of disease. Nevertheless, simultaneous 
ongoing revolutions in our understanding of CRS and the dis-
section of implicated mechanisms will complement increased 
appreciation of genetic changes. Diagnosis of particular forms of 
disease or identification of particular predisposing factors may 
help predict evolution and better tailor therapy. Identification of 
novel pathogenic mechanism may lead to increased scrutiny of 
genes in unsuspected novel pathways. 
5.2.1.8. Conclusion
It is probable that over the coming years we will identify 
individual or complex genetic traits conferring susceptibility to 
CRS, evolution of disease, and response to medical or surgical 
treatment. Given that in other disease areas, genetic traits have 
already been identified which allow administration of appropri-
ate therapy while minimizing side effects, it is certainly intri-
guing to explore what role genetic variations may play in CRS 
diagnosis and therapy. 
As knowledge regarding and our appreciation of interactions 
of immune system / microbiome / epithelial barrier improves, 
we may be able to develop multi component predictive models 
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standpoint of aetiopathogenesis, the prevailing, as yet unpro-
ven, hypothesis is that these diverse inflammatory mechanisms 
are driven by dysfunctional interactions at the mucosal surface 
between the host and environmental stressors. From the host 
standpoint, genetic and epigenetic variation of the mucosal im-
mune system is believed to play a key role in CRS, but multiple 
genes are likely involved and thus far, very few have been associ-
ated with a large effect-size. The key environmental agents also 
remain largely uncertain, but cigarette smoke, fungi, viruses, 
bacteria, pollutants and allergens have all been implicated. The 
most commonly discussed microbial agent is Staphylococcus 
aureus, but some evidence also implicates dysbiosis of the mi-
crobial community as a whole, rather than a specific dominant 
pathogen. 
Although the host-environment interactions are complex and 
begin very early in life, perhaps in utero, it is important to bear 
in mind that CRS is predominantly an adult onset disorder. This 
suggests that duration, intensity and sequence of exposure, 
including stochastic events such as viral infection, may be key 
components of pathogenesis in an individual CRS patient. In 
that integrate all of the interaction components and allow more 
rational administration of therapy and improved clinical care. 
It will be essential to continue to collect genetic material as a 
component of clinical trials to be able to verify whether iden-
tified factors and factors remaining to be discovered influence 
response to therapy and can be used for pharmacogenomic 
purposes. 
5.2.2. Inflammatory mechanisms of CRS
The inflammatory mechanisms of chronic rhinosinusitis (CRS) 
are the molecular pathways leading to the establishment of the 
mucosal inflammation and tissue remodeling that characterizes 
this broad syndrome. Multiple inflammatory mechanisms are 
operative, interacting dynamically, and resulting in variable pat-
terns of tissue inflammation that roughly correlate with clinical 
phenotype. Recent attempts have been made to subdivide CRS 
into inflammatory endotypes, defined as distinct pathobiolo-
gical mechanisms, that may vary in time and between diffe-
rent sinonasal anatomic sites in individual patients. From the 
Figure 5.2.2. This figure is a proposed model of the Type 1 immune 
response in CRS. ILC1 cells and dendritic cells set the process in motion. 
The Type 1 CRS has not been extensively studied and many of the 
molecular details have not been confirmed at the protein level. The 
degree of barrier damage, conceptually viewed as a form of tissue 
remodeling, is variable. In this figure, neutrophil activity is depicted as 
the primary driver of barrier damage but other factors such as Type 1 
cytokines may play a role. Further study is necessary. Other forms of 
remodeling such as nasal polyposis are less common than seen in Type 
2 CRS and the pathways less certain. Emerging evidence however, sug-
gests that Type 1 polyps are composed of fibrin matrix, similar to Type 2 
polyps.
Figure 5.2.1 Physiologic immune responses across mucosal boundaries 
are tailored to address particular classes of inciting pathogens. Type 
1 responses, depicted on the left, are directed against intracellular 
pathogens, most commonly viruses. The canonical cytokine is IFN-γ. 
Type 2 responses, in the center, are directed against large, extracel-
lular parasites. The canonical cytokines are IL-4, IL-5 and IL-13. Type 3 
responses are directed against extracellular bacteria and fungi and the 
canonical cytokines are IL-17 and IL-22. Each type of response utilizes a 
rapid response mediated by an innate lymphocyte subset (ILC1, 2 and 3 
respectively) that is linked to a corresponding delayed T helper subset 
(Th1, Th2 and Th17 respectively). In CRS, these pathways are typically co-
opted with chronic activation of one or more of these responses in the 
sinonasal tissue.
EPOS 2020
129
conditions of health, the sinonasal mucosa acts as a relative 
barrier, modulating environmental stimulation including com-
mensal organisms with a specific, self-limited response. In cases 
of pathogen penetration, single or combined Type 1, 2 and 3 
immunological response pathways are invoked, generating 
cytokine, chemokine, innate cellular and T helper (Th) respon-
ses designed to eliminate the identified class of pathogen with 
minimal collateral tissue damage (Figure 5.2.1.).
Type 1 canonical cytokines include IFN-gamma (IFN-g) and IL-12 
with the response geared towards addressing viral pathogens 
(Figure 5.2.2.). Canonical Type 2 cytokines are IL-4, IL-5, and 
IL-13, which promote anti-helminth immunity and regulate 
tissue regeneration following injury (Figure 5.2.3.). Type 3 
cytokines include IL-17A and IL-22 with immunologic effects 
directed against extracellular bacteria and fungi (Figure 5.2.4.). 
Each immune response pathway is orchestrated by unique in-
nate lymphoid (ILC) and T helper (Th) subsets that secrete the 
majority of the key cytokines. Importantly, in vivo responses are 
often mixed, with significant plasticity in the ILC and Th subsets 
as well as a self-limited time course. In cases of CRS, mucosal 
Figure 5.2.3. This figure is a proposed model of the Type 2 immune 
response in CRS. ILC2 cells and dendritic cells set the process in motion. 
Type 2 CRS has been been the most extensively studied subset of CRS, 
and many of the molecular details have been confirmed at the protein 
level. The degree of tissue remodeling is greatest in Type 2 CRS, particu-
larly in terms of fibrin mesh formation and barrier damage. These are 
shown in the figure as driven by IL-13 although other factors likely play 
a role as well. Inhibition of t-PA (tissue plasminogen activator) results in 
the deposition of a fibrin mesh that forms the tissue matrix of polyps. 
Fibrin mesh deposition and polyp formation is less common in Type 1 
and Type 3 CRS, but also appears to involve t-PA suppression. Barrier 
damage in Type 2 CRS is often severe, and this may be a key driver of 
treatment failure. Factors driving barrier damage include autoimmunity 
and complement activation as well as a chronically immature state of 
epithelial differentiation driven by IL-13 amongst other factors. (See text 
for more details.)
Figure 5.2.4. This figure is a proposed model of the Type 3 immune 
response in CRS. ILC3 cells and Th17 cells are key, as well as IL-17, IL-22 
and IL-23. Type 3 CRS has not been extensively studied and many of the 
details have not been confirmed at the protein level. The degree of bar-
rier damage, conceptually viewed as a form of tissue remodeling, is vari-
able. In this figure, neutrophil activity is depicted as the primary driver 
of barrier damage but other factors such as Type 3 cytokines may play a 
role. Further study is necessary but the neutrophil response is particu-
larly strong in Type 3 immunity. Fibrin deposition and polyp formation 
occurs, but with less frequency than in Type 2 CRS.
barrier penetration by environmental agents also invokes Type 
1, 2 and 3 pathways; however, in contrast to the specific, self-
limited, pathogen-directed response associated with physio-
logic host defence, the CRS response is chronic and polyclonal, 
directed against an array of thus far poorly characterized targets 
including self-antigens in some severe cases. The resulting tissue 
inflammation is of a mixed pattern and intensity, potentially in-
volving multiple endotypes and exhibiting variability in clinical 
presentation (phenotypes), natural history, comorbidities and 
outcome. 
CRS with Type 2 cytokines is most commonly associated with 
asthma and resistance to current therapies. The tissue inflam-
mation is often associated with remodeling patterns including 
fibrosis, polypoid oedema, fibrin deposition and barrier failure. It 
is unclear if factors associated with barrier failure mediate initial 
barrier penetration, but failure may promote a feed forward pro-
cess whereby the loss of barrier results in greater antigenic sti-
mulation and more inflammation, further damaging the barrier 
and potentially fostering chronicity. Future challenges include a 
better understanding of: 1) the aetiologic factors that drive CRS 
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total and relative microbial abundance of the sinonasal tract and 
the functional activity of microbiota in health and disease. Acute 
viral infection has been implicated in both the initial develop-
ment and subsequent exacerbations of asthma, yet the role of 
viruses in CRS pathogenesis remains unclear. Studies on bacteria 
have revealed the abundance and diversity of bacterial genera 
present in the nose and sinuses, further suggesting alterations 
in association with the presence of CRS. In particular, the pres-
ence of S. aureus has been hypothesized to potentiate certain 
inflammatory mechanisms of CRS. Fungi seem to affect CRS at 
least in some sporadic cases. Allergens and an array of other 
environmental agents also pay a role in CRS. The final part of this 
section will address other environmental factors such as aller-
gens and air pollutants, which have been little studied in CRS.
5.2.2.2.1. Viruses
An RNA virus has RNA as its genetic material. Usually it is single-
stranded RNA (ssRNA) but it may be double-stranded RNA 
(dsRNA). RNA viruses that contribute to respiratory infections 
include rhinovirus, respiratory syncytial virus and influenza. 
RNA viruses have high mutation rates compared to DNA viruses 
because viral RNA polymerases lack the proofreading ability 
of DNA polymerases(118). The common cold is caused by RNA 
viruses and is the most common viral disease. Ex vivo studies 
of mucosal tissue have shown that rhinovirus infection can be 
linked with exacerbations of CRS, including increased bacterial 
adhesion; increased susceptibility to secondary microbial infec-
tion (by bacteria, fungi, or other viruses), reduction of epithelial 
barrier integrity, respiratory exacerbations (as in asthma, CF and 
bronchiectasis subjects); epithelial damage, including necrosis; 
ciliary dysfunction; and impairment of mucociliary clearance 
and mucus overproduction(119, 120). A study group evaluated the 
prevalence of rhinovirus and respiratory syncytial virus by per-
forming PCR to mucus specimens that were collected from 56 
CRSwNP and 23 CRSsNP patients in Iran undergoing ESS(121). The 
prevalence of at least one virus was 33%, which is higher than 
that reported in the literature in healthy adults suffering from 
the common cold (10%)(122). Cadherin-related family member 3 
gene (CDHR3) is a rhinovirus receptor and its rs6967330 risk al-
lele (A) has been shown to be associated with childhood asthma 
with severe exacerbations(123) and adult CRS, suggesting a role 
for aberrant rhinovirus effects in the pathogenesis of both disea-
ses(124). Carlson-Jones showed virus-like particles and bacterial 
populations by performing flow cytometry to five sinus flush 
samples(125). Virus infection activates TLR3 and TLR7-9 signaling 
in human airway epithelium. Tengroth et al. showed defects in 
the TLR9 mediated microbial defence close to anatomical origin 
of polyp, which might explain virus induced polyp growth(126). 
Golebski exposed epithelial cells from CRSwNP patients to vari-
ous TLR-specific triggers and detected a higher TSLP- gene and 
protein expression in polyp compared to control epithelium, 
with a goal towards prevention; 2) the pathophysiologic inflam-
matory mechanisms and relevant endotype biomarkers with a 
goal toward targeted therapy; 3) the molecular mechanisms of 
barrier and tissue remodeling that may play a role in persistence 
and recurrence.
5.2.2.1. Introduction
Chronic rhinosinusitis (CRS) is a clinical syndrome, rather than 
a specific disease, characterized by persistent symptomatic 
inflammation of the nose and paranasal sinus mucosa for more 
than 12 weeks. This definition is purposely broad and says 
nothing about aetiology, pathogenesis, clinical presentation 
or natural history. In a small subset of patients, CRS syndrome 
occurs in association with a known systemic disorder or local 
process. For the vast majority, aetiology is uncertain although 
multiple environmental and host genetic factors have been 
implicated. From the standpoint of pathogenesis, these host 
and environmental factors interact over time to trigger one 
or more mechanistic pathways (endotypes) of chronic tissue 
inflammation that lead to the clinical presentation (phenotype). 
This chapter will review the host and environmental factors 
implicated in this process and the mechanistic pathways that 
ensue. Overall, while this remains an area of active research, 
relative consensus has emerged on three points: 1) CRS is 
typically an antegrade process with the mucosal inflammation 
triggered by a dysfunctional interaction between exogenous 
agents inhaled through the nose and the host immune system; 
2) specific causal factors likely vary in importance in individual 
patients leading to different types or patterns of tissue inflam-
mation (endotypes); 3) the clinical characteristics (phenotypes), 
natural history and response to treatment will depend on 1 and 
2. Since the last EPOS document, much research has been done 
to better characterize both the host immune response and the 
environmental stressors that interact in CRS. A Literature search 
covering January 2012 to May 2019 produced 1202 publicati-
ons in English concerning pathomechanisms of human CRS. 
The most frequently existing search words were “eosinophil” 
in 401/1202 publications, “epithelium” in 370, “bacteria” in 184, 
“type 2” in 180, “IL-25”in 132 and “lymphocyte” in 87 publicati-
ons, respectively. A systematic review of all of these publications 
was undertaken for EPOS 2020. This chapter will update the 
current understanding of CRS aetiology and pathogenesis. The 
environmental factors and host immune elements implicated in 
CRS will be reviewed first. The last section will discuss a current 
concept of aetiopathogenesis and endotypes resulting from 
host-environment interactions.
5.2.2.2. Environmental factors
Microbial agents are generally viewed as the most important 
environmental drivers of CRS. Molecular sequencing techniques 
are evolving in power and are now being applied to study the 
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suggesting that this could reflect contribution of viral infections 
to CRSwNP pathogenesis(127). Rowan et al. performed PCR-
based sequencing on sinus samples of 21 CRS patients and 14 
controls and detected positive screens in four CRSsNP patients, 
one CRSwNP patient and none of the controls(66). Coronavirus 
was the most common virus detected. Liao et al. performed 
PCR of nine common viruses from middle meatal scrapings of 
53 controls and 128 CRS patients who were without common 
cold(128). Overall about 70% of subjects had viral infections and 
there were no significant differences between subject groups by 
virus profiles, nor were there associations of viral infection with 
symptoms, computed tomography or endoscopic scores(128). 
A DNA virus has DNA as its genetic material and replicates using 
a DNA-dependent DNA polymerase. The nucleic acid is usually 
double-stranded DNA (dsDNA) but may also be single-stranded 
DNA (ssDNA), which is usually expanded to double-stranded in 
infected cells. Notable DNA-viruses in the head and neck region 
under normal conditions and during cancer pathogenesis are 
human herpes virus Epstein-Barr virus (EBV), and human papil-
lomavirus (HPV), yet their role in CRS pathogenesis still needs 
more evidence from research. Ioannidis et al. detected with 
quantitative PCR a trend that EBV and Human Herpes Virus-6 
(HHV-6) associated with nasal polyps specimens compared 
to controls(129), whereas Ha et al. did not detect EBV-positive 
lymphoid cells in the nasal mucosa of 420 patients who had 
undergone surgical resection of lesions with various diagnoses 
such as CRS(wNP), AR, papilloma, cyst, or septal deviation(130). 
Wang et al. infected cultured inferior turbinate and nasal polyp 
samples with either Herpes Simplex Virus-1 (HSV1) or S. aureus 
alone or a combination of both(131). Epithelial damage scores 
were significantly higher for HSV1 and S. aureus co-infected ex-
plants compared with control explants or S. aureus only-infected 
explants, and significantly correlated with HSV1-invasion scores, 
thus suggesting that HSV-1 infection facilitates invasion of S. 
aureus(131). Taken together, virus infection might contribute to 
development and exacerbations of CRS, via damaged airway 
barrier, though further studies are needed.
5.2.2.2.2. Bacteria
Bacteria can be classified into five groups according to their 
shapes (such as cocci) or to their metabolism (such as anaero-
bes). This classification has been replaced by an operational 
taxonomic unit (OTU), in which bacteria are grouped by DNA 
sequence similarity of a specific taxonomic marker gene, especi-
ally when analyzing small subunit 16S ribosomal RNA (16S rRNA) 
marker gene sequence datasets(132). 16S rRNA is the component 
of the 30S small and highly conserved subunit of a prokaryotic 
ribosome and thus 16S rRNA -genes are used for quantitation of 
different sinonasal bacteria. Metatranscriptomics is a functional 
technique profiling gene expression of complex microbial com-
munities enhancing our understanding of the complex com-
munity behavior of the microbiome(132). In addition to expres-
sion profiling, the place and timing of sampling are important 
to consider when investigating host-microbial events of CRS 
pathogenesis. Still the greatest challenge remains in identifying 
causality in microbial contribution to natural homeostasis and 
CRS. Acute exacerbations of CRS have been more closely linked 
to specific bacteria, perhaps following a viral infection, but it 
remains unclear whether the presence or abundance of particu-
lar bacteria are a cause or a consequence of CRS development. 
Commensals likely play important roles in immune priming 
and development of healthy sinus mucosa and most microbial 
colonies are benign or even beneficial. The resident microbiota 
imbedded in the respiratory mucus effectively provide the first 
line of defence in that commensal organisms prevent coloniza-
tion or proliferation of pathogens and also likely provide certain 
local metabolites that enhance mucosal health. Bacterial com-
munities vary more between subjects than between sites within 
a subject, although significant regional differences also exist in a 
given individual(133). 
Dysbiosis is a term indicating microbial imbalance and some 
evidence suggests that it is associated with the sinonasal 
microbiome of CRS patients(134-141). Lal et al. performed 16S 
rRNA gene sequencing and showed that microbiome profile of 
CRSsNP subjects exhibited decreased diversity and anaerobic 
enrichment(142). The size of an antrostomy(143), as well as comor-
bid asthma and purulence affect resident bacterial communities 
and may predict surgical outcome(144). Moreover, the sinonasal 
bacterial microbiomes are significantly different between heal-
thy individuals in general(136), and between sinonasal anatomic 
subsites of an individual patient. Some evidence suggests that 
CRS phenotypes are associated with distinct microbiomes(135, 142, 
145) and the microbiomes change, at least transiently, after sinus 
surgery(146). Copeland et al. detected that Escherichia was over-
represented in CRS sinuses, and that sinus samples were supe-
rior to middle meatal samples as they have less intra-patient 
variation(137). Cope et al. performed 16S rRNA gene sequencing 
for intraoperative sinus brushings from 59 CRS patients and 
10 controls, and detected that CRS patients fall into clusters 
based on co-colonization pattern of Streptococcaceae, Pseu-
domonadaceae, Corynebacteriaceae, or Staphylococcaceae(147). 
Each pathogenic microbiota was functionally distinct and was 
associated with distinct host immune responses(147). 
Traditional culture techniques, as opposed to the newer 
molecular techniques, typically reveal only the most rapidly 
growing organisms. Nevertheless, large scale studies have been 
done over the years. Liu et al. performed bacterial culture from 
middle meatal swabs of 165 CRSwNP, 76 CRSsNP and 44 control 
subjects and detected coagulase-negative staphylococci to 
be closely associated with all three subject groups, whereas S. 
aureus, Streptococcus, Haemophilus, Enterobacter and Corynebac-
terium species were associated with CRSwNP(148). The prevalence 
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extracellular matrix of polymeric substances, which makes it 
resistant to environmental stress, host defences and antimicro-
bial treatment(155). Biofilm layers can be detected by staining and 
light microscopy but characterization of bacterial species and 
dynamics of biofilms require advanced optical technology such 
as electron microscopy, confocal laser scanning microscopy, 
fluorescent tagging and in-situ hybridization(156). Pathogens 
such as Haemophilus influenzae, Streptococcus pneumoniae, 
Pseudomonas aeruginosa, Moraxella catarrhalis and S. aureus can 
all form sinonasal biofilms in CRS patients, some of which have 
been associated with a worse prognosis. The bacterial compo-
sition of biofilms vary between the ethmoid bulla and middle 
turbinate(157). An uncontrolled study detected bacteria in 29/30 
postoperative paranasal sinus specimens and 23/62 strains were 
coagulase-negative Staphylococcus epidermidis and 6/62 strains 
were Escherichia coli(155). 58/62 strains were used to assess biofilm 
formation, of which about 30% were moderate to strong biofilm 
producers(155). In a Chinese study 13 out of 19 CRSwNP patients 
and none of the controls had biofilms, which were associated 
with increased mucosal inflammatory signs(158), purulent nasal 
discharge, preoperative Lund-Kennedy scores, serum total IgE, 
and previous ESS(159). An uncontrolled study showed that 39/84 
CRS patients had both ethmoidal osteitis and bacterial biofilms, 
and their extent correlated(160). In a study by Marcinkiewicz et 
al. biofilms were found by scanning electron microcopy in 3/10 
samples from CRSwNP patients undergoing ESS; S. epidermidis 
was the primary isolated bacteria and, biofilm-associated neu-
trophil infiltration was detected with compromised antimicrobi-
al activity(161). Arjomandi et al., visualized sinonasal biofilms in 15 
of 20 patients with CRS confirmed by microbial presence using 
fluorescence in-situ hybridization, and was associated with host 
inflammatory response involving plasma cells and eosinophil 
recruitment(162). Overall, the literature indicates an association 
between the presence of biofilm-forming pathogens and CRS. 
This suggests the hypothesis that biofilms are potentially an im-
portant factor in CRS pathogenesis explaining resistance to con-
ventional therapy. Moreover, the emergence of biofilms due to 
one or more stochastic events could possibly address the ques-
tion of aetiology, serving as a potential initiating event. It should 
be kept in mind however, that the simple presence of biofilms 
does not indicate pathology since the sinonasal tract likely 
exhibits commensal and pathologic biofilms in both health and 
disease. Detection of the relative abundance of commensal and 
pathogenic biofilms would be challenging and any results very 
difficult to interpret. Moreover, biofilms are a survival adaptation 
and the presence of pathogenic biofilms may reflect a response 
to stress (e.g. antibiotics). Lastly, the presence of pathogenic 
biofilms may reflect variation in the host immune response that 
is unrelated to CRS causation. In summary, the role of biofilms in 
the aetiology and pathogenesis of CRS remains unclear.
S. aureus is the microbe most commonly associated with CRS. 
of Gram-negative aerobic and facultative anaerobic bacteria 
was high in the non-eosinophilic CRSwNP subgroup(148). Another 
study performed middle meatal cultures of 136 CRSwNP, 66 CRS-
sNP, and 49 control subjects and revealed that the isolates were 
similar in all three groups, the commonest being coagulase-
negative staphylococcus, Corynebacterium and Staphylococcus 
epidermidis and S. aureus(149). The CRSwNP group presented with 
high relative abundance of Citrobacter and the eosinophilic 
CRSwNP group presented with S. aureus(149). Tabet et al. perfor-
med culture of middle meatal swabs from 337 CRS patients and 
showed that S. aureus (33%), Corynebacterium diphtheria (26%), 
coagulase-negative staphylococci (51%), and Pseudomonas aeru-
ginosa (7%) were the most frequently recovered organisms(150). 
Relative abundance of the Bacteroidetes phylum in CRS has been 
shown to be associated with increased severity of histopatholo-
gical inflammation and the presence of mucosal ulceration(150). 
PCR studies have not detected DNA of Helicobacter pylori in na-
sal polyp tissue(151), nor C. pneumoniae or M. pneumonia in sinus 
aspirates(152) or nasal polyp tissue(153). Hauser et al. showed that 
culture of ethmoid samples from CRS patients identifies only 
about 50% of the taxa compared to 16S rRNA gene sequencing, 
and 12% of isolates detected by culture were not identified by 
16S rRNA gene sequencing, highlighting the need for replica-
tion by several methods(154). 
In summary, traditional culture techniques are still used in the 
setting of acute exacerbations, but their clinical utility and 
pathophysiologic relevance in CRS has greatly diminished in 
recent years. The newer molecular microbiome data has provide 
support for the hypothesis that dysbiosis of the community as a 
whole, as opposed to individual organisms, may trigger mucosal 
inflammation(132). From this perspective, the resident microbiota 
embedded in the respiratory mucus effectively provide the first 
line of defence. Commensal organisms would prevent coloniza-
tion of pathogens and also likely provide certain local meta-
bolites that enhance mucosal health. The results vary greatly,  
however, depending on the number of subjects, sampling me-
thodology, techniques used, depth of sequencing, phenotype 
and prior treatments. As a result, any firm conclusions about 
the precise nature of any dysbiosis remain limited, but these 
newer techniques are only now being applied to large numbers 
of patients using standardized protocols. The largest study to 
date did not indicate any key role for a specific organism but did 
show that the depletion of two genera (Corynebacterium and 
Peptonophilus) was associated with CRS. It is possible that stu-
dies using narrow CRS patient groups may reveal associations 
with characteristic microbiomes or even the presence of specific 
organisms. Nevertheless, this would only be the first step to-
wards validating the microbiome hypothesis as the association 
of a more specific microbial signature with a specific endotype 
or phenotype may not be causative. 
A biofilm consists of bacterial colony embedded within an 
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Using conventional culture techniques, this organism has been 
shown to colonize the nasal cavity of one-third of the general 
population but affects a higher percentage of patients with(163) 
eosinophilic CRS, specifically CRSwNP patients with asthma(59, 
164). This organism also has the capability to reside within nasal 
epithelial cells, the presence of which in CRS appears to confer a 
poor prognosis(102, 151, 152, 165, 166). Some molecular studies support a 
key role for staphylococcus as well, indicating a greater abun-
dance of S. aureus and altered microbial composition in CRS vs. 
controls. The largest molecular study on the sinonasal micro-
biome thus far undertaken however, did not suggest a key role 
for S. aureus in CRS in general. At this point, aggregate evidence 
would suggest that S. aureus is most closely associated with a 
subpopulation of CRS patients, specifically severe CRSwNP and 
asthma patients exhibiting high tissue eosinophilia(160). High 
tissue eosinophilia is typically associated with high levels of 
cytokines IL-4, IL-5 and IL-13, which are also known as Type 2 cy-
tokines(167). (See section 5.2.2.3 for a more complete description 
of Type 1, 2 and 3 inflammation.)
The precise nature of the association between S. aureus and 
Type 2 cytokine signaling is however, unclear. The presence 
of Type 2 inflammation should independently favor S. aureus 
colonization since Type 2 inflammation suppresses aspects 
of the normal immune response directed against S. aureus. In 
addition this organism also has the capacity to secrete supe-
rantigenic toxins that can directly alter the immune response 
of the host, in part, triggering locally produced polyclonal IgE. 
This is supported by a large, multi-institutional European study, 
which revealed the presence of staphylococcal superantigen 
effects in a subpopulation of severe, Type 2 CRSwNP patients(153). 
Polyp samples from Asian CRSwNP patients, which tend to have 
lower expression levels of Type 2 cytokines than Western polyps, 
show little evidence of superantigen effects(168, 169). Viewed 
conservatively, these findings would suggest that superantigens 
accentuate but do not initiate Type 2 inflammation. Challenging 
this perspective are recent papers suggesting that S. aureus 
is a key player actually driving Type 2 inflammation primarily 
via a specific pattern recognition receptor (TLR2) unrelated to, 
and upstream from any superantigen effects(170-172). A recent 
report has demonstrated large amounts of locally expressed 
IgE in some Type 2 polyp patients, targeting common resident 
nasal bacteria including S. aureus, Streptococcus pyogenes and 
Hemophilus influenza(172). While the mechanism is unclear, this 
study indicates that the Type2-skewing detected in CRSwNP is 
not solely directed against antigens derived from S. aureus. 
Taken together, implementation of 16s rRNA gene sequencing 
technology on a small scale has suggested that some degree of 
bacterial dysbiosis may be associated with CRS pathogenesis, 
although it is not yet known whether it is a primary or secon-
dary event. The composition of microbiota varies based on age, 
stochastic events, prior treatment, anatomic subsite and, most 
importantly, individual variation. This necessitates very large, 
well-controlled studies, which, for the most part, have yet to be 
done. While a large proportion of CRS patient heterogeneity 
could be explained by the composition of their sinus bacterial 
microbiota and related host immune response, it is unclear 
if direct manipulation of the microbiome can be an effective 
treatment modality(147). Implementation of hypothesis-free and 
functional (such as meta-transcriptomics) approaches may be 
useful in addressing both causation and therapy. 
5.2.2.2.3. Fungi
Commensal fungi are present over all mucosal surfaces of the 
body, with potentially important roles in CRS. Initial studies 
suggesting that fungi were the key drivers of CRS have not been 
validated, but their presence, nevertheless, almost assuredly im-
pacts mucosal health. Similar to bacteria, fungi are also capable 
of forming biofilms and secreting toxins but the relevance to 
CRS pathogenesis is uncertain. Fungi can be difficult to detect, 
as traditional cultures are not particularly sensitive. Molecular 
techniques (such as 18S rRNA gene sequencing) are now being 
applied however, and the knowledge gained should eventually 
expand our understanding of fungi in both health and CRS. 
Nuclear ribosomal internal transcribed spacer (ITS) region serves 
a universal DNA barcode marker for fungal species(173). Hoggard 
et al. performed middle meatal ITS2 marker amplicon sequen-
cing of 106 CRS and 38 control subjects and data demonstrated 
that there is high abundance of Malassezia spp, and while fungal 
communities vary seasonally, they vary little between subject 
groups(174). 
Zhao et al. estimated fungal biomass by extracting DNA and 
measuring ITS amplicon concentration using fluorometry of 
middle meatal swabs of 63 CRS and 27 control subjects(138). Fungi 
were identified in 14% CRS patients by conventional techniques 
(culture and histology)(138). This fungus-identified group had a 
significantly higher average ITS concentration and a significantly 
lower Shannon's diversity index compared to the other two 
groups(138). The most abundant organism sequenced was Asper-
gillus(138). Cleland et al. performed 18S rRNA gene sequencing 
of middle meatal swabs from 23 CRS and 11 control subjects, 
and detected ubiquitous and rich (a total of 207) fungal genera, 
Malassezia being the most abundant(175). Fungal richness did not 
correlate with QOL and it decreased postoperatively(175). Aurora 
et al. sequenced bacterial 16S and fungal 18S rRNA genes of 
middle meatal lavage samples from 30 CRS and 12 control 
subjects and detected quantitative increase in most bacterial 
and fungal species, and also host secreted IL-4, IL-5, IL-8, and 
IL-13, eosinophils and basophils in CRS relative to controls(176). 
Yet the microbiomes of CRS patients were qualitatively similar 
to the controls(176). Hirotsu et al. performed culture, microscopy 
and PCR on 35 middle meatal nasal polyps and 15 sphenoidal 
mucosal samples of controls(177). No microbiological growth or 
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fungal bodies were observed, whereas 16/35 samples showed 
amplification of fungal DNA (such as C. parapsilosis, R. mucilagi-
nosa and Aspergillus sp), which was associated with enhanced 
tissue eosinophils(177). Mohammadi et al. performed PCR and 
clinical examination of sinonasal samples obtained intraoperati-
vely from various locations from 100 patients with a suspicion of 
noninvasive fungal rhinosinusitis, and showed that the propor-
tion of fungal rhinosinusitis was 27% (such as Aspergillus flavus, 
Penicillium chrysogenum and Candida glabrata species complex), 
of these 41% were housekeepers by way of occupation(178). 
Fungi have the capacity to stimulate significant host responses 
in vitro, suggesting a role in CRS pathogenesis. Using ELISA, 
Sproson et al. studied cytokines in nasal polyp tissue, challenged 
ex vivo by Alternaria alternata, Aspergillus niger, Cladosporium 
sphaerospermum and Penicillium notatum. Results indicated 
that Aspergillus niger stimulation increased pro-inflammatory 
cytokines TNF-α, GM-CSF and IL-6(179). In contrast, stimulation 
with Cladosporium sphaerospermum, Alternaria alternata and 
Penicillium notatum reduced pro-inflammatory cytokines TNF-α 
and IL-6, but induced a dose-dependent increase in remode-
ling cytokines TGF-b1 and bFGF, which suggests a possible 
disease-modifying role for fungi in CRS(179). Shin et al. performed 
PCR to primary nasal polyp fibroblasts(180, 181), epithelium(182) that 
were co-cultured with Alternaria and Aspergillus. They detec-
ted induction of IL-6, IL-8, TLR2, TLR5 and extracellular matrix 
in fibroblasts(180, 181) and fungi and RV-16 induced mucin gene 
expression in epithelial cells(182). Rai et al. performed ELISA of se-
rum samples for 40 CRSwNP and 20 control subjects and PCR of 
nasal lavages for CRSwNP group and detected that serum levels 
of IL-1β, IL-17, IL-21, and TGF-β were higher in CRSwNP group 
compared to controls(183). The proportion of Aspergillus flavus 
positive CRSwNP patients was 78%, and they had increased risk 
of elevated serum IL-17(183). Lawrence et al. co-cultured sinus 
epithelial cells with Aspergillus and Alternaria, from nine CRSwNP 
and seven control subjects and demonstrated by performing 
ELISA of cell supernatants that fungi increased IL-6 and IL-8 
production in both CRSwNP and control groups, which was 
decreased by superoxide dismutase(184). In overview, fungi are 
clearly present in CRS and many have the capability to stimulate 
an inflammatory response, at least in vitro. Any generalizable 
relevance to CRS pathogenesis is, however, quite uncertain as 
fungal directed therapies were ineffective. Much more work, 
using large numbers of patients and standardized techniques, 
will be necessary before any firm conclusions can be made 
about the fungal microbiome in health and CRS. Although a 
broad role in pathogenesis is uncertain, fungi almost certainly 
play key roles in two CRS subtypes: fungal balls and allergic 
fungal rhinosinusitis (AFRS). Aspergillus can cause a fungal ball, 
which is usually unilateral, and is more prevalent in middle aged 
to elderly females. Histologically, fungal balls are characterized 
by entangled masses of fungal organisms or masses of fungi 
embedded in fibrinous, necrotic exudate, with minimal mucosal 
inflammatory reaction without tissue invasion or granulomatous 
inflammation. 
Allergic fungal rhinosinusitis was classically defined over 20 
years ago as: 1) Type 1 hypersensitivity; 2) nasal polyposis; 3) 
characteristic CT changes; 4) eosinophilic mucus; 5) presence 
of non-invasive fungus in sinus contents(185). We now know that, 
when using special techniques, fungi can be detected in the 
nose and sinuses of all patients with and without CRS, indicating 
that the fifth requirement needs revision. In contrast to normal 
patients and routine CRS, patients with fungal rhinosinusitis 
have large amounts of fungi that are readily detectable by 
routine histologic techniques. The EPOS steering group agreed 
that allergic fungal rhinosinusitis (AFRS) should be regarded as 
a subgroup of eosinophilic fungal rhinosinusitis and reserved 
for subjects with evidence of an allergic reaction to fungi e.g. a 
positive skin prick and/or specific IgE.
 In comparison to typical CRSwNP patients, AFRS patients tend 
to be younger, express consistently high serum IgE, and have 
milder asthma in general. AFRS is also more common in humid 
climates with a tendency to present unilaterally(186). Despite 
the phenotypic differences, distinguishing AFRS and generic 
CRSwNP has been problematic at the molecular level(187). More 
recent work has suggested that an innate immune defect 
(possibly in TLR4) may account for fungal accumulation in the 
sinonasal cavities of AFRS patients(186). Fungi have intrinsic 
protease effects that induce Type 2 cytokine signaling leading to 
the accumulation of eosinophilic mucin, which is histologically 
characterized by sloughed epithelial cells, eosinophils, Char-
cot–Leyden crystals, and scattered fungal hyphae. Furthermore, 
these same protease effects should foster a type 2 response as 
well, favoring local and systemic IgE responses to fungal anti-
gens(188, 189). The corollary of this hypothesis would be that fungi 
drive AFRS, with T and B cells targeting the fungi as a major 
component of the disease. Secondary barrier damage may, ho-
wever, lead to the targeting of many other colonizing microbes 
thereby blurring the distinction between AFRS and CRSwNP as 
the process evolves. 
5.2.2.2.4. Other environmental factors 
Immune responses against airborne allergens with or without 
co-existing CRS are common in Western individuals. The relati-
onship between allergic rhinitis (AR) and chronic rhinosinusitis 
has been studied for decades and remains controversial and 
while many large studies have demonstrated an association, the 
significance is unclear(190). Allergic rhinitis occurs through host 
sensitization to foreign proteins (allergens) across a mucosal 
barrier via dendritic cells and naive CD4-positive lymphocytes, 
with the generation of antigen-specific type 2 lymphocytes and 
IgE-secreting plasma cells. The sensitizations patterns for air-
borne allergens vary significantly by geography, genetics, living 
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conditions and climate, amongst other factors(191-193).
Regardless, subsequent allergen challenge across the nasal 
mucosa of sensitized individuals results in cross-linking of IgE 
bound to the surface of mast cells with degranulation, mediator, 
chemokine and cytokine release, leading to the recruitment 
of other inflammatory cells. In the unoperated state, allergens 
should have limited access to the sinus mucosa, but they can 
certainly trigger inflammation of the nasal cavity reducing sinus 
drainage. An ‘allergic phenotype of CRS’ has been proposed 
by two separate groups of investigators, with primarily central 
intense nasal inflammation and milder signs of inflammation in 
the dependent sinuses(194). Further study is necessary to validate 
whether an allergic phenotype of CRS is a significant discrete 
entity. 
Severe CRS is, in general, not regarded as an allergic disease, but 
co-existing allergic rhinitis will accentuate Type 2 inflammatory 
mechanisms of CRS. There is limited epidemiological evidence 
of an association with nasal polyposis and it has been inter-
preted that allergy does not increase the probability of CRSwNP. 
A recent study in the Chinese population showed distinct muco-
sal immunopathologic profiles in atopic and nonatopic CRSsNP 
patients, suggesting that in the Chinese population the comor-
bid CRSsNP and AR might be more related to Type 2 mechanis-
ms, whereas the phenotype CRSsNP without AR exhibits more 
non-Type 2 mechanisms(187). Clearly, there is significant overlap 
between AR and CRS in terms of Type 2 cytokines. While the 
initiating events in CRS are unknown, allergen sensitization is, in 
part, related to complex interactions with the epithelial surface. 
Allergens typically possess intrinsic protease activity that can 
interact with epithelial cells through three principle pathways: 
direct effects on junctional proteins, reaction with cell surface 
protease-activated receptors and toll-like receptor 4 (TLR4)-
dependent epithelial activation(186). Protease activity of allergens 
may elicit the release of epithelial-derived Type 2-driving cytoki-
nes and chemokines, some of which have also been implicated 
in CRS. In terms of potential overlap between AR and CRS pa-
thogenesis, Kouzaki et al. showed lower host expression of two 
protease inhibitors (cystatin A and SPINK5) in the nasal epithelial 
cells extracted from patients with eosinophilic CRS compared 
with control and non-eosinophilic CRS groups(195). This suggests 
that an imbalance of proteases and protease inhibitors within 
the epithelial barrier may contribute to the pathogenesis of 
Type 2 diseases in general(196). As we advance our understanding 
of the interactions between barrier immunity and the environ-
ment as a function of time, the relationship between allergens 
and CRS pathogenesis should become clearer. 
Exposure to tobacco smoke alters sinonasal mucosa. Xie et al. 
performed microscopy and ELISA on polyps obtained from 28 
non-smoking and 21 smoking CRSwNP patients and detected 
that cigarette smoke exposure downregulates expression levels 
of E-prostanoid receptors and stimulates the production of pros-
taglandin E2, IL-8 and TNF-α(197). Mulligan et al. isolated polyp/
mucosal dendritic cell subsets from CRSwNP and control sub-
jects and detected by flow cytometry that in general, exposure 
to tobacco smoke alters the sinonasal composition of dendritic 
cells(198). Tharakan et al. grew sinonasal epithelial cells from con-
trol patients at the air-liquid interface and were able to demon-
strate that cigarette smoke extract stimulation caused disrup-
tion of the epithelial junctional proteins and transepithelial 
electrical resistance, whereas barrier dysfunction was reversible 
by an antioxidant (Nrf2) activation(199). Huang et al. performed 
PCR on the nasal tissues of 40 asthmatic patients with/without 
CRS and detected that cigarette smoke was associated with IL-
17A activation and lesser improvement of asthma control after 
sinonasal surgery(200). Kule et al. performed polyp microscopy in 
30 smoking and 47 non-smoking CRSwNP patients and showed 
no differences between the groups in basement membrane 
thickness, goblet cell hyperplasia, subepithelial oedema, submu-
cous glands, tissue leukocyte subsets, squamous cell metaplasia, 
or stromal cell atypia(201). Shin et al. stimulated nasal fibroblasts 
with cigarette smoke extract which had a stimulatory effect on 
vascular endothelial growth factor mRNA and protein expres-
sion through the TLR4, ROS, MAPK and NF-kappaB signaling 
pathways(202). 
Ozone is an air pollutant with known proinflammatory effects 
on exposed epithelia. Zhu et al. cultured polyp/mucosa from 
CRSwNP ±ASA intolerance and control subjects and exposed 
these in vitro to ozone(203). They showed by immunohistoche-
mistry and ELISA that after ozone exposure, Cox1/2 expression 
remained unchanged in all groups, yet PGE(2) release was 
lowered more in ASA tolerant than in ASA intolerant patients 
after ozone exposure(203). Clara cell protein 16 (CC16) is produced 
by non-ciliated Clara cells in the respiratory epithelium and has 
an anti-inflammatory role in chronic upper and lower airway eo-
sinophilic inflammations(204). Decreased levels of CC16 are found 
in the nasal secretions and plasma of patients with chronic eosi-
nophilic inflammatory disorders, such as asthma, allergic rhinitis 
and CRSwNP and CRSsNP, as well as in people exposed to high 
levels of air pollutants(204). Tissue metal levels are increased due 
to smoking, environmental and occupational exposure. Khlifi 
et al. studied blood concentrations of heavy metals, cadmium 
and nickel, in 90 CRSwNP and 171 control Tunisian subjects 
and higher heavy metal concentrations were associated with 
CRSwNP, with tobacco consumers and with CRSwNP patients 
with occupational exposure(205). Among risk factors, shisha con-
sumption, environmental exposure and occupational exposure 
presented the most significant association with CRSwNP(205). The 
same study group measured cadmium, chromium, nickel and ar-
senic by atomic absorption spectrometry of polyp/nasal mucosa 
from 55 CRSwNP subjects and they detected increased heavy 
metal levels in polyp tissue compared to non-polyp tissue from 
the same patient, suggesting a role of heavy metal exposure in 
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CRSwNP pathogenesis(206). Yamin et al. stimulated with cigarette 
smoke extract or dsRNA cultured polyp/mucosa from CRSsNP, 
CRSwNP and control subjects and detected increased TGF-β1 
and activin A in CRSwNP patients, suggesting that cigarette 
smoke and viral infection might contribute to polyp remode-
ling(207).
There is limited knowledge of the effects of nutrition on CRS 
pathogenesis. Vitamin D and its receptors might be involved 
in the regulation of the immune system and may play role in 
CRS. Tomaszewska et al. performed immunohistochemistry of 
ostiomeatal complex tissue from 52 CRSsNP, 55 CRSwNP and 59 
control subjects and detected a decrease in vitamin D receptor 
nuclear staining in CRS patients as compared to controls(208). 
Vitamin D3 deficiency has been shown to cause changes in 
murine sinonasal immunity as measured by tissue immune cell 
infiltrate and nasal lavage cytokine levels(209).
5.2.2.3. Host factors
The function of the immune system is to maintain homeostasis 
and to prevent or eradicate infections, but chronic activation 
can also be seen in a range of disorders. Host defences are 
grouped under innate immunity which provides immediate 
protection against microbial invasion, and adaptive immunity 
which provides a delayed but more specialized defence against 
infections. The innate and adaptive immune systems are presen-
ted in this section as discrete functional entities, but they largely 
overlap in nature. The initial portion of this section will discuss 
the cells and molecules that are related to innate immunity 
responses. Next the adaptive immune responses are discussed. 
The final part of this section will address other host factors, such 
as remodeling, which is presumably driven by the presence of 
the chronically activated immune response.
5.2.2.3.1. Innate immunity
Innate immunity is present in healthy individuals at baseline, 
prepared to block the entry of microbes and to rapidly eliminate 
microbes entering the host tissues. The components of innate 
immune system include epithelial barrier, sentinel mucosal cells 
(resident macrophages, dendritic cells, mast cells etc.), circula-
ting and recruited phagocytes (monocytes and neutrophils), in-
nate lymphoid cells, NK cells, as well as non-cellular components 
(e.g. complement system). The major functions of the sinonasal 
innate immune system include phagocytosis, recruiting im-
mune cells to sites of infection, activation of the complement 
cascade to identify and clear off bacteria, antibody complexes 
or dead cells, identification and removal of foreign substances, 
and activation of the adaptive immune system through antigen 
presentation. 
Epithelial barrier 
The sinonasal tract is covered by ciliated pseudostratified 
columnar, olfactory, and to lesser extent layered squamous 
epithelium (in the nostril area). Airway epithelium plays a critical 
role in conducting and humidifying air, responding to trigeminal 
and olfactory stimuli, and host defence. Airway epithelial barrier 
comprises ciliated cells, olfactory cells (in olfactory epithelium) 
mucus-secreting goblet cells, and basal cells which are consi-
dered progenitor cells(210). More recently, solitary chemosensory 
cells (SCCs) have also been reported in the sinonasal epithelium, 
playing a significant role in IL-25 production contributing to 
Type 2 immunity(211).
Transcriptomics of healthy middle turbinate epithelium showed 
that about three quarters of protein coding genes are expressed, 
suggesting nasal epithelium is a very active organ(212). Both 
epithelial specification and terminal differentiation are critical 
to epithelial homeostasis. Environmental and mucosal signals 
regulate epithelial stem-cell self-renewal under normal conditi-
ons(213) and in CRS(112). Under physiological conditions environ-
mental and intrinsic signals are able to alter the composition 
and function of epithelium rapidly. Hence investigating the role 
of differentially expressed epithelial genes or proteins between 
CRS and controls in a cross-sectional set-up is challenging. 
Single cell transcriptomics detect cell subtypes exhibiting 
distinct gene expression profiles and are able to trace cell 
transitions in development and disease. Ordovas-Montanes et 
al. performed single cell transcriptomics of polyp/scraping epi-
thelium from 12 CRSwNP and 9 control subjects and detected 
differences in expression of antimicrobial genes by secretory 
cells, a loss of glandular cell heterogeneity, and that polyp basal 
progenitor cells were locked by a Type 2 memory(112). Epithelial 
basal progenitor cells are able to migrate and proliferate into 
ciliated and goblet cells in injured regions. Epithelial cells may 
also de-differentiate through squamous metaplasia or epithelial 
to mesenchymal transition (EMT), which describes a rapid and 
normally reversible modulation of the epithelial phenotype 
toward mesenchymal cells(214). Epithelial cells undergoing EMT 
lose cell-cell polarity and adhesion to become migratory and 
usually downregulate junctional proteins (such as E-cadherin) 
while acquiring mesenchymal features such as alpha-smooth 
muscle actin, vimentin, matrix metalloproteinases (MMPs), and 
the transcription factors. Studies on polyp and control tissue 
show that CRSwNP may be associated with elevated expression 
levels of MMP-1(215, 216), MMP-2(215), TIMP-1(217, 218), MMP-7(219, 220), 
MMP-9(215, 217-219, 221-224), and suppressed TIMP-2(221) and E-cadher-
in(225-227) expression. Periostin binds to several integrin molecules, 
including αVβ1, αVβ3, and αVβ5 on the epithelial cell surface to 
support adhesion and migration of epithelial cells, and elevated 
airway mucosal periostin may be useful in detecting Type-2 
CRSwNP(228-238) and asthma(239). Kim et al. suggested that a main 
cellular source of periostin in eosinophilic CRSwNP are mast 
cells(240). Regardless, it has been proposed that abnormalities of 
epithelial turnover and maturation may result in an immature, 
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leaky barrier with significance in CRS pathogenesis(230). This will 
be discussed further in section 5.2.2.3.3. 
Epithelial physical barriers are maintained by intercellular 
junctions, especially tight junctions (TJs). TJs are located most 
apically, are linked to cytoskeleton, and inhibit solute and water 
movement through the paracellular space, thus establishing 
cell polarity(214). TJ molecules and epithelial barrier function in 
CRS may be modulated by various internal and external factors 
such as inhaled allergens, microbial or viral infections, cytokines, 
hypoxia, or zinc deficiency(241). Several genes/molecules, such as 
SPINK5, S100A7, S100A8/9, PCDH1, NDRG1, SPRR, and p63 are 
involved in modulating the physical barrier function in CRS(241). 
Epithelium membrane protein 1 (EMP1) is a TJ protein media-
ting cell proliferation and its gene and protein expression has 
been shown to be lower in nasal polyp epithelium compared 
to control nasal mucosa(242). Soyka et al. detected a decreased 
trans-tissue resistance in biopsy specimens from patients with 
CRSwNP along with decreased TJ proteins(243). Suzuki et al. mea-
sured electrical impedance in vivo using a tissue conductance 
meter and performed microscopy and qRT-PCR, detecting that 
electrical impedance did not differ between the turbinate and 
polyp tissue(244). The polyp tended to show higher expression of 
claudin-1 but showed lower expression of tricellulin than the 
turbinate(244). Jiao et al. assessed transepithelial resistance in ALI-
cultured polyp/mucosal samples from 17 eosinophilic CRSwNP, 
15 noneosinophilic CRSwNP and 20 control subjects and detec-
ted that integrity of epithelial TJ barrier in the nasal epithelium 
is compromised in Chinese patients with eosinophilic and 
noneosinophilic CRSwNP, and that TGF-β1 plays an important 
role in inducing TJ barrier defects(245). Li et al. showed that the 
expression of epithelial ZO-1, claudin-1, DSG1 and DSG2 in the 
CRSwNP patient group and the expression of claudin-1, DSG1 
and DSG2 of the CRSsNP patient group was significantly lower 
compared to that of the control group(246). Overall, these data 
suggest that the mechanical barrier is more susceptible to pene-
tration in patients with CRS. 
Epithelial cell communication is mediated via, for example Gap 
junction channels, which are formed by connexin proteins and 
they facilitate communication between adjacent cells in homeo-
stasis and inflammation(247). Kim et al. performed immunofluo-
rescence microscopy and qPCR to sinus mucosa biopsies from 
11 CRS and 7 control subjects and detected increased gene and/
or protein expression of connexins in CRS compared to con-
trols(247). The relevance to CRS pathogenesis remains unclear. 
Cilia are microtubule-based hair-like organelles that are funda-
mental to the development and physiology of many organs. 
Mucociliary clearance (MCC) and apical junctional complexes 
between epithelial cells comprise a mechanical barrier between 
host and environment, which provides the first line of host 
defence for the nose and sinuses. Coordinated ciliary beating 
transports debris-laden mucus from respiratory passages 
towards the oropharynx(248). Genetic and acquired defects in 
mucociliary flow with increased mucus viscosity are associated 
with a high incidence of CRS(69, 249). Li et al. detected structural 
and functional abnormalities in the cilia obtained from CRSwNP 
patients(250, 251). The cytokines IFN-γ and IL-13, but not IL-17 
decrease differentiation of ciliated epithelial cells and secon-
dary reduction in ciliary beat frequency(251). Ma et al. cultured 
sinonasal epithelial cells and found that cilia loss and decreased 
expression of WDPCP, a ciliogenesis protein, are associated with 
CRScompared to controls(252). Overall, these studies indicate that 
CRS is commonly associated with ciliary dysfunction. 
Cilia are coated with membrane-spanning mucins and tethered 
mucopolysaccharides that exclude mucus from the periciliary 
space and promote formation of distinct mucus layers(214). Secre-
tory cells produce a different class of mucins, the polymeric gel-
forming mucins. The two major airway gel-forming mucins are 
MUC5AC and MUC5B. Some secretory cells, known as mucous 
or goblet cells, produce mucins and store them within easily 
visualized collections of mucin granules, whereas other cells 
produce and secrete mucins (especially MUC5B) but lack pro-
minent granules(214). Gel-forming mucins are secreted into the 
airway lumen and are responsible for the characteristic viscoe-
lastic properties of the mucus gel layer. Tipirneni et al. identified 
that dynamic mucus strand velocities from submucosal glands, 
a major component of MCC, were significantly decreased in CRS 
patients compared to controls(253). 
Surfactants are compounds that lower the surface tension. 
El-Anwar et al. performed PCR and immunohistochemistry on 
inferior turbinate and sinus mucosal biopsies from 30 CRS, 30 
primary atrophic rhinitis and 20 control subjects, and demon-
strated that Surfactant protein A gene expression was increased 
in CRS and decreased in primary atrophic rhinitis patients com-
pared to controls(254).
Pattern recognition receptors (PRRs) rapidly detect microbial 
and other foreign molecular patterns and either maintain 
homoeostasis or induce immune responses. Toll-like receptors 
(TLR1-TLR10), NOD receptors, RIG-like receptors and dectins are 
among the best-known pattern recognition molecules(214). Ten-
groth et al. demonstrated that nasal apical epithelium expresses 
abundant TLR3, TLR7, TLR9, RIG-I, and MDA-5, and that TLR-
agonist-stimulation leads to upregulation of several secreted 
cytokines(255). The group detected defects in the TLR9-mediated 
microbial defence in the turbinates of CRSwNP patients, which 
could in part explain virus-induced polyp growth(126). Studies 
on polyp and control tissue show that CRSwNP may be related 
to increased epithelial expression levels of TLR 2(256) and 4(256-258). 
Nasal polyp fibroblast activation may occur via TLR 2(181, 259, 260), 
TLR 4(261, 262), TLR 5(181), and TLR 9(263) might be related to polyp B 
cell activation(264). 
NOD family PRRs form a major component of the inflam-
masome, which is a multiprotein oligomer that maturates and 
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secretes pro-inflammatory cytokines interleukin 1β (IL-1β) and 
interleukin 18 (IL-18). This results in pyroptosis, a form of pro-
grammed pro-inflammatory cell death distinct from apoptosis. 
Jardeleza et al. performed microscopy and PCR of polyp/mu-
cosal samples of CRS patients with/without S. aureus biofilms, 
and detected involvement of inflammasome complexes and 
their signaling pathways in biofilm positive CRSwNP(265). Lin et 
al. performed microscopy and ELISA of polyp/mucosal samples 
from CRSwNP and control subjects and detected that NLRP3 
(NACHT, LRR and PYD domains-containing protein 3) and 
caspase-1 were overexpressed in eosinophilic CRSwNP, and that 
the inflammasome signaling pathway was augmented by LPS 
but suppressed by glyburide, suggesting that inflammasome is 
playing a pro-inflammatory role in eosinophilic CRSwNP patho-
genesis(266).
Bitter taste receptors (T2Rs), also present on epithelial cells, 
function as non-classical PRRs. They are G protein-coupled 
receptors (GPCRs), which are widely expressed in host airway 
epithelial membranes. Airway T2R-mediated immune responses 
are activated by bacterial quinolones as well as acyl-homoserine 
lactones(267) secreted by gram-negative bacteria, including Pseu-
domonas aeruginosa(268). Linkage studies have demonstrated 
associations between taste receptor genetics and CRS(269). 
Both mucosal and glandular epithelium secrete a large ar-
ray of host defence molecules (such as surfactant, lactoferrin, 
defensin) that are known to kill or neutralize microorganisms. 
Disruption of this antimicrobial action might lead to the risk of 
colonization or infection by microorganisms, which might be 
associated with the pathogenesis of chronic airway inflamma-
tion. Baseline levels are secreted into the mucus and production 
is increased with PRR stimulation. Some evidence suggests that 
decreased secretion of some host defence molecules is asso-
ciated with CRS(270). Studies on polyp and control tissue show 
that CRSwNP may be related to decreased expression levels of 
PLUNC, possibly secondary to loss of glands, as well as increased 
surfactant-B and alpha-defensin expression(265, 267, 271, 272). Protease 
inhibitors regulate environmental proteases that might compro-
mise barrier and they have been discussed in the earlier section 
on allergens (5.2.2.4).
Innate lymphoid cells
Innate lymphoid cells (ILCs) are lineage and antigen receptor-
negative lymphocytes including natural killer (NK) cells and at 
least three distinguishable cell subsets (ILC1, ILC2, ILC3)(167) that 
rapidly produce cytokines (IFN-γ, IL-5, IL-13, IL-17A, IL-22) upon 
activation(273). As such, ILCs can act as first-line defenders in 
the airway epithelial barrier. ILC1, ILC2 and ILC3 correspond to 
the Th1, Th2, and Th17 subsets of CD4+ T cells, respectively(274). 
The development of ILC2s, the best studied of ILC subsets, is 
controlled by the GATA-3 transcription factor and they pro-
duce IL-5 and IL-13(275). In response to tightly regulated local 
environmental cues, ILCs can generate characteristics of other 
subtypes, a process known as plasticity(275). ILC2s can promptly 
shift to functional IFN-γ-producing ILC1s or IL-17-producing 
ILC3s, depending on the cytokines and chemokines produced 
by antigen presenting cells or epithelial cells. Due to as yet 
unknown triggers, this complex network of signals may become 
dysregulated(275). Several distinct ILC precursors (ILCP) with pan-
ILC (giving rise to all ILCs) or subset-restricted potentials have 
been described(273). How and where these different ILCPs give 
rise to more mature tissue-resident ILCs remains unclear. Re-
cently, environmental signals have been shown to epigenetically 
influence canonical ILC differentiation pathways, generating 
substantial functional plasticity(273). Although there is significant 
intergroup plasticity, each ILC group appears to have a distinct 
physiologic role and cytokine profile described as Type 1, 2 and 
3 inflammation respectively(276). ILC1 cells respond to viruses and 
intracellular bacteria, fostering a Th1 lymphocyte response and 
release various cytokines including IFN-g which is considered 
the canonical Type 1 cytokine. ILC2 cells target parasites, assist in 
tissue repair and also mediate allergy. They foster type 2 respon-
ses and are associated with the canonical Type 2 cytokines IL-4, 
IL-5 and IL-13. ILC3 cells target extracellular organisms, foster 
Th17 responses and release IL-17 and IL-22, canonical Type 3 
cytokines(277, 278). ILC2 cells are the best studied in CRS, playing 
a significant role in eosinophilic CRSwNP, and possibly all CRS 
that exhibits Type 2 inflammation. ILC2s are likely an important 
source of Type 2 cytokines that drive tissue inflammation. On 
the other hand, while canonical Type 1 and Type 3 cytokines are 
clearly present in the tissue of some CRS patients, the impor-
tance and contribution of ILC1 and ILC3 cells to this process is 
unclear. From the standpoint of epithelial signaling to ILCs in 
CRS, the key upstream epithelial cytokines thus far identified 
include IL-25(279-281), IL-33(279-281), and thymic stromal lymphopoie-
tin (TSLP)(127, 279, 280, 282-284). They activate ILC2 cells as well as other 
cell types, which is the physiologic response to parasites. A more 
comprehensive knowledge of the molecular mechanisms that 
regulate ILC development and effector functions may allow for 
better understanding of their role in CRS. 
Neutrophils
Neutrophils, also known as polymorphonuclear leukocytes, are 
the most abundant leukocytes in the blood and are important 
in the early phagocytosis and killing of extracellular mucosal 
microbes(274). Neutrophil recruitment is driven in large part by 
microbial stimulation (via pattern recognition receptors) or tis-
sue damage signals, and epithelial release of IL-8(285). In response 
to bacterial or fungal infection, the production of neutrophils 
from bone marrow increases, rapidly leading to their increased 
levels in blood(274). Neutrophils typically live for only 1-2 days, 
expressing receptors for products of complement activation and 
for antibodies that coat microbes(274). These receptors increase 
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the ability of the neutrophils to kill ingested microbes. The role 
of the neutrophil in CRS pathophysiology remains unclear, but 
they are found in all or nearly all cases, with the highest tissue 
levels seen in CF patients(286). For other forms of CRS, differences 
appear to depend on ethnicity as well as on the presence or 
absence of nasal polyps. In Caucasians, neutrophilic infiltration 
can be demonstrated in CRS, with slightly lower levels observed 
in CRSsNP than in CRSwNP. Nevertheless, in general, the degree 
of neutrophilic infiltrate is comparable between CRSsNP and 
CRSwNP as opposed to the eosinophilic infiltrate, which is 
significantly less in CRSsNP. As a corollary, it has been suggested 
that CRSsNP is more distinctly a neutrophilic process, whereas 
CRSwNP is more eosinophilic, based on the relative degree of 
tissue infiltration(286). In the subpopulation of CRSwNP patients 
with relatively low eosinophilic infiltration, it has been sug-
gested that neutrophils may be the major pathologic driver 
of disease, analogous to ‘neutrophilic’ asthma(287). In studies of 
polyps from Chinese patients, although both neutrophilic and 
eosinophilic infiltration are decreased compared with polyps 
in Caucasian patients, the degree of eosinophilia reduction 
is much more pronounced, which suggests these polyps are 
relatively neutrophilic(288, 289). Immunologic profiling of Asian 
CRSsNP demonstrated strong Type 2 and 3 inflammation with 
dominant neutrophil-related markers, which were associated 
with disease extent(290). Neutrophils are driven most strongly by 
Type 3 cytokines and their infiltrates often co-exist with Type-2 
cytokine-driven eosinophils, suggesting the possibility that 
this tissue neutrophilia may reflect a superimposed physiologic 
response against microbiota in CRS patients(286, 290-292). Clinically, 
this may explain some degree of corticosteroid resistance seen 
in some forms of CRS(293).
The role of neutrophils in CRS pathogenesis is uncertain, but 
these cells are capable of degranulation with tissue damage 
including some loss of barrier integrity. In addition, similar to 
macrophages(286, 291), neutrophils can differentiate from the N1 
phagocytic type, into the N2 form of neutrophils in the presence 
of Type 2 cytokines. Among other factors, N2 neutrophils release 
oncostatin M (OSM), which is important in epithelial repair and 
homeostasis(291, 293, 294). OSM is believed to be operative in the 
early stages of epithelial repair but excess amounts or the dimi-
nished follow up signals have been associated with defective 
barrier regeneration(292, 295), helping to drive Type 2 CRS(293).
Monocytes
Monocytes are less abundant in the blood than neutrophils, and 
they also ingest microbes in the blood and tissues(274). During in-
flammation, monocytes extravasate into the tissue and differen-
tiate into macrophages, which may survive for a long time, even 
years(274). Macrophages exist in all connective tissue and organs 
of the body, having diverse roles that include removal of particu-
lates, primary response to pathogens, tissue homeostasis, coor-
dination of the adaptive immune response, inflammation and 
tissue repair(296). There are two types of activated macrophages, 
M1 and M2. M1 macrophages are the dominating phenotype 
observed in the early stages of inflammation, and the activation 
is driven by Type 1 cytokines that trigger a proinflammatory res-
ponse necessary to kill intracellular pathogens. The alternative 
pathway is driven by Type 2 cytokines in the local milieu, which 
leads to activation of M2 macrophages; this process is important 
in the defence against helminths, in humoral immunity, and 
in tissue repair. Conversion to M2 status may be important in 
Type 2 CRSwNP and CCL23 may be the key chemokine for the 
recruitment of macrophages into the polyp, which then convert 
to M2 in the Type 2 cytokine milieu(297). These M2 macrophages 
appear to have an impaired ability to phagocytose and also 
secrete high levels of CCL18, a cytokine known to be chemotac-
tic for dendritic cells, naïve T cells, and Th2 cells — all of which 
may contribute to the pathogenesis of CRSwNP(298). M2 macro-
phages are also important sources of factor XIII-A in Caucasian 
CRSwNP patients, which induces excessive fibrin deposition and 
secondary tissue oedema in nasal polyps(299-302). In relationship 
to CRSsNP, macrophages have not been extensively studied, but 
they are often elevated, presumably play a central role in Type 1 
CRS inflammation. Macrophages may also recruit both eosinop-
hils and neutrophils to the site of inflammation(299, 303, 304).
Basophils 
Basophils are granulocytes found mainly in the circulation 
and are known to have a role in allergic disease and immunity 
against parasites. They have been implicated in Type 2 respon-
ses in general, possibly serving as an early source of IL-4 driving 
polarization in the Th2 direction (see below)(167). They are parti-
cularly elevated in aspirin tolerant polyps as opposed to N-ERD 
polyps. Their significance in CRSwNP remains unclear. 
Mast cells
Mast cells are present in all connective tissues, especially under 
epithelia, and adjacent to blood vessels with physiologic roles in 
innate immunity and wound healing(305). They can be activated 
by microbial products binding TLRs and by components of the 
complement system as part of the innate immunity or by an 
antibody-dependent mechanism in adaptive immunity. Mast 
cell granules contain vasoactive amines such as histamine that 
cause vasodilation and increased capillary permeability, as 
well as proteolytic enzymes, lipid mediators, chemokines and 
cytokines, which provide a defence against helminths, other 
pathogens and animal venoms, and which are also responsi-
ble for early onset allergic symptoms via antigen-driven IgE 
cross-linking(305). Overall, the downstream effects of this process 
include tissue oedema, degradation of the ECM, and diminished 
barrier integrity. In CRS, interest has centred on a role for mast 
cells in nasal polyposis, in part as a result of the potential to in-
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duce, augment and maintain eosinophilic inflammation through 
IgE-dependent and IgE-independent processes(306). Specifically, 
local IgE class switching directed against common aeroallergens 
may mediate mast cell activation and contribute to subsequent 
eosinophilic inflammation in CRSwNP, but non-IgE mediated ac-
tivation mechanisms such as CD30L may also be play a role(307). 
Mast cells, along with platelets (see below), may be sources 
of proinflammatory leukotrienes (cysLTs) and prostaglandins 
(PGD2) in CRSwNP and N-ERD(308, 309). Mast cells in CRSwNP are 
localized near the glandular tissue of polyps, but the clinical 
significance is unclear(310-312). Recent clinical trials using anti-IgE 
for CRSwNP have also demonstrated efficacy independent of 
systemic allergy, which suggests the potential importance of 
the mast cell in at least a subtype of CRSwNP patients with local 
IgE production(313). Overall, however, the relative importance of 
mast cells versus other cell types in the pathogenesis of CRSwNP 
remains unclear(314). 
Eosinophils 
Eosinophils have a significant role in tissue repair and immune 
defence, in particular against helminths(274). Eosinophils are also 
an important cell type in asthma, AR and CRS; and CRS was 
at one time considered by many to be a purely eosinophilic 
disease. Eosinophilic damage to the sinonasal mucosa was be-
lieved to be the central pathophysiologic mechanism of CRS and 
the hallmark of the disorder(315, 316). It was always clear, however, 
that non-eosinophilic forms existed, and some cases of CRS de-
monstrated relatively minimal eosinophilia with a predominant 
influx of other cell types(317). Notably, separation of CRS tissue 
specimens into CRSsNP and CRSwNP demonstrated that tissue 
eosinophilia was much higher on average in polyps(318, 319). This 
close association, independent of atopy, suggested that eosi-
nophils may be critical to polyp formation, but the relationship 
between CRSwNP and mucosal eosinophilia is not maintained 
in Asian polyps or in a demonstrable minority of Western/Cau-
casian polyps(320, 321) in comparison to most Caucasian polyps(322). 
Taken together, these studies indicate that eosinophils are not 
absolutely necessary for nasal polyposis or CRS to be present. 
Although this might appear to diminish the importance of 
these cells in CRS, recent studies have demonstrated that tissue 
eosinophilia correlates with a relatively poor outcome indepen-
dent of the presence or absence of polyps(323, 324). Consequently, 
whereas eosinophils are not essential for CRS to exist, they ap-
pear to be a biomarker for severe, recalcitrant disease, and may 
still be the cell that mediates this relatively poor prognosis(325, 326). 
Systemic or tissue biomarkers for eosinophilic CRS could have, 
therefore, a significant clinical role(327, 328). 
The overall process of eosinophil recruitment, activation and 
survival in CRS is driven largely by epithelial cytokines, exoge-
nous proteases, complement proteins, eicosanoids, stem cell 
factor and Type 2 cytokines(198, 284, 329-331). The critical upstream 
cellular sources of the Type 2 cytokines in eosinophilic CRS in-
clude ILC2 and Th2 cells(332). Although the pathological effects of 
eosinophil activity in CRS are unclear, presumably degranulation 
causes tissue oedema, epithelial sloughing and possbily some 
fibrosis, as has been reported in asthma(333, 334). Eosinophils have 
also been shown to exert a host defence effect against bacteria 
at sites of barrier damage via the formation of extracellular traps, 
which may have collateral negative effects on barrier integrity 
as well(335). The mechanism for eosinophil degranulation in CRS 
is unclear, but data from other tissues suggest that cross-linking 
of receptors for IgA is an important trigger(336). High levels of IgA 
have been identified in nasal polyps, which suggests that this 
immunoglobulin may play a key role in vivo(337, 338). 
The association of eosinophilia with refractory disease makes 
this cell a potentially important target in CRS. Eosinophils are 
steroid responsive, which likely explains at least some of the 
therapeutic effects of glucocorticoids in CRS(339). A double-
blinded trial using oral corticosteroids demonstrated clinical 
efficacy and reduced IL-5 and eosinophilic cationic protein in 
nasal secretions(340). Unfortunately, systemic steroids have broad 
tissue effects resulting in significant morbidity. A more directed 
approach has been suggested by recent papers which identified 
specific features of activated eosinophils, variations that could 
potentially be targeted to reduce tissue eosinophilia(328). This 
concept has been utilized in early clinical trials using anti–IL-5 
and in CRSwNP with evidence for reduced polyp eosinophilia 
as well as clinical efficacy(341). Although the majority of CRSwNP 
in Western countries demonstrate a Type 2 cytokine profile 
with polyp eosinophilia(342-344), only about half demonstrated 
significant polyp shrinkage with anti-IL-5 mAb therapy(341). In 
addition, a recent study utilizing the oral anti-eosinophil drug, 
dexpamipexole, demonstrated a >90% decrease in both blood 
and polyp eosinophils in CRSwNP patients without significant 
improvement in symptoms or polyp shrinkage(345). These results 
suggest that despite being a predictive marker for disease-se-
verity, eosinophils may account for only a portion of Type 2 CRS 
pathophysiology. 
Natural killer cells
Natural killer (NK) cells are a type of cytotoxic lymphocyte 
critical to the innate immune system. NK cells recognize infected 
and stressed cells and respond by killing these cells and by 
secreting the macrophage-activating cytokine IFN-γ(274). NK cells 
do not express immunoglobulins or T cell receptors, the antigen 
receptors of B and T lymphocytes. On activation by (virus-) 
infected cells, NK cells empty their cytoplasmic granules(274). The 
granule proteins enter infected cells and induce apoptosis. Kim 
et al. peformed flow cytometry on peripheral blood mononu-
clear cells from 18 CRS and 19 control subjects, and detected 
that compared to the controls, impaired ability of NK cells to 
degranulate and to produce cytokines such as IFN-γ and TNF-α 
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was associated with CRSwNP, concomitant asthma and perip-
heral blood eosinophilia(346). The study group also showed that 
compared with healthy controls, eosinophil apoptosis mediated 
by NK cells was significantly decreased in CRS patients(347). Smith 
et al. performed flow cytometry to peripheral blood mononu-
clear cells and to polyp/mucosal samples from eight CRSsNP, 
eight CRSwNP and eight control subjects, and detected that 
compared to controls, sinonasal markers of cytotoxity, gran-
zyme B and perforin, CD8+ T cells, but not the NK cells, were 
decreased in CRSsNP group(331). Invariant natural killer T (iNKT) 
cells and mucosal associated invariant T (MAIT) cells express T 
cell receptors of very limited diversity(327). iNKT and MAIT cells 
recognise antigens presented by the MHC class 1-like mono-
morphic molecules CD1d and MR1, respectively. Both iNKT cells 
and MAIT cells have been identified in the skin and airways and 
can rapidly produce cytokines after activation(327). Luukkainen et 
al. stimulated with H3N2-virus a co-culture of peripheral blood 
mononuclear cells and nasal epithelium, differentiated from 
stem/progenitor cells, and detected rapid activation of mono-
cytes, NK-cells and innate T-cells (MAIT and γδ T cells) bridging 
systemic models and possibly enabling the development of tar-
geted immunomodulatory therapies(328). Taken together, innate 
immunity is crucial to maintain sinonasal homeostasis, and most 
probably disrupted homeostasis between microbiota and host 
innate immune system is a key event in CRS.
Platelets
Platelets are cytoplasmic fragments that primarily function in 
haemostasis. In addition, since they are rapidly deployed to sites 
of injury, they may potentially modulate inflammatory proces-
ses by interacting with effector cells and secreting mediators(274). 
Platelets are activated and a major source of proinflammatory 
leukotrienes (cysLTs) and prostaglandins (PGD2) in CRSwNP 
and, in particular N-ERD(348). Based on released microparticles, 
which may indicate signs of cell injury or pathology, platelets, as 
well as mast cells and basophils, were more highly activated in 
patients with N-ERD than in patients with CRS. However, overall 
it is not yet clear whether platelet activation plays a direct role in 
the development of the aspirin-induced reactions.
5.2.2.3.2. Mechanisms of adaptive immunity
The separation of the innate and the adaptive immune respon-
ses into distinct compartments is artificial; in vivo, these two 
arms of the immune response are mutually supportive and 
distinctions have been blurred. Nevertheless, the separation is 
useful for mechanistic and temporal explanations of immune 
defence across mucosal barriers. Specifically, if penetration of 
the mechanical and innate defences is sufficiently strong, an 
adaptive immune response will be initiated and maintained; 
the overall response will be specialized to address both the 
specific nature and the strength of the insult. Cytokine crosstalk 
between epithelial cells (ECs), innate lymphocytes (ILCs), and 
dendritic cells (DCs) plays a key role in matching the appropriate 
adaptive response to foreign stimuli. In health, this maintains 
mucosal homeostasis with 1) tolerance of potential allergens 
and commensals and 2) defence against pathogens without the 
development of chronic inflammation. Adaptive immunity is 
typically divided into a T-cell response and a B-cell response, and 
these will be discussed as they relate to CRS.
Antigen presentation, dendritic cells and T cell activation
The initiation of T cell responses requires that naïve T cells re-
cognize antigens presented by dendritic cells under conditions 
that require multiple receptors and co-stimulatory molecules. 
Antigen presentation is a transition phase from the innate to the 
adaptive response and is mediated mainly by DCs(274). DCs can 
activate both innate and adaptive immunity via antigen capture, 
presentation of antigen to immature T cells, and secretion of 
soluble inflammatory mediators. DCs are influenced by the col-
lective cytokine response from ECs and ILCs, and this is believed 
to be pivotal in shaping T-cell differentiation(277). Plasmacytoid 
dendritic cells are decreased in patients with a more severe type 
2 profile, suggesting an important role of the cytokines milieu 
in their functional response or that plasmacytoid dendritic cell 
could mitigate the inflamed process found in polypoid tissue(349, 
350). Zheng et al. showed increased expressions of IL-17RB and 
ST2 on myeloid DCs associated with enhanced local type 2 
inflammation in polyp(351). Shi et al. detected distinct subsets 
of lesional DCs in eosinophilic and noneosinophilic CRSwNP, 
which could prime Th2 cells, and Th1/Th17 cells respectively in 
these endotypes(352). Lin et al. investigated the functional status 
of dendritic cells (DCs) in polyp/mucosa from 30 CRSwNP and 
10 control subjects and detected infiltration of DCs in NP, with 
the majority being mature DCs, and that DCs are able to interact 
with T cells via the CD40/CD40L co-stimulatory factor(353).
Antigen presentation is regulated by co-stimulatory molecules. 
Programmed cell death-1 (PD-1) is a negative regulator of T-cell 
responses(354). Kortekaas Krohn et al. measured expression of 
PD-1 pathway molecules by RT-qPCR on tissue from 21 CRSwNP 
and 21 control subjects and detected higher PD-1 expression 
in CRSwNP compared to controls independently of atopic sta-
tus(354). In accordance with this, high PD-L1 levels were associa-
ted with Asian eosinophilic CRSwNP compared to controls(355). 
Overall however, at this point, only limited evidence exists to 
support the hypothesis that defects in antigen presentation are 
significant in CRS pathogenesis. 
T cells
T cells have multiple roles in immune defence including defence 
against intracellular and extracellular infection(274). T cells acti-
vate and recruit effector cells including phagocytes, kill infected 
cells and provide help for B cells in immunoglobulin production. 
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Memory T cells are active as a durable form of innate activity at 
barrier surfaces such as the sinus mucosa. 
A major role of CD4+ T helper cells is to send signals to other 
types of immune cells, including CD8+ killer cells(274, 356). Loss 
of T-helper cell function leaves the body vulnerable to a wide 
range of infections as have been detected in untreated HIV 
infection(274). CD4+ T cells may differentiate into different subsets 
of effector cells that produce distinct sets of cytokines that as-
sist in defence against various types of microbial infections in 
tissues, and a fourth subset that activates B cells in secondary 
lymphoid organs: Th1, Th2, Th17 and follicular helper T cell(274). 
A fifth T subset are T regulatory (Treg) cells that help turn the 
process off. Activated CD4+ cells produce a mixture of the cha-
racteristic cytokines(274). The Th1 subset is induced, with the help 
of ILC1s, by microbes that are ingested by phagocytes (primarily 
macrophages)(356). Th1 cells stimulate phagocyte-mediated 
killing of ingested microbes via secretion of interferon-γ (IFN-γ) 
and tumor necrosis factor -α and –β (TNF-α and TNF–β), leading 
to macrophage activation and enhanced antigen presentation, 
B-cell help and class switching to production of IgG subclasses 
and local tissue inflammation and neutrophil activation(356, 357). 
Th2 cells are induced by parasitic worm infections and promote 
IgE-, mast cell-, and eosinophil-mediated destruction of these 
parasites with the help of ILC2 cells(274, 358). Th2 cells secrete the 
Type 2-cytokines IL-4, IL-5, and IL-13, which have important 
protective effects that include eosinophil effector mechanisms, 
immunoglobulin class switching to IgE and IgG4 and mucus 
production(359). The Type2-cytokines also stimulate the alter-
native pathway of macrophage activation and shut down the 
classical pathway mentioned above. This terminates prolonged 
and potentially damaging reactions. Alternative M2 macropha-
ges secrete growth factors that act on fibroblasts to increase 
collagen synthesis and induce fibrosis fostering tissue repair. 
Th17 cells develop in response to extracellular bacterial and 
fungal infections and induce inflammatory reactions destroying 
these organisms. Th17 stimulate recruitment of neutrophils and 
monocytes and the production of defensins via secretion of IL-
17A, IL-17F, and IL-22.
CD4+ T cells differentiate and acquire distinct functions to com-
bat specific pathogens but can also adapt their functions in res-
ponse to changing circumstances(358, 360). Although this phenoty-
pic plasticity can be potentially deleterious, driving pathology, 
the T-cell flexibility also provides important benefits that have 
led to its evolutionary preservation(360). Studies of the human 
T cell response to microbes have advanced our understanding 
of CD4+ T cell functional heterogeneity, in particular with the 
discovery of a distinct Th1 subset involved in the response to 
Mycobacteria and the characterization of two types of Th17 cells 
specific for extracellular bacteria or fungi(356).
In CRS, the protective adaptive pathways go awry, usually with 
an excessive and prolonged response(361). In support of this, the 
numbers of regulatory T cells (Tregs) are generally reduced in 
CRS and this has been interpreted as diminished Treg activity 
leading to chronicity(362). For the other Th subsets however, 
elevated numbers have been associated with CRS(363). Elevated 
numbers of Th2 cells and eosinophils have been reported with 
Western CRSwNP, while increased Th1/Th17 and neutrophilia 
are associated with Asian CRSwNP and CF polyps(343, 344, 363). There 
is emerging evidence to suggest that the prevalence of Type 
2 CRS is increasing in Asia however(322). The aetiologic factors 
underlying this shift are both unknown and likely complex. 
Nevertheless, the speed of the process suggests changes in 
environmental exposures with secondary epigenetic variation as 
a root cause. Importantly, an overall increase in T2 diseases was 
observed in Western countries beginning in the early 20th cen-
tury, and the changes in Asia appear to be manifesting in those 
areas adopting a more Western life style. Further study of these 
real-time changes in Asian CRS may be useful in identifying key 
environmental determinants that, with avoidance, could lead to 
a reduction in the incidence of CRS. 
CD4+ T cells that express Foxp3 and with immune suppres-
sive activity are known as CD4+Tregs(274). Tregs develop in the 
thymus or peripheral tissues on recognition of self-antigens 
and suppress the activation of potentially harmful lymphocytes 
specific for these self-antigens. They are also essential for main-
taining tolerance and immune homeostasis(364-369). As mentioned 
above, Tregs appear to be reduced in CRS and autoantibodies 
have been reported. Studies show that multiple Th subsets may 
be activated in the same CRS patient, that the cytokines produ-
ced may suppress or augment the other subsets, and this may 
be part of normal immunoresponse, or may affect development 
or clinical presentation of CRS, or may affect treatment course(342, 
370). 
CD8+ cells activated by antigen and other signals differentiate 
into cytotoxic T cells (CTL, T-killer cell) that are able to kill infec-
ted (particularly with viruses) cells expressing the antigen(274). 
CTLs also kill malignant and other damaged cells(274). Memory 
T cells recirculate from the tissues to the peripheral blood. As 
mentioned above, T cell levels are higher in CRS but the CD8+/
CD4+ T cell ratio is also higher, indicating particular enhance-
ment of the cytotoxic T cell population(371, 372). Any specific role 
for cytotoxic T cells in CRS pathogenesis, however, remains 
unclear(372).
Cell adhesion molecules located on the cell surface are involved 
in binding with other cells or with the extracellular matrix. 
Adhesion molecules on leukocytes, fibroblasts and vascular 
endothelium, enabling leukocyte extravasation from vessels and 
migration to sites of inflammation(373). Increased expression of 
intercellular adhesion molecule-1 (ICAM-1) in activated eosinop-
hils is associated with eosinophil extravasation and infiltration 
into NP tissue, and seems to initiate also mucosal remodeling of 
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NP(374). Fibroblasts´ expression of vascular cell adhesion molecule 
(VCAM) has been shown to attract eosinophils and mast cells 
contributing to Type 2 cytokine skewing, while ICAM attracts 
neutrophils and to a lesser degree, eosinophils(375). VCAM expres-
sion was lowest in controls, higher in CRSsNP, and highest in 
CRSwNP, while ICAM expression was elevated in both CRS sub-
types(375). The L-selectin ligand, peripheral lymph node addressin 
(PNAd), was preferentially induced in the nasal vasculature of 
eosinophilic CRS facilitating tissue recruitment from blood(376). It 
is not clear if primary defects in cell adhesion markers in parti-
cular or effector recruitment in general, play any key role in CRS 
pathogenesis. Specifically, the above findings may simply be the 
predicted secondary effect of the tissue inflammation present in 
the sinus mucosa of the CRS patient. Regardless, this may lead to 
innovative treatments via limiting the influx of eosinophils and 
neutrophils into the sinus tissues. 
Humoral immunity is the type of host defence mediated by anti-
bodies, which are produced and secreted by B cells and plasma 
cells, functioning both in circulation and in peripheral tissues 
such as sinonasal mucosa(274). Antibodies use their antigen bin-
ding regions (Fab) to bind and block harmful effects of microbes 
and toxins. Heavy-chain isotype (class) switching and affinity 
maturation enhance the protective functions of antibodies(274). 
The major functions of antibodies are to block or neutralize 
the infectivity of microbes, coat microbes and promote their 
ingestion by NK-cells, to activate (IgE) mast cell and eosinophil 
mediated reactions against helminthic parasites, and activation 
of the complement system vs. Physiologically tonic secretion of 
secretory IgA works in concert with other innate protective fac-
tors and mucociliary flow to limit mucosal colonization without 
tissue-damaging inflammation(377). This IgA is of low affinity and 
generated by a T cell independent process by extrafollicular B 
cells. In the case of an active breach of the respiratory mucosa, 
higher-affinity IgA secretion may increase and, in combination 
with help from IgG, a robust inflammatory response ensues(378). 
These are high affinity, T dependent immunoglobulins produced 
by follicular B cells and plasma cells. IgG is the most common 
circulating antibody with four subclasses (IgG1-4) and a half-life 
of 7-21 days. IgG has several effector functions: it neutralizes 
microbes and toxins; opsonizes antigens; activates the classical 
pathway of the complement system; is responsible for NK cell 
cytotoxicity events and feedback inhibition of B cells(274). IgD is 
an enigmatic antibody isotype best known when co-expressed 
with IgM on naive B cells. Class switching to IgE is regulated 
by Type 2 cytokines and this immunoglobulin plays several 
important physiologic roles that include antigen presentation, 
increased mast cell survival, mucosal homeostasis, and defence 
against viruses, bacteria, fungi and parasites(312, 348, 379-383). The Fc 
portions of IgE and IgA are often mounted on mast cells and 
eosinophils, respectively(274). The antigen selective portions can 
bind parasites, sterically inhibiting their ability to invade and 
also leading to degranulation, which may trigger inflammation 
and some degree of tissue damage. 
B cells and immunoglobulins have been implicated in CRS and 
antibody defects are the most common immunodeficiencies, 
typically associated with CRSsNP(384). Low immunoglobulin pro-
tection can lead to recurrent acute sinus infection and ultimately 
CRSsNP(385). Most cases of CRSsNP do not have an immunoglo-
bulin deficit however, and in fact, a subset of CRSsNP patients 
has high tissue levels of IgD, although any role in pathogenesis 
remains uncertain. 
B cell activation with excessive local antibody production has 
more commonly been associated with CRSwNP(369-371, 386). Polyp 
tissue from CRSwNP patients has been found to contain high 
levels of B cells, plasma cells, follicles that resemble germinal 
centres, and high levels of IgA, IgM, IgG and IgE that indicate 
local production of immunoglobulins(337, 369-372, 387, 388). Antibody 
production in CRSwNP is driven in part by elevated levels of the 
BAFF cytokine (B-cell activating factor) in nasal polyp tissue(389). 
In addition to B-cell proliferation, BAFF has also been associ-
ated with isotype class switching to IgE and IgA as well as the 
development of autoimmune immunoglobulins. Tan et al. was 
the first to demonstrate this, with anti-dsDNA IgG and IgA auto-
antibodies at increased levels in nasal polyps in comparison with 
controls, suggesting a role for autoimmunity in the more seve-
rely affected CRSwNP patients(344). One specfic target appears 
to be the self protein BP180, which is a key anchoring protein 
in the skin and the nasal mucosa. Anti-BP180 antibodies were 
elevated in CRSwNP patients, suggesting autoimmune targeting 
of the epithelial barrier(343).
Local IgE has been the most commonly implicated antibody 
in the pathophysiology of CRSwNP. Elevated IgE levels in nasal 
polyps have been shown to be independent of systemic atopy, 
driven by BAFF with local class switching, predict poor progno-
sis and correlate with the presence of IgE against staphylococcal 
superantigenic toxins. These toxins have the capacity to act as 
both B and T cell superantigens in nasal polyps, fostering a poly-
clonal IgE response(390). Studies have demonstrated that the IgE 
in nasal polyps is polyclonal and can trigger mast cell degranula-
tion, suggesting a significant role for IgE in the pathophysiology 
of this subset of CRSwNP patients(391). The therapeutic potential 
of anti-IgE for nasal polyposis has recently been demonstrated 
in CRSwNP patients as well(313, 384). 
Similar to IgE, IgG4 is a minor IgG subtype whose production is 
also regulated by Type 2 (IL-4 and IL-13) cytokines. Local IgG4 
expression is high in serve eosinophilic CRS, with higher ILC2, 
plasma cells, B cells and activated CD8+ T cells(362, 363). 
The complement system is a collection of circulating and cell 
membrane proteins that play important roles in host defence 
against microbes and in antibody-mediated tissue injury(274). 
Complement assists the antibody-mediated lysis of microbes 
but can result in tissue injury, particularly in cases of autoimmu-
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nity. At this point, there is only weak evidence to support a com-
plement defect associated with CRS pathophysiology(366-368). The 
evidence for excessive complement activation in CRS is stronger, 
suggesting the importance of antibody-mediated events in CRS 
pathophysiology possibly related to autoimmunity(384). 
5.2.2.3.3. Other inflammatory mechanisms 
Remodeling is defined as abnormal restitution of damaged 
tissues and these processes have been widely described in 
lower airway diseases. In CRS, remodeling also takes place 
and observed changes include fibrosis, basement membrane 
thickening (BMT), goblet cell hyperplasia, epithelial barrier 
abnormalities and polyp formation, osteitis and angiogenesis(392, 
393). The remodeling patterns were thought to separate based on 
the presence or absence of polyps, but clear distinctions have 
been difficult to clearly demonstrate(394). This finding illustrates 
the limitations of this classification and CRS is now viewed as 
a heterogeneous disorder driven by an array of inflammatory 
mechanisms or endotypes. The underlying working hypothesis 
in upper airway disease is that the inflammation leads to remo-
deling with cytokines, mediators, enzymes and other factors 
determining the remodeling pattern. Essentially, the duration 
and type of inflammation would determine the outcome. The 
alternative hypothesis, that inflammation and remodeling are 
independent, remains viable although currently unsubstantia-
ted at least in the upper airway(395). 
Studies have attempted to associate cytokines and other tissue 
markers with remodeling changes in CRS. Periostin has been 
suggested as a marker for BMT and fibrosis(238). BMT has also 
been related to the duration of inflammation independent of 
the presence of tissue eosinophilia(393, 396). TGF-b has been most 
closely linked to fibrosis, but IL-13 and osteopontin have also 
been implicated in BMT and fibrosis(395, 397-399). Fibrosis may also 
be secondary to surgical trauma, confounding interpretation of 
results. 
Remodeling changes in the epithelial barrier have engendered 
much interest since the last EPOS publication. As discussed 
in 5.2.2.3.1., the epithelial barrier appears to be weakened in 
many forms of CRS, leading to increased permeability to foreign 
material suggesting this as an early factor in CRS pathogene-
sis. While specific areas of weakness have been identified (see 
section 5.2.2.43.1.), the underlying cause(s) are uncertain. Some 
evidence exists suggesting genetic and epigenetic factors, early 
stage environmental insults including an abnormal microbiome 
or viral injury, and possibly systemic hormone signaling defects, 
which could all serve as permissive factors in CRS pathoge-
nesis(218, 400). Once established, the inflammatory cytokines of 
CRS also trigger increased barrier permeability, an effect most 
closely associated with Type 2 inflammation but which likely oc-
curs in other types as well(240, 243, 401, 402). None of the above would 
be considered remodeling but epithelial cells undergo turnover 
and repair after injury through a process involving interplay with 
fibroblasts, termed epithelial to mesenchymal transition (EMT). 
Under healthy conditions, this results in maintenance of a nor-
mal barrier but in some forms of CRS, the process is abnormal, 
resulting in epithelial remodeling toward acanthosis, acan-
tholysis and a very leaky barrier(400). The EMT process is driven 
by an array of factors including WNT, reactive oxygen species, 
proteases, HIF1, IL-13 Epiregulin, Oncostatin M, and IL-1 among 
others(207, 230, 373, 374, 377, 403). There is some evidence that stem cells 
in the epithelium maintain a memory for the chronic immature 
EMT state in severe Type 2 CRS(228). This form of remodeling may 
lead to barrier failure with markedly increased antigen access 
suggesting the possibility of a feed forward mechanism, such 
that barrier failure leads to more inflammation accelerating bar-
rier damage and then accelerating inflammation(404). This con-
cept of a remodeled, immature, very leaky barrier is most closely 
associated with Type 2 CRS and may account for the higher 
treatment failure rate using conventional therapy. Directly targe-
ting the failed barrier may be necessary to limit recurrence(405). 
Nasal polyposis is associated with marked tissue oedema, 
diminished collagen and extracellular matrix degradation, 
possibly due to imbalances in metalloproteinase activity(406). 
Abnormalities of the coagulation cascade have also been as-
sociated with polyp formation including Factor X, tissue factor 
and thrombin(407-409). Supportive studies have indicated that a 
crosslinked fibrin matrix is the key component of polyps. It has 
been proposed that this matrix draws in fluid, accounting for 
the polyp mass. The pathway begins with inflammation, which 
results in the leakage of fibrinogen, amongst other plasma pro-
teins, out of the vasculature into the tissues, where components 
of the coagulation cascade catalyze formation of a fibrin matrix 
‘clot’. Under normal circumstances, plasminogen is activated 
by t-PA (tissue plasminogen activator) to form plasmin, which 
enzymatically degrades the fibrin matrix into dimers. Type 2 
cytokines inhibit t-PA activity so in the presence of high levels 
of Type 2 inflammation, the matrix will be retained and grow(300). 
The intrinsic levels of t-PA vary in the tissue and they are particu-
larly low in the ethmoid sinuses, a possible explanation for this 
site as the most commonly observed origin of nasal polyps. The 
coagulation factor XIII-A has also been shown to induce exces-
sive fibrin depostion in nasal polyps and M2 macrophages are 
the probable source(302). Eosinophils may also play a role in fibrin 
deposition in N-ERD patients through the expression of L-selec-
tin(410). Thus far, fibrin deposition has only been demonstrated 
in polyps from patients with Type 2 inflammation. Very recent 
studies have indicated that a broad reduction in the fibrinolytic 
pathways via protease inhibition accounts for accumulation of 
the fibrin matrix in CRSwNP(411). 
Tissue angiogenesis is a complex phenomenon that results in 
the growth of new blood vessels from the microcirculation. This 
process has been known to play a crucial role in tumour growth 
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as well as several benign diseases(412) and could be conside-
red a form of remodeling in CRS. Angiogenesis is regulated 
by infection and immune cells VEGF, VEGFR-1, Ang-1, Ang-2, 
Tie-2A, Tie-2B, SDF-1α and SDF-1β mRNA expression to be 
significantly higher in CRSwNP patients compared to the control 
group(412). Luukkainen et al. performed immunohistochemistry 
and counted lymphatic vessel density of sinus mucosa and 
polyp tissue of 120 subjects and detected that low, absolute 
and relative density of vessels and of lymphatic vessels was 
associated with CRSwNP and antrochoanal polyp (ACP) tissues 
compared to control inferior turbinate(413). This was observed 
also in the inflammatory hotspot area. Higher lymphatic vessel 
density seems to associate with polyp recurrence(413). In contrast, 
Mostafa et al. have detected a high density of lymphatic ves-
sels in the transitional area between the sinus mucosa and the 
pedicle of the ACPs, compared to the control group(414). Regar-
ding other growth factors, differences existed in EGF pathways 
in CRS patients and normal subjects as well as in CRSsNP and 
CRSwNP(415)). GF-1 induced MUC8 and MUC5B expression is 
regulated by activation of the ERK1 and p38 MAPK signaling 
pathway in human airway epithelial cells(416). PDGF systems play 
important roles in polyp pathogenesis. Fibroblast-derived PDGF 
may be more important than MNC-derived PDGF in the polyp 
developing process(417).
Osteitis has been described in eosinophilic CRSwNP and putati-
vely results from infection and biofilm production(418). Downre-
gulated pro-osteoblastic mucosal BMP signaling is strongly and 
significantly associated with increased osteitis in CRSwNP(419, 
420). There are phenotypic differences in adhesion and minerali-
zation between osteoblasts in patients with CRS compared to 
controls(419). Different signaling pathways are involved in osteitis 
in CRS and are activated by the TGF-β/Smad signaling pathway 
in CRSwNP versus the TGF-β/Smad-independent signaling pa-
thway in CRSsNP(418, 420). Taken together, pathways closely related 
to mucosal inflammation have been much less studied than the 
immune system. It is possible that they have a role in CRS and 
would be worthy of further investigation.
Neural function is closely related to infection(421) and the im-
mune system. Dysfunctional innervation might contribute to 
the pathogenesis of CRSwNP and could in part explain olfactory 
loss. Wu et al. detected that axonal guidance signaling and neu-
ral growth factor pathway proteins are significantly suppressed 
in eosinophilic CRSwNP(422). Elevated TRPV1 levels in comorbid 
asthma and allergy may have a function in CRSwNP(259). Sub-
stance P was released from the sensory neurons and human/
murine nasal epithelial cells within 15 minutes of local TLR7 sti-
mulation(423), highlighting a novel role for sensory neuropeptides 
as acute and local mediators of pathogen-driven inflammation, 
rapidly priming innate immune defences in the airway. Neuro-
trophin-3, a neurotrophic factor, was associated with CRSwNP 
compared to controls(424). Neuronal dysfunction has been pro-
posed as an endotype for chronic rhinitis, but it is also likely that 
these mechanistic pathways play a role in CRS as well(425).
5.2.2.4. Conclusions and future needs
A wide array of exogenous agents are inhaled through the nose 
and interact with the sinonasal mucosa, a process that begins 
at birth with rapid colonization by viruses, bacteria and fungi. 
In healthy individuals, the mucosa serves as a relative barrier 
limiting and regulating environmental interaction with the host 
immune system, a process that is likely beneficial to the host in 
a number of ways including development of tolerance, gene-
ration of important metabolites and competitive inhibition of 
pathogens(136). In healthy patients, when the barrier is breached, 
a specific, self-limited physiologic immune response is genera-
ted, characterized by a cellular and cytokine repertoire targeting 
the pathogen(s). Although the in vivo response is much more 
complex, at the basic level Type 1 immunity targets viruses, 
Type 2 parasites and Type 3 extracellular bacteria and fungi, 
resolving with elimination of the pathogens and restoration of 
barrier integrity. In cases of CRS, the current working hypothesis 
is that barrier penetration, possibly by an alternate mechanism, 
results in a chronic inflammatory response that still utilizes the 
Type 1, 2 or 3 pathways alone, or in combinations. CRS immune 
responses are: a) dynamic and heterogeneous, likely exhibiting 
plasticity; b) not self-limiting (remaining active for months to 
years); c) not clearly matched to the inciting agents; and d) often 
associated with various types of tissue remodeling, presumably 
linked to the pattern of inflammation. There is no evidence at 
this point for a specific dominant pathogen and, based on the 
limited evidence currently available, the immunologic response 
is polyclonal, targeting antigens derived from multiple orga-
nisms, including nasal bacteria(168, 172). In some severe, recurrent 
CRS cases, self antigens are also targeted but the development 
of autoimmunity is mostly viewed as a phenomenon secondary 
to the chronic process(367). 
Many questions remained unanswered including the mecha-
nism for initiation of CRS, but presumably this results from a 
combination of environmental stressors, genetic susceptibility 
and stochastic events that collectively promote barrier penetra-
tion. While the nature, intensity and sequence of the exposures 
are likely significant in triggering CRS, evidence supporting a 
role for specific environmental agents remains largely indirect, 
as no widely accepted animal model of CRS exists. Host genetic 
variation, particularly governing the sinonasal epithelium and 
immune response, also plays a major role but given that age 
of onset of CRS is typically in the fifth decade, environmental 
and epigenetic effects likely dominate from the standpoint of 
causation. Relatively few high-quality genetic studies have been 
performed to this point, but using adult onset asthma as a mo-
del, multiple genes are involved, each typically conferring a rela-
tively small effect size and most having functional implications 
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for the epithelial barrier and immune response(426). CF, with mu-
tation of the CFTR gene, is a notable exception demonstrating a 
strong association of the homozygous mutation with childhood 
onset CRS(427). Presence of the heterozygous CFTR mutation is 
also associated with a CRS signal albeit less than clinical CF, and 
usually presenting in adulthood(428). The impaired mucociliary 
flow seen with CFTR mutations is presumed to intensify micro-
bial exposure driving the process(429). The importance of CFTR in 
childhood onset CRS suggests that other barrier-related genes 
may play a role in CRS initiation. 
The identity of the antigens triggering CRS is another area 
where we have little information. The limited data available sug-
gests that common nasal bacteria, including S. aureus, are tar-
geted by the host immune system in CRSwNP(172). In AFRS, fungi 
are likely targeted as well. Both nasal bacteria and fungi should 
induce a Type 3 immune response, yet nearly 90% of Western 
CRSwNP patients (and over 50% of surgical CRSsNP patients) 
exhibit a significant if not predominant Type 2 cytokine profile. 
indicating that interactions between host and bacteria are not 
solely driven by Type 3 mechanisms(153, 342, 400, 430-434). Although the 
reason for Type 2 skewing is very unclear, it suggests that some 
of the inter-related hypotheses which have been used to explain 
atopy including dysbiosis, may be operative in Type 2 CRS as 
well. Alternatively, it has been proposed that S. aureus, via mul-
tiple pathobiologic mechanisms including superantigens, is ca-
pable of shifting the immune response in a Type 2 direction(170). 
Some evidence also suggests that environmental proteases and 
host anti-proteases interact at the mucosal surface, setting a 
threshold for barrier penetrance as well as skewing the immune 
response in the Type 2 direction(196, 400, 435). One key pathway 
for Type 2 skewing may include the gene ALOX15, as a loss of 
function variation protects against nasal polyposis(436). This gene 
encodes the enzyme 15LO (15 lipoxygenase), which is up-regu-
lated by IL-13 and promotes eoxtaxin 3 expression by epithelial 
cells, presumably driving tissue eosinophilia in CRSwNP(437). This 
pathway has also been implicated in epithelial remodeling and 
establishment of chronically immature, leaky barrier(438). Lastly, 
beyond Type 2 skewing, patients with severe Type 2 inflam-
mation tend to be resistant to treatment with a high recurrence 
rate. In theory, this could relate to remodeling changes in the 
epithelium that persist despite treatment(112, 400, 404).
The extensive pre-morbid time course, complexity of environ-
mental exposures and lack of many strong genetic signals has 
diminished current enthusiasm for studies on CRS aetiology 
and pathogenesis. Moreover, therapies focused on addressing 
proposed environmental agents have not been very successful 
in CRS management. As a result, interest has shifted to study 
the mechanistic pathways (endotypes) that result within the 
sinus mucosal tissue itself, as opposed to searching for putative 
causes. This shift has been accelerated by the recent availabi-
lity of biologic agents that target molecules operative in these 
pathways. In theory, the intensity and nature of the endotype 
should play a key role in determining the observed phenotype, 
clinical course, response to therapy, remodeling pattern in 
the tissue and possibly the presence of co-morbid pulmonary 
disease. The first large study attempting to define the endotypes 
of CRS with tissue data used a modified cluster analysis of pre-
selected tissue biomarkers including Type 1, 2 and 3 canonical 
cytokines, neutrophilic markers, IgE to staphylococcal superan-
tigens, albumin, TGF-beta, IL-6 and IL-1b. Results indicated 10 
endotypes including four that were characterized as IL-5 nega-
tive and six as IL-5 positive. Of these six, three were considered 
high IL-5 and had the strongest association with asthma and the 
presence of polyps(153, 166, 439). There was a correlation between 
the Type 2 intensity and the presence of asthma and nasal 
polyps but data on symptoms, natural history and response the-
rapy were unavailable. A second large scale attempt to define 
endotypes and tissue patterns was based on the Type 1, 2 and 3 
inflammatory patterns alone(342). The various possible combina-
tions of the three types of inflammation yields eight endotypes. 
In this study, smell loss was associated with Type 2 inflammation 
as previously shown. The presence of Type 1 inflammation was 
protective against facial pain while the presence of pus was 
associated with Type 3 inflammation. These two classifcation 
schemes are the first steps towards identifying the precise 
mechanistic pathways potentially relevant and active in an in-
dividual patient. Type 2 inflammation is the best studied in CRS, 
and it is likely that subendotypes exist that vary beyond simply 
disease-intensity. Overall, the mechanistic pathways of Type 2 
inflammation in CRS tissue are more likely to reflect an intercon-
nected lattice network as opposed to a linear progression(404). 
As a consequence, the mechanism that results in the N-ERD phe-
notype may be a distinct Type 2 subendotype with accentuated 
prostaglandin/leucotriene activity. AFRS as well as SE-IgE+ pa-
tients may be subendotypes that are more closely tied to local 
polyclonal IgE production. As a corollary, it is very possible that 
these subendotypes, if verified, would respond differently to the 
various Type 2 biologics currently available. Lastly, both of these 
CRS endotype classification schemes had one endotype (>10%) 
of surgical CRS patients that had no measured inflammatory 
markers that were significantly greater than background control 
levels. The CT and symptoms scores were, however, similar to 
other endotypes(344). Although the mechanism is unclear in this 
group, the symptoms and the mucosal oedema in the group 
appear to be driven by a mechansim distinct from the traditio-
nal inflammatory pathways associated with CRS. Neuroimmune 
dysfunction involving neuropeptides and ion channels, already 
proposed as an endotype of non-allergic rhinitis, could also be 
operative in CRS(425). 
Although much has been accomplished since the last EPOS 
document, many questions still remain regarding aetiology, 
pathogenesis and relevant inflammatory mechanisms. Future 
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challenges include a better understanding of: 1) the aetiolo-
gic factors that drive CRS with a goal towards prevention; 2) 
the pathophysiologic inflammatory mechanisms and relevant 
endotype biomarkers with a goal towards targeted therapy; 3) 
the molecular mechanisms of barrier and tissue remodeling that 
may play a role in persistence and recurrence.
5.3. Diagnosis and differential diagnosis 
5.3.1. Allergic and non-allergic rhinitis
Upper airway diseases present with a variable pattern of 
common symptoms such as nasal obstruction and discharge, 
making the epidemiological diagnosis of CRS difficult to diffe-
rentiate from allergic and nonallergic rhinitis based on symp-
tomatic grounds only. Moreover, not all patients presenting 
with symptoms meeting CRS criteria have evidence of disease if 
diagnosis is complemented with nasal endoscopy and CT.
5.3.1.1. Allergic and non-allergic rhinitis
Allergic rhinitis (AR) is clinically defined as a symptomatic 
disorder of the nose induced after allergen exposure by an IgE-
mediated inflammation of the nasal membranes. The symptoms 
include rhinorrhoea (anterior or posterior), nasal congestion, 
nasal itching, and sneezing. There is no uniform definition for 
epidemiological studies. Different definitions have been used in 
questionnaires in previous studies.
Allergic rhinitis is a very prevalent disease(440-443).
In a Dutch study using the GA2LEN questionnaire 29% of the 
population had allergic rhinitis, based on the question “Do you 
have any nasal allergies including hay fever?” and 16% CRS 
based on the EPOS criteria. In this study the risk of CRS was sig-
nificantly higher in respondents with a doctor’s diagnosis of CRS 
(OR 6.83), AR (OR 2.87), asthma (OR 2.36), an adverse response 
after taking painkillers (OR 2.34), itchy rash (OR 1.71), or active 
smoking (OR 1.45).
Data on the prevalence of non-allergic rhinitis are less abundant 
with figures of 10-19%(444, 445).
As far as we are aware there are no comparative studies in the 
literature evaluating symptom prevalence and severity in CRS, 
AR and NAR.
5.3.1.2. CT scan in allergic rhinitis versus CRS
In a group of 216 CRS patients, the patients with a positive spe-
cific in vitro allergen test result did not have higher overall rates 
of radiographic sinus inflammation(446).  Moreover, in patients 
with allergic rhinitis alone, asthma alone or both, the group with 
allergic rhinitis and asthma, 58% had some abnormalities on CT 
scan versus 74% of the patients with only asthma, 67% with only 
rhinitis versus 20% in a control group. In the group with allergic 
rhinitis CTscan abnormalities were seen significantly more often 
in the “blockers” (90%) than the “sneezers” (52%)(447).
A central radiological pattern of mucosal disease may be as-
sociated with inhalant allergen sensitization. This group may 
represent a CCAD subgroup of patients with mainly allergic 
aetiology(194) (see also CCAD). The prevalence of allergy in CRS 
may vary by phenotype, with CCAD and AFRS having a stronger 
association than CRSwNP and CRSsNP (see 5.1 and 8.1).
5.3.1.3. Differentiating AR, NAR and CRS
Combining data from different studies in one table (Table 5.3.1.) 
although incomplete, leads to a picture of a significant overlap 
in symptomatology for prevalence and severity of symptomato-
logy.
Koskinen et al.(448) compared diagnostic accuracy of symptoms, 
endoscopy and imaging signs of CRSsNP and allergic rhinitis 
patients and made a prediction model for CRSsNP. They also 
concluded that there is a significant overlap in symptoms. The 
highest area under curve value (0.93) was demonstrated for a vi-
sual analogue scale score of facial pain / pressure ≥4/10 showing 
60% sensitivity and 95% specificity for detecting the CRSsNP 
group (p<.001). The radiologic sign of an obstructed ostiomeatal 
complex showed 100% specificity and 38% sensitivity for de-
tecting the CRSsNP group (p<.001). In this study endoscopy had 
no added value.
5.3.1.4. Conclusion
It can be very difficult to discriminate between AR, NAR and 
CRS. The combination of symptoms, CT scan and maybe also 
nasal endoscopy can point in the right direction but significant 
overlap in diseases occur.
5.3.2. Smell disorders
5.3.2.1. Symptoms
Olfactory impairment, like facial pain is part of the four main 
CRS symptoms. Similar to facial pain and in contrast to nasal 
obstruction and rhinorrhoea, olfactory impairment may not 
exclusively be related to sinonasal disease and thus has a wide 
differential diagnosis(449). Olfactory impairment as a symptom 
can be roughly subdivided into distortions (qualitative disor-
der), decrease or total loss (quantitative disorders) (Table 5.3.2.). 
Patients may present with only a qualitative, quantitative or 
both complaints. Identifying the exact symptom by means of 
inquiry and measurement(450) (see section 5.3.5.5) is essential for 
establishing a correct diagnosis.
5.3.2.2. Epidemiology
The prevalence of olfactory disorders in the general popula-
tion is estimated to be 3-5 % for total smell loss (anosmia) and 
15-25 % for partial impairment (hyposmia)(451, 452). These studies 
provide reliable data on how often, but not why and for what 
reason people have impaired olfactory function. Some of these 
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epidemiological follow-up studies suggest a link between 
altered olfactory function and increased mortality or develop-
ment of neurodegenerative diseases(453, 454). This underlines the 
potential biomarker function of olfactory measurement. 
5.3.2.3. Causes and frequency
In a patient with an olfactory disorder, the most important 
question is  the cause of the smell problem. Many methods have 
been proposed to classify olfactory disorders such as conductive 
versus sensorineural or peripheral versus central. The short-
comings of these classifications are that they suggest that the 
place and mechanism of the disorder is known, which is not 
supported by the current knowledge in the field. The olfactory 
literature is very consistent with the suggestion that one should 
classify olfactory disorders currently according to the putative 
cause(449, 455-462). The most frequently identified causes of olfactory 
disorders are listed in Table 5.3.3.
The table shows that the four most frequent causes, post-
traumatic, post-infectious, CRS-related and idiopathic olfactory 
disorders occur in very different frequencies whether they are 
reported from specialized smell and taste outpatient clinics or 
from general ENT outpatient clinics. The reports from speciali-
zed clinics underreport the frequency of CRS- related olfactory 
disorders, whereas this seems to be the most frequent cause 
encountered by the average ENT physician. 
5.3.2.4. Olfactory (dys-) function in CRS
Olfactory function in CRS has a very variable degree of clinical 
manifestation, ranging from no impairment to total loss. The 
literature also shows that the extent of olfactory dysfunction 
depends on the underlying form of sinonasal disease. CRS 
with nasal polyps is more severely and more often associated 
with olfactory impairment than any other form of sinonasal 
disease(449, 463-467). The mechanism leading to olfactory impair-
ment in CRS is twofold: inflammatory and purely mechanical 
with obstruction of the olfactory cleft(468, 469). Inflammation that 
characterises CRS also modifies the olfactory epithelium(468) with 
consecutive functional impairment. Mechanical blockage to the 
olfactory cleft also decreases olfaction(469). In most CRS patients 
with olfactory impairment both mechanisms are present and a 
mechanistic view of olfactory impairment is inadequate. It ex-
plains why not all patients per se have an olfactory benefit from 
surgical removal of polyps alone, but also require subsequent 
anti-inflammatory treatment. 
CRS related olfactory dysfunction has some distinct clinical 
features that should be looked for during assessment since 
they may help to identify the olfactory impairment as sinonasal 
versus other causes. The first particularity mainly found in CRS-
related olfactory dysfunction is fluctuation of the olfactory com-
plaint(470-473). Fluctuation is hardly ever found in post-traumatic, 
post-infectious, and congenital or neurodegenerative causes. 
The second finding that can be seen more often in CRS related 
olfactory impairment is a gap between ortho- versus retronasal 
olfactory function(474-476). Although not consistently present, 
certain CRS patients have well preserved retronasal olfactory 
function and express that as intact flavour perception whereas 
their orthonasal olfaction is decreased or absent. The most likely 
explanation is a partially preserved retronasal access to the 
olfactory cleft. Third, if testing is performed with tests that have 
thresholds and identification (see chapter 5.3.5.5) CRS- related 
olfactory impairment often shows a characteristic pattern of 
low threshold and preserved identification scores(464, 477). Finally, 
CRS- related olfactory impairment shows a steroid-dependent 
reversal(478), which is a clear indicator of inflammatory related ol-
factory impairment. Olfactory dysfunction that is reversible with 
systemic steroids has also been found to be a reliable predictor 
of post-surgical olfactory outcome(479-481). 
Table 5.3.1 Prevalence and severity of symptoms in CRS, AR and NAR (data from different studies).
Symptom Chronic rhinosinusitis Allergic rhinitis Non-allergic rhinitis
Prevalence (%) Severity Prevalence (%) Severity Prevalence Severity
Nasal obstruction 92 6.8 92$ 2.7# 5.8#
Rhinorrhoea / discharge 80 5.8 86$ 3.6# 4.3#
Post-nasal drip 80 6.0 65$ 5.3$
Loss of smell 84 6.8 30@ 0&
Facial pain / pressure / headache 67 5 0.5&
Nasal / palatal itch 81$ 6.8$
Itchy eyes 45 3.2 63$ 2.4# 2.3#
Sneezing 56 3.6 80$ 4.2# 4.0#
*All values recalculated to a scale of 10; $ Data from Jaruvongvanich 2016(835); @ Data from Stuck 2015(836); # Data from Segboer 2018(837); & Data from 
Koskinen(448). Empty cells: no data available.
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5.3.2.5. Diagnosis and assessment
Diagnosing an olfactory deficit comprises several steps: the 
patient’s history is crucial and one should look for all the 
above-mentioned elements, such as the duration, concomitant 
sinonasal symptoms, possible fluctuation, distortions and events 
preceding the olfactory deficit (e.g. trauma or URTI) in order to 
delimit the major causes of olfactory deficits (Table 5.3.3.). Mea-
suring olfactory function as completely as possible (see chapter 
5.3.5.5) should be done in order to assess the measurable olfac-
tory function since purely asking is not representative of what 
eventually may be measured(482-484). Finally, a thorough nasal 
endoscopy is mandatory. If after these steps, the putative cause 
remains unclear and before stating that it might be an idiopa-
thic problem, a short systemic steroid trial and imaging (CT and 
MRI) to rule out any hidden intranasal inflammation (especially 
in the olfactory cleft) and intracranial elements that explain the 
olfactory dysfunction should be undertaken. 
5.3.2.6. Treatment
Treating CRS-related olfactory dysfunction is synonymous with 
treating CRS and is discussed elsewhere in the position paper. 
The current literature shows that olfaction mostly improves with 
varying degrees of reported success rates(463, 485). For post-infec-
tious, post-traumatic, neurodegenerative and congenital olfac-
tory disorders no real curative treatment exists. However, smell 
training, a regular and conscious exposure to odours has been 
shown to significantly improve olfactory function, especially in 
post-infectious and to a lesser extent post-traumatic olfactory 
dysfunction(486).
Table 5.3.2. Details and characteristics of olfactory symptoms and their occurrence in CRS.
Quantitative disorder Definition / characteristics 
Parosmia / troposmia Distorted smell triggered by an odour source. Mostly after post-infectious / post-traumatic olfactory 
impairment. Very rare in CRS.
Phantosmia / olfactory hallucination Distorted smell occurring independently of an odour source. Wide differential diagnosis including post-
infectious / post-traumatic but also tumour, psychiatric or idiopathic olfactory impairment. Rare but not 
impossible in CRS.
Qualitative disorder Definition / characteristics 
Normosmia Normal olfactory function
Hyposmia Decreased olfactory function. Smell perceived if odours are strong / concentrated. Very frequent in CRS.
Anosmia Total loss of olfactory function. No smell perception even if odours are very strong. Wide differential diag-
nosis but frequently encountered in severe forms of CRS.
Hyperosmia Increased, above average good olfactory function. Subjectively reported in migraine, pregnancy and mul-
tiple chemical sensitivity but rarely confirmed by psychophysical / objective measures. Literature scarce. 
Not reported in CRS.
Specific anosmia Selective loss / inability to smell certain odours while all other odours are perceived normally. Physiologi-
cal state due to variable olfactory receptor expression in humans. All of us have certain specific anosmias. 
Not related to CRS. 
Table 5.3.3. Most frequent causes of olfactory dysfunction according to their putative cause(449, 455-462, 473, 838, 839) and depending on where the patient was 
seen (specialized outpatient clinic or in a general ENT department).
Cause Frequency (observed in special-
ized smell and taste clinics)
Frequency (in general ENT 
consultations)
Presence of distortions 
(parosmia / phantosmia)
CRS related (sinonasal) 6 - 21 % 72 % rare
Post-infectious (URTI) 26 – 40 % 11 % very frequent
Post-traumatic 16 – 39 % 5 % frequent
Idiopathic 14 – 22 % 6 % variable
Neurological-neurodegenerative 1 – 2 % n/a variable
Congenital 4 – 10 % 1 % almost never
Other rare causes (e.g. toxic exposure) 9 – 15 % 5 % variable
URTI, upper respiratory tract infection.
EPOS 2020
150
Key points | What’s new since EPOS 2012
• Olfactory dysfunction is frequent in the general population
• The most frequent cause of olfactory dysfunction encoun-
tered by ENT physician is related to CRS
• CRS-related olfactory impairments have a good success rate 
of improvement if the underlying CRS is treated
• CRS-related olfactory impairments show some distinct 
clinical features that should be looked for since they help to 
accurately diagnose the olfactory dysfunction
5.3.3. Facial pain
Like all the cardinal symptoms that constitute the diagnosis of 
CRS, facial pain has a broad differential diagnosis. Unlike the 
other symptoms, however, causes for facial pain should often 
be sought in areas beyond the nose. Unfortunately, ‘common 
sense’, often strengthened by the judgement of primary care 
physicians, indicates that facial pain must derive from sinonasal 
disease. As such, ENT-surgeons regularly encounter patients 
referred for facial pain but will only diagnose CRS in the minority 
of them(487). Therefore, having a basic understanding of the vari-
ous causes of facial pain is pivotal to determine the right diag-
nosis and management. Too often patients undergo treatment, 
including surgery, aimed at supposed sinonasal disease, when 
proper history-taking would have revealed a non-sinonasal 
cause to be far more likely(488).
5.3.3.1. Facial pain in CRS
Facial pain is usually a mild complaint in CRS (see section 3.1). 
Small studies with both CRSwNP and CRSsNP patients suggest 
that they report more facial pain than controls (although the 
controls groups were really small, <10 subjects per study)(489, 
490). In patients with CRSwNP, 16-18% report moderate to severe 
facial pain, with only a good correlation between pain and sinus 
disease in those with purulent discharge(491, 492). Conversely, in 
patients with purulent secretions from the paranasal sinuses, 
only 29% report facial pain(493). As such, nasal endoscopy is 
advised when facial pain is the main symptom, as it has a strong 
negative predictive value to rule out sinogenic pain(494). 
In patients with an indication for endoscopic sinus surgery, the 
prevalence of facial pain is higher. In a surgical cohort of pa-
tients with CRSwNP, roughly half was found to report moderate 
to severe facial pain pre-operatively, with marked improvement 
after several weeks(495) up to seven months postoperatively(496). 
Studies with mixed surgical cohorts of patients with CRSsNP or 
CRSwNP also showed sustained improvement of facial pain after 
surgery(497, 498). 
Interestingly, there seems to be a difference in the prevalence or 
severity of headache/facial pain between patients with CRSwNP 
and those with CRSsNP. Studies show that both groups have 
comparable total symptom scores, but those without polyps 
have increased scores for headache and facial pain, while the 
other cardinal symptoms of CRS are more prevalent in patients 
with nasal polyps(499, 500). Moreover, the tendency for CRSsNP 
patients to report more severe facial pain can even be used to 
distinguish them from allergic rhinitis patients(501).
There is no correlation between the location of facial pain and 
abnormalities (if any) of anatomically related sinuses upon 
imaging, both for CRSsNP and CRSwNP(502, 503). Patients reporting 
facial pain as their main symptom have less abnormalities upon 
imaging than those reporting the other cardinal symptoms that 
constitute CRS(504). Moreover, in CRSsNP patients, facial pain sco-
res are negatively correlated with CT sinus abnormalities(505). As 
such, routine CT scanning in patients with facial pain is not ad-
vised, as most will have no relevant findings(506). Proper history-
taking can eliminate the need for imaging in most patients(507).
Taken together, facial pain should only be ascribed to CRS if 
there are other nasal symptoms and concordant abnormalities 
upon nasal endoscopy and/or imaging. Ideally, the pain and 
its intensity have a temporal relationship with the intensity of 
the other nasal symptoms (also indicated in the third edition of 
the Int Classification of Headache Disorders (ICHD), see https://
ichd-3.org). With the absence of any of these findings, a primary 
headache syndrome should be considered as cause of the facial 
pain (Table 5.3.4.).
5.3.3.2. Nasal complaints in primary headache syndromes
Unfortunately, patients with a primary headache syndrome also 
report nasal symptoms. In a retrospective chart review, these 
patients were found to report items as nasal congestion, rhinor-
rhea and sneezing in the majority of cases(508). When compared 
to healthy controls, patients with either midfacial segment pain 
or CRS both have increased SNOT scores(508, 509). However, the 
pattern in the subdomains is different. CRS patients have higher 
scores for the rhinological domain, while midfacial segment 
pain patients score higher in the ear/facial domain (including 
facial pain)(510). As such, a ratio of ear/facial domain over rhino-
logical domain scores > 0.66 was found to be a strong negative 
predictor of CRS(511). 
5.3.3.3. Medication overuse headache
Patients with a primary headache syndrome are prone to use 
analgesic medication in an increasing frequency. This might trig-
ger a concomitant form of headache, which is termed medica-
tion overuse headache (MOH). According to the ICHD diagnostic 
criteria, it occurs 15 or more days per month, in a patient with a 
primary headache syndrome using medication for more than 10 
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or 15 days per month (depending on the medication group) for 
more than three months. More detailed information on this form 
of headache can be found in a recent review by Diener et al.(512). 
The relevance for this chapter is that a patient referred for sinus 
disease because of headache or facial pain, might also be suf-
fering from MOH in addition to a primary headache syndrome.
5.3.3.4. Pragmatic approach
When a patient’s main complaint is facial pain:
• Invest in taking a proper history, including: 
• the presence of (other) rhinosinusitis symptoms
• the correlation between the pain and other symptoms
• medication use (especially analgesics)
• other nasal conditions than CRS (e.g., allergic rhinitis) 
• the response of the facial pain/headache to previous 
nasal treatments such as nasal and oral corticosteroids, 
antibiotics and/or surgery.
• Perform nasal endoscopy to exclude CRS or other 
rhinological causes for the facial pain
• Use CT imaging only when in doubt. 
If CRS is expected as the explanation for the facial pain:
• First treat medically
• Check whether the pain improves together with the other 
Table 5.3.4. Most frequent primary headache syndromes giving facial pain.
Trigeminovascular headache Tension-type 
headache
Midfacial 
segment pain
Migraine Trigeminal 
neuralgia
Paroxysmal 
hemicrania
Cluster headache
Paroxysmal Paroxysmal Paroxysmal Paroxysmal Paroxysmal or 
continuous
Paroxysmal or 
continuous
Location Usually frontotem-
poral, facial
In the distribution(s) 
of one or more 
divisions of the 
trigeminal nerve
Orbital, supraorbital 
and/or temporal, 
facial
Orbital, supraorbital, 
temporal, facial
Entire vertex The midface alone 
(bridge of the nose, 
paranasal, and/
or peri-orbital) in 
midfacial segment 
pain.
Side Mostly unilateral Unilateral Unilateral Unilateral Usually bilateral, 
symmetrical
Usually bilateral, 
symmetrical
Duration 4-72h Fraction of a second 
– 2 min
2-30min 15 min-3h Continuously pre-
sent to some extent 
(30 min – 7 days if 
paroxysmal)
Continuously pre-
sent to some extent
Quality Pulsating (throb-
bing, piercing, 
stabbing)
Severe, electric 
shock-like, shooting, 
stabbing or sharp
Severe pain, bur-
ning, piercing
Very severe pain, 
burning, piercing, 
pressing
Pressing, tightening 
(non-pulsating).
Pressing, tightening 
(non-pulsating).
Accompa-
nied by
Nausea, vomiting, 
photophobia, 
phonophobia
Mild autonomic 
symptoms such as 
lacrimation and/
or redness of the 
ipsilateral eye may 
be present
Any or several of 
ipsilateral nasal 
congestion, rhinor-
rhea, lacrimation, 
conjunctival injec-
tion, eyelid oedema, 
facial sweating, 
miosis or ptosis, 
sense of restlessness 
or agitation
Any or several of 
ipsilateral nasal 
congestion, rhinor-
rhea, lacrimation, 
conjunctival injec-
tion, eyelid oedema, 
facial sweating, 
miosis or ptosis, 
sense of restlessness 
or agitation
Hyperaesthesia
Increase of 
complaints when 
bending over
A sense of nasal 
obstruction
Others Prodromal state, 
aura
Attacks can be 
precipitated by 
innocuous stimuli 
within the affected 
trigeminal distri-
bution. There may 
be concomitant 
continuous pain of 
moderate intensity
Rare condition, 
mostly males. Fre-
quent attacks (>5 
daily); a chronic 
form exists as well; 
absolute response 
to indometacin
Rare condition, 
mostly males. Most 
often comes in 
bouts that last 
weeks to months
Often patients 
overuse analge-
sics without clear 
benefit; if nasal 
surgery is perfor-
med, it typically 
relieves complaints 
for several months 
only
For a full overview of neuropathies and facial pain syndromes see: https://ichd-3.org; midfacial segment pain is not yet recognized in this list as a 
separate headache syndrome, but is established as a clinical entity.
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• Many studies have explored further the relation between 
facial pain and CRS, showing that facial pain alone is rarely 
caused by CRS.
• Patterns in the different domains of disease-specific surveys 
such as the SNOT-22 help discern sinonasal facial pain from 
other causes.
• There is no relation between the location of facial pain and 
abnormalities upon imaging. 
• A pragmatic approach to the patient with facial pain is 
provided.
• Facial pain without other nasal complaints or abnormali-
ties on examination should not (primarily) be addressed 
surgically.
5.3.4.2. Viral exacerbation
Point of care viral assays are available and are now starting to be 
used clinically. The impact of these tests on antibiotic prescrip-
tion and clinical outcomes in exacerbation of airway disease is 
currently being evaluated(519). It is too early to form an opinion 
on the role of viral assays in the diagnosis of exacerbations of 
CRS but they may play a role in the future.
5.3.4.3. Bacterial exacerbation
A nasal swab with ensuing culture is often inconclusive. Ho-
wever, if positive, it will allow targeted antibiotic treatment. A 
repeated positive result is also informative and may suggest an 
antibody deficiency associated with encapsulated micro orga-
nisms such as Streptococcus Pneumonia, Haemophilus Influenzae 
and Moraxella Catarrhalis(520).
5.3.4.4. Biomarkers
No unique biomarkers have been identified to diagnose an 
acute exacerbation of CRS. Point of care CRP or ESR have proved 
to be of limited value in acute rhinosinusitis(521).
5.3.4.5. Differential diagnosis
Conditions of recurrent or cyclic nature such as migraine are 
more likely to be mistaken for AECRS. Many migraine sufferers 
have nasal symptoms with congestion, rhinorrhoea, fullness 
in cheek and forehead and which easily lead to the diagnosis. 
AECRS(522). Flare-ups of allergic rhinitis or non-allergic rhinitis are 
also easily confounded with AECRS and having a full under-
standing of the patient’s airway history and immune system 
including allergy testing is helpful in identifying this. 
Other possibilities are similar to the differential diagnosis in 
signs and symptoms of CRS. 
• If so, surgery might be helpful when medication alone 
fails to gain control of disease
• If not, reconsider the diagnosis or at least consider 
overlap with a primary headache syndrome or MOH 
and consider referral to a specialized neurologist
If the facial pain is not likely caused by CRS (or any other rhinolo-
gical condition): 
• Counsel the patient that the sinuses are not involved 
• Try to further clarify the pain according to the cha-
racteristics in Table 5.3.4. Episodic/paroxysmal pain 
alludes to a primary headache disorder. 
• It is up to the treating physician / rhinologist to what 
extent the treatment is carried out personally. Always 
consider referral to a specialized neurologist. For treat-
ment, current literature suggests (a trial of ) treatment 
with amitriptyline and/or triptans(513-516), while others 
report success by offering a team-based approach(517). 
Treating a primary headache syndrome might be challenging 
and might need multiple medication regimes to succeed. 
For example, in a small retrospective cohort of patients with 
midfacial segment pain, success was achieved in 50% within 
18 months. Most patients used a combination of drugs at that 
time(518). As such, it is advised to consult a specialized neurologist 
dedicated to neuropathies, headache and facial pain whenever 
the first-line treatment (such as amitriptyline) fails. 
5.3.4. Diagnosis and differential diagnosis 
5.3.4. 1. Host factors
As with all difficult to treat CRS patients, evaluation of the pa-
tient’s immune system is warranted (see also 8.2). Basic testing 
would include a full blood count including eosinophils, specific 
IgE for common airway allergens and serum IgE. Immune 
deficiency has to be considered if the patient’s history suggests 
frequent infections and is more common in patients with exa-
cerbation of CRS than in the healthy population, up to 11% in 
recurrent acute CRS according to a recent review(46). Revision sur-
gery should be considered if the sinus anatomy is unfavourable.
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CT with contrast or MRI is used (if there is no contraindication)
(530). However, a recent study from Spain suggested that CT 
continues to be over-used in this context(531). MRI and CT with 
contrast are also indicated if neoplasia or invasive fungal rhino-
sinusitis are suspected or in the further investigation of olfactory 
loss(525, 526, 532). 
It was unclear from the responses of the EPOS2020 steering 
group whether it was essential to do a CT of the sinuses at 
initial presentation to ENT / secondary care in a patient with 
symptoms highly suggestive of CRS irrespective of whether the 
mucosa was abnormal or normal at endoscopy (Figures 5.3.1., 
5.3.2.).
However, the majority of the EPOS2020 steering group conside-
red it was essential to do CT in CRS after failure of appropriate 
medical or surgical treatment in secondary care with continued 
symptoms and abnormal endoscopy (Figure 5.3.3.).
Many attempts have been made to semi-quantify the changes 
observed on CT scan using scoring and staging systems of 
varying complexity. The most commonly used of these is the 
Lund-Mackay system which is based on the degree of opacifi-
cation for the maxillary, anterior and posterior ethmoids, frontal 
and sphenoid sinuses (0-none; 1-partial; 2-complete) and OMC 
(0 or 2) giving a maximum score of 24 or 12/side(533). This scoring 
system has been validated in several studies(534, 535). Modifications 
of the LMS have been proposed but have not shown significant 
improvement in correlation with symptom severity scores or 
HRQOL impairment(536-538).
In CRS after failure of appropriate medical or surgical treatment 
in secondary care with continued symptoms and abnormal 
endoscopy, the EPOS2020 steering group regarded a total Lund-
Mackay score of 0 as irrelevant, the relevance of a score of 1 or 2 
due to mucosal thickening in 2 sinuses to be unclear and scores 
of 2 due to complete obstruction of one sinus, or a score of 3 or 
greater, whether uni- or bilateral to be clinically relevant (Figures 
5.3.4. - 5.3.10.).
difficult-to-treat CRS including; dental infection, GORD, cystic 
fibrosis, primary ciliary dyskinesia, vasculitis and sarcoidosis.
Conditions of recurrent or cyclic nature are more likely to be 
mistaken for AECRS such as migraine.
5.3.5. Diagnostic tools
This subchapter discusses diagnostic tools most relevant for 
CRS. For more extensive discussion of diagnostic tools in rhino-
logy please refer to the European position paper on diagnostic 
tools in rhinology(450).
5.3.5.1. Diagnostic imaging in rhinosinusitis
5.3.5.1.1. Rationale
Imaging is used to assess:
• Corroboration of clinical symptoms and endoscopic fin-
dings
• Anatomy and anatomical variants
• Pathology  
• Diagnosis 
• Extent(523, 524)
5.3.5.1.1. Tests
The different imaging modalities in diagnosing rhinosinusitis 
(conventional X-ray, computerized tomography (CT), cone beam 
CT and magnetic resonance imaging (MRI)) have been evaluated 
(525) of which overall CT scan remains the gold standard in the 
radiologic evaluation of rhinologic disease, notably CRS(526-528). 
The first guidelines that recommended CT sinus imaging and/or 
nasal endoscopy for confirmation of the symptoms-only based 
diagnosis of chronic rhinosinusitis were the EPOS guidelines in 
2005(529). 
However, in acute rhinosinusitis, the diagnosis is made on clini-
cal grounds and CT is not recommended(1) unless the condition 
persists despite treatment, or a complication is suspected when 
Figure 5.3.1. Delphi: Is it essential to do CT of the sinuses at initial presenta-
tion to ENT / secondary care with highly suggestive symptoms of CRS and 
abnormal mucosa at endoscopy ?
Figure 5.3.2. Delphi: Is it essential to do CT of the sinuses at initial presenta-
tion to ENT / secondary care in patients with highly suggestive symptoms of 
CRS but normal endoscopy ?
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When deciding if the changes are clinically relevant, the 
EPOS2020 steering group felt that the importance of the fol-
lowing were unclear: 
• Degree of mucosal thickening
• Number of sinuses affected
• Status of the ostiomeatal complex
However, the presence of complete opacification of any sinus 
was considered by the majority as clinically positive (Figures 
5.3.11., 5.3.12., 5.3.13., 5.3.14.).
For the purposes of both medical and surgical treatment in 
secondary care/ENT, the EPOS020 steering group considered 
it was acceptable to use a previously performed CT scan of the 
sinuses which has been done up to six months earlier. They 
were unclear regarding the acceptability of a scan performed >6 
months-3 years earlier but considered one performed >3 years 
earlier to be unacceptable for the purposes of medical treat-
ment of CRS (Figures 5.3.15.-5.3.24.).
How and when the scan is done will influence the results(450). 
Marked inflammatory changes may be observed following a 
viral cold which can persist for a number of weeks(539, 540) which 
probably accounts for the high percentage of normal asympto-
matic adults who have evidence of mild mucosal thickening on 
CT (~18%)(10, 541). 
Thus, on CT a “normal” Lund-Mackay score (LMS) for adults is 
4.26 (95% CI, 3.43 to 5.10)(542) and for children it is 2.81 (95% con-
fidence interval, 2.40 to 3.22), with only 19.3% having a score of 
0(543). The LMS can also be applied to MRI and does not appear 
to overstage inflammatory disease(544).
CRS studies comparing symptoms with CT and endoscopic fin-
dings have shown good correlation between CT and endoscopy 
but generally not between symptoms and CT. When comparing 
concordance between endoscopy and CT staging in CRS, the 
correlation was 65% for positive and 71% for negative results(545). 
However, more than 40% of patients who fulfil the symptom-
based diagnosis of CRS may have normal CT and endoscopy re-
sults(9, 10). The accuracy of CT in the diagnosis of CRS was tested, 
comparing CT scores with histopathologic grade of inflamma-
tion and including a control group without CRS, utilizing well 
designed criteria(543). By using the ROC method, the sensitivity of 
CT was found to be 94% and specificity 41% using an LMS score 
cut-off value for CRS of greater than 2. If the value of “normal” 
LMS scores (i.e. >4) was applied, specificity increased to 59%. 
Using the same method in paediatric rhinosinusitis, taking an 
LMS of at least 5 to indicate real disease, CT sensitivity was 86% 
and specificity 85%(546). Thus, an LMS of 2 or less has an excellent 
negative predictive value, and an LMS of five or more has an ex-
cellent positive predictive value, strongly indicating true disease. 
Weak but significant correlations were found in a small cohort 
of CRS patients between CT stage and scores on patient-based 
questionnaires in the CRSwNP subgroup but not with the CRS 
patient group as a whole(547). In a similar study using 271 CRS 
patients comparing SNOT-22 and VAS with LMS CT score, no 
association was found between total SNOT-22 score and LMS 
overall or in CRSsNP(505). However, again some independent 
associations were shown with the LMS in CRwNP and both 
SNOT-22 and VAS (p<0.001). There was no correlation between 
inflammation on CT and facial pain especially in CRSwNP(504, 
505) and in CRSsNP the higher the SNOT-22 facial pain score, the 
lower the LMS (p=0.022) . The only symptom that significantly 
correlates with CT scores is olfaction(465, 548). On the other hand, 
CT scores were found to significantly correlate with the stage 
of inflammation in histopathological analysis of sinus mucosal 
samples in CRS, most notably in CRSsNP(549, 550). 
In comparison to CT, plain sinus radiographs have shown poor 
sensitivity and specificity, so that even low irradiation does not 
justify their use. Correlation of CT scans with plain sinus radio-
graphs for maxillary sinusitis was reasonable (78%) but was only 
52% for the ethmoids(551) and CT out-performed ultrasonograp-
hy(521). However, CT cannot confirm acute bacterial rhinosinusitis 
as compared to antral puncture with positive bacteriology(552, 553). 
CT is also extremely sensitive in demonstrating ‘abnormalities’ 
in the sinonasal region. A wide range of anatomic variations are 
observed which are generally unrelated to the development of 
disease(541, 554) but are highly significant for ‘safe’ surgery e.g. the 
presence of a sphenoethmoidal cell(555). The high resolution of 
modern CT and the use of detailed three planar reconstruction 
has significantly improved our appreciation of the complex 
anatomy particularly in the frontal recess and led to Int efforts 
to agree a classification of the area(523, 524). Thus, preoperative CT 
is mandatory for sinus surgery in most countries and should be 
available in the operating theatre(556, 557) providing an anatomical 
roadmap often augmented by navigation systems and other 
techniques such as fusion of CT and MRI. 
Whilst CT is the principle modality for diagnosis in rhinosinusitis, 
extent of disease does not necessarily equate with prognosis(527, 
Figure 5.3.3. Delphi: Is it essential to do CT in CRS after failure of appropriate 
medical or surgical treatment in secondary care with continued symptoms 
and abnormal endoscopy ?
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Figure 5.3.4. Delphi: What do you regard as a clinically relevant total 
LundMackay score for CRS in this situation ? 0 
Figure 5.3.5. Delphi: What do you regard as a clinically relevant total LM 
score for CRS in this situation?  1
Figure 5.3.6. Delphi: What do you regard as a clinically relevant total LM 
score for CRS in this situation?  2 complete obstruction of one sinus
Figure 5.3.7. Delphi What do you regard as a clinically relevant total LM 
score for CRS in this situation?  2 mucosal thickening in 2 sinuses
Figure 5.3.8.: Delphi What do you regard as a clinically relevant total LM 
score for CRS in this situation?  3 or more uni or bilateral
Figure 5.3.9.: Delphi What do you regard as a clinically relevant total LM 
score for CRS in this situation?  4 or more uni or bilateral
534). In a multicentre prospective study of patients undergoing 
surgery for CRS with nasal polyps (CRSwNP) and without (CRS-
sNP), the LMS was correlated with a range of parameters in 
1840 CT scans(558). This showed as expected that the higher the 
score, the higher the grade of polyp and the more extensive 
the surgery. The score also correlated with symptom reduction 
(coeff=0.24, p=0.02), complication rate (odds ratio (OR) 1.08, 
95% confidence interval (CI) 1.06-1.1) and revision rates (OR 
1.03, 95% CI 1.001-1.06) but showed no correlation with SNOT-
22 scores. In another large multicentre cohort of refractory 
CRS patients, patients with low stage LMS are not significantly 
different than high stage LMS and did not show any difference 
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Figure 5.3.10. Delphi: What do you regard as a clinically relevant total LM 
score for CRS in this situation?  5 or more uni or bilateral.
Figure 5.3.11. Delphi: When deciding if the changes are clinically relevant, 
how important are the following in your decision, Degree of mucosal thick-
ening ?
Figure 5.3.12. Delphi: When deciding if the changes are clinically relevant, 
how important are the following in your decision. Number of sinuses 
affected? 
Figure 5.3.13. Delphi: When deciding if the changes are clinically relevant, 
how important are the following in your decision. Status of the ostiomeatal 
complex?
Figure 5.3.14. Delphi: When deciding if the changes are clinically relevant, 
how important are the following in your decision: Presence of complete 
opacification of any sinus ?
Figure 5.3.15. Delphi: For the purposes of medical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done: < 3months ago.
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Figure 5.3.16. Delphi: For the purposes of medical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done 3-6 months ago
Figure 5.3.17. Delphi: For the purposes of medical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done 6-12 months ago? 
Figure 5.3.18. Delphi: For the purposes of medical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done 1-3 years ago ?
Figure 5.3.19. Delphi: For the purposes of medical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done longer then 3 years ago ?
Figure 5.3.20. Delphi: For the purposes of surgical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done < 3months ago?
Figure 5.3.21. Delphi: For the purposes of surgical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done 3-6 months ago?
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Figure 5.3.22. Delphi: For the purposes of surgical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done 6-12 months ago ?
Figure 5.3.23. Delphi: For the purposes of surgical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done 1 - 3 years ago ?
Figure 5.3.24. Delphi: For the purposes of surgical treatment in secondary 
care/ENT is it acceptable to use the previously performed CT scan which has 
been done longer then 3 years ago?
in level of improvement after endoscopic sinus surgery(559). In 
contrast, a more recent study showed that the preoperative LMS 
in 665 patients with medically recalcitrant CRS correlated signi-
ficantly with preoperative extranasal and rhinologic symptom 
severity on the SNOT-22 and that the LMS was an indicator of 
postsurgical quality of life (QOL) outcomes(560). The LMS mea-
sures a different aspect to ‘subjective’ symptom scores as it cor-
relates well with other markers of disease severity, the nature of 
surgery offered and its outcome. Its main value lies in diagnosis, 
determining extent of disease and providing inclusion criteria 
for studies. 
The pattern of inflammation may also be important. A central 
radiological pattern of mucosal disease is likely associated with 
inhalant allergen sensitization - the so-called ‘black halo’ sign(194). 
The radiological pattern defined by centrally limited changes in 
all of the paranasal sinuses was associated with allergy status 
and predicted atopy with 90.82% specificity, 73.53% positive 
predictive value, likelihood positive ratios of 2.16 and diagnostic 
OR of 4.59. 
Other radiologic features such as the degree of neo-osteoge-
nesis in CRS may have important prognostic implications(561-563). 
Scoring systems have been developed to evaluate this on sinus 
CT based on bone thickness (Kennedy osteitis score: 0-3(564); 
Global osteitis scoring system: 0-5)(565).
In CRS, CT imaging is the primary modality, but it is not normally 
recommended until after an appropriate course of medical the-
rapy has failed(1, 566) and without an intervening acute episode. 
It should be noted that other studies suggest that early CT 
scanning may be more cost-effective as compared to exten-
ded courses of antibiotics given empirically and is preferred by 
patients(567-569). This is especially pertinent in patients with rhinitis 
or atypical facial pain(504, 570, 571) and may be facilitated by the avai-
lability of lower radiation protocols and/or cone beam. 
Hitherto, CT has not been used as an outcome measure due 
to ethical issues with additional radiation exposure but the 
technology and processing abilities of multi-detector CT (MDCT) 
scanners have continued to evolve and there has been a drive to 
reduce radiation dose whilst preserving image quality by shor-
tening the scan time and using post-processing techniques(572, 
573). Cone beam CT (CBCT), historically used for dental imaging, is 
also being utilised in sinonasal imaging producing high resolu-
tion images, but the longer scan time, subsequent susceptibility 
to motion artefact and the lack of soft tissue differentiation can 
be a drawback resulting in loss of some pathological detail such 
as the hyperdensities seen in sinonasal fungal disease(574).
However, ionizing radiation has been significantly reduced with 
multi-slice detector CT (MSCT) utilising low dose protocols, 
which reduce the dose to 0,07 mSv, 10 times lower than the 
standard protocol(575). Low dose protocols have been shown 
to significantly shorten the duration of the procedure without 
compromising anatomical accuracy(575) making them increasin-
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gly attractive as an objective outcome measure in therapeutic 
studies(576, 577). 
5.3.5.2. Health-related quality-of-life (HRQOL) measures
5.3.5.2.1. Rationale
Patient reporting outcome measures (PROMs) are question-
naires or instruments, developed and validated according to 
defined methods, that are designed to quantify patients' sub-
jective perception of the severity of their disease in terms of the 
impact on quality of life. They may be disease specific or reflect 
global QOL. While not intended as diagnostic tools, PROMS 
will normally discriminate between those with and without the 
disease in question, and for many 'normal' population scores 
have been defined. However, they are best used as repeated 
measures to detect changes in HRQOL over time, or in response 
to medical or surgical intervantion. 
Early reports of sinus surgery focused in clinician rated measures 
such as endoscopy or radiological scores, although since the 
mid 90s there has been a growing focus in the use of symtoms 
scores and PROMS, reflecting the primary aim of treatment 
being the improvement in the general well-being of the patient 
and their quality of life. CRS related quality of life has been 
shown to drive patient's decision-making regarding treatment 
options and predicting post-operative outcomes.
5.3.5.2.2. Tests
Instruments which measure health-related quality-of-life (HR-
QOL) are generally divided into generic HRQOL instrument and 
disease specific ones. 
Generic questionnaires are designed to measure different 
domains of physical, psychological and social functioning across 
all health conditions. These instruments may be used to com-
pare healthy and diseased subjects, and may also be used to 
estimate the impact of different diseases on general well-being 
of patients in comparison with other diseases patients(578), but 
are also used to measure QOL in CRS patients(36, 579-582). The EQ-5D 
responds well to changing CRS symptomatology(583).
Disease-specific instruments may be composed of different do-
mains of general health affected in a given disease but also mea-
sure the severity of the specific symptoms of the disease. Such 
instruments are developed having identified the most common 
symptoms or impairments when questioning the patients about 
the problems they experience related to the disease. These in-
struments may measure both the severity and frequency of the 
impairment. Specific questionnaires seem to discriminate better 
between those with and without disease than generic PROMS, 
and better evaluate the impairment within the domains of a 
specific disease and their interactions, such that they are more 
relevant to clinical practice. They are of less value in comparison 
with other conditions.
5.3.5.2.2. HRQOL measures in ARS
Perhaps reflecting the self-limiting nature of ARS, and its relati-
vely short duration, there are very few studies evaluating HRQOL 
in ARS and a paucity of validated measures. The SNOT-16(584), 
a derivative of the RSOM-31 questionnaire, which was initially 
developed for patients with CRS, has been validated for use in 
primary care patients with ARS. It has been shown to have high 
internal consistency and sensitivity to change, with a mean item 
score reported between 0-3 and an MCID of 0.5.
Trials of treatments in ARS report variable outcomes, but 
usually present 'cure' rates (described as complete resolution 
of symptoms, but not otherwise defined) or report scores for 
individual symptoms of facial pain, congestion, rhinorhoea, 
post-nasal drip or headache. The heteregeneity in reporting of 
outcomes precludes meta-analysis. There is no core outcome set 
for ARS.
The EPOS2020 steering group were unclear whether a QOL 
instrument was important for the management of acute rhinosi-
nusitis (ARS) (Figure 5.3.25.).
For a General Health-related quality of life instrument in ARS, 
the EPOS2020 steering group used a wide range of possibilities. 
Of these the SF36 was the most popular but the SF12 was also 
suggested (Figure 5.3.26.). 
When using a specific rhinologic health-related quality of life 
instrument in ARS, the majority of the EPOS2020 steering group 
proposed the SNOT22 (Figure 5.3.27.).
5.3.5.2.3. HRQOL measures in CRS
Chronic rhinosinusitis (CRS) has a significant impact on HRQOL 
and may affect different domains of HRQOL in addition to 
rhinological symptoms, such as fatigue, sleep quality, pain and 
emotional impairment (like anxiety and depression, productivity 
and social functioning. 
A number of HRQOL evaluating instruments have been deve-
loped during past few decades. The key features of the most 
commonly used PROMs are summarised in Table 5.3.5.
The Chronic Sinusitis Survey (CSS)(585) evaluated six item severity 
and duration based specific outcomes, primarily related to 
rhinosinusitis symptoms, pain and medication use. Rhinosinu-
sitis Disability Index (RSDI)(586) is a similar HRQOL instrument 
asking 30 questions in 3 domains, covering also some generic 
questions. The Rhinosinusitis Outcome Measure (RSOM-31), de-
veloped in 1995(587) is a HRQOL questionnaire evaluating seven 
domains in 31 questions. RSOM-31 was reduced to SNOT-20 
in 2002, and then modified into SNOT-22 in 2009. The SNOT-
22 is now regarded as the most appropriate instrument in the 
evaluation of HRQOL impairment in CRS patients, according to 
a recent systematic review of 15 CRS related PROMs which were 
analyzed using Consensus-based Standards for the selection 
of Health Measurement Instruments(588). The SNOT-22 includes 
evaluation of the severity of major and most of the minor CRS 
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symptoms with a nasal domain, and includes additional items in 
subdomains relating to sleep disturbance, emotional / psycho-
logical and aural/ facial pain domains(588, 589). Patients score each 
of 22 items on a Likert 6 points scale, or 0 to 5, with a total score 
range of 0-110. SNOT-22 scores are influenced significantly with 
several demographic confounders and comorbid disorders, like 
gender, smoking, asthma and mental illness, including anxiety 
and depression(511, 590, 591).
The SNOT 22 questionnaire was validated in 2009 relying on the 
data from a UK multicentric prospective cohort study in over 
3000 patients followed pre- and postoperatively after sinus 
surgery(592, 593). The SNOT-22 can be stratified into ‘mild’ being 
defined on the SNOT-22 score as 8-20, ‘moderate’ as >20-50 
and ‘severe’ as >50(594). It has been validated in several foreign 
languages(595-599), for children(600, 601) and it has been used as an 
outcome measure in several multicentric cohort studies(36, 590, 602). 
Patients with non-sinogenic headache have distinct SNOT-22 
score patterns compared with patients with CRS. A domain 3 
(Ear/facial)/domain 1 (Rhinologic) ratio greater than 0.66 is a 
strong negative predictor of CRS, which can be used to aid in 
patient counseling and potentially limit the use of unnecessary 
sinonasal therapeutics(511).
With regards to changes in HRQOL in the setting of chronic 
disease, many patients may experience improvement after 
intervention but many may have ongoing symptoms. Repeated 
measures allow change in HRQOL to be monitored over time. 
It may also facilitate cohort studies where the effectiveness 
of interventions can be analysed. In order to determine if a 
change at individual or population level is clinicaly significant, 
the minimal clinically important difference (MCID) can be used. 
This is the smallest change in a given outcome measure that 
can be detected by a patient as a perceptible change. The MCID 
can be calculated using a number of different methods; using 
anchor-based methodology in a large surgical cohort the MCID 
has been shown to be a change in 8.9 points on the SNOT-22, 
while for patients undergoing medical intervention, an MCID of 
12 has been proposed(603). Scores for the SNOT-22 subdomains 
have also been defined(603, 604). It can be used to help define a 
minimum threshold for ‘success’ or response rate for any given 
intervention. A limitation of the MCID is that it is a population-
derived score and the threshold for perceived benefit may vary 
between individuals. Individualized outcome measures, howe-
ver, are complex to use and preclude comparative studies.
Based on the large number of outcome measures and hete-
rogeneity of outcomes measured in the current published 
literature, a Core Outcome Set (COS) for assessing outcomes 
in CRS has been proposed(605). A COS is a standardized group 
of outcome measures that may be included in future trials to 
facilitate data comparisons and future meta-analyses. For the 
CRS COS, items in four domains were identified as imperative: 
patient reported symptoms and QOL, control of disease, impact 
Figure 5.3.25. Delphi: Is a QoL instrument important for the management 
of ARS ?
Figure 5.3.26. Delphi: If you use a general health-related quality of life 
instrument which would you use for ARS?
Figure 5.3.27. Delphi: If you use a specific rhinologic health-related quality 
of life instrument, which would you use for ARS ?
SF-36 9 (36%)
SF12 5 (20%)
I don't use one 5 (20%)
EuroQOL
2 (8%) + 1 (4%) in a research setting 
only
A short one (e.g.NOSE) 1 (4%)
SF-36 or SF-12 (generic not 
general)
1 (4%)
I don’t see ARS patients 1 (4%)
SNOT-16       1 (4%)
VAS 1 (4%)
EVA 1 (4%)
Multiple options given by some respondants.
SNOT-22 12 (48%)
SNOT20 3 (6%)
I don't use 3 (6%)
NOSE 1 (4%)
I don’t see ARS patients 1 (4%)
EVA 1 (4%)
SNOT unspecified 1 (4%)
Not all participants answered.
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Table 5.3.5. Characteristics of validated patient reported outcome measures for chronic rhinosinusitis.
QoL 
Measure
Year 
developed
Type No. of 
patients in 
validation 
study
No. of 
questions
No. of 
domains
Score 
range
Domains assessed Minutes 
to 
complete 
MCID
CSS 1995 HRQoL 104 6 2 0-100 CRS symptoms; 
medication use
5 9.75
RSOM-31 1995 HRQoL 142 31 7 0-155 Nasal; eye; ear; sleep; gene-
ral; emotional; functional
15
RSDI 1997 HRQoL 87 30 3 0-120 Physical; functional; 
emotional
5-10 10.35
SNOT-16 1999 HRQoL 47 16 0 0-48 NA 5
SNOT-20 2002 HRQoL 102 20 0 0-100 NA 5 16.0
RSI 2003 Symptom 
score
322 20 3 0-100 CRS symptoms; medication 
use; work and social
5
Rhino-
QoL
2005 HRQoL 49 17 3 0-100 Symptom severity; bother-
someness; impact scale
7 3.8-6.1
RSTF 2007 Symptom 
score
201 14 0 0-140 NA 3
SNOT-22 2009 HRQoL 2803 22 0 0-110 Rhinologic; extranasal 
rhinologic; ear/facial; 
psychosocial; sleep
7 8.9
SNQ 2009 Sinusitis 
screen
59 5 0 0-35 NA <2
DyNa-
Chron
2012 HRQoL 759 78 6 0-780 Nasal obstruction; anterior 
rhinorrhea; posterior 
rhinorrhea; sense of smell 
difficulty; facial pain; cough
15
QOD 2012 HRQoL 102 25 3 0-57 Negative items; positive 
items; social items
7-10 2.6 – 8.6
DSS 2013 HRQoL 48 6 2 0-32 Symptoms; HRQoL <2
EQ-5D 2015 Generic QoL/
Health state 
utility
350 15 5 0-100 Mobility; self-care; usual 
activity; pain/discomfort; 
anxiety/depression
<2
SCT 2015 CRS-specific 
control
50 4 3 0-16 Symptoms; productivity; 
rescue medication use
1
Data from Rudmik et al. 2015(588). CSS, Chronic Sinusitis Survey; CRS, chronic rhinosinusitis; DSS, Disease Severity Score; DyNaChron, 
Dysfonctionnement Nasal Chronique Questionnaire; EQ-5D, EuroQoL Five-dimensional Questionnaire; HRQoL, health related quality of life; NA, not 
available/applicable; QOD, Questionnaire of Olfactory Disorders;QoL, quality of life;  RhinoQoL,Rhinosinusitis Quality of Life questionnaire; RSDI, 
Rhinosinusitis Disability Index; RSI, Rhinosinusitis Severity Inventory; RSOM-31, 31-item Rhinosinusitis Outcome Measurement; RSTF, Rhinosinusitis 
Task Force; SNOT, Sinonasal Outcome Test; SCT, Sinonasal Control Test; SNQ, Sinonasal 5-item questionnaire.
on daily activity, and acceptability of treatment and side effects. 
Currently none of the established PROMS capture all the desired 
aspects of CRS; the SNOT-22 fails to capture disease duration or 
medication usage. Current recommendations include the use 
of SNOT-22 scores repeated over time, Lund-Kennedy (LK) en-
doscopic scores, and additional questions to evaluate the need 
for systemic medications or progression to surgery, compliance 
with and side effects of treatment, additional information on 
symptom frequency, and impact on ability to perform normal 
activities(605) (Table 5.3.6.).
The EPOS2020 steering group were unanimous that a QOL 
instrument was important for the management of CRS (Figure 
5.3.28.).
The General Health-related quality of life instrument which was 
used by the majority of the EPOS2020 steering group in CRS was 
the SF36 but the SNOT22 and EQ-5D were also popular (Figure 
5.3.29.).
When using a specific rhinologic health-related quality of life 
instrument in CRS, the vast majority of the EPOS2020 steering 
group used a SNOT22 (Figure 5.3.30.). 
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5.3.5.3. Nasal endoscopy
5.3.5.3.1. Rationale
Nasal endoscopy is an essential part of the rhinological exami-
nation of the nasal cavity, middle meatus, sphenoethmoidal 
recess and postnasal space, and is an essential part of the rhino-
logical examination(450). It allows identification of oedema, pus 
and/or polyps, assessment of sinus cavities following surgery 
and facilitates postoperative debridement or microbiological 
sampling when needed(606). It can be used to evaluate the res-
ponse to both medical and surgical treatment and allows photo 
/ video-documentation. It is a useful educational tool for both 
junior staff and patients, and is generally well-tolerated. 
5.3.5.3.2. Test
The standard three-pass technique for rigid nasendoscopy was 
Table 5.3.6. Core Outcome Set.
Domain Item Proposed measurement tool
Patient-reported symptoms and QOL Overall symptom severity
Frequency of symptoms
Duration of symptoms
Duration of treatment effect
Sense of smell
Runny nose/nasal discharge (anterior or posterior)
Nasal obstruction/blockage/congestion
Disease-specific quality of life
SNOT-22 repeated over time
Additional question required to address fre-
quency of symptoms
Control of disease Overall control of disease
Need for surgery
Endoscopic appearances (including presence/qua-
lity of pus, presence and size of polyps, oedema, 
crusting, inflammation)
Need for systemic medication (steroid or 
antibiotic)
Progression to surgery
Lund-Kennedy score
Impact on daily activity Ability to perform normal activities
Compliance with treatment
SNOT-22 (or specific measures of productivity)
Measurement of compliance and side effects
Acceptability of treatment and side effects Acceptability of treatment 
Side effects of treatment (including medical and 
surgical)
Figure 5.3.28. Delphi: Is a QoL instrument important for the management 
of CRS ?
Figure 5.3.29. Delphi: If you use a general health-related quality of life 
instrument, which would you use for  CRS *?
Figure 5.3.30. Delphi: If you use a specific rhinologic health-related quality 
of life instrument, which would you use for CRS *?
SF-36 12 (48%)
SNOT-22 6 (24%)
EQ-5D 6 (24%)
SF12 4 (16%)
None 1 (4%)
VAS         1 (4%)
*Multiple options given by some respondants.
SNOT-22 21 (84%)
SNOT unspecified 2 (8%)
CRS-PRO 1 (4%)
SNOT20 1 (4%)
RSDI 1 (4%)
VAS 1 (4%)
*Not all participants answered.
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originally described using a 4mm 30 degree endoscope, but 
it can be performed with a 2.7mm endoscope and/or a zero 
degree endoscope instead(607). The patient should be upright, 
and topical decongestant/anaesthetic spray may be used if ne-
cessary. The first pass is made along the floor of the nose to the 
nasopharynx, looking at the general anatomy, septum, inferior 
turbinates and nasal mucosa.The second pass runs above the 
inferior turbinate to the middle meatus then medial to the mid-
dle turbinate into the sphenoethmoidal recess.The third pass is 
made as the endoscope is withdrawn, when it may be possible 
to roll it laterally into the middle meatus. Flexible endoscopes 
can be used instead, and are particularly useful if the larynx and 
pharynx need to be assessed as well, but additional procedures 
cannot be performed(608).
Endoscopy improves diagnostic accuracy compared to anterior 
rhinoscopy alone, up to 69.1% - 85%(609, 610). It is highly specific, 
with several studies reporting specificities of up to 95%(567, 609, 
611). It is less sensitive, ranging from 30% to 73%(609, 610). Various 
endoscopic scoring systems have been described, such as the 
Lund-Kennedy system and modifications thereof(612-614). Inter-
rater reliability is variable, with some aspects of the examination 
scoring highly and others less so, although overall inter-rater 
agreement is good(615).
Recently, a systematic review analysed the accuracy of nasal 
endoscopy in diagnosing chronic rhinosinusitis (CRS) compa-
red with paranasal sinus computed tomography (CT). Sixteen 
observational or retrospective studies were included resulting 
in a high correlation [r= 0.85; 95% confidence interval (CI)
(0.78–0.94), p<.0001, I277%) between endoscopy and CT in 
terms of the diagnostic accuracy for CRS. The sensitivity and 
specificity were 0.73 [95%CI (0.58–0.83)] and 0.77 [95% CI 
(0.69–0.85)], respectively. In a subgroup analysis of studies using 
a Lund–Kennedy endoscopic score threshold ≥2, the area under 
the summary curve was 0.881, and the sensitivity and specificity 
were 0.84 [95% CI (0.78–0.93)] and 0.79 [95% CI (0.37–0.96)], 
respectively(616). 
In conclusion: nasal endoscopy is is an essential part of the 
rhinological examination and correlates quite well with CT scan 
of the sinusses in patients with CRS. 
5.3.5.4. Allergy testing
5.3.5.4.1. Rationale
The potential role of allergy in CRS has been discussed in 5.1.2.1.
5.3.5.4.2. Test
Sensitisation in the regular clinical practice can be measured 
with skin prick testing or serum specific IgE(450). It is important 
to realize the difference between sensitization to aero-allergens 
and allergic rhinitis. Around 60% of the total amount of sensiti-
zations to aero-allergens are clinically relevant(617). Depending 
on the allergen, from 40% (cockroach) to 87-89% (grass, mites) 
of the positive SPT reactions (wheal size ≥3 mm) are associated 
with patient-reported clinical symptoms when exposed to the 
respective allergen. The risk of allergic symptoms increased 
significantly with larger wheal sizes for 17 of the 18 allergens 
tested(618). 
In exceptional circumstances in the diagnosis of CRS, mainly 
when occupational allergies are involved, allergy testing may be 
done with nasal or conjunctival allergen provocation(619). Nasal 
allergen challenge tests may be performed by direct application 
of allergen extract solution sprayed into the nostril or by the ex-
posure to the inhalation of allergen in the allergen provocation 
chamber. Unlike in skin tests, where allergen is applied uniform-
ly, nasal challenges are based on the search of the allergen dose 
responsible for a verified allergic response, starting with lower 
dose of allergen, and increasing the dose several times until the 
response is reached. Several guidelines for the standardization 
of nasal allergen challenge tests have been published, the latest 
being the EAACI position paper in 2018, which are suggesting 
standardized application and outcome measures to prove posi-
tive response to allergen(620). The conjunctival provocation test is 
also an option to prove allergic response in the target organ, as 
the eye is also often involved in the response to allergen(621). The 
diagnostic efficacy of conjunctival provocation test was 89% in 
a trial where nasal allergen challenge with house dust mite was 
used as a standard reference, irrespective of whether the patient 
had ocular symptoms in natural exposure(622).
Diagnosis of allergy in vitro is primarily based on the detection 
of serum specific IgE to airborne allergens, which may confirm 
SPT results and the presence of clinical symptoms. The other in 
vitro method is the basophil activation test. In vitro methods are 
not sensitive to patients’ medication with antihistamines, have 
no risk of systemic reactions to allergens, and are more comfor-
table for the patients, as they do not result in side effects seen 
after SPT and after nasal or conjunctival challenges. This is very 
important for the diagnosis of allergy in children.
Serum specific IgE usually correlates with SPT results, and this 
correlation is stronger in patients with more severe symptoms 
and higher total IgE serum concentration. However, SPT is more 
sensitive than specific IgE in serum, and in most trials SPT is used 
as a standard reference, when testing diagnostic accuracy of 
sIgE. Specific IgE assays which are commercially available are not 
completely compatible, and results using different assays may 
differ in sensitivity and specificity, as well as for the producer, 
and the allergener(623). Different companies also produce diag-
nostic panels of specific IgE, to improve the speed and reduce 
the cost of the diagnosis if many allergens have to be tested. 
Such mixture panels for the most common airborne allergens 
have been used for years and their sensitivity and specificity 
may be moderate to high (70.8 and 90.7, respectively)(624). This 
will probably be even more pronounced in the future, as current 
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ased smell loss and less fluctuation is associated with the increa-
sing severity of sinonasal disease. For that reason, it is important 
to evaluate sense of smell both subjectively and objectively 
in CRS patients. As they are commonly not fully aware of their 
impairment, or at least they are not able to estimate the severity 
of smell loss, the use of smell tests is recommended in order to 
objectively evaluate this disorder(450, 630, 631). The tests may also be 
useful during the follow-up of the CRS patient, primarily to mo-
nitor the outcomes of anti-inflammatory or surgical treatment. 
Many olfactory tests are available but very few are well validated 
or used on a regular basis with a high number of observations 
over the last decades, especially in CRS patients(463). The most 
widely used are the North American UPSIT(629), its short version 
(SIT, B-SIT) and the European Sniffin'Sticks(632). Numerous other 
tests exist(449). Most tests used worldwide are pure identification 
tests (e.g. UPSIT) or composite tests where identification is com-
plemented by a discrimination task and an olfactory threshold 
(e.g. Sniffin'Sticks extended version). They also differ significantly 
in time consumption (4-25 minutes) which is mainly dependent 
on the number of items and aspects tested(633). For most of these 
tests, test-retest reliability is high and the cost of the test set 
more or less the same(634, 635). All identification tests have cultural 
biases, which is the main reason for the large number of dif-
ferent tests. There have been recent advances to overcome this 
with culturally unbiased, universally usable smell tests(636). 
However, in the patient with symptoms suspicious of CRS who 
complains of smell impairment, the diagnostic approach to 
olfactory assessment should also include rigid endoscopy of the 
nose, which may differentiate between potential causes for in-
flammatory olfactory loss. Polyp presence or endonasal tumour 
detected at endoscopy may help explain the smell decline, or it 
may be only obstructive or inflammatory. However, due to inter-
action of sensory epithelia with inflammation in the nose, the 
exact aetiology and level of smell impairment may be mixed and 
not always entirely due to inflammation, mechanical obstruction 
or olfactory epithelial damage due to repeated inflammation. If 
the subjective and psychophysical level of smell loss does not 
correlate with the endoscopic finding, it may raise suspicion of a 
sinonasal or skull base tumour which was not seen on endo-
scopy. Such suspicion should lead to CT and MRI imaging of the 
skull base and brain and if there is an olfactory complaint, regar-
dless of the endoscopy, there needs to be psychophysical tes-
ting. Imaging with MRI or CT may exclude olfactory and pituitary 
tumours and aneurysms and may detect reduced olfactory bulb 
volume and reduced olfactory sulcus depth in congenital smell 
loss(637-639). Regarding parosmia, different studies show morpho-
logic(640, 641) and functional differences on MRI and functional MRI 
scans(642). However, there is no tool yet available to reliably assess 
the presence of olfactory distortions in a single patient apart 
from some questionnaires(643).
Smell tests are classified into threshold (liminar) and supra-
EU regulations are likely to produce a reduction in commercially 
available diagnostic allergens for SPT or ICT(625). This will proba-
bly induce a switch to a broader panel of in vitro sIgE diagnos-
tics. Further development of in vivo molecular diagnostics is 
expected through the component resolved diagnosis (CRD). 
CRD allows us to identify single allergen molecular components 
responsible for the allergic reaction. It may help in distin-
guishing clinical symptoms resulting from allergen exposure 
from those which can be attributed to cross-reactivity.
Total serum IgE is not of much value in diagnosing allergic 
rhinitis and but might be useful to discriminate patients that are 
eligible for anti-IgE treatment. In chronic urticaria and asthma 
total serum IgE levels and their change seems to predict the 
response to treatment with omalizumab(626, 627).
The basophil activation test  (BAT) is a flow-cytometry based IgE 
functional test which detects basophil activation in the presence 
of allergen and specific IgE. The  BAT measures the expression of 
activation markers on the basophil surface which are activated 
due to cross-linking of IgE antibodies bound to the high-affinity 
IgE receptor (FcεRI). It imitates the conditions leading to type I 
hypersensitivity reaction. The use of the BAT in the diagnosis of 
allergy in CRS is limited.
To summarize, clinical history supported with the SPT will pro-
bably remain the golden standard of the upper airway allergy 
diagnosis, for some time, as it has acceptable sensitivity and spe-
cificity. The advances which are expected from the molecular in 
vitro diagnosis may change trend, due to improved technology 
which enables faster diagnosis on a broader panel of allergens. 
On the other hand, complications related to the availability of 
diagnostic allergen extracts or molecules may also shift diagnos-
tic preference towards in vitro diagnostics. For the cases which 
are difficult to diagnose, nasal and conjunctival provocations 
test as in vivo procedures, and BAT as an in vitro procedure, may 
help in establishing the final diagnosis, however in the diagnosis 
of CRS these tests are seldom necessary.
5.3.5.5. Assesment of smell
5.3.5.5.1. Rationale
Smell loss has been reported in 60 to 80% of CRS patients(463, 
467). Olfactory impairment is significantly worse in patients with 
CRSwNP and smell loss is associated with higher eosinophilic 
inflammation in nasal polyp tissue (which was not shown in the 
CRSsNP phenotype)(628). Besides nasal polyps, asthma, N-ERD, 
previous surgery and age have been shown to be predisposing 
factors for a greater smell loss(465, 629).
5.3.5.5.2. Tests
Smell impairment is a symptom which differentially affects CRS 
patients in terms of severity of smell disorder than is the case 
with rhinitis or other inflammatory sinonasal disease(470). Incre-
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threshold (supraliminar) tests(644). In threshold tests the subjects 
detect the minimum concentration of the tested odorant. Such 
tests most commonly use phenyl ethyl alcohol and n-butanol as 
the odorant substance but can be done for any substance. The 
test time in detection threshold test for a person with normal 
smell is about 15 minutes and tends to be lower for subjects 
with impaired smell. The test is done starting with lower concen-
trations with a stepwise increase until the minimally perceived 
dose is reached, which has to be confirmed several times. A less 
common type of threshold test is the recognition threshold test, 
where perception threshold is combined with recognition of 
odour. The olfactory discrimination test includes examination 
with three odour challenges, where two are the same, and the 
third is different ("find the odd one" principle). The test subject 
has to recognize the different odour in the set. Threshold tests 
can be useful in patients with CRS, where the patients with 
higher threshold concentration may still be performing well in 
the suprathreshold tests. In composite tests such as the Snif-
fin'Sticks, a pattern of test results with low threshold but normal 
suprathreshold scores have been repeatedly identified as quite 
typical for CRS-related olfactory impairment(464, 645). 
Suprathreshold tests are used much more commonly than thres-
hold and they are based on identification of different odours in 
much higher concentrations then the threshold.
These tests are usually developed as a panel of different odours, 
which stimulate either olfactory or trigeminal response. Panels 
of odours contain from 8-40 odours and in some tests they are 
applied to both nostrils. Time consumption depends primarily 
on the number of odours in the panel, and varies from 4 to 30 
minutes. Tested subjects recognize the odour through a forced 
choice response(646). The examiner tests the subject with a 
sequence of known odour stimuli which are presented to the 
tested subject, who has to recognize the right odour between 
several descriptors offered as response. The examiner usually 
offers 3-4 different distractors as a response to the presented 
odour, and the subject has to choose a single response. The 
smell test has to be culturally adjusted, which means that 
odours in the panel tested and offered responses have to be 
recognized and familiar to the vast majority of the population 
that will be tested. Only a few of the smell tests integrate liminar 
and supraliminar tests (Sniffin'Sticks full version, Connecticut 
Chemosensory Clinical Research Center Test, Barcelona Smell 
Test-24, T&T olfactometer)(647-649). 
Several trials have tested the compatibility or the correlation of 
the results of the different smell tests in the same individuals 
(normal and hyposmic). These studies confirm compatibility of 
the results with different tests. The commonly used European 
tests managed to differentiate tested individuals into anosmic, 
hyposmic and normosmic categories, with some discrepancies 
within the hyposmic group, however, all the tests
were able to differentiate anosmic from normosmic well(650). 
Compared to one or two decades ago, there are many well 
validated and especially widely used psychophysical tests availa-
ble(651, 652). It is generally admitted that the value of an individual 
test score obtained for a single patient is more meaningful the 
better the test used was. It is thus important to test whenever 
possible with standardized psychophysical tests and use a suf-
ficient amount of odours. 
A lower number of test odours may reduce the cost and time 
spent. However, it introduces, based on the distribution of the 
normative data, a certain degree of unreliability. Such short tests 
should be used for screening purposes only(653, 654). 
Identification tests should be exclusively used with a previously 
described forced choice paradigm for two reasons: hyposmic 
subjects perform better and it potentially gives hints about 
malingering or aggravation. 
Retronasal testing is combining the test of smell and taste, 
which is close to testing flavour. Such tests apply test substan-
ces transorally, or on the tongue. Retronasal olfaction is often 
better preserved in CRS with polyps compared to orthonasal 
olfaction(476). Using retronasal olfaction may give supplemen-
tary information for a possible inflammatory related olfactory 
impairment. Although many reports have been published, as 
yet there is no commercially available retronasal test available. 
However, there has been a recent European attempt for a self-
built retronasal test(655). 
Objective measurement of olfactory function can be done with 
olfactory-event related potentials. This diagnostic tool is able to 
confirm the absence of olfactory specific brain responses to a 
given olfactory stimulus and thus suspected anosmia. However, 
OERPs are not part of the routine work-up and rather time-con-
suming. Their use is largely restricted to research and medical 
expertise. 
The EPOS2020 steering group were unclear as to whether it 
was essential to do a smell test at initial presentation to ENT/ 
secondary care with highly suggestive symptoms of CRS and 
abnormal mucosa on endoscopy (Figure 5.3.31.). 
It was not essential to do a smell test at initial presentation to 
ENT / secondary care with highly suggestive symptoms of CRS 
and normal mucosa on endoscopy (Figure 5.3.32.).
The EPOS2020 steering group were unclear as to whether it was 
essential to do a smell test in CRS after failure of appropriate 
medical or surgical treatment in ENT / secondary care with con-
tinued symptoms and abnormal mucosa on endoscopy (Figure 
5.3.33.).
5.3.5.6. Objective measures of nasal airflow and patency 
5.3.5.6.1. Rationale
Chronic rhinosinusitis is characterized with chronic nasal ob-
struction and HRQOL impairment in CRS is also often related to 
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sleep disturbance and chronic fatigue(656), which may be related 
to sleep disorders. On the other hand, other upper airways disor-
ders have symptoms which overlap with CRS, such as enlarged 
adenoids (nasal obstruction, smell disorders) and laryngopha-
ryngeal reflux (postnasal drip, chronic cough). In nasal obstruc-
tion, sleep disorders and laryngopharyngeal reflux, investigation 
of the upper airways may help distinguish each disorder and 
their comorbidities. 
5.3.5.6.1. Evaluation of nasal patency
Besides nasal endoscopy (see 5.3.5.2.) nasal patency may be 
objectively evaluated with peak nasal inspiratory flowmetry 
(PNIF), (active anterior) rhinomanometry (AAR), and acoustic 
rhinometry (AR). All of these methods have been standardized 
for years and their outcomes related to subjective sensation of 
nasal patency(450, 657-660). Newer methods are computational fluid 
dynamics(661) that at the moment are mainly used for research 
purposes(661-664). 
The different tests are extensively discussed in the European 
position paper on diagnostic tools in rhinology(450). 
The simplest objective method for nasal patency measurement 
is peak nasal inspiratory flowmetry(665-668). It measures simulta-
neously one or both nostrils during maximal inspiration and 
the best of the three attempts is taken as the objective measure 
of nasal patency. This measure correlates best with subjective 
nasal patency(669, 670) and QOL after FESS(645). PNIF and AAR have 
a similar and significant power to discriminate pathologic from 
healthy subjects(671, 672). PNIF also correlates well with AR(673). Besi-
des that, this method has the advantage of being the cheapest 
and the most functional, in the sense that it measures real life 
exposure challenges, like exercise(674), aspirin(675-677) or allergen 
challenge(620). The weakness of PNIF method is that it does not 
locate the narrowest point of nasal obstruction (like acoustic 
rhinometry). It is also influenced by collapsibility of the nasal 
valve, which may occur only in maximal airflow.
Objective airway testing has been used to evaluate nasal pa-
tency in patients with CRS in the diagnostic phase(678, 679) as in the 
evaluation of treatment(670, 680-682).
5.3.5.7. Histopathology tests
5.3.5.7.1. Biopsies
5.3.5.7.1.1. Rationale
To confirm diagnosis, to assist in endotyping of inflammatory 
disease and for research purposes.
To provide tissue uncrushed and suitable for analysis.
To explore the differential diagnosis (inflammation, respiratory 
epithelial adenomatoid hamartoma (REAH), infection, granu-
loma / vasculitis, tumour).
To confirm potential aetiologic or pathogenic mechanisms (type 
Figure 5.3.31. Delphi: Is it essential to do a smell test at initial presentation 
to ENT/  secondary care with highly suggestive symptoms of CRS and abnor-
mal mucosa on endoscopy ?
Figure 5.3.32. Delphi: Is it essential to do a smell test at initial presentation 
to ENT / secondary care in patients with highly suggestive symptoms of CRS 
but normal endoscopy ?
Figure 5.3.33. Delphi: Is it essential to do a smell test in CRS after failure of 
appropriate medical or surgical treatment in ENT / secondary care with con-
tinued symptoms and abnormal mucosa on endoscopy ?
EPOS 2020
167
diagnostic discrepancy was found in 1.1% of CRSsNP and 4.5% 
of CRSwNP and routine examination of nasal polyp tissue was 
recommended. 
However, two more recent studies [from Canada (prospective) 
and the Netherlands (retrospective)] found only <0.5% had an 
unexpected histopathological diagnosis after routine endosco-
pic sinus surgery for CRS(691, 692). Yeh et al. calculated that 217 ca-
ses had to be screened to discover one unexpected pathology, 
the cost of which was >$19,000. Van der Boer et al. considered 
material from 1944 operations of which only two yielded an 
unexpected diagnosis (inverted papilloma in each case) and 
questioned the need for routine histology.
A systematic review was conducted by Wong et al. to assess 
the usefulness of routine histopathology in CRSwNP which 
included six studies of which only Yeh et al. was prospective. Of 
the 3772 patients, 3751 had a pre-operative clinical and post-
operative pathological diagnosis of inflammatory nasal polyps 
with an agreement proportion of 99.44 %. Overall there were 18 
unexpected benign and three unexpected malignant diagnoses 
identified (0.48 and 0.08 % respectively). The number needed to 
screen was 210 and 1258, respectively, and the cost to pick up 
one unexpected benign diagnosis was $14,557 and $87,204 for 
one unexpected malignancy. Despite this low yield, the authors 
concluded that there was no compelling evidence to cease 
routine histological examination(693). 
Therefore, should representative tissue removed at surgery 
in apparently uncomplicated CRS be subjected to biopsy and 
histopathology or only in cases that raise suspicions such as 
unilateral disease, friable mucosa, crusting, serosanguinous 
discharge?
Evidence from the literature is not strong but in cases of bila-
teral CRS with no other concerning clinical features, clinicians 
should exercise judgment in submitting polyp specimens for 
histopathology rather than routinely sending all polyps every 
time. However, there are sound medicolegal reasons to confirm 
the initial diagnosis in all cases and tissue may be increasingly 
important for endotyping with its therapeutic implications. For 
example, to assess eosinophils in tissue especially when consi-
dering biologics.
Subphenotyping and endotyping by degree of eosinophilic 
infiltration and other histological criteria is gaining traction(694-697) 
and has led to the development of institutional protocols for 
sampling, storing and processing samples in close collabora-
tion with histopathologists. Eosinophilic CRS (eCRS) requires 
quantification of the numbers of eosinophils ie number/high 
powered field (HPF) which varies in the literature (8-12/hpf). 
Sampling has been described as ‘approximately the three most 
dense collections of eosinophils in the stroma’(694) or ‘the mean 
number of eosinophils in the mucosa counted at HPF (×400) 
in the three densest areas with cellular infiltrate beneath the epi-
thelial surface”(698). Further stratification may be made between 
and severity of inflammation, cellular composition e.g. eosinop-
hils, bacterial and fungal elements.
To determine nature of relationship e.g. invasive or non-invasive 
fungus.
To direct potential therapies e.g. biologics.
5.3.5.7.1.2. Technique
Nasal biopsies can be performed in an outpatient clinic under 
local anaesthesia or in the operating theatre(450). The choice 
depends on a number of factors including the reason for per-
forming the biopsy and the size of the biopsy required. For re-
search purposes, the biopsy must be easily performed, painless 
and with a minimal complication rate. For clinical diagnosis the 
need for sufficient sample size has to be balanced with the bur-
den for the patient. It is important that the biopsy is not crushed 
either by surgeon or scrub nurse. This can be achieved with spe-
cific Fokkens forceps(683) or fenestrated punch forceps(684) or in the 
operating theatre with scissors(685). Small biopsies for research 
purposes can be taken from the inferior turbinate after local 
anaesthesia(683, 684). For light microscopic evaluation, the biopsy 
specimens can be embedded in Tissue-Tek II OCT compound 
in a gelatin capsule and frozen immediately. It has been shown 
that biopsies can safely be taken from the olfactory mucosa 
without affecting nasal function or the sense of smell(686).
With the advent of microdebrider powered instrumentation, 
there were initial concerns that tissue would be unsuitable for 
histological analysis. However, Zweig et al. showed in a small 
prospective blinded study (15 cases covering a range of patho-
logies) that there was no significant loss of morphologic features 
in tissue passed through the debrider(687).
In rhinosinusitis, where clinical diagnosis is based on well esta-
blished criteria in specialist care (defined symptoms + endosco-
py and/or imaging), histopathological confirmation of inflam-
mation in surgically removed sinus mucosa is very high though 
there are few high quality studies. Two retrospective studies 
from the UK published 20 years ago evaluated histopathological 
findings from CRSwNP (n=344 and 2021 respectively)(688, 689) and 
confirmed the diagnosis in 95% and 98,5%. 
Misdiagnoses included inverted papillomas, granulomatous 
disease, and malignancy in <1%. Diamantopoulos et al recom-
mended routine histology in all cases on the grounds that the 
medicolegal costs outweighed the service costs whilst Kale et 
al. concluded only first-time bilateral polyps and any unilateral 
polyps should undergo histology but that by implication, subse-
quent routine histology was not required (688, 689).
A similar retrospective cohort from the USA analyzed 380 con-
secutive patients (unilateral and microdebrider cases excluded), 
comprising 180 CRSsNP and 200 of CRSwNP(690). Two cases of 
apparent CRSsNP had sinonasal sarcoidosis and in the CRSwNP 
group, there were five inverted papillomas, two carcinomas, 
one invasive fungal rhinosinusitis, and one sarcoidosis. Thus 
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but PCR may be helpful if fungal elements cannot be detected 
by histopathology(709). A recent study involving 76 patients with 
suspected fungal rhinosinusitis, including the chronic invasive 
forms, showed that histopathology in these cases had a sensi-
tivity of <20%, whereas PCR had a sensitivity of 35%. However, 
fungal disease was proven in less than half of suspicious cases, 
and the result was calculated after considering all the diagnostic 
procedures (staining, culture, histopathology and PCR)(709). 
The EPOS2020 steering group did not consider it essential to do 
histopathology / biopsy at initial presentation to ENT / seconda-
ry care with highly suggestive symptoms of CRS irrespective of 
whether the mucosa was abnormal or normal on endoscopy but 
their responses were unclear regarding whether this was essen-
tial after failure of appropriate medical or surgical treatment in 
ENT / secondary care with continued symptoms and abnormal 
mucosa on endoscopy (Figures 5.3.34., 5.3.35., 5.3.36.).
5.3.5.7.2. Other nasal sampling
5.3.5.7.2.1. Rationale
 In addition to sinonasal tissue, nasal secretions and cells can 
also provide diagnostic and therapeutic information. The most 
common techniques are nasal lavage fluid, nasal suctioning, 
insertion of nasal packs, nasal brushing or scraping, the choice 
being determined by whether inflammatory markers, nasal cells 
for cytology or culture, or ciliary function are required. 
5.3.5.7.2.2 Techniques
Nasal blown secretions are the easiest method to collect nasal 
secretions by simply blowing the nose and collecting the mucus 
in sterile containers directly or by letting the participants blow 
into tissues(710). This method is useful in children, but the sample 
is often small. 
In nasal lavage, fluid is introduced into the nose for a certain 
amount of time and then recollected, with its associated nasal 
secretions. It is easy to perform and well tolerated. Usually 
2-10mL of saline, 0.9% sodium chloride (NaCl) at body tempe-
rature, is instilled with a syringe and the patient is asked not to 
swallow the fluid while the head is reclined. After approxima-
tely 10 seconds(711-714) the head is bent forward and the lavage 
fluid collected in sterile containers. Smaller volumes of iso- to 
mildly hypertonic saline (0.9–1.8%) can be instilled with a nasal 
spray(712). Inflating the cuff of a paediatric tracheostomy tube 
into the nostril has been described to reduce loss of lavage 
fluid(715).
Sterile nasal suctioning devices with a reservoir are also availa-
ble The mucus can be suctioned out and directly frozen at -80 to 
-90°C before further processing or a known quantity of phosp-
hate buffered saline (PBS) or similar agents can be applied which 
stop chemical activity such as proteolysis in the mucus(716). The 
those with 10-100 eosinophils per HPF in two or more areas and 
those with >100 eosinophils per HPF in two or more areas(694). In 
a systematic review of 11 articles reporting high tissue eosinop-
hilia associated with recurrence, a cut-off value of >55 eosinop-
hils / HPF showed the highest sensitivity (0.87; 95%CI, 0.82-0.91), 
specificity (0.97; 95% CI, 0.93-0.99), and Diagnostic Odds Ratio 
(232.7; 95% CI, 91.0-595.1)(699). This was not affected by other 
factors considered in a meta-regression analysis and was , there-
fore, proposed as a useful tool for the diagnosis of eCRS. 
A systematic review of 71 articles considering the histopatho-
logy of human sinus mucosa collected in vivo in patients with 
CRS was undertaken to determine if there were specific histo-
pathological markers of inflammation that help to distinguish 
between the various subgroups of CRS and if such markers 
could serve as prognostic indicators(700). Techniques used for 
the analysis included light microscopy, immunohistochemistry, 
in-situ hybridization, reverse-transcription polymerase chain 
reaction, immunoassays, Western blot, and flow cytometry. 
Twenty-eight considered histopathological findings that 
might be prognostic indicators in CRS and forty-four evaluated 
inflammatory biomarkers in the various subgroups of CRS. The 
amount of eosinophilic infiltration and the overall intensity of 
the inflammatory response were closely related to the prognosis 
and severity of disease, information that is quantifiable by light 
microscopy alone and does not require any specific immuno-
histochemistry techniques. There were discrepancies in the 
methodologies and results of the immunohistochemistry so a 
meta-analysis of the inflammatory markers was not possible, 
but the authors concluded that future studies were needed to 
determine their role as indicators of prognosis or targets for 
tailored therapy. 
Close collaboration between surgeon, radiologist and histopa-
thologist underpins optimal tissue sampling, especially when 
there is co-existent pathology in CRSwNP e.g. inverted papil-
loma or respiratory epithelial adenomatoid hamartomas (REAH)
(701, 702).
A range of specific staining techniques, immunohistochemistry 
and confocal scanning laser microscopy (CSLM) coupled with a 
fluorescence in-situ hybridization (FISH) probe can assist in more 
refined analyses(697, 703, 704). For research purposes also more ad-
vanced techniques like (RT)PCR an micro-arrays are be used(282, 
705, 706). 
The distinction between invasive and non-invasive forms of 
fungal rhinosinusitis depends on the presence or absence of 
fungal hyphae in the mucosa (section 8.6). Special fungal stains 
of the secretions may be required e.g. Gomori methenamine sil-
ver combined with the presence of Charcot Leyden crystals and 
marked eosinophilia in AFRS(707). In acute invasive fungal forms 
frozen section biopsy can assist confirmation, with a sensitivity 
of 87.5% and 100% specificity(708). Granulomatous and chronic 
invasive fungal disease should be confirmed by histopathology 
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technique is well tolerated, has the advantage of minimal sti-
mulation and/or trauma to the mucosa and can be done under 
endoscopic control(717).
Nasal packing can be used to soak up nasal secretions from 
different areas of the nasal cavity (e.g. inferior or middle meatus) 
being weighed before and after insertion into the nose. The 
packs are left in-situ for five minutes and are then placed in a co-
nical tube, washed in NaCl and mechanically squeezed out (e.g. 
with a syringe), then washed again and centrifuged at 1500 g 
for 10 min at 4°C to obtain all secretions(717). An advantage of this 
method is clear discrimination of sides as compared to lavage 
techniques but the technique is uncomfortable and irritates 
the mucosa. Another technique uses reticulated polyurethane 
foam packs (at 60 and 110 pores per inch (PPI)) that may absorb 
secretions better than standard packs with less stimulation of 
the mucosa(718).
Nasal brushing can be performed with a soft sterile brush (bron-
chial brush) in the middle or inferior meatus and then placed in 
tubes containing an appropriate growth medium. The material 
is dislodged by oscillation and the contents centrifuged at 400 g 
for 10 minutes. A specimen of cells is obtained and the superna-
tant can be discarded or the mucus it contains may be used for 
further analysis(719). Nasal scraping may also be obtained using 
a small disposable plastic cup (Rhinoprobe) which is more com-
fortable for the patient and more accurate than swabbing(720). 
The material can be spread onto a slide, fixed and airdried fol-
lowed by staining, usually with Wright-Giesma or Cresol-Red-O. 
Specimens obtained by brushing or with the Rhinoprobe can 
also be used to measure ciliary beat frequency or perform elec-
tron microscopy of particular importance in the diagnosis of pri-
mary ciliary dyskinesia (see 5.3.5.9). Several abnormalities may 
be observed in the ciliary ultrastructure including total or partial 
absence of dynein arms, aberrant organization of the dynein 
arms and/or disorientation but may also be observed in some 
cases of secondary ciliary disease. Therefore, EM evaluation may 
support diagnosis of PCD but is not 100% sensitive or specific.
The EPOS2020 steering group did not consider it essential to do 
cytology (either brushings or lavage) at initial presentation to 
ENT/ secondary care with highly suggestive symptoms of CRS 
irrespective of whether the mucosa was abnormal or normal on 
endoscopy but their responses were unclear regarding whether 
this was essential after failure of appropriate medical or surgical 
treatment in ENT/secondary care with continued symptoms and 
abnormal mucosa on endoscopy (Figure 5.3.37., 5.3.38., 5.3.39.).
5.3.5.8. Blood tests
5.3.5.8.1. Rationale
Until recently most blood tests in patients with CRS are to 
diagnose immunodeficiences and vasculitic disease with sinona-
sal manifestations. However, recently the options to treat with 
Figure 5.3.34. Delphi: Is it essential to do histopathology/biopsy at initial 
presentation in ENT/secondary care with highly suggestive symptoms of 
CRS and abnormal endoscopy ?
Figure 5.3.35. Delphi: Is it essential to do histopathology/biopsy at initial 
presentation in ENT/secondary care in patients with highly suggestive 
symptoms of CRS but normal endoscopy ?
Figure 5.3.36. Delphi: Is it essential to do histopathology/biopsy in CRS after 
failure of appropriate medical or surgical treatment in ENT/secondary care 
with continued symptoms and abnormal mucosa on endoscopy ?
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biologicals has put more emphasis on markers of type 2 disease 
although until today we are not aware of biomarkers that can 
predict response to biologicals in CRS(721).
Immunodeficiencies can be the cause or a contributing factor in 
CRS (see 5.1.2.4. Immune deficiencies and 8.2 Immunodeficien-
cies and their role in CRS). The testing of immune function in all 
patients who present with CRS is almost certainly unwarranted 
as it is likely to produce more false positive results than true 
positives. However, it is recommended that the clinical features 
listed below are used to identify those patients who warrant 
some form of immune testing for testing.
The most common immunoglobulin deficiency in the general 
population is IgA deficiency with a prevalence between 1:173 
and 1:3024(722). Most patients are asymptomatic, but a deficiency 
of IgA would appear to predispose patients to rhinosinusitis and 
allergies(723).
CRS secondary to hypogammaglobulinaemia may present to 
a rhinologist in a manner identical to idiopathic CRS. There are 
some clinical features that may elevate suspicion: association 
with lower respiratory tract infections (pneumonia, particularly 
if recurrent, or bronchiectasis) and recalcitrance to standard 
treatments (and particularly rapid recurrence of symptoms after 
stopping antibiotics). 
5.3.5.8.2. Tests
5.3.5.8.2.1. Markers of type 2 disease
The main biomarkers used at the moment to define type 2 
disease are eosinophils, IgE levels, and in some more specialized 
centres periostin. Other biomarkers are currently under investi-
gation and may provider further guidance in the future. 
There is quite some evidence showing that eosinophils are a 
reasonable surrogate marker for type 2 disease, and that blood 
eosinophils are a reasonable biomarker to predict eosinophilic 
CRS with or without nasal polyps(695, 724, 725). Blood eosinophil 
counts were found to be significantly correlated with the Lund–
Mackay CT and Lund–Kennedy endoscopic scores in patients 
with nasal polyps (r=0.353, p=0.010 and r=0.444, p=0.001, 
respectively)(724).
Receiver operating characteristic curve analysis predicted high 
tissue eosinophilia at blood eosinophil levels above 0.24109/L 
[sensitivity 70.9%, specificity 78.4%, area under the curve (AUC): 
0.792, p<0.01]. eCRS was predicted at eosinophil above 4.27% 
of total WCC (sensitivity 64.1%, specificity 88.5%, AUC 0.797; 
p<0.01; positive predictive value 89.2%, negative predictive 
value 62.4%, positive likelihood ratio 5.57, and diagnostic odds 
ratio 13.71)(695). A cut-off point of blood eosinophils >0.24 109/L 
or eosinophil ratio >4.27% of total WCC was proposed by Ho et 
al.(695).
The EPOS2020 steering group were unclear as to whether it was 
essential to evaluate blood eosinophilia either at initial presen-
Figure 5.3.37. Delphi: Is it essential to do cytology brushings or lavage at ini-
tial presentation in ENT / secondary care with highly suggestive symptoms 
of CRS and abnormal endoscopy ?
Figure 5.3.38. Delphi: Is it essential to do cytology brushings or lavage at ini-
tial presentation in ENT / secondary care in patients with highly suggestive 
symptoms of CRS but normal endoscopy ?
Figure 5.3.39. Delphi: Is it essential to do cytology brushings or lavage in 
CRS after failure of appropriate medical or surgical treatment in ENT / sec-
ondary care with continued symptoms and abnormal mucosa ?
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tation to ENT / secondary care with highly suggestive symptoms 
of CRS irrespective of whether the mucosa was abnormal or 
normal on endoscopy or after failure of appropriate medical 
or surgical treatment in ENT / secondary care with continued 
symptoms and abnormal mucosa on endoscopy (Figure 5.3.40., 
5.3.41., 5.3.42.).
Anti-IgE treatment has been shown to be effective in the 
treatment of CRSwNP (see 6.1.14). There is an association 
between increased levels of total IgE, specific IgE, and eosi-
nophilic inflammation in NPs, which may be of relevance in the 
pathophysiology of nasal polyposis(726). Increased serum IgE has 
been described in a subset of patients with N-ERD(727). A serum 
IgE cut of value of 96 kU/L was shown to be a bad predictor of 
CRSwNP (44% in CRSwNP group versus 28% in CRSsNP and 30% 
in controls)(728).
The EPOS2020 steering group were unclear as to whether it was 
essential to measure total IgE either at initial presentation to 
ENT / secondary care with highly suggestive symptoms of CRS 
irrespective of whether the mucosa was abnormal or normal on 
endoscopy or after failure of appropriate medical or surgical tre-
atment in ENT / secondary care with continued symptoms and 
abnormal mucosa on endoscopy (Figure 5.3.43., 5.3.44., 5.3.45.).
Periostin is both an extracellular matrix protein and matricel-
lular protein that is capable of activating cells by linking integrin 
molecules to cell receptors, promoting tissue remodeling. It may 
be an important biomarker for type 2 immunity and airway aller-
gic inflammation exacerbations(729). It has been established that 
periostin is a downstream molecule of interleukin (IL)-13, and 
that asthmatic patients with high serum periostin react more 
favourable to anti-IL-13 antibodies (lebrikizumab) and anti-IgE 
antibodies (omalizumab)(730). Methylprednisolone and omali-
zumab significantly reduced serum periostin levels in CRSwNP 
patients(731).
Serum periostin was found to be the sole biomarker among 
those tested for detecting the presence of nasal polyps and it 
significantly correlated with Lund-Mackay score in patients with 
chronic rhinosinusitis and asthma(732). Mean serum periostin 
levels were markedly elevated in patients with CRS versus con-
trols. In addition, mean periostin levels were significantly higher 
in CRS patients with nasal polyps as compared with those wit-
hout polyps(728, 733). In the study of Maxfield et al. periostin levels 
did not correlate with sex, smoking history, N-ERD, oral steroid 
use within 1 month of surgery, use of topical steroid nasal spray 
or number of prior sinus operations(733).
5.3.5.8.2.2. Immunoglobulin
It is not clear how much of the immunological testing should 
be undertaken by the rhinologist before referral to an immuno-
logist, and this decision may reflect the individual knowledge 
and expertise of the rhinologist. For CRS patients suspected 
of having humoral immunodeficiency because of the charac-
Figure 5.3.40. Delphi: Is it essential to evaluate blood eosinophilia at initial 
presentation to ENT/secondary care with highly suggestive symptoms of 
CRS and abnormal mucosa on endoscopy ?
Figure 5.3.41. Delphi: Is it essential to evaluate blood eosinophilia at initial 
presentation to ENT/secondary care in patients with highly suggestive 
symptoms of CRS but normal endoscopy ?
Figure 5.3.42. Delphi: Is it essential to evaluate blood eosinophilia in CRS 
after failure of appropriate medical or surgical treatment in ENT/secondary 
care with continued symptoms and abnormal mucosa on endoscopy?
EPOS 2020
172
teristics of their presentation or their response to treatment, 
measurement of serum immunoglobulin levels (IgA and IgG) 
is the key investigation. The best approach for confirming a di-
agnosis of an antibody-deficiency disorder is the measurement 
of serum-specific antibody titers (usually IgG) in response to 
vaccine antigens. This approach involves immunizing a patient 
with protein antigens (e.g., tetanus toxoid) and polysaccharide 
antigens (e.g., pneumococcus) and assessing pre- and post-
immunization antibody levels(734). If the levels are normal, but 
the suspicion of humoral immunodeficiency is high, referral to 
a clinical immunologist is optimal. Further studies, such as flow 
cytometry can then be organized by an expert in the interpreta-
tion of these tests. 
The EPOS2020 steering group did not consider it essential to do 
an objective test of immunodeficiency at initial presentation to 
ENT/ secondary care with highly suggestive symptoms of CRS 
irrespective of whether the mucosa was abnormal or normal on 
endoscopy.
Their responses were unclear regarding whether this was es-
sential after failure of appropriate medical or surgical treatment 
in ENT/secondary care with continued symptoms and abnormal 
mucosa on endoscopy (Figure 5.3.46., 5.3.47., 5.3.48.).
5.3.5.8.2.3. Testing for vasculitis
Vasculitic diseases with sinonasal manifestations usually but not 
always involve multiple organs. Rhinitis, sinusitis, septal perfora-
tion and epistaxis are the most common nasal features related 
to these diseases. There are two relatively common vasculitides 
in the sinunasal tract: 
Granulomatosis with polyangiitis (GPA, formerly Wegener’s 
granulomatosis) and Eosinophilic granulomatosis with polyan-
giitis (EGPA, formerly Churg–Strauss syndrome). Patients with 
granulomatosis with polyangiitis (GPA) affecting the sinonasal 
cavity usually have persistent bleeding, crusting and obstruc-
tion, and may develop a septal perforation. Sometimes the 
manifestations of this vasculitic condition are limited to the 
sinonasal cavity. GPA is strongly associated with anti-neutrophil 
cytoplasmic antibodies (ANCA), and the more widespread and 
severe the presentation, the more likely the serum ANCA is to be 
positive(735). In cases limited to the sinonasal tract the ANCA can 
be negative, making the diagnosis challenging. The combina-
tion of clinical features, positive ANCA serology, necrotizing 
vasculitis and granulomatous inflammation on biopsy esta-
blish the diagnosis(736). However, nasal biopsies often do not 
have enough features specific to this condition to confirm the 
diagnosis, and so biopsies from other involved organs may be 
required. Eosinophilic granulomatosis with polyangiitis (EGPA, 
formerly Churg–Strauss syndrome) is a necrotizing vasculitis 
of small and medium-sized vessels. Among a wide spectrum 
of non-pulmonary symptoms, nasal and sinonasal features are 
common and part of the diagnostic criteria for EGPA(737). This 
Figure 5.3.43. Delphi: Is it essential to measure total IgE at initial presenta-
tion to ENT/secondary care with highly suggestive symptoms of CRS and 
abnormal mucosa on endoscopy ?
Figure 5.3.44. Delphi: Is it essential to measure total IgE at initial presenta-
tion to ENT/secondary care in patients with highly suggestive symptoms of 
CRS but normal endoscopy ?
Figure 5.3.45. Delphi: Is it essential to measure total IgE in CRS after failure 
of appropriate medical or surgical treatment in ENT/secondary care with 
continued symptoms and abnormal mucosa on endoscopy ?
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condition typically develops in patients with adult onset asthma 
and the sinonasal manifestation is chronic rhinosinusitis with 
eosinophilic nasal polyps. Many of these patients also have mid-
dle ear disease(738). 
Anti-neutrophil cytoplasmic antibodies (ANCAs) are a group of 
autoantibodies, mainly of the IgG type, against antigens in the 
cytoplasm of neutrophil granulocytes and monocytes. They are 
detected as a blood test in a number of autoimmune disorders, 
but are particularly associated with systemic vasculitis, so called 
ANCA-associated vasculitides. ANCAs are associated with small 
vessel vasculitides including granulomatosis with polyangiitis, 
microscopic polyangiitis, primary pauci-immune necrotizing 
crescentic glomerulonephritis (a type of renal-limited microsco-
pic polyangiitis), eosinophilic granulomatosis with polyangiitis 
and drug induced vasculitides. PR3 directed c-ANCA is present 
in 80-90% of granulomatosis with polyangiitis, 20-40% of 
microscopic polyangiitis, 20-40% of pauci-immune crescentic 
glomerulonephritis and 35% of eosinophilic granulomatosis 
with polyangiitis. c-ANCA (atypical) is present in 80% of cystic 
fibrosis (with BPI as the target antigen) and also in inflammatory 
bowel disease, primary sclerosing cholangitis and rheumatoid 
arthritis (with antibodies to multiple antigenic targets). p-ANCA 
with MPO specificity is found 35% of eosinophilic granulomato-
sis with polyangiitis. p-ANCA with specificity to other antigens 
are associated with inflammatory bowel disease, rheumatoid 
arthritis, drug-induced vasculitis, autoimmune liver disease, 
drug induced syndromes and parasitic infections. 
Cocaine and levamisole, which is a common adulterant of co-
caine, can cause an ANCA positive vasculitis(739-741).
The EPOS2020 steering group did not consider it essential 
to do an objective test for vasculitis at initial presentation to 
ENT/ secondary care with highly suggestive symptoms of CRS 
irrespective of whether the mucosa was abnormal or normal on 
endoscopy but their responses were unclear regarding whether 
this was essential after failure of appropriate medical or surgical 
treatment in ENT/secondary care with continued symptoms and 
abnormal mucosa on endoscopy (Figure 5.3.49., 5.3.50., 5.3.51.).
5.3.5.8.2.4. Testing for sarcoidosis
Sarcoidosis is a complex disease with manifold clinical manifes-
tations. A case suspicious for sarcoidosis requires clinical, radio-
logical and histological evidence of non-caseating granulomas. 
Serum soluble interleukin-2 (sIL-2R), angiotensin converting 
enzyme (ACE) and lysozyme levels have become useful tools in 
the diagnosis of sarcoidosis and for evaluating disease activity, 
in addition to fluorodeoxyglucose-positron emission tomograp-
hy (FDG-PET). Serum ACE is the most widely used laboratory test 
for the investigation of sarcoidosis(742). Elevated serum levels of 
ACE, IL-2R, and lysozyme are usually associated with more ag-
gressive disease and multiple-organ involvement(743).
Figure 5.3.46. Delphi: Is it essential to do an objective test of immunodefi-
ciency at initial presentation in ENT/secondary care with highly suggestive 
symptoms of CRS and abnormal endoscopy ?
Figure 5.3.47. Delphi: Is it essential to do an objective test of immunodefi-
ciency at initial presentation in ENT/secondary care in patients with highly 
suggestive symptoms of CRS but normal endoscopy ?
Figure 5.3.48. Delphi: Is it essential to do an objective test of immunodefi-
ciency in CRS after failure of appropriate medical or surgical treatment in 
ENT/secondary care with continued symptoms and abnormal mucosa ?
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5.3.5.8.2.5. Testing for N-ERD
Oral provocation test with aspirin is the most common inves-
tigation used to identify hypersensitivity reactions to aspirin 
(see 5.3.5.15). For details how to perform see the recently 
published EAACI position paper: Diagnosis and management 
of NSAID-Exacerbated Respiratory Disease (N-ERD)(39). However, 
for those patients who have a higher risk of severe reactions, 
flow cytometry-assisted basophil activation testing (FAST) and 
functional-eicosanoid-test (FET) can be helpful tools to elucidate 
the diagnosis, if they are available(744, 745).
5.3.5.9. Microbiology 
5.3.5.9. 1. Rationale
Sinonasal microbiological sampling is important in the diagnos-
tic work-up of patients with rhinosinusitis. The importance of 
microbes in the aetiology of acute bacterial rhinosinusitis (ABRS) 
is well recognized(553) whereas the situation in CRS is less clear 
but is of increasing interest, facilitated by improved identifica-
tion techniques(746, 747).
5.3.5.9.2. Tests
5.3.5.9.2.1. Culture-dependent Techniques
Sinus aspirates 
A maxillary sinus tap (MST) has historically been the gold 
standard technique for obtaining sinus cultures by providing 
a representative specimen of the antral contents with minimal 
nasal contamination(748, 749). It can be performed under local 
anaesthesia via the inferior meatus or canine fossa but is often 
associated with discomfort, potentially risks orbital, dental and 
nerve injury and only provides information on the maxillary 
sinus(748).
The sphenoid sinus can also be approached directly to obtain an 
aspirate for culture(750). In the past the frontal sinus has also been 
‘punctured’ through the anterior wall to obtain a sample(751) but 
this is of greater magnitude, usually requires a general anaes-
thetic and is generally part of a therapeutic surgical procedure 
rather than being purely diagnostic(752).
Nasal swabs 
Nasal swabs are the most commonly used sampling method 
in the nasal cavity as they are easy to use, non-invasive and 
generally well tolerated without the need for local anaesthesia. 
However, there is a poor correlation between undirected nasal/
nasopharyngeal and endoscopically directed middle meatal 
(EDMM) culture swabs, largely due to contamination from the 
nasal vestibule and cavity. EDMM swabs show a high concor-
dance with maxillary sinus aspirates and cultures(753-758) and thus 
have become the mainstay of microbial sampling in patients 
with rhinosinusitis (Table 5.3.7.). A meta-analysis confirmed that 
Figure 5.3.49. Delphi: Is it essential to do an objective test for vasculitis at 
initial presentation in ENT/secondary care with highly suggestive symptoms 
of CRS and abnormal endoscopy ?
Figure 5.3.50. Delphi: Is it essential to do an objective test for vasculitis at 
initial presentation in ENT/secondary care in patients with highly suggestive 
symptoms of CRS but normal endoscopy ?
Figure 5.3.51. Delphi: Is it essential to do an objective test for vasculitis 
in CRS after failure of appropriate medical or surgical treatment in ENT/
secondary care with continued symptoms and abnormal mucosa on endos-
copy ?
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EDMM is a highly sensitive and accurate culture method for 
ABRS and may be more sensitive than maxillary sinus taps (MST) 
given the presence of pathogenic bacteria not found on antral 
lavage(759). For known pathogenic bacteria for ABRS and in com-
parison to MST, EDMM had a sensitivity of 80.9%, a specificity of 
90.5%, a positive predictive value of 82.6%, a negative predictive 
value of 89.4%, and an overall accuracy of 87.0% (95% confi-
dence interval, 81.3%-92.8%). 
The more recent meta-analysis by Smith et al. showed that bac-
terial pathogens are recovered by sinus puncture or EDMM cul-
ture in 53% of patients with suspected ABRS, based on studies 
requiring patients to meet clinical criteria, with most studies also 
requiring radiographic and/or endoscopic confirmation.
There is limited research on how representative middle meatal 
swabs are for the remaining sinuses. Although not a direct com-
parative study, a recent retrospective study by Miller et al.(760) de-
monstrated different pathogens in two or more of the swabs of 
40% of patients undergoing multiple sinus cultures. While only 
5% of the patients in this study received clinical benefit from 
changing the antibiotic, it does suggest that bacterial cultures 
from the middle meatus may not be entirely representative of all 
the sinuses.
EDMM culture swabs have become the mainstay of microbial 
sampling in patients with rhinosinusitis.
Nasal blown secretions 
Nasal blown secretions may be readily obtained in primary care, 
particularly for paediatric patients as it avoids the discomfort of 
a nasal swab. The few comparative studies comparing expelled 
mucus to standard culture swab techniques suggest a high con-
cordance rate (>90%) for the detection of common upper airway 
pathogens when nasal secretions are present, but as might be 
expected, this rate reduces to less than 50% in the absence of 
obvious secretions(710, 761).
Nasal and sinus lavage 
Nasal lavage is not an accurate technique for the culturing of 
sinus contents due to contamination by nasal flora and minimal 
Table 5.3.7. Bacteriology of rhinosinusitis. Correlation of middle meatus versus maxillary sinus.
Author, year, (ref) Number of 
samples
Type of   rhinosi-
nusitis
Technique Concordance
Joniau 2005(756) 26 ARS Endoscopic swab (MM) vs. maxillary sinus tap 88.5%
Casiano 2001(755) 29 ARS (intensive care) Endoscopic tissue culture (MM) vs. maxillary sinus tap 60.0%
Talbot 2001(840) 46 ARS Endoscopic swab (MM) vs. maxillary sinus tap 90.6%
Vogan 2000(754) 16 ARS Endoscopic swab (MM) vs. maxillary sinus tap 93.0%
Gold and Tami 1997(841) 21 CRS Endoscopic tap (MM) vs. maxillary aspiration during ESS 85.7%
Klossek 1996(757) 65 CRS Endoscopic swab (MM) vs. maxillary aspiration during ESS 73.8%
sinus penetration in an unoperated patient. These issues may be 
circumvented by direct sinus lavage through an endoscopically 
placed maxillary sinus catheter. Studies comparing direct sinus 
lavage to EDMM swabs have demonstrated higher bacterial 
yields and increased recovery of anaerobic pathogens using the 
former technique(762, 763) and this sampling technique could be 
facilitated by balloon technology as many devices have inbuilt 
catheters that can be used for lavage drainage and antibiotic 
irrigation. The clinical relevance of the anaerobic organisms and 
the targeted culture and treatment of isolated infected sinuses 
remain to be studied. 
5.3.5.9.2.2. Culture-independent techniques 
Standard culture approaches offer only a limited range of de-
fined conditions for microbial growth and , therefore, omits taxa 
that require alternative conditions, including slower-growing 
organisms that are outcompeted for a limited range of nutrient 
sources or those that depend upon cooperation to survive in 
vivo (such as cross-feeding relationships). The disparity between 
the identification of microbes by culture and those (viable but 
nonculturable or difficult to culture) identified by molecular 
methods has been termed “the great plate count anomaly,” with 
estimates of the nonculturable portion of microbial communi-
ties ranging between 25% and 99%(764, 765).
Next generation sequencing
Next generation sequencing techniques have enabled identifi-
cation of micro-organisms previously unidentifiable on routine 
culture studies(450). Samples can be obtained using guarded, 
flocculated microbial swabs or by tissue biopsy with high 
concordance noted between the two (847). DNA is extracted from 
the obtained specimens and sequenced using primers specific 
for conserved genetic regions within bacterial or fungal micro-
organisms. Sophisticated bio-informatic pipelines that reference 
known microbial libraries then allow identification and relative 
quantification of all the organisms present. Initially a research 
tool, such technology is now commercially available for clinical 
use. Studies comparing culture-directed analysis with next 
AR, acute rhinosinusitis; CRS, chronic rhinosinusitis; MM, middle meatus; ESS, endoscopic sinus surgery.
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procedures, including microbiology, can be performed. 
The role of microbial sampling in CRS remains unclear. Pros-
pective trials are needed to examine the relevance of routine 
microbiologic cultures and antibiotic treatment in CRS patients 
before sound recommendations can be made. 
It is possible that the incorporation of modern culture-indepen-
dent techniques into clinical practice may improve treatment 
outcomes, but further research is required. The EPOS2020 stee-
ring group did not consider it was essential to do microbiology 
at initial presentation to ENT/ secondary care with highly sug-
gestive symptoms of CRS irrespective of whether the mucosa 
was abnormal or normal on endoscopy.
However, they were unclear as to whether it was essential to do 
microbiology in CRS after failure of appropriate medical or surgi-
cal treatment in ENT/secondary care with continued symptoms 
and abnormal mucosa on endoscopy (Figures 5.3.52., 5.3.53., 
5.3.54.).
5.3.5.10. Mucociliary clearance testing
5.3.5.10.1. Rationale
By their coordinated movement, the cilia lining the respiratory 
epithelium transport the mucus layer with entrapped inhaled 
particles from the nasal cavity towards the hypopharynx. 
Normal mucociliary transport (MCT) is essential for the main-
tenance of healthy sinonasal cavities. With infection or conge-
nital dysfunction of the cilia as in PCD, MCT is inadequate or 
absent. In PCD, lack of MCT may lead to CRS and bronchiectasis. 
Mucostasis, hypoxia, microbial products and toxic inflammatory 
mediators in CRS may induce secondary ciliary changes, i.e. 
secondary ciliary dyskinesia (SCD), with subsequent inadequate 
MCT(450).
The mucociliary clearance (MCC) time is considered to be nor-
mal below 15 minutes and should be less than one hour. 
The saccharine test evaluates the time taken to experience a 
sweet taste after placement of a 1-2mm particle of saccharine 
on the inferior turbinate mucosa, 1cm from the anterior end. The 
patient must sit quietly with the head bent forward and without 
sniffing, coughing, sneezing, drinking or eating during the in-
vestigation. Alternatively, one can monitor the time needed for a 
dye such as methylene blue to be transported from the mucosa 
of the anterior third of the nasal cavity towards the hypopha-
rynx. Other substances including technetium- 99m-labeled iron 
oxide have also been used. 
As the MCC time can only be measured in cooperative patients 
with patent nasal cavities and in the absence of severe mucosal 
disease, it has limited diagnostic value in certain patients. It also 
has low sensitivity and specificity and requires significant time 
investment. In the context of the clinical relevance of MCT, it has 
recently been demonstrated that nasal lavages, a commonly 
recommended treatment for many sinonasal conditions, reduce 
generation sequencing have shown significant discordance, 
with sinus culture poorly predicting resident microbiota(154). In 
direct comparisons between results of culture and sequencing 
approaches, the dominant bacteria identified in most patients 
by sequencing were identified by culture only approximately 
half of the time. Of those taxa present at a relative sequence 
abundance of 1%, only about 5% were also identified by culture, 
revealing the extent of information on lower-abundance taxa 
missed by standard clinical culturing. This may in part explain 
poor treatment response despite culture-directed antibiotic 
therapy. It is possible that the incorporation of modern culture-
independent techniques into clinical practice may improve 
treatment outcomes, but further research is required.
Future techniques, particularly in the microbiology research on 
inflammatory mucosal diseases such as CRS include sequencing 
of all DNA (metagenomics) or all transcribed RNA (metatrans-
criptomics) or identification of proteins (metaproteomics) or 
metabolites (metabolomics) which should provide greater 
insights into the true diversity and structure, as well as the full 
genetic potential and in-situ activity, of the mucosa-associated 
microbiota(746).
Outcomes
 There is no evidence that microbiological assessment of nasal 
or sinus samples has any impact on outcomes in rhinosinusi-
tis. 80% of individuals with ABRS typically improve within two 
weeks without treatment(766) and there is no evidence showing 
superiority of culture-directed antibiotic therapy over empi-
ric treatment for this condition. Although low-level evidence 
suggests a possible role for culture-directed antibiotic therapy 
in the treatment of acute exacerbations of CRS, no high-level 
evidence studies exist supporting the use of antibiotics in CRS. 
Furthermore, there is a paucity of literature comparing outco-
mes of culture-directed versus empirical antibiotic treatment for 
this condition. 
Microbial sampling for uncomplicated ABRS is not routinely 
recommended.
There is no evidence that microbiological assessment of nasal 
or sinus samples has any impact on outcomes in rhinosinusitis. 
Although antibiotics provide a small but significant benefit for 
clinical outcomes in adults and children with ABRS (see 4.6.3.1. 
and 4.6.3.2.) most patients suffer from post-viral ARS where 
antibiotics are not helpful (see 4.6.3.3. and 4.6.3.4). Furthermore, 
there are no studies ishowing superiority of culture-directed 
antibiotic therapy over empiric treatment for this condition. 
Recommendations 
Microbiological assessment is not routinely recommended in 
the diagnosis of rhinosinusitis. In ABRS non-responsive to empi-
rical antimicrobial treatment and topical nasal steroids, referral 
is recommended to an ENT specialist where further diagnostic 
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Figure 5.3.52. Delphi: Is it essential to do microbiology at initial presenta-
tion to ENT/secondary care with highly suggestive symptoms of CRS and 
abnormal mucosa on endoscopy ?
Figure 5.3.53 Delphi: Is it essential to do microbiology at initial presentation 
in ENT/secondary care in patients with highly suggestive symptoms of CRS 
but normal endoscopy ?
Figure 5.3.54 Delphi: Is it essential to do microbiology in CRS after failure of 
appropriate medical or surgical treatment in ENT/secondary care with con-
tinued symptoms and abnormal mucosa on endoscopy ?
the MCC time(767).
The EPOS2020 steering group did not consider it essential to do 
an objective test of mucociliary function at initial presentation 
to ENT / secondary care with highly suggestive symptoms of 
CRS irrespective of whether the mucosa was abnormal or nor-
mal on endoscopy but their responses were unclear regarding 
whether this was essential after failure of appropriate medical 
or surgical treatment in ENT/secondary care with continued 
symptoms and abnormal mucosa on endoscopy (Figures 5.3.55., 
5.3.56., 5.3.57.).
5.3.5.11. Nasal nitric oxide
5.3.5.11.1. Rationale
Nitric oxide (NO) is a colourless, odourless gas that is present in 
air exhaled through the mouth or nose. NO is produced from 
arginine and oxygen by nitric oxide synthase (NOS). Constituti-
vely expressed neuronal and endothelial forms exist as well as 
an induced form, iNOS, which appears to be upregulated within 
the respiratory tract in response to pro-inflammatory signals. 
Exhaled NO (eNO) levels are raised in eosinophilic asthma and 
measurement of this has become a standardised, but not yet 
widespread, tool in the diagnosis and management of asthma. 
It can potentially provide a rapid, low cost objective measure of 
lower airway inflammation. Most NO is produced in the sinuses, 
far less by the nasal mucosa and the lower respiratory tract(450). 
NO and its metabolites are toxic to micro-organisms and likely 
form part of the innate defence mechanism of the respiratory 
tract. NO may also stimulate ciliary beat frequency within the 
epithelium and regulate nasal vascular tone.
5.3.5.11.2. Diagnostic accuracy
Nasal NO (nNO) can be measured in either nostril and shows 
no diurnal variation. The measurement is quick, reproducible, 
feasible and best assessed with an aspiration flow of 700 ml/min 
during breath-holding for 10 seconds(768). Humming during nNO 
measurement initially increases levels considerably in healthy 
subjects. If low values are obtained, measuring nNO during 
humming can increase the specificity of the measurement(768). 
Healthy controls usually have nNO levels above 300ppb(769).
Nasal NO testing using palatal closure manoeuvres has diag-
nostic accuracy similar to electron microscopy and/or genetic 
testing for primairy ciliairy dyskinesia  when cystic fibrosis has 
been ruled out(770). Nasal NO values below 77 ppb are very sug-
gestive of PCD but higher values are occasionally found. CF also 
has generally low values (70-300 ppb), and the presence of nasal 
polyps is associated with significantly lower nNO levels than in 
CF patients without nasal polyps(771) due to obstruction of the 
sinuses. Thus, in nasal polyps, patients may paradoxically have 
low nNO and normal or high eNO from the chest.
Nasal NO is a sensitive and specific test for PCD in cooperative 
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patients (generally over five years old) with a high clinical suspi-
cion for this disease. To a lesser extent it may also be a useful ad-
junct in a potential diagnosis of CF. Whilst not commonly used 
as a specific diagnostic tool in CRS, it may be used to monitor 
the response to treatment in these conditions.
5.3.5.12. Other tests for PCD
5.3.5.12.1. Rationale
No ideal test is available for the diagnosis of PCD in routine 
practice(772). In cases of suspected PCD in a patient with CRS 
since birth, a family history of PCD and/or associated features of 
Kartagener syndrome (situs inversus and infertility), one should 
consider diagnostic tests of ciliary function by evaluation of 
ciliary beat frequency (CBF), EM evaluation of the dynein arms 
of the cilia and/or evaluation of the cilia after ciliogenesis in 
vitro(450). Harvested epithelial cells can be evaluated for ciliary 
beat frequency (CBF) and the ciliary wave form analysed in 
detail by digital high-speed video imaging. The evaluation of the 
CBF as well as assessment of their coordinated movement can 
be performed by computerized programs using a Fast Fourier 
analysis. Normal values of CBF vary depending on the metho-
dology used, the age of the patient and the culture conditions. 
The demonstration of normal CBF and beat pattern excludes the 
diagnosis of PCD. Recently, a novel technique for quantification 
of CBF has been reported using phase-contrast microscopy 
images, estimating ciliary motion by means of an optical flow 
algorithm(773). In a tertiary referral centre, one third of patients 
referred with suspected PCD were eventually diagnosed with 
the condition(774).
As these techniques are not available in routine ENT practice, 
one should rely on measuring nNO levels in cases of suspected 
PCD; low nNO levels have been associated with PCD and , there-
fore, represent an excellent screening tool (see above). In ad-
dition, screening for genetic mutations known to be associated 
with PCD, as well as genetic counselling, is recommended(775).
5.3.5.13. Sweat testing
5.3.5.13.1. Rationale
Cystic fibrosis (CF), caused by mutations in the CF transmem-
brane conductance regulator (CFTR) gene, continues to present 
diagnostic challenges. It is recommended that diagnoses as-
sociated with CFTR mutations in all individuals, from newborn 
to adult, be established by evaluation of CFTR function with a 
sweat chloride test(776). Sweat chloride testing should be perfor-
med according to approved procedural guidelines published 
in established, Int protocols such as the CLSI 2009 Guidelines 
(https://clsi.org).
Figure 5.3.55 Delphi: Is it essential to do an objective test of mucociliary 
function at initial presentation in ENT/secondary care with highly sugges-
tive symptoms of CRS and abnormal endoscopy ?
Figure 5.3.56 Delphi: Is it essential to do an objective test of mucociliary 
function at initial presentation in ENT/secondary care in patients with 
highly suggestive symptoms of CRS but normal endoscopy ?
Figure 5.3.57 Delphi: Is it essential to do an objective test of mucociliary 
function in CRS after failure of appropriate medical or surgical treatment in 
ENT/secondary care with continued symptoms and abnormal mucosa ?
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5.3.5.13.2. Advice of the Consensus Guidelines from the 
Cystic Fibrosis Foundation
Newborns with a positive CF newborn screen (NBS), to incre-
ase the likelihood of collecting an adequate sweat specimen, 
should have the test performed bilaterally and when the infant 
weighs >2 kg, and is at least 36 weeks of corrected gestational 
age. Newborns greater than 36 weeks gestation and >2 kg body 
weight with a positive CF newborn screen, or positive prenatal 
genetic test, should have sweat chloride testing performed as 
soon as possible after 10 days of age, ideally by the end of the 
neonatal period (four weeks of age).
In infants with presumptive CF identified through NBS, CF 
treatment should not be delayed while efforts to establish a 
diagnosis of CF are initiated. Sweat chloride analysis should be 
performed within a few hours of sweat collection. In individuals 
presenting with a positive newborn screen, clinical features 
consistent with CF, or a positive family history, a diagnosis of CF 
can be made if the sweat chloride value is ≥60 mmol/L.
In individuals with a positive newborn screen, a sweat chloride 
<30 mmol/L indicates that CF is unlikely.
Individuals with clinical features that may be consistent with CF 
who have a sweat chloride <30 mmol/L indicates that CF is less 
likely. It may, however, be considered if evolving clinical criteria 
and/or CFTR genotyping support CF and not an alternative di-
agnosis. Individuals presenting with a positive newborn screen, 
symptoms of CF, or a positive family history, and sweat chlo-
ride values in the intermediate range (30-59 mmol/L) on two 
separate occasions may have CF. They should be considered for 
extended CFTR gene analysis and/or CFTR functional analysis.
Individuals who are screen-positive and meet sweat chloride 
criteria for CF diagnosis should undergo CFTR genetic testing 
if the CFTR genotype was not available through the screening 
process or is incomplete(776).
The EPOS2020 steering group did not consider it essential to do 
an objective test for CF at initial presentation to ENT/ secondary 
care with highly suggestive symptoms of CRS irrespective of 
whether the mucosa was abnormal or normal on endoscopy but 
their responses were unclear regarding whether this was essen-
tial after failure of appropriate medical or surgical treatment in 
ENT / secondary care with continued symptoms and abnormal 
mucosa on endoscopy (Figures 5.3.58., 5.3.59. and 5.3.60.).
5.3.5.13.3. Indications and possibilities of genetic testing
Genetic testing is mainly used for CF, Primary Ciliary Dyskinesia 
(PCD) and to a lesser extent in chronic rhinosinusitis (CRS)(777). 
CF results from mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) which is located on the long 
arm of chromosome 7. Normally a 6.5-kb mRNA encodes CFTR 
which is a 1490-amino acid integral membrane protein. It is an 
ion channel responsible for chloride exchange in epithelial cells. 
To date more than 2000 CFTR variants have been described(778). 
Figure 5.3.58 Delphi: Is it essential to do an objective test for cystic fibrosis at 
initial presentation in ENT/secondary care with highly suggestive symptoms 
of CRS and abnormal endoscopy ?
Figure 5.3.59 Delphi: Is it essential to do an objective test for cystic fibrosis at 
initial presentation in ENT/secondary care in patients with highly suggestive 
symptoms of CRS but normal endoscopy ?
Figure 5.3.60 Delphi: Is it essential to do an objective test for cystic fibrosis 
in CRS after failure of appropriate medical or surgical treatment in ENT/
secondary care with continued symptoms and abnormal mucosa on endos-
copy ?
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PCD. Despite promising targets for future research bitter taste 
receptors are currently tested for the phenotype of patients as 
either supertasters, intermediate or non-tasters.
5.3.5.14. Lower respiratory tract assessment
5.3.5.14.1. Rationale
A significant number of patients with rhinosinusitis have invol-
vement of the lower respiratory tract embodied in the concept 
of the 'united airways'. A patient's own assessment of their chest 
symptoms (wheeze, shortness of breath, chest tightness, and 
cough) and severity is often poor or they may even be unaware 
that the lower respiratory tract is affected so objective assess-
ment is necessary(34).
5.3.5.14.2. Techniques
Peak flow
This is a simple test in which the individual stands and blows 
as hard as possible through a disposable filtered mouthpiece 
into a peak flow meter. The best of three attempts is taken and 
compared with charts of normative data for sex, age and height. 
If the result is not within the normal range, it can be repeated 
15 minutes after administration of a bronchodilator such as 
salbutamol, to assess reversibility. A 20% increase and absolute 
improvement of 60l/min is suggestive of asthma though the 
diagnosis cannot be made on a single test. Alternatively, an 
exercise test such as running for 10-15 minutes followed by peak 
flow measurements every 5 minutes which show a decrease of 
>10% or >200ml from baseline of FEV1 for adults or a fall in PEF 
of >15% in children is also indicative of asthma(788-792).
Patients can be prescribed a peak flow meter and chart on 
which they can record their daily measurements, ideally perfor-
med at the same time morning and evening. They can be asked 
to keep the record over several weeks and to bring the chart 
to their next outpatient visit. Average daily diurnal variation is 
calculated as the day’s highest PEF minus the day’s lowest PEF, 
divided by the mean PEF for the day and then averaged over the 
course of a week. A variability of >10% in adults and >13% in 
children is suggestive of asthma(792-794).
Spirometry
This technique provides additional information in the outpatient 
setting (Table 5.3.8.). The individual is asked to blow as hard as 
possible into a tube through a filtered disposable mouthpiece 
and expiratory effort continued as long as possible. Again, the 
best of three attempts is used to derive the following values:
• Forced expiratory volume in one second (FEV1)
• Forced vital capacity (FVC)
• Ratio of FEV1/FVC. This should be >70-80% in healthy 
adults and >90% in healthy children(305, 788-791).
Comparative normative data are available. Various abnormal 
Newborn screenings date back to 1979 in New Zealand and are 
performed by serial, two-tiered, or, more recently, three-tiered/
hybrid-based methods(778). The screenings are based on im-
munoreactive trypsinogen (IRT). There are three approaches: 1) 
one starts with the measurement of IRT where measurements 
above a defined cut-off are followed up by genetic analysis to 
determine specific mutations in the CFTR gene (IRT/DNA); 2) An 
initial IRT measurement with defined cut-offs is followed by IRT 
measurement on a second specimen collected two weeks later 
(IRT/IRT); 3) Pancreatitis-associated protein is used following 
an increased IRT (IRT/pancreatitis-associated protein method). 
Direct sandwich immunoassays with either monoclonal or 
polyclonal antibodies are used and may also be multiplexed. The 
advantage is to test multiple samples in a patient at a relati-
vely low cost. The genetic analysis (from blood or oral mucosal 
scrapings) are done by Sanger sequencing and quantitative 
methods. Nowadays new high throughput approaches such as 
Next Generation Sequencing, targeted deep sequencing (TDS) 
and Droplet Digital PCR technologies are used(779). Recently, 
Zeevi et al.(780) proposed a new method called allele sensitive 
proliferation sequencing (ASP-SEQ) which is more sensitive than 
targeted deep sequencing or digital PCR methods.
PCD is a genetically heterogeneous autosomal-recessive motile 
ciliopathy associated with 32 genes. Clinical manifestations are 
situs inversus, neonatal respiratory distress, progressive bron-
chiectasis, and respiratory failure in young adulthood(781). Tests 
include including nNO, high speed videomicroscopy analysis 
(HSVA), transmission electron microscopy (TEM), immunofluo-
rescent tests of ciliary proteins and genetic testing. Structural 
abnormalities can be confirmed by genetic testing of biallelic 
mutations in known PCD(782). The most prevalent mutations 
occur in five genes (DNAH5; DNAH11; DNAI1; CCDC39; CCDC40)
(783). Genetic tests combining Intron-exon level copy number 
variations (CNVs) and whole-exome sequencing (WES) seem to 
be the most efficient approach(781). 
For CRS genomic analysis the most studied targets are bitter 
taste receptors especially T2R38(784) which are analysed by eg. 
reverse transcription polymerase chain reaction with 7900HT 
fast using allele-specific probes and primers(785) or single nu-
cleotide polymorphisms (SNPs)(117). Other genetic approaches 
target single nucleotide polymorphism genotypes in potassium 
channels (eg. by Illumnia Human-Hap550 BeadChip or Illumina 
Human610-Quad BeadChip)(786). A more recent genome-wide as-
sociation study investigated the role of ALOX15 in CRS(436). More 
targeted analyses eg. for methylated genes like FZD5 playing a 
role in CRSwNP can be detected using methyl-CpG-binding do-
main sequencing (MBD-seq) and validated using methylation-
specific polymerase chain reaction(787).
In summary, many potential genes influencing CRS have been 
investigated but for diagnosis or confirmation of the latter 
genetic testing has only been routinely established for CF and 
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5.3.5.15. Diagnosis of N-ERD
5.3.5.15.1. Rationale
NSAID-exacerbated respiratory disease (N-ERD) is a chronic eosi-
nophilic, inflammatory disorder of the respiratory tract occur-
ring in patients with asthma and/or chronic rhinosinusitis with 
nasal polyps (CRSwNP), symptoms of which are exacerbated by 
NSAIDs, including aspirin. As the condition is likely under-diag-
nosed and outcomes are worse in these patients, it is important 
to identify the hypersensitivity. It is also important so that af-
fected patients can be warned about avoidance, whilst enabling 
the non-sensitive to use therapeutic aspirin and NSAIDs and to 
allow consideration of the option of aspirin desensitization in 
those who are sensitized(797).
5.3.5.15.2. Diagnosis
Diagnosis of N-ERD is mainly based on a patient history of at 
least one documented reaction to aspirin or NSAIDs though it is 
recognised that history alone is not always reliable, especially as 
asthmatic patients are often warned to avoid these drugs(798). 
Thus, aspirin provocation tests are needed when the history is 
not clear (Figure 5.3.61.).
5.3.5.15.3. Techniques
A provocation test may be undertaken via oral, bronchial or na-
sal routes (Table 5.3.10.). An oral provocation test  with aspirin is 
the most common investigation used but is not without poten-
tial risk. Oral or bronchial challenge starts with a very low dose, 
usually around 30 mg aspirin, which is then given in gradually 
increasing doses(799). Although bronchial challenge can take only 
four hours to perform(800), both these methods can result in se-
vere symptoms in over 50% of subjects, especially in asthmatics, 
and may necessitate emergency treatment, hospital admission 
and close monitoring. Since the reaction can be delayed, the 
challenge often requires more than 1 day and and subsequent 
overnight admission.
Nasal provocation with lysine aspirin (LAS), a truly soluble form 
of aspirin, is an approach that has gained popularity as it can 
be performed in severe asthmatics due to the rarity of systemic 
reactions. It has been standardized, is reproducible(801) and may 
patterns may be seen.
1) Obstruction: FEV1 is low, FVC normal and FEV1/FVC <70-80% 
or below the lower limit of normal (lowest 5% of the reference 
population)(305, 789).
This is characteristic of asthma and likely reversible with a 
beta-agonist eg salbutamol, albuterol . The likelihood of a false 
negative result is increased if a short-acting beta-agonist was 
administered within 4 hours of the test, or if a long-acting beta 
agonist was administered within 15 hours of the test.
An increase of FEV1 by >12% from baseline (in adults and child-
ren) or an increase of >200ml after a short-acting bronchodilator 
(in adults) indicates significant reversibility.
Caution is advised with the use of a fixed FEV1/FVC ratio as a 
cut-point, as it results in false-positive diagnoses of obstruc-
tion in older adults and potentially false-negative diagnoses of 
obstruction in younger adults, given a natural decline in FEV1 
with age(795, 796).
2) Restriction: FEV1 and FVC are low with a normal FEV1/FVC.
This is characteristic of a fibrosis or granulomatous process such 
as sarcoid and is not reversible with bronchodilators. To confirm 
restriction a measurement of lung volumes (total lung capacity, 
residual volume) is necessary.
Spirometry post-initiation of controller therapy
In adults, if after four weeks of anti-inflammatory, controller 
therapy (such as an inhaled corticosteroid or combined inhaled 
corticosteroid and long-acting beta agonist), FEV1 has improved 
by over 12% and over 200 mL (or PEF by over 20%), this can also 
be seen as supportive of a diagnosis of asthma in the appropri-
ate clinical context(792).
If not already involved, the presence of abnormal measure-
ments or high clinical suspicion should prompt referal to a chest 
physician. They also have at their disposal other investigati-
ons including bronchial provocation testing, with or without 
pharmacologic agents and fractional exhaled nitric oxide as 
well as imaging of the chest. The availablility of expired nitric 
oxide measurement to rhinologists as well as pulmonologists 
has improved diagnosis and reduced the use of peak flow as this 
provides immediate confirmation of inflammation in the lower 
(and upper) respiratory tract (see 5.3.5.9.; Tables 5.3.8.; 5.3.9.).
Table 5.3.8. Comparison of peak expiratory flow and spirometry in the assessment of possible asthma (Scadding and Lund 2004(842))
Setting Advantages Disadvantages
Spirometry Outpatients Most reliable
Reproducible
Results in 15-30 mins
Pre- and post-bronchodilator
Snapshot
Expense
Trained operator
Patient compliance
Peak flow Outpatients / Home Sensitive
Easy
Cheap
Less reliable than FEV1
Patient compliance
Snapshot or wait ~ 4 weeks for home values
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be done in the outpatient setting but it should still be perfor-
med under medical supervision with resuscitation equipment 
available. The reaction does not begin until about 45 minutes 
after the nasal application and may persist for many hours. If 
nasal provocation proves negative, oral challenge should be 
considered. In a cohort of 150 difficult-to-treat CRSwNP patients, 
100 proved positive on nasal challenge, and 31 who were ne-
gative went on to oral LAS challenge of which a further 14 gave 
positive results(802).
Medication which must be stopped prior to the provocation 
test:
• Oral and intranasal corticosteroids (at least seven days);
• Antileukotrienes (at least seven days);
• Antihistamines (three days);
• Decongestants and cromones (one day).
Lysine-aspirin solutions at 0.1, 1 and 2M are instilled in the 
nose at 45-minute intervals and the effects assessed by clinical 
symptoms (VAS), objective nasal airway assessment (acoustic 
rhinometry, anterior rhinomanometry) and pulmonary function. 
A positive response is taken either as a 25% or greater decrease 
in the nasal airway (represented by a reduction of cross-secti-
onal area: Amin or volume 0– 12 cm) as assessed by acoustic 
rhinometry or a 40% decrease in nasal inspiratory peak flow(799). 
However, nasal inspiratory peak flow monitoring has been 
shown to be less sensitive to obstruction caused by aspirin than 
acoustic rhinometry(802). On pulmonary function, a drop of 20% 
FEV1 is considered positive.
If nasal provocation proves negative, oral challenge should be 
considered.
However, for those patients who have a higher risk of severe 
reactions, flow cytometry-assisted basophil activation testing 
(FAST) and functional-eicosanoid-test (FET) can be helpful tools 
to elucidate the diagnosis, if they are available(744, 745). Another 
alternative to aspirin provocation is the cellular antigen stimu-
lation test (CAST) but a study showed that whilst the leucocytes 
of patients with N-ERD produced increased amounts of cysteinyl 
Table 5.3.9. Diagnostic testing of lower respiratory tract (Brigham et al. 2015(843)).
History of variable respiratory symptoms
Confimed variable expiratory airflow limitation
Basic measurements 
Peak expiratory flow (repeated measures) 
Spirometry (repeated measures) 
Positive exercise challenge test
Assessment of a response to treatment 
Spirometry pre-bronchodilator and post-bronchodilator 
Spirometry post-initiation of a controller therapy ie inhaled steroid
Bronchial provocation 
Nonpharmacologic: exercise or eucapnic voluntary ventilation  
Pharmacologic: hypertonic saline, mannitol, or methacholine 
Other supportive tests 
Allergy testing  
Exhaled nitric oxide 
Table 5.3.10. Different challenges to assess aspirin sensitivity 
(Nizankowska 2000(844)).
History +/- Challenge
Sensitivity (%) Specificity (%)
Oral 77 93
Bronchial 77 93
Nasal 73 94
Figure 5.3.62. Is an objective test to diagnose aspirin exacerbated res-
piratory disease essential for the diagnosis N-ERD in a patient with CRS?
leukotrienes, the assay had a low sensitivity (25%), a specificity 
of 92.3%, a positive predictive value of 28.7% and a negative 
value of 90.7% which limit its usefulness(803).
The EPOS2020 steering group was unclear whether one or two 
episodes of a respiratory reaction to aspirin or NSAIDs wasves-
sential for the diagnosis AERD in a patient with CRS and whether 
an objective test was essential to diagnose aspirin exacerbated 
respiratory disease for the diagnosis AERD in a patient with CRS 
(Figures 5.3.62., 5.3.63. and 5.3.64.).
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Figure 5.3.61. Diagnosis of N-ERD (adjusted from Kowalski, 2019).
Respiratory symptoms after NSAID
• Rhinorrhoea, nasal congestion, dyspnoea
Diagnosis
 of N-ERD• >1 reaction reported
• Reaction to 2+ NSAIDs
• Latest reaction < 5 years
History of respiratory 
reaction to NSAID?
CRSwNP ± asthma?
• Recurrence of NP
• Loss of smell
• Moderate to severe asthma
• Intolerance to alcohol
• Blood eosinophilia
Check non-respiratory 
reaction to NSAID
Conrm/exclude the 
presence of CRS and asthma
Oral, bronchial or nasal 
challenge with aspirin
N-ERD
excluded
• CRS: ENT consultation, 
  endoscopy, CT-scan
• Asthma: respiratory function 
  test, bronchial hyperreactivity
-
++
+
-
? ?
Figure 5.3.63. Is a clinical history of two episodes of respiratory reaction 
to aspirin or NSAIDs essential for the diagnosis N-ERD in a patient with 
CRS?
Figure 5.3.64. Is a clinical history of one episode of respiratory reaction 
to aspirin or NSAIDs essential for the diagnosis N-ERD in a patient with 
CRS? 
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6.1. Medical Management
6.1.1. Short-term oral antibiotics for chronic 
rhinosinusitis (CRS) and exacerbations of CRS
6.1.1.1. Summary of the evidence
Short-term courses of antibiotics are prescribed at high rates 
in  patients with chronic rhinosinusitis (CRS) in primary and 
secondary care(1, 2). There is a need for stronger evidence on the 
role of antibiotics in CRS management. In this review, short-term 
antibiotic treatment is defined as a treatment duration of four 
weeks or less. To date, there have been two randomized clinical 
trials published that utilized a placebo control  investigating 
the effect of short-term antibiotics in CRS(3, 4). A single-centre 
placebo-controlled trial(3) of 32 patients with acute on chronic 
exacerbation of CRS (Table  6.1.1.1). Acute exacerbation of CRS 
was defined as an acute worsening of sinonasal symptoms in the 
last four weeks (nasal secretion, nasal obstruction/congestion, 
sense of smell, and/or facial pain) in patients with underlying 
CRS. Patients were randomized to receive amoxicillin/
clavulanate vs. placebo for two weeks. Although both groups 
had significant symptom improvement in nasal secretions and 
nasal obstruction compared to baseline, there was no significant 
between-group-differences on Visual Analog Scale-Severity 
Scoring Assessment [nasal secretion: mean difference (MD) 
-2 (-16.1, 12.1), p=0.44; nasal obstruction: MD – 6.6(−10.6, 24), 
p = 0.78]. There was no difference between nasal endoscopy 
scores at day 14 between the groups (total endoscopy score, 
p=0.88; nasal polyps, p=0.58; oedema, p=0.36; nasal secretion, 
p=0.42). The quality of life (Sino-nasal Outcome Test, SNOT-22) 
improvement was similar between groups after three months 
[MD -2.7 (-20.36, 14), p=0.75]. Bacterial eradication was observed 
in 29% of those treated with amoxicillin/clavulanate compared 
to 9% of those in the placebo group, but no significant statistical 
difference was observed between groups (p=0.37). Although 
no severe adverse events were reported in either group, two 
patients who received amoxicillin/clavulanate complained of 
mild abdominal colic and diarrhoea.
Van Zele et al.(4) conducted a double-blinded placebo-controlled 
randomized controlled trial (RCT) of the effect of doxycycline 
in treatment of CRS with nasal polyps (CRSwNP) in 28 patients. 
Doxycycline treatment significantly reduced postnasal drip 
symptom scores at week 2 (p=0.044) and showed a trend for 
reduction in rhinorrhoea at week 8 (p=0.058) (no corrections 
for multi-testing). Doxycycline had no significant effect on 
nasal congestion, or loss of sense of smell during the study 
period nor on postnasal drip and rhinorrhoea at the other time 
points. The doxycycline group was noted to have a small but 
significant reduction in nasal polyp size (0,5 on a scale of 8) 
6. Management of chronic rhinosinusitis in adults
Study Methods Participants Interventions Outcomes Results
Sabino 
2017(3)
DBPCT 32 patients (>18 
years of age) with 
acute on chronic 
exacerbation of 
CRSsNP (n=12) or 
CRSwNP (n=20)
• Amoxicillin-clavu-
lanate 875 mg/125 
mg, orally, twice 
daily for 14 days 
(n=21)
• Placebo twice daily 
for 14 days (n=11)
 • Visual Analog Scale-Se-
verity Scoring of clinical 
symptoms at 2 wks
 • Nasal endoscopy at 2 wks
 • Middle meatus swab at 
2 wks
 • Lund-Kennedy scores at 
2 wks
 • SNOT-22 at 2 wks and 3 
months
• No significant difference in symptoms scores, SNOT-
22, endoscopy scores or bacteriologic eradication 
at day 14 compared to baseline in the 2 treatment 
groups 
• No significant differences in SNOT-22 at 3 months
Van Zele 
2010(4)
DBPCT 47 patients with 
recurrent bilateral 
nasal polyps 
after surgery or 
massive bilateral 
nasal polyps 
(grade 3 or 4)
• Oral methylprednis-
olone (32 mg/d on 
days 1-5; 16 mg/d 
on days 6-10; and 8 
mg/d on days 11-
20) (n=19)
• Oral doxycycline 
(200 mg on day 1, 
100 mg/d on days 
2-20) (n=14)
• Placebo for 20 days 
(n=14)
• Nasal symptoms (anterior 
rhinorrhoea, nasal obstruc-
tion, postnasal drip, and 
loss of sense of smell) at 1, 
2, 4, 8, and 12 weeks
• Total nasal polyp score 
(0-8) at 1, 2, 4, 8, and 12 
weeks
• Nasal peak inspiratory flow 
at 1, 2, 4, 8, and 12 weeks
• Serum eosinophil counts 
and serum ECP
• IL-5, IgE, MMP-9, MPO and 
ECP in nasal secretions 
Doxycycline treatment compared to placebo resulted in: 
• Significantly reduced postnasal drip symptom scores 
at week 2 (p=0.044)
• Trend of reduction in rhinorrhoea at 8 wks (p=0.058)
• No significant differences in all other symptoms and 
time points. 
• Small (0.5 on scale of 8) but significant reduction in 
nasal polyp size for 3 months compared to placebo 
(p=0.015). 
• No significant increase in PNIF over the entire study 
period for doxycycline- treated group. 
• Significant reduction in MPO in nasal secretions for 2 
months and MPP-9 for 2 weeks 
Table 6.1.1.1. Short-term antibiotics for the treatment of  patients with CRS.
CRSwNP, chronic rhinosinusitis with nasal polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; DBPCT, double-blind placebo 
controlled trial; ECP, eosinophil cationic protein; MPP-9, Matrix metalloproteinase; MPO, myeloperoxidase; PNIF, peak nasal inspirato-
ry flow; SNOT, Sino-nasal Outcome Test.
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for three months compared to placebo (p=0.015). There were 
no significant differences in peak nasal inspiratory flow (PNIF). 
Although a significant decrease in serum IL-5Ra levels was 
observed at one month in the doxycycline group compared to 
placebo (p=0.01), this decrease was not sustained throughout 
the study period. Doxycycline had no effect on serum eosinophil 
counts or serum eosinophil cationic protein (ECP) levels 
compared to placebo. A significant decrease in ECP levels in 
nasal secretions was observed at one month in the doxycycline 
groups (p=0.032), but the significance of this difference was 
likely resultant from an increase in the mediator in the placebo 
group.  Similarly, a significantly lower level of immunoglobulin 
E (IgE) in nasal secretions was observed in the doxycycline 
treatment groups at four weeks compared to placebo (p=0.003), 
while an increase in this mediator was observed in the placebo 
group. Levels of IL-5 in nasal secretions progressively increased 
during the treatment period for the doxycycline treatment 
group (significance of change compared to placebo not 
reported). Doxycycline treatment demonstrated significantly 
reduced level of myeloperoxidase in nasal secretions compared 
to placebo during the study period (week 8; p=0.022), 
suggestive of a reduction in neutrophilic activity. A significant 
decrease in levels of matrix metalloproteinase 9 (MMP-9) was 
observed in the doxycycline group compared to placebo at 
week 1 (p=0.025) and week 2 (p=0.028). 
There were seven randomized studies identified that provided 
a parallel comparison of various antibiotic therapies (Table 
6.1.1.2). One multi-centre, double-blind, double-placebo 
study(5) evaluated the effects of short-term ciprofloxacin and 
amoxicillin/clavulanate in CRS. CRS was defined as unilateral 
or bilateral inflammation without nasal polyps of at least 
three months duration. Overall, both treatment groups had 
similar clinical cure rates (58.6% vs. 51.2%) and bacteriologic 
clearance rates (88.9% vs. 90.5%). However, patients with a 
positive culture who received ciprofloxacin were more likely 
to maintain bacteriologic clearance at 40 days post-treatment 
(83.3% vs. 67.6%, p=0.043). Endoscopy at the end of treatment 
showed purulent discharge in the middle meatus had cleared in 
a higher proportion of ciprofloxacin-treated patients (p=0.05), 
while inflammatory reaction resolved in a higher proportion of 
amoxicillin/clavulanate-treated patients (p=0.04). Ciprofloxacin 
was better tolerated during the study period with only 12.4% 
of patients reporting at least one adverse event, compared 
to 25% in the amoxicillin/clavulanate recipients (p=0.012). 
Gastrointestinal-related events were the most common 
complaints in both treatment groups and all adverse events 
resolved by the end of treatment. There was no placebo arm. 
In a single-centre, clinical trial(6), 59 patients with CRS were 
randomized to receive clarithromycin versus amoxicillin/
clavulanate. Patients that demonstrated clinical symptoms 
of chronic rhinosinusitis [headache, rhinorrhoea, coughing, 
post-nasal drip (PND), feeling of facial fullness, and nasal 
congestion for more than 12 weeks] with at least one CT finding 
(sinus opacity, air-fluid level or thickening of mucus layer) were 
recruited for the study. Clinical symptom improvement was 
found to be comparable between amoxicillin/clavulanate and 
clarithromycin for PND (40.7% vs. 46.7%; p=0.802), headache 
(40.7% vs. 50.0%; p=0.626), cough (48.1% vs. 43.3%; p=0.626), 
rhinorrhoea (48.1% vs. 43.3%; p=0.502), epistaxis (14.8% vs. 
10.0%; p=0.473), facial pain or pressure (55.6% vs. 56.7%; 
p=0.995), and nasal congestion (81.5% vs. 63.4%; p=0.255), 
respectively. The authors reported no significant difference 
in the rates of adverse events between both groups, with 
diarrhoea (10.3%) observed most commonly in the amoxicillin/
clavulanate group and anorexia (10.0%) reported in the 
clarithromycin group.
Fan et al.(7), conducted an open label study in 43 patients with 
chronic rhinosinusitis without nasal polyps (CRSsNP) comparing 
the effects of low versus high dose clarithromycin for 14 days. 
Patients recruited for the study demonstrated at least 12 weeks 
of two or more clinical symptoms (including nasal obstruction, 
nasal secretion, postnasal drip, facial pain or pressure, headache 
and reduction or loss of sense of smell), visible secretions in 
the middle nasal meatus and/or olfactory cleft on endoscopic 
examination, and no nasal polyps. Patients on low dose 
clarithromycin did not experience any significant changes in 
median visual analogue scale scores of nasal congestion (5.4 
vs. 5.4), rhinorrhoea (6.8 vs. 6.8), PND (4.5 vs. 4.3) or loss of smell 
after four weeks compared to baseline. However, those in the 
high-dose group had sustained improvement in MVAS scores up 
to week 4 for nasal congestion (3.8 vs. 5.7; p<0.025), rhinorrhoea 
(2.0 vs. 6.5; p<0.025), PND (1.6 vs. 3.9, p<0.025), and loss of 
smell (1.0 vs. 2.2, p<0.025) compared to baseline. There was also 
significant improvement in both SNOT 20 and endoscopic Lund- 
Kennedy scoring for the high-dose group at two and four weeks 
compared to baseline, as well as when compared to the low-
dose group (p<0.025). Significant differences in nasal symptom 
scores were also observed between the low-dose and high 
dose groups at week 2 and week 4 (statistical significance not 
reported). Interleukin-8 (IL-8) decreased significantly following 
low and high dose antibiotic therapy at two and four weeks 
(p<0.025). The high dose treatment group also significantly 
decreased levels of IL-5 at two and four weeks compared to 
baseline and levels of IL-5 and IL-8 when compared to the low 
dose group (p<0.025).
Namyslowski et al.(8)investigated 14 days of amoxicillin/
clavulanate vs. cefuroxime in 115 patients with clinical and 
radiographic features of CRS. CRS was defined as clinical 
symptoms of headache, facial pain, presence of purulent or 
mucopurulent nasal discharge or PND, nasal obstruction and 
objective findings including X-ray documentation of sinus 
opacification, air-fluid levels or mucosal thickening. The authors 
focused on unilateral or bilateral chronic maxillary rhinosinusitis, 
performing maxillary punctures to evaluate microbiologic status 
and bacteriologic eradication post-treatment. There was no 
significant difference in the observed rates of clinical cure in the 
amoxicillin/clavulanate group as compared to the cefuroxime 
group (98.2% vs. 91.1%, p=0.2) or efficacy of bacteriologic 
eradication (rates for this outcome variable not specified). One 
patient from each of the study arms interrupted treatment due 
to diarrhoea. 
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Fan 
2014 (7) 
Open-label, 
parallel-group 
randomized 
clinical trial
43 patients 
(>20 years 
of age) with 
CRSsNP
• Clarithromycin 
250 mg daily for 
14 days (n=20)
• Clarithromycin 
500mg twice dai-
ly for 7 days, then 
250mg twice 
daily for 7 days 
(n=23)
At 2 and 4 weeks: 
• Nasal symptom assessment 
• Endoscopic inspection 
(Lund–Kennedy scores) 
• SNOT-20 
• Interleukin-5 levels in nasal 
secretions
• Interleukin-8 levels in nasal 
secretions 
High-dose group demonstrated: 
• Significant improvement in nasal symptom 
scores, Lund-Kennedy and SNOT-20 at weeks 2 
and 4 compared with the baseline values and 
low dose group
• IL-8 levels in nasal secretions were significantly 
decreased at weeks 2 and 4 compared with the 
baseline values and low-dose group values 
• IL-5 levels were significantly decreased at 
weeks 2 and 4 compared with the baseline val-
ues and the low-dose group values 
Amini 
2009 (6)
Parallel-group 
randomized 
clinical trial
59 CRS 
patients
• Clarithromycin 
500 mg daily for 3 
weeks (n=30)
• Amoxicillin-clavu-
lanate 625 mg 
three times 
daily for 3 weeks  
(n=29)
• Clinical efficacy at 7, 17, 21, 
28, 42 and 56 days 
• Radiographic status at 8 
weeks
• Adverse effects
• No statistically significant differences in clinical 
improvement of symptoms or adverse events 
between treatment groups
Jareoncharsri 
2004 (12)
Open, 
parallel-group 
randomized 
clinical trial
60 patients 
(>16 years 
of age) 
with acute 
maxillary 
sinusitis 
(n=48) 
and acute 
exacerbation 
of CRS (n=12)
• Levofloxacin 300 
mg daily for 14 
days (n=34)
• Amoxicillin clavu-
lanate 625 mg 
three times daily 
for 14 days (n=26)
• Clinical response at day 4 
and 21
• Plain film radiologic 
evaluation at day 14
• Bacteriologic efficacy at day 
14
• Adverse drug reactions at 
day 14
• Laboratory tests at day 14
• Vital signs at day 14
• Mean total symptom score at 21 days, radio-
logic improvement, bacteriologic eradication, 
laboratory tests, vital signs and adverse events 
at 14 days were comparable between both 
groups. 
• Subgroup analysis of chronic sinusitis group 
not performed
Namyslowski 
2002 (9)
Open, 
parallel-group 
randomized 
clinical trial
231 patients 
(>18 years 
of age) with 
CRS or acute 
exacerbation 
of CRS
• Amoxicillin 
clavulanate 
875/125mg twice 
daily for 14 days 
(n=115)
• Cefuroxime 
500mg twice 
daily for 14 days 
(n=116)
• Clinical response at day 3 to 5, 
15 to 18, week 2 to 4
• Treatment compliance at day 
15 to 18
• Bacteriologic response at day 
15 to 18
• Global severity of infection 
week 2 to 4
• Adverse events 
• No significant difference in clinical cure rates 
or bacteriologic eradication between the 
amoxicillin-clavulanate treatment group vs. the 
cefuroxime treatment group at day 15-18. 
• Significant improvement in symptoms of infec-
tion at day 3 to 5 in the amoxicillin clavulanate 
group compared to cefuroxime (81% vs 56%; 
p=0.0137)
• Persistent, purulent nasal discharge following 
treatment was noted to be significantly higher 
in the cefuroxime group at day 3-5(3% vs. 12%; 
p=0.036). 
• Clinical relapse at week 2 to 4 was significantly 
higher in the cefuroxime group in the clinically 
evaluable patients (0% vs. 8%; p=0.0049) and 
the intention-to-treat population (0.09% vs. 7%; 
p=0.03). 
• Adverse events were comparable between the 
2 treatment groups. Diarrhoea was the most 
common adverse event observed in both 
treatment groups. 
Namyslowski 
1998(8) 
Parallel-group 
randomized 
clinical trial
115 patients 
(>18 years 
of age) with 
unilateral or 
bilateral CRS 
• Amoxicillin 
clavulanate 
875/125mg twice 
daily for 14 days 
(n=55) 
• Cefuroxime 
500mg twice 
daily for 14 days 
(n=56)
• Clinical efficacy evaluated at 
week 2 to 4
• Bacteriologic response 
evaluated at week 2 to 4
• Adverse events
• No significant difference in the observed rates 
of clinical cure or bacteriologic eradication in 
the amoxicillin-clavulanate group as compared 
to the cefuroxime group at week 2 to 4
• Adverse events (e.g. diarrhoea) were compara-
ble between the 2 treatment groups.
Table 6.1.1.2.  Comparison of various short-term antibiotics for the treatment of  patients with CRS.
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In a second study from Namyslowski et al.(9), 231 participants 
with either chronic rhinosinusitis or an acute exacerbation of 
CRS were randomized to receive amoxicillin/clavulanate or 
cefuroxime for 14 days. CRS was defined as at least one major 
symptom (including post-nasal discharge, rhinorrhoea, cough) 
and constitutional symptoms (including headaches, facial pain, 
tooth pain, halitosis, sore throat, earache, increased wheeze 
or fever) plus an abnormal X-ray (including opacification, 
abnormal air-fluid level or greater than 5 mm swelling of 
mucosa) lasting for at least three months. Acute exacerbation 
of CRS was defined as the presence of inflamed sinuses on 
X-ray associated with two or more symptoms (including 
purulent nasal discharge, headache, molar tenderness and 
fever) lasting ≤ four weeks, and a patient history of at least two 
episodes of acute rhinosinusitis requiring antibiotic treatment 
during the 12 months prior to study inclusion. It is unclear 
how many patients had an acute exacerbation. All patients 
had a maxillary sinus puncture confirming infection. There 
was no significant difference in clinical cure rates between the 
amoxicillin/clavulanate treatment group versus the cefuroxime 
treatment group in the clinically evaluable patients (95% vs 
88%; p=0.07; MD 95% CI =0.6% to 15% ) or the intention-to-treat 
populations (92% vs 86%; p=0.15; MD 95% CI= -2% to 14%). 
At the day 3-5 assessment, the amoxicillin/clavulanate group 
showed improvement in symptoms of infection, compared 
the cefuroxime group (81% vs. 56%, p=0.0137). Persistent, 
purulent nasal discharge following treatment was noted to be 
significantly higher in the cefuroxime group at day 15 to 18 (3% 
vs. 12%; p=0.036). 
All other signs and symptoms including inflammation of the 
sinuses (6% vs. 6%), fever (11% vs. 0%), headache (6% vs. 13%), 
and molar tenderness (5% vs. 9%) were not reported to be 
significantly different between the amoxicillin/clavulanate 
treated and cefuroxime treated patients. Bacterial eradication 
rates were similar for amoxicillin/clavulanate and cefuroxime 
in the bacteriologically evaluable population (66% vs. 68%; 
p=0.85; MD 95% CI= -18% to 15%) and the intention-to-treat 
population (42% vs. 40%). Clinical relapse was observed to be 
significantly higher in the cefuroxime group in the clinically 
evaluable patients (0% vs. 8%; p=0.0049) and the intention-to-
treat population (0.09% vs. 7%; p=0.03). Adverse events were 
observed in 7% of the amoxicillin/clavulanate treated group and 
9.5% in the cefuroxime-treated group. Diarrhoea was the most 
common adverse event observed in both treatment groups. 
Seven patients discontinued treatment due to amoxicillin/
clavulanate-related adverse events, compared to four patients 
in the cefuroxime-treated group. It was unclear if the second 
study from Namyslowski et al.(9) represented longitudinal patient 
recruitment from the first Namyslowski et al. study(10). Given 
the similarities in the two studies and the lack of clarity in their 
patient recruitment, a meta-analysis of the study outcomes 
was not attempted.  Huck et al.(11) evaluated cefaclor versus. 
amoxicillin over 10 days. The study included patients with: 
acute rhinosinusitis (ARS) (n=56), defined as patients with 
rhinosinusitis symptoms for fewer than 14 days with no previous 
episodes in the previous year; recurrent rhinosinusitis, defined 
as more than one episode per year with improvement between 
episodes (n=25); and CRS defined as non-resolving sinus disease 
(n=15). While 40% of the patients on amoxicillin and 20% of the 
patients on cefaclor were found to have improvement post-
therapy, these numbers were too small for statistical analysis. 
Jareoncharsri et al.(12) investigated the role of levofloxacin and 
amoxicillin/clavulanate in patients with acute maxillary sinusitis 
and acute exacerbation of CRS. Patients with acute rhinosinusitis 
were defined based on symptoms and signs of rhinosinusitis, 
including obstruction, purulent nasal discharge, postnasal drip, 
loss of smell, foul smell and headache, lasting less than four 
Study Methods Participants Interventions Outcomes Results
Legent 
1994(5)
Double-blind, 
parallel-group, 
double-placebo 
randomized 
clinical trial
251 patients 
(>18 years 
of age) with 
unilateral 
or bilateral 
CRSsNP
• Ciprofloxacin 
500mg twice 
daily for 9 days 
(n=122)
• Amoxicillin clavu-
lanate 500mg 
three times daily 
for 9 days (n=129)
• Clinical efficacy at day 10 
and 40
• Bacteriologic eradication at 
day 10 and 40
• Clinical tolerance at day 10
• Adverse events
• Ciprofloxacin and amoxicillin clavulanate had 
similar clinical cure rates (58.6% vs. 51.2%) and 
bacteriologic clearance rates (88.9% vs. 90.5%). 
• Endoscopy at day 10 showed purulent 
discharge in the middle meatus had cleared 
in a higher proportion of ciprofloxacin-treated 
patients (p=0.05)
• Inflammatory reaction on endoscopy at day 10 
resolved in a higher proportion of amoxicillin 
clavulanate-treated patients (p=0.04).
• Patients with a positive culture who received 
Ciprofloxacin were more likely to maintain bac-
teriologic clearance at 40 days post-treatment 
(83.3% vs. 67.6%, p=0.043).
• Ciprofloxacin-recipients had lower adverse 
events (12.4% vs. 25%, p=0.012)
Huck 
1993(11)
Parallel-group 
randomized 
clinical trial
56 acute 
rhinosinusitis, 
25 recurrent 
rhinosinusitis, 
15 chronic 
maxillary 
sinusitis
• Cefaclor 500mg 
twice daily for 10 
days (n=5)
• Amoxicillin 
500mg 3 times 
daily for 10 days 
(n=10)
• Clinical evaluation at day 2, 
16 to 18 
• Sinus X-rays at day 16 to 18
• Adverse events
• No significant differences between the groups 
in the CRS group
CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; IL, interleukin; SNOT, Sino-nasal Outcome Test.
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weeks and acute exacerbation of CRS was defined as acute 
worsening of chronic symptoms lasting less than four weeks. 
The authors demonstrated comparable symptom improvement 
(68.7% vs. 69.8%), radiological improvement (61.8% vs. 61.5%), 
bacteriologic eradication (78.5% vs. 70.0%, p>0.05) and adverse 
events (8.6% vs. 7.7%) in levofloxacin recipients as compared to 
amoxicillin/clavulanate amongst patients with acute maxillary 
sinusitis and acute exacerbation of CRS. However, the sample 
size in the subgroup of patients with acute exacerbation of CRS 
(n=12) was small.
It is uncertain whether or not the use of a short 
course of antibiotics has an impact on patient 
outcomes in adults with CRS compared with 
placebo.
6.1.1.2. Conclusion
The EPOS2020 steering group, due to the very low quality of 
the evidence,  is uncertain whether or not the use of a short 
course of antibiotics has an impact on patient outcomes in 
adults with acute exacerbations of CRS compared with placebo. 
Also, due to the very low quality of the evidence, it is uncertain 
whether or not the use of a short course of antibiotics has an 
impact on patient outcomes in adults with CRS compared with 
placebo. Gastrointestinal-related adverse events (diarrhoea 
and anorexia) are frequently reported. There is a need for larger 
high-quality trials, especially to evaluate the use of short courses 
of antibiotics in acute exacerbations of CRS.
6.1.2. Long-term antibiotics 
6.1.2.1. Long-term treatment with systemic macrolide 
antibiotics vs. placebo in CRS 
For this systematic review, long-term antibiotic treatment was 
defined as a treatment duration longer than four weeks. While 
treatment with antibiotics is common practice in the treatment 
of acute rhinosinusitis, there have been few placebo-controlled 
studies on the effects of this practice. There are two such 
studies that evaluate the outcomes after long-term treatment 
with macrolide antibiotics(13, 14). There have been multiple 
open studies evaluating the effects of long-term macrolide 
antibiotics which have had promising results with decreases 
in inflammatory markers, changes in mucus consistency, or 
endoscopic and radiographic scoring systems(15-21).  Macrolide 
antibiotics at a low-dose are thought to express an immune-
modulating effect and their use has been incorporated into 
standard cystic fibrosis (CF) care(22-24). However, there are studies 
comparing nasal steroid sprays to macrolide antibiotics without 
evidence of improvement in the macrolide group over the 
use of a nasal steroid spray(25, 26). Two meta-analysis containing 
studies in the Chinese literature have been published recently, 
however the authors indicated that none of the studies not 
reviewed here were double blind, placebo controlled trials 
(DBPCT)(21, 27).
Two studies(13, 14) (Figure 6.1.2.1.) have completed placebo-
controlled trials of the effects of long-term macrolide therapy on 
signs, symptoms, and patient reported quality of life outcomes. 
Both studies evaluated 12-week treatment, however Wallwork 
et al. evaluated roxithromycin at 150mg daily, while Videler et 
al. evaluated azithromycin (AZM) 500mg per week. Wallwork 
and colleagues showed significant improvement in SNOT-20 
scores, saccharin transit time, and nasal endoscopy. Once the 
groups were sub-divided into low and high IgE levels (<200µg/L 
vs. > 200µg/L), the low IgE group had significant improvement 
in saccharin transit time, endoscopy, and nasal lavage of 
IL-82. However, Videler et al. did not show any improvement 
in their outcomes and IgE was not measured so no subgroup 
analysis was possible. At the end of the studies, Videler and 
colleagues had an improvement in 51% of patients on AZM and 
35% of the placebo group without significance. Interestingly, 
when the groups were re-evaluated by phone 12 weeks after 
completion of the antibiotics, 50% of the AZM group reported 
“improvement/cure” compared to 9% in the placebo group. This 
was statistically significant (p=0.017). Wallwork and colleagues 
had a response rate in the roxithromycin group of 67% 
compared to 22% in the placebo group. 
While these studies had similar study sizes (60 vs. 64), their 
inclusion criteria were different. Wallwork et al. included only 
patients without nasal polyps, while Videler included patients 
both with and without nasal polyps. As stated above, the 
Wallwork et al. study sub-analyzed patients based upon low 
and high IgE levels. The high IgE group had the larger majority 
of non-responders. It is possible that sub-group analysis of the 
Videler study would have shown a high proportion of elevated 
IgE patients. These two studies highlight the importance of 
appropriate patient selection when using macrolide therapy. 
Furthermore, the once weekly dosing regime utilised by 
Videler et al may have compromised the study in comparison 
with low dose daily dosing by Wallwork et al. Further studies 
on the efficacy of macrolide therapy have evaluated different 
biochemical markers in those who do and do not respond to 
macrolide therapy, while some have identified lower levels of 
IgE to be significantly associated with response to macrolides(28), 
Figure 6.1.2.1. Forest plot of the effect of macrolides versus placebo on responder scores in CRS patients.
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others have not shown this direct correlation
Pooled data analysis of the responder score (Table 6.1.2.1.; 
Figure 6.1.2.1.) and the SNOT scores (Figure 6.1.2.2) did not 
show any significant benefit in the macrolide group [responder 
score: 0.45 (-1.32, 0.43), p=0.32, two trials, 120 patients], [SNOT 
score: standard mean difference (SMD) 0.08(-1.14, 0.97), p=0.88, 
two trials, 120 patients]. Both analyses showed significant 
heterogeneity.
6.1.2.2. Long-term antibiotics in CRS vs. topical 
corticosteroids
Two double blind studies(29, 30) evaluated long-term antibiotics 
in comparison with topical corticosteroids in patients with and 
without nasal polyps (Table 6.1.2.2.)
Haxel et al. assessed erythromycin plus fluticasone furoate 
in CRS patients with or without NP. All patients were treated 
post-surgery. There was no significant improvement in SNOT-
20, olfaction, saccharin trasit time, endoscopy scores, or nasal 
health between the groups (29). Subgroup analysis determined 
that CRSsNP patients trended towards significant improvement 
in the erythromycin group, however, only the endoscopy scores 
were significant. Amali et al.(30) evaluated azithromycin plus 
fluticasone versus fluticasone in patients with and without nasal 
polyps. There was significant improvement in SNOT-22 scores in 
the azithromycin group when compared to fluticasone. 
Pooled data analysis of SNOT scores showed no significant 
benefit in the macrolide over topical corticosteroids [SMD 
0.21(-1.28, 2.09), p=0.83, two trials, 118 patients]. The I2was 96%, 
suggesting a little heterogeneity (X2=22.94, df=1, p<0.01). For 
this analysis, mean scores from SNOT-20 and SNOT-22 were 
taken for assessment (i.e. SNOT-22 scores were divided by 22 
and SNOT-20 scores were divided by 20) (Figure 6.1.2.3). 
6.1.2.3. Long-term antibiotic in CRS vs. surgery
Two studies(31-33) evaluated treatment with long-term antibiotics 
versus surgical intervention for patients with and without nasal 
polyps. One study(32, 33) evaluated patients with and without 
polyps, while the other study(31) only evaluated patients with 
polyps (Table 6.1.2.3.) The studies could not be combined in a 
meta-analysis due to the differences in design.
Ragab et al. reported on the same group of CRS patients 
with and without polyps19,20. The long-term antibiotic group 
received erythromycin for 12 weeks in addition to nasal saline 
irrigations and intranasal corticosteroids (INCS). The surgical 
group underwent surgery followed by short-term post-
operative antibiotics (erythromycin), nasal saline irrigations, 
Dexarhinospray (DRS) for two weeks, followed by INCS. The 
patients were assessed at three, 6 and 12 months. There was 
significant improvement in visual analogue scale (VAS), SNOT-
20, Short Form 36 Health Survey (SF36), saccharin clearance 
time, and nitric oxide (NO) in each group with no significant 
differences between the two subgroups. Endoscopy scores 
increased at six and 12 months from baseline with no significant 
difference between groups.  Subgroup analysis found no 
significant difference between patients with and without 
polyps except in total nasal volume. Patients with CRSsNP had 
significant improvement in nasal volume in the surgery group 
(%∆; 57.3±37.6v41.8±42.8; p<0.01). 
One study(31) compared clarithromycin plus endoscopic sinus 
surgery (following eight weeks of antibiotics) to endoscopic 
sinus surgery alone in patients with CRSwNP. Patients were 
evaluated at the completion of antibiotic treatment as well 
as six- and 12-months post-surgery for endoscopic and nasal 
symptom scoring. Both groups had a significant decrease in 
nasal symptom score post-treatment (antibiotics vs. surgery). 
Both groups also had an increase in nasal symptom score 
from six to 12 months post-surgical intervention, but this 
was not significant between the two groups. Patients in the 
clarithromycin plus surgery group had significant improvement 
in endoscopy scores post-antibiotic treatment and post-surgical 
treatment. The surgical arm also had significant improvement 
of endoscopic scores. In both groups, there were patients with 
polyp recurrence at six and 12 months. This was significantly 
higher in the surgery only group at six (27.5%v50%; p=0.034) 
and 12 months (35%v62.5%; p=0.029). 
Figure 6.1.2.2. Forest plot of the effect of macrolides versus placebo on SNOT scores in CRS patients.
Figure 6.1.2.3. Forest plot of the effect of macrolides versus nasal corticosteroids on SNOT scores in CRS patients.
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Videler 
2011(13)
DBPCT 60 CRSwNP 
and CRSsNP
• Azithromycin 
500mg weekly for 
12 weeks (n=29)
• Placebo weekly for 
12 weeks (n=31)
All assessed at 6, 12, 14 weeks
• Patient response rating scale (1-5, 1 desperately worse, 4 cured)
• SNOT-22
• VAS (nasal obstruction, rhinorrhea, PND, facial pain, smell reduc-
tion, general health, headache, toothache, tearing, coughing, 
nasal bleeding, crusts, fatigue, nausea, vomiting/diaorrhea)
• SF36
• Endoscopy scores
• PNIF
• Olfaction
• Cultures
No significant 
effects 
Wallwork 
2006(14)
DBPCT 64 CRSsNP • Roxithromycin 
150mg daily for 12 
weeks (n=29)
• Placebo daily for 12 
weeks (n=35)
All at 12 weeks
• Patient Response rating Scale (1-6, 1 completely improved, 6 
much worse)
• SNOT-20 
• PNIF
• Saccharin transit time
• Olfaction
• Endoscopy
• IL8, fucose, alpha2-macroglobulin
Significant effect 
on SNOT-20, 
endoscopy, 
saccharin transit 
time. Subgroup 
analysis on 
low vs high IgE 
levels found 93% 
improvement in 
the low IgE group
Table 6.1.2.1. Long-term antibiotic for the treatment of patients with CRS.
CRSwNP, chronic rhinosinusitis with nasal polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; DBPCT, Double-blind place-
bo-controlled trial; IL, interleukin; IgE, immunoglobulin E; PND, post-nasal drip; PNIF, peak nasal inspiratory flow; SF-36, Short-Form 36; 
SNOT, Sino-nasal Outcome Test; VAS, visual analogue scale.
Study Methods Participants Intervention Outcomes Results
Amali 
2015(30)
DBPCT 66 CRSwNP 
and CRSsNP (60 
analysed)
• Azithromycin 250 mg once daily 
for 12 weeks (n=20)
• Placebo once daily for 12 weeks 
(n=40)
All patients received fluticasone 
proprioanate 100 mcg twice daily
• SNOT-22 at 12 weeks Significant improvement in SNOT 22 
scores in azithromycin group over 
fluticasone
Haxel 
2015(29)
DBPCT 58 CRSsNP 
andCR SwNP 
postoperatively
• Erythromycin 250mg once daily 
for 12 weeks (n=29)
• Placebo 250mg once daily for 12 
weeks (n=29
All patients received fluticasone 
fuorate 27.5 mcg once daily  
Assessed at 12 and 24 weeks
• ECP
• MPO
• SNOT-20
• Olfaction
• Saccharin transit time
• Nasal endoscopy score
• Nasal health self-rate
No significant improvement in 
SNOT20, olfaction, STT, endoscopy 
scores, or nasal health. Trend towards 
improvement in CRSsNP subgroup 
on erythromycin, but only endoscopy 
score was significant.
Table 6.1.2.2. Long-term antibiotics versus topical corticosteroids for the treatment of patients with CRS.
CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, Double-blind placebo-
controlled trial; ECP, eosinophil cationic protein; MPO, Myeloperoxidase ; SNOT, Sino-nasal Outcome Test; STT, Saccharin Transit Time.
6.1.2.4. Long-term antibiotics versus Chinese herbal medicine
One study(34) compared the effect of Chinese herbal medicine 
(CHM), specifically Tsang-Erh-San extract granules and 
Houttuynia extract powder to erythromycin 250mg bid for 
eight weeks in patients with CRSsNP. The groups were assessed 
with the Taiwanese SNOT-20 (TWSNOT-20), endoscopy scores, 
saccharin transit time, and bacterial culture. In both groups, 
there was significant decrease in TWSNOT20, with no significant 
differences between groups (Table 6.1.2.4.). Both groups also 
had a decrease in endoscopy scores, however, this did not reach 
significance. Mucociliary clearance improved more significantly 
in the CHM group than erythromycin with improvement in 
saccharin transit time.
6.1.2.5. Comparison of long-term antibiotics in CRS
One study(35) compared one macrolide antibiotic to another in 
a single blinded study. The clarithromycin group was found to 
have improved efficacy over erythromycin (Table 6.1.2.5.)
6.1.2.6. Cardiovascular risks of macrolide antibiotics
In common with a number of other drug groups, macrolides 
are known to prolong the QT interval, potentially increasing the 
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RCT, randomised controlled trial; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal pol-
yps; NO, nitric oxide; NSS, Nasal and Sinus Symptom scale ; SCT, Saccharine Clearance Time ; SF36, Short-Form 36; SNOT, Sino-nasal 
Outcome Test.
Table 6.1.2.3. Long-term antibiotics versus surgery for the treatment of patients with CRS.
Study Methods Participants Intervention Outcomes Results
Peric, 
2014(31)
RCT 80 CRSwNP • Clarithromycin 500mg daily x 8 
weeks followed by surgery (n=40)
• Surgery alone (n=40)
Assessed at 2 weeks, 6 months, and 
12 months after surgery
• Nasal polyp size
• Nasal symptom score
Significant improvement in 
NSS and Endoscopy score. 
Surgical group with significantly 
higher polyp recurrence post-
operatively.
Ragab 
2004, 
2010 (32,33)
RCT 90 CRSwNP 
and 
CRSsNP (89 
evaluated)
• Erythromycin 500mg bid x 2 weeks 
then 250mg bid + alkaline douche + 
intranasal corticosteroid x 10 weeks 
(n=45)
• Surgery + erythromycin 250mg 
bid x 2 weeks + alkaline douche 
+ intranasal corticosteroid (after 2 
weeks) (n=44)
Assessed at 6 and 12 months
• VAS (nasal blockage, nasal 
discharge, olfaction, facial pain, 
headache, overall discomfort)
• SNOT-20
• SF-36
• NO
• STT
• Acoustic rhinomanometry
• Endoscopy
Significant effect on SNOT-20, 
SF36, SCT and NO in both groups. 
No difference between groups
short-term risk of arrhythmia(36, 37). Since the CLARICOR study(38) 
there have been a number of studies exploring cardiovascular 
events in associations between macrolides, in particular 
clarithromycin, some of which have found increased risks of 
cardiovascular events up to a year beyond the exposure to 
the antibiotic(39-41) whereas this has not been demonstrated 
in a number of large observational studies(42-46), though some 
found evidence of short-term increases in risk(43-46). A meta-
analysis published by Wong et al.(47), demonstrated that the 
short-term risk of cardiovascular outcomes associated with 
macrolides in observational studies was estimated at 1.79 excess 
myocardial infarctions per 1000 patients (95% confidence 
interval (CI): 0.88 to 3.20). This risk was not observed in RCTs 
but these trials were likely underpowered to detect this. No 
long-term cardiovascular risk (ranging from 30 days to three 
years) associated with macrolides was observed. Williamson et 
al.(46) in an observational cohort of 66,331 adult CRS patients 
receiving 320,798 prescriptions for a macrolide or penicillin, 
compared prescriptions for macrolide antibiotics to penicillin. 
Outcomes were all-cause mortality, cardiac death, myocardial 
infarction, stroke, diagnosis of peripheral vascular disease, 
and cardiac arrhythmia. A non-statistically significant trend 
towards increased risk of myocardial infarction during the first 
30 days following macrolide prescription was observed. No 
statistically significant short- or long-term risks were observed 
for macrolide prescription nor for clarithromycin in particular, 
in contrast to Svanstrom et al.(48). The apparent discrepancies 
between this study and others(38, 40, 41, 43, 48) may be because 
these have predominantly investigated associations in general 
populations with a potentially greater prevalence of pre-existing 
heart conditions and other morbidities in contrast to a CRS 
population. Clarithromycin should not be given to patients with 
history of QT prolongation (congenital or documented acquired 
QT prolongation) or ventricular cardiac arrhythmia, including 
torsades de pointe or hypokalaemia (risk of prolongation of 
QT-time).
Concomitant administration of clarithromycin and astemizole, 
cisapride, pimozide and/or terfenadine is contraindicated as 
this may result in QT prolongation and cardiac arrhythmias, 
including ventricular tachycardia, ventricular fibrillation, 
and torsades de pointe. Also, concomitant administration 
of clarithromycin and ergotamine or dihydroergotamine is 
contraindicated, as this may result in ergot toxicity. Concomitant 
administration with ticagrelor or ranolazine is contraindicated. 
Furthermore, clarithromycin should not be used concomitantly 
with HMG-CoA reductase inhibitors (statins) that are extensively 
metabolized by CYP3A4 (lovastatin or simvastatin), due to the 
increased risk of myopathy, including rhabdomyolysis. As with 
other strong CYP3A4 inhibitors, clarithromycin should not be 
used in patients taking colchicine. Clarithromycin should not 
be used in patients who suffer from severe hepatic failure in 
combination with renal impairment. 
“As always a full clinical and drug history should 
be undertaken to cover these aspects and 
potential drug interactions”.
6.1.2.7. Summary
Two placebo-controlled studies were conducted with 
macrolide antibiotics. One study(13) did not find any significant 
improvement in a mixed group of patients (with and without 
nasal polyps). The other study(14) found improvement in 
SNOT-20 scores, nasal endoscopy, and saccharin transit time 
in CRSsNP patients treated with macrolides. Patients with 
low IgE were noted to have more significant improvement 
with macrolide treatment. The meta-analysis did not show a 
significant effect of macrolides over placebo for responder 
score and SNOT score. While both studies used macrolides, 
they utilized different dosages and schedules that may have 
affected the results. These two studies also did not look at the 
same subtypes of CRS. Larger placebo-controlled trials are 
warranted, in addition to more microbiological studies on the 
underlying difference in the nasal microbiome of CRSwNP and 
CRSsNP and these are presently on-going in several European 
countries(49). Both studies evaluating the efficacy of antibiotics 
over topical corticosteroids used macrolide antibiotics in a 
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Jiang(34)
RCT 83 (53 evaluated) CRSsNP • Erythromycin 
250mg bid x 8 
weeks (n=26)
• Chinese herbal 
medicine (n=27)
Assessed at 8 weeks
• Taiwanese SNOT-20
• Nasal endoscopy
• Nasal swab
• Saccharin transit time
• Saccharin transit time improved significantly 
more in the Chinese herbal medicine group 
than erythromcycin group.
• No significant difference between the 
groups for all other measurements.
Table 6.1.2.4. Long-term antibiotics vs. Chinese herbal medicine for the treatment of patients with CRS.
Table 6.1.2.5. Long-term clarithromycin vs. erythromycin for the treatment of patients with CRS.
CRSsNP, chronic rhinosinusitis without nasal polyps; RCT, randomised controlled trial; SNOT, Sino-nasal Outcome Test.
CRS, chronic rhinosinusitis.
Study Methods Participants Drug Outcomes Results
Hashiba 1997(35) Single 
blind
59 CRS Clarithromycin 400mg twice 
daily vs. erythromycin 600mg 
three times daily for 8-12 weeks
Efficacy assessed (symptoms 
and endoscopic signs) after 2, 
4, 8 and 12 weeks.
Clarithromycin was significantly 
more effective when compared to 
erythromycin
population of patients with CRSwNP and CRSsNP(29, 30). In meta-
analysis, macrolide antibiotics had no significant benefit over 
topical steroids for SNOT scores. Further studies on individual 
CRS subtypes would be useful to determine which patients 
would benefit from long-term antibiotics and more specifically 
macrolide antibiotics. 
The EPOS2020 steering group,  due to the low 
quality of the evidence,  is uncertain whether 
or not the use of long-term antibiotics has an 
impact on patient outcomes in adults with CRS, 
particularly in the light of potentially increased 
risks of cardiovascular events. There is a need for 
the larger high-quality trials that are presently 
being undertaken in Europe.
Both studies(31-33) comparing long-term antibiotics treatment 
versus surgical treatment reported similar improvement. 
However, Peric et al. reported more durable polyp control post-
surgical intervention in patients who received pre-operative 
long-term antibiotics. Two reports on the same study(32, 33) found 
similar benefit from the use of long-term macrolide therapy 
when compared to surgical treatment. 
Alternative medicinal treatments have been used routinely 
in Eastern culture and are being used more often in Western 
culture. There was no significant difference in a small study 
comparing erythromcyin versus Chinese Herbal Medicine(34).
There are indications that the use of macrolides have increased 
risks of cardiovascular events up to a year beyond the exposure 
to the antibiotic although this has not been shown in patients 
with CRS(46).
6.1.2.8. Conclusion
A small number of randomized (placebo) controlled trials 
have evaluated the potential of long-term macrolides in the 
treatment of CRS. No difference has been shown compared to 
placebo, nor could any differences compared to other proven 
effective treatments like nasal corticosteroids or surgery be 
found. There is some indication that macrolides might be more 
effective in patients with low IgE. Macrolides have been shown 
to have some potentially serious side effects at normal full 
dosage and the risk of these side effects and specifically cardiac 
toxicity should be considered when considering the prescribing 
these drugs. The EPOS2020 steering group,  due to the low 
quality of the evidence,  is uncertain whether or not the use 
of long-term antibiotics has an impact on patient outcomes in 
adults with CRS, particularly in the light of potentially increased 
risks of cardiovascular events. There is a need for the larger high-
quality trials that are presently being undertaken in Europe.
6.1.3. Topical antibiotics
6.1.3.1. Summary of the evidence
The rationale of treating patients with recalcitrant difficult-
to-treat rhinosinusitis with local antibiotics is the potential 
role of biofilm. These patients have wide open sinuses that 
are perfectly accessible for local treatment but despite rinsing 
with saline, anti- inflammatory corticosteroid treatment and/
or systemic antibiotics, the sinus mucosa remains inflamed. 
Often (biofilm-forming) Staphylococcus aureus or Pseudomonas 
aeruginosa is cultured from these sinuses(50), but more recent 
molecular microbiome studies point towards various other 
micro-organisms being possibly involved(51). Culture-dependent 
studies need to be carefully interpreted since micro-organisms 
such as S. aureus and P. aeruginosa can easily overgrow culture 
plates(52).
In this systematic review, we identified seven randomized 
trials(53-59) with topical antibiotics in difficult-to-treat CRS of 
which four were placebo (or saline)-controlled studies(53, 55, 56, 
59) (Table 6.1.3.1.) The design and outcome parameters of the 
studies were too different to allow for meta-analysis.
The four placebo controlled studies (n=141) did not 
show significant improvement in symptoms by using 
topical antibiotics (nebulization or spray) compared to 
the treatment without antibiotics(53, 55, 56, 59). Sykes et al. 
compared dexamethasone, neomycin  and tramazoline with 
dexamethasone without neomycin and a placebo group in 50 
patients with CRSsNP with vehicle alone and showed significant 
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Table 6.1.3.1. Topical antibiotics for the treatment of patients with difficult-to-treat CRS.
Study Methods Participants Interventions Outcomes Results
Bonfils 
2015(59) 
DBPCT
 
72 adults CRSwNP 
post-surgery (55 
evaluated)
• A solution of 150 mg 
tobramycin for inhalation 
by nebulization in a single 
dose of 3 ml medium 
(150mg/3ml) administered 
by the Easynose®mesh 
nebulizer (n= 32 evaluated) 
twice daily for 7 days
• Same treatment with 3 ml 
saline (n= 23 evaluated)
• Bacteriological eradication
• Congestion, anterior or poste-
rior rhinorrhea, sneezing, facial 
pain or olfactory impairment 
(VAS)
• Early withdrawal
• Adverse effects
• Significantly better bacterio-
logical eradication with active 
treatment
• No significant impact on 
symptoms
Shikani 
2013(58)
DBRCT 35 adult patients 
with refractory CRS 
(CRSwNP and CRSsNP) 
that had undergone 
prior endoscopic sinus 
surgery
• Topical regimen group 
(13 CRSwNP, 12 CRSsNP) 
daily self-administered 
topical nebulisation of 
culture-directed antibiotics 
(tobramycin, vancomycin, 
mupirocin and levofloxacin) 
and of mometasone using a 
commercial nebuliser for 6 
weeks (n=25, 13 CRSwNP, 12 
CRSsNP)
• Oral regimen group 
consisting of culture-
directed oral antibiotics 
and commercially available 
mometasone spray for 6 
weeks (n=10, (5 CRSwNP, 5 
CRSsNP)
• Lund-Kennedy symptoms score
• Lund-Kennedy endoscopic 
appearance scores
• Histological response to 
treatment
• No comparisons are given 
between treatment groups 
but in the CRSsNP there 
appears to be no difference 
between treatments. In the 
CRSwNP topical treatment 
significantly reduced both 
LK symptom score and LK 
endoscopic appearances and 
oral treatment did not
• The improvement 
in histological score 
(inflammation, oedema, 
epithelial attenuation, 
epithelial hyperplasia, 
squamous metaplasia, fibrosis 
and goblet cell hyperplasia) 
was significant for the CRSwNP 
group treated with topical 
therapy but not for CRSsNP. 
No comparison between 
treatment groups was made
Jervis 
Bardy 
2012(57)
DBRCT
 
25 Stap. aureus-
positive CRSwNP 
patients but no frank 
polyps at moment of 
trial with ongoing signs 
and symptoms of CRS 
despite complete ESS 
• 125 mg mupirocin in a in 
200 ml proprietary buffered 
salts blend (MUP group) + 
3dd placebo tablet for 28 
days (n=9)
• 200 ml proprietary buffered 
salts blend and 3dd 625 
Augmentin (n=13) for 28 
days
• Change from baseline SNOT-20 
(28 days)
• Change from baseline VAS 
battery (summation of 5 
individual symptom scores plus 
an overall symptomatology 
score; total score range, 0–60) 
(28 days)
• Change from baseline Lund-
Kennedy endoscopic score) (28 
days)
• Bacteriological culture at 28 
days
• Change from baseline SNOT-20 
just not significant (0.06)
• Change from baseline VAS 
battery: not significant
• Significantly better LK score in 
mupirocin treated group -4.0 
(-7.0 to -1.3) than Augmentin 
3.0 (-1.0 to 4.0).
• Significantly better bacterial 
eradication
Videler 
2008(56)
DBPC 
cross- 
over 
study
14 patients with 
recalcitrant CRSsNP 
[symptomatology and 
a positive nasal culture 
for Staph. aureus 
returned, despite 2 
previous attempts to 
treat the disease with 
appropriate antibiotics 
(at least 2 weeks) and 
nasal saline irrigation]
• 8 ml solution of bacitracin/
colimycin (830/640 μg/
ml) twice daily for 8 weeks 
(n=14)
• 8 ml placebo solution 
(n=14)
• Severity of symptoms (rhinor-
rhoea, postnasal drip, crusts, 
headache, facial pain, smell 
disturbance, nasal pain, nose 
bleeds, fever, malaise, tired-
ness) measured using VAS
• Disease-Specific Symptom 
Score
• SF-36 questionnaire
• Nasal endoscopic findings
• No difference in severity of 
symptoms measured by VAS, 
disease specific symptom 
score, SF-36 or nasal endo-
scopic findings
EPOS 2020
214
Desrosiers 
2001(55)
DBRCT 20 patients with 
refractory rhinosinusitis 
who had failed 
maximal surgical and 
medical therapies 
without immune 
deficiencies
• 3-times daily applications 
of 4 mL of a 20 mg/mL 
tobramycin-saline solution 
as a 4-week course of 
large-particle nebulized 
aerosol therapy (n=10?)
• 3-times daily applications 
of 4 mL of saline solution 
as a 4-week course of 
large-particle nebulized 
aerosol therapy (n=10?)
• Symptoms pain, congestion, 
PND (VAS) 0, 2, 4 and 8 weeks 
after start of treatment
• Quality of life (RQLQ)
• Mucosal oedema and secretion 
evaluated by nasal endoscopy 
0, 2, 4 and 8 weeks after start of 
treatment (0-3)
• No benefit from the addition 
of tobramycin on symptoms, 
quality of life and/or mucosal 
oedema or secretion
Sykes 
1986(53)
DBPCT CRSsNP defined as 
chronic mucopurulent 
rhinorrhoea (50), nasal 
blockage (28/50) and/
or facial pain (15/50), 
abnormalities at sinus 
radiograph (25/50), 
abnormalities at 
nasendoscopy (28/50)
• Dexamethasone-
tramazoline-neomycin nasal 
spray 1 application to each 
nostril 4 times daily for 2 
weeks (n = 20)
• Dexamethasone-tramazo 
line nasal spray 1 application 
to each nostril 4 times daily 
for 2 weeks (n = 20)
• Placebo spray 1 application 
to each nostril 4 times daily 
for 2 weeks (n = 10)
• Daily symptom diary card
• Sinus radiograph
• Nasal mucociliary clearance 
measured by the modified 
saccharin method
• Nasal airways resistance 
measured by active anterior 
rhinomanometry
• No significant impact on 
symptoms, sinus radiograph, 
nasal mucociliary clearance
CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, double blind placebo 
controlled trial; dd, dose/day; LK, Lund-Kennedy; PND, post-nasal drip; VAS, visual analogue scale; Short-Form 36; SNOT, Sino-nasal 
Outcome Test.
Study Methods Participants Interventions Outcomes Results
effect of the dexamethasone/tramazoline compared to placebo 
but no additive effect of neomycin(53). 
Desrosiers et al. investigated 20 recalcitrant CRS patients 
(CRSsNP and CRSwNP) in a randomized, double-blind trial of 
tobramycin-saline solution or saline with quinine as control, 
administered thrice daily by means of a nebulizer for four weeks, 
followed by a four-week observation period. Both patient 
groups experienced improvement in signs and symptoms but 
the addition of tobramycin appears of no benefit (55). The bitter-
masking quinine used for the placebo in this trial is now being 
used therapeutically to stimulate taste receptors and potentially 
to clear gram-negative bacteria(60).
Videler et al. investigated the effect of nasal irrigation with 
bacitracin/colimycin or placebo after two weeks of  levofloxacin 
500 mg twice daily for two weeks in a randomised, double 
blind, cross-over study in 14 patients with recalcitrant CRS in 
spite of surgery with positive S.aureus culture.  Both groups 
improved and there was no difference in SF-36 and endoscopic 
appearance(56).
Bonfils et al. showed in 59 patients with CRSwNP with symptoms 
after surgery that inhalation by nebulization of a solution 
of 150 mg tobramycin twice daily for seven days eradicated 
bacteria based upon post-treatment culture significantly better 
than placebo. Bacteriological analysis was performed on day 
0 and day 10, following Day et al.(61) studying the presence of 
pathogenic strains in culture and their antibiotic susceptibility, 
with cytological analysis of the presence and concentration 
of leukocytes (D0 and D10). Pre-treatment and day 10 post-
treatment bacterial isolates were compared (Table 6.1.3.1.). 
Presence of leukocytes and sensitivities to antimicrobials were 
also evaluated. However, there was no significant impact on 
symptoms(59).
Of the  non-placebo controlled randomised trials (RTs) Jervis-
Bardy et al.(57) evaluated the effect of 125 mg mupirocin in a 200 
ml proprietary buffered salts blend (MUP group) + 3dd placebo 
tablet for 28 days (n=9) with Augmentin 200 ml proprietary 
buffered salts blend and 3dd 625 Augmentin (n=13) for 28 days 
in 25 CRSwNP patients but no frank polyps at the time of trial 
with ongoing signs and symptoms of CRS despite complete 
endoscopic sinus surgery (ESS). The MUP treatment eradicated 
S. aureus significantly more effectively than Augmentin at 
one month and five patients remained S. aureus negative for 
a period of two months after the treatment, based on middle 
meatus swab cultures. The Lund-Kennedy (LK) endoscopic 
score change from baseline was significantly better in the MUP 
treated group -4.0 [-7.0 to -1.3] vs. Augmentin 3.0 [-1.0 to 4.0]. 
The change from baseline in the SNOT-20 scores approached 
significance (MUP -7.0 [-10.0 to -1.0] vs. Augmentin -1.0 [-4.5 
to 3.0], P 0 .06), whereas the VAS scores were not significantly 
different.
Finally, Shikani 2013(58) conducted a randomized study in 35 
patients with refractory chronic rhinosinusitis (CRSwNP and 
CRSsNP) that had undergone prior endoscopic sinus surgery. 
Twenty-five patients (13 CRSwNP, 12CRSsNP) daily self-
Table 6.1.3.1. Topical antibiotics for the treatment of patients with difficult-to-treat CRS (continued).
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administered topical nebulisation of culture-directed antibiotics 
(tobramycin, vancomycin, mupirocin and levofloxacin) and 
mometasone using a commercial nebuliser for six weeks. The 
control group of 10 patients (five CRSwNP, five CRSsNP) received 
culture-directed oral antibiotics and commercially available 
mometasone spray for six weeks. No comparisons are given 
between treatment groups but in the CRSsNP there appears to 
be no difference between treatments, in the CRSwNP topical 
treatment significantly reduced both LK symptom score and 
LK endoscopic appearances whereas oral treatment did not. 
The improvement in histological score (inflammation, oedema, 
epithelial attenuation, epithelial hyperplasia, squamous 
metaplasia, fibrosis and goblet cell hyperplasia) was significant 
for the CRSwNP group treated with topical therapy but not for 
CRSsNP. No comparison between treatment groups was made. 
Topical antibacterial therapy does not seem to 
be more effective than placebo in improving 
symptoms in patients with CRS. However, it may 
give a clinically non-relevant improvement in 
symptoms, SNOT-22 and LK endoscopic score 
compared to oral antibiotics.
6.1.3.2. Conclusion
There are six RCTs evaluating the efficacy of topical antibacterial 
therapy in recalcitrant CRS. The four placebo controlled studies 
(n=141, 3 in CRSsNP, 1 in CRSwNP) did not show significant 
improvement in symptoms compared to the treatment without 
antibiotics(53, 55, 56, 59).  
High-volume rinsing with mupirocin seems able to eradicate 
S. aureus significantly better than oral Augmentin and  LK 
endoscopy score and SNOT-22 showed (near) significant 
improvement compared to Augmentin(57). Also, topical 
nebulisation of culture-directed antibiotics seemed to be more 
effective than oral treatment especially in CRSwNP patients(58). 
The latter two studies lack a placebo group and have significant 
other methodological issues reducing the certainty of the 
findings.
Topical antibacterial therapy does not seem to be more effective 
than placebo in improving symptoms in patients with CRS. 
However, it may give a clinically non-relevant improvement in 
symptoms, SNOT-22 and LK endoscopic score compared to oral 
antibiotics. The EPOS2020 steering group, due to the very low 
quality of the evidence, is uncertain whether or not the use of 
topical antibacterial therapy has an impact on patient outcomes 
in adults with CRS compared with placebo.
6.1.4. Intravenous antibiotics 
There are no randomized studies evaluating the effectiveness of 
intravenous (IV) antibiotics in CRS. 
There is one uncontrolled case series of 45 patients reporting 
a significant improvement in symptoms in patients receiving 
home IV antibiotics when previous oral antibiotic treatment 
and/or surgery had failed(62).
6.1.4.1. Conclusions
Due to the very low quality of the evidence, it is uncertain 
whether or not the use of intravenous antibiotics therapy has an 
impact on patient outcomes in adults with chronic rhinosinusitis 
compared with placebo.
6.1.5. Nasal corticosteroids 
6.1.5.1. Summary of the evidence
In this analysis, DBPCT trials after the year 1990, assessing 
the effects of nasal corticosteroids for patients with chronic 
rhinosinusitis, both with and without polyps are included. 
Diagnostic criteria for CRS should meet the current EPOS 
criteria for chronic rhinosinusitis(63). Patients with allergic fungal 
rhinosinusitis, cystic fibrosis, immunodeficiency, primary ciliary 
dyskinesia, fungal balls, granulomatosis with polyangiitis are 
excluded. Corticosteroids delivered into the nose and the 
paranasal sinuses by any delivery methods generally available in 
clinical practice are included. Trials administering corticosteroids 
via catheter(64, 65)  and polyp injection(66) are excluded. Outcomes 
analysed in this analysis are symptoms, quality of life, endoscopy 
polyp size, polyp recurrence and adverse events.
Of the 42 studies included in this review (43 articles), 40 studies 
were placebo-controlled trials assessing the effects of nasal 
corticosteroids (Table 6.1.5.1.). Four studies compared different 
delivery methods of nasal corticosteroids (Table 6.1.5.2.)(67-70). 
One article(71)included data of a previously published article(72)for 
re-analysis. Thirty-two studies evaluated patients with CRSwNP, 
five studied patients with CRSsNP and the other five studied a 
mixed population. In 24 trials most patients had previous sinus 
surgery and in 14 trials most had no surgery. Patients’ sinus 
surgery status was not mentioned in four trials. A variety of nasal 
corticosteroids was used such as triamcinolone, mometasone 
furoate, hydrocortisone, budesonide, FP, and dexamethasone. 
Corticosteroids were delivered using nasal spray in 26 trials, 
nasal drop in seven trials, nebulizer in two trials, aerosol in three 
trials, nasal irrigation in 4 trials and turbuhaler in two trials. Four 
trials used a bi-directional exhalation device which generated 
airflow in the nose after patients blew through the device. In 
13 trials postoperative nasal corticosteroids were administered. 
Endoscopic sinus surgery was not performed in 29 trials. 
6.1.5.2. Impact of nasal corticosteroids on quality of life 
(QOL) in patients with CRS
There were twelve studies assessing quality of life (QOL)(73-80)(67, 
81)(82, 83). Of the 12 studies, 10 assessed disease-specific quality 
of life(73-75, 78-80)(67, 81)(82, 83) and two studies assessed general 
health-related quality of life(76, 77).  Disease-specific quality of life 
questionnaires used were the Sinonasal Outcome Test-22 (SNOT-
22)(73-75)(67, 81)(82, 83), Rhinosinusitis Outcome Measure (RSOM-31)(78)
(82), the Chronic Sinusitis Survey (CSS)(79), Rhinosinusitis Disability 
Index (82), and a questionnaire designed by the investigators(80). 
Nasal corticostereoids have a positive impact on 
disease specific and general QOL in patients with 
CRS
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Leopold 
2019(73)
DBPCRCT 323 CRSwNP, 
27% previous 
sinus surgery
• FP   using exhalation 
delivery system 93µg 
b.i.d. for 16 weeks 
(n=81)
• FP   using exhalation 
delivery system 186µg 
b.i.d. for 16 weeks 
(n=80)
• FP   using exhalation 
delivery system 372µg 
b.i.d. for 16 weeks 
(n=82)
• Placebo for 16 weeks 
(n=80)
• Disease specific quality 
of life (SNOT-22) at 16, 
24 weeks
• Proportion of respond-
ers at 16 weeks
• Symptom score 
improvement (0-3, 4 
symptoms) at 4 weeks
• Polyp score (0-3) 
reduction at 4, 8, 12, 16, 
24 weeks
• Adverse events
• At 16 weeks, greater number of responders 
in symptoms and polyp score reduction 
significantly favoured FP   versus placebo 
• SNOT-22, symptoms, polyp grade were 
significantly improved in each FP   group at 
weeks 8, 12, 16
• There were no differences between active/
placebo groups in intraocular pressure and 
cataract
• Serious AEs were reported in 1 patient 
receiving placebo (meningitis and 
sinusitis) and 1 patient receiving 372mg FP   
(positional vertigo)
• Local adverse events were more common in 
FP   (epistaxis and nasal septal ulcer)
Kobayashi 
2018(74)
DBPCRCT CRSwNP, 35% 
previous sinus 
surgery 
• Beclomethasone dipro-
pionate metered-dose 
inhaler, inhalation 
through the mouth 
followed by exhalation 
through the nose for 4 
weeks (n=11)
• Placebo for 4 weeks 
(n=12)
• Disease specific quality 
of life (SNOT-22) at 4 
weeks 
• Proportion of respond-
ers at 4 weeks
• Polyp score (0-4) reduc-
tion at 4 weeks
• At 4 weeks, greater number of responders in 
polyp score reduction significantly favoured 
beclomethasone dipropionate versus 
placebo 
• At 4 weeks, SNOT-22 improved significantly 
in the beclomethasone dipropionate group
• At 4 weeks, beclomethasone dipropionate 
reduced polyp size significantly
Tait 2018(81) DBPCRCT 74 CRS 
(25%CRSwNP), 
28% previous 
sinus surgery 
(61 analyzed)
• Budesonide irrigation 
1000µg o.d. in 240ml 
bottle for 4 weeks 
(n=29)
• Saline irrigation with 
placebo (lactose) for 4 
weeks (n=32)
• Quality of life (SNOT-22 
(0-110) at 4 weeks)
• Symptoms (Likert scale 
of improvement 1-7, 
scale at 4 weeks)
• Endoscopy score (LKES 
(0-20) at 4 weeks)
• Adverse event
• The SNOT-22 scores at 4 weeks were not 
different between the 2 groups
• Symptoms at 4 weeks were not different
• LKES change at 4 weeks was not different
There were no related adverse events.
Venkatesan 
2016(107)
DBPCRCT 22 CRSwNP, 
without sinus 
surgery
• Fluticasone fuorate 
nasal spray 110µg o.d. 
for 12 weeks (n=18)
• Placebo nasal spray for 
12 weeks (n=2)
• Symptom score (0-3, 5 
symptoms) improve-
ment at 12 weeks
• Polyp score (0-3) reduc-
tion at 12 weeks
• At 12 weeks, improvement by corticosteroid 
treatment over placebo on symptom scores 
and the polyp score were not significant
Zhou 
2016(106)
DBPCRCT 748 CRSwNP, 
24% previous 
sinus surgery
• MFNS 200µg b.i.d. for 
16 weeks (n=375)
• Placebo spray for 16 
weeks (n=373)
• Proportion of respond-
ers at 16 weeks
• Symptom score (0-3, 4 
symptoms) improve-
ment at 4, 8, 12, 16 
weeks
• Polyp score (0-3) 
reduction at 4, 8, 12, 16 
weeks
• At 16 weeks, a greater number of 
responders was significant for MFNS 
compared to placebo 
• MFNS was significantly effective in 
symptom improvement over placebo. Nasal 
obstruction, anterior rhinorrhoea, smell 
improvements were significant at 4, 8, 12, 16 
weeks. It was significant for postnasal drip at 
8, 12 weeks.
• Change from baseline in total polyp size 
score was significantly greater for MFNS vs. 
placebo at 4, 8, 12, 16 weeks
Dixon 
2015(75)
DBPCRCT 388 CRSsNP 
(237 adult and 
151 children) 
without sinus 
surgery
• MFNS 200µg/day for 
24 weeks (n=189)
• Placebo for 24 weeks 
(n=199)
• Disease specific quality 
of life (SNOT-22) at 24 
weeks
• Symptom score (1-60) 
improvement at 24 
weeks
• At 24 weeks, there was no difference 
between corticosteroid and placebo in 
SNOT-22
• At 24 weeks, there was no difference 
between groups in symptom improvement
Table 6.1.5.1. Nasal corticosteroids versus placebo for the treatment of  patients with CRS.
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Wang 
2015(85)
DBPCRCT 57 CRSwNP, 
without sinus 
surgery
• Budesonide 1000µg 
b.i.d. transnasal neb-
ulization for 14 days 
(n=29)
• Placebo nebulization 
for 14 days (n=28)
• Symptom (4 symp-
toms) improvement at 
2 weeks
• Polyp score (0-3) reduc-
tion at 2 weeks
• Adverse events
• At 2 weeks, budesonide transnasal 
nebulization significantly improved total 
nasal symptoms and 4 individual symptoms
• At 2 weeks, budesonide transnasal 
nebulization significantly reduced polyp size 
compared with placebo 
• Morning plasma cortisol levels showed no 
significant difference between the initial 
treatment and the end of treatment. There 
was no symptom of adrenal suppression in 
any of the participants. 
• No serious adverse events were reported
Rawal  
2015(82)
SBPCRCT 50 CRSwNP 
postoperative 
(42 analyzed)
• Budesonide irrigation 
500µg in 240ml bottle. 
60ml/nostril b.i.d. for 
24 weeks (n=24)
• Saline irrigation alone 
for 24 weeks (n=18)
• Quality of life (SNOT-22 
(0-110), RSOM-31 (0-
155), RSDI (0-120) at 2 
weeks, 3, 6 months)
• SNOT-22, RSOM31, and RSDI scores were not 
different between 2 arms at all 3 timepoints 
(2 weeks, 3, 6 months).
Nordin 
2013(76)
DBPCRCT 60 CRSwNP, 
postoperative
• Peri-operative FPND 
400µg b.i.d. for 14 
weeks (n=26)
• Peri-operative placebo 
b.i.d. for 14 weeks 
(n=34)
• General quality of life, 
using General Well 
Being Schedule (0-110, 
14 questions with a 
6-point scale and 4 
questions with an 
11-point scale) at weeks 
4 and 5
• At 5 weeks, both groups increased in 
general quality of life score to a similar 
extent without difference
Vento 
2012(105)
DBPCRCT CRSwNP, 
postoperative
• Postoperative triam-
cinolone acetonide 
nasal aerosol 220µg 
⁄ day as 2 actuations 
of 55µg, each for 9 
months (n=30)
• Postoperative placebo 
spray for 9 months 
(n=30)
• Symptom score (0-3, 10 
symptoms) improve-
ment at month 3, 6, 9
• Polyp score (0-3) reduc-
tion at month 3, 6, 9
• Polyp recurrence at 9 
months
• Adverse events
• There was no difference in symptom 
improvement
• At 3 months, triamcinolone acetonide 
reduced polyp size and prevented regrowth 
of nasal polyps significantly in acetylsalicylic 
acid-tolerant patients, but it was not 
significant at 6 and 9 months. It was not 
significant in acetylsalicylic acid-intolerant 
patients
• No serious adverse events reported. 
There was no difference in blood in nasal 
secretions.
Mosges 
2011(90)
DBPCRCT 59 CRSsNP, 
without sinus 
surgery
• MFNS 200µg b.i.d. for 
16 weeks (n=29)
• Placebo for 16 weeks 
(n=30)
• Proportion of respond-
ers at 16 weeks
• Symptom score (0-3, 5 
symptoms) improve-
ment at weeks 1, 4, 8, 
12, 16
• LK endoscopy score at 
weeks 1, 4, 8, 12, 16
• Adverse events
• At 16 weeks, greater number of responders 
significantly favoured MFNS over placebo
• At 16 weeks, symptom score was 
significantly improved by MFNS
• At 16 weeks, the LK endoscopy score 
showed a significant difference between 
the MFNS group and the placebo group
• No serious adverse events reported. No 
difference between groups in non-specific 
complaints
Rotenberg 
2011(83)
DBPCRCT 64 CRSwNP 
(N-ERD) 
postoperative 
(60 analyzed)
• Budesonide irrigation 
60ml/nostril 500µg 
b.i.d. (total 1000µg) for 
52 weeks (n=20)
• Saline irrigation 
60ml/nostril and 
budesonide spray 
64µg/nostril b.i.d. 
(total 256µg) for 52 
weeks (n=19)
• Saline irrigation alone 
for 52 weeks (n=21)
• Quality of life (SNOT-21 
(0-105) at 6,12 months)
• Endoscopy score (LKES 
(0-12) at 6,12 months)
• CT score (LM score (0-
24) at 6,12 months)
• Ocular events (IOP at 
6,12 months)
• HPA axis (ACTH (nor-
mal/abnormal) at 6,12 
months)
• SNOT-21, LKES, and LM score results of both 
intervention groups were not different from 
placebo group at both 6 and 12-month 
timepoints (significant level was defined at 
p < .0167)
• IOP and ACTH level were not changed at 
both 6 and 12-month timepoints
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Hansen 
2010(78)
DBPCRCT 20 CRSsNP, all 
previous sinus 
surgery
• FPNS 400µg b.i.d. 
using a bi-directional 
exhalation delivery 
device for 12 weeks 
(n=10)
• Placebo b.i.d. using a 
bi-directional exhala-
tion delivery device 
for 12 weeks (n=10)
• Proportion of respond-
ers at 12 weeks
• Symptom improve-
ment at 4, 8, 12 weeks
• Disease specific quality 
of life (RSOM-31) at 4, 8, 
12 weeks
• LK endoscopy score at 
4, 8, 12 weeks
• At 12 weeks, a significantly greater 
number of responders reported symptom 
improvement in the FP   group than in the 
placebo group.
• Combined symptom score was significantly 
improved by FP   compared to placebo at 
8, 12 weeks
• Overall RSOM-31 score and nasal subscale 
were not different at 12 weeks but nasal 
subscale was significantly improved with FP   
compared to placebo at 4, 8 weeks
• Endoscopy score showed a significant 
improvement of FP   in oedema at 4, 8, 12 
weeks but no difference for nasal discharge.
Olsson 
2010(77)
DBPCRCT 68 CRSwNP, 
postoperative
• Perioperative FPND 
400µg twice daily. for 
10 weeks (n=30)
• Perioperative placebo 
b.i.d. for 10 weeks 
(n=38)
• Health related quality 
of life (SF-36, 0-100, 
8 health domains) 
at week 5 after sinus 
surgery
• At 5 weeks after sinus surgery no effect on 
total SF36 but significant improvement in 
the FPND group of the mental component 
summary  and  3 domains (role physical, 
vitality, social functioning).
Ehnhage 
2009(95)
DBPCRCT 68 CRSwNP, 
postoperative
• Perioperative FPND 
400µg b.i.d. for 10 
weeks (n=100)
• Perioperative placebo 
b.i.d. for 10 weeks 
(n=47)
• Symptom score (3 
symptoms, each score 
0-3) improvement at 10, 
17 weeks
• Nasal Polyp score (0-3) 
reduction at 4, 6, 10, 17 
weeks
• Adverse events
• There was no difference between FP   and 
placebo in symptom improvement and 
nasal polyp score reduction at 10 and 17 
weeks
• No difference in adverse events
Jankowski 
2009(99)
DBPCRCT 245 CRSwNP, 
without sinus 
surgery
FPNS 200µg bid for 8 
months (n=81)
• FPNS 200µg bid for 1 
month followed by FP  
NS 200µg daily for 7 
months (n=83)
• Placebo spray for 2 
months followed by 
FPNS 200µg bid for 6 
months (n=81)
• Symptom score (0-3, 
3 symptoms), VAS im-
provement at 4 weeks
• Polyp score (0-3) reduc-
tion at 4 weeks
At 4 weeks, FPNS 400 µg/ day was significantly 
more effective than placebo
•  in  reduction of intensity of three symptoms 
• polyp reduction 
Jorissen 
2009(93)
DBPCRCT 91 CRS (45% 
CRSwNP), 
postoperative
• Postoperative MFNS 
200µg bid for 6 
months (n=46)
• Postoperative placebo 
bid for 6 months 
(n=45)
• Symptom score (4 
symptoms and overall 
discomfort, 0-10 VAS) 
improvement at 
months 1, 2, 4, 6
• Endoscopy score (0-2, 
8 characteristics) at 
days 7, 14 and months 
1, 2, 4, 6
• Adverse events
• At 6 months, there was no difference 
between MFNS and placebo in symptoms
• At 6 months, endoscopy scores were 
reduced in both groups without difference
• Serious adverse events were rare without 
difference between MFNS and placebo
Stjarne 
2009(114)
DBPCRCT 162 CRSwNP 
postoperative
• Postoperative MFNS 
200µg o.d. for 8 weeks 
(n=80)
• Postoperative placebo 
for 8 weeks (n=82)
• Time to relapse for 
polyp recurrence at 24 
weeks
• Adverse events
• At 24 weeks follow-up, postoperative use 
of MFNS 200 µg once daily, provided a 
statistically significant longer time to relapse 
with nasal polyps than with placebo
• The frequency of AEs with MFNS and 
placebo was comparable.
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Vlckova 
2009(72)
Djupesland 
2010(71)
DBPCRCT 109 CRSwNP 
(65% previous 
sinus surgery)
• FP   400µg b.i.d. using 
a bidirectional exha-
lation delivery device 
for 12 weeks (n=54)
• Placebo b.i.d. for 12 
weeks (n=55)
• Proportion of respond-
ers at 4, 8, 12 weeks
• Polyp score (0-3) reduc-
tion at 4, 8, 12 weeks
• Adverse events
• At 4, 8, 12 weeks, a greater number of 
responders was significant for FP compared 
to placebo.
• At 4, 8, 12 weeks, a significantly greater 
reduction in polyp score was observed for 
FP   
• No serious adverse events reported. 
Epistaxis occurred in 11% subjects treated 
with FP   and none in the placebo group. 
Morning plasma cortisol concentrations 
were unchanged.
Stjarne 
2006a(104)
DBPCRCT 274 CRSwNP, 
sinus surgery 
status not 
mentioned
• MFNS 200µg o.d. for 
16 weeks (n=94)
• MFNS 200µg b.i.d. for 
16 weeks (n=93)
• Placebo for 16 weeks 
(n=87)
• Symptom score (0-3, 4 
symptoms) improve-
ment at months 1, 2, 
3, 4
• Polyp score (0-3) reduc-
tion at months 1, 2, 3, 4
• Adverse events
• At 4 months, both o.d. and b.i.d. doses 
of MFNS significantly improved in nasal 
obstruction score and anterior rhinorrhoea 
compared to placebo. At 4 weeks, only the 
b.i.d. dose significantly improved postnasal 
drip.
• At 4 months, MFNS significantly produced 
greater reductions in bilateral polyp grade 
than placebo
• Most adverse events were mild or moderate 
in severity without difference among 3 
groups.
Stjarne 
2006b(80)
DBPCRCT 298 CRSwNP 
(26% previous 
sinus surgery)
• MFNS 200µg o.d. for 
16 weeks (n=153)
• Placebo for 16 weeks 
(n=145)
• Proportion of respond-
ers at 16 weeks
• Symptom score (0-3, 3 
symptoms) improve-
ment at 12, 16 weeks
• Polyp score (0-3) reduc-
tion at 12, 16 weeks
• Quality of life (4 items, 
1-3 for 2 items and 0-3 
for 2 items) at 12, 16 
weeks
• Adverse events
• At 16 weeks, a greater proportion of 
the MFNS-treated group than the 
placebo group experienced a significant 
improvement in 3 symptoms of nasal 
obstruction, rhinorrhoea and sense of smell
• At 16 weeks, polyp size reduction 
significantly favoured MFNS.
• At 16 weeks, MFNS significantly improved 
quality of life in nose breathing, daily 
activities, sleep disturbance. It was not 
significant for taste and smell.
• Most adverse events were mild or moderate 
in severity without difference between 
groups.
Aukema 
2005(110)
DBPCRCT 54 CRSwNP, 
(83% previous 
sinus surgery )
• FPND 400µg/day for 
12 weeks (n=27)
• Placebo nasal drops 
for 12 weeks (n=27)
• Proportion of respond-
ers at 12 weeks
• Symptom score (VAS 
0-10) at 2, 6, 12 weeks
• Polyp volume estimat-
ed by endoscopy using 
VAS at 2, 6, 12 weeks
• At 12 weeks, the number of responders who 
did not require surgery was significantly 
greater with FPND versus placebo
• Nasal blockage scores were significantly 
lower with FPND at 6, 12 weeks
• Polyp volume was significantly reduced in 
the FPND group at 12 weeks
Rowe-
Jones 
2005(92) 
DBPCRCT 109 CRS (71% 
CRSwNP), 
postoperative
• Postoperative FPNS 
200µg b.i.d. for 6 
weeks (n=55)
• Postoperative placebo 
spray for 6 weeks 
(n=54)
• Symptom score (VAS, 6 
symptoms) improve-
ment at week 6 and 
year 1, 2, 3, 4, 5
• Polyp score (0-2) reduc-
tion at week 6 and year 
1, 2, 3, 4, 5
• LK endoscopy score at 
week 6 and year 1, 2, 
3, 4, 5
• At 5 years, ‘How do you feel overall’ VAS 
favoured FPNS significantly but total VAS 
was not different.
• At 1 year, improvement in polyp score was 
significantly better with FPNS but it was not 
different at 5 years
• There was no difference in endoscopy 
oedema and discharge score at 1 and 5 
years.
Small 
2005(103)
DBPCRCT 354 CRSwNP, 
sinus surgery 
status not 
mentioned
• MFNS 200µg o.d. for 
16 weeks (n=115)
• MFNS 200µg b.i.d. for 
16 weeks (n=122)
• Placebo for 16 weeks 
(n=117)
• Symptom score (0-3, 4 
symptoms) improve-
ment at day 8 and 
months 1, 2, 3, 4
• Polyp score (0-3) 
reduction at day 8 and 
months 1, 2, 3, 4
• Adverse events
• At months 1, 2, 3, 4, MFNS significantly 
improved nasal obstruction, loss of smell, 
anterior rhinorrhoea, and postnasal drip 
• At 4 months, improvement in polyp grade 
was significantly better by MFNS
• Most adverse events were mild or moderate 
in severity without difference among 3 
groups. 24-hour urinary free cortisol was not 
different between groups
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Dijkstra 
2004(111)
DBPCRCT 162 CRS (42% 
CRSwNP) 
postoperative
• Postoperative FPNS 
400µg b.i.d. for 1 year 
(n=53)
• Postoperative FPNS 
800µg b.i.d. for 1 year 
(n=53)
• Postoperative placebo 
b.i.d. for 1 year (n=56)
• Number of patients 
with recurrence of at 
1 year
• Adverse events
• No difference in percentage of recurrence of 
disease between the groups
• The incidence of epistaxis was similar 
between FPNS and placebo
Lund 
2004(112)
DBPCRCT 167 CRSsNP, 
without sinus 
surgery
• Budesonide nasal 
spray 128µg b.i.d. for 
20 weeks (n=81)
• Placebo for 20 weeks 
(n=86)
• Proportion of respond-
ers at 20 weeks
• Disease specific quality 
of life (CSS) at 20 weeks
• Symptom score (0-3, 4 
symptoms) improve-
ment at 20 weeks
• Adverse events
• At 20 weeks, greater number of responders 
significantly favoured budesonide over 
placebo
• At 20 weeks, CSS was not different between 
groups
• At 20 weeks, budesonide significantly 
improved combined symptom score 
compared to placebo.
• There were no serious adverse events 
reported. Minor effects were not different 
between groups.
Gulati 
2001(859)
DBPCRCT 63 CRSwNP, 
postoperative
• Postoperative 
Budesonide nasal 
sprays 400µg/day for 
12 weeks (n=38)
• Postoperative saline 
nasal sprays for 12 
weeks (n=25)
• Proportion of respond-
ers at 12 weeks
• Symptom improve-
ment (4 symptoms) at 
12 weeks
• Polyp recurrence at 12 
weeks
• At 12 weeks, greater responder of symptom 
improvement in the Budesonide group 
than placebo group was significant for 
rhinorrhoea and sneezing. 
• At 12 weeks, budesonide treated patients 
had significantly lower rate of polyp 
recurrence.
Jankowski 
2001(98)
DBPCRCT 183 CRSwNP, 
all previous 
sinus surgery
• Budesonide nasal 
spray 128µg daily for 8 
weeks (n=48)
• Budesonide nasal 
spray 128µg bid for 8 
weeks (n=48)
• Budesonide nasal 
spray 256µg daily for 8 
weeks (n=42)
• Placebo spray for 8 
weeks (n=45)
• Symptom score (0-4, 4 
symptoms) improve-
ment at 4, 8 weeks
• Polyp score (0-3) reduc-
tion at 4, 8 weeks
• Adverse events
• Combined symptom scores improved 
significantly in all budesonide-treated 
groups at 4, 8 weeks. 
• Budesonide nasal spray (all regimens) 
significantly reduced polyp size at 4, 8 
weeks.
• Budesonide nasal spray was well 
tolerated. The adverse events reported 
more frequently with budesonide nasal 
spray treatment were blood-tinged nasal 
secretions.
Parikh 
2001(91)
DBPCRCT 22 CRS 
(18%CRSwNP), 
>50% 
previous sinus 
surgery
• FPNS 200µg b.i.d. for 8 
weeks (n=9)
• Placebo for 8 weeks 
(n=13)
• Symptom score (VAS, 9 
symptoms) improve-
ment at 8 weeks
• LK endoscopy score at 
8 weeks
• There was no difference between FPNS and 
placebo in symptoms and endoscopy score.
Filiaci 
2000(96)
DBPCRCT 157 CRSwNP, 
41% previous 
sinus surgery
• Budesonide turbuhal-
er 140µg b.i.d. for 8 
weeks (n=39)
• Budesonide turbu-
haler 280µg o.d. for 8 
weeks (n=40)
• Budesonide turbu-
haler 140µg o.d. for 8 
weeks (n=41)
• Placebo for 8 weeks 
(n=37)
• Proportion of respond-
ers at 8 weeks
• Symptom score (3 
symptoms, each score 
0-3) improvement at 8 
weeks
• Polyp score (0-40) 
reduction at 8 weeks
• Adverse events
• At 8 weeks, substantial control of symptoms 
was significantly superior in patients 
receiving budesonide (70%)  than placebo 
(45%)
• At 8 weeks, the mean reduction in total 
polyp score was significantly greater in the 
group receiving budesonide, 140 µg twice 
daily, than in the placebo group
• Budesonide was well tolerated, and the 
proportion of patients reporting adverse 
events were similar in the four treatment 
groups.
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Keith 
2000(100)
DBPCRCT 104 CRSwNP, 
69% previous 
sinus surgery
• FPNS 400µg daily for 
12 weeks (n=52)
• Placebo for 12 weeks 
(n=52)
• Proportion of respond-
ers at 12 weeks
• Symptom score (0-3, 
nasal blockage, overall 
rhinitis, smell) improve-
ment at 4, 8, 12 weeks
• Polyp score (0-3) reduc-
tion at 12 weeks
• Adverse events
• At 12 weeks, number of responders 
significantly favoured FP nasal spray over 
placebo in reduction of nasal blockage 
• At 12 weeks, symptom score reduction 
significantly favoured FP nasal spray in nasal 
blockage and overall rhinitis but smelling 
score was not significant
• At 12 weeks, number of responders was 
not statistically significant in polyp size 
reduction
• No serious adverse events. More patients 
reported epistaxis in the FPNS group 
(19%) than in the placebo group (4%). No 
individual’s serum cortisol level fell below 
the lower threshold limit.
Pentilla
2000(102)
DBPCRCT 142 CRSwNP, 
71% previous 
sinus surgery
• FPNS 400µg o.d. for 12 
weeks (n=48)
• FPNS 400µg b.i.d. for 
12 weeks (n=47)
• Placebo for 12 weeks 
(n=47)
• Proportion of respond-
ers at 12 weeks
• Symptom score 
(0-3, nasal blockage 
and overall rhinitis) 
improvement at weeks 
4, 8, 12
• Polyp score (0-3) reduc-
tion at weeks 4, 8, 12
• Adverse events
• At 12 weeks, greater number of responders 
significantly favoured FPNS over placebo
• At 12 weeks, nasal blockage showed 
significant improvements with both doses 
of FPNS over placebo, but overall rhinitis 
showed significant improvement only for 
FPNS 400 µg o.d.
• At 4, 8, 12 weeks, polyp size was reduced 
significantly by FPNS 400 mg b.i.d. as 
compared with placebo
• There were no serious adverse events. There 
was no difference in side effects between 
groups.
Holmstrom 
1999(97)
DBPCRCT 100 CRSwNP 
without sinus 
surgery
• FPNS 400µg/day for 
12 weeks (n=49)
• Placebo spray for 12 
weeks (n=51)
• Proportion of respond-
ers at 12 weeks
• Polyp score (0-3) reduc-
tion at 26 weeks
• Adverse events
• At 26 weeks, a greater number of 
responders in polyp score reduction was 
found with FPNS versus placebo 
• No serious adverse events reported
Lund 
1998(79)
DBPCRCT 29 CRSwNP, 
66% previous 
sinus surgery 
• FPNS 200µg b.i.d. for 
12 weeks (n=10)
• Beclomethasone 
dipropionate 200µg 
b.i.d. for 12 weeks 
(n=10)
• Placebo for 12 weeks 
(n=9)
• Symptom score (0-4, 4 
symptoms) improve-
ment at 12 weeks
• Polyp score (0-3) reduc-
tion at 12 weeks
• Adverse events
• At 12 weeks, the overall symptom score 
was lower for both treatment groups, it 
did not reach statistical significance when 
compared with placebo 
• At 12 weeks, the polyp score reduction 
was significant in the FPNS-treated group 
but not significant in the beclomethasone 
group
• No serious adverse events. No drug related 
adverse events.
Tos 1998(69) DBPCRCT 138 CRSwNP, 
all previous 
sinus surgery
• Budesonide aqua 
spray 128µg b.i.d. for 6 
weeks (n=46)
• Budesonide turbuhal-
er 200µg b.i.d. for 6 
weeks (n=45)
• Placebo aqua spray for 
6 weeks (n=24)
• Placebo turbuhaler for 
6 weeks (n=23)
• Proportion of respond-
ers at 6 weeks
• Symptom score (0-3, 3 
symptoms) improve-
ment at 6 weeks
• Polyp score (0-3) reduc-
tion at 6 weeks
• Adverse events
• The proportion of responders after 6 weeks 
treatment was not significantly different 
between the aqua and turbuhaler-treated 
groups
• At 6 weeks, budesonide aqua spray showed 
a significantly superior efficacy over 
turbuhaler for blocked nose, runny nose and 
sneezing
• At 6 weeks, there was no statistical 
difference between aqua and turbuhaler in 
polyp size reduction
• No serious adverse events
Holmberg 
1997(109)
DBPCRCT 55 CRSwNP, all 
previous sinus 
surgery
• FPNS 400µg/day for 
26 weeks (n=15)
• Beclomethasone 
dipropionate aqueous 
nasal spray for 26 
weeks (n=16)
• Placebo nasal spray for 
26 weeks (n=11)
• Proportion of respond-
ers at 26 weeks
• Symptom improve-
ment (0-3, 5 symptoms) 
at 4, 8, 26, 38 weeks
• Polyp score (0-4) 
reduction at 4, 8, 26, 28 
weeks
• Adverse events
• At 26 weeks, greater response of symptom 
improvement in the corticosteroids group 
than in the placebo group, but it was 
significant only for beclomethasone
• At 26 weeks, symptom score improvement 
was significantly greater than placebo only 
for beclomethasone
• Reduction in polyp size at 26 weeks 
was only statistically significant for 
beclomethasone 
• A drug related adverse event was 
epistaxis. No serious adverse events were 
experienced.
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Lildholdt 
1995(101)
DBPCRCT 126 CRSwNP, 
sinus surgery 
status not 
mentioned
• Budesonide turbuhal-
er 200µg b.i.d. for 4 
weeks
• Budesonide turbuhal-
er 400µg b.i.d. for 4 
weeks
• Placebo for 4 weeks
• Proportion of respond-
ers at 4 weeks
• Symptom score (0-3, 3 
symptoms) improve-
ment at 4 weeks 
• Polyp score (0-3) reduc-
tion at 4 weeks
• Adverse events
• At 4 weeks, greater number of responders 
significantly favoured budesonide over 
placebo
• At 4 weeks, significant improvement 
of symptom score and polyp score in 
budesonide group
• No serious adverse events reported.
Johansen 
1993(70)
DBPCRCT 86 CRSwNP, 
sinus surgery 
status not 
mentioned
• Budesonide nasal 
spray 100µg bid for 3 
months
• Budesonide aerosol 
100µg bid for 3 
months
• Placebo for 3 months
• Symptom score (0-3, 3 
symptoms) improve-
ment weekly up to 12 
weeks
• Polyp score (0-3) reduc-
tion at 4, 8, 12 weeks
• Adverse events
• After 4 weeks, both budesonide spray 
and aerosol were significantly effective in 
patients with small and medium sized polyp 
symptoms 
• At 4, 8, 12 weeks, budesonide reduced 
polyp size significantly
• Few side effects were reported without 
difference between groups.
Qvarnberg 
1992(868)
DBPCRCT 40 CRSsNP, all 
previous sinus 
surgery
• Budesonide aerosol 
200µg b.i.d. for 12 
weeks (n=20)
• Placebo for 12 weeks 
(n=20)
• Proportion of respond-
ers at 12 weeks
• Symptom score (0-3, 4 
symptoms) improve-
ment at weeks 1, 2, 12
• At 12 weeks, the number of responders was 
not different
• At 12 weeks, facial pain and facial sensitivity 
were significantly improved by budesonide 
but not nasal blockage, nasal discharge and 
postnasal drip. 
Ruhno 
1990(113)
DBPCRCT 36 CRSwNP, 
previous 
sinus surgery 
unclear
• Budesonide spray 
400µg b.i.d. for 4 
weeks (n=18)
• placebo spray for 4 
weeks (n=18)
• Symptom score (0-4, 6 
symptoms) improve-
ment at week 4.
• Adverse events
• At 4 weeks, effect on mean symptom score 
was not significant. Only improvement in 
blockage significantly favoured budesonide
• No serious adverse events reported.
ACTH, Adrenocorticotropic Hormone ; AE, Adverse Event ; b.i.d., twice daily; CSS, Chronic Sinusitus Survey ; CRSsNP, chronic rhinosinusitis with-
out nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCRCT, double blind placebo controlled randomised controlled trial; FPND, 
Fluticasone Propionate Nasal drops ; FPNS, Fluticasone Propionate Nasal spray ; HPA, Hypothalamic Pituitary Adrenal ; IOP, intraocular pressure; LK, 
Lund-Kennedy; LKES, Lund-Kennedy endoscopy scoring ; LM, Lund-Mackay; MFNS, Mometasone fuorate nasal spray; N-ERD, NSAID-exacerbated 
respiratory disease ; o.d., once daily; RSOM-31, Rhinosinusitis Outcome Measure-31 ; RSDI, Rhinosinusitis Disability Index; SNOT, Sino-nasal Outcome 
Test.
The studies evaluating the Sinonasal Outcome Test-22 were 
combined in a meta-analysis although the treatment time 
evaluated was quite different (from four weeks(74) to 24 weeks(73). 
The meta-analysis favoured nasal corticosteroids over placebo 
in the improvement of disease specific quality of life (MD 
--5.46, 95% CI -8.08 to -2.84, p<0.001; 6 RCTs, n = 715; Figure 
6.1.5.1). Although statistically significant, the effect size of 5.46 
with 95% CI of -8.08 to -2.84 is smaller than the MCID (minimal 
clinically important difference) of 8.9 and may not be clinically 
significant(84). When general QOL was measured with SF-36, 
nasal corticosteroids significantly improved the Mental subscale 
but not the Physical subscale at five weeks(77). However, when 
psychological well-being was measured with General Well 
Being Schedule, improvement in general QOL was not different 
between nasal corticosteroids and placebo(76).
6.1.5.3. Impact of nasal corticosteroids on symptoms in 
patients with CRS 
Eighteen studies evaluating symptoms could be combined 
in a meta-analysis (Figures 6.1.5.2-6.1.5.3). The meta-analysis 
favoured nasal corticosteroids over placebo in the improvement 
in symptoms for both symptom score [SMD -0.63, 95% 
confidence interval (CI) -0.89 to -0.37, p<0.01; 12 randomised 
controlled trials (RCTs), n = 1690; Figure 6.1.5.2] and the 
proportion of responders (RR 0.66, 95% CI 0.59 to 0.73, p<0.01; 
12 RCTs, n = 1646; Figure 6.1.5.3). 
When subgroup analysis by CRS subtype was performed, the 
magnitude of beneficial effects of nasal corticosteroids in the 
symptoms score improvement was significantly greater (p<0.01) 
in patients with polyps (SMD -0.93, 95% CI -1.43 to -0.44, p<0.01; 
6 RCTs, n= 1096), than patients without nasal polyps (SMD -0.30, 
95% CI -0.46 to -0.14, p<0.01; 6 RCTs, n= 594; Figure 6.1.5.4) but 
the proportion of responders was similar (Figure 6.1.5.5). 
Patients who had previous sinus surgery had similar change in 
symptoms score and proportion of responders than patients 
without sinus surgery (RR 0.63, 95% CI 0.47 to 0.84, p<0.01; 5 
RCTs, n = 298 versus RR 0.67, 95% CI 0.59 to 0.77, p<0.01; 6 RCTs, 
n = 1264; Figure 6.1.5.6).
6.1.5.4. Regimes varied across studies 
When the impact of type of corticosteroids on symptoms was 
assessed, benefits in symptom improvement were found in 
all types without difference. Beneficial effects on symptom 
scores reduction favoured fluticasone propionate (SMD -0.50; 
95%CI [-0.76, -0.23]), budesonide (SMD -1.35; 95%CI [-2.60, 
-0.11]) and mometasone furoate (SMD -0.37; 95%CI [-0.53, 
-0.22]) significantly over placebo without difference among 
Table 6.1.5.1. Nasal corticosteroids versus placebo for the treatment of  patients with CRS (continued).
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Figure 6.1.5.1. Forest plot of the effect of nasal corticosteroids versus placebo on disease specific quality of life (SNOT-22) in patients 
with CRS. 
corticosteroids type (p=0.24) (Figure 6.1.5.7).
Corticosteroid dosages varied across studies. In general, nasal 
corticosteroids were administered with dosages not higher 
than doubling rhinitis dosages. Nevertheless, there were studies 
giving higher dosages (e.g. fluticasone propionate >400 µg 
per day; budesonide >512 µg per day; mometasone furoate 
>400 µg per day)(72, 73, 78, 85). When impact of different dosages 
of nasal steroids on symptoms in CRS patients compared to 
placebo was assessed, there was a trend toward greater effects 
in the subgroup of studies giving higher dosages (SMD -1.20; 
95%CI [-2.06, -0.33]) than regular dosages (SMD -0.35; 95%CI 
[-0.50, -0.20]). However, this difference did not reach statistical 
significance (p=0.06) (Figure 6.1.5.8).
Long term treatment with nasal corticosteroids is 
effective and safe in patients with CRS.
Duration of treatment varied across studies from four weeks 
to 52 weeks. Of the 42 studies included in this review, there 
were 13 studies giving nasal corticosteroids for less than 12 
weeks and there were three studies giving nasal corticosteroids 
for as long as 52 weeks. As nasal corticosteroids are aimed 
for controlling chronic inflammatory process of CRS so that, 
in general they are administered for a period of 12 weeks or 
greater. Nevertheless, when impact of duration of nasal steroids 
treatment on symptoms in CRS patients compared to placebo 
was assessed, there was no difference between the duration 
of treatment of <12 weeks and ≥12 weeks in symptoms (SMD 
-1.42; 95%CI [-2.70, -0.14] versus SMD -0.39; 95%CI [-0.52, -0.26]), 
p=0.12) and the proportion of responders  (RR 0.63; 95%CI [0.51, 
0.77] versus RR 0.64; 95%CI [0.55, 0.75]), p=0.84).
6.1.5.5. Delivery methods 
Devices affect the beneficial effects of nasal corticosteroids over 
placebo in the improvement in symptoms score.
One study reported on the delivery via a nebulizer and showed 
the largest effect (SMD -2.79, 95% CI -3.53 to -2.05, p<0.001; 1 
RCT, n = 57), followed by a study reporting on turbuhaler (SMD 
-1.06, 95% CI -1.58 to -0.55, p<0.01; 1 RCT, n = 47), bi-directional 
exhalation device (SMD -0.68, 95% CI -0.92 to -0.44, p<0.01; 3 
RCTs, n = 285) and nasal spray (SMD -0.30, 95% CI -0.41 to -0.19, 
p<0.01; 7 RCTs, n = 1281) (Figure 6.1.5.9.). Data from trials using 
nasal drops could not be pooled. Differences are statistically 
significant for both three-subgroup comparison and pair 
comparisons (p<0.01 for all comparisons). However, there was 
no difference between subgroups in proportion of responders.
Four studies compared different delivery methods of nasal 
corticosteroids directly(Table 6.1.5.2). Corticosteroid nasal spray 
was compared to corticosteroid nasal drops(68), corticosteroid 
irrigation(67), corticosteroid aerosol(70) and corticosteroid 
turbuhaler(69). Data favoured corticosteroid drops and 
corticosteroid nasal irrigation over corticosteroid spray. Demirel 
and colleagues(68) randomized 34 patients with CRSwNP to 
receive fluticasone propionate in the form of aqueous nasal 
spray 100μg twice daily, or nasal drop 400μg once or twice 
daily for 12 weeks and they found that corticosteroid drop 
brought the greatest effects in decreasing nasal polyp size, 
and improving symptoms. Harvey and colleagues performed 
a double-blind placebo-controlled randomized trial by giving 
post-operative 2mg mometasone delivered by either spray 
or irrigation to 44 patients with CRS(67). The corticosteroid 
nasal irrigation group showed greater improvement than 
corticosteroid spray in nasal blockage, drainage, total visual 
analogue scale, endoscopy score and radiological score at 12 
months.
Nasal corticosteroid irrigation is an alternative delivery 
method which aims to increase the exposure of corticosteroid 
onto the sinus mucosa. Harvey and colleagues investigated 
total paranasal sinus distribution in 10 cadaver heads after 
nasal irrigation and nasal spray with water-soluble iodinated 
radiopaque contrast medium. Blinded scan assessment showed 
significantly greater total sinus distribution by nasal irrigation 
with netipot and squeeze bottle than pressurized spray(86).
When a human study to define the fluid dynamics during nasal 
irrigation was conducted by the same group, the data revealed 
the exposure of fluid onto the sinus mucosa with retention 
of fluid of around 2.5% or 5.8mL for the 240mL irrigations(87). 
In addition, these two studies also assessed the impact of 
endoscopic sinus surgery on fluid distribution and showed that 
sinus surgery greatly enhanced the delivery of nasal solutions. 
Apart from the general therapeutic goals of topical 
management in providing pharmaceutical delivery, 
simultaneous mechanical lavage by nasal corticosteroid 
irrigation enhances the mechanical removal of mucus, 
inflammatory products, and bacteria/ biofilm(87).
To assess the effects of nasal corticosteroid irrigation compared 
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Figure 6.1.5.2. Forest plot of the effect of nasal corticosteroids versus placebo on change in symptom score in patients with CRS. 
Figure 6.1.5.3. Forest plot of the effect of nasal corticosteroids versus placebo on the proportion of responders in patients with CRS. 
to control, four RCTs were identified (Table 6.1.5.3).There were 
three double-blind (67, 81, 83)  and one single-blind randomized 
controlled trial(82). Of a total of four RCTs, one trial studied 
patients with CRSwNP (82), one trial studied a mixed population 
of CRS with a majority of CRSsNP(81), one trial studied a mixed 
population of CRS with a majority of CRSwNP(67)and one trial 
studied patients with aspirin exacerbated respiratory disease(83). 
All studies used a sinus rinse bottle kit as a device for nasal 
corticosteroid irrigation. However, volumes of corticosteroid 
irrigation varied. Two studies utilized a volume of 60ml on each 
nostril twice daily(82, 83), while the other two studies used a higher 
volume of 240ml once daily(67, 81). Three trials administered nasal 
corticosteroid irrigation after ESS(67, 82, 83) and one trial used it 
without sinus surgery(81 ). Regarding extension of surgery, one 
study explicitly stated it would perform a complete full-house 
ESS(67) while one study stated that basic functional endoscopic 
sinus surgery (FESS) was performed(83)and one study did 
not provide information(82). The study of nasal corticosteroid 
irrigation without sinus surgery stated that the majority (77%) 
of patients were un-operated patients(81 ). Three studies followed 
the patients up for more than three months (12 months for two 
trials(67, 83) and six months for one trial(82)). One study assessed the 
outcome at four weeks(81).
Three RCTs compared nasal corticosteroid irrigation with 
placebo irrigation. There were heterogeneities across studies 
regarding patient population, surgical status and the volume 
of corticosteroid irrigation. Tait et al. performed a double blind 
RCT giving nasal corticosteroid irrigation without sinus surgery 
to patients with CRS with a majority of CRSsNP. At the short 
term of four-week irrigation, disease-specific quality of life and 
endoscopy scorewere not different when compared to saline 
irrigation with placebo(81).
Rawal et al. performed a single blind RCT studying patients with 
CRSwNP. They gave nasal corticosteroid irrigation after ESS. 
Although a total volume of 240ml was rinsed per day, a volume 
of 60ml was used per nostril for each irrigation. At 24 weeks, 
disease-specific quality of life was not different when compared 
with control. Rotenberg et al. performed a double blind RCT 
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Figure 6.1.5.4. Forest plot of the effect of nasal corticosteroids versus placebo on the change in symptom score in subgroups of CRS 
patients.
Figure 6.1.5.5. Forest plot of the effect of nasal corticosteroids versus placebo on the proportion of responders in patients with 
subgroups of CRS with (CRSwNP) and without (CRSsNP) nasal polyps compared to placebo.with CRS. 
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Figure 6.1.5.6. Forest plot of the effect of nasal corticosteroids versus placebo on the proportion of  responders in subgroups of CRS 
patients with and without sinus surgery.
Figure 6.1.5.7. Forest plot of the effect of nasal corticosteroids versus placebo on change in symptom score in CRS.
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studying postoperative patients with aspirin exacerbated 
respiratory disease. Likewise, a volume of 60ml was used per 
nostril for each irrigation and disease-specific quality of life 
and endoscopic score were not different when compared with 
control at one-year timepoint(82).
One trial compared nasal corticosteroid irrigation with nasal 
corticosteroid spray. Harvey et al. performed a double blind, 
double dummy, placebo-controlled RCT studying patients 
with CRS (77% CRSwNP). They established a neo-sinus cavity 
that could be managed with topical medication by creating a 
complete spheno-ethmoidectomy, wide antrostomy with either 
a complete Draf IIa or Draf III. Nasal corticosteroid irrigation 
was administered using a squeeze bottle to deliver a total 
volume of 240ml. When compared to corticosteroid spray at 
one year, the mometasone irrigation group had significantly 
greater improvement than spray in symptoms improvement and 
endoscopic score reduction.
When meta-analysis was performed to assess the impact of 
corticosteroid irrigation on SNOT improvement at six months, 
data were pooled from two RCTs(82, 83). A study by Tait et al.(81)was 
not included because SNOT was assessed at four weeks. A study 
by Harvey et al.(67)was not included because the control group 
received mometasone nasal spray. Meta-analysis showed no 
difference between nasal corticosteroid irrigation and placebo 
in SNOT improvement at six months (SMD -0.17, 95% CI -0.61 
to 0.26, p=0.44; 2 RCTs, n = 83). (Figure 6.1.5.10.) It is not clear 
why benefits of corticosteroid irrigation over saline irrigation 
are not shown yet by meta-analysis. Patients with high tissue 
eosinophilia are the most corticosteroid responsive and should 
be favourable cases(88). Various factors impact corticosteroid 
penetration and influence the effectiveness of corticosteroids. 
These factors include patients’ surgical status with a wide access 
for topical medical therapy and delivery methods using high 
pressure and large volume(89). It is notable that trials reporting 
no benefit used budesonide irrigation 1000µg per day in a 
240ml bottle with a volume of 60ml after a basic FESS(82, 83) while 
a trial reporting benefits used mometasone irrigation 2000µg 
per day in a 240ml bottle with a volume of 240ml after a full-
house FESS(67).
6.1.5.6. Impact of nasal corticosteroids on nasal endoscopy 
Endoscopy score was assessed in six studies. Lund-Kennedy 
endoscopy score was assessed in six studies evaluating 
discharge, oedema, crusting, polyp and scars or adhesions(78, 
90-92)(81, 83). Jorissen and colleagues used their own scoring system 
assessing sinus ostia stenosis, polypoid change, synechia, 
remucosalized areas, secretions, inflammation, oedema and 
crusts(93). The standardized mean difference was used for 
data analysis. When data were pooled for endoscopy score 
assessment, nasal corticosteroids were effective in decreasing 
endoscopy scores over placebo (SMD -0.49, 95% CI -0.73 to 
-0.25, p<0.01; 6 RCTs, n = 286; Figure 6.1.5.11).   
Nasal polyp size reduction was assessed in 25 studies. NPS on 
a 3-point scale (0-2) per side (0-4 for both sides), taken from 
endoscopic score described by Lund and Mackay(94) was used in 
one study Rowe-Jones 2005(92). NPS on a 4-point scale (0-3) per 
side (0-6 for both sides), described by Johansen et al.(70) (0 = no 
polyps; 1 = polyps in the middle meatus, not reaching below the 
inferior border of middle turbinate; 2 = nasal polyps reaching 
below the inferior border of the middle turbinate, but not the 
lower border of the inferior turbinate; 3 = nasal polyps reaching 
lower than the inferior border of the inferior turbinate and/
Figure 6.1.5.8. Forest plot of the effect of different dosages of nasal corticosteroids versus placebo on symptoms in CRS patients. 
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or medial to the middle turbinate) was used in 18 studies(69-73, 
80, 95-106). NPS on a 4-point scale (0-3), described by Lund et al.(79) 
(0=no nasal polyps; 1= nasal polyps within the middle meatus; 
2= nasal polyps outside the middle meatus; 3= completely 
obstructive nasal polyps) was used in 3 studies(79, 85, 107). NPS on a 
5-point scale (0-4), described by Meltzer et al.(108). (0= no visible 
nasal polyps; 1= small amount of polypoid disease confined 
within the middle meatus; 2= multiple nasal polyps occupying 
the middle meatus; 3= nasal polyps extending beyond the 
middle meatus, within the sphenoethmoid recess but not totally 
obstructing, or both; 4= nasal polyps completely obstructing 
the nasal cavity) was used in one study by Kobayashi et al.(74). 
NPS on a 5-point scale (0-4) (0= No nasal polyps; 1= small nasal 
polyps not requiring polypectomy; 2= medium nasal polyps 
not requiring polypectomy; 3= large nasal polyps requiring 
polypectomy; 4= completely obstructive nasal polyps requiring 
polypectomy) was used in one study by Holmberg et al. (109). 
Visual analogue scale was assessed in one study(110).
Nasal corticosteroids  reduced polyp score (SMD -0.87, 95% 
CI -1.17 to -0.57, p<0.01; 2 RCTs, n = 184; Figure 6.1.5.12) and 
brought greater proportion of responder over placebo in polyp 
size reduction (RR 0.45, 95% CI 0.36 to 0.57, p<0.01; 7 RCTs, n = 
889; See Figure 6.1.5.13). 
In addition, when nasal corticosteroids were administered after 
endoscopic sinus surgery, they prevented polyp recurrence 
significantly better than placebo (RR 0.73, 95% CI 0.56 to 0.94, 
p<0.01; 3 RCTs, n = 256; Figure 6.1.5.14).
Patients who had previous sinus surgery had significantly 
greater change of polyp size reduction than placebo (RR 0.31, 
95% CI 0.20 to 0.49, p<0.01; 3 RCTs, n = 307 versus RR 0.54, 95% 
CI 0.41 to 0.70, p=0.04; 4 RCTs, n = 582; Figure 6.1.5.15). 
6.1.5.7.Adverse events of nasal corticosteroids
Of the 42 double-blind randomized controlled studies 
Study Methods Participants Interventions Outcomes Results
Harvey 
2018(67)
DBPCRCT 44 CRS (77% 
CRSwNP), 
postoperative
• Mometasone spray and 
placebo irrigation for 1 
year (n=23)
• Mometasone irrigation 
and placebo spray for 1 
year (n=21)
Quality of life (SNOT-22) 
at 1 year
Symptom score (VAS total 
and 10 symptoms) at 1 
year
Endoscopy score (MLKS) 
0-6 for inflammation, 0-2 
for mucus, 0-2 for pus, 
assessment of 10 cavities) 
at 1 year
Adverse events
• At 1 year, there was no difference in SNOT-
22 between the mometasone irrigation and 
mometasone spray groups
• At 1 year, the mometasone irrigation group 
had significantly greater improvement than the 
mometasone spray group in total VAS, nasal 
blockage and nasal drainage
• A significantly greater improvement on 
endoscopy score in the mometasone irrigation 
group was revealed at 1 year.
• There were no medication reactions observed 
in either group
Demirel 
2008(68)
DBRCT 34 CRSwNP, 
postoperative 
(13/34 
patients had 
polypectomy)
• FPNS 100μg twice daily for 
12 weeks (n=11)
• FPND 400μg once daily for 
12 weeks (n=10)
• FPND 400μg twice daily for 
12 weeks (n=13)
Symptom score (0-3, 4 
symptoms) improvement 
at 12 weeks
Polyp score (0-3) reduc-
tion at 12 weeks
• At 12 weeks, FPNS showed significantly greater 
efficacy than FPND in improving rhinitis 
symptoms, smelling and nasal blockage,
• At 12 weeks, FPNS showed significantly greater 
efficacy than FPND in decreasing nasal polyp 
size and increasing total nasal volume.
Tos 
1998(69)
DBPCRCT 138 CRSwNP, 
postoperative
• Budesonide aqua spray 
128µg twice daily for 6 
weeks (n=46)
• Budesonide turbuhaler 
200µg twice daily for 6 
weeks (n=45)
• Placebo aqua spray for 6 
weeks (n=24)
• Placebo turbuhaler for 6 
weeks (n=23)
Proportion of responders 
at 6 weeks
Symptom score (0-3, 3 
symptoms) improvement 
at 6 weeks
Polyp score (0-3) reduc-
tion at 6 weeks
Adverse events
• The proportion of responders after 6 weeks 
treatment was not significantly different 
between the aqua and turbuhaler-treated 
groups
• At 6 weeks, budesonide aqua spray showed a 
significantly superior efficacy over turbuhaler 
for blocked nose, runny nose and sneezing
• At 6 weeks, there was no statistical difference 
between aqua and turbuhaler in polyp size 
reduction
• No serious adverse events
Johansen 
1993(70)
DBPCRCT 86 CRSwNP, 
sinus surgery 
status not 
mentioned
• Budesonide nasal spray 
100µg twice daily for 3 
months
• Budesonide aerosol 100µg 
twice daily for 3 months
• Placebo for 3 months
Symptom score (0-3, 3 
symptoms) improvement 
weekly up to 12 weeks
Polyp score (0-3) reduc-
tion at 4, 8, 12 weeks
Adverse events
• budesonide spray and aerosol were not 
different in symptom improvement and polyp 
size reduction 
• Few side effects of budesonide spray and 
aerosol were reported without difference 
between groups.
Table 6.1.5.2. Comparison of different delivery methods of nasal corticosteroids for the treatment of  patients with CRS.
CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCRCT, double blind placebo controlled randomised controlled trial; 
DBRCT, double blind randomised controlled trial; FPNS, Fluticasone Propionate Nasal spray ; MLKS, Modified Lund-Kennedy Score; SNOT, Sino-nasal 
Outcome Test; VAS, visual analogue scale.
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Study Methods Participants Interventions Outcomes Results
Harvey 
2018(67)
DBPCRCT 44 CRS (77% CRSwNP), 
postoperative (35 
analyzed)
• Mometasone irrigation 
2000µg in 240ml saline 
and placebo spray for 52 
weeks (n=15)
• Mometasone spray 
2000µg and placebo 
irrigation 240ml for 52 
weeks (n=20)
• Quality of life (SNOT-22 
(0-110) at 52 weeks)
• Symptoms (VAS (0-100) at 
52 weeks)
• Endoscopy score (MLKS 
(0-100) at 52 weeks)
• CT score (LM score (0-24) 
at 52 weeks)
• Adverse event
• SNOT-22 changes at 12 months 
are not different between 
mometasone irrigation and spray
• Total VAS scores at 12 months 
significantly favoured 
mometasone irrigation over spray 
• Endoscopy scores at 12 
months significantly favoured 
mometasone irrigation over spray
• CT scores at 12 months 
significantly favoured 
mometasone irrigation over spray
• No treatment-related adverse 
event was observed.
Tait 
2018(81)  
DBPCRCT 74 CRS (25%CRSwNP), 
with 28% history of 
prior ESS (61 finally 
analysed)
• Budesonide irrigation 
1000µg once daily in 240ml 
bottle for 4 weeks (n=29)
• Saline irrigation with pla-
cebo (lactose) for 4 weeks 
(n=32)
• Quality of life (SNOT-22 
(0-110) at 4 weeks)
• Symptoms (Likert scale of 
improvement 1-7, scale at 
4 weeks)
• Endoscopy score (LKES 
(0-20) at 4 weeks)
• Adverse event
• The SNOT-22 scores at 4 weeks 
were not different between 2 
groups
• Symptoms at 4 weeks were not 
different
• LKES change at 4 weeks was not 
different
• There were no related adverse 
events.
Rawal 
2015(82)
SBPCRCT 50 CRSwNP, with 100% 
postoperative (42 finally 
analysed)
• Budesonide irrigation 500µg 
in 240ml bottle. 60ml/nostril 
twice daily for 24 weeks 
(n=24)
• Saline irrigation alone for 24 
weeks (n=18)
• Quality of life (SNOT-22 
(0-110), RSOM-31 (0-155), 
RSDI (0-120) at 2 weeks, 3, 
6 months)
• SNOT-22, RSOM31, and RSDI 
scores were not different between 
2 arms at all 3 timepoints (2 weeks, 
3, 6 months).
Rotenberg 
2011(83)
DBPCRCT 64 CRSwNP (Samter’s 
triad), with 100% post-
operative (basic FESS) 
(60 finally analysed)
• Budesonide irrigation 60ml/
nostril 500µg twice daily 
(total 1000µg) for 52 weeks 
(n=20)
• Saline irrigation 60ml/nostril 
and budesonide spray 64µg/
nostril twice daily (total 
256µg) for 52 weeks (n=19)
• Saline irrigation alone for 52 
weeks (n=21)
• Quality of life (SNOT-21 (0-
105) at 6,12 months)
• Endoscopy score (LKES 
(0-12) at 6,12 months)
• CT score (LM score (0-24) 
at 6,12 months)
• Ocular events (IOP at 6,12 
months)
• HPA axis (ACTH (normal/
abnormal) at 6,12 months)
• SNOT-21, LKES, and LM score 
results of both intervention groups 
were not different from placebo 
group at both 6 and 12-month 
timepoints (significant level was 
defined at p< .0167)
• IOP and ACTH level were not 
changed at both 6 and 12-month 
timepoints
Table 6.1.5.3. Nasal corticosteroid irrigation in CRS patients. 
ACTH, Adrenocorticotropic Hormone ; CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCRCT, double blind placebo 
controlled randomisedcontrolled trial; FESS, functional endoscopic sinus surgery; HPA, Hypothalamic Pituitary Adrenal ; IOP, intraocular pressure; 
LKES, Lund-Kennedy endoscopy scoring ; LM, Lund-Mackay; MLKS, Modified Lund-Kennedy Score; SBPCRCT, single blind placebo controlled ran-
domised controlled trial; SNOT, Sino-nasal Outcome Test;  VAS, visual analogue scale; RSDI, Rhinosinusitis Disability Index; RSOM-31, Rhinosinusitis 
Outcome Measure-31.
included in this review (43 articles), adverse events of nasal 
corticosteroids compared to placebo were assessed in 26 
studies(67, 69, 70, 72, 73, 79-81, 83, 85, 90, 93, 95, 96, 98, 100-105, 109, 111-114). All these 
studies found that nasal corticosteroids were well tolerated 
and safe. Drug related major adverse events were not reported. 
Minor adverse events (if any) had mild to moderate severity. 
Of the 26, 18 studies found that adverse events (including 
epistaxis) caused by nasal corticosteroids were not different 
from placebo(69, 70, 79, 80, 85, 90, 93, 95, 96, 101-105, 111-114). Five studies reported 
that a greater number of patients in the nasal corticosteroid 
group had epistaxis than in the placebo group(72, 73, 98, 100, 109). 
When data were pooled for meta-analysis, nasal corticosteroids 
resulted in increase in the risk of epistaxis compared to placebo 
(RR 3.49, 95% CI 2.42 to 5.05; 16 RCTs, n=2021; Figure 6.1.5.16).  
Nasal septal ulcer was reported more frequently in the nasal 
corticosteroid group in one study(72, 73). The hypothalamic–
pituitary–adrenal axis suppression assessed in four studies 
found that serum cortisol(72, 85, 100) and 24-hour urinary free 
cortisol(103) were unchanged with no difference from the 
placebo group. No patients in both groups had clinical adrenal 
insufficiency. Nasal steroids did not increase intraocular pressure 
and did not cause cataract(73). This is concordance with a 
systematic review that also concluded that nasal corticosteroids 
do not affect intraocular pressure or lens opacity: a systematic 
review of controlled trials(115). There was no difference between 
nasal steroids and placebo in asthma exacerbation(95), and acute 
bacterial rhinosinusitis(95, 116). although one study did describe 
more infections(117).
6.1.5.7.Conclusion
There is high-quality evidence that long term use of nasal 
corticosteroids is effective and safe for treating patients with 
CRS. They have impact on nasal symptoms and quality of life 
improvement, although the effect on SNOT-22 is smaller the 
EPOS 2020
230
Figure  6.1.5.9.   Forest plot of the effect of different delivery methods of nasal corticosteroids versus placebo on symptoms scores in 
CRS patients. 
Figure 6.1.5.10. Forrest plot of the effect on SNOT score at six months after steroid irrigation versus saline irrgation in CRS patients. 
Figure 6.1.5.11. Forest plot of the effect of nasal corticosteroid versus placebo on nasal endoscopy score in patients with CRS.
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Figure 6.1.5.12. Forest plot of the effect of nasal corticosteroid versus placebo on nasal polyp score in patients with CRSwNP.
Figure 6.1.5.13. Forest plot of the effect of nasal corticosteroid versus placebo on the proportion of responders in nasal polyp score 
reduction.
Figure 6.1.5.14. Forest plot of the effect of nasal corticosteroid versus placebo on the prevention of nasal polyp recurrence after sinus 
surgery in CRSwNP patients 
minimal clinically important difference. The effect size on 
symptomatology is larger in CRSwNP (SMD -0.93, 95% CI -1.43 
to -0.44) than in CRSsNP (SMD -0.30, 95% CI -0.46). The meta-
analysis did not show differences between different kinds of 
nasal corticosteroids. Although in meta-analysis higher dosages 
and some different delivery methods seem to have a larger 
effect size on symptomatology direct comparisons are mostly 
missing. For chronic rhinosinusitis with nasal polyposis, nasal 
corticosteroids reduce nasal polyp size. When administered 
after endoscopic sinus surgery, nasal corticosteroids prevent 
polyp recurrence. Nasal corticosteroids are well tolerated. 
Most adverse events reported are mild to moderate in severity. 
Nasal corticosteroids do not affect intraocular pressure or lens 
opacity. The EPOS2020 steering committee advises to use nasal 
corticosteroids in patients with CRS. Based on the low to very 
low quality of the evidence for higher dosages or different 
delivery methods and the paucity of direct comparisons the 
steering committee cannot advise in favour of higher dosages 
or certain delivery methods.
6.1.6. Corticosteroid-eluting implants
6.1.6.1. Corticosteroid-eluting implants following 
endoscopic sinus surgery, summary of the evidence
Steroid-eluting stents, spacers and dressings can improve local 
drug delivery immediately following endoscopic sinus surgery 
or be placed in office in postoperative patients. The placement 
immediately after surgery will be discussed in chapter 6.2.7.4.
6.1.6.2. Corticosteroid-eluting implants in office, summary 
of the evidence
 In addition to the postoperative studies, two studies evaluated 
the effect of placement of a corticosteroid-eluting sinus implant 
delivering 1350µg of mometasone furoate (MF) in the ethmoid 
of patients with recurrent polyposis after sinus surgery over 
approximately 90 days(118, 119), as well as the follow-up of Han(120). 
Both the treated and the placebo group also used 200µg 
mometasone furoate nasal spray once daily (Table 6.1.6.1.) 
Some of the parameters could be combined for the two studies: 
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Figure 6.1.5.15. Forest plot of the effect of nasal corticosteroid versus placebo on the proportion of patients with nasal polyp score 
reduction in subgroups of CRS patients with and without sinus surgery.
Figure 6.1.5.16. Forest plot of the effect of nasal corticosteroid versus placebo on the proportion of CRS patients with epistaxis. 
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the change from baseline to day 90 in nasal obstruction/
congestion score (0-3), evaluated for seven days before clinic 
visits, showed MD 0.28 (95% CI 0.09, 0.48); 366 participants; two 
studies (I2 = 43%), lower = better, indicating less symptoms of 
nasal obstruction/congestion in the patients that were treated 
with corticosteroid-eluting sinus implant than the placebo 
(Figure 6.1.6.1).
The change from baseline to day 90 in bilateral polyp grade (0-
8/0-4), showed an SMD 0.40 (95% CI 0.19, 0.61); 392 participants; 
two studies; I2 = 0%), lower = better, indicating less disease in 
the patients  that were treated with corticosteroid-eluting sinus 
implant than the placebo (Figure 6.1.6.2).
The patients indicated for sinus surgery at day 90 (%) showed an 
OR of 0.37 (95% CI 0.23, 0.61); 398 participants; two studies (I2 
= 0%), indicating less likelihood that the patients treated with 
corticosteroid-eluting sinus implant than the placebo would 
need sinus surgery (Figure 6.1.6.3).
In one study(118) sense of smell (scale 0-5) and facial pain (scale 
0-5) were also evaluated. There was a significant improvement 
in smell MD - 0.46 (95% CI -0.85;-0.06) in the patients  that were 
treated with corticosteroid-eluting sinus implant compared with 
the placebo. No differences in facial pain scores were found.
Figure 6.1.6.1. Forest plot of the effect of corticosteroid-eluting implants versus placebo on the change from baseline to day 90 in 
nasal obstruction/congestion score in patients with CRS.
Figure 6.1.6.2. Forest plot of the effect of corticosteroid-eluting implants versus placebo on the change from baseline to day 90 in 
bilateral Nasal Polyp Score (NPS) in patients with CRS.
Figure 6.1.6.3. Forest plot of the effect of corticosteroid-eluting implants versus placebo on the reduction of indicated sinus surgery 
at day 90 (%).
Figure 6.1.7.1. Forest plot of the effect of short course of systemic corticosteroid therapy versus placebo on total symptom score 2-3 
weeks after start of the therapy in CRS patients.
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Study Methods Participants Interventions Outcomes Results
Kern 
2018(118)
DBRPCT 301 CRSwNP 
patients
• Bioabsorbable drug-eluting 
stent releasing 1350μg of 
mometasone furoate over ap-
proximately 90 days removed 
at 60 days and 200µg mometa-
sone furoate nasal spray once 
daily (n=201)
• Bioabsorbable drug-eluting 
placebo stent and1350µg 
mometasone furoate nasal 
spray once daily (n=100)
• Change from baseline to day 30 and day 90 in 
nasal obstruction/congestion score (0-3)
• Change from baseline to day 90 in bilateral 
polyp grade (0-8), as determined by indepen-
dent, blinded panel
• Patients indicated for sinus surgery at day 90 
(%)
• Change from baseline to day 90 of ethmoid 
sinus obstruction (0-100) by independent, 
blinded panel
• Change from baseline to day 90 in sense of 
smell (0-5) and facial pain (0-5)
• Adverse events
• All outcomes 
significant better in 
the mometasone 
furoate stent group 
than the placebo stent 
group but facial pain.
• No difference in 
adverse events.
Forwith 
2016(120)
DBRPCT
(Follow-
up of Han 
2014(119))
100 CRSwNP 
patients 
• Bioabsorbable drug-eluting 
stents releasing 1350μg of 
mometasone furoate over 
approximately 30 days (n=53)
• Placebo stents (n=47)
• Change from baseline to day obstruction/
congestion score (0-3) (subset of patients) at 
6 months
• Change from baseline in bilateral polyp grade 
(0-4) at 6 months
• Patients indicated for sinus surgery at 6 
months (%)
• Change from baseline of ethmoid sinus 
obstruction (0-100) at 6 months
• Adverse events
At 6 months, treated 
patients compared to 
placebo patients had:
• Significant reduction 
in ethmoid snus 
obstruction (p < 0.001) 
and bilateral polyp 
grade (p = 0.018) 
• Significantly smaller 
change of sinus 
surgery
Han 
2014(119)
DBRPCT 100 CRSwNP 
patients
• Bioabsorbable drug-eluting 
stents releasing 1350μg of 
mometasone furoate over ap-
proximately 90 days removed 
at 60 days and 200µg mometa-
sone furoate nasal spray once 
daily (n=53)
• Bioabsorbable drug-eluting 
placebo stent and 1350µg 
mometasone furoate nasal 
spray once daily (n=47)
• Change from baseline to day obstruction/
congestion score (0-3) (subset of patients) at 
day 7, 14, 30,45,60, and 90
• Change from baseline in bilateral polyp grade 
(0-4) at day 7, 14, 30,45,60, and 90
• Patients indicated for sinus surgery an inter-
vention at day 90 (%)
• Change from baseline of ethmoid sinus ob-
struction (0-100) at day 7, 14, 30,45,60 and 90
• Adverse events
• Ocular safety
• Significant reduc-
tion in obstruction/
congestion (day 
30 and 90), polyps 
grade, ethmoid sinus 
obstruction
• No significant 
differences in adverse 
events or ocular safety
Table 6.1.6.1. Corticosteroid-eluting implants for the in the office treatment of patients with CRS.
CRSwNP, chronic rhinosinusitis with nasal polyps; DBRPCT, double blind randomised placebo controlled trial.
6.1.6.3. Safety of corticosteroid-eluting implants
Most of the safety studies have been performed directly after 
surgery and the full safety data are discussed in chapter 6.2.7.3. 
None of the studies showed impact on ocular safety(119, 121, 
122). Local (drug related) adverse events were limited and not 
reported more often in the local corticosteroid group than the 
placebo group. 
6.1.6.4. Conclusion
The placement of corticosteroid-eluting sinus implants in the 
ethmoid of patients with recurrent polyposis after sinus surgery 
has a significant but small (0.3 on a 0-3 scale) impact on nasal 
obstruction but is significantly reduced the need for surgery 
[odds ratio (OR) 0.34] and reduced nasal polyp score. Based on 
the moderate to high quality of the evidence the steering group 
considered the use of corticosteroid-eluting sinus implants 
in the ethmoid an option. Larger studies including long term 
safety data are needed.
6.1.7. Short courses of systemic corticosteroids
A short course of systemic corticosteroid, with or 
without local corticosteroid treatment results in a 
significant reduction in total symptom score and 
nasal polyp score in patients with CRSwNP.
6.1.7.1. Summary of the evidence
Short courses of systemic corticosteroids (7-21 days), usually 
combined with local corticosteroids, are a widely used 
treatment for chronic rhinosinusitis with nasal polyps. Systemic 
corticosteroids reduce the inflammatory response and may 
reduce the size of nasal polyps. Interestingly especially 
inflammation of the olfactory mucosa is reduced often resulting 
in a rapid improvement in olfaction (days) without visual change 
in polyp volume.  
In this analysis, only studies comparing a short course of 
systemic corticosteroids using a DBPCRT design are included. 
Different forms of systemic corticosteroids were used (Table 
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6.1.7.2. for comparison of corticosteroids) although most 
studies used prednis(ol)one. In seven DBPCRCTs a short course 
of systemic corticosteroids, sometimes combined with local 
corticosteroids, was compared to placebo (4, 123-128)(Table 6.1.7.2.). 
All studies were done in patients with CRSwNP. We are not aware 
of any RCTs with systemic corticosteroids in CRSsNP. Five studies 
evaluated the effect of oral (methyl)prednis(ol)one in dosages 
ranging from 25-60 mg for 7-20 days(4, 124, 126-128). Three studies 
only used the systemic corticosteroids(4, 124, 128) and two studies 
used a form of local corticosteroids after the systemic course(126, 
127). All five studies measured some form of symptom score 
2-4 weeks after the start of the treatment (for Hissaria we took 
the nasal domain of the Rhinosinusitis Outcome Measure-31 
(RSOM-31)) and the meta-analysis showed a significant effect 
on total symptom score (SMD -1.51 (95% CI -1.08, -1.57); 266 
participants; four studies; I2 = 0%)(p<0.00001) (Figure 6.1.7.1). 
However, at 10-12 weeks after the start of the treatment the 
difference was no longer significant SMD –0.13 (95% CI -0.41, 
0.15); 200 participants; 3 studies; I2 = 0%), (p=0.38) (Figure 6.1.7.2).
Four studies could be included in a meta-analysis on nasal 
polyp score at 2-3 weeks after the start of the corticosteroid 
therapy. The meta-analysis showed a significant effect of oral 
corticosteroid treatment over placebo: SMD -1.51 (95% CI -2.12, 
-0.90); 237 participants; four studies; I2 = 70%; p<0.00001) 
(Figure 6.1.7.3). 
At 10-12 weeks after the start of the treatment the difference 
was still significant SMD –0.51 (95% CI -0.80, -0.21); 203 
participants; three studies; I2 = 4%), (p=0.0007) (Figure 6.1.7.4).
Two studies (118 postoperative CRSwNP patients) evaluated the 
postoperative use of systemic corticosteroids(123, 125). Both studies 
reported no significant differences in SNOT-22 in the first 2-3 
months after surgery (Figure 6.1.7.5) and in Shen et al. even six 
months after surgery. Shen et al.(123) found a significantly lower 
Lund-Kennedy endoscopy score in the prednisone group for 
the high eosinophils group at three months and a trend at six 
months (no correction for multitesting).
The adverse effects of short courses of systemic corticosteroids 
can include insomnia, mood changes and gastrointestinal 
changes. Short-term courses of systemic corticosteroids are 
generally safe, but there have been reports of associated 
avascular necrosis and a few cases of fatal varicella-zoster in 
immunocompetent patients(129). It is not clear from the literature 
whether the dose or duration of the systemic corticosteroids are 
Figure 6.1.7.3. Forest plot of the effect of short course of systemic corticosteroid therapy versus placebo on polyp score 2-3 weeks 
after start of the therapy in CRS patients.
Figure 6.1.7.4. Forest plot of the effect of short course of systemic corticosteroid therapy versus placebo on polyp score 10-12 weeks 
after start of the therapy in CRS patients.
Figure 6.1.7.2. Forest plot of the effect of short course of systemic corticosteroid therapy versus placebo on total symptom score 10-
12 weeks after start of the therapy in CRS patients.
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Figure 6.1.7.5. Forest plot of the effect on SNOT-22 of postoperative short course of systemic corticosteroid therapy versus placebo 
2-3 months after surgery in CRS patients.
Table 6.1.7.1. Short courses of systemic corticosteroids for the treatment of patients with CRSwNP.
 Author Methods Participants Interventions Outcomes Results
Shen 
2019(123)
DBPCT, 
postoperative
100 patients with 
bilateral CRSwNP 
postoperatively 
(82 included) 
stratified 
by tissue 
eosinophils 
(> 10 tissue 
eosinophils/HPF)
• Oral prednisolone 
15mg twice a day for 2 
weeks combined with a 
nasal spray of 100μg of 
mometasone furoate once 
daily (n=35)
• Placebo twice a day for 
2 weeks combined with 
a nasal spray of 100μg of 
mometasone furoate once 
daily (n=47)
• Symptoms: head fullness, smell, 
cough, nasal obstruction, head-
ache, foul odour, facial pressure, 
post nasal drip, and rhinorrhoea 
(VAS) 
• SNOT-22 at 1, 3 and 6 months 
postoperatively
• LKESs 2 weeks and 2, 3 and 6 
months postoperatively.
• Safety and side effects assess-
ment
• No differences in symptoms and 
SNOT-22 at 1, 3 and 6 months
• LKES: trend (0,05) at 6 months 
for whole group, significantly 
lower in prednisolone group for 
the high eosinophils group at 3 
months and trend at 6 months 
(no correction for multi-testing)
Ecevit 
2015(124)
DBPCT 23 patients with 
bilateral CRSwNP
• Prednisolone 60 mg (60 
tablets) for 7 days, then 
reduced to 10mg taken 
every other day, stopping 
on day 17 (n=11)
• Placebo (6 tablets) for 7 
days, then reduced to 1 
tablet every other day, 
stopping on day 17 (n=12)
• Symptoms (VAS) at day 15-17
• Sense of smell (CCCRC) (butanol 
olfactory threshold test) day 
15-17
• Nasal polys score (0-6)
PNIF day 15-17
• Adverse events
• Significantly more improvement 
in the corticosteroid group 
compared to placebo in disease 
severity, smell, and PNIF 
• No differences in adverse events
Dautremont 
2014(125)
DBPCT 36 CRSwNP 
patients 
postoperatively
• Prednisone 30 mg daily for 
7 days and 1 dissolvable 
spacer soaked with 2ml 
triamcinolone (40mg/
ml) and high-volume 
budesonide irrigation 
once daily (1mg in 240 ml 
of saline (n=18)
• Placebo daily for 7 days 
and 1 dissolvable spacer 
soaked with 2ml triam-
cinolone (40mg/ml) and 
high-volume budesonide 
irrigation once daily (1mg 
in 240 ml of saline (n=18)
• Endoscopy (LK score) at 1 week, 
3 weeks, and 2 months postop-
eratively.
• SNOT-22 at 1 week, 3 weeks, and 
2 months postoperatively.
• No significant differences in 
mean endoscopic scores or 
SNOT-22 at any of the timepoints.
Kirtsreesakul 
2012(126)
DBPCT 3:2 
randomization
117 CRSwNP 
(114 included)
• Oral prednisolone 50 mg 
daily for 14 days followed 
by mometasone furoate 
nasal spray (MFNS) at 200 
micrograms twice daily for 
10 weeks (n=67)
• Placebo for 14 days 
followed by MFNS at 200 
micrograms twice daily for 
10 weeks (n=47)
• Disease severity (added symp-
tom score (0-7) for blocked 
nose, runny nose, sneezing, na-
sal itching, hyposmia, postnasal 
drip, cough and sinonasal pain 
at 2, 7 and 12 weeks 
• Nasal polyp score (0-6)
• PEFR
• Adverse events
The prednisolone treated group 
showed compared to placebo:
• Significantly greater improve-
ments in all nasal symptoms, 
nasal airflow, and polyp size at 
2 weeks 
• Significantly greater improve-
ments in most symptoms, nasal 
airflow, and polyp size at 7 weeks
• Significantly greater improve-
ments in smell, nasal airflow, and 
polyp size at 12 weeks
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Vaidyanathan 
2011(127)
DBPCT 60 CRSwNP (51 
included)
• Prednisolone tablets, 
25 mg/day for 2 weeks 
followed by fluticasone 
propionate nasal drops, 
400µg twice daily, for 8 
weeks then fluticasone 
propionate nasal spray, 
200µg twice daily for a 
further 18 weeks (n=27)
• Placebo tables for 2 
weeks followed by 
fluticasone propionate 
nasal drops, 400µg twice 
daily, for 8 weeks then 
fluticasone propionate 
nasal spray, 200µg twice 
daily for a further 18 
weeks (n=24)
• RQLQ at 2 weeks and 6 months
• Total nasal symptoms score at 2 
weeks and 6 months
• Nasal polyps score (0-6)
• PNIF
• Responders at 28 weeks (im-
provement more that MID)
• Serum eosinophil-derived 
neurotoxin
• High-sensitivity C-reactive 
protein levels
• Overnight urinary free cortisol 
and corrected for creatinine
• 08:00 am serum cortisol
• Low-dose 1µg adrenocortico-
tropic hormone-simulation test
• Markers of bone turnover
Oral corticosteroid therapy 
followed by topical steroid therapy 
compared to nasal corticosteroid 
alone resulted in a significant larger 
reduction in:
• % responders at 28 wks
• RQLQ at 2 wks
• Total nasal symptom score at 
2 wks
• Nasal polyp score at 2 and 10 
wks
• PNIF at 2 wks
Van Zele 
2010(4)
DBPCT 33 CRSwNP • Oral methylprednisolone 
(32mg/day on days 1 to 
5; 16mg/day on days 6 to 
10; 8mg/day on days 11 
to 20) (n=14)
• Placebo, 20 days (n=19)
• Disease severity, measured by 
patient-assessed symptoms 
(anterior rhinorrhoea, nasal 
obstruction, post-nasal drip 
and loss of sense of smell) at 20 
days and 12 weeks. 
• Nasal polyp score (0-8)
• PNIF
• Blood eosinophils
• Serum ECP, soluble IL-5rα
• ECP, IL-5, IgE, MMP9 and MPO in 
nasal secretion
• Need for rescue surgery/ nasal 
steroids
• Adverse events
Oral corticosteroids compared to 
placebo for 20 days resulted in:
• Reduced symptoms for 4 weeks
• Reduced polyp score and PNIF 
for 55 days
Hissaria 
2006(128)
DBPCT 40 CRSwNP • 50mg of prednisolone 
once daily for 14 days 
(n=20)
• Placebo once daily for 14 
days (n=20)
• Nasal symptoms
• RSOM-31, and nasal domain of 
RSOM-31 at 2 weeks
• Polyp score
• MRI
• Responders at 2 weeks
Significantly better results of 
systemic corticosteroid compared 
to placebo for:
• Symptoms of stuffy/blocked 
nose, runny nose, sneezing, 
decreased sensation of smell, 
and postnasal drip showed 
significant improvement after 
treatment with corticosteroids 
(p<.05) as opposed to placebo
• RSOM-31 and nasal domain of 
RSOM-31
CCCRC, The Conneticut Chemosensory Clinical Research Centre ; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, double blind placebo 
controlled trial; ECP, eosinophil cationic protein; IgE, immunoglobulin E; IL-5, interleukin-5; LK, Lund-Kennedy; LKES, Lund-Kennedy Endoscopic 
Scores; MFNS, Mometasone furoate nasal spray; MID, Minimal important difference ; MMP9, matrix metalloproteinase 9; MPO, Myeloperoxidase ; MRI, 
magnetic resonance imaging; PEFR, Peak Expiratory Flow Rate ; PNIF, peak nasal inspiratory flow; RSOM-31, Rhinosinusitis Outcome Measure-31 ; 
RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire ; SNOT, Sino-nasal Outcome Test; VAS, visual analogue scale.
important.  In the lower airways, evidence is not strong enough 
to reveal whether shorter or lower-dose regimens are generally 
less effective than longer or higher-dose regimens in asthma 
or indeed that the latter are associated with more adverse 
events(130) although in chronic obstructive pulmonary disease 
(COPD) there is data that shorter courses are equally effective(131). 
When given over the longer term, or through many repeated 
short courses, it is possible to develop osteoporosis(132).
6.1.7.2. Conclusion
A short course of systemic corticosteroid, with or without local 
corticosteroid treatment results in a significant reduction in total 
symptom score and nasal polyp score. Although the effect on 
the nasal polyp score remains significant up to three months 
after the start of treatment by that time there is no longer an 
effect on the symptom score. The EPOS2020 steering group 
felt that 1-2 courses of systemic corticosteroids per year can be 
a useful addition to nasal corticosteroid treatment in patients 
with partially or uncontrolled disease. A short course of systemic 
corticosteroid postoperatively does not seem to have an effect 
on quality of life.
Table 6.1.7.1. Short courses of systemic corticosteroids for the treatment of patients with CRSwNP (continued).
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Equivalent Dose Steroid
1.2mg Betamethasone (long-acting)
1.5mg Dexamethasone (long-acting)
8mg Methylprednisolone (intermediate-acting)
8mg Triamcinolone (intermediate-acting)
10mg Prednisone (intermediate-acting)
10mg Prednisolone (intermediate-acting) [4,5]
40mg Hydrocortisone (short-acting)
50mg Cortisone (short-acting)
Table 6.1.7.2. Corticosteroid dose equivalents(869-872)
6.1.8. Antihistamines (oral and topical)
6.1.8.1. Summary of the evidence
The role of sensitisation in CRSsNP is unclear (see 5.1.2). It is 
tempting to speculate that allergic inflammation in the nose 
predisposes the atopic individual to the development of CRS. 
However, papers evaluating atopy as a risk factor to CRS are 
conflicting.
Notwithstanding the lack of hard epidemiologic evidence for 
a clear causal relationship between allergy and CRS, there is 
some indication that failure to address allergy as a contributing 
factor to CRS diminishes the probability of success of a surgical 
intervention(133). In a real life retrospective study among allergy 
patients undergoing immunotherapy, those who felt most 
helped by immunotherapy were the subjects with a history of 
recurrent rhinosinusitis, and about half of the patients who had 
had sinus surgery before believed that the surgery alone was 
not sufficient to completely resolve the recurrent episodes of 
infection(133). 
In a large German retrospective database, both ENT specialists 
(3.5%) and GPs (2.2%) prescribed low rates of antihistamines in 
patients with CRSsNP and slightly higher rates in CRSwNP (5.4% 
and 3.1%, respectively)(134).
There are no studies evaluating the effect of antihistamines in 
patients with CRSsNP(135).
There is one study evaluating the effect of antihistamines in 
patients with CRSwNP(135, 136)
Haye et al. in a DBPCT randomised 45 patients with CRSwNP (of 
which 16 were allergic) to receive either 20 mg of cetirizine or 
placebo for three months (Table 6.1.8.1). The authors reported 
that cetirizine reduced days with a score for nasal sneezing and 
rhinorrhoea lower than one from 70-80% (rhinorrhoea) and 80-
90% (sneezing) in the placebo group to 90-100% in the cetirizine 
treated group(136) at all time points). However, data for patients 
with allergies and those without were not reported separately. 
There was no effect of the cetirizine on nasal polyp size(136).
6.1.8.1. Conclusion
The quality of the evidence using GRADE comparing 
antihistamines with placebo was very low. Evidence was 
downgraded because of the small number of studies and 
because the most important measures of efficacy were not 
reported. There is insufficient evidence to decide on the effect 
of the regular use of antihistamines in the treatment of patients 
with CRS.
6 .1.9. Anti-leukotrienes
6.1.9.1. Summary of the evidence
Cysteinyl leukotrienes (CysLT) are a class of inflammatory 
mediators synthesized by eosinophils and mast cells through 
the breakdown of arachidonic acid. CysLT are known to play a 
role in the pathophysiology of rhinitis, asthma and possibly also 
CRSwNP, promoting bronchoconstriction, mucus production, 
oedema and chemotaxis of eosinophils and neutrophils. 
Overproduction of CysLTs and upregulation of the receptor has 
been demonstrated in allergic rhinitis, asthma, and CRS with 
nasal polyposis (CRSwNP) (5.1.2).
There are no data on the efficacy of CysLT in CRSsNP
There are limited data on the efficacy of CysLT in CRSwNP, mainly 
on montelukast. There are no RCTs performed in patients with 
CRSwNP with other CysLT inhibitors such as zafirlukast, zileuton 
(-lipoxygenase inhibitor) and pranlukast.
Wentzel et al.(137) performed a systematic review in 2013 
Table 6.1.8.1. Antihistamines for the treatment of patients with CRS.
Study Methods Participants Interventions Outcomes Results
Haye 1998(136) DBPCT 45 patients 
with CRSwNP
• 20 mg of cetirizine 
for 3 months (n=23)
• Placebo for 3 
months (n=22)
• Total symptom score at 4, 8 and 12 
weeks
• Days with a symptom score ≤1 for na-
sal obstruction, rhinorrhoea, sneezing 
at 4, 8 and 12 weeks
• Polyp score at 4, 8 and 12 weeks
• No difference in total symptom score
• Cetirizine significantly reduced days 
with a score for nasal sneezing and 
rhinorrhea ≤1 at all time points and 
nasal obstruction at week 8
• No change in polyp score
CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, double blind placebo controlled trial.
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Figure 6.1.9.1. Forest plot of the effect of the added effect of montelukast on intranasal corticosteroids at 12 weeks in CRSwNP 
patients
describing two placebo-controlled RCTs of which only one 
was double blind(138, 139) and three non-placebo controlled 
RTs(140-142) which included a total of 179 CRSwNP patients. The 
study by Mostafa indicates that it was double blind but no 
explanation of how the blinding was done is given, the other 
two studies were not blinded. The non-placebo controlled 
RCTs compared montelukast to intranasal corticosteroids(140, 
142) postoperatively and the combination of montelukast and 
nasal corticosteroids versus nasal corticosteroids alone after a 
course of oral steroids(141). They concluded that both placebo-
controlled RTs showed significant improvements in symptoms 
and local inflammatory mediators over the four- to six-week 
course of treatment compared to placebo. It was not possible 
to combine the two studies in a meta-analysis. The two small 
studies comparing montelukast to nasal corticosteroids showed 
similar improvement compared to baseline for both treatments 
(Table 6.1.9.1.). 
Two studies have been performed after the publication of the 
Wentzel review(137) both of which were prospective RCTs, adding 
oral montelukast to regular treatment. Suri et al.(143) randomized 
40 consecutive adult CRSwNP patients into two groups. Subjects 
were treated with oral prednisolone for 14 days and budesonide 
nasal spray for eight weeks with or without additional oral 
montelukast. Subjects treated with additional oral montelukast 
reported a statistically significant improvement in overall 
symptom score, sense of smell, and sneezing after eight weeks 
which remained for the four weeks after stopping the treatment 
(Table 6.1.9.2.). 
Van Gerven et al.(144) evaluated the efficacy of montelukast as 
an add-on treatment to intranasal corticosteroids spray (INCS) 
in 72 postoperative CRSwNP patients for one year. They found 
no significant differences between the two treatment arms in 
total symptom score, nasal polyp score and LMK score. They 
concluded that the addition of montelukast to INCS should not 
be recommended in the treatment of postoperative CRSwNP 
patients.
The EPOS2020 steering group does not advise 
adding montelukast to nasal corticosteroid but 
studies evaluating the effect of montelukast in 
patients that failed nasal corticosteroids are 
missing.
We performed a meta-analysis of the three studies evaluating 
the addition of montelukast to INCS either postoperatively or 
after systemic corticosteroid treatment for eight weeks. There 
was no significant additional effect from adding montelukast 
to intranasal corticosteroids after either surgery(144) or systemic 
corticosteroids for two weeks(141, 143) (Figure 6.1.9.1.).
Various neuropsychiatric events have been reported as adverse 
events of anti-leukotrienes; however, the evidence of the 
association is conflicting(145-148).
6.1.9.2. Conclusion
The quality of the evidence using GRADE comparing 
montelukast with placebo was very low. Evidence was 
downgraded because of the small number of studies and 
patients in the studies and because only one study was double 
blinded. Based on the available evidence, the EPOS2020 steering 
group is unsure about the potential use of montelukast in CRS 
and does not recommend its use unless in situations where 
patients do not tolerate nasal corticosteroids. Also, the quality of 
the evidence comparing montelukast with nasal corticosteroid 
is low. Based on the evidence, the steering group does not 
advise adding montelukast to nasal corticosteroid but studies 
evaluating the effect of montelukast in patients that failed nasal 
corticosteroids are missing.
6.1.10. Decongestants 
6.1.10. 1. Summary of the evidence
The use of topical decongestants has the theoretical potential 
to reduce mucosal oedema by inducing vasoconstriction(149). 
However, prolonged use can lead to rhinitis medicamentosa 
and worse symptoms of nasal obstruction upon decongestant 
discontinuation(150).
Nasal decongestion per se does not have effect on nasal polyp 
size(151).
Two RCTs have been performed evaluating the effect of local 
decongestants in the treatment of CRS (Table 6.1.10.1).
Kirtsreesakul et al. evaluated in a DBPCT the additive effect of 
oxymetazoline administration on nasal steroid therapy and 
whether rebound congestion develops after oxymetazoline 
treatment in 68 CRSwNP patients(152). Patients were randomly 
assigned in a 1:1 ratio to receive either oxymetazoline plus 
mometasone furoate nasal spray (MFNS) or placebo plus 
MFNS, two sprays per nostril twice daily, with an interval of 
five minutes between each medication for four weeks. All the 
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Study Methods Participants Interventions Outcomes Results
Schaper, 
2011(139)
SBPCT 
crossover
24 CRSwNP 
patients and 
asthma (12 
with N-ERD) 
• Montelukast 10 
mg 1dd for 6 
weeks (n=24)
• Placebo 1dd for 4 
weeks (n=24)
• Nasal symptoms (0-12)
• Nasal endoscopy
• Anterior rhinomanometry
• Olfactometry
• Mediators in nasal secretion 
and blood
• Lung function
• Total symptom score improved from 5.9 to 1.75 in 
montelukast group and not in placebo. No direct 
comparison. No data for placebo
• Significant reduction in oedema, hypersecretion, 
blockage compared to placebo at nasal endoscopy
• Significant improvement in nasal airflow
• Significant reduction in inflammatory mediators 
and eosinophils in nasal secretion
• Significant improvement in lung function
Pauli, 2007(138) DBPCT 30 CRSwNP 
patients
• Montelukast 10 
mg 1dd for 4 
weeks (n=20)
• Placebo 1dd for 4 
weeks (n=10)
• HRQL (health related quality 
of life questionnaire) at 4 
wks
• Nasal endoscopy at 4 wks
• ECP in nasal secretion at 
4 wks
• Significant reduction in most domains of HRQL
• No significant difference in nasal endoscopy score 
or ECP in nasal secretion
Table 6.1.9.1. Montelukast for the treatment of  patients with CRS.
CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, double-blind placebo-controlled trial; ECP, eosinophil cationic protein; HRQOL, health relat-
ed quality of life; N-ERD, NSAID-exacerbated respiratory disease; SBPCT, single-blind placebo-controlled trial.
Table 6.1.9.2. Montelukast added to intranasal corticosteroids for the treatment of  patients with CRS.
BAST-24, Barcelona Smell Test 24 odours; CRSwNP, chronic rhinosinusitis with nasal polyps; LMS, Lund-McKay score; RCT, randomized clinical trial; SF-
36, short form 36; T5SS; Total 5 Symptom Score.
Study Methods Participants Interventions Outcomes Results
Van Gerven 
2018(144)
RCT 72 CRSwNP 
postoperative 
• CRSwNP montelukast 10 mg 1dd together with 
mometasone furoate 200 µg 2 times a day for 
1 year (n=36)
• CRSwNP mometasone furoate 200 µg 2 times a 
day for 1 year (n=36)
• T5SS (T5SS) at 3, 6 
and 12 months
• Nasal polyp score 
(NPS) at 3, 6 and 
12 months
• LMS at 3, 6 and 12 
months
• BAST 24 at 3, 6 and 
12 months
• No significant difference 
between the treatments for any 
outcome measured
Suri 
2015(143)
RCT 40 CRSwNP • Montelukast 10 mg for 8 weeks+ prednisolone 
35 mg reducing by 5 mg every second day 
over 14 days+ budesonide nasal spray 2 me-
tered doses to each nostril for 8 weeks (n=20)
• Prednisolone 35 mg reducing by 5 mg every 
second day over 14 days+ budesonide nasal 
spray 2 metered doses to each nostril for 8 
weeks (n=20)
Total symptoms 
and nasal blockage, 
headache, facial 
pain, sense of smell, 
nasal discharge and 
sneezing (0-10) at 8 
and 12 weeks
• Significant better effect of 
montelukast group for total 
symptoms (8 and 12 wks), 
headache (12 wks), sense 
of smell (8 and 12 wks) and 
sneezing (8 wks)
Stewart 
2008(141)
RCT 38 CRSwNP 
(35 analysed)
• Montelukast 10 mg for 8 weeks+ prednisolone 
35 mg reducing by 5 mg every second day over 
14 days+ budesonide nasal spray 2 metered 
doses to each nostril for 8 weeks (n=20)
• Prednisolone 35 mg reducing by 5 mg every 
second day over 14 days+ budesonide nasal 
spray 2 metered doses to each nostril for 8 
weeks (n=20)
• Total symptoms 
and nasal block-
age, headache, 
facial pain, sense 
of smell, nasal dis-
charge, sneezing 
at 8 and 12 weeks
• SF36
• Significant better effect of 
montelukast group for facial 
pain (8 wks) headache (8 wks), 
sneezing (8 wks)
• No significant difference 
between the treatments for any 
outcome measured at 12 wks
• No significant difference in SF36
patients were then treated with MFNS, two sprays per nostril 
twice daily for two weeks. At four weeks after beginning the 
treatment, the oxymetazoline-MFNS group showed significantly 
greater improvement in blocked nose, hyposmia, peak nasal 
inspiratory flow (PNIF), nasal mucociliary clearance time 
(NMCCT) and total nasal polyps score (NPS) than the placebo-
MFNS group. During the two weeks in which all patients were 
only treated with MFNS both groups showed continuing 
improvement in all outcome variables but the oxymetazoline-
MFNS group still showed significantly greater improvement in 
blocked nose, hyposmia, NMCCT and total NPS, but not PNIF, 
than the placebo-MFNS group at the end of the study. There 
was no evidence of rebound congestion after four weeks of 
oxymetazoline treatment. This lack of rebound congestion when 
nasal decongestants are combined with nasal corticosteroids 
has also been shown in two studies in allergic rhinitis where 2-4 
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Table 6.1.10.1. Nasal decongestants for the treatment of patients with CRS.
DBPCRCT, double-blind placebo-controlled randomized clinical trial; MFNS, mometasone furoate nasal spray; NMCCT, nasal mucocil-
iary clearance time.
Study Methods Participants Interventions Outcomes Results
Kirtsreesakul, 
2016(152).
DBPCRCT 68 CRSwNP 
patients 
• Oxymetazoline plus MFNS 2 sprays per 
nostril twice daily, with an interval of 5 
minutes between each medication for 
4 weeks followed by 2 weeks of MFNS 
only (n=34)
• Placebo plus MFNS, 2 sprays per nostril 
twice daily, with an interval of 5 minutes 
between each medication for 4 weeks 
followed by 2 weeks of MFNS only 
(n=34)
• Symptoms,
• Nasal patency
• Nasal polyp size
• NMCCT was evaluated at 
4 and 6 weeks 
• Adverse events
• Combination of oxymetazoline 
plus MFNS significantly more 
effective than MFNS alone on:
•  Symptoms of nasal blockage 
and smell at 4 and 6 wks
• Nasal patency at 4 wk
• Nasal polyp size at 4 and 6 wks
• NMCCT at 4 and 6 wks
• No signs of rebound swelling
Humphreys, 
2009(155)
DBPCT 47 CRS 
patients 
postoperative
• Xylometazoline hydrochloride 0.1% 
adult nasal spray (n=24)
• A physiological sterile saline aerosol 
(n=23)
• Symptom scores at day 
10 postoperatively
• No differences between the 
groups 
weeks’ treatment with the combination of nasal decongestant 
and corticosteroid was more effective than nasal corticosteroid 
alone and did not show rebound swelling(153, 154).
In the second trial Humphreys at al. compared topical 
decongestant, xylometazoline, to a saline spray in 47 patients 
in the FESS early postoperative period(155). Postoperative VAS 
symptom scores for nasal obstruction, rhinorrhoea, pain, loss of 
sense of smell and bleeding assessed at day 10 postoperatively 
did not show any difference between the groups.
6.1.10.2. Conclusion
There is one small study in CRSwNP patients showing a 
significantly better effect of oxymetazoline combined with 
MFNS than MFNS alone without inducing rebound swelling(152). 
This is consistent with effects seen in the treatment of allergic 
rhinitis where the combination of nasal corticosteroid with 
decongestant also seemed to prevent rebound swelling(153, 154).
There was no effect of xylometazoline compared to saline in 
the early postoperative period(155). This review found a low level 
of certainty that adding a nasal decongestant to intranasal 
corticosteroids improves symptomatology in CRS. Although 
the risk of rebound swelling was not shown in this study, the 
EPOS2020 steering group suggests in general not to use nasal 
decongestants in CRS. In situations where the nose is very 
blocked, the temporary addition of a nasal decongestant to the 
nasal corticosteroid treatment can be considered.
6.1.11. Saline
6.1.11.1. Summary
Nasal saline irrigation is considered to be an important aspect 
of  the management of CRS. Saline nasal irrigation may 
improve nasal mucosa function through several physiological 
effects  including mechanical removal of mucus and crusts, 
improvement in mucus clearance, enhanced ciliary beat activity, 
disruption and removal of antigens, biofilms and inflammatory 
mediators, and increases hydration of the sol layer. Also, saline 
can be the carrier to supply sufficient volume to  transport 
medication into the sinus. There is however little consensus on 
the  best method of irrigation and the tonicity (concentration) 
of the saline solution, nor on the volume (low or high), pressure 
(low or high), and frequency, devices, and head position when 
rinsing. 
This systematic review identified 33 RCT studies (14 in the 
postoperative phase after FESS) evaluating the impact of nasal 
saline irrigations/spray on clinical outcomes in adult CRS (Tables 
6.1.11.1- 6.1.11.8). The studies were very different in design, 
duration and outcome measurements.  Twenty studies reported 
a positive effect of some form of saline irrigation(156-175).
Eight reported no effect (158, 176-182)and in five studies the effect 
compared to baseline was not mentioned(183-187).
Six studies evaluated the effect of a form of saline irrigation 
versus a form of no irrigation of the nose (Table 6.1.11.1). The 
studies could not be combined in a meta-analysis. Four studies 
showed no or hardly any (e.g. on one symptom) effect of 
saline irrigation. The two most recent studies((163, 165) did show 
significant positive effect of isotonic saline irrigation versus no 
irrigation. The differences between the positive and negative 
studies are not very clear but potential reasons for them could 
be the length of the treatment/evaluation (the positive studies 
had a mean duration of 7.5 months (3-12 months), the negative 
ones of six weeks (1-13 weeks). 
In conclusion, studies evaluating a form of saline irrigation 
versus a form of no irrigation of the nose do not lead to a 
concurrent conclusion. More studies are necessary to further 
analyse this important question for patients and professionals.
6.1.11.2. What is the best method?
Two studies evaluated different methods of applying saline.  A 
prospective, cross-over study evaluated the effectiveness of 
three methods of nasal irrigation (nasal spray, nebulisation with 
RinoFLow and nasal douching while kneeling with the head 
on the floor) on distribution of saline to the nasal cavity and 
paranasal sinuses(188). The authors showed that nasal douches 
are more effective in distributing irrigation solution to the 
maxillary sinus and frontal recess, but all techniques were able 
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Table 6.1.11.1. Saline nasal irrigation versus no irrigation for the treatment of patients with CRS.
Study Methods Participants Interventions Outcomes Results
Giotakis 
2016(163)
RCT not blinded 174 CRSwNP 
patients (158 
evaluated), 
postoperative
• 250ml of 1,175% Emser Salt® solution 
(EmsSalt) (n=59) twice daily for one year
• 250ml of isosmotic mineral salt mixture 
(IsoMix) (n=58) twice daily for one year
• No irrigation (n=57) for one year
All patients were allowed to use 
budesonide nasal spray in limited doses 
in the first 6 months and corticoid and 
antibiotic nasal ointment in the first 14 
days.
At 3, 6, 9 and 12 
months: 
• Nasal symptoms
• RQLQ
• Missed work days
• Postoperative condi-
tion of the mucosa
• Significantly better results in 
nasal symptoms and RQLQ 
between irrigation and no 
irrigation
• No significant difference 
in missed work days and 
mucosa
• No significant differences 
between Emser Salt and 
the isosmotic mineral salt 
mixture 
Nikakhlagh 
2016(165)
RCT not blinded 185 CRS 
patients
After 3 weeks of antibiotics patients 
received:
• Hypertonic lavage (volume and 
frequency unclear) for 3 months
• Isotonic lavage  for 3 months
• Hypertonic lavage  for 3 months
• No lavage for 3 months
After 3 months:
• Percentage of 
patients with symp-
toms of headache, 
discharge from nose 
and throat, nasal ob-
struction, coughing, 
olfaction, feeling of 
fullness in the face
• Isotonic was more effective 
than hypertonic, hypotonic 
and no lavage
Jiang 
2014(179)
RCT, no blinding, 
postoperative
185 patients 
undergoing 
FESS (110 
evaluated)
EAW for nasal irrigation daily for 2 months 
starting 1 months after FESS (n=36)
Neutral NS daily for 2 months starting 1 
months after FESS (n=35)
No nasal irrigation after surgery (n=39)
Two months after FESS:
• SNOT-20
• Mean MCA
2
• Smell threshold
• UPSIT-TC
• Saccharine transit 
time
• Endoscopic score
• No significant differences 
in postoperative SNOT-20 
scores, mean MCA
2
, smell 
threshold, UPSIT-TC scores, 
saccharine transit time, and 
endoscopic scores among 
the three groups.
Freeman, 
2008 (158)
Within-subject, 
single-
blinded RCT 
postoperatively
22 CRS patients • 2ml isotonic saline via a mucosal atomi-
sation device one side of the nose, three 
times per day for 6 weeks
• No saline other side of the nose
At 3 weeks and 3 
months:
• Adhesions, 
discharge, polyps, 
crusting, oedema (0-
3) at endoscopy 
• Significant positive effect of 
saline atomisation on dis-
charge, no other differences
Liang 
2008(175)
RCT, no blinding, 
postoperative
77 patients 
undergoing 
FESS 
• Pulsatile nasal irrigation for 3 months 
• No treatment
At 2 weeks and 1, 
2 and 3 months 
postoperatively:
• Symptom score
• Endoscopy score
• No significant effect of 
nasal irrigation for the whole 
group
• Significant positive effect of 
nasal irrigation in patients 
with mild CRS but not with 
severe CRS (based on CT 
scan > LM >12)
Pinto 
2006(178)
Postoperative, 
RCT, double 
blinded for 
sprays
60  patients 
with histories 
of frequent 
sinusitis after 
FESS
• NS (n=20) four times per day, two puffs 
on each side, for the first 5 postoperative 
days.
• Buffered HS (n=20) 4 times per day, 2 
puffs on each side, for the first 5 postop-
erative days.
• No spray (n=20)
For 5 days:
• Symptoms (nasal 
obstruction/conges-
tion, nasal discharge/
postnasal drip, pain/
pressure, headache, 
and trouble sleep-
ing/insomnia) (0-4) 
• Pain medication 
• Significantly more nasal 
discharge in hypertonic 
saline group compared to 
the other groups
• No other significant differ-
ences
Heatley 
2001(177)
RCT, no blinding 150 CRS 
patients (128 
completed the 
study)
• Nasal irrigation with bulb syringe with 
hypertonic saline for 2 weeks
• Nasal irrigation with nasal irrigation pot 
with hypertonic saline for 2 weeks
• Reflexology massage for 2 weeks
• RSOM-31 at 2 weeks
• SF-36 at 2 weeks
• Use of medication at 
2 weeks
• No significant differences 
between the groups
CRS, chronic rhinosinusitis; CRSwNP, Chronic Rhinosinusitis with nasal polyps; CT, computed tomography; EAW, electrolyzed acid water ; FESS, 
functional endoscopic sinus surgery; HS, hypertonic saline; LM, Lund-Mackay; MCA
2 ,
 second minimal crosssectional area; NS, normal saline; RCT, 
randomised controlled trial; RSOM-31, Rhinosinusitis Outcome Measure-31; SF-36, Short Form 36; UPSIT-TC, University of Pennsylvania Smell Identifi-
cation Test - Traditional Chinese.
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to reach the anterior and posterior nasal cavity in patients post-
FESS and healthy subjects. The spray and the nebulizer were 
unable to penetrate any of the sinuses or the frontal recess in 
the  controls. However, effect on symptoms was not measured. 
One study in 86 CRS patients compared a squeeze bottle with 
a nasal spray for one month and found no differences between 
the SNOT-22, Nasal and Sinus Symptom Scale (NSS) or Peri-
Operative Sinus Endoscopy (POSE) score between the two ways 
of administration(162). Although the study showed a significant 
improvement in both groups there was no difference between 
patients treated with the squeeze bottle compared to saline 
nasal spray (Table 6.1.11.2). The same was shown by Salib et 
al. who evaluated a low-volume high-pressure nasal spray and 
high-volume low-pressure saline application system following 
functional endoscopic sinus surgery and found no differences 
in SNOT-22 and only one timepoint difference for the LK score 
in favour of high volume(189). The studies could not be combined 
into a meta-analysis because of insufficient data.
To conclude, although nasal douches have been shown to be 
more effective in distributing  irrigation solution to the sinuses, 
there are no studies that show that nasal douches are also more 
effective in reducing symptoms and signs of CRS.
Nasal irrigation with isotonic saline or Ringer’s 
lactate is an effective treatment in CRS patients.
6.1.11.3. What is the best content?
Six studies evaluated the differences between hypertonic and 
normal saline(157, 161, 163, 165, 178, 184) (Table 6.1.11.3). Three studies 
(325 patients) found, in general, better results with isotonic than 
hypertonic saline(157, 165, 178). Two studies (248 patients) found no 
difference(161, 163) and one study (60 patients) showed hypertonic 
nasal spray to have significantly better results on congestion 
and cough than isotonic saline(184). 
Two studies(156, 159) evaluated the differences between Dead 
Sea salt and other hypertonic saline irrigation alone(156) or in 
combination with fluticasone dipropionate(159). The studies 
showed that hypertonic saline alone was less effective than the 
other two treatments. One study in 74 CRS patients directly after 
FESS evaluated the differences between isotonic saline irrigation 
(n=25) with lactated Ringer’s irrigation (n=26) and hypertonic 
saline nasal irrigation (n=23) for six weeks(161). Lactated Ringer’s 
resulted in a  significantly larger reduction in SNOT and VAS total 
symptom score over six weeks than the other two irrigations. 
In conclusion, in general, studies do not show that rinsing with 
hypertonic saline is more effective than with isotonic saline. 
There is one postoperative study showing that irrigation with 
lactated Ringer’s solution is more effective than both isotonic 
and hypertonic saline irrigation(161).
6.1.11.4. What is the best temperature?
One study compared a single saline irrigation at room 
temperature with irrigation with saline at 40 
degrees Celsius on mucociliairy transit time and nasal 
obstruction and found no differences(164) (Table 
6.1.11.4).
6.1.11.5. Will additions help?
6.1.11.5.1. Antiseptic/mucolytic/baby shampoo
Three studies evaluated the addition of antiseptic/mucolytic/
baby shampoo solution and showed little or no differences 
between the groups but the baby-shampoo group was reported 
to have significantly more side effects and had more patients 
stop the solution(160, 174, 183) (Table 6.1.11.5). Moreover, it has been 
shown in healthy persons to create congestion and reversible 
smell loss (190).
6.1.11.5.2. Sodium hyaluronate in CRS patients (both 
CRSsNP and CRSwNP).
Six Italian DBPCT or single blind (blinding often not clearly 
described) studies evaluated the addition of 9mg of sodium 
hyaluronate to saline(166-168, 185, 186, 191). Five studies evaluated 
nebulisation with a small volume(167, 168, 185, 186, 191) and one study 
rinsing with 250ml. The five studies evaluating nebulization 
in general reported positive outcomes, the study evaluation 
addition of sodium hyaluronate  to saline rinsing found in 
general no significant effect (Table 6.1.11.6). 
In conclusion, sodium hyaluronate might have a positive effect 
on postoperative symptoms when compared to a saline spray. 
Adding sodium hyaluronate to saline rinsing postoperatively did 
not show an effect in one study.
6.1.11.5.3. Honey in nasal saline irrigation
Honey is a viscous, supersaturated sugar solution derived from 
nectar gathered and modified by the honeybee, Apis mellifera. 
Honey has been used since ancient times as a remedy in wound 
care. Honey appears to heal partial thickness burns more quickly 
than conventional treatment (which included polyurethane film, 
paraffin gauze, soframycin-impregnated gauze, sterile linen and 
leaving the burns exposed) and infected post-operative wounds 
more quickly than antiseptics and gauze(192). In otolaryngology, 
studies have investigated the effect of honey and other bee 
products like propolis and royal jelly in oral infections, infections 
of the respiratory tract, in rhinosinusitis, tonsillectomy and head 
and neck surgery(193). 
Three studies(169, 170, 176) evaluated the addition of honey to saline 
irrigation(169, 176) or spray(170). None of the studies did find any 
relevant differences between the honey treated group and the 
placebo group (Table 6.1.11.7). However, in all studies patients 
also received oral antibiotics and/or nasal corticosteroids which 
reduces the possibility of finding significant differences. 
The addition of Xylitol, sodium hyaluronate, and 
xyloglucan to nasal saline irrigation may have a 
positive effect.
6.1.11.5.4. Xylitol nasal irrigation
Xylitol is a five-carbon sugar alcohol that occurs naturally in 
many fruits and vegetables and is used widely in the food 
industry as a sweetener. It has gained extensive attention in the 
past decade as a natural antibacterial agent and more recently 
as an anti-biofilm agent, particularly in periodontics. It decreases 
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the salt concentration of human airway surface liquid that 
contains many antimicrobial substances, which can contribute 
to the improvement of the innate immune system, and thereby 
prevent airway infections. Moreover, through disruption of the 
glucose cell-wall transport and intracellular glycolysis, xylitol can 
inhibit bacterial growth. 
Two  small studies analysed the efficacy of xylitol rinsing in the 
treatment of patients with CRS(180, 181).  Both studies reported 
a significant better effect of xylitol compared to saline in the 
reduction of SNOT and total symptoms visual analogue scale 
(VAS). The studies could not be combined into a meta-analysis 
because of missing data (Table 6.1.11.8). 
6.1.11.5.5. Dexpanthenol in nasal saline irrigation
Dexpanthenol is an analog of pantothenic acid, which has been 
claimed to promote wound healing(194). It has been shown to 
improve symptoms in patients with atrophic rhinitis(195).  Two 
studies evaluated the effect of dexpanthenol in saline(171, 187). 
Both studies showed no effect on the majority of symptoms and 
endoscopy but a superior efficacy over placebo on mucociliary 
clearance (in the Fooanant study only in patients with CRSwNP) 
(Table 6.1.11.9).
6.1.11.5.6. Xyloglucan in nasal saline irrigation
Xyloglucan, a natural polysaccharide derived from tamarind 
seeds, possesses a “mucin-like” molecular structure that confers 
mucoadhesive properties, allowing xyloglucan formulations 
to act as a barrier capable of reducing bacterial adherence 
and invasion and to preserve tight junctions and paracellular 
flux, as observed in different in vitro and in vivo studies(196). 
There is one study(182) evaluating the effect of xyloglucan nasal 
spray compared to saline that indicated that xyloglucan spray 
resulted in a significant reduction in symptoms and signs of 
disease (Table 6.1.11.10) and saline did not. However, no direct 
comparison between the groups was made.
In conclusion there is limited evidence that xyloglucan nasal 
spray may have a positive effect on symptoms and signs of 
disease in patients with CRS [level 2b (downgraded because of 
Table 6.1.11.2. Methods of nasal irrigation for the treatment of patients with CRS.
Study Methods Participants Interventions Outcomes Results
Macdonald 
2015(162)
Single blind RCT 
postoperative
86 CRS patients 
(55 CRSwNP) 
directly 
postoperatively
• Saline squeeze bottle (n=43) for 1 month
• Saline nasal spray (n=43) for 1 month
• SNOT-22
• POSE
• Nasal and 
sinus symp-
tom scale 
(0-15)
• Significant improvement 
in both groups for SNOT-
22, POSE, NSS
• No difference between 
treatment groups
Salib 
2013(189)
Single blind RCT 
postoperative
31 CRS patients 
directly 
postoperatively 
(24 evaluated) (17 
CRSwNP)
• SterimarTM Isotonic two sprays three times 
daily in one nostril for a period of 12 weeks 
after surgery (n=24).
• Sinus RinseTM 120ml three times daily in one 
nostril for a period of 12 weeks after surgery.
All patients received 1-week course of antibiotics, 
topical nasal steroids, and a 10-day course of 
oral steroids in patients with nasal polyposis. 
At 2, 4 and 
12 weeks 
following 
surgery:
• SNOT-22
• LK score
At 2, 4 and 12 weeks:
• No difference in SNOT-22 
at any timepoint
• Statistical difference for 
LK score at 4 weeks and 
trend at 2 weeks
CRS,Chronic Rhinosinusitis; Single blind RCT, Single Blind Randomised Controlled Trial; CRSwNP, Chronic Rhinosinusitis with nasal 
polyps;SNOT-22, Sino-Nasal Outcome Test-22; POSE, Perioperative Sinus Endoscopy score; NSS, Nasal and Sinus Symptom scale; LK 
score, Lund-Kennedy score;
Table 6.1.11.3. Hypertonic versus isotonic saline irrigation for the treatment of  patients with CRS.
Study Methods Participants Interventions Outcomes Results
Giotakis 2016(163) RCT not 
blinded
174 CRSwNP 
patients (158 
evaluated), 
postoperative
• 250ml of 1,175% Emser Salt® solution 
(EmsSalt) (n=59) twice daily for one 
year
• 250ml of isosmotic mineral salt 
mixture (IsoMix) (n=58) twice daily 
for one year
• No irrigation (n=57)
• All patients were allowed to use 
budesonide nasal spray in limited 
doses in the first 6 months and corti-
coid and antibiotic nasal ointment in 
the first 14 days.
At 3,6,9 and 12 months: 
• Nasal symptoms
• RQLQ
• Missed work days
• Postoperative condi-
tion of the mucosa
• Significantly better 
results in nasal 
symptoms and RQLQ 
between irrigation and 
no irrigation
• No significant differ-
ence in missed work 
days and mucosa
• No significant differ-
ences between Emser 
Salt and the isosmotic 
mineral salt mixture 
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Study Methods Participants Interventions Outcomes Results
Nikakhlagh 
2016(165)
RCT not 
blinded
185 CRS 
patients
After 3 weeks of antibiotics patients 
received:
• Hypertonic lavage (volume and 
frequency unclear) for 3 months
• Isotonic lavage  for 3 months
• Hyptonic lavage  for 3 months
• No lavage for 3 months
After 3 months:
• Percentage of patient 
with symptoms of head-
ache, discharge from 
nose and throat, nasal 
obstruction, coughing, 
olfaction, feeling of 
fullness in the face
• Isotonic was more 
effective than hypertonic, 
hypotonic and no lavage
Low 
2014(161)
DBRCT 
postoperative
74  CRS 
patients directly 
postoperative
• Normal saline irrigation (n=25) for 
6 wks
• Lactated Ringer’s irrigation (n=26) 
for 6 wks
• Hypertonic saline nasal irrigation 
(n=23) for 6 wks
After 6 weeks:
• SNOT-20
• Symptom scores (VAS)
• Mucociliary clearance 
(MCC)
• All groups showed signifi-
cant improvement over 6 
wks for SNOT and VAS
• Lactated Ringer’s was 
significantly better over 
6 wks than the other two 
irrigations
• No differences in MCC
Friedman 
2012(159)
Double blind 
RCT
145 CRS 
patients  (114 
evaluated)
• 20 ml hypertonic DSS solution 2dd 
and DSS nasal spray (n=59) for 4 wks
• 20 ml hypertonic saline irrigation 2dd 
and nasal spray + 1dd fluticasone 50 
μg (n=57) for 4 wks
At 4 weeks
• SNOT-20
• UPSIT
• Nasal endoscopy 
• Acoustic rhinometry 
• Significant improvement 
in SNOT-20 in both groups
• No significant differences 
between the groups
• No significant difference 
compared to baseline or 
between the groups for 
UPSIT, nasal endoscopy or 
acoustic rhinometry 
Culig 
2010(184)
RCT 60 CRS patients • Hypertonic nasal spray (2,12%) (Steri-
mar) 3-6 times daily for 2 weeks
• Normal saline nasal spray (Sterimar) 
3-6 times daily for 2 weeks
After 1 and 2 wks:
• Rhinorrhea, congestion, 
cough, headache and 
sinus region sensitivity 
on palpation after 1 and 
2 wks
• Hypertonic nasal spray 
had significant better 
results on congestion (1 
and 2 wks) and cough (at 
2 wks) than normal saline
Hauptman 
2007(157)
Double blind 
RCT
80 patients with 
CRS
• Buffered hypertonic saline (3%) 1ml 
(10 puffs of 100 microlitre) in the 
most obstructed nasal cavity once
• Normal saline (3%) 1ml (10 pufs 
of 100 microlitre) in the most 
obstructed nasal cavity once
• Acute effect on:
• Symptoms of nasal stuffi-
ness,  nasal obstruction 
and nasal burning/irrita-
tion  (0-10)
• Acoustic rhinometry
• (Change in) MCT
• Normal saline resulted in 
significantly less stuffiness, 
nasal obstruction and 
burning/irritation than 
hypertonic saline
• MCT was significantly 
better after normal saline 
but change in MCT sign. 
Better after hypertonic,
• MCA2 significantly better 
after normal saline
Friedman 
2006(156)
DBPCT 57 patients 
with CRS (42 
evaluated)
• Hypertonic Dead sea salt (DSS) solu-
tion 2dd (n=22) for 1 month
• Hypertonic saline irrigation 2dd  
(n=20) for 1 month
• RQLQ
• Total symptoms score 
(0-48)
• RQLQ and total symptom 
score significantly better 
for DSS than hypertonic 
saline
Table 6.1.11.3. Hypertonic versus isotonic saline irrigation for the treatment of  patients with CRS (continued).
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CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, double blind placebo controlled trial; DBRCT, 
double blind randomised controlled trial; dd, daily dosage; DSS, Dead Sea Salt solution; FESS, functional endoscopic sinus surgery; 
HDSS, Hypertonic Dead sea salt; HS, hypertonic saline; MCA2, Minimal cross-sectional area 2; MCT, mucociliary clearance time; NS, 
normal saline; RCT, randomised controlled trial; RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire .
Table 6.1.11.4. Temperature of nasal saline for irrigation for the treatment of patients with CRS.
Study Methods Participants Interventions Outcomes Results
Nimsakul 
2018(164)
RCT not 
blinded
23 CRS patients • 250ml saline at room temperature (n=9)
• 250ml saline at 40o C (n=12)
• Saccharin transit time (STT)
• PNIF
• Total nasal resistance measured 
by anterior rhinomanometry
• Total nasal volume measured by 
acoustic rhinometry
• Nasal obstruction score (0-5)
• Breathe-comfort score (0-5)
• Adverse events.
• Significant im-
provement in STT 
in both groups
• No differences 
between the 
groups
• No differences in 
other outcomes
CRS, chronic rhinosinusitis; PNIF, peak nasal inspiratory flow; RCT, randomised controlled trial; STT, saccharin transit time.
Study Methods Participants Interventions Outcomes Results
Yu 2016(174)  DBPCT 43 CRS patients 
(39 evaluated)
• Low-concentration HOCl 
30 ml twice daily using a 
Salicid device
• Saline 30 ml twice daily 
using a Sham Salicid 
device
At 1,2,4 and 8 weeks:
• SNOT-20
• RSDI
• Endoscopy (LK score)
• Adverse events
Low-concentration HOCl versus saline 
resulted in significantly reduced 
• SNOT-20 at 2 and 4 weeks 
• None of the other outcomes 
• No treatment related adverse events
Farag 2013(160) Single 
blind RCT 
postoperative
40 CRS patients 
directly 
postoperative
• 120ml hypertonic Saline 
solution 3dd until 4 
months postop
• 120ml of 1% baby sham-
poo solution 3dd until 4 
months postop
• RSOM-31
• SNOT-22
• Olfaction with phenyl 
ethyl alcohol (PEA) 
threshold test
• Adverse events
• Significant decreases in scores for 
both the SNOT-22and RSOM-31 
overtime for both treatments but no 
difference between the treatments
• PEA thresholds showed improve-
ment but no difference between 
the treatments
• The baby-shampoo group reported 
significantly more side effects and 
had more patients stop the solution 
Pigret 1996(183) Single-
blind RCT 
postoperative
20 CRSwNP 
patients after 
endoscopic 
endonasal 
ethmoidectomy 
• Pressurized seawater (vol-
ume unclear) (n=10) 3dd
• 10ml of saline plus benzo-
dodecinium (antiseptic) 
plus oleosorbate (mucol-
ytic) (n=10) 3dd
• Residual nasal crusts 
weight at 21±2 days 
secretions after 21±2 
days
• Visual analogue scale 
for nasal obstruction, 
rhinorrhoea, cacosmia 
and facial pain
No significant differences although 
the mean residual crust weight  was 
higher in the pressurized seawater 
group (1,756±688mg) than in the 
antiseptic/mucolytic saline group 
(932±414mg)
Table 6.1.11.5. Saline irrigation with addition of antiseptic/mucolytic/baby shampoo solution for the treatment of patients with CRS.
DBPCT, double blind placebo controlled trial; LK, Lund-Kennedy; HOCl, Hypochlorous acid; PEA, phenyl ethyl alcohol; RSDI, Rhinosi-
nusitis Disability Index; SNOT, Sino-nasal Outcome Test; RCT, randomised controlled trial; RSOM-31, Rhinosinusitis Outcome Mea-
sure-31.
Table 6.1.11.3. Hypertonic versus isotonic saline irrigation for the treatment of  patients with CRS (continued).
Pinto 
2006(178)
Postoperative, 
RCT, double 
blinded for 
sprays
60  patients 
with histories 
of frequent 
sinusitis after 
FESS
• Normal saline (NS; n = 20) 4 times 
per day, two puffs on each side, for 
the first 5 postoperative days.
• Buffered hypertonic saline (HS; n = 
20) 4 times per day, two puffs on 
each side, for the first 5 postoperative 
days.
• No spray (n = 20)
• Symptoms (nasal 
obstruction/congestion, 
nasal discharge/postna-
sal drip, pain/pressure, 
headache, and trouble 
sleeping/insomnia) (0-4) 
for 5 days
• Pain medication for 5 
days
• Significantly more nasal 
discharge in hypertonic 
saline group compared to 
the other groups
• No other significant 
differences
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Study Methods Participants Interventions Outcomes Results
Mozzanica 
2019(166)
DBPCT 56 CRSsNP 
patients 
postoperatively
• 250ml saline plus 9mg sodium 
hyaluronate twice daily for 6 
weeks (n=26)
• Saline twice daily for 6 weeks 
(n=30)
At 3 and 6 weeks 
postoperatively:
• SNOT-22 
• NOSE 
• Symptoms (VAS)
• LK score
• No differences in SNOT-22, NOSE, 
symptoms and total LK score at 6 
weeks
• Significantly better result of NOSE 
score at 3 weeks in sodium hyaluronate 
group
• Significantly better result for headache 
and smell alteration at three weeks in 
sodium hyaluronate group
• Significantly reduced scar formation (3 
and 6 weeks), crusting (3 weeks) and 
secretion (6 weeks) 
Cantone 
2016(191) 
DBPCT 80 CRS patients 
(40 allergic and 
40 non-allergic)
• 9 mg (3 mL) of high-molecular-
weight sodium hyaluronate 
in 2 ml saline solution 
administered twice a day for 15 
consecutive days per month for 
3 consecutive months by using 
a nebulizer ampoule for nasal 
douche (n=40)
• 2 ml saline solution 
administered twice a day for 15 
consecutive days per month for 
3 consecutive months by using 
a nebulizer ampoule for nasal 
douche (n=40)
All patients used mometasone 
fuorate nasal spray200µg o.d. for 
3 months 
At 3 months:
• SF-36
• SNOT-22
• Obstruction (VAS)
• Nasal discharge (VAS) 
• LK score
Significantly better result of sodium 
hyaluronate than saline on top of MFNS 
for:
• SF36
• SNOT-22
• Obstruction (VAS)
• Nasal discharge (VAS) 
• LK score
Cantone 
2014(185)
DBPCT 124 CRSwNP 
(122 evaluated) 
postoperatively
• Intranasal nebulization of 9mg 
sodium hyaluronate (3mL) plus 
saline solution (2mL) twice daily 
for 30 days (n=62)
• Intranasal nebulization of saline 
(5ml) twice daily for 30 days 
(n=60)
At 30 days postoperatively:
• SF-36
• SNOT-22
• Symptoms (VAS)
• Endoscopic score
Significantly better result of sodium 
hyaluronate than saline for:
• SF36
• SNOT-22
• Total symptoms (VAS)
• Endoscopic score
Casale, 
2014(167)
RCT 
(single 
blind?)
33 CRS patients 
postoperatively
• Nebulization of 3mL containing 
9mg sodium hyaluronate nasal 
washes plus saline twice daily 
for 1 month (n=18)
• Nebulization of 5mL saline 
twice daily for 1 month (n=15)
At 2 and 4 weeks 
postoperatively:
• CRS questionnaire 
• Visual analogic scale (VAS)
• Nasal endoscopy
• VAS score of hyaluronate significantly 
lower than saline at 2 and 4 weeks
• CRS score significantly lower than 
saline at 2 and 4 weeks 
• Significantly less crusts and oedema 
and secretions
Gelardi 
2013(186)
RCT 
(single 
blind?)
36 CRSwNP 
postoperative
• Intranasal nebulization of 
sodium hyaluronate 9mg in 
3mL twice daily for 30 days 
(n=19)
• Intranasal nebulization saline 
5mL twice daily for 30 days 
(n=17)
At 30 days postoperatively:
• Nasal obstruction, burning, 
dryness of the mucosa 
(VAS) 
• Presence or absence of 
rhinorrhoea
•  Mucociliary clearance time 
• Presence of exudate at 
endoscopy
Sodium hyaluronate group had 
compared to saline:
• Significantly faster mucociliary clear-
ance 
• Lower incidence of rhinorrhoea
• Less nasal obstruction
• A lower incidence of exudate on 
endoscopy 
• Better tolerability 
Macchi 
2013(168)
DBPCT 46 CRSwNP 
patients 
postoperatively
• Nebulization of 6ml containing 
9mg sodium hyaluronate nasal 
washes plus saline for 15 days/
mo over 3 months (n=23)
• Nebulization of 6mL isotonic 
saline for 15days/mo over 3 
months (n=23)
At 3 months postoperatively:
• Prevalence of symptoms
• Endoscopy 
• Cytology
• Biofilm
Significantly better result of sodium 
hyaluronate than saline for:
• Nasal dyspnea (obstruction?)
• Normal mucosa
• Absence of secretion
Table 6.1.11.6. Saline irrigation with addition of sodium hyaluronate for the treatment of patients with CRS.
CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps; 
DBPCT, double blind placebo controlled trial; LK, Lund-Kennedy; MFNS, Mometasone fuorate nasal spray; NOSE, Nasal Obstruction 
Symptom Evaluation; RCT, randomised controlled trial; SF 36, Short Form 36; SNOT, Sino-nasal Outcome Test; VAS, 
visual analogue scale. 
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Table 6.1.11.7. Saline irrigation with addition of honey for the treatment of  patients with CRS.
CRS, chronic rhinosinusitis; LK, Lund-Kennedy; SNOT, Sino-nasal Outcome Test; UPSIT, University of Pennsylvania Smell Identification 
Test; VAS, visual analogic scale.
Table 6.1.11.8. Saline irrigation with addition of xylitol for the treatment of patients with CRS.
CRS, chronic rhinosinusitis; DBPC, double blind placebo controlled; DBPCT, double blind placebo controlled trial; iNOS, inducible 
Nitic Oxide; mRNA, messenger Ribonucleic Acid; NO, nitric oxide; SNOT, Sino-nasal Outcome Test; VAS, visual analogue scale.
Study Methods Participants Interventions Outcomes Results
Ooi 
2019(176)
Single blind 
(investigator) 
placebo 
controlled 
trial
25 recalcitrant 
CRS patients 
• 14 days of twice-daily 16.5% Manuka Honey + 
1.3mg/mL augmented methylglyoxal sinonasal 
rinses 
• 14 days of twice-daily saline sinonasal rinses 
Both groups received 10 days of culture-directed 
antibiotic therapy 
At 14 days:
• SNOT-22
• Symptom scores (VAS)
• UPSIT
• Endoscopy (LK score)
• Microbiology 
• Adverse events
• No significant 
differences 
in SNOT-22, 
symptoms, 
UPSIT, LK score, 
microbiology or 
adverse events
Lee 
2016(169)
Single blind 
(investigator) 
placebo 
controlled 
trial 
49 CRS patients 
(42 analysed) 
postoperatively
• 120ml saline containing 12mg of manuka honey 
twice daily for 30 days
• 120ml saline twice daily for 30 days
• All patients received culture-directed oral antibi-
otic, and/or oral steroids for up to 3 weeks, and/
or high-volume topical steroid sinus irrigations 
(budesonide 0.5mg/2mL vial or 0.6mg/2mL cap-
sule, 0.5 bottle to each nasal cavity twice daily) 
polyps or inflammation for 30 days.
• The dose of budesonide was determined when 
the patient filled the prescription; if insur-
ance covered it, then the vial version at the 
0.5mg/2mL dose was used, and if not covered, 
then the capsule version at the 0.6mg/2mL dose 
was used.
At 30 days:
• SNOT-22
• LK endoscopy score
• Bacterial culture
• No significant 
differences 
between the 
groups
• In the subgroup 
not using 
antibiotics manuka 
honey significantly 
reduced bacteria
Hashemian 
2015(170)
DBPCT 64 CRS patients 
postoperatively 
(53 analysed) 
• Thyme/honey nasal spray 2 puffs per nostril 
twice daily (n=27)
• Placebo nasal spray 2 puffs per nostril twice daily 
(n=26)
All patients received cefixime 400mg daily for 10 
days postoperatively and were instructed to 
rinse their nasal cavity initially with saline three 
times daily, and then use fluticasone nasal spray 
(50mcg) twice daily.
At 60 days:
• SNOT-22
• CT-scan
• Endoscopy score (0-8)
• No significant 
differences 
between the 
groups
Study Methods Participants Interventions Outcomes Results
Lin 
2017(180)
DBPCT 30 CRS 
patients (25 
evaluated)
• 240 ml of water containing 12 g xylitol once 
daily for 30 days (n=13)
• 240 ml of saline once daily for 30 days
• 3 days washout between treatments (n=12)
At 30 days:
• SNOT-22
• VAS (symptoms)
• Nasal NO
• iNOS mRNA in the right max-
illary sinus
At 30 the xylitol group 
had significant better 
result than the saline 
group for:
• SNOT-22
• VAS (symptoms)
• Nasal NO
• Induction of iNOS
Weissman 
2011(181)
DBPC 
crossover 
study
20 CRS 
patients (15 
evaluated)
• 240ml of water containing 12g xylitol once 
daily for 10 days (n=20)
• 240ml of saline once daily for 10 days 3 days 
washout between treatments (n=20)
• Change in SNOT-20 versus 
baseline
• Change in VAS (how you think 
your nose/sinuses are feeling 
overall) versus baseline
Significant larger 
reduction in SNOT-20 in 
the xylitol group versus 
the saline group
No differences in VAS 
score
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Table 6.1.11.9. Saline irrigation with addition of dexpanthenol for the treatment of  patients with CRS.
CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, double blind placebo controlled trial; RCT, 
randomized controlled trial.
Table 6.1.11.10. Saline irrigation with addition of Hyaluronate for the treatment of patients with CRS.
Study Methods Participants Interventions Outcomes Results
Tantilipikorn 
2012(171)
DBPCT 50 CRS patients 
postoperatively 
• Dexpanthenol nasal spray 4 
times a day for 6 weeks (n=25)
• Saline nasal spray 4 times a 
day for 6 weeks (n=25)
• % of patients with symp-
toms at 2, 4 and 6 wks
• % of patients with endo-
scopic abnormalities at 2, 4 
and 6 wks
• Mucociliary clearance time 
at 6 wks
• Majority of symptoms and signs did 
not show significant differences
• Dexpanthenol nasal spray has 
superior efficacy compared 
with normal saline nasal spray 
on improvement of mucociliary 
clearance and smell at 6 wks and 
inferior effect on nasal discharge
Fooanant 
2008(187)
RCT 128 CRS 
patients (110 
evaluated) 
postoperatively
• Dexpanthenol (5%) in sea 
water nasal spray 2 puffs per 
nostril, twice a day for 4 weeks
• Saline nasal irrigation (volume 
unclear) twice a day for 4 
weeks
• At 1, 2, 3, 4, 6 and 12 weeks:
• Total nasal symptom score 
• Symptoms
• Nasal crusts
• Mucociliary clearance (only 
at 4 wks) 
• No significant differences in total 
nasal symptom score, nasal crusts 
(but at wk 2 less in saline group), 
mucociliary clearance (but for 
subgroup of CRSwNP) 
Study Methods Participants Interventions Outcomes Results
Mozzanica 
2019(166)
DBPCT 56 CRSsNP 
patients 
postoperatively
• 250ml saline plus 9mg sodium 
hyaluronate twice daily for 6 weeks 
(n=26)
• Saline twice daily for 6 weeks (n=30)
At 3 and 6 weeks 
postoperatively:
• SNOT-22 
• NOSE 
• Symptoms (VAS)
• LK score
• No differences in SNOT-22, NOSE, 
symptoms and total LK score at 6 weeks
• Significantly better result of NOSE score 
at 3 weeks in sodium hyaluronate group
• Significantly better result for headache 
and smell alteration at three weeks in 
sodium hyaluronate group
• Significantly reduced scar formation (3 
and 6 weeks), crusting (3 weeks) and 
secretion (6 weeks) 
Cantone 
2016 (191) 
DBPCT 80 CRS patients 
(40 allergic and 
40 non-allergic)
• 9 mg (3 mL) of high-molecular-
weight sodium hyaluronate in 2 ml 
saline solution administered twice 
a day for 15 consecutive days per 
month for 3 consecutive months by 
using a nebulizer ampoule for nasal 
douche (n=40)
• 2 ml saline solution administered 
twice a day for 15 consecutive days 
per month for 3 consecutive months 
by using a nebulizer ampoule for 
nasal douche (n=40)
All patients used MFNS 200µg once 
daily for 3 months 
At 3 months:
• SF-36
• SNOT-22
• Obstruction (VAS)
• Nasal discharge 
(VAS) 
• LK score
Significantly better result of sodium 
hyaluronate than saline on top of MFNS for:
• SF36
• SNOT-22
• Obstruction (VAS)
• Nasal discharge (VAS) 
• LK score
Cantone 
2014(185)
DBPCT 124 CRSwNP 
(122 evaluated) 
postoperatively
• Intranasal nebulization of 9mg 
sodium hyaluronate (3mL) plus saline 
solution (2mL) twice daily for 30 days 
(n=62)
• Intranasal nebulization of saline (5ml) 
twice daily for 30 days (n=60)
At 30 days 
postoperatively:
• SF-36
• SNOT-22
• Symptoms (VAS)
• Endoscopic score
Significantly better result of sodium 
hyaluronate than saline for:
• SF36
• SNOT-22
• Total symptoms (VAS)
• Endoscopic score
Casale, 
2014(167)
RCT 
(single 
blind?)
33 CRS patients 
postoperatively
• Nebulization of 3ml containing 9mg 
sodium hyaluronate nasal washes 
plus saline twice daily for 1 month 
(n=18)
• Nebulization of 5mL saline twice daily 
for 1 month (n=15)
At 2 and 4 weeks 
postoperatively:
• CRS questionnaire 
• Visual analogic 
scale (VAS)
• Nasal endoscopy
• VAS score of hyaluronate significantly 
lower than saline at 2 and 4 weeks
• CRS score significantly lower than saline 
at 2 and 4 weeks 
• Significantly less crusts and oedema and 
secretions
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Gelardi 
2013(186)
RCT 
(single 
blind?)
36 CRSwNP 
postoperative
• Intranasal nebulization of sodium 
hyaluronate 9mg in 3ml twice daily 
for 30 days (n=19)
• Intranasal nebulization saline 5ml 
twice daily for 30 days (n=17)
At 30 days 
postoperatively:
• Nasal obstruc-tion, 
burning, dryness of 
the mucosa (VAS) 
• Presence or ab-
sence of rhinor-
rhoea
•  Mucociliary clear-
ance time 
• Presence of exu-
date at endoscopy
Sodium hyaluronate group had compared 
to saline:
• Significantly faster mu-cociliary clearance 
• Lower incidence of rhinorrhoea
• Less nasal obstruction
• A lower incidence of exudate on endos-
copy 
• Better tolerability 
Macchi 
2013(168)
DBPCT 46 CRSwNP 
patients 
postoperatively
• Nebulization of 6ml containing 9mg 
sodium hyaluronate nasal washes 
plus saline for 15 days/mo over 3 
months (n=23)
• Nebulization of 6mL isotonic saline 
for 15days/mo over 3 months (n=23)
At 3 months 
postoperatively:
• Prevalence of 
symptoms
• Endoscopy 
• Cytology
• Biofilm
Significantly better result of sodium 
hyaluronate than saline for:
• Nasal dyspnea (obstruction?)
• Normal mucosa
• Absence of secretion
CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps; DBPCT, 
double blind placebo controlled trial; LK, Lund-Kennedy; MFNS, Mometasone fuorate nasal spray; NOSE, Nasal Obstruction Symptom 
Evaluation; RCT, randomized controlled trial; SF-36, Short Form-36; SNOT, Sino-nasal Outcome Test; VAS, visual analogue scale.
Study Methods Participants Interventions Outcomes Results
Ottaviano 
2011(197)
DBPCT 80 CRS 
patients 
• Sulphurous, salty, bromic, iodic (SSBI) 
thermal water (5mL, 4 times daily for 
one month (n=40)
• Saline 5mL, 4 times daily for one month 
(n=40)
At 1 month:
• Nasal endoscopy
• Rhinomanometry
• No significant differences 
between thermal water and 
saline
Salami 
2010(873)
DBPCT Eighty 
patients with 
CRS
• Sulphurous thermal water (Tabiano SPA 
Mineral Water) applied as warm inhala-
tion (38°C, at a distance of 20 cm from 
the patient’s face for 10 min) combined 
with nasal irrigations with the same 
water for 6 minutes for 12 days (n=40)
• Placebo water (saline made white and 
with sulphur) applied as warm inhala-
tion (38°C, at a distance of 20 cm from 
the patient’s face for 10 min) combined 
with nasal irrigations with the same 
water for 6 minutes for 12 days (n=40)
At 12 days and 3 months:
• Symptoms (VAS)
• Clinical parameters of 
recurrence
• Nasal resistance measured 
with anterior active rhino-
manometry
• Mucociliary clearance
At 12 days and 3 months the 
thermal water compared to placebo 
significantly reduced
• Symptoms (VAS)
• Clinical parameters of recurrence
• Nasal resistance measured with
 anterior active rhinomanometry
• Mucociliary clearance
Passali 
2008(198)
RCT 55 CRS 
patients or 
patients with 
recurrent RS
• Thermal (salt-bromine-iodic) water 
nasal spray 4 times daily (n=30) for 
4 weeks
• Saline nasal spray (n=25) for 4 weeks
At 4 weeks:
• Symptoms of headache, 
rhinorrhoea, hyposmia 
(0-3)
• Nasal endoscopy
• Nasal resistance measured 
with anterior active rhino-
manometry
• Mucociliary clearance
At 4 weeks a significant reduction in 
the thermal water nasal spray versus 
saline in:
• Symptoms
• Nasal endoscopy
• Rhinomanometry
• Mucociliary clearance
Passali 
2008(199)
RCT 120 CRS 
patients or 
patients with 
recurrent RS
• Crenotherapy treatment (vapour 
inhalation, aerosol and nasal douching) 
with thermal (salt-bromine-iodic water) 
water for 14 days at Salsomaggiore 
Thermal baths
• Nasal douching and aerosol with saline 
twice a day for 14 days at the Rhino-
logic Centre of the ENT Clinic of Siena 
University.
At 2 weeks:
• Symptoms of nasal 
obstruction, rhinorrhoea, 
nightly awakenings
• Percent of patients with 
hyposmia
• Nasal endoscopy (conges-
tion, secretion)
• Mucociliary clearance
At 4 weeks a significant reduction in 
the thermal water nasal spray versus 
saline in:
• Symptoms
• Nasal endoscopy
• Mucociliary clearance
• No difference in percentage of 
patients with hyposmia
Table 6.1.11.11. Thermal water for the treatment of patients with CRS.
CRS, chronic rhinosinusitis; DBPCT, double blind placebo controlled trial; RCT, randomised controlled trial; SPA, ; VAS, visual analogue scale.
Table 6.1.11.10. Saline irrigation with addition of Hyaluronate for the treatment of patients with CRS (continued)
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quality of the study.
6.1.11.5.7. Thermal water
Three Italian studies evaluated the use of thermal water, as nasal 
irrigation (197), nasal spray (198) or as a combination treatment 
(vapour inhalation, aerosol and nasal douching)(199) (Table 
6.1.11.11). Only one study was double blind (197).
The double blind study of Ottaviano showed no significant 
differences between the treatments (calculated from data 
given). The other two studies showed significant improvement 
of symptoms,  nasal endoscopy and nasal mucociliairy 
clearance. The studies were of very low-quality making 
conclusions difficult.
6.1.11.6. Adverse effects
Adverse effects of saline irrigations are rare, but include local 
irritation, ear pain, nosebleeds, headache, nasal burning, and 
nasal drainage are mentioned. The use of baby-shampoo has 
been shown to create congestion and reversible smell loss.
6.1.11. 7. Conclusions
There are a large number of trials evaluating the efficacy 
of nasal irrigation. However, the quality of the studies is 
not always very good which makes it difficult to give a 
strong recommendation. However, the data show: 
Nasal irrigation with isotonic saline or Ringer’s lactate 
has efficacy in CRS patients.
There is insufficient data to show that a large volume is 
more effective than a nasal spray. 
The addition of xylitol, sodium hyaluronate, and 
xyloglucan to nasal saline irrigation may have a positive 
effect. The addition of baby shampoo, honey, or 
dexpanthenol as well as higher temperature and higher 
salt concentration do not confer additional benefit.
The steering group advises the use of nasal saline 
irrigation with isotonic saline or Ringer’s lactate 
potentially with the addition of xylitol, sodium 
hyaluronate, and xyloglucan and advises against the 
use of baby shampoo and hypertonic saline solutions 
due to side effects.
6.1.12. Aspirin treatment after desensitization 
(ATAD) in N-ERD
6.1.12.1. Summary of the evidence
Non-steroidal anti-inflammatory drug (NSAID)-exacerbated 
respiratory disease (N-ERD) is a chronic eosinophilic, 
inflammatory disorder of the respiratory tract occurring in 
patients with asthma and/or CRSwNP, symptoms of which 
are exacerbated by NSAIDs, including aspirin. Upper airway 
disease in N-ERD patients is usually CRSwNP. On average, upper 
respiratory symptoms are worse, extent of opacification on 
computed tomography (CT) scan and recurrence of nasal polyps 
after surgery are more frequent in N-ERD than in NSAIDs-
tolerant CRSwNP patients(200, 201).
The management options are essentially based on strict 
avoidance of the culprit drug and cross-reactive drugs. Patient 
education is important, since NSAIDs respiratory symptoms are 
not limited to a specific drug, but may appear after the intake 
of other, strong cyclooxygenase (COX)-1 inhibitors. Weak COX-1 
inhibitors (paracetamol) as well as preferential (meloxicam, 
nimesulide) and selective (celecoxib and etoricoxib) COX-2 
inhibitors are usually well tolerated by most N-ERD patients(201). 
In N-ERD patients, aspirin may induce a period lasting 24 to 
72 hours, in which patients are refractory to repeated aspirin 
challenges and experience clinical improvement(202). Based on 
this observation, several oral and nasal aspirin desensitization 
protocols were developed. Most widely used is the Scripps-
clinics oral aspirin desensitization protocol, in which, following 
a stepwise dose increase, 625mg aspirin is orally administered 
twice daily(203). Desensitization procedures can be performed 
in both outpatient and hospital settings and should be 
supervised by an experienced physician, but to ensure safety 
and effectiveness of desensitization, it is advised that one of 
the well-established protocols is followed with gradual dose 
increase, with at least 90-120 min intervals between doses(203).
6.1.12.2. Aspirin treatment after desensitization with oral 
aspirin
Since EPOS2012 four DBPCTs with ATAD have been performed 
(Table 6.1.12.1)(204-207). Three of these studies could be meta-
analysed to show that ATAD results in a significant and clinically 
relevant reduction of the SNOT score of 11,9 points (based on 
SNOT-22)(204-206). Pooled data analysis of the SNOT score showed 
significant benefit in the ATAD group over placebo (MD -0.54[-
0,76, -0,31], p=0.00001, three trials, 85 patients). The I2 was 0%. 
For this analysis, mean scores from SNOT-20 and SNOT-22 were 
taken for assessment (i.e. SNOT-22 scores were divided by 22 
and SNOT-20 scores were divided by 20) (Figure 6.1.12.1.). 
Also, two studies from the same group reported on a significant 
reduction in total symptoms.
Pooled data analysis of the total symptoms score (total score 
27) showed significant benefit in the ATAD group over placebo  
(MD -3.51 [-5.2-, -1.81], p=0.0001, two trials, 70 patients) (Figure 
6.1.12.2.) and Forced Expiratory Volume 1 (FEV1) (MD 6.43 [3.26-, 
9.61], p=0.0001, two trials, 70 patients) (Figure 6.1.12.3.).
Aspirin treatment after desensitization (ATAD) 
with oral aspirin is effective in improving QOL  and 
total nasal symptom score in patients with N-ERD.
The study by Fruth(207) was interesting in that it had a 36 months 
follow-up. Unfortunately, 39 out of 70 patients, 18 of the aspirin 
and 21 of the placebo group, discontinued the treatment in that 
period, although none because of side effects of the aspirin. 
In the patients that completed the full follow-up period there 
was a trend to less recurrences of polyps in the ATAD group 
compared to placebo and the ATAD groups showed significantly 
fewer overall nasal and paranasal complaints, less quality-of-
life impairment by nasal and paranasal complaints, and better 
general health condition.
6.1.12.3. Aspirin treatment after desensitization with nasal 
lysine-aspirin
Nasal administration of lysine-aspirin reduces the risk of severe 
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Mortazavi 
2017(204)
DBPCT 41 CRSwNP 
(38 analysed) 
with aspirin 
intolerance
• 650 mg of aspirin twice 
every day for 1 month 
and 325 mg of the same 
twice daily for the next 5 
months (n=19)
• Placebo (n=19)
• SNOT-22 at 6 months
• Symptom Score (0-27) at 6 months
• Medication Score at 6 months
• CT scan (LM score) at 6 months
• Serum IL-4 and IL-5
• Asthma exacerbations
In the aspirin treated group 
compared to placebo at 6 
months:
• Decreased SNOT, symptom 
score, medication score
• Higher FEV1 
• Lower serum IL-5
Esmaeilzadeh, 
2015(205)
DBPCT 34 CRSwNP 
(32 analysed) 
with aspirin 
intolerance
• 650 mg of aspirin twice 
every day for 1 month 
and 325 mg of the same 
twice daily for the next 5 
months (n=16)
• Placebo (n=16)
• SNOT-22 at 1 and 6 months
• Symptom Score at 1 and 6 months
• Medication Score at 1 and 6 months 
• CT scan (LM score) at 6 months
• FEV1 at 1 and 6 months 
• Serum IL-10, IFN-γ and TGF-β at 6 
months
• Asthma exacerbations
• Adverse events
In the aspirin treated group 
compared to placebo at 6 
months:
• Decreased SNOT and symptom 
score 
• Higher FEV1 
• No significant difference in 
other parameters measured
• 1 patient in aspirin groups had 
severe intestinal bleeding
Świerczyńska-
Krępa 2014(206)
DBPCT 34 CRSwNP 
[20 aspirin 
intolerant 
(AIA), 14 
aspirin 
tolerant (ATA)]
• 624 mg of aspirin 1dd 
for 6 months [n=18 (12 
AIA)]
• Placebo for 6 months 
[n=16 (8 AIA)]
• Nasal symptoms monthly
• SNOT20 monthly
• PNIF monthly
• Asthma Control Questionnaire (ACQ) 
monthly
• Spirometric parameters (and PEF) 
monthly 
• Blood eosinophilia monthly
• Corticosteroid doses monthly 
• Urinary leukotriene E4 and the (PG) 
D2 metabolite 9a,11b-PGF2 after 1, 3, 
5 and 6 months.
• Only the patients with AIA 
subjected to AD reported 
improvements in smell and 
reductions in sneezing and 
nasal blockade
• The SNOT20 and Asthma 
Control Questionnaire scores 
of these patients decreased, 
and their peak nasal inspiratory 
flows increased
• The dosages of inhaled 
corticosteroids were reduced
• No changes in leukotriene E4 
or 9a,11b-PGF2 levels after AD
Fruth 
2013(207)
DBPCT 6 
wks post-
operative
70 CRSwNP 
with N-ERD 
(30 evaluated) 
• After desensitization 
maintenance dose of 
100 mg daily for 36 
months (n=18)
• After desensitization 
maintenance dose of 
placebo daily for 36 
months (n=13)
• QOL (Rhinosinusitis Disability Index 
questionnaire) at 6, 12, 24 and 36 
months
• Symptoms scores (0-4) for nasal 
airway obstruction, postnasal drip, 
cephalgia, impairment of olfactory 
function
• Coughing and sneezing (0-2)
• Total symptom score (0-20)
• Smell (Sniffin’ Sticks) at 6, 12, 24 and 
36 months
• Nasal polyp score (0-3)
• Overall nasal and paranasal com-
plaints [1 (best)-7 (worst)]
• Quality-of-life impairment by nasal 
and paranasal complaints (1-7)
• General health condition (1-7)
• Revision sinus surgery
In aspirin treated group compared 
to placebo at 36 months:
• Significantly better quality of 
life score 
• Significantly lower total 
symptom score 
• Lower quality of life 
impairment by nasal and 
paranasal complaints 
• Lower overall nasal and 
paranasal complaints, quality 
of life impairment by nasal 
and paranasal complaints and 
general health condition 
• Less revision sinus surgery 
Table 6.1.12.1. ATAD in the treatment of CRS patients with N-ERD.
ACQ, Asthma Control Questionnaire; ; AD, Aspirin Desensitizatio ; AIA, Aspirin-induced Asthma ; ATA, Aspirin-tolerant Asthma ; CRSwNP, 
chronic rhinosinusitis with nasal polyps; CT, computed tomography; DBPCT, double blind placebo controlled trial; FEV1, forced expirato-
ry volume 1; IFN, interferon; IL, interleukin; LM, Lund-Mackay; N-ERD, NSAID-exacerbated respiratory disease ; PEF, Pulmonary Expira-
tory Flow ; PG, Prostaglandin ; PNIF, peak nasal inspiratory flow; QOL, quality of life; SNOT, Sino-nasal Outcome Test; TGF, Transforming 
Growth Factor . 
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Parikh 2005(211) DBPC 
cross-over 
trial
22 aspirin-
sensitive patients 
(19 CRSwNP), 11 
completed the 
full study (2 one 
phase of cross-
over)
• Incremental doses of lysine aspirin 
solution (LAS) until a dose of 16 mg 
was tolerated followed by LAS every 
48 hours for 6 months (n=11)
• Incremental doses of lysine aspirin 
solution (LAS) until a dose of 16 mg 
was tolerated followed by placebo 
every 48 hours for 6 months (n=11)
• Nasal and pulmonary symptom 
scores 
• Peak expiratory flow rate (PEFR)
• Nasal inspiratory flow (PNIF), 
• Acoustic rhinometry
• No significant 
differences 
between the 
groups
Table 6.1.12.2. Nasal lysine aspirin solution for the treatment of CRS patients with N-ERD.
Table 6.1.12.3. Low salicylate diet for the treatment of CRS patients with N-ERD.
RCT, Randomised Controlled Trial ; SNOT, Sino-Nasal Outcome ; NSSS, Nasal Symptom Severity Score; LK, Lund-Kennedy; POSE, 
Perioperative Sinus Endoscopy score ; ACQ, Asthma Control Questionnaire
Table 6.1.12.4. Prasugrel for the treatment of CRS patients with N-ERD.
CRS, Chronic Rhinosinusitis; DBPC, Double Blind Placebo Controlled
DBPC, Double Blind Placebo Controlled ; CRSwNP, Chronic Rhinosinusitis with nasal polyps; LAS, lysine aspirin solution; PEFR, peak 
expiratory flow rate; PNIF, peak nasal inspiratory flow
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Sommer 
2015(874)
Crossover 
RCT
14 aspirin-sensitive 
patients (10 
evaluated)
• 6 weeks low-salicylate 
(n=10)
• 6 weeks normal diet 
(n=10)
• SNOT-22
• Nasal Symptom Severity Score (NSSS) 
• Lund-Kennedy score
• POSE
• ACQ-7
• No significant differences 
apart from POSE
Sommer 
2016(875)
Partially 
single blind 
crossover 
RCT
30 aspirin-sensitive 
patients (27 
evaluated) including 
the patients 
from(874)
• 6 weeks low-salicylate 
(n=30)
• 6 weeks normal diet 
(n=30)
• SNOT-22
• Nasal Symptom Severity Score (NSSS) 
• Lund-Kennedy score
• POSE
• ACQ-7
• All parameters significantly 
better in patients on low-
salicylate diet
Study Methods Participants Interventions Outcomes Results
Laidlaw 
2018(876)
DBPC 
crossover 
trial
46 aspirin-
sensitive patients 
(40 evaluated), 
unclear how many 
had CRS
• Prasugrel 5 mg/d for patients weigh-
ing <60 kg or Prasugrel 10 mg/d for 
patients weighing ≥60 kg after a 60-
mg loading dose) for 4 weeks (n=40)
• Placebo for 4 weeks n=40)
• Change in the provocative dose of aspirin 
at 4 weeks 
• Changes in lung function, urinary eicosa-
noids, plasma tryptase, platelet-leukocyte 
aggregates, and platelet activation at 4 
weeks
• No 
significant 
differences
hypersensitivity reactions and the frequency of gastrointestinal 
side effects associated with oral aspirin desensitization. Some 
retrospective studies reported clinical benefit from nasal 
lysine-aspirin treatment(208-210). In a randomized, double-blind 
placebo-controlled cross over trial, N-ERD patients with positive 
nasal lysine-aspirin challenge received either 16mg nasal lysine 
aspirin or placebo every 48 hours for six months. Of 22 patients 
entering the trial, 11 were eligible for analysis. Multivariate 
analysis of measured parameters did not reveal a significant 
clinical benefit to patients receiving topical lysine-aspirin 
compared with placebo(211) (Table 6.1.12.2).
6.1.12.4. Diets
Recently two crossover RCTs evaluated the effect of a low 
salicylate diet on sinus (SNOT-22) and asthma (ACQ-7) quality 
of life. The second study contained the data of the first study. 
The second study showed significant and clinically relevant 
improvement in SNOT22 (15.5 points) and ACQ-7 (5 points). 
Also, the Nasal Symptom Severity Score, the Lund-Kennedy 
score and the POSE showed significantly better results with the 
low salicylate diet than with the normal diet (Table 6.1.12.3). 
Moreover, a cohort study was performed on the effect of a 
high omega-3/low omega-6 diet for the treatment of aspirin 
exacerbated respiratory disease (AERD)(212). The authors 
concluded that a high omega-3/low omega-6 diet may be an 
appropriate adjunct treatment option for patients with AERD.
6.1.12.5. Prasugrel
Finally, a DBPC crossover trial was performed with Prasugrel. 
Prasugrel is a platelet inhibitor and an irreversible antagonist 
of P2Y
12
 ADP receptors. The study showed no significant effects 
on change in aspirin provocation dose or lung function (Table 
6.1.12.4).
6.1.12.6. Side effects of ATAD
ATAD is associated with adverse effects (mostly gastrointestinal), 
and the incidence of adverse symptoms related to aspirin intake 
ranges from 0% to 34%(201). In order to reduce the prevalence of 
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Figure 6.1.12.2. Forest plot of the effect of ATAD versus standard treatment alone on the symptom score 
six months after start of the treatment in patients with CRSwNP.
Figure 6.1.12.1. Forest plot of the effect of ATAD versus standard treatment alone on the SNOT score 
six months after start of the treatment in patients with CRSwNP.
Figure 6.1.12.3. Forest plot of the effect of ATAD versus standard treatment alone on the FEV1 six months after start of the treatment 
in patients with CRSwNP.
adverse effects associated with aspirin treatment, appropriate 
preventive measures (Helicobacter pylori eradication, PPI, and 
H2blockers) should be introduced and continued during the 
treatment(201).
6.1.12.7. Conclusions
Oral ATAD has been shown to be significantly more effective and 
clinically relevant than placebo in improving QOL (measured 
with SNOT) and total nasal symptom score in patients with 
N-ERD. However, the change in SNOT from treating with 
oral ATAD compared to placebo did not reach the clinically 
important mean difference (CIMD) (MD -0.54[-0,76, -0,31], 
p=0.00001, three trials, 85 patients). ATAD reduced symptoms 
after six months compared to placebo (with MD -3.51 [-5.2-, 
-1.81], p=0.0001, two trials, 70 patients on a scale of 27), the 
FEV1 showed a significant reduction compared to placebo 
and the data were consistent. However, ATAD is associated 
with significant adverse effects, and the risks of not taking the 
medication strictly on a daily basis puts a burden on patient 
and caregiver. Based on these data, the EPOS2020 steering 
group suggests that ATAD can be a treatment for N-ERD patients 
with CRSwNP whenever there is confidence in the patient’s 
compliance.
Lysine aspirin and platelet inhibitors (like Prasugrel) have not 
been shown to be an effective treatment in CRSwNP patients 
with N-ERD and are not advised. Diets, like low salicylate diet 
were shown to improve endoscopic scores and may improve 
symptoms compared to a normal diet in patients with N-ERD. 
However, the quality of the data at this moment is not enough 
to draw further conclusions.
6.1.13. Antimycotics
6.1.13.1 Introduction
Although the aetiology of chronic rhinosinusitis is not fully 
understood, it may involve abnormalities in the host response to 
irritants, commensal and pathogenic organisms and allergens. 
There is much debate regarding the role of fungus in the 
aetiology of chronic rhinosinusitis. Intranasal fungus can be 
demonstratedin nearly all diseased and normal sinuses(213-215). 
Although fungi are ubiquitous in our environment, there are 
several forms of sinus disease that are associated with fungi 
as pathogens. However, rather than the fungi determining 
the disease process, it is usually the host immune state that 
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Figure 6.1.13.2. Forest plot of the effect of local antifungal treatment versus placebo on total symptom score in patients with CRSwNP 
after 2-3 months of treatment.
Figure 6.1.13.3. Forest plot of the effect of local antifungal treatment versus placebo on nasal endoscopy score in patients with 
CRSwNP after 2-3 months of treatment.
Figure 6.1.13.1. Forest plot of the effect of local antifungal treatment versus placebo on SNOT score in patients with CRSwNP after 2-3 
months of treatment.
determines the clinical presentation. The role of antifungal 
therapies in the setting of established fungal-related CRS is 
summarised in Fungal associated RS (Chapter 9.6). This chapter 
summarises the role of antimycotics in the setting of CRSwNP 
and CRSsNP.
Based on fungal detection and the presence of allergic mucus 
in almost all patients with chronic rhinosinusitis, Ponikau 
and co-authors proposed that CRS is generally caused by a 
dysregulated, but IgE independent immune response to fungal 
elements present on the mucosal surface(213). 
Consequently, reduction of fungus load should influence 
disease severity in all subtypes of CRS. This hypothesis led to a 
series of investigations, as proof of this concept of fungal-driven 
inflammation in CRS. In these studies, patients complying with 
the AAO-HNS or EPOS definitions of CRS were included(216, 
217) irrespective of the presence of eosinophilic mucus and/or 
fungus detection. In this systematic review studies of patients 
fulfilling the AAO-HNS or EPOS definitions of CRS (with or 
without nasal polyps) are evaluated. Subgroup analyses explore 
potential differences where possible.
6.1.13.2. Topical amphotericin B 
In most trials with antifungals in CRS, amphotericin B was 
applied topically, either as a nasal spray or as a nasal irrigation. 
The majority of patients included in these trials suffered from 
CRSwNP. However, the presence of nasal polyps was not 
explicitly reported in all trials. Recently a Cochrane review has 
been published evaluating the effect of topical amphotericin 
B in CRS with or without NP but not in patients that recently 
had surgery(218). The authors included eight studies (490 adult 
participants). No studies that specifically investigated the effect 
of antifungals in patients with AFRS were included (Chapter 
8.6.5.4). Seven studies (437 participants) were included that 
used amphotericin B (six studies; 383 participants). The authors 
concluded that due to the very low quality of the evidence, it is 
uncertain whether the use of topical or systemic antifungals has 
an impact on patient outcomes in adults with CRS compared 
with placebo or no treatment. In terms of adverse effects, they 
concluded that topical antifungals may lead to more local 
irritation compared with placebo. 
Local and systemic antifungal treatments do not 
have a positive effect of QOL, symptoms and signs 
of disease in patients with CRS.
We systematically reviewed the literature and included nine 
studies [627 CRS patients (373 CRSwNP;  567 CRS patients) 
completed the trials], local antifungal treatment, eight studies 
comparing amphotericin B and in one study, fluconazole nasal 
drops(219)with placebo (usually yellow coloured saline)(219-227) 
(Table 6.1.13.1.). Three studies involved patients with CRSwNP(220, 
222, 224), one study(223) involved patients with CRSsNP, and the other 
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Figure 6.1.13.4. Forest plot of the effect of local antifungal treatment versus placebo on CT scan score in patients with CRSwNP after 
2-3 months of treatment
Study Methods Participants Interventions Outcomes Results
Jiang 
2018(227)
DBPCT 79CRS 
patients (26 
CRSwNP) (73 
completed the 
trial) starting 
1 month 
postoperative 
FESS
• 50 mL of 200 μg/mL of amphotericin 
B per nostril (daily dose 20 mg) once 
a day (n=37) for 2 months
50 mL of saline (n=36)
• Taiwanese SNOT-22 at 2 
months
• Endoscopy at 2 months
• Smell test at 2 months
• Saccharine transit test at 2 
months
• Bacterial culture at 2 months
No significant difference for any 
outcome
Yousefi 
2017(226) 
DBPCT 80 CRS patients 
(40 CRSwNP) 
• 10 mL (5 mL per nostril) of 200 μg/
mL amphotericin B twice daily (daily 
dose 8 mg) for 3 months
• 10 mL placebo (5 mL per nostril) 
twice daily for 3 months
• RSOM-31 at 3 months
• VAS symptom score (for nasal 
congestion, post-nasal drip, 
reduction in the sense of smell 
and facial pain) at 3 months
• Nasal endoscopy at 13 weeks
• Blood levels of IgE,  IL- 4, IL-
5,and IL-13 
• CT and MRI
No significant difference for 
any outcome apart from facial 
pain that was better in the 
amphotericin-treated group
Hashemian 
2016(219)
DBPCT 54 CRS patients 
(21 CRSwNP) 
(48 completed 
the study)
• 12 drops per day, 2 times a day of 
fluconazole nasal drops (0.2%,) (daily 
dose 1.2 mg) for 8 wks (n = 27) 
• Placebo nasal drops (12 drops per 
day, 2 times a day) for 8 wks (n = 27)
• SNOT-20 at 8 wks
• Endoscopy at 8 wks
• CT scan at 8 wks
• Adverse effects
No significant difference for any 
outcome
Jiang 
2015(225)
DBPCT 87 CRS 
patients (33 
CRSwNP) (77 
completed the 
trial) starting 
1 month 
postoperative 
FESS
• 50 mL of 100 μg/mL of amphotericin 
B per nostril (daily dose 20 mg) once 
a day (n=37) for 2 months
• 50 mL of saline (n=36)
• Taiwanese SNOT-22 at 2 
months
• Endoscopy at 2 months
• Smell test at 2 months
• Saccharine transit test at 2 
months
• Bacterial culture at 2 months
No significant difference for any 
outcome
Gerlinger 
2009(224)
DBPCT 33 CRSwNP 
patients (30 
completed the 
trial) directly 
postoperative 
FESS
• Amphotericin B (5 mg/mL), nasal 
spray, 2 puffs per nostril (100 µl per 
nostril), twice daily (total daily dose 
= 4.8mg) for 8 wks (n=16)
• Placebo nasal spray (0.2 µg/mL  
acriflavin  chloride solution ) for 8 
wks  (n=17)
• CT scan at 8 wks
• SNAQ-11(877) at 8 wks
• Nasal endoscopy at 8 wks
No significant difference for any 
outcome
Liang 
2008(223)
DBPCT 70 CRSsNP (64 
completed the 
study)
• 250 mL of amphotericin B 
(containing 10 mg of amphotericin 
B) per nostril once daily (total daily 
dose = 20 mg) for 4 wks (n=35)
• 250 mL of placebo per nostril once 
daily (total daily dose = 20 mg) for 4 
wks (n=35)
• Chinese RSOM-31 at 2 and 
4 wks
• Endoscopy
• Fungal and bacterial cultures 
No significant difference for any 
outcome
Table 6.1.13.1. Local antifungal treatment for the treatment of patients with CRS.
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Ebbens 
2006(222)
DBPCT 116 CRSwNP 
patients (111 
completed the 
study)
• 25 mL of amphotericin B (100 µg/
mL) in 2.5% glucose applied to 
each nostril twice daily for 13 weeks 
(n=59) (daily dose 10 mg)
• 25 mL of placebo nasal lavage (3.4 
mL/L Cernevit in 2.5% glucose) 
applied to each nostril twice daily for 
13 weeks (n=57)
• RSOM-31 at 13 weeks
• Total VAS symptom score (the 
sum of VAS for nasal block-
age, rhinorrhoea, facial pain, 
postnasal drip and anosmia) at 
13 weeks
• SF36 at 13 weeks
• Endoscopy at 13 weeks
• PNIF at 13 weeks
• Levels of pro-inflammatory 
cytokines, chemokines and 
growth factors and albumin
• Adverse effects
No significant differences in any 
parameter measured
Ponikau 
2005(221)
DBPCT 30 CRS patients 
(24 completed 
the study)
• 20 mL amphotericin B solution (250 
µg/mL) per nostril twice daily for 6 
months (n=15) (daily dose 20 mg)
• 20 mL placebo solution per nostril 
twice a day for 6 months (n=15)
• SNOT-20 at 3 and 6 months
• Endoscopy at 3 and 6 months. 
• CT scan at 6 months
• Adverse effects 
• No significant differences in 
SNOT-20 at 3 and 6 months
• Significant better change 
from baseline for endoscopy 
at 3 and 6 months and for 
CT scan at 6 months in 
the amphotericin B group 
compared to placebo
• 2 patients in the amphotericin 
B group complained of 
burning
Weschta 
2004(220)
DBPCT 78 CRSwNP 
patients (60 
completed the 
study)
• Amphotericin B (3 mg/mL), nasal 
spray, 2 puffs per nostril (200 µLper 
nostril), 4 times daily (total daily dose 
= 4.8mg ) for 8 wks  (n=39)
• Placebo nasal spray: saline solution 
containing tartrazine, chinin sulfate, 
1-(4-sulfo-1-phenylazo)-2-naphthol-
6-sulfo acid, choline in 5% glucose 
solution, 2 puffs per nostril, 4 times 
daily for 8 wks (n=39)
• Rhinosinusitis quality of life 
score (RQL) (0-36) at 8 wks
• VAS for nasal blockage, facial 
pain, smell, nasal discharge 
sneezing at 8 wks
• Endoscopy at 8 wks
• CT scan at 8 wks
• Adverse events
No significant differences in any 
parameter but symptom scores 
that were better in the placebo 
treated group than in the 
amphotericin B treated group
CRS, Chronic Rhinosinusitis; CRSsNP, Chronic Rhinosinusitis without nasal polyps ; CRSwNP, Chronic Rhinosinusitis with nasal polyps; DBPCT, Double 
Blind Placebo Controlled Trial ; SNOT, Sino-Nasal Outcome ; RSOM-31, Rhinosinusitis Outcome Measure-31 ; VAS, Visual Analogue Scale ;anti IgE, 
anti-immunoglobulin E ; IL, Interleukin; CT, computed tomography; MRI, Magnetic Resonance Imaging; SNAQ, Sino-nasal Questionnaire ; SF-36, Short 
Form 36 ; PNIF, Peak Nasal Inspiratory Flow ; RQL, Rhinosinusitis quality of life score.
studies were either mixed populations or it was not clear what 
kind of CRS patients were included.
The volumes and total daily dose of local antifungal treatment 
varied and we also included three studies(224, 225, 227) that were 
performed postoperatively.
None of the studies showed a significant difference for total 
symptoms or QOL in favour of the antifungal. 
Three studies using SNOT (SNOT-22 or SNOT-20) could be 
combined in a meta-analysis (Figure 6.1.13.1).
The analysis showed a trend for placebo to have a better impact 
on SNOT score than local fungal treatment.
Two studies could be combined in a meta-analysis, showing a 
more favourable outcome in symptomatology for placebo than 
for oral antifungal treatment (Figure 6.1.13.2).
Five studies(219, 222, 225-227) could be combined into a meta-analysis 
evaluating the effect of local antifungal on nasal endoscopy. 
The analysis showed no difference between local antifungal 
treatment and placebo (Figure 6.1.13.3).
Finally, five studies could also be meta-analysed concerning 
the effect of local antifungal treatment on CT scan 
opacification(219-221, 224, 226). Also, in this analysis no significant 
difference was found between the two options (Figure 6.1.13.4).
6.1.13.3. Systemic antifungal treatment
One study evaluated the effect of systemic antifungal treatment 
with terbinafine vs. placebo (53 participants) and reported that 
there was little or no difference between the groups in disease-
specific health-related quality of life or disease severity score 
(both low-quality evidence)(886). Systemic antifungals may lead 
to more hepatic toxicity events (RR 3.35, 95% CI 0.14 to 78.60) 
but fewer gastrointestinal disturbances (RR 0.37, 95% CI 0.04 
to 3.36), compared to placebo, although the evidence was of 
low quality. This study did not find a difference in CT scan score 
between the groups. Generic health-related quality of life and 
nasal endoscopic score were not measured. 
6.1.13.3. Conclusions
Local and systemic antifungal treatments do not have a positive 
effect of QOL, symptoms and signs of disease in patients with 
CRS. The EPOS2020 steering group advises against the use of 
these treatments in patients with CRS. The EPOS2020 steering 
group advises against the use of anti-mycotics in CRS.
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6.1.14. Anti-IgE 
6.1.14. 1. Summary of the evidence 
The pathophysiology of CRSwNP is characterized by prominent 
local production of IgE that may contribute to chronic 
inflammation by continuously activating mast cells(228). Two 
randomized clinical trials(229, 230) have investigated the role of 
omalizumab, a recombinant humanized monoclonal antibody, 
in CRS management (Table 6.1.14.1). The mechanism of action 
of omalizumab involves its selective binding to free circulating 
IgE which decreases the expression of IgE receptors on mast 
cells, basophils and dendritic cells, and interferes with activation 
of these effector cells(229, 231, 232).
In the study by Gevaert et al.(229), 24 patients with CRSwNP  and 
comorbid asthma for more than two years were randomized 
to the subcutaneous administration of four to eight doses of 
omalizumab or placebo. Total serum IgE levels were between 
20 and 700 kU/mL. The subcutaneous administration of four to 
eight doses of omalizumab was not found to result in significant 
reduction in RSOM-31 or SF-36. But the physical domain of 
SF-36 and the Asthma Quality of Life Questionnaire (AQLQ) 
demonstrated a significant improvement in the omalizumab 
group, whereas no significant changes were seen in the placebo 
group. Anti-IgE resulted in significantly lower symptoms scores 
for nasal congestion (p=0.003), anterior rhinorrhoea (p=0.003), 
loss of sense of smell (p=0.004), wheeze (p=0.02) and dyspnoea 
(p=0.02) compared to baseline. Cough and spirometric results 
did not improve with anti-IgE treatment.
A linear mixed model demonstrated a lower total nasal polyp 
score (NPS) in the omalizumab group compared to the placebo 
group throughout the study period (p=0.2). Lund-MacKay scores 
were significantly better in the omalizumab group compared 
to placebo (p=0.04) on radiologic imaging. The clinical and 
radiographic improvements following use of anti-IgE therapy 
were seen independent of serum IgE levels. At 16 weeks, a 
decrease in total NPS was seen in allergic (-2.57; p= 0.03) and 
non-allergic patients (-2.75; p=0.06). An improvement in Lund-
Mackay CT scan scores was observed in the allergic patients 
(22.61, p=0.04), but this was not observed in nonallergic patients 
(20.66, p=0.75). By contrast, the total AQLQ score demonstrated 
an improvement in the nonallergic group (259.4, p=0.03), but 
not in the allergic group (212.3, p=0.12). At least one adverse 
event was observed in 22 of 23 (95.7%) included patients. The 
most commonly reported adverse event was a common cold in 
the omalizumab group which occurred at a higher rate in the 
treatment group compared to the control (p=0.02). One patient 
developed fatal lymphoblastic lymphoma in the omalizumab 
group one year following the study. Of note, four of eight (50%) 
of patients in the control group were excluded from the analysis.
Pinto et al.(230) conducted a randomized, double-blind, placebo-
controlled trial of anti-IgE for CRS in 14 patients (12 of 14 
with CRSwNP) refractory to standard treatment. Participants 
were required to have a serum total IgE between 30 - 700 IU/
ml. All patients received omalizumab, 0.016 mg/ kg per IU 
subcutaneously, or placebo injections every two to four weeks 
for six months. There was no significant net difference in SNOT-
20 scores across treatments (median omalizumab –5.5, placebo 
–2.3, p < 0.60). The median change in SNOT-20 scores across 
the study period was consistent with a clinically significant 
improvement (defined as at least 0.8) in the omalizumab group 
and no clinically significant change in the placebo group 
(-1.05 vs. -0.20, p<0.78). There were no significant differences 
between treatments for any domain except for vitality 
(omalizumab 9.4, placebo 12.5, p < 0.05). Similarly, there were 
no statistical differences in total University of Pennsylvania Smell 
Identification Test (UPSIT) score, nasal endoscopy scores, sinus 
opacity in CT scan, median change in percent eosinophils in 
nasal lavage, median PNIF), and median total nasal symptom 
scores between the omalizumab and placebo groups. Patients 
on omalizumab used fewer courses of steroids over the trial 
(median 0 vs. 1, p<0.043) and less use of antibiotics (0 vs. 1, 
p<0.32) compared to placebo. No side effects or adverse events 
occurred during the study. The investigators were limited by 
poor subject recruitment due to perceived risk of placebo, high 
time commitment, high patient volume not meeting study 
inclusion criteria and a U.S. Food and Drug Administration 
(FDA)-issued warning about anaphylaxis associated with 
omalizumab.  Recent unpublished data point to a significant 
impact on baseline in nasal polyp score and change from 
baseline in average daily nasal congestion score, SNOT-22 and 
sense of smell.  
Concerning side effects, at this moment there is a vast 
experience with anti-immunoglobulin-E (IgE) treatment 
indicating a very small chance of anaphylaxis(233) but some 
indication of an association with arterial and venous 
thromboembolic events leading to cardiovascular and 
cerebrovascular accidents(234).
6.1.14.2. Conclusion
Anti-IgE therapy has been proposed as a promising biologic 
therapy for CRS. Two RCTs that evaluated anti-IgE monoclonal 
antibody included patients with serum IgE levels between 20 
kU/mL and 700 kU/mL and compared omalizumab (0.016 mg/
kg per IU total serum IgE/mL; max dose of 375 mg) to placebo. 
Both these small studies (<30 patients) did not show impact 
on disease specific QOL but one study did show an effect 
on the physical domain of SF-36 and AQLQ(229). One study(229) 
demonstrated lower symptom scores (change from baseline in 
anti IgE group) for nasal congestion, anterior rhinorrhoea, loss 
of sense of smell, wheeze and dyspnoea, a significant reduction 
of NPS on endoscopic examination, and Lund-MacKay scores 
on radiologic imaging. Due to the small study population in the 
existing studies, further studies with larger population sizes are 
needed and are underway. The available data are insufficient to 
advise on the use of anti-IgE in CRSwNP at this moment. 
6.1.15. Anti-IL5 
6.1.15.1. Summary of the evidence
Previous treatment of CRS has included both topical and 
systemic corticosteroids, long-term antibiotics, and surgical 
intervention. However, some patients have recalcitrant disease 
despite utilization of best practices. Interleukin 5 (IL-5) is 
essential for final differentiation into an eosinophil and prolongs 
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Table 6.1.14.1. Anti-IgE therapy for the treatment of patients with CRSwNP.
Study Methods Participants Interventions Outcomes Results
Gevaert et al. 
2013(229)
DBPRCT 24 patients 
(>18 years) 
with CRSwNP
• Omalizumab 
every 2 weeks/8 
injections in 
total or every 
4 weeks/4 in-
jections in total 
based on total 
serum IgE levels 
and body weight 
(maximum 
dose of 375mg) 
(n=16)
• Placebo (n=8)
At 16 weeks:
• Quality of life question-
naires (RSOM-31, AQLQ, 
SF-36)
• symptoms score 
• Total endoscopic polyp 
score 
• Lund-Mackay CT score 
• Spirometric results
•  Adverse events 
Anti-IgE compared to placebo resulted in:
• No significant impact on QOL but significant im-
provement compared to baseline of anti-IgE treated 
group for AQLQ, physical domain of SF-36 and some 
subdomains of RSOM-31
• Lower symptoms scores (change from baseline in anti 
IgE group) for nasal congestion, anterior rhinorrhea, 
loss of sense of smell, wheeze and dyspnea 
• Reduction of polyp size on endoscopic examination 
• Improvement in Lund-MacKay scores 
• Increased common colds (p=0.02)
• One event of fatal lymphoblastic lymphoma in 1 year 
following the study
Subgroup group analysis of allergic vs non-allergic 
patients demonstrated:
• A decrease in total polyps score in allergic (-2.57; p= 
0.03) and non-allergic patients (-2.75; p=0.06). 
• Improvement in Lund-Mackay CT scan scores was 
observed in the allergic patients (22.61, p=0.04), but 
not observed in nonallergic patients. 
• Improvement in total AQLQ score in the nonallergic 
group (259.4, p=0.03), but not in the allergic group 
(212.3, p=0.12)
Pinto et al. 
2010(230)
DBPRCT 14 patients 
with CRS
(12 CRSwNP, 
2 CRSsNP)
7 patients received 
omalizumab (0.016 
mg/kg per IU total 
serum IgE/mL 
subcutaneously)
7 patients received 
placebo injections
• SNOT 20 at month 1, 2, 
3, 4, 5, 6
• SF-36 at 6 months
• Total nasal symptom 
score (nasal obstruction, 
nasal discharge, facial 
pain, hyposmia, 0-4 each) 
at 6 months
• UPSIT at 6 months
• Sinus CT % opacification 
at 6 months
• Nasal endoscopy polyp 
score at 6 months
• PNIF at 6 months
• Use of rescue medica-
tions at 6 months
• Nasal lavage for eosino-
phil counts at 6 months
• Adverse events at 6 
months
Omalizumab compared to placebo resulted in:
• No significant difference in SNOT-20 or SF-36
• Increased median change in sinus opacity in coronal 
CT scans 
• Fewer courses of steroids over the trial (median 0 vs 1, 
p<0.043) 
• Less use of antibiotics (0 vs 1, p<0.32)
• No significant net difference in SNOT-20 No side 
effects or adverse events in either treatment group
CRSwNP,Chronic Rhinosinusitis with nasal polyps; RSOM-31, Rhinosinusitis Outcome Measure-31; AQLQ, Asthma Quality of Life Ques-
tionnaire; SF-36, Short Form 36; QOL, Quality of Life; IgE, Immunoglobulin E; CRS, Chronic Rhinosinusitis; CRSsNP, Chronic Rhinosi-
nusitis without nasal polyps; SNOT, Sino-Nasal Outcome; UPSIT, University of Pennsylvania Smell Identification Test; PNIF, Peak Nasal 
Inspiratory Flow.
survival of the mature cell in the tissue(235). IL-5 has been noted 
to be elevated in nasal polyp tissue, and therefore has made it 
a potential target for the management of patients with non-
allergic asthma and CRSwNP(236, 237). A few drugs have undergone 
testing and been available on the market, for the purpose of 
this review we will discuss mepolizumab and reslizumab, both 
blockers of free IL-5, as they have undergone randomized 
controlled trial testing. RCT studies on benralizumab, a blocker 
of IL-5Rα, are ongoing. 
Three placebo-controlled studies(238-240) evaluating anti-IL5 
monoclonal antibodies were identified. Two of these studies 
evaluated mepolizumab(238, 239), while one study evaluated 
reslizumab(240). Despite, these studies being placebo-controlled 
trials, the data was unable to be pooled for meta-analysis, 
therefore each paper will be discussed below (Table 6.1.15.1.). 
Bachert et al.(238)evaluated the efficacy of mepoluzimab in 
patients with CRSwNP who were also on INCS (FPNS 200µg). 
All patients were given an infusion every four weeks for a total 
of six doses of either mepolizumab 750mg or placebo. Efficacy 
was measured as the number of patients who no longer needed 
revision surgery based upon VAS scores of CRS severity and NPS 
following the implementation of mepolizumab. Assessments of 
other QOL, symptoms, and lung function were also completed. 
One-hundred-and-five patients were initially included and 
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74 ultimately completed treatment through to week 25 for 
assessment. More patients in the mepolizumab group no longer 
met the criteria for surgery when compared to those in the 
placebo group at week 25 (ITT, 16(30%) vs. 5 (10%);p=0.006). 
There were also significant differences in VAS scores for 
rhinorrhoea, nasal blockage, mucus, and loss of smell (treatment 
difference: -2.3(-3.4 to -1.2); p<0.001, -1.8(-2.9 to -0.7); p=0.002, 
-2.1(-3.2 to -1.0); p<0.001, -1.9(-2.9 to -0.9);p<0.001). SNOT-22 
scores also significantly improved in the mepolizumab group 
at weeks 25 (treatment difference: -13.2(-22.2 to -4.2); p=0.005). 
There was statistical benefit in PNIF at 25 weeks (treatment 
difference: 26.7(3.1 to 50.2); p=0.027), but no statistical 
difference in olfaction or pulmonary function testing. There 
were no significant differences in adverse events. 
Gevaert et al.(239) performed a double blind, placebo-controlled 
trial evaluating the effect of mepolizumab on nasal polyposis 
in 30 patients with grade 3 or 4 polyps or those who had 
recurrence following surgery. Patients received either 750mg 
of mepolizumab or placebo via IV injection 28 days apart from 
two doses. Patients were assessed for changes in symptom 
scores, NPS, CT scores, PNIF, and biological activity (defined 
as blood eosinophil counts, cytokine measurements in nasal 
secretions). Safety and adverse events data was also collected. 
The mepoluzimab group showed no significant difference in 
symptoms but had a greater change from baseline polyp score 
resulting in a significant treatment difference when compared to 
placebo (-1.30(1.51); p=0.028). There was a significant reduction 
in the mepolizumab treated group when compared to placebo 
in blood eosinophil counts, serum eosinophil cationic protein 
(ECP) levels, and serum IL-5Rα between the groups (raw data not 
available). There was no difference in the nasal ECP, IL-5, or total 
IgE levels.
Gevaert et al.(240) performed a double blind, placebo-controlled, 
two-centre safety and pharmacokinetics study evaluating 
reslizumab in 24 patients with CRSwNP. Biologic activity of 
the monoclonal antibody was assessed via endoscopic NPS, 
sinonasal symptoms, peripheral eosinophils, peripheral and 
local eotaxin levels, ECP, and IL5 levels. Patients (n=24) were 
divided into three groups: receiving 1mg/kg of reslizumab, 
3mg/kg of reslizumab, or a placebo via IV for one dose. Adverse 
events and safety data were also obtained. Twenty-three (95.8%) 
subjects reported at least one adverse event, which was most 
often a URI. There was no significant difference in symptom 
scores or peak nasal inspiratory flow in both treatment groups 
compared to placebo. The NPS was only significantly less at 
week 12 in the 1mg/kg treatment group compared to baseline 
values. However, this study was not powered to determine 
differences in efficacy variables. Reslizumab caused a significant 
decrease in blood eosinophil counts in both treatment groups 
when compared to the placebo group. These results were 
evident as early as 12 hours following administration. Similar 
findings were also true of serum ECP and IL5Rα, however, 
eosinophil counts did undergo significant rebound in both 
treatment groups at week 24 and 32 following treatment 
administration.
6.1.15.2. Safety
The only data that was able to be pooled for meta-analysis was 
the number of patients who suffered from an adverse event. 
There was no statistical significance between the placebo and 
anti-IL-5 monoclonal antibody group (SMD 0.72(0.29,1.77), 
p=0.48, two trials, 129 patients) (Figure 6.1.15.1.). 
Unlike in CRS, there is a significant experience with anti-Il5 in 
other Th2 driven diseases like asthma that do show a favourable 
safety profile for the time used until now(241-244). In all these 
studies, patients had previously undergone conventional 
therapy including sinus surgery and topical corticosteroid 
irrigations with these medications reserved as a treatment 
option for patients who are considered recalcitrant despite best 
efforts. This is an important adjunct to our armamentarium for 
treatment of these difficult to control CRS patients. The relative 
position of the different monoclonal antibodies one to another 
has to be determined.
6.1.15.3. Conclusion
At the moment the only anti-Il-5 treatment studied in CRS is 
mepolizumab. There is only one large sufficiently powered study 
that showed a  significant reduction in patients’ need for surgery 
and an improvement in symptoms. The EPOS2020 steering 
group advises use  of mepolizumab in patients with CRSwNP 
fulfilling the criteria for treatment with monoclonal antibodies 
(245) (see chapter 1).
Dupilumab is the only monoclonal antibody that 
is approved for the treatment of CRSwNP at the 
moment.  The panel advises to use dupilumab 
in patients with CRSwNP fulfilling the criteria for 
treatment with monoclonal antibodies.
Figure 6.1.15.1. Forest plot of the effect of anti-IL-5 biologics versus placebo on adverse events in patients with CRSwNP.
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Study Methods Participants Interventions Outcomes Results
Bachert 
2017(238)
DBPCT 105 Severe 
CRSwNP
Mepolizumab 750 
mg IV 4 weeks x 6 
months (n=54) v 
placebo infusion q 
4 weeks x 6 months 
(n=53)
Assessed at 25 weeks
• Number of patients no longer 
needing revision surgery
• VAS polyp severity (0-10),
• Endoscopic polyp score (0-8)
• Symptom scores - VAS symp-
toms - (rhinorrhoea, mucus, nasal 
blockage, loss of sense of smell), 
SNOT22, EQ-5D, PNIF, olfaction 
(0-12)
• Eosinophils
• FEV1/FVC/PEFR 
• Patients in the mepolizumab group no longer 
met criteria for surgery compared to placebo 
(ITT< 16(30%) vs 5(10%);p=0.006)
• Significant improvement in the mepolizumab 
group for VAS scores (rhinorrhoea, mucus, nasal 
blockage, and loss of smell, in SNOT22 (28.8(22) 
vs 38.2(24.5), and PNIF (mean difference, 26.7(3.1-
50.2), p=0.027)
• Significant improvement in the mepolizumab 
group over placebo in nasal polyp severity VAS 
scores (mean change; -1.8(-2.9-0.8), p=0.001
• Blood eosinophils decreased in the mepolizumab 
group, but not placebo group.
• No difference in EQ-5D scores, smell scores, or 
lung function between the groups.
Gevaert 
2011(239)
DBPCT 30 Severe 
or recurrent 
CRSwNP
Mepolizumab 
750mg IV 4weeks 
x 2 doses (n=20) v 
placebo q4weeks x 
2 doses (n=10)
Assessed at 8 weeks
• Nasal polyp score (0-8)
• CT scan (improved, worse, no 
change)
• PNIF
• Symptom score - anterior rhinor-
rhoea, nasal obstruction, PND, loss 
of smell (0-12)
• Biological activity (peripheral 
blood eosinophil counts, serums 
ECP, serum IL5Rα, nasal ECP, IL5, 
IgE).
• No significant changes in symptom scores
• Significant improvement in total polyp score at 
week 8 (treatment difference of -1.3(SD, 1.51), 
p=0.028) with increased improvement in the me-
polizumab group (60% v 10%, OR 13.5, p=0.018)
• Improved change from baseline in PNIF in mepo-
lizumab group compared to placebo (raw data 
not available)
• Significant reduction in blood eosinophil counts, 
serum ECP levels, and serum IL5Rα in the mepoli-
zumab group, but not in nasal ECP, IL5, or IgE
Gevaert 
2006(240)
DBPCT 24 CRSwNP Reslizumab 3mg/
kg (n=8) or 1mg/
kg (n=8) x 1 dose v 
placebo (n=8)
Assessed at 4 weeks
• Endoscopy polyp size (0-8)
• Symptoms (anterior rhinorrhoea, 
nasal obstruction, PND, loss 
of sense of smell) (scoring not 
obvious)
• Nasal peak inspiratory flow
• Eosinophil count (local and pe-
ripheral), ECP (local and peripher-
al), eotaxin (local and peripheral), 
IL5 (local and peripheral)
• No significant improvement in symptom scores 
or nasal peak inspiratory flow
• Nasal polyp score was significantly decreased 
at 1 time point for 1mg/kg group (raw data not 
available)
• Significant decrease in blood eosinophils, serum 
ECP, and soluable IL5Rα (raw data not available)
Table 6.1.15.1. Anti-IL-5 for the treatment of patients with CRSwNP.
CRSwNP, Chronic Rhinosinusitis with nasal polyps; PND, post nasal drip, ECP, eosinophil cationic protein; PNIF, peak nasal inspiratory flow; DBPCT, 
double blind placebo controlled trial; OR, Odds ratio; SD , Standard deviation; FEV1, forced expiratory volume 1; FVC, Forced Vital Capacity, PEFR, Peak 
Expiratory Flow Rate; SNOT, Sino-Nasal Outcome.
6.1.16. Anti-IL4/IL13 
6.1.16.1. Summary of the evidence
IL-4 and IL-13 are potent mediators of type 2 immunity with 
both overlapping and distinct functions. IL-13 and IL-4 partly 
share the same receptor and signalling pathways and both 
are deeply involved in IgE synthesis, eosinophil activation, 
mucus secretion and airways remodelling. IL-4 is a major 
differentiation factor driving a TH2 type response by initiating T 
cell differentiation toward the TH2 subtype. IL-4 also induces the 
production of type 2 associated cytokine and chemokines such 
as IL-5, IL-9, IL-13, TARC and fotaxin. Furthermore, IL-4 and IL-13 
are primarily responsible for isotype class switching of B cells to 
produce Ig(246).
6.1.16.1.1. Dupilumab
There is recent data on the efficacy of dupilumab in CRSwNP 
(Table 6.1.16.1). Dupilumab is a fully human monoclonal 
antibody to the IL-4 receptor a subunit, which inhibits signaling 
of IL-4 and IL-13 that is given as a subcutaneous injection.  
There are no other RCT’s performed in patients with CRSwNP 
with the other anti-IL-4/IL-13 agents such as Tralokinumab and 
Lebrikizumab-IL-13. 
Bachert et al.(247) performed a proof of concept double blinded, 
placebo controlled parallel group study in 2013, which 
randomized 60 adult CRSwNP into two groups. After a four-
week run-in period of treatment with mometasone, patients 
were randomly allocated to add-on therapy with subcutaneous 
dupilumab (600mg loading followed by 15 weekly doses of 
300mg) or matched placebo for 16 weeks. Patients treated 
with dupilumab had significant improvement in SNOT-22, 
rhinosinusitis disease severity (VAS), nasal blockage, UPSIT smell 
score, nasal polyp score (NPS), and CT score (LMS), and asthma 
outcomes (FEV
1
 and control) compared to placebo. 
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Bachert et al.(248)published the results of two randomised 
double-blind, multicentre, placebo-controlled, parallel 
group phase 3 trials which evaluated dupilumab added to 
standard-of-care in adults with severe CRSwNP. In the liberty 
NP SINUS-24 study, patients were randomized 1:1 to 24 weeks 
subcutaneous dupilumab 300mg or placebo every two weeks. 
Liberty NP SINUS-52, patients were randomized 1:1:1 to 52 
weeks dupilumab 300mg every two weeks, 24 weeks every two 
weeks then 28 weeks dupilumab 300mg every four weeks, or 
52 weeks placebo every two weeks. In both studies, treatment 
with dupilumab significantly improved SNOT-22, rhinosinusitis 
disease severity (VAS), nasal blockage, UPSIT smell score, NPS, 
LMS, and asthma outcomes (FEV
1
 and control) compared to 
control.
There was one study from Wenzel et al.(249) evaluating SNOT-22 in 
a group of patients with persistent, moderate-to-severe asthma 
and eosinophilia. Unfortunately, it was not evaluated whether 
these patients actually had CRS so we could not include the 
study. Four posthoc studies have been performed that are not 
taken into account in this meta-analysis(250-253).
The Bachert studies were very much done in the same way and 
could be combined into a meta-analysis of the three studies 
evaluating dupilumab added to standard-of-care treatment to 
patients with CRSwNP(247, 248).
The SNOT-22 score (scale 0-110) at 4-6 months showed a 
significant and clinically relevant decrease of MD - 19.61 (95% CI 
-22.53 -  -16.69); 784 participants; two studies; I2 = 0%), (Figure 
6.1.16.1).
The Rhinosinusitis disease severity (VAS) at 4-6 months showed 
a significant and clinically relevant decrease of MD – 2.54 (95% 
CI -2.84 - -2.23); 784 participants; two studies; I2 = 40%), (Figure 
6.1.16.2).
The nasal congestion/obstruction score at 4-6 months showed 
a significant and clinically relevant decrease of MD – 0.86 (95% 
CI -0.98 - -0.75); 784 participants; two studies; I2 = 0%), (Figure 
6.1.16.3). 
Smell was evaluated using the UPSIT. The UPSIT score at 4-6 
months showed a significant and clinically relevant decrease of 
MD 10.83 (95% CI 9.59 – 12.08); 784 participants; two studies; I2 
= 0%), (Figure 6.1.16.4).
The nasal polyp score was the primary endpoint in these studies. 
The mean nasal polyp score in these studies was around 6 
indicating severe polyp disease. The nasal polyp score at 4-6 
months showed a significant decrease of MD -1.79 (95% CI 
-2.01 – -1.56); 784 participants; two studies; I2 = 65%), (Figure 
6.1.16.5). 
The Lund-Mackay score (scale 0-48) at 4-6 months showed a 
significant decrease of SMD -1.50 (95% CI -1.84 –  -1.16); 784 
participants; two studies; I2 = 71%), (Figure 6.1.16.6).
Finally, there was a significant impact on ACQ and FEV1. Because 
ACQ5 and ACQ6 were used, the data could not be combined 
into a meta-analysis but both studies showed a significant 
improvement over placebo. The FEV1 could be combined into a 
meta-analysis and showed a significant improvement in FEV1 (l) 
at 4-6 months of MD 0.21 (95% CI 0.20 – 0.22); 488 participants; 
two studies; I2 = 0%), (Figure 6.1.16.7).
The most common adverse events (nasopharyngitis, worsening 
nasal polyps and asthma, headache, epistaxis, injection-site 
erythema) were more frequent with placebo. When evaluating 
all trials with dupilumab the drug seems to induce conjunctivitis 
in trials in patients with atopic dermatitis but no trials with 
asthma and CRSwNP(254). No other adverse events have been 
reported in the literature up until now. 
6.1.16.2. Conclusion
Dupilumab is the only monoclonal antibody that is approved for 
the treatment of CRSwNP at the moment.  The panel advises to 
use dupilumab in patients with CRSwNP fulfilling the criteria for 
treatment with monoclonal antibodies(245).
6.1.17. Probiotics
6.1.17.1. Summary of the evidence
A locally disturbed commensal microbiome might be an 
aetiological factor in chronic rhinosinusitis. Despite significant 
heterogeneity in study design, tissue sampling, processing 
and bioinformatics analysis, consistent findings have emerged 
from the recent literature. Healthy individuals and CRS patients 
have similar overall bacterial burden of disease and share 
many common phyla. CRS patients, however, routinely show 
reductions in markers of biodiversity. Both medical and surgical 
treatments appear to influence the sinonasal microbiome, 
with certain bacterial strains associated with better treatment 
outcomes. The presence of microbial dysbiosis in CRS is now 
supported by numerous studies. Whether this dysbiosis is a 
cause or rather an association of the disease process remains 
unclear(255, 256). 
We identified two studies on probiotic therapy, one oral(257) and 
one evaluating a nasal spray(258) (Table 6.1.17.1.). Both studies 
evaluated SNOT and showed no significant difference between 
probiotic and placebo. The study of Mukerji et al. showed a 
significant reduction in SNOT-20 and symptoms after four weeks 
of treatment in the probiotic group and not the placebo group 
compared to baseline, but the differences between the groups 
were not significant and the change from baseline was not 
found after eight weeks. 
Also, no differences in the bacteria cultured or inflammatory 
mediators were found. 
6.1.17.2. Conclusion
Although probiotic therapies show theoretical promise, the 
two studies performed so far did not show any differences 
compared to placebo. For this reason, the EPOS2020 steering 
group advises against the use of probiotics for the treatment of 
patients with CRS.
6.1.18. Muco-active drugs
6.1.18.1. Summary of the evidence
Mucoactive drugs are regularly used as a therapeutic 
option for mucus alteration, including hypersecretion. The 
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Figure 6.1.16.2. Forest plot of the effect of Dupilumab versus placebo on the rhinosinusitis disease severity (VAS) in CRSwNP patients 
at 4-6 months.
Figure 6.1.16.5. Forest plot of the effect of Dupilumab versus placebo on the change in nasal polyp score in CRSwNP patients at 4-6 
months.
Figure 6.1.16.3. Forest plot of the effect of Dupilumab versus placebo on the change in nasal congestion/obstruction score in 
CRSwNP patients at 4-6 months.
Figure 6.1.16.1. Forest plot of the effect of Dupilumab versus placebo on SNOT-22 score in CRSwNP patients at 4-6 months.
Figure 6.1.16.4. Forest plot of the effect of Dupilumab versus placebo on UPSIT score in CRSwNP patients at 4-6 months.
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Figure 6.1.16.7. Forest plot of the effect of dupilumab versus placebo on the change in FEV1 in CRSwNP patients at 4-6 months.
Figure 6.1.16.6. Forest plot of the effect of dupilumab versus placebo on the Lund-Mackay score in CRSwNP patients at 4-6 months.
Table 6.1.16.1. Dupilumab for the treatment of patients with CRSwNP.
Study Methods Participants Interventions Outcomes Results
Bachert 
2019(248)
2x DBPRCT SINUS-24: 
276 CRSwNP 
patients
SINUS-52:
448 CRSwNP 
patients
pts 
SINUS-24:
• Dupilumab (300mg q2w) for 24 weeks 
(n=143)
• 1 placebo for 24 weeks (n=133)
SINUS-52:
• Dupilumab 300mg every 2 week for 52 
weeks (n=150)
• Dupilumab 300mg every 2 week for 24 
weeks then 300 mg every 4 weeks for 
28 weeks (n=145)
• Placebo every 2 week for 52 weeks 
(n=153)
• Both studies 4 weeks run-in and during 
the trial mometasone nasal spray 100 
μg in each nostril twice daily
At 24 and 52 weeks:
• SNOT-22
• Rhinosinusitis disease 
severity (VAS)
• Nasal congestion 
• Smell (UPSIT)
• Nasal polyp score (NPS)
• CT scan (LMS) 
• ACQ5
• FEV1
Dupilumab resulted in significant 
improved outcomes in both studies 
compared to placebo at 24 and 52 
weeks:
• SNOT 22 
• Rhinosinusitis disease severity (VAS)
• Nasal congestion 
• Smell (UPSIT)
• NPS
• LMS
• ACQ5
• FEV1
Bachert 
2016 (247)
DBPRCT 60 CRSwNP 
patients 
refractory to 
INCS 
• Dupilimab (600mg loading, 300mg 
weekly) (n=30)
• Placebo (n=30)
• 4 weeks run-in and during the trial 
mometasone nasal spray 100μg in 
each nostril twice daily
At 16 weeks:
• QOL (SNOT-22)
• Rhinosinusitis disease 
severity (VAS)
• Nasal congestion 
• Smell (UPSIT)
• Nasal polyp score (NPS)
• CT scan (LMS)
• ACQ6
• FEV1
Dupilumab resulted in significant 
improved outcomes in both studies 
compared to placebo at 16 weeks:
• SNOT 22
• Rhinosinusitis disease severity (VAS)
• Nasal congestion 
• Smell (UPSIT)
• NPS
• LMS
• ACQ6
• FEV1
DBPRCT, Double Blind Placebo Controlled Trial; CRSwNP, Chronic Rhinosinusitis with nasal polyps; pts,patients; SNOT, Sino-Nasal 
Outcome; VAS, Visual Analogue Scale; UPSIT, University of Pennsylvania Smell Identification Test; NPS, Nasal Polyp Score; LMS, 
Lund-Mackay Score; ACQ5, Asthma Control Questionnaire 5 ; FEV1, Forced Expiratory Volume; INCS, Intranasal corticosteroids spray; 
QOL, Quality of Life; ACQ6, Asthma Control Questionnaire 6;
EPOS 2020
265
Table 6.1.17.1. Probiotics for the treatment of patients with CRS.
CRS, Chronic Rhinosinusitis; CRSsNP, Chronic Rhinosinusitis without nasal polyps ; DBPC, Double blind placebo controlled; DBPCT, 
Double Blind Placebo Controlled Trial ; SNOT-22, Sino-Nasal Outcome Test-22 ; SNOT-20, Sino-Nasal Outcome Test-20.
Study Methods Participants Interventions Outcomes Results
Martensson 
2017(258)
DBPC 
crossover 
trial with at 
least 4 wks 
washout
21 CRSsNP 
patients
• Nasal spray containing LAB (a mixture of 9 
lactobacilli and 4 bifidobacteria) for 14 days
• Placebo nasal spray for 14 days
• SNOT-22
• Microbiology
• Inflammatory mediators in 
nasal lavage fluid
• No significant 
differences in any 
parameter evaluated
Mukerij 
2009(257)
DBPCT 77 CRS 
patients 
• Probiotic Lactobacillus rhamnosus R0011 
strain (500 million active cells/tablet) twice 
daily for 4 weeks (n = 39) 
• Oral placebo treatment twice daily for 4 
weeks (n = 38)
At 4 and 8 weeks:
• SNOT-20
• Symptoms
• No significant 
differences between 
probiotic and placebo
drugs can be divided into expectorants (like hypertonic 
saline), mucoregulators that regulate mucous secretion (like 
carbocisteine and anticholinergic agents), mucolytics that 
decrease mucous viscosity (like N-acetylcysteine, erdosteine 
and DNase) and mucokinetics: drugs that increase mucociliary 
clearance by acting on the cilia (like bronchodilators and 
surfactants).
Evaluation in the lower airways has shown that treatment 
with mucolytics may produce a small reduction in acute 
exacerbations and a small effect on overall quality of life in 
patients with chronic bronchitis or COPD(259). Small benefits of 
mannitol, inhalation of normal and hypertonic saline has been 
found in patients with chronic lung diseases outside CF(260). 
Adverse effects of rhDNase on lung function suggest this should 
not be administered in non-CF bronchiectasis(260).
Data in CRS patients are very limited (Table 6.1.18.1.). There is 
one RCT evaluating the addition of S-carboxymethylcysteine 
(1500mg/day) to clarithromycin (200mg/day)(261). The authors 
found no significant differences in effect on SNOT-20 or CT scan 
at 12 weeks but a significantly higher percentage of patients 
with a remarkably effective symptomatic response at 12 weeks, 
but not at four and eight weeks and also a significantly higher 
percentage of patients with improved characteristics of nasal 
discharge and reduced post-nasal discharge. There were slightly 
more adverse events than with clarithromycin alone, but none 
were serious.
A second study is a non-randomized prospective non-
interventional study evaluating the effect of erdosteine(262).
Erdosteine was originally developed as a mucolytic agent. 
Moreover, it has also been shown to have anti-bacterial, anti-
oxidant and most importantly anti-inflammatory effects(262, 263).
6.1.18.2. Conclusion
Data on the effect of muco-active agents in CRS are very limited. 
The only DBPCT showed a significantly higher percentage of 
patients with effective response and improved characteristics 
of nasal discharge at 12 weeks. The EPOS2020 steering group 
considered the quality of the data insufficient to advise on the 
use of muco-active agents in the treatment of patients with CRS.
6.1.19. Herbal treatment
6.1.19.1. Summary of the evidence
Herbal medicine represents a relatively frequently used 
complementary and alternative treatment for CRS. However, the 
safety and efficacy of herbal medicine for the treatment of CRS is 
currently uncertain. Most of the studies are not randomized. 
We found five RCTs: four with a local application(264-267)and one 
very large study with the tablet BNO 1016(268). 
BNO 1016 has been established for use in patients with 
acute rhinosinusitis and is marketed under the brand name 
‘Sinupret extract CT’. It contains the dry extract of five herbal 
drugs, namely gentian root, primula flower, sorrel herb, elder 
flower, verbena herb, in a ratio of 1:3:3:3:3. The efficacy in acute 
rhinosinusitis has been demonstrated in a randomised, placebo-
controlled trial(269).
A DBPCT with 929 patients examined BNO 1016 (Sinupret 
extract) in CRS. Two different Sinupret extract doses (240mg 
or 480mg daily) were compared to placebo, with a treatment 
period of 12 weeks. The primary endpoint was the mean 
Major Symptom Score (MSS) in weeks 8 and 12 of treatment. 
Secondary endpoints included symptom severity by VAS, 
work activity and QOL (SNOT-20 score).  Sinupret extract was 
not superior over placebo regarding the primary endpoint. 
However, in patients with a diagnosis of CRS for >1 year and a 
baseline MSS >9 (out of max 15) a post-hoc sensitivity analysis 
showed a significant benefit in MSS and work activity (WPAI:GH) 
at 12 weeks of treatment with the use of Sinupret extract when 
compared to placebo(268). In total, 1,215 adverse events were 
reported by 528 (57.0%) patients during the treatment period, 
most of mild to moderate intensity. A relationship with the 
study drug was suspected in 18 patients (5.9%) treated with 
the 480mg Sinupret extract, 14 patients (4.4%) treated with 
240mg and in 12 patients (3.9%) who received placebo. The 
most common drug-related adverse events reported for the 
480mg, 240mg and placebo were upper abdominal pain (1.3%, 
1.3%, 0.7%), diarrhoea (0.3%, 0.6%, 1.3%) and headache (1.3%, 
0.3%, 0.7%). Adverse events led to discontinuation in 20 patients 
(total 2.2%, 1.6% in placebo group, 2.0% in 240mg and 3.0% 
in 480 mg). Serious adverse events were noted in 11 patients 
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Table 6.1.18.1. Muco-active drugs for the treatment of patients with CRS.
Study Methods Participants Interventions Outcomes Results
Hoza 
2013(262)
Non-
randomized 
prospective 
non-
interventional 
post-
authorisation 
study
60 CRSwNP 
patients
• Erdosteine 300mg twice 
a day for the period of 3 
months (n=33)
• Erdosteine 300mg twice 
a day combined with 
mometasone nasal spray 
(dosage unknown) for the 
period of 3 months (n=27)
• SNOT-22
• NPS
• Adverse events
• After 3 months the erdosteine only 
group compared to the erdosteine and 
mometasone groups had significantly 
better change in SNOT-22 and polyp 
score
• There was no difference in adverse 
events and adverse events were mild
Majima 
2012 (261)
RCT 425 CRS 
(318 
analysed)
• Clarithromycin (200mg/day) 
for 12 weeks (n=213)
• Clarithromycin (200mg/
day) and S-carboxymeth-
ylcysteine (1500mg/day; 
combination group) for 12 
weeks (n=212)
• SNOT-20 at 12 weeks
• CT scan at 12 weeks
• % of patients with remark-
ably effective or effective 
response at 4, 8 and 12 
weeks
• % of patients with im-
provement of endoscopy
• Adverse events
• No significant difference in effect of 
SNOT-20 or CT scan at 12 weeks
• Significantly higher % of patients 
with remarkably effective or effective 
response at 12 weeks, but not at 4 and 
8 weeks
• Significant higher % of patients with im-
proved characteristics of nasal discharge 
and reduced post-nasal discharge
• No serious adverse events
CRS,Chronic Rhinosinusitis; CRSwNP, Chronic Rhinosinusitis with nasal polyps; SNOT-22, Sino-Nasal Outcome Test-22; NPS, Nasal 
Polyp Score; SNOT-20, Sino-Nasal Outcome Test-20; RCT, Randomised Controlled Trial;
(1.2%) during the treatment period; no causal relationship with 
the study medication was seen for all of these. No medically 
relevant differences in laboratory parameters or vital signs were 
observed for patients treated with Sinupret extract compared to 
placebo. 
Of the four local studies, three measured quality of life with 
SNOT(264-266), two symptoms severity(265, 267)and two CT scan(264, 
266 ). The studies were too different to combine into a meta-
analysis. One study found a significant improvement in the 
group treated with Nigella sativa nasal spray versus saline in 
SNOT-20, endoscopy and CT scan at four weeks’ treatment. Two 
studies compared to treatment with FPNS.  One showed no 
difference compared to fluticasone diproporanate nasal spray 
(FPNS) but in the other comparing intranasal administration of 
Sinupim (P. anisium) drops to FPNS, interestingly, the intranasal 
administration of P. anisium led to a significantly greater 
improvement (p=0.012) in SNOT-22 score when compared to 
FPNS. However, the lack of blinding increases performance 
bias(266). Sinupim was well tolerated by patients. There were no 
serious adverse effects in either group. 
6.1.19.1. Conclusion
Of five RCTs evaluating herbal treatment, a large DBPCT, 
although a post-hoc sensitivity analysis, showed a significant 
benefit in major symptom score at 12 weeks of treatment over 
placebo in patients with a diagnosis of CRS for >1 year and a 
baseline MSS >9 (out of max 15) showed overall no effect(268). Of 
the four studies evaluating different local herbal treatment three 
showed a favorable effect. However, not all studies were blinded 
and the quality of the studies was variable. 
The treatment does not show significantly more adverse events 
than placebo. The quality of the evidence for the local treatment 
is low. 
Based on the available data, the EPOS2020 group cannot advise 
on the use of herbal medicine in CRS.
6.1.20. Traditional Chinese medicine and 
acupuncture
Complementary and alternative medicine (CAM) is commonly 
inquired about and often used by patients with CRS(270). 
Many different CAM therapies are available including herbal 
medications, homeopathy and traditional Chinese medicine. We 
identified five RCTs for review. 
6.1.20.1. Traditional Chinese Medicine
 Two studies examined the use of Traditional Chinese Medicine 
in CRS. One study in 53 CRSsNP compared the Chinese 
herbal medicine (CHM) Tsang-Erh-San with Houttuynia with 
an erythromycin control group(34)(Table 6.1.20.1). At eight 
weeks both groups had a significant improvement in their 
SNOT-20 score, however there was no significant difference 
between the two groups.  Neither intervention influenced the 
endoscopic score or bacterial culture rate. The validity of these 
improvements is unclear due to the lack of placebo control. 
Another study in 97 postoperative CRS patients compared the 
same CHM (Tsang-Erh-San with Houttuynia) with amoxicillin 
and placebo(271). All three groups had significant improvements 
in their RSOM-31 and endoscopic score at eight weeks post-
operatively, however there was no significant difference 
between the three groups. There was no significant difference 
post-operatively between the three groups on their acoustic 
rhinometry and CT scores. 
6.1.20.2. Traditional Chinese acupuncture
In some countries acupuncture is used to treat CRS although 
there is hardly any documentation on the effect. We found 
two studies from the same group evaluating health-related 
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Table 6.1.20.2. Acupuncture for the treatment of patients with CRS.
CSS, Chronic sinusitis survey ;CRS,Chronic Rhinosinusitis; CRSsNP, Chronic Rhinosinusitis without nasal polyps ; RCT, Randomised 
Controlled Trial ; SF-36, Short form 36; QOL, Quality of Life ; VAS, Visual Analogue Scale ; CT, computed tomography.
Study Methods Participants Interventions Outcomes Results
Stavem 
2008(272)
RCT 
(Investigator 
not blinded. 
Patient’s 
partially 
blinded.)
66 CRSsNP (49 
evaluated)
• Traditional Chinese Acupuncture 
(10 treatments over 4 weeks) (n=17)
• Sham acupuncture (10 treatments 
over 4 weeks) (n=15)
• Medical management (xylometazo-
line and normal saline irrigation 
for 1 week, oral corticosteroids for 
14 days, and antibiotics – either 
cephalexin 1,500mg daily for 10 
days or azithromycin 500mg for 7 
days) (n=17)
• CSS
•  SF-36 at baseline 
and 12 weeks
• No significant difference in any endpoints 
between the groups
Rössberg 
2005(274)
RCT 55 CRS patients 
(49 evaluated at 
4 weeks, 37 at 
12 weeks and 
29 at 1 year)
• Traditional Chinese acupuncture 10 
treatments with bilateral acupoints 
over a period of 4 weeks (n=25)
• Minimal acupuncture at non-acu-
points 10 treatments with bilateral 
acupoints over a period of 4 weeks 
(n=19)
• Conventional medical therapy 
consisting of xylometazoline 
saline locally for 1 week, and oral 
corticosteroids for 14 days (n=21). 
In addition, cefalexin 1500 mg daily 
for 10 days (n=14) or azithromycin 
500 mg for 7 days (n=6)
• SF-36 at 12 
weeks
• QOL (VAS) at 12 
weeks
• Total symptom 
score at 4, 12 
and 52 weeks
• CT scan at 4 
weeks
• Conventional treatment improved CT 
scan at 4 weeks contrary to both acu-
puncture groups
• Total symptom score at 4 weeks trend to 
improvement (p=0.06) compared both 
acupuncture groups 
• Significant improvement in SF-36 and 
QOL (VAS) at 12 weeks for conventional 
treatment contrary to both acupuncture 
groups
• After 12 months, 15 patients reported 
having had surgical intervention for 
chronic sinusitis (conventional group 5, 
acupuncture 6, sham 4), and there was lit-
tle difference in symptom score between 
the groups (p = 0.32).
Table 6.1.20.1. Traditional Chinese Medicine for the treatment of patients with CRS.
Study Methods Participants Interventions Outcomes Results
Jiang 
2012(34)
DBPCT 53 CRSsNP 
patients
• Chinese Herbal Medicine (2g of Tsang-Erh-
San extract granules and 1gm of Houttuyn-
ia extract powder twice daily  for 8 weeks) 
with erythromycin placebo (n=26)
• Erythromycin (250mg twice daily for 8 
weeks) with CHM placebo (n=27)
• SNOT-20
• Endoscopic score
• Saccharin transit test
• Bacterial culture rate before and 
at 8 weeks of treatment
• No significant differ-
ence in any endpoints 
between the groups
Liang 
2011(271)
DBPCT 97 CRS 
postoperative 
• Chinese Herbal Medicine (2g of Tsang-Erh-
San extract granules and 1gm of Houttuyn-
ia extract powder twice daily for 8 weeks) 
with 4 weeks of amoxicillin placebo (n=33)
• Amoxicillin (250mg three times dailly  for 
4 weeks and CHM placebo for 8 weeks 
(n=34)
• Placebo (n=30)
• RSOM-31
• Endoscopic score
• Acoustic rhinometry
• Nasal swabs at 8 weeks post-
operative
• CT (LM-scoreat 12 weeks post-
operative
• No significant differ-
ence in any endpoints 
between the groups
CRS, Chronic Rhinosinusitis;CRSsNP, Chronic Rhinosinusitis without nasal polyps ; DBPCT, Double Blind Placebo Controlled Trial ; 
CHM, Chinese Herbal Medicine ; SNOT-20, Sino-Nasal Outcome Test-20 ; RSOM-31, Rhinosinusitis Outcome Measure-31 ; CT, comput-
ed tomography; LM, Lund-Mackay
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quality of life comparing traditional Chinese acupuncture, sham 
acupuncture, and 2-4 weeks of medication with antibiotics, 
corticosteroids, 0.9% sodium chloride solution, and local 
decongestants(272, 273). Change in health-related quality of life 
was assessed over 4-52 weeks using the Chronic Sinusitis Survey 
(CSS), Short form 36 (SF-36) questionnaires, total symptom 
scores and CT scan. One study(274) in general showed better 
effect of the conventional treatment than both traditional 
Chinese acupuncture and sham acupuncture, the other did 
not show difference in effects on CSS or SF-36 between the 
traditional Chinese acupuncture and the sham acupuncture 
groups (Table 6.1.20.2). 
6.1.20.3. Conclusion
There is no evidence that traditional Chinese medicine or 
acupuncture is more effective than placebo in the treatment 
of CRS. The safety of Chinese medicine is unclear because most 
of the papers are not ready accessible(275). Minor and serious 
adverse events can occur during the use of acupuncture and 
related modalities, contrary to the common impression that 
acupuncture is harmless(276). For this reason, the EPOS2020 
steering group advises against the use of traditional Chinese 
medicine or acupuncture.
6.1.21. Topical furosemide and oral verapamil 
6.1.21.1.  Summary of the evidence
While surgical intervention has often been the mainstay in 
treatment of nasal polyps, the propensity for some patients to 
relapse has led to further investigations with therapies aimed at 
preventing recurrence. Two of these medications are verapamil 
and furosemide. 
Verapamil is a non-dihydropyridine Ca+-channel blocker, given 
orally, and an inhibitor of P-gp and can block IL-5, IL-6, and 
thymic stromal lymphopoietin (TSLP) secretion. One double 
blind placebo-controlled trial(277) evaluated the use of oral 
Verapamil for treatment of patients with CRSwNP. Patients were 
treated with either 80mg of Verapamil three times per day 
versus placebo for eight weeks. 
Patients were evaluated at two, four and eight weeks for 
changes in quality of life (SNOT-22), symptoms (VAS), or changes 
in CT scan (LMS). Patients were also evaluated for side effects 
from the medication. There was significant improvement from 
baseline to week eight in SNOT-22 scores (MD -27.7 95%CI[-
49.36 to -6.05], p=0.01) and VAS scores (MD -37.97 95%CI[-
60.01 to -15.93], p=0.001) in the verapamil group compared to 
placebo. There was also improvement in Lund-Mackay score 
in the verapamil group with an absolute mean difference of 
-5.20 (95% CI, -9.66 to -0.74; p=0.02). There were also significant 
decreases in total Lund-Kennedy score in the verapamil group 
at week four with an LSM difference of -2.8 (95%CI, -4.3 to 
-0.98; p=0.003). This trend continued to week eight but was 
no longer statistically significant. Patients with higher BMIs 
had less improvement with verapamil and this is thought to 
be due to higher required doses that would otherwise be 
supratherapeutic (Table 6.1.21.1). Studies with local verapamil 
are ongoing (https://ichgcp.net/clinical-trials-registry/
NCT03102190).
Furosemide, in contrast, is a loop diuretic that acts on Na+ and 
K+ channels and can increase absorption of these ions, as well 
as water. This dehydrates the respiratory epithelial surface. 
A few studies have been completed evaluating their efficacy 
in the prevention of nasal polyp recurrence (Table 6.1.21.2). 
Hashemian et al.(887) conducted a double-blind, placebo-
controlled trial assessing the efficacy of topical furosemide 
on nasal polyps. Patients were randomly assigned to receive 
either postoperative nasal spray, two puffs twice daily for two 
months of either 300μg of furosemide per day or placebo. 
Patients were assessed six months after surgery for NPS (Meltzer 
score), CT scoring (LMS), QOL (SNOT-22), and VAS polyp scoring. 
Eighty-four patients completed treatment and were able to be 
evaluated, with 42 patients in each group (n=84). During the 
study time, there were no clinically significant adverse effects. 
After treatment, significantly more patients in the furosemide 
group had a polyp score of 0, compared to the placebo 
group (79% vs 38%; p<0.01). There was a significant effect of 
furosemide on SNOT-22 scores (MD, 8.05; 95%CI, 3.24-12.85) and 
VAS scores (MD, 0.81; 95%CI, 0.22-1.39) compared to placebo. 
However, the Lund-Mackay score did no show significant 
differences (MD, 2.52; 95%CI, -0.35-5.39). 
Kroflic et al.(278) evaluated the efficacy of oral 
methylprednisolone (1mg/kg/day) or inhalation of 6.6mmol/l 
furosemide solution/10 min through a jet nebulizer—i.e., max. 
20mg/day furosemide for seven days on patient reported 
symptoms (nasal obstruction, nasal hypersecretion, loss of 
smell (0-3), postnasal drip, snoring, sneezing, cough, swelling, 
epistaxis, headache (0-1), fatigue, temperature, previous surgery 
(0-1) adding up to a total symptom score of 20), NPS (Malm 0-6), 
and histomorphometric analysis of eosinophils, mastocytes, 
and edema. Both groups showed significant improvement 
in subjective symptom scores (pre-steroid mean 15.5±3.4 to 
post-steroid 9.5±3.6, p<0.001; pre-furosemide 15.6±3.9 to 
post-furosemide 9.8±3.7, p<0.001) and NPS (steroid: 2.4±0.7 
to 2.0±0.8, p<0.001; furosemide: 2.2±0.9 to 1.7±0.9; p<0.001). 
Table 6.1.21.1. Oral Verapamil for the treatment of patients with CRSwNP.
Study Methods Participants Interventions Outcomes Results
Miyake 
2017 (277)
DBPCT CRSwNP 
(n=20)
• Verapamil 80mg four 
times daily for 8 weeks 
(n=10) vs placebo for 8 
weeks (n=10)
At 2, 4, and 8 weeks
• Quality of life (SNOT-22)
• Symptoms (VAS)
• CT scan (LM score)
• Nasal endoscopy (Lund 
Kennedy Score)
• Significant improvement in SNOT-22, VAS, 
and LM score at 8 weeks
• Significant improvement in Lund-Kennedy 
score at 4 weeks, but not significant at 8 
weeks
• Less improvement patients with higher BMI
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There was no significant difference between the two groups. 
Given the small sample size, this may be considered to be a 
type 2 error. The steroid group had significant improvement 
in polyp eosinophil counts (50-2.35±392.66 to 190.65±291.41; 
p<0.01), while the furosemide group did not (280.95±364.58 to 
382.80±370.60; p=0.185). Neither group had significant changes 
in oedema or tissue mastocytes.
Passali et al.(279) conducted a pseudo-randomized trial on 
patients with CRSwNP following surgery. Patients were 
randomized to either receive topical furosemide, no treatment, 
or topical mometasone furoate nasal spray (MFNS) post-
operatively after either anterior or full ethmoidectomy. For six 
years (1991-1997) patients were randomized between topical 
furosemide and no treatment and after 1997 randomization 
was done between furesomide and MFNS. No details about 
the randomization process are given. Follow-up ranged from 
1-9 years over the group as a whole. Patients in the furosemide 
group received two puffs per day per nostril (each puff= 50µg) 
for 30 days, then one month of no treatment and then repetition 
of the furesomide treatment until a total of four months per 
year. The MFNS group received two puffs per day per nostril 
(puff= 100µg) for 30 days then following a similar regimen to 
the furosemide group, and the no treatment group received no 
further intervention following surgery. Patients were assessed 
for relapse. Relapse was based on acoustic rhinometry active 
anterior rhinomanometry, and the presence of nasal polyp 
recurrence. Acoustic rhinometry and nasal endoscopy was 
assessed every six months in each patient. NPS was as follows: 
stage 0, no nasal polyps seen; stage 1, nasal polyps confined to 
the middle meatus, with acoustic rhinometry values within the 
normal range (24.5±1.5cm3); stage 2, nasal polyps prolapsing 
beyond the middle turbinate, with less than a 10% reduction 
of nasal volumes (per AR); and stage 3, sub-obstructive 
nasal polyps requiring another operation (>50% reduction 
of nasal volumes). The no treatment group had a significant 
worsening of nasal volumes at the end of their six-year follow-
up (16.6±1.3cm3; p= 0.02). More patients in the untreated 
group had relapse compared to furosemide or mometasone 
Table 6.1.21.1. Oral Verapamil for the treatment of patients with CRSwNP.
Study Methods Participants Interventions Outcomes Results
Hashemian 
2016 (887)
DBPCRCT CRSwNP
(N=84)
• 2 puffs twice daily for 2 
months of either 300μg of 
furosemide per day (n=42) 
• 2 puffs twice daily for 2 
months placebo per day 
(n=42) 
Assessed at 6 months:
• QOL (SNOT-22, 0-110)
• VAS polyps score (0-10)
• NPS (Meltzer score, 0-8)
• CT PNS scoring (0-30)
At 6 months furosemide versus placebo 
resulted in:
• Significantly reduced SNOT-22 scores 
(difference, 8.05;95% CI, 3.24-12.85) and 
VAS polyp scores (difference, 0.81; 95% CI, 
0.22-1.39). 
• Significantly more patients with a polyp 
score of 0 (79% vs 38%; p<0.01). 
• No differences in CT PNS scores
Kroflic 
2006 (278)
RCT CRSwNP 
(n=40)
• Inhaled 6.6mmol/L furo-
semide over 10 minutes 
(max 20mg/day) (n=20) 
for 7 days
• Methylprednisolone 1mg/
kg/day (n=20)
After 1 week:
• Total symptom score (0-20)
• Nasal obstruction, nasal 
hypersecretion, loss of smell 
(0-3), postnasal drip, taste, 
snoring, sneezing, cough, 
swelling, epistaxis, headache 
(0-1), and fatigue, tempera-
ture, previous surgery (0-1) 
adding up to total symptom 
score (0-20)
• NPS (Malm score, 0-6)
• Tissue eosinophil count
• Tissue mastocyte count
• Tissue oedema
• No significant differences between furo-
semide and Methylprednisolone =§ Both 
treatments were significantly effective in 
reduction of nasal symptoms and polyp 
scores
• Steroid group has significant reduction in 
eosinophils, but no effect on mastocytes 
or oedema. There was no improvement in 
the furosemide group
Passali 
2003(279)
RCT CRSwNP post-
operatively 
(n=170)
• Furosemide 2 puffs (50µg/
puff ) per day per nostril 
for 30 days (n=97) vs. 
mometasone fuorate 
nasal spray 2 puffs per day 
per nostril (puff = 100µg) 
for 30 days (n=33) both 
with months of no treat-
ment) vs. no additional 
treatment (n=40)
Assessed every 6 months (for 
up to 9 years)
• Acoustic rhinometry
• Nasal endoscopy
• Surgery restored normal patency in all 
patients during the first year of follow-up
• The untreated group had significant 
worsening of nasal volumes at the end of 
6 years (16.6±1.3cm3;p=0.02)
• More patients in the untreated group had 
relapse of nasal polyps compared to furo-
semide or MFNS (30% vs. 17.5% vs. 24.2%; 
no p value available)
• Patients without treatment had a signifi-
cantly higher NPS of recurrence compared 
to furosemide and mometasone (20% vs. 
2% vs. 3%; p<0.05)
CRSwNP: chronic rhinosinusitis with nasal polyps; DBPCRCT: Double-blind placebo-controlled randomiced control trial; RCT: ran-
domiced control trial; QOL: Quality of Life; SNOT-22: Sino-Nasal Outcome Test-22; VAS: Visual analogue score; NPS: Net promoter 
score; CT PNS; Computed Tomography para nasal sinuses. 
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Table 6.1.22.1. Capsaicin for the treatment of patients with CRSwNP.
Study Methods Participants Interventions Outcomes Results
Zheng 
2000(282)
DBPCRCT CRSwNP post-
polypectomy 
(n=51)
• Capsaicin (3x10-6 mol, 
dissolved in 70% ethanol) 
(n=29)
• vehicle alone (70% etha-
nol) (n=22) once a week 
times 5 weeks
Assessed at 9 months:
• Nasal blockage (0-5)
• Rhinorrhoea (0-5)
• NPS (0-6)
At 9 months there was no difference in 
subjective rhinorrhoea in either group. 
• The capsaicin group at 9 months group had 
a significant decrease in NR compared to 
the vehicle group
• NPS data?
Filiaci 
1996(281)
DBPCRCT CRSwNP (n=30) • Capsaicin 0.1mL (30μmol) 
in each fossa once weekly 
for 5 weeks (after anes-
thetizing the nasal cavity) 
(n=15)
• 0.1mL physiologic solution 
(n=15) in each fossa once 
weekly for 5 weeks
Assessed at 1 and 3 months:
• Nasal symptoms: obstruc-
tion, secretion, itching, 
sneezing (0-5)
• NPS (0-6)
• Nasal resistance (active 
anterior rhinomanometry)
• Specific nasal hyperreactivi-
ty (provocation testing with 
cold water with rhinoma-
nometric assessment)
• Nasal tissue eosinophils
At 1 and 3 months when comparing the 
capsaicin group versus the controls, the 
capsaicin group had:
• A significantly larger decrease in all nasal 
symptoms
• A significant larger decrease difference in 
NPS 
• Significantly larger improvement in nasal 
resistance
• Significantly improved nasal hyperreactivity
• Significantly increased nasal tissue eosin-
ophils
CRSwNP, Chronic Rhinosinusitis with nasal polyps; DBPCRCT, Double Blind Placebo Controlled Randomised Controlled Trial ; NPS, Nasal Polyp Score.
Figure 6.1.22.1. Forest plot of the effect of capsaicin versus placebo on nasal obstruction in CRSwNP patientsmonths.
(30%v17.5%v24.2%; no p value available). Patients without 
treatment had a significantly higher NPS of polyp recurrence 
compared to furosemide and mometasone fuorate nasal spray 
(20% vs 2% vs 3%; p<0.05).
Another report of Passali(280) appears to report on a subgroup of 
the patients of the 2003 study(279). 
6.1.21.2. Conclusion
There is some indication that verapamil might have anti-
inflammatory effects. A very small pilot study showed significant 
improvement in QOL (SNOT-22), polyp score (VAS), and CT scan 
(LMS) of oral verapamil over placebo. (Potential) side effects 
limited the dosage. 
There is some indication that topical furosemide might have a 
beneficial effect on symptoms and signs of CRSwNP. A recent 
DBPCT study showed significantly reduced QOL (SNOT-22) 
scores and polyp score (VAS), and significantly more patients 
with an NPS of 0 in the furosemide nasal spray treated group 
versus placebo. There was no indication of a difference in 
adverse events between topical furosemide and placebo.
The quality of the evidence for oral verapamil and topical 
furosemide is very low. Based on the potential side effects 
the EPOS2020 steering group advises against the use of oral 
verapamil. The group also cannot advise on local furosemide.
Further placebo-controlled studies on both local furosemide 
and local verapamil are needed to determine efficacy and 
appropriate patient selection.
6.1.22. Capsaicin 
6.1.22.1 Summary of the evidence
Neuropeptides and parasympathetic nerves in the nasal 
mucosa are thought to potentially play a role in the formation 
of nasal polyps. Therefore, capsaicin, a medication that can be 
applied topically has been considered for possible prevention 
of nasal polyp recurrence. Capsaicin, which acts upon the C 
fibers, is thought to neuromodulate nasal hyper-reactivity 
and potentially prevent nasal polyp recurrence. Two studies 
completed double blind, placebo-controlled, randomized trials 
(Table 6.1.22.1). 
Filiaci et al.(281), evaluated 30 patients, with half of them receiving 
capsaicin 0.1mL (30μmol) in each fossa versus 0.1mL physiologic 
solution in each fossa once weekly for five weeks. Patients were 
then assessed at three months for nasal symptoms, including 
obstruction, itching, and sneezing, endoscopic polyp scoring, 
nasal resistance, specific nasal hyperreactivity, and eosinophils 
in nasal polyp tissue. The capsaicin group had a significant 
decrease in all nasal symptoms compared to placebo (p<0.01). 
There was a significant difference in the nasal polyp scores (NPS) 
between the capsaicin and control group at one month (p<0.05) 
and three months (p<0.01). There was significant improvement 
in nasal resistance in the capsaicin group compared to the 
control group at three months post-treatment (p<0.01). There 
was a significant difference in nasal hyperreactivity between 
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the capsaicin and control group at three months (p<0.01). Nasal 
tissue eosinophils were significantly increased in the patients 
undergoing capsaicin treatment at one and three months 
(<0.01).
Zheng et al.(282), also conducted a double blind, placebo-
controlled trial comparing capsaicin (3x10-6mol, dissolved in 
70% ethanol) versus vehicle alone (70% ethanol) once a week 
for five weeks, following nasal polypectomy. Patients were 
assessed at nine months for nasal resistance (0-5), rhinorrhoea 
(0-5), and NPS (0-6 unilateral). The capsaicin group had a 
significant decrease in nasal resistance compared to the vehicle 
group. (p<0.01). There was no difference in subjective rhinorrhea 
in either group. Patients treated with capsaicin had lower nasal 
polyp score when compared to the control group (stage 0: 41% 
vs 4.5%, p<0.01). Adverse events were not mentioned in both 
studies but are know from studies in NAR to be mostly limited to 
local irritation(283).
Pooled data analysis of the nasal obstruction measurement 
(0-5) showed significant benefit in the capsaicin group (SMD 
-0.68 [-1.05, -0.31], p<0.0003, two trials, 81 patients). The I2 was 
0%, suggesting no heterogeneity (X2=0, df=1, p=0.98) (Figure 
6.1.22.1).
Pooled data analysis of nasal polyp score showed significant 
benefit in the capsaicin group (SMD -1.82[-2.93, -0.7], 
p<0.01, two trials, 81 patients). The I2 was 0%, suggesting no 
heterogeneity (X2=0, df=1, p=0.98) (Figure 6.1.22.2).
6.1.22.2. Conclusion
Two small double-blind placebo-controlled studies(281, 282) 
have evaluated the efficacy of capsaicin. Capsaicin showed a 
significant decrease in nasal obstruction and nasal polyp score, 
however data on other symptoms like rhinorrhea and smell are 
either non-significant or unreported. The data were consistent 
over the two studies, but we downgraded for imprecision and 
risk of bias. It has to be mentioned that blinding of capsaicin 
treatment is very difficult/impossible. The quality of the 
evidence is low and the EPOS steering group concludes that 
Capsaicin may be an option in treatment of CRS in patients with 
CRSwNP but that larger studies are needed.
6.1.23. Proton-pump inhibitors in patients with 
GORD
6.1.23.1. Summary of the evidence
 There is some of evidence demonstrating an association 
between gastro-oesophageal reflux disease (GORD) and CRS. 
GORD is defined by reflux of gastric contents, resulting in 
troublesome symptoms and/or complications. CRS patients 
have been shown to have significantly higher incidences of 
gastro-oesophageal reflux compared with asymptomatic 
controls(284).
CRS is more prevalent in GORD sufferers than those without 
GORD although the diseases have overlapping symptoms 
like the feeling of mucus in the throat(285). While CRS is a 
multifactorial process, the evidence suggests that GORD 
may play a role in CRS, at least in some patients. Potential 
pathogenic roles for GORD in CRS could be a greater prevalence 
of intranasal Helicobacter pylori and acid reflux into the nose/
nasopharynx. Evidence is conflicting for GORD as a factor in CRS 
treatment failure(286).
There is one DBPCRCT evaluating the role of proton-pump 
inhibitors in CRS(287) (Table 6.1.23.1). Sixty patients (28 women, 
aged 19-87 years) with CRS and GORD were treated with eight 
weeks of omeprazole 20mg once daily (o.d.). Although the 
Table 6.1.24.1. Bacterial lysates for the treatment of patients with CRS.
CRS,Chronic Rhinosinusitis; DBPCT, Double Blind Placebo Controlled Trial ; RS, Rhinosinusitis
Study Methods Participants Interventions Outcomes Results
Heintz 1989(294) DBPCT 284 CRS patients 
(some patients had 
persistent RS after 
sinus puncture) (258 
analysed)
• Broncho-Vaxom, 1 capsule 
daily for a period of 10 days per 
month during 3 consecutive 
months (n=127)
• Placebo 1 capsule daily for a 
period of 10 days per month 
during 3 consecutive months 
(n=121)
• Symptom score (0-4) 
for headache, purulent 
nasal discharge, cough 
and expectoration
• X-ray sinus
• Adverse events
• Significant reduction in 
symptoms 
• Significant reduction in 
opacification of X-ray sinus
• No difference in adverse 
events
Table 6.1.23.1. Omeprazole for the treatment of patients with CRS.
CRS,Chronic Rhinosinusitis; DBPCT, Double Blind Placebo Controlled Trial ; GORD, Gastro-oesophageal reflux disease ; RSI, Reflux symptom index; RFS, 
Reflux finding score.
Study Methods Participants Interventions Outcomes Results
Anzic 
2018(287)
DBPCT 60 CRS 
patients with 
GORD
• Omeprazol 20mg once 
daily (n=33) for 8 weeks
• Placebo  once daily (n=27) 
for 8 weeks
At 8 weeks: 
• CRS symptom score (0-48)
• Nasal endoscopy score
•  RSI score 
•  RFS
No significant differences at 8 weeks 
between Omeprazole and placebo apart 
from reflux finding score
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authors conclude that CRS symptom score, nasal endoscopy 
score, reflux symptom (index) score, and reflux finding scores 
were significantly reduced after eight weeks omeprazole 
treatment compared to placebo using ANOVA for repeated 
measurements or McNemar’s test, only the reflux finding score 
showed a significant difference between the groups at the 
eight weeks measurement. Unfortunately, the matching of 
the groups at baseline was not good as the CRS and RSI were 
significantly different from each other at baseline. The long-term 
use of proton pump inhibitors is not without risk and has been 
associated with increased risk of cardiovascular disease and 
morbidity(288, 289).
6.1.23.1. Conclusion 
There is one DBPCT trial evaluating the effect of omeprazole 
20mg once daily for eight weeks in 60 patients that was ill-
matched at baseline making evaluating of the results difficult. 
At the end of the eight weeks treatment period there were no 
differences in CRS and nasal endoscopy scores. Moreover, long 
term use of proton pump inhibitors has been associated with 
increased risk of cardiovascular disease. The EPOS2020 steering 
group therefore does advise against the use of proton pump 
inhibitors in the treatment of CRS.
6.1.24. Bacterial lysates
6.1.24.1. Summary of the evidence
Bacterial lysates are constituted by a mixture of bacterial 
antigens derived from different respiratory bacterial species. 
Different antigens are mixed and excipients are added in 
order to prepare lysate tablets. Bacterial lysates have both 
a specific and non-specific immunostimulating properties. 
Broncho-Vaxom® (OM-85 BV) is  a lysate of 21 strains of 8 
bacteria(Staphylococcus  aureus,  Haemophilus  influenzae, 
Streptococcus pyogenes, Moraxella catarrhalis, Klebsiella 
pneumoniae, Klebsiella ozaenae, Streptococcus viridans and, 
Diplococcus pneumoniae), that is used as an immunostimulant 
for the prevention and treatment of upper and lower airway 
infections and has the ability to enhance mucosal barrier 
function and regulate immune responses(290, 291).A recent meta-
analysis showed that Broncho-Vaxom was positively correlated 
with a reduction in the frequency of respiratory infection 
[MD=-2.33, 95% CI (-2.75, -1.90), P<0.00001] compared to the 
control group. The Broncho-Vaxom group was more effective 
than control groups in relation to the duration of antibiotics 
course, infections, fever, cough, and wheezing, increasing serum 
immunoglobulin levels (IgG, IgA or IgM), and T-lymphocytes 
subtype (CD3+, CD4+, or CD8+)(292). OM-85 BV has 
ciliostimulatory and immunogenic properties in an epithelial 
cell culture system that may be partially responsible for its 
observed efficacy as a respiratory therapeutic. These responses 
were NO-dependent and consistent with T2R activation(293). 
Oral administration of Broncho-Vaxom(R) (OM-85 BV) was also 
shown to alleviate allergic rhinitis symptoms and to improve 
the overall mucosal immunity via restoring and maintaining 
the normal Th1/Th2 cytokine balance as an underlying cellular/
signaling mechanism(290).
There is one DBRCT in adults with potential CRS patients 
Table 6.1.26.1. Phototherapy for the treatment of patients with CRS.
CRSsNP, Chronic Rhinosinusitis without nasal polyps ;CRSwNP, Chronic Rhinosinusitis with nasal polyps; DBPCT, Double Blind Placebo Controlled 
Trial ; RCT, Randomised Controlled Trial ; mUV/VIS, Mixed ultraviolet and visible light; UVA, Ultraviolet A; UVB, Ultraviolet B; MFNS, Mometasone 
Furoate Nasal spray ; RSDI, Rhinosinusitis Disability Index; VAS, Visual Analogue Scale ; NOSE, Nasal Obstruction Sympton Evaluation ; PNIF, Peak Nasal 
Inspiratory Flow ; NO, Nitric Oxide.
Study Methods Participants Interventions Outcomes Results
Dulguerov 
2017(296)
DBPCT 50 CRSsNP 
patients
• Mixed visible and 
ultraviolet (UVA and 
UVB) light source ap-
plication for 3 weeks 
(n=26)
• Low intensity visible 
light alone for 3 weeks 
(n=24)
At the end of 3 wk treatment and 
one month after treatment:
• RSDI 
• symptom severity (nasal obstruc-
tion, sense of smell, rhinorrhoea, 
and facial pain) (VAS)
• Rhinomanometry 
• Olfactory thresholds 
• Nasal nitric nxide 
• Carbon monoxide 
• No significant difference in any outcome 
measured except carbon monoxide
• Significant increase in carbon monoxide 
production in the treatment group as 
compared to controls at the end of treat-
ment (5.24 vs. 3.88, p=0.048), however no 
significant difference at 1 month following 
treatment (5.25 vs. 4.07, p=0.13)
Kiricsi et al.
2017(300)
RCT 87 subjects 
(76 evaluated) 
CRSwNP 
patients
• intranasal mUV/VIS 
phototherapy 3 times 
per week for 12 weeks 
and MFNS  200μg 
twice daily for 12 
weeks (n=52)
• MFNS  200μg twice 
daily for 12 weeks 
(n=24)
At week 12, week 16 and 26 weeks 
• NOSE questionnaire
• Nasal symptom score (total nasal 
symptom score and separate 
symptom) 
• Nasal endoscopy and polyp size 
(0-5) 3
• PNIF 
• Acoustic rhinometry 3
• Smell threshold 
• Exhaled nasal nitric oxide 
Patients that received phototherapy 
demonstrated significant improvement in: 
• NOSE (p < 0.001) at week 12, 16 and 26 
• Total nasal symptom score and in nasal con-
gestion, discharge at week 12, 16 and 26 
• Smell threshold test (p<0.001) at week 12, 
16 and 26 
• PNIF at week 26
• Nasal polyp size at week 16 and 26 
• No significant change in acoustic rhinome-
try or exhaled nasal nitric oxide
• In control group, no significant changes 
were measured at week 12, 16 and 26 
• No statistics between groups performed
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although the population has been insufficiently described and 
some patients had persistent RS after sinus puncture(294) (Table 
6.1.24.1). Broncho-Vaxom or placebo (one capsule daily for a 
period of 10 days per month during three consecutive months) 
was administered to 284 patients presenting with chronic 
purulent rhinosinusitis. Patients were clinically examined before 
admittance to the study and at one, two, three and six months 
after treatment initiation Broncho-Vaxom therapy resulted in a 
significant decrease in purulent nasal discharge and headache 
over the full six months period compared to placebo. Also, the 
effect on the opacification of the sinus X-ray was significantly 
better in the Broncho-Vaxom treated group than the placebo 
group. No major side effects were reported, with comparable 
and good tolerability for OM-85 and placebo.
6.1.24.2. Conclusion
There is one DBRCT from 1989 comparing the bacterial lysate 
Broncho-Vaxom to placebo in a large group of CRS patients 
resulting in a significant decrease in purulent nasal discharge 
and headache over the full six months period compared to 
placebo and reduced opacification of the sinus X-ray. Based 
on this limited evidence the EPOS2020 steering group cannot 
advise on the use of Broncho-Vaxom in the treatment of CRS. 
Larger studies of longer duration are needed with proper 
patient characterization and outcome evaluation.
6.1.25.   Homeopathy
6.1.25.1. Summary of the evidence
Homeopathy is an alternative medicine. Its practitioners, called 
homeopaths, believe that a substance that causes symptoms 
of a disease in healthy people would cure similar symptoms in 
sick people. Homeopathic preparations are termed remedies 
and are made using a process of homeopathic dilution, in 
which a chosen substance is repeatedly diluted in alcohol or 
water, typically until nothing of the original substance remains 
in the product. Homeopathy in CRS involves treating both 
the underlying disease and its predominant symptoms with 
dilutions of substances that create/start the disease. There is 
much debate as to whether these dilutions actually contain any 
molecules of the original substance and hence whether any 
clinical effect is attributable to a placebo effect or study bias. 
6.1.25.2. Conclusion
We could not retrieve RCTs on homeopathy in CRS published 
after 1990.  Based on the available evidence, the steering group 
of EPOS2020 cannot advise on the use of homeopathy in the 
treatment of CRS.
6.1.26. Phototherapy
6.1.26.1. Summary of the evidence
The immunomodulative effect of phototherapy has been 
investigated as a potential therapeutic target for CRS patients. 
Ultraviolet phototherapy has been found to have a profound 
immunosuppressive effect with reduction of Langerhans cell 
number and function, induction of apoptosis in infiltrating T 
cells, and induction of immune-modulatory cytokines such 
as TNF-α and IL-10(295). Two RCT have been performed (Table 
6.1.26.1.). Dulguerov et al. (2017)(296) conducted a randomized, 
blinded and placebo-controlled study of mixed visible and 
ultraviolet light therapy (310-600 nm light spectrum) as 
compared to visible light alone in 50 patients with CRS without 
nasal polyps according to the EPOS diagnostic criteria(297). 
Patients in the treatment group did not demonstrate a 
significant improvement in quality of life (QOL) (RSDI; 0.71 vs. 
0.72; p=0.84), nasal obstruction (4.87 vs. 4.56, p=0.63), sense of 
smell (3.78 vs. 4.25; p=0.54), rhinorrhoea (5.56 vs. 4.18; p=0.09), 
facial pain (3.76 vs. 3.78, p=0.43), total nasal resistance (0.65 vs. 
0.67, p=0.88), total nasal resistance after vasoconstrictor (0.56 vs. 
0.44, p=0.12), difference in total nasal resistance before and after 
vasoconstrictor (0.09 vs. 0.24, p=0.21), or nitric oxide production 
(571.45 vs. 656.85, p=0.21) as compared to the controls at the 
end of treatment. Similar findings were observed at one month 
post-treatment. The authors observed an increase in carbon 
monoxide production in the treatment group as compared 
to controls at the end of treatment (5.24 vs. 3.88, p=0.048), 
however this difference was not sustained at one month 
following treatment (5.25 vs. 4.07, p=0.13)
Studies of mixed ultraviolet/visible light have demonstrated 
the penetrative effect of this light therapy into polyp tissue 
to reach the inflammatory cells in the stroma and induce a 
dose-dependent increase of eosinophil and T-cell apoptosis(298, 
299). Kiricsi and colleagues conducted a randomized clinical trial 
comparing a combination therapy of mixed ultraviolet/visible 
6.1.27. Filgastrim (r-met-HuG-CSF) for the treatment of patients with CRS.
CRS, Chronic Rhinosinusitis ;CRSsNP, Chronic Rhinosinusitis without nasal polyps ; DBPCT, Double Blind Placebo Controlled Trial ; SF-36, Short Form 36.
Study Methods Participants Interventions Outcomes Results
Van Agthoven 
2001(301)
DBPCT 56 CRSsNP 
patients with 
recalcitrant 
CRS
• Filgastrim 300mg subcutaneously once a day for 
the first 14 days and every other day for another 
10 weeks 
• Placebo subcutaneously once a day for the first 
14 days and every other day for another 10 weeks 
• At 4,8,12 and 24 weeks:
• SF-36
• EuroQol
• McGill pain question-
naire
• No significant 
differences between 
the groups
All patients were treated at the beginning of the trial 
with a combination of 500–750mg of ciprofloxacin 
twice daily and 450–600mg of clindamycin three 
times a day for 14 days.
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light phototherapy and intranasal corticosteroids and intranasal 
steroids in 87 subjects with CRSwNP(300). The authors used a 
mixed ultraviolet/visible light device containing 5% ultraviolet 
B, 25% of ultraviolet A and 70% of visible light, with the 
spectrum between 280 and 650 nm. Mixed ultraviolet/visible 
light phototherapy led to a significant improvement in nasal 
congestion, nasal discharge, total nasal score, Nasal Obstruction 
Symptom Evaluation (NOSE) score and sense of smell (p<0.001). 
The authors observed a significant improvement in nasal 
endoscopic scores in staging of polyps on the left and right side 
(p<0.001 and p<0.008, respectively). There was no significant 
improvement in these parameters in the control group. There 
was no significant improvement in acoustic rhinometry scores 
or exhaled nasal NO in the phototherapy or control groups. No 
comparisons were made between the two groups.
6.1.26.2. Conclusion
Two randomized clinical trials of phototherapy in CRS has shown 
variable results. The DBPCT trial did not show any effect. The 
non- blinded RCT in CRSwNP patients with phototherapy on top 
of nasal corticosteroid treatment showed a significant reduction 
in NOSE scale, symptomatology, smell and polyp score in the 
phototherapy group and not in the nasal corticosteroid only 
group. However, no comparisons between the groups were 
made.
The quality of the evidence for the use of phototherapy in 
patients with CRS is very low. Based on the evidence the 
EPOS2020 steering group cannot make recommendation on the 
use of phototherapy in patients with CRS.
6.1.27. Filgastrim (r-met-HuG-CSF)
The proliferation and differentiation of neutrophils are 
promoted by the administration of recombinant human 
granulocyte colony-stimulating factor (rG-CSF) (Table 
6.1.27.). Clinical studies in subjects who are non-neutropenic 
indicate that rG-CSF may be beneficial as adjunctive therapy 
for treatment of serious bacterial and opportunistic fungal 
infections in patients who are nonneutropenic, including those 
with alterations in neutrophil function. Van Agthoven et al. 
evaluated in a double-blind placebo-controlled randomized 
clinical trial, the influence of filgastrim administration on QOL 
using the EuroQol, the Short Form (SF)-36, and the McGill pain 
questionnaire of 56 refractory chronic rhinosinusitis patients 
who did not respond to regular treatments during a 24-week 
trial(301). There was no significant difference in effect on QOL 
between the two groups.
6.1.28. Topical barriers e.g. algae – carrageenans
One alternative approach to prevention and treatment of 
infections of the nasal mucosa is the creation of a protective 
physical barrier in the nasal cavity with carrageenans, high 
molecular weight sulphated polysaccharides derived from red 
seaweed (Rhodophyceae). Several randomized clinical trials 
have investigated carrageenans as a potent antiviral agent in 
the management of upper respiratory tract infections(302-305).
To date, there have been no randomized clinical trials of topical 
carrageenans in CRS.
6.1.29. Collodial Silver
Colloidal silver (CS), a widely used naturopathic agent, has 
shown anti-biofilm properties both in vitro and within a 
rhinosinusitis animal model. A study in 22 patients evaluated the 
efficacy of CS as a topical nasal spray in patients with refractory 
CRSsNP and found no meaningful subjective or objective 
improvements(306). No participants experienced negative health 
effects directly attributable to the administration of intranasal CS.
6.1.30. Immunotherapy
A systematic review evaluating the effect of immunotherapy (IT) 
found no RCTs. Lower level evidence resulted in seven studies of 
which three were prospective(307). 
The authors concluded that symptom scores improved in 
patients treated with IT when compared with baseline data 
and control patients. Objective endoscopic exam measures 
improved with IT treatment in short-term studies. Significant 
improvements were observed in radiographic assessments, 
and there was a decreased necessity for revision surgery, 
interventional office visits, and intranasal and oral steroid use. 
After highlighting the paucity of the data, they concluded that 
there is weak evidence to support the use of IT as an adjunctive 
treatment in CRS patients, particularly in the postoperative 
period. We are not aware of studies published after this 
systematic review.
6.1.31. New potentials not on the market today
6.1.31.1. Introduction
Many cytokines, alarmins, markers on effector cells, and novel 
options (like DNAzyme and biophages) that could potentially 
be used as therapeutic targets have been discussed in chapter 
5.2.2. and more details can be found there. Here we focus on 
cytokines, alarmins, markers on effector cells, and novel options 
that are considered as new potential treatments at the moment.
 
6.1.31.2. GATA-3 DNAzyme
It is obvious that type 2 immune reactions are the most clinically 
relevant immune deviations in nasal polyposis as type 2 is 
associated with comorbid asthma and recurrent disease after 
sinus surgery and comorbid asthma(308). Clinical relevance 
has been underscored by, current Phase 3 trials with anti-IgE, 
anti-IL-5 or IL-5 receptor alpha strategies, or anti-IL-4 receptor 
alpha (see chapter 6.1.14 – 6.1.16 for more details). Future 
concepts using more upstream targets, including GATA-3, 
focus even more on type 2 immune responses, as GATA-3 is the 
transcription factor essential for Th2 and ILC2 development 
and function(309). DNAzymes are single-stranded catalytic 
DNA molecules that bind and cleave specific sequences in a 
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target mRNA molecule, such as GATA3 mRNA; this prevents 
the development of Th2 and ILC2 cells(310). Their potential as 
novel therapeutic agents has been demonstrated in a variety of 
disease models, including allergic asthma(310, 311) and COPD(312). 
As compared to baseline, GATA3-specific DNAzyme attenuated 
the late asthmatic airway response in subjects with allergic 
asthma and sputum eosinophilia by on average 34% and the 
early asthmatic response by on average 11%(313). The study also 
showed penetration of the drug into nasal polyp tissue and 
specifically into Th2 cells, underscoring its potential in CRSwNP. 
At the same time, the treatment was well tolerated. There is 
potential to develop a local nasal therapy for CRSwNP, as it has 
been demonstrated for asthma.
6.1.31.3. Anti-siglec-8 
Eosinophils, mast cells, and basophils selectively express sialic 
acid-binding immunoglobulin-like lectin (Siglec) 8, which 
is highly expressed in healthy and diseased subjects. As its 
activation may cause cell death, Siglec-8 represents a potential 
therapeutic target(314). Siglec-8 engagement in short-term IL-5-
activated eosinophils causes reactive oxygen species production 
and Src family kinases phosphorylation: both are essential in 
mediating Siglec-8-induced cell death(315). A proof-of-concept 
study with the antibody AK001 however failed to show efficacy 
(unpublished). Presently, new antibodies against Siglec-8 are in 
early clinical development. 
6.1.31.4. Anti-OX40L
In severe asthma, anti-OX40L may be a potential therapeutic 
target(316), as it allows the development of regulatory T (Treg) 
cells, which might suppress inflammatory T cells. However, the 
combination of two monoclonal antibody therapies (anti-OX40L 
and anti-TSLP) on Treg frequency using a human model of 
allergic asthma failed to deliver the expected suppression(317). 
In addition, despite anti-inflammatory efficacy, decreasing 
serum IgE (by 17%) and sputum eosinophils (by 75%), treatment 
with anti-OX40L monoclonal antibodies failed to attenuate the 
early and late airway response to inhaled allergen(318). So far, no 
studies with anti-OX40L have been performed in CRSwNP.
6.1.31.5. Anti-TNF alpha
In addition to type 2 inflammatory components, also non-
type2/type 2-low or type 1, bacteria or endotoxins-triggered, 
neutrophilic responses may comprise future targets for 
monoclonal antibody therapy in CRS(319). In a placebo-controlled 
study in healthy volunteers comparing anti-TNF with oral 
corticosteroids (OCS), the endotoxin-induced neutrophilic 
response in sputum was significantly modulated by anti-TNF in 
contrast to OCS and control treatment(319). Therefore, anti-TNF 
could have potential in patients with neutrophilic COPD without 
infectious cause(320), but also in mixed T1/T2 immune responses 
in severe asthma(321, 322). Theoretically, also in CRS anti-type 1 
strategies may be useful, but no trials have been performed 
yet. As a caveat: in several studies, anti-TNF treatment was 
associated with serious side effects, especially infections(323).  
6.1.31.6. Anti-IL-17 alpha 
Neutrophilic inflammation in CRSsNP, as well in as in NP from 
patients with cystic fibrosis (CF) is predominantly driven by IL-
17, with ILC3s being an important source of IL-17, while its role 
in CRSwNP with or without asthma is questionable(324). Findings 
from early clinical studies with anti-IL-17 agents, including 
brodalumab, secukinumab, and ixekizumab provide strong 
evidence for the role of IL-17 signaling in the pathophysiology 
of a range of inflammatory diseases(325). However, data from a 
pivotal randomized, placebo-controlled double-blind trial with 
brodalumab in 300 patients with moderate to severe asthma, 
appeared rather disappointing(326). Studies in CRSsNP and CF 
patients with CRSwNP should be performed to understand the 
potential of this approach in this disease.
6.1.31.7. Anti-CXCR2 receptor
Another therapeutic strategy in neutrophilic airway 
disease targets the IL-8 receptor CXCR2 to reduce airway 
neutrophilia(327). Two placebo-controlled studies with CXCR2 
antagonists have been conducted in patients with uncontrolled 
severe (neutrophilic) asthma(328, 329). Despite reductions in 
sputum and blood neutrophils in one study(328), substantial 
clinical effectiveness was not obtained in either study. In line 
with the negative outcomes in clinical studies targeting IL17RA, 
these findings challenge a crucial role of neutrophils as potential 
therapeutic targets in asthma, while so far no studies in CRS 
targeting neutrophils have been conducted.
6.1.31.8. Anti-GM-CSF/IL-3/IL-5
Granulocyte-macrophage colony stimulating factor (GM-
CSF), IL-3 and IL-5 stimulate pro-inflammatory activities of 
haematopoietic cells, through interaction with the receptor 
complex incorporating the shared β common (βc, CD131) 
receptor(330). These cytokines are critical mediators in the 
pathogenesis of inflammatory airway disease. A novel human 
monoclonal antibody (CSL311) may interact with all three 
cytokines at the same time, specifically targeting eosinophil 
survival. In an ex vivo study, CSL311 inhibited the survival of 
inflammatory cells in induced sputum from allergic asthmatic 
subjects undergoing allergen bronchoprovocation(330). Presently, 
a phase 1 study of CSL311 in mild asthma has commenced 
(https://clinicaltrials.gov/ct2/show/NCT04082754). 
6.1.31.9. Anti-TSLP
Upon stimulation of the airway epithelium, several alarmins may 
be released, including thymic stromal lymphopoietin (TSLP), 
IL-33, and IL-25 which may induce downstream type 2 responses 
both via the innate and adaptive pathways. These cytokines 
may serve as targets for future treatment of type 2 disease(331). 
TSLP is a cytokine that triggers dendritic cell-mediated TH2 
inflammatory responses, enhances IL-1-dependent TH2 cytokine 
production in mast cells and together with IL-33 or IL-25 
activates ILC2s. Exposure of nasal polyp-derived epithelium to 
a virus, in contrast to healthy control epithelium, triggers the 
production of TSLP(332). Although increased levels of TSLP mRNA 
have been found in nasal polyps of CRSwNP patients compared 
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to uncinate tissue from patients with CRS or control subjects, the 
TSLP protein was significantly decreased, obviously degraded 
by tissue proteases(333). A relatively small double-blind, placebo-
controlled trial in 31 patients with mild allergic asthma was 
performed using three monthly doses of AMG 157 (700 mg) or 
placebo intravenously(334). AMG 157 attenuated allergen-induced 
early and late asthmatic responses, and decreased blood and 
sputum eosinophils. Whether anti-TSLP therapeutics will have 
clinical value in CRSwNP remains to be demonstrated
6.1.31.10. Anti-IL-25
As mentinoned above, upon stimulation of the airway 
epithelium, several alarmins may be released, including IL-25 
which may induce downstream type 2 responses both via the 
innate and adaptive pathways and may thus serve as targets 
for future treatment of type 2 disease. IL-25 expression has also 
been found to be upregulated in the mucosa of patients with 
CRSwNP versus healthy controls and to positively correlate 
with the expression of several inflammatory markers, including 
GATA3 (see above), TGF-β1, and TGF-β2. Anti-IL-25 treatment 
reduced the number of nasal polyps and mucosal thickness 
due to oedema as well as the infiltration of inflammatory cells 
in a mouse model of CRSwNP(335). Based on these data, it has 
been speculated that IL-25 antagonism could be specifically 
promising in Asian nasal polyposis. 
6.1.31.11. Anti-IL33
Interleukin 33 is a key upstream mediator of type 2 
inflammation within the airways. This alarmin binds to a 
heterodimeric cell-surface receptor consisting of a IL-1 receptor 
accessory protein and ST2 on immune cells, such as TH2 cells, 
ILC2s, basophils, eosinophils, mast cells, dendritic cells (DCs) 
and others, activating intracellular signaling pathways and thus 
supporting the allergic airway inflammation. Direct exposure 
of airway epithelium to S. aureus increases the expression 
of IL-33 and TSLP, and consecutively of IL-5 and IL-13 in nasal 
polyp tissue, accompanied by elevated expression levels of 
TSLP and IL-33 receptors(336). In mice, repeated intratracheal 
exposure to SplD, a staphylococcal protein, led to IL-33 and 
eotaxin production, eosinophilia, bronchial hyperreactivity, 
and goblet cell hyperplasia in the airways. Blocking IL-33 
activity with a soluble ST2 receptor significantly decreased the 
numbers of eosinophils in this model(337). Furthermore, IL-33 
may induce mucus overproduction in human epithelial cells(338). 
In CRSwNP, ILC2s were found to be increased versus control 
and CRSsNP tissue , spontaneously releasing type 2 cytokines 
including IL-5 and IL-13(339). ILC2s can be found specifically in 
high numbers in CRSwNP patients with comorbid type 2 disease 
such as asthma(340, 341). The regulation of IL-33 and thus the effect 
of serine-protease like proteins (SPLS) in tissue are strongly 
dependent on the regulation of proteases and anti-proteases(342). 
This regulation, as well as specific antibodies to IL-33 or its 
receptor, may be used for therapeutic intervention in CRSwNP in 
the future.  
6.1.31.12. Biphasic antibodies
Novel highly potent bispecific antibodies, e.g. anti-TSLP/IL13 
antibodies, that concurrently inhibit the signaling of two or 
more cytokines, e.g. anti-IL4Ralpha/anti-IL5, may be designed 
and developed for human airway disease(343).
6.1.31.13. Anti-IL7R (CD127)
Interleukin (IL)-7 is a cytokine that is constitutively produced by 
stromal cells in non-haematological tissues, by lymphoid tissue 
(thymus and bone marrow), and by lymphatic endothelial cells. 
An increasing body of both pre-clinical and clinical evidence 
suggests that elevated levels of IL-7 and/or the IL-7 receptor 
(IL-7R, CD127) are associated with various disease/inflammatory 
states. In inflamed tissues, several cell types, including 
macrophages, dendritic cells, and fibroblasts produce IL-7. IL-7 
primarily acts on T cells and ILCs, which are increased at the 
inflammatory sites that abundantly express CD127(344). 
Although IL-7R signalling is crucial to most T lymphocytes 
and ILCs, most predominantly ILC2 and ILC3s(345), regulatory T 
cells (Tregs) exhibit low - to - undetectable expression of the 
receptor. It was hypothesized that blocking IL- 7R signalling may 
selectively spare Tregs function while exerting inhibitory effects 
on other potentially pathogenic T cell types (346).
The substantial amelioration of inflammation and 
immunopathology in experimental animal models for these 
diseases by blocking IL-7(receptor) supports this role of IL-7 and 
demonstrates that IL-7 and its receptor represent novel targets 
for immunotherapy(347).
CD127 is also a component of TSLPR and is required for efficient 
TSLP signalling(348). Furthermore, TSLPR complex-mediated 
inflammation has been associated with a number of allergic 
inflammatory diseases(349). 
To date, one double-blind (a study of a single intravenous 
infusion of anti-CD127 mAb) has been performed(350). Therapy 
was well tolerated and blocked IL-7 receptor signalling upon full 
target engagement. Although there was no discernible impact 
on peripheral T cell subsets in healthy subjects, anti-CD127 
may effectively modulate the autoinflammatory activity of 
pathogenic T cells/ILCs in diseased tissues. 
6.1.31.14. Anti-DP2 or CRTH2 
Prostaglandin D2 (PGD2) is a metabolite of the arachidonic acid 
via the cyclooxygenase (COX) pathway and a key mediator in 
the pathophysiology of allergic rhinitis, chronic rhinosinusitis 
and asthma(351). PGD2 exerts its bio-active activities through 
interaction with the DP1 receptor and DP2 or chemoattractant 
receptor-homologous molecule on Th2 cells (CRTH2), located 
on several structural and inflammatory cells. Through DP2 
receptors located on Th2 cells, innate lymphoid type 2 cells 
(ILC2), and eosinophils, PGD2 interlinks the adaptive and innate 
immune pathways and, hence, seems an attractive target for 
type2 disorders(352, 353). CRTH2 antagonists represent a category 
of small molecules (SM) currently under development for 
the treatment of asthma and related syndromes(354, 355). In the 
initial proof of concept studies, CRTH2 antagonists showed an 
overall modest protection against allergen-mediated airway 
responses of the upper(356) and lower respiratory tract(357, 358). 
When given as monotherapy or on top of standard controllers 
to patients with mild to moderate asthma for four to 12 weeks, a 
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similarly modest effectiveness was observed on clinical indices 
such as symptom scores, disease control, lung function and 
inflammatory markers(359-362). Until recently, in studies of allergic 
airway disease, the overall therapeutic effectiveness of CRTH2 
antagonists compared to antihistamines(356) and leukotriene 
receptor antagonists (LTRA)(362), while some studies showed 
improved effectiveness in selected patient populations(361, 363). 
While previous data showed upregulation of the PGD2 pathway 
and CRTH2 in (more) severe uncontrolled type 2 asthma(364), 
12 weeks of treatment with a dual DP/CRTH2 antagonist 
(AMG853) failed to show clinical effectiveness in patients with 
moderate to severe asthma uncontrolled by corticosteroids(365). 
Alternatively, in a similar study population, another CRTH2 
receptor antagonist, fevipiprant, on top of corticosteroids for 
12 weeks, reduced airway eosinophils and improved clinical 
and physiological parameters in patients with moderate-severe 
asthma with sputum eosinophils(366). 
Although, no data have been published on CRTH2 antagonists 
in CRSwNP so far, based on their mechanism of action, it is 
plausible to assume that these SM may have clinical potential 
in patients with type2 disease despite different clinical 
presentations which include severe eosinophilic and/or 
corticosteroid-resistant asthma and CRSwNP. Future studies of 
CRTH2 antagonists or combinations with LTRA or biologicals on 
top of corticosteroids should provide the evidence(367).
6.1.31.15. Bacteriophages and anti-biofilm agents
As antibiotic treatment may not be effective or may lead to 
resistance of germs, alternative therapeutic strategies against 
S. aureus and other frequent germs in the nose and paranasal 
sinuses may be useful. Theoretically, viruses targeting and 
killing germs (called bacteriophages) have been proposed to 
kill even multidrug resistant S. aureus(368). In addition, a cocktail 
of bacteriophages could possibly reduce biofilm formation in 
vitro(369, 370). This approach may be enforced by targeting the 
essential iron metabolism for bacterial growth, survival and 
pathogenesis(371). In an ex-vivo experiment using nasal polyp 
mucosa, it was shown that a S. aureus-bacteriophage could kill 
naturally occurring nasal S. aureus and reduce the S. aureus 
driven IL-5 synthesis(372). However, no clinical studies have been 
performed yet in human airway disease, while potential safety 
issues need to be addressed first. 
During pregnancy it is advised to  continue nasal 
corticosteroid sprays for CRS maintenance.
6.1.32. CRS treatment during pregnancy
6.1.32.1. Summary of the evidence
A recent systematic review evaluating CRS treatment during 
pregnancy found no relevant level 1, 2, or 3 studies(373).  A 
panel of experts formulated a number of recommendations. 
They advised to continue using nasal corticosteroids because 
modern nasal corticosteroids including budesonide, fluticasone 
and mometasone should be safe to use for CRS maintenance 
during pregnancy at recommended doses. The off-label use of 
budesonide irrigations or CCS nasal drops is not recommended. 
There is fairly good evidence for the safety of inhaled CCS 
in asthma during pregnancy. Budesonide is category B in 
pregnancy and remains the agent for which the preponderance 
of safety data exists(374). Newer generation sprays have negligible 
systemic absorption and may be safe to use, but evidence that 
these medications during pregnancy are not associated with any 
untoward risks is lacking. 
The panel concluded that oral corticosteroids in short bursts 
may be safe after the first trimester. Use is better justified in 
severe CRS, especially if causing exacerbation of asthma. They 
advised consultation with patient’s obstetrician. 
Based upon the asthma literature, oral corticosteroids use 
would be expected to be associated with slightly increased risk 
of cleft lip with or without cleft palate, increased incidence of 
preeclampsia, and the delivery of both preterm and low birth 
weight infants. Oral corticosteroids cause hyperglycaemia and 
can lead to/worsen diabetes, causing additional maternal-
foetal risks. Patients should undergo diabetes testing prior 
to use, especially if a longer course of corticosteroids is 
being considered. First trimester use has the greatest risk of 
potential teratogenicity. The risks of oral corticosteroids use 
are outweighed by risks of undertreated asthma, but this 
justification is less so in CRS and clinical judgment must be 
exercised. Oral corticosteroids are considered to be compatible 
with breastfeeding. The panel advised to use oral antibiotics 
that do not harm the foetus for ABRS or acute exacerbations 
of CRS. Penicillin and cephalosporin are the safest classes, 
and can be given when endoscopic evidence of purulence 
is present. Antibiotics that put the foetus at risk such as 
tetracyclines, aminoglycosides, trimethoprim-sulfamethaxazole 
and fluoroquinolones should not be used during pregnancy, 
nor long-term macrolide or doxycycline.  The panel advises 
to avoid anti-leukotrienes for CRS maintenance during 
pregnancy because of the low-quality evidence of efficacy of 
Figure 6.2.1.1. Forest plot of the effect of preoperative use of corticosteroids versus placebo on surgical blood loss.
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Figure 6.2.1.3. Forrest plot of the effect of preoperative use of corticosteroids versus placebo on duration of surgery.
Figure 6.2.1.2. Forrest plot of the effect of perioperative use of corticosteroids versus placebo on the quality of the surgical field.
Table 6.2.1.1. Effect of preoperative corticosteroids on sinus surgery.
DBPCT, Double Blind Placebo Controlled Trial; CRSwNP, Chronic Rhinosinusitis with nasal polyps; VAS, Visual Analogue Scale; FESS, 
Functional Endoscopic Sinus Surgery.
Study Methods Participants Interventions Outcomes Results
Ecevit 
2015(124)
DBPCT 23 CRSwNP pa-
tients having FESS 
(22 evaluated)
• 60 mg prednisolone once daily for 7 
days followed by 10 mg predniso-
lone every other day for 8-10 days 
preoperatively
• Placebo once daily for 7 days fol-
lowed by placebo every other day 
for 8-10 days preoperatively
• Blood loss (ml)
• Surgical field quality 
(Boezaart, 0-5)
• Operation time
• Hospital stay
Treatment with topical 
corticosteroid  compared to 
placebo resulted in significantly:
• Reduced blood loss
• Improved surgical field quality
• Decreased operation time
• Hospital stay
Gunel 
2015(379)
DBPCT 65 CRSwNP pa-
tients having FESS
• Oral prednisolone (1 mg/kg), once 
daily for 2 days and then tapered 
down until day 10 (n=36) preoper-
atively
• Placebo once daily for 2 days and 
then tapered down until day 10 
(n=29) preoperatively
• Blood loss (ml)
• Surgical field quality 
(VAS)
Treatment with oral corticosteroid  
compared to placebo  resulted in 
• No difference in blood loss or 
surgical field quality
Albu 
2010(380)
DBPCT 70 CRS (33 CRSwNP) 
patients having FESS
• Mometasone nasal spray 200 mcg 
twice daily 4 weeks preoperatively 
(n=35)
• Placebo nasal spray twice daily 4 
weeks preoperatively (n=35)
• Blood loss (ml)
• Surgical field quality 
(Boezaart, 0-5)
• Operation time
Treatment with topical 
corticosteroid  compared to 
placebo resulted in significantly:
• Reduced blood loss
• Improved surgical field quality
• Decreased operation time
Wright 
2007 (381)
DBPCT 26 CRSwNP patients 
having FESS
• Oral prednisolone 30 mg daily for 5 
days preoperatively
and then 30 mg daily for 9 days 
preoperatively (n=11) 
• Placebo once daily for 5 days pre-
operatively
and for 9 days preoperatively (n=15) 
• Blood loss (ml)
• Operation time
Treatment with oral corticosteroid 
compared to placebo resulted 
in no difference in blood loss or 
surgical field quality
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anti-leukotrienes in CRS (see 6.1.9.2.). However, montelukast 
can be continued / initiated for recalcitrant asthma during 
pregnancy, especially in those with prior response. Furthermore, 
they advised to avoid oral decongestants and first-generation 
antihistamines should be avoided given their sedative and 
anticholinergic properties. Allergen immunotherapy is likely safe 
to continue during pregnancy. However, initiation or build-up of 
immunotherapy should be not be conducted during pregnancy. 
Aspirin therapy for AERD should be discontinued during 
pregnancy.
6.1.32.2. Conclusion
Expert panel recommendations for rhinosinusitis management 
during pregnancy included continuing nasal corticosteroid 
sprays for CRS maintenance, using pregnancy-safe antibiotics for 
acute rhinosinusitis and CRS exacerbations, and discontinuing 
aspirin desensitization for aspirin exacerbated respiratory 
disease. 
6.2. Surgical treatment
6.2.1 Primary endoscopic surgery 
6.2.1.1 Preoperative CT scanning – is the timing of the scan 
prior to the operation important?
To date, previous iterations of EPOS and other guidelines have 
not stipulated clear guidance on timing, although the current 
American College of Radiology (ACR) appropriateness criteria 
describe CT scanning without contrast as the imaging modality 
of choice for diagnosing CRS3.  A CT scan may or may not have 
already been performed as part of the diagnostic work-up for 
CRS patients; for those where endoscopic findings confirm the 
diagnosis, the CT scan may be reserved until the point at which 
surgical intervention is being contemplated, unless concerns 
exist at first presentation about any unusual features such as a 
mucocoele(375). 
A CT scan is mandatory prior to surgery, both to 
confirm the presence and extent of disease.
A scan is mandatory prior to surgery, both to confirm the 
presence and extent of disease, and to identify any anatomical 
features that may predispose to the risk of complications. 
Multiplanar images are required to fully assess the anatomy. 
There are a number of systems published to facilitate systematic 
preoperative interpretation of the images;  the CLOSE mnemonic 
is widely used (376). 
C Cribriform niche – depth and asymmetry should be evaluated
L Lamina papyracea – examined for dehiscence
O (Onodi) spheno-ethmoidal cells
S Sphenoid sinus – examined for dehiscence of bone overlying 
the optic nerve and carotid artery
E Ethmoidal arteries – the position of the anterior and posterior 
ethmoid artery relative to the skull base should be assessed
Provided no surgical procedures have been 
performed in the interim period, it is not essential 
to repeat CT imaging.
Provided no surgical procedures have been performed in 
the interim period, it is not essential to repeat CT imaging if 
a scan has been performed at an earlier date. Only one study 
has evaluated this to date; Huang et al. identified 56 patients 
undergoing repeated imaging prior to ESS, with a median 
interval of 782 days. There was no significant difference in 
radiological extent of disease measured using Lund-Mackay 
scores and the repeat scan did not change the proposed extent 
of surgery.
 
6.2.1.2. Preoperative medication – what should this consist 
of to optimise the surgical field and outcome?
Excess bleeding during sinus surgery may result in an increase 
in operative time, difficulty of surgery and potentially serious 
complications. Bleeding during FESS is evaluated by measuring 
the amount of blood loss, although this is quite a crude method, 
assessment of the surgeon of the quality of the surgical field and 
the operating time (see also 5.3.5.1.).
Methods to reduce bleeding are the pre-operative stopping of 
medication that can cause bleeding like anti-coagulants and/
or aspirin/NSAIDS although we are not aware of any studies in 
endoscopic sinus surgery showing a difference. However, for 
tonsillectomy a meta-analysis on reoperation for postoperative 
haemorrhage reveals a 7.2-fold increased risk in the aspirin 
group(377). 
6.2.1.2.1. Corticosteroids
It has been shown that increased inflammation increases 
bleeding during surgery(378). The use of preoperative 
corticosteroids improves the quality of the surgical filed, the 
duration of the surgery and the operation time.
Four DBPCT studies evaluated the effect of corticosteroids 
during the surgery(124, 379-381) (Table 6.2.1.1.). Two of these studies 
used systemic corticosteroids 5-15 days before the surgery(124, 
379). One study used systemic corticosteroids five days before the 
surgery and nine days after surgery(381), and one a corticosteroid 
nasal spray for four weeks before the surgery(380). All studies 
evaluated surgical blood loss. One study did not report 
standard deviations(381) and one did not estimate blood loss. 
Three studies(124, 379, 380)could be combined into a meta-analysis 
showing a significant but rather small mean reduction of blood 
loss of  -54 ml (CI -100 - -7). There was a significant heterogeneity 
(I2 74%) so data are presented as SMD (SMD -0.81 (CI -1.19 - 
-0.43), three studies, 120 patients (Figure 6.2.1.1.). 
Two studies evaluated the quality of the surgical field using the 
Boezaart scale (0-5)(382) and could be combined into a meta-
analysis(124, 380 ). It showed a significant impact on the quality of 
the surgical field of the use of preoperative corticosteroids (MD 
-0.98 (CI -1.37 - -.059, two studies, 55 patients) (Figure 6.2.1.2.).
Finally, data were pooled from two out of four studies which 
evaluated the effect of corticosteroids on the duration of the 
surgery(124, 380). Corticosteroids resulted in a significant reduction 
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of surgery time of almost 14 minutes (MD -13.84 CI -21.02 - -6.68, 
2 studies, 55 patients) (Figure 6.2.1.3.).
Interestingly there does not seem to be a difference between 
four weeks of local corticosteroids or 15 days of systemic 
corticosteroids. It is not always clear whether the systemic 
corticosteroids were given on top of local corticosteroids or 
separate. The study of Ecevit(124)  giving systemic corticosteroids 
after local steroids failed, but it was not disclosed whether the 
local corticosteroids were continued.
In conclusion: The use of perioperative corticosteroids reduces 
blood loss and operation time and improves the quality of the 
surgical field. This effect was shown to occur  in one study with 
nasal corticosteroids and three with systemic corticosteroids. 
Whether there is an additive effect on systemic corticosteroids 
on top of nasal corticosteroids is unclear. The EPOS steering 
group advises to use (nasal) corticosteroids before endoscopic 
sinus surgery. 
There are no other medications that have been shown to 
improve the surgical field and outcome. Antibiotics are not 
helpful (see also 6.1.1.).
Peroperatively a number of measures can be taken to improve 
the surgical field. For a review of those please see 6.2.4.
6.2.1.3. Indications for surgery – what evidence do we have 
for when to operate?
The principle that sinus surgery should be considered only in 
patients with sinus disease refractory to a trial of primary medical 
therapy has been upheld since endoscopic surgery was first 
introduced(383). However, there is a lack of clarity regarding what 
constitutes an adequate trial of medical therapy (both in terms 
of therapeutic classes, modes of delivery and duration), the 
importance of patient compliance with treatment and how to 
determine failure of this approach. This likely contributes to wide 
variations in surgical intervention rates, found in North America 
and Europe, both between states and between countries. In 
the USA, a mean adjusted rate of 0.94 was found per 1000 
population in 2015, with a four-fold difference between highest 
(1.8) and lowest rates (0.5)(384). In the UK the mean adjusted 
rate is nearly half; 0.53 per 1000 population, with a five- fold 
difference between highest and lowest regions (https://www.
england.nhs.uk/rightcare/products/atlas/). Mean annual adjusted 
rates in Alberta, Canada are 0.33/1000(385) and in Finland(386) 
the nationwide annual rate of ESS is 0.71 per 1000 people, but 
variation remains very high. In Finland hospital district rates 
varied from 0.25/1000 (95% CI 0.18 to 0.32) to 1.15/1000 (95% CI 
1.09 1.21). In the Canadian study, the mean extremal quotient 
for health status areas was 6.9, indicating a seven-fold difference 
between the highest and lowest regions. Overall, there has been a 
progressive increase in intervention rates, despite declining rates 
of CRS diagnoses being recorded(387), and increases in the number 
of sinus procedures being performed. Geographical variation 
in disease prevalence, access to healthcare and varying patient 
preferences may account for some of the variation, but in each 
study areas of high variation were found immediately adjacent to 
areas of low variation. A recent study shows that variation persists 
when separating CRS according to polyp status(388).
There is a lack of clarity regarding what constitutes 
an adequate trial of medical therapy (both in 
terms of therapeutic classes, modes of delivery and 
duration), the importance of patient compliance 
with treatment and how to determine failure of 
this approach.
There are few attempts in the literature to standardise 
indications for surgery. A systematic review of studies reporting 
outcomes from ESS identified 387 published studies in a five-
year period, however only 21% reported medical treatment 
employed prior to surgical intervention(389). Medical therapy 
regimens reported included topical intranasal corticosteroids 
in 91% studies (mean duration eight weeks), systemic 
corticosteroids in 61% (18 days), oral antibiotics in 89% (23 
days), saline irrigations in 39% and oral antihistamines in 11%.
As the aim of surgery is to improve the severity 
of patient’s symptoms, the decision to operate 
should only be made in patients with symptomatic 
disease, with the exception of patients with actual 
or impending complications. 
One study to evaluate factors (including demographics, 
clinical measures, social support and personality type) that 
influence a patient’s choice to pursue surgery found that only 
their preoperative symptom severity, measured using the 
Sino-Nasal Outcome Test (SNOT)-22, predicted the choice for 
surgical intervention(390). Preoperative symptom scores are 
predictive of postoperative improvement and the chance of 
achieving a clinically significant change in symptom scores(84, 391). 
Furthermore, postoperative changes in symptom scores can also 
predict need for revision surgery(392).  
As previously mentioned, a CT scan is considered mandatory 
prior to undertaking sinus surgery for surgical planning. 
However, there is evidence that a relatively high proportion 
of patients undergoing surgery have CT scores, measured 
using the Lund-Mackay score, within the range of the normal 
population; in the 2006 UK comparative audit of surgery, a 
prospective study enrolling 3128 patients undergoing sinus 
surgery in 87 different hospitals(393), 35% patients with CRSsNP 
had a LMS<=4, as did 8% CRSwNP. There is a poor correlation 
between preoperative LMS and quality of life measures(394), 
nonetheless, evidence of at least some disease on CT scan 
would be desirable. In a small study of patients with low-stage 
CRS on CT (LMS1-3) by Rudmik et al., improvements in QOL 
were comparable to those with more extensive disease(395). In a 
2017 publication evaluating the severity of disease in patients 
undergoing balloon sinus dilation, 57% had LMS <=4, with 19% 
of the total study cohort having no opacification or mucosal 
oedema in any sinus. In contrast to the study in low-stage 
disease, a randomised trial of balloon dilatation in patients with 
no evidence of sinus disease (LMS=0), surgery was no better 
than a sham procedure in terms of improving QOL or headache 
severity(396). 
An early paper on indications for sinus surgery summarised 
“if the patient has an appropriate history, appropriate physical 
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findings, and appropriate CT, endoscopic sinus surgery 
typically will be indicated and beneficial”(383). In the 25 years 
following publication there has been little to further refine that 
description. In an attempt to define evidence-based indications 
for surgery, Rudmik utilised the RAND/UCLA appropriateness 
methodology, with an international, multidisciplinary panel 
of 10 experts in CRS who completed two rounds of a modified 
Delphi ranking process along with a face-to-face meeting(397). 
A total of 624 clinical scenarios were ranked, 312 scenarios 
each for CRS with and without nasal polyps. For adult patients 
with uncomplicated CRS with nasal polyps, it was agreed that 
ESS could be appropriately offered when the CT Lund-Mackay 
score was >/= 1 and there had been a minimum trial of at least 
eight weeks’ duration of a topical intranasal corticosteroid 
plus a short-course of systemic corticosteroid with a post-
treatment total SNOT-22 score >/= 20. For adult patients 
with uncomplicated CRS without nasal polyps, ESS could be 
appropriately offered when the CT Lund-Mackay score is >/= 
1 and there had been a minimum trial of at least eight weeks’ 
duration of a topical intranasal corticosteroid plus either a 
short-course of a broad spectrum/culture-directed systemic 
antibiotic or the use of a prolonged course of systemic low-
dose anti-inflammatory antibiotic with a post-treatment total 
SNOT-22 score >/= 20. These criteria were considered the 
minimal threshold, and not all patients who meet the criteria 
should have surgery, but application should reduce unnecessary 
surgery and practice variation. A subsequent study applied 
the criteria retrospectively to patients recruited to a multi-
centre cohort study and found that patients where surgery was 
deemed ‘inappropriate’ reported significantly less improvement 
in their quality of life(398).
As there are strong recommendations for use of intranasal 
corticosteroids and saline irrigation, based on high-quality level 
1 evidence(399, 400), guidelines are consistent in recommending 
usage prior to offering surgery. In contrast, international 
guidelines are conflicted regarding whether long-term 
antibiotics and oral steroids should be included as part of 
adequate medical therapy (AMT), reflecting conflicting evidence 
in the current literature(297, 397, 401), and concerns with regards to 
side-effects. 
6.2.1.4. Prediction of the success of surgery
Brooks et al. studied whether Lund-McKay CT score (LMS) was 
predictive of postoperative QOL outcomes in adult patients 
with medically recalcitrant CRS (n = 665) in a prospective, 
observational cohort study(402). It showed a significant 
association of preoperative CT scores with preoperative 
SNOT-22 scores and postoperative SNOT-22 scores, driven by 
extranasal and rhinologic subdomains of the QOL questionnaire. 
Patients in the lowest preoperative LMS quartile had the lowest 
mean change in SNOT-22 scores at 12 months (16.8 points; 95% 
confidence interval [CI], 12.2-21.3). Patients in the second and 
third lowest preoperative LMS quartiles had mean changes at 12 
months of 21.1 points (95% CI, 16.7-25.4) and 23.1 points (95% 
CI, 18.3-27.9). Patients in the highest preoperative LMS quartile 
had the greatest improvement in SNOT-22 scores after FESS 
(29.9 points; 95% CI, 24.9-34.8). The difference in QOL change 
at 12 months between the highest and lowest preoperative 
LMS quartiles was 13.1 points (95% CI, 6.0-20.2; p<0.001). The 
key limitation of this study may be the setting, as this was 
conducted in a large tertiary otolaryngology setting and thus 
may not be transferable to wider practice.
Lal et al. tried to assess retrospectively features that might 
predict outcomes from endoscopic sinus surgery (ESS) with 
the help of clinical and endotypic features, CT, histopathology 
and the SNOT-22 in 146 adults that underwent ESS(403). They 
were able to differentiate severity grades of CRSsNPs as clusters 
from middle burdened (cluster D) to severely burdened (cluster 
A), the latter with high scores in all four domains. Asthma 
burden and eosinophilia were significantly higher in cluster C 
(p=0.03) and three months after ESS, all groups had significantly 
improved (p<0.0001). At six months, patients in cluster C tended 
to worsen.
In a prospective, observational multi-centre study on 690 
patients with CRS, Soler et al. tried to identify clusters of patients 
based on three common clinical variables(404). SNOT-22 was 
completed at baseline and 18 months after continued medical 
or surgical treatment (according to patient preferences). Forty-
two percent (289/690) of patients had undergone prior sinus 
surgery and comorbidities, such as allergy (25%, 172/690), 
asthma (37%, 255/690), and nasal polyps (37%, 254/690) were 
common. To assess factors associated with achieving a minimal 
clinically important difference (MCID) for each QOL measure 
after either medical or surgical treatments, controlling for 
baseline value and follow-up duration, a logistic regression 
was performed. Three variables were shown to allow a 
discrimination of patients: preoperative SNOT-22 score, age and 
missed productivity. Extent of the surgery was, however, left 
to the criterion of each treating surgeon, which does not allow 
one to draw conclusions about the potential effect of various 
extensions of the surgical procedure. 
Using a similar regression to determine risk adjusted outcomes 
in a prospective cohort of 3128 patients undergoing sinus 
surgery, Hopkins  et al.(393) found the preoperative SNOT-22 score 
to be a strong predictor of postoperative SNOT-22, with those 
having higher preoperative scores achieving greater reductions 
in symptom scores but having persistently higher scores 
postoperatively. Older patients achieved greater improvement, 
patients with asthma less improvement. Male patients reported 
lower scores at all time points, but there was no difference in the 
overall amount of symptom improvement by gender.
More recently, a systematic review and meta-analysis with 
meta-regression analysis identified the variables among 3048 
patients that significantly correlated with an improved SNOT-22 
outcome(405) namely: older age, asthma, prior ESS, and a high 
preoperative SNOT-22 score. It seems obvious that a higher 
SNOT-22 at baseline is more likely to be reduced after surgery. 
This association applied to older patients as well, who reported 
a higher SNOT-22 score preoperatively. Current tobacco use 
status and the length of follow-up correlated with poorer SNOT-
22 outcomes. 
In summary, the preoperative symptom score has consistently 
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been shown to the best predictor of success of surgery with 
those with higher preoperative scores achieving greater 
improvement in symptoms scores.
The preoperative symptom score has consistently 
been shown to the best predictor of success of 
surgery with those with higher preoperative scores 
achieving greater improvement in symptoms 
scores.    
6.2.1.5. Timing of the surgery relevant to the duration of the 
disease – does this affect outcome?
In order to evaluate the impact of timing of surgery on 
outcomes, data from both the UK prospective audit of surgery 
for CRS and electronic datasets were analysed by Hopkins et 
al.(406). Patients were classified according to the duration of their 
CRS until their first surgical intervention for CRS. Three cohorts 
of patients were defined: early cohort – less than 12 months; 
mid cohort – 12-60 months; and late cohort – more than 60 
months of symptoms. In the UK Audit 1493 patients having 
primary surgery were identified; 11.5% in the early group, 50.2% 
in the mid group and 38.2% in the late group. Patients in the 
early group had not only a greater percentage improvement in 
their symptoms, but the improvement was better maintained 
over five years. At five years there was a significantly higher 
proportion of patients in the early group maintaining a clinically 
significant improvement over baseline (71.5%) than in either the 
mid (57.3%) or late (53.0%) groups. Using healthcare interactions 
as a proxy for symptomatic improvement in CPRD (assuming 
that higher frequency of healthcare visits and prescription 
medications reflect a poorer outcome from surgery), a similar 
pattern was found. Patients having early surgery saw their GP 
less frequently and received fewer prescription medications 
each year after surgery than the mid or late cohorts. These 
results were further replicated in a US based electronic dataset, 
MarketScan(407).
Perhaps of even greater interest to the population as a whole, 
the impact of ESS on the subsequent development of asthma 
was also analysed. It was found, using both UK and US datasets, 
that ESS was associated with a reduction in the incidence of new 
asthma diagnoses following surgery, and that the reduction was 
greatest in those having early surgery(408). 
Other groups have subsequently studied the impact of timing 
of surgery.  A prospective study in Sweden found that patients 
with less than 12 months of sinus disease derived greatest 
benefit after ESS(409). In contrast, a multi-centred cohort study 
in the US found that improvements in QOL were greater in 
those with longer pre-operative symptom duration. The most 
recently published study evaluated the effect of surgical wait 
times and found that prolonged wait times were associated with 
detrimental outcomes(410).
Although the timing of surgery has not been formerly evaluated 
in a randomised trial, there is a growing body of evidence 
suggesting that lengthy delays in intervention are detrimental 
to symptom improvement. The mechanism for this is not yet 
clear. Reduction in type 2 inflammation and prevention of 
irreversible remodeling of the mucosa by facilitating improved 
access to topical therapies are potentially disease-modifying 
benefits of surgery.
There is a growing body of evidence suggesting 
that lengthy delays in intervention are detrimental 
to symptom improvement.
6.2.1.6. Does the type or extent of surgical procedure affect 
outcomes? 
Many acronyms have been applied to FESS since its inception 
in the 1980s to characterise extent of the surgical procedure. 
First reported in 1996, minimally invasive sinus technique 
(MIST) is a conservative approach involving simple ventilation 
of the lower sinuses and has been considered to settle cases 
even when severe disease is present some advocating its use in 
current practice(411, 412); however, it is likely that selecting cases 
with less aggressive endotypes of CRS may be the appropriate 
for the use of MIST. A key advocate of MIST in the literature 
is Peter Catalano at Massachusetts, USA who first published 
a case series of 85 patients undergoing MIST in 2003(413).  The 
series included a diverse age range from four to 81 years old but 
with an equal male/female divide. Using the Chronic Sinusitis 
Survey, patients were followed up for two years on average. The 
mean CSS symptom score showed 124% improvement, with 
a 30% improvement in the mean CSS medication score and a 
62% improvement in the mean CSS total score (all p-values < 
0.00001).  Thirteen percent of patients were symptomatically 
worse and 8% were unchanged. By the end of the follow up 
period, 6% had had revision MIST surgery and were reported to 
have improved afterwards.
6.2.1.6.1. Maxillary sinus
After the anterior ethmoid sinuses, the maxillary sinus is most 
frequently targeted in all forms of sinus surgery, regardless of 
extent(393) with a historic principle of the value of addressing 
this sinus to improve OMC functionality or vice versa(414). 
Wadwongtham and Aeumjaturapat studied differences in the 
patency rate between a large middle meatal antrostomy and 
an undisturbed maxillary ostium in endoscopic sinus surgery 
for CRSwNP in 60 cases with a similar extent of polyposis in 
a randomized setting(415). The patency rate of a large middle 
meatal antrostomy was 71.7-85% compared to 61.7-65% of the 
undisturbed maxillary ostium cases. There was a statistically 
significant difference only in early phase evaluation between the 
two surgical techniques (p-value = 0.002). Thirty-six of 60 cases 
(60%) had good results with adequate drainage openings, no 
infection and no recurrent polyps at the final evaluation. Early 
and small nasal polyps (grade I polyp) was the main correlation 
factor to the success of endoscopic sinus surgery for CRSwNP 
(p= 0.017). Patency was strongly dependent on the recurrence 
rate of the polyposis causing blockage. 
Albu and Tomescu conducted a prospective randomised 
controlled study on 133 patients to assess whether the size 
of a small middle meatal antrostomy (<6mm) or a large 
one (>16mm) had an influence in relieving the symptoms 
of rhinogenic chronic maxillary rhinosinusitis (obstruction, 
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headache, and nasal discharge). The postoperative size of the 
ostia did not correlate with the clinical outcome. However, 
persistent accessory maxillary ostia and scarring within the 
ethmoid cavity/sinuses were statistically significant predictors of 
poor surgical outcome(416). 
Similarly, Kim et al. studied 98 patients with CRSwNPs 
undergoing a maxillary antrostomy where 32 patients (group 
A), had the inflamed/polypoid mucosa radically (but not 
completely) removed with a powered microdebrider, 28 patients 
(group B), where only part of the mucosa was removed (mucosa 
in the inferior half of the sinus was preserved), and 38 patients 
(group C), where only enlargement of the maxillary ostium 
was performed without any removal of mucosa(417). Pre- and 
postoperative changes in symptoms, endoscopic polyp grade, 
and Lund-Mackay CT score were compared between the 
three groups. After twelve months follow up, the study found 
no significant differences in symptoms (on VAS), endoscopic 
4-point grading of the sinus mucosa or CT scores (LMS) between 
the three groups.
In a prospective, randomized, single-blinded study Myller 
et al. compared sides of the nose for either preservation or 
enlargement of the maxillary sinus ostium(418). In 30 patients 
with CRSsNP they performed ESS with uncinectomy on one 
side and an additional maxillary antrostomy on the other 
side. On the enlarged side, the natural ostium was widened 
posteriorly to double its size; of note 25 of the 30 patients 
also had a bilateral ethmoid bullectomy. LMS and the ostial 
diameters were analysed with 1mm slice thickness CT scans 
taken preoperatively and nine months post-operatively and 
were used for comparison of the two operative techniques. Also, 
the correlation between CT findings and subjective outcomes 
was studied with simple questionnaires using a total symptoms 
score out of 16 points; intervals for the latter were one month 
pre-operatively and one, 9 and 36 months postoperatively. 
Comparison of the preoperative and postoperative CT scans 
revealed a significant reduction of LM score was achieved on 
both sides, regardless of the type of procedure performed. The 
postoperative area of the ostium remained significantly larger 
on the antrostomy side compared to the uncinectomy side. A 
large maxillary sinus ostium size was associated with a lower 
postoperative LMS, however, the postoperative symptoms 
scores did not correlate to any of the postoperative CT-values (p 
> 0.05) suggesting that it does not provide superior symptom 
relief. 
Byun and Lee compared partial vs total resection of the 
uncinate process by assigning 25 patients with unilateral 
maxillary sinusitis (chronic maxillary sinusitis, fungal sinusitis, 
antrochoanal polyp, and odontogenic sinusitis) randomly to 
either surgical procedure(419). CRSwNP cases were excluded. The 
lower half of the uncinate process was resected in the partial 
group. Time required for the uncinectomy, healing period for 
the uncinectomy site and complications such as synechiae 
formation in the middle meatus were compared between the 
groups. Partial uncinectomy had a lower complication rate, a 
shorter surgical procedure and more rapid healing. However, 
outcomes with respect to symptom benefit, or the status of 
the maxillary sinus were not assessed either radiologically or 
endoscopically.
It is notable that some of these studies fail to address the normal 
physiology of the maxillary sinus. The critical factor is whether 
the natural ostium is patent or not, as the mucociliary pathway 
always beats towards the natural ostium, regardless of the size 
of the surgical antrostomy. (See Chapter 6.2.1.6.4. for more 
radical maxillary sinus procedures.)
A randomised prospective study comparing a limited approach 
at one centre with a more extensive approach at another 
centre was conducted by Kuehnemund et al. in 2002 on 65 
CRS patients (polyp status unknown)(420). The limited approach 
involved infundibulotomy, ethmoid bullectomy and maxillary 
antrostomy; the extensive approach involved infundibulotomy, 
ethmoidectomy, sphenoidotomy, opening of the frontal recess, 
maxillary antrostomy and reduction of the middle turbinate. 
With the caveat that a non-validated symptom score was used, 
the authors concluded that a more limited surgical approach 
may avoid perioperative complications in less experienced 
hands while still achieving the goal of improved ventilation and 
drainage; these findings obviously require corroboration two 
decades on with the use of a validated PROM to compare the 
groups and better patient characterisation.
Antral washout is now mainly of historic interest and a study by 
Pang et al. in 1996 failed to show any benefit for the addition 
of antral washout to medical treatment of CRS in an RCT on 
114 patients(421). However, a study in 2013 from South Korea 
compared canine fossa puncture (CFP) with middle meatal 
antrostomy (MMA) in 25 patients with severely diseased 
unilateral maxillary sinuses(422). Subjective outcomes were 
evaluated preoperatively and at three, 6, and 12 months 
postoperatively using the SNOT-20 and a visual analogue scale 
(VAS). SNOT-20 and VAS scores improved significantly at three, 
6, and 12 months post-procedure in both groups. However, 
significant improvement of SNOT-20 at 12 months and VAS 
scores for purulent discharge, foul odour, and postnasal drip at 
six and 12 months were observed in the CFP group compared 
with the MMA group which was attributed to the removal 
of severe maxillary mucosal disease that cannot be reached 
through MMA. 
6.2.1.6.2. Ethmoid sinuses
A small prospective study published in 2017 explored the 
role of ethmoid punch sinusotomy using the Relieva Circa™ 
device in a group of 10 CRSsNP patients who failed medical 
management(423).management. At follow up, 90% of puncture 
sites in anterior and posterior ethmoids remained patent with 
stenosis present in 28%.  Comparative LM scores showed a 
reduction of a score of 1 or 2 down to 0. Comparative pre and 
post SNOT-22 scores showed a significant mean reduction of 
33.1 (p<.0001), but clearly this device requires further evaluation 
in an appropriately powered RCT setting to determine its place 
as part of MIST surgical strategy.
6.2.1.6.3. Olfactory niche
A single RCT has looked at the role of clearing of olfactory cleft 
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polyps with a microdebrider during ESS for CRSwNPs to assess 
olfactory outcomes(424). The University of Pennsylvania Smell 
Identification Test (UPSIT), along with VAS and SNOT-20 were 
used to assess patients at baseline and six months. Seventeen 
patients were randomised to receive either cleft polyp removal 
or to have the cleft left undisturbed. All parameters improved 
in those having olfactory cleft surgery but only the VAS in 
those without (p<0.05). There was a statistically significant 
difference in UPSIT scores between the groups at six months 
postoperatively (p=0.00512), although long-term results 
showed regression to baseline. Whilst 17 patients is a small 
sample size, this gives some indication that careful debridement 
in the olfactory cleft may be effective in managing olfactory 
dysfunction in patients undergoing ESS for CRSwNPs, with the 
caveat that decline may be observed over a longer period.
6.2.1.6.4. Radical approaches
A cohort study published in 2016 reported that extended ESS 
(EESS )was taken to include resection of the middle and superior 
turbinates along with a total ethmoidectomy(425). Forty-seven 
patients with CRSwNP and asthma underwent either EESS or less 
radical “FESS”. Outcomes measured at one year suggested better 
outcomes for olfaction (as measured by VAS only) in the EESS 
group; endoscopic changes were improved in this group too but 
otherwise there were no differences between the groups. This 
study has a small sample size and without randomisation and 
psychophysical olfactory testing, limit its applicability.
A randomised, controlled trial with parallel design was 
conducted between July 2000 and December 2004, including 
119 patients with CRSwNP (grade III or higher)(426). Patients 
were randomly allocated to two treatment groups: classical 
endoscopic middle meatal antrostomy and endoscopic radical 
antrectomy. The description of the latter corresponds to a 
medial maxillectomy with complete removal of the maxillary 
sinus mucosa, a mega-antrostomy through the middle meatus 
and an adjuvant canine fossa puncture. The antrostomy was 
inferiorly extended to the level of the inferior meatus (with 
resection of the middle part of the inferior turbinate) and 
superiorly to the orbital floor.  There was a significant difference 
between the groups: 32% of patients in the endoscopic middle 
meatal antrostomy group were considered surgical failures, 
compared with 14.5% of the endoscopic radical antrectomy 
group (p=0.023). Unhealthy maxillary sinuses were significantly 
more prevalent in the endoscopic middle meatal antrostomy 
group (p=0.029).
In a RCT, Jakob et al. compared outcomes of 40 cases with 
chronic maxillary sinusitis treated with a Caldwell-Luc against 
40 cases with a middle meatal antrostomy(427). Over 77.5% 
of participants had CRSwNP. After 12 months, 44% of the 
Caldwell-Luc patients and 89% of the FESS patients reported 
improvement of their symptoms, showing that endoscopic 
middle meatal antrostomy is superior to Caldwell-Luc in 
managing patients with CRSwNP surgically and further evidence 
that the Caldwell-Luc approach should no longer be part of 
practice for routine ESS(428). An older RCT of 150 patients with 
chronic maxillary rhinosinusitis found that while both the 
Caldwell Luc and ESS approaches improved post-operative 
symptoms, there was stenosis of the maxillary ostium in 18.6% 
of the operated sinuses in the ESS group and stenosis of 
31.4% of the sinuses in the Caldwell-Luc group but with large 
polyps found more frequently after ESS. In addition 41% of the 
Caldwell-Luc patients had problems with changes in sensation 
of the cheek and 23% experienced severe pain. However, it is 
worth noting that 16 surgeons undertook the Caldwell-Luc 
procedure whereas only one surgeon performed ESS(102). A 
follow-up study was published in 1997 on 128 of the original 
cohort 5-9 years after their operation. One year after surgery 
51% of the C-L patients and 77% of the FES patients reported no 
symptoms or distinct improvement in their global symptoms, 
whereas 5-9 years postoperatively 82% of the C-L and 76% of 
the ESS patients reported this outcome, respectively. Thirteen 
C-L operated patients (18%) and 14 FES patients (20%) have 
been reoperated during 7-9 years follow-up(429).
Medial maxillectomy for CRS was considered by Woodworth et 
al, but only in patients having failed primary surgery(430).
6.2.1.6.5. Extended frontal sinus approaches
Alsharif et al. conducted a retrospective cohort  study of 50 
consecutive CRSwNPs patients(431). In those patients (n=12) in 
whom a full resection of the mucosa (“reboot technique) in 
all sinuses, including the frontal sinuses via a  Draf type III was 
performed the recurrence of nasal polyposis was significantly 
reduced for 30 months postoperatively compared to the current 
mucosa-sparing ESS. This is a novel approach but needs further 
studies, and it is not clear whether the improved outcome was 
related to mucosal removal or the more extensive approach 
itself required to achieve complete clearance.
In 2009, Silvermann et al. performed a systematic review on 
endoscopic frontal sinus surgery including retrospective case 
series without control (16 articles), prospective case series 
without control (three articles), and retrospective case series 
with internal control (four articles); mostly level 3 evidence(432). 
The surgical technique was described as frontal sinusotomy 
(n=4), frontal sinusotomy or frontal sinus drillout (n=1), frontal 
sinus drillout alone (n=1), endoscopic modified Lothrop 
procedure (EMLP) (n=9), Draf types I, II, or III (n=6); trans-septal 
frontal sinusotomy (n=1); and frontal sinus rescue procedure 
(n=1). The mean number of subjects was 44, and the average 
follow-up period was 23.6 months. Surgical success rate ranged 
from 50 to 100%. Unfortunately, due to the limitations of the 
literature base at the time of this particular review, there is little 
to conclude.
Abuzei et al. provided a thorough meta-analysis of the Draf  III 
after failure of primary FESS(433). Although this evidence would 
support the use of the Draf III approach in recalcitrant frontal 
sinus disease following failure of primary ESS, it is not relevant 
here in considering primary surgery. A prior review performed 
in the same year as Silverman et al, also only included revision 
cases(434); other studies are also irrelevant to the considerations 
of primary surgery for the same reason(435-440).
6.2.1.7. Recommendations for when more extensive or 
radical surgery is required 
Regarding whether all sinuses should be opened regardless 
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of disease extent or whether surgery should be targeted to 
affected sinuses, DeConde considered this dilemma in their 
observational study(441). Their results allowed them to compare 
147 subjects undergoing complete “full house” surgery with 
164 subjects where the surgery was targeted to less than all 
of the sinuses. The “complete” group had a significantly higher 
prevalence of asthma, acetylsalicylic acid (ASA) sensitivity, 
CRSwNPs and revision cases (p≤0.002). They also had a higher 
mean improvement in SNOT-22 and smell test scores (B-SIT) 
(p=0.011 and 0.005 respectively). The key limitation of the study 
was composition of the comparator groups, as inevitably in a 
non-RCT setting the patients with a higher burden of global 
airway disease received the complete surgical option. 
Masterson et al. conducted a retrospective review of 149 
patients who underwent “extensive” ESS (EESS) in a district 
general hospital(442). SNOT-22 scores were collected pre- and 
post-op as well as surgical revision rates and perioperative 
complications and this data was compared with the UK 
National Comparative Audit, the majority of whom underwent 
polypectomy alone or limited sinus surgery extending to 
the anterior ethmoid cavity. Revision rate at 36 months 
was significantly lower at 4% as compared to 12.3% in the 
national audit. No differences were seen in complication rates 
and significant improvements in SNOT-22 scores were seen. 
Although described as “extensive”, this cohort can probably be 
considered as “complete” as per the DeConde study above.
For primary surgery in CRSsNPs, more extensive surgery, such 
as a Draf III or endoscopic medial maxillectomy is traditionally 
less likely to be warranted given the nature of the pathology. 
The question for the surgeon counselling the patient will be as 
to what the goal of the surgery is in the individual patient. Even 
in CRSwNPs, the weight of evidence for extended approaches 
lies in revision cases and not for primary surgery, especially with 
respect to the frontal sinus where a more conservative approach 
is usually deemed appropriate(443, 444).
6.2.1.8. What is the value of adjunctive surgery?
6.2.1.8.1. Septoplasty
An underpowered prospective trial including 26 patients, 
designed to determine the role of addressing a deviated nasal 
symptom in ESS, claimed that septoplasty alone could be more 
effective than septoplasty and ESS in treating CRS(445). This used 
a 14-item symptom questionnaire and CT scores to compare the 
two groups and suggested that 93% felt symptomatically better 
from septoplasty alone compared to 81% from septoplasty and 
ESS (n=9). Another study considered this with specific reference 
to maxillary rhinosinusitis and again had a small sample size 
(n=40), but showed the opposite, that ESS with septoplasty 
was superior for overall symptom control when CRSwNPs was 
present(446). 
There are three questions the sinus surgeon should consider 
about a deviated nasal septum (DNS) when deciding whether to 
address it during ESS:
• Does the DNS contribute to significant nasal obstruction?
• Does the DNS prevent access to the sinuses during ESS?
• Will correction of the DNS facilitate better postoperative care?
A study by Smith et al. looking at surgical outcomes across three 
academic North American centres found not only that septal 
deviation prevalence varied significantly across the sites (from 
16% to 54%), as did subsequent rates of septoplasty, but also 
that septoplasty significantly improved postoperative SNOT-22 
scores(447). The reasons for the difference in rate of septoplasty 
in the centres was unclear and the authors concluded that 
further study was needed to determine clear indications for 
septal surgery within the scope of ESS. However, given that 
it was not just the nasal domain of the SNOT-22 that showed 
improvements, there appear to be wider benefits to this 
adjunctive procedure that may well be due to improved delivery 
of postoperative topical medications to the sinuses. 
6.2.1.8.2. Turbinate surgery
As per adjunctive septal surgery, evidence for turbinate 
surgery is limited. One study considered two methods of 
turbinate surgery during ESS where 54 patients with CRS were 
randomised to receive either an out-fracture and radiofrequency 
ablation of the ITs or just out-fracture alone. SNOT-20 and 
Lund-Kennedy scores were significantly better in the coblation 
group(448). Another small-scale study of only 16 patients 
showed no discernible benefit of middle turbinate resection 
for CRSwNPs cases within six months postoperatively but as an 
underpowered study is of little value(449).
6.2.1.8.3. Septoplasty and turbinate surgery together
Data from Hospital Episode Statistics in the UK shows that in 
2017-8 in England, there were 11,177 cases of ESS for CRSwNP 
in which 6% also underwent septoplasty and turbinate surgery, 
13% also underwent septoplasty and 11% underwent turbinate 
surgery, equating to approximately 1 in 3 of all cases of ESS for 
CRSwNP. The same data for CRSsNP shows that of 3876 cases 
of ESS, 12% underwent septoplasty and turbinate surgery, 
16% underwent septoplasty and 14% underwent turbinate 
surgery; thus approximately 40% of all cases of CRSsNPs. Overall 
for all cases of CRS, 33% of ESS cases underwent adjunctive 
septoplasty and/or turbinate surgery. Whilst this data does 
not tell us anything about outcomes, it does indicate surgeon 
choice in these cases. It is not clear whether “turbinate surgery” 
involved the middle or inferior turbinates.
6.2.1.9. Powered instruments
Although powered instrumentation is now the standard of 
care in many hospitals, only four studies have looked at this 
specifically. In 2013, Saafan et al. conducted a prospective RCT to 
compare the efficacy and safety of powered versus conventional 
endoscopic sinus surgery instruments in patients undergoing 
ESS for CRSwNPs with a sample size of 200 patients(450). The study 
addressed both intra-operative conditions and postoperative 
outcomes including complications across the peri-operative 
period. The only key notable statistically significant difference 
in symptom improvement on VAS at 12 months between the 
two groups was for olfaction in the powered group (p<0.001). 
The operative time and surgical conditions, as well as the 
incidence of post-operative synechiae were significantly better 
in the powered group with a trend towards improvement in 
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time to mucosalisation of the sinus cavities. In a separate study 
of 60 patients randomised by side of nose to have powered 
instrumentation on only one side of the nose, also supported 
reduced operative times in the powered sides(451). However, a 
more recent trial found that there was no significant difference 
at 13 months between 48 patients managed with conventional 
instruments and 49 patients where the microdebrider was used, 
when using Kupferberg nasal endoscopy grades, 20-item SNOT 
scores, Lund-Mackay scores and mucociliary clearance time 
as outcome measures(452). This corroborated the findings of an 
older study from 2003 looking at similar outcomes(453). Indeed 
Tirelli et al. in 2013 analyzed 311 cases of bilateral CRSwNP in a 
prospective randomized single-blind study using eachpatient 
as their own control, in that one side was operated on using the 
Blakesley forceps and the opposite side using the microdebrider. 
After a follow-up mean of 13.3 ± 1.2 months the Blakesley 
forceps caused a significantly lower NP recurrence rate than the 
microdebrider (p<0.001), though the microdebrider was more 
effective in preventing synechia formation (p<0.05)(454).
Interestingly a study comparing conventional cutting and 
non-cutting instruments also showed less synechiae in those 
patients where cutting instruments were used at a mean of 12 
years follow-up(455).
Initially concerns that tissue taken with powered instruments 
would not be suitable for histological diagnosis were dismissed 
by a study from McGarry et al. which showed that tissue could 
be collected in an in-line specimen trap and was comparable to 
conventionally obtained tissue for histology(456).
A more recent development by Medtronic is the “hydrodebrider” 
using a pressurised saline irrigation to clean the sinus cavities 
during ESS. However, a study looking at the sinus “jet wash” 
showed no subjective or objective treatment benefits, although 
was an underpowered study with only 12 patients and 
compared sides of the nose(457).
6.2.1.10. Balloon sinuplasty
A RCT in 2012, the REMODEL trial, in 2012 tested the hypotheses 
that symptom improvement after balloon dilation was non-
inferior to ESS and that balloon dilation was superior to ESS 
for post-operative debridements. The study recruited CRS 
patients with disease limited to the maxillary sinuses with 
or without anterior ethmoid disease. Ninetytwo patients (50 
balloon dilation; 42 ESS) were treated and the results showed a 
mean SNOT-20 improvement of 1.67 ± 1.10 and 1.60 ± 0.96 in 
the balloon and FESS arms, respectively. Both groups showed 
clinically meaningful and statistically significant (p<0.0001) 
improvement and the balloon arm was non-inferior to FESS 
(p<0.001). The balloon arm showed superiority for reduction 
in post-operative debridements (p<0.0001). Postoperative 
complications such as epistaxis, analgesic use and recovery 
time were all significantly lower in the balloon arm (p<0.01). 
No other complications were reported but one revision surgery 
was reported in each arm. This study serves to underline that 
in a healthcare model where patients present early, the balloon 
sinuplasty may have a role to play in milder cases of CRS (458).
In the UK, the National Institute for Health and Care Excellence 
has sanctioned use of the XprESS multi-sinus dilation system 
for treating uncomplicated chronic rhinosinusitis after medical 
treatment has failed. The specific criteria they recommend for 
the application of balloon sinuplasty include selecting CRS 
patients who do not have severe nasal polyposis or complicated 
cases and recommend for the procedure to be performed under 
local anaesthesia, however the economic modelling for this 
does not reflect UK practice(459). 
These recommendations were supported by a systematic 
review(460) of 9 studies including the REMODEL RCT, which 
included the original 92 patients, but as an expanded cohort 
of 135 patients with medically refractory CRS, treated with ESS 
or in-office balloon dilation. One hundred thirty patients had 
12-month data, 66 had 18-month data, and 25 had 24-month 
data. Outcomes were comparable for FESS and balloon dilation, 
with significant reductions in symptom scores, absenteeism, 
health care visits and antibiotic usage in both groups. Recovery 
was faster in the balloon dilation group. It should be noted 
that all included patients had very limited sinus disease 
radiologically.
Bizhaki et al. whose 2014 study was included by Jenks 
subsequently published three papers considering quality of life, 
mucociliary clearance and nasal airway resistance at six month 
follow-up in their cohort(461-463). They showed improvement 
in QoL (as measured by SNOT-22), no change in mucociliary 
clearance (as measured by saccharine test, methylene-blue 
dye and albumin labelled with Tc99m) and a decrease in nasal 
airway resistance (as measured by acoustic rhinometry and 
rhinomanometry) in both groups, but no statistical difference 
between balloon sinuplasty and ESS.  
A more recent study by Minni et al.(464) randomised 102 patients 
into mild and moderate/severe frontal CRS based on the LM 
score and by balloon catheter dilation (BCD) or ESS. The primary 
outcomes were radiology score and SNOT-20. No significant 
differences were shown between the groups except in those 
patients undergoing BCD for moderate/severe CRS who had a 
significant improvement in SNOT-20.
6.2.1.11. Drug-eluting stents (DESs)
6.2.1.11.1. Nasal packing/spacers soaked with medications
(See also section below on nasal packing)
Drug eluting stents are expensive; a cheaper alternative 
utilizing absorbable dressings soaked in triamcinolone 
has been evaluated in a number of trials; however, the rate 
and amount of drug-elution is unknown. Cote and Wright 
randomized 19 patients to receive either a steroid or saline 
soaked absorbable dressing, with significant improvements in 
post-operative endoscopy scores being seen up to six months 
postoperatively(465). Xu et al. replicated the study in 80 patients, 
with similar outcomes of improved endoscopy scores with 
triamcinaolone(466). Hong et al.(467) found that serum cortisol 
levels were suppressed on day 2 after surgery in patients 
receiving triamcinolone soaked dressings, but that levels had 
normalized by day 10, suggesting that the triamcinolone is 
absorbed in a short pace of time. Unlike the drug-eluting stents 
that achieve controlled release over longer periods.
Dautremont et al. took this a step further and in patients 
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receiving a Nasopore dressing soaked in 2ml (80mg) of 
triamcinolone during ESS, randomised 36 patients to receive 
either prednisolone 30mg for seven days or placebo tablet 
equivalent(125). There was no significant difference between the 
two groups in terms of SNOT-22 or endoscopic scores up to two 
months, but the small sample size and short follow up period 
probably preclude too much being derived from this in terms of 
abandoning the use of perioperative OCS.
Triamcinolone versus saline soaked polyvinyl alcohol packs 
were considered in a recent study. The pack was removed 
on the second postoperative day and the cavities evaluated 
endoscopically in the third postoperative week, showing a 
significant reduction in the average Lund-Kennedy score in 
the treatment side compared to the control site and a greater 
reduction in crusting, oedema and scarring though only the 
reduction in oedema was statistically significant(468). 
In a pilot study of only 10 CRS patients undergoing ESS, a 
doxycycline releasing stent significantly lowered MMP-9 
concentrations and bacterial colonization on the treated side 
compared with a placebo stent on the opposite side, and 
improved postoperative healing quality at 3 months after ESS(469). 
6.2.1.11.2.DESs placed during ESS
A growing number of DESs are emerging in the market for 
which the PROPEL system has the most data(470). The Propel 
bioabsorbable steroid-releasing implants contain mometasone 
furoate 370µg and have been specifically assessed for improving 
postsurgical outcomes in the frontal sinus ostia(471). This 
publication reported data from the pooled analysis of two RCTs 
considered160 patients randomised by side of nose to receive 
an implant in one frontal sinus ostium with the contralateral side 
as a control and patients were followed up for three months. A 
key outcome assessed was the need for postoperative surgical 
interventions (debridement of obstructive adhesions or scar 
tissue formation in the frontal recess), which were reduced 
on the treated side by 47% (95% confidence interval -60.7 to 
-27.9) at one month; this was significantly reduced at three 
months (p<0.05, relative reduction 30.2%). The need for oral 
corticosteroids was also reduced by 37%. There was also 
an increase in the estimated frontal sinus ostium diameter 
(absolute difference, 1mm), favoring the treated side. Other 
subgroup analyses did not show any significant findings for 
the influence of the LMS and the use of the Draf IIB procedure. 
However, the studies are undermined by the failure to include 
an arm with an implant that did not release steroid.
However, another product, Sinuband FP, a bioabsorbable, 
fluticasone propionate (FP)-eluting implant, was used in a 
small randomized, partially double-blind, single-tertiary-
referral-centre, controlled trial (n=30) for patients with CRSwNP, 
undergoing ESS that included an ethmoidectomy. Sinuband 
with and without steroid was compared with Merocel as a 
control. Postoperative endoscopic appearances were better 
in the Sinuband FP arm(121). A systematic review of two RCTs 
covering 143 patients found that DESs led to some significant 
post-operative changes including a 40% reduction in the use of 
OCS and 46% reduction in frank polyposis with improvements in 
synechiae formation compared to the Merocel group(472). 
A systematic review in 2015 considered seven studies (five 
prospective randomized controlled trials and two prospective 
single-cohort studies) involving 394 sinuses receiving 
steroid-eluting bioabsorbable intranasal devices. Patients 
were followed up for two to six months. Six studies showed 
efficacy with statistical significance (p<0.05) for their use in 
reducing adhesion formation, polyp formation, inflammation, 
LundKennedy scores, and perioperative sinus endoscopy 
scores(473).
Economic modelling has been undertaken to support the use of 
a steroid stent after ESS based on prevention of post-operative 
division of adhesions within 60 days of ESS(474), however this 
is clearly a very short period for the ongoing management of 
CRS patients, and adhesions may not be of clinical significance. 
A more recent economic analysis by the same in a US setting, 
also considering a reduction in polyp recurrence, gave similar 
support to DESs being cost-effective to use(475). 
6.2.1.11.3. DESs placed in outpatients
Other stents have been designed with the outpatient clinic 
setting in mind. One of these is the SINUVA implant, which 
is designed to deliver 1350μg of mometasone furoate to the 
ethmoid sinus mucosa over a three-month period. As a follow 
on to the RESOLVE I trial(120), month period. As a follow on to the 
RESOLVE I trial, the RESOLVE II RCT by Kern et al, recruited 301 
adult patients with CRSwNPs who had undergone a previous 
ethmoidectomy, had failed further medical therapy including 
INCS and ≥1 course of OCS and were being considered for 
revision ESS (118). Eligible patients had bilateral placement of 
the implants into the ethmoids under local anaesthesia. The 
control arm was a sham procedure to insert the implants 
and then remove them immediately. Patients in both arms 
received mometasone furoate 200μg nasal spray once daily. 
Nasal obstruction/congestion symptom scores and endoscopic 
polyp scores were used as outcome measures. There was a 2:1 
randomisation resulting in 201 stent recipients and 99 sham 
procedure recipients (allowing for 1 excluded for extensive 
adhesions). In the treatment arm there were significant 
reductions in symptom score (p=0.0074) and polyp grade 
(p=0.0073) compared to controls. After threemonths significant 
reductions were also seen in the secondary outcomes: 39% of 
patients went on to revision ESS compared to 63% of controls 
(p=0.0004), symptom scores for nasal obstruction and smell loss 
were significantly better in the implant group (p=0.0248 and 
0.0470). Facial pain/pressure was not better in the treatment 
group (p=0.9130) but there was only one serious adverse event 
for one patient who suffered epistaxis. The SINUVA implant 
requires removal at the end of the three-month period and 
thus far has only been trialed in patients who have already 
undergone surgery.
By contrast, an alternative delivery vehicle for mometasone 
furoate is the LYR-210 (Lyra) which delivers corticosteroid to the 
sinonasal mucosa over six months and can be used for patients 
who have not had ESS following failure of conventional medical 
therapy. The LYR-210 system is placed into the middle meatus 
under local anaesthesia and slowly expands. The device has 
been evaluated in a small prospective, multicentre, open-label 
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study including 20 patients with CRS (12 CRSsNPs and eight 
CRSwNPs) destined for ESS(476).ESS. As an early phase trial, the 
study was set up to assess adverse events within four weeks 
as the primary outcome measure and found none. There were 
no safety concerns regarding plasma drug concentration, 
morning serum cortisol levels and intraocular pressures (IOPs). 
Although designed to be bioabsorbable, 86% of the devices 
were still retained in the middle meatus at six months. There 
were significant reductions in their SNOT-22 scores through 
to the end of the study period (p<0.01). This device clearly 
requires further trial evaluation and may need removal after 
the treatment period, but does hold additional promise for a 
clinic based alternative treatment to ESS, which may be useful 
for those patients with other comorbidities less suitable for ESS 
under general anaesthesia. 
 
6.2.1.12. Packing and spacers
At the present time the use of packing and spacers remains 
largely a matter of surgeon preference. They can be divided into 
spacers and non-absorbable materials and absorbable material 
including gels and other haemostats that may be instilled into 
nasal and/or sinus cavities.
6.2.1.12.1. Gels, haemostats and absorbable dressings
A meta-analysis by Coey et al. looking at fibrin tissue adhesive 
(FTA) compared to nasal packing was limited to only four studies 
with significant heterogeneity and bias, so mainly concluded 
that although there was a trend towards packing reducing 
bleeding and FTA reducing obstruction and granulation, the 
decision to use FTA has to be a cost-based one currently as there 
were no significant differences(477). Carboxymethylcellulose 
(CMC) (mesh or gel) was evaluated in one study randomising by 
side of nose and showed no improvement in patient comfort on 
the treated side as compared to the unpacked opposite side(478). 
Similar findings for improved comfort were found with a study 
using Nasopore in one side of the nose and gauze packing in 
the other(479). 
A gelatin dressing called Cutanplast was studied by Cho et 
al, randomizing 100 ESS patients by side of the nose(480). Both 
the Merocel control and Cutanplast packs were effective at 
avoiding post-operative bleeding until the point of removal of 
the Merocel where bleeding did occur. There was no significant 
difference between the two in terms of cost or wound healing 
but the Cutanplast was associated with less patient discomfort.
A study comparing polyurethane packing (Nasopore) versus 
no packing showed benefit for this packing with significant 
improvement in the patency of the OMC on the side with 
resorbable material at 4 weeks after surgery and at week 12, 
a significant improvement in synechiae formation and nasal 
discharge(481).
Impregnation of dissolvable dressings with corticosteroids 
has been studied by Zhao et al. who randomised 64 CRSwNP 
patients undergoing bilateral ESS by side of the nose, to receive 
4 mL or 8 mL of mometasone furoate soaked Nasopore on one 
side and the same amount of normal saline-soaked Nasopore 
on the contralateral side(482). The Nasopore was subsequently 
removed at seven or 14 days post-operatively, thus giving four 
comparators of treatment. Using the POSE and Lund-Kennedy 
scores to assess outcomes, they found that leaving 8ml of 
steroid soaked Nasopore for two weeks resulted in the best 
outcome with significant differences sustained at three months 
postoperatively. Similarly, Xu et al. used triamcinolone soaked 
Nasopore in 80 CRSwNPs undergoing bilateral ESS(466). In this 
trial, patients were randomised by treatment, not by side of 
nose but were followed up for the same interval postoperatively. 
They utilised the same endoscopic scores but also included 
the SNOT-20 and the Sniffin’ Sticks as outcome measures and 
found significant improvements in all except the SNOT-20 scores 
when comparing the triamcinolone dressing group to the saline 
control group. Another trial to compare triamcinolone soaked 
Nasopore also found significant differences in endoscopic scores 
at six months compared to the saline soaked dressing, albeit 
with a sample of only 19 patients(465). The most recent study 
from Brazil used Nasopore soaked with either betamethasone 
or ciprofloxacin and compared with saline soaked Nasopore; the 
steroid group had the best 90-day appearance with respect to 
reduction of mucosal oedema (p=0.007)(483). These studies give 
credence to the use of steroid impregnation of nasal dressings 
at the end of ESS. In a recent study by Bing et al., 31 patients 
with CRS were randomised to receive gelatin sponge (control) 
or the topical application of acellular dermal matrix held with 
gelatin sponge in one or other surgical cavity. Lund-Kennedy 
scores in the acellular dermal matrix group were significantly 
decreased compared with the control group at 8 vs. 2 (p<0.05) 
weeks and epithelialization time at eight weeks in the acellular 
dermal matrix groups was significantly decreased compared to 
the control group(484). 
Calcium alginate absorbable dressings were compared with 
chitin-coated gauze in a cohort of 40 CRS patients undergoing 
ESS, finding that the absorbable dressing was associated with 
lower postoperative symptoms, improved QoL and reduced 
pain though there was no control arm(485). Calcium alginate was 
compared with CMC in 27 CRS patients undergoing ESS, After 
surgery, one nostril was packed with calcium alginate and the 
other with carboxymethyl cellulose. In contrast to Okushi, no 
significant differences in VAS scores for postoperative pain, 
discomfort from nasal discharge or pain during packing removal 
was found between the two sides. However, adhesion severity 
and oedema scores at four weeks were significantly lower with 
calcium alginate packing(486).
6.2.1.12.2. Spacers and non-absorbable dressings
A range of commercially available materials exist, although 
spacers can be created at low cost using simple nasal tampons 
and surgical gloves; a study looking at the impact on healing 
comparing a tampon with and a tampon without a glove finger 
covering (randomised by side of nose) showed only a benefit 
for the former in terms of patient comfort(487). Evidence for the 
use of spacers is limited by the quality of the existing studies; a 
meta-analysis looking at post-operative outcomes showed only 
a trend towards reduced synechiae formation, but again, despite 
18 included studies suffered from significant heteroegeneity(488).
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Another RCT by Baguley et al. included 42 patients undergoing 
ESS for CRS who were randomized to have a silastic splint placed 
into the middle meatus on one side of the nose but not the 
other at the completion of surgery. Splints were removed two 
weeks postoperatively and symptom scores were recorded for 
each side of the nose up to 12 weeks after surgery and ethmoid 
cavities were graded at the six- and 12-week visits along with 
assessment of adhesions. The middle meatal silastic splints 
reduced adhesions but increased early nasal obstruction and 
discomfort. Their use did not significantly change symptom or 
ethmoid cavity scores at 12 weeks(489).
A similar study by Chan in 36 patients also investigated the 
effect of a unilateral middle meatal silastic stent up to 24 weeks. 
Middle turbinate lateralization was observed in
13 sides without a stent vs. one side with a stent. There was a 
significant reduction in adhesions at weeks 2 and 8 (p<0.001) 
and crusting (p<0.01) in the stent side compared to control 
but little difference at six months, nor for symptoms and in this 
study, the stent was well-tolerated(490).
A meta-analysis comparing absorbable and non-absorbable 
dressings found no major differences in terms of symptoms after 
surgery(491). A subsequent meta-analysis did not favour one over 
the other, again due to the issue of heterogeneity, although 
there were trends to reduced synechiae in patients receiving 
absorbable dressings(492). A single RCT did however favour 
improvement in adhesions in those with absorbable dressings 
compared to saline irrigations only(493). The most recent meta-
analysis available gave greater conviction in its findings (grade 
of recommendation in brackets)(494).
Reduction in postoperative bleeding: no difference when 
comparing absorbable packing to no packing (A) but slightly 
more effective than non-absorbable (C). 
Reduction in postoperative synechiae: Absorbable packing was 
more effective than non-absorbable packing (B) and no packing 
(C); non-absorbable packing was also more effective than none 
(A). Reduction in postoperative comfort: Absorbable packing 
is more comfortable compared to non-absorbable (A) or no 
packing (B).
An interesting take on the packing debate was published by 
Stern-Shavit et al. who conducted a systematic review of all 
randomized control trials comparing packing to no packing in 
ESS, and generated a decision-analysis model which indicated 
that middle meatal packing is not advantageous for patients 
undergoing ESS though absorbable packing materials have 
a less adverse effect on quality of life than non-absorbable 
materials(495). 
Nonetheless, all the meta-analyses concluded that better 
designed studies are needed to derive more conclusive findings 
in the future. Further discussion on the role of packs and spacers 
in prevention of synechiae can be found below in section 
6.2.1.22.
6.2.1.13. Role of image guidance and robotics  
6.2.1.13.1  Image guidance, computer navigation and 
augmented reality
The use of image guidance for ESS has been gradually 
increasing and in the USA has been supported by the AAONHS 
guidelines for ESS and the International Consensus Statement 
on Allergy. and Rhinology. for Rhinosinusitis in 2016(496)(401, 497). 
The examples they list as appropriate for IGS include:
• Revision sinus surgery.
• Distorted sinus anatomy of development, postoperative, or 
traumatic origin.
• Extensive sino-nasal polyposis.
• Pathology involving the frontal, posterior ethmoid and 
sphenoid sinuses.
• Disease abutting the skull base, orbit, optic nerve or carotid 
artery.
• CSF rhinorrhea or conditions where there is a skull base 
defect.
• Benign and malignant sino-nasal neoplasms.
In terms of evaluating the role of image-guided surgery (IGS) or 
computer-assisted sinus surgery (CASS), key issues to address are:
• Its role in reducing complication rates
• Its role in improving clinical outcomes
• Its value in training
• Its cost-effectiveness
6.2.1.13.1.1. Complication rates in IGS surgery
A systematic review by Smith et al. in 2007 identified five 
studies for inclusion but made limited conclusions suggesting 
merely that the studies that needed to be done to determine 
safety were not ethically possible(498). Tabee et al. compared 
complication rates from a single centre before and after 
the introduction of IGS (499). The series included 179 non-IGS 
cases and 60 IGS cases. No statistically significant difference 
in the incidence of major intraoperative or postoperative 
complications was seen (all 5-6%). The key notable difference 
was of a higher incidence of intraoperative cerebrospinal fluid 
leak in the non-IGS group (0% vs. 2.2%). A retrospective cohort 
study from the USA in 2005-8 looked at 78,944 primary FESS 
cases and 4151 revision cases from insurance databases for 
Florida and California and found that in those who had surgery 
involving the frontal sinus or IGS were at higher risk for major 
complications(500). Their findings are probably likely to reflect 
the case selection including factors such as disease extent, 
anatomical factors and possibly surgical overconfidence. 
Masterson et al. reported on an eight-year case series of ESS 
using IGS and included 110 CRS patients(501). Their results 
showed that four patients had a major complication (3%) and 
three cases were abandoned due to excessive bleeding during 
surgery. Masterson et al. used IGS in a case series of 250 CRS/
AFRS patients undergoing ESS and reported  a 1.2% major 
complication rate with only two cases requiring revision during 
the study period of four years(502).
Considering the measures of operative time and blood loss, 
Fried et al compared cases with (n=97) and without (n=63) 
IGS during ESS(503). The disadvantage of this study was that the 
groups differed in composition with the IGS group having 74% 
of patients with CRSwNPs as compared to 40% in the non-IGS 
group. The IGS group had an average estimated blood loss 
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(EBL) of 134ml and an average procedure time of 154 minutes 
as compared to 94ml and 133 minutes in the non-IGS group. 
However, the non-IGS group had seven major complications and 
one minor complication compared to one and three respectively 
in the IGS group and three revision operations in three months 
as compared to one. So from this study, the higher disease 
burden most likely contributed to longer operation times and 
higher blood loss in the IGS group but nonetheless they had 
lower complication rates.
Dalgorf et al. undertook a more recent systematic review 
and meta-analysis in 2013(504). Of the 55 included studies, 14 
were comparative cohorts of IGS and non-IGS cases used for 
the meta-analysis. In contrast to some of the above studies 
and previous meta-analyses(505), they found that major and 
total complications were more common in the non-IGS 
group (major RR = 0.48; 95% confidence interval [CI], 0.28-
0.82; P = 0.007), (total RR = 0.66; 95% CI, 0.47-0.94; P = 0.02). 
Looking specifically at orbital, intracranial and haemorrhage 
complications separately, the forest plots also favoured IGS but 
the RRs were not statistically significant. Finally, they considered 
completion of the operation but again there was no significant 
advantage shown by IGS in this respect.  Conversely, another 
systematic review was published that same year with opposite 
findings(506), finding that the use of IGS did not decrease 
surgical complications or improve surgical outcomes. However, 
their recommendations were based on only six studies with 
limitations in the studies’ methodology. Interestingly, despite 
this, within the paper the authors state a preponderance 
of benefit over harm and suggest that IGS helps reduce 
complications.
6.2.1.13.1.2. Clinical outcomes of IGS surgery
With respect to quality of life outcomes using IGS, Javer et 
al. used the RSOM-31 to compare IGS and non-IGS cases(507). 
Statistically significant improvements between preoperative 
and postoperative were seen for both groups considered as a 
whole but when the two groups were compared, the IGS group 
demonstrated an overall greater improvement in quality of life 
(p<0.001). Tabee et al. found no difference with IGS in SNOT-22 
scores in their single centre study with mean postoperative 
scores of 23.6 and 23.4 in the IGS and non-IGS groups 
respectively(499).
Tabee et al. also compared and revision rates from a single 
centre before and after the introduction of IGS and found no 
significant differences in revision rates (7%)(499). A previous study 
from the same centre in 2003 reported an 8% revision rate for 
ESS when using IGS but with no comparator group this simply 
underlines the 7% rate reported in the more recent study(508). 
Masterson et al. reported that 11 patients needed revision 
surgery (10%) in their aforementioned series(501) and Farhadi et 
al. reported revision rates of 11.11%, and 7.1% for CRSwNPs and 
CRSsNPs cases after ESS with IGS in a case series of 62 patients 
over five years, but again with no comparator group(509). 
One  of the key advantages of  image guided 
surgery is the  enhancement of  the learning curve 
in training of ESS.
6.2.1.13.1.3.Training value of IGS
A small number of studies have addressed the value of IGS 
with respect to training. Theodoraki et al. reported on eight 
trainee surgeons undertaking 32 ESS cases and the influence 
of IGS on stress levels(510). The cases were randomised by 
side of nose such that one side of each patient was operated 
using IGS and the other without. The trainee surgeons were 
monitored throughout for various parameters including heart 
rate variability, respiratory rate and masticator EMG. Stress was 
identified as an increase of heart rate frequency and a decrease 
of heart rate variability. They showed that stress levels were 
higher compared to before and after ESS but that the use of IGS 
did not significantly alter this except in those trainees who had 
performed more than 30 FESS procedures already who had a 
slightly decreased mental workload when using the navigation 
(unquantified statistically). In a separate publication, based on 
the same set of trainees and procedures, the authors reported 
how often the trainee used the navigation pointer and then 
changed their technique during the IGS side of the ESS(511). They 
showed that procedures lasted on average 16 minutes longer 
with the navigation, but that in only 10-13% of cases, did it 
change the surgical strategy after the use of the pointer. The 
questionnaire completed by participants revealed a significantly 
increased willingness to take risks when using the image 
guidance system. No trainee complained of diminished surgical 
skills when using the navigation system. On the contrary, almost 
all surgeons reported a better anatomical understanding with 
the additional information from image guidance.
Augmented reality is starting to become available to 
rhinologists in the field, with preliminary work suggesting the 
accuracy of this approach to be submillimetric(512, 513). Initial 
systems available include features such as targets planned 
by the surgeon pre-operatively and “anti-targets” such as key 
structures to avoid and help prevent complications(514). Future 
systems are likely to enable overlays of critical anatomy on 
to the live endoscopic images(515). Certainly, one of the key 
advantages to these new developments will be for training to 
enhance the learning curve in ESS(513).
6.2.1.13.1.4. Cost effectiveness of IGS
Masterson et al. considered the cost of providing an IGS 
service and estimated that during their study period of eight 
years it was approximately £110,000-120,000(501). However, 
their suggestion that IGS would reduce overall costs by 
approximately £70,000 when compared to non-IGS was based 
on 19 CRSsNPs patients in a military cost model, so the likely 
generalisability is low. The ICOR guidelines assessment was that 
the benefits of IGS outweigh the risk and potentially outweigh 
the costs(401). Further studies to determine any specific cost 
benefit from the use of IGS during ESS need to be undertaken.
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6.2.1.13.2. Robot-assisted ESS
Robotic surgery in ESS has yet to find its place mainly due to 
the limitations on the size of instrumentation, but development 
is underway(516-523). It is certainly not at the stage of trans-oral 
robotic surgery now being used increasingly for oropharyngeal 
cancers(524). One application considered is for a robot to hold the 
endoscope freeing the surgeon to undertake the ESS with both 
hands(525, 526). Beyond this there are yet to be trials reported on 
the use of robot-assisted ESS for CRS management.
6.2.1.14.  Office procedures
Given the relative costs of an operating theatre setting 
compared to an ambulatory outpatient setting, there has 
been an increasing vogue to perform more procedures out 
of the conventional theatre setting including polypectomy, 
stent placement and balloon sinuplasty. Balloon technology 
lends itself well to this setting, as it avoids cutting tissue and 
thus reduces likely associated bleeding. The role of balloon 
sinuplasty is discussed in detail above, but with specific respect 
to the outpatient setting, this section considers key advantages 
and disadvantages to techniques that can be utilized. The 
aforementioned RESOLVE trial proposed steroid-eluting 
sinus implants for in-office treatment of recurrent sinonasal 
polyposis(119, 120), however, the selected patients had already 
failed a primary procedure. The LYR-210 device placement is also 
discussed above in section 6.2.1.11.3.
Levy et al. reported on two studies that looked at patients 
undergoing balloon sinuplasty as part of ESS in the clinic 
compared to the operating theatre showed that the outcomes 
were better when conducted in theatre(527). It should be noted 
that these patients appeared to have mild to moderate disease 
based on a mean LMS of 8 in the Achar study. Kilty et al. recently 
published their data from the EPIC study showing that with 
good patient selection, a local anaesthetic polypectomy using 
the POLYPVAC could achieve good quality of life outcomes(528).
6.2.1.15. Postoperative interventions, e.g. debridement
6.2.1.15. 1. Post-operative debridement
A recent Cochrane review has considered the role of post-
operative debridement in managing post-operative patients 
after ESS(529). Four studies incorporating 152 participants and 
a duration of follow up between three and 12 months were 
included. Two studies were split-nose studies comparing 
differing interventions by side of the nose in the same patients. 
As patients were unblinded, the risk of bias was high and with 
only one study considering HRQoL scores, there is limited 
inference from the analysis. However, just one study did show 
lower, but not statistically significant lower, SNOT-22 scores 
at six months in the debridement group. Other studies using 
VAS scores showed no significant differences in total symptom 
score. All four studies assessed the postoperative endoscopic 
appearance of the sinonasal cavities using the Lund-Kennedy 
score. The ‘split-nose’ studies revealed better, but not statistically 
significant endoscopic scores in the debridement group but a 
closer focus on the adhesion formation score found this was 
significantly lower in the debrided patients and the number 
needed to treat was five patients for at least one patient to 
avoid an adhesion. Overall, it is not possible to comment on 
what impact this has in the longer term without further studies. 
A prior systematic review had similar conclusions with the 
addition that patients undergoing debridement appeared to 
suffer more postoperative pain(530) which was also confirmed by 
Varsak in 2016(531).
6.2.1.15. 2. Saline irrigations
Rudmik et al.(532) undertook a systematic review of the 
literature and identified six RCTs which evaluated the effects 
of postoperative saline irrigation; studies suggest improved 
symptom-based and endoscopic outcomes with low risk of 
harm and therefore that recommend use, commencing 24–48 
hours after surgery. This was also supported by a more recent 
study concentrating on the maxillary sinus in which those using 
1000ml of saline with an irrigation system, twice a week for the 
first two weeks, once a week for the next two weeks, and twice 
in the last month had significantly better healing than those 
who used no irrigation(533). A more recent meta-analysis found 
only three trials deemed eligible for inclusion but nonetheless 
reported that nasal irrigation using normal saline and various 
solutions was found to be effective in reducing symptom scores 
and endoscopic scores for CRS after FESS(534). 
6.2.1.15.3. Intranasal medications
Given the nature of CRS as a chronic condition, maintenance 
treatment is more often than not an essential feature of 
ongoing treatment. However, the evidence supporting any 
specific regimen is variable. A study looking at 60 patients with 
N-ERD, randomised to receive either saline, budesonide and 
saline separately or budesonide and saline together showed 
no obvious benefit in any one arm, however the sample 
size of this study would appear too small to show sufficient 
benefit(83). Fandino et al. published a systematic review and 
meta-analysis to look at the role of INCS in CRSwNPs(535). Eleven 
studies including 10 RCTs and one prospective cohort study 
demonstrated a significant benefit in symptom scores and 
polyp scores up to one year postoperatively, with a significant 
reduction in the odds of polyp recurrence. Three studies in the 
analysis also collected data adrenocorticotropic hormone levels 
postintervention finding no elevations postoperatively. 
Budesonide irrigations have become a popular choice for 
rhinologists managing post-operative CRSwNPs, but there is 
now a growing body of evidence to support their use(81, 88, 536-538). 
Snidvongs et al.(88) studied the use of either budesonide 1mg 
or betamethasone 1mg delivered in a 240mL sinus squeeze 
bottle daily in a cohort of 111 patients. After a mean follow 
up period of 56 weeks, baseline and posttreatment SNOT-22 
and endoscopy scores revealed significant improvements 
(all, p<0.001). Those with high tissue eosinophilia had 
significantly more improvement on symptom and endoscopic 
scores than those without. These findings were confirmed 
by a more recent study by the same team, showing that the 
corticosteroid nasal irrigation group (using mometasone) 
had greater improvement in nasal blockage (p=0.029), a 
greater improvement on LMS (p=0.031) and less inflammation 
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endoscopically at 12 months (p=0.018)(67). One-year on from 
surgery, symptom scores were all lower in the corticosteroid 
irrigation group (Table 6.1.11.9.).
One study from Thailand considered the use of dexpanthenol 
topically(171). Dexpanthenol is an alcoholic analogue of 
D-pantothenic acid and acts as a precursor of coenzyme A 
necessary for acetylation and thus may enhance the effect of 
acetylcholine; it is used typically as a dermatological agent. 
Fifty patients enrolled were randomised to receive either 
dexpanthenol or normal saline nasal spray intranasally four 
times a day for six weeks postoperatively. Overall there were no 
significant differences in symptoms between the two groups 
with nasal discharge reportedly better but olfactory loss worse 
in the dexpanthenol group. The main claim was improvement 
in mucociliary clearance time, however this test is increasingly 
acknowledged to have little bearing on patient symptoms.
6.2.1.15.4. Postoperative antibiotics
There is no evidence to date for the use of postoperative 
antibiotics. In a study randomising post-ESS patients to co-
amoxiclav or no treatment, no differences were observed in 
the symptom and endoscopic scores, between the two groups 
after ESS(539). Furthermore, there were no differences seen in 
rates of bacterial culture and drug sensitivity to co-amoxiclav. 
A prospective single-blind comparative effectiveness trial 
including 187 Chinese patients with CRS randomised subjects to 
receive fluticasone propionate nasal spray (200 microgram) or 
clarithromycin (250mg once daily) for three months after ESS(540). 
Patients were followed up to one year after randomisation and 
outcomes included symptom severity (VAS) and endoscopic 
findings. Both groups saw reductions in the total and individual 
symptom scores, and total and individual endoscopic scores. 
There was no significant difference between the groups 
even when stratified to CRSsNP and eosinophilic and non-
eosinophilic CRSwNP. Neither group showed a preponderance 
to rescue medications either. The study design is unusual in 
comparing an INCS against an antibiotic rather than an INCS 
being included in both arms to see the additive effect of the 
long-term macrolide therapy after ESS.
Whilst a meta-analysis in 2012 had been unable to demonstrate 
a statistically significant reduction in infection, symptom 
scores, or endoscopic scores to support the routine use of 
postoperative prophylactic antibiotics following endoscopic 
sinus surgery, there have been concerns about the 
possibility of toxic shock when packs have been left in place 
postoperatively(541). However, a meta-analysis was performed 
in 2017 to examine this issue(542). Six studies, with a total of 
990 patients undergoing ESS or septoplasty, met the inclusion 
criteria and there were no reports of toxic shock syndrome.  
The application of topical antibiotics was considered in a 
prospective randomized multicentre trial included 321 CRS 
patients undergoing ESS who received either one week of oral 
antibiotics and a saline-soaked bioabsorbable middle meatal 
(MM) sponge (control group) or no oral antibiotics and the 
placement of a bacitracin-soaked bioabsorbable sponge in 
the MM (study group). The three-week postoperative infection 
rate was not significantly different between the study and 
control groups: 5.4% versus 3.8% and there was no significant 
difference in MM granulations, synechia, middle turbinate 
lateralization, or sponge retention. However, no control group 
of no antibiotics was included and the use of antibiotics in any 
form is questionnable(543).
6.2.1.15.5. Postoperative systemic steroids 
One randomised trial has shown no impact of postoperative 
systemic steroids in symptom scores but did find improved 
endoscopic appearances at two weeks postoperatively(381). The 
risks of systemic steroids must be considered against this short-
term benefit. 
6.2.1.16. How do we measure success versus failure?
Early retrospective reports of endoscopic sinus surgery, whilst in 
its infancy, simply report ‘success’, as deemed by the operating 
surgeon without any attempt to define how this was measured. 
Need for revision surgery was often used to define failure. 
As outcome assessment evolved, focus moved to reporting 
symptom improvement(544) and then to utilizing validated 
patient-rated outcome measures(545) (See also chapter 5.3.5.2).
The UK Audit of Sinonasal surgery was one of the first large 
multi-centered prospective cohort studies to use PROMS to 
measure the effectiveness of surgery. This study reported a 
statistically significant, large improvement in disease specific 
quality of life, maintained over a five-year period(546). A recent 
publication has shown this improvement to be durable for 
more than 10 years in patients available for long term follow-
up(547). A systematic review of outcomes in 40 unique cohorts 
has shown a mean improvement of 24.4 points(548). Few 
studies have specifically compared outcomes of CRSwNP and 
CRSsNP with different reported effects. However, the meta-
analysis performed by Soler et al. found no impact; only pre-
operative symptom scores and asthma status were found to 
be significantly associated with improvement in HRQOL (with 
studies with higher pre-operative SNOT-22 scores and higher 
asthma prevalence reporting greater improvement after ESS). 
However, looking at population means overlooks chance of 
success at an individual patient level. To better understand 
a ‘successful’ outcome, the concept of a ‘minimal clinically 
important difference’ is usually applied, that is the smallest 
change in patient rated outcome scores that a patient can 
perceive as a real change. This has been calculated for a number 
of different PROMS; for the SNOT-22 it is 8.9 points(549). Applying 
this to cohort series suggests that only 65–75% patients achieve 
a successful outcome from surgery. Baseline preoperative 
SNOT-22 score is the best predictor of achieving improvement 
in HRQOL greater that the MCID(84, 391); a baseline threshold of 
20 points in the SNOT-22 is required to have a greater than 50% 
chance of achieving the MCID.
A limitation of the MCID is that it is usually calculated from 
population-defined statistics (using Cohen’s effect size or 
comparing global ratings of improved versus no change to 
mean changes in symptom scores), while individual patients 
may hold different values. Asking patents simply about 
postoperative satisfaction or improvement does not allow for 
baseline measures to be used to mitigate against a placebo 
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effect of intervention. This likely explains in part why patient 
satisfaction after surgery is higher than reported rates of 
achieving the MCID(550). In addition, patients may also prioritize 
improvement in individual symptoms above overall quality of 
life. Improvement in nasal obstruction was rated as the most 
important symptom by 93% CRS patients, change in sense 
of smell second, with lower rates of importance placed on all 
other symptoms in a study evaluating the relationship between 
patient satisfaction and changes in overall symptom scores 
alongside individual symptoms. It found that satisfaction was 
better correlated with the magnitude of change in symptom 
scores and achieving improvement in the most important 
symptoms than achieving the MCID(550). An independent study 
also found that in patients with sub MCID improvement in 
SNOT-22 scores, improvement in the nasal subdomain was 
also associated with reporting overall improvement in CRS 
symptoms(551). 
A systematic review by Chester et al. considered symptom 
specific outcomes after ESS(552). A total of 2070 patients with CRS 
were studied a mean of 13.9 months after ESS. All symptoms 
demonstrated improvement compared with their respective 
preoperative severity scores by an overall effect size (ES) of 1.19 
(95% confidence interval, 0.96 to 1.41; I(2) = 81.7%) using the 
random-effects model. Nasal obstruction (ES, 1.73) improved 
the most, with facial pain (ES, 1.13) and postnasal discharge 
(ES, 1.19) demonstrating moderate improvements. Hyposmia 
(ES, 0.97) and headache (ES, 0.98) improved the least. A recent 
systematic review looking specifically at olfactory outcomes 
included thirty-one studies and demonstrated significant 
improvement in mixed CRS patients (those with and without 
polyps) through visual analog scales (-0.83, p=.001), altered 
taste/smell item on Sinonasal Outcome Test (-1.32, p<.00001), 
40-item Smell Identification Test (3.49, p=.0010), and Sniffin’ 
Sticks identification (0.34, p=.03). When separated, polyp 
patients and dysosmic patients experienced the highest levels 
of olfactory improvement.
The need for revision surgery should not necessarily be 
considered a treatment failure in the setting of chronic disease. 
However, it is important that patients are made aware of the 
chance of subsequent revision surgery. Prospective cohort 
studies report revision surgery rates of 11% at three years(393), 
19% at five years(546), and 17% at 10 years(547). Patients with 
CRSwNP report higher rates of revision surgery (11%, 21% 
and 25% at three, five and 10 years respectively) than CRSsNP 
(10%, 15% and % at three, five and 10 years respectively). A 
population-based study using electronic healthcare records 
found long-term revision rates of 15.9% with a mean follow-
up of 9.7 years, with female gender, older age at first surgery, 
presence of nasal polyps, comorbid asthma and allergy and 
a family history of CRS all being associated with a higher risk 
of requiring revision(553). Revision rates in CRSwNP were 29.9% 
compared with 9.8% for CRSsNP. Loftus et al. have performed a 
systematic review looking at revision surgery rates in 45 studies 
and 34220 patients with CRSwNP(554). There was a mean revision 
rate of 16.2% with a weighted mean follow-up of 89 months. 
Increased rates were reported in allergic fungal rhinosinusitis 
(28.7%), N-ERD (27.2%), asthma (22.6%) and prior polypectomy 
(26%). A recently published study with endoscopic follow-up at 
over 12 years after surgery, found 78.9% of CRSwNP patients had 
endoscopic recurrence of disease, and 36.8% had undergone 
revision surgery(555).
6.2.1.17. What are the outcomes of endoscopic sinus 
surgery?
A large body of evidence from non-randomised cohort studies 
demonstrates clinically significant QoL improvements for 
patients after ESS. In 2009, long-term outcomes were reported 
on 3128 patients who underwent surgery for CRS from the 
National Comparative Audit of Surgery for Nasal Polyposis and 
Chronic Rhinosinusitis in England and Wales(393). Mean SNOT-
22 score was found to significantly and clinically improve from 
a preoperative baseline value of 40.9 to 28.2 postoperatively, 
with greater improvement found in patients with CRSwNP 
compared with CRSsNP, although in both subgroups the effect 
was large. Improvements in QOL were maintained up to five 
years following surgery(546). In 2010, Smith and colleagues(556) 
published a multi-institutional cohort study of 302 patients 
with CRS from three medical centres followed for an average 
of 17.4 months after ESS. Subsequent prospective, multi-
institutional studies demonstrated that patients who elected 
to pursue ESS experienced clinically significant improvements 
in QoL, decreased utilization of oral antibiotics and systemic 
corticosteroids, fewer missed days of work/school(557), and a 
reduction in the consumption of rhinosinusitis-related health 
care and imaging studies(558, 559). A systematic review performed 
in 2005(560) identified forty-five studies that reported either 
symptoms or QoL changes following ESS, with 44 of 45 studies 
being level 4 or 5 evidence. Although heterogeneity in study 
design and outcome measures utilized precluded meta-analysis, 
all studies were found to report significant improvement 
in at least one outcome measure. A systematic review and 
meta-analysis of cohort studies using the SNOT-22 to evaluate 
outcomes after sinus surgery included 40 unique patient 
cohorts published from 2008 to 2016(548). All studies showed a 
statistically significant change in mean SNOT-22 scores between 
baseline and postoperative time points (p<.001), ranging 
from 12.7 to 44.8, at an average follow-up of 10.6 months. The 
summary change in mean SNOT-22 across all studies was 24.4 
(95% CI: 22.0-26.8 The magnitude of change is quite variable 
across the cohorts and appeared to be influenced by a number 
of factors including baseline SNOT-22 score, asthma prevalence, 
and length of follow-up.
There are few comparative studies that allow direct comparison 
between medical and surgical treatment. Ragab et al.(32) 
randomised ninety patients with CRS, both with and without NP 
were equally randomized to either medical or surgical therapy. 
Both the medical and surgical treatment of CRSsNP significantly 
improved almost all the subjective and objective parameters 
of CRS measured (p<0.01), with no significant difference being 
found between the medical and surgical groups at 12 months 
after randomisation (p>0.05), except for the total nasal volume 
in CRS (p<.01) and CRS without polyposis (p<0.01) groups, in 
which the surgical treatment demonstrated greater changes. 
All patients received six weeks of Dexarhinaspray prior to 
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recruitment and patients who were no longer symptomatic 
were excluded, although there was no threshold for ongoing 
symptoms. A limitation of this study is that patients had only 
received a relatively short course of intranasal corticosteroids 
for six weeks prior to surgery, which does not reflect current 
practice of surgery being utilised after ‘maximum’ medical 
therapy has failed. 
Blomquist et al. also compared medical and medical-surgical 
treatment of CRSwNP in 32 patients but using sinus CT. They 
were randomized to unilateral endoscopic sinus surgery after 
pretreatment with oral prednisolone for 10 days and nasal 
budesonide bilaterally for one month. Postoperatively, they 
were given nasal steroids (budesonide) bilaterally for one year. 
They were assessed with nasal endoscopy, symptom scores, 
and olfactory thresholds and followed for 12 months. CT of the 
sinuses was performed before and one year after operation. This 
showed a significant improvement on the operated side in the 
CT total LM scores, and scores of the OMC and maxillary sinus, 
but no significant differences on the unoperated side. Similarly 
olfaction was less improved on the unoperated side(561).
Several studies have compared outcomes in patients with 
refractory CRS who chose to undergo surgery, compared with 
those who elected not to pursue surgery and instead continued 
with medical therapy(557, 562). Patients who elected surgical 
management reported more improvement than patients 
who were medically managed on both the RSDI and CSS QoL 
instruments; in addition, surgical patients reported less use of 
oral antibiotics and oral steroids and fewer missed days of work 
and/or school, maintained through to 12 months follow-up. A 
subset of patients who had initially elected medical therapy 
crossed over to the surgical cohort, and outcomes in this 
crossover group mirrored those of the surgical cohort overall. A 
subsequent prospective study evaluated patients with refractory 
CRS who received ongoing medical therapy while awaiting 
surgery(563), during which time SNOT-22 scores deteriorated from 
mean 57.6 to 66.1, while after ESS SNOT-22 scores improved 
from mean 66.1 to 16.0 with an average follow up of 15 months. 
Patients also experienced improvements in endoscopy scores 
and a reduction in lost workdays and medication utilization 
following ESS. Patel et al. undertook a meta-analysis in 2017 
that demonstrated that ESS, resulted in greater QoL scores and 
nasal endoscopy scores than medical therapy, and that patients 
undergoing surgery experienced greater improvement in health 
utility, olfaction, and cost-effectiveness following ESS(564). A 
systematic review concentrating solely on olfaction by Kohli 
et al considered 31 studies and concluded that ESS improves 
nearly all subjective and objective measures of olfaction in CRS. 
Patients with CRSwNP or preoperative olfactory dysfunction 
improve the most(565).This can be anticipated up to one year 
postoperatively(566).
A study designed to look specifically at changes in pain 
following ESS enrolled 252 patients (567). Amongst those 
included, 42% had no preoperative pain. Patients were followed 
up at six and 12 months. In the patients with no preoperative 
pain, none developed any new pain postoperatively. Among 
the 146 patients with preoperative pain, 56% had no pain, 
residual symptoms, or further sequelae, 29% reported a marked 
improvement of pain or discomfort, 6% had the same degree 
of pain or discomfort as before, 2% reported worse pain or 
discomfort and 7% reported new pain or discomfort. 
A meta-analysis looking at symptom response to ESS, found 
that depression is associated with poorer preoperative and 
postoperative quality-of-life scores but that the majority of 
major CRS symptoms improve to a similar degree(568). The 
overall effect size was 1.19 (95% confidence interval, 0.96-1.41; 
I (2) = 82%), with specific symptoms effect sizes as follows: 
headache 0.98, hyposmia 0.97 and nasal obstruction 1.73. 
Fatigue and bodily pain were found to be more severe than 
general population normative values but were also found 
to improve following ESS (effect size 0.5 SD). Chester et al. 
performed a meta-analysis of 28 studies specifically considering 
fatigue finding substantial improvement after ESS based on 
pre- and postoperative comparisons. A subgroup analysis of 
11 studies reporting results by the SF-36 vitality domain scores 
demonstrated a moderate-sized combined effect(569). 
As up to 75% of CRS patients suffer from sleep disturbance, 
Sukato et al. undertook a meta-analysis of seven papers 
considering sleep improvement after ESS(570). There was high 
heterogeneity in the studies (I2 = 95%-99%) but sleep quality, as 
measured by the Epworth Sleepiness Scale and Pittsburgh Sleep 
Quality Index surveys, shows substantial improvement after 
surgery for CRS, with smaller improvement seen for Apnoea-
Hypopnoea Index. The future conduct of better studies was 
recommended.
The effect of ESS on the lower respiratory tract has been 
considered in a number of studies. A meta-analysis in 2013 
identified 22 studies involving 891 patients. Patients reported 
improved overall asthma control in 76.1% (95% CI,71.9%-
80.3%) of cases. The frequency of asthma attacks decreased 
in 84.8% (95% CI, 76.6%-93.0%) of patients and the number 
of hospitalizations decreased in 64.4% (95% CI, 53.3%-75.6%). 
Decreased use of oral corticosteroids was seen in 72.8% (95% 
CI,67.5%-78.1%); inhaled corticosteroid use decreased in 28.5% 
(95%CI, 22.6%-34.5%) and bronchodilator use decreased in 
36.3% (95% CI, 28.9% to 43.7%) of patients. Mean improvement 
in predicted forced expiratory volume at one second (FEV1) 
was1.62%,but was not statistically significant (p=0.877). Overall 
ESS in patients with concomitant asthma can anticipate clinical 
improvement(571).   
6.2.1.18. How do we manage expectation of patients? (see 
also chapter 9)
Expectations of patients need to be considered with respect 
to outcomes of surgery, risk of complications, perioperative 
recovery and return to normal activities, and likely benefits of 
surgery and need for ongoing treatment. 
A survey of patient concerns prior to ESS found that overall 
patients had a low-level concern before surgery, with the risk 
of revision surgery and waiting time being the most important 
drivers(572). Revision rates are discussed in 6.2.2.
Patients should be informed of the likelihood of success based 
on population studies above, their preoperative symptom 
severity and most important symptoms. Many different factors 
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have been proposed to predict outcome; Some factors have 
been associated with a greater mean improvement following 
ESS, such as CRSwNP subtype, while others have been 
associated with decreased mean improvement postoperatively, 
such as comorbid obesity and anxiety(573). 
The majority of patients are still likely to achieve clinically 
significant improvements regardless of associated demographic 
factors. The best predictor of surgical outcomes with respect to 
improvements in HRQOL is the patient’s preoperative disease 
burden.  A prospective cohort study of 2,263 patients found that 
improvement in SNOT-22 scores after ESS, and the proportion 
of patients achieving an improvement of at least one MCID 
increased with greater baseline disease severity(84). Only those 
patients with a baseline SNOT-22 score of more than 21 to 30 
had a mean change greater than or equivalent to the MCID, 
while patients with a score of 31 or more had a greater than 70% 
chance of achieving a MCID. However, patients with more severe 
baseline scores remained more symptomatic following surgery 
despite greater SNOT-22 improvement. 
It is likely that in time, biomarkers and better endotyping will 
allow more accurate prediction of risk of recurrent disease. 
Cluster and multivariate analyses have shown that patients with 
eosinophil dominant CRSwNP have the highest level of polyp 
recurrence(574, 575). One study found that a cutoff value of 27% 
tissue eosinophils predicted recurrence with 96.7% sensitivity 
and 92.5%(575); and an absolute count of 55 eosinophils per high 
power field predicted recurrence with 87.4% sensitivity and 
97.1% specificity(576).
It should be made clear to patients that the aim of surgery is to 
improve disease control, and postoperative medication will be 
required. Studies have shown lower revision rates with ongoing 
use of intranasal corticosteroid sprays(92), and increased benefits 
of corticosteroid irrigation over sprays alone with respect to 
endoscopy scores(67). A cure is often an unrealistic aim except 
in the setting of isolated sinus obstruction. Patients should be 
counselled that their symptom load will likely be reduced, but 
many will not achieve post-operative scores comparable to the 
normal population.
6.2.1.19. Postoperative recovery – pain, return to normal 
activity
It seems obvious that the less extensive the surgery, the 
faster the recovery. Byun and Lee found a healing duration 
for partial uncinectomy to be of 1.77 ± 0.59 weeks, while total 
uncinectomy took 2.42 ± 0.79 weeks (p=0.034)(419). Sinus surgery 
usually involved more than just an uncinectomy, and the 
difference between these two groups is perhaps unexpected.
In a randomized trial Wu et al. studied a protocol of 
perioperative care for enhanced recovery after (ESS) surgery 
(ERAS) in 102 patients with CRSwNP(577), including giving 
NSAIDs prior to and after surgery, and  short acting opiods and 
topical local anaesthesia  to the enhanced recovery group, who 
reported significantly better  post-operative scores measured 
with the Medical Outcomes Study Sleep Scale and Kolcaba 
Comfort Scale Questionnaire. The incidence rates of nausea/
emesis, haemorrhage, aspiration and falls, were not increased in 
the ERAS group compared with those in the control group. 
Kemppainen et al. studied the effect of acetaminophen / 
paracetamol intake on the recovery of 78 patients after FESS 
in a randomized study(578). The “scheduled” group (n=38) 
was asked to take two paracetamol/acetaminophen 665 mg 
modified-release tablets three times a day during the first five 
postoperative days, whereas the control group (n=40) took 
them only as needed. Most patients underwent a limited FESS 
procedure. Return to normal daily activities occured after 8.8 (SD 
4.8) days in the “scheduled” group versus in 10.3 (SD 7.0) days 
in the “as needed” group (mean difference 1.5; 95% CI of the 
difference –1.3 to 4.2; p=0.29). The mean of worst pain was 3.4 
(2.9) in the scheduled group compared with 5.2 (3.0) in the “as 
needed” group on an 11-point scale (mean difference 1.7; 95% 
CI of the difference 0.4–5.2; p=0.019).
Tyler et al. compared the efficacy of perioperative intravenous 
acetaminophen with that of placebo in improving early 
postoperative pain after ESS in a RCT on 62 patients. Although 
in the first postoperative hour the VAS scale favoured the active 
group, at 12 and 24h average pain scores were lower in the 
placebo group. The authors concluded that considering the high 
costs and inconclusive results the administration of intravenous 
acetaminophen (ivAPAP) could not be recommended for the 
control of perioperative pain reduction after ESS(579).
Given the growing concerns with opioid over-use and addiction, 
a number of recent studies have assessed the need for post-
operative opioid analgesia. In a single-institution retrospective 
study, Raikundalia et al. the opioid usage was assessed at the 
first postoperative visit in 136 patients who underwent FESS. 
Multinomial logistic regression with backward stepwise variable 
selection method revealed that concurrent septoplasty and 
young age were found to increase the odds of opioid usage. The 
number of sinuses opened and the presence of extended frontal 
and maxillary sinusotomies were not associated with increased 
opioid use. Patients undergoing bilateral FESS had higher opioid 
consumption than those who underwent unilateral FESS(580).
Locketz et al. surveyed 219 patients undergoing ESS surgery 
across five different centres(581). Opiod consumption was 
positively correlated with postoperative, but no association 
was found with the procedure performed. The majority of 
patients took less than five opioid based tablets in the first three 
postoperative days; 23% did not require any. Certainly, if opioids 
are prescribed on discharge, only a small number should be 
given.
Szczygielski and co-workers compared Stammberger Sinus 
Dressing (SSD) with dissolvable sinu-knit (DSK) (n=26 sides) 
to routine nasal packing in latex gloves finger (RNP) (n=23 
sides) for pain, among other issues(582). Mean pain level for 
SSD was 0.85 (range from 0 to 3) and for DSK 2.1 (range 0 to 
5) whereas for RNP was 5.6 (range from 2 to 9). Akbari et al. 
compared sides of the nose where 35 patients undergoing ESS 
for CRS were randomly allocated to receive a covered Merocel 
spacer on one side of the nose; the other side then received 
an uncovered spacer(487). There was no significant difference in 
histopathological evaluation of mucosal inflammation but a 
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significant difference in discomfort experienced by patients on 
removal of the spacers at one week, favoured the rubber glove 
covered spacers. 
Studies suggest that use of absorbable packing 
will reduce pain and discomfort associated with 
sinus surgery.
Comparison of Merocel on one side and Nasopore on the other 
in 30 patients with moderate to severe CRS found comparable 
outcomes with regards to ease of nasal packing and control 
of postoperative bleeding(583). Sequential postoperative nasal 
endoscopy revealed that Nasopore is kinder to the mucosa 
with a lower incidence of synechiae, infection and oedema, 
with better biocompatibility and safety. Patients’ symptom 
questionnaires showed a significant difference in favour of 
Nasopore as no pack removal was needed. Also, in a separate 
study, Nasopore was able to significantly reduce nasal 
obstruction within the first 10 days after surgery (p<0.005), with 
significant improvement of the headache and pressure in the 
forehead on the first follow-up visit as well as the pain in the 
nose on the first and second visit (p<0.005)(487, 582-585). 
Shinkwin et al. compared Surgicel Nu-knit (a haemostatic 
material) with Vasolene ribbon gauze and Merocel packs, in 
60 patients undergoing bilateral nasal surgery (ESS or inferior 
turbinaectomy). Surgicel Nu-knit caused significantly less 
discomfort and less bleeding following removal than Vasolene 
gauze or Merocel (p<0.01, respectively). Compared to Merocel 
sponges, Surgicel Nu-knit caused significantly less discomfort 
on removal (p<0.01). Bleeding following removal was also 
significantly less compared to the other packs(586).
Lignocaine-soaked polyurethane foam packs as compared 
to saline soaked foam significantly reduced postoperative 
pain without serious changes on vital signs during the early 
postoperative period after ESS in an RCT on 63 patients(587). 
Haytoglu et al. reported on the use of packing soaked in 
different anaesthetic agents in the management of pain after 
FESS in 150 patients with CRSw/sNP, using 2 % lignocaine, 0.25 
% bupivacaine, 0.2 % ropivacaine, 2 % prilocaine and 0.9 %NaCl 
as control. All received acetaminophen (250mg/5 ml) was used 
in 10–15mg/kg per dose (four times a day). In the saline group, 
93% of the patients needed additional painkiller whereas, in 
the bupivacaine group, additional painkiller use was 20% less 
than the other groups(588). Similarly levobupivacaine-soaked 
PVA sponge sinus packs after FESS has been shown to be an 
effective, easy, and quick method to control postoperative 
pain(589). 
Fentanyl–soaked absorbable packing (Nasopore or Merocel) has 
also been shown to significantly reduced acute postoperative 
pain after FESS and septoplasty without serious adverse 
effects(590). Fentanyl–soaked absorbable packing (Nasopore or 
Merocel) has also been shown to significantly reduced acute 
postoperative pain after FESS and septoplasty without serious 
adverse effects(590).
A systematic review of the use of sphenopalatine ganglion block 
(SPGB) with a local anaesthetic to decrease postoperative pain 
after endoscopic sinus surgery (ESS) is controversial, especially 
given that the procedure generally is associated with only 
mild pain post-operatively(591). Eight articles were included for 
analysis and showed that intraoperative bleeding, postoperative 
pain, nausea and vomiting and recovery from sedation in the 
treatment group were significantly reduced compared with 
the control group with no notable adverse effects (p<0.02). 
The transnasal approach also had better outcomes than the 
transoral route.
6.2.1.20. Complications of surgery – acute and chronic
Acute / perioperative complications
The advent of powered instrumentation does bring with it 
the increased potential for microdebrider related injuries(592, 
593). However, the microdebrider is not the sole source of 
intraoperative complications and as mentioned above, close 
inspection of and familiarisation with patients’ preoperative CT 
scans is key to avoiding complications(594). Key areas for potential 
pitfalls include:
 · Anterior ethmoid arteries – in a minority of cases the 
anterior ethmoid artery may lie within a bony “mesentery” 
beneath the skull base where it is at greater risk of injury 
from through-cutting instruments, particularly in the 
presence of a supra-orbital ethmoid  cell.
 · Aerated posterior spheno-ethmoidal (Onodi) cells - 
greater risk of optic nerve injury during ethmoidectomy/
sphenoidotomy; these anatomical variants are more 
common in some ethnic groups e.g. South East Asians(595, 
596).
 · Dehiscence of the lamina papryacea can be identified 
on coronal and axial CT sequences – this may be due to 
expansion by polyps in the ethmoids or to preceding facial 
trauma but in primary surgery will not be due to any prior 
intervention.
 · Hypoplasia of the maxillary sinus – results in the possibility 
of the lamina lying more medial in the nose than the 
maxillary wall; thus, a surgeon may breach the lamina 
believing they are entering the anterior ethmoids 
 · Infra-orbital ethmoid (Haller) cells – seen best on coronal 
CT planes; may affect entry to the maxillary sinus and 
ethmoid infundibulum 
 · Skull base defects – again in primary surgery, this would 
only be a consideration if there had been previous trauma 
or neurosurgery,in cases where massive expansion by 
uncontrolled polyp disease had eroded bony margins or if 
there was a congenital dehiscence eg meningocoele
 · Dehiscence of the internal carotid artery – this can 
be found in the sphenoid sinuses (and in some cases 
sphenoethmoidal cells) and renders the artery vulnerable 
to injury during surgery.
In 2014 a retrospective cohort analysis of two American state 
EPOS 2020
297
insurance databases was undertaken from 2005 to 2008(500). This 
yielded data from 78,944 primary ESS cases where 288 major 
complications were identified (0.36%, 95% CI 0.32%-0.40%). 
The rate of major complications was 0.36% in primary cases 
(n=288). Risk factors for major complications identified in their 
multivariate analysis include age >40 years, frontal sinus surgery 
and use of image guidance. 
The rate of major complications following revision FESS 
(0.46%) was found to be similar to primary cases. Skull base 
complications were defined as a CSF leak or dural injury 
within 180 days, or bacterial meningitis within 30 days, after 
ESS. Orbital complications were defined as diplopia, paralytic 
strabismus, optic nerve injury, epiphora, orbital haemorrhage, or 
blindness/visual disturbance within 30 days after ESS. 
Additionally, a patient was considered to have an orbital compli-
cation if a person had canthotomy/canthoplasty, strabismus 
surgery, or orbital decompression in the same time frame. 
Haemorrhagic complications were counted if a diagnosis of 
internal carotid artery injury, epistaxis requiring transfusion, or a 
procedure to control haemorrhage occurred within 30 days after 
surgery. Some caution should be applied in interpreting these 
results, as in the time period studied, use of image guidance 
would have been relatively uncommon and these results may 
represent a learning curve with respect to the technique. 
Another study based on an insurance database from the USA 
was also published the same year by Benninger et al(597). This 
reported adverse events in 388 patients of 9105 patients as 
follows: haemorrhage 0.24%, cerebrospinal fluid leak 0.14% and 
orbital complications 0.58%); 6.28% of patients had revision 
surgery.
A retrospective study of one surgeon’s practice over a 25 
year period looked at 3,402 CRS patients and found a total of 
105 patients who had suffered complications for an overall 
patient complication rate of 3%: haemorrhage 1.2%, orbital 
complications 0.9%, and CSF leak 0.6%(598). In this series, risk 
factor identified were age, revision surgery, CRSwNPs, anatomic 
variation, extensive disease, overall health, medications and 
powered instrumentation. The use of image guidance or surgical 
experience did not eliminate complications from occurring. 
Another large study from one department looked at data from 
2,596 patients with ARS or CRS undergoing ESS between 2000 
and 2005. They reported minor complications (minor bleeding, 
perforation of the lamina papyracea) in 3.1%, and major 
complications such as severe haemorrhage and CSF leaks in 
0.9% with only one serious complication of meningitis (0.04%)
(599). In the UK the Sinonasal Audit performed in 2001 collected 
data on 3128 patients undergoing ESS for CRS and reported 
the following complication rates: excessive bleeding in 5% of 
patients during the operation and in 1% of patients after the 
operation, intra-orbital complications in 0.2% and CSF leak 
in 0.06%(600). A smaller series over a four year period included 
250 CRS/AFRS patients undergoing ESS and five complications 
were reported: two patients suffered significant epistaxis, one 
patient who underwent concurrent microlaryngoscopy suffered 
a pneumocephalus, there were no orbital complications and 
two general complications (transient ischaemic attack and 
pulmonary embolus)(502).
Table 6.2.1.1. Grading system for complications of ESS (599)
Grade Complication Frequency
Grade-I: minor complication 
(intraoperative management, 
no persistent harm)
Diffuse or arterial bleeding <1,000 ml
Injury of the lamina papyracea 3.1%
Emphysema and periorbital ecchymosis
Intranasal and soft tissue infection
Grade-II: major complication 
(intraoperative management or 
revision, no persistent harm)
Diffuse or arterial bleeding >1,000 ml
Bleeding requiring selective cauterising/clipping of sphenopalatine artery or anterior 
ethmoidal artery
0.9%
Bleeding requiring revision
CSF leak
Injury of the lacrimal duct
Grade-III: serious complication 
(high risk of persistent deficit)
Meningitis with or without proven leak 0.04%
Intracerebral haemorrhage
Intracerebral abscess
Temporary or persistent neurologic deficit
Retro-orbital haemorrhage
Injury of optic nerve
Injury of orbital muscles with diplopia
Any reduction of vision and blindness
Injury of the internal carotid artery
Toxic shock syndrome
Sepsis
Death
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The aforementioned study by Siedek et al. proposed a grading 
system for complications of ESS as follows(599) (Table6.2.1.1.):
Grade I complications
Breach of the lamina papryacea and orbital fat injury
Fortunately, serious ophthalmic injuries from ESS are rare but 
the initial recognition and management of them is crucial to 
avoiding any permanent sequelae(601-603).The most common 
site of orbital injury during ESS is the medial orbital wall(604) 
during ethmoidectomy or even (aberrant) maxillary antrostomy 
or uncinectomy. Proponents of the retrograde approach 
to uncinectomy would support the notion that this avoids 
penetrating the orbit as the target for removal is pulled away 
from the orbit.
Epistaxis
Postoperative haemorrhage is typically reported as occurring 
as frequently as 2-4%(605), with one case series reporting 22 
of 290 patients with post-operative epistaxis being admitted 
to hospital as a consequence(597); admission with or without 
packing appears to be a criterion for defining significant 
postoperative epistaxis although most of the relevant 
publications do not specify this. One aforementioned study that 
did specify this defined the significance of bleeding within two 
weeks postoperatively as follows:0 = no bleeding, 1 = bleeding 
from the nose that ceased with a gauze soaked in a mixture of 
1:1000 epinephrine and 1% lignocaine applied intra-nasally 
for five minutes, 2 = continuous bleeding that could not be 
controlled with a temporary gauze, and requiring repacking(606). 
This trial found a mean score of 1.11 on the side of the Merocel 
dressing and 0.13 on the side of the Merogel dressing which was 
statistically significant (p=0.001).
Hot saline irrigation during surgery is a potential therapeutic 
modifier of the surgical field and may modify blood loss during 
surgery. Gan et al. randomised 62 patients with CRS patients to 
receive either hot saline irrigation (HSI) at 49°C or saline at room 
temperature (18°C), 20mL every 10 minutes, for the duration of 
ESS(607). The Boezaart scores were only significantly better for HSI 
if the surgery lasted more than two hours but did significantly 
reduce the blood loss per minute for all cases in which HSI 
was used compared to the saline at room temperature. So, the 
inference for practice is that HSI may have a role for complex 
cases lasting over two hours and may be another therapeutic 
option for sinus surgeons to consider, especially if other 
treatment adjuncts are contraindicated.
Two almost identical RCTs have considered injection of the 
pterygopalatine canal with local anaesthetic  (xylocaine 1 or 
2%) and adrenaline (1:100,000 or 1:80,000)(608, 609). The weaker 
solution (Valdes) produced no decrease in intraoperative 
surgical field bleeding, blood loss or duration of surgery 
whereas in the other, there was a significant reduction in blood 
loss.
An RCT to look at the use of a fibrin sealant in 494 patients 
undergoing endonasal surgery showed a significant lower 
postoperative bleeding rate when used(610, 611). The trial 
randomised patients to receive fibrin sealant or nasal packing 
and they were further defined as receiving one of three 
interventions: septoplasty, ESS or both ESS and septoplasty; all 
groups received turbinate surgery. Postoperative haemorrhage 
occurred in 22.9-25% of patients with nasal packing whereas 
3.12-4.65% in the fibrin sealant groups experienced late 
haemorrhage only. No allergic reactions to the sealant were 
reported.  
Grade II complications
Nasolacrimal injury
It is thought that lacrimal duct injury is relatively common in 
ESS but that it rarely causes clinical sequelae(612). The natural 
ostium of the maxillary sinus usually lies directly posterior to 
the nasolacrimal duct and the relationship can be seen on axial 
slices of preoperative CT imaging. Use of angled endoscopes 
will help the surgeon to avoid unnecessary injury after removal 
of the uncinate process.
Cerebrospinal fluid leak
In addition to the aforementioned reports of CSF leaks from 
ESS in large cohorts, recent evidence from an interesting study 
has suggested that occult CSF leaks may be as numerous as 
13% of cases(613). This particular study collected samples from 
57 patients after ESS to perform a hydrogel 6 beta2-transferrin 
assay and where CSF positive samples were detected with 
continuing rhinorrhoea, reanalysis after more than one year was 
conducted but they found that the clinical course was more 
often uneventful. 
Grade III complications
Medial rectus injury
These complications typically occur when the lamina is 
breached and the microdebrider is being used(593, 614). If the 
appearance of orbital fat is not quickly recognised, damage 
of the medial rectus can quickly follow(615). Injuries range from 
simple contusion to complete transection of the medial rectus, 
with and without entrapment(603). Unless seen promptly by 
ophthalmology, these injuries can be very difficult to rectify 
and lead to disabling diplopia and strabismus(602, 616). Botox A 
injections have been proposed in one study to treat strabismus 
due to medial rectus injury(617).
Retrobulbar haemorrhage
Orbital bleeding typically occurs due to either arterial damage 
such as to the anterior ethmoid artery, or venous bleeding that 
may occur with pulling of peri-orbital fat(601). The consequence of 
such of bleeding into the orbit is a rapid increase in intraocular 
pressure leading to ischaemia of the optic nerve and if 
unresolved, irreversible damage causing blindness(593).  
Direct optic nerve injury
Injury to the optic nerve is most likely to occur in the presence 
of a spheno-ethmoidal cell where the optic nerve can lie 
dehiscent, however, the nerve can also lie close to the lamina at 
the back of the posterior ethmoid(602). 
EPOS 2020
299
Damage to the internal carotid artery
Internal carotid artery (ICA) injury is a recognised and feared 
complication of ESS which  can result in stroke, cranial nerve 
palsies, and death. A systematic review by Chin et al. in 2016 
found 25 articles reporting 50 cases. The majority occurred 
during skull base procedures (34 cases) with 16 associated 
with CRS. The most commonly injured ICA segment was the 
cavernous (34 cases), followed by the ophthalmic (three cases). 
Injuries occurred more commonly on the left (1.3:1). Stereotactic 
image guidance was reported in two cases. Initial hemostasis 
was achieved with packing in 35 cases, endoscopic clip sacrifice 
in four cases, bipolar coagulation with the intent to seal 
defect in three cases, and bipolar coagulation with the intent 
to sacrifice the ICA in one case. Intraoperative or immediate 
postoperative interventional angiography was reported in 27 
cases(618). 
One of most successful strategies to deal with the immediate 
aftermath of ICA damage based on a sheep model is the 
application of a crushed muscle patch(619). Subsequent imaging 
to exclude a pseudoaneurysm is strongly recommended.
Chronic complication
Synechiae
Synechiae formation after ESS is common with reports in 
frequency of between 4 and 35%(450, 620). A recent retrospective 
case series to consider this specifically found that 38 of 200 
ESS cases (19%) had synechiae formation with concurrent 
septoplasty found to be the key risk factor for this(621). Some 
trials have looked at the role of absorbable and non-absorbable 
packs in preventing synechiae. Verim et al. in 2013 compared 
Nasopore with standard Merocel in 56 ESS patients comparing 
sides of the nose and found no significant differences, although 
a coin toss was used for randomisation of side of the nose(606). 
In a separate trial of 66 ESS patients comparing the hyaluronic 
acid pad Merogel versus the standard Merocel dressing, the 
percentage of adhesions seen at 12 weeks was only 5% but 
30% in the Merocel group (p<0.001)(622).A systematic review in 
2013 concluded that data from six RCTs showed no significant 
difference in adhesion rates if non-absorbable spacers are 
used for at least 48 hours postoperatively and whilst steroidal 
spacers may reduce adhesions, more consistent data reporting 
is required for future meta-analyses(623). 
The anti-adhesive properties of a thermosensitive poloxamer 
was compared to Merogel in ESS and showed similar anti-
adhesion rates of 92 vs. 89%. Adhesions, oedema, and infection 
in the middle meatus were not significantly different between 
the thermosensitive poloxamer group and the Merogel group at 
all postoperative periods(624).
A systematic review and meta-analysis of hyaluronan nasal 
dressings in 2017 included 352 patients but concluded that 
compared to controls the hyaluronan had no benefit in reducing 
synechiae formation(625).Whilst the hyaluronan significantly 
promoted reepithelization (OR 3.18, 95% CI 1.33-7.59; p=0.009) 
and reduced oedema (OR 0.45, 95% CI, 0.23-0.89; p=0.02) 
after ESS, the ORs for synechiae, crusting and infection were 
0.45, 1.00, and 0.84 respectively. Fong et al. also conducted a 
meta-analysis published in 2017 considering 13 (501 patients) 
and also demonstrated a lower risk ratio of adhesions in the 
hyaluronic acid intervention group (42 out of 283 cases) 
compared to the control group (81 out of 282) of 0.52 (95% 
confidence interval=0.37–0.72(626)). 
A meta-analysis of whether chitosan dressings improved healing 
after ESS was conducted by Zhou et al. in 2017(627). Four RCTs 
involving 268 patients were included in the meta-analysis. 
Overall following ESS, compared with control intervention, 
chitosan dressing significantly reduced synechia (RR = 0.25; 
95% CI 0.13–0.49; p<0.0001) and promoted hemostasis (RR = 
1.70; 95% CI 1.37–2.11; p<0.00001), but showed no impact on 
granulations, mucosal oedema, crusting and infection (RRs = 
1.18, 0.88, 0.85 and 0.88 respectively). Compared to control 
intervention, chitosan dressing could significantly decrease 
synechiae and improve hemostasis, but had no effect on 
granulations, mucosal oedema, crusting and infection.
Access to the middle meatus for postoperative care and 
inspection can be compromised by middle turbinate 
lateralisation and synechiae formation in this area. Bolger(628) 
recommended scarifying the medial side of the middle 
turbinate and adjacent septum to achieve stabilization of 
the middle turbinate and maintain access to the middle 
meatus back in 1999. A more recent RCT on 120 patients 
using a turbinate-septal suture showed this to be effective in 
preventing lateralization(629). Maharaj et al. proposed the basal 
lamella relaxing incision as a means to achieve this but only 
found a non-significant difference in olfaction as a potential 
advantage(630).
Mucocoele formation
The time of mucocele formation after initial ESS in one series 
was <22 months as compared to <10 years after external 
sinonasal surgery or trauma(631); however, another series 
reported mucocoele development 15-24 years after initial 
surgery(632). Of course, not all mucocoeles are caused by ESS 
with  case series reporting  25% to 35% having a prior history 
of ESS(633); another reported on 36 cases of CRSwNP where 92% 
had a prior history of ESS and the remaining three patients 
had previously unoperated disease(634); certainly the presence 
of CRSwNP regardless of prior ESS appears to be a potential 
predisposing factor(633). The mucocoele location is typically 
frontal or ethmoidal in origin(635). 
Key points | What’s new since EPOS 2012
• This is a new chapter, expanding on the brief section 
on surgery and associated outcomes in 2012. There has 
been a large number of prospective studies and large 
datasets exploring outcomes in surgical series. As a 
result, we are better able to predict outcome, both at 
population level but also for the individual patient.
• As yet we cannot fully account for variation in interven-
tion rates or define what the optimum extent of surgery 
should be. There remains a need for randomised trials 
comparing outcomes with medical treatment. 
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There are many reasons why patients require 
revision surgery Phenotyping and endotyping, 
where possible, may facilitate counselling the 
patient regarding prognosis and expected out-
come of the surgery itself and aid identification of 
the postoperative medical management that has 
the greatest likelihood of controlling the patient’s 
symptoms.
6.2.2. Revision endoscopic surgery   
 
The surgeon’s goals in revision surgery can vary greatly. 
Revision surgery may imply more comprehensive dissection 
or exteriorization of the existing sinuses. It may be as simple 
as removal of adhesions, scarring or correcting lateralized 
turbinates. Alternatively, it may be a decision to apply more 
extended techniques such as Draf III frontal surgery, medial 
maxillectomy or bone removal of the sphenoid face. Future 
studies should clarify what is the goal of any revision surgery.
6.2.2.1. Consider the type of rhinosinusitis / phenotype 
which benefits or is likely to fail and the reasons which 
increase the chance of revision 
There are many reasons why patients require revision surgery. 
Phenotyping and endotyping, where possible, may facilitate 
counselling the patient regarding prognosis and expected 
outcome of the surgery itself and aid identification of the 
postoperative medical management that has the greatest 
likelihood of controlling the patient’s symptoms. They may also 
assist in identifying those at risk of poor outcome though failure 
of primary sinus surgery is often multifactorial and inadequate 
surgery is only one aspect, with host immunity and adherence 
to medical management equally important to consider. 
From a practical clinical perspective, in the CRSsNP phenotype 
group, patients with previous multiple surgeries or frank pus 
and / or purulent crusting in the nasal cavity on endoscopy 
or at the time of surgery are likely to do worse. Several 
prospective blinded studies have shown a correlation between 
in vitro biofilm-producing Pseudomonas aeruginosa and 
Staphylococcus aureus found in post-operative cavities and 
poor outcomes with increased rates of revision surgery(636, 637).
Tomassen at al. investigated cytokines in CRSsNP and found 
that four IL-5 negative clusters made up the majority of CRSsNP 
patients. However, there was also an important subgroup of 
CRSsNP patients with a type 2 profile(638).
A recent study in CRSsNP patients, using preoperative SNOT 
scores, revealed four clusters. Highest disease burden was 
found in patients with tissue eosinophilia and asthma. Other 
subgroups included those with a high score in the rhinologic 
domain, and those with a high score in the psychological-
sleep domain in both the moderately burdened and a mildly 
burdened group. All groups experienced improvement six 
months after surgery but those with asthma and a high tissue 
eosinophil count had higher SNOT-22 scores postoperatively(403).
Whilst revision surgery may be related to the pathomechanisms 
of the mucosal inflammation, indicated by clinical signs 
or biomarkers, another reason may be iatrogenic due to 
inadequate initial surgery for the disease endotype leading to 
suboptimal postoperative results and continuing symptoms. The 
most common findings in patients undergoing revision surgery 
due to iatrogenic reasons are middle turbinate lateralization, 
adhesions and scar formation in the middle meatus, 
incompletely resected uncinate process and retained ethmoid 
cells (see below)(639). 
Another important factor that contributes to the need for 
revision ESS is surgeon-specific performance studied by Rudmik 
et al.(640). This may explain why the frontal sinus, which is the 
hardest to approach, is the sinus with the highest revision rates. 
They found that 16% of surgeons followed for five years had 
lower-than-expected performance, indicating a potential area 
for improvement in quality of care. The presence of nasal polyps, 
repeated systemic corticosteroid courses, allergy, asthma, 
female gender, family history of CRS, older age at initial surgery 
and occupational dust exposure were associated with increased 
risk of undergoing ESS revision, while concurrent septoplasty 
reduced the rate of revision ESS. It has also been shown that the 
time between revision surgeries decreases with each additional 
revision surgery performed in a large mixed CRS population(553). 
In CRSwNP, rates of revision ESS tend to be higher. In several 
studies, recurrence of nasal polyps has been found to occur 
earlier in time and more frequently(641-644) A retrospective study 
included 23,542 CRS patients followed for one year showed that 
the frequency of revision ESS for CRSwNP was 3.5% vs. 1.6% 
for CRSsNP(645). Miglani et al.(646) reported a similar result in a 
retrospective review of 424 CRS patients with and without nasal 
polyps, finding an overall frequency of 4% for revision ESS, 88% 
of which were necessary in the CRSwNP patients. According to 
Chen et al.(647) CRSwNP associated with asthma also has a higher 
rate of revision ESS (25%).The authors recommend extensive 
endoscopic sinus surgery (EESS) or radical sinus surgery for 
refractory CRS, since it is associated with better outcomes 
compared to FESS, specifically when CRSwNP is present. EESS 
improved olfaction and did not increase frontal ostium stenosis 
compared to FESS(425). 
Other co-morbidities such as N-ERD and cystic fibrosis (CF) 
also increase the chances of repeated surgery.  In a study 
comprising 106 CF patients, the necessity for revision surgery 
was 28% within three years of surgery(648).A review of risk 
factors for recurrent sinus surgery in 81 patients with CF found 
that the most relevant was a high Lund-Mackay scores at their 
initial surgery(649). Similarly, another retrospective study on 
49 CF patients found the grade of polyp (0-3) correlated with 
revision(650).
In a systematic review by Adelman et al. on the management 
of N-ERD (Samter’s Triad) looked at 18 studies (686 patients), of 
whom 59.4% had undergone previous surgery(651). This ranged 
from a mean of 1.9-5.4 times and was mainly ESS, but 14% had 
undergone a Caldwell-Luc procedure.
Immunodeficiency and GPA patients also required more revision 
surgery. Another study with 61,339 patients (mixed population 
of CRS) followed for five years, demonstrated that 4,078 patients 
(6.65%) required revision ESS. The mean time to revision surgery 
EPOS 2020
301
was 20 months, with 43% of the patients having revision surgery 
during the first year. CRSwNP patients accounted for 9.9% of all 
revision cases vs. 7.9% for CRSsNP, concluding that patients with 
nasal polyps are approximately twice more likely than those 
without NP to require revision ESS(652). 
Modifiable exposures to risk factors associated with recurrence 
must be identified and patients must be encouraged to 
discontinue their exposure if possible. Occupational dust 
exposure has been associated with higher rates of recurrence 
of polyps i.e. 48%, of which 13% needed revision surgery, 
compared with recurrence rates of 3% in the patients with 
no exposure, and for which none required re-intervention(4,6). 
Smoking is another modifiable risk factor, described by Wu(653) in 
a retrospective analysis of 490 patients with CRSwNP followed 
over a 25-year period who underwent revision ESS by a single 
surgeon. They reported a mean time to revision of 4.8 years, 
shorter by almost half in patients who smoked (2.82 years).  
One of the first studies that showed a difference of inflammatory 
patterns in recurrent and non-recurrent CRSwNPs was 
performed by Van Zele et al.(654) CRSwNP patients who needed 
revision surgery showed a predominant Th2-type inflammation 
and higher concentrations of IL-5, ECP, IgE, and Staphylococcus 
enterotoxin IgE (SE-IgE). IL-5 protein within the polyp and SE-IgE 
were linked to recurrence after the first surgery, in contrast to 
IFN-γ which was linked to non-recurring disease. Thus, the type 
of inflammation, specifically Th-2 inflammation, can predict 
whether a patient is likely to have recurrence and revision ESS.  
Identifying inflammatory patterns in CRSwNP by endotyping(638) 
therefore, may be helpful to identify patients who need more 
extensive surgery, or may be suitable for specific treatments 
with biologics(655).
6.2.2.2. What are the goals of revision? 
In both CRSsNP and wNP, the surgeon’s goal is often to create a 
common cavity accessible to local therapy. It may be necessary 
to address anatomical variations which obstruct access, removal 
of residual cells, scarring or neo-osteogenesis, widening of ostia 
and removal of partitions, mainly in the ethmoids. Addressing 
the middle turbinate by partial trimming has shown improved 
results in some studies without seeming to cause any negative 
effects, although the latter  has mainly been investigated in 
CRSwNP(656, 657).
The patient’s goal is to experience symptom reduction, reduced 
need for medication and improved quality of life and these 
are generally the primary outcomes evaluated by surgeons in 
patients with CRS. In CRSwNP, the prolongation of recurrence-
free time or avoidance of recurrence are further goals. 
There is a well-defined consensus that optimization of patient-
reported outcome measures (PROMs) is the primary goal 
of treatment(654). Several tools are used for the evaluation of 
medical and surgical interventions, including the Rhinosinusitis 
Disability Index (RSDI), 20 and 22-item Sino-Nasal Outcome Test 
(SNOT-20, SNOT-22), Chronic Sinusitis Survey (CSS), Adelaide 
Disease Severity Score (ADSS), Patient Response Score (PRS), 
Rhino-sinusitis Symptom Inventory (RSI) and Rhinosinusitis 
Outcome Measure (RSOM)(see section 5.3.4.2). For medically 
recalcitrant cases, surgery is the most effective way to 
improve QoL. In a prospective cohort study of 668 CRS (mixed 
population) patients undergoing primary FESS with a 60-month 
follow-up by Rudmik et al.(640) failing to achieve an improvement 
of more than one minimal clinically important difference (MCID; 
9 points in SNOT-22) at three months after primary ESS and a 
deterioration of greater than one MCID (> 9 points) from the 
three- to 12-month follow-up periods was associated with an 
increased risk of revision ESS. 
The goal of revision surgery can be different for the 
surgeon and the patient. These discrepancies have 
to be discussed
A multi-institutional observational study demonstrated a 
tendency of improvement in postoperative PROMs and olfactory 
measures in complete surgery (Draf IIa, IIb, or III) compared to a 
targeted approach in CRS(441, 655).
A systematic review included 12 studies containing data from 
1308 CRS patients (mixed population) to evaluate the impact of 
PROMs in revision ESS. The authors found improvements in five 
main symptoms of nasal obstruction, rhinorrhoea, post-nasal 
drip, facial pain and anosmia. The benefits persisted for a mean 
of 21.7 months follow-up after revision surgery. The review 
described the importance of using PROMs to report primary and 
revision sinus surgery outcomes, with the SNOT-22 test being 
the most commonly used(658).
6.2.2.4. When should revision surgery be performed? 
Revision surgery is often seen as the last resort when medical 
therapy has failed. It should be considered when there is 
persistence of post-treatment symptoms together with 
objective CT and endoscopic evidence of mucosal thickening 
or mucopurulent discharge, nasal polyps or mucosal oedema 
after at least a two-month course of culture-directed 
antibiotics, topical and oral steroids, and nasal douching(431, 
659). It is important to ascertain that the patient has adhered 
to this medical therapy prior to revision surgery. Whereas the 
recurrence of symptomatic nasal polyps in CRSwNP prompts 
surgery, the indication for revision surgery in CRSsNP is not so 
easily determined, especially in the absence of any obvious 
obstruction. It is not clear from the literature whether surgery in 
the absence of mucocoele formation, drainage issues or residual 
cells is of benefit in CRSsNP. Studies investigating the timing of 
revision surgery in CRSsNP are lacking. However, in a mixed CRS 
population, delayed surgery does not seem to negatively affect 
postoperative improvement(660).
6.2.2.5. Preoperative assessment 
When symptoms persist after ESS, and optimal clinical treatment 
with antibiotics and steroids fail, a nasal endoscopy and a CT 
is indicated in an attempt to confirm the site and extent of the 
inflammation and to help the planning of surgery. 
In revision surgery a number of features on the CT scan are of 
interest(639, 661).
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Sinus anatomy and post-operative findings
i) Anterior-posterior diameter in the frontal recess, and overall 
size of the sinuses (pneumatisation)
ii) Remaining cells that may obstruct drainage or block access to 
local treatment 
(incomplete anterior or posterior ethmoidectomy)
iii) Lateralisation of the middle turbinate
iv) Residual uncinate process
iv) Synechiae or stenosis of previously opened sinuses
It is evident from the literature that frontal sinus clearance is 
the most challenging part of endoscopic sinus surgery. The 
most common findings are retained agger nasi cells, neo-
osteogenesis within the frontal recess, lateral scarring of the 
middle turbinate, residual anterior ethmoid air cells, and residual 
frontal cells(662).
Remaining/recurring mucosal disease despite patent drainage 
pathways 
This finding would indicate ongoing inflammation and/or 
infection in spite of patent drainage pathways.  Although this is 
not an unusual situation in a clinical setting, there is no literature 
available to advise on a treatment algorithm.
Neo-osteogenesis
Neo-osteogenesis is positively correlated to disease severity 
and as such is a poor prognostic factor and should be part of 
the evaluation of the preoperative CT in preparation for revision 
surgery. A recent study concluded that the presence of P. 
aeruginosa in the sinuses is an independent predictor of neo-
osteogenesis, whereas S. aureus is not. The number of previous 
surgeries and the Lund-Mackay score are also independently 
associated with the severity of neo-osteogenesis(663).
6.2.2.6. What should be the extent of a revision operation and 
what are the outcomes?
It is difficult to draw any firm conclusion from the literature 
regarding the ideal extent of surgery as many studies are 
retrospective, lack a control group and do not make a distinction 
between CRSwNP and CRSsNP. Furthermore, the patient-
reported outcome is not dependent on surgery alone, but a 
combination of surgery, post-operative medical management 
and patient phenotype / endotype. 
Nonetheless, recent review publications have confirmed that 
revision surgery in both CRSwNP and CRSsNP provides tangible 
benefits in the majority of patients though extent of the surgery 
is rarely addressed. Revision surgery is equally effective as 
primary surgery for CRSwNP  and CRSsNP on QoL outcome 
instruments, in a cohort of 48(664). In contrast, a prospective 
multi-institutional study in 302 patients showed that primary 
surgery was approximately 2 times more likely to improve than 
revision cases. This may reflect the grade of disease severity 
in the revision group which was composed of a mixed CRS 
population(556). Bhattacharrya addressed the issue of outcomes 
in a small prospective cohort of 21 adult patients undergoing 
revision ESS(665). Data were analyzed for symptom score changes 
and effect sizes, changes in medication, and economic variables 
and compared with those of a contemporaneous control group 
of patients undergoing primary ESS and matched for age, sex, 
and Lund-Mackay score at a mean follow-up of 12.4 months. 
Large effect sizes indicating significant symptom improvements 
were noted for nasal obstruction (effect size,−1.9), hyposmia 
(−0.9), and headache (−0.6), as well as nasal (−1.1) and 
total symptom domains (−0.9; p<.05 in all cases). These 
improvements in clinical symptoms were statistically similar to 
corresponding improvements in the matched cohort of patients 
undergoing primary ESS.
A systematic review was undertaken by Prasad et al. in 2017 
to evaluate the impact of revision ESS(RESS) on PROMs(658). 
This produced 12 studies (1308 patients), three used the 
Rhinosinusitis Disability Index and Chronic Sinusitis Survey in 
tandem; four used the 20-item Sino-Nasal Outcome Test (SNOT-
20)(403) and the 22-item Sino-Nasal Outcome Test (SNOT-22)(403); 
the remaining five used either the Adelaide Disease Severity 
Score, Patient Response Score (PRS), Rhinosinusitis Symptom 
Inventory, Rhinosinusitis Outcome Measure 31, or the Chinese 
version of the University of Pennsylvania Smell Identification 
Test. Studies consistently reported improvement in the five key 
symptoms of nasal obstruction, rhinorrhea, postnasal drip, facial 
pain, and anosmia, although improvement in halitosis, fever, 
dental pain, and cough were modest. 
A study in CRSsNP patients comparing different sizes of the 
maxillary ostial antrostomy could not detect any influence 
of this on the main rhinosinusitis symptoms (obstruction, 
headache, and nasal discharge)(416). Another retrospective review 
in CRSsNP patients suggests that endoscopic maxillary mega-
antrostomy is beneficial in recalcitrant maxillary rhinosinusitis 
in which medical therapy and previous endoscopic antrostomy 
have been unsuccessful. In a cohort of 122 patients (163 sides) 
who underwent endoscopic maxillary mega-antrostomy, 
outcomes were 72.4% reporting complete or significant 
improvement, 27.6% reporting partial improvement and 0% 
reporting worsening(666).
There is still conflicting evidence regarding middle turbinate 
resection (MTR), but recent cadaveric studies confirmed 
better distributions of topical drugs after partial and complete 
middle turbinate resection(667, 668).The resulting postponement 
of revision surgery(647) can justify MTR in primary surgery, 
especially in diffuse sinus pathology andevidence in a mixed 
CRS population is emerging that it may also improve patient-
reported outcomes in revision surgery(657). However, if one 
subscribes to the ‘reboot’ concept, the middle turbinate should 
be maintained as it rarely develops polyps and provides the 
epithelium for re-epithelialization of the sinuses after ‘reboot’ 
surgery(655).
The extent of the surgery depends on the severity of the disease 
and the type of inflammation (endotype). Schalek et al.(667) 
suggest that in cases of severe, diffuse or recurrent polypoid 
disease, better outcomes can be achieved by more extensive 
surgical approaches. The concept of completely removing 
diseased sinus mucosa in the ethmoids to reduce disease 
burden and allow a healthier mucosa to develop was proposed 
by Jankowski in 2006(669). It was considered controversial at the 
time but in recent years it has been relaunched as ‘rebooting’ 
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of the mucosa. Not only the extent of inflammation seen on 
the CT but intraoperative judgment will be the main factors 
to determine the scope of the surgery(425, 431). Thus severe Th2 
CRSwNP disease, often accompanied by asthma, which is 
associated with an increased risk of recurrence, might better 
be approached by ‘reboot’ surgical techniques(647). To date the 
role of complete diseased mucosa removal in CRSsNP remains 
unclear. Jankowski et al.(699) compared radical with conservative 
surgery for CRSwNP and showed reduced recurrence after the 
radical approach, albeit with different surgeons responsible 
for the two approaches. A recent retrospective case-control 
study in patients with Th-2 pattern CRSwNP done by Alsharif 
et al.(431) reported an important reduction in polyp recurrence 
and prolongation of recurrence-free time after complete 
removal of the diseased sinus mucosa. This allowed healthy 
re-epithelialization from the preserved nasal mucosa, using the 
partial and full ‘reboot’ techniques as compared to the classical 
ESS approach. 
This paper defined ‘reboot surgery’ as complete removal of 
all inflamed sinus mucosa to allow the regrowth of functional 
mucosa and divided it into ‘partial’ and ‘full’. Partial involves 
the clearance of all sinonasal polyps and mucosa down to 
the periosteum whereas a full reboot procedure includes the 
mucosa of the frontal recess and the frontal sinuses with Draf III 
access and removal of all frontal sinus mucosa and a sufficiently 
large frontal opening to avoid stenosis(655).  The full ‘reboot’ 
approach showed a better result as compared to a partial 
‘reboot’ ESS though this was not statistically significant. Further 
research is needed to support the ‘reboot’ vs. EESS approaches 
to identify the role of complete removal of the sinus mucosa. 
Postoperative obstruction of the frontal sinus drainage as 
a cause of chronic frontal sinusitis and mucocoeles are a 
major concern after CRSwNP surgery(670, 671). In these cases, an 
endoscopic modified Draf III can be offered. This procedure is 
generally reserved for revision surgery after primary FESS. If 
the patient’s primary FESS was not performed adequately by 
the previous surgeon, a revision Draf IIa can be offered before 
a Draf III is undertaken. If the previous frontal surgery has been 
properly performed and failed, then a Draf III  is indicated(436). 
The Draf III is generally undertaken in severe cases, showing 
statistically significant improvement in recurrence rates in 
CRSwNP, especially in patients with asthma and aspirin-
exacerbated respiratory disease(672). As might be expected, 
revision Draf III has a higher failure rate compared to primary 
Draf III(673). With advancement in technology, instrumentation, 
and techniques, the Draf III has evolved into an efficient and safe 
procedure, and likely will be more commonly used as a primary 
procedure in high-risk patients If the risk factors for all patients 
undergoing Draf III are assessed, these factors (asthma, CRSwP, 
LM >16, narrow frontal ostium <4mm) provide a reasonable 
basis for considering a Draf III in patients who otherwise would 
undergo revision ESS. This particular subset may well benefit 
from a primary Draf III(672).
The revision rate reported by Bassiouni et al. after ESS including 
a Draf IIa was 37% compared to 7% for patients that underwent 
a Draf III, suggesting the superiority of Draf III surgery in patients 
with CRSwNP(674). After long-term follow-up for a minimum of 
seven years of 153 CRSwNP patients, Benkhatar et al. found that 
6.5% required at least one revision surgery for chronic frontal 
sinusitis, with a mean delay from initial procedure to diagnosis 
of 46 months (four months to 11 years). Circular mucosal 
damage in combination with a narrow frontal opening can lead 
to closure of the frontal sinus drainage pathway and hence a 
higher risk of frontal sinus revision ESS(670). 
A meta-analysis of the Draf III or endoscopic modified Lothrop 
procedure (EMLP), as it is often called in the United States was 
conducted from 1990 to 2016 by Shih et al.(438) reporting clinical 
outcomes of Draf III. A total of 1,205 patients were abstracted 
from 29 articles with a mean follow-up of 29.1 +/- 10.3 
months. The overall rate of significant or complete symptom 
improvement was 86.5% (95% confidence interval [CI]: 84.2%-
88.7%). The overall patency rate was 90.7% (95% CI: 89.1%-
92.3%), with a revision rate of 12.6% (95% CI: 10.6%-14.3%). 
Table 6.2.3.1. Potential indications for external approaches to the maxillary and frontal sinuses in CRSsNP and CRSwNP.
CRSsNP, Chronic Rhinosinusitis without nasal polyps; CRSwNP,Chronic Rhinosinusitis with nasal polyps.
Maxillary sinus Frontal sinus
Anterolateral/-inferior pathology requiring access but inaccessible 
endonasally
Narrow frontal recess that cannot be kept open.
Far lateral pathology or pathology on the orbital roof requiring access but 
inaccessible endonasally.
Osteoneogenesis that cannot be treated endoscopically Some forms of frontal osteomyelitis.
Previous trauma and severe frontal recess stenosis.
Complicated acute frontal sinusitis e.g. sub-periosteal frontal abscess that does not 
resolve with antibiotics.
Extensive neo-osteogenesis at frontal recess area.
Failure of endoscopic approach Failure of endoscopic approach.
Need for fat obliteration or cranialisation.
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Compared to the early cohort, patients in the contemporary 
cohort underwent Draf III more often for tumours (p<.001), had 
higher rates of complete or significant symptom improvement 
(90.0% vs. 82.6 %, p<.001); and trended toward greater patency 
rates (92.1% vs. 88.6%, p=5 .052). Overall 79% were performed 
for recalcitrant CRS but when the cohort was divided into 1990-
2008 vs. 2009-2016, whilst there was no difference in symptom 
improvement or patency, the revision rate was higher in the 
more recent group (14.5% vs. 9.2%, p=5.016) when Draf III has 
been performed more frequently for tumors. Among 114 failure 
cases in 16 studies, 82.5% patients were revised with Draf III, 
11.4% salvaged with an osteoplastic flap and 6.1% with standard 
revision ESS. The revision rate increased significantly when 
follow-up exceeded two years which may also have reflected the 
indications for surgery.
Abuzeid et al. also published a meta-analysis in 2018 but only 
considered studies from 2000-2016, including 11 studies and 
778 patients, 86.5% of whom had CRS(433). Mean follow-up 
duration was 28.4 months and the mean number of surgeries 
prior to Draf III was 3.5. In a subgroup analysis of seven studies 
in which all 357 patients had CRS, symptom improvement was 
75.9% of cases and 23.1% experienced polyp recurrence. The 
cerebrospinal fluid leak rate was 2.5% and restenosis of the neo-
ostium occurred in 17.1% with complete closure occurring in 
3.9% of cases. The reoperation rate for Draf III was 9.0%. Aspirin 
sensitivity was associated with an increased risk of cerebrospinal 
fluid (CSF) leak (p=0.0339) and a reduced incidence of neo-
ostium closure (p=0.0001). Aspirin sensitivity and asthma were 
associated with a reduced incidence of reoperation (p=0.001) 
and increased symptom improvement (p<0.005). Restenosis 
or closure of the frontal neo-ostium was associated with less 
symptom improvement (p<0.04) but not with reoperation, as 
above. 
6.2.2.7. Is there any difference in postoperative 
management for revision vs. primary?
Current postoperative management of ESS patients varies 
greatly between individual surgeons. This variation in current 
practice indicates the lack of consensus on the topic. Generally 
postoperative management is aimed at maintaining a clean 
surgical cavity, in which topical steroids can act and to 
maintain patency of the sinus cavities, especially the frontal 
drainage pathway. The long-term follow-up will depend on 
the underlying pathophysiology, sinus patency, and control of 
sinonasal inflammation with medical therapy.
Topical steroids and saline washes
Escalation of treatment beyond nasal steroid sprays and saline 
washes is called for in a revision case. Steroid nasal lavage was 
shown to have superior distribution in the postoperative sinuses 
compared to steroid nasal sprays. Harvey et al.’s DBRCT in a 
mixed CRS population (n=35 analysable) showed benefit for 
mometasone irrigation as compared to spray delivery up to one 
year post-surgery, though both groups showed improvement(67). 
No trial of steroid washes has exclusively studied the CRSsNP 
population.  An undefined CRS population, (n=61), participated 
in a double-blind, placebo-controlled, randomized clinical trial 
comparing saline/lactose with saline/budesonide large volume, 
low pressure washes. The average improvement in SNOT-22 
scores was 20.7 points for those in the budesonide group and 
13.6 points for those in the saline/lactose group, with a mean 
difference of 7 points in favour of the budesonide group(81). 
A recent meta-analysis pooled three studies (mixed CRS 
population) and concluded that nasal irrigation was beneficial, 
but found no clinical benefit from adding corticosteroid in nasal 
lavage compared to saline alone as post-operative treatment(534). 
Long term antibiotic treatment
Long-term treatment, four weeks or more, with macrolide 
antibiotics has support in the literature in CRSsNP patients 
where the eosinophilic inflammation is low to moderate and 
serum IgE within the normal range(14, 27, 675). So far doxycycline 
has only been investigated in CRSwNP(4). Trimethoprim / 
sulfamethoxazole has been shown to improve patient reported 
outcomes in 2 uncontrolled clinical observational trials of 
‘purulent CRS’(676) and ‘recalcitrant CRS’(677). None of these studies 
have focused specifically on patients undergoing revision 
surgery. The use of culture-directed antibiotic therapy and 
topical and/or systemic steroid administration depends on 
the underlying pathophysiology and postoperative wound 
healing(678).
Antimicrobial photodynamic therapy (aPDT)
Antimicrobial photodynamic therapy (aPDT) has demonstrated 
in vitro efficacy for the eradication of bacterial biofilms 
associated with chronic rhinosinusitis (CRS) as well as anti-
inflammatory properties(679-682). Previous case series have 
suggested effectiveness in patients with CRS unresponsive 
to medication and surgery(683). More recently an RCT was 
undertaken to evaluate the clinical effects of aPDT for refractory 
CRS and included 47 patients at two centres(684). Twenty-three 
patients with CRSsNPs and 24 with CRSwNPs unresponsive 
to medical and surgical therapy underwent one of three 
treatments: a single treatment with aPDT, two treatments with 
aPDT separated by a four-week interval, or endoscopic irrigation 
with saline (control). Outcome measures included SNOT-22, 
endoscopic scores, UPSIT, microbiology results and endoscopic 
scores. Significant improvements were seen following aPDT 
treatment in both symptomatic and endoscopic scoring, with 
the greatest effect occurring in the CRSwNPs group receiving 
two treatments (p=0.007). The aPDT treatments were well 
tolerated, with temporary mild pressure in the treated sinus(es) 
being the most common adverse event. The formal trial results 
have yet to be reported but these findings do show early 
promise
More active debridement?
Debridement improves postoperative endoscopic appearances, 
minimizing postoperative infection, granulation, and potential 
restenosis especially in patients who had significant mucosa and 
bone removal (Draf IIB and III), but it is unclear if it has any long-
term positive effects on disease-specific health-related quality 
of life or disease severity as reported by two recent reviews in an 
mixed CRS population(529, 530).
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Generally, as in primary ESS, the first postoperative debridement 
is seven to 10 days after surgery and thereafter the visits are 
individualized depending on the specific needs of the patients. 
Revision surgery may be an indication for the parallel use of 
biologics in the future(685). The surgery should be performed 
after several months of biologic treatment to establish its 
efficacy, and the need for surgery should then be determined 
depending on presence of polyps, symptoms and QoL of the 
patients.
6.2.2.8. General conclusions
Clinical experience and evidence in the literature suggest that 
revision surgery in CRSwNP and to a lesser extent CRSsNP is 
beneficial. However, the quality of the scientific evidence is 
generally low. 
6.2.3. Indications for external surgery 
The need for external approaches in CRS is radically reduced 
with the introduction of endoscopic sinus surgery (ESS) led by 
a philosophical move away from radical removal of diseased 
mucosa to minimally invasive functional restoration of drainage 
pathways and enabling postoperative topical medication 
delivery to the sinonasal cavities. With the exception of a small 
number of indications in the maxillary and frontal sinuses, few 
areas of the sinuses cannot now be reached endoscopically, 
facilitated by advanced techniques using angled endoscopes 
and powered instrumentation. Thus, the indications for external 
approaches are now limited areas that cannot be reached/kept 
open endoscopically. Nevertheless, in the absence of adequate 
instrumentation or experience, external approaches still provide 
an option and may be combined with endoscopic techniques 
to provide a postoperative transnasal route for topical medical 
treatment delivery. The current potential indications for an 
external approach are listed in Table 6.2.3.1.
There are only three papers on two prospective randomised 
trials on this topic(426, 429, 686)the rest of the publications being 
non-comparative cohorts which are largely retrospective.
6.2.3.1. Maxillary sinus
The Caldwell-Luc operation, or radical antrostomy is done 
through a sublabial anterior maxillotomy which has proven 
its value in several large published series(687-689). This approach 
is now rarely used for inflammatory diseases, supplanted by 
the many variants of ESS(690) but in spite of high success rates 
obtained with endoscopic approaches, maxillary antrostomy 
failures still occur(414) and among revision endoscopic surgery 
patients, one study reported 39% stenosis of the middle meatal 
antrostomy(691). 
The major concerns in recalcitrant maxillary rhinosinusitis 
include impaired mucociliary clearance either primary such 
as occurs in cystic fibrosis or primary ciliary dyskinesia, or 
associated with biofilm formation or secondary to previous 
surgery(692). Today even in the presence of persistent disease 
requiring surgical management, extended endoscopic 
approaches such as endoscopic modified medial maxillectomy 
or inferior meatal antrostomy are generally utilized as the next 
option in preference to Caldwell-Luc (C-L)(690). Nevertheless, 
in spite of these efforts, if the disease is difficult to reach 
endonasally, involves a large foreign body or infected bone, 
a classical C-L procedure(693), an external endoscopic-assisted 
sublabial anterior maxillotomy(690) or a Denker procedure still 
remain viable options(694). Canine fossa trephination has also 
been reported to be of use in patients with N-ERD and in 
removal of debris and polyps in allergic fungal rhinosinusitis(695). 
Pentilla et al.(686) performed one of the few prospective 
randomised studies comparing standard C-L to FESS in 150 
consecutive adult patients with chronic maxillary rhinosinusitis 
after failure of medical treatment. The endoscopic surgery was 
performed by one surgeon whereas 16 surgeons undertook 
the C-L. There were 143 patients available for the follow-up at a 
median of 12 months. The patients’ global evaluation showed 
marked improvement in 51% of the C-L group and in 77% of 
the FESS group. Overall subjective symptoms deteriorated 
in 5.5% of C-L operated patients, but not at all in the FESS 
group. At the time, these results seemed to favour FESS over 
C-L. However, a contemporaneous study compared pre- and 
post-operative histopathologic mucosal changes in chronic 
maxillary rhinosinusitis after FESS (60 sinuses) and C-L (55 
sinuses)(696). The C-L operation reduced almost all parameters, 
whereas only oedema and inflammatory cells were significantly 
reduced after FESS. No valid correlations were found when 
comparing histology with patient symptoms. Furthermore, in 
1997 Pentilla et al.(429) published a reassessment of their cohort 
with questionnaires obtained from 128 patients (85%) 5–9 years 
after operation. At this point 82% of the C-L and 76% of the FESS 
patients respectively reported significant improvement. Thirteen 
C-L operated patients (18%) and 14 FESS patients (20%) had 
been re-operated during the 7–9 years follow-up. 
A second randomised, controlled trial with parallel design, 
including 119 patients who fulfilled the clinical, radiological and 
histopathological criteria for chronic, hyperplastic, eosinophilic 
rhinosinusitis was performed by Abd el-Fattah(426). Patients 
were randomly allocated to two treatment groups: classical 
endoscopic middle meatal antrostomy as part of FESS and 
endoscopic radical antrectomy through a combination of 
canine fossa puncture and an endonasal endoscopic procedure, 
with complete removal of maxillary sinus mucosa. The radical 
group showed significantly better impact on symptoms of 
nasal obstruction and rhinorrhoea.  Thirty-two per cent of 
patients in the endoscopic middle meatal antrostomy group 
were considered surgical failures, compared with 14.5% of the 
endoscopic radical antrectomy group (p=0.023). Unhealthy 
maxillary sinuses were significantly more prevalent in the 
endoscopic middle meatal antrostomy group (p=0.029). 
The authors concluded that in patients fulfilling the criteria 
suggestive of chronic, irreversible sinonasal pathology, primary 
endoscopic radical antrectomy was significantly better than 
endoscopic middle meatal antrostomy, based on subjective and 
objective findings.
In a study of Denker’s procedure, Videler et al. conducted a 
prospective questionnaire-based study on 23 patients with 
refractory CRS.  They had undergone a median of six previous 
sinonasal operations (range, 3-11) prior to undergoing the 
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Denker’s procedure, which combines all sinuses, except the 
frontal sinus, into one large cavity, via a sublabial approach to 
the anterior angle between the bony nose and antral walls. 
Preoperative and postoperative symptoms at 12 and 24 months 
were compared. Patients reported a significant improvement 
in rhinorrhoea (p=0.001), feelings of congestion (p=0.02), and 
nasal obstruction (p=0.03). Reduced olfactory perception and 
asthma did not improve.
Interestingly in a review of 670 Caldwell-Luc procedures, the 
most frequent complication was recurrent nasal obstruction, 
which occurred in 28% of patients(687). Informed consent should 
also include other possible complications such as paraesthesia, 
facial pain, oroantral fistula, dacrocystitis, facial asymmetry and 
devitalised teeth(686, 687, 689, 697). Techniques that may help reduce 
complications include gentle tissue retraction, protection of 
the infraorbital nerve, limitation of the size of the anterior 
antrostomy, and avoidance of cracks in the bony wall of the 
antrum(698). The best area in which to perform a canine fossa 
puncture without injuring the infraorbital nerve or anterior 
superior alveolar nerve has been shown to be at the intersection 
of the mid-pupillary line and a horizontal line through the floor 
of the nasal vestibule(699).
6.2.3.2. Ethmoid and sphenoid sinuses
Endonasal ESS, due to its minimally invasive nature, has largely 
supplanted external approaches to the ethmoids and sphenoid 
in CRS(690). An external ethmoidectomy through a modified 
Lynch-Howarth incision made along the inferior border of the 
medial eyebrow and carried inferiorly in a curvilinear fashion 
allows access to the ethmoid sinuses, medial orbit, anterior skull 
base, frontal recess, supero-medial orbit, sphenoid sinus and 
orbital apex. However, in addition to the usual risks engendered 
by proximity to the orbit and skull base, it carries the additional 
risk of complications such as facial scars, forehead paraesthesia, 
and telecanthus. The removal of the medial orbital bone 
frequently led to medialisation of the orbital contents which 
combined with failure to preserve mucosa produced stenosis of 
frontal sinus outflow with secondary inflammatory problems, 
contributing to its loss of popularity(689, 690, 700-702).
In the era of ESS, external approaches to the 
frontal sinuses still have value used as an adjunct 
or alone but their indications are diminishing. 
However, external approaches should be kept in 
our rhinosurgical armamentarium and taught to 
the younger generations.  
6.2.3.3. Frontal sinus
The frontal sinuses remain a challenge for the sinus surgeons 
even in the endonasal endoscopic era, due to their complex 
anatomy. Traditionally, all frontal sinus pathologies including 
CRS were addressed via external approaches such as frontal 
sinus trephination, external frontoethmoidectomy, and 
frontal sinus osteoplastic flap with or without obliteration or 
cranialization(688-690, 700, 703-708). These have largely been replaced 
by endoscopic techniques culminating in median drainage 
(Draf III or an endoscopic modified Lothrop procedure (EMLP)). 
However, the classical external procedures may still be used 
alone or in combination with endoscopic approaches for lesions 
that cannot be reached endoscopically, very narrow entrance 
to the frontal sinus that cannot be kept open e.g. due to 
neoosteogenesis in the frontal recess and very rarely recalcitrant 
inflammation, particularly involving the far lateral region of the 
frontal sinus, disease in a type III/IV frontal cell, osteomyelitis, 
and/or previous trauma (Table 6.2.3.1.). 
For the inflammatory diseases of the frontal sinus, a frontal 
sinus trephine as an adjunct to endonasal procedures can be 
performed(709). Frontal sinus trephination is a safe procedure 
where complications are relatively rare. Nowadays, this 
technique is mainly performed as a mini-trephination, enhanced 
by the use of an endoscope, which improves visualization and 
facilitates instrumentation through the trephine. Indications 
include: complicated chronic frontal rhinosinusitis or frontal 
osteomyelitis; frontal sinusitis with difficult anatomic variants, 
such as type III and IV or intrafrontal cells(595); and far lateral 
frontal sinus diseases as well as complicated acute frontal 
sinusitis(688-690). Seiberling et al.(710) reported a 92% frontal sinus 
patency rate after 188 mini-trephination procedures, with an 
average follow-up of 25.5 months and with 12 complications, 
the most common being infection of the trephine site. The 
indications for trephination were difficulty in finding the frontal 
recess, severe oedema / polyps, frontal cells (type III or IV or 
intrafrontal cells and intersinus septum cell), as an adjunct 
during a Draf III and when there was a need for postoperative 
irrigation. In a systematic review, Patel et al.(711) concluded 
that in the era of ESS, frontal sinus trephination has remained 
the most routinely utilized of all external procedures either 
as a supplement to the endonasal endoscopic approach or 
used alone to provide adequate access for both endoscopic 
visualization and instrumentation into the far lateral and 
superior areas of the frontal sinus. 
External frontoethmoidectomy through a Lynch-Howarth 
incision have been used historically in CRSsNP, usually as a 
transorbital approach to the frontal sinus by resection of the 
ethmoid sinuses and the creation of a contiguous space into the 
nasal cavity. Nevertheless, it had high failure rate due to orbital 
medialisation as mentioned above(702). Although this procedure 
is rarely used nowadays, it may still have some limited utility 
in the presence of complex anatomy and in the presence of 
significant neo-osteogenesis of the frontal recess(688, 689).
Use of the frontal sinus osteoplastic flap (OPF) with or without 
obliteration (FSO) for recalcitrant frontal sinus disease has also 
decreased significantly with the advancement of endoscopic 
techniques. This procedure is extensive and requires a coronal, 
mid-forehead or brow incision, as well as osteotomies to create 
the OPF. With this approach, the entire frontal sinus pathology 
can be exposed, removed and all the frontal sinus mucosa 
drilled out, followed by abdominal fat obliteration of the sinus 
if required(688-690, 704, 705, 712-717). Extensive neo-osteogenesis of 
the frontal recess secondary to previously failed endoscopic 
approaches is the most common indication for this technique 
in inflammatory disease, followed by some cases of laterally 
placed frontal sinus mucocoeles with very narrow diameter of 
the Draf III opening , some cases of osteomyelitis that cannot 
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be cured with antibiotics, some cases of ‘allergic’ fungal frontal 
rhinosinusitis and other laterally located pathologies.
Despite success rates up to 85-90%, long term studies have 
shown that the OPF with FSO can have significant morbidity 
with cosmetic deformity, cerebrospinal fluid leak, forehead 
numbness and postoperative headaches(703-705). Weber et al.(705) 
described a 10% incidence of mucocoele formation after 
FSO detected five years after surgery by MRI. Hansen et al.(706) 
demonstrated that the prevalence of mucocoeles and revision 
rate  was 7,5% in 40 consecutive obliterations with an average 
follow-up of 80 months. Even more problematic is infection 
of the frontal bone flap which in the 1970s was reported at 
18%(704). If this occurred, removal of the affected frontal bone 
as in a Reidel procedure could be considered with a view to 
reconstruction at a later date(718). 
In the most severe cases of refractory frontal rhinosinusitis that 
have failed traditional endoscopic and open approaches, or in 
cases of osteomyelitis of the posterior table of the frontal sinus, 
cranialization of the sinus may be the final surgical resort(707, 708). 
In 2011, van Dijk et al.(708) reported 15 patients with refractory 
chronic frontal rhinosinusitis treated by cranialization of the 
frontal sinus, from 1989 to 2008. All of the patients had better 
quality of life after a mean follow-up of 6.5 years. 
In a retrospective review of 717 frontal sinus procedures for 
inflammatory disease in 683 patients at a tertiary academic 
centre over a three-year period, Hahn et al.(715) reported that 
most cases of chronic frontal rhinosinusitis can be treated by 
endoscopic sinus surgery though this may be unsuccessful 
in some situations such as  distortion of critical landmarks, 
neo-osteogenesis of the frontal recess, and lateral location of 
diseased mucosa. Whilst, > 94% of these cases were successfully 
treated endoscopically, 38 external procedures were performed 
in 32 patients (5.3%).  Fourteen external procedures (2%) 
were performed in isolation and 24 procedures (3.3%) in 
combination with ESS, 16 of whom had concurrent obliteration. 
The osteoplastic flap was used in 24 cases (3.3%), the remaining 
external procedures were frontal sinus trephines. In this series, 
the most common indication for the external approach was 
the neo-osteogenesis of the frontal recess (63.2%). More 
significantly, 79.1% of the cases of neo-osteogenesis were 
associated with previous ESS with a mean of 2.5 procedures, 
indicating that repeated surgical manipulation in the frontal 
recess leads to scarring and osteoneogenesis that limit the 
success of subsequent endoscopic approaches. In these 
cases, the osteoplastic flap may provide a viable alternative. 
Although there were no major complications with the external 
operations, but 9/38 (23.7%) patients required revision surgery 
for persistent/recurrent symptoms.
In the era of ESS, external approaches to the frontal sinuses still 
have value used as an adjunct or alone but their indications are 
diminishing. However, external approaches should be kept in 
our rhinosurgical armamentarium and taught to the younger 
generations.   
Figure 6.2.4.3. Forest plot of the effect of reverse Trendelenburg position compared to the horizontal position on operation time.
Figure 6.2.4.1. Forest plot of the effect of reverse Trendelenburg position compared to the horizontal position on surgical field quality.
Figure 6.2.4.2. Forest plot of the effect of reverse Trendelenburg position compared to the horizontal position on blood loss.
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6.2.4. Peroperative measures to improve surgical 
field and outcomes
Successful ESS highly depends on accurate identification of 
anatomic landmarks within a circumscribed surgical field. 
Bleeding from the sinonasal mucosa impairs endoscopic 
visualization and may lead to complications due to the close 
proximity to the skull base, orbit and vital neurovascular 
structures. Actions should be taken to minimise peroperative 
bleeding and optimize surgical visualization, whilst maintaining 
the physiological homeostasis of the patient. These include 
patient position, local anaesthetics and vasoconstrictors, type of 
general anaesthetic agent and controlled hypotension.
6.2.4.1. Patient positioning
A reverse Trendelenberg position of 5-15’ (head elevation) 
has been shown to improve the surgical field in other surgical 
disciplines by reducing the central venous pressure from 9.2-
1.7mm Hg(719). 
Three studies have been performed evaluating the effect of 
reverse Trendelenburg position on surgical field quality, blood 
loss and operation time (Table 6.2.4.1). The studies could be 
combined into a meta-analysis where reverse Trendelenburg 
position (10-20 degrees) was compared to horizontal position 
(0-5 degrees).
The positioning in reverse Trendelenburg position compared 
to the horizontal position resulted in a significant improvement 
of the surgical field quality measured with the Boezaart 
scale(382) with a MD of - 0.58 (CI -0.78 - -0.38), three trials, 194 
patients, p<0.00001 (Figure 6.2.4.1.). The positioning in reverse 
Trendelenburg position compared to the horizontal position 
also resulted in a significant mean reduction of the per-
operative blood loss of 120 ml (CI -78. – 164 ml), 3 trials, 194 
patients, p<0.00001 (Figure 6.2.4.2.).
Finally, the positioning in reverse Trendelenburg position 
compared to the horizontal position also resulted in a significant 
reduction of operation time with a MD of – 17 min (CI -30 - -5 
min), three trials, 194 patients, p<0.0007 (Figure 6.2.4.3.).
6.2.4.2. Local anaesthesia and vasoconstrictors
Since its inception, it has been possible to conduct ESS under 
local anaesthesia. There are a number of potential advantages 
and disadvantages though there are few scientific studies 
on these topics. Gittelman et al.(720) considered 232 patients 
undergoing ethmoidectomy, 149 under local (LA) and 83 under 
general anaesthesia (GA) in a retrospective study without 
statistical analysis. There was less blood loss in the LA group 
(23ml vs. 58ml) but the complication rate was higher under LA 
(8.7% vs. 2.4%) which included four cases of severe bleeding. In 
contrast Lee et al.(721) reported 1.4% complication rate (only 0.5% 
major) in a non-comparative series of 554 patients having ESS 
under LA with sedation.  
A range of sedatives may accompany LA, given by mouth, 
intramuscular or intravenous routes. These include 
benzodiazepines such as midazolam(721), opiates such as 
morphine(721) or pethidine(722).  Local anaesthetic agents (and 
vasoconstrictors) may be applied topically to the mucosa or as 
regional blocks related to the sinonasal neurovascular anatomy 
as described by Rontal et al.(723). Common combinations of 
anaesthetic agents and vasoconstrictors include cocaine or 
lignocaine (lidocaine) with adrenaline  +/- xylometazoline in 
varying concentrations(721, 722, 724-728). Few high-quality studies 
have been performed to investigate these regimes. However, 
in an RCT Sarmento et al.(729) divided 49 patients undergoing 
ESS into three groups using only topical solutions of adrenaline 
in different concentrations (1:2,000, 1:10,000 and 1:50,000). 
Surgery time was shorter in the group using adrenaline 1:2,000, 
which also showed less bleeding in all evaluations (objective 
and subjective - p<0.0001). 
6.2.4.2.1. Regional blocks
A systematic review of the literature up to 2018 was 
performed on preoperative injections of local anaesthetic and 
vasoconstrictor into the greater palatine canal (GPC) to decrease 
surgical bleeding during endoscopic sinus surgery (ESS)(730). 
Five articles comparing preoperative GPC injection (treatment 
group) with a placebo or no treatment (control group) were 
included(609, 731-734). The endoscopic grade of nasal bleeding in 
the treatment group was significantly reduced when compared 
with the control group and no significant adverse effects 
were reported in the studies. A subgroup analysis showed 
Table 6.2.4.1. Effect of reverse Trendelenburg position on endoscopic sinus surgery.
RCT,Randomised Controlled Trial; CRS,Chronic Rhinosinusitis; FESS, Functional Endoscopic Sinus Surg; CRSwNP, Chronic Rhinosinusitis with nasal 
polyps; VAS, Visual Analogue Scale.
Study Methods Participants Interventions Outcomes Results
Gan 
2014(878)
RCT CRS patients 
having FESS 
(22 evaluated) 
(n=75)
 · Reverse Trendelenburg 20 degree
 · Reverse Trendelenburg 10 degree
 · Reverse Trendelenburg 5 degree
 · Blood loss (ml)
 · Surgical field quality 
(Boezaart, 0-5)
 · Operation time
 · Larger degrees of reverse Trendelenburg 
improved surgical field quality but did 
not improve blood loss or operation 
time
Hathorn 
2013(879)
RCT CRS patients 
having FESS 
(n=64)
 · Reverse Trendelenburg 15 degree
 · Horizontal position
 · Blood loss (ml)
 · Surgical field quality 
(VAS)
 · Reverse Trendelenburg position 
improved surgical field quality and 
reduced blood loss and operation time
Ko 
2008(880)
RCT CRS (33 CRSwNP) 
patients having 
FESS (n=70)
 · Mometasone nasal spray 200 
mcg twice daily 4 weeks preoper-
atively (n=35)
 · Placebo nasal spray twice daily 4 
weeks preoperatively (n=35)
 · Blood loss (ml)
 · Surgical field quality 
(Boezaart, 0-5)
 · Operation time
Treatment with topical corticoid compared 
to placebo resulted in significantly:
 · reduced blood loss
 · improved surgical field quality
 · decreased operation time
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adrenalin 1:80,000 was significantly more effective in reducing 
intraoperative bleeding than adrenalin 1:100,000 (Level of 
evidence Ia).
6.2.4.2.2. Topical agents
Cocaine is an excellent anaesthetic and vasoconstrictor but is 
potentially cardiotoxic. In three national studies on the use of 
cocaine in the Netherlands, UK and USA, the majority of ENT 
respondents (84-90%) had used cocaine as an anaesthetic 
and between 11-26% had observed adverse effects, mainly 
tachycardia(735-737). To avoid these, it is recommended that 
serum levels should not exceed 3-4mg/kg body weight which 
generally equates to a maximum of 200mg in a healthy 
adult(722, 726). In theory the cardiotoxicity might be enhanced by 
the combination of cocaine with adrenaline though this was 
not supported by Pfleiderer and Brockbank’s study(738). In 30 
patients, they showed peak serum cocaine concentrations were 
lower in those receiving the combined agents. In a series of 554 
patients undergoing ESS Lee et al.(721) used 25% cocaine paste 
and 0.01% adrenaline and reported <10% tachycardia and no 
arrhythmias or other adverse reactions.
A combination of topical lignocaine and oxymetazoline 
has been shown to be as effective  as cocaine in terms 
of anaesthesia and vasoconstriction(739, 740). In a study on 
children undergoing FESS, oxymetazoline alone was shown 
to be as effective as phenylephrine or cocaine in terms of 
vasoconstriction which improved bleeding and visualisation(741). 
Tetracaine combined with oxymetazoline was even more 
effective than both lignocaine with oxymetazoline or cocaine 
in terms of analgesia(742, 743). However, this latter study measured 
pain thresholds associated with stimulation of the septum in 
healthy subjects which may not be relevant to the surgical 
situation. Of greater clinical relevance, cocaine was shown to be 
superior when compared directly with lignocaine for intranasal 
antroscopy(744).
Javer et al.(745) showed that infiltration with 2-3mls of 0.25% 
bupivacaine plus 1:200,000 adrenaline (one side) versus saline 
(one side) gave a no significant reduction in intraoperative 
blood loss during FESS (n=46). An RCT comparing 1:200,000 
and 1:100,000 adrenaline also failed to show any difference in 
blood loss(746), indicating that neither concentration is effective 
as a vasoconstrictor when used as infiltration. Furthermore, 
Lee et al.(747) could show no difference in blood loss when they 
compared infiltration versus topical application of 4-5mls of 
1:100,000 adrenalin. However, when four concentrations of 
topical adrenaline (20mls) were compared, Sarmento et al.(729) 
showed haemostatic superiority for 1:2000 adrenalin over lower 
concentrations. 
Adrenaline may also produce potential cardiovascular side 
effects including effects on the blood pressure, tachycardia and 
arrhythmias. These have been investigated using infiltration 
with concentrations of 1:100,000-1:400,000 during ESS though 
effects have been variable with both increases(746, 748, 749) and 
reductions(746, 750) in heart rate and blood pressure. This is 
attributed to the biphasic effect of adrenalin, which produces 
vasoconstriction at low concentrations and vasodilation at high 
concentrations.
Whilst injection of lignocaine (4ml of 1%) produced no 
circulatory change(748, 749), the addition of 10-20ug of adrenalin 
dropped the blood pressure by 25-35% and increased the heart 
rate slightly during the first two minutes post-infiltration but the 
effect was transitory. It is noteworthy that although tachycardia 
occurred in up to 21% of the 1022 individuals studied, no 
serious side effects were experienced.
The EPOS steering group advises to use TIVA, 
and to put the patient in a reverse Trendelenberg 
position during endoscopic sinus surgery.
6.2.4.2.3. Anaesthetic agent
Total intravenous anaesthesia (TIVA) has been suggested as 
an alternative option to traditional inhalational agents, due 
to the physiologic decrease in cardiac output but without the 
peripheral vasodilation associated with inhalational anaesthesia 
(IA)(751). This potentially produces a better visualisation of 
the surgical field but there were significant limitations in all 
the studies included in this systematic review, leading to the 
inevitable conclusion that better high-quality studies are 
required(752) (Table 6.2.4.2.). A randomized controlled trial 
performed by Brunner et al.(753) compared the effect of TIVA 
versus IA on intraoperative visualization of patients undergoing 
ESS in high-grade inflammatory sinus disease defined as either 
sinonasal polyposis or a preoperative Lund-Mackay score of >12. 
Visibility was measured using the 10-point Wormald Surgical 
Field Grading Scale. Operative blood loss, complications, 
and change in quality of life evaluated by SNOT-22 were also 
measured. TIVA appeared to significantly improve endoscopic 
visualization and total blood loss during ESS but no difference 
in operative time, total time of hospital stay, or postoperative 
antiemetic requirement. No complications or serious adverse 
events were reported in either study arm.
Little et al.(754) conducted an RCT on 30 fit patients undergoing 
bilateral ESS for CRS randomised to maintenance anaesthesia 
with i.v. propofol or inhaled desflurane and showed that TIVA 
was associated with a statistically significant reduction in mean 
Wormald score of the surgical field compared to desflurane (4.21 
vs. 5.53, p=0.024). Mean Boezaart score was also lower in the 
TIVA arm (2.18 vs. 2.76, p=0.034). Secondary outcomes including 
surgical duration, time to extubation, and estimated blood loss 
were not found to be statistically significant between the two 
groups.
These two studies(753, 754) confirm the earlier findings of Wormald 
et al. who compared the effects of TIVA using propofol and 
remifentanil with IA agents, sevoflurane and fentanyl on blood 
pressure, heart rate and surgical field (Boezaart scale). TIVA 
improved the surgical field and there was a reduction in both 
blood pressure and heart rate(726). 
The majority of studies included in a subsequent review of the 
literature on TIVA versus IA also showed improvement in the 
surgical field and reduced blood loss(755). Another more recent 
meta-analysis done by Lu et al.(756) analysed 157 articles and 
identified 15 RCTs (828 ESS cases) that satisfied their selection 
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criteria. the pooled analysis demonstrated significantly superior 
surgical visibility scores for TIVA compared to IA based on 
10-point grading scores (p=0.049, visual analog scale; p=0.009, 
Wormald scale) and 5-point grading scores (p=0.002, Boezaart 
scale). Blood loss was significantly less following TIVA (p=0.003) 
with no significant difference in heart rate, mean arterial 
pressure, duration of surgery and anaesthesia.
However, not all studies show superiority for TIVA over IA such 
as that by Beule et al.(757) who showed no advantage in respect 
to heart rate, blood loss and surgical field. These authors also 
considered platelet function which was impaired in both groups 
but was worse in the propofol and fentanyl group.
Raised CO2 potentially has an adverse effect on bleeding in the 
surgical field as it is known to cause smooth muscle relaxation 
and vasodilation. However, Nekhendzy et al.(758) could not show 
a difference in either the surgical field or amount of blood loss 
during ESS when patients with hyper-, hypo- or normocapnia 
were compared. 
Controlled hypotension is an important tool for better 
visualisation of the surgical site(759) and several additional 
methods such as beta blocker premedication or intraoperative 
infusions, either with nitroglycerin or beta blockers have 
been used to achieve controlled hypotension during ESS. 
Other agents such as α2 agonists are also being used, either 
replacing or as adjuncts to classical TIVA agents (remifentanil 
and propofol) for their enhanced hypotensive effects(760, 761). A 
meta-analysis performed by Khosla et al.(762) of 1148 patients 
in 2015 indicated that total intravenous anaesthesia (TIVA) 
was statistically more beneficial than conventional balanced 
anaesthesia, providing an average difference in blood loss of 
75.3 mL and the use of preoperative steroids is statistically more 
beneficial than placebo, with an improved difference in blood 
loss of 28 mL.
In 2016 Boonmark et al.(763) conducted a Cochrane review of 
deliberate hypotension with propofol under anaesthesia for 
functional endoscopic sinus surgery (FESS).  Only four studies 
with 278 participants fulfilled the inclusion criteria of an RCT 
which compared propofol with other hypotensive techniques 
during FESS with regard to blood loss and operative conditions 
in both adults and children(726, 764-766). The primary outcome was 
total blood loss (TBL). Other outcomes included surgical field 
quality, operation time, mortality within 24 hours, complications, 
and failure to reach target blood pressure. Deliberate 
hypotension with propofol did not decrease TBL (millilitres) 
Table 6.2.4.2. Studies describing anaesthetic techniques in endoscopic sinus surgery.
Intravenous agents: F:fentanyl; P:propofol;R:remifentanil 
Inhalational agents: D:Desflurane; I:isoflurane; S:sevoflurane, BP, blood pressure; CT, computed tomography; HR, heart rate; LM, Lund-Mackay; NSD, no 
significant difference; TIVA, total intravenous anaesthetic; VAS, visual analogue scale, Adapted from Timperley 2010(755).
Study Comparison Outcome measure n Findings
Beule 2007(757) S/F v P/F
LM >12
HR, blood loss, blood loss/min, 
platelet function, surgical field 
(VAS)
52 HR:NSD
Blood loss: NSD
Blood loss/min: NSD
Surgical field: NSD
Platelet function: reduced both gps, worse P/F gp
Eberhart 2003(764) TIVA (P/R) v I/A BP, HR, surgical field (VAS, 
Boezaart), dryness (VAS), blood 
loss
90 BP:NSD
TIVA: HR lower
           Surgical field improved
           Blood loss: NSD
Nekhendzy 2007(758) Hyper v 
hypo v normocapnia
Blood loss
Surgical field
180 Blood loss: NSD
Surgical field: NSD
Hypocapnia gp:
Higher need for antihypertensives
Increased blood loss with increased CT score, duration of 
surgery
Tirelli 2004(765) TIVA (P/R) 
v I/F
BP, HR, surgical field (Boezaart) 64 Surgical field: better with TIVA
HR, BP: NSD (trend to be lower in TIVA gp)
Wormald 2005(726) TIVA (P/R)
 v S/F
BP, HR, surgical field (Boezaart) 56 TIVA:
Surgical field: better
Improvement correlated independently with lower BP and HR
Ahn 2008(881) S/R v P/R Hb, blood loss
Surgical field
L-M score
40 High L-M score P/R gave less blood loss, better surgical field
Kaygusuz 2008(882) D/R v I/R BP, HR, 
Blood loss
Surgical field
Time to extubation
63 Blood loss NSD
Surgical field NSD
Time to extubation quicker with D/R
Yoo 2010(883) TIVA (P/R)
v S/R v D/R
BP, HR, surgical field 60 BP, HR, surgical field NSD
Brunner 2018(753) TIVA (P/R)
V IA (S/F)
LM>12
Surgical field (Wormald)
Blood loss
Complications
SNOT 22
72 TIVA:
Surgical field ((Wormald):
better
Blood loss:better
Complications and SNOT22: NSD
Little 2018(754) TIVA (P/R) v IA (D) Surgical field (Wormald and 
Boezaart)
30 TIVA:
Surgical field (Wormald and Boezaart): better
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when compared with inhalation anaesthetics in either children 
(one study; 70 participants; very low-quality evidence), or 
adults (one study; 88 participants; moderate-quality evidence). 
Propofol improved the surgical field by less than one category 
on a scale from 0 (no bleeding) to 5 (severe bleeding) (mean 
difference -0.64, 95% CI -0.91 to -0.37; four studies; 277 
participants; low-quality evidence), but there was no difference 
in operation time (three studies; 214 participants; low quality 
evidence). Failure to lower blood pressure to target was less 
common in the propofol group (risk ratio of failure with propofol 
0.24, 95% CI 0.09 to 0.66; one study; 88 participants; moderate-
quality evidence). The authors concluded that using propofol to 
achieve deliberate hypotension probably improves the surgical 
field, but the effect is small and deliberate hypotension with 
propofol did not decrease TBL and the operation time. However, 
as most studies included few participants and provided low-
quality evidence, results should be interpreted with caution and 
better powered RCTs are required.
Dexmedetomidine, one of these recent agents, is a selective 
α2 agonist, used in combination with general anaesthesia for 
its sedative, analgesic, and haemodynamic stability. Gupta et 
al.(767) compared two groups of 25 patients. Patients from group 
D received dexmedetomidine 1 μg/kg for 10 min, followed 
by an infusion at 0.4–0.7 μg/kg/h and patients in group C 
received the same amount of saline. Surgeons experienced an 
ideal surgical site with minimum bleeding and only sporadic 
suction in 21 (84%) patients in group D, compared to no 
patients in group C despite a low systemic blood pressure. 
Also group D patients needed less isoflurane to maintain the 
systolic blood. The authors concluded that dexmedetomidine 
is effective and safe in providing an ‘dry’ surgical field together 
with its many inherent advantages of analgesia, sedation, and 
anaesthetic-sparing effect. It was also associated with a longer 
but smoother recovery time from anaesthesia. However, Kim 
and colleagues(768) did not find any significant improvement 
in surgical field with an infusion of dexmedetomidine in 
comparison with remifentanil though the extubation time was 
significantly shorter .Two earlier RCTs(769, 770) showed an infusion 
of dexmedetomidine of benefit when FESS was performed 
under local anaesthesia or conscious sedation. Qiao et al.(771) 
also showed the drug is also effective in an intranasal atomised 
form at significantly decreasing blood loss by a median of 
75ml compared to 100ml in the control group, thus optimising 
surgical field visualisation.
In contrast, Karabayirli et al.(772) compared dexmedetomidine 
with remifentanil in two groups of 25 patients. No significant 
differences were found between the groups in intraoperative 
bleeding, surgical field, requirement of sevoflurane, rates of 
nausea, vomiting, or demands for additional analgesia. These 
authors concluded that for controlled hypotension during FESS, 
dexmedetomidine had no additional benefits compared to 
remifentanil and was associated with higher recovery time and 
first-hour postoperative sedation scores.
Clonidine, another α2 agonist, may also be considered. A 
randomised comparison of a clonidine-based vs remifentanil-
based hypotensive anaesthetic regimen was conducted 
during ESS in patients with CRSwNP and CRSsNP (n=47)(773).  
Assessment of video recordings were blindly assessed by a 
third surgeon not involved in patient care. A significantly lower 
proportion of patients in the clonidine arm had Boezaart scores 
higher than 2, with significantly lower mean Boezaart scores 
both at 60 and 120 minutes. 
A systematic review of the use of α2-adrenergic agonists in 
13 RCTs (n=896 patients) assessed the efficacy of clonidine, 
dexmedetomidine, or both(774). The RCTs consistently showed 
that α2-adrenergic agonists reduced bleeding and improved 
surgical field quality during ESS. However, adverse event 
reporting was often omitted. 
In another RCT, a single preoperative single dose of bisoprolol 
fumarate 2.5 mg, (a cardioselective β1-adrenergic blocking 
agent used to treat high blood pressure) has also been shown to 
significantly reduce the blood loss during surgery and improved 
the visualization of the operating field during FESS (n=50)(775). 
Esmolol infusion, another β1-adrenergic blocking agent, has 
also been shown to improve surgical fields during sevoflurane 
anaesthesia for FESS(761).
Another method for achieving controlled hypotension is 
magnesium sulphate infusions. An RCT comparing magnesium 
sulphate, diltiazem or saline each given as a bolus (n=45) 
showed significant reduction in blood loss in both active 
arms(776). However, when magnesium sulphate was compared 
with remifentanil in an RCT of 104 patients undergoing ESS, 
remifentanil was superior in reducing operative bleeding, better 
visibility, shorter operative time, and earlier recovery with 
minimum postoperative sedation, allowing ESS to be performed 
as a day case(777).
Although controlled hypotension is an important tool for 
creating an optimal surgical field, its systemic effects should be 
closely monitored and adjusted accordingly throughout the 
operation. It should also be acknowledged that intraoperative 
hypotension can be a major risk factor for several complications 
due to end organ injury such as perioperative stroke, cognitive 
dysfunction and renal failure. Thus, its level should be set 
according to the risks stratified for each individual patient. 
The POISE study(778) revealed the impact of perioperative 
haemodynamics on postoperative events. A higher incidence of 
postoperative stroke in patients on β-blockers was emphasized 
in this study, potentially due to the hypotension they induce. 
Bijker et al.(779) considered the relationship of intraoperative 
hypotension to postoperative stoke and found that a decrease 
in mean arterial blood pressure of more than 30% from 
baseline and the cumulative duration of these episodes were 
associated with an increased risk of postoperative stoke. In 
another study, Futier et al.(780) showed that intraoperative blood 
pressure management targeting an individualized systolic 
blood pressure, according to patients’ resting blood pressure, 
decreased postoperative organ dysfunctions and neurological 
complications. 
Di Mauro et al.(781) considered the role of intraoperative stroke 
volume variation on bleeding during FESS in 55 patients, ASA I 
to III. Intraoperative bleeding was assessed using the Boezaart 
score and from a wide range of haemodynamic parameters, only 
a negative correlation between surgical bleeding and stroke 
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volume variation (SVV) was found. Furthermore, a cut-off of 
12.5% in SVV is optimal to distinguish the group with the better 
surgical visibility from the group with the worst one. 
Overall, patient preoperative status, the specific surgical 
needs and the vulnerability of end organs should guide 
perioperative blood pressure management. Individualised 
planning of the perioperative haemodynamic target, based 
on close cooperation between surgeon and anaesthetist is 
crucial, combined with accurate and continuous physiological 
monitoring. 
Finally, there are some other aspects, such as the mode of 
anaesthesia which can impact on surgical field. Gilbey et al.(782) 
considered a small cohort of 22 patients undergoing FESS who 
were randomly assigned to be ventilated during surgery under 
general anaesthesia by either high frequency jet ventilation 
(HFJV)  or intermittent positive pressure ventilation (IPPV). 
When the quality of the surgical field was assessed (Boezaart 
score) and the total blood loss was measured, HFJV significantly 
reduced the amount of intraoperative bleeding and thus 
significantly improved the quality of the surgical field possibly 
due to increased venous return due to lower intrathoracic 
pressures resulted in less bleeding and improved operating 
conditions.  The use of pharyngeal packs during FESS have 
not been shown to increase postoperative pain, nausea or 
vomiting(783) as compared to no packing whereas one RCT in 47 
patients showed superiority for packing the nasopharynx rather 
than hypopharynx(784) but the need for packs of any sort has 
largely been superseded by the use of the laryngeal mask(785).
6.2.4.3. Desmopressin
The benefits of intranasal desmopressin in achieving the same 
benefits as steroids during ESS, have been demonstrated in a 
recent RCT(786, 787).
6.2.4.4. Tranexmic acid
Perioperative tranexamic acid has been evaluated in seven 
placebo controlled RCTS, including 562 participants, reviewed 
in a 2019 systematic review(788). Operative time (standardized 
mean difference (SMD) = -0.60) and intraoperative blood loss 
(SMD = -0.66) were statistically lower in the tranexamic group 
than placebo group. This achieved over 100ml reduction in 
blood loss in the active treatment groups. The quality of the 
surgical field and surgeon satisfaction were statistically higher 
in the treatment group than the placebo group. By contrast, 
there were no significant differences in the hemodynamic and 
coagulation profiles of the two groups, and tranexamic acid 
had no significant effect on thrombotic events compared to 
placebo. The relatively small number of patients included in 
RCTs may miss important differences in rare adverse events. A 
large population-based cohort study, including nearly 45,000 
patients undergoing hip arthroplasty, which has a high risk 
of thromboembolic events, found no difference in the risk 
of thrombo-embolic or cardiovascular events or death(789). 
Although there are no similar studies specifically in sinus 
surgery, the absence of increased risk should not differ from that 
found for arthroplasty.
In a study looking at both intravenous tranexamic acid (TXA) 
and epsilon aminocaproic acid (EACA) on bleeding and surgical 
field quality during FESS similar improvements in duration of 
surgery and volume of blood loss were observed in the TXA 
and EACA groups compared to control. The postoperative 
haemoglobin was significantly lower in the control group 
compared to TXA group and EACA group and both TXA and 
EACA groups had comparable improved quality of the surgical 
field with most of patients classified as grade 1 and 2 according 
to Boezaart scale while the control group had most of the 
patients in grade 3(790). 
6.2.4.5.Mitomycin
Mitomycin C is an antibiotic isolated from the broth of 
Streptomyces caespitosus, which acts as an alkylating agent 
able to inhibit DNA synthesis. It has also been shown to 
inhibit fibroblast proliferation and activity, which can reduce 
scar formation. Topical MMC has been used at diverse places 
in the otorhinolaryngological surgery like ear, larynx and in 
endoscopic sinus surgery.  A significant number of randomized 
controlled trials have been performed to evaluate the effect of 
mitomycin c on adhesions formation during sinus surgery(791-799). 
Most studies used 0.4 or 0.5 mg/ml mitomycin on a carrier like 
cotton pledgets, neuropatties, or otowick placed in the relevant 
sinus for 4-5 minutes. Patients were evaluated between one 
week and mean 15 months.  Six studies could be included 
in a meta-analysis: there was a significant positive effect of 
mitomycin versus control on adhesion formation after sinus 
surgery RR 0.51 CI 0.34 0 0.76), 480 patients six studies, p=0.001) 
(Figure 6.2.4.4.). However, in some studies the difference 
becomes smaller over time(798). 
Figure 6.2.4.4. Forest plot of the effect of mitomycin versus control on adhesion formation after sinus surgery.
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Two studies evaluated whether mitomycin could prevent 
stenosis(793, 795). Both concluded that mitocycin was not able to 
improve the relative size over an extended period of time.
No adverse events were observed.
In conclusion: The application of mitomycin for 4-5 minutes at 
the end of surgery prevents adhesions compared to control 
but is not able to improve the relative size of ostia over time. 
No adverse events were observed. Based on the quality of the 
evidence the EPOS2020 steering groups advises that mitomycin 
can be used to prevent adhesion formation after sinus surgery. 
6.2.4.4. Conclusion
There is Level 1 evidence that preoperative injections of local 
anaesthetic and vasoconstrictor into the greater palatine canal 
reduces intraoperative bleeding in ESS and a concentration of 
1:80,000 adrenaline is the most effective. When used topically, 
1:2000 adrenaline showed haemostatic superiority over lower 
concentrations. 
The evidence is less clear as to whether cocaine, lignocaine 
+ oxymetazoline or tetracaine + oxymetazoline is superior 
for local anaesthesia and vasoconstriction.There is level l 
evidence that simple strategies like patient positioning in the 
reverse-Trendelenberg position and more complex controlled 
hypotension on an individualised basis can be successful in 
reducing intraoperative bleeding. Use of propofol to achieve 
deliberate hypotension probably improves the surgical field, 
but the effect is small whereas there is level 1 evidence that α2-
adrenergic agonists reduce bleeding and improve surgical field 
quality during ESS. However, overall the literature shows TIVA is 
superior to IA in improving the surgical field and reduced blood 
loss.
The EPOS steering group advises based on the evidence above 
to use TIVA, and to put the patient in a reverse Trendelenberg 
position during endoscopic sinus surgery. The quality of 
the evidence does not allow for an advice on the best local 
anaesthesia and vasoconstriction.
6.2.5. Informed consent/patient information in CRS
6.2.5.1. Informed consent in clinical practice
Informed consent is "a process for getting permission before 
conducting a healthcare intervention on a person (or for disclosing 
personal information about them)".
For consent to be valid, it must be voluntary and informed, 
and the person consenting must have the capacity to make 
the decision. This means that consent must not be influenced 
by pressure from others and the individual must understand 
the information given to them. They must receive information 
regarding the benefits and risks of the treatment, whether there 
are alternative treatments and what will happen if treatment 
does not go ahead. 
The principle of consent is an important part of medical ethics 
and international human rights law with significant medicolegal 
implications. This is increasingly pertinent with the expanding 
field of genomics(800). Lynn-Macrae et al.(801) found informed 
consent issues in 37% of 41 medicolegal cases involving ESS 
and this issue remained at 27% in the following 10 years(802). The 
advent of precision or personalised medicine has emphasised 
the patient-physician interaction, which has proved particularly 
pertinent to chronic rhinosinusitis(803). In the UK, since 2015 there 
has been a statutory Duty of Candour on all health professionals 
to be “open and honest with patients and their families when 
something goes wrong that appears to have caused or could 
lead to significant harm in the future” even if it has not yet done 
so(804). This has also had a major impact on informed consent. 
Informed consent applies to all treatments, both medical 
and surgical but surgery features more prominently in the 
literature where the balance of benefit versus risk may be more 
immediately evident(805).  
The level of detail given for any particular procedure varies 
considerably from country to country and institution to 
institution(806, 807). Traditionally, the “prudent patient standard’ 
in which the physician disclosed all risks that it was deemed a 
reasonably prudent patient would consider material to their 
decision to undergo or refuse a particular procedure” has often 
been adopted(807, 808). When discussing endoscopic surgery for 
an essentially non-fatal condition such as CRS, complications 
range from mild to catastrophic which has previously made the 
consent process difficult. An American survey nearly 20 years 
ago found that 60% of responding surgeons would discuss with 
patients pre-operatively risks likely to occur in 1% or greater of 
cases(806). However, specifically the majority mentioned CSF leaks 
(99%), bleeding (97%), orbital injury (97%) and infection (85%) 
whereas 40% discussed smell impairment, cerebrovascular 
accident (18%), myocardial infarct (8%) and 28% death.
In the last decade a more ‘patient-centred’ approach has evolved 
as studies have shown that the majority of patients undergoing 
ENT procedures expect to be told about all complications(808, 809) 
(see section 6.2.1.20.). Interestingly when Wolf et al. repeated 
their survey in patients, 69% wanted to be informed about any 
risk occurring at a frequency of 1% or greater but for the specific 
complications, 83% wanted to know about orbital damage 
and CSF leaks, 76% revision surgery, 74% smell impairment, 
73% bleeding and myocardial infarct and 72% cerebrovascular 
accident, highlighting a discrepancy in priorities(807). 
In the UK, the case of Montgomery vs. Lanarkshire Health Board 
2015(810) established that patients must have all information 
available pre-operatively, not what the doctor thinks they 
should know. In some respects, this legal imperative to explain 
all complications makes the situation easier, however distressing 
it may be to the patient. It is also incumbent on the surgeon to 
discuss their own results, both outcomes and complications in 
the context of their peers.
Studies have shown that age and educational status affect 
consent, with higher education and younger age improving 
understanding and retention of information(809, 811-814). Similarly, 
these factors are also associated with an increased wish to know 
about complications associated with the lowest incidence, 
irrespective of their severity(812).
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Whatever the process of informed consent, after a relatively 
short time, many patients have poor recall of the information 
given, which is important when there can be a significant 
interval between consent and an elective procedure(808, 809, 815). 
Aremu et al.(816) showed that only 51% recalled complications of 
common ENT procedures, including for CRS, after a mean of 21 
days. This was significantly improved to 62% if a handout was 
also given. The length of time spent on surgical consent is also 
an important predictor of comprehension and is maximised 
when it takes between 15 and 30 minutes, albeit in non-ENT 
procedures(817). 
Those physicians perceived by their patients as concerned, 
accessible and wiling to communicate, at least in obstetrics, 
are least likely to be sued(818). In the USA and elsewhere many 
physicians will bring the patient in for a visit shortly before 
surgery and obtain consent to improve recall of risks. Others 
obtain consent on the day of surgery though in some countries 
such as the UK, doctors are encouraged or mandated to obtain 
consent more than 24 hours in advance of surgery and definitely 
before a premedication has been given on the day of surgery.
A variable proportion of patients (8-66%), will also seek further 
information elsewhere which is now greatly facilitated by the 
internet(808, 809). While sometimes contributing misinformation, 
some issues around consent might be improved by the use of 
modern technology. A significant early improvement in overall 
risk recall was demonstrated in patients who completed a 
multimedia consent educational module compared to a control 
group although this difference was not found 3-4 weeks later(819). 
Whatever the environment, the consent process is greatly 
strengthened by careful documentation and individual checklist 
forms are recommended by many authors(820).  Bagnall and 
colleagues(821) conducted a systematic review of the literature 
on taking consent combined with semi-structured interviews 
to identify key components of the surgical consent procedure. 
Thirty-three components were identified, the most frequently 
cited of which were explaining the diagnosis and procedure, 
general and specific risks, assessing the patient’s mental 
capacity to give consent and offering alternative options. Least 
common was disclosure of outcomes for the same procedure by 
the individual surgeon and others. The need for better training 
in this area was highlighted. The EPOS panel members provided 
comment on informed consent in their respective countries. The 
following had similar systems and legislation to the UK in place : 
Australia, Canada, China, New Zealand, Singapore and USA. 
In Sweden and Denmark written consent is not required prior 
to a surgical procedure. This is also the case in the Netherlands 
where the Dutch Medical Treatment Agreement Act (WGBO) 
regulates the rights of the patient. This law states that patients 
are entitled to information and that they must give permission 
for treatment. The WGBO also regulates the privacy of the 
patient, the right to a second opinion, the right of patients 
to view their own medical records and the representation of 
patients if they cannot decide for themselves. In addition, the 
WGBO requires healthcare providers to keep a medical record 
but the law does not dictate exactly what must be discussed nor 
are percentages of complications given. Similarly, in Greece and 
Denmark, there is no uniform nationwide documentation and 
only complications occurring more often than 1% are usually 
discussed. As in the UK, consent must be given at least 24 hours 
in advance of the surgery. In several countries, for example 
Brazil and Spain, the national ENT society, often with legal input, 
provides templates for consent to its members. These usually 
include explanations of the operation (indications, technique, 
consequences of surgery, potential complications and post-
operative care). The form is signed by both patient and surgeon.
Many countries have now adopted the WHO checklist [www.
WHO.int] which requires that informed consent has been 
given and signed by both parties, without which the operation 
cannot proceed.  In Spain having a signed informed consent is 
not always deemed sufficient and in some trial cases, evidence 
of physical interaction between patient and doctor has been 
deemed necessary. As a consequence, doctors are strongly 
encouraged to make handwritten comments on the discussion 
that took place.
Most consent forms include sections for minors/parents/
guardians and those with language problems. In the case of 
children, some countries such as Greece require the signature 
of both parents. For linguistic issues, the name and signature 
of the translator is also required to signify that the patient has 
understood the procedure.  
Several respondents commented that since the European 
Union’s GDPR (General Data Protection Regulations) were 
implemented in May 2018, these had led to increased 
complexity of the consent documentation, particularly with 
respect to any research implications(822, 823).
6.2.5.2. Informed consent in research
Following the declaration of Helsinki in 1975(824), the next major 
milestone in protecting patients who volunteer for medical 
research was the introduction of the International Clinical 
Harmonisation of Good Clinical Practice guidelines in 1996(825). 
With regards to the consent process within this framework, the 
guidelines stipulate the following parameters:
"In any research on human beings, each potential subject must be 
adequately informed of the aims, methods, anticipated benefits 
and potential hazards of the study and the discomfort it may 
entail. He or she should be informed that he or she is at liberty to 
abstain from participation in the study and that he or she is free 
to withdraw his or her consent to participation at any time. The 
physician should then obtain the subject’s freely-given informed 
consent, preferably in writing".
"When obtaining informed consent for the research project, 
the physician should be particularly cautious if the subject is in 
a dependent relationship to him or her or may consent under 
duress. In that case the informed consent should be obtained by 
a physician who is not engaged in the investigation and who is 
completely independent of this official relationship".
"In case of legal incompetence, informed consent should be 
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obtained from the legal guardian in accordance with national 
legislation. Where physical or mental incapacity makes it 
impossible to obtain informed consent, or when the subject is a 
minor, permission from the responsible relative replaces that of 
the subject in accordance with national legislation. Whenever 
the minor child is in fact able to give consent, the minor’s consent 
must be obtained in addition to the consent of the minor’s legal 
guardian".
In some institutions in the USA child consent is referred to as 
“assent” and is usually obtained from children above seven years 
old.
In both future diagnosis and research, especially in the fields 
of genetics and genomics, where big data can be shared or 
published, data protection is mandatory and has been the 
subject of a number of publications(826-830). 
Excerpt from ICH E6 Guideline for Good Clinical Practice: 
Informed Consent Explanation
Both the informed consent discussion and the written informed 
consent form and any other written information to be provided 
to subjects should include explanations of the following: 
a) That the trial involves research. 
b) The purpose of the trial. 
c) The trial treatment(s) and the probability for random as-
signment to each treatment. 
d) The trial procedures to be followed, including all invasive 
procedures. 
e) The subject’s responsibilities. 
f ) Those aspects of the trial that are experimental. 
g) The reasonably foreseeable risks or inconveniences to 
the subject and, when applicable, to an embryo, fetus, or 
nursing infant. 
h) The reasonably expected benefits. When there is no intend-
ed clinical benefit to the subject, the subject should be 
made aware of this. 
i) The alternative procedure(s) or course(s) of treatment that 
may be available to the subject, and their important poten-
tial benefits and risks. 
j) The compensation and/or treatment available to the sub-
ject in the event of trial-related injury. 
k) The anticipated prorated payment*, if any, to the subject 
for participating in the trial. 
l) The anticipated expenses, if any, to the subject for partici-
pating in the trial. 
m) That the subject’s participation in the trial is voluntary and 
that the subject may refuse to participate or withdraw from 
the trial, at any time, without penalty or loss of benefits to 
which the subject is otherwise entitled. 
n) That the monitor(s), the auditor(s), the IRB/IEC**, and the 
regulatory authority(ies) will be granted direct access to 
the subject’s original medical records for verification of 
clinical trial procedures and/or data, without violating the 
confidentiality of the subject, to the extent permitted by 
the applicable laws and regulations and that, by signing a 
written informed consent form, the subject or the subject’s 
legally acceptable representative is authorising such access. 
o) That records identifying the subject will be kept confiden-
tial and, to the extent permitted by the applicable laws 
and/or regulations, will not be made publicly available. If 
the results of the trial are published, the subject’s identity 
will remain confidential. 
p) That the subject or the subject’s legally acceptable repre-
sentative will be informed in a timely manner if information 
becomes available that may be relevant to the subject’s 
willingness to continue participation in the trial. 
q) The person(s) to contact for further information regarding 
the trial and the rights of trial subjects, and whom to con-
tact in the event of trial-related injury. 
r) The foreseeable circumstances and/or reasons under which 
the subject’s participation in the trial may be terminated. 
s) The expected duration of the subject’s participation in the 
trial. 
t) The approximate number of subjects involved in the trial. 
* NB. Some countries e.g. Spain, do not allow payments to 
participants in clinical studies.
** Similar documents are produced in other countries and refer 
to the relevant regulatory authorities such as the FDA (Federal 
Drugs Administration in the USA.
6.2.6. Training in surgery 
As in other surgical disciplines, training for FESS involves 
personal studies using a variety of materials from textbooks 
to online resources (anatomy, pathophysiology etc.), lectures, 
clinical rounds, clinical fellowships and physical models(831). 
The use of audiovisual techniques during FESS allows 
trainees to directly observe their teachers on screens that 
compensates for the impracticability of assisting as occurred 
in open surgeries(832). In addition, teachers can supervise every 
surgical step of their trainees on screen and give focused 
commands and instructions. Sandhaus et al. proposed a 
standardized terminology of commands to facilitate the trainees’ 
understanding of what they are supposed to do so as to clearly 
execute  single surgical steps(833).
An additional benefit to audio-visually enhanced training is the 
use of intraoperative navigation to integrate the knowledge 
of endoscopic and CT anatomy. This is particularly important 
in CRSwNP where the sinonasal anatomy may be distorted 
by the pathology as well as previous surgery. It was shown 
that the sense of direction and orientation during surgery 
was enhanced, the latter being a critical factor in training(834). 
However, especially in inexperienced trainees, over-confidence 
and dependence on the system and risk overestimation must be 
considered(835).
Functional endoscopic sinus surgery techniques can 
furthermore be practiced through cadaveric dissections(836). An 
understanding of the endoscopic view of sinonasal anatomy 
is essential and, in particular fresh frozen, cadavers offer an 
optimal simulation of real surgery though polyp tissue itself 
cannot be simulated in cadavers. However, the handling of 
powered instruments and potential complications can be 
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practised in cadavers,and the dissections can be evaluated in 
a variety of ways (e.g. pre- and post-dissection CTs) to improve 
training outcomes(837). The shortcomings of cadaveric dissections 
are the costs and limited availability in certain centres and 
countries. Despite this a large number of dissection courses are 
held around the globe. 
A more accessible and cheaper alternative to human cadaveric 
dissection are animal models like sheep or lamb heads, 
synthetic human models and simulator training dissection(838). 
Despite the fact that sheep sinus anatomy differs from human 
anatomy, its similarities are appropriate to train surgical skills, 
handling instruments, visualisation and orientation with the 
endoscope and dissection steps can be practiced especially 
when standardized training steps are applied(839-841). 
Apart from cadaveric dissection, synthetic models of human 
heads and the sinonasal tract like the S.I.M.O.N.T. (Sinus Model 
Otorhino Neuro Trainer) have been introduced. Here silicone/
plastic anatomic models based on CT anatomy have been 
created to train endoscopic sinus surgery(842). The advantage 
here lies in the availability and reproducibility as well as the 
assessment of different tasks accomplished by the trainees(843). 
A disadvantage of these models is that the haptic feedback 
of tissue composition such as mucosa cannot be simulated. 
However, these models can be combined with animal 
specimens to simulate surgical complications such as carotid 
artery injury and their management. The carotid arteries of 
anaesthetised sheep dissected and attached to the S.IM.O.N.T. 
model can be injured to create live bleeding scenarios(619). As 
with cadavers, the costs of production of these models need to 
be considered. To overcome these shortcomings 3D printing 
could be a future alternative where the sinonasal system is 
printed according to CT anatomy and various materials are 
utilised to simulate the difference between e.g. bone and 
mucosa(844) offering cheap and reproducible training prior to a 
specific surgical case(844, 845).
Virtual Reality (VR) simulators are another tool to teach and 
learn endoscopic sinus surgery and do not rely on cadavers and 
models allowing almost unlimited access. The first simulators 
appeared in the late 1990s and were combined with head 
models to simulate working through the nose and could 
be combined with mechanical arms to the endoscope and 
instruments for haptic feedback. The surgical steps could be 
followed in a VR programmed environment on the monitor(846, 
847). Advances in computer technology have led to more detailed 
graphical 3D anatomy representation and implementation of 
various training programs(831, 848). Also, it is possible to simulate 
powered instrumentation like shavers, irrigation and other 
tools that can be activated by foot pedals similar to real life 
surgery(849). Examples of sinonasal VR simulators are Madigan 
Endoscopic SinusSurgery Simulator: ES3, Nasal Endoscopy 
Simulator: NES, Voxel-Man SinuSurgery and the Dextroscope(850, 
851). Validity of these simulators was studied by comparing the 
surgical performance of two groups after simulator training 
vs conventional material training(852) or sinonasal anatomic 
knowledge after training with VR simulator versus textbooks(853). 
Despite further technological advances, VR simulators still need 
more improvement to approach real-life or cadaver conditions, 
but are considered as a useful additional tool in surgical 
training(849). Training of spatial orientation and mechanical 
manipulation of instruments and endoscopes are considered 
more important than haptic feedback in simulators(834). To 
date the quality of evidence in validation studies is still low. 
Moreover, no studies focus on outcomes after surgery correlated 
to previous VR training(854, 855).
6.2.7. Peri-operative medication
6.2.7.1. Introduction
Medication can be given before, during or after the surgery. An 
overview of medication for CRS in general is given in chapter 
6.1. Medication given before surgery to enhance the surgical 
field are discussed in 6.2.1.2., peri-operative medication and 
measures to enhance the surgical field during surgery are 
discussed in 6.2.4. This chapter discusses the effect of peri-
operative treatment on the period directly after surgery.
6.2.7.2. Antibiotics
6.2.7.2.1. Summary of data
There have been four randomized clinical trials investigating 
short-term postoperative antibiotics following ESS, including 
three placebo-controlled studies (Table 6.2.7.1). Short-term 
antibiotics was defined as less than 30 days of treatment. To 
date, there have been no studies of short-term preoperative 
antibiotics. None of the studies(539, 856-858)showed differences 
between antibiotics versus placebo/control apart from a short-
term reduction in symptoms of nasal obstruction and nasal 
discharge on day 5 postoperatively and significant lower POSE 
endoscopy scores on day 5 and 12 in the study of Albu(857). After 
stopping the antibiotics no differences were seen. It was not 
possible to include the trials in a meta-analysis.
Jiang(539)  compared amoxicillin/clavulanic acid to no treatment 
following ESS and showed  that the bacterial culture rate  
became higher after FESS in the antibiotic group  but that the 
rate of antibiotic sensitivity to amoxicillin/ clavulanic acid did 
not change. No changes were seen in the control group.  
One study from Huvenne et al. evaluated the effect of 
placement of a doxycycline-releasing stent in the ethmoid in 10 
postoperative CRS patients and showed that the doxycycline-
releasing stents significantly improved postoperative healing 
quality after functional endoscopic sinus surgery and lowered 
MMP-9 concentrations and bacterial colonization locally(469).
6.2.7.2.1. Conclusions
The use of postoperative antibiotics in four (placebo) controlled 
trials in 371 patients did not show significant difference in 
objective or subjective clinical outcomes compared to controls 
but these studies may have been underpowered to detect a 
benefit. Based on the low quality of the current evidence the 
EPOS2020 steering group is not able to advise on the use of 
postoperative short-term antibiotics after endoscopic sinus 
surgery. There is a need for large-scale RCTs to answer this for 
daily practice very relevant question. Studies are also needed to 
evaluate the effect of short-term preoperative antibiotics.
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Study Methods Participants Interventions Outcomes Results
Albu 
2010(857)
DBPCT 75 CRS 
patients (40 
CRSwNP)
• Amoxicillin + clavulanate 625 
mg twice daily for 14 days 
(n=40)
• Placebo twice daily for 14 
days (n=35)
• Symptom questionnaire day 
5, 12, 21 and 30
• Perioperative sinus endosco-
py (POSE) score at day 5, 12, 
21 and 30
• Endoscopic examination at 
day 5 until all blood crusts 
resolved
Amoxicillin + clavulanate versus placebo 
resulted in:
• Significant lower scores for nasal 
obstruction and nasal discharge on 
postoperative day 5
• Significant lower POSE scores on day 5 
and 12 
• No statistical difference between groups 
in overall symptom scores or POSE 
scores at 21 or 30 days
• Patients displaying blood crusts within 
12 days post-surgery were lower in the 
antibiotic treated group as compared to 
the placebo group (p=0.02)
Schalek 
2009(856)
DBPCT 23 CRS 
patients
• Amoxicillin + clavulanate, 
quinolone or co-trimoxazole 
for 3 weeks (n=13)
• Placebo for 3 weeks (n=10)
• SNOT-22 (Czech translation) 
at 3 and 6 months
• Clinical symptom-specific 
scores at 3 and 6 months
• Endoscopic score at 3 and 6 
months
• No statistically significant difference in 
SNOT-22 quality of life scores, average 
symptom score, or endoscopic scores 
compared to placebo at 3 and 6 months
• Mean endoscopic scores after 3 months 
approached significance (p=0.056)
• There was no statistical difference with 
regard to which particular antibiotic was 
used
Jiang 
2008(539)
RCT 71 CRS 
patients
• Amoxicillin + clavulanate 375 
mg three times daily for 3 
weeks (n=31)
• No treatment (n=40)
• Rhinosinusitis symptom 
scores at week 3
• Antibiotic sensitivity rate at 
week 3
• Culture rate at week 3
• Endoscopic scores at week 3
• No significant difference in the short-
term subjective or objective outcomes 
of CRS 3 weeks after endoscopic sinus 
surgery
• Bacterial culture rates increased in the 
study group after FESS (38.7% vs. 61.3%, 
p=0.014) but no significant difference 
in antibiotic sensitivity to amoxicillin/
clavulanate
Annys 
2000(858)
DBPCT 202 CRS 
patients
• Cefuroxime axetil 250 mg 
twice daily (n=101)
• Placebo twice daily 
all patients received 
nasal saline and nasal 
corticosteroids (n=101)
• Symptoms
• Nasal endoscopy
• No significant differences between the 
groups
DBPCT, Double Blind Placebo Controlled Trial; CRS,Chronic Rhinosinusitis; CRSwNP, Chronic Rhinosinusitis with nasal polyps; RCT, 
Randomised Controlled Trial; SNOT-22, Sino-Nasal Outcome Test-22; POSE, Perioperative Sinus Endoscopy score;
The use of peri-operative corticosteroids reduces 
blood loss and operation time and improves the 
quality of the surgical field.
6.2.7.3. Peri-operative corticosteroids
Studies evaluating the effect of corticosteroids peri-operatively 
can be divided in studies evaluating the effect of the treatment 
during the surgery and studies evaluating the postoperative 
period. The studies evaluating the effect of corticosteroids 
during surgery are discussed in chapter 6.2.1.2.
6.2.7.3.1. Summary of data of effect of peri-operative 
corticosteroids on postoperative state of disease in CRS
Next to the direct effect of peri-operative corticosteroids 
during surgery one might wonder whether it is useful to 
give (intranasal) corticosteroids after the surgery to prevent 
recurrence of disease/reduce symptoms after surgery.
Eleven papers on 10 studies evaluated the effect of 
corticosteroids starting peri-operatively on the signs and 
symptoms of disease in the weeks-years after the surgery (Table 
6.2.7.2).
Three studies(76, 77, 83)evaluated the effect of peri-operative 
corticosteroids on postoperative QOL using different outcome 
measurements. Two studies(76, 77)evaluated general quality of life 
five weeks after surgery and found no impact of postoperative 
FNDP on general quality of life although one  study(76, 77)found an 
impact on the mental component summary and three domains 
of the SF-36.
Three studies evaluated the proportion of patients that was 
relapse free at nine months, although relapse was differently 
defined. When combining the three studies into a meta-analysis 
no significant impact was seen on the proportion of patients 
that was relapse free at nine months RR 1.33 (CI 0.59-2.98), three 
studies, 284 patients, p=0.49) (Figure 6.2.7.1).
Table 6.2.7.1. Short-term postoperative antibiotics in CRS.
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Table 6.2.7.2. Effect of corticosteroid treatment versus placebo postoperatively.
Study Methods Participants Interventions Outcomes Results
Nordin 
2013(76)
DBPCRCT 60 CRSwNP, 
postoperative
• Perioperative FPND 400µg 
b.i.d. for 14 weeks (n=26)
• Perioperative placebo b.i.d. 
for 14 weeks (n=34)
• General quality of life, using Gen-
eral Well Being Schedule (0-110, 14 
questions with a 6-point scale and 4 
questions with an 11-point scale) at 
weeks 4 and 5
At 5 weeks, both groups increased in general 
quality of life score to a similar extent without 
difference
Vento 
2012(105)
DBPCRCT CRSwNP, 
postoperative
• Postoperative triamcinolone 
acetonide nasal aerosol 
220µg ⁄ day as 2 actuations 
of 55µg, each for 9 months 
(n=30)
• Postoperative placebo spray 
for 9 months (n=30)
• Symptom score (0-3, 10 symptoms) 
improvement at month 3, 6, 9
• Nasal polyp score (0-3) reduction at 
month 3, 6, 9
• Polyp recurrence at 9 months
• Adverse events
Postoperative triamcinolone versus placebo 
resulted in:
• No difference in symptom improvement
• No difference in nasal polyp score reduction
• Reduction in polyp size/regrowth in N-ERD 
patients at 3 months, but not 6 and 9 months 
acid-intolerant patients
• No serious adverse events reported. 
Rotenberg 
2011(83)
DBPCRCT 64 CRSwNP (N-ERD) 
postoperative (60 
analyzed)
• Budesonide irrigation 
60ml/nostril 500µg b.i.d. 
(total 1000µg) for 52 weeks 
(n=20)
• Saline irrigation 60ml/
nostril and budesonide 
spray 64µg/nostril b.i.d. 
(total 256µg) for 52 weeks 
(n=19)
• Saline irrigation alone for 52 
weeks (n=21)
• Quality of life (SNOT-21 (0-105) at 6,12 
months)
• Endoscopy score (LKES (0-12) at 6,12 
months)
• CT score (LM score (0-24) at 6,12 
months)
• Ocular events (IOP at 6,12 months)
• HPA axis (ACTH(normal/abnormal) at 
6,12 months)
• SNOT-21, LKES, and LM score results of both 
intervention groups were not different from 
placebo group at both 6 and 12 month 
timepoints (significance level was defined 
at p<.0167)
• IOP and ACTH level were not changed at 
both 6 and 12 month timepoints
Olsson 
2010(77)
DBPCRCT 68 CRSwNP, 
postoperative
• Perioperative FPND 400µg 
twice daily. for 10 weeks 
(n=30)
• Perioperative placebo b.i.d. 
for 10 weeks (n=38)
• Health related quality of life (SF-36, 
0-100, 8 health domains) at week 5 
after sinus surgery
• At 5 weeks after sinus surgery no effect on 
total SF36 but significant improvement in 
the FPND group of the mental component 
summary  and  3 domains (role physical, 
vitality, social functioning)
Ehnhage 
2009(95)
DBPCRCT 68 CRSwNP 
(52 evalauted) 
postoperative
• Perioperative FPND 400µg 
b.i.d. for 10 weeks (n=23)
• Perioperative placebo b.i.d. 
for 10 weeks (n=29)
• Symptom score (3 symptoms, each 
score 0-3) improvement at 10, 17 
weeks
• Nasal Polyp score (0-3) reduction at 4, 
6, 10, 17 weeks
• Adverse events
• There was no difference between FPND   and 
placebo in symptom improvement and nasal 
polyp score reduction at 10 and 17 weeks 
• No difference in adverse events
Jorissen 
2009(93)
DBPCT 99 CRSwNP patients 
having FESS (67 
evaluated)
• 2mg betamethasone 
daily for 7 days followed by 
mometasone nasal spray 
200µg twice daily for six 
months (n=35)
• Placebo daily for 7 days 
followed by placebo nasal 
spray  twice daily for six 
months (n=32)
At 1 and 2 weeks and 1, 2, 4 and 6 
months postoperatively
• Total symptom score (VAS)
• Nasal endoscopy score (0-14)
• Endoscopic combination score (for 
inflammation, oedema, and polyps)
• % subjects requiring rescue medi-
cation
At 1 and 2 weeks and 1, 2, 4 and 6 months:
• No significant difference in total symptom 
score, nasal endoscopy or % subjects 
requiring rescue medication
• Significant reduction in endoscopic 
combination score at 1,2 weeks and 1 and 
2 months
Stjarne 
2009(114)
DBPCRCT 162 CRSwNP 
postoperative
• Postoperative MFNS 200µg 
o.d. for 8 weeks (n=80)
• Postoperative placebo for 8 
weeks (n=82)
• Time to relapse for polyp recurrence 
at 24 weeks
• Adverse events
• At 24 weeks follow-up, postoperative use 
of MFNS, 200 µg once daily, provided a 
statistically significant longer time to relapse 
with nasal polyps than with placebo
• The frequency of AEs with MFNS and placebo 
was comparable.
Wright 
2007(381)
DBPCT 26 CRSwNP patients 
having FESS
• Prednisone 30 mg daily for 
5 days preoperative and 9 
days postoperative (n=11)
• Placebo daily for 5 days 
preoperative and 9 days 
postoperative (n=15)
Measured at 2,4,12 and 26 weeks:
• Overall symptomatology
• Separate symptoms
• LK score
• POSE score
Treatment with oral corticoid compared to 
placebo resulted in 
• No difference in total and/or separate 
symptoms
• Improved LK score at 2,4, and 26 weeks
• Improved POSE score at 2 weeks
Rowe-Jones 
2005(92)
DBPCT 109 CRS patients 
(77 CRSwNP) 
having FESS (72 
evaluated after 5 
years)
• FPANS 200 mcg twice daily 
(n=40)
• Placebo twice daily (n=32)
Yearly evaluation of:
How do you feel today (VAS)
• Total symptoms (VAS)
• Nasal polyp score
• Oedema score
• Discharge score
• Olfaction
• Nasal volume (acoustic rhinometry)
Treatment with FPANS resulted in:
• No significant differences in total symptoms 
at 1 and 5 years follow-up
• Significant difference at 1 and 5 years in nasal 
endoscopy score and total nasal volume
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Dijkstra 
2004(111)
DBPCT 162 CRS patients 
(55 CRSwNP) 
having FESS 
• FPANS 800 mg twice daily 
for 1 year (n=54)
• FPANS 400 mg twice daily 
daily for 1 year (n=54)
• placebo twice daily for 1 
year daily (n=54)
During one year: 
• Recurrence or persistent disease
No significant difference in the recurrence rate 
during one year between the groups
Gulati 
2001(859)
DBPCRCT • 63 CRSwNP, 
postoperative
• Postoperative budesonide 
nasal spray 400µg/day for 
12 weeks (n=38)
• Postoperative saline nasal 
sprays for 12 weeks (n=25)
• Proportion of responders at 12 weeks
• Symptom improvement (4 symptoms) 
at 12 weeks
• Polyp recurrence at 12 weeks
• At 12 weeks, greater responder of symptom 
improvement in the budesonide group than 
placebo group was significant for rhinorrhoea 
and sneezing. 
• At 12 weeks, budesonide treated patients 
had significantly lower rate of polyp 
recurrence.
Table 6.2.7.3. Corticosteroid-eluting implants as postoperative treatment in patients with CRS.
DBPCRCT, Double Blind Placebo Controlled Randomised Controlled Trial; DBPCT, Double Blind Placebo Controlled Trial; CRSwNP, Chronic 
Rhinosinusitis with nasal polyps; N-ERD, NSAID-exacerbated respiratory disease; FESS, Functional Endoscopic Sinus Surg; FPND, Fluticasone 
Propionate Nasal drops; SNOT-21,; LKES, Lund-Kennedy endoscopy scoring; LM, Lund-Mackay; IOP, Intraocular Pressure; ACTH, Adrenocorticotropic 
Hormone; HPA, Hypothalamic-Pituitary-Adrenal; CT, computed tomography; VAS, Visual Analogue Scale; FPANS, Fluticasone propionate aqueous 
nasal spray; MFNS, Mometasone Furoate Nasal spray; POSE, Perioperative Sinus Endoscopy score; LK, Lund-Kennedy; CRS,Chronic Rhinosinusitis.
Study Methods Participants Interventions Outcomes Efficacy
Gyawali, 
2019(468)
DBPCT 58 CRSwNP 
postoperative
• Non-absorbable nasal pack soaked 
in triamcinolone (2ml of 40mg/ml 
solution) to one side (removed on 
second postop day)
• Non-absorbable nasal pack soaked 
in saline on the contralateral side 
removed on second postop day)
• POSE and LK score in third postopera-
tive week
Significantly better results with 
corticosteroid pack than placebo pack for 
both scores 
Hwang 
2018(860)
SBPCT 22 CRSwNP 
postoperative
• Calcium alginate soaked with 2mL of 
triamcinolone (40mg/mL) (n=22)
• Calcium alginate soaked with 2mL 
saline (n=22)
• POSE score at 1, 4 and 8 weeks post-
operatively
Significant difference in POSE score at 
week 8 
Luong 2018 
(884)
DBPCT 80 CRS patients 
having frontal 
sinus surgery
• Bioabsorbable drug-eluting stents 
releasing 370μg of mometasone 
furoate over approximately 30 days 
unilateral frontal sinus ostium (n=79)
• Stent without corticosteroid unilater-
al frontal sinus ostium (n=79)
• Postoperative interventions at 30 
days post-ESS (oral steroid or surgery) 
(independent observer)
• Postoperative interventions (cortico-
steroid or surgery) at 30 and 90 days 
post-ESS (clinical investigator)
• Endoscopic evaluation of frontal sinus 
ostium region (inflammation, steno-
sis,patency)
Implant coated with MF compared to non-
coated implant 
• Significant less need for postoperative 
intervention at 30 days (independent 
observer)
• Significant less need for postoperative 
intervention at 30 and 90 days (clinical 
investigator)
• Reduction in inflammation and reste-
nosis and greater diameter at 30 days
Zhao 
2018(482)
DBPCT 64 CRSwNP 
postoperative
• 64 sides: 2 pieces of 8cm biodegrad-
able nasal dressing impregnated 
(BND) with 4mL or 8mL of mometa-
sone furoate 0.35mg/ml taken out 
after 1 week or after 2 weeks
• 64 contralateral cavities received an 
identical BND soaked in the same 
amount of normal saline taken out 
after 1 week or after 2 weeks
• POSE and LK score at 7th or 14th 
postoperative days and at 1, 2 and 3 
postoperative months.
• The POSE and Lund-Kennedy scores 
showed that in the 4mL, 1-week group, 
no significant differences between the 
sides treated with MF-soaked BNDs and 
the normal saline-soaked control were 
observed at any postoperative visits. 
In the 4mL, 2-week group, significant 
differences were found at the 2-week 
and 1-month postoperative visits but 
not at the 2-month and 3-month visits. 
In the 8-mL, 1-week group, significant 
differences were found at the 1-week, 
1-month, and 2-month postoperative 
visits but not at the 3-month visit. In 
the 8mL, 2-week group, significant 
differences were found at all 
postoperative visits.
Sow 
2018(861)
DBPCT 8 patients with 
CRS (CRSwNP 
unclear) 
postoperative
• Hydrocortisone-impregnated 
bioabsorbable dressing in one nasal 
cavity and normal saline-impreg-
nated bioabsorbable dressing in the 
contralateral nasal cavity 
• SNOT and POSE at 1, 3 wks and 3 
months post-operative
• No statistical significance between 
impregnated and saline dressing at 1 
and 3 wks and 3 months postop.
Table 6.2.7.2. Effect of corticosteroid treatment versus placebo postoperatively (continued).
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Ha 2018(862) SBPCT 12 CRS (7 
CRSwNP) 
patients 
postoperative
Part of 36 
patients in 
non-blinded 
RCT
• Chitosan-dextran gelwith 1 mg/ 2 mL 
budesonide (n=5)
• Chitosan-dextran gel (n=7)
• Percentage of baseline intraoperative 
areas for sinus ostia at 2 weeks, 3 
months, and 12 months postoperative
• Adhesion presence (%) and severity (0-
3) , mucosal oedema (0-3), granulation 
tissue formation (0-3), evidence of pus 
0-2) and crusting (0-2) at 2 weeks, 3 
months and 12 months postoperative
• All sinus ostia significantly larger at 2 
weeks and frontal and sphenoid ostia 
significantly larger at 12 months. 
• Other data not analysed
Sabarinath, 
2017(863)
DBPCT 75 CRS patients 
postoperative
• Non-absorbable nasal pack soaked 
in triamcinolone (2ml of 40mg/ml 
solution) to one side (removed on 
second postop day)
• Non-absorbable nasal pack soaked 
in saline on the contralateral side 
removed on second postop day)
• Crusting, oedema, polypoidal change 
(Absent; Mild; Severe) at 1 and 2 weeks, 
1 and 3 months
• Discharge (Absent; thin/clear; thick/
purulent) at 1 and 2 weeks, 1 and 3 
months
Adriaensen 
2017(121)
DBPCT 30 patients 
with CRSwNP 
randomized 
to 2 out of 3 
treatments 
on two sides 
postoperative
• SinuBand with fluticasone propionate 
160µg per side (n=20)
• SinuBand (without FP) per side 
(n=20)
• Standard nasal pack per side (Mero-
cel(R)) (n=20)
• Intraocular pressure
• Lens opacity
• 24-hour urine cortisol
• Ethmoid inflammation (VAS) at 
5/15/30/60 days
• % of sinuses developing polypoid 
changes through first 15/30/60 days
• Adhesion formation at 5/15/30/60 days
• Lund-Kennedy score at 5/15/30/60 
days
• Postoperative pain at 5/15/30/60 days
• Nasal congestion at 5/15/30/60 days
• Nasal discharge at 5/15/30/60 days
• No significant change in 24-hour urine 
cortisol
• No differences in ethmoid 
inflammation, adhesions or LK score
• Significantly lower polypoid changes in 
sides with Sinuband FP than Sinuband 
without FP and Merocel at 60 days
• Significantly less pain and congestion 
at 60 days for Sinuband FP than 
Sinuband without FP
Smith 
2016(885)
DBPCT 80 CRS patients 
having frontal 
sinus surgery
• Bioabsorbable drug-eluting stents 
releasing 370μg of mometasone 
furoate over approximately 30 days 
unilateral frontal sinus ostium (n=79)
• Stent without corticosteroid unilater-
al frontal sinus ostium (n=79)
• Postoperative interventions at 30 
days post-ESS (oral steroid or surgery) 
(independent observer)
• Postoperative interventions (cortico-
steroid or surgery) at 30 and 90 days 
post-ESS (clinical investigator)
• Endoscopic evaluation of frontal sinus 
ostium region (inflammation, steno-
sis,patency)
Implant coated with MF compared to non-
coated implant 
• Significant less need for postoperative 
intervention at 30 days (independent 
observer)
• Significant less need for postoperative 
intervention at 30 and 90 days (clinical 
investigator)
• Reduction in inflammation and 
restenosis and greater diameter at 30 
days
Xu 2016(466) DBPCT 80 CRSwNP 
postoperative 
(58 evaluated)
• 28 x two pieces of 4cm biodegrad-
able dressing impregnated with 2ml 
of a 10mg/ml of triamcinolone
• 32 pieces of 4cm biodegradable 
dressing impregnated with 2ml saline
• SNOT-20 and the Sniffin’ Stick test 1 and 
3 months
• Lund–Kennedy (L–K) and POSE score at 
1, 2 and 3 months.
• No significant difference in SNOT
• Significant lower POSE and LK score in 
the triamcinolone group compared to 
the place group at 1 and 2 months
Bardaranfar 
2014(864)
DBPCT 60 CRSwNP 
postoperative 
• A sterile piece of compressed 
Gelfoam combined with 10 mg/
mL of triamcinolone at the olfactory 
cleft between the nasal septum and 
middle turbinate, above anterior 
attachment. 
• A sterile piece of compressed 
Gelfoam combined with saline at 
the olfactory cleft between the nasal 
septum and middle turbinate, above 
anterior attachment. 
• Butanol threshold test 8 weeks post-
operative
• The triamcinolone resulted in a signifi-
cant better butanol threshold test at 8 
weeks than saline
Table 6.2.7.3. Corticosteroid-eluting implants as postoperative treatment in patients with CRS (continued).
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Hong 
2013(467)
DBPCT 20 CRS patients 
postoperative
• Triamcinolone (20 mg) impregnated 
bioresorbable dressing (n=10)
• Saline impregnated bioresorbable 
dressing (n=10)
• Serum cortisol levels at day 1, 2 and 10
• 12-hour urine cortisol level at day 10
• Osteocalcin, blood eosinophil count, 
and adreno-corticotropic hormone 
(ACTH) levels at day 2 and 10
• Serum cortisol levels significantly 
depressed at day 1, 2 
• 12-hour urine cortisol level significantly 
depressed compared to placebo at 
day 10*
• Significant difference in osteocalcin 
at day 2*
Rudmik 
2012(865)
DBPCT 36 CRSsNP 
patients 
postoperative
• Dexamethasone Sinu-FoamTM(16mg 
dexamethasone) (n=18)
• Sinu-FoamTM (n=18)
• LK score at 1 week, 4 weeks and 3 
months
• Adverse events
• No significant differences between 
groups
Marple 
2012(122)
DBPCT L 105 CRS (62 
CRSwNP) 
patients 
postoperative
• Bioabsorbable drug-eluting stents 
releasing 370μg of mometasone 
furoate over approximately 30 days 
(n=105)
• Placebo stents (n=105)
• Frank polyposis (yes/no) at day 30 by 
• Adhesion formation (0-5) at day 30
• Need of intervention (oral corticoste-
roids or adhesion lysis) at day 30 
• All data analysed by independent panel 
and investigators
• Ocular safety
• Drug related adverse events
• Significant difference in mometasone 
furoate group in need for intervention 
and frank polyposis (independent 
panel)
• No significant differences difference in 
mometasone furoate group in need 
of intervention and frank polyposis 
(clinical investigators)
• Significant reduction in adhesions 
(clinical investigators)
Murr 
2011(866)
DBPCT 38 CRS (31 
CRSwNP) 
patients 
postoperative
• Bioabsorbable drug-eluting stents 
releasing 370μg of mometasone 
furoate over approximately 30 days 
(n=38)
• Placebo stents (n=38)
• Ethmoid sinus inflammation (VAS) at 7, 
14, 21, 30, 45 and 60 days
• % of sinus with polypoid change > 
1(0-5) at day 30
• % of sinus with adhesion formation 
(0-5) and middle turbinate lateralisation 
up to day 30
• Plasma mometasone fuorate and 
cortisol concentrations at 7, 14, 21 and 
30 days (in 5 patients with bilateral 
mometasone furoate releasing stent)
• Significant reduction in ethmoid 
inflammation in mometasone furoate 
group at 21,28 and 45 days
• Significant reduction in % of sinus with 
polypoid change at day 30
• Significant reduction in % with sinus 
adhesion formation up to day 30
• No differences in plasma 
concentrations
Coté 
2010(465)
DBPCT 19 CRSwNP 
patients 
postoperative
• Triamcinolone (80 mg) impregnated 
bioresorbable dressing on one side 
(n=19)
• Saline-impregnated bioresorbable 
dressing on the other side
• LK and POSE scores at postoperative 
days 7, 14, 28 and at 3 and 6 months 
• Adverse events
• Significantly better LK and POSE scores 
at days 7 and 14 and 3 and 6 months in 
triamcinolone-impregnated group
DBPCT, Double Blind Placebo Controlled Trial; SBPCT, Single Blind Placebo Controlled Trial; CRS, Chronic Rhinosinusitis; CRSwNP, Chronic 
Rhinosinusitis with nasal polyps; POSE, Perioperative Sinus Endoscopy score; LK, Lund-Kennedy; MF, Mometasone Furoate; post-ESS, Post Endoscopic 
Sinus Surg; BND, Biodegradable Nasal Dressing; SNOT, Sino-Nasal Outcome; RCT, Randomised Controlled Trial; ACTH, Adrenocorticotropic Hormone; 
VAS, Visual Analogue Scale;  *Significance between the groups calculated based on data given in paper.
Table 6.2.7.4. Postoperative saline nasal irrigation versus no irrigation in CRS patients.
RCT, Randomised Controlled Trial; FESS, Functional Endoscopic Sinus Surg; CRS, Chronic Rhinosinusitis.
Study Methods Participants Interventions Outcomes Results
Liang 
2008 (175)
RCT, no blinding, 
postoperative
77 patients 
undergoing FESS 
• Pulsatile nasal irrigation for 3 
months 
• No treatment
At 2 weeks and 1, 2, and 3 
months postoperatively:
• Symptom score
• Endoscopy score
• Significant positive effect 
of nasal irrigation in pa-
tients with mild CRS but 
not with severe CRS
Freeman 
2008(158)
Within-subject, 
single-
blinded RCT 
postoperatively
22 CRS patients • 2ml isotonic saline via a mucosal 
atomisation device one side of 
the nose, three times per day for 
6 weeks
• No saline other side of the nose
At 3 wks and 3 months:
• Adhesions, discharge, 
polyps, crusting, oedema 
(0-3) at endoscopy 
• Significant positive effect 
of saline atomisation 
on discharge, no other 
differences
Pinto 
2006(178)
Postoperative, 
RCT, double 
blinded for sprays
60  patients 
with histories of 
frequent sinusitis 
after FESS
• Normal saline (NS; n = 20) four 
times per day, two puffs on each 
side, for the first 5 postoperative 
days.
• Buffered hypertonic saline (HS; n 
= 20) 4 times per day, 2 puffs on 
each side, for the first 5 postoper-
ative days.
• Or no spray (n = 20)
For 5 days:
• Symptoms (nasal obstruc-
tion/congestion, nasal 
discharge/postnasal drip, 
pain/pressure, headache, 
and trouble sleeping/in-
somnia) (0-4) 
• Pain medication 
• Significantly more nasal 
discharge in hypertonic 
saline group compared to 
the other groups
• No other significant 
differences
Table 6.2.7.3. Corticosteroid-eluting implants as postoperative treatment in patients with CRS (continued).
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Six studies evaluated symptoms(92, 93, 95, 105, 859). Five studies 
found no differences in symptom scores(92, 93, 95, 105). One 
study only evaluating nasal blockage and sneezing, found 
a difference in sneezing(859). Two studies could be combined 
into a meta-analysis and showed no significant reduction in 
symptomatology in the corticosteroid treated group versus the 
placebo group MD 1.2 (CI -1.1.4 -3.54), two studies, 201 patients, 
p=0.31) (Figure 6.2.7.2).
Four studies evaluated a nasal polyp score. Three studies 
showed no difference between corticosteroid treatment and 
placebo(93, 95, 105), the study of Rowe-Jones showed a significant 
reduction in nasal polyp score after one and five years of nasal 
corticosteroids use versus placebo. The studies could not be 
combined into a meta-analysis. 
Three studies evaluated a nasal endoscopy score(83, 93, 381). None 
found a significant difference of corticosteroid treatment versus 
placebo. Two studies could be combined into a meta-analysis 
(Rotenberg had two arms) and showed a trend in reduction 
of endoscopy score at six months in the corticosteroid treated 
group versus the placebo group SMD -0.51 (CI -1.04 -0.03), 
two studies (one with two arms) 168 patients, p=0.06) (Figure 
6.2.7.3).
6.2.7.3.2. Conclusion
The quality of the evidence concerning the effect of peri-
operative corticosteroids to prevent recurrence of disease/
reduce postoperative was (very) low. The studies were in general 
small with significant heterogeneity. 
There is no indication that use of peri-operative corticosteroids 
is more effective than placebo on the postoperative QOL, 
symptoms and of nasal endoscopy. Based on the quality of the 
available evidence the EPOS steering group cannot advise on 
the use of peri-operative/postoperative (nasal) corticosteroids.
6.2.7.4. Corticosteroid-eluting implants
6.2.7.4.1. Summary of the evidence
Steroid-eluting stents, spacers and dressings can improve local 
drug delivery immediately following endoscopic sinus surgery 
and reduce the recurrence of inflammation warranting systemic 
corticosteroids. For chronic rhinosinusitis with nasal polyposis 
(CRSwNP), the need for systemic corticosteroids immediately 
following endoscopic sinus surgery when using a steroid-eluting 
spacer has not been studied.
In this analysis only studies comparing a local corticosteroid 
containing device versus placebo are included: in 14 DBPCRCTs 
local corticosteroids containing steroid-eluting stents, spacers 
and dressings were placed in the ethmoid  after surgery and 
compared to placebo(121, 122, 465-468, 482, 860-866) (Table 6.2.7.3.).
Twelve studies used impregnated biodegradable and two a 
non-absorbable packing(468, 863) impregnated with a variety 
of local corticosteroids including triamcinolone(465-468, 860, 
863, 864), mometasone furoate(122, 482, 866), hydrocortisone(861), 
budesonide(862), fluticasone proprionate(121), and 
dexamethasone(865).
Of these, seven studies evaluated patients with CRSwNP, one 
study(865) patients with CRSsNP and the other six either a mixed 
population or the phenotype is not indicated. 
Figure 6.2.7.1. Forest plot of the effect of peri-operative corticosteroids versus placebo on relapse at nine months.
Figure 6.2.7.2. Forest plot of the effect peri-operative corticosteroids versus placebo on 6-12 months postoperative total symptoms.
Figure 6.2.7.3. Forest plot of the effect of peri-operative corticosteroids versus placebo on six months postoperative nasal endosco-
py score.
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Dosages were varied and depended on the corticosteroid used. 
One study compared four different scenarios with two dosages 
and removal one and two weeks postoperatively(482). Also, the 
duration of corticosteroid release varied significantly from short 
(1-2 weeks max) for the dressings soaked in local corticosteroids, 
to 30 days for the drug eluting stents(122, 866).
Two studies evaluated the effect of steroid-eluting stents, 
spacers and dressing placement postoperatively on QOL (SNOT)
(466, 861). Both studies found no difference in SNOT score in the 
steroid treated patients/sides compared to placebo.
Symptoms were not evaluated apart from smell in two 
studies(466, 864) and congestion, pain and discharge in the study 
by Adriaensen(121). In the study by Xu there were no significant 
differences between the triamcinolone treated group and 
the placebo group in the postoperative results of the Korean 
version of the Sniffin’ Stick II (KVSS II) test nor the TDI (threshold, 
discrimination, and identification). Also, when only the anosmic/
hyposmic patients were evaluated (TDI score < below 27) 
no significant differences between the groups were found. 
Bardaranfar on the other hand found significant impact of the 
placement of a sterile piece of compressed Gelfoam combined 
with 10mg/mL of triamcinolone at the olfactory cleft between 
the nasal septum and middle turbinate, above anterior 
attachment on the butanol threshold test(864). Adriaensen 
reported significantly less nasal congestion and pain reported 
by the patients on the side treated with local corticosteroids 
than on the placebo side at day 60 (p=0.036). All the other 
timepoints/measurements were not significant(121). 
A number of studies evaluated endoscopic scores (POSE)(381) 
(Figure 6.2.7.4.) and/or Lund-Kennedy score(867) (Figure 6.2.7.6.) at 
comparable timepoints and could be combined into a meta-
analysis.  The POSE score at three weeks – 1 mnd showed score: 
SMD -1.03 (95% CI -1.83, -0.23); 138 participants; eight studies; 
I2 = 89%), scale range: 0 to 16, lower = better, indicating less 
disease in the patients  that were treated with corticosteroid-
eluting stents, spacers or dressings than the placebo (Figure 
6.2.7 4.) .  The result at three months still showed a significant 
effect: SMD -0,63 (95% CI -1.23, -0.03); 88 participants; six studies; 
I2 = 88%), (p=0.06) (Figure 6.2.7.5.).
Lund-Kennedy score at three months showed: SMD -0.72 (95% 
Figure 6.2.7.4. Forest plot of the effect of corticosteroid-eluting stents, spacers or dressings versus placebo on the POSE score after 3 
weeks -  1 month postoperatively
Figure 6.2.7.5. Forest plot of the effect of corticosteroid-eluting stents, spacers or dressings versus placebo on the POSE score after 3 
month postoperatively
Figure 6.2.7.6. Forest plot of the effect of corticosteroid-eluting stents, spacers or dressings versus placebo on the Lund-Kennedy 
score after 3 month postoperatively
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Table 6.2.7.5. Methods of nasal irrigation in postoperative CRS patients.
RCT, Randomised Controlled Trial; CRS, Chronic Rhinosinusitis; CRSwNP, Chronic Rhinosinusitis with nasal polyps; SNOT-22, Sino-Nasal Outcome Test-
22; POSE, Perioperative Sinus Endoscopy score; NSS, Nasal and Sinus Symptom scale.
Study Methods Participants Interventions Outcomes Results
Macdonald 
2015(162)
Single 
blind RCT 
postoperative
86 CRS patients 
(55 CRSwNP) 
directly 
postoperatively
• Saline squeeze bottle 
(n=43) for 1 month
• Saline nasal spray 
(n=43) for 1 month
• SNOT-22
• POSE
• Nasal and sinus 
symptom scale 
(NSS) (0-15)
• Significant improvement in both groups for SNOT-
22, POSE, NSS
• No difference between treatment groups
Table 6.2.7.6. Postoperative saline irrigation with antiseptic/mucolytic/babyshampoo solution in CRS patients.
CRS, Chronic Rhinosinusitis; RCT, Randomised Controlled Trial; CRSwNP, Chronic Rhinosinusitis with nasal polyps; dd, dose/day; RSOM-31, 
Rhinosinusitis Outcome Measure-31; SNOT-22, Sino-Nasal Outcome Test-22; PEA, Phenyl Ethyl Alcohol.
Study Methods Participants Interventions Outcomes Results
Farag 
2013(160)
Single 
blind RCT 
postoperative
40 CRS patients 
directly 
postoperative
• 120ml Hypertonic 
Saline solution 3dd until 
4 months postop
• 120ml of 1% baby 
shampoo solution3dd 
until 4 months postop
• RSOM-31
• SNOT-22
• Olfaction with phenyl 
ethyl alcohol (PEA) 
threshold test
• Adverse events
• Significant decreases in scores for both the 
SNOT-22and RSOM-31 overtime for both 
treatments but no difference between the 
treatments
• PEA thresholds showed improvement but no 
difference between the treatments
• The baby-shampoo group reported 
significantly more side effects and had more 
patients stop the solution 
Pigret 
1996(183)
Single-
blind RCT 
postoperative
20 CRSwNP 
patients after 
endoscopic 
endonasal 
ethmoidectomy 
• Pressurized seawater 
(volume unclear) (n=10) 
3dd
• 10ml of saline plus 
benzododecinium (anti-
septic) plus oleosorbate 
(mucolytic) (n=10) 3dd
• Residual nasal crusts 
weight at 21±2 days 
secretions after 21±2 
days
• Visual analogue scale 
for nasal obstruction, 
rhinorrhoea, cacosmia 
and facial pain
• No significant differences although the mean 
residual crust weight  was higher in the 
pressurized seawater group (1,756±688mg) 
than in the antiseptic/mucolytic saline group 
(932±414mg)
CI -1.36, -0.07); 98 participants; seven studies; I2 = 79%), scale 
range: 0 to 10, lower = better, indicating less disease in the 
patients  that were treated with corticosteroid-eluting stents, 
spacers or dressings than the placebo (Figure 6.2.7.6.). 
Only one very small study evaluating off-label drug-eluting 
middle-meatal spacer of dexamethasone and Sinu-FoamTM 
in patients with CRSwNP did not show an improvement 
in endoscopic outcomes in the early postoperative period 
following ESS(865).
For both POSE and Lund-Kennedy score there was a significant 
heterogeneity most likely caused by variations in the dosage 
of local corticosteroids: the studies reporting no effect 
used low potency corticosteroids like hydrocortisone(861) 
and triamcinolone(466, 860), and the study by Zhao(482) using 
mometasone furoate showed a dose response.
It can be concluded that postoperative placement of steroid-
eluting stents, spacers and dressings compared to placebo 
does not have an influence on QOL and most likely also not 
on symptomatology but has a significant and most likely dose 
dependent effect on POSE and Lund-Kennedy scores. Whether 
the effect on POSE and Lund-Kennedy score (around 1 point of 
the mean around 5 (POSE) or 3 (LK) in the placebo group) is of 
imporatnce clinically remains unclear.
6.2.7.4.2. Safety of corticosteroid-eluting implants
Finally, the safety/adverse events associated with treatments 
with steroid-eluting stents, spacers and dressings were 
evaluated(121). In this evaluation also spacers placed in the office 
are taken into account (see chapter 6.1.6.3; Table 6.2.7.3.) Three 
studies evaluated ocular safety(119, 121, 122) and none showed 
clinically significant change in IOP and or modifications in 
lens opacity. Three studies evaluated systemic corticosteroid 
levels(121, 467, 866).   Hong found the serum cortisol levels to be 
significantly suppressed at postoperative days 1 and 2 and 
the 12-hour urine cortisol level at day 10 significantly lower 
in the local corticosteroid group compared to placebo(467). All 
but one patient (taking inhaled asthma medication) had 24-
hour urine cortisol levels within the normal range at baseline 
and postoperative day 15 in the study of Adriaensen and the 
study of Murr showed no abnormalities in serum cortisol  and 
mometasone furoate concentrations in five patients at 7, 14, 21 
and 30 days postoperatively(121, 467, 866).
Local (drug related) adverse events (seven studies) were limited 
and not reported more often in the local corticosteroid group 
than the placebo group. 
6.2.7.4.3. Conclusion
It can be concluded that postoperative placement of steroid-
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Table 6.2.7.7. Postoperative saline irrigation with sodium hyaluronate in CRS patients.
CRS, Chronic Rhinosinusitis; DBPCT, Double Blind Placebo Controlled Trial; CRSsNP, Chronic Rhinosinusitis without nasal polyps; CRSwNP, Chronic 
Rhinosinusitis with nasal polyps; SNOT-22, Sino-Nasal Outcome Test-22; NOSE, Nasal Obstruction Sympton Evaluation; VAS, Visual Analogue Scale; LK, 
Lund-Kennedy; RCT, Randomised Controlled Trial; SF-36, Short Form 36.
Study Methods Participants Interventions Outcomes Results
Mozzanica 
2019(166)
DBPCT 56 CRSsNP 
patients 
postoperatively
• 250ml saline plus 9mg sodi-
um hyaluronate twice daily 
for 6 weeks (n=26)
• Saline twice daily for 6 weeks 
(n=30)
At 3 and 6 weeks 
postoperatively:
• SNOT-22 
• NOSE 
• Symptoms (VAS)
• LK score
• No differences in SNOT-22, NOSE, symptoms 
and total LK score at 6 weeks
• Significantly better result of NOSE score at 3 
weeks in sodium hyaluronate group
• Significantly better result for headache and 
smell alteration at three weeks in sodium 
hyaluronate group
• Significantly reduced scar formation (3 and 
6 weeks), crusting (3 weeks) and secretion (6 
weeks) 
Cantone 
2014(185)
DBPCT 124 CRSwNP 
(122 evaluated) 
postoperatively
• Intranasal nebulization of 
9mg sodium hyaluronate 
(3mL) plus saline solution 
(2mL) twice daily for 30 days 
(n=62)
• Intranasal nebulization of 
saline (5mL) twice daily for 
30 days (n=60)
At 30 days 
postoperatively:
• SF-36
• SNOT-22
• Symptoms (VAS)
• Endoscopic score
Significantly better result of sodium hyaluronate 
than saline for:
• SF36
• SNOT-22
• Total symptoms (VAS)
• Endoscopic score
Casale, 
2014(167)
RCT 
(single 
blind?)
33 CRS patients 
postoperatively
• Nebulization of 3ml contain-
ing 9mg sodium hyaluronate 
nasal washes plus saline 
twice daily for 1 month 
(n=18)
• Nebulization of 5mL saline 
twice daily for 1 month 
(n=15)
At 2 and 4 weeks 
postoperatively:
• CRS questionnaire 
• Visual analogic scale 
(VAS)
• Nasal endoscopy
• VAS score of hyaluronate significantly lower 
than saline at 2 and 4 weeks
• CRS score significantly lower than saline at 2 
and 4 weeks
• Significantly less crusts and oedema and 
secretions
Gelardi 
2013(186)
RCT 
(single 
blind?)
36 CRSwNP 
postoperative
• Intranasal nebulization of 
sodium hyaluronate 9mg in 
3mL twice daily for 30 days 
(n=19)
• Intranasal nebulization saline 
5mL twice daily for 30 days 
(n=17)
At 30 days 
postoperatively:
• Nasal obstruc-tion, 
burning, dryness of the 
mucosa (VAS) 
• Presence or absence of 
rhinorrhoea
• Mucociliary clearance 
time 
• Presence of exudate at 
endoscopy
Sodium hyaluronate group had compared to 
saline:
• Significantly faster mucociliary clearance 
• Lower incidence of rhinorrhoea
• Less nasal obstruction
• A lower incidence of exudate on endoscopy 
• Better tolerability 
Macchi 
2013(168)
DBPCT 46 CRSwNP 
patients 
postoperatively
• Nebulization of 6mL contain-
ing 9mg sodium hyaluronate 
nasal washes plus saline for 
15 days/mo over 3 months 
(n=23)
• Nebulization of 6mL isotonic 
saline for 15days/mo over 3 
months (n=23)
At 3 months 
postoperatively:
• Prevalence of symp-
toms
• Endoscopy 
• Cytology
• Biofilm
Significantly better result of sodium hyaluronate 
than saline for:
• Nasal dyspnea (obstruction?)
• Normal mucosa
• Absence of secretion
Table 6.2.7.8.Postoperative saline irrigation with addition of honey in CRS patients.
CRS, Chronic Rhinosinusitis; SNOT-22, Sino-Nasal Outcome Test-22; LK, Lund-Kennedy.
Study Methods Participants Interventions Outcomes Results
Lee 
2016(169)
Single blind 
(investigator) 
placebo 
controlled 
trial 
49 CRS patients 
(42 analysed) 
postoperatively
• 120ml saline containing 12mg of manuka honey twice daily 
for 30 days
• 120ml saline twice daily for 30 days
• All patients received culture-directed oral antibiotic, and/or 
oral steroids for up to 3 weeks, and/or high-volume topical 
steroid sinus irrigations (budesonide 0.5mg/2mL vial or 
0.6mg/2mL capsule, 0.5 bottle to each nasal cavity twice daily) 
polyps or inflammation for 30 days
• The dose of budesonide was determined when the patient 
filled the prescription; if insurance covered it, then the vial ver-
sion at the 0.5mg/2mL dose was used, and if not covered, then 
the capsule version at the 0.6mg/2mL dose was used
At 30 days:
• SNOT-22
• LK endoscopy 
score
• Bacterial 
culture
• No significant 
differences between 
the groups
• In the subgroup not 
using antibiotics 
manuka honey 
significantly 
reduced bacteria
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eluting stents, spacers and dressings compared to placebo 
does not have an influence on QOL and most likely also not 
on symptomatology but has a significant and most likely dose 
dependent effect on POSE and Lund-Kennedy scores. The 
EPOS2020 steering group felt the quality of the evidence was 
low and that based on the evidence they could not advise about 
the use of corticosteroid-eluting implants following endoscopic 
sinus surgery. For now,  the use of relatively expensive ready-
made implants does not seem to be cost effective in the average 
CRSwNP patient. Larger studies including long term safety data 
are needed.
6.2.7.5. Anti-leukotrienes
Cysteinyl leukotrienes (CysLT) are a class of inflammatory 
mediators synthesized by eosinophils and mast cells through 
the breakdown of arachidonic acid. CysLT are known to play a 
role in the pathophysiology of rhinitis, asthma and possibly also 
CRSwNP, promoting bronchoconstriction, mucus production, 
oedema and chemotaxis of eosinophils and neutrophils. 
Overproduction of CysLTs and upregulation of the receptor has 
been demonstrated in allergic rhinitis, asthma, and CRS with 
nasal polyposis (CRSwNP) (see chapter 5.1.2).
The quality of the evidence comparing montelukast with 
placebo is very low (see chapter 6.1.9.). 
The only study evaluating the use of montelukast 
postoperatively is done by Van Gerven et al. (144). They evaluated 
the efficacy of montelukast as an add-on treatment to INCS 
in 72 postoperative CRSwNP patients for one year and  found 
no significant differences between the two treatment arms 
in total symptom score, nasal polyp score and LM score. They 
concluded that the addition of montelukast to INCS should not 
be recommended in the treatment of postoperative CRSwNP 
patients.
6.2.7.6. Decongestants 
The use of topical decongestants has the theoretical potential 
to reduce mucosal oedema by inducing vasoconstriction(149). 
However, prolonged use can lead to rhinitis medicamentosa 
and worse symptoms of nasal obstruction upon decongestant 
discontinuation(150). Nasal decongestion per se does not 
have effect on nasal polyp size(151). There is one small study 
in CRSwNP patients showing a significantly better effect of 
oxymetazoline combined with MFNS than MFNS alone without 
inducing rebound swelling(152). This is consistent with effects 
seen in the treatment of allergic rhinitis where the combination 
of nasal corticosteroid with decongestant also seemed to 
prevent rebound swelling(153, 154) (see chapter 6.1.10). There is 
one  by Humphreys et al. who compared topical decongestant, 
xylometazoline, to a saline spray in 47 patients in the FESS early 
postoperative period(155). Postoperative VAS symptom scores for 
nasal obstruction, rhinorrhoea, pain, loss of sense of smell and 
bleeding assessed at day 10 postoperatively did not show any 
difference between the groups. The EPOS2020 steering group 
suggests not to use nasal decongestants in the postoperative 
period although the quality of the evidence is low.
6.2.7.7. Saline
6.2.7.7.1. Summary of the evidence
Nasal saline irrigation is considered to be an important aspect of  
the management of CRS, especially in the postoperative phase.  
For details on saline irrigation in general please refer to chapter 
6.1.11. 
This systematic review identified 13 randomized controlled 
(RCT) studies evaluating nasal saline irrigation on clinical 
outcomes in adult CRS in the month after FESS (Tables 6.2.7.4.- 
6.2.7.9). The studies were very different in design, duration and 
outcome measurements. 
Three studies evaluated the effect of a form of saline irrigation 
versus a form of no irrigation of the nose (Table 6.2.7.4.). The 
studies could not be combined in a meta-analysis. One showed 
a significant positive effect of saline atomisation on discharge, 
but no other differences, one showed mainly positive effect in 
patients with mild CRS and not in patients with severe effect and 
Table 6.2.7.9. Postoperative saline irrigation with addition of dexpanthenol in the treatment of CRS.
DBPCT, Double Blind Placebo Controlled Trial; RCT, Randomised Controlled Trial; CRS, Chronic Rhinosinusitis; CRSwNP, Chronic Rhinosinusitis with 
nasal polyps.
Study Methods Participants Interventions Outcomes Results
Tantilipikorn 
2012(171)
DBPCT 50 CRS patients 
postoperatively 
• Dexpanthenol nasal 
spray 4 times a day for 6 
weeks (n=25)
• Saline nasal spray 4 
times a day for 6 weeks 
(n=25)
• % of patients with symp-
toms at 2, 4 and 6 wks
• % of patients with endo-
scopic abnormalities at 2, 
4 and 6 wks
• Mucociliary clearance time 
at 6 wks
• Majority of symptoms and signs did not 
show significant differences
• Dexpanthenol nasal spray has superior 
efficacy compared with normal saline 
nasal spray on improvement of mucociliary 
clearance and smell at 6 wks and inferior 
effect on nasal discharge
Fooanant 
2008(187)
RCT 128 CRS patients 
(110 evaluated) 
postoperatively
• Dexpanthenol (5%) in 
sea water nasal spray 2 
puffs per nostril, twice a 
day for 4 weeks
• Saline nasal irrigation 
(volume unclear) twice a 
day for 4 weeks
At 1, 2, 3, 4, 6 and 12 weeks:
• Total nasal symptom score 
• Symptoms
• Nasal crusts
• Mucociliary clearance 
(only at 4 wks) 
• No significant differences in total nasal 
symptom score, nasal crusts (but at wk 2 
less in saline group), mucociliary clearance 
(but for subgroup of CRSwNP) 
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one did not show any differences between saline rinsing or no 
rinsing(158, 175, 178).
One study in 86 CRS patients compared a squeeze bottle with 
a nasal spray for one month and found no differences between 
the SNOT-22, Nasal and Sinus Symptom Scale (NSS) or POSE 
between the two ways of administration(162). 
Two small studies evaluated the addition of antiseptic / 
mucolytic / baby shampoo solution and showed no differences 
between the groups but the baby-shampoo group was reported 
to have significantly more side effects and had more patients 
stop the solution(160, 183) (Table 6.2.7.6.). Moreover, it has been 
shown in healthy persons to create congestion and reversible 
smell loss(190).
Five Italian DBPCT or single blind (blinding often not clearly 
described) postoperative studies evaluated the addition of 
9mg of sodium hyaluronate to saline(166-168, 185, 186). Four studies 
evaluated nebulisation with a small volume(167, 168, 185, 186) and 
one study rinsing with 250ml. The four studies evaluating 
nebulization in general reported positive outcomes, the study 
evaluation addition of sodium hyaluronate  to saline rinsing 
found in general no significant effect (Table 6.2.7.7.).
In conclusion, sodium hyaluronate might have a positive effect 
on postoperative symptoms when compared to a saline spray. 
Adding sodium hyaluronate to saline rinsing postoperatively 
did not show an effect in one study. One study(169) evaluated 
the addition of honey to saline irrigation. The study did find any 
relevant differences between the honey treated group and the 
placebo group (Table 6.2.7.8.).
Dexpanthenol is an analogue of pantothenic acid, which has 
been claimed to promote wound healing(194). It has been shown 
to improve symptoms in patients with atrophic rhinitis(195).  Two 
studies evaluated the effect of dexpanthenol in saline(171, 187). 
Both studies showed no effect on the majority of symptoms and 
endoscopy but a superior efficacy over placebo on mucociliary 
clearance (in the Fooanant study only in patients with CRSwNP) 
(Table 6.2.7.9.).
Adverse effects of saline irrigations are rare, but include local 
irritation, ear pain, nosebleeds, headache, nasal burning, and 
nasal drainage are mentioned. The use of baby shampoo has 
been shown to create congestion and reversible smell loss.
6.2.7.7.2. Conclusions
The quality of the evidence evaluating the use of nasal irrigation 
in the postoperative phase after FESS is low. Nasal irrigation 
with isotonic saline or Ringer’s lactate seems to be effective 
in CRS patients. There is insufficient data to show that large 
volume is more effective than nasal spray. Addition of sodium 
hyaluronate to nasal saline rinsing may have a positive effect 
in the postoperative period.  Addition of baby shampoo, 
honey, or dexpanthenol as well as higher temperature and 
higher salt concentration do not show additional benefit. 
The steering group advises the use of nasal saline irrigation 
with isotonic saline or Ringer’s lactate potentially with the 
addition sodium hyaluronate and against the use of baby 
shampoo and hypertonic saline solutions due to side effects 
in the postoperative period after FESS. However, larger well 
designed studies are necessary to improve the quality of our 
understanding.
6.2.7.8. Antimycotics
Local and systemic antifungal treatments do not have a positive 
effect of QOL, symptoms and signs of disease in patients with 
CRS.  There is one study evaluating direct postoperative use of 
local amphotericin B nasal spray versus placebo in 33 CRSwNP 
patients. Eight weeks postoperatively they found no differences 
in the QOL questionnaire SNAQ-11, nasal endoscopy and/or CT 
scan(224).  The EPOS2020 steering group advises against the use 
of postoperative anti-mycotics in CRS.
6.2.7.9. Capsaicin
The quality of the evidence about the effect of capsaicin versus 
placebo is low (see chapter 6.1.22).  Zheng et al.(282), conducted 
a DBPCT comparing capsaicin (3x10-6mol, dissolved in 70% 
ethanol) versus vehicle alone (70% ethanol) once a week in 51 
patients for five weeks, following nasal polypectomy. Patients 
were assessed at nine months for nasal resistance, rhinorrhoea 
and nasal polyp score. The capsaicin group had a significant 
decrease in nasal resistance compared to the vehicle group 
(p<0.01) and had lower nasal polyp score when compared to the 
control group (stage 0: 41% vs 4.5%, p<0.01).
There was no difference in subjective rhinorrhoea. 
A small study showed a significantly decrease in nasal resistance 
and nasal polyp score after five weeks of postoperative capsaicin 
treatment versus placebo. The quality of the evidence is low and 
the EPOS2020 steering group concludes that capsaicin may be 
an option in postoperative treatment of CRS in patients with 
CRSwNP but that larger studies are needed.
6.2.7.10. Conclusion
The quality of the evidence for the use of commonly 
administered peri-operative medication such as (nasal) 
corticosteroids and antibiotics is low, mainly due to insufficient 
and small studies. The use of peri-operative corticosteroids 
reduces blood loss and operation time and improves the 
quality of the surgical field. There is also high-quality evidence 
that long term use of nasal corticosteroids is effective and 
safe for treating patients with CRS with significant impact 
on nasal symptoms and quality of life improvement. Nasal 
corticosteroids reduce nasal polyp size and when administered 
after endoscopic sinus surgery, nasal corticosteroids prevent 
polyp recurrence. Although the quality of direct evidence 
postoperatively is missing, the EPOS2020 steering committee 
recommends using nasal corticosteroids postoperatively. Based 
on the low positive evidence and the excellent safety profile 
the group also recommends using nasal saline irrigation with 
isotonic saline or Ringer’s lactate, potentially with the addition 
of sodium hyaluronate, and advise against the use of baby 
shampoo and hypertonic saline solutions due to side effects in 
the postoperative period after FESS. Otherwise, based on the 
low-quality evidence, the steering group cannot recommend the 
use of peri-operative antibiotics. The group also advises against 
the use of anti-mycotics. 
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7.1. Epidemiology, predisposing factors, and 
comorbidities
7.1.1. Epidemiology
Estimates from the National Health Interview Survey in the 
United States in 1996 suggest that young people under the 
age of 18 years are affected by chronic rhinosinusitis (CRS) 
at a rate of 63.9 per 1000 individuals(1).  Overall health care 
expenditures attributable to rhinosinusitis (acute and chronic) 
in 1996 were estimated at $5.8 billion, of which $1.8 billion 
(30.6%) was for children 12 years or younger(2).  Despite growing 
knowledge related to the diagnosis and treatment of this 
disease in children, its true epidemiology in the world is not yet 
well described. Factors thought to contribute to the difficulty 
in accurate diagnosis include false positive diagnoses due to 
difficulty in differentiating CRS  from adenoid hypertrophy, 
adenoiditis, and (allergic) rhinitis,  incomplete evaluation (nasal 
endoscopy and/or imaging are not performed in many children), 
neglect of the disease by both doctors and care-takers, and 
incomplete follow-up evaluation in some children.
Furthermore, race and socioeconomic status have recently 
been reported to influence the prevalence of the disease.  
Smith et al. assessed 174 children aged between six months 
and 18 years who presented to a single academic tertiary 
paediatric otolaryngology centre with a primary diagnosis of 
CRS (classified through the Current Procedural Terminology 
(CPT) codes) from March 2008 to July 2011(3). A control group 
consisted of 430 children, seen in the same department 
over a three-month period, with other otorhinolaryngologic 
diagnoses. There was a higher percentage of white children and 
children with private health insurance among the patients with 
a primary diagnosis of CRS. These findings suggest that racial/
ethnic disparities and socioeconomic variables may influence 
the diagnosis, and this is likely related to differences in access 
to tertiary care, parental perception of disease severity, or 
different natural course of the disease process in different ethnic 
populations. 
Despite these limitations, several studies have tried to assess 
the prevalence of CRS in the paediatric population. Using data 
obtained from a US national survey acquired over a 2 year time 
frame which sampled 42.1 million school age patients, Sidell 
et al. identified approximately 4% of the studied population 
(corresponding to 1.7 million individuals) with a diagnosis of 
CRS, based on physician diagnoses and procedure codes for 
medical visits/encounters(4). Sami and Scadding used the 
MSYPQ, a disease specific quality of life questionnaire, in 213 
secondary school children (11-16 years) in East London to 
identify the prevalence of rhinosinusitis symptoms and impact 
on quality of life(5). They show that 31.5% suffered from a 
combination of symptoms suggestive of rhinitis, and between 
13-15% of the respondents reported facial pain or anterior/
posterior nasal drainage, symptoms suggestive of a sinus origin. 
More than 20% of students suffered from effects on quality of 
life related to these symptoms. In total, out of those with nasal 
and sinus symptoms, 22% had their symptoms for more than six 
weeks but for less than a year. 
Gilani and colleagues analysed national survey databases 
between 2005 and 2012 and showed that CRS accounted for 5.6 
million visits per year among patients 0-20 years of age(6). CRS 
was diagnosed in 2.1% of all visits, acute rhinosinusitis in 0.6% 
and as comparators, allergic rhinitis in 2.6%, upper respiratory 
tract infections in 8% and otitis media in 6.7%. The 5-10 year-old 
and 10-15 year-old age groups were the most affected. 
While most of the available data is based on diagnosis codes 
and subjective, questionnaire-derived, information, Westman 
and colleagues estimated the 12-month prevalence of CRS 
based on questionnaire to be 1.5% in a Swedish population-
based study of 3112 adolescents(7). They went ahead and 
attempted to follow-up with objective confirmation of the 
diagnosis leading to a reduction of the estimate of prevalence to 
between 0.3% to 0.8%.
Together, these studies suggest that the prevalence of CRS in 
the paediatric population is lower than in adults. As in adults, 
paediatric CRS is a relevant disease in terms of quality of life. The 
impact of CRS on the quality of life of children is greater than 
that of diseases such as asthma, attention deficit hyperactivity 
disorder, juvenile rheumatoid arthritis, and epilepsy(8). All 
these studies reflect an important negative impact on the 
lives of children, particularly in terms of missed classes and 
concentration in school, sleep quality, and physical and 
emotional health(5). 
Although studies of CRS in children are less 
common, the prevalence is lower than in adults 
(2-4 %), but the negative impact on quality of life 
seems to be similar to that observed in adults. 
7.1.2. Predisposing factors and comorbidities
Although the understanding of the role of predisposing/
comorbid factors has evolved considerably, it is not yet clear 
whether these host factors (systemic and local) and the 
environmental conditions that affect CRS in a child induce the 
disease or if they share a common pathway of pathogenesis.
7.1.2.1. Anatomic variations in the sinuses 
To date, there is no evidence that anatomic abnormalities 
contribute, in any way, to the development and maintenance 
of CRS in children. Studies from 1997 to 2008 suggested that, 
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despite the common occurrence of these anatomical variations 
(concha bullosa, concha hypertrophy, septal deviation, etc.), 
they did not seem to correlate with the degree and existence of 
CRS in children(9-11). A more recent study examining anatomical 
abnormalities in an observational cohort of children showed 
the common occurrence of anatomic abnormalities in healthy 
sinuses(12). Whereas gender did not influence the prevalence 
of these abnormalities, some (deviated septum and concha 
bullosa) seemed to have a higher point prevalence in older 
children.   Haruna et al. investigated whether the presence 
of paediatric middle turbinate pneumatisation causes a 
narrowing of the OMC and is associated with the development 
of rhinosinusitis by analysing CT scans obtained from 95 
children 1-15 years old(9). Middle turbinate pneumatisation was 
detected in 4.6% of the nasal cavities, and the middle turbinate 
pneumatisation itself did not obstruct the ostiomeatal complex. 
Thus, a direct causal relationship between middle turbinate 
pneumatisation and the development of rhinosinusitis was not 
observed. Equally, Al-Qudah performed a prospective study 
of 65 cases of paediatric chronic rhinosinusitis (average age 
of 11.4 years) that persisted after appropriate medical therapy 
and examined their CT scans(11). Agger nasi cell was the most 
common anatomical variation, followed by concha bullosa 
of the middle turbinate. No significant correlation was found 
between these anatomical variants and the extent of chronic 
rhinosinusitis, again suggesting that these abnormalities 
are unlikely to predict the extent and severity of chronic 
rhinosinusitis in the paediatric population.
Anatomic variations are more frequent in older 
children, but do not seem to be related to the 
presence of CRS. 
7.1.2.2. Environmental factors
7.1.2.2.1. Viral infection
It is speculated that upper respiratory tract infections (URTIs) 
play a role in the development of CRS, by leading to mucosal 
oedema, mucus production and retention, impaired mucociliary 
clearance, secretion stasis, and decreased aeration of the sinus 
mucosa(13). Wood et al. used the polymerase chain reaction to 
look for respiratory viruses in the sinus mucosa from 13 adult 
patients with CRS and two patients with normal sinuses and 
were not able to detect a signal for any of several common 
respiratory viruses(14). Therefore, to date, the contribution of viral 
infection to paediatric CRS is poorly studied with no evidence to 
support the importance of viral infections to CRS in children.  
Thus far, there is no credible evidence that viral 
infections contribute to paediatric CRS. 
 
7.1.2.2.2. Exposure to tobacco smoke 
Environmental exposure to tobacco smoke inhibits mucociliary 
clearance and epithelial regeneration. Both active and passive 
smoking have been identified as significant risk factors for the 
development of CRS(15, 16). Reh et al.conducted an excellent 
review of the adult and paediatric literature examining the 
effect of cigarette smoke on CRS(15). Several of the included 
articles had mixed paediatric and adult populations and only 
Kakish et al.included data specifically related to children(17). 
They reported a 68% prevalence of acute rhinosinusitis among 
children exposed to passive smoking, compared to a prevalence 
of 1.2% among children without exposure(17). While valuable, 
this study only evaluated acute rhinosinusitis. Christensen et 
al. performed a systematic review of large population studies 
to determine if there was a correlation between cigarette 
smoke exposure and the prevalence of CRS(16). They reported on 
studies that evaluated outcomes of CRS surgery in the presence 
of passive and/or active smoke in the paediatric population 
(age <18 years).All the studies demonstrated worse outcomes 
in children exposed to cigarette smoke.  These included an 
increase in surgical revision rates(18, 19),worse SNOT scores(19),or 
lack of symptom improvement after surgery(18-20).Thus, there is 
some evidence that cigarette smoke worsens CRS in children, 
however, longitudinal and mechanistic studies are required to 
determine the causative effect in children. 
Children with CRS who are exposed to passive 
smoking present with more severe disease, worse 
clinical scores and higher rates of revision surgery. 
7.1.2.3. Allergic rhinitis
Allergic inflammation can alter the sinonasal physiology with 
regards to mucociliary clearance and patency of the ostia 
and a late-phase allergic inflammation may contribute to CRS 
development(21). However, evidence tying allergic rhinitis to CRS 
in children is at best equivocal. 
A large study in paediatric patients with CRS reported that 
29.9% had both a positive skin test and an elevated serum IgE 
level(22). This prevalence of atopy in children with CRS was similar 
to that of the general paediatric population in Italy. Importantly, 
only 7.4% of the children under the age of three had positive 
testing compared to 31.4% of the children between 3-6 years 
and 33.3% of children older than six suggesting a low yield for 
allergy testing in patients under three years of age.  
Sedaghat et al. evaluated a series of 4044 consecutive patients 
(age ≤18yrs) with a diagnosis of chronic rhinosinusitis in the 
otorhinolaryngology or allergy and immunology clinics of 
Boston Children’s Hospital between 2002 and 2012(23). Twenty 
seven percent of the children with CRS were also diagnosed 
with AR which is equivalent to the typical prevalence of the 
disease in the paediatric age group and does not support a 
higher prevalence of allergic rhinitis in children with CRS. Not 
surprisingly, there was a significantly higher prevalence of 
asthma in the population of children with CRS and AR (40.7%) 
than in the children without AR (9.8%). In fact, a strong positive 
association was detected between the diagnosis of asthma and 
AR in children with CRS. Other studies have shown a higher 
percentage of atopy in patients with CRS than in the general 
population. In a study in Thailand of 100 children with a clinical 
diagnosis of rhinosinusitis and abnormal plain radiographs, a 
positive skin test to common aeroallergens was reported in 53% 
of the patients, which suggests a correlation between allergic 
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rhinitis and CRS(24). Georgalas et al. studied the Bradford-Hill 
criteria for causation applied to the evaluation of these studies 
and concluded that a clear and definitive causal relationship 
cannot be established, especially in children(25).
Most recently, Anamika et al. studied 110 patients, between 
seven and 18 years of age, diagnosed with CRS based on history 
and clinical examination including nasal endoscopy(26).Patients 
underwent skin prick tests against 65 common aeroallergens 
for evidence of atopy. A positive skin prick test to at least one 
of the common aeroallergens was present in 52.7% of patients. 
Patients with CRS and atopy had significantly higher mean 
Lund Mackay endoscopic score and SN-5 score (denoting worse 
quality of life) than nonatopic patients.  In contrast, an older 
study evaluated CT scans from allergic and nonallergic children 
and noted the presence of sinus opacification in 61% and 64% 
of allergic and nonallergic children, respectively, which argues 
against an important role for allergy in sinus CT abnormalities(27).
In summary, the available studies evaluating the importance 
of allergic disease in CRS in children do not clearly elucidate 
the interaction of the two diseases. They suffer from many 
potential pitfalls: 1) biased populations as many of the studies 
are from allergy and otolaryngology clinics which are more likely 
to be seeing patients with allergic rhinitis, 2) lack of objective 
confirmation of the diagnosis of CRS, 3) lack of differentiation 
between atopy (positive skin test) and relevant clinical allergic 
rhinitis (positive skin tests and relevant correlating clinical 
symptoms). Despite these limitations, allergy testing should be 
considered in the older child with CRS.
According to the studies above PCRS patients are 
more likely to also present with AR and/or asthma. 
However, research on the prevalence of CRS within 
the population with or without AR is needed to 
support this correlation.
7.1.2.4. Asthma
Both CRS and asthma are inflammatory diseases of the airways. 
It has been hypothesised that rhinosinusitis impacts bronchial 
asthma in all age groups as part of the unified airway theory(28).  
In their review of Boston Children’s data, about coexistent 
diseases, Sedaghat and colleagues reported that 18.1% of 4044 
children with CRS had concomitant asthma(23). As mentioned 
above, there was a higher chance of asthma if the child also 
had allergic rhinitis. Anfuso and colleagues evaluated cytokine 
expression in sinus tissues of children with CRS and normal 
controls and found that children with CRS and asthma had 
significantly higher sinus levels of multiple inflammatory 
cytokines supporting the contribution of upper airways disease 
to lower airway inflammation in patients with CRS(29). Older, 
non-controlled studies have shown that pharmacologic or 
surgical intervention for CRS resulted in discontinuing asthma 
medications in 80% of a cohort of 48 children(30). Furthermore, 
asthma recurred when rhinosinusitis subsequently exacerbated. 
These and other studies support the concept that clinical control 
of CRS may be important in optimizing the control of difficult-
to-treat asthma. However, the limitations of most available 
studies include the lack of good controls or randomization 
to different treatment modalities; therefore, the relationship 
Table 7.1.1. Adenoidectomy for paediatric CRS.
Author Type Intervention Outcome measure Result
Vandenberg 
1997(140)
Retrospective case series, 
n=48
Adenoidectomy or 
adenotonsillectomy
Symptoms Complete or near symptom resolution 
in 58% of patients
Brietzke 
2008(33)
Systematic literature 
review Average sample 
size =46 (range
10—121).
Adenoidectomy (8 studies 
adequate for systematic 
literature review)
Proportion of patients who 
improved after surgery
69% of patients improved after 
surgery 
Ramadan 
2007(142)
Retrospective review of 
prospectively collected 
data, n=121
Adenoidectomy
55 patients underwent ESS 
after adenoidectomy and had 
data available
Failure of adenoidectomy, 
Factors that contributed to 
early failure
61/121 (50%) children failed 
adenoidectomy.  
Asthma and age <7 yrs. predicted 
earlier failure and faster ESS
Ramadan 
2014(169)
Retrospective 10 yr. review, 
n=233
Adenoidectomy preceded 
by a CT
Success of adenoidectomy 
based on CT score
Success rate=
43% in CRS group (CT score ≥5),
65% in chronic adenoiditis group (CT 
score <5) 
Bettadahalli 
2017(143)
Prospective, n=60 Adenoidectomy Sinus symptoms and quality 
of life scores 6 months post-
intervention
88% of children had a significant 
improvement in outcome measures
Ramadan 
2008(144)
Retrospective review of 
prospectively collected 
data, n=60
Adenoidectomy or 
adenoidectomy with a 
maxillary sinus wash
Improvement of symptoms at 
12 months
88% of adenoidectomy with sinus 
wash showed improvement, 61% of 
adenoidectomy showed improvement
CT, computed tomography; ESS, endoscopic sinus surgery.
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between CRS and asthma in children remains largely descriptive.
We observe a strong correlation between asthma 
and PCRS.  More research is required to elucidate 
the nature of the pathophysiologic events 
underlying this observation.
7.1.2.5. Adenoids 
Recent literature reviews have supported the hypothesis 
that adenoids have a significant impact on the development 
of CRS in younger children(31, 32) (Table 7.1.1.).  Supporting 
evidence of the importance of the adenoids is data that shows 
improvement in CRS in children after adenoidectomy which 
will be discussed in the surgical management portion of this 
chapter(33). In addition to improvement of CRS symptoms 
after adenoidectomy in a series of 35 children, one study has 
shown improved mucociliary transport in these children after 
surgery(34). Despite this, no studies have shown a correlation 
between the size of the adenoid pad and the presence of 
sinonasal symptoms in paediatric CRS, neither when analysing 
adenoid size by X-ray(35), by volume(36), or by weight of the 
tissue removed at surgery(37). These findings suggest that the 
adenoids can contribute to the development of CRS not just 
by mechanical obstruction but also by serving as a bacterial 
reservoir. In support of this hypothesis, a study by Coticchia 
and colleagues observed that the surface area of adenoids 
covered by biofilm was 94.9% in patients with CRS compared to 
1.9% in patients with obstructive sleep apnoea without CRS(38). 
Shin and colleagues examined adenoid size and bacteriology 
in 410 children under 14 years of age who underwent an 
adenoidectomy due to adenoid hypertrophy(35). Common upper 
respiratory pathogens (Haemophilus influenzae, Streptococcus 
pneumoniae, and Streptococcus pyogenes) were isolated from 
79.3% of the adenoids, and the rate of bacterial isolation from 
the adenoids correlated with the severity of sinus disease on 
Water’s radiographs again supporting the bacterial reservoir 
hypothesis. Therefore, available evidence suggests that the 
function of adenoids as a bacterial reservoir is more important 
than their size in the pathophysiology of paediatric CRS.
There is also some older evidence that supports a contribution 
of the adenoids as an immunological organ in children with 
CRS. One study showed a significantly lower expression of IgA 
in the adenoids of children with CRS compared to those with 
obstructive adenoids(39). This study could not elucidate, however, 
whether this was primary or secondary to chronic infection, as 
the design was cross-sectional. Shin and colleagues showed 
higher levels of tissue-remodelling cytokines in adenoids 
obtained from patients with CRS compared to tissue obtained 
from patients without CRS suggesting a relationship between 
the adenoids and the sinuses in children with CRS(40).
In summary, the adenoids seem important in the 
pathophysiology of CRS in children. Indeed, the first line 
of surgical management of CRS in younger children is an 
adenoidectomy and the data supporting efficacy will be 
discussed in the management section. 
7.1.2.6. Gastro-oesophageal reflux disease 
Gastro-oesophageal reflux disease (GORD) might be related 
to CRS in some paediatric patients; however, its association 
with the respiratory disease and its incidence remain doubtful. 
Data are conflicting and scarce. Reflux of gastric acid into 
the pharynx and nasopharynx is thought to cause sinus 
ostium inflammation, impaired mucociliary clearance, and 
consequently, rhinosinusitis.
GORD has been reported at higher rates in paediatric patients 
with rhinopharyngitis symptoms than in a control group(41). In 
a large case-control study that included 1980 children aged 
two to 18 years with GORD and 7920 controls, a diagnosis 
of rhinosinusitis was significantly more likely in the children 
with GORD (4.19%) compared with the control group (1.35%)
(42). A prospective study by Phipps and colleagues in 30 
paediatric patients with CRS who were evaluated with a 
24-h pH probe showed that 63% of the children with CRS 
had gastroesophageal reflux(43). This study also showed that 
79% of the children with CRS experienced improvement in 
rhinosinusitis symptoms after medical treatment for GORD. 
Similar results were reported in a retrospective study showing 
that the rate of surgery could be reduced by 89% in children 
with severe CRS treated with a proton pump inhibitor 
for GORD(44). In 2014, Nation and colleagues performed a 
retrospective chart review of 63 children, aged six months to 10 
years, with rhinorrhoea, nasal congestion, and chronic cough(45). 
The patients underwent maxillary cultures, adenoidectomy, and 
distal third oesophageal biopsies. Children with oesophageal 
biopsies showing oesophagitis were classified as positive for 
gastro-oesophageal reflux disease, and maxillary antral swabs 
growing a high density of bacteria were classified as positive 
for chronic rhinosinusitis. Younger children aged six months to 
five years tended to have either chronic rhinosinusitis or gastro-
oesophageal reflux disease, whereas older children, aged six to 
10, tended to have a more complicated aetiology of CRS and 
GORD. In all of these patients, GORD played an important role 
in many of these patients, as over 40%  had gastro-oesophageal 
positive biopsies. Another potential causative agent that has 
been investigated for adenoiditis and/or CRS is Helicobacter 
pylori. Cedeno and colleagues failed to detect the presence of 
H. pylori in adenoid tissue or maxillary sinuses in patients with 
CRS(46).
In summary, there is some evidence to support a potential role 
of GORD in CRS in children.  However, the studies suffer from 
significant limitations including retrospective design, lack of 
placebo group in treatment studies, and poor characterization 
of the presence and extent of CRS. Therefore, routine treatment 
for GORD is not currently justified in children with CRS. Indeed, 
this conclusion is supported by the consensus statement on 
paediatric rhinosinusitis published by the American Academy of 
Otolaryngology Head and Neck Surg(47).
The relationship between GORD and CRS seems 
to be strong in children. However, the evidence is 
weak and does not support the routine treatment 
of GORD in children with CRS. 
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7.1.2.7. Immaturity or deficiency of the paediatric immune 
system
Studies in children with recurrent rhinosinusitis or CRS have 
demonstrated a variable percentage of immune dysfunction, 
including a decrease in the levels of immunoglobulins A, 
G, and subclasses, with a poor response to pneumococcal 
vaccine and low levels of immunoglobulin in response to 
normal vaccines. Shapiro et al. evaluated immunologic 
competence in 61 children with CRS who were referred for 
an allergy evaluation(48). Roughly 50% of the children had 
evidence of environmental allergies and at least 23 of the 61 
patients with refractory rhinosinusitis had impaired humoral 
immunity manifested by low immunoglobulin levels or 
vaccine hyporesponsiveness. This is clearly a much higher 
rate than in adults. Hidalgo and colleagues report that 6% of 
78 children with CRS failed to mount an immune response 
to pneumococcal vaccine(49).In 27 children with chronic or 
recurrent rhinosinusitis, Costa Carvalho and colleagues detected 
one patient with IgA andIgG2 deficiency, and another with 
IgG3 deficiency(50). Eight and12 of 27 patients had IgG2 and 
IgG3 serum levels below 2.5thpercentile, respectively and no 
patient had an abnormalresponse to vaccination. In a large 
study of 307 subjects with refractory rhinosinusitis (261 adults 
and 46 children), Vanlerberghe et al. found laboratory evidence 
of humoral immunodeficiency, including IgA deficiency or 
IgG subclasses deficiencies, in 21.8% of the cases with no 
difference in prevalence between children and adults(51). Baek 
and colleagues evaluated 16 children with recurrent acute or 
CRS and found that 50% had defects in the humoral immunity 
including poor responsiveness to a pneumococcal vaccine(52).
In the study by Sedaghat et al., mentioned above, 496 (12.3%) 
of the 4044 children diagnosed with CRS had a diagnosis 
consistent with an immune disorder(23). 
On the other hand, in 2006, Bernatowska et al. evaluated the 
incidence of CRS in 425 children with different types of primary 
humoral deficiency(53). CRS was observed most frequently in 
the group of patients with agammaglobulinemia (85.96%) 
and less often in patients with dysgammaglobulinemia 
(81.81%) and other antibody deficiencies (72.72%). As to 
immunoglobulin replacement, a pilot study in six children with 
CRS refractory to medical management treated with intravenous 
immunoglobulin (IVIG) for one year showed a decrease in 
antibiotic intake, rhinosinusitis episodes, and an improvement in 
sinus imaging studies(54).
Clearly, the reports of humoral immune deficiency in children 
with recurrent or chronic rhinosinusitis vary widely. This 
is likely influenced by the types of populations studied, 
measures of immune function, and accuracy in the diagnosis of 
rhinosinusitis.  It therefore seems prudent to evaluate immune 
function in the child with chronic / recurrent rhinosinusitis 
with an immunoglobulin quantitation and titers to tetanus and 
diphtheria in addition to pneumococcal titers. If responses are 
abnormal, a repeat set of titers after pneumococcal vaccination 
is appropriate and if the response is not adequate, then referral 
to an allergist/immunologist is warranted.
Children with CRS refractory to appropriate 
medical treatment should be evaluated for 
humoral immune deficiency. 
7.1.2.8. Cystic fibrosis (CF) (see also chapter 8.4.)
CF is an autosomal recessive disease caused by mutations in 
the CFTR gene that leads to the formation of thick viscous 
secretions, favouring infections in the respiratory tract. It is 
diagnosed by abnormally elevated sweat chloride levels or by 
genetic testing. Because the sweat chloride test is not 100% 
specific, the diagnosis of CF is based on the presence of one 
or more clinical features of CF, in addition to evidence of an 
abnormality in the CFTR gene or protein. P. aeruginosa and S. 
aureus are the microorganisms most frequently cultured when 
the infection affects the sinuses(55). It is the most common 
disorder encountered in children with CRSwNP. In fact, the 
prevalence of CRS in the population with CF is nearly 100%(55-57). 
Despite newborn screening, otorhinolaryngologists continue 
to receive children without a confirmed diagnosis of CF. In 
children with polyps and sinus disease, physicians should have 
a high index of suspicion for CF, particularly in the context 
of poor weight gain, respiratory disease and gastrointestinal 
abnormalities. The finding of expansion of the paranasal 
sinuses (pseudomucocele of the maxillary sinuses) and 
hypodevelopment of the frontal and sphenoidal sinuses, 
without evidence of bone erosion on CT scan, are strong 
Key points | What’s new since EPOS 2012
• The prevalence of CRS in paediatric patients has been shown to be between 2.1 to 4%.
• Children of 10 to 15 years are most often affected with CRS. When comparing the frequency of the disease with that of 
other common conditions, CRS was more prevalent than ARS in all age groups and more numerous than otitis media in the 
group between 15 to 20 years (0.9%).
• Both passive and active cigarette smoking are associated with chronic rhinitis and rhinosinusitis in children. 
• A clear and definitive causal relationship between AR and CRS cannot be established, especially in children.
• The adenoid may act as a reservoir for pathogenic bacteria, rather than a source of obstruction.
• The relationship between GORD and CRS in children is controversial.
• The most common immunodeficiencies related to refractory CRS in children are immunoglobulin deficiency (including IgG 
subclasses) and poor response to vaccines.    
•  Physicians treating children with nasal polyps and sinus disease should have a high index of suspicion for CF, particularly in 
the context of poor weight gain, respiratory disease, and gastrointestinal abnormalities.
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radiographic indicators of CF(58-60). Wentzel et al. evaluated a 
group of 50 consecutive patients with CF aged 2-12 years who 
presented to a rhinology practice(60). The quality-of-life visual 
analogue scale was strongly negatively correlated with SN-5 
scores. Additionally, worse sinus-specific QOL as measured 
by the SN-5 score was associated with increased incidence in 
the diagnosis of rhinosinusitis, prescription of antibiotics, and 
missed days of school or recreational activities due to sinonasal 
symptoms. The authors concluded that the SN-5 was a quick 
and qualitative method for monitoring CRS in this patient 
population. Chan et al. evaluated a group of 102 paediatric 
patients with CF with an age range of 2-20 (average 12.9) years 
by a screening questionnaire for the diagnosis of CRS and the 
SN-5 during a routine clinic visit(61). Of the 102 participants, 47 
completed the surveys. Depending on the diagnostic criteria 
used, 11-38% of the patient population had CRS. Mean domain 
and overall visual-analogue scale scores on the SN-5 were 
consistent with a minimal effect on QOL. The authors concluded 
that there was a high prevalence of symptomatic CRS in this 
patient population, but that it had a low impact on quality of 
life. 
In cases of nasal polyps among paediatric 
patients, investigations for CF should be 
performed. Sweat chloride test remains important 
to confirm the disease, although newborn 
screening has significantly decreased the age of 
diagnosis of this disease.
 
7.1.2.9. Primary ciliary dyskinesia (see also chapter 8.5.)
PCD is a rare autosomal recessive disorder with an estimated 
incidence of one in 15,000 to 20,000 births. It consists of defects 
in ciliary beating, resulting in decreased mucociliary clearance(62).
It is associated with frequent sinus and ear infections, situs 
inversus totalis (in 50% of patients), heterotaxy or situs 
ambiguous (in 12% of patients), and infertility (in 50% of male 
patients)(63, 64).The symptoms of CRS in children with complex 
mucociliary disorders such as PCD may be debilitating and result 
in respiratory compromise with decreased pulmonary function. 
Purulent nasal secretions, typically transported by gravity or 
airflow due to the decreased ciliary clearance, are observed in 
children with PCD during active sinus infections(65). Indeed, in a 
series of 84 patients with PCD from Australia, recurrent cough 
and rhinosinusitis were the most common symptoms occurring 
in 71% and 81% of the children respectively(66).
Screening tests for PCD include nasal nitric oxide (lower 
levels than controls) (see 9.5.3.3) and in vivo tests, such as the 
saccharin test, which documents slower mucociliary transit 
times. Specific diagnosis requires examination of the cilia by 
light and transmission electron microscopy, which is usually 
available only in specialised centres(67). The most commonly 
described structural abnormality involves lack of the outer 
dynein arms, or a combined lack of both inner and outer dynein 
arms. Additionally, genetic testing in specialized centres is 
now available for roughly 20 different genes that underlie the 
pathophysiology of PCD (see 9.5.3.2). Nasal polyps occur in 
approximately 18% to 33% of patients with PCD,most often 
starting in adolescence.Kartagener’s syndrome, a triad of 
rhinosinusitis, chronic bronchitis with bronchiectasis, and situs 
inversus, occurs in approximately 50% of patients with PCD(63, 65, 
68). 
The management of CRS in children with PCD is challenging 
due to the rare incidence of PCD and the paucity of high-quality 
primary literature. Control of the CRS symptoms is especially 
important in these children to maintain an adequate quality 
of life and pulmonary function. Given the rare prevalence of 
PCD and the insufficient evidence concerning the treatment 
effectiveness for CRS, Mener et al. support future development 
of an international, multicentre database for prospective data 
collection(63). This database should include the diagnosis, 
treatment and outcomes of CRS for children with PCD and 
would encourage implementation of validated and standardised 
outcome measures in these children. 
PCD should be suspected in children with 
refractory CRS and pulmonary diseases, especially 
in those with concomitant bronchiectasis, situs 
inversus totalis or spermatozoid abnormalities. 
7.2. Pathophysiology 
7.2.1. Genetics
The information available about the genetics of CRS in children 
is very limited and the studies suffer from some limitations but 
show some interesting trends that deserve further investigation. 
Orb and colleagues explored the familial risk of CRS in children 
by mining the Utah population database which consists of 
computerized data records for >7.3 million people(69). They 
identified 496 children with CRS as follows: 12 years or younger 
with an index ICD-9 diagnosis of CRS appearing in the medical 
record between 1996 and 2011, and a coupled procedural 
code related to CRS (nasal endoscopy, adenoidectomy and/or 
sinus surgery). The authors randomly selected 4959 ethnically 
matched controls with no history of CRS from the Utah 
population and individually matched 10:1 on sex and birth year 
to corresponding paediatric CRS cases. Siblings of patients with 
CRS demonstrated a 57.5-fold increased risk of having paediatric 
CRS compared to controls. First cousins had a 9.0-fold increased 
risk and second cousins a 2.9-fold increased risk of paediatric 
CRS, all significant associations. Parents, first and second-degree 
relatives, and first cousins of paediatric cases demonstrated 
significant increased risks of having adult-onset CRS. Although 
these results suggest a significant familial risk associated with 
CRS, the study is limited by the accuracy of the diagnosis 
of CRS as it is based on review of diagnostic codes without 
confirmation by clinical evidence of disease.   
Purkey and colleagues studied a case control sample of 828 
children (average age 11.9 years) with CRS and 5,083 healthy 
controls from the Children’s Hospital of Philadelphia(70). Index 
patients had a history of CRS diagnosed by a paediatric 
otolaryngologist using symptom criteria, flexible endoscopy 
and CT evidence in almost half the cases. Children with cystic 
fibrosis were excluded. Single nucleotide polymorphism (SNP) 
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genotyping of potassium channel genes was undertaken and 
showed that the locus yielding the strongest signal was at the 
KCNMA1 gene in Caucasian children with CRS (p=0.022). There 
was borderline evidence for association in the KCNQ5 gene with 
CRS in African American children. This report suggests a genetic 
association between potassium channel epithelial physiology 
and the development of CRS in children.  
In an earlier study in 58 Caucasian children with CRS (diagnosed 
by persistent symptoms and objective evidence of disease) 
and no known cystic fibrosis, 12.1% were found to carry 
heterozygous mutations in the cystic fibrosis transmembrane 
regulator (CFTR) gene, higher than the expected rate of 3-4% in 
the same ethnic group(71). These results suggest a predisposition 
to CRS in children who are carriers for CFTR mutations.  
Sedaghat and colleagues investigated the presence of 
mutations in genes encoding connexins, that maintain 
epithelial integrity via gap junctions, in patients with chronic 
and recurrent acute rhinosinusitis diagnosed by persistence of 
symptoms and objective evidence of disease by either nasal 
endoscopy or CT scan(72). Of the eight paediatric patients (age 
between six and 16 years), only one child had a mutation in 
connexin 32 and of their 11 adult patients, one had a mutation 
in connexin 43. A previous study by the same group had shown 
no mutations in connexins 26 and 30 in the same group of 
patients(73). Although these results suggest that mutations 
in the connexin gene family might not be important in the 
pathophysiology of CRS, the number of observations are too 
small to make definitive conclusions.    
In summary, it is likely that the pathophysiology of paediatric 
CRS involves both genetic and environmental influences. 
Indeed, studies of monozygotic twins have not shown that both 
siblings always develop polyps, indicating that environmental 
factors are as likely as genetic ones to influence the occurrence 
of nasal polyps(74, 75).
Based on existing slim research, it is likely that the 
pathophysiology of paediatric CRS involves both 
genetic and environmental influences.  
Key points | What’s new since EPOS 2012
• A large database study suggests a significant familial 
risk associated with paediatric CRS.
• Studies on gene mutations in paediatric CRS show 
some preliminary promising results. 
7.2.2. Inflammatory mechanisms
7.2.2.1. Sinus and adenoid tissue studies
Early studies of the cellular response in paediatric CRS in 
older children indicate that eosinophils and CD4-positive 
lymphocytes play a significant role in tissue inflammation(76, 77). 
In later similar studies performed in younger children, Chan and 
colleagues(78) showed that paediatric maxillary sinus mucosa had 
more neutrophils and significantly more lymphocytes than adult 
mucosa but had fewer eosinophils and major basic protein–
positive cells, with less epithelial disruption and less basement 
membrane thickening. These authors also showed higher 
numbers of CD8-positive cells, neutrophils, macrophages, B 
lymphocytes, and plasma cells in younger children with CRS 
compared with adults(79). In another comparative study of sinus 
tissues between adults and children, paediatric tissue had 
scant eosinophils and abundant lamina propria fibrosis(80). The 
differences in eosinophil versus neutrophil predominance in 
the specimens studied above probably relate to the age group 
of the children studied (eosinophil predominance in the older 
children and neutrophil predominance in the younger ones).
In more recent studies, Wu and colleagues investigated 
inflammatory gene expression in tissues obtained from the 
sinuses of children with CRS and normal controls(81). Using 
microarray analyses and validation by gene mRNA expression 
levels by real-time PCR, they showed that five inflammatory/
immune response gene products were significantly upregulated 
in tissues from CRS compared to control. Two of the products 
were the cytokines CXCL5 (neutrophil chemoattractant), and 
CXCL13 (B lymphocyte chemoattractant), contributors to 
the adaptive immune response. The other three were serum 
amyloid A1/A2 (SAA1/SAA2), serpin peptidase inhibitor 
member 4 (SERPINB4), and β-defensin 1 (DEFB1). The latter are 
proteins involved in the innate immune system.  In a follow 
up study, the investigators evaluated the tissue distribution 
and cellular localization of these inflammatory markers using 
immuno-histochemical staining and immunofluorescence(82). 
They showed that all five mediators were strongly expressed 
in submucosal glands and in ciliated and basal cells within the 
epithelium. Further, CXCL13 was expressed in macrophages, T 
and B cells but not in neutrophils and CXCL5 was detected only 
in T cells. 
Anfuso and colleagues evaluated cytokine expression in 
sinus and adenoid tissues of children with CRS and normal 
controls and found more abundant cytokines in the tissues 
of the children with CRS compared to controls supporting 
ongoing inflammation in the disease group(29). Importantly, 
compared with children with CRS and without asthma, children 
with CRS and asthma had significantly higher sinus levels 
of tumor necrosis factor-α and adenoid levels of epidermal 
growth factor, eotaxin, fibroblast growth factor-2, growth-
related oncogene, and platelet-derived growth factor-AA. This 
supports the contribution of upper airways disease to lower 
airway inflammation in patients with CRS. Shin and colleagues 
evaluated inflammatory markers in adenoid homogenates of 
children with and without CRS undergoing adenoidectomy(40). 
The adenoids from children with CRS had significantly higher 
levels of the T cell activation marker soluble interleukin-2 
receptor (sIL-2R), as well as the levels of cytokines associated 
with tissue remodelling, such as transforming growth factor β-1 
(TGFβ-1), matrix metalloproteinases (MMP) 2 and 9, and tissue 
inhibitor of metalloproteinase (TIMP-1). Whereas there was no 
difference between the two groups in levels of the eosinophil 
activation marker, eosinophilic cationic protein (ECP), its levels 
were significantly higher in patients with severe CRS compared 
to those with mild and moderate disease.
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7.2.2.2. Nasal lavage
Passariello and colleagues evaluated levels of the cytokine 
(TNF-α) the antimicrobial peptide human β-defensin 2 and 
neutrophil-released calprotectin in nasal lavages of children 
(average age 3.4 years) with CRS and healthy control(83). This 
was done in the context of a study evaluating the benefit of 
crenotherapy (sulfate sodium-chloride thermal water with 
different mineral components by nasal aerosol administered 
for 15 minutes daily) in childhood CRS. They show significantly 
higher levels of all these proinflammatory substances in the 
lavage of patients with CRS compared to the control subjects.   
7.2.2.3. Serum
Shin and colleagues performed allergy testing and obtained 
serum eosinophil counts and serum ECP and IgE levels in 
a group of children with CRS treated with antibiotics and 
controls(84). They further divided the CRS group into responders 
and non-responders to a prolonged course of antibiotics. The 
prevalence of atopy and a family history of allergic diseases 
were significantly higher in the non-responder group than in the 
responder and control groups. Further serum eosinophil counts 
and levels of ECP and total IgE were significantly higher in the 
non-responder group than in the responder and control groups. 
This data suggests that eosinophilic inflammation in the context 
of allergy was an important factor in children with CRS who do 
not respond to antibiotics.
Although more evidence is emerging to support 
upregulation of inflammatory markers in paranasal 
sinus tissues and nasal lavages of children with CRS, 
the data is relatively limited and heterogeneous and 
does not yet lend itself to endotyping.  
7.2.2.4. Mucus
Mucus production is an important component of the clinical 
picture in children with CRS. Many mucin glycoproteins 
have been identified and the most frequently studied are 
the secretory mucins MUC5AC and MUC5B. In healthy lower 
airways, MUC5AC is typically expressed in the goblet cells, while 
MUC5B is restricted to the submucosal glands(85). In paediatric 
CRS, submucosal glandular hyperplasia is the characteristic 
phenotype and MUC5B is the predominant glandular mucin(86). 
Saieg and colleagues collected secretions from patients with 
CRS and normal controls(87). Many mucin glycoproteins were 
identified, but the relative abundance of MUC5B was found to 
be significantly higher in patients with CRS suggesting a parallel 
between the tissue and secretion glycoprotein production.
In summary, multiple studies suggest upregulation of different 
inflammatory substances important in adaptive and innate 
immunity as well as tissue remodelling in sinus tissues, 
adenoids, nasal lavage, mucus and serum in children with CRS. 
Although the evidence is still scarce, these studies suggest a role 
for inflammatory mechanisms in paediatric CRS.  Although many 
of the markers parallel those seen in adults, the data is very 
heterogeneous and does not yet lend itself to endotyping.  
Key points | What’s new since EPOS 2012
• Evidence of the presence of adaptive and innate 
immunity markers in paranasal sinus tissues and nasal 
lavages have been obtained from children with CRS.
• Inflammatory cytokines are present in sinus tissues 
of children with CRS and are more abundant when 
concomitant asthma is present. 
• Submucosal glandular hyperplasia is the 
characteristic phenotype in paediatric CRS, and 
MUC5B is the predominant glandular mucin.
7.3. Diagnosis and differential diagnosis
7.3.1. Allergic and non-allergic rhinitis
Generally speaking, the differentiation between allergic rhinitis 
(AR), non-allergic rhinitis (NAR) and CRS can be challenging, 
although in adults careful history-taking, nasal endoscopy 
and allergy tests usually suffice to make a distinction (see 
chapter 5.3.1). In children, however, this distinction can be 
more complicated. Just as in CRS, both AR and NAR can present 
with rhinorrhoea and nasal obstruction. Furthermore, patients 
with AR can show increased sinus opacification on imaging(88), 
although this has not been studied for children specifically. To 
complicate matters even further, CRS and AR often coincide, 
with the incidence of AR already reaching a prevalence as high 
as 40%(89).
The role of NAR in children is less well studied(90). Most NAR 
subtypes are unlikely to be present in (young) children, such 
as drug-induced rhinitis, occupational rhinitis, hormonal 
rhinitis, or senile rhinitis, leaving idiopathic rhinitis as the main 
diagnosis of NAR in children. Several studies have investigated 
the prevalence of NAR in the paediatric population. In Europe, 
large studies indicate a prevalence varying between 6.3% 
(Sweden, eight-year-olds), 8.1% (Sweden, four-year-olds) and 
9.6% (Belgium, 15 years or older)(91, 92). In an American study of 
619 children with asthma, the prevalence of NAR was 11.3%(93).A 
study from Singapore with 6600 children found a prevalence 
of 24.9% (mean age: 7.8 years), decreasing to 10-15% in older 
children(94). A Chinese study including 56 children below 15 
years of age, reports a prevalence of 34%. In the age group 
between 15 and 30 years of age, the prevalence of NAR was still 
20%(95). Taken together, the prevalence of NAR in the paediatric 
population is between 6.3-34%, with considerable regional 
differences.
In (very) young children, one could debate whether the group 
having complaints, but no allergic sensitization represents 
‘true’ NAR patients. Possibly, those suffering from adenoid 
hypertrophy, CRS, or other sinonasal disease are erroneously 
included, thus inflating the numbers. Therefore, a safe estimate 
of the prevalence of NAR in the paediatric population would 
be between 10-15%. These numbers are at least equal to 
the prevalence of paediatric CRS, making NAR an important 
differential diagnosis.
In order to determine the right diagnosis, a full history, physical 
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examination and several diagnostic tools should be used 
(Table 7.3.1.). Additional attention should be paid to the child’s 
environment, such as the presence of parental smoking, pets 
etc.
7.3.1.1. Adenoid hypertrophy/adenoiditis
Adenoid hypertrophy/adenoiditis and CRS can be hard to 
distinguish, especially in the very young(96).This has been 
elaborately described in chapter 7.1 and will be alluded to in the 
treatment section (7.4).
7.3.2. Chronic cough
In contrast to adult CRS, paediatric CRS can encompass chronic 
cough (rather than loss of smell). The important differential 
diagnoses to consider here are: adenoid hypertrophy/
adenoiditis, asthma, or gastro-oesophageal reflux disease. These 
are all addressed in chapter 7.1.
7.3.3. Smell disorders
In general, loss of smell can be an important sign of CRS. 
However, for the paediatric population, this statement does not 
apply consistently. Children (or their care givers) hardly ever 
complain of olfactory dysfunction, the very reason why “loss of 
smell” has been replaced by “cough” in the diagnostic construct 
of paediatric CRS(96). Indeed, in a large cohort of self-declared 
healthy participants, up to 3.4% were found to be anosmic (and 
unaware). In the age group between 5-10 years, the number was 
as high as 7%; and in the group between 11-20 years of age, it 
was still 1.4%(97). 
 The real extent of CRS related olfactory impairment in children 
is not yet known, however it is estimated that the most frequent 
cause of olfactory disorders in children is also CRS related(98). 
This lack of data is largely due to the inaccuracy of the testing 
tools available to detect olfaction problems, especially in young 
children, and the fact that olfactory symptoms reach the level 
of social consciousness only after a child reaches a certain age. 
The latter is currently observed in congenital anosmics whereas 
both the patient and their environment become aware of the 
absence of olfaction only in late childhood on average(99). The 
way most clinical olfactory identification tests work is probably 
unsuited and unreliable for children below the age of 6 years 
(see chapter 7.3.5.5).
Acquired olfactory dysfunction due to diseases other than 
CRS is rare in children(98, 100). Primary disorders such as isolated 
congenital anosmia or syndromic forms such as Kallmann 
syndrome are even more uncommon. When a child presents 
with loss of smell, careful history-taking combined with nasal 
endoscopy and olfaction tests (see chapter 8.3.5.5) usually 
suffices to discern CRS from other causes (congenital, traumatic, 
oncology, psychiatric disorders etc.). In the (very) young, 
identification of the right diagnosis can be hard, but again, 
olfactory dysfunction will hardly ever be noticed or sought help 
for in the first place. 
7.3.4. Facial pain
Facial pain or headache as a main (or only) complaint is usually 
unrelated to sinus disease. Unfortunately, patients often 
undergo a myriad of nasal treatments including surgery before 
a primary headache syndrome is suspected or diagnosed. For 
the paediatric population, this is true as well, although the 
percentage of misdiagnoses tends to be lower(101). The fact that 
the paranasal sinuses are not fully developed in childhood 
might limit the suspicion of sinonasal disease as a cause of 
headaches. Of the children presenting with headache, most are 
diagnosed with migraine. Smith and co-workers have provided 
a thorough systematic review on rhinogenic headache in 
the paediatric population which is recommended for further 
reading(102). The recommendations for children presenting with 
headache are the same as those for adults (see chapter 5.3.3.).
7.3.5. Diagnostic tools in children
In 2019, the European Position Paper on Diagnostic Tools in 
Rhinology. (EPPDRT) was published, providing an excellent, 
state-of-the-art overview of the diagnostic tools available to 
physicians treating sinonasal disease(103). Below, several of these 
diagnostic tools will be discussed briefly, with emphasis on 
applicability and considerations in paediatric CRS. For more 
detailed information, the reader is advised to read the European 
Table 7.3.1. Differentiating CRS, AR and NAR.
CRS AR NAR
Complaints Nasal obstruction
Rhinorrhoea
Cough
Facial pain/pressure
Nasal itching
Sneezing
Nasal obstruction
Rhinorrhoea
Seasonal variation
Nasal itching
Sneezing
Nasal obstruction
Rhinorrhoea
Specific triggers (smoke, mist, cold 
dry air etc.)
Nasal endoscopy Relevant pathology in the middle 
meatus (thick secretions, pus, polyps, 
oedema etc.)
Generalized mucosal involvement, watery 
rhinorrhoea, nasal hyperreactivity upon 
endoscopy
Generalized mucosal involvement, 
watery rhinorrhoea, nasal 
hyperreactivity upon endoscopy
Skin prick test or 
serum specific IgE
Negative or not clinically relevant for 
aeroallergens#.
Positive if AR coincides
Positive for aeroallergens# Negative or not clinically relevant for 
aeroallergens#
Imaging  
(CT^ or MRI)
Opacification of sinuses (if developed) Ideally: none, however opacification might 
be present
Ideally: none, however opacification 
might be present
CT, computed tomography; MRI, multi-resonance imaging; ^routinely using CTs in children is not advised because of exposure to radiation
#only clinically relevant when complaints are concordant
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Position Paper (which will be referred to as “the EPPDTR” below).
7.3.5.1. CT scan / MRI
The (upfront) use of imaging in children with CRS is debatable. A 
sinus CT-scan is mandatory when complications are suspected, 
or when surgery is considered/planned. In every other case, a 
balanced consideration must be made on the harm of the study 
(in case of CT: radiation; in case of MRI: long scanning times) and 
the possible gain in information. Current guidelines recommend 
“imaging gently” due to the reported increased chance of 
leukemia and brain tumours in children who receive CT scans, 
with higher risk associated with higher radiation exposure(104).  
Therefore, most paediatric facilities adopt paediatric protocols 
that allow acquisition of the appropriate information with the 
least amount of radiation.  In children, higher Lund-Mackay 
scores are generally found than in adults, which does not 
necessarily reflect CRS. In adults, a cut-off score of >3 is often 
used, but it has been suggested to use a higher cut-off of >5 in 
the paediatric population(105). It seems that sinus opacification 
alone in the paediatric population should be interpreted with 
caution, even if multiple sinuses are involved. Indeed, in a cohort 
of 192 children (mean age: 9.0 years) with CT scans of the orbits 
or brain without a history of sinonasal disease, only 19.3% had 
completely normal sinuses(106).
7.3.5.2. QoL / SNOT
Most of the quality-of-life (QoL) instruments described in the 
EPPDTR are not suitable for the paediatric population. The 
general QoL questionnaires depend on items as self-care, social 
function, etc. which are not applicable for a child. Furthermore, 
most disease-specific questionnaires for CRS are not validated 
for lower age groups. The often-used SNOT-22 was originally 
validated in an adult cohort (1.6)(107). Its use in children is 
incidentally reported (for example in a CF-cohort(108).
The only validated disease-specific QoL questionnaire for 
paediatric CRS is the Sinus and Nasal Quality of Life Survey (SN-
5). It is validated for children aged 2-12 and filled in by their 
parents/care givers(109). However, there are only a few studies 
using this questionnaire to generate data on QoL outcomes in 
paediatric CRS(110).
7.3.5.3. Endoscopy
Performing nasal endoscopy is a pivotal step in the diagnosis of 
CRS. Usually it is well tolerated, even in children. Use of topical 
decongestants and/or anaesthetics is at the discretion of the 
physician. Endoscopy in children is regularly used and published 
upon, for example in allergic rhinitis with patients as young as two 
years of age(111).
7.3.5.4. Allergy test
As in adults, allergy tests can be performed by a skin prick 
test or blood tests (see 5.3.5.4.). According to the guidelines 
published by the European Academy of Allergy and Clinical 
Immunology (EAACI) Section on Pediatrics, there is no lower 
age limit for skin prick testing(112). However, in younger children 
(roughly younger than seven years of age) regular aeroallergens 
are best tested using blood samples for specific IgE for reasons 
of patient comfort. In very young children, specific IgE can be 
elevated without clinical relevance and return to normal levels 
during their development, which could be a reason to repeat 
the measurement if an allergic diagnosis is doubtful despite 
previously elevated specific IgE levels. 
7.3.5.5. Assessment of smell
As described in the EPPDRT, it is feasible to use odour 
identification tests in children; the Sniffin’ Sticks have been 
validated in a cohort of 201 Dutch children(113). Moreover, 
specific tests for young children (age five and above) have been 
developed(114, 115). One should be aware, however, that these 
cannot be simply applied to every country/language, as cultural 
differences can influence the performance of subjects on the 
test. Therefore, these tests need to be validated before they can 
be reliably applied in clinical practice or research. Below a cut-
off age between five and six years and, depending on the child’s 
cognitive maturation, currently used identification tests turn out 
to be unreliable and even suggest that children have lowered 
olfactory function. This is just a reflection of the fact that 
smelling and picking the right odour from a list of descriptors 
requires familiarity, associative and verbal capacities, and 
sufficient concentration which might be difficult to achieve for 
the younger child. It is possible to test even new-born and infant 
olfactory ability but that requires a different way of testing(116). 
The scarce literature on olfaction in human new-borns, babies, 
and toddlers shows that they have an extremely developed 
olfactory function(117, 118).    
7.3.5.6. Upper airway tests
The EPPDRT elaborates on three upper airway tests, which all 
can be applied in (older) children: peak nasal inspiratory flow 
(PNIF), acoustic rhinometry, and rhinomanometry. Of these, the 
PNIF is easiest to use and has been validated in children six years 
and older(119). Still, in children these investigations are not very 
clinically relevant and are predominantly used in the research 
setting.
7.3.5.7. Pathology test including ciliary morphology and 
function
Taking mucosal biopsies in children is rarely needed. Unilateral 
processes warrant suspicion of malignancy or inverted 
papilloma, even in children. Some authors advise to routinely 
send antrochoanal polyps for histopathological examination 
as they might represent inverted papilloma(120).For bilateral 
disease, biopsies are only needed if one suspects primary ciliary 
dyskinesia. Several tests for ciliary function are available (see 
EPPDTR).
7.3.5.8. Blood tests
As explained in detail in chapter 5.3.5., routine lab testing 
in (paediatric) CRS is not advised. As mentioned above, one 
should consider evaluation of the humoral immune response 
in children with CRS unresponsive to therapy and/or with lower 
airway manifestations such as recurrent pneumonia.
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7.3.5.9. Nitric oxide
Measuring nasal nitric oxide is indicated if PCD (and to some 
extent CF) is suspected. This non-invasive test can be performed 
in cooperative children, usually from the age of five onwards. It 
is described in detail in the EPPDTR and in chapter 5.3.5.
7.3.5.10. Genetic testing
Although there might be a genetic susceptibility for developing 
CRS as discussed in chapter 7.2.1, routing genetic testing is not 
advised. Whenever there is a suspicion of CF or PCD, genetic 
testing might be used. For CF, it is possible to test for mutations 
in the CFTR gene through a blood test or cells taken from a 
cheek swab. Also, sweat testing is advised. For specific details, 
see chapter 8.4. For PCD, genetic testing is also recommended 
and has greatly improved the ability to diagnose the disease 
(see chapter 5.3.5. for more details). This genetic test is part of 
a panel of diagnostic tests, which also includes microscopic 
evaluation of the ciliary function (see chapter 7.3.5.7.) and 
exhaled nitric oxide levels (see chapter 7.3.5.9.).
Key points | What’s new since EPOS 2012
• In children, differentiating between CRS, AR and 
NAR, and adenoid hypertrophy/adenoiditis can be 
challenging.
• In children, olfactory dysfunction is hardly reported, 
even in the presence of CRS.
• As in adults, facial pain or headache as main 
complaints point towards a primary headache 
syndrome.
• Most diagnostic tools that are available for adults, 
can be used in children as well. Additionally, tests for 
congenital diseases (genetic testing, nitric oxide and 
ciliary morphology) should be considered in selected 
cases.
7.4.  Management of paediatric CRS and co-
morbidities
Medical therapy is the mainstay of management of paediatric 
chronic rhinosinusitis. The most commonly used therapies 
include antibiotics, intranasal steroids, and saline nasal irrigation 
(Table 7.4.1.). There is less scientific support for other ancillary 
therapies.    
7.4.1. Antibiotics
There is no good evidence in the literature to support the use 
of antibiotics for CRS in children. Two clinical trials conducted 
by the same group do not show significant differences between 
treatment with placebo and systemic antibiotics in children 
with clinical criteria commensurate with CRS(121, 122). The studies 
have significant limitations as the initial study did not randomize 
or blind the patients to the treatments and the placebo group 
actually received saline drops which might have been helpful 
in and of themselves(121). Furthermore, one of the arms included 
drainage and irrigation of the maxillary sinus before initiating 
antibiotic therapy. The second, later study, was a randomized, 
double-blind comparison of cefaclor to placebo in 79 healthy 
children between the ages of two and 12 years with chronic 
rhinosinusitis(122). All patients had a puncture and washout 
and were then randomized to cefaclor or placebo PO for one 
week and were followed at six weeks. There was no significant 
difference in resolution rate between the children on cefaclor 
(64.8%) and those on placebo (52.5%). The initial maxillary 
puncture and washout could have helped the whole group 
even before enrolment and influenced the outcome, making 
the antibiotic irrelevant, and plain radiographs were used to 
evaluate the sinuses. Shin and colleagues performed a case 
control study of patients with CRS to evaluate predictors of 
response to therapy(84). They treated them with antibiotics for 
12 weeks and identified responders (n=22) and non-responders 
(n=36) at the end of therapy by evaluating persistent symptoms 
and abnormal Waters views. The prevalence of allergic diseases 
and levels of serum IgE and eosinophil cationic protein as well 
as the number of serum eosinophils were significantly higher in 
the non-responder group. 
Iino and colleagues investigated the effect of a low dose 
clarithromycin regimen administered for 8-15 weeks in a 
group of children (1-14 years) with chronic rhinosinusitis or 
otitis media with effusion(123). They also followed another 
group of children with the same disease with no therapy as 
control. Sixty-three percent of the children with CRS were free 
of disease at the end of therapy and there was no correlation 
between success of therapy and carriage in the nasopharynx of 
erythromycin-resistant S. pneumonia. The authors suggest that 
the efficacy is related to the potential anti-inflammatory effects 
of clarithromycin. The study is limited by lack of placebo controls 
and poor reporting of the improvement in disease in the control 
group, thus definitive conclusions about the efficacy of long-
term macrolides in children is not justified.
Despite the lack of supportive evidence, it is common but 
unsubstantiated practice to include a course of antibiotics 
as part of maximal medical therapy in children with CRS. It 
is likely that, in many of these instances, treatment targets 
acute exacerbations on top of pre-existing chronic disease.  
Careful review of existing data suggests that the role for short 
term antibiotics in CRS is close to nil (see also data in adults).  
Furthermore, double blind, placebo-controlled  trials with long 
term antibiotics are also negative in adults with a possibility that 
certain endotypes might benefit.  As seen from the above, there 
are no supportive data for either short or long-term antibiotic  
regimens in the treatment of children with CRS.
Intravenous antibiotic therapy for resistant CRS has been 
advocated as an alternative to surgical intervention. In a 
retrospective analysis of 70 children aged 10 months to 15 years 
with CRS, Don et al. found that 89% had complete resolution 
of symptoms after maxillary sinus irrigation and selective 
adenoidectomy followed by one to four weeks of culture-
directed intravenous antibiotics(124).Only eight patients required 
subsequent functional endoscopic sinus surgery (FESS). 
Cefuroxime IV was most frequently used, followed by ampicillin-
sulbactam, ticarcillin, clavulanate, and vancomycin. As expected, 
there were complications of intravenous therapy related 
both to line placement and the side effects of the antibiotics 
administered. More importantly, all the patients had irrigation of 
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the maxillary sinuses, and some underwent an adenoidectomy, 
which, as will be detailed later, are in themselves therapeutic. 
It is therefore not clear from these studies whether the 
intravenous antibiotics, per se, were solely responsible for the 
success rate.  Because of these issues, intravenous antibiotics 
are not advocated for the treatment of CRS in children and are 
essentially reserved to treat the complications of ARS. 
There is currently no evidence to support 
treatment of children with CRS with either oral or 
intravenous antibiotics. There is also no evidence 
to support the utilization of prolonged macrolide 
therapy in children with CRS. 
Proper randomized, controlled trials to evaluate 
the use of oral antibiotics in children with CRS 
are needed.  
7.4.2. Intranasal steroids
Intranasal steroids have become an important part of the 
treatment algorithm in light of increasing recognition of 
inflammation in the aetiology of CRS. To date, there is no 
evidence from randomized controlled trials to support the 
efficacy of intranasal steroids in paediatric CRS. A multinational, 
randomized, double blind study evaluated the safety of 
mometasone furoate 100 or 200mcg administered either 
once or twice daily in children 6-17 years of age with nasal 
polyposis(125). The change in 24-hour urinary free cortisol was the 
primary endpoint and did not differ between the mometasone 
and placebo treated subjects supporting the safety of treatment. 
Unfortunately, the study was not powered to evaluate efficacy 
but available data showed that mometasone administered 
twice daily was associated with the greatest reduction from 
baseline compared to placebo in polyp size, congestion and 
nasal drainage (anterior and posterior). Although evidence is not 
available to support the use of intranasal steroids in children with 
CRS, their efficacy in CRS with/without polyps in adults (as detailed 
elsewhere), as well as their favourable safety and efficacy profile in 
children with allergic rhinitis support the recommendation that they 
be part of first line therapy in children with CRS(47, 126-128). 
7.4.3. Systemic steroids
Systemic steroids have also been used in children with CRS 
because of their potent anti-inflammatory properties. Ozturk 
and colleagues treated children with CRS with amoxicillin 
clavulanate for 30 days and with either a prednisone taper 
course for 15 days or placebo(129). The steroid taper was given at 
the beginning of therapy. Compared to placebo, treatment with 
steroids resulted in significant improvements in CT scan score 
as well as symptoms of cough, nasal obstruction, postnasal 
discharge and total symptom score. Even though systemic 
steroids are effective, use for CRS in children is limited because 
of safety concerns.
Intranasal steroids are recommended for use in 
children with CRS despite the absence of good 
level evidence.  This is based on safety in children 
and favorable efficacy data in adults with CRSsNP.
There is one study that supports systemic steroid 
use in children with CRS.
A randomized, placebo controlled trial evaluating 
the efficacy of intranasal steroids in children with 
CRS is needed.
7.4.4. Intranasal saline
A Cochrane review analysed randomized controlled trials 
in which saline was evaluated in comparison with either no 
treatment, a placebo, as an adjunct to other treatments, or 
against other treatments(130). A total of eight trials satisfied 
inclusion criteria of which three were conducted in children. 
The studies included a broad range of delivery techniques, 
tonicity of saline used, and comparator treatments. Overall there 
was evidence that saline is beneficial in the treatment of the 
symptoms of CRS when used as the sole modality of treatment. 
Evidence also exists in favour of saline as a treatment adjunct. 
In one of these studies, 34 children with chronic maxillary 
rhinosinusitis from 3-16 years were randomized to two groups 
receiving 10 drops (1ml) of either 3.5% or isotonic saline three 
times a day for four weeks(131). Four patients withdrew (three 
hypertonic, one isotonic) due to nasal burning sensations. 
Primary outcomes were symptom and radiological scores. Both 
hypertonic and isotonic saline led to significant improvements 
from baseline in postnasal drip score but only hypertonic saline 
therapy significantly reduced cough score and maxillary sinus 
opacification as assessed by Waters view. Group comparison 
favoured the hypertonic saline group for cough score and 
radiologic scores.   
Wei and colleagues enrolled 40 children with CRS in a 
randomized, prospective, double-blind study comparing once 
daily irrigation with saline or saline/gentamicin for six weeks(132). 
There were statistically significant improvements in quality of 
life scores at three and six weeks and a reduction of CT scores 
after six weeks in both groups with no significant difference 
between the groups. This suggests that nasal saline irrigation 
is an effective therapy in children with CRS and that addition of 
gentamicin to saline provided no additional benefit. A smaller 
prospective study enrolled 10 children with CRS refractory to 
antibiotics and intranasal steroids and treated them with high 
volume nasal irrigation once daily for 30 days(133). Compared 
to baseline the children had a significant improvement in 
SN-5 and nasal quality of life scores after saline irrigation. Cho 
and colleagues performed a randomized, prospective study 
to investigate the efficacy of four weeks of nasal irrigation 
with low-concentration hypochlorous irrigation (HOCL, 
demonstrated to have bactericidal and fungicidal activity) or 
normal saline in children with CRS(134). Total symptom scores 
significantly improved with both HOCl and normal saline 
nasal irrigation, with no significant difference between the 
two groups. Plain radiographs, obtained at baseline and after 
treatment, showed improvement in both groups, which was 
significantly greater in the group on HOCl. Hong and colleagues 
retrospectively reviewed the records of children with CRS who 
had received nasal saline irrigation for a month and showed 
that 64% of the children had good compliance and carried out 
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the irrigations during the follow up period(135). Improvement 
of symptoms and nasal endoscopy findings were seen in the 
73% of the compliant patients and the rate of surgery was 
significantly lower (16.3%) for these children compared to the 
ones who did not show good compliance with therapy (42.9%). 
In another retrospective review evaluating compliance with 
saline irrigation therapy, irrigations were well tolerated 
by more than 80% of children and adolescents and when 
questioned, over 70% of patients / parents thought there was an 
improvement in nasal symptoms with irrigation(136). Based on the 
above data and the safety of this therapy, saline nasal irrigation 
has become mainstay of treatment of CRS in the paediatric 
age group. Indeed, in a survey of paediatric otolaryngologists 
and rhinologists in the US, 93% and 97% of the respondents 
respectively reported using nasal saline irrigations as part of 
appropriate medical therapy in paediatric CRS(124, 137, 138).  
Saline nasal irrigation is recommended for 
the treatment of CRS in children. Addition of 
antibiotics to saline irrigations is 
not recommended.  
7.4.5. Ancillary therapies
There is no good evidence to support ancillary therapies such 
as antihistamines (intranasal or oral), leukotriene modifiers, 
decongestants (intranasal or oral), or mucus thinners in CRS in 
children. The use of these agents is reserved for treatment of 
concomitant symptomatic allergic rhinitis. Chen and colleagues 
performed a prospective study that evaluated the efficacy of 
bacterial lysate (of 21 strains of eight bacteria) administered 10 
days per month for three months on recurrence of rhinosinusitis 
symptoms in children who had entered a remission phase 
after treatment for CRS(139). At one year of follow up, the visual 
analogue score, nasal discharge and obstruction scores, number 
of days with rhinitis attacks per month and number of days with 
antibiotic use per month were significantly decreased in the 
prevention group versus the control group (nasal saline).
Treatment of children with CRS for concomitant gastro-
oesophageal reflux disease (GORD) has been suggested by 
some weak evidence. Phipps and colleagues conducted a 
prospective study of paediatric patients with CRS and found 
that 63% of children with CRS had GORD documented by 
pH probe(43). In addition, 79% experienced improvement in 
rhinosinusitis symptoms after medical treatment of GORD. A 
retrospective study that lacked a placebo control showed that 
treatment for GORD in patients with CRS allowed many patients 
to improve and avoid surgery(44). These studies were not blinded 
and did not include a placebo group. They also do not account 
for spontaneous improvement in CRS symptoms in many 
children over time. Therefore, routine anti-reflux treatment of 
children with CRS is not warranted.  This conclusion is supported 
by the consensus statement on paediatric rhinosinusitis(47).
We do not recommend the addition of any specific 
ancillary therapy to the treatment regimen of 
children with CRS.  Exceptions are using ancillary 
therapies when indicated for concomitant disease 
such as allergic rhinitis or GORD.
7.4.6. Surgical treatments
Surgical intervention is considered for patients with CRS who 
have failed appropriate medical therapy (and, less commonly, 
in complicated acute rhinosinusitis). Adenoidectomy with 
or without antral irrigation and functional endoscopic sinus 
surgery (FESS) are the most commonly used modalities.
CRS, chronic rhinosinusitis; FESS, functional endoscopic sinus surgery; AMT, appropriate medical therapy.
Table 7.4.1. Evidence supporting therapy of CRS in children.
Therapy
Level of 
evidence
GRADE recommendation
Antibiotics 1b (-) There is no high level evidence to support the efficacy of either short or long term antibiotics 
for CRS in children.  
Nasal corticosteroids 5 There is no evidence regarding the efficacy of intranasal steroids in the treatment of CRS in 
children.  Nevertheless the EPOS steering group is supportive of their use in light of their anti-
inflammatory effects and excellent safety record in children.
Systemic Steroids 1b (+) Adding a taper course of systemic steroids to an antibiotic (not effective on its own) is more 
effective than placebo in the treatment of paediatric CRS.  Judicious use of this regimen is 
advised considering systemic side effects. 
Saline Irrigation Ib (+) There are a few clinical trials demonstrating the efficacy of saline irrigations in paediatric 
patients with CRS. The EPOS steering group is supportive of the use  of saline in light of the 
excellent safety record in children.
Adenoidectomy 4 Adenoidectomy is effective in younger children with symptoms of CRS.  The EPOS steering 
group supports adenoidectomy in young children refractory to appropriate medical therapy.
FESS 4 FESS is safe and effective for the treatment of older children with CRS refractory to medical 
therapy or previous adenoidectomy.
EPOS 2020
361
7.4.7. Adenoidectomy
Adenoidectomy is often the first-line surgical option in children 
with CRS, with success rates ranging between 47 and 58% 
of cases(140).Anatomic obstruction and/or biofilm formation 
and the notion of the adenoids as a bacterial reservoir are the 
primary underlying rationale for adenoidectomy. In general, the 
revision rate for adenoidectomy is very low (1.9%)(141). In a meta-
analysis of the results of adenoidectomy for symptoms of CRS in 
children, Brietzke and colleagues included eigth studies with a 
cumulative success rate of 69%(33). Ramadan and Tiu reported on 
the failures of adenoidectomy over a 10-year period and found 
that children younger than seven years of age and those with 
asthma were more likely to fail after an adenoidectomy and go 
on to require FESS(142).  
Clearly, adenoidectomy seems to help irrespective of whether 
the cause of the symptoms is adenoiditis or CRS, which are 
difficult to distinguish on clinical grounds. In a study that 
attempted to address this issue, Bhattacharyya and colleagues 
evaluated CT scans of two paediatric populations: 66 
children with CRS about to undergo surgery and 192 children 
undergoing a CT scan for non-sinusitis related complaints(105). 
Lund-Mackay scores of 2 or less had an excellent negative 
predictive value, whereas scores of 5 or more had an excellent 
positive predictive value for CRS, with sensitivity and specificity 
of 86% and 85%, respectively.A score of 3-4 was considered 
equivocal and more weight needed to be placed on the clinical 
picture and endoscopic exam in these cases. It, therefore, stands 
to reason that a child with the typical symptoms, and a CT-LM 
score <5 probably has adenoiditis. Ramadan and colleagues 
hypothesized that adenoidectomy would be more successful 
therapy for children with adenoiditis (low CT score) as opposed 
to CRS (high CT score)(143). To this end, they reviewed their 
patients with symptoms of CRS who underwent adenoidectomy 
and divided them into two groups based on their Lund Mackay 
CT score: the CRS group (Lund-Mackay score ≥5) and the 
adenoiditis group (Lund-Mackay score <5). When the success 
rate of adenoidectomy at one year was evaluated, it was 65% for 
the adenoiditis group and 43% for the CRS proper group (with 
high CT scores). This supports the notion that adenoidectomy 
is more effective when sinus disease is not severe and the 
symptoms are related to adenoiditis.
Bettadahalli and colleagues report significant improvements 
in symptom severity scores before and six months after 
adenoidectomy in children with CRS(143). Using the SN-5 
instrument, a total of 53 out of 60 children (88%) had improved 
quality of life scores at the end of follow up with a significant 
improvement in QOL scores in all domains compared to 
baseline. The consensus statement of the American Academy 
of Otolaryngology-Head and Neck Surgery supported 
adenoidectomy as an effective first-line surgical procedure 
for children up to 12 years of age and was unable to reach 
consensus on the utility of adenoidectomy in patients age 13 
years and older due to the absenceof supporting data for that 
age group(47).
Maxillary antral irrigation is frequently performed in conjunction 
with an adenoidectomy. To evaluate the efficacy of this added 
intervention, Ramadan and colleagues analysed 60 children who 
underwent an adenoidectomy for CRS, 32 of which also had a 
sinus wash and culture via the middle meatus(144). All children 
received postoperative antibiotics for two weeks and outcomes 
were assessed at least 12 months postoperatively. Patients 
who underwent an adenoidectomy alone had a 61% success 
rate at 12 months compared with children who underwent an 
adenoidectomy with a sinus wash, who had a higher success 
rate of 88%. Children with a high Lund-Mackay CT score and 
asthma had better success with an adenoidectomy with a wash 
compared with an adenoidectomy alone. These data suggest 
that antral irrigation should be considered in addition to an 
adenoidectomy in children with asthma who have more severe 
disease on preoperative CT scans.
Adenoidectomy with/without antral irrigation is 
the simplest and safest first procedure to consider 
in younger children with symptoms of CRS.
7.4.8. Balloon sinuplasty
Balloon sinuplasty was approved by the U.S. Food and Drug 
Administration for use in children in the United States in 2006, 
and a preliminary study in children has shown the procedure 
to be safe and feasible(145).  Since EPOS 2012, multiple studies 
have been performed evaluating the efficacy of balloon 
sinuplasty in paediatric CRS(146-151). Many of the studies included 
other procedures (adenoidectomy, sinus irrigation, anterior 
ethmoidectomy, turbinate reduction, ESS) that were performed 
simultaneously and might have contributed to success. 
Furthermore, none of the studies included appropriate control 
groups with no intervention to account for spontaneous 
resolution of symptoms in children.  
To address whether balloon dilation provides additional 
benefit to maxillary sinus irrigation, Gerber and colleagues 
prospectively randomized children (ages 2-12 years.) with 
CRS to undergo either adenoidectomy with maxillary sinus 
irrigation (with 18 gauge needle) or adenoidectomy with 
maxillary sinus balloon dilation and irrigation(152). While both 
groups showed significant improvement in SN-5 scores at both 
postoperative time points, there were no significant differences 
between the groups suggesting lack of additional value of 
maxillary sinuplasty.  Ference and colleagues analysed data 
from ambulatory surgery databases in four states to study the 
utilization of balloon catheter dilation (n=316) compared to 
traditional FESS (n=2346) in patients under 18 years of age. 
Balloon dilation was used in 11.9% of paediatric sinus surgery 
and had higher average charges with no decrease in operating 
room time compared to procedures that only utilized FESS(153). 
In a cost-effectiveness study based on decision tree analysis of 
different surgical scenarios in children with CRS, adenoidectomy 
as the sole first procedure was found to be more cost effective 
than adenoidectomy with balloon sinus dilation(154). 
From the above, it is clear that balloon dilation in children is safe 
but efficacy and cost effectiveness has no supporting evidence.  
Therefore, this modality was not endorsed by the consensus 
panel of the American Academy of ORL(47), and similarly, is not 
recommended by the EPOS2020 steering group.
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Type Intervention Outcome measure Result
Lusk 2006(155) Retrospective, age-
matched, cohort 
outcome study n=67
Endoscopic sinus 
surgery or medical 
management
Post intervention symptom 
scores (10 years after therapy)
ESS resulted in significant improvements in 
nasal obstruction and rhinorrhoea.  Parental 
assessment of improvement and satisfaction 
were higher in the ESS group
Ramadan 1999(156) Prospective, 
nonrandomized 
study, n=66 enrolled, 
n=61 had follow up
ESS or adenoidectomy Symptoms 6 months postop 
and need for revision surgery
Significantly more children had improved 
symptoms with ESS (77%) compared to 
adenoidectomy (47%).  
Hebert 1998(158) Systematic literature 
review of studies on 
outcomes of ESS
ESS
8 articles (n=832 
patients) and one set 
of unpublished data 
were evaluated
Positive outcome after ESS Positive outcome for published, unpublished 
and combined data was 88.4%, 92%, and 
88.7% respectively.
Vlastarakos 
2013(159)
Systematic literature 
review of ESS
15 studies with a 
total number of 1301 
treated patients
Positive outcome of ESS Positive outcome between 71 and 100% of 
operated children
Jiang 2012(160) Prospective study 
including 270 
patients with ESS 
and 273 healthy 
controls
ESS SNOT-20 before and 3-8 years 
postop
Significant improvement in quality of life after 
surgery
Cornet 2013(161) Combined 
prospective and 
retrospective study
ESS, n=44 (18/44 had 
both pre and post op 
data)
R-SOM quality of life 
questionnaire obtained 
an average of 4 years post 
operatively
Significant improvement in R-SOM 
postoperatively 
Table 7.4.2. Functional endoscopic sinus surgery (FESS) for paediatric CRS.
There is no solid evidence to support the use of 
balloon sinuplasty in the management of CRS in 
children.  This modality is not recommended as 
part of the surgical armamentarium. 
7.4.9. Functional endoscopic sinus surgery
There is some indication that FESS is superior to medical 
management (Table 7.4.2.). In a 10-year follow-up of patients 
who underwent FESS versus medical management alone, 
surgery resulted in a greater relief of nasal obstruction and 
purulent discharge, as well as higher parent satisfaction(155). A 
prospective study by Ramadan et al. examined the outcome 
differences between FESS and adenoidectomies, and found 
that FESS resulted in improved symptom status six months 
post intervention(156).Furthermore, retrospective questionnaires 
to the parents of children having undergone FESS for the 
treatment of CRS indicated a success rate that varied between 
70 and 80%(157).A systematic review of FESS case series results 
has shown that surgery is effective at reducing symptoms, 
with an 88% success rate(158). A more recent systematic review, 
confirms these positive results showing a positive outcome in 
between 71-100% of children after FESS as well as a significant 
improvement in quality of life after surgery which was evaluated 
in a subset of the studies(159). In that review, the rate of major 
complications following paediatric FESS was 0.6%, and the 
rate of minor complications 2%.  Other studies support these 
conclusions with improvement in symptom scores and quality 
of life measures after FESS in children with CRS with and without 
polyposis(160, 161). However, there are no RCT and the possibility of 
spontaneous improvement cannot be excluded. On average, the 
postoperative follow up periods ranged from 1-8 years. 
FESS is a safe and possibly effective surgical 
modality children with CRS and can be used as 
after failure of adenoidectomy in older children 
refractory to medical therapy.  Decisions on use 
depends on severity of disease, age and existing 
co-morbidities.
As to predictors of success of FESS in children, the data is scant. 
El Sharkawy and colleagues followed 87 patients prospectively 
after FESS: 45 patients had allergy, 36 had no allergy, and six 
had nasal polyposis(162). After a mean postoperative follow up 
of 28 months, the success rate (determined by improvement in 
CT score, nasal examination and postoperative symptoms) was 
not different between the groups and ranged from 85.7% to 
93%. The presence of asthma and higher severity of disease on 
CT decreased the subjective postoperative improvement and 
performing an adenoidectomy with FESS increased it. In another 
study, Lee and colleagues retrospectively reviewed the charts of 
children who received FESS for CRS and designated 21 patients 
with protracted disease and 32 patients as resolved based on 
the presence or lack thereof of mucopurulent discharge for more 
than three months after FESS(163). Sinonasal polyposis, history of 
ESS, endoscopic sinus surgery; SNOT-20, sino-nasal outcome test 20; R-SOM, rhinosinusitis outcome measure.
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allergic rhinitis, and male gender were more frequently observed 
in the protracted group than the resolved group.    
Many advocate a limited approach to FESS in children, consisting 
of the removal of any obvious obstruction (such as polyps and 
concha bullosa), as well as an anterior bulla ethmoidectomy, and 
a maxillary antrostomy. This approach typically yields significant 
improvements in nasal obstruction (91%), rhinorrhoea (90%), 
PND (90%), headache (97%), hyposmia (89%), and chronic cough 
(96%)(164). Whereas second look procedures were common after 
FESS to clean the cavities, the advent of absorbable packing has 
made it possible to avoid a second look procedure. Walner et al. 
found comparable rates of revision sinus surgery in children with 
and without a second look procedure, suggesting that it may 
not be necessary(165). Ramadan and colleagues observed that 
the use of corticosteroids during an initial FESS might obviate a 
second look procedure(166).Younis, in a review of available data, 
suggested that a second look is not necessary in most children 
after FESS(167). Initial concerns about possible adverse effects of 
FESS on facial growth have been allayed by a long-term follow-
up study by Bothwell and colleagues that showed no impact of 
FESS on qualitative and quantitative parameters of paediatric 
facial growth, as evaluated up to 10 years postoperatively(168).
Current literature supports the use of FESS in children with CRS 
who have failed appropriate medical treatment and possibly 
an earlier adenoidectomy. Other indications include orbital and 
intracranial complications of ARS, obstructing nasal polyposis 
and severe disease in cases of CF, and patients with allergic fungal 
rhinosinusitis.
As seen from this section, much remains to be done relating to 
investigating best surgical practices for CRS in children. It is clear 
that initial adenoidectomy with/without irrigation is effective 
followed by FESS (Table 7.4.2.). Ideally, prospective, randomized, 
multicentre trials should be conducted where the severity of 
disease on CT scans and the symptom questionnaire would be 
matched preoperatively and the following interventions would be 
compared: adenoidectomy alone, adenoidectomy with a wash, 
and endoscopic sinus surgery. 
Key points | What’s new since EPOS 2012
• There is no (new) evidence to support the use of either 
short or long-term antibiotics in the treatment of CRS in 
children.
• Saline irrigation and intranasal corticosteroids remain 
acceptable modalities for the medical therapy of children 
with CRS.  
• Adenoidectomy is useful in the surgical therapy of CRS in 
young children, especially if there is limited pathology on 
paranasal sinus CT scans.
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8.1. Role of allergy in chronic rhinosinusitis
8.1.1. Epidemiology and predisposing factors
The contribution of allergic inflammation to chronic 
rhinosinusitis (CRS) development, severity and therapeutic 
response are still not fully understood. It seems logical that 
allergic inflammation of the nasal mucosa with mucosal swelling 
and delayed mucociliary clearance might contribute to the 
development and/or severity and/or therapeutic response of 
CRS(1-3). Literature is however not conclusive on the contribution 
of allergic inflammation to CRS, both in chronic rhinosinusitis 
without nasal polyps (CRSsNP) as well as chronic rhinosinusitis 
with nasal polyps (CRSwNP)(4). In a systematic review Wilson et 
al. found nine articles that examined the relationship between 
allergy and CRSsNP, with four articles showing an association 
and five articles showing no association.
In CRSwNP they identified 18 articles, with ten showing an 
association, seven none and one a possible link / relationship 
Four studies directly compared the role of allergy in CRSwNP 
and CRSsNP and, again, the results were mixed. No articles 
examined the outcomes of CRSsNP or CRSwNP following allergy 
treatment. The authors concluded that the role of allergy in 
CRSwNP and CRSsNP continues to be controversial, with the 
very low level of evidence. 
Since 2014 a few noteworthy studies have been published. 
A more recent non-systematic review points to the fact that 
different phenotypes / endoptypes of CRS, such as allergic 
fungal rhinosinusitis (AFRS) or central compartment atopic 
disease(5), may have variable associations with allergy(6). This 
point was also made in a recent study from the UK that analysed 
differences between different phenotypes of CRS and controls 
in secondary care(7) and found the prevalence of self-reported 
inhalant allergy to be  20% in CRSwNP versus 31% in CRSwNP 
with the main difference in house dust mite (HDM) sensitization 
(9% versus 16%).
Earlier studies also showed that perennial allergy seems to be 
much more common than seasonal allergy in patients with 
CRS(1, 8) and positivity for perennial allergy was a risk factor of 
CRS(9, 10). 
The effect of atopy on CRS symptom severity is unclear. Studies 
show no difference in symptom severity between patients with 
or without atopy in CRSwNP patients(2, 11-15). But in patients with 
CRSsNP the outcomes are more diverse with two recent studies 
showing a difference(11, 16) and two others no difference(2, 13).
Table 8.1.1. summarizes recent studies after EPOS2012 reporting 
on the association  between atopic sensitisation and CRS. 
8.1.2. Pathophysiology
Allergic inflammation of the nasal mucosa causes swelling of 
the mucosa with reduced mucociliary clearance(17, 18), that may  
contribute to the reduced clearance of pro-inflammatory agents. 
In addition, patients with CRSwNP usually present with type 2 
helper T-cell (Th2) cytokine-mediated inflammation in the nasal 
mucosa, which is similar to allergic inflammation, particularly 
in individuals with predominant eosinophil infiltration in 
tissue(19-21). 
Recently, CRS has been further classified into different 
endotypes based on the association with type 1 or 2 
inflammatory patterns(12, 22, 23). Likewise, allergy is also 
characterized by type 2 inflammation(23), indicating the 
inflammatory similarity between allergy and CRS. However, the 
underlying mechanisms of how allergy influences CRS are very 
different (see also chapter 5.2.2.). 
Allergic rhinitis occurs through host sensitization to foreign 
proteins (allergens) across a mucosal barrier via dendritic cells 
and naive CD4-positive lymphocytes, with the generation of 
antigen-specific Th2 lymphocytes and immunoglobulin E (IgE)-
secreting plasma cells. Subsequent allergen challenge across the 
nasal mucosa of sensitized individuals may result in cross-linking 
of IgE bound to the surface of mast cells with degranulation, 
mediator, chemokine and cytokine release, leading to the 
recruitment of other inflammatory cells. In the unoperated 
state, allergens should have limited access to the sinus mucosa, 
but they can certainly trigger inflammation of the nasal cavity 
reducing sinus drainage. 
Severe CRS is, in general, not regarded as an allergic disease, but 
co-existing allergic rhinitis may accentuate Type 2 inflammatory 
mechanisms of CRS. A recent study in the Chinese population 
showed distinct mucosal immunopathologic profiles in atopic 
and non-atopic CRSsNP patients, suggesting that in the Chinese 
population the comorbid CRSsNP and allergic rhinitis (AR) might 
be more related to Type 2 mechanisms, whereas the phenotype 
CRSsNP without AR exhibits more non-Type 2 mechanisms(24). 
Allergens typically possess intrinsic protease activity that can 
interact with epithelial cells through three principle pathways: 
direct effects on junctional proteins, reaction with cell surface 
protease-activated receptors and toll-like receptor 4 (TLR4)-
dependent epithelial activation(25). Protease activity of allergens 
may elicit the release of epithelial-derived Type 2-driving 
cytokines and chemokines, some of which have also been 
implicated in CRS. In terms of potential overlap between AR and 
CRS pathogenesis, Kouzaki et al. showed lower host expression 
of two protease inhibitors (cystatin A and SPINK5) in the nasal 
epithelial cells extracted from patients with eosinophilic CRS 
compared with control and non-eosinophilic CRS groups(25). 
8. Concomitant diseases in patients with chronic 
rhinosinusitis
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This suggests that an imbalance of proteases and protease 
inhibitors within the epithelial barrier may contribute to the 
pathogenesis of Type 2 diseases in general(26). As we advance our 
understanding of the interactions between barrier immunity 
and the environment as a function of time, the relationship 
between allergens and CRS pathogenesis should become 
clearer. 
In patients with CRSwNP, local polyclonal  IgE is present in 
the polyp tissue(27-29). In atopic nasal polyp patients, local IgE 
production can be the effect  of  stimulation  with  allergens(30).  
However,  local  hyperimmunoglobulinemia  is  also  present  
in  non-atopic  patients,  meaning that elevated IgE levels 
result from other pathways as well. The cytokines interleukin 
(IL)25 and IL33 can induce IgE-mediated inflammation  by  
stimulating  a  non-T  cell  source  to  produce  IL4.  Alternatively, 
IgE is produced by stimulating innate lymphoid cells to release 
IL4, IL5, and IL13. IL5,  and  IL13,  namely  innate  lymphoid  
cells  (ILC). A  role  of  mast  cells  in  enhancing  eosinophilic  
inflammation  in  chronic  rhinosinusitis  is  suggested(31).
8.1.2.1. Central compartment atopic disease and allergy in 
CRS
Central compartment atopic disease (CCAD)  is a recently 
described variant of CRS that is significantly associated with 
allergy. In 2014, White et al.(32) first presented polypoid and 
oedematous changes in the middle turbinate in 25 patients who 
tested positive for inhalant allergens. The proposed aetiology 
was that the anterior aspect of the middle turbinate is exposed 
to inhalant allergens via nasal airflow. Brunner et al.(33) have 
similarly shown a higher association of allergen sensitization 
in patients with isolated middle turbinate changes than in 
those with diffuse polyposis. DelGaudio et al.(18) revealed that 
other central structures, including the posterior–superior 
nasal septum, middle turbinates, and superior turbinates, are 
involved. Hamizan et al.(5) reported that a central pattern of 
mucosal disease is significantly associated with allergy. Overall, 
this central pattern of inflammatory changes is highly associated 
with allergy. Further studies must be conducted to validate the 
aetiology and clinical course of this CRS subtype. 
Table 8.1.1. The association  of sensitisation with CRS. Recent studies after EPOS2012.
Author Patients Effect Department
Benjamin et al. 
2019(11) 
CRSsNP 
CRSwNP
The prevalence of atopy was 52% in CRSsNP and 76% in CRSwNP.  
The atopic patients had more severe radiographic disease compared with non-
atopic patients in CRSsNP.
Tertiary Allergology 
Department, ENT
Shen et al. 
2019(2)
CRS The ImmunoCAP test was 51% positive in CRS patients.  
The peripheral eosinophil count in the allergic group was higher than the non-
allergic group.
Department of 
Otolaryngology
Ho et al. 
2019(16)
CRS Positive allergen sensitization was 53% in CRS patients. 
Atopy was associated with younger age at the time of surgery, CRSwNP, asthma, 
and eosinophilic CRS.  
Atopy was also associated with increased severity in nasal symptom score and 
worse scores in the loss of smell/taste  and need to blow nose questions in the CRS 
population.
Rhinology. and Skull Base 
Research Group
Philpott et al. 
2018(7) 
CRSwNP 
CRSsNP 
Allergic fungal 
rhinosinusitis
The prevalence of self-reported confirmed inhalant allergy was 13.1% in control, 
20.3 in CRSsNP, 31.0% in CRSwNP and 33.3% in AFRS respectively.  
The self-reported house dust mite allergy was significantly higher in CRSwNPs 
(16%) compared to CRSsNPs (9%).  
The prevalence of self- reported aspirin sensitivity was 2.26% in control, 3.25% in 
CRSsNP, 9.61% in CRSwNP and 40% in AFRS respectively. 
Population study
Hamizan et al. 
2017(482)
Patients had 
undergone 
nasal 
endoscopy
Diffuse oedema and polypoid oedema demonstrated the strongest association 
with inhalant allergy.
Department of 
Otolaryngology–Head and 
Neck Surg
Li et al. 
2016(12) 
CRSwNP Atopic patients were younger than non-atopic patients. 
There was no association between atopy status and either disease severity or 
recurrence in patients with chronic rhinosinusitis with nasal polyps.
Department of 
Otorhinolaryngology – Head 
and Neck Surg
Yacoub 
2015(483)
CRSwNP 60% of patients were atopic. Patients with atopy had higher recurrence rate.
Green et al. 
2014(8) 
CRS In CRS patients, 73% had at least one of the postive allergen extracts in the skin 
prick test compared with 32% of the control patients with chronic idiopathic 
urticarial.  
The perennial allergy was more common than seasonal allergy in CRS
Allergy and Clinical 
Immunology Branch
CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps.
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8.1.3. Diagnosis and differential diagnosis 
A suggestive history supplemented by confirmation of 
sensitization by demonstration of allergen-specific IgE using 
skin prick testing or blood analysis is as important in CRS 
patients as in allergic rhinitis patients. However, there is a 
significant overlap in symptomatology between CRS and AR. 
AR is a very prevalent disease (see also 5.3.1.). It is not always 
easy to evaluate the role of sensitization to allergens in patients 
with CRS especially in perennial sensitisations (Table 8.1.1.).  If in 
doubt, optimal treatment of the AR seems advisable.
8.1.4. Treatment
Reports on the efficacy of allergy therapy in improving the 
symptoms and quality of life of patients with CRS are limited. 
In general, the therapeutic principles for concomitant allergic 
diseases, such as allergic rhinitis, including allergen avoidance, 
pharmacotherapy and allergen-specific immunotherapy, are 
relevant in patients with CRS. The use of nasal corticosteroids 
is the mainstay of treatment for both patients with chronic 
rhinosinusitis and allergic rhinitis. One study observed less 
improvements in symptom scores, polyp score, nasal peak 
flow, and overall response to therapy in the skin prick test 
positive group than in the negative skin test group treated with 
budesonide nasal spray(34). However, the presence of allergy 
showed no influence on the cumulative consumption of steroids 
between baseline and after one year in patients with CRSwNP, 
which indicated that the specific treatment of allergy in patients 
with nasal polyps may not be beneficial(14). Current studies 
yield insufficient evidence to recommend oral or intranasal 
H1-antihistamines in non-allergic CRS patients (see 6.1.8. ). A 
systematic review evaluating the effect of immunotherapy 
found no RCTs and concluded after highlighting the paucity 
of the data that there is weak evidence to support the use of 
immunotherapy(IT) as an adjunctive treatment in CRS patients, 
particularly in the postoperative period(35).
In conclusion: allergic rhinitis and CRS both benefit from nasal 
corticosteroids. There is insufficient quality evidence to advise 
other treatments, such as antihistamines or immunotherapy, in 
allergic patients with CRS. More studies are needed.
8.2. Immunodeficiencies and their role in CRS
Conditions that are associated with immunodeficiency are 
of clinical importance to rhinologists because some patients 
who present with CRS were predisposed to their condition 
by an underlying immunodeficient state. Immunodeficiency 
conditions may cause CRS patients to respond less favourably 
to standard therapies, and some patients require specific 
treatment for their immunodeficiencies in order for their CRS to 
be optimally treated.
Immunodeficiency states can be primary or secondary to other 
diagnoses or to immunosuppressive medication. Primary 
immunodeficiency conditions may be categorized according 
to whether the deficiency affects B cells (humoral immunity), T 
cells (cellular immunity), phagocytes or the complement system 
(both innate immunity)(36). In some cases, there is a combination 
of defects.
CRS is primarily associated with conditions that cause 
humoral deficiency, and in this section the discussion of 
primary immunodeficiency will be largely confined to 
hypogammaglobulinaemia(37).
8.2.1. Epidemiology
There is good evidence that immune deficiencies are more 
common in patients with CRS. A meta-analysis, which included 
1418 individuals with CRS from 13 studies, found that 23% of 
patients with difficult- to-treat CRS and 13% of individuals with 
recurrent CRS had immunoglobulin deficiencies(38).  However, 
many of the patients diagnosed in the series included in the 
meta-analysis had subclass or specific antibody deficiency. 
The laboratory criteria for diagnosing these conditions, and 
the clinical implications once the diagnoses are made, are not 
uniformly accepted. Many of the studies of the meta-analysis 
were performed in tertiary referral centres and this may have 
biased the population of patients studied towards having 
underlying immune defects. These reservations aside, it is likely 
that the prevalence of hypogammaglobulinemia in CRS patients 
is very significantly higher than in the general population.
8.2.2. Pathophysiology
Most cases of hypogammaglobulinaemia are caused by 
genetic mutations. The majority of cases are sporadic, 
although a family history of hypogammaglobulinaemia would 
raise diagnostic suspicions. Immunoglobulins primarily act 
by opsonizing encapsulated bacteria, and consistent with 
that action patients with hypogammaglobulinaemia tend 
to be susceptible to infections with Streptococcal species, 
Haemophilus influenzae and Moraxella catarrhalis(39). Patients 
with hypogammaglobulinaemia are predisposed to developing 
rhinosinusitis, pneumonia, bronchiectasis and otitis media.
8.2.3. Diagnosis and differential diagnosis
The causes of primary hypogammaglobulinaemia are:
1. X-linked agammaglobulinaemia
2. Common variable immunodeficiency (CVID)
3. Selective immunoglobulin A (IgA) deficiency
4. Immunoglobulin G (IgG) subclass deficiency
5. Selective antibody deficiency
There are other very rare causes such as Good’s syndrome, which 
is CVID associated with thymoma and Hyper-IgE syndrome 
in which patients have eczema and Staphylococcal furuncles. 
The number of causes of primary hypogammagloblinaemia 
keeps expanding as the genotypes of these conditions are 
determined(40). 
X-linked agammaglobulinaemia presents with recurrent 
respiratory tract infections in infant boys. Symptoms develop 
after age six months when passive protection from maternal 
immunoglobulins has been lost. 
Common variable immunodeficiency (CVID) is more likely than 
X-linked agammaglobulinaemia to present to rhinologists 
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because its age of onset is often in adulthood. It is diagnosed by 
low immunoglobulin levels and a poor response to vaccinations. 
In 2015, the International Consensus Document on CVID was 
published proposing six diagnostic criteria for this condition, 
which have clarified the clinical and laboratory aspects of its 
diagnosis(41). Patients with CVID are also predisposed to some 
autoimmune conditions as well as certain malignancies such as 
gastric lymphoma.
IgA deficiency is the most common immunoglobulin 
deficiency in the general population. The prevalence has been 
reported variably between 1:173 and 1:3024(42). Most patients 
are asymptomatic, but a deficiency of IgA would appear to 
predispose patients to rhinosinusitis and allergies(36). 
IgG has four variants, or subclasses, each of which has slightly 
different functions. Subclass deficiencies are diagnosed when 
the serum IgG level is normal, but one or more of the subclasses 
are found to be deficient. Laboratory determination (both 
analysis and normal values) may differ between laboratories. IgG 
subclass deficiency is a controversial diagnosis and experts are 
increasingly disagreeing about the importance of this finding 
as a cause of repeated infections(37). The overdiagnosis of IgG 
subclass deficiency as a cause of presumed immunodeficiency 
is not uncommon, and may lead to unnecessary long-term 
treatment.
Selective antibody deficiency (SAD) is diagnosed when patients 
have a normal serum immunoglobulin levels but attenuated 
responses to polysaccharide antigens(43). The antibody response 
to polysaccharide vaccines such as Pneumovax is determined, 
however the diagnostic criteria are not universally accepted, 
again leading to the possibility of overdiagnosis.
CRS secondary to hypogammaglobulinaemia may present in a 
manner identical to idiopathic CRS. This explains why there is 
often a long delay between initial presentation and diagnosis 
of an underlying immunodeficiency. There are some clinical 
features that may elevate suspicion: recalcitrance to standard 
treatments (and particularly rapid recurrence of symptoms after 
stopping antibiotics) and association with lower respiratory 
tract infections (pneumonia, particularly if recurrent, or 
bronchiectasis). 
The testing of immune function in all patients who 
present with CRS is almost certainly unwarranted 
as it is likely to produce more false positive results 
than true positives. However, it is recommended 
that the above clinical features are used to identify 
those patients who warrant some form of immune 
testing for testing.
8.2.4. A work-up by ENTs before referring to immunologists
It is not clear how much of the immunological testing 
should be undertaken by the rhinologist before referral to an 
immunologist, and this decision may reflect the individual 
knowledge and expertise of the rhinologist. 
Further studies, such as antibody responses to vaccines 
and flow cytometry can then be organized by an expert 
in the interpretation of these tests. The best approach for 
confirming a diagnosis of an antibody-deficiency disorder is 
the measurement of serum-specific antibody titers (usually 
IgG) in response to vaccine antigens. This approach involves 
immunizing a patient with protein antigens (e.g. tetanus 
toxoid) and polysaccharide antigens (e.g., pneumococcus) and 
assessing pre- and post-immunization antibody levels(44).
For CRS patients suspected of having 
humoral immunodeficiency because of the 
characteristics of their presentation or their 
response to treatment, measurement of serum 
immunoglobulin levels is the key investigation. If 
the levels are normal, but the suspicion of humoral 
immunodeficiency is high, referral to a clinical 
immunologist is optimal. 
8.2.5. Treatment
For many patients with CRS who have subtle humoral 
immundeficiencies on laboratory testing, specific treatment 
options  are  not available (such as IgA deficiency) or may 
not be indicated (such as in IgG subclass deficiencies). It is of 
paramount importance that the diagnosis and its implications 
are established in collaboration with a clinical immunologist. 
It is possible for some results to be overinterpreted, leading 
to unnecessary treatment with IgG replacement or excessive 
antibiotic prescribing.
8.2.5.1. Immunoglobulin replacement therapy
The mainstay of treatment of hypogammaglobulinaemia is 
immunoglobulin replacement therapy. The immunoglobulin 
fraction is extracted from the plasma of a large number of 
donors so that passive immunity to an enormous number of 
antigens can be achieved. The optimal route of administration 
(intravenous or subcutaneous) has not been established(45).  
However, the decision about whether to start a patient on 
intravenous immunoglobulin therapy and ongoing oversight 
of this treatment would in almost all circumstances involve a 
clinical immunologist.
A series of 31 patients from a single institution, most of whom 
had CVID, were followed closely. They had fewer sinus and 
chest infections, and a significant reduction in Lund-Mackay 
scores while receiving immunoglobulin replacement therapy(46). 
However, an earlier European study did not find such a 
favourable impact of therapy(47).
Various antibiotic agents and regimens have been 
used, and often at half the usual dose. Periodically 
changing antibiotics monthly to every 6 months 
is sometimes practiced in order to reduce the 
development of resistance, but there are no studies 
that evaluated the efficacy of this practice(48).
8.2.5.2. Prophylactic antibiotics
Although long-term antibiotic therapy has transformed 
the outcomes in some types of primary immunodeficiency 
syndromes, controlled trials are few in the context of 
hypogammaglobulinaemia(48). One long-term observational 
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study of CVID patients treated with prophylactic antibiotics 
as they continued to have infections despite immunoglobulin 
replacement therapy, failed to find a reduction in the frequency 
of infections(49).
8.2.5.3. Vaccinations
It has been found that some patients with low antibody levels to 
pneumococcal serotypes will respond favourably to conjugated 
pneumococcal vaccinations, reducing their requirement for 
antibiotics(50).  
8.2.5.4. Surgery
The relative efficacy of surgery in the context of 
hypogammaglobulinaemia compared to idiopathic CRS has 
not been extensively reported.  A nested case control study 
comparing the outcome of functional endoscopic sinus surgery 
(FESS) in patients with immunodeficiency (mostly secondary) 
and idiopathic CRS patients found that the immunodeficient 
patients responded as well as their controls(51). 
8.2.6. CRS and secondary immune deficiencies
In a recently reported study in patients who received rituximab 
for management of systemic autoimmune disorders, moderate-
to-severe hypogammaglobulinaemia was seen in 26% of 
patients, but approximately 50% of these cases improved 
and resolved spontaneously(53). In addition, immunoglobulin 
replacement was initiated in 4.2% of patient due to recurrent 
infections. 
A recent review on the HIV-associated manifestations in 
otolaryngology underscores the high prevalence of CRS in HIV 
patients(54). These authors also mention that physicians need 
to have a high level of suspicion for atypical pathogens in this 
clinical context. Also iron overload, protein-energy malnutrition, 
or transplant patients on azole prophylaxis are also at risk(237).
Diabetes mellitus, particularly when poorly controlled, impairs 
both immune function and wound healing. There is however no 
evidence to suggest that it is a risk factor for the development of 
CRS. Whether having diabetes mellitus affects the outcome after 
FESS has been determined in a nested control study, and it was 
found that the diabetic patients fared as well postoperatively as 
the non-diabetic patients(55).
The prevalence of secondary immune 
deficiency is rising due to the increased use of 
immunosuppressive agents such as rituximab, 
corticosteroids and other drugs(52). Rituximab is 
a monoclonal antibody directed against CD20 
that causes B-cell depletion. As the indications 
for rituximab are growing so is the incidence of 
rituximab-induced hypogammaglobulinaemia. 
8.2.7. Summary
CRS may be associated with primary humoral immunodeficiency 
conditions. Most of the patients with significant humoral 
immunodeficiency conditions also have associated lower 
respiratory tract problems such as recurrent pneumonia. 
The best screening tests for ORL surgeons to request are 
serum immunoglobulin levels. More sophisticated tests 
of immune function should generally be undertaken by 
clinical immunologists, as their interpretation requires 
specific expertise. The decision to treat with intravenous 
immunoglobulin replacement and the supervision of 
that treatment should ideally be made by a clinical 
immunologist. The potential influence of secondary causes 
of immunodeficincies (resulting either from co-morbidities 
or immunosuppressive therapy) should be considered in the 
management of CRS patients.
8.3. Lower airway disease including asthma in 
relation to CRS
8.3.1. Introduction
Health care providers dealing with CRS proactively ask for the 
presence of lower airway symptoms such as cough, wheezing, 
shortness of breath, and are ideally aware of the diagnostic and 
therapeutic guidelines like EPOS and GINA to optimally treat 
both CRS and asthma(56-58).
Lower airway inflammation often co-exists in CRS, with up 
to two thirds of patients with CRS affected by comorbid 
asthma(7, 59, 60), chronic obstructive pulmonary disease (COPD) 
or bronchiectasis(61, 62) (figure 8.3.1.). Pulmonary function in 
CRS patients is significantly reduced compared to non-CRS 
individuals, even in patients that do not report bronchial 
symptoms(63). Rhinitis / rhinosinusitis is demonstrated to be the 
most prevalent co-morbidity of asthma(64). Asthma, COPD and 
bronchiectasis patients have a reported prevalence of CRS in 
up to 57%(59, 65),  40%(62), and  45 %(66, 67) respectively. The HELIUS 
study showed CRS to be associated with adult-onset asthma(68) 
and the Asthma Clinical Research Network demonstrated that 
CRS is associated with increased risk of asthma exacerbation(69). 
In asthma patients with CRS, acute exacerbations of CRS lead to 
poor asthma control(70). GINA 2019 recommends the assessment 
of comorbidities including CRS in every step of the therapeutic 
approach for asthma(71). The presence of chronic rhinitis was 
associated with 30-day asthma and COPD-related hospital 
readmissions, in both allergic and non-allergic patients(72). In 
COPD, the presence of CRS negatively impacts the severity of 
bronchial inflammation and COPD severity(73).
Several immune mechanisms have been reported to be involved 
in the naso-bronchial interaction in patients with global airway 
disease. Both asthma and COPD patients show the typical 
sinonasal inflammatory pattern with the classic Th2 and Th2 
biomarkers in the nasal secretions, as seen in rhinitis / CRS 
patients(26, 74).Therefore, it is not a surprise that novel biological 
treatments targeting inflammatory molecules such as IL4, 
IL-5 and IgE in both upper and lower airway inflammation are 
effective on both asthma and CRSwNP(75, 76)(77).
In the field of respiratory allergy and asthma, the naso-bronchial 
interaction has been studied by Braunstahl and coworkers(78, 79) 
with involvement of a systemic and/or neurogenic inflammatory 
component. The systemic pathway leading to bronchial disease 
via nasal inflammation is most likely facilitated by transmucosal 
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passage of exogenous particles among which are allergens(80), 
and by nasal epithelial barrier dysfunction found in both rhinitis 
and in CRS(81). A neurogenic pathway linking upper and lower 
inflammation has been demonstrated using animal models 
highlighting the bronchial release of neural mediator substance 
P in the bronchi upon activation of a nasal inflammation(82). In 
addition to the neural and systemic parts of the nasobronchial 
interaction, it seems that the microbiome in the sino-nasal 
cavity also plays a role in lower airway inflammation, as nasal 
colonization with Staphylococcus aureus showed significant 
relationships with asthma prevalence(83) for both CRSwNP 
and CRSsNP. Animal studies have indeed demonstrated the 
aggravation of bronchial eosinophilia by nasal presence of 
Staphylococcus aureus enterotoxin B(84). The contribution of 
the microbiome to asthma development in CRS patients is still 
under investigation(85).
Given the epidemiologic and pathophysiologic connection 
between CRS and lower respiratory airway disease(86), the 
concept of global airway disease has gained more interest,  
leading to better diagnosis and therapeutic approaches in 
patients with global airway disease(87). Recently, a simple 
Visual Analogue Scale (VAS) for total sino-nasal symptoms 
has shown to correlate well with the more extended SNOT-22 
questionnaire, and could be used for screening of CRS in asthma 
/ COPD patients(88).
The impact of lower airway disease on CRS can be arbitrarily 
divided into impact on disease severity and control, and 
outcomes of medical and surgical treatment. 
8.3.2. Impact of endoscopic sinus surgery on asthma / COPD
Endoscopic sinus surgery in asthma has been reported to 
improve multiple clinical asthma parameters(89). In this meta-
analysis, mean follow-up across all studies was 26.4 months. 
Patients reported improved overall asthma control in 76.1% 
[95% confidence interval (CI), 71.9% to 80.3%] of cases. The 
frequency of asthma attacks decreased in 84.8% (95% CI, 
76.6% to 93.0%) of patients and the number of hospitalizations 
decreased in 64.4% (95% CI, 53.3% to 75.6%). Decreased use of 
oral corticosteroids was seen in 72.8% (95% CI, 67.5% to 78.1%) 
of patients; inhaled corticosteroid use decreased in 28.5% (95% 
CI, 22.6% to 34.5%) and bronchodilator use decreased in 36.3% 
(95% CI, 28.9% to 43.7%) of patients. Mean improvement in 
predicted forced expiratory volume at 1 second (FEV1) was 
1.62% but was not statistically significant (p=0.877). Surgical 
treatment for CRS has shown to be beneficial in severe asthma, 
with better asthma control in the most severe asthma group(90). 
Contrary to asthma, at present, there is limited evidence on the 
impact of sinus surgery in COPD patients with CRS.
8.3.3. Impact of asthma / COPD on CRS severity
Patients with CRS often present with uncontrolled asthma, and 
endoscopic sinus surgery (ESS) improves both mini-Allergen 
Quality of Life Questionnaire (AQLQ) and asthma control 
test (ACT)(90). In a large-scale study on outcomes after sinus 
surgery in a tertiary referral centre(91), asthma did not have an 
impact on the degree of control after ESS, whereas NSAID-
exacerbated respiratory disease (N-ERD) was significantly 
associated with higher prevalence of uncontrolled CRS. In 
another study evaluation success of the endoscopic modified 
Lothrop procedure, failure rates of endoscopic modified Lothrop 
procedure were 8.9% for primary procedures and 21% for 
revision surgery. Also in this study, one of the risk factors for 
failure of primary endoscopic modified Lothrop procedure was 
N-ERD(92).
In COPD, there is a higher occurrence of nasal symptoms and 
pathological findings on nasal endoscopy compared with the 
control group, with overall reduced nasal airflow and increased 
nasal resistance. Pathological opacity of one or more sinuses was 
Figure 8.3.1. Global airway disease concept.
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confirmed in 38% of COPD patients(62). In bronchiectasis, CRS 
is associated with a greater degree of bronchiectasis severity, 
poorer health-related quality of life (HRQOL), reduction in smell 
detection, elevated levels of inflammatory markers, and reduced 
time to first exacerbation(67).
8.4.   Cystic fibrosis
Cystic fibrosis (CF) is a life-shortening genetic condition caused 
by a mutation in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene leading to defective chloride channels. 
CF is the most frequent lethal autosomal recessive disorder in 
the Caucasian population, but it affects all races. Ireland and 
the Faroe Islands have the highest prevalence of CF in the 
world with prevalence of respectively 68 per 100,000 (1:1461) 
in Ireland(93) and 56 per 100,000 (1:1775) in the Faroe Islands(94). 
The CFTR gene encodes the cAMP-dependent chloride channel, 
and a defect in the gene results in abnormaltransport of 
chloride and sodium across the cell. As a consequence, airway 
secretions contain a lower concentration of salt, causing the 
secretions to have more than double the viscosity of secretions 
of a non-CF individual. The mucus is thus dehydrated and 
sticky, which reduces mucociliary clearance and promotes 
infections; most severely leading to increased susceptibility of 
bacterial infections in the lower airways with the CF-pathogenic 
gram-negative bacteria, particularly Pseudomonas aeruginosa, 
Achromobacter xylosoxidans, and Burkholderia cepacia, causing 
progressive decline in lung function and ultimately death. 
Staphylococcus aureus encountered early in childhood, is 
generally considered to be related to poor clinical outcomes. 
Methicillin-resistant strains are also encountered and have 
been associated with worsening progression of lung disease. 
Often, gram-negative bacteria become the dominant pathogens 
in adulthood. If this is not the case, the Staph. aureus bacteria 
are often present as a pathogenic chronic infection of the upper 
and lower airways. A major goal in the treatment of patients 
with CF is thus to prevent or delay chronic lung infections. 
Preventing chronic lung infection is, however, difficult to achieve 
and the vast majority of patients with CF has been colonized or 
infected when reaching adulthood(95).
There is a high concordance of bacteria cultured 
from the paranasal sinuses (based on irrigations, 
swabs, or mucosal biopsies) and from the lungs(96).
Over time, P. aeruginosa develop common phenotypic traits, 
including conversion into alginate-overproducing mucoid 
variants, reduced growth rates, and loss of virulence factor 
production, quorum sensing, and motility. Infections  often 
originate in the paranasal sinuses and can be responsible for the 
initial and temporary lung colonization or for the chronic lung 
infections in CF patients(97-99). The latter is presumably due to an 
advantageous environment in CF sinus secretions of a higher 
immunoglobulin(Ig) A:IgG ratio, reduced inflammation(100), 
low oxygen concentration(101), bacterial biofilm formation(102), 
and lower bioavailability efficacy of IV-antibiotic treatment 
compared to the lungs(103). In addition, the presence of 
intramucosal bacterial colonies are difficult to eradicate(104).
Bilateral nasal polyposis in children are often 
a clinical indication of CF(111); nasal polyposis 
in CF patients becomes more common as the 
children age with a prevalence of up to 50% in 
adolescents(112). 
Anatomically, CF patients often have hypoplastic sinuses, 
independent of previous surgery. A study on adult CF patients 
demonstrated 66% of the frontal sinuses were either aplastic 
or hypoplastic(105). Mucoceles often leading to pyoceles and 
bone sclerosis are common, as well as typical inflammatory 
patterns, e.g. CRSwNP, mucosal swelling and bulging, or even 
missing the lateral nasal wall(105). The majority of CF patients 
have characteristic CT findings from early childhood(106), 
thus the Lund-Mackay scoring system may not be of optimal 
use. Alternative CT sinus scoring systems addressing CF as 
proposed by Eggesboe(107), Sheikh(108) or  Rasmussen(109) may be 
more useful.
Only 7% of CF patients are free from inflammatory changes in 
their sinonasal histology(110). 
Nasal polyps in CF tend to be more neutrophilic and less 
eosinophilic compared to the non-CF population(113). CF patients 
are likely to under-report their symptoms of CRS(114, 115). Several 
patient-reported outcome measures (PROM) conclude that 
CF patients have symptoms of CRS two-third of whom fulfil 
the EPOS criteria(116, 117). Individuals who are carriers for one 
defective CFTR gene may be more predisposed to developing 
CRS. Symptoms include thick nasal discharge, postnasal 
discharge, nasal blockage, facial pressure, and decreased sense 
of smell(118). There is a strong association between nutritional 
status and pulmonary function in CF and a decreased sense 
of smell is known to influence nutritional status in non-CF 
patients. Inexplicably and in contrast to patients with primary 
ciliary dyskinesia, patients with CF have a lower incidence of 
otitis media compared with the general population(119). Several 
studies have investigated a correlation between CF genotype 
and severity of sinonasal disease, however, conflicting results 
were foundf(120, 121). Patients who are heterozygous for mutations 
in the CFTR gene may be at increased risk of CRS. However, 
the evidence regarding an association between heterozygote 
patients and CRS is sparse. Calton et al. argued in their study 
treating CRS in a university setting that CFTR heterozygotes 
have significantly higher risk for CRS and who also have smaller 
paranasal sinuses(120, 121). 
8.4.1. Diagnosis and differential diagnosis
The diagnosis of CF is a multistep process, which involves a 
sweat chloride test, genetic analysis, and a clinical evaluation(122). 
The diagnosis of CF is made when a patient has both clinical 
presentations of the disease as well as evidence of a defective 
CFTR channel. 
Early detection accomplished by screening can prevent 
malnutrition and delay the imminent lung infections, and 
several studies have proven that the national screening program 
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improves survival and reduces morbidity in patients with CF(123-
125). 
In the western part of the world national screening 
programs on specific genetic disorders including 
CF have been implemented for newborns. 
Diagnostic testing/possible tests:
	· Neonatal screening: a heel prick is performed in the first 
couple of days after birth and is tested for raised levels 
of immunoreactive trypsinogen, a pancreatic enzyme. 
Elevated level of immunoreactive trypsinogen is suggestive 
of CF. However, immunoreactive trypsinogen can also be 
elevated due to other aetiologies e.g. prematurity, stressful 
delivery, or if a person is a carrier of the cystic fibrosis 
gene. Due to this, the screening test must be followed by a 
diagnostic test before the CF diagnosis can be made.
	· Genetic testing: it is possible to test for mutations in the 
CFTR gene through a blood test or cells taken from a cheek 
swab. Identification of two disease-causing mutations in 
the CFTR gene confirms the diagnosis. The specificity and 
sensitivity are estimated as high where two disease-causing 
mutations are identified. However, a positive gene test is 
accompanied by a sweat chloride test.
	· Sweat chloride test: measures the amount of chloride 
in the sweat. A higher amount of chloride in the sweat 
(>60mmol/l) compared to normal values indicates a 
diagnosis of CF. The test is done by placing a solution on 
the forearm or thigh and stimulating with a mild electric 
current to produce sweating. The test is tolerated well with 
only minor discomfort reported. 
8.4.2. Pathophysiology 
CFTR mutations can be grouped into six classes (see Table 
8.4.1.), all of which alter the function of the CFTR channels and 
cause CF. Class I mutations result in no functional CFTR proteins 
being made. Class II are the most common form of mutations 
and result in incorrect trafficking of the CFTR to the cell surface. 
Class III are gating mutations and affect the channels’ opening 
probability, and class IV mutations reduce the function of 
the CFTR channel by decreasing channel conductance. Class 
V mutations reduce the synthesis of the channels and class 
VI decrease CFTR stability(126). The most frequently observed 
mutation is the ΔF508, a class II mutation, but approximately 
2000 different mutations have been identified.
The presence of two mutations from either class I, II, or III 
are categorized as high-risk genotypes whereas at least one 
class IV, or V mutation are categorized as low-risk genotype. 
High-risk genotypes have been associated with significantly 
worse survival and lower lung function compared to low-risk 
genotype(127).
As mentioned above, the effect of genotypes on sinonasal 
disease is controversial. Ferril et al.(128) retrospectively reviewed 
sinonasal disease in CF patients and found a significant 
difference in severity of sinonasal disease when comparing 
patients with high-risk genotypes to low-risk genotypes. 
They describe how high-risk genotypes were associated with 
increased incidence of hypoplasia/aplasia and bony sclerosis 
evaluated by CT scans. Abuzeid et al.(129)on the other hand 
did not demonstrate worse sinonasal disease with high-
risk genotypes compared to low-risk genotypes when they 
retrospectively reviewed CF patients, evaluating SNOT-22 scores, 
nasal endoscopy scores, and CT staging scores. 
The taste receptor, T2R38 has been shown to play a role in 
detection and clearance of gram-negative organisms(130). 
Non-functional polymorphisms in the T2R38 gene 
correlate with sinus disease severity in patients 
with deltaF508 homozygous mutation(131).
Genetic markers as a prognostic indicator for the severity of CRS 
in CF patients as well as a diagnostic tool that can aid in tailored 
treatment for patients with CF could potentially improve 
sinonasal QOL in patients with CF while also minimizing 
unnecessary healthcare treatments. Further studies on the use 
of genetic markers to assess sinus disease in CF patients are 
needed and may eventually aid in future treatment modalities. 
8.4.3. Treatment
8.4.3.1. Gene therapy
The treatment of CF is currently symptomatic and treatment of 
the underlying gene defect, and thus curing the disease, has not 
yet been possible. 
Restoration of CFTR and its function by transferring correct 
versions of the CFTR gene to the airways may be a first step in 
gene therapy. A CFTR gene replacement would be an effective 
treatment of CF regardless of the underlying gene mutation 
class. 
Delivery of the CFTR gene via adeno-associated virus has so far 
Table 8.4.1. CFTR mutation classes.
CFTR mutation classes Description Mutation example
Class I No functional CFTR being made G542X
Class II Incorrect trafficking of the CFTR to the cell surface F508del
Class III “Gating mutations” - the channels opening probability is affected G551D
Class IV The channels conductance is decreased R117H
Class V The synthesis of the channel is reduced A455E
Class VI The stability of the CFTR channel is decreased r-delta-F508
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solely been shown in a pig model(132). Further studies with other 
gene vectors and in vivo models are needed.
To date there is no FDA-approved gene therapy. 
8.4.3.2. TgAAV-CF
TgAAC-CF, an adeno-associated cystic fibrosis transmembrane 
conductance regulator (CFTR) viral vector/gene construct, 
has been suggested as a therapeutic agent for the treatment 
of sinus disease in patients with cystic fibrosis. However, no 
significant effect of TgAAC-CF has been found so far, and the 
latest study of the effect of TgAAC-CF is more than 17 years 
old(133). The scientific evidence of the use of TgAAC-CF in the 
treatment of sinus disease is thus not currently available. 
8.4.3.3. Ivacaftor
Ivacaftor is a gene-based therapeutic agent approved, by the 
US Food and Drug Administration and the European Medicines 
Agency for the treatment of patients with specific CF mutations. 
Ivacaftor is a CFTR potentiator, which increases the opening 
probability of the CFTR channels at the cell surface, thus 
increasing the flow of ions through the channel(134). Ivacaftor 
is approved for the treatment of various class III mutations 
(G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N 
andS549R), and for the treatment of one class IV mutation 
(R117H)(135, 136). 
Recently it has been shown in CF patients that the intraflagellar 
transport protein, IFT88, abnormally accumulates in the basal 
body region in ciliated respiratory epithelial cells. The latter 
demonstrates a novel potential pathophysiologic intracellular 
mechanism; and of interest in CF patients receiving ivacaftor a 
normalization of IFT88 localization was obtained(137).
Ivacaftor has been shown to improve lung function in patients 
with CF(138, 139) and has recently demonstrated several other 
beneficial off-target effects, including a beneficial impact on 
chronic rhinosinusitis. Ivacaftor has been proven to improve 
rhinologic QOL in patients with CF evaluated by SNOT-20(140). 
Furthermore, several case reports document the reversal of 
sinus disease in CF patients after Ivacaftor treatment with 
normalized CT findings of CF sinus disease and resolved sinus 
symptoms(141, 142). Ivacaftor has also been shown to enhance the 
effect of some antibiotics, including ciprofloxacin(143) and even 
exhibits antibacterial properties itself(144). 
Further studies on combination therapy and the specific effect 
of Ivacaftor on chronic rhinosinusitis in vivo are warranted.
8.4.3.4. Tezacaftor/Ivacaftor
Tezacaftor is a selective CFTR corrector that facilitates the 
cellular transport of CFTR and restores the CFTR protein in the 
correct position on the cell surface.Tezacaftor in combination 
with Ivacaftor has been approved for the treatment of patients 
with F508del mutations, a type II mutation(145).
8.4.3.5. Mucolytic 
As in non-CF CRS patients, treating sinonasal symptoms starts 
with medical therapy prior to surgical intervention(146). 
8.4.3.5.1. Dornase alfa (rhDNAse)
Nasal irrigation combined with dornase alfa 
inhaled as a vibrating aerosol has been shown 
to be even more efficient than nasal irrigation 
solely(147). In contrast, the use of hypertonic saline 
does not add significant benefit(148). 
8.4.3.5.2. Topical antimicrobials
The use of topical antibiotics correlates with improvement in 
symptom and endoscopic scoring in uncontrolled studies and is 
safe(149, 150). With regards to post-surgical treatment, most studies 
use topical and/or systemic antibiotic treatment. However, 
recurrent infections are often seen. Installation of resorbable 
antibiotics/bacteriophages/CFTR-modulating drugs/Poloxamer/
etc may help eradicate bacteria after surgery(151-153).
8.4.3.5.3. Other treatment
There is high level of evidence that high volume nasal irrigations 
with saline relieve symptoms in CF patients, and the procedure 
is well-tolerated.
The effects of topical steroids as a medical treatment for CRS in 
CF patients are controversial. 
A Cochrane review (including 1 placebo 
controlled study) concluded that 
topical steroids for nasal polyposis have no 
significant effect on subjective nasal symptom 
scores but are effective in reducing nasal polyps 
size(154). 
A systematic review addressing the effect of topical steroids 
on CRS in CF patients did, however, including non-placebo-
controlled- trials demonstrated significant benefits in CRS 
treatment(155). There are no studies addressing an impact on 
sinonasal symptoms in CF patients with systemic steroids. 
8.4.3.6. Surgery
CRS among CF patients is often refractory to medical therapy 
and thus sinus surgery is often recommended. Endoscopic sinus 
surgery in CF children and adults is a safe procedure despite 
anatomical variations in patients(156). Several reports have shown 
that sinus surgery reduces sinonasal symptoms in CF patients 
although this is often only a temporary improvement with the 
need for revision surgery. In a study comprising 106 CF patients, 
the necessity for revision surgery was 28% within three years 
of surgery(157). When describing the surgical procedures, several 
studies reported it was necessary to perform more extensive 
surgery, e.g. total ethmoidectomy, medial maxillectomy(158) and 
various Draf procedures. Sinus surgery is also recommended to 
be performed in CF patients without chronic lung infection or 
with a transplanted lung in order to attempt to eradicate gram-
negative bacteria in the paranasal sinuses, thereby avoiding or 
preventing re-colonisation of the lungs(157, 159). In these cases it 
is important to address all the paranasal sinuses independent 
of the preoperative CT findings with the goal of extending the 
time to lung infection(109) although even after sinus surgery the 
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sinuses are not always easy to reach with local medication(160). 
Children with CF undergoing sinus surgery may experience 
some improvement of lung function parameters, although this 
change may be temporary and not uniform(120).
To conclude, several studies have evaluated the effect of sinus 
surgery on pulmonary function with divergent conclusions. 
When evaluating the reports, it is important to take into account 
the pre-operative lung infection status, the extent of sinus 
surgery, the post-operative treatment, and to keep in mind that 
the natural course of CF is declining lung function.
Detecting gram-negative sinus bacteria at 
an early stage is an important step towards 
eradicating the bacteria and avoiding a chronic 
bacterial sinus infection. 
Cultures from the middle meatus, cultures of nasal lavages, 
rising antibodies against P. aeruginosa, and declining lung 
function all indicate sinus infections. Nevertheless, gram-
negative bacteria are also detected in the paranasal sinuses 
during surgery in CF patients, despite preoperative negative 
cultures obtained from the middle meatus or from nasal 
lavages(161, 162). The importance of the microbial diversity is still 
unknown. 
8.5. Primary ciliary dyskinesia
8.5.1. Epidemiology and predisposing factors
Primary ciliary dyskinesia (PCD), a collection of rare inherited 
disorders that affects motile cilia was initially termed ‘immotile 
cilia syndrome’ (163).  Later, it was discovered that the cilia were 
not completely immotile and the name was changed to primary 
ciliary dyskinesia to distinguish it from secondary acquired 
causes(164) .In the late 1990s, several genotype variants for PCD 
were identified. Despite the diversity of mutations that can 
cause PCD, clinical presentations tend to be consistent for 
all patients – productive cough, rhinitis, and recurrent upper 
and lower respiratory infections (165). Patients with PCD have 
impaired mucociliary clearance, which leads to an elevated risk 
of developing recurrent respiratory infections from the time of 
birth (166).  Precise incidence and prevalence of PCD are difficult 
to estimate as there are no clinical and paraclinical criteria 
specific to the disease (167). Thus, current epidemiological records 
for PCD might be largely underestimated due to the absence of 
a single, ‘gold standard’’ diagnostic test (168, 169). 
Current estimated prevalence for PCD is 1:15-
30,000 live births(170). 
In 2010, Kuehni et al. conducted a large international survey 
of 1,192 pediatric patients from 26 European countries and 
reported an incidence for PCD of 1 per 10,000-20,000 births 
(171). With consanguinity as a risk factor for PCD, high prevalence 
exists in the Pakistani community in the United Kingdom 
(1:2265) (172) and in Amish and Mennonite Communities 
in the United States (173). While large discrepancies exist in 
epidemiological data for PCD, the challenge of confirming PCD 
is appreciated in all studies, with diagnostic practices possibly 
contributing to inaccurate estimates. Mirra et al. support this 
by demonstrating that many patients have an extraordinary 
number of physician visits (50-100) before their PCD is 
diagnosed. With this accounted for, they estimated the median 
age in Europe for diagnosis to be 5.3 years (174). 
Key points | What’s new since EPOS 2012
• There is a high concordance of bacteria cultured from the paranasal sinuses (based on irrigations, swabs, or mucosal biopsies) and from the 
lungs(96).
• In the western part of the world national screening programs on specific genetic disorders including CF have been implemented for 
newborns. 
• Non-functional polymorphisms in the T2R38 gene correlate with sinus disease severity in patients with ΔF508 homozygous mutation.
• Ivacaftor is a gene-based therapeutic agent approved, by the US Food and Drug Administration and the European Medicines Agency for 
the treatment of patients with specific CF mutations. Ivacaftor is a CFTR potentiator, which increases the opening probability of the CFTR 
channels at the cell surface, thus increasing the flow of ions through the channel.
• Ivacaftor has been shown to  improve rhinologic QOL in patients with CF evaluated by SNOT-20.
• Tezacaftor in combination with Ivacaftor has been approved for the treatment of patients with F508del mutations, a type II mutation.
• The use of topical antibiotics correlates with improvement in symptom and endoscopic scoring in uncontrolled studies and is safe.
• Some studies recommend that sinus surgery is performed in CF patients without chronic lung infection or with a transplanted lung in 
order to attempt to eradicate gram-negative bacteria in the paranasal sinuses, thereby avoiding or preventing re-colonisation of the lungs.
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8.5.2. Pathophysiology
PCD is primarily caused by mutations in genes that affect motile 
cilia (175)and is primarily inherited in an autosomal recessive 
manner, making family history of PCD and consanguinity among 
ascendants strong risk factors. There are more than 35 causal 
genes identified (176), adding to the challenge of effectively 
detecting PCD at an early stage (177). 
The five genes most commonly mutated are 
DNAH5; DNAH11; DNAI1; CCDC39; CCDC40, but 
more than 20 other genes are associated with 
specific ethnic groups and geographic regions. 
Knowles et al. estimates that of the 35 published PCD genes, 
65-70% of patients with PCD have two mutations in one of 
these genes (178). Given that cilia have many important functions 
within the body, defects in these structures manifest themselves 
in a broad spectrum of diseases. Associated conditions of 
PCD include hydrocephalus (169), polycystic kidney disease 
(168, 169), biliary atresia (169), scoliosis (5%-10%) (178), humoral 
immunodeficiency (6.5%), congenital heart disease (5%) 
and retinitis pigmentosa (169). Situs inversus (i.e. Kartagener 
syndrome) exists in approximately half of all PCD cases. Both 
men and women diagnosed with PCD commonly present 
with fertility disorders due to the reproductive process largely 
dependent on ciliary function (169, 176). 
PCD has a strong association with history of 
chronic rhinosinusitis (CRS).
PCD has a strong association with history of chronic 
rhinosinusitis (CRS) as it is part of the initial triad descriptor. 
In a critical evaluation of sinonasal disease in 64 adults 
with PCD, all patients reported a history of CRS (179). PCD is 
associated with CRSwNP in 15% (168) to 30% of patients (180), and 
is commonly seen in children with CRS.  PCD also predisposes 
to bacterial infections commonly including Staphylococcus 
aureus, Moraxella catarrhalis,  Haemophilus influenzae (181), 
Streptococcus pneumoniae (182), and Pseudomonas aeruginosa(183, 
184).   Confirming these findings, a 2017 meta-analysis of 46 
studies (1823 patients) with PCD or CF concluded that the most 
common organisms found in the sinuses of PCD patients were 
H. influenza followed by S. pneumoniae and P. aeruginosa(185). 
The upper airway bacteriology mirrored the 
organisms recovered in the lower airways of PCD 
patients(186, 187).
8.5.3. Diagnosis and differential diagnosis
In the absence of hard clinical and paraclinical criteria for 
diagnosing PCD, confirming the diagnosis of PCD with clinical 
exam is a challenge because characteristic symptoms such as 
rhinitis, secretory otitis media, cough, and recurrent bronchitis 
are frequently seen in PCD- negative patients (188). They 
frequently have a clinical history of lower airway disease and 
almost always chronic rhinitis. These symptoms can manifest as 
nasal discharge, episodic facial pain, and anosmia (188). 
Whenever nasal polyps are evident on nasal 
endoscopy of a child the diagnosis of PCD or CF 
must be considered.  
Lucas et al. (189) provide a decent set of conditions that support 
PCD diagnostic testing: 
1. Situs inversus plus respiratory or nasal symptoms
2. Neonatal respiratory distress of unknown cause
3. Sibling with primary ciliary dyskinesia (PCD), 
particularly if symptomatic
4. Daily lifelong wet cough (note: maybe suppressed by 
child and under-recognized by parents)
5. If considering testing for cystic fibrosis, also consider 
testing for PCD particularly if rhinitis, rhinosinusitis or 
glue ear are present
6. Unexplained bronchiectasis
7. Serous otitis media in association with lower and upper 
airway symptoms
8. Cardiac disease associated with heterotaxy if there is 
suspicion of respiratory, nasal or ear problems
8.5.3.1 Microscopy
It should be noted that cilia may appear normal 
in patients that present with symptoms strongly 
suggestive of PCD due to mutations that can result 
in normal structure.
Recent advances in technology have significantly improved 
diagnostic approaches to PCD. An electron microscropic analysis 
of cilia can yield valuable information about ciliary ultrastructure 
and function (188, 190). However, it should be noted that cilia 
may appear normal in patients that present with symptoms 
strongly suggestive of PCD due to mutations that can result in 
normal structure. In a respiratory epithelial biopsy with electron 
microscopy (EM), ciliary axonemes can be examined for defects 
in outer and inner dynein arms, radial spokes, and/or central 
microtubules (189, 191). This technique is sensitive to 70% of all PCD 
cases (192). To assess cilia waveform, high speed videomicroscopy 
can be utilized to confirm PCD. While the technology requires 
experienced personnel to operate, high speed videomicroscopy 
is recommended as part of a panel of PCD diagnostic tests 
(168)– although the number of centers that can perform this 
worldwide is limited. Ciliary beat frequency calculations 
and visual assessment of ciliary motion without high speed 
recording devices is discouraged due to high potential for 
false positive and false negative results (168).   Several highly 
specialized centres are capable of growing primary respiratory 
cultures at an air liquid interface (ALI) with subsequent analysis 
of ciliary motion as an alternative approach to assess cilia 
dysfunction(193).
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8.5.3.2 Genetics
To test a deficiency in specific ciliary proteins such as 
DNAH5, DNAI2, DNALI1, and RSPH4A/RSPH1/RSPH9, 
immunofluorescence testing can be performed. Staining of 
these proteins can yield quantitative and qualitative results 
in determining if ciliary protein deficiencies explain the 
phenotype of a patient suspected of PCD. Genetic testing is 
also recommended as part of a panel of diagnostic PCD tests 
and has greatly improved the ability to diagnose PCD. With 
currently 35 genes known to underlie the pathophysiology of 
PCD, a multi-gene panel of 19 of these genes can be performed, 
and this is becoming more affordable, as several Clinical 
Laboratory Improvement Amendments (CLIA) approved labs 
and companies have recently begun to offer such services (178). 
Genetic testing costs traditionally ranged from $1,500 to $4,500 
(168), which may have discouraged many individuals from being 
referred. Genetic panel tests can include full cystic fibrosis 
transmembrane regulator protein analysis (168). 
8.5.3.3 Exhaled nasal nitric oxide
A number of studies have shown that exhaled nitric oxide (NO), 
particularly nasal NO (nNO) production levels are low in PCD 
patients (176, 190). Nasal NO may then serve as a good diagnostic 
marker in assessing patients with symptoms suggestive of PCD. 
While a few patients with PCD have been shown to have normal 
NO levels, a high or normal nasal NO can assist physicians in 
excluding PCD as a differential, especially in patients that have 
a clinical history weakly suggestive of PCD (194). Noone et al. 
showed in an experimental design involving 110 patients that 
there was a significant difference in the NO levels observed 
between PCD patients (n=78) and the normal control group. 
NO measures for the PCD group had a clear separation from 
measures of the healthy control subjects, with a number of 
recordings below 100 nl/minute (190). While the mechanism of 
low nNO in PCD is not well understood (195), measurements of 
nNO is recommended as part of a panel of diagnostic tests for 
PCD in adults and children ≥5 years old (196). 
An nasal NO cutoff value of <77 nl/min can allow 
detection of PCD with a sensitivity and specificity 
of 98% and >99%, respectively, after excluding 
cystic fibrosis and acute viral respiratory infections 
(168).
8.5.3.4 Radiology
Radiographic evaluation of PCD patients demonstrates that 
opacified paranasal sinuses on CT scans are very common and 
hypoplasia or aplasia of the frontal or sphenoid sinuses is found 
in >50% of adult patients with PCD (197).  
8.5.4. Treatment
High-level evidence in managing patients with PCD is poor, 
with current treatment protocols mostly adopted from studies 
in CF or derived from small observational studies with limited 
follow-up period. Once a diagnosis is made, establishing a long-
term relationship with an otorhinolaryngologist is encouraged. 
Paediatric patients with PCD are advised to visit a paediatric 
otorhinolaryngologist every six months (168, 188) while adult 
patients should visit their otorhinolaryngologists when needed 
(168). 
Prolonged macrolide therapy has been shown to produce 
marked improvement in symptomatology of PCD due to the 
anti-inflammatory and immune-mediating properties of the 
antibiotic (180). 
Conservative therapy of CRS in PCD focuses on relieving 
symptoms. Therapeutic options include sinonasal irrigation 
with saline, topical steroids and long-term antibiotics. However, 
no prospective studies have so far evaluated the medical 
treatment of CRS in PCD. Presumably, sinonasal irrigation with 
saline is a safe method for clearing mucostasis in the upper 
airways as a result of impaired mucociliary clearance. Intranasal 
corticosteroids have a positive effect on CRS in general, and may 
also reduce inflammation in PCD. However, inhalation therapy 
with steroids is not recommended for the treatment of lower 
airway inflammation in PCD except in patients with concomitant 
asthma. 
Surgical intervention (ESS) may be required when medical 
therapy has failed. A few minor case series and retrospective 
case series (198, 199) and a single prospective study (200) have 
evaluated the potential benefits of CRS treatment with ESS in 
PCD and all these studies consistently show subjective benefit. 
However, further randomized controlled studies are needed to 
delineate the effects of surgery and adjunctive therapy. 
Key points | What’s new since EPOS 2012
• The number of genetic loci contributing to PCD has 
expanded to more than 35. 
• Diagnostic criteria now include nasal nitric oxide 
(nNO).
8.6. Fungal rhinosinusitis
Fungi are ubiquitous in our environment and with dedicated 
assessments they can be found in nasal mucus from almost 
all healthy and diseased sinuses(201).  However, there are 
several forms of sinus disease that are associated with fungi 
as pathogens. In these situations, rather than the fungi 
determining the disease process, it is usually the host immune 
state that determines the clinical presentation (Figure 8.6.1.).  
The definition and categorization of fungal rhinosinusitis is still 
controversial but the most commonly accepted system divides 
patients with normal immunity and immunocompromised 
patients(202).  For a patient with an immunocompetent state, 
fungi become a pathogen when they cannot be cleared by the 
mechanical action of mucus. In contrast to inert and non-viable 
material that settles on the mucus layer, fungi can multiply and 
create a ball or concretion of fungal hyphae. When this occurs, 
it becomes a fungal concretion and is widely referred to as a 
fungal ball. Fungal balls of the sinuses were previously referred 
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to as ‘mycetoma’. The fungal hyphae are not invasive, and the 
immune response is similar to other foreign body reactions 
in the immunocompetent patient. In an immunologically 
suppressed patient, the fungi can turn from ubiquitous material 
in our environment to a true invasive infective disease. It is likely 
that the type of fungi and the severity of immunosuppression 
bring about the variety of acute/chronic and granulomatous 
descriptions of invasive fungal rhinosinusitis. Aspergillus is 
common and a similar distribution of fungal species across 
simple fungal ball and invasive disease have been reported(203), 
highlighting the importance of the host factors in the disease 
process. Finally, in a setting of an exuberant or hypersensitivity 
immune response, the fungi, if allowed to contact the mucosa 
for any length of time, induce a strong Th2 immune response 
and in turn leads to a polypoid inflammatory phenotype, 
referred to as Allergic Fungal Rhinosinusitis (AFRS). This can be 
so exuberant that distortion of the local anatomy, including the 
eye, cranial cavity and face is common.
Fungi are ubiquitous in our environment and 
with dedicated assessments they can be found in 
nasal mucus from almost all healthy and diseased 
sinuses.
There was much prior debate regarding the role of fungi in 
CRSwNP. Some authors had proposed that a response to fungi 
might be the basis for most Th2 dominated polypoid forms of 
CRS. However, subsequent research has not supported this(204).
Thus, this chapter will discuss these three phenotypes of ‘fungal’ 
related CRS. An intentional focus is made on AFRS as a unique 
phenotype, and its treatment, within the broader definition of a 
CRS. 
8.6.2. Fungal ball
8.6.2.1. Terminology
Fungal ball Is a concretion or collection of fungal debris usually 
within a single sinus. The maxillary and sphenoid sinuses are 
most commonly affected.  By definition, there is no invasive 
component to the fungal colonization. There may be an 
associated mixed inflammatory reaction in the involved sinus 
and occasionally this inflammatory reaction will involve sinuses 
within the same function unit, such as frontal and anterior 
ethmoid in the case of maxillary sinus fungal ball. To describe 
this entity, confusing or misleading terms such as mycetoma, 
aspergilloma or aspergillosis  are best avoided(205).
8.6.2.2. Epidemiology and predisposing factors 
There is a reported female pre-disposition has high as 2:1(206) 
and others have suggested this but not to the same strength of 
association(207). Fungal ball is a condition that affects most in the 
fifth and sixth decade(206) with reported means of 55 years (208) 
and 56±14 years(209). In a systematic review of isolated maxillary 
and sphenoid sinus opacifications, the reported age range 
was 38-59 years for the maxillary sinus and 38-57 years for the 
sphenoid sinus(210). 
Fungal ball can be present for long periods with documented 
cases up to 17years(211). For newly diagnosed or formed fungal 
balls, enlargement is seen in 58% over time(211). Although, fungal 
ball is often an incidental finding, most produce symptoms. 
In 70 radiologically observed fungal balls, only 22-26.3% were 
asymptomatic(203, 211).
Prior endodontic treatment is a risk factor for maxillary fungal 
ball formation. Case control studies with patients with fungal 
ball versus CRS controls demonstrated endodontic treatment 
was more common in both prevalence (89% vs. 37%, p<0. 
01) and in the number of prior procedures (1.39±0.86 vs. 
0.53±0.81, p<0.01)(212). Such findings have been repeated with 
similar associations, demonstrating an increased prevalence 
of endodontic care (36% vs. 16%, p=0.001) and number of 
teeth endodontically treated (0.63±1.04 vs. 0.27±0.61, p=0.001) 
and on a multivariate regression, endodontic  treatment was 
strongly associated (Exp(B) 2.15[CI 1.26-3.67], p=0.005) and 
asthma was negatively associated(213). 
Most local anatomical variants have been assessed as possible 
risk factors for fungal ball formation. Septal deviation amongst 
Figure 8.6.1. An overview of the interaction of fungi and the human immune response.
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other variants, including concha bullosa, has been implicated 
along with infundibulum length compared to normal controls 
(9.71±1.43 vs. 8.6.23±172, p<0.01(209) but a repeat study could 
not demonstrate this septal association and even suggested an 
association with the deviation away from the involved side(214).
The largest cross-sectional study, using the contra-lateral side as 
a control, of 538 patients could find no relationship with septal 
deviation, infraorbital (Haller) cells nor concha bullosa(206). It 
is likely that anatomic variants are not a major contributor to 
fungal ball formation.
It is likely that anatomic variants are not a major 
contributor to fungal ball formation.
8.6.2.3. Pathophysiology 
It is presumed that the fungal ball forms during a period of 
impaired mucociliary function. The relationship with endodontic 
treatment may simply be either that the sinus mucosa was 
inflamed either from periapical dental disease or from the 
procedure itself and this provided a period of impaired 
mucociliary clearance from the maxillary sinus. The potential of 
extrusion of root canal filling material into the sinus has been 
postulated as copper and zinc elements are found in both 
fungal ball and in endodontic materials and thought to be a co-
factor for fungal growth(215).
The role of primary ostiomeatal complex (OMC) obstruction 
has been assessed. Firstly, fungal ball was less likely to have 
OMC occlusion than CRS controls with similar maxillary 
sinus involvement(216). Fungal ball patients were less likely to 
have frontal and anterior ethmoid radiologic changes. Sinus 
hypoventilation from simple OMC obstruction and thus 
providing an environment for growth seems unlikely and there 
are cases of fungal ball formation in the setting of a patent 
OMC(217).
Neo-osteogenesis  of maxillary sinus wall is common in fungal 
ball compared to normal patients and is independent of 
bacterial coinfection(218). This bony change produces a smaller 
maxillary sinus, but a smaller maxillary sinus volume has been 
reported in patients with fungal ball of the maxillary sinus 
compared to the normal contralateral side. This finding was 
independent of hyperostosis on sub analysis(219). 
8.6.2.4. Diagnosis and differential diagnosis  
DeShazo’s initial criteria and description is still accurate for 
fungal ball(220).
1. Radiologic evidence of sinus opacification with or 
without associated flocculent calcifications 
2. Mucopurulent, cheesy, or clay-like material within a sinus 
3. A matted, dense conglomeration of hyphae separate 
from but adjacent to sinus respiratory mucosa 
4. A chronic inflammatory response of variable intensity in 
the mucosa adjacent to fungal elements. This response 
includes lymphocytes, plasma cells, mast cells, and 
eosinophils without an eosinophil predominance or a 
granulomatous response. Allergic mucin is absent on 
hematoxylin-eosin-stained material. 
5. No histologic evidence of fungal invasion of mucosa, 
associated blood vessels, or underlying bone visualized 
microscopically on Gomori methenamine silver or other 
special stains for fungus. 
On radiology assessment, “calcifications” and erosion of the 
inner wall of the sinus are the two features most diagnostic for 
fungal ball(221). Although the term “calcifications’ is used, they 
are probably more accurately referred to do as hyperdensities 
as they represent trace metal elements in the fungus. The 
hyperdensities are seen in the majority and reported to affect 
52-77%(206, 222, 223). On cone beam tomography, the hyperdensities 
are less commonly seen(224). On magnetic resonance imaging, 
fungal ball appears hypointense on T1-weighted images (64.7%) 
and hyperintense on T2-weighted images (88.6.2%) even in 
patients without X-ray hyderdensities(223).
Single sinus AFRS might be similar, and some historical 
publications have used the term mycetoma to describe classic 
AFRS(225) and thus the absence of a dominant eosinophil 
response, eosinophil mucin and a widely expanded sinus is still 
important, as per the above criteria, to separate fungal ball from 
isolated AFRS.
Isolated maxillary or sphenoid sinus opacification is a marker 
of neoplasia in 18% and malignancy in 7-10% of patients 
presenting with these radiologic findings. Clinicians should be 
wary of conservative management given the high incidence 
of neoplasia and consider a lower threshold for early surgical 
intervention(210). Odontogenic rhinosinusitis can present with 
concomitant fungal ball or isolated maxillary sinus disease. 
However, in studies on single sinus opacification, 10-45% of 
isolated sphenoid sinus cases and 0-55% of isolated maxillary 
sinus cases are fungal balls (unpublished data)(210).
Isolated maxillary or sphenoid sinus opacification 
is a marker of neoplasia in 18% and malignancy 
in 7-10% of patients presenting with these 
radiologic findings so clinicians should be wary of 
conservative management.
8.6.2.5. Treatment
Surgery is the primary treatment for fungal balls. Although 
surgery was once thought to be ‘curative’ for fungal ball(205), 
there is evidence that persistent inflammation and recurrence 
can occur.  Asymptomatic disease does not mean that surgery 
should be avoided(226). In some studies, 16% of sphenoid fungal 
balls were associated with orbital infective complications 
and the loss of bone wall architecture was associated with 
this complication(208). Additionally, intracranial infective 
complications can also be seen(227, 228). Although, fungal ball 
may follow an indolent course with disease present for many 
years(223), the natural history of the condition is that low grade 
inflammation occurs, expansile changes are seen in the majority 
and infective complications can occur(229).
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8.6.2.5.1. Oral corticosteroids
No data or studies have suggested a role for oral corticosteroids 
but they are often given as part of the initial perioperative care 
in the initial surgical removal. 
8.6.2.5.2. Topical corticosteroids
No data or studies have suggested a role for topical 
corticosteroids but it is acknowledged that INCS are often given 
as part of the perioperative care after the initial surgical removal. 
8.6.2.5.3. Allergen immunotherapy (fungal or other)
Immunotherapy does not play a role in the management 
of fungal ball and no studies have reviewed their use. Nor is 
inhalant allergy considered to play a role in the etiology of sinus 
fungal balls.
8.6.2.5.4. Anti-fungals – topical or systemic 
Although it is recognized that fungal balls will develop in 
patients who might eventually be diagnosed with invasive 
fungal rhinosinusitis, it is their host immune factors that 
appear to predict this(203). There are no controlled studies to 
provide data to support the use of antifungals in the absence of 
invasion.
8.6.2.5.5. Other medical interventions
Saline irrigations, concomitant use of antibiotics and intranasal 
corticosteroids are all reported in the perioperative care of sinus 
fungal ball, but no published data supports their use.
8.6.2.5.6. Surgery
Surgery is the mainstay of management of fungal ball. Most 
authors promote a simple antrostomy, and many reports have 
short-term follow up. However, a recurrence of the fungal 
ball itself has been reported in 4% and 3.2% in two studies 
with longer follow up(207, 230). Additionally, some authors 
have reported 50% of post treated fungal ball patients had 
inflammation and 14% residual debris with a simple antrostomy, 
whereas when an antrostomy was combined with an inferior 
meatal window, none had residual or inflammation(231). 
Persistent dysfunction of the sinus cavity with mucostasis 
was reported to be as high as 18%(217) and some authors have 
proposed a medial maxillectomy for some maxillary fungal ball 
patients,  especially in a smaller contracted sinus and when 
there are  concerns of poor function(232). Some studies suggest 
allergy and polyps are poor prognostic factors post-surgery(233) 
but there is some uncertainty of the true conditions being 
treated in this study.
8.6.3. Invasive fungal rhinosinusitis
8.6.3.1. Terminology
Invasive fungal rhinosinusitis is a disease almost exclusively 
of immunocompromised patients, and defined as any state in 
which fungal hyphae can be seen ‘within’ the mucosal tissue, 
demonstrating classic angio-invasion or other infiltrative 
patterns(234). Although originally several forms of invasive disease 
were described, granulomatous, chronic and fulminant, they all 
potentially represent an immunocompromised host reaction to 
the fungus(220). Due to the variability in chronicity of the disease, 
some have divided it into acute (less than four weeks) or chronic 
(greater than four weeks)(235). The type of fungus and the degree 
of host immune suppression is likely to create these differences 
and thus for the purpose of classification they are all forms of 
‘invasive fungal rhinosinusitis’. 
Invasive fungal rhinosinusitis is a disease almost 
exclusively of immunocompromised patients, and 
defined as any state in which fungal hyphae can 
be seen ‘within’ the mucosal tissue.
8.6.3.2. Epidemiology and predisposing factors 
Overall, diabetes (50%) and haematologic malignancy (40%) 
account for 90% of the immunosuppression reported in over 
800 invasive rhinosinusitis patients(236). Although neutropenia 
is often considered the most significant risk factor, patients 
with HIV/AIDS, iron overload, protein-energy malnutrition, or 
transplant patients on azole prophylaxis are also at risk(237).
Although invasive disease has been reported in patients 
without immunosuppression(238, 239) these studies were either 
historical or had too few survivors to evaluate whether 
immunosuppression was truly excluded. A subtype of chronic 
invasive granulomatous rhinosinusitis has been described in 
otherwise healthy individuals. There are reports of such cases, 
often in older immunocompetent patients(240, 241)  but are more 
prevalent from India(242-244). Although invasive disease may occur 
in the absence of a well-defined immune suppression, it is likely 
to be uncommon. 
8.6.3.3. Pathophysiology 
Invasive fungal rhinosinusitis is any state in which fungal 
hyphae can be seen ‘within’ the mucosal tissue, demonstrating 
classic angio-invasion or other infiltrative patterns. The most 
common causative pathogens are the Zygomycetes (Rhizopus, 
Mucor, Rhizomucor) and the Aspergillus species. The phylum 
Zygomycota are part of the class Zygomycetes and order 
Mucorales and thus the term ‘mucormycosis’ is occasionally 
used. The disease process is characterized by angioinvasion of 
fungal hyphae (fungi within vessel walls and vascular lumen) 
producing thrombosis and mucosal infarction and subsequent 
tissue necrosis While a low grade sub-mucosal granulomatous 
inflammation with diffuse fibrosis and with limited fungal 
elements, has been described in immunocompetent hosts, 
this is mainly limited to India(243) . Aspergillus sp. have a uniform 
width, acute-branching septate (dichotomous) hyphae, often 
described as branching at 45 degrees, whereas Zygomycetes 
have non-septate hyphae with wide angle branching.
8.6.3.4. Diagnosis and differential diagnosis  
The two most important diagnostic criteria for any form of 
‘invasive’ fungal disease are(220):
1. Rhinosinusitis confirmed by radiological imaging (although 
this can be minimal) or show tissue destruction(245, 246) and 
2. Histopathological evidence of hyphal forms within sinus 
mucosa, submucosa, blood vessels, or bone.
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There is no pathognomonic symptom for invasive fungal 
disease, but facial pain, facial swelling, nasal obstruction and 
fever, are most common and present in 50–65% of patients(236, 
247). Numbness of the face or palate, ophthalmoplegia (51%) 
and/or cerebral involvement can follow quickly thereafter.
The endoscopic appearance of necrosis is a hallmark sign. 
The middle turbinate is classically involved, as this is where 
aeroallergen deposition is thought to occur,  but palatal, inferior 
turbinate and lateral wall necrosis is described(248). Endoscopy is 
essential in the setting where radiologic changes are minimal.
The endoscopic appearance of necrosis is a hallmark sign
Unilateral disease on radiology is typical(247, 248).Loss of contrast 
enhancement on magnetic resonance imaging is more sensitive 
(86%) than computerized tomography (69%) in detecting 
invasive fungal disease(249). Frozen section analysis of tissue 
during surgery(250, 251) and in situ hybridization have both been 
used to define invasive disease(252).
Serum analysis via PCR (serum or whole blood) and/or 
galactomannan for invasive aspergillosis can be useful. When 
both PCR and galactomannan for aspergillus  were negative, 
the negative predictive value was 100% and, when both 
tests were positive, the positive predictive value was 88%(253). 
Galactomannan and (1,3)-beta-D-glucan are components of 
the Aspergillus cell wall and are therefore helpful in confirming 
a diagnosis of invasive Aspergillosis. Galactomannan and 
(1,3)-beta-D-glucan each have a sensitivity and specificity of 
around 80% in the detection of invasive aspergillosis from all 
body sites(253).
8.6.3.5. Treatment
The three principals consistently reported in studies included:
1. Systemic antifungals therapy should be started
2. Patients should undergo, at least endoscopic surgical 
debridement of necrotic sinonasal tissue
3. The patient’s immune suppression should be reduced 
when feasible
A large systematic review has been performed, 52 studies 
and 807 patients, 398 of whom were used for prognostic 
factor analysis. They reported an overall survival rate of about 
50%, with the following factors predicting worsened survival: 
advanced age, aplastic anaemia (20%), renal / hepatic failure 
(24%), intracranial and cavernous sinus extension (25%), and 
neutropenia (29%). They reported improved survival in patients 
who were diabetic (50%), received liposomal amphotericin 
B(60%) or underwent open (54%) or endoscopic sinus surgery 
(ESS) (64%)(236). However, survival and outcomes from invasive 
fungal rhinosinusitis remained relatively stable, over the past 20 
years,  with survival at 50-60%(236, 254).
Patients should undergo, at least endoscopic 
surgical debridement of necrotic sinonasal tissue.
Prognostic factors associated with worse survival included: 
haematologic malignancy (hazard ratio [HR]=3.7); recent 
chemotherapy (HR=2.3); recent bone marrow transplant (BMT) 
(HR=2.5;); and infection with atypical fungi (HR=3.1). Improved 
survival in univariate analysis included increasing A1c% (HR=0.7) 
and surgical debridement (HR=0.1). One third of patients with 
a haematologic malignancy and invasive fungal rhinosinusitis 
had an absolute neutrophil count (ANC) >1000 at the time 
of diagnosis(247). The role of an absolute neutrophil count as a 
prognostic factor is still debated(247, 255). 
8.6.3.5.1. Oral corticosteroids
Oral corticosteroids are generally avoided as part of the 
treatment in invasive fungal disease due the potential additive 
immunosuppressive effects. However, their use may be 
balanced by the need to reduce oedema associated with orbital 
or cerebral involvement.
8.6.3.5.2. Topical corticosteroids
Topical corticosteroids do not play a role in the management of 
invasive fungal rhinosinusitis and no studies have review their 
use. 
8.6.3.5.3. Allergen immunotherapy (fungal or other)
Immunotherapy does not play a role in the management of 
invasive fungal rhinosinusitis and no studies have reviewed their 
use.
8.6.3.5.4. Anti-fungals – topical or systemic 
Although patients with invasive fungal rhinosinusitis need 
surgical debridement of involved tissue, medical therapy 
is critical for treatment of invasive fungal rhinosinusitis. 
Amphotericin and the liposomal version have been shown 
to have positive predictive value to survival and time to 
commencement associated with survival(236). In the setting 
of Aspergillus species, voriconazole maybe superior 
over amphotericin for aspergillosis(256) and voriconazole 
is recommended(257). The newer Azoles may have better 
bioavailability and less toxicity from studies on invasive 
aspergillosis that includes invasive fungal rhinosinusitis(258).
Transcutaneous retrobulbar injection of amphotericin B 
has been reported. Kalin et al. summarized the six cases 
documenting its use(259). The amount of amphotericin injected 
ranged from 1-1.5 ml at concentrations ranging from 1-3.5 mg/
ml on a daily to weekly basis. Two patients died for reasons not 
directly related to fungal infection, but visual acuity stabilized or 
improved in all cases. 
Conclusions Level
Systemic anti-fungal therapies are an essential part 
of managing invasive fungal disease
1c
Transcutaneous retrobulbar injection of 
amphotericin B may be beneficial in orbital 
involvement in invasive fungal rhinosinusitis
4
8.6.3.5.5. Other medical interventions
Immune stimulating interventions have variably been reported 
and in multivariate analyses were associated with a 70% 
reduction in mortality at one month(247). Hyperbaric oxygen has 
been used with some evidence for the diabetic patient(260, 261) 
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and there is some evidence for iron chelating agents (desfirozx)
(262). These studies include invasive fungal rhinosinusitis within a 
population of patients with invasive soft tissue fungal disease. 
8.6.3.5.6. Surgery
Multiple studies have shown that ESS is an independent positive 
prognostic factor for survival(236, 247, 248, 263).
The extent of surgical resection is largely guided by 
preoperative imaging and the tissue appearance during surgery. 
Intraoperative frozen section has been employed to guide 
surgical debridement. Although frozen section has an excellent 
PPV (100%) for invasive disease, the NPV is 70%, so a negative 
result does not guarantee a clear margin(250, 264).
Timing of surgery is less important than the initiation of 
antifungal therapy(265) but delay of surgery >30 days of diagnosis 
predicted a poorer outcome. 
Managing the orbit
At the time of diagnosis, 50-60% of patients will have orbital 
involvement(234, 236).  In 15 patients with orbital involvement, 
survival was similar to patients with disease limited to the 
sinuses, and only one of those patients had an exenteration(263). 
A meta-analysis of 224 patients with orbital mucormycosis, 
reported no survival benefit from orbital exenteration except in 
patients with fever over 38,6ºC (101.5 8F)(266). Similarly, Turner et 
al. found a similar outcome with orbital removal and survival(236) 
but authors from both studies acknowledge the bias that exists 
in assessing these outcomes as those patients with significant 
orbital disease were likely to have been offered surgical 
removal whereas limited disease was conservatively managed.  
Transcutaneous injection of amphotericin remains an option as 
described previously. Of note, in a study on patients only with 
orbital involvement, 2/14 patients survived and both had orbital 
removal(238). Persistent enhancing tissue is a marker of infected 
tissue and thus many suggest conservative treatment when 
enhancement can still be seen on imaging.
Conclusion Level
Surgical debridement is an essential part of invasive 
fungal rhinosinusitis management
3a
8.6.4. Allergic fungal rhinosinusitis (AFRS)
8.6.4.1. Terminology
Allergic fungal rhinosinusitis (AFRS) is a subset of polypoid 
chronic rhinosinusitis that is characterized by the presence of 
eosinophilic mucin with non-invasive fungal hyphae within the 
sinuses and a Type I hypersensitivity to fungi. It was originally 
described by Safirstein(267)  and Katzenstein(268), but some 
clinicians who work in parts of the world where AFRS is not 
so common, have questioned whether the condition really 
exists as a separate clinical entity or is part of eosinophilic CRS 
or CRSwNP. Although there is some controversy about the 
definition of AFRS, and even whether it is a distinct clinical 
phenotype of CRSwNP, most terminology groups define it 
as a unique  and distinct phenotype(269, 270). Bent and Kuhn 
included IgE sensitization as an inclusion criteria in their 
original description(271). AFRS is, for the most part, considered 
an IgE mediated mucosal hypersensitivity directed against 
fungal antigens deposited on sinus mucosa(272). The EPOS 
steering group discussed whether the term ‘eosinophilic 
fungal rhinosinusitis’ would be a better umbrella term for 
fungal rhinosinusitis but it was agreed that ‘allergic fungal 
rhinosinusitis’ should be retained as the principle term due to 
common usage, recognising that not all cases have evidence of 
an allergic reaction to fungi.
Allergic fungal rhinosinusitis (AFRS) is a subset 
of polypoid chronic rhinosinusitis that is 
characterized by the presence of eosinophilic 
mucin with non-invasive fungal hyphae within the 
sinuses and a Type I hypersensitivity to fungi.
8.6.4.2. Epidemiology and predisposing factors 
AFRS accounts for about 5% to 10% of CRS cases(273, 274). Patients 
presenting with AFRS do so at a younger age than other forms 
of CRS and with a greater proportion of females(275). AFRS also 
has an association with a lower socioeconomic demographic, 
African Americans (in North America) and those living in warmer 
climates near the coast(276, 277). Atopy is a pre-defining feature of 
patients with AFRS and concomitant allergic disease, such as 
allergic rhinitis and childhood onset asthma, are common in this 
group. 
8.6.4.3. Pathophysiology 
The defining pathophysiology in AFRS is sensitization to the 
causative fungus as a primary and requisite feature along with 
mucin colonized with non-invasive fungus(278). Although fungal 
sensitization may exist in CRSwNP, typically IgE levels are higher 
in AFRS(273, 274) studies that define AFRS as a unique phenotype in 
CRSwNP (Table 8.6.1.).
8.6.4.4. Diagnosis and differential diagnosis  
Ideally all five of the major criteria in the original Bent-Kuhn 
diagnostic criteria should be met to make the diagnosis as three 
of the five are common in most CRSwNP. These major criteria 
consist of the following(271):
1. Nasal polyposis;
2. Fungi on staining;
3. Eosinophilic mucin without fungal invasion into sinus 
tissue;
4. Type I hypersensitivity to fungi and;
5. Characteristic radiological findings with soft tissue 
differential densities on CT scanning and unilaterality or 
anatomically discrete sinus involvement.
The minor criteria include bone erosion, Charcot Leyden 
Crystals, unilateral disease, peripheral eosinophilia, positive 
fungal culture along with prior criteria from DeShazo(279):
1. the demonstration of the characteristic eosinophil-rich 
allergic mucin visually or histopathologically(280);
2. a positive fungal stain or culture from the sinus at 
surgery;
3. the absence of immunodeficiency or diabetes;
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Table 8.6.1. compares AFRS with the broader group of eCRS or 
CRSwNP patient features. 
Clinically, the younger allergic patient with unilateral disease 
and the typical allergic “peanut-butter-like” mucin is classic and 
this mucin is different from the ‘chewing gum’ mucin commonly 
associated with eosinophilic CRS(281, 282).
Imaging with computed tomography shows densely packed 
hyperdensities in the sinuses with expansion and erosion of the 
bony walls. These are a combination of the various metals (e.g. 
iron, magnesium, and manganese) concentrated by the fungal 
organisms as well as the low water and high protein content 
of the mucin(283). On magnetic resonance imaging, signal voids 
occur on both T1 and T2 sequences. The high protein and low 
free water content in allergic mucin along with the presence of 
calcium, air, and paramagnetic metals, such as iron, magnesium, 
and manganese creates this classic pattern(283) and is not from 
ferromagnetic elements, as previously speculated(284).
Imaging with computed tomography shows densely packed 
hyperdensities in the sinuses with expansion and erosion of the 
bony walls.
AFRS has these defining features: 1) the fungi never invade 
the sinus tissue, and 2) the mucin of AFRS is the product of an 
allergic hypersensitivity reaction to the fungi as opposed to a 
simple overgrowth of mycelial elements as is seen in fungus 
balls.
8.6.4.5. Treatment
Unlike the management of classical CRS, the foundation of 
AFRS treatment is surgery. The vast majority of clinical studies 
in the AFRS literature indicate that medical therapy alone is 
usually ineffective in alleviating symptoms and that surgical 
intervention, alone or in combination with medical therapy, 
leads to improved clinical outcomes. Treatment of AFRS almost 
always requires surgical debridement of the involved sinuses, 
thus removing the antigenic stimulation for AFRS patients, but 
also provides wider access for surveillance, clinical debridement, 
and application of topical medication. Oral corticosteroids 
decrease recurrence after surgery, but other adjunctive 
pharmacologic agents, including topical and oral antifungal 
agents, have less evidence base for effectiveness.
Most reports on treatment options for AFRS are combined 
into larger series addressing CRSwNP patients and this issue is 
Table 8.6.1. Studies that define AFRS as a unique phenotype in CRSwNP.
AFRS CRSwNP Ref
Demographics Warmer coastal climates
Younger
Female preponderance
Older age at presentation 
unless CCAD
Lu-Myers et al. 2015(275)
Miller et al. 2014(277)
Wise et al. 2008(276)
Ferguson et al. 2000(484)
Comorbidities AR
Asthma (less)
Adult onset asthma more 
severe
Manning et al. 1998(485)
Associated ABPA Uncommon Rare Shah et al. 2001(486)
Secretions “Peanut butter” mucin “Chewing gum” mucin
Lund Mackay scores Very high High
CT changes Hyper attenuation
Unilateral
Less likely to have bone erosion Ghegan et al. 2006(487)
Fungal colonization Easily identified
Aspergillus species most common (others 
include: Bipolaris, Curvularia)
Alternaria and Cladosporium 
species
Granville et al. 2004(488)
Ferguson et al. 2000(484)
Immune status Atopic Allergen sensitization 
approaches background rate
Fungal sensitization Multiple fungi
IgG to fungi more common 
Greater fungal specific IgE
Less common Hutcheson et al. 2010(489)
Stewart et al. 2002(490)
Immunohistochemistry Fungal specific IgE present in tissues Poorly selected IgE in mucosa Collins et al. 2004(491)
Pratt et al. 2010(492)
Serum IgE Higher (500 IU/mL) Variable Hutcheson et al. 2010(489)
Bakhshaee et al.(274)
Telmesani et al. 2009(493)
Staph. aureus co-infection High Less common Clark et al. 2013(494)
Dutre et al. 2013(495)
T cell responses CD4+ only Both CD4+ and Cd8+ Pant et al. 2014(496)
Gene expression Lacking Cathepsin B,
sialyltransferase 1, GM2 ganglioside activator 
protein, and S100
calcium-binding protein
Broad activation Orlandi et al. 2007(497)
Serum proteomics Spectrometry able to identify patients with 
AFRS with 84% sensitivity and 90% specificity 
to CRSwNP
Broad Das et al. 2008(498)
HLA-MHC class II associations HLA-DQB1*03 common Less common Schubert et al. 2004(499)
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Table 8.6.2. Systemic corticosteroids for the treatment of patients with AFRS.
Study Methods Participants Interventions Outcomes Results
Prasad et al. 
2017(286)
RCT 60 AFRS post-
surgery
	· 6 month postoperative corticosteroid use 
(prednisolone, 1 mg/kg/day, for 1 week 
preoperatively and 0.5 mg/kg/day for 4 
weeks, oral prednisolone 0.4 mg/kg/day for 
the next 4 weeks, tapered to 0.2 mg/kg/day 
for the next 2 months and to 0.1 mg/kg/day 
for the last 2 months 
	· 2 month taper (prednisolone, 1 mg/kg/day, 
for 1 week preoperatively and 0.5 mg/kg/
day for 4 weeks postoperatively)
	· Recurrence 	· 6 month 
corticosteroid use 
associated with less 
recurrence
Rupa et al. 
2010(285)
RCT 24 AFRS post-
surgery
	· Oral prednisolone (50mg qd x 6 weeks, then 
additional 6 week taper) 
	· Placebo
	· Both groups used itraconazole orally and 
INCS
	· Symptom scores 
at 6 weeks and 12 
weeks
	· Endoscopic scores
	· Adverse effects
	· Corticosteroid 
group significantly 
improved over 
placebo
Ikram et al. 
2007(287)
Retrospective 
cohort
63 AFRS post-
surgery
	· Postoperative corticosteroids (n=30)
	· No post-operative corticosteroids (n=33)
	· Recurrence (at 
2yrs post-surgery)
	· Favours 
corticosteroid use 
postoperative 
with lower 
recurrence15.2% vs. 
50%
covered elsewhere in this document. It is, therefore, difficult to 
discern if there are varying effects in the AFRS population as 
opposed to the entire CRSwNP population. In general, medical 
therapies have been divided into oral and topical steroids, oral 
and topical anti-fungals, immunotherapy and others. In all but 
the mildest cases of AFRS, it is felt that medical therapy alone 
without surgical intervention, is not effective in the long term, 
thus most efficacy studies examining medical treatments have 
been performed postoperatively.
Medical therapy alone is usually ineffective in alleviating 
symptoms and that surgical intervention, alone or in 
combination with medical therapy, leads to improved clinical 
outcomes
8.6.4.5.1. Oral corticosteroids
Oral corticosteroid studies specific to AFRS patients have 
generally been conducted in the postoperative setting where 
benefit has been demonstrated.  There are several controlled 
studies (Table 8.6.2.).  In a randomized double blinded, 
placebo-controlled trial of n=24 AFRS patients examining the 
effectiveness of postoperative oral steroids, as well as the side 
effects, patients received oral prednisolone (50mg qd x 6 weeks, 
then additional six week taper) or placebo for two weeks after 
surgery(285). All patients received fluticasone nasal spray and oral 
itraconazole for 12 weeks. At 12-week follow up, all 12 patients 
in the corticosteroid group were asymptomatic and only one 
in the placebo arm. All 12 patients in the corticosteroid group 
suffered some weight gain, five developed Cushingoid features 
and one developed steroid induced diabetes mellitus. 
In what is best described as nonblinded randomized trial, Prasad 
et al. describe the management of 30 patients with AFRS with 
six month postoperative corticosteroid use (prednisolone, 1mg/
kg/day, for one week preoperatively and 0.5mg/kg/day for four 
weeks, oral prednisolone 0.4mg/kg/day for the next four weeks, 
tapered to 0.2mg/kg/day for the next two months and to 0.1mg/
kg/day for the last two months) compared to a group of 30 AFRS 
patients tapering within two months (prednisolone, 1mg/kg/
day, for one week preoperatively and 0.5mg/kg/day for four 
weeks postoperatively). This study concluded that recurrence 
and further surgery was less likely in the six month group(10% 
vs. 30%)(286). See Figure 8.6.2. for the combined odds ratio of 
prevention of recurrence. 
In a retrospective cohort by Ikram et al. a two year follow-
up of AFRS patients treated with and without postoperative 
Figure 8.6.2. Forrest plot of the effect of oral corticosteroids for the prevention of recurrence in AFRS.
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corticosteroid demonstrated a 15.2% vs. 50% recurrence along 
with a standardized topical corticosteroid regime(287). Kinsella 
et al. reported a similar finding in 25 patients treated and 
none of the eight patients with recurrent disease were treated 
with postoperative corticosteroid(288). Schubert et al. utilized 
a minimum two-month postoperative corticosteroid regime 
in a case series of 67 AFRS patients and demonstrated benefit 
in those utilizing therapy up to 12 months. Those on oral 
corticosteroid had the best outcomes with reduced recurrence 
and prolonged the time to revision surgery(289).
Landsberg et al. demonstrated that preoperative corticosteroids 
given at 1mg/kg for 10 days prior to  surgery, had a more 
dramatic effect in AFRS compared to CRSwNP patients, with 
near normalization of the mucosa in the AFRS group at the time 
of surgery and a similar response on computed tomography(290). 
Similarly, Woodworth et al. demonstrated a significant reduction 
in AFRS patients with postoperative corticosteroid over three 
weeks compared to eCRS and control patients(291). A number of 
other non-placebo controlled case series have been reported 
with highly variable dosing protocols and durations, but 
generally reporting a positive effect when using postoperative 
oral corticosteroids(272, 292).
Conclusions Level
Preoperative systemic corticosteroids are likely to 
reduces AFRS mucosa inflammation and radiologic 
scores
2b
Postoperative systemic corticosteroids improve 
short-term outcomes in AFRS 
1b
Postoperative systemic corticosteroid  are likely to 
reduce long term recurrence in AFRS
2b
8.6.4.5.2. Topical corticosteroids
AFRS patients have been included in the “eCRS or CRSwNP” 
subgroups of other studies on intranasal corticosteroids with 
a general consensus that they are beneficial, safe and well 
tolerated(293). There are several studies that assess INCS in a 
dedicated AFRS population. A case-controlled study of surgery 
alone vs. surgery plus the combination of postoperative oral and 
topical steroid spray in AFRS patients demonstrated benefits 
for the combined therapy at a minimum of two year follow 
up, as 50% of the no steroid group recurred, while only 15% of 
the combined steroid group recurred(287). Another study of low 
quality but an RCT, compared 34 postoperative AFRS patients 
which were randomized into three arms: (1) itraconazole + 
nasal douche (n=11); (2) topical nasal steroid + nasal douche 
(n=12); and (3) nasal douche alone (n=11). Normal mucosa was 
observed similarly between INCS and saline only groups (16 vs. 
14%, p=0.22). The type of topical steroid used was not defined 
and the study was both underpowered and incompletely 
reported or analyzed(294).
Dai et al. describes a study of 30 AFRS patients, randomized 
in a unblinded controlled study, to nebulized budesonide or 
topical nasal sprays. Nebulized budesonide was more effective 
in preventing recurrence compared to intranasal corticosteroid 
spray (26.7% vs. 0% , p=0.03)(295).
Several studies confirm that non-compliance with INCS is 
associated with recurrence in AFRS (Table 8.6.3.)(286, 287).
Conclusions Level
Non-standard INCS (nebulization) is better than 
simple INCS sprays
1b
INCS of any type may be useful in controlling AFRS 3b
Table 8.6.4. Immunotherapy for the treatment of patients with AFRS.
Study Methods Participants Interventions Outcomes Results
Bassichis et 
al. 2001(298)
Retrospective 
cohort
60 AFRS post-
surgery 
	· Immunotherapy with standard care 
(n=36)
	· Standard care alone (n=24)
	· Immunotherapy to both fungal and non-
fungal antigens (minimum 12mths)
	· Revision surgery
	· Clinic intervention
	· Less revision surgery 
(11% vs. 33%) and less 
clinic visits in the IT 
treated arm (4.79 vs. 
3.17)
Folker et al. 
1998(300)
Retrospective 
cohort
22 AFRS post-
surgery
	· Immunotherapy with standard care 
(n=11)
	· Standard care alone (n=11)
	· Immunotherapy to both fungal and non-
fungal antigens (mean 33 months)
	· Chronic Sinusitis 
Survey
	· Kupferberg grades
	· Corticosteroid use 
(oral and topical)
	· All outcomes better in 
the IT treated group 
Table 8.6.3. Nasal corticosteroids for the treatment of patients with AFRS.
Study Methods Participants Interventions Outcomes Results
Dai et al. 
2017(295)
RCT 30 AFRS 
post-surgery 
	· Budesonide transnasal nebulization (n=15)
	· Topical nasal steroids (n=15)
	· Symptoms
	· Lund Mackay scores
	· Kupferberg grades 
	· Adverse events
	· Nebulised budesonide 
superior to INCS spray in 
reduction of recurrence 
(27% vs. 0%)
Gupta et al. 
2007(294)
RCT 34 AFRS 
post-surgery
	· Oral itraconazole (200mg BD) and nasal douche 
(n=11)
	· Topical steroids (budesonide 100mg BD) and 
nasal douche (n=12)
	· Nasal douches only (n=11)
	· Kupferberg grades 	· No differences between 
the groups 
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Table 8.6.5. Oral antifungals for the treatment of patients with AFRS.
Study Methods Participants Interventions Outcomes Results
Verma et al. 
2017(307)
RCT 100 AFRS 
assessed post-
surgery
	· Itraconazole (4 weeks) preoperative (n=25)
	· Itraconazole (4 weeks) post-operative (n=25)
	· Surgery with antifungal therapy (n=50)
	· Prednisone 1mg/kg on 6 week taper and nasal 
douching to all groups
	· Itraconazole 200mg (5mg/kg in children) 
twice daily for 2 days followed by 100mg (3 
mg/kg in children) twice daily for remaining 4 
weeks therapy
	· Symptoms
	· Kupferberg 
grades
	· Radiology 
(LM scores)
	· All assessed 
at 24 weeks
	· Although both preoperative 
and postoperative itraconazole 
showed significant improvement 
in the SNOT, LM, and Kupferberg’s 
grades in the follow-up period, 
the difference was only seen 
between no antifungal and the 
preoperative antifungal group 
but included endoscopy and 
radiology but SNOT scores were 
similar.
Rojita et al. 
2017(308)
RCT 60 AFRS post-
surgery
	· Oral corticosteroid (prednisone 30mg/daily 
for 1mth) then INCS to 6 months
	· Itraconazole 100mg bd for 6 months
	· Symptoms
	· Kupferberg 
grades
	· Serum IgE
	· Recurrence
	· No difference between groups
	· Only 23 and 26% of patients had 
normal mucosa at 6mths
Nikakhlagh 
et al. 
2015(500)
RCT 50 AFRS post-
surgery
	· Itraconazole 100mg BD (n=25)
	· No antifungals (n=25)
	· Both groups received post-surgical 
corticosteroid and INCS spray (not defined)
	· Recurrence 	· No evidence of recurrence higher 
in anti-fungal group (44% vs. 
24%) but no statistical analysis 
performed
Khalil et al. 
2011(309)
RCT 50 AFRS post 
surgery 
	· Oral itraconazole (n=10)
	· Fluconazole nasal spray (n=10)
	· Oral itraconazole and Fluconazole nasal spray 
(n=10)
	· Fluconazole nasal irrigation (n=10)
	· No antifungal therapy (n=10)
	· Recurrence 	· Oral itraconazole did not show 
benefit over other groups and 
similar to controls (66.7% vs. 75%)
Gupta et al. 
2007(294)
RCT 34 AFRS post- 
surgery
	· Oral itraconazole (200mg BD) and nasal 
douche (n=11)
	· Topical steroids (budesonide 100mg BD) and 
nasal douche (n=12)
	· Nasal douches only (n=11)
	· Kupferberg 
grades
	· No differences between the 
groups 
Kupferberg 
et al. 
1997(292)
Retro-
spective 
cohort
26 AFRS Post 
surgery
	· No treatment (n=11);
	· Oral corticosteroids alone (n=10); (40mg × 4 
days, then 30mg × 4 days, followed by 20mg 
per day until first month)
	· Oral corticosteroids and oral antifungals (not 
described) (n=2)
	· Oral antifungals alone (n=3)
	· Symptoms
	· Kupferberg 
grades
	· 33% of antifungal alone patients 
had benefit but corticosteroid 
groups did best.
Chan et al. 
2008(501)
Case 
series
32 AFRS post-
surgery and 
refractory
	· Itraconazole 300mg daily tapered over 3 mths 	· Symptoms
	· Kupferberg 
grades
	· Symptoms improved
	· Endoscopic scores similar
Seiberling 
et al. 
2009(304)
Case 
series
10 AFRS and 
13 AFRS 
(without 
atopy) post 
surgery
	· Itraconazole 100mg twice daily for 6 months 	· Symptoms
	· Endoscopy 
scores
	· 83% improvement in symptoms 
and associated endoscopic 
improvement
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Study Methods Participants Interventions Outcomes Results
Rains et al. 
2003(305)
Case 
Series
139 AFRS 
post-surgery
	· Itraconazole 400mg/day for 1 month, 300mg/
day for 1 month, 200mg/day for 1 month or 
until clear by endoscopy
	· All patients give oral prednisone (30mg/day 
for 3 days, 20mg/day for 3 days, and 10mg/
day for 7 days
	· INCS from two weeks post-surgery
	· Recurrence 	· Improved by 50% with recurrence 
and 20% with further surgery
Table 8.6.6. Topical antifungals for the treatment of patients with AFRS.
Study Methods Participants Interventions Outcomes Results
Khalil et al. 
2011(309)
RCT 50 AFRS post surgery 	· Oral itraconazole (n=10) daily 3 months
	· Fluconazole nasal spray (n=10) bd for 3 
months
	· Oral itraconazole and fluconazole nasal 
spray (n=10) both daily for 3 months
	· Fluconazole nasal irrigation once/week for 
6 weeks (n=10)
	· No antifungal therapy (n=10)
	· Recurrence 	· Fluconazole spray 
(10% recurrence). 
Combined (14.3%) 
compared to 
oral and control 
(66.7% vs. 75%)
	· Not statistically 
significant
Jen et al. 
2004(315)
Case series 16 AFRS post surgery 	· Fluconzole nasal spray (100mg/500ml, 5 
sprays twice daily) (3mths)
	· Oral corticosteroid 
	· Oral itraconzole
	· Symptoms 	· Stable or 
improvement in 
75%
	· Reduction in 
oedema seen in 
75%
8.6.4.5.3. Allergen immunotherapy (fungal or other)
Allergen immunotherapy (AIT) lends itself to placebo controlled 
randomized trials. However, there is a lack of such trials in 
AFRS. Several reviews have been undertaken, SCIT may have 
efficacy in the short-term(3-4 years), however, its long-term 
efficacy is unclear(296, 297). In a large retrospective series with 
immunotherapy for all fungal and non-fungal antigens, a 
3-4 year course of subcutaneous immunotherapy (SCIT) 
demonstrated benefit 12-26 months after discontinuation by 
less recurrence(298, 299) and decreased revision surgery in the 
immunotherapy group(298, 300). However, a subsequent study by 
the same group on a smaller subset of patients with longer term 
follow-up ranging from 46-138 months failed to demonstrate 
any benefit of SCIT with 60% of SCIT patients having normal 
mucosa or only mild oedema on endoscopy, while 100% of non-
SCIT patients had normal mucosa or mild oedema(301). This study 
was not randomized and obviously has the potential for bias in 
selecting treatment arms. Uncontrolled studies on sublingual 
immunotherapy have shown a benefit in IgE levels along with 
objective parameters(302). Unfortunately, the atopic nature of 
AFRS and the inclusion of Type 1 hypersensitivity makes the 
concomitant treatment of AR and asthma in AFRS patients a 
significant confounder and clouds the results(303).
The systematic review by Gan et al. identified two retrospective 
cohort studies, although misclassified as case-controlled, 
these studies were assessing patients with and without 
immunotherapy in a common population of post-surgical AFRS 
patients(293) and thus more accurately had a retrospective cohort 
design. Both studies conclude a benefit but the confounding 
factors mentioned above act as potential bias (Table 8.6.4.).
Conclusion Level
Immunotherapy to both fungal and non-fungal 
antigens in atopic individuals with AFRS is likely to 
improve symptoms and reduces revision surgery
2b
8.6.4.5.4. Anti-fungals – topical or systemic 
Limited data exists to support the use of oral antifungal agents 
in AFRS. Several case series have reported the benefits of 
systemic anti-fungal therapies in patients with AFRS(292, 304, 305). It 
is recognized that itraconzole has anti-inflammatory effects and 
thus a controlled study is required(306).
Two recent RCTs are noteworthy. The first, Verma et al., has 
a ‘no antifungal treatment’ control group(307). Although the 
authors found some evidence of reduction of inflammation on 
endoscopy and radiology, it was only between the preoperative 
treated and controls and symptom outcomes were similar. The 
other study by Rojita et al. found no difference between oral 
corticosteroid and itraconazole and declared them similar but 
a very low overall response rate was seen (<25%) and no nasal 
irrigation was used(308). The combine effect on symptoms after 
surgery did not favour antifungal therapy (Figure 8.6.3.) and the 
prevention of recurrence, including adjustment for those lost to 
follow-up, also did not support anti-fungal use (Figure 8.6.4.).
Three very low quality RCTs have been reported. The first 
Table 8.6.5. Oral antifungals for the treatment of patients with AFRS continued.
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assessing a two-month treatment of oral itraconazole (100mg/
twice a day) compared to no antifungal therapy and both 
groups received systemic and topical corticosteroids. This study 
demonstrated little benefit from the addition of antifungal 
therapy. However, although the authors suggested there ‘may 
be a benefit’, incomplete data reporting and a lack of statistical 
analysis does not support this and the outcomes appear similar 
between groups. A similar low quality RCT by Gupta et al. 
did not find any benefit in a study on 34 postoperative AFRS 
patients which were randomized into three arms: 1) itraconazole 
+ nasal douche (n=11); 2) topical nasal steroid + nasal douche 
(n=12); and 3) nasal douche alone (n=11). The authors 
acknowledge that the study may be underpowered(294). Kahil 
et al. reported an RCT of low quality in 50 patients in multiple 
treatment arms but included a ‘no-antifungal treatment’ 
group(309). This study lacked a statistical analysis and the control 
group and oral antifungal group were similar and had the 
highest recurrences between all groups.
The prior systematic reviews on antifungal treatment in CRS 
included a study assessing oral antifungal (terbinafine 625mg/
daily for six weeks). In this study AFRS patients were included 
within a broader CRS population(310). This study found no benefit 
and along with the data from the three RCTs of low quality it 
is difficult to make a judgement beyond the summary meta-
analysis and prior Cochrane review of topical and systemic anti-
fungal therapies in all CRS patients, which failed to demonstrate 
any benefit(311) (Table 8.6.5.). 
Topical antifungals
There are very few studies that assess topical anti-fungal therapy 
in a dedicated AFRS population. A systematic review of the topic 
by Mistry and Kumar(312) identified two RCTs that included AFRS 
within a broader CRS population but neither of them found 
convincing evidence of benefit(313, 314). Of the two studies with 
dedicated treatment groups in AFRS, one is a case series(315) and 
the other an underpowered RCT with incomplete reporting and 
analysis(309) (Table 8.6.6.).
Conclusions Level
Oral antifungals may reduce inflammation and 
recurrence in AFRS
1b
Oral antifungals may reduce recurrence in AFRS, 
although meta-analysis is negative
4
Oral antifungals do not improve symptoms in AFRS 4
Topical antifungal may be beneficial in AFRS 4
8.6.4.5.5. Other medical interventions
One single case study of leukotriene antagonist therapy in AFRS 
has been reported with benefit(316). 
A randomized, single-blind, prospective study of AFRS patients, 
who failed surgery and maximal postoperative medical 
management, used Manuka honey in one nostril. Overall, the 
group failed to demonstrate improvement(317).
There are 8 patients from a case report and a small case series 
on the successful use of omalizumab to treat AFRS refractory 
to surgery and oral corticosteroids(318). The seven (n=7) patients 
with AFRS and asthma on omalizumab had a seven month 
mean treatment regime with significant reduction in SNOT22 
and a 60% reduction in burden of inflammation on endoscopic 
scores(319). Both studies show a reduction in corticosteroid use 
and other therapies. 
Conclusions Level
Antileukotrienes may reduce  symptoms in AFRS 5
Manuka honey topically does not improve outcomes 1b(-)
Omalizumab (anti-IgE) may improve outcomes in 
AFRS
4
Figure 8.6.4. Forrest plot of the effect of oral antifungals for the prevention of recurrence in AFRS.
Figure 8.6.3. Forrest plot of the effect of oral antifungals for post-operative treatment of symptoms in AFRS.
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8.6.4.5.6. Surgery
There is a near unanimous recommendation that surgery 
is required as a first stage intervention for AFRS(278, 293, 320, 321). 
The goal of surgery requires surgical debridement of the 
involved sinuses, thus removing the antigenic stimulation. A 
retrospective review reported that incomplete removal of all 
fungal and eosinophilic mucin contributed to disease recurrence 
and the need for revision surgery(322). The recurrence rate in the 
surgery arm of the Ikram study (287) was 50% at two years. Overall 
recurrence rates after surgery have been reported from 10% to 
100%(320).
When skull base erosions occur with cranial neuropathies, 
surgery is the only successful intervention and spontaneous 
resolution has not been reported(323-326). Similarly, longterm 
correction of proptosis is not reported without surgery. Sinus 
surgery alone, to address the AFRS,  is usually all that is required 
and orbital reconstructions are not necessary(327). 
Treatment of the uninvolved contralateral side is controversial. 
A recent study reported that up to 30% of ‘normal’ contralateral 
sides become involved in the disease process. A recent study 
showed that up to 30% of “normal” contralateral sides become 
affected. However, the authors reported that the use of 
corticosteroid post-surgically dramatically reduced contralateral 
recurrence (OR 0.11, 95% CI 0.01-0.87, p value 0.01). If the 
contralateral side has early pre-operative symptoms and/or 
signs of inflammation radiologically then it was more likely to 
become involved (OR 3.49, 95% CI 1.19-10.22, p value 0.02)(328).
Conclusions Level
Surgery is required to resolve and treat AFRS 
including its complications
1c
Orbital reconstruction is not required in resolving 
proptosis
4
The contralateral sinus should be treated if there are 
radiologic changes of inflammation
4
8.7. Vasculitis, granulomatous diseases and their 
role in CRS
8.7.1. Vasculitis
8.7.1.1.  Classification
The classification of vasculitis is challenging due to the 
heterogenous nature of the conditions. In 2012 the Chapel Hill 
Consensus on vasculitis nomenclature was revised(329) (Table 
8.7.1.) but remains mainly based on pathology, specifically 
affected blood vessel size (large, medium and small) which has 
limited clinical applicability(330-332). The classification recognises 
primary and secondary vasculitis as well as single-organ 
disease. The latter category should not be confused with 
localised forms of vasculitis which may become systemic such 
as granulomatosis with polyangiitis (GPA) and eosinophilic 
granulomatosis with polyangiitis (EGPA). It may also be difficult 
to determine in GPA, EGPA, Behcet’s and Kawasaki disease 
which size of vessels are involved. Similarly, the use of the anti-
neutrophil circulating antibodies (ANCA) as a classification trait 
is not applicable to a subset of ANCA associated vasculitis with 
no detectable ANCAs. There are numerous other classification 
systems notably from the American College of Rheumatology, 
European Medicines Agency and the ACR/EULAR endorsed 
study to develop diagnostic and classification criteria for 
vasculitis (DCVAS)(333). ANCA-associated vasculitis includes GPA, 
EGPA and microscopic polyangiitis (MPA) and frequently affect 
the upper respiratory tract and specifically the sinonasal region 
where they may be mistaken for more common forms of chronic 
rhinosinusitis.
8.7.2.Granulomatosis with polyangitis (GPA)
Granulomatosis with polyangitis (GPA) (previously 
Wegener’s Granulomatosis) is defined as an idiopathic 
chronic inflammatory disease characterised by necrotizing 
granulomatous lesions and systemic vasculitis strongly 
associated with antineutrophil cytoplasmic antibodies (C-ANCA)
(334).
8.7.2.1. Epidemiology 
The true incidence of GPA has been underestimated in the past. 
Even with the advent of the ANCA test, many localised forms 
of the disease may go unrecognised. In Europe a prevalence 
of 23.7 per million has been reported and in the USA 30 per 
million(335). The overall incidence ranges from 2.9-12/106/year 
depending on the geographic region. 
8.7.2.2.  Pathophysiology
The pathophysiology of GPA is most likely autoimmune. A 
number of in vitro and in vivo studies have indicated that ANCA 
induces the systemic vasculitis(334) by binding to and activating 
neutrophils which causes the release of oxygen radicals, lytic 
enzymes and inflammatory cytokines. ANCA may also induce 
immune complex formation and may directly adhere to and kill 
endothelial cells thereby causing vasculitis(336). Whilst PR3-ANCA 
(proteinase-3) is highly specific for GPA, the initial trigger may be 
infection or other environmental factors possibly combined with 
a genetic susceptibility. Staphylococcus aureus colonization 
of the nose is found more frequently in GPA as compared to 
CRS and controls (72% v 28% v 25%)(337) and has been strongly 
implicated as a causative agent, especially in relapses(338, 339) 
which are reduced  by the use of an anti-staph agent such as 
trimethoprim/sulfamethoxazole(340). A large genome wide study 
on 1233 patients showed a strong association with HLA-DP and 
genes encoding alpha
1
 antitrypsin (SERPINA1) and proteinase 
3 (PRTN3)(341). A review by Relle et al.(342) also identified some 
susceptibility gene-CTLA4, PTPN22, COL11A2, SERPINA1 and 
MHCC class II gene cluster.
8.7.2.3. Diagnosis and differential diagnosis
Clinical (Table 8.7.2.)
The peak incidence is in the fourth to fifth decades, mean 50 
years but GPA can occur at any age (range 9-97 years)(343-345). 
Patients >65 years at onset have a different pattern of organ 
involvement, less upper respiratory tract involvement and 
higher morbidity and mortality(346, 347). Men and women seem 
equally affected and the vast majority are Caucasian (93%)(348). 
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However, there is some evidence that males are more likely to 
have ‘severe’ disease and females the more ‘limited’ phenotype.
Classically GPA affects the nose, lungs and kidneys but can 
present in any system and limited forms of the disease are 
recognised(348). The European Vasculitis Study Group (EUVAS) 
distinguishes ‘localized’ (i.e GPA restricted to the respiratory 
tract) and ‘early systemic’ GPA (i.e., non-imminent GPA without 
renal organ involvement) from ‘generalized’ GPA(349).
Two thirds of patients initially present with an ENT related 
symptom, of which the majority are rhinological (~40%), then 
otologic (~15%) and laryngopharyngeal (~5%)(350-352). Nasal 
symptoms were commoner in those diagnosed < 40 years 
(55%) as compared to those > 60 years (27%). During the course 
of the disease, the majority experience nasal symptoms with 
patients experiencing crusting (75%), discharge (70%), nasal 
stuffiness (65%), bleeding (59%), reduced sense of smell (52%) 
and facial pain (33%)(351). Hyposmia may be due to mechanical 
obstruction of the olfactory region, specific cranial nerve 
involvement(353), secondary to immunosuppressive treatment(354) 
or due to any systemic autoimmune process(355, 356). Taste is 
also reduced but less than smell(353). Deep seated facial pain 
may be secondary to sinus involvement or due to an osteitis of 
midfacial bone, indicative of disease activity. A characteristic 
supratip collapse occurs in18-25% which may or may not be 
associated with septal perforation in up to 30%. On endoscopic 
examination the nasal mucosa is usually very friable, granular 
and covered with old blood and crust, together with adhesions. 
There may be thickening of bone and/or erosion which can 
result in meningitis if the skull base is involved and fibrosis of 
the nasolacrimal duct producing epiphora. The entire internal 
structure of the nose may disappears creating a large featureless 
cavity(344,369).  
Elsewhere in the upper respiratory tract, patients may 
experience hearing loss (conductive, sensorineural or mixed), 
vertigo, tinnitus and facial nerve palsy. 
In the mouth there may be gingivitis, ulceration and oro-antral 
fistulas though less extensively than is seen with cocaine abuse. 
In addition, subglottic stenosis (16%) and vocal fold paralysis 
may occur, the symptoms of which may be wrongly attributed 
to the lower respiratory tract. Subglottic stenosis should be 
considered in any patients with dyspnoea, hoarseness or 
inspiratory stridor and is estimated to occur in about 16% of GPA 
patients(357).
Although GPA can present in many ways, often the development 
of relatively minor upper respiratory symptoms is associated 
with disproportionate unwellness, fatigue, weight loss and night 
sweats heralding generalised disease, the systemic symptoms 
and signs of which are legion. Quality of life is significantly 
affected in GPA as shown by the general Short Form-36(344, 
358) which improves with remission. The Sinonasal Outcome 
Test- SNOT-22 demonstrated the significant effect of sinonasal 
involvement on the general health-related QOL(344). 
Disease activity can be measured using the Birmingham 
Vasculitis Activity Score (BVAS)(359), a Vasculitis Damage Index 
(VDI)(360) and an ELK-classification of organ involvement (ENT, 
lung, kidney)(361).
Diagnosis can be delayed by 6 months or longer(343, 351), 
rendering the condition potentially life threatening. The delay 
was greatest when patients presented with eye symptoms (>14 
months) but ENT symptoms were associated with the second 
longest delay of >8 months). This is particularly disappointing 
as over half the patients (56%) saw an ENT surgeon prior to their 
diagnosis. 
In a retrospective non-controlled cohort of 89 GA patients 
diagnosed between 1996 and 2016, those who presented with 
ENT involvement had a higher survival rate at 5 years than those 
who presented with other systematic disease (98% v 78%) and 
ENT involvement was an independent predictor of a better 
outcome (OR 0.37, 95% CI 0.2-0.8, 0.019)(362).
Investigations (Table 8.7.3.)
ANCA tests have become the mainstay of diagnosis in vasculitis. 
Indirect immunofluorescence (IIF) testing for neutrophil 
cytoplasmic antibodies is commonly ordered first, followed by 
enzyme-linked immunosorbent assays (ELISAs) for antibodies 
directed against proteinase 3 (PR3) and myeloperoxidase 
(MPO). Having been divided into c-ANCA and p-ANCA 
(cytoplasmic versus perinuclear) by IIF, the ELISA links them 
with the presence of PR3 and MPO respectively.  The cANCA 
is 99% specific with a sensitivity of 73% using combined IIF 
and ELISA techniques but the increasing availability of reliable 
antigen-specific immunoassays (ELISA) is replacing the need for 
indirect immunofluorescence(363). A positive c-ANCA test and 
proteinase-3 (PR3) will confirm the clinical diagnosis of GPA in 
up to 95% of patients with active systemic disease. However, 
the c-ANCA lacks sensitivity in the limited forms of the disease 
dropping to 50% and/or following therapy with corticosteroids 
so a negative ANCA does not exclude GPA.
Whilst a positive c-ANCA is usually associated with GPA and a 
p-ANCA with MPO and EGPA, it is recognised that ~5% of GPA 
patients have a positive p-ANCA/MPO. 
Sequential monitoring of the c-ANCA can be useful in predicting 
relapse(364) but not all patients show the classical pattern of 
fluctuation with disease activity. 
The ANCA testing is complemented by a raised ESR (erythrocyte 
sedimentation rate) and CRP (c-reactive protein), altered renal 
function on blood and urine testing (proteinuria, microscopic 
haematuria and red cell casts) and chest imaging (showing 
granulations, infiltration, necrotic cavitation, fibrosis).
An ANCA test should be considered in any 
patient with suspicious clinical manifestations, in 
particular nasal crusting and bleeding, especially 
if they feel disproportionally unwell.
Cocaine abuse
Cocaine abuse in the form of ‘snorting’ can induce significant 
midline destruction of the nose and palate(365) often preceded 
by progressive nasal obstruction, epistaxis and crusting 
which closely resembles the sinonasal symptoms of GPA. The 
degree and distribution of destruction is greater in cocaine-
induced vasculitis than GPA and was thought to arise from the 
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abnormal boosting of apoptosis and cellular damage caused by 
cocaine(366). It is now thought that this is more likely caused by 
the illicit addition of levamisole to cocaine(367). The c-ANCA and 
PR-3 can also be positive, making differentiation between the 
conditions difficult(365, 368) but massive apoptosis with abundant 
caspase-3 and 9 expression is found in the cocaine users but 
not in GPA patients and ANCA reacts with human neutrophil 
elastase (HNE) in the cocaine group but not in autoimmune 
vasculitis so this may assist the differential diagnosis, supported 
by tissue cocaine levels. 
Imaging
In a patient without a history of previous sinonasal surgery, a 
combination of bone destruction (60-75%), septal loss (59%) 
and new bone formation (50-78%) on CT is highly suspicious 
of GPA (both localised and systemic)(352, 369-374) especially when 
accompanied on MRI by a fat signal from the sclerotic sinus wall 
(‘tramlines’) giving a high-signal on T1-weighted sequences(369). 
However, early in the disease the most frequent finding is of 
non-specific mucosal thickening in the nose or paranasal sinuses 
(87%) which may not raise suspicions of a vasculitis(369, 373). In 
contrast, progressive loss of midfacial structures can mimic an 
NK/T cell lymphoma. 
Imaging of the lungs should be undertaken to reveal diffuse 
infiltration, multiple pulmonary nodules (2-4cm in diameter) or 
large necrotic cavitating granulomatous masses (10cm diameter 
or larger) some with fluid levels. Imaging of the orbit and larynx 
should be considered depending on clinical symptoms.
Histopathology
GPA is characterised by three key findings:
granulomatous inflammation, necrosis and vasculitis affecting 
small to medium vessels (capillaries, venules, arterioles and 
arteries). The granulomas are composed of CD4+ and CD8+ T 
cells, CD28- T cells, histiocytes, CD20+ B lymphocyte, neutrophil 
granulocytes, macrophages and multinucleated giant cells 
surrounding an area of central necrosis(334). Occasional 
eosinophils may confuse the diagnosis with EGPA.
Tissue biopsy from the kidneys or lung can confirm the 
diagnosis but nasal biopsy, though easier to obtain, is less 
reliable and may be reported as ‘consistent with’ rather than 
definitively GPA as all three criteria of necrosis, granulomatous 
inflammation and vasculitis have to present(375, 376). Abnormal 
tissue from the sinuses is likely to provide a better yield(377) as 
can careful endoscopically directed biopsy after cleaning and 
decongesting the nose(378). Mucosal biopsy is most helpful in 
c-ANCA negative, localised GPA patients. A study by Borner et 
al.(379) showed that although the biopsy had lower sensitivity 
(47%) than the ANCA test generally, in these circumstances it 
had a specificity of 96% and a positive predictive value of 78% v 
73% with c-ANCA. 
Differential diagnosis
The differential diagnosis includes any of the other 
granulomatous conditions such as sarcoid, NK/T cell lymphoma, 
a range of infectious conditions such as tuberculosis, 
rhinoscleroma or fungal diseases, particularly rhinosporidiosis 
and other autoimmune conditions e.g. SLE or polyarteritis 
nodosa. 
8.7.2.4. Treatment
Without treatment the mean survival of systemic GPA is five 
months. Modern immunosuppressive treatment following a 
strategy of combined remission induction and maintenance 
has markedly improved this to a mean survival of 21.7 years 
from diagnosis(380) with a significant improvement over the last 
four decades assisted by higher awareness and diagnosis(381). 
However, ~10% never achieve remission, relapses occur in up to 
50% of individuals and mortality rates of 5% or higher are still 
reported(382).
Systemic
In generalised and/or severe disease regimes of high dose 
systemic steroids and pulsed cyclophosphamide are aimed 
at rapidly inducing remission to limit organ damage and to 
maintain this with the lowest dose to minimise the side effects 
of the medications(383). Methotrexate is sometimes used to 
obtain remission in non-organ threatening disease and as 
maintenance(384).
Monoclonal antibodies, in particular the anti-CD20 antibody, 
rituximab, are now widely used(385, 386). The RAVE (Rituximab for 
ANCA-associated Vasculitis) study(387) on 197 patients showed 
intermittent infusion of rituximab to be equivalent to daily 
cyclophosphamide for induction of remission and superior 
in relapsing disease but may not improve their chronic ENT 
problems(388). 
For longer-term maintenance, in addition to low dose 
prednisolone and rituximab, azathioprine and mycophenolate 
mofetil have been used. These act as ‘steroid-sparing’, thus 
reducing the requisite dose of prednisolone or are used as 
monotherapy as they are less often associated with significant 
side-effects(383). TNF-alpha inhibitors such as infliximab and 
etanercept have been less effective and other monoclonals 
such as belimumab (IgG1 antibody against B-Lys) are under 
investigation(386).
Because relapses can be triggered by many events from an 
episode of influenza to pregnancy, treatment needs constant 
surveillance. Titration of treatment against the activity of 
the condition and the side-effects of the drugs are generally 
monitored with regular ANCA, full blood counts, ESR, CRP, renal 
and pulmonary function tests, ideally in a multi-disciplinary 
setting, although the methodological range in the literature 
make it difficult to show the best protocol(389). A CD8+-T cell 
signature may be used to identify relapse(383).  Those on long-
term steroids need bone densitometry and prophylaxis against 
osteoporosis should be considered. 
As it is not known if all localised forms spread systemically nor 
whether treatment of limited disease prevents dissemination, 
the decision to start immunosuppression can be difficult. 
It is unclear for how long patients need to be treated but 
maintenance is recommended for 18 months. In many 
individuals the disease eventually burns-out but they may still 
require a small replacement dose of steroid.
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Nasal
Nasal irrigation, a topical intranasal corticosteroid sprays or 
creams e.g. triamcinolone and/or a nasal lubricant such as 25% 
glucose and glycerine drops, honey ointment  or an aqueous gel 
are usually recommended together with regular debridement of 
the crusts(377) (Level IV evidence).
The possible aetiological role of Staphylococcus aureus has led 
to the use of long-term oral co-trimoxazole (trimethoprim-
sulfamethoxazole) and topical anti-staphylococcal creams in the 
nose(390) (Level I evidence).
Endoscopic surgery has a very limited role and is associated with 
poor outcomes, increased scarring and adhesions so should be 
a last resort. Occasionally endoscopic exploration of an opaque 
sinus may be done to confirm that  opacification is granulation/
fibrosis rather than infection, rarely a dacrocystorhinostomy may 
be undertaken or repair of the skull base secondary to bone 
erosion in cases of meningitis(345, 377).
Repair of the septal perforation is unlikely to be successful in the 
long-term so septal buttons are sometimes offered though can 
increase the crusting.  Cosmetic improvement of the external 
nasal deformity has been successfully undertaken once the 
disease has been quiescent for a reasonable period of time (e.g. 
one year)(391). 
8.7.3. Eosinophilic granulomatosis with polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) (previously 
Churg Strauss Syndrome)(329, 392), is a rare form of vasculitis 
characterised by adult onset asthma, severe rhinitis, nasal polyps 
and other systemic manifestations as a result of widespread 
eosinophilic granulomatous infiltration of tissues. 
The Chapel Hill consensus defined it as ‘eosinophil-rich 
granulomatous inflammation of the respiratory tract and 
necrotizing vasculitis of small to medium-sized vessels, 
associated with eosinophilia’. However, the nomenclature has 
been challenged as only 59% of patients with this diagnosis 
have evidence of polyangiitis(393).
8.7.3.1. Epidemiology 
The overall prevalence of the condition ranges from 10.7-13 
cases/million inhabitants with an annual incidence of 0.5-6.8 
new cases/million inhabitants(394). However, among asthma 
patients the incidence is as high as 67 per million(395).
8.7.3.2. Pathophysiology 
The aetiology is unknown though it is probably an idiopathic 
autoimmune Th2 mediated disease affecting eosinophils, 
endothelial cells and lymphocytes. It has been suggested 
that exposure to certain allergens, drugs, vaccinations, 
corticosteroid withdrawal, and pulmonary infection may 
initiate the inflammatory cascade(396-398). It has been suggested 
that antileukotriene antagonists such as zafirlukast and 
montelukast(396) when used for asthma in some patients, could 
unmask EGPA. However, the consensus is that these drugs may 
be used if needed in EGPA, as the onset was either coincidental 
or resulted when symptoms of EGPA were unmasked after 
oral glucocorticosteroids were tapered and/or withdrawn(399, 
400). Other drugs implicated in triggering EGPA include 
antibiotics (macrolides), oestrogen replacement therapy, and 
carbamazepine suggesting a hypersensitivity reaction. 
There is also some evidence for a genetic predisposition in 
respect of the HLA-DRB1*04 and *07 alleles and the related 
HLADRB4(401, 402). In EGPA the anti-myeloperoxidase ANCA may 
be associated with HLA-DQ(341).
Eosinophilic infiltration and endothelial damage are likely the 
most important pathophysiological mechanisms. Peripheral 
T-cell lines from EGPA patients can produce Th2 associated 
cytokines such as IL4 and IL13 and IL5 is upregulated in 
active disease, offering therapeutic possibilities(403). However, 
an exaggerated Th2 response cannot account for all the 
manifestations of EGPA and there is evidence of involvement of 
Th1 and Th17 cells secreting large amounts of IL-17a in the late 
stages of the disease. Eoxtaxin-3 produced by endothelial and 
epithelial cells may contribute to eosinophilic tissue infiltration 
and further tissue damage may be caused by eosinophilic 
cationic protein from activated eosinophils. They also secrete 
large amounts of IL25 which elicits Th2 responses, maintaining a 
vicious circle(403).
Increased levels of IgG4 and IgG4/IgG ratios in EGPA have led 
to the suggestion that EGPA may be part of the IgG4 disease 
spectrum(404).
As with GPA, it is thought that localised early forms of EGPA may 
exist, particularly in the upper respiratory tract(403).
8.7.3.3. Diagnosis and differential diagnosis
According to the American College of Rheumatology criteria(405), 
at least four out of six criteria must be present:
1) A medical history of asthma
2) Eosinophilia >10%
3) Mono- or polyneuropathy
4) Nonfixed pulmonary infiltrates
5) Paranasal sinus abnormalities
6) Biopsy including an artery, arteriole or venule showing 
accumulated eosinophils in the extravascular tissue.
Clinical (Table 8.7.2.)
The male to female ratio in the literature ranges from 58:43 to 
39:54 with mean age of between 49-52 years in the 28 studies 
included in a systematic review by Goldfarb(406). It can manifest 
between 7-74 years with a mean age of onset of 38-54 years(403). 
No ethnic predisposition has been determined(407).
The condition often follows three clinical stages. The prodromal 
stage is characterised by allergic rhinitis, CRS with or without 
polyps and asthma(408, 409). This stage may predate the overt 
vasculitis by months to many years (mean eight years)(396).
The second ‘eosinophilic’ stage is characterised by tissue and 
peripheral eosinophilia.
The final ‘vasculitic’ phase involves extrapulmonary disease 
with vasculitis, associated with severe and fatal manifestations 
including polyneuropathies, myocarditis, cerebral haemorrhage, 
ischaemic strokes and bowel perforations. 
In a systematic review(406) of 1175 patients with EGPA, 48-96% 
presented with head and neck manifestations, which are often 
sinonasal(410). These include nasal obstruction (95%), crusting 
(75%), bleeding (60%), rhinorrhoea (95%), facial pain, loss of 
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smell (90%) and sneezing (80%) associated with allergic rhinitis 
(43%) and chronic rhinosinusitis with (54%) and without nasal 
polyposis (70%).  In addition to nasal crusting, hypertrophy of 
the inferior turbinates, mucosal oedema, synechia and nasal 
polyps may be seen on endoscopy(411, 412). Olfactory testing 
using Sniffin’ sticks in 62 subjects showed normosmia in 79%, 
hyposmia in 11%, anosmia in 29% and dysosmia in 40%(412). 
Anterior rhinomanometry in 86 subjects showed severe nasal 
obstruction in a third. A mean SNOT-22 of 41.5 has been found, 
comparable to patients with CRS without vasculitis(410).
As a consequence, patients are frequently seen by the ENT 
community who may not appreciate the potential for a more 
serious systemic disease but are in a unique position to make 
an early diagnosis and prevent late complications of the 
condition(413). 
EGPA should be considered in any patient with 
severe nasal polyposis who is not responding to 
conventional therapy 
ENT and systemic manifestations are shown in Table 8.7.2.  In 
one series the mean delay between diagnosis and presenting 
to the physician with worsening symptoms was 18.5 months 
(range 1-71 months, SD 21.6)(410) whereas a mean delay from 
diagnosis of asthma to diagnosis of EGPA of 11.8±18.2 years has 
been reported(414).  
Investigations (Table 8.7.3.)
Active EGPA is characterised by marked peripheral eosinophilia 
(usually >1500 cells/ul or >10%)(403). There is usually a non-
specific increase in IgE if the patients are not taking systemic 
steroids for their asthma.
EGPA is one of the antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitides. Immunofluorescent patterns with 
ELISA detecting antibodies to myeloperoxidase (MPO) is the 
most common EGPA ANCA-positivity finding but figures for 
p-ANCA positivity vary. Between 26-48% have been reported 
to have a positive p-ANCA but this increases to 75% with renal 
involvement(415) and other  studies quote 35-77% so a negative 
ANCA does not rule out EGPA and a positive ANCA may not be 
essential for the diagnosis in the head and neck phenotype(329, 
395, 416-419).Overall pANCA-positive patients are more likely to have 
peripheral neuropathy, glomerulonephritis and purpura (due to 
small vessel vasculitis) as compared to those with myocardial, 
respiratory and gastrointestinal involvement who are more 
often pANCA negative(416, 420).
Other biomarkers have been investigated including serum 
TARC/CCL17, eotaxin-3, IgG4 and IgG4/IgG ratio but none 
were useful in discriminating between active disease and 
remission(421).
Imaging
Sinus CT does not show anything other than what would 
be expected in diffuse polypoid rhinosinusitis i.e. pan-
opacification(422). Mean Lund-Mackay scores of 9-17 have been 
reported in large cohorts of EGPA(412, 422). Expansion and bone 
erosion may be seen in the ethmoid complex with widening of 
the intercanthal distance. In addition, there may be evidence of 
mucocele formation, notably in the fronto-ethmoidal region. 
High resolution CT of the chest is recommended to demonstrate 
atypical ‘fluffy’ or nodular migratory pulmonary infiltrates which 
would only be seen in 64% of plain chest x-rays(423). Peripheral 
nodules (25%), ground glass opacities (86%) and bronchial wall 
thickening and bronchiectasis (66%) are also found on CT. 
 
Histopathology
Histopathologically the condition is characterised by 
eosinophilic inflammation and infiltration, extravascular 
granulomas and necrotizing vasculitis in the presence of 
asthma. However, in studies where sinonasal tissue was 
examined, eosinophilic infiltration was seen in 35-100%, whilst 
necrotising vasculitis and eosinophilic granulomas were not 
seen(408, 424).
Although the histology is important, this combined with clinical 
criteria are required to make the diagnosis and a low threshold 
of suspicion is required in any patient with eosinophilic diseases 
i.e. significant adult-onset asthma, recurrent CRSwNP and 
allergic rhinitis. Once EGPA is diagnosed, investigation for lung, 
kidney, heart, gastrointestinal and peripheral nerve involvement 
is recommended as these are associated with poor prognosis(394). 
This can include imaging, biopsy, bronchoalveolar lavage, renal 
and cardiac function tests.
Differential diagnosis
The differential diagnosis is from other eosinophilic 
pneumonias, idiopathic hypereosinophilic syndrome, c-ANCA 
positive granulomatosis and microscopic polyangiitis, sarcoid, 
allergic bronchopulmonary aspergillosis and parasitic infections. 
Thus in addition to ANCA, the EGPA Consensus Task Force 
recommended as a minimum initial differential diagnostic work-
up the following: serologic testing for toxocariasis, HIV, specific 
IgE and IgG for Aspergillus spp, a search for Aspergillus spp 
in sputum and/or bronchoalveolar lavage fluid, tryptase and 
vitamin B12, full blood count and CT of the chest(394). However, 
EGPA can usually be distinguished from other primary systemic 
vasculitides by the presence of asthma and a marked blood 
eosinophilia.
8.7.3.4. Treatment 
In 2009, the European League Against Rheumatism (EULAR) 
published treatment recommendations for small to medium 
sized vessel vasculitides. Without treatment, the mortality 
rate is high once the vasculitis phase is reached(425, 426). A 
multidisciplinary management is widely recommended in the 
literature(394) and with appropriate treatment, survival rates are 
comparable to GPA(426). 
Long –term studies have shown that overall remission rates are 
good, ranging from 81-92% but over a quarter do relapse either 
within the first year of treatment or much later(427). This is higher 
in MPO /pANCA positive patients. Overall mortality in treated 
patients who relapsed was only 3.1%. 
Factors predicting poor outcome are: cardiomyopathy (an 
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independent risk factor) or two features of the ‘five-factor’ score 
(FFS) (creatininemia >140umoles/litre; proteinuria >1g/day; 
involvement of central nervous system, gastrointestinal or heart)
(426, 428). If one of these factors is present at onset, the five year 
mortality is 25.9%, when two or more are present, this increases 
to 46% at five years(428). Survival at one and five years was 100% 
if the score was 0. The FFS was revisited in 2011 by the French 
Vasculitis Study group as follows: 1) age >65yrs; 2) cardiac 
symptoms; 3) gastrointestinal involvement; 4) renal insufficiency 
characterised by a serum creatinine >150 umol/l; 5) absence 
of ENT manifestations. With each factor accorded one point, a 
revised FFS of 0, 1 and 2 is associated with a five-year mortality 
rate of 9%, 21% and 40% respectively(429). A subsequent study 
showed that age >65 years was the only factor associated with 
higher risk of death during follow-up(427).
Systemic
In most patients, disease control is achieved with 
immunosuppressant therapy, usually oral prednisolone +/- 
cytotoxic drugs such as pulsed cyclophosphamide, azathioprine, 
mycophenolate mofetil and methotrexate dependent on the 
severity of the disease at presentation.  Patients without poor 
prognostic factors can often be managed with glucocorticoids 
alone. Additional systemic treatments include intravenous 
immunoglobulin, leflunomide, anti-TNFa, interferon-a and 
plasma exchange(430).
Rituximab is now frequently being used in selected ANCA-
positive patients with renal involvement or refractory disease 
though the evidence is less robust that in GPA(394, 431-434) and 
other new biologic therapies may be helpful e.g. anti-IL 5 
(mepolizumab)(435-437) or anti-IgE (omalizumab) monoclonal 
antibodies(438, 439).
Nasal
Alkaline/saline nasal irrigations, topical intranasal corticosteroids 
and nasal lubricants are the mainstay of treatment (Level IV). 
Endoscopic surgery can be successfully undertaken in those 
whose CRS with nasal polyps do not respond to systemic and 
local steroids. The numbers of reported EGPA surgical cases in 
the literature is small(440) and surgery is often associated with a 
high recurrence rate though patients may still obtain benefit(422). 
A number of patients develop paranasal sinus mucoceles which 
may also be dealt with endoscopically. In a series of 25 patients, 
48% had undergone endoscopic sinus surgery, often multiple 
times(410).
8.7.4. Sarcoidosis
8.4.7.1. Definition
Sarcoidosis is a chronic multi-system inflammatory disease of 
unknown aetiology characterised by non-caseating granuloma. 
The first description is sometimes ascribed to Besnier in 1889 
who coined the term ‘lupus pernio’ for the cutaneous lesions(441). 
It is usually associated with bilateral hilar lymphadenopathy, 
pulmonary, ocular and skin lesions(411, 442).
8.7.4.2. Epidemiology
The age-adjusted incidence is 11 cases/100,000 population in 
Caucasians and it is commoner in northern Europe (Sweden, 
Iceland) affecting an estimated 20/100,000 population versus 
1.3/100,000 in Japan. In the United States it is more prevalent 
in African Americans than whites (35.5/100,000 versus 
10.9/100,000 respectively). It is twice as common in women 
than men, who also have higher morbidity, mortality and 
extrapulmonary involvement. Incidence peaks in the third – 
fourth decades, with a second peak in women between 45-65 
years though any age can be affected(443, 444). 
8.7.4.3. Pathophysiology
The aetiology of this condition remains unknown. It appears 
to be an exaggerated immune response to an unknown 
antigen for which a wide range of agents have been suggested. 
This includes infective agents such as mycobacteria or 
propionibacteria, chemicals (beryllium and zirconium), pine 
pollen and peanut dust(445).
It is one of the few pulmonary diseases commoner in non-
smokers. Working on the World Trade Centre debris after 
9.11.2001 was associated with development  of sarcoidosis(446).
It is associated with cell-mediated and humoral immune 
abnormalities. T cells play a central role with an accumulation 
of CD4+ T cells, accompanied by release of IL2 followed by a 
non-caseating granuloma. There may be an inverted CD4+/
CD8+ ratio. TH1 cytokines such as interferon are increased as is 
tumour necrosis factor (TNF). There is B cell hyperreactivity and 
immunoglobulin production. Glycoprotein KL-6 and surfactant 
protein D are increased in pulmonary sarcoid(447) and Th17 cells 
are also thought to play a role(448).
8.7.4.4. Diagnosis and differential diagnosis
Clinical (Table 8.7.2.)
Sarcoidosis is classically a multisystem disease and can therefore 
present in protean ways, the distribution of which reflects the 
origin of the individual series. The chances of possible organ 
involvement can be assessed with the WASOG sarcoidosis 
organ assessment instrument(449) or more recently through the 
Genotype-Phenotype Relationship in Sarcoidosis study(450). 
However, the disease can also be asymptomatic, found 
incidentally e.g. on chest imaging (5%). 
It has a propensity for the lower respiratory tract to be affected 
in  up to 95% in some studies(451). The upper respiratory tract 
is involved infrequently(452), in approximately 3-4% of patients 
with generalised disease. Notably the nose is affected with 
blockage, crusting and bleeding(445, 453-455). Nasal polyps and 
septal perforations leading to saddle nose deformity have also 
been reported(411, 456-458). Lupus pernio of the external nose, face 
and ears often accompanies sinonasal sarcoidosis(451). The ears, 
mouth and larynx may also be affected(459-461).
In a series of 148 patients with proven sarcoid and referred 
to a specialist rhinological practice, nearly 90% suffered nasal 
congestion or blockage and two thirds had crusting. Bleeding 
or spotting of blood affects 40% and nearly a quarter had facial 
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Table 8.7.1. Classification of vasculitides adopted by the 2012 International Chapel Hill Consensus Conference on the Nomenclature 
of Vasculitides(329).
Large vessel vasculitis (LVV)
	· Takayasu arteritis (TAK)
	· Giant cell arteritis (GCA)
Medium vessel vasculitis (MVV)
	· Polyarteritis nodosa (PAN) 
	· Kawasaki disease (KD) 
Small vessel vasculitis (SVV) 
	· Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) 
Microscopic polyangiitis (MPA) 
Granulomatosis with polyangiitis (Wegener’s) (GPA) 
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) 
	· Immune complex SVV 
Anti–glomerular basement membrane (anti-GBM) disease 
Cryoglobulinemic vasculitis (CV) 
IgA vasculitis (Henoch-Schonlein) (IgAV) 
Hypocomplementemic urticarial vasculitis (HUV) (anti-C1q vasculitis) 
Variable vessel vasculitis (VVV) 
	· Behcet’s disease (BD) 
	· Cogan’s syndrome (CS) 
Single-organ vasculitis (SOV) 
	· Cutaneous leukocytoclastic angiitis 
	· Cutaneous arteritis Primary central nervous system vasculitis 
	· Isolated aortitis 
	· Others
Vasculitis associated with systemic disease
	· Lupus vasculitis 
	· Rheumatoid vasculitis 
	· Sarcoid vasculitis 
	· Others 
Vasculitis associated with probable aetiology 
	· Hepatitis C virus–associated cryoglobulinemic vasculitis 
	· Hepatitis B virus–associated vasculitis 
	· Syphilis-associated aortitis 
	· Drug-associated immune complex vasculitis 
	· Drug-associated ANCA-associated vasculitis 
	· Cancer-associated vasculitis 
	· Others
Table 8.7.2. Symptoms associated with different system involvement in granulomatosis with polyangiitis (GPA), eosinophilic 
granulomatosis with polyangiitis (EGPA) and sarcoidosis.
GPA EGPA Sarcoid
Ear 	· Otalgia, otorrhoea, conductive and 
sensorineural deafness
	· Dizziness
	· Tinnitus
	· Chronic otitis media
	· Otitis externa
	· Otalgia, otorrhoea, conductive 
and sensorineural deafness
	· Serous otitis media, 
mastoiditis, facial nerve palsy
	· Sensorineural and conductive deafness
	· Vestibular dysfunction
	· Facial nerve paralysis
Nose and throat 	· Nasal obstruction
	· Crusting
	· Bleeding
	· Rhinorrhea
	· Facial pain, loss of smell
	· Rhinosinusitis
	· Septal perforation
	· External ‘saddle’ deformity
	· Adhesions
	· Nasal obstruction (95%) 
	· Crusting (75%)
	· Bleeding (60%) 
	· Rhinorrhea (95%)
	· Facial pain, loss of smell (90%) 
	· Sneezing (80%)
	· Septal perforation (rare) 
CRSsNP (70%), CRSwNP (54%)
	· Allergic rhinitis (43%)
	· Nasal obstruction (90%)
	· Crusting (66%)
	· Blood stained discharge (40%) 
	· Facial pain (25%)
	· Anosmia (70%)
	· Septal perforation
	· ‘Strawberry skin’ nasal mucosal nodules
	· Nasal bones – rarefaction and soft 
tissue infiltration, adhesions  
Mouth 	· Oral ulceration
	· Gingivitis
	· Fistula
	· Cranial nerve palsies
	· Cranial nerve palsies
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GPA EGPA Sarcoid
Larynx 	· Hoarseness, stridor
	· Vocal fold palsy
	· Subglottic and tracheal stenosis
	· Hoarseness, stridor
	· Supraglottic granulomas and stenosis
	· Vocal fold palsies
Lower respiratory tract
 
	· Dyspnoea, pleuritic pain, hemoptysis
	· Pulmonary infiltrates, nodules, 
abscesses or haemorrhage
	· Asthma (~100%)
	· Pulmonary infiltrates, nodules, 
bronchiectasis, bronchial wall 
thickening
	· Dyspnoea, cough, chest pain, wheeze 
(50-95%)
	· Hemoptysis (rare)
	· Pulmonary infiltrates
	· Hilar lymphadenopathy (+ fever, 
polyarthralgias = Lofgren syndrome, 
mainly Scandinavians)
Ophthalmic 	· Proptosis, pain, visual loss, epiphora
	· Scleritis, episcleritis, retinitis, retro-
orbital granuloma
Rare 	· Epiphora, red, painful eye, 
photophobia, dry eye, visual loss
	· Anterior and posterior uveitis, 
iridocyclitis, keratoconjunctivitis, scleral 
plaques
	· Lacrimal enlargement
Cardiac 	· Arrhythmias
	· Pericardial effusion
	· Infarction, myocarditis
	· Vasculitic myocarditis (23-
45%)
	· Pericarditis
	· Myocardial infarction
	· Cardiac failure and ventricular 
arrhythmia – heart block, sudden death
Renal 	· Glomerulonephritis
	· Renal impairment
	· Renal failure
	· Glomerulonephritis
	· Renal impairment
	· Renal failure
Gastrointestinal 	· Diarrhoea
	· Bleeding
	· Abdominal pain, nausea, 
vomiting, diarrhoea, 
haemetemesis, melaena
	· Small bowel perforation
Peripheral nervous 
system
	· Sensory or motor polyneuropathy
	· Mononeuritis (10-50%)
	· Sensory or motor peripheral 
neuropathy (50-70%) 
	· Mononeuritis esp. peroneal 
nerve
	· Polyneuritis
	· Peripheral mononeuritis
	· Myelopathy
Central nervous system 	· CNS lesions
	· Meningitis
	· Meningeal vasculitis
	· Intracranial abscess
	· Cranial neuropathies
	· Lymphocytic meningitis
	· Cranial neuropathies
	· Hypothalamic / pituitary dysfunction 
(rare)
Skin 	· Purpura
	· Subcutaneous nodules
	· Non-healing ulceration (40-50%)
	· Purpura
	· Subcutaneous nodules
	· Non-healing ulceration (40-
50%)
	· Violaceous rash 
	· Erythema nodosum
	· Lupus pernio
	· Maculopapular plaques (rare)
Musculoskeletal 	· Arthralgia
	· Myalgia
	· Arthralgia
	· Myalgia
	· Arthralgia
	· Myalgia
	· Dactylitis
General / Other 	· Fever
	· Weight loss
	· Fatigue
	· Nocturnal sweats
	· Fever
	· Weight loss
	· Fatigue
	· Fever
	· Weight loss
	· Fatigue (45%)
	· Peripheral lymphadenopathy
	· Parotitis (Heerfordt’s syndrome)
	· Hepatosplenomegaly
Table 8.7.3. Investigations in granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and 
sarcoidosis.
GPA EGPA Sarcoid
Blood 	· c-ANCA/PR3 (95% +ve with systemic 
disease; 50% +ve with limited 
disease)
	· p-ANCA (5% +ve)
	· Raised erythrocyte sedimentation 
rate (ESR)
	· Raised c-reactive protein
	· Blood eosinophilia (>10%)
	· IgE – non-specific increase
	· p-ANCA/MPO +ve (in 26-48%, increasing 
to 75% with renal involvement)
	· Hypercalcaemia (in 10-13%)
	· Hypercalciuria (in ~30%)
	· Raised alkaline phosphatase
	· Raised angiotensin-converting 
enzyme (in 60-83%)
Imaging 	· HRCT chest
	· CT sinuses
	· HRCT chest
	· CT sinuses 
	· CXR / CT chest
	· CT sinuses
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pain. Anosmia can result from mechanical obstruction of the 
olfactory region and/or sensorineural(453). The co-existence of 
chronic rhinosinusitis and two of the following: nasal crusting, 
anosmia and epistaxis were shown to be highly specific for 
sarcoid rhinosinusitis(454). This means that many of these 
patients may present to the ENT community but as with other 
granulomatous diseases, they may go unrecognised. To put 
this in context, the diagnosis of nasal sarcoid was made in 23 
patients who presented with ‘chronic rhinosinusitis’ in a cohort 
of 5000 patients presenting to the aforementioned rhinology 
clinic and this has been the experience of others(459, 460, 462, 463).
On endoscopic examination, the mucosa has been described 
as a ‘strawberry skin’ with small pale granulomas dotted over an 
erythematous and granular mucosa(411, 460). These appearances 
may be obscured by extensive crusting and eventually may 
become atrophic. Within the nasal cavity, the inferior turbinate 
and adjacent nasal septum are particularly affected with a 
nodular hypertrophy. However, any of the paranasal sinuses, 
nasopharynx, soft palate, hypopharynx and supraglottis can be 
involved.
Investigations (Table 8.7.3.)
There is no definitive test for sarcoid other than a positive 
biopsy, usually endobronchial(444) or from skin, minor salivary 
glands or lymph nodes(411). The classic appearance is of a non-
caseating granuloma composed of a central area of tightly 
packed epithelioid, giant cells, CD4+ T cells surrounded by CD8+ 
T and B lymphocytes and fibroblasts at the periphery. Special 
stains should be negative for mycobacteria and fungi. Biopsying 
the nasal mucosa if it appears macroscopically abnormal is 
worthwhile as the majority will be positive (91%) whereas if it 
appears normal, the biopsy will usually be negative (92%)(453).
Blood tests may include raised serum and urinary calcium levels, 
raised alkaline phosphatase and raised serum angiotensin-
converting enzyme (SACE) but none are diagnostic (sensitivity 
60%; specificity 70%). 
Other tests may include pulmonary and cardiopulmonary 
function, perfusion studies, broncho-alveolar lavage and ECG. 
Imaging
CT scanning of the nose and sinuses often shows a non-
specific generalised opacification similar to that seen in chronic 
rhinosinusitis. This may be due to an active granulomatous 
process, or fibrosis after the condition has regressed and/or 
non-specific inflammation or infection(461). In addition turbinate 
or septal nodularity (21%), osteoneogenesis (15%) and bone 
erosion (8%) may be seen(464). The bone erosion in the sinuses 
may even suggest malignancy.
The nasal bones may show rarefaction or punctuate osteolysis 
similar to that seen in the metacarpals or metatarsals.  In CT 
scans of the sinuses of 39 biopsy-proven sarcoid patients, the 
mean Lund-Mackay score was a modest 6.2 but the nodularity of 
the mucosal thickening should suggest the diagnosis(464).
MRI of the sinuses may also show abnormalities consistent 
with the CT changes as will gallium(159)scanning and positron 
emission tomography(465). The lacrimal glands may be enlarged 
bilaterally. 
Chest radiography and CT of the lungs may show multiple 
nodules or nodular infiltration but occasional these may be 
solitary or unilateral between 1-5 cm in diameter(466).
Gallium(159) perfusion scans can demonstrate increased uptake in 
the sarcoid granuloma but have low sensitivity and specificity.  
MRI of the brain may show granulomatous involvement of the 
basal meninges. 
FDG-PET is being used to monitor response in severe cases. 
Sarcoid is staged according to pulmonary involvement(466):
0: Normal chest imaging
I: Bilateral hilar lymphadenopathy, normal lung fields
II: Bilateral hilar lymphadenopathy and infiltrates
III: Infiltrates alone 
IV: Fibrosis
Differential diagnosis
The differential diagnosis is between other granulomatous 
diseases such as syphilis, tuberculosis, rhinoscleroma, GPA and 
EGPA as well as berylliosis, leprosy, fungal disease, cat scratch 
fever, a range of lymphomas and diffuse granulomatous disease 
Lower respiratory 
tract
 
	· Pulmonary function
	· Flow volume loop spirometry to 
exclude subglottic stenosis
	· Pulmonary function 	· Pulmonary function test
	· Gallium67 perfusion test
	· Broncho-alveolar lavage
	· Bronchoscopy - biopsy
Cardiac 	· Myocardial assessment 	· Cardiopulmonary exercise 
testing
	· ECG
Renal 	· Urinalysis
	· Renal function tests
	· Tissue biopsy
	· Urinalysis
	· Renal function tests
Peripheral nervous 
system
	· Biopsy if neuropathy
Central nervous 
system
	· MRI brain
Skin 	· Negative tuberculin skin test in 
a BCG vaccinated patient
	· Biopsy of lupus pernio
General / Other 	· FDG-PET CT
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in common variable immune deficiency(369, 371, 462, 467).
 An elevated serum angiotensin-converting enzyme is 
suggestive of sarcoid but can be raised in other conditions such 
as TB, lymphoma, leprosy and Gaucher’s disease.
8.7.4.5. Treatment
Sarcoidosis can present to a wide range of disciplines including 
ENT so as with other vasculitic/granulomatous diseases, it 
requires a low threshold of suspicion to make the diagnosis 
and is best managed in a multi-disciplinary environment(451). In 
many cases, particularly Stage 1 disease, the disease undergoes 
spontaneous remission within two years without specific 
treatment.  Around 75% can be managed symptomatically with 
NSAIDS. In those with Stage 2, 65% spontaneously regress, 
Stage 3 patients with just lung disease have a 30% of remission 
chance and an 18% mortality rate whereas 85% of those with 
erythema nodosum and acute arthritis remit spontaneously. 
Those with more advanced disease as evidenced by raised 
SACE or extrapulmonary involvement will usually require 
treatment and about 50% may experience a relapse, with 1 in 
10 developing serious disability(468). Severe cardiac or pulmonary 
involvement may lead to death in some cases and lung 
transplantation has been undertaken though up to two thirds 
develop recurrence in the allograft(469, 470). Lung function should 
be monitored every 6-12 months.. 
Systemic
The mainstay of treatment, when it is required, remains oral 
corticosteroids. They are used for Stage II and III pulmonary 
disease and for extrapulmonary involvement of critical 
organs(468, 471).
Hydroxychloroquine / chloroquine are used for cutaneous 
and bone lesions and neurologic sarcoid as well as acute and 
maintenance treatment of the chest. However, they can cause 
retinal toxicity. 
Steroid-sparing cytotoxic agents such as methotrexate 
(weekly), cyclophosphamide and azathioprine may be used as 
alternatives or in addition to systemic steroids(468).
TNF-alpha antagonists such as infliximab(468, 472-474) and 
thalidomide(475) have been used in refractory disease, 
in particular for cutaneous, ophthalmic, hepatic and 
neurosarcoidosis.
Nasal
Nasal symptoms may be improved by the systemic treatment(461, 
476).  In addition standard topical treatments with saline or 
alkaline irrigations, corticosteroid sprays or drops and lubricants 
such as 25% glucose and glycerine drops, honey ointment  or 
an aqueous gel are usually recommended together with regular 
debridement of the crusts can be used(451) (Level IV).
Surgery has a very limited role, confined to biopsy, occasionally 
debulking of granulomatous masses and associated inferior 
turbinate hypertrophy(477) and endoscopic sinus surgery 
to elucidate CT changes and possibly reduce the need for 
systemic steroids(442, 457, 461, 462, 478). Surgery on the septum is not 
recommended, especially if the disease is active as perforation 
may result from the procedure(461). Nasal reconstruction and 
resurfacing have also been anecdotally described for persistent 
lupus pernio(479-481).
Key points | What’s new since EPOS 2012
• A low threshold of suspicion should be maintained 
for ANCA-associated vasculitis (granulomatosis with 
polyangitis (GPA), eosinophilic granulomatosis with 
polyangitis (EGPA)) and sarcoidosis, all of which can affect 
the upper respiratory tract and present with apparent 
chronic rhinosinusitis.
• The ANCA test has become the mainstay of diagnosis 
in vasculitis but lacks sensitivity in limited forms of GPA 
(c-ANCA) and  EGPA (p-ANCA).
• Cocaine abuse can produce a midline destructive 
process which mimics GPA.
• In GPA and EGPA systemic treatment with 
immunosuppression is being replaced in many cases by 
rituximab and other monoclonal antibodies.
• Sarcoidosis is a chronic multi-system inflammatory 
disease of unknown aetiology characterised by non-
caseating granuloma.
• There is no definitive test for sarcoid other than a positive 
biopsy.
• Systemic steroids remain the mainstay of treatment in 
sarcoidosis, though hydroxychloroquine, steroid-sparing 
cytotoxic agents such as methotrexate andTNF-alpha 
antagonists such as infliximab are being used.
• In all these conditions, local treatment includes nasal 
rinsing, topical steroids and lubricants.
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9.1 Patient participation in CRS
9.1 Patient participation in CRS 
Patient participation in rhinosinusitis can relate on an individual 
basis to participation of the patient in the design and/or discus-
sion of the treatment plan, or to participation in the follow-up 
after medical or surgical treatment. There is limited research on 
the impact of patient participation on outcomes of treatment in 
CRS. 
Patient involvement, moreover, is recognized as a key compo-
nent of research and clinical practice guideline development 
with important implications for guideline implementability(1). 
For optimal implementation, guideline development must 
include all key stakeholders, thus including patients from the 
start and recommendations should be relevant and applicable 
and address patients’ needs. Patient involvement in guidelines 
is important because it appreciates that patients are experts, 
empowers and informs consumers in health care decisions, 
and will lead to the development of more patient-centred 
and trustworthy guidelines. Therefore, the Agree II instrument 
requires that guideline developers seek the views of the target 
population (https://www.agreetrust.org/agree-ii/). In EPOS2020, 
patients were included in every step of the development from 
the first questions to the dissemination. 
There is limited research on the impact of patient participation 
on outcomes of treatment in CRS. In this chapter we discuss the 
data on individual patient participation.
9.1.1. Areas of patient participation. 
Patient participation in the decision-making process of the 
therapeutic plan is one of the four cardinal principles of 
Precision Medicine(2), which are considered to lead to good/
better adherence to treatment, high patient satisfaction and/or 
cost-savings. Attempts to study the impact of a patient-centred 
decision on the medical treatment of CRS have not been con-
vincingly showing a major benefit(3). In real-life, patient partici-
pation requires efforts from both patients as well as physicians, 
both physicians’ efforts to educate patients on the nature of the 
disease and the different treatment options, including predic-
tion of success and failure of the different treatment options 
and patients’ willingness to be educated and take part in the 
decision-making process of any medical or surgical treatment 
for CRS.
Patient participation in the decision-making process of 
the therapeutic plan is one of the four cardinal 
principles of Precision Medicine.
Patient participation in the follow-up of medical or surgical tre-
atment of CRS is also considered important to achieve optimal 
outcomes, but needs further study. The current follow-up stra-
tegy of CRS patients after initiation of medical and/or surgical 
care depends on the regional health care system and treating 
physician, and on the patients’ willingness and capabilities of 
being followed-up on a regular base. 
Recent mobile health initiatives to educate patients on CRS, 
on correct medication use and treatment options have been 
implemented in certain areas in Europe with success(4). Whilst 
they allow a more pro-active follow-up of patients with remote 
monitoring of symptoms by physicians(4, 5) the impact of e-health 
on CRS outcomes still needs to be defined and proven.
9.1.2 What’s important to patients in sinus care?
Although there is increasing awareness of the need to engage 
patients both in their own care, and in the design and delivery 
of trials, there are very few studies that set out to evaluate what 
issues are most important to patients with rhinosinusitis, and 
which should be addressed during a consultation. A previous 
study in allergic rhinitis demonstrated that up to half of patients 
have no specific opinion on any recommended treatment, but 
that the other half do have an opinion that should ideally be 
addressed(6).
Vennik et al.(7) have undertaken structured interviews with 25 
patients with CRS, and used thematic analysis to identify key 
areas of importance;
• Recognising the impact of the disease (symptom severity 
and the impact on both work and social activities);
• Seeking resolution with treatment (self-management, in-
cluding dietary changes and complementary therapies and 
medical treatment options, including how to use medical 
treatments, concerns regarding potential side effects);
• Surgical intervention (role of surgery, including advice on 
the optimum time for intervention, the aims of surgery and 
its anticipated outcome).
Patients in this study also expressed concerns regarding some of 
their experience with different healthcare interactions, highligh-
9. Patient participation, prediction, precision medicine and 
implementation
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ting that some doctors fail to recognise the impact that sinus 
disease can have on a patient, a failure to take a holistic appro-
ach to both upper and lower airway disease, inadequate time to 
answer questions fully, and long intervals between reviews. 
Alanin et al.(8) undertook a qualitative analysis of patients’ posts 
made on the Samter’s Society Support Group, with the per-
mission of the members. This is a closed group formed by the 
Samter’s Society, and patient advocacy group for those with N-
ERD. Similar themes were identified, including the impact of the 
disease, and the isolation that can arise from having a condition 
that can be poorly understood by friends and family members. 
Patients are keen to explore dietary modifications that can help, 
as well as find out more about all different treatment options. 
At a time when there are a number of novel treatments emer-
ging, patients are very keen to share experiences before making 
decisions regarding whether to try new medications, but also 
express concerns about the potential for unknown side-effects. 
Lack of awareness among physicians was a common frustration. 
Conflicts between different healthcare providers involved in 
their care was a significant concern, with patients describing a 
‘tug of war’ between surgeons and allergists / pulmonologists 
with regards to different options, highlighting the need for a 
multi-disciplinary approach in the setting of upper and lower 
airway conditions. 
Conflicts between different healthcare providers highlights the 
need for a multi-disciplinary approach in the setting of upper 
and lower airway conditions. 
9.1.3 Patient compliance
Intranasal corticosteroids (INCS) form the first line of treatment 
options for almost all subgroups of CRS. However, a large po-
pulation based study(9) found that only one in five CRS patients 
identified on the administrative database had used an INCS in 
the preceding calendar year, and the mean usage was 2.4 bottles 
in one year (at recommended dosage that one bottle should last 
4 -8 weeks). There is, therefore, clear evidence of both failure to 
use INCS and under-dosage in those that do. This may reflect 
under-prescribing, lack of patient education regarding the need 
for ongoing usage, and concerns with regards to costs or poten-
tial side effects.
Guo et al.(10) found that postoperative adherence with medical 
treatment in patients undergoing ESS was poor in patients 
experiencing their first surgery, with only 42.3% following their 
recommended treatment regimen, but was higher in patients 
undergoing multiple revisions, at 88.9%. Yoo et al.(11) also found 
compliance with post-operative irrigation to be better in those 
undergoing revision, but highlighted that language barriers may 
contribute to non-compliance.
In order to improve compliance, it is important to explain the 
aim of ongoing usage or any maintenance treatments to both 
control symptoms and reduce need for recurrent interventions. 
Information on the safety of treatment and instructions for use 
must be provided in all necessary languages. Recent initiatives 
in e-health make attempts to better educate patients on any 
chronic condition, hopefully leading to better compliance and 
outcomes(12). One could speculate that a patient who is properly 
educated on the disease, on correct use of medication, on the 
treatment options and alternatives, and the expected outcomes 
of treatment may have better outcomes than the non-educated 
patient(13). It can be expected that patients who are conscious of 
and reminded of the lack of control of CRS despite medical and 
or surgical treatment are more adherent to therapy and avoid 
more external triggers like cigarette smoke and/or occupational 
triggers of CRS. Reminders using digital platforms have been 
shown to be of benefit in improving compliance, at least in the 
short term(14).
Recent initiatives in e-health make attempts to better 
educate patients on any chronic condition, hopefully 
leading to better compliance and outcomes
Actively engaging patients in their own care and facilitating 
self-management using written action plans has been shown to 
improve compliance and patient satisfaction in asthma care(15), 
as well as reducing acute exacerbations(16) and improving symp-
tom control and quality of life(17). A CRS action plan has been 
developed by Nayan et al.(18) which incorporates triggers to alert 
the patient as to when to step up treatment or seek medical 
attention. 
9.1.4 Expectation management (see also 9.3.3.)
While physicians are likely to understand the chronic nature 
of sinus disease in many patients and the need for ongoing 
treatment, it is essential to share this with the patient from the 
outset. The aim of treatment is to achieve adequate control of 
symptoms with as little need for intervention as possible; for 
many this will involve ongoing usage of intranasal treatments 
and in some, repeated need for systemic treatments or surgical 
interventions. Some patients will remain inadequately control-
led despite receiving optimum current evidence-based care. 
Cure, with an absence of symptoms in the setting of no ongoing 
medication usage, is unusual with the exception of localized 
sinus disease where there has been a curable cause, such as an 
odontogenic source. 
Patient advocacy groups and online resources can be valuable 
to patients and supplement information received during face 
to face consultations. Sharing personal experiences with other 
patients may help reduce frustration with limitations in current 
treatments and also help patients navigate their way through 
complex healthcare systems. 
Patients will often seek out a variety of sources of information. 
Signposting useful and reliable resources such as the EUFOREA 
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• Inspire researchers to further study acute rhinosinusitis and 
chronic rhinosinusitis;
• Support the use of standard definitions and measurements 
of the disease;
• Hopefully reduce unnecessary (antibiotic) treatment; 
• Encourage people to form new collaborations to answer 
unmet research questions.
Q. Who will use the EPOS2020 guidelines?
A. Many individuals and groups from doctors through to govern-
ment bodies.
EPOS2020 will provide guidance for relevant government bo-
dies, national and international drug agencies [e.g. the European 
Medicines Agency (EMA) and the Food and the Drug Adminis-
tration (FDA) in the USA] and scientific societies, particularly 
regarding the use of terminology, definitions and classifications 
for clinical trials. Most importantly it will be used by doctors tre-
ating patients with sinus disease to help ensure that all patients 
are offered evidence-based care.
Q. Which conditions does it cover?
A. Not just rhinosinusitis and nasal polyposis but other upper 
airway and related diseases. 
The EPOS2020 guidelines apply to children and adult patient 
populations with acute rhinosinusitis (ARS); viral/common cold, 
post-viral, bacterial; chronic rhinosinusitis without nasal polyps 
(CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP). 
It will also be relevant to patients with associated conditions, 
such as allergic rhinitis, asthma, bronchiectasis, chronic obstruc-
tive pulmonary disease (COPD), severe upper airway disease and 
rare diseases including primary ciliary dyskinesia (PCD), cystic 
fibrosis, vasculitis and immune deficiencies. EPOS2020 will also 
address patients with associated symptoms such as facial pain 
/ pressure, sleep disorders, smell disorders and odontogenic 
problems, many of which are key symptoms in the diagnosis of 
rhinosinusitis.
Q. Who writes EPOS?
A. An international group of experts who are leaders in the field of 
rhinosinusitis and nasal polyps.
It took approximately 18 months and around 80 people from 
over 20 different countries to review all the latest information 
and then write and publish these guidelines. 
This group consisted of renowned experts including:
• Ear, Nose and Throat Surgeons
• Allergists
• Pharmacists
• Microbiologists 
• General Practitioners 
• Paediatricians 
• Pulmonologists 
site, with both videos and written advice for patients will ensure 
that they receive correct information (www.euforea.eu/patient-
platform).
9.2. What does EPOS 2020 mean for patients?
The following section is written by patients involved in the deve-
lopment of the EPOS2020 guidelines to help explain what the 
guidelines mean for patients.
Q. What does EPOS stand for?
A. EPOS stands for the European Position Paper on Rhinosinusitis, 
covering the diagnosis and management of both acute and chronic 
rhinosinusitis in primary and secondary care.
Q. What are the EPOS2020 guidelines?
A. The guidelines are a summary of the most up-to-date informa-
tion regarding the treatment and management of rhinosinusitis 
and nasal polyposis. 
The first EPOS guidelines were developed in 2005 and have 
subsequently been updated in 2007, 2012 and now 2020. 
In essence, the guidelines are a summary of the very latest 
knowledge in rhinosinusitis and nasal polyposis. To develop the 
guidelines, academic and clinical leaders in this field, along with 
the help of some patients, looked at all the information available 
in this area, from as far back as 1960 through to the present day, 
and summarised the most important elements. 
The guide represents what all those experts agree should be 
recommended practice at this current time.
Q. Why are they needed?
A. To ensure that everyone who is in any way connected to the 
treatment or management of rhinosinusitis and nasal polyposis 
has the best information available.
The field of medicine is constantly changing. The continual 
emergence of new research and improved practices means it 
is important from time to time, to take stock of these develop-
ments and ensure that current clinical practice reflects the latest 
thinking. 
This process happens in all areas of medicine from heart disease 
to child health and it is vital to ensure everyone around the 
world has access to the best information available.
Q. What is the objective of the EPOS2020 guidelines?
A. It is primarily to provide management strategies for rhinosinusi-
tis based on relevant research.
Beyond this, there are many things that the EPOS2020 guideli-
nes hope to achieve. The guidelines aim to:
• Provide healthcare professionals with a summary of the 
best methods for diagnosing and managing patients in 
both the hospital and the wider community setting;
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Key points | What’s new since EPOS 2012
• Aspects of patient participation are covered for the 
first time in EPOS2020.
• Relatively few studies have been published on CRS in 
this area.
• Recent mobile health application initiatives to educate   
patients on CRS are now available but the impact of 
e-health on CRS outcomes still needs to be defined 
and proven.
• Patient involvement is essential in the development of 
their future care.
early detection and appropriate management, returning a pa-
tient to full health and preventing disease persistence. This aims
to reduce the severity and impact of disease from the outset.
Tertiary prevention aims to reduce the impact of ongoing chro-
nic disease and its complications in order to maintain quality of 
life and normal functioning as much as possible.
9.3.2. Primary prevention
CRS is a heterogeneous disease, where inflammation, mucocilia-
ry dysfunction and changes in the microbial community interact 
with differing influences to cause disease(19), the aetiology is 
likely multifactorial, and opportunities to prevent targeting 
specific causes will likely vary between subgroups. 
9.3.2.1. Occupational and environmental factors (see also 
5.1.2.9 and 5.1.2.10
Exposure to toxins, especially tobacco smoke, ozone and 
particulate air pollutants such as diesel exhaust particles, may 
exacerbate airway inflammation. The significance of most toxin 
exposures in the prevalence of CRS is unclear.
A systematic review of risk factors for CRS performed in 2015 
highlights the lack of clear definition of CRS used in available 
studies, reliance on self-reporting of exposure levels, failure 
to address confounding and almost uniformly poor quality of 
the available literature in this area(20). Given the poor quality, 
the conclusion of this study was that it was not possible to 
make strong conclusions regarding the role of occupation and 
environmental exposure. Of 41 studies identified, most failed 
to use a robust definition of CRS. Both Kim et al. and Alexiou et 
al.(21) classified both environmental and occupational exposure, 
and adjusted for smoking status, finding increased risk preva-
lence of nasal polyps for those exposed compared with controls. 
Woodstove use was associated with higher risk than tobacco or 
occupational exposure. In a subsequent study, Gao et al. found 
a significant association between occupational and environ-
mental factors and CRS(22), more specifically exposure to gases, 
• Neurologists
There were also patients involved in the guidelines to ensure the 
recommendations were always seen from a patient’s perspec-
tive.
EPOS2020 is also supported by professional organisations, such 
as the European Rhinologic Society (ERS) and the European 
Academy of Allergology and Clinical Immunology (EAACI).
Q. Is this just for use in Europe?
A. No, EPOS2020 will have relevance around the world.
Although EPOS has the word European in its title, and a strong 
European representation among the people who developed it, it 
is intended to be used beyond Europe. Individuals from all over 
the world have contributed to the development of these guide-
lines and they will have relevance in many countries outside of 
Europe.
Q. Does a healthcare professional have to follow the guide-
lines?
A. This is intended to be guidance and represents best practice but 
is just one aspect of what informs the decisions a healthcare profes-
sional makes. 
Healthcare systems around the world are all different and the 
healthcare professionals within them will base their decisions on 
how to manage a patient on many factors. EPOS2020 provides 
guidance on the latest information that a healthcare professio-
nal may use to inform the decisions they make but they are not 
obliged to follow them.
Q. Where can patients get further information about allergy 
and airway diseases?
A. Further information for patients can be found at www.euforea.
eu/patient-platform.
The European Forum for Research and Education in Allergy and 
Airway diseases (EUFOREA) is an international non-profit orga-
nization working towards preventing and reducing the burden 
of chronic respiratory diseases (asthma, rhinitis, and rhinosinu-
sitis). Further information for patients about allergy and airways 
disease can be found on their website at www.euforea.eu/
patient-platform. The EPOS2020 paper and a patient summary 
can be found on https://epos2020.eu/
9.3 Prevention of disease
9.3.1. Primary, secondary and tertiary disease prevention in 
CRS
Prevention of disease may be thought of in three main dimen-
sions:
Primary prevention aims to reduce incidence of disease by redu-
cing exposure to risk factors or triggers.
Secondary prevention aims to reduce disease prevalence by 
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fumes, and smoke have been shown to be associated with in-
creased risk of CRS(23). Hox et al. found occupational exposure to 
irritants was both a risk factor for disease development, but also 
for recalcitrance, reflected in higher rates of revision surgery(24).
Some studies have looked at specific occupations, with grain 
farmers(25) and those working in the textile industry(26) being 
shown to have a higher prevalence of CRSwNP. Regular follow-
up of the first responders following the 9/11 attack on the World 
Trade Centre have offered a unique opportunity to prospectively 
study the risk of developing CRS; rates were higher in firefighters 
involved in digging and rescue work than emergency medical 
services workers. Those arriving at the site early, with higher 
levels of exposure to irritants, or those with prolonged exposure 
had highest rates of CRS, approaching 50% using an epidemio-
logical definition 10 years after the event(27).
Wolf found no correlation between CRS and outdoor air quality 
in Cologne(28), similarly there was no difference in CRS prevalen-
ce in rural or urban areas of South Korea(29) nor in the Nether-
lands(30). In contrast weak correlations have been found in US 
studies(31), where improvements in air quality were also associa-
ted with a decreased prevalence of both hay fever and rhinosi-
nusitis. More recent studies have shown a stronger association; 
Park et al.(32) found a linear association with levels of particulate 
matter and CRS, although the study sampled only patients with 
known ENT disease and did not include a control population. 
Mady et al.(33) found an association between exposure to air 
pollutants and disease severity in patients with known CRS, but 
again did not include a control group. 
While a causal link cannot be clearly established, evidence is cer-
tainly mounting, and it is worth clinical questioning to include 
environmental and occupational exposure to irritants. There 
is no available evidence to inform on safe levels of exposure 
or preventative measures in those exposed. Global action to 
reduce pollution is clearly beyond the remit of this document, 
but must be made a priority(34, 35) and the effects of global war-
ming closely monitored. Ensuring compliance with international 
standards for indoor air quality may help at an individual level.
There is direct evidence that tobacco smoke diminishes muco-
ciliary clearance and is a potential contributing and/or exacer-
bating factor in exposed individuals with chronic rhinosinusitis 
(36, 37).
Evidence for both active and passive smoking leading to incre-
ased risk of CRS is much stronger. The GA2LEN survey of over 
50,000 patients across Europe found that CRS was more com-
mon in smokers (OR1.7) compared with non-smokers(38). 
A 2018 systematic review identified 13 studies evaluating the 
effect of primary tobacco smoke, with 11 reporting an increased 
prevalence of CRS in smokers. There was a dose-dependent 
association found in three studies, with a 1.5% increase in preva-
lence for every additional year of smoking(39). 
There is direct evidence that tobacco smoke dimi-
nishes mucociliary clearance and is a potential 
contributing and/or exacerbating factor in 
exposed individuals with chronic rhinosinusitis 
Passive smoking, with exposure, both in childhood and adult 
life, also seems to have a significant association with CRS(40-42). 
Aggressive taxation on tobacco products, plain packaging with 
warning labels and repeated counselling at every healthcare 
consultation are important to maintain the declining prevalence 
of smoking.
9.3.2.2. Allergy (see also 5.1.2.1 and 8.1.1)
It has been proposed that mucosal oedema within the ostio-
meatal complex (OMC) in allergic rhinitis may compromise 
ventilation and even obstruct sinus ostia, leading to mucus 
retention and infection, however the causal role of allergy in CRS 
has been long debated(43-46). On one hand, rates of positive skin 
prick tests are not statistically different between CRS patients 
or healthy controls, or between CRS sufferers with or without 
polyps(43) although patients with CRS had a higher number of 
sensitivities. One recent systematic review evaluated 18 articles 
examining the relationship between allergy and CRSwNP, 10 
articles found an association, seven found no association and 
one article showed a possible association. Of nine articles which 
examined the relationship between allergy and CRSsNP, four ar-
ticles found an association compared with five articles showing 
no association(47). In a large population based study there was a 
significantly increased risk of AR prior to a subsequent diagnosis 
of CRS (OR 2.4 for CRSsNP and 2.6 for CRSwNP)(48). One recent 
prospective study of a large cohort followed from birth under-
took allergy testing at nine months and six years(49). Of patients 
who developed CRS, three phenotypes were identified; transient 
childhood rhinosinusitis, early onset adult rhinosinusitis and late 
onset adult rhinosinusitis. The early onset CRS group had signi-
ficantly higher rates of inhalant allergy and asthma than other 
groups. Childhood onset rhinosinusitis symptoms were the 
biggest risk factor – providing an opportunity to screen children 
with symptoms of CRS and potentially target immunotherapy in 
this group; approximately one-third of children with rhinosinu-
sitis in childhood received further investigation or treatment as 
adults. 
No studies have assessed the effectiveness of management of 
allergic rhinitis on the outcome of established CRS, or on the risk 
of subsequent development of CRS, and further research in this 
area is needed before AR management can be recommended 
as a means of CRS prevention. However, early detection and 
management of AR has been shown to have a positive impact 
on the development of lower airway disease(50, 51), and is recom-
mended for that aim.
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expected levels in the normal population. Of course, genetic 
risk factors may not change, but reduction of environmental 
exposure in ‘at risk’ populations, screening of high-risk groups, 
and identification of genes which are of prognostic value will be 
of value.
Bitter taste receptor T2R38 polymorphisms are associated with 
an increased risk of CRS, but additionally has been shown to be 
associated with prognosis, with significantly lower rates of ‘super 
tasters’ being found amongst CRS patients undergoing surgery.
9.3.2.5. Microbial exposure (see also 5.1.2.7)
The natural history of CRS, and the relationship between ARS 
and CRS development have been very poorly studied. Using the 
definitions of ARS and CRS based on duration alone, all episodes 
of CRS must start as ARS. However, what allows persistence of 
disease, or whether CRS is a completely different pathophysio-
logy from the outset is little known. Tan et al. found that pre-
morbid ARS (OR 2.2 for CRSwNP, OR 3.2 for CRSsNP) and acute 
upper respiratory tract infections (URTIs) (OR 1.3 for CRSwNP, 
OR 1.6 for CRSsNP) were more prevalent in patients developing 
CRS compared to those who did not; however, this data was 
extracted from electronic health records, and may simply reflect 
the diagnostic dilemma above. One study followed patients 
with ARS using repeated aspirates; those that developed chronic 
symptoms showed transitions from bacteria commonly associa-
ted with ARS (Strep. Pneumonia, Moraxella) to a mixed infection 
which also involved anaerobes(66). However, there is no evidence 
to suggest that active management of ARS or URTIs may reduce 
the risk of subsequent development of CRS. Indeed, increased 
use of antibiotics may cause profound and detrimental effects 
on the microbiome(67). 
One study of children treated for CRS, defined according to 
EPOS2012 criteria, and in remission, compared prophylactic use 
of bacterial lysate for three months to no treatment in an open-
label study and showed significant reduction in subsequent use 
of antibiotics, nasal obstruction and discharge in the treatment 
group at one year(68). However, given the lack of blinding further 
studies are necessary.
The balance of resident microbes is increasingly recognized as 
important in onset of CRS(69) and reduced diversity is found in 
patients with CRS compared to controls(70) and in CRS patients 
following antimicrobial therapy(71). Given that current evidence 
suggests that the human microbiome becomes established 
early in childhood(67), there may be only limited opportunity to 
influence this later in life.
Unlike many chronic diseases, there is little data suggesting an 
increased risk of CRS in those with poor socio-economic status, 
which may be linked to both microbial exposure and higher 
rates of tobacco exposure. Indeed, one study of CRS in children 
suggests that when compared to controls, children with CRS 
were more likely to be white and privately insured(72) this, howe-
Although patients often attribute their CRS to food allergies, 
with the exception of non-steroidal-exacerbated respiratory 
disease (N-ERD), where there is an increased risk of CRSwNP, 
there are only limited studies assessing the association between 
CRS and food allergies. One study showed that milk allergy may 
be a predisposing factor for CRS(52), however, overall the evi-
dence is poor(47, 53) and certainly there is no evidence to support 
exclusion diets to prevent CRS. In N-ERD, CRSwNP typically deve-
lops after the onset of asthma, but again there are no studies 
evaluating the effectiveness of desensitization in preventing 
onset of CRSwNP.
9.3.2.3. Asthma (see also 5.1.2.2)
There is strong evidence to show that asthma and CRS, especi-
ally CRSwNP, frequently coexist. Several studies have shown that 
patients with asthma have a higher likelihood of having CRS(44, 
54-56) and the GA2LEN Survey showed that in all age groups, men 
and women, and irrespective of smoking behavior, asthma was 
associated with CRS(55). The Greisinger Health study(48) found 
higher rates of premorbid asthma in those developing CRS 
compared with healthy controlled (OR 2.8 for CRSwNP and 1.7 
for CRSsNP). Similarly, higher premorbid rates of bronchitis, 
pneumonia and bronchiectasis have been reported. Again, a 
causal relationship has not been confirmed, but it is postulated 
that acute infective exacerbations may modifiy susceptibility to 
developing CRS.
9.3.2.4. Genetic risk factors (see also 5.2.1)
A number of genetic disorders, including cystic fibrosis and 
primary ciliary dyskinesia are associated with a high prevalence 
of CRS, however these account for only a very small proportion 
of CRS cases. Currently over 70 genes have been genetically as-
sociated with CRS, summarized by a number of recent reviews(57, 
58). Genes associated with CRS can be broadly categorised into: 
genes associated with ion channels (e.g. CFTR); immunological 
genes (HLA, CD, IL); genes involved in tissue remodelling and in 
arachidonic acid metabolism(57-59), and genes associated with CF. 
Until recently, outside of CFTR, there were no replication studies 
validating the gene associations with CRS, and no studies 
demonstrating their biological relevance(59). Henmyr et al. found 
a significant association in only seven genes of the previous 53 
genes associated with CRS(60). One potential target gene, CDHR3, 
part of the cadherin family expressed primarily in respiratory 
epithelium, has a number of polymorphisms which determine 
susceptibility to both rhinovirus infection and adult CRS, sug-
gesting a potential role of rhinovirus as a trigger(61). There has 
been growing recent interest in the bitter taste receptor T2R38; 
polymorphisms are associated with an increased risk of CRS, 
but additionally has been shown to be associated with progno-
sis, with significantly lower rates of ‘super tasters’ being found 
amongst CRS patients undergoing surgery(62-65) compared to 
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not provide full insight into underlying cellular and molecular 
pathophysiologic mechanisms of CRS(80) and further differentia-
tion or “endotyping” will better predict the likely natural course 
of disease and prognosis in terms of recurrence after surgery 
and risk of comorbid asthma but also in responsiveness to dif-
ferent treatments, including topical intranasal corticosteroids, 
surgical interventions, and biological agents. In this regard, no-
vel biological treatments may be given to patients who can be 
predicted to have an otherwise recalcitrant path, based on their 
biomarkers, before undergoing ineffective cycles of treatment 
with corticosteroids and surgery. 
Guidelines have traditionally attempted to drive all patients 
through the same pathway; in reality multiple interconnected 
pathways are likely to be required to facilitate precision medi-
cine.
9.3.3.3. Optimising the outcome of surgical intervention 
(see chapter 6.2)
Surgery may be optimized according to two main domains; 
9.3.3.3.1. Timing of surgery
Once the diagnosis of CRS is made, EPOS advocates surgical 
treatment when optimal medical management has made no 
improvement in symptoms after 12 weeks(78).
Current evidence fails to show clear benefit of surgery over 
medical treatment at first presentation, supporting a role for 
primary medical treatment(81, 82). However, after failed medical 
therapy, patients who elected to continue with medical therapy 
achieved poorer outcomes than those choosing surgery(83).
Furthermore, delayed surgery in the setting of persistent CRS 
after failed medical therapy has been shown to be associated 
with higher ongoing healthcare utilisation postoperatively(84, 
85) surgical intervention after a trial of medical therapy may also 
deliver better symptomatic outcomes that are sustained for as 
long as five years(84).
Appropriate indications for ESS are currently poorly defined and 
the lack of clear surgical indications for ESS likely contributes to 
the large geographic variation in surgical rates. A recent study 
by Rudmik et al. clearly states that ESS can only be indicated 
after medical treatment has failed with patients still having 
significant symptoms (SNOT-22 ≥20) and at least some abnor-
malities on a CT scan(86). Pre- and post-operative patient-rated 
outcome scores such as the SNOT-22 may be used to predict 
benefit from surgery and identify early failure(84, 87). Improved 
patient selection for surgery is likely to improve outcomes and 
reduce risk of harm.
9.3.3.3.2. Extent of surgery
There is little comparative evidence to direct surgeons as to 
whether a conservative, aggressive or tailored approach to sinus 
ver, may simply reflect inequity of access to healthcare.
9.3.2.6. GORD (see also 5.1.2.5)
The relationship between gastroesophageal reflux disease 
and upper and lower airway diseases has been debated in the 
past(73). However, Wong et al. describe a possible vagal neural 
reflex existing between the oesophagus and the paranasal sinu-
ses(74). A causal relationship between GORD and CRS has yet to 
be firmly established but GORD does appear to be a risk factor 
for development(75). Few studies specifically assess whether 
treatment of reflux has an impact on development of CRS or 
severity of symptoms, and there is insufficient current evidence 
to consider anti-reflux therapy for refractory CRS in adults(76).
Recent epidemiologic studies using electronic health registries 
and systematic reviews report that GORD and CRS often coexist.
9.3.3. Secondary prevention
Secondary prevention of CRS is concerned with detecting a 
disease in its earliest stages, intervening to achieve disease and 
symptom control and preventing future exacerbations. Implicit-
ly, secondary prevention takes place when primary prevention 
fails. Early diagnosis and selection of the optimal treatment is 
central to secondary prevention. Recent data suggest that there 
is still a large portion of the population with CRS not receiving 
treatment; as above, it is estimated from population studies that 
CRS affects approximately 5–15% of the general population 
both in Europe and the USA in contrast with 2-4% prevalence 
of doctor-diagnosed CRS(77, 78). It is unclear whether patients are 
unable to access care, or effectively self-manage symptoms of 
CRS.
9.3.3.1. Early establishment of diagnosis
State-of-the-art guidelines like EPOS(78) provide clinicians with 
evidence-based diagnostic and treatment algorithms for CRS 
based on symptom duration and severity. However, a symptom 
based definition alone is likely to over-estimate disease(79) and 
currently findings on endoscopy or radiological imaging are 
required to support the diagnosis. It is likely that the diagnostic 
criteria will be further defined as biomarkers for disease are 
identified. The Finnish allergy programme(50) has shown the 
effectiveness of screening for inflammatory airway disease. 
However, with current financial constraints in healthcare, it is 
unlikely that such schemes will become widespread. However, 
symptom-based screening of patients at high risk of secondary 
CRS, such as those with systemic vasculitides, or those with 
eosinophilic airway disease and aspirin –exacerbated respiratory 
disease (N-ERD) is likely to be beneficial.
9.3.3.2. Selection of optimal treatment (see also chapter 6)
Currently CRS is broadly categorised into two subgroups: CRS 
with and without nasal polyps. However, clinical phenotypes do 
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adverse effects are minor. A recent Cochrane review found no 
difference in the reported side effects between topical cortico-
steroids and placebo(96), except for an increase in reported epis-
taxis. Moreover, there seems to be no clinically relevant impact 
on either ocular pressure, glaucoma, lens opacity or cataract 
formation(97).
The use of prolonged courses of anti-inflammatory antibiotics 
needs to be balanced with the potential gastrointestinal distur-
bances and serious adverse effects of rhabdomyolysis and pro-
longed QT(98), effects on bacterial resistance and as yet largely 
unknown consequences to the sinus microbiome. A study in 
CRS patients receiving macrolide antibiotics found a short-term 
increase in risk of myocardial infarction, highlighting the need to 
evaluate cardiac risk factors prior to usage(99). 
In comparison with medical therapy, there is more data repor-
ting the rate of surgical complications. The National Sinonasal 
Audit reported a total adverse event rate of 6.6 %, most of which 
was related to minor bleeding. This rate of major complications 
from the UK (0.4 %) compares with a rate of 1.1 % reported in 
a meta-analysis from 10 years previously of 4691 patients who 
underwent ESS in the US(100-102). There is conflicting evidence 
regarding whether use of image guidance may mitigate against 
the risk of complications(103, 104).
9.3.4. Tertiary prevention
Tertiary prevention aims to minimise the impact of an ongoing 
illness or injury that has lasting effects. This is done by helping 
surgery should be taken(88). Data from the UK audit of sinus 
surgery found no additional benefit of additional sinus surgery 
over simple polypectomy in terms of symptomatic benefit, and 
only a small benefit in terms of revision rates(89). However, the 
additional sinus surgery performed in most cases was very con-
servative, and less than 2% of the surgical cohort had complete 
frontoethmoidectomy and sphenoidotomy. The effectiveness of 
intranasal steroids has been shown to be increased in the posto-
perative state, suggesting improved access to topical therapy is 
an important aspect of the benefits of surgery(90). Furthermore, 
eosinophilic CRS has been shown not to be associated with os-
tiomeatal occlusion(91) and therefore simple measures to address 
the OMC are unlikely to be effective. There is some evidence to 
support a more extensive approach, particularly in eosinophilic 
disease or CRSwNP(92, 93).
9.3.3.4. Minimising risks of treatment
As a general rule, any treatment should have benefits that al-
ways outweigh the risks. When considering medical and surgical 
interventions, we must consider the risk of harm to the patient.
Short courses of oral corticosteroids are widely used, and may 
result in insomnia, mood and gastrointestinal disturbances(94). 
There is a paucity of data on the threshold of dose that may 
expose patients to major complications such as avascular 
necrosis and osteoporosis, and repeated courses should be used 
judiciously(95). In contrast, topical corticosteroids are safe and 
Figure 9.3.1. Tertiary prevention factors in poorly controlled CRS.
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CRSsNP(115). Patients with co-existing depression report poorer 
disease specific health related quality of life both before and 
after treatment for CRS(116). Although treatment for CRS has been 
shown to reduce depression scores, there is no evidence on 
whether treatment of depression may result in improvement of 
CRS-related QOL.
Nayan et al.(117) undertook a systematic review of dietary modi-
fications that might have the potential to reduce inflammation 
in recalcitrant CRS. They did not identify any studies outside of 
those undertaken in the N-ERD population (reviewed in chapter 
6.1.12.4). In acute URTI probiotics are better than placebo in 
reducing the number of participants experiencing episodes of 
acute URTI, the mean duration of an episode of acute URTI, an-
tibiotic use and cold-related school absence. This indicates that 
probiotics may be more beneficial than placebo for preventing 
acute URTIs. However, the quality of the evidence was low (see 
chapter 4.6.2.11). Extrapolating from other chronic inflammatory 
conditions, there is potential benefit in the use of probiotics, and 
diets promoting healthy gut microbiota, but their role in CRS is 
yet to be established. 
Key points | What’s new since EPOS 2012
• Prevention may be considered as primary, secondary 
and tertiary.
• Occupational and environmental factors are of increa-
sing importance in primary prevention and the effects 
of global warming carefully monitored.
• Co-morbidities such as allergy, asthma and GORD 
should be considered.
• Genetic and microbiological factors will likely become 
of greater importance.
• Early diagnosis and selection of the optimal treatment 
is central to secondary prevention.
• Optimising medical treatment and consideration of 
the timing and extent of surgery can improve outco-
mes.
• In tertiary prevention, a careful review of ongoing 
treatment, technique and compliance with medication 
should be undertaken.
• Growth in digital healthcare and patient apps may 
encourage self-management and increase compliance.
9.3.2. Prevention of asthma
There is extensive literature concerning primary prevention of 
asthma with respect to allergen avoidance, dietary manipulation 
and immunotherapy; it is beyond the scope of this document to 
review these here. 
 There are a small number of studies using big data sets that 
people manage long-term, often-complex health problems and 
injuries (e.g. chronic rhinosinusitis) in order to improve as much 
as possible their ability to function, their quality of life and their 
life expectancy. Ongoing poorly controlled upper airway disease 
may result from disease-related factors, inadequate treatment, 
poor compliance or failures in the diagnostic pathway to identify 
secondary CRS, or perhaps incorrectly diagnosed CRS in the first 
place(105) (Figure 9.3.1.). A recent study found that at least 40% of 
CRS patients would be considered to have uncontrolled disease 
within 3-5 years of endoscopic sinus surgery(106).
In patients with poor disease control, a careful review of on-
going treatment, technique and compliance with medication 
should be undertaken. Growth in digital healthcare and patient 
apps may encourage self-management and increase compli-
ance. The evidence of the impact of ongoing tobacco exposure 
on quality of life outcomes of CRS treatment is conflicting(107, 
108), but higher rates of revision surgery are seen in smokers(109), 
and cessation should therefore be encouraged. Management of 
individuals with recalcitrant CRS is based on the understanding 
that this is a chronic condition, and that “cure”, as achieved in 
acute bacterial infections such as tonsillitis, cannot and should 
not be expected. Caregivers and allied health personnel all share 
in the task of educating the patient to understand the chronic, 
ongoing nature of the disorder, and to adjust their expectations 
accordingly.
Growth in digital healthcare and patient apps may 
encourage self-management and increase 
compliance.
The diagnosis should be reconfirmed, particularly when facial 
pain is the ongoing primary symptom, and systemic diseases 
should be considered and excluded when indicated. Conditi-
ons such as granulomatosis with polyangiitis (Wegener’s) or 
eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 
may present with sinonasal disease and the systemic nature 
of disease may not be apparent in the early stages (section 
8.7). Underlying immune deficiency should be considered, 
particularly where there is a history of concomitant lower 
airway, ear or skin infections (section 9.2). Up to 10% patients 
with refractory CRS were found to have common variable 
immunodeficiency(CVID), 20% had decreased IgG, IgA or IgM, 
and 11-67% had an inadequate functional response to pneu-
mococcal vaccine(110-112), although all studies were conducted 
at tertiary institutions, thus it is likely that there is significant 
selection bias.
Higher levels of anxiety and depression are found in patients 
with CRS, although it is often undiagnosed(113, 114). It is unclear 
if this is a causative relationship; however, it appears likely that 
co-existing depression results in both higher rates of symp-
tom reporting and amplifies symptom severity, particularly in 
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systematic reviews have shown benefit in terms of early symp-
tom scores and endoscopic appearances(125) there is no signifi-
cant impact on long-term outcomes, and current trials have no 
compared to high-volume saline irrigation alone. Routine use of 
antibiotics in all patients after ESS is not supported by the litera-
ture and increasing bacterial resistance must be considered, but 
it may be used in selected cases(125).
There are a growing number of drug-eluting stents and topical 
dressings that may promote early healing and restoration of mu-
cociliary function. A recent systematic review studied steroid-
eluting bioabsorbable intranasal devices, and demonstrated 
improved objective and subjective outcomes following ESS(126); 
although their role in preventing recurrence has not been 
assessed, prevention of adhesions and stenosis may potenti-
ally reduce the risk of revision and therefore warrants further 
study. Currently, costs may restrict widespread usage, although 
cost-effectiveness may be enhanced by reduced post-operative 
debridement.
A small number of studies have found that ongoing occupati-
onal exposure to irritants may increase risk of recurrence(24, 127). 
Any factors thought to be involved in the underlying aetiology 
of CRS in each individual patient should be addressed where 
possible to reduce risk of recurrence.
9.3 Prevention of patient dissatisfaction after CRS treatment
In contrast, to the large number of studies evaluating changes 
in HRQOL after treatment, few studies have evaluated patient 
satisfaction with outcomes of treatment, and only following 
surgical interventions. 
A 2003 study found high levels of overall satisfaction after sinus 
surgery, with 72% patients being very satisfied. Lower education 
level and higher severity of disease were found to be associated 
with lower rates of satisfaction(128).
The UK prospective audit of sinus surgery asked patients to rate 
change in overall symptoms after surgery and found that this 
was strongly associated with changes in their SNOT-22 scores(100). 
Seventy seven percent of  patients rated the results of surgery 
overall as good or excellent. Eighty four percent of patients re-
ported information provided regarding their operation as good 
or excellent, while only 58% rated information on post-operative 
treatment as good or excellent. 
Mattos et al.(129) set out to evaluate the association between 
improvement in patient’s symptoms and meeting pre-operative 
expectations with post-operative satisfaction. Patients were 
asked to identify if post-operative improvement in specific 
symptoms was felt to be important; 92% responded that impro-
vement in nasal obstruction, 77% need to blow nose and 72% 
sense of smell were very important. Eighty two percent of the  
patients were satisfied overall following surgery; on multivariate 
logistic regression this was associated with improvement in the 
symptoms most important to patients, and matching preope-
suggest that endoscopic sinus surgery for CRS reduces the 
yearly incidence of new asthma diagnoses(84, 118). In a cohort free 
of asthma at enrolment, the preoperative asthma incidence was 
4.5% in patients with allergic rhinitis (AR), and 4.2% in patients 
without AR, but fell to 0.4% post-ESS. Those patients who had 
later surgery had higher rates of asthma than those who under-
went surgery at an earlier timepoint; patients having surgery 
within two years of CRS diagnosis had an asthma prevalence of 
9% compared to 22% in patients having surgery 4-5 years after 
diagnosis. There is a risk of confounding and further studies are 
required to establish if this a true consequence of sinus surgery, 
and to assess if successful medical therapy has the same effect. 
Key point | What’s new since EPOS 2012
• Those patients who have later surgery may develop hi-
gher rates of asthma than those who undergo surgery 
at an earlier timepoint. 
9.3.3. Prevention of recurrence
Patients should be encouraged to continue to use intrana-
sal corticosteroids after surgery, as continued use has been 
shown to improve post-operative endoscopic scores in all CRS 
patients(119) and, in those with CRSwNP, reduce risk of recur-
rence(120). Adherence with prescribed postoperative medications 
dropped to only 42% at 12 months after surgery in one study 
despite regular telephone contact(121) strategies to improve this, 
such as utilizing digital technology, will likely be important in 
future. As mucosal eosinophilia has been shown to be highly 
correlated with risk of polyp recurrence, more so than basic phe-
notype of CRSwNP, in future this may provide a better indicator 
for the need for long term INCS use(122). Patients who underwent 
a single polyp exacerbation after surgery, but were then well 
controlled were found to have significantly lower adherence to 
postoperative medications compared to those with no recurren-
ce(10), suggesting that patient education regarding the need for 
ongoing therapy is important and may avoid recurrence in some 
patients. In contrast, those patients with ongoing recurrence 
were found to have significantly higher levels of eosinophilia, 
and had recurrence despite good compliance with post-opera-
tive care, suggesting that different strategies may be required to 
achieve disease control in this group. 
Continued use of intranasal corticosteroids after surgery has 
been shown to improve post-operative endoscopic scores in all 
CRS patients and, in those with CRSwNP, reduce risk of recur-
rence.
Saline douching has improves symptoms after surgery(123, 124) 
and may reduce need for nasal cavity debridement. The value 
of postoperative debridement remains controversial; although 
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with elevated IgE(133). When used postoperatively, responders 
were found to have lower tissue and serum eosinophil levels(134). 
Ebbens et al.(135) showed that CRS patients with higher levels of 
mucosal eosinophils are less likely to suffer from postoperative 
recurrent sinonasal disease when treated post-operatively with 
nasal corticosteroids than patients with lower mucosal eosinop-
hils.
When predicting outcomes following sinus surgery with respect 
to improvement in symptoms scores measured with PROMs, a 
number of studies have shown that the preoperative score is 
the best predictor of outcomes(136, 137).Patients with preoperative 
SNOT-22 scores less than 20 failed to achieve mean improve-
ment greater than the MCID, scores of >30 have a 70-75% chan-
ce of achieving improvements greater than the MCID. Patients 
on average achieve a 45-50% reduction in SNOT-22 scores(138, 139).
When predicting outcomes following sinus surgery, a number of 
studies have shown that the pre-operative symptom score is the 
best predictor of outcome.
Smith et al.(140) prospectively evaluated 119 adults with CRS to 
determine other preoperative factors that predicted improve-
ment in endoscopy and quality of life. Smokers, and patients 
with depression and N-ERD had least benefit in both respects, 
but still reported improvements in both domains. In a separate 
study he also demonstrated that patients undergoing primary 
surgery were more likely to achieve significant improvements 
in HRQOL than patients undergoing a revision procedure(141). 
Higher income and better socioeconomic status are associated 
with greater improvements in quality of life(142, 143) it is not clear if 
this reflects differing access to care. 
With respect to olfactory outcomes, Bogdanov et al.(144) demon-
strated that for patients with olfactory loss, the response in 
olfactory function to oral corticosteroids (OCS) predicted the 
outcome of surgery; improvements after OCS and surgery were 
significantly correlated and no patient responded to surgery 
who did not respond to OCS. This would be a useful test to avoid 
patient dissatisfaction after surgery if hyposmia was their main 
driver to seek intervention. 
Key points | What’s new since EPOS 2012
• When predicting outcomes following sinus surgery, a 
number of studies have shown that the pre-operative 
symptom score such as SNOT22 is the best predictor of 
outcome.
• Primary surgery has better outcomes than revision.
• When loss of smell is a major symptom, response in 
olfactory function to oral corticosteroids (OCS) predicts 
the outcome of surgery.
rative expectations. Achieving an improvement greater than 
the MCID was not a predictor of satisfaction; 86% of patients 
not achieving the MCID were still satisfied with the outcome of 
surgery and 87% would recommend sinus surgery to others. In 
a similar study, Phillips et al.(130) studied patients who reported 
overall improvement in their CRS symptoms despite failing to 
achieve change in SNOT22 scores of greater than the MCID; they 
found that significant improvement in the nasal subdomain 
resulted in patients reporting overall improvement, but no other 
subdomains were associated with overall improvement.
Although data is limited, it appears that pre-treatment coun-
selling to ensure that a patient has realistic expectations of 
treatment outcomes, both with respect to overall improvement 
and achieving improvement in symptoms deemed to be most 
important to the patient, as well as optimizing outcomes with 
respect to nasal symptoms is important to avoid a dissatisfied 
patient. Provision of information both regarding the likely risks 
and benefits of treatment and the need for ongoing care may 
need to be tailored to a patient’s educational level.
9.4. Prediction
9.4.1. Prediction of the natural course of disease
There are no studies evaluating the natural history of untreated 
CRS. The fact that the prevalence of disease peaks between the 
ages of 45-54 years, and then declines suggests that remission 
occurs with later age (54). 
De Corso et al.(131) prospectively followed patients with CRSsNP 
with endoscopy and evaluated the risk of developing nasal 
polyps. Patients with eosinophilic inflammation demonstrated 
on nasal cytology were significantly more likely to develop po-
lyps, compared with those with neutrophilic inflammation and 
controls with vasomotor rhinitis. 
Key point | What’s new since EPOS 2012
• There is an urgent need for research to address the 
natural course of CRS.
9.4.2 Prediction of ‘success’ or symptomatic improvement
There are few studies predicting success of medical therapy – 
response rates for individual treatment options are discussed 
in chapter 6. A meta-analysis(132) evaluated factors predicting 
success of low-dose macrolides; patients with CRSsNP achieved 
greater improvements in symptoms scores, longer courses (24 
weeks compared to eight and 12 weeks) and half dose (compa-
red with very low dose) were also more effective. IgE was not 
assessed, but a randomised trial found that patients with normal 
IgE achieved greater benefit in symptom scores than patients 
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went revision surgery. The presence of nasal polyps and female 
gender were again shown to be predictive of revision surgery. 
Revision surgery rates are an imprecise estimate of recurrent 
disease as they are influenced by both the patient’s and the 
surgeon’s willingness to undergo / perform revision surgery and 
therefore, likely underestimate the rate of recurrent disease.
DeConde(149) studied endoscopic recurrence in CRSwNP and 
found that 38% patients had recurrent polyps at 12 months 
after surgery, while 82% had mucosal oedema. Not all of these 
would appear to go on to revision but it would be helpful to be 
able to predict who will develop recurrent disease in order to 
target treatment. A number of studies have looked at the role of 
biomarkers to predict disease recurrence. A systematic review(150) 
identified 11 articles evaluating tissue eosinophilia; >55 eosi-
nophils per high powered field had both high sensitivity (0.87) 
and specificity (0.97) in predicting recurrent disease. Further 
attempts to avoid the need for tissue biopsy have shown that 
blood eosinophil levels may be used to identify patients with 
eosinophilic CRS, but has lower sensitivity; Ho et al.(151) reported 
that blood eosinophil levels >0.24 x 109/L (sensitivity 71%, speci-
ficity 78%) or eosinophil ratio of >4.27% of total white cell count 
(sensitivity 64%, specificity 89%) could be used to predict eCRS. 
In a multivariate analysis, eosinophilic CRS were the only signifi-
cant predictor of recurrence after controlling for other variables, 
and also showed that the disease-free interval was significantly 
shorter(152) . Both blood and tissue eosinophilia were predictors 
of poor disease control, alongside more extensive radiological 
disease (LMS ≥15) (152) . A number of other biomarkers have been 
evaluated with respect to predicting recurrent disease. CRSwNP 
patients who undergo revision surgery had significantly higher 
polyp tissue levels of IgE, ECP and IL-5, while non recurrent 
patients had a mixed pattern of cytokines with higher levels of 
IFN-gamma (154). 
In another study, CST2, PAPP-A and periostin levels in mucus 
9.4.3. Prediction of recurrent disease
There is a paucity of studies evaluating the success rate or re-
lapse rate following appropriate medical therapy of CRS. Young 
et al. prospectively enrolled 80 patients receiving treatment with 
systemic steroids and antibiotics in addition to topical steroid 
sprays and saline irrigation (145). 53% failed the trial of medical 
treatment and underwent surgery. Relatively younger age, male 
gender, European ethnicity, presence of asthma, and positive 
endoscopic as well as CT findings were factors predictive of a 
need for surgery. Presence of polyps was not a predictive factor 
for failure of medical therapy.
A number of long-term studies have reported on the rates of re-
vision surgery. Hopkins et al. reported long-term outcomes from 
a multi-institutional cohort study, with 1459 patients comple-
ting five-year follow-up. 19.1% patients had undergone revision 
surgery (21% of CRSwNP, 16% of CRSsNP). Patients undergoing 
additional sinus surgery were found to have lower revision rates 
than those undergoing simple polypectomy for CRSwNP. Im-
provements in SNOT-22 scores were maintained over a five-year 
period(146).
Smith et al.(147) prospectively followed 59 adult patients electing 
endoscopic sinus surgery over a 10 year follow-up period; 
17% patients (25% of CRSwNP, 7% of CRSsNP) had undergone 
revision surgery. Those undergoing subsequent revision had sig-
nificantly poorer endoscopy scores at their first post-operative 
visit and were more likely to have developed frank recurrence 
of polyps by 18 months. Using electronic health records, Smith 
et al. identified nearly 30,000 patients with a mean follow-up of 
9.7 years(143). The long-term revision rate was reported at 15.9% 
(29.9% of CRSwNP, 7% of CRSsNP), with CRSwNP patients also 
being more likely to require multiple revision procedures. When 
examining factors associated with increased risk of revision, 
female gender, older age at time of first surgery, a history of 
asthma, allergy and nasal polyps were associated with higher 
risk of revision, with the presence of polyps having the largest 
impact. Similarly, Stein et al.(148) looked at a large electronic da-
taset of 61,000 patients undergoing ESS, of which 6.7% under-
Figure 9.5.1. Historical approaches to care. Figure 9.5.2.  Current medical practice versus precision medicine.
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Key points | What’s new since EPOS 2012
• Prediction of recurrent disease involves many factors 
including age, gender, ethnicity, co-morbidities, and 
duration of disease. 
• Both blood and tissue eosinophil levels can be measu-
red with little additional expense and may be used to 
help predict risk of recurrence and need for targeted 
postoperative care.
9.5 Precision medicine
In 2015, President Obama launched the precision medicine 
initiative: “delivering the right treatment at the right time, every 
time, to the right person”. Precision medicine (PM) is an emer-
ging approach for disease treatment and prevention targeted to 
the needs of individual patient, taking into account individual 
variability in environment, lifestyle and genes for each person(156, 
157). PM represents a novel approach in medicine, embracing four 
key features: personalized care based on molecular, immunolo-
gic and functional endotyping of the disease, with participation 
of the patient in the decision-making process of therapeutic ac-
tions, and taking into account predictive and preventive aspects 
were significantly reduced after surgery, but increased postope-
ratively in patients who went on to require revision surgery(155). 
The limitation of many of these studies is the selection of a small 
number of markers, and the failure to include commonly availa-
ble markers such as blood or tissue eosinophilia in a regression 
model to allow comparison of the predictive value. This study 
also found that increasing levels of all markers was significantly 
correlated with worsening of the SNOT-22 score at each time 
point. Indeed, deterioration of the SNOT-22 score of more than 
the MCID has also been shown to be a good predictor of need 
for revision surgery. 
While the perfect biomarker to predict failure remains elusive, 
both blood and tissue eosinophil levels can be measured with 
little additional expense and may be used to help predict risk of 
recurrence and need for targeted post-operative care. Sequen-
tial measurement of symptoms scores using the SNOT-22 may 
allow remote monitoring of these patients if resources cannot 
support direct follow-up.
Figure 9.5.3. Implementing precision medicine in CRS.
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of the treatment. The major scientific and economic challenges 
in airway diseases may be addressed through the promising 
possibilities of PM underpinned by trials and evidence to under-
stand how to use it(157) . It has evolved from evidence-based me-
dicine, ‘the conscientious, explicit, and judicious use of current 
best evidence in making decisions about the care of individual 
patients” which still remains the basis of our clinical practice(158, 
159) (Figures 9.5.1. and 9.5.2.). 
Based on the knowledge of mechanisms of the disease, PM 
generally combines diagnosis and treatment to select optimal 
management(160, 161). Precise endotyping of patients using novel 
methods like proteomics, metabolomics, genomics, diverse 
cellular assays, biobanks, registries and even mobile health tech-
nology(162), allows the design of therapeutic strategies with pre-
dictive, preventive, personalized and participatory aspects(163). 
PM has already gone through its own evolution from persona-
lised medicine to precision medicine and now, 4P medicine. The 
four Ps constitute the basis of precision medicine (Figure 9.5.3.).
• Personalized care is a medical practise that proposes cus-
tomization of healthcare, with medical decisions, practises 
and/or products being tailored to the individual patient. 
• Prediction of the natural progress of disease and of the suc-
cess of treatment allow the medical doctor as well as the 
patient to decide on the best therapeutic strategy. 
• Prevention of disease should be distinguished in primary, 
secondary and tertiary prevention. Preventive measures 
should be advised to prevent the disease from occurring 
(primary), to prevent the disease from becoming sympto-
matic (secondary) and to prevent from causing damage or 
disability (tertiary). 
• Participation of the patient in the therapeutic plan is crucial 
for achieving good adherence and hence optimal efficacy 
of treatment.
PM is not new in other areas of medicine but has been more 
recently applied to other respiratory diseases such as allergy 
and asthma and now chronic rhinosinusitis(164, 165). This has been 
promoted by organisations such as EUFOREA, the European 
Forum for Research and Education in Allergy and Airway disease 
(www.euforea.eu).
Thus the principles of PM can be implemented within existing 
adult treatment algorithms for chronic rhinosinusitis (CRS) (165). 
At the time of diagnosis, prediction of success of the initiated 
treatment as well as patient participation in the decision of the 
treatment plan can be implemented. The second level approach 
ideally involves strategies to prevent progression of disease, in 
addition to prediction of success of therapy, and patient partici-
pation in the long-term therapeutic strategy. At the tertiary level 
of care, endotype-driven treatment, which is part of a persona-
lized approach, should be positioned, given the high cost, both 
financial and in effort of implementation, of molecular diagnosis 
and biological treatment. 
Precision medicine allows real-time clinical decision support 
at the point of care with implementation of harmonized care 
based on quality criteria and patients to be treated and monito-
red more precisely and effectively to better meet their individual 
needs(167). It brings together clinicians from many inter-related 
specialities, scientists and above all patients in a collaborative 
effort to provide the most efficient and effective management.
9.6. Implementation
The implementation of high-quality guidelines and position 
papers is essential to improve clinical practice and public health. 
It is well recognised that clinical guidelines are often ignored, 
which is perhaps not surprising when so many are published 
on every conceivable topic (168-170). A clinical practice guideline 
can be defined as “systematically developed statements to 
assist practitioners’ decisions about appropriate health care for 
specific clinical circumstances” (171) thereby decreasing the gap 
between research and current practice and reducing inappropri-
ate variability in practice (172). Their development and implemen-
tation is intended to organize and provide the best available 
evidence to support clinical decision making in order to improve 
quality of care, patient outcomes and cost effectiveness (173,174). 
The criteria and prerequisites for developing guidelines are: a 
highly prevalent disease or frequently used medical procedure, 
high associated costs and current variations in practice. They 
are of particular value for a disease such as rhinosinusitis which 
has significant negative effects on health-related quality of 
life. However, in medicine in general, it is estimated that about 
30%–40% of patients receive treatment that is not based on 
scientific evidence, and 20%–25% receive treatments that are 
either not needed or potentially harmful (168, 175, 176).
The successful introduction of guidelines involves the three 
steps of: development, dissemination and implementation (177) 
and the success of implementation depends on determining the 
barriers and developing strategies tailored to overcome these. 
Several reviews have considered and categorised the most im-
portant barriers and suitable strategies (178, 179) based on 76 and 
69 articles respectively, of which the latter is the more recent 
and rigorous systematic analysis. 
Cabana et al classified the barriers to implementation into three 
main categories: barriers related to physicians’ knowledge (e.g., 
lack of awareness and lack of familiarity), barriers that affect phy-
sicians’ attitudes (e.g., lack of agreement and lack of familiarity), 
barriers that affect physicians’ attitudes (e.g., lack of agreement 
and lack of motivation) and external barriers (e.g., patient-, 
guideline- and environment-related factors) (178). 
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Barriers Interventions
Guideline related factors
Access to guideline Provide easy access to guideline
Decision support systems
Poor layout Design and development of guideline
Short and user-friendly versions of guidelines
Lack of evidence/plausibility of recommendations Use of methods of evidence-based medicine
Appraisal of evidence in recommendations
Regular updates
Delphi
Lack of applicability Sensitivity for differences in healthcare systems
Organisational constraints Standardisation of processes and procedure
Link to quality management
Lack of resources (time restrictions, heavy workload, facilitation Financial incentives/compensation
Providing time for documentation and utilization of guidelines
Social and  clinical norms Local consensus groups
User factors
Physicians’ knowledge Lack of awareness Increased dissemination of guideline
Use of mass media to increase awareness
Continuous Medical Education (CME)
Lack of familiarity Making guideline available with practical instruments
Education
Lack of agreement Opinion leaders
Stakeholder participation in guideline
Society endorsement of guideline
Physicians’ attitudes Lack of self-efficacy Interactive learning / group training
Audit and feedback of individual performance
Lack of skills CME focusing on skills
Lack of learning culture Promoting learning organizations
Lack of motivation Motivational strategies that utilize audit and feedback
Opinions leaders
External factors
Organisational constraints Standardisation of processes and procedures
Guideline development needs to consider the care setting
Link to quality management
Lack of resources (time restrictions, heavy workload, facilitation) Financial incentives/compensation
Providing time for documentation and utilization of guidelines
Lack of collaboration Improving multiprofessional collaboration with other healthcare profes-
sionals
Social and clinical norms Local consensus groups
Table 9.6.1. Barriers and interventions in guideline implementation (adapted from Fisher(179))
The systematic review by Fischer et al. included publications 
from many countries which were both generic and disease-
specific, with several covering asthma but none on rhinologic 
topics (179). They divided the barriers into guideline-related 
factors, personal factors, and external factors which are summa-
rised in  Table 9.6.1. The scoping review revealed the following 
aspects as central elements of successful strategies for guideline 
implementation: dissemination, education and training, social 
interaction, decision support systems and standing orders.  Avai-
lable evidence indicates that a structured implementation can 
improve adherence to guidelines (179).
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EPOS is an established ‘brand’ with a strong legacy from 2005 
onwards. However, as it is 7 years since the last edition we have 
tried to improve EPOS2020 implementation:
• by writing a clear and concise executive summary follo-
wed by extensive chapters containing all the supportive 
evidence. 
• by a stronger focus on patient-relevant outcomes and 
patient involvement during its development. 
• by greater involvement of other stakeholders in its deve-
lopment and writing e.g. primary care, pharmacists and 
neurologists.
• by containing summaries and versions relevant to these 
other stakeholders to support the implementation process.
• by translating the Executive Summary into a wide range of 
languages. 
• by reaching out to many key opinion leaders all over the 
world to review and comment on the document and inclu-
ding their suggestions in the final text.
• by widespread presentation, discussion and dissemination 
at scientific meetings, publications, via websites and deve-
loping core sets of slides for presenters to use.
However, we do realize that not all advice in EPOS2020 can be 
followed in all health care systems and social circumstances. The 
advises can be adjusted locally depending on the possibilities in 
the health care system. 
EPOS2020 plans a rolling programme of revision and update in 
response to future research and responses. A full implementa-
tion plan for EPOS2020 will be published separately in the near 
future.
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10.1. Differentiating rhinitis and rhinosinusitis in 
the community pharmacy setting
Many patients with rhinosinusitis self-manage their condition 
in the community pharmacy with advice from their local 
pharmacist. This is particularly true if patients consider their 
symptoms mild and not bothersome, or that over the counter 
(OTC) medication is adequate(1, 2).
Pharmacists are in an excellent position to identify symptoms of 
rhinosinusitis and recommend appropriate treatment or referral 
to a physician(3,4). According to the PGEU (Pharmaceutical Group 
of the European Union) Annual Report 2018 (https://pgeu-
annual-report.eu), 58% of European Union (EU) citizens can 
reach their nearest community pharmacy within five minutes 
and 98% of EU citizens can reach their nearest community 
pharmacy within 30 minutes, making community pharmacists 
the most easily accessible healthcare professionals. Thus, 
community pharmacists can facilitate the development of 
effective self-management techniques that can have important 
health and economic ramifications.
Although there are no studies evaluating pharmacist 
intervention in rhinosinusitis outcomes, results from systematic 
reviews in other chronic respiratory diseases, namely asthma(5) 
and COPD(6), showed that pharmacists have positive impacts 
on the outcome, scores, severity and control of said diseases. 
Nevertheless, education programmes are needed to increase 
awareness and compliance of pharmacists with international 
guidelines(7).
A cross-sectional observational study of pharmacy customers 
purchasing OTC medications for nasal symptoms revealed that 
69.9% out of 296 participants self-manage their symptoms 
with OTC medications. The majority of participants (68%) 
experienced allergic rhinitis symptoms,   while the most 
frequent symptom was nasal congestion. The study indicated 
suboptimal therapeutic choices made by the participants, 
highlighting the need for pro-active interventions from 
community pharmacists in the form of patient therapy 
guidance, including referring to a physician if needed(8).
Some patients consulting the pharmacist will have had a 
previous diagnosis of rhinosinusitis or allergic rhinitis by a 
physician, others will have made an appropriate self-diagnosis, 
and some will have no diagnosis at all or may have an incorrect 
diagnosis(9). General symptoms of several conditions (common 
cold, postviral ARS, allergic rhinitis, or CRS) are similar and may 
be confused both by the patients and the pharmacist(10).
Patient-reported symptoms and duration should be ascertained 
(Table 10.1.1.). The presence of nasal congestion, rhinorrhoea, 
facial pain or pressure and reduction of sense of smell are 
usually characteristic of rhinosinusitis. In children, the loss 
of smell component is less important, but cough might be 
a frequent symptom at presentation. The presence of nasal 
itching, rhinorrhoea, sneezing and eye symptoms is usually 
consistent with allergic rhinitis. Patient’s relevant demographic 
information, medical and medication history, along with other 
non-pharmacological measures that the patient has tried should 
be taken into consideration when counselling treatment (Table 
10.1.1.)(11).
In some countries, pharmacists may carry out rapid diagnostic 
tests in order to determine whether infections are bacterial or 
viral in origin, or to diagnose group A streptococcal infections 
or influenza (http:www.sante.gouv.fr/IMG/pdf/IASS_ext-int.
pdf )(12). Access to point-of-care tests may help to reduce the 
dispensing of antibiotics among antibiotic-requesting subjects 
with respiratory tract infections(13). 
There is also a significant overlap in symptoms between primary 
headache disorders and chronic rhinosinusitis(14-16), with up to 
42% of patients with primary headache disorders mistakenly 
diagnosed with rhinosinusitis(16). The 22-item Sino-Nasal 
Outcome Test (SNOT-22) is a validated non-invasive diagnostic 
tool. This score can be used to aid in patient counselling 
as different score patterns exist for patients with CRS and 
headache(17).
Specific guidelines for allergic rhinitis management at 
community pharmacies were first issued in 2004(18), and have 
recently been updated(19). Computerized decision support 
systems for rhinosinusitis similar to those proposed for allergic 
rhinitis might be helpful when counselling patients(20).
10.2. Dispensing and use of non-prescription 
antibiotics in URTIs
ARS subgroups (viral ARS or common cold, post-viral ARS 
and ABRS) are distinguished based on symptom severity and 
duration. Thus, common cold / acute viral rhinosinusitis is 
defined by the duration of symptoms for less than 10 days, 
while acute post-viral rhinosinusitis is defined as an increase of 
symptoms after five days or persistent symptoms after 10 days 
with less than 12 weeks duration. Acute bacterial rhinosinusitis 
is linked to the presence of at least three symptoms / signs 
of: discoloured discharge, severe local pain (with unilateral 
predominance), fever (>38ºC), elevated ESR/CRP and ‘double 
sickening’ (i.e. a deterioration after an initial milder phase of 
illness) ( for details please see chapter 4.1 and 4.3.). 
Antibiotics are not effective in the treatment of viral infectious 
diseases such as the common cold and acute postviral 
rhinosinusitis.
A systematic review of double-blind placebo-controlled 
randomized trials on antibiotics in post-viral ARS revealed no 
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benefit of antibiotic prescribing in such patients (for details 
please see chapters 4.6.3.3. and 4.6.3.4.). Conclusively, careful 
selection of ABRS patients that could respond to antibiotic 
therapy is highlighted to avoid injudicious use of antibiotics and 
related side effects.
Generally, acute rhinosinusitis (ARS) is predominantly viral 
with a small percentage (0.5-2.0%) progressing to secondary 
bacterial infection(21). Antibiotics are effective in a group of adult 
patients with symptoms and signs strongly suggestive of ABRS 
(see above). Even though available data are limited, it seems 
that especially amoxicillin / penicillin (beta-lactams) are effective 
(for details please see chapter 4.6.3.1.). Very limited data on the 
effect of antibiotics in ABRS in children revealed no significant 
difference over placebo while showing a significantly higher 
percentage of adverse effects (for details please see chapter 
4.6.3.2.). 
Antibiotics should not be obtained without medical prescription 
or an evidence-based indication. 
As for the EP3OS published in 2007, a divergence between 
European recommendations and antibiotic prescription practice 
in ARS was reported by Jorgensen and co-workers in 2013(22). 
Thus, effort should be made to implement rational antibiotic 
prescription following the relevant guidelines in the daily 
practice of all healthcare providers.
The inappropriate use of antibiotics to treat upper respiratory 
tract infections (URTIs) is a global public health problem. It 
has implications regarding the cost of treatment and the 
development of resistance to antimicrobial agents. Most URTIs 
are viral in origin, self-limiting and resolve in the same amount 
of time with or without an antibiotic; that is antibiotics do not 
hasten recovery and do not prevent more serious illness(23-25). 
Antibiotics should not be obtained without 
medical prescription or an evidence-based 
indication. 
Despite the fact that dispensing of non-prescription antibiotics 
is prohibited by law and legal regulatory frameworks in many 
countries, a large amount of antibiotics are dispensed without 
a prescription all over the world(26-36). This particularly refers 
to developing countries where the regulation of medicine 
distribution itself or regulation enforcement is lacking. 
Community pharmacies have been reported as important 
sites of non-prescription supply of antibiotics(37-40). Recently, 
a systematic review with meta-analysis of non-prescription 
supply of antibiotics in community pharmacy across the world 
was performed by Auta et al. (2019), taking into consideration 
relevant studies published from January 2000 to September 
2017(41). Studies included in the review originated from 24 
countries, with 23 of them classifying antibiotics as prescription-
only medicines. Results revealed the overall pooled proportion 
of the non-prescription supply of antibiotics to be 62%. 
Globally, the extent of supply of antibiotics without prescription 
upon patient request and following community pharmacy 
staff recommendation was 78% and 58%, respectively. It was 
highlighted that antibiotics were commonly supplied in cases of 
Questions Observations
Are your symptoms unilateral? Newly developed unilateral symptoms is a reason for referral
What symptoms are you experiencing? Check for nasal congestion and/or obstruction, rhinorrhoea, 
facial pain, reduction or loss of smell, cough
What is your main symptom? Look for the most troublesome symptom for the patient
Do you have  nasal blockage? Check if the nasal blockage is unilateral, alternating or 
bilateral; alternating or bilateral is usually caused by 
inflammation
Is your nasal discharge clear and watery or mucopurulent? Clear bilateral discharge suggests allergic; purulent discharge 
suggests rhinosinusitis
How long have you had these symptoms? Chronic rhinosinusitis symptoms will be present for more 
than 3 months
Do you have the symptoms all the time or do they come and go?
Has a doctor ever diagnosed rhinosinusitis, hay fever or allergic 
rhinitis?
Are you aware of anything that seems to bring the symptoms on? Consider being outdoors, pollen seasons, contact with 
animals, substances handled at work or at home
Do you have any pain in your face? Facial pain is suggestive of rhinosinusitis if combined with 
nasal symptoms
Do you have any sneezing, itchy nose, watery or itchy eyes? This is suggestive of an allergic cause
Have there been any hormonal changes? Pregnancy, menstruation, oral contraception, and 
hypothyroidism can give rise to rhinitis symptoms
Do you use OTC topical nasal decongestants? Long term use of nasal decongestants can cause nasal 
rebound congestions (rhinitis medicamentosa)
Do you use any other medication? Take special interest in beta-blockers, aspirin or NSAIDs use
Table 10.1.1. Questions to assist in managing rhinosinusitis (adapted from Carter et al. 2019(11)).
INCS: intranasal corticosteroids; OTC: over the counter
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acute and self-limiting conditions, including upper respiratory 
tract infections (URTIs) for which the pooled proportion was 
reported to be 67%. Penicillins were found to be the most 
frequently dispensed antibiotics for URTI indications (amoxicillin 
and amoxicillin-clavulanic acid, followed by macrolide antibiotic 
azithromycin). 
The practice of antibiotic dispensing for URTIs in community 
pharmacies continues, especially in low- and middle-income 
countries. 
In addition to the irrational sale of non-prescribed antibiotics 
upon patient request, self-medication also refers to the use of 
saved / shared antibiotic leftovers(37-39, 42-45) leading to a high 
rate of misuse and incomplete courses of antibiotics. Higher 
incidence of self-medication with antibiotics is found within 
low- and middle-income countries(46). A population survey 
conducted in 2007 in 19 European countries revealed that 
previous experience with prescribed use of antibiotics for URTIs 
increased the probability for self-medication with antibiotic 
leftovers for similar symptoms(43). Therefore, in case of not seeing 
a doctor, the patient should consult with a pharmacist about 
suitable therapy for URTI symptoms to avoid inappropriate 
antibiotic use.
Extensive use of non-prescribed antibiotics augments the 
risk of injudicious antibiotic therapy of viral infections, 
acute and self-limiting conditions, and, on the other hand, 
inadequate antibiotic therapy of bacterial infections, referring 
to inappropriate antibiotic selection, antibiotic dose and 
therapy duration. Such practice increases the risk of microbial 
resistance, particularly in the case of broad-spectrum antibiotics. 
At the same time, injudicious and inappropriate antibiotic use 
can result in masking the diagnosis of infectious disease and 
causing adverse effects such as allergies including anaphylactic 
reactions, drug interactions and increase in drug therapy 
costs(24).
Enforcing the laws prohibiting non-prescription dispensing of 
antibiotics is certainly needed to reduce the extent of irrational 
antibiotic use. However, it should be pointed out that over-
the-counter availability of antibiotics could contribute to 
timely access to antibiotics in certain circumstances, especially 
when access to healthcare facilities is limited and community 
pharmacies present the first (or even the only) point of contact 
with healthcare professionals. In some developed countries 
like Canada, UK, New Zealand, pharmacists are authorised to 
prescribe and dispense antibiotics for certain defined conditions 
– short-term uncomplicated urinary tract or cutaneous 
infections – redistributing the workload of GPs(47). Pharmacists 
are generally well educated in the field of rational antibiotic 
therapy(48). Nonetheless, updating of pharmacists’ training 
/ knowledge in terms of antibiotic stewardship and clear 
assessment and treatment protocols for URTI diseases should 
serve as support in ensuring adequate patient counselling 
and treatment regimen, providing timely access and rational 
dispensing of antibiotics in the pharmacy setting. A recent 
cross-sectional survey of community pharmacy staff in Sri 
Lanka revealed a positive correlation between pharmacists’ 
knowledge on antibiotics (legal aspect of antibiotic use and 
antibiotic resistance) and antibiotic dispensing practice(26). Any 
recognition of antibiotic knowledge gaps of pharmacists might 
serve as a basis for elaborating the education strategies to lower 
inappropriate antibiotic supply and provide adequate patient 
counselling. Pharmacists’ knowledge and attitudes towards non-
prescribed antibiotic dispensing present very important points 
in antibiotic stewardship, particularly in URTIs which present 
quite frequent acute problems often related to irrational use 
of antibiotics(49). In the countries where antibiotics are legally 
or illegally available over the counter, pharmacists are the key 
players in restricting antibiotic dispensing only to patients who 
really need them(49). 
The global respiratory infection partnership (GRIP) designed a 
pentagonal (‘five P’; i.e. policy, patient, prevention, pharmacy 
and prescriber) framework for the non-antibiotic management 
of upper respiratory tract infections, addressing the problem 
related to antimicrobial resistance(49). In the mentioned 
framework the antibiotic stewardship role of pharmacists as 
community educators on appropriate and rational antibiotic 
use was pointed out. Pharmacists are ideally positioned for 
antibiotic stewardship since they have contact with both 
patients and prescribers. Therefore, pharmacists can promote 
adherence to guidelines resulting in appropriate prescribing 
and optimal treatment regimens, as well as advise and educate 
patients on common / minor ailments and their management(48). 
Engaging pharmacists to provide minor ailment services 
represents an innovative strategy reducing patient visits to 
GPs and allowing for greater overall access to primary health 
care(50, 51). The pharmacist, often being the first point of call, 
provides full support in the symptomatic management of 
URTIs considering patient preferences and referring the patient 
to a physician if needed. Pharmacy staff should inform the 
patient on the common duration of the disease explaining 
the possibilities of symptomatic treatment while highlighting 
the fact that antibiotics cannot reduce the severity or duration 
of symptoms(49, 52). In addition to recommending the dosage 
regimen, pharmacists should inform the patient on possible 
side effects of dispensed medicine(28),  describe the measures of 
infection prevention and control including hand and respiratory 
hygiene(53),  and provide education on paths of infection 
transmission(48).
In cases when pharmacists are authorised and in a position 
to dispense an antibiotic, apart from consultation related to 
the symptoms of respiratory disease and past medical and 
medication history, they should pose questions related to 
allergy and pregnancy status before antibiotic dispensing, 
ensuring both effectiveness and safety of antibiotic 
administration(41). Information on potential drug interactions 
should also be provided. Whenever dispensing antibiotics, 
the pharmacist should instruct the patient to complete the 
antibiotic course promoting compliance with the dosage 
regimen and to dispose of any antibiotic leftover properly to 
reduce the chance of subsequent antibiotic misuse (i.e. self-
medication and antibiotic sharing)(48). 
Antibiotic prescription and dispensing are influenced by a 
combination of factors such as the knowledge and attitude of 
health care providers and patient / parent expectations related 
to antibiotic therapy(54, 55). A decrease in antibiotic dispensing 
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rates owing to implementation of medicine policies aimed 
at rationalizing antibiotic use, electronic decision support, 
awareness campaigns, educational interventions or multifaceted 
interventions have been observed in different parts of the 
world(28, 56-60) indicating the rationale for the continuation 
of such initiatives. Delayed antibiotic prescribing has also 
been recognised as a successful approach aimed at reducing 
the rate of antibiotic use for respiratory tract infections(61-64). 
Pharmacists are in a position to provide full support to patients 
when presented with a delayed prescription. Point-of-care 
tests(13) and antibiotic shared decision-making tools(65) have the 
potential to help pharmacists to reduce unnecessary antibiotic 
use. Nonetheless, developed communication skills are of great 
importance for pharmacists to raise behavioural change in 
patients by increasing their knowledge and changing their 
attitude towards antibiotic use(49).
10.3. Management of rhinitis and rhinosinusitis in 
the pharmacy 
Viral ARS (common cold) and acute postviral rhinosinusitis can 
be readily managed in the community pharmacy starting with 
symptomatic relief (Figure 10.1.1.) with the additional use of 
topical steroids(66). Only one systematic review that we know 
of addressed the benefits of increased fluid intake during an 
acute respiratory infection.  This review by Guppy (2011)(67) 
reported no evidence for or against this advice, implying the 
need for more studies on this subject. It is important to consider 
that interests, needs and priorities of professionals might not 
coincide with those of the patient, and different patients might 
require different management approaches(68). Patient self-
management can be further enhanced through information 
provision and regular, supportive feedback. Some studies have 
identified patients’ frustration with inadequate treatment and 
lack of coordinated care(69). Effective shared decision making has 
shown to improve adherence and lead to better outcomes in 
respiratory chronic diseases, namely asthma(70) and could also 
be a valuable strategy in this setting. Moreover, in integrated 
care centred on the patient, the community pharmacist can act 
as a bridge between primary (GP) and secondary care (specialist 
care).
10.3.1. Over the counter (OTC) medication 
Patients with upper airway symptoms rely on self-medication 
and/or OTC treatment to deal with the first symptoms of ARS 
or during acute exacerbation of CRS(2). When appropriate, self-
medication can be beneficial in terms of significant involvement 
of the patient and economic benefits(71). However, patients 
Figure 10.1.1. Rhinitis and rhinosinusitis assessment in the community pharmacy.
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with acute exacerbations of CRS should see their physician and 
should not rely on OTC medication.
OTC medications can be sold directly to patients without a 
medical prescription and are selected by regulatory agencies 
to ensure that they are safe and effective when used without a 
physicians’ advice. However, some OTC medications may only be 
dispensed after an assessment of the patient by a pharmacist, 
and provision of patient education. 
10.3.1.1. Intranasal corticosteroids
In patients with chronic rhinosinusitis symptoms, intranasal 
corticosteroids are the mainstay and there is a need for long-
term adherence to therapy(72). Intranasal corticosteroids 
may also be recommended to patients with acute post-viral 
rhinosinusitis if a reduction of symptoms is considered 
necessary. In contrast, currently, there is no evidence to support 
the use of intranasal corticosteroids for symptomatic relief from 
the common cold. 
All of the available intranasal corticosteroids are efficacious 
in controlling symptoms, although mometasone furoate, 
fluticasone propionate and fluticasone furoate are generally 
preferred for safety reasons(11) because they have negligible 
bioavailability and less potential to cause side effects. 
Moreover, they only require once daily usage. As such, product 
differentiation involves factors such as cost, ease of dosage, 
OTC status, and sensory issues, such as aroma and taste, which 
can affect patient preferences(73-75). Patients should be aware 
of the common side effects that they can expect and the 
serious side effects that they should report to their pharmacist 
and physician(76). In most developed countries, intranasal 
medications containing fluticasone are classified as OTC, and 
can be dispensed with pharmacists’ advice (for details please see 
chapters 4.6.2., 4.6.4. and 6.1.5.). 
10.3.1.2. Other OTC medication for the treatment of ARS 
The use of other OTC medical treatments such as decongestants, 
analgesics, antihistamines and herbal medication is commonly 
reported(77-79)  and has been evaluated in chapter 4.4. (ARS).
For common cold many OTC medications are available. 
Antihistamines, analgesics (paracetamol or NDAIDs) and 
decongestants  alone or as combination have some general 
benefit in adults and older children with common cold. These 
benefits must be weighed against the risk of adverse effects. 
There is no evidence of effectiveness in young children. 
10.3.1.2.1. Nasal decongestants
Nasal decongestants (vasoconstrictors) have been shown to 
be able to reduce symptoms of nasal blockage. However, the 
use of decongestants is symptomatic and does in general not 
influence the course of the disease; moreover they should only 
be used in the short term(80).
10.3.1.2.2. Zinc
Zinc administered as zinc acetate or zinc gluconate lozenges 
at a dose of >=75 mg/day and taken within 24 hours of onset 
of symptoms significantly reduces the duration of common 
cold. For those considering using zinc it is advised to use it at 
this dose throughout the cold (for details please see chapter 
4.6.2.16.). 
10.3.1.2.3. Herbal medicines (excluding Echinacea)
Some herbal medicines (excluding Echinacea) like BNO1016 
(Sinupret) (both common cold and postviral ARS), Cineole 
(common cold), Andrographis paniculata SHA-10 extract 
(common cold), Myrtol (post-viral ARS) and pelargonium 
extracts (post-viral ARS)  have significant impact on symptoms 
of common cold  and/or post-viral ARS without important 
adverse events (for details please see chapter 4.6.2.17.). 
10.3.1.2.4. Echinacea
Echinacea plant preparations are widely used for the prevention 
and treatment of common colds. However, a 2014 Cochrane 
systematic review by Karsch-Völk(81) concluded after analysing 24 
double-blind trials with 4631 participants, that most Echinacea 
products are not effective. Some Echinacea products had some 
possible weak benefit, however the potential effects were of 
questionable clinical relevance (for details please see chapter 
4.6.2.15.)
10.3.1.2.5. Vitamin C
Given the  consistent effect of vitamin C on the duration and 
severity of colds in regular supplementation studies, and the low 
cost and safety, it may be worthwhile for common cold patients 
to test on an individual basis whether therapeutic vitamin C is 
beneficial for them(82) (for details please see chapter 4.6.2.12.).
10.3.1.2.6. Homeopathic products
Homoeopathic products have been used for the treatment 
of acute respiratory tract infections in children and adults. 
A systematic review by Hawke aimed at assessing the 
effectiveness and safety of oral homoeopathic medicinal 
products compared with placebo or conventional therapy to 
prevent and treat acute respiratory infections in children(83). 
After analysis of eight RCTs involving 1562 children, the 
authors reported no significant benefit of homoeopathic 
products compared to placebo on infection recurrence or 
cure rates in children(83). No similar study was found for the 
use of homoeopathic products in adults with respiratory 
tract infections. We found one study evaluating the effect 
of homeopathy (Sinfrontal) in acute post-viral rhinosinusitis 
showing a significant reduction of symptoms and radiographic 
improvement versus placebo (for details see chapter 4.6.19). 
10.3.1.2.7. Medication with no proven benefits in the 
treatment of ARS
Some medication has been shown to be ineffective (e.g. 
homeopathy, steam inhalation or antibiotics) and sometimes 
even harmful. Examples are the use of mucolytics (not effective 
and even harmful in young children) and antibiotics in 
almost all forms of ARS (not effective and harmful, not only in 
producing side effects in the individual patient but also pushing 
antimicrobial resistance).
OTC treatments for the common cold and rhinosinusitis 
symptoms (analgesic associations, decongestants, 
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antihistamines, expectorants and cough suppressants) have not 
been adequately studied in children, especially children under 
six years old, and should not be routinely counselled without 
physician indication(84-88).
10.3.1.3. OTC medication for the prevention of ARS 
Some OTC medication and measures have been shown to 
reduce the incidence of ARS. 
The effectiveness and safety of probiotics in the prevention of 
acute respiratory infections were assessed in a systematic review 
by Hao in 2015. The authors report that overall probiotics are 
better than placebo in preventing acute infections(89) however, 
the quality of the evidence was low. Moreover, one must bear in 
mind that different strains of probiotics are available and may be 
administered using different pharmaceutical preparations (for 
details please see chapter 4.6.2.11). 
Regular, moderate-intensity exercise may have an effect on the 
prevention of the common cold.
The results of individual prophylaxis trials with Echinacea plant 
preparations consistently show positive (if non-significant) 
trends, although potential effects are of questionable clinical 
relevance.
There are no conclusive results to support the use of vaccines for 
preventing the common cold in healthy people.
Regarding prophylactic zinc supplementation, currently no firm 
recommendation can be made because of insufficient data.
10.3.1.4. Saline irrigation
Patients with rhinosinusitis commonly use nasal saline solutions 
to improve symptoms. There are several available options 
available at the community pharmacy: hypotonic, isotonic or 
hypertonic; low-volume nebulized, large-volume irrigation; 
etc. Nasal irrigation works by thinning and removing mucous, 
clearing proteins that cause inflammation, and flushing out 
irritants, and bacteria from the nose and sinus cavities. Irrigation 
with isotonic saline or Ringer’s lactate is recommended, but 
there is insufficient data to show that a large volume is more 
effective than a nasal spray, or that temperature of the solution 
influences the outcome.  
In ARS, the majority of studies did not find a difference between 
saline nasal treatment versus control, but one larger trial in 
children suggests that nasal saline irrigation has benefits for 
relieving ARS symptoms (for details please see chapter 4.6.2.9). 
In CRS, nasal saline irrigation is considered to be an important 
aspect of treatment by improving nasal mucosa function (for 
details please see chapter 6.1.11.) and should be recommended.
In the case of patients with allergic rhinitis, saline irrigation may 
reduce patient-reported disease severity when compared to no 
irrigation at up to three months, but no data is available for any 
outcomes beyond this period(90).
10.3.2. Adherence
Medication adherence is defined as active, cooperative 
and voluntary participation of the patient in following 
recommendations from a healthcare provider. Personal volition 
and autonomy, and perceived competence are positively 
related to optimal health self-management behaviours, such 
as medication adherence. Especially in chronic rhinosinusitis, 
patients may be concerned about possible side effects of 
medication taken long-term.
Adherence in randomized control trials is high but does not 
reflect the real-life situation(91-93). In real life adherence to 
treatment is low, especially in mild / moderate disease where 
patients use “on-demand” instead of continuous treatment(94). 
Non-adherence to medications is a major obstacle to the 
effective delivery of health care. Better adherence may reduce 
the burden of uncontrolled disease and improve clinical 
outcomes. 
Community pharmacists are uniquely positioned to help 
mitigate the high risk of medication discontinuation and non-
adherence to therapy; they improve adherence for patients 
starting new therapies and continuing existing regimens. In the 
special case of intranasal steroids, patients must be informed 
that full benefit may not be evident for two weeks. Patients 
should be encouraged to continue to use their medication 
and counselled on the appropriate administration technique 
for intranasal formulations (especially in avoiding the nasal 
septum). Special caution is recommended when using nasal 
decongestants; the pharmacist should emphasize that such 
medication should only be used in the short term for congestion 
relief, as prolonged use can lead to rhinitis medicamentosa(80).
According to the PGEU (Pharmaceutical Group of the European 
Union) 2017 and 2018 Annual Reports, 53% of all responding 
countries indicated that they provide type 2 medication reviews, 
which involve a structured, private consultation between the 
pharmacist and the patient and focus on issues of adherence 
and the safe, effective and rational use of medicines. Moreover, 
pharmacists are involved in disease management programs 
and are the first providers of advice and OTC medication for 
winter illnesses such as colds, ENT disorders and influenza(7). 
In addition to giving therapeutic and educational advice at 
baseline, pharmacists play a crucial role in the follow-up and 
monitoring of patients(95). Structured community pharmacy 
services, involving patient assessment, individualized treatment 
recommendations and follow-up might be of interest in 
this setting(96). It is important to review the recommended 
treatment plan at regular intervals and to assess adherence and 
administration techniques.
Patient information leaflets should be handed out to patients 
as a supplement to good communication. Leaflets should 
reinforce recommendations on pharmacological and non-
pharmacological treatment, administration techniques and 
provide contacts in case of any doubts.
Many mobile phone apps and services are available to support 
people in taking their medications / to improve medication 
adherence(97-100). However, one meta-analysis found that the 
majority of them did not have many of the desirable features 
and were of low quality(97). Nevertheless, mobile applications 
with self-monitoring and medication adherence features can 
assist with self-management and improve patient control over 
their illness(99, 101, 102).
mySinusitisCoach is an app registered as a class I medical device 
that enables patients to monitor rhinosinusitis symptoms 
and their impact on lower airway symptoms, quality of sleep 
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and daily life. It also provides longitudinal information on 
disease control and adherence to therapy for the healthcare 
professional(103). 
MASK is an app for patients with allergic rhinitis to track their 
nasal, ocular or lung symptoms and share this with their 
healthcare providers(94). 
10.4. When and how to refer to a physician or to a 
specialist (ENT)
Acute viral and post-viral rhinosinusitis can be treated 
symptomatically and in the case of post-viral rhinosinusitis 
with INCS as described above. Some signs and symptoms are 
indicative of an emergency or severe disease and require urgent 
referral to an ENT physician or to the emergency services (Box 
1). Orbital and neurological complications are considered 
emergencies.
Box 1. Signs and symptoms of emergency or severe disease 
(see Chapter 1, the integrative care pathways) .
	· Periorbital oedema / erythema
	· Displaced globe
	· Double vision
	· Ophthalmoplegia
	· Reduced visual acuity
	· Severe unilateral or bilateral frontal headache
	· Frontal swelling
	· Neurological signs (a sign of meningitis)
	· Reduced consciousness (a sign of meningitis)
In addition, patients should be referred to a physician if the 
patient is pregnant, has asthma, shows signs of dyspnoea, is 
immunocompromised or is on any medication that may be 
causing the symptoms (aspirin, NSAIDs, angiotensin-converting 
enzyme inhibitors, alpha-blockers, beta-blockers). Patients who 
have persistent symptoms of rhinosinusitis despite appropriate 
treatment, correct technique and adherence should be of 
special concern(11). 
In chronic rhin(osinus)itis referral to a physician should be 
considered in case of symptoms that are uncontrolled despite 
treatment with INCS(19, 104).
10.5 Advice to pharmacists on explaining to 
patients how to use medication 
10.5.1. Nasal sprays
Pharmacists have a very important role in implementing 
efficient nasal spray use in rhinitis and rhinosinusitis patients, 
thus contributing to proper treatment, alleviation of symptoms 
and improvement of patient’s quality of life. The role of 
pharmacists becomes even more pronounced in the era of 
prescription-to-OTC switches of intranasal corticosteroid 
sprays(66, 68).
All nasal spray products include instructions on their proper use 
in patient information leaflets. Nonetheless, it is recommended 
that pharmacists demonstrate to patients how to use a nasal 
spray properly using a placebo device(19). Namely, teaching 
patients the proper spray administration technique can improve 
drug efficacy, reduce the likelihood of side effects and enhance 
patient adherence / compliance(7, 105, 106). 
Instructions available in patient information leaflets related 
to the use of nasal sprays differ from each other in terms of 
recommended head position, nasal spray direction within the 
nostril, breathing pattern during spraying and closing the free 
nostril. 
The EPOS2020 steering group advises:
	· To prime the bottle before first use.
	· To shake the bottle prior to spraying. Since most nasal 
corticosteroids are formulated in suspensions usually 
containing thixotropic agents that increase the viscosity. 
Bottle shaking before use decreases the viscosity of the 
drug suspension, allowing the creation of fine mist by 
spraying (107, 108), needed to achieve appropriate deposition 
in the nose.
	· To blow the nose prior to using the spray.
	· To keep the head in an upright position.
	· To hold the spray in the opposite hand in relation to the 
nostril in which the spray should be applied(109, 110). That 
way the spray is aimed away from the septum reducing 
the possibility of epistaxis and in exceptional cases even 
perforation(106, 111). In a survey on patients using intranasal 
corticosteroid spray, it was shown that ipsilateral spray 
technique resulted in four times higher incidence of 
epistaxis and three times higher incidence of quitting 
intranasal steroid spray compared to the contralateral 
technique(106).
	· To breath in gently or slowly during spraying.
	· Not to close the opposite nostril to prevent pushing the 
septum to the side of the spray.
In cases when nasal saline irrigations are recommended, the 
patient should be advised to perform them prior to topical spray 
administration so as not to rinse out the medicine from the 
nose(112).
Special attention should be given to patients with certain 
physical limitations such as arthritis or Parkinson’s disease, and 
patients unable to coordinate recommended breathing pattern 
with spray administration, since they may have difficulties 
using some nasal spray devices (113, 114). While data on nasal 
spray devices are lacking, a systematic review on critical inhaler 
errors in asthma and COPD patients revealed an increase in 
handling error frequency in relation to age, comorbidities, 
education and socioeconomic class(115). A prospective 
randomised controlled trial in children aged between five and 
16 years with moderate to severe intermittent or persistent 
allergic rhinitis showed significantly higher competency in 
using intranasal corticosteroid spray in children taught using 
an animated cartoon, in relation to oral presentation without 
demonstration(116), indicating the need for special care and 
approach in such population. The same study suggested 
repeating the teaching procedure periodically to ensure the 
long-term correct use of the nasal spray.
In the case of nasal steroid sprays, apart from instructions on 
appropriate administration technique, the pharmacist should 
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provide the patient with explanations related to clinical steroid 
effectiveness profile including delayed onset of action (12h) and 
maximal efficacy reached in days to weeks(117). Patients should 
be instructed to use intranasal corticosteroids regularly in order 
to maintain symptom control and not to apply a use-as-needed 
approach(68). 
10.5.2. Nasal drops
Nasal drops are available in multi-dose and single-dose 
containers. Like nasal sprays, nasal drops are dispensed 
with recommendations on their use provided in the patient 
information leaflets. Most manufacturers recommend 
administering drops in the head-back position obtained 
easily by extending the neck. However, research evidence 
supports administration of nasal drops in the head upside-
down position(118, 119), most easily attained by hanging off the 
edge of a bed (i.e. Mygind’s position)(120) or in lying on the side 
in a head down position (i.e. Ragan position) with drug being 
administered to the lower nostril(121, 122). Mygind’s position 
was shown to enable easier administration of drops, while 
Ragan position was reported to be more comfortable for the 
patient(121). Krinsky et al. recommend Mygind’s position (i.e. lying 
on the bed with head tilted back and over the side of the bed), 
with gently tilting head from side to side, after administration of 
drops in the nostril(123). 
Effective drops delivery to the olfactory epithelium (e.g. for the 
treatment of anosmia), can be achieved by adopting the Kaiteki 
position, i.e. lying on one side with the head tilted downwards 
20-30° and the chin turned upward 20-40°, with the drops being 
administered to the upper nostril aiming for the superior margin 
of the nasal septal mucosa and holding the position for 30 
seconds(124). 
Because penetration of the sinuses by nasal sprays and drops 
is minimal, even in patients that have been operated on(125, 126) 
many rhinologists now advise combining nasal drops with saline 
irrigation. Using a larger volume results in better penetration 
the sinuses and this combination has been shown to be more 
effective than nasal spray(127). Whether it is more effective than 
nasal drops needs further investigation.
To minimize the risk of spreading infections, patients should be 
advised not to share nasal delivery devices(128).
A proposed technique for the use of nasal sprays and nasal 
drops provided by the EPOS group is given in Table 10.5.1. 
However, it should be pointed out that drug deposition pattern 
within the nasal cavity, apart from administration technique, 
depends also on nasal formulation properties, the volume of 
the applied dose, performance of the delivery device, individual 
anatomical differences and pathological conditions. Therefore, 
it is difficult to come up with definitive conclusions and 
identification of a general single-best technique for nasal drug 
administration(125, 126).
Nasal 
drug 
products
Before spray / 
drops 
administration a
Head position Spray / dropper tip 
direction
Free nostril Spray / drops 
administration and 
breathing pattern 
during spray / drops 
administration
After spray / drops 
administration
Nasal spray 1. Gently blow your 
nose.
2. Shake the nasal 
spray vigorously.
3. Remove the cap.
4. Keep your 
head upright.
5. Gently insert the 
nozzle tip into one 
nostril. 
6. Aim the tip of the 
product away from 
the nasal septum; use 
the right hand to spray 
the left nostril and vice 
versa, to direct the 
spray away from the 
septum.
7. DO NOT 
close the 
nostril not 
receiving the 
medication.
8. While slowly 
breathing in activate the 
spray 
9. Apply the number of 
sprays recommended by 
the doctor.
10. Take the nozzle out 
and breathe out through 
your mouth.
11. Repeat spray 
administration steps in 
the other nostril.
12. The spray nozzle 
should be cleaned 
according to the product 
directions and the cap 
replaced.
Nasal 
drops
1. Gently blow your 
nose.
2. Shake the drops 
container.
3. Lie down 
in a supine 
position with 
the head just 
off the bed 
and the chin 
being the 
highest point 
of the head.
- - 4. While breathing 
normally, instil the drops 
in each nostril according 
to the product 
directions.
5. Hold the position for 
two minutes after the 
drop instillationb.
6. The dropper should be 
cleaned according to the 
product directions.
Table 10.5.1. EPOS2020 proposed technique for the use of nasal sprays and nasal drops.
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11.1 Introduction
Although there has been significant progress since EPOS2012, 
in virtually every area covered by EPOS2020, there is recognition 
of the need for further high quality studies. The following is a 
summation of these gaps in our knowledge that require further 
investigation (Figure 11.1). We placed the research needs in the 
same order as the chapters in EPOS2020 without any further 
prioritisation.
11.2. Classification and definition
	• International agreement on terminology
	• There remains the need for clear and widely accepted 
guidelines on the design of clinical trials which indicate: 
	• How to define the study population;
	• Choice of outcome measurements;
	• Choice of instruments to evaluate quality of life (QoL).
	• It may also be advantageous to introduce some form of 
additional aetiological qualification to our classification 
systems which might be based on International 
Classification of Diseases (ICD) coding.  
11.3. Burden of acute rhinosinusitis and chronic 
rhinosinusitis
	• Further studies to assess the impact of acute rhinosinusitis 
(ARS) on quality of life.
	• As most data thus far is produced from the USA, further 
studies on direct and indirect costs across Europe and 
globally.
	• Create awareness for the government and industry for non-
polyp disease.
	• Carefully constructed prospective epidemiological studies 
with valid diagnoses of ARS to give a clearer picture of the 
real burden of ARS, in particular the prevalence of acute 
post-viral and bacterial rhinosinusitis.
	• To develop a validated disease-specific QoL questionnaire 
specific to acute rhinosinusitis.
	• Development of patient-reported outcome measure 
(PROMS) that capture all aspects of CRS not presently 
covered by established instruments.
	• Real life studies evaluating and validating cut off levels 
for visual analogue scale (VAS) or other measurements of 
control.
	• Studies looking at cost-effectiveness and the socio-
economic impact of implementation of phenotyping and 
endotyping into care pathways.
11.4. Acute rhinosinusitis including common cold - 
and recurrent ARS in adults and children
11.4.1. Epidemiology of acute rhinosinusitis
	• To know what factors determine whether ARS patients in 
the community consult with a doctor, pharmacist or self-
manage without professional support.
	• To demonstrate the prevalence of ARS in low, middle 
and high income countries and consider whether any 
predisposing factors differ dependant on income. 
	• Large population studies characterizing co-morbidities in 
patients with ARS, compared to matched controls to identify 
significant co-morbidities or risk factors. 
11.4.2. Pathophysiology of ARS
	• Studies to establish how allergic rhinitis increases the 
predisposition for rhinosinusitis and specifically if it 
increases the likelihood of S. pneumoniae sinus infection. 
	• Assuming this is confirmed, studies to establish whether 
regular antihistamines and/or leukotriene receptor 
antagonists are effective in reducing ARS episodes in 
patients with allergic rhinitis. 
	• The role of gastro-oesophageal reflux disease (GORD) in the 
pathogenesis of ARS.
	• To determine how exposure to cigarette smoke increases 
the predisposition for ARS, to establish whether exposure 
to cigarette smoke (active or passive) augments the 
predisposition for ARS in patients with allergic rhinitis and to 
show whether smoking cessation improves the frequency of 
ARS compared to active smokers. 
11.4.3. Diagnosis and differential diagnosis
	• To confirm if there are combinations of symptoms and signs 
that predict acute bacterial rhinosinusitis in primary and 
secondary care.
	• To show if the relative frequency of different symptoms 
and signs in ARS predict a differential response to different 
therapies, such as topical steroids and antibiotics? 
	• A trial to show if the purulence of nasal discharge is truly an 
indicator of bacterial infection and can be used as a clinically 
important response to antibiotics in chronic rhinosinusitis 
(CRS) and what constitutes a clinically important response 
to antibiotics in ARS, e.g. change in purulence of nasal 
discharge. 
	• To determine biomarkers (e.g. c-reactive protein(CRP), 
procalcitonoin) that can predict acute bacterial rhinosinusitis 
or a clinically important response to antibiotics in ARS? 
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11.4.4. Medical management of ARS
	• To confirm whether topical nasal corticosteroids can be the 
first-line treatment for ARS in primary care and consider 
whether there are clinically important differences between 
different topical nasal corticosteroid molecules and dosing 
regimes.
	• Further RCTs in acute bacterial rhinosinusitis on the full 
range of medications and in particular, topical and oral 
corticosteroids, antihistamines, decongestants, saline and 
steam inhalations. 
	• Large RCTs on the effect of antibiotics on the cure/
improvement of symptoms in ABRS in children and 
consideration of why there is an apparent difference 
between the response children and adults. 
	• To show whether the provision of educational and 
information materials for patients improve outcomes of ARS 
and reduce non-essential antibiotic use? 
	• To demonstrate whether professional education and 
efficient dissemination of evidence-based guidelines 
to clinicians improve outcomes of ARS and reduce non-
essential antibiotic use? 
	• Further randomised controlled trials (RCTs) in acute viral 
rhinosinusitis on prophylactic medications including Vitamin 
C, vaccines, probiotics, Echinacea and zinc. 
	• Maxillary puncture for acute rhinosinusitis is currently only 
being performed in a limited number of countries because 
there is no evidence to prove that it is effective. Clinicians 
from those countries should therefore be encouraged to set 
up studies to evaluate whether puncture reduces pain in the 
acute phase.
	• To show if the clinical and economic outcomes of ARS differ 
depending on which health professionals (e.g. rhinologists, 
ENT specialists, GPs, pharmacists?) manage patients. 
	• Large epidemiological data collection on the true incidence 
of complications in ARS, determining the role of primary 
care physicians in the detection and/or prevention of 
complications and whether complications of ARS relate to 
access to medical care?
	• To establish if early use of therapies in viral URTI prevent 
bacterial ARS, particularly in those with recurrent ARS or at 
risk of complications 
	• A large prospective study on the role of antibiotics in the 
prevention of acute complications.
	• A randomised trial of drainage versus intravenous 
antibiotics for small abscesses in young children (orbital and 
intracranial). 
	• Conduct multicentre trials on endoscopic versus open 
management of complications of ABRS, both intracranial 
and orbital. 
11.5.Epidemiology, predisposing factors, pathophysiology, 
and diagnosis of CRS
11.5.1. Epidemiology
	• Studies evaluating the natural history of untreated CRS and 
the impact of age on disease.
	• Epidemiologic studies on the disease process [chronic 
rhinosinusitis without / with nasal polyps (CRSs/wNP), 
asthma, N-ERD], prevalence and disposing factors and its 
impact across the world as there are many areas without 
much data egMiddle East, Africa, South Americaand 
compare low, middle and high income countries.
	• Create a network with institutions around the world to 
establish good epidemiologic data and create a unified 
survey that can be applied globally to collect epidemiologic 
data on impact of CRS.
	• To establish what, if any, childhood events increase chances 
of developing CRSwNP. 
	• To establish how smoking increases the risk of CRS and 
whether the risk is reduced by smoking cessation. 
	• To show if recognition of and appropriate treatment 
of allergic rhinitis reduce the incidence of CRSsNP and 
CRSwNP? 
	• To consider the role of GORD in CRS. 
	• To investigate the role of pollution and climate change on 
disease process of CRS.
	• To investigate nutrition effects, including obesity, on CRS.
11.5.2.1. Genetics and epigenetics of CRSsNP and CRSwNP
	• Role of genetics using improved technology. 
	• Understand the environmental factors that alter gene 
expression which may predispose to CRS which may allow 
us to recognize disease-causing agents versus disease-
modifiers or exacerbating agents and in turn may allow us to 
alter behaviour or implement therapies that can counteract 
any genetic predispositions and reverse/ moderate 
epigenetic pre-disposition.
	• Understand epigenetic regulation of upper airway disease
11.5.2.2. Inflammatory  mechanisms of CRS
	• Develop a classification of CRS of phenotypes / endotypes 
based on “hypothesis-free” cluster analyses. 
	• Understand the regulation of TGF-ß and related molecules in 
remodelling processes. 
	• Understand the T regulatory cell deficit and the role of T 
effector cells in nasal polyp disease. 
	• Understand the role of dendritic cells in CRS. 
	• To increase our understanding of the role of ILC and 
epithelial barrier
	• Understand the links between inflammation and 
remodelling. 
	• Understand the impact of the microbiome on inflammation. 
Further research is needed on the impact of bacterial, 
fungal or other microbial colonization / infection, with clear 
definition of such impact and we need some standardized 
methodology for research. For example should measures of 
minimal undetectable colonization, like PCR, or molecular 
cultivating techniques or hardly detectable immune 
response to colonizer be taken into account and if so, when? 
	• If infection is characterized by invasion, as well as by 
immune response to the micro-organism, we need to define 
how this invasion is established at both a local and systemic 
level.
	• There are variations in local anatomic immune response 
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that are not related to airflow and environmental exposures. 
Research is needed into variations in immune response of 
the ethmoid / middle meatus for example, as this is different 
from the mucosal response of the septum or inferior 
turbinate.  
	• There is thus a need for innovative experimental models in 
CRS. Nearly all of the currently conducted human research is 
performed in patients who already have established disease 
or controls who do not. While this is useful in identifying 
unique contributors to the pathophysiology of CRS and 
subsequent treatments, it does not identify the actual cause 
of the disease. Currently available animal models are either 
allergic models or genetically manipulated animals that 
artificially generate an inflammatory response and again, do 
not answer the cause of the disease. 
	• Differences between CRSwNP in Western patients and 
elsewhere in the world. What are the key cytokines which 
mediate Th2 skewing across the epithelial barrier: TSLP vs. IL-
25 vs. IL-33 vs.? Identification of the key effector cell(s): mast 
cells vs. esoinophils vs. neutrophils. 
	• For endotyping and phenotyping, to define the minimal 
criteria for measuring sinus inflammation, e.g. sampling 
procedures and expression of data should be unified (ng of 
cytokine per ml, mg of tissue or protein content) so that a 
meta-analysis may be done. 
	• A long-term study on the natural history of osteitis. 
	• The role of viruses and microbial dysbiosis in the 
pathogenesis of acute exacerbations of CRS (AECRS). 
	• Understand the pathogenesis of ‘allergic’ fungal 
rhinosinusitis and N-ERD.
11.5.3. Diagnosis and differential diagnosis
	• To determine the relative frequency and prognostic 
significance of different symptoms and signs in CRSsNP and 
CRSwNP in primary care. 
	• The correlation of CRS (severity, etc.) and mental health, 
either directly or indirectly.
	• Determine when a mucus sample indicates sinusitis and 
then determine the criteria to lead to subtypes of CRS and 
personalized medicine.
	• Inclusion criteria for non-ENT control groups.
	• To investigate the impact of psychological problems such 
as depression, stress exposure and anxiety on subjective 
severity scores and to consider the impact of neurological 
co-morbidities like chronic fatigue, post-traumatic stress 
disorder, neurological hyposmia, and measures of other 
neural-based disorders that play a role in non-allergic 
rhinitis, which may have an impact on rhinosinusitis scores. 
Figure 11.1. Research priorities in acute and chronic rhinosinusitis.
Research priorities in acute and chronic rhinosinusitis
GENERAL
Classication and denition
• International agreement 
  on terminology
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  success and failure?
Patient participation
• Self-management
• Compliance
• Empowerment
Prevention and prediction
• Can treatment prevent
  development of disease?
• Can reaction to treatment
  be predicted?
PRECISION MEDICINE ARS
Burden of ARS
• QoL in ARS
• Direct and indirect costs
Management of ARS
• Predictors for need of
  antibiotics
• (Early) warning signs of
  serious disease
• Treatment of acute
  postviral rhinosinusitis
CRS
Management of CRS
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  surgery + medical treatment
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• Impact of extent of surgery
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  course of the disease
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	• To consider neural aspects of facial pain, headache, smell 
disorders and hypersecretion and investigate better tools for 
the diagnosis and differential diagnosis of facial pain. 
	• Comparative studies evaluating symptom prevalence and 
severity to distinguish CRS, allergic rhinitis and non-allergic 
rhinitis.
	• Studies on sinus computed tomography (CT) to determine 
which changes eg degree and pattern of mucosal 
thickening, number of sinuses affected and the status of the 
ostiomeatal complex  are clinically relevant in CRS.
	• Development of an objective smell test to assess the 
presence of olfactory distortions.
	• Development of a reliable commercially available test of 
retronasal olfaction.
	• Studies on tissue eosinophilia to determine an 
internationally agreed value for number of eosinophils / 
high powered field.
	• Studies on specific histopathological and serological 
markers of inflammation to determine their role as 
indicators of prognosis or targets for tailored therapy. 
	• Studies on the role and methodology of microbial sampling 
in CRS. 
11.6. Management of chronic rhinosinusitis in 
adults
	• Demonstrate whether the relative frequency of different 
symptoms and signs in CRSwNP and CRSsNP predict a 
differential response to different therapies, such as topical 
steroids and antibiotics. 
	• Studies to determine the optimum biomarker before we 
initiate treatment (surgery, steroid or biologic).
	• Investigate management recommendations based upon 
lifestyle factors.
	• Improve professional education and efficient dissemination 
of evidence-based guidelines to optimise outcomes and 
reduce referral rates to secondary care.
	• Conduct multicentre RCTs on surgery versus no treatment 
for patients with CRS to establish the natural course of 
disease in the different phenotypes. 
	• A randomised trial comparing different treatment options 
for patients with CRS with significant osteitis.
	• Test the criteria for concept of control from a data 
standpoint.
11.6.1. Medical
	• Develop therapeutic approaches based on endotypes of 
disease 
	• Studies regarding what constitutes an adequate trial of 
medical therapy (both in terms of therapeutic classes, 
modes of delivery and duration), the importance of patient 
compliance with treatment and how to determine failure of 
this approach.
	• Trials on medications specifically in AECRS, in particular 
large, high-quality trials to evaluate the use of short courses 
of antibiotics in acute exacerbations of CRS.
	• High quality RCTs on topical antibiotics in CRS.
	• RCTs comparing different delivery methods, dosage and 
duration of topical intranasal corticosteroids.
	• Conduct an RCT on oral steroids versus surgery on the long 
term outcomes of CRSwNP.
	• Conduct an RCT studying the effects of oral corticosteroids 
on olfactory function in CRSwNP. 
	• Investigate why there is a lack of response to corticosteroids 
in some cases of CRS, e.g. smell, QOL, etc.
	• Larger long-term studies on efficacy and safety of steroid-
eluting stents.
	• Further studies on individual CRS subtypes to determine 
which patients would benefit from long-term antibiotics and 
more specifically macrolide antibiotics. To seek better local 
therapies for immunomodulation. 
	• Studies evaluating the effect of antihistamines in patients 
with CRSsNP.
	• Studies evaluating the effect of montelukast in CRSwNP 
patients that failed nasal corticosteroids.
	• Studies on saline irrigation to consider if a large volume is 
more effective than a nasal spray.
	• RCTs to evaluate aspirin desensitisation with topical lysine 
aspirin.
	• RCTs to evaluate the effect of probiotics in CRS.
	• Further placebo-controlled studies on local furosemide 
and local verapamil to determine efficacy and appropriate 
patient selection.
	• Larger studies of longer duration on bacterial lysates with 
proper patient characterization and outcome evaluation.
	• Establish whether aspirin desensitization or biologics has 
better efficacy in patients with N-ERD.
	• Studies with larger populations and longer follow-up for all 
biologics
	• Establish a register of patients treated with biologicals. 
	• Is biological treatment life long?
	• Is there a shift based upon age for treatment with 
biologicals?
	• Auto-immunity effect?
	• Investigating type 1 CRS patients
	• How to choose between different biological treatments.
	• How to choose between or combine surgery and biologicals. 
11.6.2. Surgical
	• Studies to agree definitions of surgical procedures.
	• Characterisation of CRS endotypes likely to respond best to 
endoscopic sinus surgery (ESS).
	• Studies to show if any pre-operative medication improves 
surgical field and specifically the role of preoperative 
antibiotics and oral steroids.
	• Studies to show best local anaesthesia and vasocontriction 
regime to improve surgical field and reduce blood loss.
	• Studies/Delphi consensus to consider standardisation of 
indications for surgery.
	• Comparative RCTs of medical versus surgical treatment.
	• Further studies on impact of surgery on development of 
asthma and sleep disturbance.
	• Indications for and timing of ESS to see if it alters the course 
of the disease.
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	• RCTs of minimal versus extensive ESS.
	• Evidence from RCTs on adjunctive surgery – possibly 
pragmatic trials comparing different centres
	• RCTs for balloon sinuplasty in non-US cohorts with higher 
disease burden.
	• Longer term data on drug eluting stents efficacy, safety and 
economic benefits.
	• Long-term follow up of post-operatively debrided versus 
non-debrided ESS cases.
	• Studies on use of robotic transnasal ESS as this progresses.
	• RCTs for novel interventions such as antimicrobial 
photodynamic therapy
	• RCTs for optimal peri-operative medical treatment and use 
of dressings/packings.
	• Pooled multi-centre data on ESS outcomes including 
complications, revision rates and mucocoele formation.
	• Data on extensive surgery vs. limited (bad?)surgery – we 
have no proof that “bad” surgery equals bad outcomes.
	• Evaluation on when to perform revision surgery and to 
define the goals and extent.
	• Large-scale RCTs to answer whether postoperative short-
term antibiotics, oral and topical corticosteroids or saline 
irrigations after endoscopic sinus surgery are beneficial. 
	• Training: Studies on new technologies including augmented 
reality, artificial intelligence (AI) and latest image guidance.
11.7. Paediatric chronic rhinosinusitis
	• Population studies on prevalence of CRS in children.
	• Further studies on gene mutations in paediatric CRS. 
	• The contribution of viral infection to development of 
paediatric CRS.  
	• The importance of allergic disease in the pathogenesis of 
CRS in children.
	• The relationship between CRS and asthma in children.
	• The role of adenoids in CRS as a reservoir for pathogenic 
bacteria or a source of obstruction.
	• The role for inflammatory mechanisms in paediatric CRS to 
facilitate endotyping by better evaluating tissues obtained 
at the time of surgery for CRS through well organized, multi-
centre collaborations.
	• Develop tools/tests in the context of clinical trials to 
differentiate the role of chronic adenoiditis from that 
of chronic rhinosinusitis in children with chronic nasal 
complaint 
	• Establish the relevance of CT abnormalities in children with 
chronic nasal symptoms. 
	• Improve olfactory testing and reporting in children.
	• Definitions of what constitutes a controlled response in the 
paediatric population.
	• Trials on the use of intranasal steroids in children with CRS.
	• Randomized, controlled trials to evaluate the use of short 
and long-term oral antibiotics in children with CRS.  
	• Better studies on the role and impact of treatment of GORD 
in children.
	• Investigation of best surgical practices for CRS in children 
required. Prospective, randomized, multicentre trials 
should be conducted where the severity of disease on CT 
scans and the symptom questionnaire would be matched 
preoperatively and the following interventions would be 
compared: adenoidectomy alone, adenoidectomy with 
a washout, adenoidectomy with a washout and balloon 
maxillary sinuplasty, and endoscopic sinus surgery. An 
additional arm that includes medical therapy should also be 
included.
11.8. Concomitant diseases in patients with chronic 
rhinosinusitis
11.8.1. Role of allergy and chronic rhinosinusitis  
	• Studies to assess the effectiveness of management of 
allergic rhinitis on the outcome of established CRS, or on the 
risk of subsequent development of CRS.
11.8.2. Immunodeficiencies
	• Large scale studies to determine true incidence and 
importance of IgG subclass deficiency in general population 
as a predisposing factor for CRS.
11.8.3. Lower airway disease including asthma
	• To conduct research on the basic physiology of the nose, 
including humidification and heat exchange and its effect 
on pulmonary function.
	• To establish whether treatment of CRS affects outcomes 
of co-morbid lower airways disease [e.g. asthma, chronic 
obstructive pulmonary disease (COPD)].
	• To undertake further RCTs studying the effects of surgery 
and medical treatment on the lower airways (lung function/ 
QoL/symptoms) in CRSwNP and concomittant asthma.
	• Define predictive factors for the development of asthma in 
CRS patients, allowing the implementation to preventive 
strategies.
	• Understanding the natural course of disease and 
mechanisms in N-ERD, with impact of upper on lower airway 
inflammation and vice versa.
	• Further exploration of the involvement of the microbiome 
and the immune responses to the microbiome in relation to 
CRS and asthma/COPD development.
	• Study the neurogenic pathway involved in CRS and 
asthma/COPD, with better understanding of mediators and 
therapeutic options for treatment of nasal and bronchial 
hyperreactivity.
	• Study the relevance and best method for screening of upper 
and lower airway inflammation in CRS and asthma/COPD 
patients’ outcomes.
	• Studies highlighting the impact of personalized follow-up 
and patient education via e-health tools, leading to early 
diagnosis and better outcomes of treatment in patients with 
CRS and asthma/COPD.
11.8.4. Cystic fibrosis
	• A study to consider correlation between cystic fibrosis (CF) 
genotype and severity of sinonasal disease.
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	• A study to elucidate an association between heterozygote 
CF patients and CRS.
	• A study to determine the best CT staging system in this 
condition.
	• A study to consider whether extent of sinus surgery is 
important in CF.
11.8.5. Primary ciliary dyskinesia
	• A study to determine the precise incidence and prevalence 
of primary ciliary dyskinesia (PCD).
	• To establish the prevalence of ARS in the primary ciliary 
dyskinesia population, to determine whether aggressive 
treatment of ARS in patients with PCD prevents recurrence 
of ARS or development of CRS and to establish if aggressive 
treatment of ARS affects the progression of PCD-related 
bronchiectatic lung disease.
	• Randomized controlled studies are needed to delineate the 
effects of surgery and adjunctive therapy.
11.8.6. Fungal rhinosinusitis
	• The factors predisposing individuals to allergic fungal 
rhinosinusitis (AFRS) need further study.
	• Large RCTs to consider dosage and duration of oral and 
topical corticosteroids in AFRS.
	• An RCT to consider the role of immunotherapy, oral and 
topical antifungals in AFRS.
	•
11.8.7. Vasculitis, granulomatous diseases 
	• A large prospective study considering the use of anti-
neutrophil cytoplasmic antibodies (ANCA) in limited 
rhinologic cases of granulomatosis with polyangiitis (GPA) 
and eospinophilic granulomatosis with polyangiitis (EGPA).
	• A study of the topical medications used in vasculitis.
	• What is the best treatment of limited GPA?
11.9. Patient participation, prediction, precision 
medicine and implementation
	• To achieve uniformity in the routine application and 
interpretation of the existing tools for assessment of CRS 
control.
	• Large-scale studies to confirm the high percentage of 
uncontrolled patients after surgery shown by earlier reports.
	• Prospective studies comparing EPOS control criteria 
before and after surgery with long follow-upare needed to 
further evaluate the responsiveness of the EPOS criteria to 
treatment.
	• Explore differences in disease control (based on EPOS 
criteria) between men and women, patients undergoing 
primary or revision functional endoscopic sinus surgery 
(FESS), and between different phenotypes e.g. with or 
without nasal polyps, allergic rhinitis, asthma, N-ERD, and 
endotypes based on inflammatory patterns to assist in 
predicting patients at risk of having uncontrolled disease.
	• Further studies are required on patient participation, 
compliance and self-management.
11.10. Pharmacist perspective on rhinosinusitis 
	• Determining the best way to predict acute bacterial 
rhinosinusitis
	• To show whether the provision of educational and 
information materials for patients improve outcomes of ARS 
and reduce non-essential antibiotic use? 
	• To demonstrate whether professional education and 
efficient dissemination of evidence-based guidelines to 
pharmacists improve outcomes of ARS and reduce non-
essential antibiotic use?
11.11. General principles 
	• Research on implementation of guidelines.
	• Interdisciplinary collaboration is needed. 
	• Publication of negative as well as positive studies should be 
stimulated in order to have a better understanding of the 
efficacy and safety of interventions in AR and CRS. 
	• Quantitative research in real-life studies evaluating large 
number of patients should be reinforced. 
	• Application of health information technology for data 
collection, real-time analysis and feedback for clinical 
decision support systems and for education should be 
available for all stakeholders, including patients, researchers, 
clinicians, administrators, and politicians. 
	• Setup of biobanks for biomarker mining and rapid validation 
of novel candidates.
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12.1. Introduction
Patients with rhinosinusitis, acute and chronic deserve the 
best possible management of their disease. Our aim is for this 
next European Position Paper on Rhinosinusitis to promote 
better-informed decision-making by patients, members of the 
community, clinicians, and public health policy-makers on the 
management of rhinosinusitis. 
The European Position Paper on Rhinosinusitis (EPOS 2020) is 
the latest in the EPOS series of guidelines on rhinosinusitis from 
an international cohort of experts in the field.
The first European Position Paper on Rhinosinusitis and Nasal 
Polyps (EP3OS)(1) was published in 2005, and was soon followed 
by EP3OS 2007(2, 3) in response to the first position paper’s 
extremely positive reception and the growing body of research 
in this area. 
The guideline development group included all relevant 
stakeholders including medical specialists of all relevant 
specialities, microbiologists, primary care physicians, 
pharmacists and patients were involved. A much larger group of 
stakeholders and experts from all over the world has been asked 
to review and comment the document. Their comments have 
been used to further improve the document. 
The development strategy used in EPOS2020 has been 
published before we started the work(4) and we refer here to 
that document for details of the methods used. We followed the 
AGREE II framework(5), a tool which aims to ensure consistency in 
quality of clinical practice guidelines, provide a methodological 
strategy for the development of guidelines and clarify what 
and how information ought to be reported in guidelines. 
In summary, the EPOS 2020 guideline applies to the adult 
and paediatric patient population with ARS (viral / common 
cold, post-viral, bacterial), and all forms of CRS. The EPOS 
steering committee started to review whether definitions and 
classifications made in earlier versions of EPOS were still relevant 
and precise. In ARS the in EPOS2012 proposed classification 
into acute viral rhinosinusitis (common cold, acute post-viral 
rhinosinusitis and acute bacterial rhinosinusitis (ABRS)) was 
considered to still be relevant and now the whole of chapter 4 
uses this classification to evaluate the evidence. 
Based on new insights developed in the past decade on the 
different phenotypes and endotypes of CRS it was decided to 
move away from the phenotypical classification into CRSwNP 
and CRSsNP and come with a new classification that used  
anatomical aspects and endotype of disease. We expect that this 
new classification will be better suited to discuss  treatments in 
the near future.
We used evidence-based medicine (EBM) methodologies to 
search for evidence, incorporating randomized controlled 
trials (RCTs) with ‘Real World Experience (RWE) – observational 
studies (surgery) / real-life studies, and using meta-analysis of 
systematic reviews to combine results from clinical trials. Most 
surgical evidence is based on observational studies, with recent 
research showing some justification for incorporating non-
randomized studies(6, 7).Some parts of the document did not lend 
themselves to systematic analysis of the literature (e.g. the parts 
on pathophysiology). In those (sub)chapters the search used has 
been indicated. Many questions could not be answered with the 
existing literature. For that reason, Delphi trials were performed 
directed to ENT / rhinology specialists / primary practitioners to 
reach expert consensus on areas including (but not limited to) 
diagnostics, certain treatments for acute rhinosinusitis, and in 
CRS, appropriate medical therapy and surgery (and technique to 
use) in adult and paediatric rhinosinusitis. Two full new chapters 
focus on patient participation, prevention of disease and the 
role of the pharmacy in the management of the disease. 
12.2. Search methods to identify RCTs
12.2.1 Abstract selection
An information specialist (J.L.) performed an electronic search 
in the Cochrane Central Register of Controlled Trials (CENTRAL), 
OVID MEDLINE and OVID EMBASE using controlled term, such as 
MeSH-terms, and textwords for chronic or acute rhinosinusitis 
including nose polyps, Kartagener syndrome, adenoid 
hypertrophy, common cold and URTI. In MEDLINE and EMBASE 
the search was combined with a methodological search filter 
to identify RCTs. No language, date or other restrictions were 
used. The records identified were downloaded in EndNote and 
duplicates were removed. The complete search strategies for 
ARS and CRS are shown at the bottom of this chapter. The search 
was performed 18/02/2019. For the chapters on management 
of the disease we decided to only evaluate RCT and systematic 
reviews (SR). The references (20524 on treatment and 3840 
diagnostic) were imported into Rayyan (https://rayyan.qcri.org) 
and two independent reviewers selected papers based on the 
abstract. All the papers that had inconclusive selections were 
discussed.Additional relevant papers found in the SR and newly 
published in 2019 were added during the writing process.
This resulted in 2214 papers of which the full texts were 
assessed. All SRs were analysed for additional references and 
156 SR are referenced in the document. Eventually 26 SRs 
(on common cold (see below)) and 294 RCTs were used for 
treatment analyses that are mainly reported in chapters 4,6 and 
7.  A total of 3182 references were used in the full document, 
12. Methods used in EPOS2020
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Studies that were included/excluded during the abstract 
selection that needed discussion were:
- Prevention studies of common cold in subpopulations 
based on age (elderly, day care centres) (included)
- Studies on behavioral changes in prescribing antibiotics 
(included)
- Studies on wound healing in sinus surgery (included)
- Open randomized studies (excluded)
- Studies in subpopulations of ARS based on other things 
than age (athletes, swimmers) (excluded)
- Fever not related to ARS (excluded)
- Reaction time and alertness in ARS (excluded)
- Sore throat (excluded)
12.2.2. Full paper selection
12.2.2.1. Included studies
In the phase of evaluating full papers we noted that the 
number of papers on the treatment of URTI/common cold was 
very large. We decided to only include SRs in our analysis on 
treatment of common cold. All relevant papers on diagnosis, 
however, are included in the review.
We only included peer-reviewed papers. Papers were retrieved 
from international libraries around the world. Occasionally 
authors were contacted to provide a paper. Papers were 
translated/extracted from their original language by volunteer 
specialists who were able to read the language and had 
sufficient knowledge of EBM to find the relevant data. Especially 
for Chinese papers, the volunteers were often asked to evaluate 
whether the paper was an RCT and whether the population 
evaluated was relevant to the question before full translation of 
the paper was done.
Papers that evaluated mixed patient populations were included 
when the relevant data for the relevant patient group (fulfilling 
the criteria of ARS or CRS as defined by EPOS) were reported 
separately. The division of ARS into viral ARS (common cold), 
post-viral ARS and ABRS suggested in EPOS2012 has obviously 
not been followed in most earlier papers. For papers evaluating 
ARS, papers were included when it was clear that the majority 
of the patients fulfilled the EPOS criteria. E.g. for post-viral 
ARS a study evaluating patients with symptoms for more than 
three days but with a table indicating that the mean symptom 
duration at inclusion was 12 days was included. A study where 
inclusion was more than three days and no indication of 
symptom duration was excluded. Studies indicating that 70% 
of the patients had symptoms for more than 10 days were 
included. 
For ABRS, papers that used either the EPOS criteria or a 
combination of most of the EPOS criteria for ABRS and radiology 
and/or positive antral puncture were included. 
PRISMA 2009 Flow Diagram
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For evaluating safety of effective medication, when possible, 
systematic reviews on other diseases than CRS were evaluated.
12.2.2.2. Excluded studies
• Comparison of  medication in ARS or CRS that was not 
effective. 
• Comparison of  antibiotics in the treatment of ARS because 
either antibiotics were not effective (post-viral ARS) or 
insufficient RCT were performed (ABRS). 
• Evaluation of  treatment of the lower airways.
• Studies evaluating safety when efficacy of the medication 
has not been shown.
• Studies evaluating combination treatment versus single 
treatment when the single treatment has not been shown 
to be effective.
• Studies evaluating two treatment options when no 
comparison with a placebo or with another treatment 
proven not to be more effective than placebo was made.
• Studies evaluating the treatment of side-effects of 
treatment (e.g. treatment of osteoporosis in patients with 
CRSwNP).
• Studies on treatment only evaluating non-clinical 
outcomes (histology).
12.2.3. Evaluation of the evidence
In CRS and ARS, excluding common cold, when enough RCTs 
with sufficient patient numbers were available, other evidence 
was not primarily included.  We started to evaluate whether 
DBPCT trials were evaluable. If more than threeDBPCT were 
available, we did not look for other evidence unless the 
outcomes of the trials were either not useful or incongruent.  
When sufficient DBPCTs were not available, other single blind 
or open RCTs were used to accumulate the evidence. When 
no RCTs were available,occasionally other forms of evidence 
such as case control, cohort studies, real-life studies and Delphi 
rounds were used. Studies were only included when relevant 
between group data (e.g. mean and s.d. or non-parametric 
data) could be evaluated either directly from the paper or after 
recalculation. We accepted either post-treatment comparisons 
or changes from baseline. Papers only giving statistics for 
changes from baseline within groups (not between groups) 
could not be included. If needed statistics were recalculated 
based on the data reported in the paper, especially in situations 
where data compared to baseline within groups were reported 
but statistics of the group comparison after treatment were 
not reported. If sufficient RCTs were available, we did a meta-
analysis. Systematic reviews and meta-analysis from others were 
used when no new papers appeared after the meta-analysis was 
done and the relevant questions were evaluated. 
Evidence(8)tables were assimilated. GRADE (Grading of 
Recommendations Assessment, Development and Evaluation, 
http://www.gradeworkinggroup.org/) was used whenever 
possible. Harm either for the patient directly or for the 
population (like costs, or resistance to antibiotics) was 
consistently part of the evaluation. In surgery in general RCT’s 
were very limited and other evidence is reported.  We only used 
the data that were available in the reported evidence. Finally, 
the chapters on diagnosis and treatment were combined into 
integrated care pathways starting at self-management and 
OTC treatment, via primary and secondary care to specialist 
management of the disease (see chapter 1).
12.3. Delphi rounds
Despite considerable increases in the amount of quality 
publications in recent years, a large number of practical 
clinical questions remain. It was agreed that the best way to 
address these was to conduct a Delphi exercise which is a 
structured communication technique, originally developed as 
a systematic, interactive forecasting method which relies on 
a panel of experts. The EPOS2020 group firstly prioritised the 
areas for consideration by several rounds of questionnaires 
and discussion as a result of which we have concentrated on 
diagnostic issues in the first instance. The final Delphi questions 
were circulated in several tranches and the respondents were 
asked to grade their answer from 1-9, where 1 was least and 
9 most (essential/clinically relevant/acceptable etc) When 
the results were analysed, there were three possible results – 
positive, negative or unclear as shown below depending on the 
percentage of answers from the whole group. The results have 
been integrated into the respective sections of EPOS2020. 
It is our intention to develop a rolling Delphi programme under 
the aegis of EPOS2020 and ERS to achieve expert consensus for 
other areas of clinical management across the full spectrum of 
rhinosinusitis in the future.
12.4.Dissemination and future updates
The number of relevant papers in our field is growing 
exponentially. This has resulted in a doubling of the number 
of pages of EPOS2020 compared to EPOS2012. We hope that 
the executive summary (chapter 1) will be used to disseminate 
the new knowledge. Including everything in all-compassing 
documents like EPOS2020 becomes more and more challenging. 
The EPOS group plans to come with yearly smaller updates on 
the most relevant changes and as already mentioned, a group 
will be formed to organize frequent Delphi rounds on relevant 
clinical questions that are difficult to answer with RCTs in the 
Positive answer  ≥70% Grade 7-9; ≤15% 
Grade 1-3
Unclear
Negative answer   ≥70% Grade 1-3; ≤15% 
Grade 7-9
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near future.
This guideline will again be disseminated in many countries 
over the world. The executive summary (chapter 1) has a concise 
format and is easy to read. A website (www.epos2020.com) 
has been launched and pocket guides for different stakeholder 
groups including patients will be prepared in the near future. On 
the website, education material for different stakeholders can be 
found. 
12.5. Editorial Independence
This position paper has been funded by the European 
Rhinologic Society, Journal Rhinology and the Rhinology 
Foundation. No other funding has been used. All guideline 
development members have provided their competing interest. 
12.6. Details of search strategies used
12.6.1. CORE search OVID MEDLINE CRS and ARS 2019-01-30
We advised all authors to use the core searches for CRS and 
ARS in OVID MEDLINE. We advised them to seek assistance of 
your local librarian to adapt the search and add the topic(s) of 
interest. We advised to use a similar approach as below to search 
for additional concepts, thus controlled terms, including MeSH-
terms, and textwords (tw,kf ).
12.6.1.1.CORE ARS-search
Database(s): Ovid MEDLINE(R) and Epub Ahead of Print, In-
Process and Other Non-Indexed Citations and Daily 1946 to 
January 28, 2019 
Search Strategy: 2019-01-30
# Searches Results
1 exp sinusitis/ 19569
2 rhinitis/ or rhinitis, atrophic/ or rhinitis, vasomotor/ 13071
3
exp paranasal sinuses/mi or (exp paranasal sinuses/ 
and (respiratory tract infections/ or chronic disease/))
2604
4
(sinusit* or rhinit* or ozena* or rhinosinusit* 
or nasosinusit* or pansinusit* or ethmoidit* or 
sphenoidit*).tw,kf.
46748
5
((inflamm* or microb*) adj5 (rhino* or sinus or sinuses 
or sinusal)).tw,kf.
2191
6 nasal muc?us.tw,kf. 830
7
(rhinorr*.ti,ot,kf. not (ci.fs. or (CSF or ((leak* or fluid*) 
and cerebr*) or safet*).ti,ot,kf.)) or (purulent adj3 
rhinorr*).tw,kf.
586
8 or/1-7 [ rhinosinusitus both ARS and CRS] 56505
9 common cold/ 4131
10 ((common or head) adj cold*).tw,kf. 3819
11 coryza.tw,kf. 619
12
((upper adj4 (respiratory or airway) adj2 infection*) 
or URTI).tw,kf.
8937
13
ARS.tw,kf. and (sinonas* or nasal or naso* or rhin* 
or ENT).mp.
166
14 or/9-13 [ ARS ] 15102
15
8 or 14 [ ARS (incl. umbrella terms for 
rhinosinusitis - B) ]
69906
16 exp animals/ not exp humans/ 4541167
17 15 not 16 [ ARS in humans ] 66289
Notes:
1. The core search for ARS consists of a broad rhinosinusitus 
search (or/1-7) and a specific search for ARS (or/9-13).
2. You may omit terms that are not relevant for the specific 
question.
3. If the general part is too broad for the specific topic you 
may narrow the general terms down by adapting this part 
conf. Lemiengre, MB et al (instead of or/1-7 given]
1 exp Sinusitis/ 
2 sinusit*.tw. 
3 Rhinitis/ 
4 rhinit*.tw. 
5 rhinosinusit*.tw. 
6 nasosinusit*.tw. 
7 ((suppurative or purulent) adj2 (nasal discharge 
or rhinitis or rhinorrhoea or rhinorrhoea)).tw.8 or/1‐7
4. italic grey terms are optional (these terms did not result 
in additional relevant hits in the search aimed to identify 
SRs). i.e. additional records found with rhinitis are generally 
about allergic rhinitis
5. row 16 is a search filter meant to safely exclude animal 
studies. In case of many animal studies, you may want to 
use a broader filter instead 
(exp animals/ not exp humans/) or animal.jw. or (rodent* 
or rabbit* or mice or mouse or murine or rat or rats or 
chicken* or (animal* adj3 (experiment* or model*))).ti.  
[jw=journal word]
12.6.1.2. CORE CRS-search
Database(s): Ovid MEDLINE(R) and Epub Ahead of Print, In-
Process & Other Non-Indexed Citations and Daily 1946 to 
January 28, 2019  
# Searches Results
1 exp sinusitis/ 19569
2 rhinitis/ or rhinitis, atrophic/ or rhinitis, vasomotor/ 13071
3
exp paranasal sinuses/mi or (exp paranasal sinuses/ 
and (respiratory tract infections/ or chronic disease/))
2604
4
(sinusit* or rhinit* or ozena* or rhinosinusit* 
or nasosinusit* or pansinusit* or ethmoidit* or 
sphenoidit*).tw,kf.
46748
5
((inflamm* or microb*) adj5 (rhino* or sinus or sinuses 
or sinusal)).tw,kf.
2191
6 nasal muc?us.tw,kf. 830
7
(rhinorr*.ti,ot,kf. not (ci.fs. or (CSF or ((leak* or fluid*) 
and cerebr*) or safet*).ti,ot,kf.)) or (purulent adj3 
rhinorr*).tw,kf.
586
8 or/1-7 [ rhinosinusitus both ARS and CRS] 56505
9 nasal polyps/ 6141
10
((nose or nasal or nasi or rhino* or sinus* or 
sinonasal) adj3 (papilloma* or polyp*)).tw,kf.
7987
11 (rhinopolyp* or CRSwNP*).tw,kf. 822
12 CRSSNP*.tw,kf. 373
13
ECRS.tw,kf. or (CRS.tw,kf. and (sinonas* or nasal or 
naso* or rhin* or ENT).mp.)
2846
14
(kartagener* syndrom* or primary ciliary 
dyskinesi*).mp. not (COPD or thoracic or pulmonary 
disease or bronchiectas*).ti,ot.
1939
15 adenoids/ab or (adenoids/ and hypertrophy/) 963
16
((adenoid* adj2 (hypertroph* or obstruct*)) or 
adenoidit*).tw,kf.
1056
17 or/9-16 [ CRS ] 14635
18
8 or 17 [ CRS (incl. umbrella terms for 
rhinosinusitis -B) ]
64185
19 exp animals/ not exp humans/ 4541167
20 18 not 19 [ CRS in humans ] 60937
21
remove duplicates from 20 [only possible if #20 
<6000 hits) 
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Search Strategy: 30-01-2019
Notes:
1. The core search for CRS consists of a broad rhinosinusitis 
search (or/1-7) and a specific search for CRS (or/9-16).
2. You may omit terms that are not relevant for the specific 
question, i.e. if adenoids are not relevant you can discard 
rows 15 and 16 
3. If the general part is too broad for the specific topic you 
may narrow the general terms down by combining these 
terms with terms for chronic, thus combine or/1-7 with for 
example (i.e. adapted from Chong et al):  
exp chronic disease/ or exp recurrence/ or (chronic* or 
persis* or recurr* or long-last* or longlast*).tw,kf.
4. italic grey terms are optional (these terms did not result in 
additional relevant hits in the search aimed to identify SRs) 
5. row 19 is a search filter meant to safely exclude animal 
studies. In case of many animal studies, you may want to 
use a broader filter instead 
(exp animals/ not exp humans/) or animal.jw. or (rodent* 
or rabbit* or mice or mouse or murine or rat or rats or 
chicken* or (animal* adj3 (experiment* or model*))).ti.  
[jw=journal word]
12.6.2. Searches for RCT on treatment and diagnostics (used 
for CH4,6 and 7)
CENTRAL Date Run: 18/02/2019 18:37:17
# Searches Results
1 [mh sinusitis] 888
2
[mh ^rhinitis] or [mh ^"rhinitis, atrophic"] or [mh 
^"rhinitis, vasomotor"]
917
3
[mh "paranasal sinuses"/mi] or ([mh "paranasal 
sinuses"] and  ([mh ^"respiratory tract 
infections"] or [mh ^"chronic disease"]))
95
4
(rhinosinusit* or nasosinusit* or 
ozena* or  pansinusit* or ethmoidit* or 
sphenoidit*):ti,ab,kw
1008
5 sinusit*:ti,ab,kw 2324
6 rhinit*:ti,ab,kw 8352
7
((inflamm* or microb*) near/5 (rhino* or sinus or 
sinuses or sinusal)):ti,ab,kw
172
8 (nasal NEXT mucus):ti,ab,kw 51
9
(rhinorr*:ti,kw) not ([mh /CI] or (CSF or ((leak* or 
fluid*) and cerebr*) or safet*):ti,ab,kw)
344
10 [mh "nasal polyps"] 319
11
((nose or nasal or nasi or rhino* or sinus* or 
sinonasal) near/3 (papilloma* or polyp*)):ti,ab,kw
787
12 (rhinopolyp* or CRSwNP* or CRSSNP*):ti,ab,kw 75
13
((kartagener* NEXT syndrom*) or (primary NEXT 
ciliary NEXT dyskinesi*)):ti,ab,kw not (COPD 
or thoracic or (pulmonary NEXT disease) or 
bronchiectas*):ti
43
14
[mh ^adenoids/AB] or ([mh ^adenoids] and [mh 
^hypertrophy])
57
15
((adenoid* near/2 (hypertroph* or obstruct*)) or 
adenoidit*):ti,ab,kw
125
16 [mh ^"common cold"] 497
17 ((common or head) NEXT cold):ti,ab,kw 1088
18 coryza:ti,ab,kw 36
19
((suppurat* or purulent) near/3 ((nasal NEXT 
discharg*) or rhinor*)):ti,ab,kw
37
20
((upper near/4 (respiratory or airway) near/2 
infection*) or URTI or (U next R next T next 
I)):ti,ab,kw
3814
21 {OR #1-#20} 15326
22 #21 in Trials 15166
23* #22 not Clinicaltrials:so 14041
24* #22 and Clinicaltrials:so 1125
* do not use = #23 en #24 when the trial registers are not kept separate. 
Database(s): Ovid MEDLINE(R) and Epub Ahead of Print, In-
Process & Other Non-Indexed Citations and Daily 1946 to 
February 15, 2019  
Search Strategy: 2019-02-18
# Searches Results
1 exp sinusitis/ 19603
2 rhinitis/ or rhinitis, atrophic/ or rhinitis, vasomotor/ 13106
3
exp paranasal sinuses/mi or (exp paranasal sinuses/ 
and (respiratory tract infections/ or chronic 
disease/))
2607
4
(rhinosinusit* or nasosinusit* or ozena* or 
pansinusit* or ethmoidit* or sphenoidit*).tw,kf.
9023
5 sinusit*.tw,kf. 15829
6 rhinit*.tw,kf. 26038
7
((inflamm* or microb*) adj5 (rhino* or sinus or 
sinuses or sinusal)).tw,kf.
2180
8 nasal muc?us.tw,kf. 828
9
rhinorr*.ti,ot,kf. not (ci.fs. or (CSF or ((leak* or fluid*) 
and cerebr*) or safet*).ti,ot,kf.)
474
10 nasal polyps/ 6150
11
((nose or nasal or nasi or rhino* or sinus* or 
sinonasal) adj3 (papilloma* or polyp*)).tw,kf.
7958
12 (rhinopolyp* or CRSwNP* or CRSSNP*).tw,kf. 869
13
(kartagener* syndrom* or primary ciliary dyskinesi*).
mp. not (COPD or thoracic or pulmonary disease or 
bronchiectas*).ti,ot.
1932
14 adenoids/ab or (adenoids/ and hypertrophy/) 964
15
((adenoid* adj2 (hypertroph* or obstruct*)) or 
adenoidit*).tw,kf.
1051
16 common cold/ 4136
17 ((common or head) adj cold*).tw,kf. 3808
18 coryza.tw,kf. 617
19
((suppurat* or purulent) adj3 (nasal discharg* or 
rhinor*)).tw,kf.
279
20
((upper adj4 (respiratory or airway) adj2 infection*) 
or URTI or U-R-T-I).tw,kf.
8909
21 or/1-20 [ rhinosinusitis ] 77127
22
(exp animals/ not exp humans/) or animal.jw. or 
(rodent* or rabbit* or mice or mouse or murine or 
rat or rats or chicken* or (animal* adj3 (experiment* 
or model*))).ti.
4819005
23 21 not 22 [ human rhinosinusitis ] 72948
24
(controlled clinical trial/ or randomized controlled 
trial/ or random allocation/ or double-blind 
method/ or single-blind method/ or (randomi?ed or 
randomi?ation or placebo* or randomly or (random 
adj3 allocat*) or ((random* or controlled) adj2 (study 
or trial)) or ((singl* or doubl* or treb* or tripl*) adj 
(blind*3 or mask*3))).tw,kf. or trial.ti.) not ((review or 
editorial).pt. or review.ti.) [ RCT filter - adapted from 
the Cochrane]
1073418
25 23 and 24 [ RCTs on human rhinosinusitis ] 7258
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Database(s): EmbaseClassic+Embase 1947 to 2019 February 15 
Search Strategy: 2019-02-18
# Searches Results
1 exp rhinosinusitis/ 9352
2 exp sinusitis/ 43919
3 rhinitis/ or atrophic rhinitis/ or vasomotor rhinitis/ 22552
4
(rhinosinusit* or nasosinusit* or ozena* or 
pansinusit* or ethmoidit* or sphenoidit*).tw,kw.
11984
5 sinusit*.tw,kw. 23044
6 rhinit*.tw,kw. 40889
7
((inflamm* or microb*) adj5 (rhino* or sinus or 
sinuses or sinusal)).tw,kw.
3184
8 nasal muc?us.tw,kw. 1394
9
(*rhinorrhea/ or rhinorr*.ti,ot,kw.) not (si.fs. or (CSF 
or ((leak* or fluid*) and cerebr*) or safet*).ti,ot,kw.)
893
10 chronic rhinitis/ 1209
11 nose polyp/ 10758
12
((nose or nasal or nasi or rhino* or sinus* or 
sinonasal) adj3 (papilloma* or polyp*)).tw,kw.
10773
13 (rhinopolyp* or CRSwNP* or CRSSNP*).tw,kw. 1222
14
(kartagener* syndrom* or primary ciliary 
dyskinesi*).mp. not (COPD or thoracic or 
pulmonary disease or bronchiectas*).ti,ot.
2896
15 adenoid hypertrophy/ 609
16
((adenoid* adj2 (hypertroph* or obstruct*)) or 
adenoidit*).tw,kw.
1440
17 common cold/ 9118
18 ((common or head) adj cold*).tw,kw. 5178
19 coryza.tw,kw. 842
20
((suppurat* or purulent) adj3 (nasal discharg* or 
rhinor*)).tw,kw.
421
21
((upper adj4 (respiratory or airway) adj2 
infection*) or URTI or U-R-T-I).tw,kw.
14860
22 or/1-21 [ rhinosinusitis ] 128236
23
((animal/ or animal experiment/ or exp animal 
model/ or nonhuman/ or exp female animal/) not 
human/) or exp veterinary medicine/ or animal*.
jw. or (rodent* or rabbit* or mice or mouse or 
murine or rat or rats or chicken* or (animal* adj3 
(experiment* or model*))).ti.
6618264
24 22 not 23 [ rhinosinusitis in humans ] 122363
25
(exp controlled clinical trial/ or randomization/ 
or double blind procedure/ or single blind 
procedure/ or (randomi?ed or randomi?ation or 
placebo* or randomly or (random adj5 (allocat* or 
control*)) or ((random* or controlled) adj2 (study 
or trial)) or ((singl* or doubl* or treb* or tripl*) adj 
(blind*3 or mask*3))).tw,kw. or trial.ti.) not (review/ 
or editorial/ or (review or editorial).pt. or review.ti.)
1503658
26 24 and 25 [ RCTs on rhinosinusitis ] 14635
12.6.3. Searches per chapter
12.6.3.1. Introduction
Here per chapter the searches are given. Often searches were 
done per subchapter
12.6.3.2. Classification, definitions and terminology
Control
A literature search was performed in Pubmed using the terms: 
“chronic rhinosinusitis”, “EPOS” and “control”. Publication date 
was set between the third EPOS update in March 2012 and 
June 2019. This search resulted in 13 articles which were further 
analyzed. Eventually, we identified 3 studies that evaluated the 
burden of uncontrolled CRS using the EPOS control criteria. 
12.6.3.3. Burden of acute and chronic rhinosinusitis      
12.6.3.3.1. Quality of life
Main search strategy AND (impact or burden or severity),  
12.6.3.3.2.Costs of rhinosinusitis
The search utilized for these references was performed in 
Pubmed with search terms: “sinusitis” “costs” “total” “direct” 
“indirect” “economic.”
12.6.3.4. Acute rhinosinusitis including common cold - and 
recurrent ARS in adults and children
12.6.3.4.1. Epidemiology of acute rhinosinusitis (ARS)
Database(s): Ovid MEDLINE(R) and Epub Ahead of Print, 
In-Process & Other Non-Indexed Citations, Daily and 
Versions(R) 1946 to February 15, 2019
Search Strategy: February 15, 2019
# Searches Results
1
((Acute rhinosinusitis or Acute sinusitis) and 
prevalence).mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, floating
sub-heading word, keyword heading word, 
organism supplementary concept word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier, 
synonyms]
  84
2
limit 1 to (abstracts and english language and humans 
and yr="2011 -Current")
  34
12.6.3.4.2 Pathophysiology of ARS
 ((((((((“Common Cold”[Mesh]) OR “Sinusitis”[Mesh] OR 
“Respiratory Tract Infections”[Mesh:NoExp])) OR ((((acute[Title/
Abstract] OR viral[Title/Abstract] OR virus[Title/Abstract]))) 
AND ((rhinit*[Title/Abstract] OR rhinosinusit*[Title/Abstract] 
OR sinusit*[Title/Abstract] OR paranasal sinusit*[Title/Abstract] 
OR nasosinusit*[Title/Abstract])))) OR ((Acute upper respiratory 
tract infection*[Title/Abstract]) OR viral upper respiratory tract 
infection*[Title/Abstract] OR respiratory viral infection*[Title/
Abstract] OR respiratory virus infection*[Title/Abstract])) OR 
((((rhinit*[Title/Abstract] OR rhinosinusit*[Title/Abstract] OR 
sinusit*[Title/Abstract] OR paranasal sinusit*[Title/Abstract] OR 
nasosinusit*[Title/Abstract]))) AND ((pathophysiology[Title/
Abstract] OR pathogenic[Title/Abstract]))))))=> 64,939 results.
Many studies on the pathophysiology of acute rhinosinusitis 
were published with key words including common cold, 
viral infection and respiratory tract infection. Therefore, our 
search strategy had to include these key words in different 
combinations. The relevant articles were then selected after 
screening the abstracts.
12.6.3.4.3.Diagnosis and differential diagnosis of ARS in 
adults and children
Central search, see above.
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12.6.3.4.4.Medical management of ARS
Central search, see above.
12.6.3.4.5 Complications of ARS
No search provided.
12.6.3.5. Epidemiology and predisposing factors of CRS
12.6.3.5.1.  AECRS:  
((((((((((chronic[ti] OR persis*[ti]))) AND ((Acute[tiab] 
OR exacerbation*[tiab]))) AND (((“Sinusitis”[Mesh] OR 
“Rhinitis”[Mesh] AND “Chronic Disease”[Mesh]) OR 
rhinosinusitis[tiab] OR nasosinusitis[tiab] OR sinusitis[tiab] OR 
pansinusitis[tiab] OR ethmoiditis[tiab] OR ethmoiditis[tiab] 
OR sphenoiditis[tiab] OR (kartagener* [ti] AND syndrome* 
[ti])))) AND “last 10 years”[PDat] AND English[lang])) NOT (“case 
reports”[Publication Type] AND “last 10 years”[PDat] AND 
English[lang])) AND “last 10 years”[PDat] AND English[lang])) 
NOT ((animals[mh] NOT humans[mh]))
 
12.6.3.5.2.Genetics and epigenetics of CRSsNP and CRSwNP
OVID search history
1. exp sinusitis/
2. exp paranasal sinuses/mi or (exp paranasal sinuses/ and (respiratory 
tract infections/ or chronic disease/))
3. (sinusit* or rhinit* or ozena* or rhinosinusit* or nasosinusit* or 
pansinusit* or ethmoidit* or sphenoidit*).tw,kf.
4. (sinusit* or rhinosinusit* or nasosinusit* or pansinusit* or ethmoidit* 
or sphenoidit*).tw,kf.
5. ((inflamm* or microb*) adj5 (rhino* or sinus or sinuses or sinusal)).
tw,kf.
6. nasal muc?us.tw,kf.
7. or/1-6
8. nasal polyps/
9. ((nose or nasal or nasi or rhino* or sinus* or sinonasal) adj3 
(papilloma* or polyp*)).tw,kf.
10. (rhinopolyp* or CRSwNP*).tw,kf.
11. CRSSNP*.tw,kf.
12. ECRS.tw,kf. or (CRS.tw,kf. and (sinonas* or nasal or naso* or rhin* or 
ENT).mp.)
13. or/8-12
14. 7 or 13
15. (pathophysiol* or mechanism* or biology* or molecul* or cell* or 
inflammat* or eosinophil* or cytokine* or epitheli* or pathology* or 
leukocyt* or prostaglandin* or morphology* or anatom* or physiology* 
or biomedic* or genom* or gene* or mRNA or RNA or transcript* 
or microarray* or sequenc* or protein* or biomark*).mp. [mp=title, 
abstract, original title, name of substance word, subject heading 
word, floating sub-heading word, keyword heading word, organism 
supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms]
16. 14 and 15
17. exp animals/ not exp humans/
18. 16 not 17
19. 16 not 17
20. limit 19 to (english language and yr="2012 -Current")
This OVID search produced a total of 9491 publications. Manual 
curation was performed by reading (STS and HW) all abstracts/
titles and by excluding the publications not meeting with 
inclusion criteria such as case reports, animal experiments, 
allergic rhinitis, no English language, no inflammatory 
mechanisms presented, GWAS, etc. After the manual curation of 
the search data, the final number of publications was 1202. Of 
these about 300 have been referred in this EPOS chapter 5.2.2.
12.6.3.5.3.Diagnosis and differential diagnosis
Search strategy
The search for CRS and olfaction was performed on November 
17th 2019 in OVID Medline. It was combined with “olfactory 
function or smell” giving 406 hits.  These were screened. 
Exclusion criteria were: keyword coincidences without any 
information given regarding olfactory measures, children only 
and wrong subject. 
The EPOS 2020 core search for CRS was performed on June 17th 
2019 in OVID Medline. It was combined with “(facial pain or 
headache).ti” giving 330 hits. To exclude case reports all “(case).
ti” were removed resulting in a total of 304 records, containing 
1 duplicate. These were screened. Exclusion criteria were:. 
publication before 1996 (101 records), case reports (57 records), 
children only (12 records) and wrong subject, wrong population 
or methodological shortcomings (73 records). Thus, 60 records 
were included. Of these, only 25 (42%) contained original data. 
The others were reviews, editorials, letters, comments etc.
After a first review by the EPOS steering group, members were 
asked to supply any missing yet relevant references. This way, 
another seven papers were included, most of which were not 
written primarily for facial pain but contained data relevant to 
this chapter.
12.6.3.6. Management of chronic rhinosinusitis in adults
Central search, see above.
12.6.3.7. Paediatric CRS
12.6.3.7.1. Epidemiology, predisposing factors, and 
comorbidities
A PubMed and Scopus (EMBASE) search was performed and 
relevant data were extracted accordingly. The first search 
was for the following terms: chronic sinusitis in children or 
chronic rhinosinusitis in children; paediatric chronic sinusitis or 
paediatric chronic rhinosinusitis. All of them followed by and:
• Epidemiology or prevalence
• Anatomic variations of the paranasal sinuses
• The effect of environmental exposures 
• Occupational and environmental risk factors for 
• Risk factors 
• The role of pollution, toxins and dust at home 
• The role of viral infections in inducing or exacerbating CRS 
• The role of viral infections in the onset of CRS in children
• Smoking
• Active and passive tobacco smoke exposure with the 
prevalence of chronic sinusitis in children
• Allergic rhinitis or allergy
• Asthma
• Role of the Adenoid
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• Relationship between sinusitis and adenoid size in paediatric 
age group
• Adenoid bacteriology and sinonasal symptoms
• Identification of adenoid biofilms
• Immunological investigation in the adenoid tissues
• Adenoidectomy outcomes 
• Gastroesophageal reflux disease 
• Humoral immunodeficiency
• Immunologic defects in 
• Deficiency of the paediatric immune system
• Immaturity immune system 
• Cystic fibrosis
• Diagnosis of cystic fibrosis in newborns
• Primary ciliary dyskinesia
12.6.3.7.2. Pathophysiology of chronic rhinosinusitis with or 
without nasal polyposis
12.6.3.7.2.1. Genetics
Pubmed
Search words: Sinusitis/Children/genetics
10-year limit
82 hits reviewed and 14 selected for review.
Eliminated irrelevant abstracts and studies that involved adults 
only.
12.6.3.7.2.2. Inflammatory mechanisms
Pubmed
Search words: Inflammation, Rhinosinusitis
Limits: previous 10 years/Age <18y/Humans 
178 hits reviewed and 56 selected for review.
Eliminated adult studies, reviews, and non-English language 
abstracts.
12.6.3.7.3. Diagnosis and differential diagnosis
Given the nature of this chapter (differential diagnosis and use 
of diagnostic tools, with emphasis on issues specific for the 
paediatric population) a systematic search on the CRS core set 
was deemed unfruitful. References were hand-searched. After 
the first version, the EPOS steering group was asked for input on 
any missing relevant papers.
12.6.3.7.4. Management of CRS and co-morbidities
Pubmed
Search words: Chronic Rhinosinusitis and Antibiotics
Limits: 10-year, Humans, English, Child: birth-18y
70 hits reviewed and 12 selected for review.
Eliminated irrelevant abstracts, reviews, studies dealing with CF, 
and studies that involved adults only.
Pubmed
Search words: Chronic Rhinosinusitis and Saline
Limits: 10-year, Humans, English, Child: birth-18y
26 hits reviewed and 7 selected for review.
Eliminated irrelevant abstracts, reviews, studies dealing with CF, 
and studies that involved adults only.
Pubmed
Search words: Chronic Rhinosinusitis and Corticosteroids
Limits: 10-year, Humans, English, Child: birth-18y
31 hits reviewed and 3 selected for review.
Eliminated irrelevant abstracts, reviews, studies dealing with CF, 
and studies that involved adults only.
Pubmed
Search words: Chronic Rhinosinusitis and Balloon
Limits: 10-year, Humans, English, Child: birth-18y
28 hits reviewed and 12 selected for review.
Eliminated irrelevant abstracts, reviews, studies dealing with CF, 
and studies that involved adults only.
Pubmed
Search words: Chronic Rhinosinusitis and Adenoidectomy
Limits: 10-year, Humans, English, Child: birth-18y
38 hits reviewed and 15 selected for review.
Eliminated irrelevant abstracts, reviews, studies dealing with CF, 
and studies that involved adults only.
Pubmed
Search words: Chronic Rhinosinusitis and Endoscopic Sinus 
Surgery
Limits: 10-year, Humans, English, Child: birth-18y
248 hits reviewed and 26 selected for review.
Eliminated irrelevant abstracts, reviews, studies dealing with CF, 
and studies that involved adults only.
Many of the selected articles overlapped.
12.6.3.8. Concomitant diseases in patients with chronic 
rhinosinusitis
12.6.3.8.1.Role of allergy and chronic rhinosinusitis
No search provided.
12.6.3.8.2.Immunodeficiencies and their role in CRS
Search strategy
1. Medline (Ovid)
- terms: chronic rhinosinusitis immunodeficiency 
- limits: 2012-current 
- results: 4671
2. Medline (Ovid)
- terms: primary immunodeficiency 
- limits: 2012-current 
- results: 1713
3. Medline (Ovid)
- terms:  secondary immunodeficiency chronic rhinosinusitis 
- limits: 2012-current 
- results: 2811
4. Medline (Ovid)
- terms:  secondary immunodeficiency 
- limits: 2012-current 
- results: 120
5. Google scholar
- terms:  chronic rhinosinusitis immunodeficiency 
- limits: 2012-current 
- results: 4530
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6. Google scholar
- terms:  chronic rhinosinusitis secondary immunodeficiency 
- limits: 2012-current 
- results: 2740
12.6.3.8.3. Lower airway disease including asthma in relation 
to CRS
Pubmed Search:
Chronic Rhinosinutis and asthma: 1489
Chronic Rhinosinusitis and COPD: 159 articles
Chronic Rhinosinusitis and lower airway disease: 199
Selection criteria for inclusion: English language, articles with 
novel insights and properly conducted trials and/or reviews, 
preference of recent (last 10 years) over historic reports
12.6.3.8.4.Cystic fibrosis
Search strategy
PubMed and Embase were systemically searched for articles 
addressing chronic rhinosinusitis in patients with cystic 
fibrosis (CF). The search was last updated on April 21, 2019. 
The literature search generated 1762 articles of which 40 were 
included. Nine additional studies were identified through 
reference lists. Further 17 studies elaborating on the included 
findings and concerning the CF diagnosis in general were 
included. The included studies were published between 1991 
and 2019. 
12.6.3.8.5.Primary ciliary dyskinesia and its role in CRS
Search strategy
PubMed and Embase were systemically searched for articles 
addressing chronic rhinosinusitis in patients with primary ciliary 
dyskinesia. The search was last updated on August 19, 2019. 
After exclusion of duplicates the literature search generated 609 
articles of which 37 were included. The included studies were 
published between 1981 and 2019. 
12.6.3.8.6.Fungal rhinosinusitis
Search strategy (see pag 460)
(Search for the keywords fungal.mp OR fungi.mp or fungus.mp 
with the prior search produced n=372 articles. Fungal ball was 
supplemented by the search below and PRISMA, invasive fungal 
disease includes).
Separate prisma and search was done for fungal ball.
# Searches Results
1. fungal ball.mp. 128
2. Mycetoma/ 1153
3. 1 or 2 1274
4.
(rhinosinusitis or $rhinosinusitis or crs or sinus$ 
or nose or nasal).mp.
219127
5. 3 and 4 228
6. (fungus or fungal or fungi).mp. 216128
7. invasive.mp. 268714
8. (invasive adj3 (fungus or fungal or fungi)).mp. 4866
9. 8 and 4 474
10. limit 9 to (english language and humans) 393
12.6.3.8.7. Vasculitis, granulomatous diseases and their role 
in CRS
12.6.3.8.7.2.Granulomatosis with polyangitis (GPA)
Search strategy
The EPOS 2020 core search for CRS was performed in June 
2019 in OVID Medline. It was combined with “(Wegener).ti” and 
“(granulomatosis with polyangiitis), giving 421 hits. These were 
screened. Exclusion criteria were: case reports (125 records), 
language other than English (30 records), children only (three 
records) and wrong subject (57 records). A further 102 non-
landmark publications <1996 were removed. Thus, 104 records 
were included. Of these, only 41 (39%) contained original data. 
The others were reviews, editorials, letters etc.
12.6.3.8.7.3.Eosinophilic granulomatosis with polyangiitis
Search strategy
The EPOS 2020 core search for CRS was performed in June 
2019 in OVID Medline. It was combined with “(Churg-Strauss).
ti” and “(polyangiitis), giving 195 hits. These were screened. 
Exclusion criteria were: case reports (61 records), language 
other than English (21 records), children only (four records) and 
wrong subject (five records). Thus, 104 records were included 
for review. Of these, only 31 (29%) contained original data. The 
others were reviews and editorials.
12.6.3.8.7.4.Sarcoidosis
Search strategy 
The EPOS 2020 core search for CRS was performed in June 
2019 in OVID Medline. It was combined with “(sarcoidosis).ti” 
giving 110 hits. These were screened. Exclusion criteria were: 
publication before 1996 (with two exceptions) (12 records), case 
reports (23 records), language other than English (16 records), 
children only (one record) and wrong subject (six records). Thus, 
52 records were included of which 44 were used. Of these, 22 
(50%) contained original data, the others were reviews. 
12.6.3.9. Integrated care pathways in CRS and precision 
medicine
12.6.3.9.1. Patient participation in CRS 
Pubmed Search: 
Participation, (rhino)sinusitis: 51 results
Mobile health, (rhino)sinusitis: 20 results
Empowerment patients, (rhino)sinusitis: 11 results
12.6.3.9.3. and 9.4.Prevention and prediction 
Search terms; (prevent* OR predict* OR risk OR success OR 
failure OR recurrence OR revision) AND full search dataset  - 
Search Identified 7599 papers, 269 full papers reviewed
12.6.3.10. Pharmacist perspective on rhinosinusitis
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12.6.3.8.6.Fungal rhinosinusitis  Search strategy
12.6.3.8.6. Fungal rhinosinusitis  Prisma 2009 flow diagram.
PRISMA 2009 Flow Diagram 
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MEDLINE /Ovid, search date: 10-07-2019
# Searches
1. exp Pharmacy/
2. (pharmacy OR pharmacy practice pattern*.tw
3. Community Pharmacy Services/
4. pharmac* service* community.tw
5. Pharmacists/
6. (pharmacist* OR clinical pharmacist* OR community pharmacist*).tw
7. Pharmacy Technicians/
8. (pharmacy technician* OR pharmacist*' aide*).tw
9. Pharmacies/
10. (pharmacies OR pharmac* distribution* OR pharmac* community).tw
11. exp Prescriptions
12. exp Drug Packaging/
13. (packaging drug* OR drug* container*).tw
14. drug dispensing.tw
15. exp Drug Utilization/
16. drug utilization*.tw
17. exp Nonprecsription Drugs/
18. (drug* non prescription OR OTC drug*).tw
19. exp Drug Resistance Microbial/
20.
(antibiotic drug resistance* OR antibiotic resistance* 
OR antimicrobial drug resistance* OR antimicrobial 
resistance*).tw
21. exp Drug Information Services
22. Attitude of Health Personnel/
23. exp Interprofessional Relations
24. exp Patient Compliance/
25.
(patient compliance* OR patient adherence OR patient 
cooperation OR treatment compliance* OR therapeutic 
compliance* OR patient non compliance* OR patient 
nonadherence OR medication adherence OR medication 
compliance* OR medication nonadherence OR 
medication non compliance*).tw
26. exp Counseling/
27. (counseling OR advice).tw
28. exp Health Education/
29. Health Communication/
Scopus search date: 22-10-2019
SET 1
Field: keywords
1. pharmacy OR “community pharmacy“
2. pharmacist OR “pharmacy technician
3. prescription
4. “drug packaging” OR “drug utilization” OR “non prescription 
drug”
 5. “antibiotic resistance” 
6. “drug information“
7. “health personnel attitude“
8. “interpersonal communication“ OR “public relations
9. “patient compliance“ OR  “patient counseling
10. “medical education“ OR “patient education“
11. “medical information“ OR  “consumer health information“ 
Field: abstract
12. pharmacy OR “pharmacy practice pattern*
13. “pharmac* service* community“ OR pharmacist* OR “clinical 
pharmacist*“ OR “community pharmacist*
14. “pharmacy technician*“ OR “pharmacist* aide*“ OR 
pharmacies OR “pharmac* distribution*“ OR “pharmac* 
community
15. “packaging drug*“ OR “drug* container*
16. “drug dispensing“ OR “drug utilization*“ OR “drug* non 
prescription“ OR “OTC drug*
17. “antibiotic drug resistance*“ OR “antibiotic resistance*“ OR 
“antimicrobial drug resistance*“ OR “antimicrobial resistance*“
18. “patient compliance*“ OR “patient adherence“ OR “patient 
cooperation“ OR “treatment compliance*“ OR “therapeutic 
compliance*“ OR “patient non compliance*“ OR “patient 
nonadherence“           
19. “medication adherence“ OR “medication compliance*“ OR 
“medication nonadherence“ OR 
20.“medication non compliance*
21. counseling OR advice 
22. OR/1-21
23. animal AND NOT human (keywords)
24. 22 AND NOT 23
SET 2  
Field: keywords
1.sinusitis OR “paranasal sinus“
2. “paranasal sinuse“ and (“respiratory tract infection“ or “chronic 
disease“)
3. “common cold“ OR “nasal polyps“ OR “nose polyp“ OR 
“adenoid hypertrophy“ OR adenoid
Field: abstract
4. rhinitis or “rhinitis atrophic“ or “rhinitis vasomotor“ 
5. sinusit* or rhinit* or ozena* or rhinosinusit* or nasosinusit* or 
pansinusit* or ethmoidit* or sphenoidit
6. “inflamm* rhino*“ or “inflamm* sinus“ or “inflamm* sinuses“ or 
“inflamm* sinusal
7. “microb* rhino*“ or “microb* sinus“ or “microb* sinuses“ or 
“microb* sinusal“ or rhinorr* or “purulent rhinor“ OR “ nasal 
muc?us
8. “common cold“ or “head cold“ or coryza or “upper respiratory 
infection*“ or “upper airway infection*“ or URTI or “upper 
respiratory tract infection
9. ARS and (sinonas* or nasal or naso* or rhin* or ENT)
10. “nose papilloma*“ or “nasal papilloma*“ or “nasi papilloma*“ 
or “rhino papilloma*“ or “sinus papilloma*“ or “sinonasal 
papilloma*“
11. rhinopolyp* or CRSwNP* or CRSSNP* or ECRS  
12. “nose polyp*“or “nasal polyp*“or “nasi polyp*“or “rhino 
polyp*“ or “sinus polyp*“or “sinonasal polyp*“
13. CRS and (sinonas* or nasal or naso* or rhin* or ENT)
14. (“kartagener* syndrom*“ or “primary ciliary dyskinesi*“) and 
not (COPD or thoracic or “pulmonary disease“ or bronchiectas*)
15. adenoid* hypertroph* or adenoid* obstruct* or adenoidit* 
16. OR/1-15
17. animal AND NOT human (keywords)
18. 16 AND NOT 17
SET1 AND SET2
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